<SEC-DOCUMENT>0001641172-25-009319.txt : 20250508
<SEC-HEADER>0001641172-25-009319.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508172842
ACCESSION NUMBER:		0001641172-25-009319
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		130
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celularity Inc
		CENTRAL INDEX KEY:			0001752828
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				831702591
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38914
		FILM NUMBER:		25927536

	BUSINESS ADDRESS:	
		STREET 1:		170 PARK AVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932
		BUSINESS PHONE:		(908) 768-2170

	MAIL ADDRESS:	
		STREET 1:		170 PARK AVE
		CITY:			FLORHAM PARK
		STATE:			NJ
		ZIP:			07932

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GX Acquisition Corp.
		DATE OF NAME CHANGE:	20180912
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:CELU="http://celularity.com/20241231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD) -->
<!-- Field: Set; Name: xdx; ID: xdx_039_CELU_celularity.com_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04C_20240101_20241231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001752828 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_061_Integer_0_Integer -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_Segment_0_Segment -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_sqft_0_utr%2D%2Dsqft -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000004" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000006" name="dei:EntityCentralIndexKey">0001752828</ix:nonNumeric>
  <ix:nonFraction name="CELU:PromissoryNotesReceivable" contextRef="AsOf2024-12-31" id="xdx2ixbrl0088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:AccruedResearchAndDevelopmentSoftware" contextRef="AsOf2024-12-31" id="xdx2ixbrl0136" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0140" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0168" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-12-31" id="xdx2ixbrl0185" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2023-12-31" id="xdx2ixbrl0186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-12-31" id="xdx2ixbrl0191" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl0192" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-12-31" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0286" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0385" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:FairValueOfWarrantModificationForProfessionalService" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0391" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:FairValueOfWarrantModificationForProfessionalService" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:FairValueOfWarrantModificationForProfessionalService" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0444" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueATMAgreement" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueATMAgreement" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0451" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueATMAgreement" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0457" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0458" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0463" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0464" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0466" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0504" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0518" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0525" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0526" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0544" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0549" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0557" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0568" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0575" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0576" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0581" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0584" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0630" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0633" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:AcquiredInProcessResearchAndDevelopment" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0642" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:IssuanceOfCommonStockUsedInResearchAndDevelopment" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0645" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:IssuanceOfCommonStockAsConsiderationForSettlementAgreement" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0649" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:IssuanceOfCommonStockAsCompensationExpense" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0655" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:DiscountsArisingFromLoanArrangementRelatedParty" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0660" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0664" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ChangeInFairValueOfContingentStockConsideration" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0669" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:NonCashInterestExpense" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0673" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0715" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0717" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ProceedsFromConvertibleNote" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0721" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ProceedsFromTheSaleOfCommonStockInAtmOffering" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0735" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:PaymentOfSepaCommitmentFee" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0742" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:RepaymentsOfShortTermDebtRelatedParty" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0745" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0756" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0759" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ModificationOfCVStarrWarrantsInConnectionWithForbearance" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0790" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:IssuanceOfRwiWarrantsInConnectionWithForbearance" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0793" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:IssuanceOfWarrantsOnSeniorSecuredBridgeLoan" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0795" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0798" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:PIPERelatedCostsIncludedInAccruedExpenses" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0801" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0804" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0808" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:InventoryAcquiredInConnectionWithReboundAssetAcquisition" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0811" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0814" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:AssumptionOfShorttermDebtUnaffiliatedByRelatedParty" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl0817" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="xdx2ixbrl0878" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl0886" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1032" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1033" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ContingentStockConsideration" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1037" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ContingentStockConsideration" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1038" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShorttermDebtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1042" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShorttermDebtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1043" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1047" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1048" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrantsTwo" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1052" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrantsTwo" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1053" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1057" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1058" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1062" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1063" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPurchaserWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1067" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPurchaserWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1068" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPlacementAgentWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1072" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPlacementAgentWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1073" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilitySponsorWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1077" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilitySponsorWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1078" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPublicWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1083" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPublicWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1084" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1088" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ReceivablesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1097" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ReceivablesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1098" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1102" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1103" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1113" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ContingentStockConsideration" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1117" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ContingentStockConsideration" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1118" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShorttermDebtFairValue" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1122" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShorttermDebtFairValue" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1123" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrantsTwo" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1127" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrantsTwo" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1128" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1132" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1133" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1137" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1138" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilitySponsorWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1142" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilitySponsorWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1143" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPublicWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1148" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:WarrantLiabilityPublicWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1149" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1153" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1171" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1175" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ReceivablesFairValueDisclosure" contextRef="AsOf2024-12-31" id="xdx2ixbrl1177" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" contextRef="From2024-01-012024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember" id="xdx2ixbrl1199" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" contextRef="From2024-01-012024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember" id="xdx2ixbrl1201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" contextRef="From2023-01-012023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember" id="xdx2ixbrl1209" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" contextRef="From2023-01-012023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember" id="xdx2ixbrl1211" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" contextRef="From2024-01-012024-12-31_custom_ContingentStockConsiderationMember" id="xdx2ixbrl1221" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" contextRef="From2024-01-012024-12-31_custom_ContingentStockConsiderationMember" id="xdx2ixbrl1223" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2024-01-012024-12-31_custom_ContingentStockConsiderationMember" id="xdx2ixbrl1225" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" contextRef="From2023-01-012023-12-31_custom_ContingentStockConsiderationMember" id="xdx2ixbrl1231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" contextRef="From2023-01-012023-12-31_custom_ContingentStockConsiderationMember" id="xdx2ixbrl1233" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" id="xdx2ixbrl1477" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" id="xdx2ixbrl1479" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" id="xdx2ixbrl1481" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_ConstructionInProgressMember" id="xdx2ixbrl1646" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl1670" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl1803" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ShortTermDebtUnaffiliated" contextRef="AsOf2024-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="xdx2ixbrl1818" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ShortTermDebtUnaffiliated" contextRef="AsOf2023-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember" id="xdx2ixbrl1822" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:ShortTermDebtUnaffiliated" contextRef="AsOf2023-12-31_custom_UnsecuredSeniorConvertibleNoteMember" id="xdx2ixbrl1825" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:OtherShortTermDebt" contextRef="AsOf2024-12-31" id="xdx2ixbrl1827" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl1855" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:AccruedResearchAndDevelopmentSoftware" contextRef="AsOf2024-12-31" id="xdx2ixbrl2240" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2668" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2684" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2686" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="xdx2ixbrl2700" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="xdx2ixbrl2736" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2920" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2921" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2923" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2926" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2935" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2936" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2938" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2955" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2961" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl2967" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl2968" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELU:DeferredTaxAssetsIrcSectionInterest" contextRef="AsOf2023-12-31" id="xdx2ixbrl3003" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" contextRef="From2023-01-012023-12-31" id="xdx2ixbrl3021" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" contextRef="From2024-01-01to2024-12-31" id="xdx2ixbrl3025" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_CellTherapyMember" id="xdx2ixbrl3064" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_CellTherapyMember" id="xdx2ixbrl3129" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-12-31_custom_CellTherapyMember" id="xdx2ixbrl3134" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="celu-20241231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-01-01to2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ClassCommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CELU:ClassCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CELU:WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-04-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-04-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_LicenseRoyaltyAndOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CELU:LicenseRoyaltyAndOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_LicenseRoyaltyAndOtherMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CELU:LicenseRoyaltyAndOtherMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-22_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-222024-02-22_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-22</xbrli:startDate>
        <xbrli:endDate>2024-02-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-222025-04-22_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-22</xbrli:startDate>
        <xbrli:endDate>2025-04-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LetterOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LetterOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CellTherapyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:CellTherapyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CellTherapyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:CellTherapyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:ThreeCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:TwoCustomersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:CustomerOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:CustomerTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:CustomerOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:CustomerTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_BuildingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_SoftwareDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">CELU:SequenceLifeScienceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-09</xbrli:startDate>
        <xbrli:endDate>2024-10-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-10-09_custom_SequenceLifeScienceIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">CELU:SequenceLifeScienceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-10-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_SequenceLifeScienceIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">CELU:SequenceLifeScienceIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:AcquisitionRelatedContingentConsiderationObligationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ContingentStockConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:ContingentStockConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_UnsecuredSeniorConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_GXSponsorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:GXSponsorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_srt_MinimumMember_custom_LetterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SanuwaveForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:LetterAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-10</xbrli:startDate>
        <xbrli:endDate>2024-05-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_srt_MaximumMember_custom_LetterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SanuwaveForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:LetterAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-10</xbrli:startDate>
        <xbrli:endDate>2024-05-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_custom_LetterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SanuwaveForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:LetterAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-10</xbrli:startDate>
        <xbrli:endDate>2024-05-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-032024-06-03_custom_SanuwaveForbearanceAgreementMember_custom_LetterAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SanuwaveForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:LetterAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-03</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_YorkvilleMember_custom_UnsecuredSeniorConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-312023-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-31</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-312023-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-31</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-312023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-31</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:AcquisitionRelatedContingentConsiderationObligationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:AcquisitionRelatedContingentConsiderationObligationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:AcquisitionRelatedContingentConsiderationObligationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:AcquisitionRelatedContingentConsiderationObligationsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ContingentStockConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:ContingentStockConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ContingentStockConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:ContingentStockConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ContingentStockConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:ContingentStockConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ContingentStockConsiderationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:ContingentStockConsiderationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_YorkvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_YorkvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_YorkvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_YorkvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_YorkvilleMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputCreditSpreadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputCreditSpreadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-312024-12-31_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-31</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_us-gaap_MeasurementInputPriceVolatilityMember_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-312024-12-31_custom_UnsecuredSeniorConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-31</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-25</xbrli:startDate>
        <xbrli:endDate>2024-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-032024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-03</xbrli:startDate>
        <xbrli:endDate>2024-12-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-25</xbrli:startDate>
        <xbrli:endDate>2024-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-032024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-03</xbrli:startDate>
        <xbrli:endDate>2024-12-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_UnsecuredSeniorConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_us-gaap_MeasurementInputPriceVolatilityMember_custom_UnsecuredSeniorConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-162024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-16</xbrli:startDate>
        <xbrli:endDate>2024-01-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-252024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-25</xbrli:startDate>
        <xbrli:endDate>2024-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-032024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-03</xbrli:startDate>
        <xbrli:endDate>2024-12-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-252024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-25</xbrli:startDate>
        <xbrli:endDate>2024-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-12-032024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-03</xbrli:startDate>
        <xbrli:endDate>2024-12-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorsWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SponsorsWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InventoryFinishedGoodsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">CELU:InventoryFinishedGoodsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InventoryWorkInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">CELU:InventoryWorkInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LaboratoryAndProductionEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:LaboratoryAndProductionEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LaboratoryAndProductionEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:LaboratoryAndProductionEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MachineryEquipmentAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:MachineryEquipmentAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MachineryEquipmentAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:MachineryEquipmentAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_CellTherapyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:CellTherapyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_custom_CellTherapyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:CellTherapyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_InProcessResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_DevelopedTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_DevelopedTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_DevelopedTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MinimumMember_us-gaap_DevelopedTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_DevelopedTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MaximumMember_us-gaap_DevelopedTechnologyRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_TrademarksAndTradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TrademarksAndTradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_TrademarksAndTradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MinimumMember_us-gaap_TrademarksAndTradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_TrademarksAndTradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_srt_MaximumMember_us-gaap_TrademarksAndTradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ReacquiredRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">CELU:ReacquiredRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ReacquiredRightsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">CELU:ReacquiredRightsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:UnsecuredSeniorConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_UnsecuredSeniorConvertibleNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:UnsecuredSeniorConvertibleNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CVStarrBridgeLoanNetOfDiscountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CVStarrBridgeLoanNetOfDiscountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CVStarrBridgeLoanNetOfDiscountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CVStarrBridgeLoanNetOfDiscountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RWIBridgeLoanNetOfDiscountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:RWIBridgeLoanNetOfDiscountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_RWIBridgeLoanNetOfDiscountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:RWIBridgeLoanNetOfDiscountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CEOPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_CEOPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-15</xbrli:startDate>
        <xbrli:endDate>2022-09-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-122024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-12</xbrli:startDate>
        <xbrli:endDate>2024-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-01_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-012024-11-30_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-01</xbrli:startDate>
        <xbrli:endDate>2024-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-162025-03-16_custom_YorkvilleMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-16</xbrli:startDate>
        <xbrli:endDate>2025-03-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-172025-03-17_custom_YorkvilleMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-17</xbrli:startDate>
        <xbrli:endDate>2025-03-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-17_custom_YorkvilleMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_srt_MaximumMember_custom_UnsecuredSeniorConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-25</xbrli:startDate>
        <xbrli:endDate>2024-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-11-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-11-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-252024-11-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-25</xbrli:startDate>
        <xbrli:endDate>2024-11-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_UnsecuredSeniorConvertibleNotesMember15557562">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember15557609">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-212023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-21</xbrli:startDate>
        <xbrli:endDate>2023-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-122023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-12</xbrli:startDate>
        <xbrli:endDate>2023-10-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ChairmanAndChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-172023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-17</xbrli:startDate>
        <xbrli:endDate>2023-03-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_WarrantMember_custom_LoanAgreementMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember_custom_TrancheTwoWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheTwoWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember_custom_TrancheTwoWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheTwoWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-15_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-122025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-12</xbrli:startDate>
        <xbrli:endDate>2025-02-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:InitialLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-162023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:InitialLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-16</xbrli:startDate>
        <xbrli:endDate>2023-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:AdditionalLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-21_us-gaap_BridgeLoanMember_custom_InitialLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:InitialLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-212023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:AdditionalLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-21</xbrli:startDate>
        <xbrli:endDate>2023-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-14_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:AdditionalLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-122024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:AdditionalLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-12</xbrli:startDate>
        <xbrli:endDate>2024-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember_custom_AdditionalLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheOneWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:AdditionalLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheOneWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-16_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheOneWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-07-15_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheOneWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_InitialAndSecondTrancheMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:InitialAndSecondTrancheMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_InitialAndSecondTrancheMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:InitialAndSecondTrancheMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_us-gaap_BridgeLoanMember_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember15559390">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-05_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-02-122025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-02-12</xbrli:startDate>
        <xbrli:endDate>2025-02-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_BridgeLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CELU:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-13</xbrli:startDate>
        <xbrli:endDate>2019-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CELU:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CELU:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-14_custom_FlorhamParkNewJerseyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CELU:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-09-142023-09-14_custom_FlorhamParkNewJerseyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CELU:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-09-14</xbrli:startDate>
        <xbrli:endDate>2023-09-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_HLICellularTherapeuticsLLCAndAnthrogenesisMember_custom_LegacyCelularitysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:HLICellularTherapeuticsLLCAndAnthrogenesisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularitysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_HLICellularTherapeuticsLLCAndAnthrogenesisMember_custom_LegacyCelularitysMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:HLICellularTherapeuticsLLCAndAnthrogenesisMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularitysMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-052021-05-05_custom_PalantirTechnologiesIncMember_custom_MasterSubscriptionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:PalantirTechnologiesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:MasterSubscriptionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-05</xbrli:startDate>
        <xbrli:endDate>2021-05-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-03-31_custom_PalantirTechnologiesIncMember_custom_SoftwareCeaseUseCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:PalantirTechnologiesIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">CELU:SoftwareCeaseUseCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-102024-01-10_custom_PalantirTechnologiesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:PalantirTechnologiesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-10</xbrli:startDate>
        <xbrli:endDate>2024-01-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-062024-05-06_custom_PalantirTechnologiesIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:PalantirTechnologiesIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-06</xbrli:startDate>
        <xbrli:endDate>2024-05-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-12-012021-12-31_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-12-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-212024-06-03_custom_SettlementAndReleaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SettlementAndReleaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-21</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-212024-06-03_us-gaap_CommonClassAMember_custom_SettlementAndReleaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SettlementAndReleaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-21</xbrli:startDate>
        <xbrli:endDate>2024-06-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-172023-04-17_custom_EvolutionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">CELU:EvolutionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-17</xbrli:startDate>
        <xbrli:endDate>2023-04-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-072024-05-07_custom_EvolutionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">CELU:EvolutionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-07</xbrli:startDate>
        <xbrli:endDate>2024-05-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-04-212025-04-21_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-21</xbrli:startDate>
        <xbrli:endDate>2025-04-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-03-272025-03-27_custom_HackensackMeridianHealthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELU:HackensackMeridianHealthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-03-27</xbrli:startDate>
        <xbrli:endDate>2025-03-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_srt_MinimumMember_custom_LegacyCelularityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-082022-09-08_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-08</xbrli:startDate>
        <xbrli:endDate>2022-09-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AtTheMarketSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AtTheMarketSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-20</xbrli:startDate>
        <xbrli:endDate>2023-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-20_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_srt_MaximumMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-20_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-20_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-20</xbrli:startDate>
        <xbrli:endDate>2023-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_ChairmanAndChiefExecutiveOfficerMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-20</xbrli:startDate>
        <xbrli:endDate>2023-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-14_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-142023-03-14_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-14</xbrli:startDate>
        <xbrli:endDate>2023-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-102023-04-10_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-10</xbrli:startDate>
        <xbrli:endDate>2023-04-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-10_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-102023-04-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-10</xbrli:startDate>
        <xbrli:endDate>2023-04-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-18_srt_MaximumMember_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-18_srt_MinimumMember_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-102023-04-10_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-10</xbrli:startDate>
        <xbrli:endDate>2023-04-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-312023-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-31</xbrli:startDate>
        <xbrli:endDate>2023-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-182023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-18</xbrli:startDate>
        <xbrli:endDate>2023-05-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-182023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-18</xbrli:startDate>
        <xbrli:endDate>2023-05-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-122024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-12</xbrli:startDate>
        <xbrli:endDate>2024-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-122024-01-12_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-12</xbrli:startDate>
        <xbrli:endDate>2024-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-122024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-12</xbrli:startDate>
        <xbrli:endDate>2024-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_srt_MinimumMember_custom_InvestorRightsAgreementMember_custom_DragasacLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:InvestorRightsAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:DragasacLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_srt_MaximumMember_custom_InvestorRightsAgreementMember_custom_DragasacLimitedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:InvestorRightsAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:DragasacLimitedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-162024-02-16_custom_ChiefAdministrativeOfficerMember_custom_AmendedEmploymentAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChiefAdministrativeOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:AmendedEmploymentAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-16</xbrli:startDate>
        <xbrli:endDate>2024-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-162024-02-16_custom_ChiefAdministrativeOfficerMember_custom_AmendedEmploymentAgreementMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChiefAdministrativeOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:AmendedEmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-16</xbrli:startDate>
        <xbrli:endDate>2024-02-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-122024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-12</xbrli:startDate>
        <xbrli:endDate>2024-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_us-gaap_CommonStockMember_custom_RwiForbearanceAgreementMember_us-gaap_WarrantMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RwiForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_RwiForbearanceAgreementMember_us-gaap_WarrantMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RwiForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-12_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JuneTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JuneTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_us-gaap_CommonStockMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_YorkvilleMember_us-gaap_CommonClassAMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_custom_YorkvilleMember_us-gaap_CommonClassAMember_custom_StandbyEquityPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember15564515">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-13</xbrli:startDate>
        <xbrli:endDate>2024-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_DragasacWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:DragasacWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_PublicWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:PublicWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:SponsorWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JuneTwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JuneTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPurchaseWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember15565437">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-24_custom_JanuaryTwoThousandTwentyFourPIPEWarrantMember_us-gaap_SubsequentEventMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPIPEWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-24_custom_JanuaryTwoThousandTwentyFourPIPEWarrantMember_us-gaap_SubsequentEventMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPIPEWarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_CommonClassAMember_custom_DragasacWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:DragasacWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_SponsorWarrantsMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:SponsorWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_StarrForbearanceAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:StarrForbearanceAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13_custom_CVStarrCoIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-242025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-24</xbrli:startDate>
        <xbrli:endDate>2025-01-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-01-01_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-09-30_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember15566546">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember15566546">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-162022-08-16_custom_AwardsWithPerformanceConditionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-16</xbrli:startDate>
        <xbrli:endDate>2022-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-162022-08-16_custom_AwardsWithPerformanceConditionsMember_custom_InitialTrancheMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:InitialTrancheMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-16</xbrli:startDate>
        <xbrli:endDate>2022-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-16_custom_AwardsWithPerformanceConditionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-01_custom_AwardsWithPerformanceConditionsMember_custom_SecondTrancheMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:SecondTrancheMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-01_custom_AwardsWithPerformanceConditionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_AwardsWithPerformanceConditionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-162023-08-16_custom_AwardsWithPerformanceConditionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-16</xbrli:startDate>
        <xbrli:endDate>2023-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember15566875">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:MarketConditionStockUnitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:MarketConditionStockUnitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:MarketConditionStockUnitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_MarketConditionStockUnitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:MarketConditionStockUnitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MarketConditionStockUnitMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:MarketConditionStockUnitMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandTwentyOnePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandTwentyOnePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_TwoThousandTwentyOnePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandTwentyOnePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CostOfSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-252023-08-25_custom_RegeneronResearchCollaborationServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RegeneronResearchCollaborationServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-25</xbrli:startDate>
        <xbrli:endDate>2023-08-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RegeneronServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RegeneronServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-12-31_custom_RegeneronServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RegeneronServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_RegeneronServicesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RegeneronServicesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PultheraLLCBindingTermSheetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:PultheraLLCBindingTermSheetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_PultheraLLCBindingTermSheetMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:PultheraLLCBindingTermSheetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-172023-03-17_custom_PultheraLLCBindingTermSheetMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:PultheraLLCBindingTermSheetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-17</xbrli:startDate>
        <xbrli:endDate>2023-03-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-172023-03-17_custom_PultheraLLCBindingTermSheetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:PultheraLLCBindingTermSheetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-17</xbrli:startDate>
        <xbrli:endDate>2023-03-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:LicenseAgreementWithBiocellgraftIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-11</xbrli:startDate>
        <xbrli:endDate>2023-12-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_UnitedStatesFederalAndStateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CELU:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_UnitedStatesFederalAndStateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CELU:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_UnitedStatesFederalAndStateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CELU:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_BiobankingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:BiobankingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_DegenerativeDiseaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:DegenerativeDiseaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_BiobankingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:BiobankingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_DegenerativeDiseaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:DegenerativeDiseaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_DrRobertHaririMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:DrRobertHaririMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-252023-01-25_custom_DrRobertHaririMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:DrRobertHaririMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-25</xbrli:startDate>
        <xbrli:endDate>2023-01-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:DrRobertHaririMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-25</xbrli:startDate>
        <xbrli:endDate>2023-01-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-252023-01-25_custom_AmendedAndRestatedEmploymentAgreementMember_custom_DrRobertHaririMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:AmendedAndRestatedEmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:DrRobertHaririMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-25</xbrli:startDate>
        <xbrli:endDate>2023-01-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_SecuritiesPurchaseAgreementMember_custom_DrRobertHaririMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:DrRobertHaririMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-20</xbrli:startDate>
        <xbrli:endDate>2023-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_DrHaririMember_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:DrHaririMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-20</xbrli:startDate>
        <xbrli:endDate>2023-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2003-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2003-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-10-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConsultingAgreementMember_custom_DrAndrewPecoraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:DrAndrewPecoraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-21_custom_ConsultingAgreementMember_custom_DrAndrewPecoraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ConsultingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:DrAndrewPecoraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-01_custom_ScientificAndClinicalAdvisorAgreementMember_custom_DrAndrewPecoraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ScientificAndClinicalAdvisorAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:DrAndrewPecoraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-01_custom_ScientificAndClinicalAdvisorAgreementMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ScientificAndClinicalAdvisorAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-01_us-gaap_RestrictedStockUnitsRSUMember_custom_ScientificAndClinicalAdvisorAgreementMember_custom_DrAndrewPecoraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ScientificAndClinicalAdvisorAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:DrAndrewPecoraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:RobinLSmithMdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:AdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-16</xbrli:startDate>
        <xbrli:endDate>2022-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember_custom_InitialTrancheMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:RobinLSmithMdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:AdvisoryAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:InitialTrancheMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-16</xbrli:startDate>
        <xbrli:endDate>2022-08-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-012022-09-01_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:RobinLSmithMdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:AdvisoryAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-01</xbrli:startDate>
        <xbrli:endDate>2022-09-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:RobinLSmithMdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:AdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:RobinLSmithMdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:AdvisoryAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_COTAIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:COTAIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_COTAIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:COTAIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_CryoportSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:CryoportSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CryoportSystemsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:CryoportSystemsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-17_custom_CVStarLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:CVStarLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-17</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CVStarLoanMember_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:CVStarLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_CVStarLoanMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:CVStarLoanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-16_custom_ResortsWorldIncPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-12_custom_ResortsWorldIncPteLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-16_custom_ResortsWorldIncPteLtdMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_custom_ResortsWorldIncPteLtdMember_us-gaap_CommonClassAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-012024-12-31_custom_MsHaririMember_custom_EmploymentOfImmediateFamilyMemberMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:MsHaririMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MsHaririMember_custom_EmploymentOfImmediateFamilyMemberMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:MsHaririMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELU:GenesisEquityGroupFundingLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-05-012025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELU:GenesisEquityGroupFundingLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-01</xbrli:startDate>
        <xbrli:endDate>2025-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-10-012024-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001752828</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-10-01</xbrli:startDate>
        <xbrli:endDate>2024-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Integer">
      <xbrli:measure>CELU:Integer</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>CELU:Segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact001309" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001311" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001313" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001315" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001319" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001321" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001323" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001325" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001329" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001331" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001335" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001337" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001339" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001341" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001345" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001347" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001349" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001351" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001355" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001357" toRefs="Footnote001358"/>
  <ix:relationship fromRefs="Fact001436" toRefs="Footnote001453"/>
  <ix:relationship fromRefs="Fact001459" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001461" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001463" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001465" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001467" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001469" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001471" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001473" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001475" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001485" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001487" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001491" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001493" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001495" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001497" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001501" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001503" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001505" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001507" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001511" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="Fact001513" toRefs="Footnote001514"/>
  <ix:relationship fromRefs="xdx2ixbrl1477" toRefs="Footnote001515 Footnote001524"/>
  <ix:relationship fromRefs="xdx2ixbrl1479" toRefs="Footnote001515 Footnote001524"/>
  <ix:relationship fromRefs="xdx2ixbrl1481" toRefs="Footnote001515 Footnote001524"/>
  <ix:relationship fromRefs="Fact002497" toRefs="Footnote002616 Footnote002641"/>
  <ix:relationship fromRefs="Fact002499" toRefs="Footnote002616 Footnote002641"/>
  <ix:relationship fromRefs="Fact002501" toRefs="Footnote002616 Footnote002641"/>
  <ix:relationship fromRefs="Fact002503" toRefs="Footnote002623"/>
  <ix:relationship fromRefs="Fact002505" toRefs="Footnote002623"/>
  <ix:relationship fromRefs="Fact002507" toRefs="Footnote002623"/>
  <ix:relationship fromRefs="Fact002509" toRefs="Footnote002623"/>
  <ix:relationship fromRefs="Fact002511" toRefs="Footnote002623"/>
  <ix:relationship fromRefs="Fact002513" toRefs="Footnote002623"/>
  <ix:relationship fromRefs="Fact002533" toRefs="Footnote002630"/>
  <ix:relationship fromRefs="Fact002535" toRefs="Footnote002630"/>
  <ix:relationship fromRefs="Fact002537" toRefs="Footnote002630"/>
  <ix:relationship fromRefs="Fact002557" toRefs="Footnote002630"/>
  <ix:relationship fromRefs="Fact002559" toRefs="Footnote002630"/>
  <ix:relationship fromRefs="Fact002575" toRefs="Footnote002641"/>
  <ix:relationship fromRefs="Fact002577" toRefs="Footnote002641"/>
  <ix:relationship fromRefs="Fact002579" toRefs="Footnote002641"/>
  <ix:relationship fromRefs="Fact002714" toRefs="Footnote002737"/>
  <ix:relationship fromRefs="Fact002716" toRefs="Footnote002737"/>
  <ix:relationship fromRefs="Fact002718" toRefs="Footnote002737"/>
  <ix:relationship fromRefs="Fact002720" toRefs="Footnote002737"/>
  <ix:relationship fromRefs="Fact002860" toRefs="Footnote002871"/>
  <ix:relationship fromRefs="Fact002861" toRefs="Footnote002871"/>
  <ix:relationship fromRefs="Fact002863" toRefs="Footnote002873"/>
  <ix:relationship fromRefs="Fact002864" toRefs="Footnote002873"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-size: 18pt"><b>UNITED STATES </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-size: 18pt"><b>SECURITIES AND
EXCHANGE COMMISSION </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-size: 12pt"><b>Washington, D.C.
20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><span style="font-size: 10pt">&#160;</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-size: 18pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-size: 18pt"><b>FORM <span id="xdx_909_edei--DocumentType_c20240101__20241231_zgbEMCMzvLCd"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000015" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.1in"><b>(Mark One) </b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><b><span id="xdx_903_edei--DocumentAnnualReport_c20240101__20241231_zWNFtiURSLC1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000016" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>For the fiscal year ended <span id="xdx_90B_edei--DocumentPeriodEndDate_c20240101__20241231_z3nzy0bh8qdg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000017" name="dei:DocumentPeriodEndDate"><span id="xdx_90C_edei--CurrentFiscalYearEndDate_c20240101__20241231_z79Rlx3vp8G3"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayen" id="Fact000018" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>,
<span id="xdx_90A_edei--DocumentFiscalYearFocus_c20240101__20241231_z6QI9DpYUskg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000019" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric></span></ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>OR</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><b><span id="xdx_900_edei--DocumentTransitionReport_c20240101__20241231_ztqBQfyYorJa"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000020" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>For the transition period from
&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Commission file number <span id="xdx_90F_edei--EntityFileNumber_c20240101__20241231_zPFABLTDMxri"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000021" name="dei:EntityFileNumber">001-38914</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-size: 18pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-size: 18pt"><b><span id="xdx_906_edei--EntityRegistrantName_c20240101__20241231_zSRPYhca8Zd6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000022" name="dei:EntityRegistrantName">Celularity Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20240101__20241231_z9d3EVkdxCr9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:stateprovnameen" id="Fact000023" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20240101__20241231_zeTlV9cV4Vvg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000024" name="dei:EntityTaxIdentificationNumber">83-1702591</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>(State or other jurisdiction of</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>incorporation or organization)</b></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>(I.R.S. Employer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Identification No.)</b></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20240101__20241231_zoGHOKWa6E77"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000025" name="dei:EntityAddressAddressLine1">170 Park Ave</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><span id="xdx_905_edei--EntityAddressCityOrTown_c20240101__20241231_z1NwXw3C9It1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000026" name="dei:EntityAddressCityOrTown">Florham Park</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressStateOrProvince_c20240101__20241231_zqumse1Bx8A2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000027" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></b></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20240101__20241231_zxFQDq9MI62d"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000028" name="dei:EntityAddressPostalZipCode">07932</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>(Address of principal executive offices)</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><b>(Zip Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Registrant&#8217;s telephone number,
including area code: <span id="xdx_905_edei--CityAreaCode_c20240101__20241231_zkYpOY3QJtU2"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000029" name="dei:CityAreaCode">(908)</ix:nonNumeric></span> <span id="xdx_90E_edei--LocalPhoneNumber_c20240101__20241231_zMfksECg8rIf"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000030" name="dei:LocalPhoneNumber">768-2170</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 44%; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 14%; vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Trading Symbol(s)</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 38%; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_909_edei--Security12bTitle_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--ClassCommonStockParValue0.0001PerShareMember_zxXSSkE9oOc3"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_ClassCommonStockParValue0.0001PerShareMember" id="Fact000031" name="dei:Security12bTitle">Class A common stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--ClassCommonStockParValue0.0001PerShareMember_zTyhdf7YkK9l"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_ClassCommonStockParValue0.0001PerShareMember" id="Fact000032" name="dei:TradingSymbol">CELU</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_90A_edei--SecurityExchangeName_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--ClassCommonStockParValue0.0001PerShareMember_zx9n4mkIE7g3"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_ClassCommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000033" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember_zEtTWvHAnhW8"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" id="Fact000034" name="dei:Security12bTitle">Warrants, each exercisable
    for one share of Class A common stock at an exercise price of $115 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember_zIUum6XzXpVd"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" id="Fact000035" name="dei:TradingSymbol">CELUW</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt"><span id="xdx_901_edei--SecurityExchangeName_c20240101__20241231__us-gaap--StatementClassOfStockAxis__custom--WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember_zarezubcvs02"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" format="ixt-sec:exchnameen" id="Fact000036" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Securities registered pursuant to Section 12(g) of the Act: <b>None</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span> <span id="xdx_90A_edei--EntityWellKnownSeasonedIssuer_c20240101__20241231_zAdwljrpjcek"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000037" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Segoe UI Symbol,sans-serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Indicate by check mark if the registrant is not required to
file reports pursuant to Section 13 or 15(d) of the Act. Yes <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span> <span id="xdx_905_edei--EntityVoluntaryFilers_c20240101__20241231_znhryYdflUmg"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000038" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Segoe UI Symbol,sans-serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Indicate by check mark whether the registrant: (1) has filed
all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. <span id="xdx_90B_edei--EntityCurrentReportingStatus_c20240101__20241231_znXQFwQ46z5b"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000039" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> <span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span> No <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Segoe UI Symbol,sans-serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_907_edei--EntityInteractiveDataCurrent_c20240101__20241231_z8wyHOjUvKv"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000040" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>
<span style="font-family: Segoe UI Symbol,sans-serif">&#9746;</span> No <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Segoe UI Symbol,sans-serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font-size: 10pt">Large accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 43%"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 22%"><span style="font-size: 10pt">Accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 5%"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><span id="xdx_90C_edei--EntityFilerCategory_c20240101__20241231_zDtaeqMpN8f4"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000041" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">Smaller reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_900_edei--EntitySmallBusiness_c20240101__20241231_z1XrWuvTDIg6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000042" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Emerging growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><span style="font-family: Segoe UI Symbol,sans-serif; font-size: 10pt"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20240101__20241231_zWrC91NFC0Ug"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000043" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Segoe UI Symbol,sans-serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Indicate by check mark whether the registrant
has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_90F_edei--IcfrAuditorAttestationFlag_c20240101__20241231_zLgaPOmB2Lq6"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000044" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Segoe UI Symbol,sans-serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If securities are registered pursuant to
Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the
correction of an error to previously issued financial statements. <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_90C_edei--DocumentFinStmtErrorCorrectionFlag_c20240101__20241231_zACcwYGSu1F9"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000045" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Segoe UI Symbol,sans-serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Indicate by check mark whether any of those
error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Segoe UI Symbol,sans-serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Segoe UI Symbol,sans-serif">&#9744;</span>
No <span style="font-family: Segoe UI Symbol,sans-serif"><span id="xdx_901_edei--EntityShellCompany_dbF_c20240101__20241231_z6kNVCkXwhdb"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000046" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Segoe UI Symbol,sans-serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The aggregate market value of the voting
and non-voting common equity held by non-affiliates of the registrant, based on the closing price of the shares of Class A common stock
on the Nasdaq Stock Market on June 30, 2024, was $<span id="xdx_906_edei--EntityPublicFloat_iI_pn5n6_c20240630_zrIXr95IOSCk"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-06-30" id="Fact000047" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">38.5</ix:nonFraction></span> million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The number of shares of the registrant&#8217;s
Class A common stock outstanding as of May 6, 2025 was <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_c20250406_zTfhRDf5Ek0j"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-04-06" id="Fact000048" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">23,949,229</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="xdx_90E_edei--DocumentsIncorporatedByReferenceTextBlock_c20240101__20241231_zr917FDYqdJ1"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000049" name="dei:DocumentsIncorporatedByReferenceTextBlock">None</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%">&#160;</td><td style="width: 33%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b></b>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Table of Contents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.15in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b><a href="#a_001Yosu3">PART I</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; vertical-align: top"><span style="font-size: 10pt">Item 1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#a_001Yosu1">Business</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; vertical-align: top"><span style="font-size: 10pt">Item 1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#a_001Yosu2">Risk
    Factors</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">31</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; vertical-align: top"><span style="font-size: 10pt">Item 1B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#NA_001">Unresolved Staff Comments</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; vertical-align: top"><span style="font-size: 10pt">Item 1C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#NA_002">Cybersecurity</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">68</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; vertical-align: top"><span style="font-size: 10pt">Item 2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#NA_003">Properties</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; vertical-align: top"><span style="font-size: 10pt">Item 3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#NA_004">Legal Proceedings</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; vertical-align: top"><span style="font-size: 10pt">Item 4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#NA_005">Mine Safety Disclosures</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">69</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b><a href="#NA_006">PART II</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#NA_007">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#NA_008">[Reserved]</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">70</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 7.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#NA_009">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">71</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 7A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#a_001YV1">Quantitative and Qualitative Disclosures About Market Risk</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 8.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#a_001YV2">Financial Statements and Supplementary Data</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">82</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 9.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#m_001">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">140</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 9A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#m_002">Controls and Procedures</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">140</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 9B.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#m_003">Other Information</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">141</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 9C.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#m_004">Disclosure Regarding Foreign Jurisdiction that Prevents Inspections</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">141</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b><a href="#m_005">PART III</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 10.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#m_006">Directors, Executive Officers and Corporate Governance</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">142</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 11.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#m_007">Executive Compensation</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">142</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 12.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#m_008">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">142</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 13.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#m_009">Certain Relationships and Related Transactions, and Director Independence</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">142</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 14.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#m_010">Principal Accounting Fees and Services</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">142</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b><a href="#m_011">PART IV</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 15.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#m_012">Exhibits, Financial Statement Schedules</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">142</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt">Item 16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#m_013">Form 10-K Summary</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><span style="font-size: 10pt; line-height: 120%">147</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Unless the context indicates
otherwise, references in this annual report on Form 10-K to the &#8220;Company,&#8221; &#8220;Celularity,&#8221; &#8220;we,&#8221; &#8220;us,&#8221;
&#8220;our&#8221; and similar terms refer to Celularity Inc. (f/k/a GX Acquisition Corp.) and its consolidated subsidiaries (including
Celularity LLC, or Legacy Celularity).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The Celularity logo,
Celularity IMPACT, Biovance, Biovance 3L, Rebound, Interfyl, Lifebank, CentaFlex and other trademarks or service marks of Celularity Inc.
appearing in this annual report on Form 10-K are the property of Celularity Inc. This annual report on Form 10-K also contains registered
marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the
property of their respective holders. Solely for convenience, trademarks and trade names referred to, including logos, artwork and other visual displays, may appear without
the &#174; or &#8482; symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert,
to the fullest extent under applicable law, their rights thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On February 28, 2024, we
effected a 1-for-10 reverse stock split of our outstanding shares of Class A common stock. Unless specifically provided otherwise herein,
all share and per share information in this annual report on Form 10-K has been adjusted to reflect the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><span style="text-decoration: underline">SUMMARY RISK FACTORS</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our business involves significant
risks. Below is a summary of the material risks that our business faces, which makes an investment in our securities speculative and risky.
This summary does not address all these risks. These risks are more fully described below under the heading &#8220;Risk Factors&#8221;
in Part I, Item 1A of this annual report on Form 10-K. Before making investment decisions regarding our securities, you should carefully
consider these risks. The occurrence of any of the events or developments described below could have a material adverse effect on our
business, results of operations, financial condition, prospects and stock price. In such event, the market price of our securities could
decline, and you could lose all or part of your investment. In addition, there are also additional risks not described below that are
either not presently known to us or that we currently deem immaterial, and these additional risks could also materially impair our business,
operations or market price of our Class A common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;<span style="font-size: 10pt; line-height: 112%"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">We have incurred net losses in every period since our inception, have no cellular therapeutic candidates approved for commercial sale and we anticipate that we will incur substantial net losses in the future. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 112%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">Our historical operating results indicate substantial doubt exists related to our ability to continue as a going concern. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 112%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">We will need substantial additional financing to develop our therapeutics and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our therapeutic candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 112%">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 112%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">We have substantial indebtedness, which is secured by all of our assets. Payments on our outstanding debt and debt maturities could impact our liquidity, require us to modify our operations to meet any payment obligations and could force us to seek protection under the provisions of the U.S. Bankruptcy Code. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -20pt">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our Class A common stock may be delisted from the Nasdaq and begin trading
in the over-the-counter markets if we are not successful in regaining compliance with the Nasdaq&#8217;s continued listing standards,
which may negatively impact the price of our common stock and our ability to access the capital markets.</p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 107%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 107%">If sales of our currently commercialized biomaterial products decline significantly and we do not have alternative products to market, our business would be significantly harmed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 120%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">Our placental-derived cellular therapy candidates represent a novel approach to cancer, infectious and degenerative disease treatments that creates significant challenges. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 107%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 107%">We rely on distribution arrangements for the sale of our biomaterials products. We may incur costs to meet demand forecasts that do not materialize or we may be unable to meet demand if our distribution partners do not provide adequate forecasts.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 107%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 107%">Our
    commercial biomaterials business may be impacted if The Centers for Medicare &amp; Medicaid Services and Medicare Administrative
    Contractors do not reverse their Local Coverage Determination, or LCD, for skin substitute grafts and cellular and tissue-based
    products, or CTPs, before the LCD effective date of January 1, 2026.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 107%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 107%">The U.S.
    Food and Drug Administration, or FDA, regulatory approval process is lengthy and time-consuming, and we may experience significant
    delays in the clinical development and regulatory review of our therapeutic candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 107%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 107%">We operate our own manufacturing and storage facility, which requires significant resources; manufacturing or other failures could adversely affect our clinical trials and the commercial viability of our therapeutic candidates and our biobanking and degenerative diseases businesses. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 107%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 107%">We rely on donors of healthy human full-term post-partum placentas to manufacture our therapeutic candidates and biomaterials products, and if we do not obtain an adequate supply of such placentas from qualified donors, development of our placental-derived allogeneic cells may be adversely impacted.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 107%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 107%">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are inadequate, we may not be able to compete effectively in our market.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 107%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 107%">We will continue to rely on third parties to conduct potential future clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of, or commercialize, our therapeutic candidates.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 107%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 107%">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 107%"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 107%">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits or such alliances or licensing arrangements.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 107%">Our business could be materially adversely affected by the effects of health pandemics or epidemics in regions where we or third parties on which we rely have concentrations of clinical trial sites or other business operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">Some of the statements
contained in this annual report on form 10-K constitute forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking
statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions
concerning matters that are not historical facts. These statements relate to our future events, including our anticipated operations,
research, development and commercialization activities, clinical trials, operating results and financial condition. These forward-looking
statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements
to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.
Forward-looking statements may include, but are not limited to, statements about:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">the success, cost, timing and potential indications of our cellular therapy candidate development activities and clinical trials, as well as our ability to expand our biomaterials business and leverage our core expertise in cellular therapeutic development and manufacturing to generate revenues by providing contract manufacturing and development services to third parties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">the size of the markets for our therapeutic candidates and biomaterials products, and our ability to serve those markets;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">the timing of the initiation, enrollment and completion of planned clinical trials in the United States and foreign countries;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">our ability to obtain and maintain regulatory approval of our therapeutic candidates in any of the indications for which we plan to develop them, and any related restrictions, limitations, and/or warnings in the label of any approved therapeutic;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">our ability to regain compliance with Nasdaq&#8217;s continued listing standards;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">our ability to obtain funding for our operations, including funding necessary to complete the clinical trials of any of our therapeutic candidates;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">our ability and plans to research, develop, manufacture and commercialize our therapeutic candidates, as well as our degenerative disease products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">our ability to attract and retain collaborators with development, regulatory and commercialization expertise;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">our ability to successfully commercialize our therapeutic candidates and biomaterials products and the ability for such therapeutic products and biomaterials products to qualify for reimbursement;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">our ability to develop and maintain sales and marketing capabilities, whether alone or with potential future collaborators;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">our estimates regarding future expenses, revenues, capital requirements and needs for additional financing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">our use of cash and other resources; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">our expectations regarding our ability to obtain and maintain intellectual property protection for our therapeutic candidates, degenerative disease products, and our ability to operate our business without infringing on the intellectual property rights of others.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In some cases, you can
identify these forward-looking statements by the use of terminology such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221;
&#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221;
&#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;outlook,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221;
&#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;strive,&#8221; &#8220;target,&#8221; &#8220;will,&#8221;
&#8220;would&#8221; and the negative version of these words or other comparable words or phrases, but the absence of these words does
not mean that a statement is not forward-looking. These statements reflect our current views with respect to future events, are based
on assumptions and are subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on
these forward-looking statements. We discuss many of these risks in greater detail under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s
Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this annual report on Form 10-K. Because forward-looking
statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond
our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected
in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the
forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Moreover, we operate in a
very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict
all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks,
uncertainties and assumptions, the forward-looking events and circumstances discussed in this annual report may not occur and actual results
could differ materially and adversely from those anticipated or implied in the forward-looking statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">You should not rely upon forward-looking
statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the
forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility
for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking
statements for any reason after the date of this annual report on Form 10-K to conform these statements to actual results or to changes
in our expectations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">You should read this annual
report on Form 10-K and the documents that we reference in this annual report on Form 10-K completely and with the understanding that
our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary
statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events, changed circumstances, or otherwise. Readers are cautioned not to place
undue reliance on the forward-looking statements, which speak only as of the date of this annual report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><span id="a_001Yosu3"></span>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><span id="a_001Yosu1"></span>Item 1. Business.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are a regenerative and
cellular medicines company focused on addressing aging-related and degenerative diseases. We believe that by harnessing the placenta&#8217;s
unique biology and ready availability, we will be able to develop therapeutic solutions that address a significant unmet global need for
effective, accessible and affordable therapeutics. Our advanced biomaterials business today is comprised primarily of the sale of Biovance
3L and Rebound product lines, both directly and through our distribution network. Biovance 3L is a tri-layer decellularized, dehydrated
human amniotic membrane derived from the placenta of a healthy, full-term pregnancy. It is an intact, natural extracellular matrix that
provides a foundation for the wound regeneration process and acts as a scaffold for restoration of functional tissue. Rebound is a full
thickness extracellular matrix that contains amnion and chorion. We are developing new placental biomaterial products to deepen the biomaterials
commercial pipeline. We also develop off-the-shelf placental-derived allogeneic cell therapy product candidates including mesenchymal-like
adherent stromal cells, or MLASCs, for which we have clinical datasets from Phase I and Phase II clinical studies and are prioritizing
advanced stage programs in diabetic foot ulcer, or DFU, and Crohn&#8217;s Disease, or CD. It also includes natural killer, or NK cells,
product candidates for which we have clinical datasets from Phase I and Phase II clinical studies and are currently investigating in preclinical
studies as senoablatant candidates. We also are leveraging our core expertise in cellular therapeutic development and manufacturing to
generate revenues by providing contract manufacturing and development services to third parties. The initial focus of this new service
offering is to assist development stage cell therapy companies and others with the development and manufacture of their therapeutic candidates
for clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are working toward a set
of milestones with respect to off-the-shelf placental-derived allogeneic biomaterial product candidates and cell therapy product candidates,
respectively. With respect to our biomaterial product candidate pipeline, we expect to submit a 510(k) application for our Celularity
Tendon Wrap, or CTW, in the second half of 2025. We expect to advance the development of our FUSE Bone Void Filler, or FUSE, with the
objective of a 510(k) filing in the second half of 2026, and to advance the development of our Celularity Placental Matrix, or CPM, with
the objective of a 510(k) filing in the second half of 2027. With respect to our MLASCs cell therapy product candidate for DFU (PDA 002),
we expect in the first half of 2025 to request an end of Phase 2, or EOP2, meeting with the FDA as part of which we intend to discuss
with the FDA our Phase 3 plan and protocols. In addition, with respect to our MLASCs cell therapy product candidate (PDA 001), we expect
to complete, in the first half of 2025, our safety and efficacy assessment of previously generated data that is one factor in determining
whether to progress our MLASCs cell therapy product candidate in CD to a Phase 3 clinical trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our Celularity IMPACT manufacturing
platform is a seamless, fully integrated process designed to optimize speed and scalability from the sourcing of placentas from full-term
healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific chemistry, manufacturing
and controls, or CMC, advanced cell manufacturing and cryopreservation. The result is a suite of allogeneic inventory-ready, on demand
placental-derived cell therapy products. We also operate and manage a commercial biobanking business that includes the collection, processing
and cryogenic storage of certain birth byproducts for third-parties. A biobank is an organized collection of biological human material,
and its associated information stored for future retrieval and use in research, regenerative medicine, and innovation. We provide a fee-based
biobanking service to expectant parents who contract with us to collect, process, cryogenically preserve and store certain biomaterial,
including umbilical cord blood and placenta derived cells and tissue. We receive a one-time fee for the collection, processing, and cryogenic
preservation of the biomaterials, and a storage fee to maintain the biomaterials in our biobank payable annually generally over a period
of 18 to 25 years. We intend to explore opportunities to diversify our biobanking business, including adult cell banking.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our current science is the
product of the cumulative background and effort over two decades of our seasoned and experienced management team. We have our roots in
Anthrogenesis Corporation, or Anthrogenesis, a company founded under the name Lifebank in 1998 by Robert J. Hariri, M.D., Ph.D., our founder
and Chief Executive Officer, and acquired in 2002 by Celgene Corporation, or Celgene. The team continued to hone their expertise in the
field of placental-derived technology at Celgene through August 2017, when we acquired Anthrogenesis. We have a robust global intellectual
property portfolio comprised of over 290 patents and patent applications protecting our Celularity IMPACT platform, our processes, technologies
and cell therapy programs that we are actively developing on our own or seeking to out-license or to find a collaboration partner to develop.
We believe this know-how, expertise and intellectual property will drive the rapid development and, if approved, the commercialization
of these potentially lifesaving therapies for patients with unmet medical needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Our Advanced Biomaterial Products</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We develop and market off-the-shelf
placental-derived allogeneic advanced biomaterial products including allografts and connective tissue matrices for soft tissue repair
and reconstructive procedures in the treatment of degenerative disorders and diseases including those associated with aging. Our advanced
biomaterial products include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">Biovance&#174;, a human amniotic membrane allograft designed to cover or offer protection from the surrounding environment in soft tissue repair and reconstructive procedure.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">Biovance&#174;3L, a Tri-Layer Biovance&#174; human amniotic membrane allograft designed for use as a covering, barrier, or wrap to surgical sites.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">Biovance&#174; 3L Ocular, a tri-layer Biovance&#174; human amniotic membrane allograft designed to support the treatment of ocular surface disease and ocular surgical applications.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">Interfyl&#174;, a decellularized human placental connective tissue matrix designed for use to replace or supplement damaged or inadequate integumental tissue.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">CentaFlex&#174;, a decellularized human placental matrix allograft derived from human umbilical cord designed for use as a surgical covering, wrap, or barrier to protect and support the repair of damaged tissues.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">Rebound<sup>TM</sup>, a full thickness, placental derived extracellular matrix that contain amnion and chorion for use as a wound covering or barrier to protect and support full thickness wounds. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We also are developing new
placental-derived advanced biomaterial products to deepen our commercial pipeline. We plan to explore opportunities to generate revenue
and leverage our core expertise in advanced biomaterial product manufacturing by providing contract manufacturing services under which
we manufacture one or more of our advanced biomaterial products for a distributor to sell under its own brand name(s). We also pursue
opportunities to generate revenues that leverage our core expertise in cellular therapeutic development and manufacturing by providing
contract manufacturing and development services to third parties. Contract manufacturing and development optimization services can help
accelerate translational and clinical discoveries and mitigate the complexity and risk associated with introducing new cell therapeutics,
including process variability, vulnerable supply chains, and manufacturing capacity constraints on scalability. Likewise, our biomaterial
contract manufacturing and development services support scale-up for small and large commercial volumes, including tissue procurement,
prototyping, private branding, and product distribution. Leveraging over three decades of experience in human tissue procurement and biobanking,
we maintain a supply of cryopreserved placental tissue procured from informed consent donors so it is available on demand to be converted
rapidly to finished biomaterial products, thereby addressing the structural vulnerabilities and inefficiencies inherent to most tissue
supply chains.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>Addressable Markets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">According to Global Market
Insights, the global tendon repair market was valued at approximately $2.2 billion with a 10-year compounded annual growth rate of
7.8% and the global bone graft substitute market was valued at approximately $3.4 billion with a 10-year compounded annual growth
rate of 6.8%. Furthermore, according to Nova 1 Advisors, the U.S. wound care market was valued at approximately $14.6 billion
with a 10 year compounded annual growth rate of 5.1% and, according to Allied Market Research, the global dermal filler market is
estimated to be approximately $5.1 billion with a 10 year compounded annual growth rate of 10.8%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>Our Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our goal is to lead the next
evolution in regenerative and cellular medicine by delivering off-the-shelf allogeneic cellular therapies, at greater scale and quality
with attractive economics. We believe achieving this goal will result in placental-derived allogeneic cellular therapies becoming a standard
of care in various indications across aging-related and degenerative diseases, and enable us to make potentially lifesaving therapies
more readily accessible to more patients throughout the world. We plan to achieve this mission by:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;<span style="font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><b><i>Leveraging the inherent advantages of placental-derived cells.</i></b> Our cells come from the postpartum placenta donated by healthy donors who have signed an informed consent, representing a renewable, economical, and highly scalable starting material collected under rigorous controls. We use those cells to produce on-demand, off-the-shelf investigational allogeneic cellular therapy products that are designed to sidestep treatment delays inherent to autologous cellular therapies and other allogeneic cellular therapy approaches, all while offering the potential for greater <i>in vivo</i> expansion, persistence, potency, and acceptance. Further, we believe the immunological na&#239;vet&#233; of placental cells may allow for potentially less toxicity.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 115%"><b><i>Capturing efficiencies through our integrated Celularity IMPACT platform.</i></b> Manufacturing allogeneic cell therapeutic candidates involves a series of complex and precise steps. We believe a critical component to our success will be to leverage our rapidly scalable, end-to-end supply chain. Applying proprietary manufacturing know-how, expertise and capacity utilizing our purpose-built U.S.-based cGMP, compliant facility, we believe our fully integrated manufacturing operations and infrastructure will allow us to improve the manufacturing process, eliminate reliance on other contract manufacturing organizations, or CMOs, and more rapidly advance therapeutic candidates. We also plan to leverage this core expertise to generate revenues by providing contract manufacturing and development services to third parties.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 115%"><b><i>Selectively targeting indications with unmet patient need with potential for accelerated development.</i></b> Our pipeline reflects our intent to leverage the unique biology of the placenta to develop placental-derived allogeneic cells for indications where the demonstrated properties of such cells could provide an advantage, both in terms of development (sourcing and proliferation) and potential efficacy (affinity). In selecting indications, we evaluate where the biological properties of placental-derived cells position them for success, as well as where there is a clearly defined regulatory pathway providing the potential for accelerated development to address unmet patient need.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%"><b><i>Growing our existing commercial business and deepening the pipeline of placentally derived biomaterial products. </i></b>We intend to grow our existing commercial business through higher volumes of product sold through existing domestic distribution relationships and potentially through distribution relationships outside of the United States. We plan to continue to invest in new biomaterials programs, some or all of which may require different regulatory pathways than Section 361 HCT/Ps. We are currently developing a tendon wrap indicated for the management and protection of tendon injuries in which there has been no substantial loss of tendon tissue. We are also developing a bone void filler product for use in orthopedic surgical markets. We have preliminary data from a knee osteoarthritis animal model that placentally derived extracellular matrix may decrease joint pain and promote chondrogenesis in damaged cartilage. These products were developed in part to achieve two goals: first, to address significant unmet needs in their particular medical specialties; and second, to accommodate likely changes in the reimbursement environment under the control of the Center for Medicare &amp; Medicaid Services, or CMS.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 115%"><b><i>Continuing to invest in basic and translational research. </i></b>We intend to continue to invest in the discovery and development of additional pipeline cell franchises and explore other placental-derived cell opportunities. Preclinical and early clinical data demonstrating the unique biological activity and potential of placental-derived stem cells, provide potential for multiple highly effective cellular therapy programs targeting aging-related and degenerative diseases.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%"><b><i>Benefiting from collective experience of deep, seasoned management team.</i></b> We have a deep, seasoned management team with experience in all aspects of regenerative and cellular medicine, including discovery and translational research, clinical development and product approval, process development and manufacturing, and commercialization. For over two decades, the team has been at the vanguard of regenerative and cellular medicine, and has collectively seen a number of programs through FDA-approval to commercialization.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>Our Pipeline</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Leveraging our Celularity
IMPACT platform, we can derive four allogeneic cell types from a single source material, the postpartum human placenta: T cells, or pT
cells; unmodified NK cells, or pNK cells, or CYNK-001; MLASCs, or PDA-001 and PDA-002; and HPDSCs, or PSC-100. In 2022, we had active
and approved clinical trials under development utilizing CYNK-001, a placental derived unmodified NK cell, for the treatment of AML, a
blood cancer, and for glioblastoma multiforme, or GBM, a solid tumor cancer. We also had an active clinical trial utilizing CYNK-101,
a genetically modified NK cell, for the treatment of HER2+ gastric cancer. Due to a need to prioritize corporate resources, in January
2023 we announced our intention to cease recruitment in the GBM and the HER2+ gastric trials. In addition, in April 2023, we announced
based on the preliminary results of the Phase 1 trial data of CYNK-001, the AML trial would be closed to further enrollment and completed
follow up. We are not actively investigating CYNK-001 for any indication although we are evaluating it in senolytic/senoablation for age-related
conditions while we seek a collaboration partner. During the second quarter of 2023, we fully impaired the in-process research and development,
or IPR&amp;D, assets associated with CYNK-001. In the first quarter of 2022, we submitted an IND to investigate CYCART-19, a placental-derived
CAR-T cell therapy targeting the cluster of differentiation 19, for the treatment of B-cell malignancies. In late May 2022, we received
formal written communication from FDA requesting additional information before we could proceed with the Phase 1/2 clinical trial. After
assessing the status of the IND to determine an optimal path forward for the CYCART-19 program, we elected to terminate development of
CYCART-19 for B-cell malignancies during the third quarter of 2023 and have discontinued our internal CYCART development efforts. We may
continue pre-clinical development of other T-cell candidates. MLASC is in development for the treatment of Crohn&#8217;s disease, and
other degenerative diseases. Due to an internal alignment of corporate resources, we paused development in exosomes to focus on other
priorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, we can derive
genetically modified versions of three of these cell types: a pT cell that is genetically modified with a CAR, or CYCART; a pNK cell that
is genetically modified with a CAR, or CYNK; and a MLASC that is genetically modified via CRISPR-mediated tissue factor gene knockout,
or APPL. We also are researching a placenta-derived adherent cell exosome, or pEXO, and an exosome derived from a placental-derived immune
cell such as a pT cell or a pNK cell.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In the fourth quarter 2023
following a strategic review, we refocused our cellular therapeutics pipeline. We plan to continue to develop T cell and NK cell products
at the IND-enabling study stage to target aging-related and degenerative disease indications. These programs have built on the learnings
from our previous clinical programs to help us ensure we have product candidates that are optimized for efficacy, safety, and persistence
to offer first-in-class or best-in-class potential. We have developed a novel approach to addressing age-related conditions by using our
healthy young NK cell to attack and destroy senescent cells using the mechanism of attacking stress-ligand expressing cells, a process
we have termed &#8220;senoablation&#8221;. Data on our preclinical NK cell senoablation study has also been submitted for presentation
at the American Society of Gene and Cell Therapy. We continue to assess opportunities to advance our preclinical autoimmune candidates,
modified NK cells and T cells, in SLE, scleroderma and multiple sclerosis. We are evaluating CYNK-001 and seeking collaboration partners
in senolytic/senoablation for aging-related conditions. We also plan to continue to explore the opportunity to investigate PDA-001 and
PDA-002 to build on our existing data for our MLASC in Crohn&#8217;s disease, an autoimmune disease that leads to chronic inflammation
of the gastrointestinal tract; Facioscapulohumeral muscular dystrophy, or FSHD, a rare progressive genetic muscle disease; and Sarcopenia,
or age-related muscle loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<img src="form10-k_001.jpg" alt="" style="height: 300px; width: 670px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt; line-height: 115%">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-size: 10pt; line-height: 115%"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Also following a strategic
review in fourth quarter 2023, we reconfirmed our advanced biomaterial product pipeline&#8217;s focus on three developmental-stage medical
devices intended to treat aging-associated and other degenerative diseases and disorders characterized by the progressive loss of function
and/or structure of the affected tissues. The three medical devices are Celularity Tendon Wrap, or CTW, Celularity Bone Void Filler, or
CBVF, and Celularity Placental Matrix, or CPM. We are developing our CTW medical devices for the treatment and management of tendon injuries
in which there has been no substantial loss of tendon tissue as a structural barrier for injured tendon tissue and does not depend on
chemical action (pharmacological activity) to mediate this effect. We are developing our CBVF medical device for use as a passive osteoconductive
bone filler in the pelvis, extremities, and posterior-lateral spinal fusion settings as well as other skeletal defects that are not dependent
on chemical action to mediate an effect. We are developing our CPM medical device for use as a passive temporary wound covering which
is not meant to achieve its primary intended purpose through chemical action (pharmacological activity) and is not dependent on being
metabolized for the achievement of its intended purpose. CPM is a fully resorbable device composed of extracellular matrix, or ECM derived
from decellularized human placental tissue and intended to treat partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic
ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds. We intend to seek premarket
review and clearance by the FDA for CTW, CBVF and CPM through the 510(k) premarket notification procedure. With respect to our biomaterial
product candidate pipeline, we expect to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">Submit a 510(k) application for CTW in the second half of 2025.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">Advance the development of CBVF with the objective of a 510(k) filing in the second half of 2026.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">Advance the development of CPM with the objective of a 510(k) filing in the second half of 2027.</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 10pt; line-height: 115%"><img src="form10-k_002.jpg" alt="" style="height: 380px; width: 670px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.1in; text-align: justify">TCR KO = T-cell receptor knock out, TF
KO = tissue factor knock out, MCL = mantle cell lymphoma</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Regulatory Pathway denotes FDA submissions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We also intend to develop
and commercialize cellular medicine therapeutic product candidates, advance our preclinical pipeline, and utilize our technical operations
infrastructure and expertise in multiple clinical areas, subject to the availability of research funding and the prioritization described
above regarding our three developmental-stage medical devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Mesenchymal-like Adherent Stromal Cells (MLASCs)/Placenta-Derived
Adherent Cells (PDA)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">PDA cells are a mesenchymal-like
cell population derived from normal, full-term human placental tissue. PDA-001 for intravenous administration and PDA-002 for intramuscular
administration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">PDA-001: Five indications
were studied with PDA-001 product among 88 patients. CD was the first indication where in one Phase 1, one Phase 2a, and one Phase 1b
studies were completed among 53 patients. The first Phase I clinical study involved investigating two dose levels of PDA-001 (150 million
and 600 million cells) among six patients each. On both day 365 and day 730, a clinical response of 83% and a clinical remission of 50%
were observed among the 150 million PDA-001 cell group after only two doses of treatment. During the second Phase 2a study, the primary
efficacy endpoint of clinical response at both weeks four and six was achieved in 33.3% of patients who received 150 million PDA-001 cells
in comparison to 0% response within the placebo group. The secondary endpoint of clinical remission was noted to be 13.3% in patients
who received 150 million PDA-001 cells versus 0% in the placebo group. In the third Phase 1b study, a lower dose of 37 million PDA-001
cells was investigated with only seven patients treated among the PDA-001 group versus five patients within the placebo group. The PDA-001
cell group demonstrated a 42% clinical response and 28% clinical remission versus 0% placebo patients that were assessed on the day 365
follow-up visit. The overall safety among all three studies was concluded to be favorable with Grade 1 and Grade 2 local thrombophlebitis
being the most common adverse event.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The second indication with
PDA-001 included a Phase 2a Multiple Sclerosis study where six patients in each of the two dose levels of PDA-001 (150 million and 600
million cells) were compared to four patients within the placebo group. The study met the primary endpoint of Cutter&#8217;s rule ( &#8805;
five new lesions present on two consecutive monthly scans), warranting a proof-of-concept study. The remaining three indications for PDA-001
cells included Rheumatoid arthritis (17 patients), stroke (two patients), and Sarcoidosis (four patients) which were closed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">PDA-002: Two indications
were studied with PDA-002. DFU with or without Peripheral Artery Disease was the first indication wherein one Phase I and one Phase II
studies were completed. The Phase II study was a randomized, placebo-controlled, double-blind study that investigated two doses of PDA-002
intramuscularly at three dose levels (3 x 106, 10 x 106, 30 x 106 cells) versus placebo. Safety was well-tolerated with injection-site
reactions being the most comment adverse event among the 145 patients. The primary efficacy endpoint was the rate of response, defined
as complete wound closure within three months after dosing and retention of wound closure for the subsequent four weeks. The highest response
rate, observed in the 3 x 106 PDA-002 cells group was 38.5% compared to the 22.6% response rate within the placebo group. The response
rates were 29.6% in the 10 x 106 PDA-002 cells group and 35.7% in the 30 x 106 PDA-002 cells group. A sub-group analysis was conducted
to compare the ulcer closure at 12-week and 20-week timepoints with the currently approved FDA products which demonstrated equivalent
closure rate of 42.8% and 53.8% with 3 x 106 PDA-002 dose level.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Diabetic Peripheral Neuropathy
was the second indication that involved a Phase 2a study wherein 16 patients were treated with PDA-002 cells versus nine patients with
placebo. The safety was well-tolerated. An increase in nerve fiber density was observed, warranting a proof-of-concept study.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">CYNK-001 [discontinued internal
development in oncology]: CYNK-001 is an allogeneic off-the-shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental
CD34+ cells. We conducted four clinical trials of CYNK-001 among four indications: the CYNK-001-AML-001 is a Phase 1, open-label dose-escalation
study in adults with either Minimum Residue Disease, or MRD, or Relapsed/Refractory, or R/R, AML patients. In December 2023, the results
of this study were presented at the American Society of Hematology. A total of eight patients (17 with R/R AML and 11 with MRD positive
AML) were enrolled during dose escalation, and 27 received at least one dose of CYNK-001. In R/R AML patients treated, three of the six
patients achieved an objective response of Morphologic Leukemia-Free State on day 28. One of the three patients with MRD positive patients
achieved MRD negativity until day 120.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The remaining three clinical
studies were completed in Multiple Myeloma (CYNK-001-MM-002), Glioblastoma (CYNK-001-GBM-001), and COVID-19 (CYNK-001-COVID-19) wherein
a total of nine, three, and seven subjects were treated respectively. The safety was well-tolerated among all 46 patients with Grade 1
and 2 Cytokine Release Syndrome being the most common adverse event. There were no events of GvHD associated with the CYNK-001 treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are evaluating CYNK-001
and seeking collaboration partners in senolytic/senablation for age-related conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">CYNK-101 [discontinued internal
development]: CYNK-101 is a human placental hematopoietic stem/progenitor cell derived NK cell product, that is genetically modified to
express a variant of CD16, Fc gamma receptor III (Fc&#947;RIII), via lentiviral vector transduction. We initiated a Phase 1 open-label
study of CYNK-101 in combination with Trastuzumab and Pembrolizumab in newly diagnosed patients with Locally Advanced Unresectable or
Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma. One patient was treated with five doses of CYNK-101
with no reported safety concerns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Celularity IMPACT Platform</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Placental-derived cellular
therapies offer potentially lifesaving therapies for patients with unmet medical needs. We have developed and acquired proprietary technology
for collecting, processing, and storing placental stem cells with potentially broad therapeutic applications in the treatment of aging-associated
and other degenerative disorders and diseases. These span various therapeutic areas for which aging is known to be a major risk factor,
including cancer, regenerative medicine, and immune disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Common to all degenerative
disorders and diseases is the progressive loss of function or structure (or both) of affected tissues and organs based on a continuous
process of degenerative cell changes. We use our proprietary Celularity IMPACT platform for the development of allogeneic cellular therapies
that we believe exert immunomodulatory and regenerative effects. Immunomodulation is the regulation and modulation of immunity achieved
by reducing or enhancing the immune response, for example, promoting immune tolerance to cellular therapies. We believe that by harnessing
the placenta&#8217;s unique biology and ready availability, we will be able to develop therapeutic solutions that address a significant
unmet global need for effective, accessible, and affordable therapeutics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our Celularity IMPACT manufacturing
process is a seamless, fully integrated process that is built to optimize speed and scale, from the sourcing of human full term healthy
postpartum placentas from informed consent donors through proprietary processing methods, cell selection, product-specific CMC, advanced
cell manufacturing, and cryopreservation resulting in allogeneic inventory-ready and on-demand cellular therapy products. The fully integrated
process is housed in our purpose-built manufacturing, translational research, and biobanking facility located in Florham Park, NJ.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our Celularity IMPACT platform
capitalizes on our integrated processes and the unique biologic characteristics of placental-derived allogeneic cells to target degenerative
disorders and diseases including those associated with aging that span various therapeutic areas including cancer, regenerative medicine,
and immune disorders, and infectious diseases. The platform is designed to accelerate the speed at which therapies can be provided to
patients while ensuring manufacturing excellence of high quality and pure placental-derived cellular therapy products at a lower cost.
We believe our IMPACT platform enables cellular therapy inventory to be available to physicians on demand to treat patients in need and
to enable repeat dosing regimens that other cellular therapy platforms will not be able to support.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-size: 10pt; line-height: 115%"><img src="form10-k_003.jpg" alt="" style="height: 298px; width: 670px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Allogeneic Placental-Derived Cells</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Biomaterials Collection</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The initial source material
for our four allogeneic cell types is the postpartum human placenta. We source human placental birth material used for the manufacture
of our products from accredited hospitals and birth centers, with collections performed by licensed health care professionals. Eligibility
for donation is determined by a donor screening process that includes education about the donor program, obtaining informed consent from
the donor, and completion of a detailed maternal health questionnaire and family health history. These forms are completed by the donor,
with assistance from trained collection technicians as needed. Donors providing birth materials do not encounter any fees and are not
renumerated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Licensed health care professionals
collect donor material utilizing our proprietary collection kits, which include barcode labels for biomaterials (cord blood, placenta,
and maternal blood samples) along with appropriate chain of custody documentation. Once collected, the donated material and a maternal
blood sample are shipped in an insulated container via courier to our Florham Park, New Jersey laboratory and manufacturing facility.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upon arrival at our facility,
the donated material is reviewed for labeling completeness and accuracy of the barcoded kit and is electronically coded into a validated
software database. If all quality criteria are met, the donated material is then individually evaluated and forwarded to the appropriate
production suite for processing and manufacturing. We believe that our sourcing is rapidly scalable due to numerous established procurement
relationships that provide a constant renewable supply to meet current and future manufacturing needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Unique Biology of Placenta-Derived Cells</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Placental-derived cells
have unique biology related to immunological na&#239;vet&#233;, stemness, persistence and proliferation that makes them a biologically
preferred starting material with the potential for less toxicity and superior biological activity relative to adult bone marrow or peripheral
blood-derived cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Research has shown that
the human placenta is a novel and valuable source of multi potential stem/progenitor cells of mesenchymal and hematopoietic origin, which
have multiple therapeutic applications. Our characterization data show that approximately one to five percent of placental-derived cells
are CD34+ hematopoietic stem cells, or HSCs, among which expression of certain markers suggests that such HSCs have more self-renewal
capacity and the potential to facilitate the early engraftment of the placental-derived cells. In addition, further characterization has
shown low T-cell content and immature T subpopulations. This demonstrated immunological na&#239;vet&#233; further suggests the potential
for low or no GvHD in transplant. Furthermore, mesenchymal-like cells have been shown to possess other characteristics, capabilities,
and effects (e.g., osteogenic, chondrogenic, adipogenic differentiation capabilities and immunomodulatory effects). The high quantity
of mesenchymal-like cells and Treg cells indicate that placental-derived cells can potentially contribute to prevention of GvHD and host
microenvironment modulation. In summary, we believe the stemness, potential capacity of proliferation and persistence of placental-derived
cells support multiple potential therapeutic applications, including those in development by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are also researching placental-derived
exosomes for potential therapeutic applications. Exosomes are a kind of extracellular vesicle that act as communication channels between
cells and cause functional changes in recipient cells. Exosomes enable intercellular communication by transferring specific cargo contents
to a recipient cell and can confer epigenetic changes in the recipient cells by delivering microRNAs, or miRNAs. Exosomes have been identified
as the primary factors responsible for paracrine effects detected in all types of stem cells and for the transfer of genetic material
from stem cells to the tissue-specific cell that needs regeneration. Exosomes have been shown to possess powerful regenerative potential,
including immune-modulatory properties and anti-inflammatory properties. We discovered a type of exosome that we call a placenta-derived
adherent cell exosome, or pEXO. Rich in growth factors, deoxyribonucleic acid, or DNA, fragments, miRNAs, and messenger RNAs, pEXO exhibit
particular markers that distinguish them from other exosomes that are not derived from placenta-derived adherent cells. We are investigating
purified pEXO formulated into pharmaceutical compositions for human administration to promote angiogenesis and/or vascularization, to
modulate immune activity, and to repair tissue damage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Overview of CAR-T Cells</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">White blood cells are a component
of the immune system and responsible for defending the body against infectious pathogens and other foreign material. T cells are a type
of white blood cell and are involved in both sensing and killing infected or abnormal cells, including cancer cells, as well as coordinating
the activation of other cells in an immune response.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Unlike adult peripheral
blood mononuclear cell, or PBMC, derived T cells, placental-derived T cells are mostly na&#239;ve and can be readily expanded while maintaining
an earlier differentiation phenotype, such as greater expression of na&#239;ve/memory markers and lower expression of effector/exhaustion
markers. These characteristics allow for greater proliferative potential of these cells <i>ex vivo</i>. Placental-derived T cells are
also known to have greater immune tolerance and display impaired allogeneic activation, contributing to lower incidences of severe GvHD,
which makes them an attractive cell population for use as an allogeneic, adoptive cellular therapy. We have developed a robust process
for the isolation, transduction, and expansion of placental-derived T cells to generate &#8220;off-the-shelf&#8221; allogeneic CAR-T cells.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Allogeneic human placental
T cells are derived from healthy donor placentas. We separate out mononuclear cells using a mononuclear cell separation method to isolate
placental T cells prior to cryopreservation. Our allogeneic CAR-T cell product begins with the thawing and activation of the isolated
placental T cells, followed by viral transduction of the cancer-targeting CAR construct and an additional genetic modification step to
minimize any risk of GvHD. Once transduced and transfected, the CAR-T cells are expanded to yield large quantities of these cells prior
to harvest, final formulation, and cryopreservation of the cellular therapeutic.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Overview of NK cells &#8212; Unmodified
and Genetically Modified</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">NK cells are potent effector
cells of the innate immune system responsible for identifying and eliminating abnormal and stressed host cells. They are equipped with
NK cell-specific activating receptors that recognize conserved antigens induced by cellular stress while being simultaneously tuned with
inhibitory receptors to avoid mistakenly targeting healthy cells. NK cells are particularly relevant in combating viral infections and
mediating anti-tumor immunity in which normal cellular processes are stressed for the purposes of perpetuating viral infection and cancer
cell proliferation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Commercializing NK cellular
therapies has been limited by the difficulty and cost to scale the production of mature NK cells for clinical dosing. Utilizing our Celularity
IMPACT platform, our proprietary process has mitigated these limitations by expanding and differentiating placental-derived stem cells
into NK cells over a period of 35 days. We derive the HSCs from healthy donor placentas, then propagate and differentiate these cells
into NK cells. This process can produce hundreds of doses per donor placenta. We also developed technologies that can achieve high genetic
modification efficiency by transducing placenta HSCs and producing downstream stable gene modified CYNK cells with enhanced cancer killing
activities. These cells are then cryopreserved and available to be shipped upon request.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For our genetically modified
NK cells, our allogeneic modified NK cell product begins with the thawing and activation of the isolated placental NK cells. We then use
a lentiviral vector transduction to augment the effector functions of the NK cells and to sustain their tumor-killing properties. We believe
that our genetically modified NK cells can be used in combination with therapeutic mAbs to boost antibody-dependent cellular cytotoxicity,
or ADCC, potential.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Overview of MLASCs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Placental-derived MLASCs
are a novel, culture-expanded mesenchymal-like cell population derived from placental tissue. <i>In vivo</i>, we demonstrated that MLASCs&#8217;
immune-modulatory properties alleviate autoimmunity and possess anti-inflammatory activity. Both intravenous and intramuscular administration
formulations of the first generation of MLASCs have been developed and investigated in clinical studies in Crohn&#8217;s Disease, multiple
sclerosis, rheumatoid arthritis, stroke, diabetic foot ulcers and diabetic peripheral neuropathy. We are developing next generation genetically
modified MLASCs for the treatment of degenerative diseases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Allogeneic human placental
MLASCs are derived from healthy donor placentas. Our allogeneic MLASC product begins with the thawing and activation of the isolated placental-derived
MLASCs, followed by genetic modification of tissue factor to reduce potential toxicities and lower risk of adverse effects. Once modified,
we expand the MLASCs to large quantities prior to harvest, final formulation, and cryopreservation of the cellular therapeutic.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Overview of Exosomes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Exosomes are acellular, nano-size
lipid bilayer membrane particles released by cells into extracellular space and play important roles in cell to cell, tissue to tissue
and organ to organ communications. Also referred to as intraluminal vesicles, or ILVs, exosomes are a subtype of extracellular vesicles,
or EVs, along with microvesicles, or MVs, and apoptotic bodies from which exosomes are differentiated based upon their biogenesis, release
pathways, size, content, and function. Exosomes are generated from late endosomes with 30-200 nanometers in diameter. When fused with
the targeted cells, the molecular cargos (e.g., proteins, lipids, DNAs, mRNAs, and microRNAs) carried by exosomes are inserted into the
cells to exert the functions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Recently, exosomes are being
recognized as promising candidates in the treatment of degenerative diseases. Evidence has suggested that part of the observed cell therapeutic
effects is mediated by exosomes and that mesenchymal stem cell exosomes can act as a therapeutic entity to help reduce tissue injury or
when it occurs, to contribute to injury recovery. Other evidence suggests exosome-based therapy may be superior in anti-senescence and
anti-inflammatory effects to stem cell&#8211;based therapy. Exosome therapy has certain advantages over cellular therapy such as: low/non-immunogenicity,
easy storage, and administration. In addition, due to their nano-size, exosomes can cross the brain-blood barrier and be delivered to
broader target tissues and organs than cell-based therapeutics.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">pExo-001 is a human postpartum
placenta derived exosome product which consists of cytokines, chemokines, and growth factors that have been reported to have regenerative
and immuno-regulatory activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Allogeneic Cellular therapies &#8212; an
&#8220;Off-the-Shelf&#8221; Approach</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">There are two primary approaches
to engineered cellular therapies: autologous and allogeneic. Autologous therapies use engineered cells derived from the individual patient,
while allogeneic therapies use cells derived from an unrelated third-party healthy donor. We believe our human placental-derived allogeneic
platform is leading the next evolution of cellular medicine because we aim to deliver off-the-shelf allogeneic cellular therapies, at
greater scale and quality with attractive economics, potentially making lifesaving therapies more readily accessible to more patients
throughout the world.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our human placental-derived
allogeneic cryopreserved, off-the-shelf platform currently includes placental CAR-T cells, or CYCART, NK cells MLASCs, or APPL-001, and
exosomes, or pEXO-001.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>CYCART</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Currently, autologous CAR-T
products are manufactured by isolating T cells from the patient&#8217;s blood through a process known as leukapheresis. The cancer-targeting
construct expressing specific CAR proteins is virally transduced into the T cells and the engineered T cells are then propagated until
a sufficient number are available for infusion. The engineered T cells are then shipped back to the clinical center for administration
to the patient. The process from leukapheresis to delivery to the clinical center takes approximately four weeks. While the autologous
approach has been revolutionary, with other companies&#8217; previously approved products demonstrating compelling efficacy in many patients,
it can be burdened by lengthy vein-to-vein time, high production cost, variable potency, and/or manufacturing failures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Conversely, our allogeneic
placental-derived T cells are derived from healthy donors that have undergone rigorous donor screening and selection. Manufactured drug
product can be deployed from inventory to patients immediately in sufficient quantities because administration is not limited by patient
cell sourcing and individual drug product expansion. As an &#8220;off-the-shelf&#8221; treatment, CYCART cells also offer the potential
to re-dose patients, if necessary. Healthy births are in hundreds of millions worldwide, and the placenta provides an abundant, renewable
source of healthy, ready to use lymphocytes. In addition, placental-derived T cells contain an abundance of stem cell memory T cells,
which confer high proliferation and durability. Placental T cells are known to be immune-privileged and have low donor to host toxicity,
or GvHD. We are therefore potentially a generally safer cell population. Furthermore, allogeneic placental T cells can be genetically
engineered to minimize the risk of GvHD and avoid being destroyed by the patient&#8217;s immune system. Therefore, CYCART cells may possess
an advantageous safety profile while delivering effective tumor eradication activity and durable persistence in patients. Our CYCART development
efforts were previously under IND for cancer and has been discontinued internally. We will seek to out-license the technology or find
a collaboration partner to further develop.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>CYNK</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Similarly, autologous NK
cells and genetically modified autologous NK cells have been used in the setting of immuno-oncology. NK cells can directly kill cancer
cells by recognizing signals of cellular stress and carry no risk of GvHD. However, autologous peripheral blood derived NK cells have
limited proliferation capacity and usually require leukemia cell line-based technology to assist production. In addition, autologous CAR-NK
was shown to encounter technical challenges due to low transduction efficiency of CAR vectors in the peripheral NK cells. Our NK platform
propagates human placenta derived HSCs and differentiates these cells into unmodified NK cells (CYNK-001). This process can produce hundreds
of doses per placenta donor. We have also developed technologies that can achieve high genetic modification efficiency by transducing
placenta HSCs and produce downstream stable gene modified CYNK cells with enhanced and selective cytotoxic and senolytic activity for
potential use in age-related diseases, including cancer, and autoimmune diseases. These cells are cryopreserved and can be shipped to
clinical administration immediately upon request. Our CYNK-001 development efforts were previously under IND for cancer and has been discontinued
internally. We are evaluating CYNK-001 as a senolytic/senablatant for age-related conditions and will seek to out-license the technology
or find a development partner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>MLASCs</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Both autologous and allogeneic
bone marrow or adipose tissue derived MLASCs have been used in human clinical trials. Autologous MLASC therapies have advantages including
the absence of donor cell related adverse events and fewer regulatory hurdles since cell products are derived from a donor&#8217;s own
cells. However, autologous MLASC products carry the inherited or aging-related biological defects of the donor, which may impair therapeutic
value. Furthermore, in most cases, autologous cells still require cultivation before patient administration and there is a risk of manufacturing
failure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Conversely, allogeneic MLASCs
can provide an off-the-shelf product with high quality and flexibility of dosing. MLASCs are regarded as immune-privileged due to their
relative low-level major histocompatibility complex class I and II protein expression. Our placenta tissue derived MLASCs are potentially
more immune privileged due to their fetal origin. In addition, because MLASCs have higher proliferative capability, they are expected
to be more suitable for genetic manipulations to engineer the cells to have specific features to enhance their functions or to mitigate
risk factors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>pEXOs</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Exosomes derived from certain
cell or tissue types including mesenchymal stem cells, or MSCs, affect angiogenesis, inflammation, and bone remodeling. Recent studies
have demonstrated that MSC-derived exosomes, or MSC-EXOs, alleviate inflammation and restore matrix homeostasis in knee osteoarthritis,
or KOA, a leading degenerative joint disease in the aging population.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Therapeutic Candidate Pipeline and Development
Strategy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are researching and developing
multiple placental-derived allogeneic cellular therapeutic candidates for the treatment of indications across aging-related and degenerative
diseases. From a single source material, the placenta, we focus on four allogeneic cell types: CAR-T cells, unmodified NK cells, genetically
modified NK cells, and MLASCs. We are also researching pEXO. Our product pipeline is presented above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Future Pipeline Opportunities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We plan to utilize our Celularity
IMPACT platform to pursue additional targets of interest. These may include the additional indications for the four allogeneic cell types
currently in the pipeline as well as other targets that might be validated in the future. Our placental-derived T cell platform has potential
to target other receptors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In addition, we regularly
survey the scientific and industry landscape for opportunities to license, partner or acquire technologies that may help us advance current
or new cellular therapies for the benefit of patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our ability to prosecute
future opportunities including those with scientific and potential commercial merit may be influenced by our ability to raise sufficient
capital to pursue those opportunities or to find commercial partners that are willing and able to fund portions of their development.
Co-developed or partnered programs may have longer term economics that are less favorable than internally funded programs, but those programs
also may have higher odds of success with a well-capitalized development partner with specific expertise in the disease state under investigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Commercial Businesses</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are continuing to invest
in new biomaterials programs to expand our pipeline of placenta-derived advanced biomaterial products. We are currently developing a tendon
wrap indicated for the management and protection of tendon injuries in which there has been no substantial loss of tendon tissue; a bone
void filler product for use in orthopedic surgical markets; and a placenta-derived extracellular matrix, or PECM, for use as a passive
temporary wound covering. We have preliminary data from a knee osteoarthritis animal model that our PECM may decrease joint pain and promote
chondrogenesis in damaged cartilage. Our product pipeline is presented above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Advanced Biomaterial Products for Degenerative
Diseases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We report sales of advanced
biomaterial products within the Degenerative Disease operating segment, which includes products for use in wound care and the treatment
of degenerative disease. The National Cancer Institute defines &#8220;degenerative disease&#8221; as a disease in which the function or
structure of the affected tissues or organs changes for the worse over time. Our advanced biomaterials business today is comprised primarily
of the sale of our Biovance 3L and Rebound products, directly or through our distribution network. Biovance 3L is a tri-layer decellularized,
dehydrated human amniotic membrane derived from the placenta of a healthy, full-term pregnancy. It is an intact, natural extracellular
matrix that provides a foundation for the wound regeneration process and acts as a scaffold for restoration of functional tissue. Rebound
is a full thickness extracellular matrix that contains amnion and chorion. We are developing new placental biomaterial products to deepen
the biomaterials commercial pipeline. We also market our Biovance and Interfyl products, directly or through our distribution network.
Biovance is decellularized, dehydrated human amniotic membrane derived from the placenta of a healthy, full-term pregnancy. It is an intact,
natural extracellular matrix that provides a foundation for the wound regeneration process and acts as a scaffold for restoration of functional
tissue. Interfyl is human connective tissue matrix derived from the placenta of a healthy, full-term pregnancy. It is used by a variety
of medical specialists to fill soft tissue deficits resulting from wounds, trauma, or surgery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have focused our marketing
and sales strategy within the Advanced Biomaterial Products segment on developing strong distribution partners for our products rather
than building out our own direct sales force. On May 7, 2021, we entered into a six-year supply and distribution agreement with Arthrex,
Inc., that includes: (i) an exclusive Biovance, Interfyl, and Centaflex license for distribution and commercialization within the United
States in the field of orthopedic surgery; and (ii) an exclusive license to commercialize and distribute Interfyl and Centaflex within
the United States in the field of acute and chronic non-healing wound care. On December 11, 2023, we entered into an exclusive commercialization
agreement with BioCellgraft Inc., or BioCellgraft, to manufacture advanced biomaterial products for BioCellgraft that it will distribute
under private label brand names for use in dental and oral healthcare applications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We continue to invest in
creating new or differentiated products for the Degenerative Disease segment to supplement sales of our mature commercial products, Biovance
and Interfyl. For example, we are developing three investigational advanced biomaterial products: Celularity Tendon Wrap, or CTW; Fuse
Bone Void Filler, and Celularity Placental Matrix, or CPM. We are developing our CTW investigational product for the management and protection
of tendon injuries in which there has been no substantial loss of tendon tissue as a structural barrier for injured tendon tissue and
does not depend on chemical action (pharmacological activity) to mediate this effect, to be classified as a surgical mesh. Based on the
FDA Office of Combination Products&#8217;, or OCP, preliminary assessment we now intend to submit a 510(k) notification for CTW in the
first half of 2025. We are developing our Fuse Bone Void Filler investigational product for use as a passive osteoconductive bone filler
in the pelvis, extremities, and posterior-lateral spinal fusion settings as well as other skeletal defects that are not dependent on chemical
action to mediate an effect. Based on OCP&#8217;s preliminary assessment, we now intend to submit a 510(k) notification for FUSE in the
second half of 2025. We are developing our CPM investigational product for use as a passive temporary wound covering which is not meant
to achieve its primary intended purpose through chemical action (pharmacological activity) and is not dependent on being metabolized for
the achievement of its intended purpose. CPM is a fully resorbable device composed of extracellular matrix (ECM) derived from decellularized
human placental tissue. Its wound management indications include partial and full-thickness wounds; pressure ulcers; venous ulcers; diabetic
ulcers; chronic vascular ulcers; tunneled/undermined wounds; surgical wounds; trauma wounds; and draining wounds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Biobanking</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We provide a fee-based biobanking
service to expectant parents who contract with us to collect, process, cryogenically preserve and store certain biomaterial, including
umbilical cord blood and placenta derived cells and tissue. We receive a one-time fee for the collection, processing, and cryogenic preservation
of the biomaterials, and a storage fee to maintain the biomaterials in our biobank payable annually generally over a period of 18 to 25
years. We acquired our biobanking business in May 2017 from HLI, which HLI operated as LifebankUSA, along with the degenerative disease
products Biovance and Interfyl, and in October 2018, we acquired CariCord Inc., or CariCord, a family cord blood bank.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Manufacturing</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have a 147,215 square
foot purpose-built facility located in Florham Park, New Jersey, which includes a cGMP-ready manufacturing center, along with dedicated
research and office spaces and space for shared services. Our facility includes nine Grade C/ISO-7 and six Grade D/ISO-8 manufacturing
suites designed for commercial production of cellular therapies and advanced biomaterials. We intend to manufacture all finished product
in-house at our Florham Park, New Jersey, manufacturing facility. We have invested resources to optimize our manufacturing process, including
the development of improved analytical methods. We plan to continue to invest in process science, product characterization and manufacturing
to improve our production and supply chain capabilities over time. We have in the past also used CMOs, as needed, on a non-exclusive basis,
and may elect to do so in the future, for certain of our therapeutic candidates. For example, we used a CMO for the clinical manufacture
and supply of CYNK-001 through 2022 subsequent to which we manufactured CYNK-001 in house. Other than <span style="background-color: white">Rebound&#8482;,
</span>all other finished products currently are manufactured in-house. Notwithstanding, we will engage CMOs as necessary to ensure continuous
supply of clinical and commercial grade product based on demands.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our cellular therapeutic
candidates are designed and manufactured via a platform comprised of defined unit operations and technologies. The process is gradually
developed from small to larger scales, incorporating compliant procedures to create cGMP conditions. Notwithstanding this platform-based
model, each therapeutic is unique and for each new therapeutic candidate, a developmental phase is necessary to individually customize
each engineering step and to create a robust procedure that can later be implemented in a cGMP environment to ensure the production of
clinical batches. This work is performed in a research and development environment to evaluate and assess variability in each step of
the process in order to define the most reliable production conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We plan to leverage our core
expertise in cellular therapeutic development and manufacturing to generate revenues by providing contract manufacturing and development
services to third parties. The initial focus of this new service offering will be to assist development stage cell therapy companies with
the development and manufacturing of their therapeutic candidates for clinical trials. We believe that we will be able to provide a flexible
and cost-effective alternative to the larger contract manufacturing organizations currently serving this market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Licensing Agreements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in">We enter into license agreements in the ordinary
course of our business. As part of the acquisition of Anthrogensis from Celgene, we granted Celgene a worldwide, royalty-free, fully paid
up, non-exclusive license, to use certain intellectual property for both research and commercial purposes, and granted Celgene the CVRs,
which provide Celgene the right to future milestone and royalty payments in certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Celgene Corporation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In August 2017, in connection
with the Anthrogenesis acquisition, we entered into a license agreement, or the Celgene License, with Celgene, which has since been acquired
by Bristol Meyers Squibb. Pursuant to the Celgene License, we granted Celgene a worldwide, royalty-free, fully-paid up, non-exclusive
license, without the right to grant sublicenses (other than to its affiliates), under Anthrogenesis&#8217; intellectual property in existence
as of the date of the Celgene License or as developed by Celgene in connection with any transition services activities related to the
merger for non-commercial pre-clinical research purposes, as well as to develop, manufacture, commercialize and fully exploit products
and services that relate to the construction of any CAR, the modification of any T-cell or NK cell to express such a CAR, and/or the use
of such CARs or T-cells or NK cells for any purpose, which commercial license is sublicensable. Either party may terminate the Celgene
License upon an uncured material breach of the agreement by the other party or insolvency of the other party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In August 2017, Legacy Celularity
also issued shares of its Series X Preferred Stock to Celgene as merger consideration and entered into a contingent value rights agreement,
or the CVR Agreement, with Celgene pursuant to which Legacy Celularity issued one contingent value right or CVR, in respect of each share
of Legacy Celularity Series X Preferred Stock issued to Celgene in connection with the Anthrogenesis acquisition. The CVR Agreement entitles
the holders of the CVRs to an aggregate amount, on a per program basis, of $50.0 million in regulatory milestones and an aggregate $125.0
million in commercial milestone payments with respect to certain of our investigational therapeutic programs. In addition, with respect
to each such program and calendar year, the CVR holders will be entitled to receive a royalty equal to a mid-teen percentage of the annual
net sales for such program&#8217;s therapeutics from the date of the first commercial sale of such program&#8217;s therapeutic in a particular
country until the latest to occur of the expiration of the last to expire of any valid patent claim covering such program therapeutic
in such country, the expiration of marketing exclusivity with respect to such therapeutic in such country, and August 2027 (i.e., the
tenth anniversary of the closing of the acquisition of Anthrogenesis). No payments under the CVR Agreement have been made to date. We
estimate the liability associated with the CVR quarterly. Changes to that liability include but are not limited to changes in our clinical
programs, assumptions about the commercial value of those programs and the time value of money.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our commercial success depends
in part on our ability to obtain and maintain proprietary protection for the technologies supporting our Celularity IMPACT platform, and
our future therapeutic candidates, as well as novel discoveries, product development technologies, and know-how. Our commercial success
also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing
our proprietary rights. Our policy is to develop and maintain protection of our proprietary position by, among other methods, filing or
in-licensing U.S. and foreign patents and applications related to our technology, inventions, and improvements that are important to the
development and implementation of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We also rely on trademarks
and copyright law, trade secrets, know-how, continuing technological innovation, confidentiality agreements, and invention assignment
agreements to develop and maintain our proprietary position. The confidentiality agreements are designed to protect our proprietary information,
and the invention assignment agreements are designed to grant us ownership of technologies that are developed for us by our employees,
consultants, or other third parties. We seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining
physical security of our premises and physical and electronic security of our information technology systems. While we have confidence
in our agreements and security measures, either may be breached, and we may not have adequate remedies. In addition, our trade secrets
may otherwise become known or independently discovered by competitors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">With respect to both licensed
and Company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications
or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents
that may be granted to us in the future will be commercially useful in protecting our commercial therapeutics and methods of using and
manufacturing the same. In addition, our patents and patent applications could face other challenges, such as interference proceedings,
opposition proceedings, re-examination proceedings, and other forms of post-grant review. Any of these challenges, if successful, could
result in the invalidation of, or in a narrowing of the scope of, any of our patents and patent applications subject to challenge. Any
of these challenges, regardless of their success, would likely be time consuming and expensive to defend and resolve, and would divert
our management and scientific personnel&#8217;s time and attention.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are actively building
our intellectual property portfolio around our Celularity IMPACT platform, our four allogeneic cell types and our therapeutic candidates
based on our own intellectual property as well as licensed intellectual property. As of the date of this annual report on Form 10-K, we
have a robust global intellectual property portfolio comprised of over 290 patents and patent applications protecting our Celularity IMPACT
platform, our processes, technologies and cell therapy programs that we are actively developing or are seeking to out-license/find a collaboration
partner to develop.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our patent portfolio includes
patents and patent applications directed toward our five allogeneic placental-derived cell and extracellular vesicle types: CAR-T cells,
unmodified NK cells, genetically modified NK cells, MLASCs and exosomes as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">We have five utility patent families in the CAR-T technology area supporting our internally discontinued CYCART-19 therapeutic candidate comprising two patent families owned by us and three patent families in-licensed from Sorrento. These patent applications include placental-derived CAR-T patent families directed toward early CAR receptor technology, CAR receptor method and composition, anti-CD19 CAR receptor and product characterization. Patents issuing from these families have expected expiry dates (assuming current pending applications are granted) ranging from 2039 to 2040 and include pending applications in the United States and under the PCT and include approximately 28 pending patent applications in the United States and under the PCT: Australia, Brazil, Canada, China, European Patent Convention, Hong Kong, India, Japan, Korea, Mexico, New Zealand, Philippines, Singapore, and South Africa. As stated above, although we have discontinued our internal development of the product candidate, we are seeking to out-license/find a collaboration partner to develop.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">We own approximately 15 utility patent applications in the NK technology area that include granted patents and pending patent applications covering process, treatment of indications, and product characterization. Patents issuing from these families have expected expiry dates (assuming current pending applications are granted) ranging from 2028 to 2041 and include pending patent applications in the United States and under the PCT, e.g., Brazil, Canada, China, Colombia, European Patent Office, Hong Kong, Israel, India, Japan, Republic of Korea, Mexico, Malaysia, New Zealand, Singapore. Taiwan R.O.C., and South Africa.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">We own approximately 25 utility patent families applications owned by us that support our APPL-001 therapeutic candidate and former MLASC (a.k.a. PDAC) technology, which include pending patent applications and issued patents covering product characterization, method of production, as well as product description and indications. Patents issuing from these families have expected expiry dates (assuming current pending applications are granted) ranging from 2026 to 2046 and include patents issued and pending patent applications in the United States and under the PCT, China, European Patent Office, Hong Kong, Israel, India, Japan, Republic of Korea, Mexico, Malaysia, Taiwan R.O.C., Vietnam, and South Africa. Althoughpatent families in this technology area began to expire in 2021, we have numerous patent families in this technology area directed to improvements in the cells and methods/indications for their use, which include recently filed applications directed towards APPL-001, a second generation, genetically modified MLASC therapeutic candidate. These applications have projected expiration dates to 2041 and are expected to replace the early-expiring applications. Accordingly, we do not expect that the expiry of the early-filed MLASC patents will have a material effect on our business.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%">We have approximately 19 utility patent applications in the exosome technology area supporting our placental exosome candidates, which include issued patents and pending applications. These patent applications include product characterization focused on identifying and protecting the key molecular markers that define these unique exosome populations and establish protection for their anti-inflammatory and immunomodulatory properties as well as for their use in the treatment of specific indications such as osteoarthritis and GLP=1 agonist induced muscle loss. Patents issuing from these families have expected expiry dates (assuming current pending applications are granted) ranging from 2035 to 2045 and include issued patents and pending patent applications in the United States and under the PCT: Australia, Canada, China, European Patent Convention, India, Japan, Korea, Mexico, New Zealand, Singapore, and South Africa.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Additional patent portfolios
protecting other products in development include our biomaterials portfolio, which includes patent protection for Interfyl, Biovance,
and Biovance 3L (approximately 40 patents and pending applications having anticipated expiration between 2025-2045) and our bio-banking
portfolio (6 patents having expiration between 2025-2033). We are seeking to out-license/find a collaboration partner to develop our CYNK
portfolio (approximately 1 pending application having anticipated expiration in 2039) and our PSC portfolio (15 patents and pending applications
having expiration between 2026-2034).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">More generally, our patent
portfolio and filing strategy is designed to provide multiple layers of protection by pursuing claims directed toward composition of matter,
methods of making, and methods of use, amongst others. We strive to protect and enhance the proprietary technologies that we believe are
important to our business, including seeking patent protection intended to cover our technology and related technologies and uses thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The term of individual patents depends upon the
legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years
from the date of filing of the first non-provisional application to which priority is claimed. In the United States, patent term may be
lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark
Office in granting a patent or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. In the United States,
the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman
Act, which is designed to, among other things, compensate for the patent term lost during the FDA regulatory review process. The length
of the patent term extension is calculated based on the length of time we take for regulatory review. A patent term extension under the
Hatch-Waxman Act is the earlier of up to five years from grant date of the patent to 14 years from the date of product approval, and only
one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended only once. Thus, if a single patent
is applicable to multiple products, the term of the patent can only be extended based on one product. Provisions designed to restore patent
term lost during the regulatory review process are available in Europe and certain other foreign jurisdictions to extend the term of a
patent that covers an approved drug.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our products will compete
with novel therapies developed by biopharmaceutical companies, academic research institutions, governmental agencies, and public and private
research institutions, in addition to existing standard of care treatments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Due to the promising therapeutic
effect of cellular therapies in other companies&#8217; clinical trials, we anticipate increasing competition from existing and new companies
developing these therapies, as well as in the development of allogeneic cellular therapies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Potential cellular therapy
and biomaterials competitors include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 115%"><i>allogeneic CAR-T cellular therapies:</i> Allogene Therapeutics, Inc., Atara Biotherapeutics, Inc., Cellectis S.A., Fate Therapeutics Inc., Precision Biosciences, Inc., Sana Biotechnology, CRISPR Therapeutics, Caribou Bio and Wugen.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 115%"><i>allogeneic NK cellular therapies:</i> Fate Therapeutics Inc., Century Therapeutics, Inc., Nkarta, Inc., Artiva Biotherapeutics, Wugen, and Shoreline Biosciences.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 115%"><i>allogeneic MLASC therapies:</i> Mesoblast Limited and, Longeveron.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%"><i>Exosomes:</i> Aegle Therapeutics Corporation, Capricor Therapeutics, Inc., and Evox Therapeutics Ltd.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%"><i>Cellular therapy competition:</i> Allogene Therapeutics, Inc., Atara Biotherapeutics, Inc., Adaptimmune Therapeutics PLC, Celyad S.A., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Gilead Sciences, Inc., Poseida Therapeutics, Inc., Precision Biosciences, Inc., Sangamo Therapeutics, Inc., Fate Therapeutics, Sana Biotechnology, Caribou Bio, and Artiva Biotherapeutics</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%"><i>Biomaterials competition:</i> Mimedx Group, Inc., Organogenesis Holdings Inc., Skye Biologics Holdings LLC, Regenerative Labs, and Legacy Medical Consultants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Competition will also arise
from non-cell-based therapies pursued by small-cap biotechnology and large-cap pharmaceutical companies including Amgen Inc., AstraZeneca
plc, Bristol Myers Squibb Company, Incyte Corporation, Merck &amp; Co., Inc., and F. Hoffmann-La Roche AG.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Many of our competitors,
either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development,
preclinical testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and acquisitions may
result in further resource concentration among a smaller number of competitors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our commercial potential
could be reduced or eliminated if our competitors develop and commercialize therapeutics that are safer, more effective, have fewer or
less severe side effects, are more convenient or are less expensive than cellular therapeutics that we may develop. Our competitors also
may obtain FDA or other regulatory approval for their therapies more rapidly than we may obtain approval for ours, which could result
in our competitors establishing a strong market position before we are able to enter the market or make development efforts more complicated.
The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety, and convenience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">These competitors may also
vie for a similar pool of qualified scientific and management talent, sites, and patient populations for clinical trials, as well as for
technologies complementary to, or necessary for, our programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Government Regulation and Product Approval</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As a biopharmaceutical company
that operates in the United States, we are subject to extensive regulation. All of our products are subject to regulation in the United
States under the Federal Food, Drug, and Cosmetic Act, or FDCA, as implemented and enforced by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our cell therapeutics will
be regulated as biologics. With this classification, commercial production of our cellular therapeutics will need to occur in registered
facilities in compliance with cGMP for biologics. The FDA categorizes human cell or tissue-based products as either minimally manipulated
or more than minimally manipulated, and has determined that more than minimally manipulated products require clinical trials to demonstrate
product safety and efficacy and the submission of a biologics license application, or BLA, for marketing authorization. Our cellular therapeutic
candidates are considered more than minimally manipulated and will require evaluation in clinical trials and the submission and approval
of a BLA before we can market them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our developmental advance
biomaterial products will be regulated as medical devices. The FDA categorizes medical devices into one of three classes&#8212;Class I,
Class II or Class III&#8212;depending on the degree of risk associated with each medical device and the extent of control needed to ensure
safety and effectiveness. Class I devices are those for which safety and effectiveness can be assured by adherence to FDA&#8217;s general
controls for medical devices, or General Controls, which include compliance with the applicable portions of the FDA&#8217;s Quality System
Regulation, or QSR, facility registration and product listing, reporting of adverse medical events, and appropriate, truthful and non-misleading
labeling, advertising, and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k)
premarket notification process described below. Class II devices are subject to FDA&#8217;s General Controls, and any other special controls
as deemed necessary by FDA to ensure the safety and effectiveness of the device. Premarket review and clearance by the FDA for Class II
devices is accomplished through the 510(k) premarket notification procedure, unless an exemption applies. A Class III product is a product
which has a new intended use or uses advanced technology that is not substantially equivalent to that of a legally marketed device. The
safety and effectiveness of Class III devices cannot be assured solely by the General Controls and the other requirements described above.
These devices almost always require formal clinical studies to demonstrate safety and effectiveness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Government authorities
in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the research,
development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising,
distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are
developing. Our therapeutic candidates must be approved by the FDA before they may be legally marketed in the United States and by the
appropriate foreign regulatory agencies before they may be legally marketed in foreign countries. Generally, our activities in other countries
will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important
differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation
remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate
federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>U.S. Product Development Process</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In the United States,
the FDA regulates pharmaceutical and biological products under the FDCA, the Public Health Service Act and their implementing regulations.
The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes
and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements
at any time during the product development process, approval process or after approval, may subject an applicant to administrative or
judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal
of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension
of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.
Any agency or judicial enforcement action could have a material adverse effect on our operation and business. The process required by
the FDA before a biological product may be marketed in the United States generally involves the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before the trial is commenced;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations commonly referred to as good clinical practices and any additional requirements for the protection of human research patients and their health information, to establish the safety and efficacy of the proposed biological product for its intended use;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">submission to the FDA of a BLA for marketing approval that includes substantial evidence of safety, purity, and potency from results of nonclinical testing and clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices, or GTPs, for the use of human cellular and tissue products;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">FDA review and approval, or licensure, of the BLA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Before testing any biological
product candidate, including our cellular therapeutic candidates, in humans, the therapeutic candidate enters the preclinical testing
stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation,
as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must
comply with federal regulations and requirements including GLPs. The clinical trial sponsor must submit the results of the preclinical
tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol,
to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective
30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the trial
on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before
the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical
trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization
and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing
clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In addition to the submission
of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or
synthetic nucleic acid molecules are subject to oversight of IBCs as set forth in the NIH Guidelines for Research Involving Recombinant
or Synthetic Nucleic Acid Molecules, or NIH Guidelines. Under the NIH Guidelines, recombinant and synthetic nucleic acids are defined
as: (i) molecules that are constructed by joining nucleic acid molecules and that can replicate in a living cell (i.e., recombinant nucleic
acids); (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically
or otherwise modified but can base pair with naturally occurring nucleic acid molecules (i.e., synthetic nucleic acids); or (iii) molecules
that result from the replication of those described in (i) or (ii). Specifically, under the NIH Guidelines, supervision of human gene
transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing
recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential
risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH
Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding
of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines
voluntarily follow them.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Clinical trials involve
the administration of the biological product candidate to patients under the supervision of qualified investigators, generally physicians
not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things,
the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor
subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol
and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in
accordance with the FDA&#8217;s regulations comprising the GCP requirements including the requirement that all research patients provide
informed consent. Further, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at
which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers
such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated
benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his
or her legal representative and must monitor the clinical trial until completed. Some studies also include oversight by an independent
group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization
for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the
clinical trial if we determine that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.
There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Human clinical trials
are typically conducted in three sequential phases that may overlap or be combined:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%"><i>Phase 1.</i> The biological product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%"><i>Phase 2.</i> The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 112%"><i>Phase 3</i>. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Post-approval clinical
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are
used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety
follow-up. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities,
clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted
to the FDA. Written IND safety reports must be promptly submitted to the FDA, and the investigators for serious and unexpected adverse
events, any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human patients,
or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator
brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies
for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven
calendar days after the sponsor&#8217;s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed
successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate
a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health
risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical
trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological
product has been associated with unexpected serious harm to patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Human cellular therapy
products are a new category of therapeutics. Because this is a relatively new and expanding area of novel therapeutic interventions, there
can be no assurance as to the length of the trial period, the number of patients the FDA will require to be enrolled in the trials in
order to establish the safety, efficacy, purity and potency of cellular therapy products, or that the data generated in these trials will
be acceptable to the FDA to support marketing approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Concurrently with clinical
trials, companies usually complete additional studies and must also develop additional information about the physical characteristics
of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP
requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes
the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable
of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing
the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected
and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable
deterioration over its shelf life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>U.S. Review and Approval Processes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><i>FDA Biologics License
Application</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">After the completion
of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product.
The BLA submission must include results of product development, laboratory and animal studies, human trials, information on the manufacture
and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial
time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be
granted on a timely basis, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Under the Prescription
Drug User Fee Act, as amended, or PDUFA, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on
an annual basis. PDUFA also imposes an annual program fee for biological products. Fee waivers or reductions are available in certain
circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees
are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Within 60 days following
submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts
it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may
request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application
also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth
substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent,
and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance
with cGMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications
for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee,
typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application
should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such
recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a
Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product. A REMS is a safety strategy
to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines
by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as
restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor
of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Before approving a BLA,
the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the therapeutic unless it determines
that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production
of the therapeutic within required specifications. For cellular therapies, the FDA also will not approve the product if the manufacturer
is not in compliance with the GTPs, to the extent applicable. These are FDA regulations and guidance documents that govern the methods
used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue based products, or
HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. Additionally,
before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in
compliance with IND trial requirements and GCP requirements. To assure cGMP, GTP and GCP compliance, an applicant must incur significant
expenditure of time, money and effort in the areas of training, record keeping, production and quality control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In November 2017, the
FDA released a guidance document entitled &#8220;Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue &#8212; Based
Products: Minimal Manipulation and Homologous Use &#8212; Guidance for Industry and Food and Drug Administration Staff&#8221;, which it
revised and reissued in July 2020, or the Guidance. The document confirmed the FDA&#8217;s stance that sheet forms of amniotic tissue
are appropriately regulated as solely Section 361 HCT/Ps when manufactured in accordance with 21 CFR Part 1271 and intended for use as
a barrier or covering. The primary intent of the GTP requirements is to ensure that cell and tissue-based therapeutics are manufactured
in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue
establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.
Although FDA had indicated in its Guidance that the agency would exercise enforcement discretion under limited conditions with respect
to the IND application and pre-market approval requirements for certain HCT/Ps, this period of enforcement discretion ended May 31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Notwithstanding the
submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval
and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret
the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes
all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling
changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended
actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the
applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If a therapeutic receives
regulatory approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited,
which could restrict the commercial value of the therapeutic. Further, the FDA may require that certain contraindications, warnings or
precautions be included in the labeling. The FDA may impose restrictions and conditions on distribution, prescribing, or dispensing in
the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical
trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness,
and testing and surveillance programs to monitor the safety of approved therapeutics that have been commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In addition, under the
Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product
for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation
for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. Unless otherwise
required by regulation, PREA does not apply to any product for an indication for which orphan designation has been granted. However, if
only one indication for a therapeutic has orphan designation, a pediatric assessment may still be required for any applications to market
that same therapeutic for the non-orphan indication(s).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>510(k) Clearance Marketing Pathway for Devices</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">When a 510(k) is required,
the manufacturer must submit to the FDA a premarket notification submission demonstrating that the device is &#8220;substantially equivalent&#8221;
to a predicate device already on the market. A predicate device is a legally marketed device that is not subject to premarket approval,
i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a premarket approval application,
or PMA, is not required, a device that has been reclassified from Class III to Class II or I, or a device that was found substantially
equivalent through the 510(k) process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">If the FDA agrees that the
device is substantially equivalent to a predicate device, it will grant clearance to commercially market the device in the U.S. The FDA&#8217;s
510(k) clearance process usually takes from three to twelve months from the date the application is submitted and filed with the FDA but
may take significantly longer and clearance is never assured. Although many 510(k) pre-market notifications are cleared without clinical
data, in some cases, the FDA requires significant clinical data to support substantial equivalence. In reviewing a pre-market notification,
the FDA may request additional information, including clinical data, which may significantly prolong the review process. If the FDA determines
that the device, or its intended use, is not &#8220;substantially equivalent,&#8221; the FDA may deny the request for clearance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">After a device receives 510(k)
clearance, any subsequent modification of the device that could significantly affect its safety or effectiveness, or that would constitute
a major change in its intended use, will require a new 510(k) clearance or could require pre-market approval. The FDA requires each manufacturer
to make this determination initially, but the FDA may review any such decision and may disagree with a manufacturer&#8217;s determination.
If the FDA disagrees with a manufacturer&#8217;s determination, the FDA may require the manufacturer to cease marketing or recall the
modified device, or both, until 510(k) clearance or pre-market approval is obtained. We have modified aspects of some of our devices since
receiving regulatory clearance and we have made the determination that new 510(k) clearances or pre-market approvals were not required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Over the last several years,
the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data
and a longer review period or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products.
For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification
pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers
utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices
that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on
the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. The FDA also announced that it
intends to finalize guidance to establish a premarket review pathway for &#8220;manufacturers of certain well-understood device types&#8221;
as an alternative to the 510(k) clearance pathway and that such premarket review pathway would allow manufacturers to rely on objective
safety and performance criteria recognized by the FDA to demonstrate substantial equivalence, obviating the need for manufacturers to
compare the safety and performance of their medical devices to specific predicate devices in the clearance process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In May 2019, the FDA solicited
public feedback on its plans to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates,
including whether the FDA should publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence
to predicate devices that are more than 10 years old. The FDA requested public feedback on whether it should consider certain actions
that might require new authority, such as whether to sunset certain older devices that were used as predicates under the 510(k) clearance
pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through
legislation. More recently, in September 2019, the FDA finalized the aforementioned guidance to describe an optional &#8220;safety and
performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate
substantial equivalence under the 510(k) clearance pathway, by demonstrating that such device meets objective safety and performance criteria
established by the FDA, obviating the need for manufacturers to compare the safety and performance of their medical devices to specific
predicate devices in the clearance process. The FDA maintains a list of device types appropriate for the &#8220;safety and performance
based pathway&#8221; and develop product-specific guidance documents that identify the performance criteria for each such device type,
as well as the testing methods recommended in the guidance documents, where feasible.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>FDA PMA Approval Process for Devices</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Although unlikely for the
types of medical devices we are currently developing, the FDA may classify devices, or the particular use of a device, into Class III,
and the device sponsor must then fulfill more rigorous PMA requirements. A PMA application, which is intended to demonstrate that a device
is safe and effective, must be supported by extensive data, including extensive technical and manufacturing data and data from preclinical
studies and human clinical trials. After a PMA application is submitted and filed, the FDA begins an in-depth review of the submitted
information, which typically takes between one and three years, but may take significantly longer. During this review period, the FDA
may request additional information or clarification of information already provided. Also, during the review period, an advisory panel
of experts from outside the FDA will usually be convened to review and evaluate the application and provide recommendations to the FDA
as to the approvability of the device. In addition, the FDA will conduct a pre-approval inspection of the manufacturing facility to ensure
compliance with the QSR, which imposes stringent design development, testing, control, documentation and other quality assurance procedures
in the design and manufacturing process. The FDA may approve a PMA application with post-approval conditions intended to ensure the safety
and effectiveness of the device including, among other things, restrictions on labeling, promotion, sale and distribution and collection
of long-term follow-up data from patients in the clinical study that supported approval. Failure to comply with the conditions of approval
can result in materially adverse enforcement action, including the loss or withdrawal of the approval. New PMA applications or PMA supplements
are required for significant modifications to the manufacturing process, labeling of the product and design of a device that is approved
through the PMA process. PMA supplements often require submission of the same type of information as an original PMA, except that the
supplement is limited to information needed to support any changes from the device covered by the original PMA and may not require as
extensive clinical data or the convening of an advisory panel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A clinical trial is typically
required to support a PMA application and is sometimes required for a 510(k) pre-market notification. Clinical trials generally require
submission of an application for an Investigational Device Exemption, or IDE, to the FDA. The IDE application must be supported by appropriate
data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the investigational
protocol is scientifically sound. The IDE application must be approved in advance by the FDA for a specified number of patients, unless
the product is deemed a non-significant risk device and eligible for more abbreviated IDE requirements. Clinical trials for a significant
risk device may begin once the IDE application is approved by the FDA as well as the appropriate institutional review boards at the clinical
trial sites, and the informed consent of the patients participating in the clinical trial is obtained. After a trial begins, the FDA may
place it on hold or terminate it if, among other reasons, it concludes that the clinical subjects are exposed to an unacceptable health
risk. Any trials we conduct must be conducted in accordance with FDA regulations as well as other federal regulations and state laws concerning
human subject protection and privacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Orphan Drug Designation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Under the Orphan Drug
Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease
or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and
for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic
for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation
must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent
and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten
the duration of, the regulatory review or approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If a therapeutic that
has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the therapeutic
is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market
the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority
to the therapeutic with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic
for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan
drug designation are tax credits for certain research and a waiver of the BLA application user fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">A designated orphan
drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan
designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for
designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs
of patients with the rare disease or condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In April 2021, the FDA
granted orphan drug designation to our non-genetically modified cryopreserved human placental hematopoietic stem cell-derived NK cell
therapy, CYNK-001, for the treatment of patients with malignant gliomas. However, we have discontinued development as to this indication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Expedited Development and Review
Programs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The FDA has programs
intended to facilitate and expedite the development and review of new drugs to address unmet medical needs in the treatment of a serious
or life-threatening condition. These programs include fast track designation, breakthrough therapy designation, accelerated approval,
and priority review designation. Specifically, new therapeutics are eligible for fast track designation if they are intended to treat
a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition.
Fast track designation applies to the combination of the therapeutic and the specific indication for which it is being studied. Unique
to a fast track product, the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted,
if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines
that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Any therapeutic submitted
to the FDA for approval, including a therapeutic with a fast track designation, may also be eligible for other types of FDA programs intended
to expedite development and review, such as priority review and accelerated approval. A therapeutic is eligible for priority review if
it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement
in the treatment, diagnosis or prevention of a disease compared to marketed therapeutics. The FDA will attempt to direct additional resources
to the evaluation of an application for a new therapeutic designated for priority review in an effort to facilitate the review. Additionally,
a therapeutic may be eligible for accelerated approval. Therapeutics studied for their safety and effectiveness in treating serious or
life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate
endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible
morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit,
taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a
condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate
and well-controlled post-marketing clinical studies with due diligence and, under the Food and Drug Omnibus Reform Act of 2022, or FDORA,
the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after
the date of approval for a product granted accelerated approval. Under FDORA, the FDA has increased authority for expedited procedures
to withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify
the predicted clinical benefit of the product. In addition, for products being considered for accelerated approval, the FDA currently
requires, unless the sponsor is otherwise informed by the agency, that all advertising and promotional materials intended for dissemination
or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period, which
could adversely impact the timing of the commercial launch of the product. In addition, breakthrough therapy designation is intended to
expedite the development and review of therapeutics that treat serious or life-threatening conditions. The designation by the FDA requires
preliminary clinical evidence that a therapeutic candidate, alone or in combination with other drugs and biologics, demonstrates substantial
improvement over currently available therapy on one or more clinically significant endpoints, such as substantial treatment effects observed
early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development
and review of the application, which may include (i) holding meetings with the sponsor and the review team throughout the development
of the therapy, (ii) providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug
to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable,
(iii) involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review, (iv) assigning
a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as
a scientific liaison between the review team and the sponsor and (v) considering alternative clinical trial designs when scientifically
appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number
of patients exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast
track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied,
including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user
fees before the FDA may initiate a review. The breakthrough therapy designation is a distinct status from both accelerated approval and
priority review, which can also be granted to the same product if relevant criteria are met. If a product is designated as breakthrough
therapy, FDA will expedite the development and review of such product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">Fast track designation,
priority review and breakthrough therapy designation do not change the standards for approval but may expedite the development or approval
process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In March 2021, we received
fast track designation from the FDA for our non-genetically modified cryopreserved human placental hematopoietic stem cell-derived NK
cell therapy. This program is currently not active.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Post-Approval Requirements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Any therapeutics for
which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements,
reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and
distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer
advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved
labeling (known as &#8220;off-label use&#8221;), limitations on industry-sponsored scientific and educational activities, and requirements
for promotional activities involving the internet. Although a physician may prescribe a legally available product for an off-label use,
if the physicians deems such product to be appropriate in his/her professional medical judgment, a manufacturer may not market or promote
off-label uses. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s
FDA approved labeling. A company that is found to have promoted off-label use of its product may be subject to significant liability,
including administrative, civil and criminal sanctions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In addition, quality
control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the long-term
stability of the product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding
maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other
entities involved in the manufacture and distribution of approved products, and those supplying products, ingredients, and components
of them, are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced
inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Manufacturers and other parties involved in
the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and for notifying
the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution
in the United States. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality
control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer,
or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market. In addition, changes
to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before
being implemented. Other types of changes to the approved product, such as adding new indications and claims, are also subject to further
FDA review and approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The FDA also may require
post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously
unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse
publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with
doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes
to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation
of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established,
or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our therapeutics under development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>U.S. Marketing Exclusivity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The Biologics Price
Competition and Innovation Act, or BPCIA, amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly
known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish its molecule as highly similar
to an approved innovator biologic, among other requirements. The BPCIA, however, bars the FDA from approving biosimilar applications for
12 years after an innovator biological product receives initial marketing approval. This 12-year period of data exclusivity may be extended
by six months, for a total of 12.5 years, if pediatric exclusivity is granted. Pediatric exclusivity is another type of regulatory market
exclusivity in the United States. This six-month exclusivity, which runs from the end of other exclusivity protection, may be granted
based on the voluntary completion of a pediatric trial that fairly responds to an FDA-issued &#8220;Written Request&#8221; for such a
trial.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Depending upon the timing,
duration and specifics of the FDA approval of the use of our therapeutic candidates, some of its U.S. patents, if granted, may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the
Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years, as compensation for patent term lost during
product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent
beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between
the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that
application. Only one patent applicable to an approved therapeutic is eligible for the extension and the application for the extension
must be submitted prior to the expiration of the patent. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and
approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent
term for one of our currently owned or licensed patents to add patent life beyond our current expiration date, depending on the expected
length of the clinical trials and other factors involved in the filing of the relevant BLA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Federal and State Licenses and Registrations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The health care industry
is subject to stringent regulation by a wide range of authorities. Accordingly, our business requires us to maintain certain licenses,
registrations, permits, authorizations, approvals, certifications, accreditations and other types of federal, state, and local governmental
permissions and to comply with various regulations in every jurisdiction in which we operate. For example, we are required to maintain
licenses and registrations in several states, and has obtained biologics, tissue bank and blood bank licenses, permits and registrations
in states where such licensure is required for us to market and support our products and services. Some states, such as New York, impose
state law restrictions on products that have not been the subject of a BLA based upon their interpretation of guidance issued under federal
law, including the FDA&#8217;s guidance on HCT/Ps, which can lead to different, and potentially conflicting, regulatory frameworks applicable
to our degenerative disease products on a state by state basis. We also maintain an annual registration with the FDA as a tissue bank,
and national accreditation by the American Association of Blood Banks. The failure to comply with such licensure requirements can result
in enforcement actions, including the revocation or suspension of the licenses, registrations or accreditations, or subject us to plans
of correction, monitoring, civil money penalties, civil injunctive action and/or criminal penalties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Other U.S. Healthcare Laws and Compliance
Requirements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In the United States,
our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including
but not limited to, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human
Services (<i>e.g.</i>, the Office of Inspector General), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices
within the DOJ, and state and local governments. For example, our business practices, including our research and sales, marketing and
scientific/educational grant programs may be required to comply with the fraud and abuse provisions of the Social Security Act, false
claims laws, anti-kickback and anti-bribery laws, the data privacy and security provisions of the Health Insurance Portability and Accountability
Act, or HIPAA, federal transparency requirements and similar state laws, each as amended.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The federal Anti-Kickback
Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any
remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or
in return for, either the referral of an individual for, or the purchasing, leasing, ordering or arranging for the purchase, lease or
order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been
interpreted broadly to include anything of value. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between
pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory
exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly
and require strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to
induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure
to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per
se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on
a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection
under a statutory exception or regulatory safe harbor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Additionally, the intent
standard under the federal Anti-Kickback Statute was amended by the Patient Protection Affordable Care Act of 2010, as amended by the
Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act, to a stricter standard such that a person
or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have
committed a violation. Rather, if &#8220;one purpose&#8221; of the remuneration is to induce referrals, the federal Anti-Kickback Statute
is violated. In addition, the Affordable Care Act codified case law that a claim that includes items or services resulting from a violation
of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (discussed
below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The federal civil monetary
penalties statute imposes penalties against any person or entity who, among other things, is determined to have knowingly presented or
caused to be presented a false or fraudulent claim to, among others, a federal healthcare program that the person knows or should know
is for an item or service that was not provided as claimed or is false or fraudulent. Further, violations of the Anti-Kickback Statute
are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment,
and exclusion from government healthcare programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The federal civil and
criminal false claims laws, including the federal civil False Claims Act, prohibit, among other things, individuals or entities from knowingly
presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal government programs that
are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the
federal government, including federal healthcare programs. As a result of a modification made by the Fraud Enforcement and Recovery Act
of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. Pharmaceutical
and other healthcare companies are being investigated or, in the past, have been prosecuted under these laws for, among other things,
allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In
addition, pharmaceutical and other healthcare companies also have been prosecuted for causing false claims to be submitted because of
the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses. The federal False Claims Act also permits
a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations
of the federal False Claims Act and to share in any monetary recovery.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">HIPAA created additional
federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain,
by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody
of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering
up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the
delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does
not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">We may be subject to
data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended
by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, imposes
requirements on certain types of individuals and entities, including covered entities (<i>i.e</i>., certain healthcare providers, health
plans and healthcare clearinghouses), relating to the privacy, security and transmission of individually identifiable health information.
Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates (and their subcontractors)
that are independent contractors or agents of covered entities that receive or obtain protected health information in connection with
providing a service for or on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA
to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file
civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs
associated with pursuing federal civil actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">State laws also govern
the privacy and security of personal information. Many state laws differ from each other in significant ways, thus complicating compliance
efforts. For example, the California Consumer Privacy Act, or CCPA establishes data privacy rights for individuals located in California,
and imposes certain requirements on how businesses can collect and use personal information about such individuals. The California Privacy
Rights Act, or CPRA, which became effective on January 1, 2023, the CPRA imposes additional obligations on companies covered by the legislation
and significantly modifies the CCPA, including by expanding consumers&#8217; rights with respect to certain sensitive personal information
and establishes a state agency vested with the authority to enforce the CCPA. It is not yet fully clear how the CCPA (as amended by the
CPRA) will be enforced and how it will be interpreted. The evolving nature of the CCPA may require us to modify our data collection or
processing practices and policies and to incur substantial costs and expenses in an effort to comply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The CCPA (as amended
by the CPRA) has prompted the enactment of similar, comprehensive privacy and data protection legislation in other states, such as Virginia,
Colorado, Utah and Connecticut, which will all become effective in 2023. Furthermore, a number of other U.S. states have proposed similar
privacy and data protection legislation, and it is possible that certain of these proposals will pass. Although many of the existing state
privacy laws exempt clinical trial information and health information governed by HIPAA, future privacy and data protection laws may be
broader in scope. Further, the proliferation of state privacy laws has heightened risks and uncertainties concerning our collection and
use of personal information. This could lead to significant compliance costs and expenses on our business, increase our potential exposure
to regulatory enforcement and/or litigation and have a negative effect on our ability to attract and retain new customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Additionally, the
federal Physician Payments Sunshine Act created under the Affordable Care Act, and its implementing regulations, require that certain
manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s
Health Insurance Program (with certain exceptions) annually report information to CMS related to certain payments or other transfers of
value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching
hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report
annually certain ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022,
applicable manufacturers were also required to report information regarding payments and other transfers of value provided during the
previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist
assistants and certified nurse-midwives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The Foreign Corrupt
Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything
of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision
of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies
whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that
accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an
adequate system of internal accounting controls for international operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Also, many states
have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs,
or, in several states, apply regardless of the payor. In order to distribute therapeutics commercially, we must comply with state laws
that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain
states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business
within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain
of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product
as it moves through the distribution chain. Several states and local jurisdictions have enacted legislation requiring pharmaceutical and
biotechnology companies to establish marketing compliance programs and comply with the pharmaceutical industry&#8217;s voluntary compliance
guidelines and the relevant compliance guidance promulgated by the federal government, file periodic reports with the state, make periodic
public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as
well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology
companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially
subject to federal and state consumer protection and unfair competition laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If our operations are
found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply
to us, we may be subject to significant penalties, including without limitation, civil, criminal and/or administrative penalties, damages,
fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, contractual
damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight
if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws,
and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our
results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Coverage, Pricing and Reimbursement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Significant uncertainty
exists as to the coverage and reimbursement status of any therapeutic candidates for which we obtain regulatory approval. In the United
States and certain markets in other countries, sales of any therapeutics for which we receive regulatory approval for commercial sale
will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such
products. No uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly
from payor to payor. As a result, the coverage determination process is often time-consuming and costly. In the United States, third-party
payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process
for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price
of a product or from establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage
to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular
indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness
of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic
studies in order to demonstrate the medical necessity and cost-effectiveness of our therapeutics, in addition to the costs required to
obtain the FDA approvals. Our therapeutic candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision
to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Net prices for our therapeutics
may also be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation
of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Further,
one payor&#8217;s determination to provide coverage for a therapeutic does not assure that other payors will also provide coverage for
the therapeutic. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an
appropriate return on our investment in therapeutic development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Different pricing and
reimbursement schemes exist in other countries. In the European Union, or EU, governments influence the price of pharmaceutical products
through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those
products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a
reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of
clinical trials that compare the cost-effectiveness of a particular therapeutic candidate to currently available therapies. Other member
states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health
care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition,
in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country. Accordingly,
in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient
to generate commercially reasonable revenue and profits. Pricing and rebate programs must comply with the Medicaid rebate requirements
of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Patient Protection Affordable Care Act of 2010,
as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act. If products are made available
to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The marketability of
any therapeutic candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors
fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect
will continue to increase the pressure on healthcare pricing. For example, actions by federal and state governments and health plans may
put additional downward pressure on pharmaceutical pricing and health care costs, which could negatively impact coverage and reimbursement
for our products if approved, our revenue, and our ability to compete with other marketed products and to recoup the costs of our research
and development. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement
status is attained for one or more therapeutics for which we receive regulatory approval, less favorable coverage policies and reimbursement
rates may be implemented in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Healthcare Reform</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In the United States
and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding
the healthcare system that could prevent or delay marketing approval of therapeutic candidates, restrict or regulate post-approval activities,
and affect the ability to profitably sell therapeutic candidates for which marketing approval is obtained. Among policy makers and payors
in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of
containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular
focus of these efforts and has been significantly affected by major legislative initiatives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">For example, the Affordable
Care Act has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the Affordable Care
Act provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs that began in 2011;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price (AMP);</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#8217; outpatient drugs to be covered under Medicare Part D;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">expansion of the entities eligible for discounts under the 340B Drug Discount Program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">requirements to report certain financial arrangements with physicians and teaching hospitals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">a requirement to annually report certain information regarding drug samples that manufacturers and distributors provide to physicians;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">a licensure framework for follow on biologic products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">There remain executive,
legal and political challenges to certain aspects of the Affordable Care Act. For example, in December 2019, the Further Consolidated
Appropriations Act (H.R. 1865), which repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax,
was signed into law. Moreover, the Bipartisan Budget Act of 2018, effective January 2019, among other things, amended the Affordable Care
Act to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole&#8221;. In June 2021, the U.S.
Supreme Court dismissed the most recent judicial challenge to the Affordable Care Act brought by several states without specifically ruling
on the constitutionality of the Affordable Care Act. Prior to the Supreme Court&#8217;s decision an Executive Order was issued to initiate
a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through
the Affordable Care Act marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their
existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver
programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage
through Medicaid or the Affordable Care Act. The ultimate content, timing or effect of any healthcare reform legislation on the United
States healthcare industry is unclear.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Previously, in October
2017, an Executive Order was signed terminating the cost-sharing subsidies that reimburse insurers under the Affordable Care Act. The
former administration concluded that cost-sharing reduction, or CSR, payments to insurance companies required under the Affordable Care
Act have not received necessary appropriations from Congress and announced that it will discontinue these payments immediately until those
appropriations are made. Several state Attorneys General filed suit to stop the administration from terminating the subsidies, but their
request for a restraining order was denied by a federal judge in California in October 2017. In August 2020, the U.S. Court of Appeals
for the Federal Circuit ruled in two separate cases that the federal government is liable for the full amount of unpaid CSRs for the years
preceding and including 2017. For CSR claims made by health insurance companies for years 2018 and later, further litigation will be required
to determine the amounts due, if any. Further, in June 2018, the U.S. Court of Appeals for the Federal Circuit ruled that the federal
government was not required to pay more than $12 billion in Affordable Care Act risk corridor payments to third-party payors who argued
the payments were owed to them. In April 2020, the United States Supreme Court reversed the U.S. Court of Appeals for the Federal Circuit&#8217;s
decision and remanded the case to the U.S. Court of Federal Claims, concluding the government has an obligation to pay these risk corridor
payments under the relevant formula.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">We anticipate that the
Affordable Care Act, if substantially maintained in its current form, will continue to result in additional downward pressure on coverage
and the price that we receive for any approved therapeutic, and could seriously harm our business. Any reduction in reimbursement from
Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment
measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our therapeutics.
Such reforms could have an adverse effect on anticipated revenue from therapeutic candidates that we may successfully develop and for
which we may obtain regulatory approval and may affect our overall financial condition and ability to develop therapeutic candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Further legislation
or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have
been proposed and adopted since the Affordable Care Act was enacted. For example, in August 2011, the Budget Control Act of 2011 was signed
into law, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending
reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for
fiscal years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate
reductions to Medicare payments to providers of up to 2% per fiscal year. These reductions went into effect in April 2013 and, due to
subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from
May 1, 2020, through March 31, 2022. Then, a 1% payment reduction occurred beginning April 1, 2022 through June 30, 2022, and the 2% payment
reduction resumed on July 1, 2022. Further, in January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among
other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment
centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In addition, on May
30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to
access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for
FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining
FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products
available to eligible patients as a result of the Right to Try Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">There has also been
increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. At the federal
level, an Executive Order was signed in July 2021 affirming the administration&#8217;s policy to (i) support legislative reforms that
would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, imposing inflation
caps and supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a
public health insurance option. Among other things, the Executive Order also directs the Department of Health and Human Services, or HHS
to provide a report on actions to combat excessive pricing of prescription drugs, to enhance the domestic drug supply chain, to reduce
the price that the Federal government pays for drugs, and to address price gouging in the industry; and directs the FDA to work with states
and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement,
and Modernization Act of 2003, and the FDA&#8217;s implementing regulations. FDA released such implementing regulations in September 2020,
which went into effect in November 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further,
in November 2020, CMS issued an Interim Final Rule implementing the Most Favored Nation Model under which Medicare Part B reimbursement
rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic
Cooperation and Development countries with a similar gross domestic product per capita. In December 2021, CMS rescinded the Most Favored
Nation rule. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. If implemented,
importation of drugs from Canada may materially and adversely affect the price we receive for any of our therapeutic candidates. Additionally,
in December 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to
plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule
also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements
between pharmacy benefit managers and manufacturers. In December 2020, HHS published a regulation removing safe harbor protection for
price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers,
unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale,
as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order,
the removal and addition of the aforementioned safe harbors were delayed, and recent legislation imposed a moratorium on implementation
of the rule until January 2026. The Inflation Reduction Act of 2022, or the IRA, further delayed implementation of this rule to January
2032.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In August 2022, the
IRA was signed into law. The IRA includes several provisions that will impact our business to varying degrees, including provisions that
create a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, impose new manufacturer financial liability on all drugs in Medicare
Part D, allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic
or biosimilar competition, require companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay
the rebate rule that would require pass through of pharmacy benefit manager rebates to beneficiaries. The effect of IRA on our business
and the healthcare industry in general is not yet known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Although a number of
these and other proposed measures may require authorization through additional legislation to become effective, and the Executive branch
may reverse or otherwise change these measures, both the current administration and Congress have indicated that they will continue to
seek new legislative measures to control drug costs. Individual states in the United States have also become increasingly active in passing
legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Additional Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In addition to the foregoing,
state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act,
the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use,
handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If
our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages
and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance
therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our
future operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Europe/Rest of World Government
Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">In addition to regulations
in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials
and any commercial sales and distribution of our therapeutics. Whether or not we obtain FDA approval of a therapeutic, we must obtain
the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of
the therapeutic in those countries. Certain countries outside of the United States have a similar process that requires the submission
of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical
trial application must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the
FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#8217;s requirements, clinical
trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be
restricted in some countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The requirements and
process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases,
the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that
have their origin in the Declaration of Helsinki.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">To obtain regulatory
approval of an investigational drug or biological product under EU regulatory systems, we must submit a Market Authorization Application.
The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things,
country-specific document requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">For other countries
outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials,
product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted
in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration
of Helsinki.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">If we fail to comply
with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory
approvals, product recalls, seizure of therapeutics, operating restrictions and criminal prosecution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Employees and Human Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024,
we had 123 full-time employees and 16 non-employee leased workers. Of these employees, 19 held Ph.D. and/or M.D. degrees, 25 were engaged
in research and development and 60 were engaged in technical operations. Substantially all of our employees are located in Florham Park,
New Jersey. Our employees are not represented by labor unions or covered by collective bargaining agreements. We consider our relationship
with our employees to be good.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our human capital resources
objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and additional employees.
The principal purposes of our incentive plans are to attract, retain and motivate selected employees, consultants, and directors through
the granting of stock-based compensation awards and when available, cash-based performance bonus awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Available Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We post our annual report
on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports filed or furnished pursuant
to Section 13(a) or 15(d) of the Exchange Act, free of charge, on the Investors section of our public website (www.celularity.com) as
soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. In addition, you can read our
SEC filings over the Internet at the SEC&#8217;s website at www.sec.gov. The contents of these websites are not incorporated into this
annual report on Form 10-K. Further, our references to the URLs for these websites are intended to be inactive textual references only.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><span id="a_001Yosu2"></span>Item 1A. Risk Factors. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>You should carefully consider
the following risk factors, as well as the other information in this annual report on Form 10-K, and in our other public filings. The
occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause
our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may
make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business. </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Risks Related to Business and Industry</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We have incurred net losses in every period
since our inception, have no cellular therapeutics approved for commercial sale and anticipate that we will incur substantial net losses
in the future.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company, have no cellular therapeutics approved for commercial sale, have not generated any revenue from cellular therapeutic sales to
date, and will continue to incur research and development and other expenses related to our ongoing operations. Investment in biopharmaceutical
product development is highly speculative because it entails substantial upfront expenditure and significant risk that any potential therapeutic
candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially
viable. As a result, we are not profitable and have incurred net losses in each period since our inception. We reported a net loss of
$57.9 million and $196.3 million for the years ended December 31, 2024 and 2023, respectively. We had an accumulated deficit of $899.7
million at December 31, 2024 and $0.7 million of cash and cash equivalents at such date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Even after significant reductions
in headcount in 2023, our strategic review to refocus our pipeline, and capital raises in 2024, we expect to incur significant expenditures
for the foreseeable future, and we expect these expenditures to increase as we continue production of our commercial products that have
seen strong demand. We will continue to incur research and development and other expenditures to develop and market therapeutic candidates.
We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.
The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue
from our current and future biomaterial products. Our prior losses and expected future losses have had and will continue to have an adverse
effect on our stockholders&#8217; equity and working capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Our historical operating results indicate
substantial doubt exists related to our ability to continue as a going concern.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have incurred net losses
and used significant cash in operating activities since inception, have no cellular therapeutic candidates approved for commercial sale
and we anticipate that we will incur substantial net losses in the future. We had an accumulated deficit of $899.7 million and have cash
and cash equivalents of $0.7 million as of December 31, 2024, and as of the date of this filing, had no available additional sources of
outside capital to sustain our operations for a period of six months beyond the issuance date. Accordingly, there is substantial doubt
about our ability to continue as a going concern, which may affect our ability to obtain future financing and may require us to further
curtail our operations and our independent registered public accounting firm included in its opinion for the year ended December 31, 2024
an explanatory paragraph referring to our recurring losses, and net cash outflows from operations and outstanding debt and expressing
substantial doubt in our ability to continue as a going concern without additional capital becoming available. For additional details,
see the discussion under &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211;
Overview - Going Concern.</i>&#8221; We will need to raise additional capital to support our operations. This additional funding may not
be available on acceptable terms or at all. Failure to obtain this necessary capital or address our liquidity needs may force us to delay,
limit or terminate our operations, make further reductions in our workforce, discontinue our commercialization efforts for our biomaterials
products as well as other clinical trial programs, liquidate all or a portion of our assets or pursue other strategic alternatives, and/or
seek protection under the provisions of the U.S. Bankruptcy Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We will need substantial additional financing
to develop our therapeutics and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete
the development and commercialization of our therapeutic candidates. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We will need substantial
additional financing to develop our therapeutics and implement our operating plans. Further, if approved, we will require significant
additional amounts in order to launch and commercialize our therapeutic candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024 and
2023, we had $0.7 million and $0.2 million in cash and cash equivalents, respectively. We will need to raise additional capital to implement
our plans. Further, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may
need to spend more money than currently expected because of circumstances beyond our control. We may also need to raise a large amount
of capital sooner than currently anticipated if we choose to expand more rapidly than our present plans. In any event, we will require
additional capital for the further development and commercialization of our therapeutic candidates, including funding our internal manufacturing
capabilities and growth of our degenerative disease business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We cannot be certain that
additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable
to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue
the development or commercialization of our therapeutic candidates or other research and development initiatives. We could be required
to seek collaborators for our therapeutic candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable
than might otherwise be available or relinquish or license on unfavorable terms our rights to our therapeutic candidates in markets where
we otherwise would seek to pursue development or commercialization ourselves. Any of the above events could significantly harm our business,
prospects, financial condition and results of operations and cause the price of our securities to decline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>We may expend our limited resources to
pursue product candidates that do not yield a successful product and fail to capitalize on development opportunities or therapeutic candidates
that may be more profitable or for which there is a greater likelihood of success. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Due to the significant resources required for
the development of our product candidates, we must focus on specific treatment pathways and decide which product candidates to pursue
and the amount of resources to allocate to each such product candidate. Specifically, we are focused on the development of cellular therapeutic
candidates, targeting indications across cancer, infectious and degenerative diseases. Our decisions concerning the allocation of research,
development, collaboration, management and financial resources toward particular product candidates may not lead to the development of
any viable product and may divert resources away from better opportunities. Similarly, any decision to delay, terminate or collaborate
with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities.
If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misinterpret
trends in the pharmaceutical, biopharmaceutical or biotechnology industry, our business, financial condition and results of operations
could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities,
be required to forego or delay pursuit of opportunities with other product candidates that may later prove to have greater commercial
potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or
other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development
and commercialization rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Our placental-derived cellular therapy
candidates represent a novel approach to cancer, infectious and degenerative disease treatments that creates significant challenges. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are developing a pipeline
of allogeneic cellular therapeutic candidates that are derived from healthy, full-term, human donor placentas, and in certain cases, are
genetically modified. Allogeneic cells are intended to be &#8220;off-the-shelf&#8221; for use in any patient. Advancing these novel therapeutic
candidates creates significant challenges, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">manufacturing cellular therapeutic candidates to our and regulatory specifications and in a timely manner to support our clinical trials, and, if approved, commercialization; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">biosourcing placentas and other materials and supplies for the manufacture of our therapeutic candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">any variability in placental-derived cells, or a higher-rejection rate, which could ultimately affect our ability to produce therapeutics in a reliable and consistent manner and treat certain patients; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">educating medical personnel regarding the potential advantages and potential disadvantages such as the side effect profile of our therapeutics, if approved, such as the potential adverse side effects related to GvHD, cytokine release syndrome, or CRS, neurotoxicity, prolonged cytopenia and neutropenic sepsis; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">using medicines to manage adverse side effects of our therapeutic candidates that may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">obtaining regulatory approval, as the FDA, and other regulatory authorities have limited experience with development of allogeneic cell therapies for cancer, infectious and degenerative diseases; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt; line-height: 120%">establishing sales and marketing capabilities for our therapeutic portfolio upon obtaining any regulatory approval to gain market acceptance of a novel therapy. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
gene-editing technology we use is relatively new, and if we are unable to use this technology in our intended therapeutic candidates,
our revenue opportunities will be materially limited. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
use gene editing techniques to modify certain of the placental-derived cell types. We use these technologies to either reduce the risk
of toxicity or improve the potential for efficacy. These technologies are relatively new and may not be shown to be effective at achieving
the expected effect in clinical studies, or may be associated with safety issues, either in our clinical development programs or those
of others using these novel technologies. Any issues with the novel gene editing technologies, even if not experienced by us, could negatively
affect our development programs. Genetic modifications may create unintended changes to the DNA of the edited cell, such as a non-target
site gene-editing, a large deletion, or a DNA translocation, any of which could lead to unwanted side-effects. The gene-editing of our
therapeutic candidates may also not be successful in limiting the risk of GvHD or thrombosis or in increasing affinity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
competitors in the allogeneic cell therapy space and more broadly in the gene therapy space have had clinical trials put on hold by the
FDA. Based on findings in those clinical trials, the FDA may request additional testing, request different types of testing or even substantially
revise the methodology used to evaluate clinical trials for other companies pursuing similar therapeutic avenues. We cannot control the
actions of our competitors, cannot influence the results of their clinical trials and cannot know how FDA may react to a specific fact
pattern arising in another clinical trial. Additional testing, different types of testing or a revised regulatory approach may delay
our future clinical trials, increase costs in our future trials or otherwise preclude our trial from being given permission to proceed
absent substantial time, effort and resources on our part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gene-editing industry is rapidly developing, and our competitors may introduce new technologies that render the technologies that we
employ for our therapeutic candidates obsolete or less attractive. New technology could emerge at any point in the development cycle
of our therapeutic candidates. As competitors use or develop new technologies, any failures of such technology could adversely impact
our programs. We also may be placed at a competitive disadvantage, and competitive pressures may force us to implement new technologies
at a substantial cost. In addition, our competitors may have greater financial, technical and personnel resources that allow them to
enjoy technological advantages and may in the future allow them to implement new technologies before we can. We cannot be certain that
we will be able to implement technologies on a timely basis or at an acceptable cost. If we are unable to maintain technological advancements
consistent with industry standards, our operations and financial condition may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will rely on licensed gene editing technology for future cell therapy product candidates. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on patents, know-how and proprietary technology, both our own and licensed from others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
certain of these technologies are available from multiple commercial vendors, were any of these vendors to refuse to supply us, it could
negatively impact our development of our modified NK cells and mesenchymal stem cell-like adherent stromal cells, or MLASCs, which depend
on genetic modification to achieve the intended clinical benefits. Moreover, some gene editing technology that is currently available
without license, could become patented or proprietary to a third party. If we are unable to obtain a license on commercially reasonable
terms when needed, we could be forced to redesign our cellular therapeutics and or stop development. Any of these occurrences could have
a material adverse effect on our business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may also arise between us and our current and future licensors regarding intellectual property subject to a license agreement, including
those related to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    scope of rights granted under the license agreement and other interpretation-related issues; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the
    licensing agreement; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    right to sublicense patent and other rights to third parties under collaborative development relationships; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of
    our therapeutic candidates, and what activities satisfy those diligence obligations; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and
    our partners. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
disputes over intellectual property that we have licensed, or may license in the future, prevent or impair our ability to maintain our
licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected therapeutic candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are generally also subject to all of the same risks with respect to protection of intellectual property that we license as for intellectual
property that we own. If we or our current and future licensors fail to adequately protect this intellectual property, our ability to
commercialize products could suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
therapeutic candidates are based on novel technologies, which makes it difficult to predict the time and cost of therapeutic candidate
development and obtaining regulatory approval. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be concentrating our research, development and manufacturing efforts on our placental-derived allogeneic T cell, NK cell and MLASC
therapeutic candidates. We have developed our Celularity IMPACT platform, which covers biosourcing through manufacturing of cryopacked
cells, and continues to invest in optimizing and improving our technologies. There can be no assurance that any development problems
we experience in the future will not cause significant delays or unanticipated costs, or that such development problems can be overcome.
We may also experience delays in scaling our manufacturing process when appropriate for commercialization, which may prevent us from
completing future clinical studies or commercializing our therapeutics on a timely or profitable basis, if at all. Finding a suitable
dose for our cell therapeutic candidates may delay our anticipated clinical development timelines. In addition, our expectations with
regard to our scalability and costs of manufacturing may vary significantly as we develop our therapeutic candidates and understand these
critical factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical study requirements of the FDA, European Medicines Agency, and other regulatory agencies and the criteria these regulators use
to determine the safety and efficacy of a therapeutic candidate are determined according to the type, complexity, novelty and intended
use and market of the potential therapeutics. The regulatory approval process for novel therapeutics candidates such as ours can be more
complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other therapeutic
candidates. In addition, under guidelines issued by the National Institutes of Health, or NIH, gene therapy clinical trials are also
subject to review and oversight by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees
research utilizing recombinant or synthetic nucleic acid molecules at that institution. Before a clinical trial can begin at any institution,
that institution&#8217;s institutional review board, or IRB, and its IBC assesses the safety of the research and identifies any potential
risk to public health or the environment. While the NIH guidelines are not mandatory unless the research in question is being conducted
at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and
other institutions not otherwise subject to the NIH guidelines voluntarily follow them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we expect reduced variability in our allogeneic cell therapeutic candidates compared to autologous products, we do not have clinical
data supporting any benefit of lower variability and the use of healthy donor full-term placentas, and related screening requirements,
may create separate variability challenges. More generally, approvals by any regulatory agency may not be indicative of what any other
regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new therapeutic
candidates. Moreover, our therapeutic candidates may not perform successfully in clinical trials or may be associated with adverse events
that distinguish them from the autologous therapies that have previously been approved. For instance, allogeneic T cell therapeutic candidates
may result in GvHD not experienced with autologous T cell products. Even if we collect promising initial clinical data of our therapeutic
candidates, longer-term data may reveal new adverse events or responses that are not durable. Unexpected clinical outcomes would significantly
impact our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
therapeutic candidates may cause undesirable side effects or have other properties that could halt our clinical development, prevent
our regulatory approval, limit our commercial potential or result in significant negative consequences.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undesirable
or unacceptable side effects caused by our therapeutic candidates could cause us or regulatory authorities to interrupt, delay or halt
clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable
foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects
or unexpected characteristics. Autologous cell therapies that approved for, or under development by other companies, have shown frequent
rates of CRS and neurotoxicity, and adverse events have resulted in the death of patients. Our potential future therapeutic candidates
may undergo genetic engineering. As these are novel technologies, errors may occur or may not present until used in humans in the clinic,
and could cause adverse events. While we believe that placental-derived cells have an inherent safety profile that may limit adverse
events, there can be no assurance that this is the case as these are novel therapeutics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we continue to evolve our placental-derived therapeutic programs, we may need to halt or modify development of certain candidates as
a result of adverse events. For example, in designing APPL-001, we made certain modifications and adjustments, including a genetic modification
due to an increased risk of thrombosis observed in a Phase 1 clinical trial of a legacy placental-derived MLASC done at Celgene Cellular
Therapeutics. The APPL-001 program has since been discontinued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
any of our planned clinical trials, patients may experience severe adverse events related to our allogeneic cell therapeutic candidates,
some of which may result in death. If unacceptable toxicities arise in the development of our therapeutic candidates, we could suspend
or terminate our trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval
of our therapeutic candidates for any or all targeted indications. The data safety monitoring board may also suspend or terminate a clinical
trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk,
including risks inferred from other unrelated immunotherapy trials. Treatment-related side effects could also affect patient recruitment
or the ability of enrolled subjects to complete the trial or result in potential product liability claims. In addition, these side effects
may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from cell therapy are not normally
encountered in the general patient population and by medical personnel. Any of these occurrences may harm our business, financial condition
and prospects significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Planned
future clinical trials for our product candidates may fail to demonstrate the safety and efficacy of any of our therapeutic candidates,
which would prevent or delay regulatory approval and commercialization. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
obtaining regulatory approvals for the commercial sale of any cell therapeutic candidates, we must demonstrate through lengthy, complex
and expensive preclinical testing and clinical trials that the therapeutic candidates are both safe and effective for use in each target
indication. Clinical testing is expensive and can take many years to complete, and our outcome is inherently uncertain. Failure can occur
at any time during the clinical trial process. The results of preclinical studies and early clinical trials of any therapeutic candidates
may not be predictive of the results of later-stage clinical trials, including in any post-approval studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is typically an extremely high rate of attrition from the failure of therapeutic candidates proceeding through clinical trials. Therapeutic
candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through
preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks
in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding
promising results in earlier trials. Most therapeutic candidates that commence clinical trials are never approved as therapeutics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, for any future trials that may be completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret
the results as we do, including, for example, any re-analysis of legacy data that we perform, and more trials could be required before
we submit our therapeutic candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign
regulatory authorities for support of a marketing application, approval of our therapeutic candidates may be significantly delayed, or
we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support
of potential approval of our therapeutic candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Initial,
interim and preliminary data from any clinical trials that we announce or publish from time to time may change as more patient data become
available and are subject to audit and verification procedures that could result in material changes in the final data. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publish initial, interim or preliminary data from our clinical studies. Interim data from clinical trials that we
may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues
and more patient data become available. Preliminary data also remain subject to audit and verification procedures that may result in
the final data being materially different from the preliminary data previously published. As a result, initial, interim and preliminary
data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final
data could significantly harm our business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to submit INDs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit
such trials to proceed. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to submit INDs for our therapeutic candidates in the future. We cannot be certain that submission of an IND or IND amendment will
result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate
such clinical trials. The manufacturing of allogeneic cell therapies remains an emerging and evolving field. Accordingly, we expect chemistry,
manufacturing and control related topics, including product specification, will be a focus of IND reviews, which may delay the clearance
of INDs. Additionally, even if the FDA permits the initiation of the clinical trials set forth in an IND or clinical trial application,
we cannot guarantee that the FDA will not change our requirements in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
HCT/P products are subject to extensive government regulation and our failure to comply with these requirements could cause our business
to suffer.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
sell human tissue-derived products, which are referred to by the FDA as HCT/Ps. Certain HCT/Ps are regulated by the FDA solely under
Section 361 of the Public Health Service Act and are referred to as &#8220;Section 361 HCT/Ps,&#8221; while other HCT/Ps are subject
to FDA&#8217;s regulatory requirements applicable to medical devices or biologics. Section 361 HCT/Ps do not require 510(k) clearance,
PMA approval, biologics license application, or BLA, or other premarket authorization from FDA before marketing. We believe our HCT/Ps
are regulated solely under Section 361 of the PHSA, and therefore, we have not sought or obtained 510(k) clearance, PMA approval, or
licensure through a BLA. While certain determinations by FDA have been provided regarding Interfyl and Biovance, the FDA could disagree
with our determination that other of our human tissue products are Section 361 HCT/Ps and could determine that these products are biologics
requiring a BLA or medical devices requiring 510(k) clearance or PMA approval, and could require that we cease marketing such products
and/or recall them pending appropriate clearance, approval or license from the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter substantial delays in our planned clinical trials or may not be able to conduct our trials on the timelines we expect.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned
or completed on schedule, if at all. Even if our trials begin as planned, issues may arise that could cause us or relevant regulatory
authorities to suspend or terminate such clinical trials. A failure of one or more clinical studies can occur at any stage of testing,
and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development
include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
    to generate sufficient preclinical, toxicology or other <i>in vivo</i> or in vitro data to support the initiation of clinical studies;
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
    sourcing healthy full-term donor placentas of sufficient quality and in sufficient quantity to meet our development needs; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in developing suitable assays for screening patients for eligibility for trials with respect to certain therapeutic candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching a consensus with regulatory agencies on study design; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the
    terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in obtaining required IRB approval at each clinical study site; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition
    of a temporary or permanent clinical hold by regulatory agencies for a number of reasons; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in patient recruitment, difficulty collaborating with patient groups and investigators, or other issues involving patients, such
    as completing participation or return for post-treatment follow-up, or dropping out; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by our CROs, other third parties or us to adhere to clinical study requirements; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to perform in accordance with the FDA&#8217;s GCP requirements or applicable regulatory guidelines in other countries; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issues
    with manufacturing of cellular therapeutics, including delays in manufacturing, testing, releasing, validating sufficient stable
    quantities of our therapeutic candidates for use in clinical studies or the inability to do any of the foregoing; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">occurrence
    of adverse events associated with the therapeutic candidate that are viewed to outweigh its potential benefits; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in regulatory requirements and guidance that require amending or submitting new clinical protocols; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the standard of care on which a clinical development plan was based, which may require new or additional trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of clinical studies of our therapeutic candidates being greater than we anticipate; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
    or inconclusive results from clinical studies, which may result in us deciding, or regulators requiring us, to conduct additional
    clinical studies or abandon development programs; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet its quantity or
    quality requirements for necessary raw materials. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
pandemics may increase the risk of certain of the events described above and delay our development timelines. For example, in early 2020
and again in mid-2021, we experienced delays in enrolling our Phase 1 clinical trial of CYNK-001 for acute myeloid leukemia, or AML,
as a result of the COVID-19 pandemic. We have since discontinued development of CYNK-001 for AML and are only evaluating it in senolytic/senoablation
for age-related conditions while we seek a collaboration partner. Any inability to successfully complete preclinical and clinical development
could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation
changes to our therapeutic candidates, we may be required to, or we may elect to conduct additional studies to bridge our modified candidates
to earlier versions or may need to conduct additional studies on newly discovered candidates. Clinical study delays could also shorten
any periods during which our therapeutics have patent protection and may allow our competitors to bring cell therapies to market before
we do, which could impair our ability to successfully commercialize our therapeutic candidates and may harm our business and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business could be materially adversely affected by the effects of health pandemics or epidemics in regions where we or third parties
on which we rely have concentrations of clinical trial sites or other business operations. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be materially adversely affected by the effects of health pandemics or epidemics. Additionally, our ability to collect
healthy, full-term donor placentas was limited during the height of the COVID-19 pandemic in New Jersey and the tri-state area as hospital
resources were diverted. We are now also subject to risk of outbreaks at our facilities, and potential exposure to employee claims regarding
workplace safety, and unanticipated shutdowns or quarantines could be imposed in the future, which would disrupt our operations. Policies
and restrictions enacted to counter a future pandemic might negatively impact productivity, disrupt our business and delay clinical programs
and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our
ability to conduct our business in the ordinary course, which could negatively impact our business, operating results and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Monitoring
and managing toxicities in patients receiving therapeutic candidates is challenging, which could adversely affect our ability to obtain
regulatory approval and commercialize our therapeutic candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to contract with academic medical centers and hospitals experienced in the assessment and management of toxicities and adverse
events arising during clinical trials. Even with appropriate procedures in place, these centers and hospitals may have difficulty observing
patients and treating toxicities or any other adverse events, which could lead to more severe or prolonged toxicities or even patient
deaths. If there are any serious issues with GvHD or any other unanticipated events, it could result in us or the FDA delaying, suspending
or terminating one or more of our clinical trials, which could jeopardize regulatory approval of our therapeutic candidates. Moreover,
to the extent our cellular therapies are used outside of hospitals or medical centers, and upon any approval if our therapies are made
more widely available on a commercial basis, it may become even more difficult to observe and manage adverse events. Moreover, medicines
used at centers to help manage adverse side effects of our therapeutic candidates, such as any GvHD, may not adequately control the side
effects and/or may have a detrimental impact on the efficacy of the treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials are expensive, time-consuming and difficult to design and implement.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human
clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements.
Because our allogeneic placental-derived cell therapeutic candidates are based on new technologies and will require the creation of inventory
of mass-produced, off-the-shelf therapeutics, we expect that they will require extensive research and development and have substantial
manufacturing and processing costs. In addition, costs to treat patients with certain cancers or other targeted indications, including
treating any potential side effects, could be significant. Accordingly, our clinical trial costs for our cellular therapeutic candidates
are likely to be significantly higher than for more conventional therapeutic technologies or drug products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to develop additional therapeutic candidates, our commercial opportunity will be limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a pipeline of potential commercial products in the biomaterials segment of our business. We have requested and received preliminary
feedback from FDA regarding the appropriate regulatory pathway for those product candidates. Our current development assumptions and
timelines reflect our expectation of the appropriate regulatory pathway. Issues arising from further product development may mean that
a longer and more expensive pathway may eventually be required. This could limit our commercial opportunities or cause us to abandon
those development candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
organizational changes and cost cutting measures may not be successful. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2022 and January 2023, we implemented reductions-in-force that affected a majority of our workforce, and in the fourth quarter
of 2023, we refocused our cellular therapeutics pipeline to align with the results of clinical trials and ongoing evaluations of our
development plans. While these measures were intended to optimize resources and address our evolving operational needs, they have also
resulted in significant organizational changes and could have unintended adverse consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notably,
we have experienced attrition beyond the intended reductions-in-force, including the departure of key personnel in administrative functions
such as finance and legal. This loss of critical expertise has created challenges in maintaining operational continuity, meeting regulatory
and financial reporting requirements, and supporting our strategic objectives. Replacing these personnel with qualified individuals may
be difficult and could require additional and unanticipated costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to maintain the necessary operational and administrative infrastructure, we may face delays or difficulties in resuming
suspended development activities, pursuing new initiatives, or fulfilling our ongoing obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
departure of several executive officers and other key personnel has further compounded these risks, potentially impairing our ability
to execute our business plan, comply with regulatory requirements, and manage our financial and operational risks effectively. Any of
these consequences could materially and adversely affect our business, financial condition, and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
operate our own manufacturing and storage facility, which requires significant resources; manufacturing or other failures could adversely
affect our clinical trials and the commercial viability of our therapeutic candidates and our biobanking and degenerative diseases businesses.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a purpose-built facility located in Florham Park, New Jersey, where we process healthy full-term donor placentas for use in cell
therapy and tissue products and operate our biobanking business. While we have experience managing the process for our research and early
stage clinical trial needs, we may not be able to mass-produce off-the-shelf placental-derived allogeneic cellular therapeutics to satisfy
demands for any of our therapeutic candidates as we expand into later stage clinical trials, or for commercial production post-approval.
While we believe the manufacturing and processing approaches are appropriate to support our current needs and that we have a scalable
process, we cannot be sure that our scaled process will result in allogeneic cells that will be safe and effective. Further, our manufacturing
and storage facility, including for our biobanking and degenerative disease businesses, must comply with current good manufacturing practices,
or cGMP, which includes, as applicable, the FDA&#8217;s current good tissue practices, or GTPs, for the use of human cellular and tissue
products. Accordingly, we are subject to ongoing periodic unannounced inspection by the FDA and other governmental agencies to ensure
strict compliance with cGMP, including GTPs as applicable, and other government regulations. For example, in August 2023, the FDA conducted
an inspection at our Florham Park, New Jersey manufacturing facility. The FDA issued a Form FDA 483, which is a list of inspectional
observations provided at the conclusion of the inspection, relating to our Interfyl and CentaFlex human tissue-based biomaterial products.
We provided detailed written responses to the FDA and took actions in response to the FDA&#8217;s observations. As of February 2025,
FDA has taken no further action in connection with this inspection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing
techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling
out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production
costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified
personnel, as well as compliance with strictly enforced federal, state and foreign regulations. The application of new regulatory guidelines
or parameters, such as those related to release testing, may also adversely affect our ability to manufacture our therapeutic candidates.
Furthermore, if contaminants are discovered in our supply of therapeutic candidates or in the manufacturing facilities, such supply may
have to be discarded, and our manufacturing facilities may need to be closed for an extended period of time to investigate and remedy
the contamination. We cannot assure any stability or other issues relating to the manufacture of our therapeutic candidates will not
occur in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
or any other of our vendors may fail to manage the logistics of storing and shipping our raw materials, including donor placentas. Storage
failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, health pandemics
or epidemics, could result in the inability to manufacture therapeutics, the loss of usable therapeutics or prevent or delay the delivery
of therapeutic candidates to patients and clinical trial sites. We may also experience manufacturing difficulties due to resource constraints
or as a result of labor disputes. If we were to encounter any of these difficulties, our ability to provide our therapeutic candidates
to patients would be jeopardized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently have no cellular therapeutics marketing sales force. If we are unable to establish future marketing and sales capabilities
or enter into agreements with third parties to market and sell our therapeutic candidates once approved, we may not be able to generate
cell therapy product revenue. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current sales force is limited to our degenerative disease and biobanking businesses. We may develop an in-house specialized marketing
organization and sales force for our cellular therapeutic candidates, if such candidates receive regulatory approval, which will require
significant expenditures, management resources and time. If we elect to develop an in-house sales force, we will have to compete with
other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. If we are unable or
decide not to establish internal sales, marketing and distribution capabilities for our cellular therapeutics once approved, we will
pursue collaborative arrangements regarding the sales and marketing of cellular therapeutics; however, there can be no assurance that
we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that they will have effective sales
forces. Any revenue we receive from the sale of cellular therapeutics will depend upon the efforts of such third parties, which may not
be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from therapeutic
sales may be lower than if we had commercialized our therapeutic candidates directly, as we do for our degenerative disease products
and biobanking business. We also face competition in our search for third parties to assist us with the sales and marketing efforts of
our therapeutic candidates. There can be no assurance that we will be able to develop in-house sales and distribution capabilities or
establish or maintain relationships with third-party collaborators to commercialize any therapeutic that receives regulatory approval
in the United States or in other markets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>A
variety of risks associated with conducting research and clinical trials abroad and marketing our therapeutic candidates internationally
could materially adversely affect our business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to globally develop our therapeutic candidates and market our degenerative disease products outside the United States. Accordingly,
we expect that we will be subject to additional risks related to operating in foreign countries, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    regulatory requirements in foreign countries; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected
    changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    standards for the conduct of clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    difficulties in managing the logistics and transportation of storing and shipping therapeutic candidates or biomaterials produced
    in the United States and shipping the therapeutic candidate to the patient abroad, which may necessitate local or regional manufacture,
    including the need to source healthy full-term donor placentas outside the United States; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">import
    and export requirements and restrictions, including as they pertain to donor placentas and human tissue collection and manufacture;
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
    weakness, including inflation, or political instability in particular foreign economies and markets; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    taxes, including withholding of payroll taxes; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign
    currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to
    doing business in another country; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    staffing and managing foreign operations; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce
    uncertainty in countries where labor unrest is more common than in the United States; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    liability under the FCPA or comparable foreign regulations; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect
    intellectual property rights to the same extent as the United States; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">production
    shortages resulting from any events affecting raw material supply, including obtaining sufficient donor placentas, and other issues
    with manufacturing abroad; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    interruptions resulting from natural or man-made disasters, including earthquakes, tsunamis, fires or other medical epidemics, or
    geo-political actions, including war and terrorism. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable
operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail
to compete effectively. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other
compounds, drugs or biomaterials that are able to achieve similar or better results. Our potential competitors for our cellular therapeutics
and biomaterials include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical
companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and
other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established
sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more
resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability
of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative
partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective,
safer, more easily commercialized or less costly than our therapeutic candidates or may develop proprietary technologies or secure patent
protection that we may need for the development of our technologies and products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval of our therapeutic candidates, the availability and price of our competitors&#8217; products could limit
the demand and the price we are able to charge for our therapeutic candidates. We may not be able to implement our business plan if the
acceptance of our therapeutic candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods
of treatment to our therapeutic candidates, or if physicians switch to other new drug or biologic products or choose to reserve our therapeutic
candidates for use in limited circumstances. For additional information regarding our competition, see the section entitled &#8220;<i>Business
- Competition</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may
not be able to successfully implement our business strategy. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and
retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and
medical personnel, including our Founder and Chief Executive Officer, Robert Hariri, M.D., Ph.D. The loss of the services of any of
our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable
replacements could result in delays in product development and harm our business. For example, we have had the departure of key
personnel in administrative functions such as finance and legal. This loss of expertise and background knowledge has created
challenges in maintaining operational continuity, meeting regulatory and financial reporting requirements, and supporting our
strategic objectives. Replacing these personnel with qualified individuals may be difficult and could require additional and
unanticipated costs and challenges including costs associated with engaging additional financial and legal advisors and the
challenges of bringing such third-party advisors current on our operations. We conduct substantially all of our operations at our
facilities in New Jersey. This region is headquarters to many other biopharmaceutical companies and many academic and research
institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly
qualified personnel on acceptable terms or at all. Despite efforts to retain valuable employees, members of our management,
scientific and development teams may terminate their employment on short notice. Although we have employment agreements with our key
employees, these employment agreements provide for at-will employment, which means that any of our employees could leave employment
at any time, with or without notice. We do not maintain &#8220;key person&#8221; insurance policies on the lives of these
individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and
motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical
personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may experience difficulties in managing the growth of our business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
our development and commercialization plans and strategies developed, and as we began operations as a public company, we expanded our
employee base and expected to add managerial, operational, sales, research and development, marketing, financial and other personnel.
However, in January 2023, we announced reprioritization of efforts, which resulted in a reduction of approximately 70 full-time employees
and 20 non-employee leased workers in March 2023. Accordingly, as of December 31, 2024, we had 123 full-time employees and 16 non-employee
leased workers. As we reposition our business and our personnel requirements evolve, we may be constrained in our ability to bring on
the necessary personnel to expand operations when and as required given our recent reduction in force.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
current and future growth imposes significant added responsibilities on members of management, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    recruiting, integrating, maintaining and motivating additional employees; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">managing
    our internal development efforts effectively, including the clinical and FDA review process for our therapeutic candidates, while
    complying with our contractual obligations to contractors and other third parties; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improving
    our operational, financial and management controls, reporting systems and procedures. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future financial performance and our ability to commercialize our therapeutic candidates will depend, in part, on our ability to effectively
manage our growth, and our management may also have to divert a disproportionate amount of attention away from day-to-day activities
in order to devote a substantial amount of time to managing these growth activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors,
we may not be able to successfully implement the tasks necessary to further develop, manufacture and commercialize our therapeutic candidates
and, accordingly, may not achieve our research, development, manufacturing and commercialization goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits
of such alliances or licensing arrangements. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third
parties that we believe will complement or augment our development and commercialization efforts with respect to our therapeutic candidates
and any future therapeutic candidates that we may develop. Any of these relationships may require us to incur non-recurring and other
charges, increase our near and long-term expenditures, issue securities that dilute stockholders or disrupt our management and business.
We licensed certain intellectual property back to Celgene in connection with the Anthrogenesis acquisition. Given the broad scope of
the license, Celgene could use our intellectual property to develop therapeutics that compete with us in the <span style="background-color: white">chimeric
antigen receptor, or</span> CAR, field. Additionally, we have potential obligations to Celgene under <span style="background-color: white">a
contingent value rights agreement, or </span>CVR Agreement, under which we may be required to make certain payments to Celgene with respect
to certain of our future therapeutic candidates. Our payment obligations to Celgene under the CVR Agreement may limit our ability to
partner such assets, were we choose to do so. See &#8220;<i>Business - Licensing Arrangements - Celgene Corporation.&#8221; </i>for more
information regarding the Celgene relationship.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and
complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for
our therapeutic candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third
parties may not view our therapeutic candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering
into new strategic partnership agreements related to our therapeutic candidates could delay the development and commercialization of
our therapeutic candidates in certain geographies for certain indications, which would harm our business prospects, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have in the past and in the future will continue to explore entering into new strategic alliances, collaborations, and licensing arrangements
with third parties related to non-core areas. Such arrangements are entered into based on information available at the relevant time
and may not lead to long-term collaborations after initial research and development is conducted. We are party to certain agreements,
and may in the future enter into new agreements, that contain non-competes or otherwise restrict our ability to operate in a particular
field.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
disputes may arise under our current or future strategic alliances, collaborations, or other agreements or arrangements that include
grants of intellectual property rights to or from us, or payments related thereto, including disagreements over scope of rights granted,
proprietary rights, payment obligations, contract interpretation or the preferred course of research, development or commercialization.
As a result of such disagreements, we may be required to pay additional amounts, there may be a reduction or delay in amounts payable
to us, or there may be delays in research, development or commercialization activities, or termination of the arrangements, which could
adversely impact our business and operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate
them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will
achieve the results, revenue or specific net income that justifies such transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not realize the benefits of acquired assets or other strategic transactions. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well
as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions and any future strategic
transactions depends on the risks and uncertainties involved, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    liabilities related to acquired companies or joint ventures; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    integrating acquired personnel, technologies and operations into our existing business; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">retention
    of key employees; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration
    challenges; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases
    in our expenses and reductions in our cash available for operations and other uses; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
    in our relationships with collaborators or suppliers as a result of such a transaction; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">possible
    write-offs or impairment charges relating to acquired businesses or joint ventures. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally,
foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across
different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic,
political and regulatory risks associated with specific countries. Future acquisitions or dispositions could result in potentially dilutive
issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill,
any of which could harm our financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
internal computer systems, or those used by our CROs, collaborators or other contractors or consultants, may fail or suffer security
breaches. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internal computer systems and those of our CROs, collaborators, and other contractors or consultants are vulnerable to damage from computer
viruses, unauthorized access, cybersecurity threats, and telecommunication and electrical failures. Cyber-attacks, denial-of-service
attacks, ransomware attacks, business email compromises, computer malware, viruses, and social engineering (including phishing) continue
to increase generally. Accordingly, if our cybersecurity measures or those of our service providers fail to protect against unauthorized
access, attacks (which may include sophisticated cyberattacks), compromise or the mishandling of data by our employees or contractors,
then our reputation, customer trust, business, results of operations and financial condition could be adversely affected. Cyber incidents
have been increasing in sophistication and can include third parties gaining access to sensitive data using stolen or inferred credentials,
computer malware, viruses, spamming, phishing attacks, ransomware, card skimming code, and other deliberate attacks and attempts to gain
unauthorized access. The techniques used to sabotage or to obtain unauthorized access to our internal computer systems in which data
is stored or through which data is transmitted change frequently, and we may be unable to implement adequate preventative measures or
stop security breaches while they are occurring. Because the techniques used by threat actors who may attempt to penetrate and sabotage
our computer systems change frequently and may not be recognized until launched against a target, we may be unable to anticipate these
techniques. While we have not experienced any such material system failure or security breach to date, if such an event were to occur
and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations.
For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach in
our systems or infrastructure (including provided by third party vendors) were to result in a loss of, or damage to, our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization
of our therapeutic candidates could be delayed. In addition, our increased reliance on personnel working from home could increase our
cybersecurity risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could
adversely impact our business. As an early-stage company without significant investments in data security protection, we may not be sufficiently
protected against such occurrences and may not have the resources to allocate to such efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel,
prevent new therapeutics and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from
performing normal functions on which the operation of our business may rely, which could negatively impact our business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the FDA to review and approve new therapeutics can be affected by a variety of factors, including government budget and funding
levels, ability to hire and retain key personnel and accept payment of user fees, statutory, regulatory and policy changes, and business
disruptions, such as those that may be caused by the pandemics. Average review times at the agency have fluctuated in recent years as
a result. In addition, funding of government agencies on which our operations may rely, including those that fund research and development
activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies
may also slow the time necessary for new biologics to be reviewed and/or approved by necessary government agencies, which would adversely
affect our business. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during
the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency
has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application
until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete
response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside
the U.S. may adopt similar restrictions or other policy measures and may experience delays in their regulatory activities. If a prolonged
government shutdown or disruption occurs, it could significantly impact the ability of the FDA or other regulatory authorities to timely
review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government
shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue
our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business
disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the business disruptions and clinical trial delays caused by the pandemics as described above, our operations, and those
of our CROs and other contractors and consultants, could be subject to other disruptions, including those caused by power shortages,
telecommunications failures, water shortages, floods, hurricanes, tornadoes, fires, earthquakes, extreme weather conditions, medical
epidemics and other natural or man-made disasters or business interruptions. The occurrence of any of these business disruptions could
seriously harm our operations and financial condition and increase our costs and expenses. Our ability to manufacture our therapeutic
candidates could be disrupted if our operations or those of our suppliers are affected by a man-made or natural disaster or other business
interruption. Moreover, because our core operations are concentrated at our purpose-built facility in Florham Park, New Jersey, any disruptions
at this site, if prolonged, could materially harm our business and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we do not obtain and maintain federal and state licenses and registrations required for our current and future operations, our ability
to generate revenue will be limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health care industry is subject to stringent regulation by a wide range of authorities. Accordingly, our business requires us to maintain
certain licenses, registrations, permits, authorizations, approvals, certifications, accreditations and other types of federal, state,
and local governmental permissions and to comply with various regulations in every jurisdiction in which we operate. For example, we
are required to maintain licenses and registrations in several states, and have obtained biologics, tissue bank and blood bank licenses,
permits and registrations in states where such licensure is required for us to market and support our products and services. We also
maintain an annual registration with the FDA as a tissue bank, and national accreditation by the American Association of Blood Banks.
The failure to comply with such licensure requirements can result in enforcement actions, including the revocation or suspension of the
licenses, registrations or accreditations, or subject us to plans of correction, monitoring, civil money penalties, civil injunctive
action and/or criminal penalties. While we believe that, given our current and proposed business, we are not presently required to obtain
additional licenses or registrations to market our products or services, we cannot predict whether additional regulatory approval will
be required in the future and, if so, whether such approval will at such time be obtained, whether for the stem cells and/or any other
services that we are developing or may attempt to develop. Our failure to obtain and maintain required federal and state licenses and
registration will limit our ability to generate revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
relationships with customers, physicians, and third-party payors are subject to numerous laws and regulations. If we or our employees,
independent contractors, consultants, commercial partners and vendors violate these laws, we could face substantial penalties. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in a highly regulated industry, and our relationships with customers, physicians, and third-party payors are subject to numerous
laws and regulations. See &#8220;Business - Government Regulation and Product Approval - Other U.S. Healthcare Laws and Compliance Requirements&#8221;.
Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation
and prescription of any therapeutic candidates for which we obtain marketing approval. Our current and future arrangements with healthcare
providers, third-party payors, customers, and others may expose us to broadly applicable fraud and abuse and other healthcare laws and
regulations. These laws may impact, among other things, our clinical research and development programs, as well as our proposed and future
sales, marketing and education programs for our cellular therapeutics, as well as the sales and marketing of our degenerative disease
products and biobanking business. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive
laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict
or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements.
We may also be subject to federal, state and foreign laws governing the privacy and security of identifiable patient information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that
some of our business activities, or our arrangements with physicians, some of whom may receive stock options as compensation for service
on our scientific advisory board, could be subject to challenge under one or more of such laws. If we or our employees, independent contractors,
consultants, commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions or significant
penalties. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct
or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling
unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from
a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable
healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business
practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare
laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourself or asserting our
rights, those actions could have a significant impact on our business, including the imposition of significant penalties and corrective
measures, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval
and commercialization of any of our therapeutic candidates or our degenerative disease products outside the United States will also likely
subject us to an additional overlay of foreign equivalents of the healthcare laws, among other foreign laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies often scrutinize interactions
between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements
in the healthcare industry. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible
investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing,
storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
collection, use, processing, and cross-border transfer of personal information, including individually identifiable health information,
is governed by restrictive regulations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is broadly regulated by U.S. and foreign regulatory authorities, and we must comply with all applicable rules and regulations
concerning our use, processing, handling, maintenance, and protection of personal information. In the U.S., <span style="background-color: white">the
Health Insurance Portability and Accountability Act, or </span>HIPAA, imposes requirements at the federal level relating to the privacy,
security and transmission of individually identifiable health information, while individual states, such as California and Virginia,
have adopted privacy regulations restricting the use of personal information and providing individuals certain rights with respect to
the collection and use of their data. See &#8220;Business - Government Regulation and Product Approval - Other U.S. Healthcare Laws and
Compliance Requirements&#8221; for more information regarding U.S. privacy and data protection laws. Further, the collection and use
of personal information in Europe is governed by the European Union&#8217;s, or EU&#8217;s, General Data Protection Regulation and the
United Kingdom&#8217;s implementation of the same, or the GDPR. Failure to comply with the requirements of the GDPR and other applicable
data protection laws of the EU member states and the United Kingdom, or other applicable privacy rules and regulations in other countries,
may result in significant fines and other administrative penalties. We may be required to put in place additional mechanisms to comply
with current and future privacy and data protection regulations applicable to our business. This may interrupt or delay our development
activities and/or require us to change our business practices, which could adversely affect our business, financial condition, results
of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization
of our therapeutic candidates. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face an inherent risk of product liability as a result of the clinical testing of our therapeutic candidates and will face an even greater
risk if we commercialize any cellular therapeutics, in addition to the risks from the sale of our degenerative disease products. For
example, we may be sued if our therapeutic candidates or degenerative disease products cause or are perceived to cause injury or are
found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include
allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the therapeutic or product, negligence,
strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully
defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of
our therapeutic candidates. Even successful defense would require significant financial and management resources. Regardless of the merits
or eventual outcome, liability claims may result in a number of adverse effects, any of which could materially harm our financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims
could prevent or inhibit the commercialization of therapeutics we develop, alone or with corporate collaborators, or negatively impact
our degenerative disease business. Our insurance policies may also have various exclusions, and we may be subject to a product liability
claim for which we have no coverage. While we have obtained and expect to obtain clinical trial insurance for our clinical trials, we
may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered
by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any
future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should
any claim arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, if a corporation
undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the equity
ownership of certain stockholders over a rolling three-year period), our ability to use our pre-change federal net operating loss, or
NOL, carryforwards and other pre-change tax attributes to offset our post-change income and taxes may be limited. We may experience ownership
changes in the future as a result of subsequent shifts in our stock ownership. As of December 31, 2024, we had approximately $121.8 million
of NOL carryforwards, and these NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities, which
could adversely affect our profitability. We anticipate incurring significant additional net losses for the foreseeable future, and our
ability to utilize NOL carryforwards associated with any such losses to offset future taxable income may be limited to the extent we
incur future ownership changes. In addition, at the state level, there may be periods during which the use of NOL carryforwards is suspended
or otherwise limited, which could accelerate or permanently increase state taxes owed. As a result, we may be unable to use all or a
material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in tax law could adversely affect our business and financial condition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rules dealing with U.S. federal, state, and local income taxation are constantly under review by persons involved in the legislative
process and by the U.S. Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive
application) could adversely affect us or holders of our securities. In recent years, many such changes have been made and changes are
likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow,
financial condition or results of operations. For example, the Inflation Reduction Act of 2022, or IRA, includes a 15% corporate alternative
minimum tax and a 1% excise tax on share repurchases. We urge investors to consult with their legal and tax advisers regarding the implications
of changes in tax laws on an investment in our securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fluctuations
in the cost and availability of raw materials, equipment, labor, and transportation could cause manufacturing delays or increase our
costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
price and availability of key components used to manufacture our products has been increasing and may continue to fluctuate significantly.
In addition, the cost of labor could increase significantly due to regulation or inflationary pressures. Additionally, the cost of logistics
and transportation fluctuates in large part due to the price of oil, and availability can be limited due to political and economic issues.
Any fluctuations in the cost and availability of any of our raw materials, packaging, or other sourcing or transportation costs could
harm our gross margins. If we are unable to successfully mitigate a significant portion of these product cost increases or fluctuations,
our results of operations could be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><i>Failure
to maintain effective internal controls could cause our investors to lose confidence in us and adversely affect the market price of our
Class A common stock. If our internal controls are not effective, we may not be able to accurately report our financial results or prevent
fraud.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Effective
internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. A material weakness
is a significant deficiency, or a combination of significant deficiencies, in internal controls over financial reporting such that it
is reasonably possible that a material misstatement of the annual or interim financial statements will not be prevented or detected on
a timely basis. We have identified the following material weaknesses in our internal control over financial reporting: (i) we failed
to demonstrate a commitment to attract, develop and retain competent and sufficient qualified resources with an appropriate level of
knowledge, experience, and training in certain areas around our financial reporting process; (ii) we failed to design and implement certain
risk assessment activities related to identifying and analyzing risks to achieve objectives and identifying and assessing changes in
the business that could impact our system of internal controls; (iii) we failed to design and implement certain control activities that
address relevant risks and retain sufficient evidence of the performance of control activities; (iv) we failed to design and implement
certain information and communication activities related to obtaining or generating and using relevant quality information to support
the functioning of internal control; and (v) we failed to design and implement certain monitoring activities to ascertain whether the
components of internal control are present and functioning. While we intend to take steps to remediate the material weakness in our internal
control over financial reporting by (i) hiring additional accounting personnel to ensure timely reporting of significant matters; (ii)
designing and implementing controls to formalize roles and review responsibilities to align with our team&#8217;s skills and experience
and designing and implementing formalized controls to operate at a level of precision to identify all potentially material errors; (iii)
designing and implementing procedures to identify and evaluate changes in our business and the impact on our internal controls in order
to plan and perform more timely and thorough monitoring activities and risk assessment analyses; (iv) designing and implementing formal
processes, policies and procedures supporting our financial close process; and (v) engaging an outside firm to assist with the documentation,
design and implementation of our internal control environment, we may not be successful in remediating such weaknesses in a timely manner,
if at all, which may undermine our ability to provide accurate, timely and reliable reports on our financial and operating results. Furthermore,
if we remediate our current material weakness but identify new material weaknesses in our internal control over financial reporting in
the future, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our Class
A common stock may be negatively affected. As a result of such failures, we could also become subject to investigations by Nasdaq, the
SEC, or other regulatory authorities, and become subject to litigation from investors and stockholders, which could harm our reputation,
financial condition or divert financial and management resources from our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have substantial indebtedness, which is secured by all of our assets. Payments on our outstanding debt and debt maturities could impact
our liquidity, require us to modify our operations to meet any payment obligations and could force us to seek protection under the provisions
of the U.S. Bankruptcy Code.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024, we have outstanding debt in the principal amount of $36.4 million that is secured by all of our assets. Payments
on our outstanding debt and debt maturities could impact our liquidity, require us to modify our operations to meet any payment obligations
and could force us to seek protection under the provisions of the U.S. Bankruptcy Code.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance on Third Parties </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out
their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of, or commercialize, our therapeutic
candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, CROs
and strategic partners to conduct our preclinical and clinical trials. We negotiate budgets and contracts with CROs and study sites,
which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course
of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each
of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third
parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are
regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for therapeutic candidates in clinical development.
Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If
we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may
be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before
approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any
of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biological product produced
under cGMP and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations
or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process.
Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws
and regulations or healthcare privacy and security laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us under our
agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical,
clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors,
for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance. If
these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to
be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical
protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not
be able to complete development of, obtain regulatory approval of or successfully commercialize our therapeutic candidates. As a result,
our financial results and the commercial prospects for our therapeutic candidates would be harmed, our costs could increase and our ability
to generate revenue could be delayed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If any of our relationships with trial
sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites
or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial
cost and requires extensive management time and focus. In addition, there is a natural transition period when a new third party commences
work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
rely on donors of healthy human full-term placentas to manufacture our therapeutic candidates, and if we do not obtain an adequate supply
of such placentas from qualified donors, development of our placental-derived allogeneic cells may be adversely impacted.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are reliant on biosourcing healthy donor placentas to manufacture our therapeutic candidates, and on hospital personnel to obtain the
necessary donor consent. Healthy donor placentas vary in type and quality, and this variation makes producing standardized therapeutic
candidates more difficult and makes the development and commercialization pathway of our therapeutic candidates more uncertain. We have
developed a process designed to enhance the quality and consistency of the placental-derived cells used in the manufacture of our three
allogeneic cell types (CAR-T cells, NK cells and mesenchymal-like stromal cells), but our process may fail to identify suitable donors
or detect all issues, and we may discover failures with the material after production. We may also have to update our specifications
for new risks that may emerge, such as to screen for new viruses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have strict specifications for donor material, which include specifications required by regulatory authorities and rely on informed donor
consent. If we are unable to identify and obtain donor material that satisfy specifications, agree with regulatory authorities on appropriate
specifications, incentivize hospital personnel to solicit consent to donation or address variability in donor placentas, there may be
inconsistencies in the therapeutic candidates we produce or we may be unable to initiate or continue ongoing clinical trials on the timelines
we expect, or scale up our manufacturing process for later-stage clinical trials or commercialization, which could harm our reputation
and adversely impact our business and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cell-based
therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
therapeutic candidates require many specialty raw materials, including viral vectors that deliver the CAR sequence and other raw materials,
some of which are manufactured by small companies with limited resources and experience to support a commercial therapeutic, or to deliver
raw materials to our specifications. We generally do not have dedicated supply contracts with many of our suppliers, and we may not be
able to contract with them on acceptable terms, or at all. Some of our suppliers may not be able to scale-up as we move to later-stage
clinical trials or commercialization. Accordingly, we may experience delays in receiving, or fail to secure entirely, key raw materials
to support clinical or commercial manufacturing. Certain raw materials also require third-party testing, and some of the testing service
companies may not have capacity or be able to conduct the testing that we request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also face competition for supplies from other cell therapy companies. Such competition may make it difficult for us to secure raw materials
or the testing of such materials on commercially reasonable terms or in a timely manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
raw materials, including the post-partum human placenta obtained through informed consent, are currently available from a small number
of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors
or another company that is not interested in continuing to produce these materials for our intended purpose. In addition, the lead time
needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we
must switch to a new supplier. The time and effort to qualify a new supplier, including to meet any regulatory requirements for such
qualification, could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively
impact our operating results. Further, we may be unable to enter into agreements with a new supplier on commercially reasonable terms,
which could have a material adverse impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 52 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we or third party suppliers acting on our behalf use hazardous, non-hazardous, biological or other materials in a manner that causes
injury or violates applicable law, we may be liable for damages. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development and manufacturing activities involve the controlled use of potentially hazardous substances, including chemical
and biological materials. We are subject to federal, state and local laws and regulations in the United States governing the use, manufacture,
storage, handling and disposal of medical and hazardous materials. Although we believe our procedures, as well as the procedures of our
third party suppliers for using, handling, storing and disposing of these materials comply with legally prescribed standards, neither
we nor our third party suppliers can completely eliminate the risk of contamination or injury resulting from medical or hazardous materials.
As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the
use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized
with fines, and the liability could exceed our resources. We do not have any insurance for liabilities arising from medical or hazardous
materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations
may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Government Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and
regulatory approval of our future therapeutic candidates. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including
biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted
to market any biological drug product in the United States until we receive approval of a biologics license application, or BLA, from
the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable foreign authorities. A BLA must
include extensive preclinical and clinical data and supporting information to establish the therapeutic candidate&#8217;s safety and
effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and
controls for the product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect the novel nature of our potential future therapeutic candidates to create further challenges in obtaining regulatory approval.
For example, the FDA has limited experience with commercial development of allogeneic cell therapies. The FDA may also require a panel
of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure.
The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the
therapeutic candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#8217;s recommendations.
Accordingly, the regulatory approval pathway for our therapeutic candidates may be uncertain, complex, expensive and lengthy, and approval
may not be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also experience delays in completing planned clinical trials for a variety of reasons, including if physicians encounter unresolved
ethical issues associated with enrolling patients in clinical trials of our therapeutic candidates in lieu of prescribing existing treatments
that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the
institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors. The FDA&#8217;s
review of our data for future clinical trials may, depending on the data, also result in the delay, suspension or termination of one
or more of our potential clinical trials, which would also delay or prevent the initiation of our other planned clinical trials. If we
experience termination of, or delays in the completion of, any clinical trial of our therapeutic candidates, the commercial prospects
for our therapeutic candidates will be harmed, and our ability to generate revenue will be delayed. In addition, any delays in completing
our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence therapeutic
sales and generate revenue. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials
may ultimately lead to the denial of regulatory approval of our therapeutic candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
the extent a regulatory authority determines that any of our currently-marketed advanced biomaterials products do not qualify for regulation
as <span style="background-color: white">human cells, tissues, and cellular and tissue based products</span>, or HCT/P, solely under
Section 361 of the <span style="background-color: white">Public Health Service Act, or</span> PHSA, this could result in removal of these
products from the market.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Advanced Biomaterials products are marketed without a specific FDA approval, but rather are marketed based on our belief that these products
are exempt from prior FDA approval pursuant to Section 361 of the PHSA. In 2004 and 2005 FDA issued determinations that the product now
marketed as Interfyl, and the Biovance product, qualified to be regulated solely under section 361, subject to limitations on claims
that could be made for such products&#8217; intended uses. In November 2017, the FDA released a guidance document entitled &#8220;Regulatory
Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for
Industry and Food and Drug Administration Staff&#8221; (&#8220;Guidance&#8221;), which it revised and reissued in July 2020. The document
confirmed the FDA&#8217;s stance that sheet forms of amniotic tissue are appropriately regulated as solely Section 361 HCT/Ps when manufactured
in accordance with 21 CFR Part 1271 and intended for use as a barrier or covering. However, wound healing is not a homologous use of
amniotic tissue, and to the extent we make claims for Biovance, Interfyl, CentaFlex and Rebound that extend beyond homologous use, we
may be subject to the requirement for prior FDA approval and to FDA enforcement action. The Guidance stated that the FDA intended to
exercise enforcement discretion under limited conditions with respect to the IND application and pre-market approval requirements for
certain HCT/Ps for a period that expired on May 31, 2021. The FDA&#8217;s approach is risk-based, and the Guidance clarified that high-risk
products and uses could be subject to immediate enforcement action. New York has interpreted the Guidance such that it has restricted
the marketing of such products without BLA approval, notwithstanding the current exception in the Guidance, and other states may make
similar determination, which would limit the market for such products until a BLA is approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 53 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amniotic
tissue is generally eligible for regulation solely as a HCT/P under Section 361 of the PHSA depending on whether the specific product
at issue and the claims made for it are consistent with the applicable FDA criteria for minimal manipulation and homologous use. HCT/Ps
that do not meet these minimal manipulation and homologous use criteria are subject to more extensive regulation as drugs, medical devices,
biological products, or combination products. Such HCT/Ps must comply with both the FDA&#8217;s requirements for HCT/Ps and the requirements
applicable to biologics, devices or drugs, including pre-market clearance or approval from the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may need to either modify our claims or cease selling our Biovance, Interfyl, CentaFlex and Rebound products until the FDA approves a
BLA, and then we will only be able to market such products for indications that have been approved in a BLA. The loss of our ability
to market and sell these products would have an adverse impact on our revenues, business, financial condition and results of operations.
In addition, we expect the cost to manufacture our products will increase due to the costs to comply with the requirements that apply
to Section 361 biological products, such as current cGMP and ongoing product testing costs. Increased costs relating to regulatory compliance
could have an adverse impact on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA might, at some future point, modify its position on which current or future products qualify as Section 361 HCT/Ps.
Any regulatory changes could have adverse consequences for us and make it more difficult or expensive for us to conduct our business
by requiring pre-market clearance or approval and compliance with additional post-market regulatory requirements with respect to those
products. It is also possible that the FDA could require us to recall our Biovance, Interfyl, CentaFlex and Rebound products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
expect the cell therapy therapeutic candidates we may develop will be regulated as biological products, or biologics, and they may be
subject to competition sooner than anticipated. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<span style="background-color: white">Biologics Price Competition and Innovation Act, or</span> BPCIA, was enacted as part of the Affordable
Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway
establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar
as &#8220;interchangeable&#8221; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product
cannot filed with FDA until four years after the reference product was be approved by the FDA, and cannot be approved until 12 years
after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As
a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended
to implement the BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial
prospects for our biological products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that any of the therapeutic candidates we develop that are approved in the United States as a biological product under a BLA
should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional
action or otherwise, or that the FDA will not consider the subject therapeutic candidates to be reference products for competing products,
potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once
approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for
non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
regulatory landscape that will govern our therapeutic candidates is uncertain; regulations relating to more established cellular therapy
products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our
therapeutic candidates or unexpected costs in obtaining regulatory approval. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are developing novel cellular therapeutic candidates that are unique biological entities, the regulatory requirements that we will
be subject to are not entirely clear. Regulatory requirements governing gene therapy products and cell therapy products have changed
frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible
for regulation of existing gene therapy products and cell therapy products. Although the FDA decides whether individual therapy protocols
may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even
if the FDA has reviewed the study and approved its initiation. Conversely, the FDA can place an IND application on clinical hold even
if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent
IRB at or servicing each institution at which a clinical trial will be conducted. In addition, adverse developments in clinical trials
of gene or cell therapy products conducted by others may cause the FDA or other regulatory bodies to change the requirements for approval
of any of our therapeutic candidates. Complex regulatory environments exist in other jurisdictions in which we might consider seeking
regulatory approvals for our therapeutic candidates, further complicating the regulatory landscape.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 54 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
various committees and advisory groups involved in regulatory review, and new or revised guidelines that they promulgate from time to
time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes
in regulatory positions and interpretations, delay or prevent approval and commercialization of our therapeutic candidates or lead to
significant post-approval limitations or restrictions. Because the regulatory landscape for our placental-derived cell therapeutic candidates
is new, we may face even more cumbersome and complex regulations than those for more traditional pharmaceutical or biological products.
Furthermore, even if our therapeutic candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result
of changes in regulations or the interpretation of regulations by applicable regulatory agencies. Delay or failure to obtain, or unexpected
costs in obtaining, the regulatory approval necessary to bring a potential therapeutic to market could decrease our ability to generate
sufficient revenue to maintain our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA may disagree with our future regulatory plans and we may fail to obtain regulatory approval of our cell therapeutic candidates</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled,
Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase 3 clinical studies typically involve
hundreds of patients, have significant costs and take years to complete. The FDA may require that we conduct a comparative trial against
an approved therapy including potentially an approved autologous cell therapy, which would significantly delay our development timelines
and require substantially more resources. In addition, the FDA may only allow us to evaluate patients that have failed or who are ineligible
for autologous therapy, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and our future
therapeutic candidates may fail to improve outcomes for such patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
potential future clinical trial results may also not support approval. In addition, our therapeutic candidates could fail to receive
regulatory approval for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our therapeutic candidates
    are safe and effective for any of their proposed indications; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory
    authorities for approval, including due to the heterogeneity of patient populations; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to demonstrate that our therapeutic candidates&#8217; clinical and other benefits outweigh their safety risks; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical
    trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from clinical trials of our therapeutic candidates may not be sufficient to the satisfaction of the FDA or comparable
    foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain
    regulatory approval in the United States or elsewhere; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA or comparable foreign regulatory authorities will review our manufacturing process and inspect our commercial manufacturing facility
    and may not approve our manufacturing process or facility; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering
    our clinical data insufficient for approval. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 55 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
plan to seek orphan drug designation for some or all of our therapeutic candidates across various indications, but we may be unable to
obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may
cause our revenue, if any, to be reduced. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition. In the
United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical
trial costs, tax advantages, and user-fee waivers. Orphan drug designation does not convey any advantage in, or shorten the duration
of, the regulatory review and approval process, but if a product that has orphan drug designation subsequently receives the first FDA
approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity,
which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with
the same principal molecular structural features) for the same indication for seven years, except in limited circumstances. If a competing
company also obtains ODD for a product that is deemed the &#8220;same drug&#8221; as ours for the same orphan indication, and obtains
FDA approval before we do, that company would qualify for Orphan Exclusivity which would block approval of our product for seven years.
See &#8220;Business - Government Regulation and Product Approval&#8221; for more information regarding orphan drug designation. Even
if the FDA grants orphan drug designation to one or more of our investigational cell therapies, the FDA can still approve other biologics
that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic
for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable
to manufacture sufficient supply of our therapeutic or if a subsequent applicant demonstrates clinical superiority over our product.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to seek orphan drug designation for some or all of our therapeutic candidates in specific orphan indications in which there is a
medically plausible basis for the use of these therapeutics. Even if we obtain orphan drug designation, exclusive marketing rights in
the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost
if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities
of the therapeutic to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical
superiority over our therapeutics, if approved.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not elect or be able to take advantage of any expedited development or regulatory review and approval processes available to therapeutic
candidates granted breakthrough therapy or fast track designation by the FDA. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to evaluate and engage in discussions with the FDA on regulatory strategies that could enable us to take advantage of expedited
development pathways for certain of our therapeutic candidates, although we cannot be certain that our therapeutic candidates will qualify
for any expedited development pathways or that regulatory authorities will grant, or allow us to maintain, the relevant qualifying designations.
Potential expedited development pathways that we could pursue include breakthrough therapy and fast track designation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breakthrough
therapy designation is intended to expedite the development and review of therapeutic candidates that are designed to treat serious or
life-threatening diseases when &#8220;preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over
existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development.&#8221; The designation of a therapeutic candidate as a breakthrough therapy provides potential benefits that include more
frequent meetings with the FDA to discuss the development plan for the therapeutic candidate and ensure collection of appropriate data
needed to support approval; more frequent written correspondence from the FDA about such things as the design of the proposed clinical
trials and use of biomarkers; intensive guidance on an efficient drug development program, beginning as early as Phase 1; organizational
commitment involving senior managers; and eligibility for rolling review and priority review. Fast track designation is designed for
therapeutic candidates intended for the treatment of a serious or life-threatening disease or condition, where nonclinical or clinical
data demonstrate the potential to address an unmet medical need for this disease or condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we have previously received fast track designation for certain of our cell therapy candidates, we may elect not to pursue either of breakthrough
therapy or fast track designation for our other therapeutic candidates, and the FDA has broad discretion whether or not to grant these
designations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
even if we believe that a particular therapeutic candidate is eligible for breakthrough therapy or fast track designation, we cannot
assure you that the FDA would decide to grant such designation. Breakthrough therapy designation and fast track designation do not change
the standards for product approval, and there is no assurance that such designation or eligibility will result in expedited review or
approval or that the approved indication will not be narrower than the indication covered by the breakthrough therapy designation or
fast track designation. Thus, even if we do receive breakthrough therapy or fast track designation, we may not experience a faster development
process, review or approval compared to conventional FDA procedures. The FDA may withdraw breakthrough therapy or fast track designation
if it believes that the product no longer meets the qualifying criteria. Our business may be harmed if we are unable to avail ourself
of these or any other expedited development and regulatory pathways.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 56 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining regulatory approval of our therapeutic candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our therapeutic candidates in other jurisdictions. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining regulatory approval of our therapeutic candidates in one jurisdiction does not guarantee that we will be able to obtain
or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction
may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a
therapeutic candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and
promotion of the therapeutic candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements
and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies
or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions.
In many jurisdictions outside the United States, a therapeutic candidate must be approved for reimbursement before it can be approved
for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have
requirements for approval of therapeutic candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign
regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for
it and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements
in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize
the full market potential of our therapeutic candidates will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we receive regulatory approval of our therapeutic candidates, we will be subject to ongoing regulatory obligations and continued regulatory
review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements
or experience unanticipated problems with our therapeutic candidates. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approvals that we receive for our therapeutic candidates will require surveillance to monitor the safety and efficacy of the
therapeutic candidate. The FDA may also require a Risk Evaluation and Mitigation Strategy, or REMS, in order to approve our therapeutic
candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe
use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable
foreign regulatory authority approves our therapeutic candidates, the manufacturing processes, labeling, packaging, distribution, adverse
event reporting, storage, advertising, promotion, import, export and recordkeeping for our therapeutic candidates will be subject to
extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information
and reports, registration, as well as continued compliance with cGMP and current GCPs for any clinical trials that we conduct post-approval,
and compliance with applicable product tracking and tracing requirements. As such, we will be subject to continual review and inspections
to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional
observations. Accordingly, we and others with whom we work with must continue to expend time, money and effort in all areas of regulatory
compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to
obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which
include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations
that are not described in the product&#8217;s approved uses (known as &#8220;off-label use&#8221;), limitations on industry-sponsored
scientific and educational activities and requirements for promotional activities involving the internet and social media. The FDA and
other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to
have improperly promoted off-label uses may be subject to significant liability. However, physicians may, in their independent medical
judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice
of treatments, but the FDA does restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Later
discovery of previously unknown problems with our therapeutic candidates, including adverse events of unanticipated severity or frequency,
or with our third-party suppliers, or our manufacturing processes, or failure to comply with regulatory requirements, may result in revisions
to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks;
or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other
things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the marketing or manufacturing of our therapeutic candidates, withdrawal of the therapeutic from the market or voluntary or mandatory
    product recalls; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    warning letters or holds on clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license
    approvals; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizure or detention, or refusal to permit the import or export of our therapeutic candidates; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
    or the imposition of civil or criminal penalties. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 57 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our therapeutic candidates. We cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we
are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able
to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Negative
public opinion and increased regulatory scrutiny of genetic research and therapies involving gene editing or modified cells may damage
public perception of our therapeutic candidates or adversely affect our ability to conduct our business or obtain regulatory approvals
for our therapeutic candidates. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gene-editing technologies that we use are novel. Public perception may be influenced by claims that gene editing is unsafe, and products
incorporating gene editing may not gain the acceptance of the public or the medical community. In particular, our success will depend
upon physicians specializing in our targeted diseases prescribing our therapeutic candidates as treatments in lieu of, or in addition
to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of gene
editing may result in fewer physicians prescribing our treatments or may reduce the willingness of patients to utilize our treatments
or participate in clinical trials for our therapeutic candidates. In addition, given the novel nature of gene-editing and cell therapy
technologies, governments may place import, export or other restrictions in order to retain control or limit the use of the technologies.
Increased negative public opinion or more restrictive government regulations either in the United States or internationally, would have
a negative effect on our business or financial condition and may delay or impair the development and commercialization of our therapeutic
candidates or demand for such therapeutic candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we obtain regulatory approval of our therapeutic candidates, the cell therapies may not gain market acceptance among physicians, patients,
hospitals, cancer treatment centers and others in the medical community.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
use of engineered placental-derived cells as a potential treatment is a recent development and may not become broadly accepted by physicians,
patients, hospitals, cancer treatment centers and others in the medical community. We may not be able to educate these persons on the
benefits of using our therapeutic candidates for many reasons. For example, certain of the therapeutic candidates that we will be developing
target a cell surface marker that may be present on cancer cells as well as non-cancerous cells. It is possible that our therapeutic
candidates may kill these non-cancerous cells, which may result in unacceptable side effects, including death. Additional factors will
influence whether our therapeutic candidates are accepted in the market, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    clinical indications for which our therapeutic candidates are approved; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians,
    hospitals, cancer treatment centers and patients considering our therapeutic candidates as a safe and effective treatment; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential and perceived advantages of our therapeutic candidates over alternative treatments; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    prevalence and severity of any side effects; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    labeling or product insert requirements of the FDA or other regulatory authorities; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings contained in the labeling approved by the FDA; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    timing of market introduction of our therapeutic candidates as well as competitive products; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of treatment in relation to alternative treatments; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of coverage and adequate reimbursement by third-party payors and government authorities; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government
    authorities; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
    convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    effectiveness of our sales and marketing efforts. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 58 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our therapeutic candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment
centers or others in the medical community, we will not be able to generate significant revenue. Even if our cell therapies achieve market
acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more
favorably received than our therapeutics, are more cost effective or render our therapeutics obsolete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and reimbursement may be limited or unavailable in certain market segments for our therapeutic candidates, which could make it difficult
for us to sell our cell therapies, if approved, profitably. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
sales of our therapeutic candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party
payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among
others. Significant uncertainty exists as to the coverage and reimbursement status of any therapeutic candidates for which we obtain
regulatory approval. In addition, because our therapeutic candidates represent new approaches to the treatment of cancer, infectious
and degenerative diseases, we cannot accurately estimate the potential revenue from our therapeutic candidates. For more information
on coverage and reimbursement requirements see &#8220;Business - Government Regulation and Product Approval - Coverage, Pricing and Reimbursement.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated
with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend
upon a number of factors, including, but not limited to, the third-party payor&#8217;s determination that use of a therapeutic is:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    covered benefit under our health plan; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">safe,
    effective and medically necessary; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appropriate
    for the specific patient; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effective;
    and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">neither
    experimental nor investigational. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
coverage and reimbursement of a therapeutic from a government or other third-party payor is a time-consuming and costly process that
could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our therapeutics.
Even if we obtain coverage for a given therapeutic, if the resulting reimbursement rates are insufficient, hospitals may not approve
our therapeutic for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients
are unlikely to use our therapeutic candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion
of the cost of our therapeutic candidates. Separate reimbursement for the therapeutic itself may or may not be available. Instead, the
hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our therapeutic is used.
Further, from time to time, Center for Medicare &amp; Medicaid Services, or CMS, revises the reimbursement systems used to reimburse
health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced
Medicare payments. In some cases, private third-party payors rely on all or portions of Medicare payment systems to determine payment
rates. Furthermore, in November 2024, the CMS and Medicare Administrative Contractors, or MACs, simultaneously finalized nearly identical
Local Coverage Determinations, or LCDs, that will deny coverage for virtually all amniotic tissue products that are used to cover and
treat chronic wounds. While, as of the date of this annual report on Form 10-K, these LCD determinations will become effective as of
January 1, 2026, the Trump administration may suspend such determinations; however, no assurance can be provided that such suspension
will occur, or if it does occur that it will occur in a timely manner, if at all. If the Trump administration does not suspend the LCD
determinations by January 1, 2026, the sales of our amniotic tissue products may be affected. Changes to government healthcare programs
that reduce payments under these programs may negatively impact payments from private third-party payors and reduce the willingness of
physicians to use our therapeutic candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage
and reimbursement for products can differ significantly from payor to payor. Further, one payor&#8217;s determination to provide coverage
for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not
be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 59 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to seek approval to market our therapeutic candidates in both the United States and in selected foreign jurisdictions. If we obtain
approval in one or more foreign jurisdictions for our therapeutic candidates, we will be subject to rules and regulations in those jurisdictions.
In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries,
pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a therapeutic candidate.
Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular therapeutic
candidate to currently available therapies. Other EU member states allow companies to fix their own prices for medicines but monitor
and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers
are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a
commercial pressure on pricing within a country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
marketability of any therapeutic candidates for which we receive regulatory approval for commercial sale may suffer if government and
other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to
continue. Further, coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement
status is attained for one or more therapeutics for which we receive regulatory approval, less favorable coverage policies and reimbursement
rates may be implemented in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
advancement of healthcare reform may negatively impact our ability to sell our therapeutic candidates, if approved, profitably. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling
healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory
changes to the health care system that could impact our ability to sell our therapeutic candidates, if approved, profitably. Further
legislation or regulation could be passed that could harm our business, financial condition and results of operations. See &#8220;<i>Business
- Government Regulation and Product Approval</i> - <i>Healthcare Reform</i>&#8221; for a discussion of these laws and regulations. There
have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at
broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures
or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our therapeutics.
Such reforms could have an adverse effect on anticipated revenue from therapeutic candidates that we may successfully develop and for
which we may obtain regulatory approval and may affect our overall financial condition and ability to develop therapeutic candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing
practices. Specifically, there have been several recent U.S. congressional inquiries and federal and state legislative activity designed
to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient assistance
programs, and reform government program reimbursement methodologies for drugs. Individual states in the United States have also become
increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict the initiatives that may be adopted in the future. Additionally, the continuing efforts of the government, insurance companies,
managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls
may adversely affect:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    demand for our therapeutic candidates, if we obtain regulatory approval; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to set a price that we believe is fair for our therapeutics; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to generate revenue and achieve or maintain profitability; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    level of taxes that we are required to pay; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of capital. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors,
which may adversely affect our future profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 60 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Intellectual Property </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our efforts to protect the proprietary nature of the intellectual property related to our technologies is not adequate, we may not be
able to compete effectively in our market.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other biopharmaceutical companies, our success depends in large part on our ability to obtain and maintain protection
of intellectual property. We rely upon a combination of patents, trade secret protection and license agreements to protect the intellectual
property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information
could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our
market. We have filed additional patent applications, and we anticipate additional patent applications will be filed in the future, both
in the United States and in other countries, as appropriate. However, we cannot predict:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    and when patents will issue; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    degree and range of protection any issued patents will afford us against competitors, including whether third parties will find ways
    to invalidate or otherwise circumvent our patents; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
    we will need to initiate litigation or administrative proceedings, which may be costly whether we win or lose. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and enforcing biopharmaceutical patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary
or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable
cost or in a timely manner. It is also possible that we may fail to identify patentable aspects of our research and development output
before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent
applications licensed from third parties, or to maintain the rights to patents licensed to third parties. Therefore, these patents and
applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that the claims in our pending patent applications will be considered patentable by the United States Patent and Trademark
Office, or USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid
and enforceable by courts in the United States or foreign countries. The strength of patents in the biotechnology and pharmaceutical
field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail
to result in issued patents with claims that cover our therapeutic candidates or uses thereof in the United States or in other foreign
countries. Even if the patents do successfully issue, third parties may challenge the patentability, validity, enforceability or scope
thereof, which may result in such patents being canceled, narrowed, invalidated or held unenforceable. Furthermore, even if they are
unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing
their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications
we hold with respect to our therapeutic candidates is threatened, it could dissuade companies from collaborating with us to develop,
and threaten our ability to commercialize, our therapeutic candidates. Further, if we encounter delays in our clinical trials, the period
of time during which we could market our therapeutic candidates under patent protection would be reduced. Further, changes in U.S. patent
law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depending
on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable
ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Confidentiality
agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect
proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product
discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We take
steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements,
non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, corporate partners and, when
needed, advisers. Trade secrets, however, may be difficult to protect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 61 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monitoring
unauthorized disclosure and detection of unauthorized disclosure is difficult, and we do not know whether the steps we have taken to
prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using
our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we require all of our employees to assign their inventions to us, and requires all of our employees and key consultants who have access
to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade
secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our
trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries
do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter
significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to
prevent unauthorized material disclosure of our confidential information or intellectual property to third parties, we will not be able
to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results
and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information
of third parties. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed
at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants, advisors and independent
contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or
our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including
trade secrets or other proprietary or confidential information of these third parties or our employees&#8217; former employers. Litigation
may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may
lose valuable intellectual property rights and face increased competition to business. A loss of key research personnel work product
could hamper or prevent our ability to commercialize potential technologies and solutions, which could harm our business. Even if we
are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management
team and employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with
each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property
rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties,
or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the
foregoing could harm our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third-party
claims of intellectual property infringement may prevent or delay our product discovery and development efforts and our ability to commercialize
our therapeutic candidates. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on us avoiding infringement of the patents and proprietary rights of third parties. There is a substantial
amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. Numerous
U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are
developing our therapeutic candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk
increases that our therapeutic candidates may give rise to claims of infringement of the patent rights of others.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert that we infringe their patents or are otherwise employing their proprietary technology without authorization and may
sue. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result
in issued patents that our therapeutic candidates may be alleged to infringe. In addition, third parties may obtain patents in the future
and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction
to cover the manufacturing process of our therapeutic candidates, constructs or molecules used in or formed during the manufacturing
process, or any final therapeutic itself, the holders of any such patents may be able to block our ability to commercialize the therapeutic
candidate unless we obtain a license under the applicable patents, or until such patents expire or they are finally determined to be
held not infringed, unpatentable, invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction
to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection
methods, the holders of any such patent may be able to block our ability to develop and commercialize the therapeutic candidate unless
we obtain a license or until such patent expires or is finally determined to be held not infringed, unpatentable, invalid or unenforceable.
In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary
license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our therapeutic candidates
may be impaired or delayed, which could in turn significantly harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 62 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Parties
making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further
develop and commercialize our therapeutic candidates. Defense of these claims, regardless of their merit, would involve substantial litigation
expense and would be a substantial diversion of employee resources from our business and may impact our reputation. In the event of a
successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees
for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may
be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at
all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to
obtain licenses from third parties to advance our research or allow commercialization of our therapeutic candidates. We may fail to obtain
any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and
commercialize our therapeutic candidates, which could harm our business significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through
acquisitions and in-licenses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presently,
we have rights to the intellectual property, through licenses from third parties and under patent applications that we own or will own,
that we believe will facilitate the development of our therapeutic candidates. In the future, we may identify third party intellectual
property and technology that we may need to acquire or license in order to engage in our business, including to develop or commercialize
new technologies or services, and the growth of our business may depend in part on our ability to acquire, in-license or use this technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be unable to acquire or in-license any third-party intellectual property rights from third parties that we identify. We may fail
to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain
a license, we may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we
may be required to expend significant time and resources to develop or license replacement technology. We may need to cease use of the
compositions or methods covered by such third-party intellectual property rights to the extent we are unable to maintain our license
with any such third-party licensors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established,
or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights
that we may consider necessary or attractive in order to commercialize our therapeutic candidates. More established companies may have
a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If such licenses are available,
we may be required to pay the licensor in return for the use of such licensor&#8217;s technology, lump-sum payments, payments based on
certain milestones such as sales volumes, or royalties based on sales. In addition, our licenses may also place restrictions on our future
business opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate
the license agreements, thereby removing our ability to develop and commercialize technology covered by these license agreements. If
these licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would
have the freedom to seek regulatory approval of, and to market products that use technologies identical to those licensed to us. This
could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.
Additionally, termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our
ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result
in us having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements,
including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization
of one or more technologies that rely on such agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the above risks, intellectual property rights that may be licensed now or in the future could include sublicenses under intellectual
property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to
use sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should
our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain
the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize therapeutic
candidates may be materially harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we may not have the right to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual
property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not
be forthcoming. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce licensed
and sublicensed intellectual property effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not
the sole and exclusive owners of the patents and patent applications in-licensed. If other third parties have ownership rights to patents
or patent applications in-licensed by us, they may be able to license such patents to our competitors, and our competitors could market
competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions,
results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business, financial condition, results of operations and prospects could be materially and adversely affected if we are unable to enter
into necessary agreements on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensors fail
to abide by the terms of the licenses or fail to prevent infringement by third parties, or if the acquired or licensed patents or other
rights are found to be invalid or unenforceable. Moreover, we could encounter delays in the introduction of services while we attempt
to develop alternatives. Further, defense of any lawsuit or failure to obtain any of these licenses on favorable terms could prevent
us from commercializing products, which could harm our business, financial condition, or results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be involved in lawsuits or other legal proceedings to protect or enforce our patents or the patents of our licensors, which could
be expensive, time-consuming and unsuccessful. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Competitors
may infringe our patents or the patents of our licensors or misappropriate or otherwise violate our intellectual property rights or the
intellectual property rights of our licensors. In the future, we or our licensors may initiate legal proceedings to enforce or defend
our intellectual property rights or the intellectual property rights of our licensors, to protect our trade secrets or the trade secrets
of our licensors, or to determine the validity or scope of intellectual property rights we own or control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming.
Third parties may also initiate legal proceedings against us or our licensors to challenge the validity or scope of intellectual property
rights we own, control or to which we have rights. In an infringement proceeding, a court may decide that one or more of our patents
are not valid or are unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents
do not cover the technology in question. An adverse result in any litigation or defense proceeding could put one or more of our patents
at risk of being invalidated, held unenforceable or interpreted narrowly and could put one or more of our pending patent applications
at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be
a substantial diversion of employee resources from our business. Additionally, many of our adversaries or adversaries of our licensors
in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can.
In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217;
fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which
may be impossible or require substantial time and monetary expenditure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
pre-issuance submission of prior art to the USPTO, or opposition, derivation, revocation, reexamination, inter partes review or interference
proceedings, or other pre-issuance or post-grant proceedings or other patent office proceedings or litigation in the United States or
other jurisdictions provoked by third parties or brought by us or our licensors, may challenge or be necessary to determine the inventorship,
priority, patentability or validity of inventions with respect to us or our licensor&#8217;s patents or patent applications. An unfavorable
outcome could leave our technology or therapeutic candidates without patent protection, allow third parties to commercialize our technology
or therapeutic candidates and compete directly with us, without payment to us, or could require us or our licensors to cease using the
related technology or to obtain license rights from the prevailing party in order to be able to manufacture or commercialize our therapeutic
candidates without infringing third-party patent rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or other legal
proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract
our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets
or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive
these results to be negative, it could have a substantial adverse effect on the price of our Class A common stock. If the breadth or
strength of protection provided by us or our licensor&#8217;s patents and patent applications is threatened, it could dissuade companies
from collaborating with us to license, develop or commercialize therapeutic candidates. Moreover, the uncertainties associated with litigation
could have a material adverse effect on our ability to raise the funds necessary to continue clinical trials, continue research programs,
license necessary technology from third parties, or enter into collaborations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees on any issued patent are due to be paid to the USPTO, and foreign patent agencies in several stages over the lifetime
of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured
by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure
to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal
documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
lives of our patents may not be sufficient to effectively protect our products and business. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection
it affords, is limited. Even if patents covering our therapeutic candidates are obtained, once the patent life has expired for a product,
we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United States a patent&#8217;s
life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays
caused by the patent applicant during patent prosecution. If our technologies require extended development and/or regulatory review,
patents protecting our technologies might expire before or shortly after we are able to successfully commercialize them. If we do not
have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
or our licensors may be subject to claims challenging the inventorship of our patents and other intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
or our licensors may in the future be subject to claims that former employees, collaborators, or other third parties have an interest
in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from
conflicting obligations of consultants or others who are involved in developing our therapeutic candidates. Litigation may be necessary
to defend against these and other claims challenging inventorship. If we or our licensors fail in defending any such claims, in addition
to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable
intellectual property. Such an outcome could have a material adverse effect on our business. Even if we or our licensors are successful
in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 65 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to protect our intellectual property rights throughout the world. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to protect our intellectual property rights outside the United States. Filing, prosecuting and defending patents on therapeutic
candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries
outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not
protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection
is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Whether filed in the
United States or abroad, our patents and patent applications may be challenged or may fail to result in issued patents. Consequently,
we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling
or importing products made using its inventions in and into the United States or other jurisdictions. Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing
products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products
may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them
from competing. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses
to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies
or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value
of any patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, particularly
those relating to biotechnology, which could make it difficult for us to stop the misappropriation or other violations of our intellectual
property rights including infringement of our patents in such countries. Proceedings to enforce our patent rights in foreign jurisdictions
could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk
of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert
claims against us. We may not prevail in any lawsuits that we initiate, or that are initiated against us, and the damages or other remedies
awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts in the United States
and foreign countries may affect our ability to obtain adequate protection for our technologies and the enforcement of intellectual property.
Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that we develop or license.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in patent law, including recent patent reform legislation, could increase the uncertainties and costs surrounding the prosecution of
our patent applications and the enforcement or defense of our issued patents. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value
of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third party
patents. We may not develop additional proprietary technologies that are patentable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
that other requirements for patentability are met, prior to March 16, 2013, in the United States, the first to invent the claimed invention
was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On or
after March 16, 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted on September 16, 2011, the United
States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first
inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first
to invent the claimed invention. A third party that files a patent application in the USPTO on or after March 16, 2013, but before us,
could therefore be awarded a patent covering an invention of ours, even if we have made the invention before it was made by such third
party. This will require us to be cognizant of the time from invention to filing of a patent application. Because patent applications
in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain
that we or our licensors were the first to either (i) file any patent application related to our technology or (ii) invent any of the
inventions claimed in us or our licensor&#8217;s patents or patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also
may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional
procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes
review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard
in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding
sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first
presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims
that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the
America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed
patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse
effect on our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the patent position of companies in the biotechnology field is particularly uncertain. Various courts, including the United
States Supreme Court have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to
biotechnology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law
of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what
constitutes a law of nature or abstract idea is uncertain, and it is possible that certain aspects of our technology could be considered
natural laws. Accordingly, the evolving case law in the United States, and abroad, may adversely affect us and our licensor&#8217;s ability
to obtain new patents or to enforce existing patents and may facilitate third party challenges to any owned or licensed patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain any competitive advantage. For example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may be able to make products that are similar to any therapeutic candidates we may develop or utilize similar technology that are
    not covered by the claims of the patents that we license or may own in the future; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    or our, current or future collaborators, might not have been the first to make the inventions covered by the issued patents and pending
    patent applications that we license or may own in the future; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we,
    or our, current or future collaborators, might not have been the first to file patent applications covering certain of our intellectual
    property or our inventions; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
    may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or
    licensed intellectual property rights; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    is possible that our pending patent applications or those that we may own in the future will not lead to issued patents; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
    patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    competitors might conduct research and development activities in countries where we do not have patent rights and then use the information
    learned from such activities to develop competitive therapeutics for sale in our major commercial markets; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable
    therapeutic candidates or will provide us with any competitive advantages; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    cannot ensure that our commercial activities or therapeutic candidates will not infringe upon the patents of others; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    cannot ensure that we will be able to successfully commercialize our therapeutic candidates on a substantial scale, if approved,
    before the relevant patents that we own or licenses expire; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include
    claims having a scope sufficient to protect our therapeutic candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not develop additional proprietary technologies that are patentable; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patents or intellectual property rights of others may harm our business; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may choose not to file a patent application in order to maintain certain trade secrets or know-how, and a third party may subsequently
    file a patent covering such intellectual property. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and
prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Ownership of Our Securities </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>There
may not be an active trading market for our securities, which may make it difficult to sell shares of Class A common stock. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is possible that an active trading market for our securities will not develop or, if developed, that any market will not be sustained.
This would make it difficult for us to sell our securities at an attractive price or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
market price of our securities may be volatile, which could cause the value of an investment to decline. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
price of our securities may fluctuate significantly due to general market and economic conditions. An active trading market for our securities
may not develop or, if developed, it may not be sustained. In addition, fluctuations in the price of our securities could contribute
to the loss of all or part of the investment in us. Even if an active market for our securities develops and continues, the trading price
of our securities could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control.
Any of the factors listed below could have a material adverse effect on your investment in our securities and our securities may trade
at prices significantly below the price you paid for them. In such circumstances, the trading price of our securities may not recover
and may experience a further decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Factors
affecting the trading price of our securities may include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    realization of any of the risk factors presented in this annual report on Form 10-K; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar
    to us; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the market&#8217;s expectations about our operating results; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    operating results failing to meet the expectation of securities analysts of investors in a particular period; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    and share price performance of other companies that investors deem comparable to us; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    volume of shares of Class A common stock available for public sale; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    issuances, sales, resales or repurchases or anticipated issuances, sales, resales or repurchases of our securities; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    commencement, enrollment or results of our ongoing and planned clinical trials of our therapeutic candidates or any future clinical
    trials we may conduct, or changes in the development status of our therapeutic candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    results or delays in clinical trials; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    delay in our regulatory filings for our therapeutic candidates and any adverse development or perceived adverse development with
    respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance
    of a &#8220;refusal to file&#8221; letter or a request for additional information; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to commercialize our therapeutic candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    regulatory decisions, including failure to receive regulatory approval of our therapeutic candidates; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in laws or regulations applicable to our therapeutic candidates, including but not limited to clinical trial requirements for approvals;
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    developments concerning manufacturers or suppliers; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to manufacture or obtain adequate supply for any approved therapeutic or inability to do so at acceptable prices; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to establish collaborations if needed; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key scientific or management personnel; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    serious safety concerns related to cellular therapies; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"/>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction
    of new therapeutics or services offered by our competitors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
    of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to effectively manage growth; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in quarterly operating results; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    cash position; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication
    of research reports about us or our industry, or cellular therapy in particular, or positive or negative recommendations or withdrawal
    of research coverage by securities analysts; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the structure of healthcare payment systems; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in the market valuations of similar companies; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall
    performance of the equity markets; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation
    in the press or investment community; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
    of Class A common stock by us or our stockholders in the future; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    trading volume of our Class A common stock; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in accounting practices; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ineffectiveness of our internal control over financial reporting; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
    or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain or maintain
    patent protection for our technologies; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant
    lawsuits, including patent or stockholder litigation; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
    political and economic conditions, including health pandemics, such as COVID-19; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    events or factors, many of which are beyond our control. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry
factors may negatively affect the market price of our Class A common stock, regardless of its actual operating performance. In the past,
securities class action litigation has often been instituted against companies following periods of volatility in the market price of
a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s
attention and resources, which would harm our business, operating results or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not intend to pay cash dividends for the foreseeable future. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation
and expansion of our business, and we do not expect to declare or pay any cash dividends in the foreseeable future. As a result, you
may only receive a return on your investment in our Class A common stock if the trading price of your shares increases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Class A common stock is currently listed on Nasdaq. If we are unable to maintain listing of our Class A common stock on Nasdaq or any
stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could
be impaired and it may be more difficult for our stockholders to sell their securities.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our Class A common stock is currently listed on Nasdaq, we may not be able to continue to meet the exchange&#8217;s minimum listing requirements
or those of any other national exchange. The Listing Rules of Nasdaq require listing issuers to comply with certain standards in order
to remain listed on its exchange. If, for any reason, we should fail to maintain compliance with these listing standards and Nasdaq should
delist our securities from trading on its exchange and we are unable to obtain listing on another national securities exchange, we anticipate
that our securities would begin trading on the over-the-counter market. Delisting from Nasdaq and trading on the over-the-counter market
could adversely affect the liquidity of our securities. Securities traded on the over-the-counter market generally have limited trading
volume and exhibit a wider spread between the bid/ask quotation, as compared to securities listed on a national securities exchange.
Consequently, you may not be able to liquidate your investment in the event of an emergency or for any other reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On April 22, 2025, we were notified by Nasdaq
that we had not paid certain fees required by Listing Rule 5250(f) totaling $70,000, and as a result, we will be delisted unless we
appeal this determination. We paid the assessed fees on April 24, 2025 and Nasdaq informed us on April 30, 2025 that we were in
compliance with Listing Rule 5250(f) and the matter is now closed. Additionally, on April 16, 2025, Nasdaq provided formal notice to
us that as a result of our failure to timely file this annual report on Form 10-K, we no longer complied with the continued listing
requirements under the timely filing criteria outlined in Nasdaq Listing Rule 5250(c)(1). Pursuant to Listing Rule 5810(d)(2), this
delinquency serves as an additional and separate basis for delisting, and as such, our common stock will be suspended from trading
on May 1, 2025, unless we appeal Nasdaq&#8217;s determination before a Hearing Panel. On April 29, 2025, we filed an appeal
requesting an oral hearing with a Nasdaq Hearing Panel. There can be no assurance that the appeal will be successful or that we will
maintain compliance with the Nasdaq listing requirements. If relief is not granted by the Nasdaq Hearing Panel or we are unable to
regain compliance, our securities will be delisted from the Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
Nasdaq delists our securities from trading on its exchange for failure to meet the listing standards, we and our stockholders could face
significant negative consequences including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    availability of market quotations for our securities; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    determination that the Class A common stock is a &#8220;penny stock&#8221; which will require brokers trading in the Class A common
    stock to adhere to more stringent rules; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">possibly
    resulting in a reduced level of trading activity in the secondary trading market for shares of the Class A common stock; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    limited amount of analyst coverage; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decreased ability to issue additional securities or obtain additional financing in the future. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
sales and issuances of our Class A common stock or rights to purchase common stock, including pursuant to our equity plans, could result
in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that significant additional capital may be needed in the future to continue our planned operations, including, commercialization
efforts, expanded research and development activities, conducting clinical trials and costs associated with operating as a public company.
To raise capital, we may sell shares of our Class A common stock, convertible securities or other equity securities in one or more transactions
at prices and in a manner we determine from time to time. We may also sell our Class A common stock as part of entering into strategic
alliances, creating joint ventures or collaborations or entering into additional licensing arrangements with third parties that we believe
will complement or augment our development and commercialization efforts. If we sell shares of our Class A common stock, convertible
securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material
dilution to existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our Class
A common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Anti-takeover
provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price
of our Class A common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
second amended and restated certificate of incorporation, as amended (&#8220;certificate of incorporation&#8221;), and our amended and
restated bylaws (&#8220;bylaws&#8221;) contain provisions that could delay or prevent a change of control of our Company or changes in
our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    board of directors divided into three classes serving staggered three-year terms, such that not all members of our board of directors
    will be elected at one time; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our
    stockholders; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    requirement that special meetings of stockholders be called only by the chairman of our board of directors, the chief executive officer,
    or by a majority of the total number of authorized directors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance
    notice requirements for stockholder proposals and nominations for election to our board of directors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition
    to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then
    entitled to vote in the election of directors; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder
    action or to amend specific provisions of our certificate of incorporation; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    authority of our board of directors to issue preferred stock on terms determined by the directors without stockholder approval and
    which preferred stock may include rights superior to the rights of the holders of common stock. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which may prohibit certain
business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other
provisions in our charter and bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board
of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender
offer or proxy contest involving our Company. These provisions could also discourage proxy contests and make it more difficult for you
and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention
of a change of control transaction or changes in our board of directors could cause the market price of our Class A common stock to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United
States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our
stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of
the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all
such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the exclusive forum
for the following types of actions or proceedings under Delaware statutory or common law:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    derivative claim or cause of action brought on our behalf; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    claim or cause of action for breach of a fiduciary duty owed by any of our current or former directors, officers or other employees
    to us or our stockholders; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    claim or cause of action against us or any of our current or former directors, officers or other employees, arising out of or pursuant
    to any provision of the DGCL, our charter or the bylaws; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    claim or cause of action seeking to interpret, apply, enforce or determine the validity of our charter or bylaws; </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    claim or cause of action against us or any of our directors, officers or other employees governed by the internal affairs doctrine,
    in all cases to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable
    parties named as defendants. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the
U.S. federal courts have exclusive jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly,
both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions
and the threat of inconsistent or contrary rulings by different courts, among other considerations, our charter provides that the federal
district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under
the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder
may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we
would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our charter. This may require
significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions
will be enforced by a court in those other jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes
with our Company or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers
and other employees. If a court were to find either exclusive-forum provision in our charter to be inapplicable or unenforceable in an
action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sales
of a substantial number of our shares of Class A common stock in the public market could cause our stock price to fall.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may issue and sell additional shares of Class A common stock in the public markets. Sales of a substantial number of shares of our Class
A common stock in the public markets or the perception that such sales could occur could depress the market price of our c Class A common
stock and impair our ability to raise capital through the sale of additional equity securities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
exercise of our outstanding options and warrants and the vesting of outstanding restricted stock units will dilute stockholders and could
decrease our stock price.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise of our outstanding options and warrants and the vesting of outstanding restricted stock units may adversely affect our stock
price due to sales of a large number of shares or the perception that such sales could occur. These factors also could make it more difficult
to raise funds through future offerings of our securities and could adversely impact the terms under which we could obtain additional
equity capital. Exercise of outstanding options and warrants or any future issuance of additional shares of Class A common stock or other
equity securities, including, but not limited to, options, warrants, restricted stock units or other derivative securities convertible
into our Class A common stock, may result in significant dilution to our stockholders and may decrease our stock price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General
Risk Factors </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unstable
market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global credit and financial markets have experienced extreme volatility and disruptions in the past <span style="background-color: white">including
severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, inflationary pressure
and interest rate changes, increases in unemployment rates and uncertainty about economic stability</span>. <span style="background-color: white">The
financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including
the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries
in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy,
and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. Furthermore, the
closures of Silicon Valley Bank and Signature Bank and their placement into receivership with the Federal Deposit Insurance Corporation
(&#8220;FDIC&#8221;) created bank-specific and broader financial institution liquidity risk and concerns. Although the Department of
the Treasury, the Federal Reserve, and the FDIC jointly confirmed that depositors at SVB and Signature Bank would continue to have access
to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception, future adverse developments
with respect to specific financial institutions or the broader financial services industry may lead to market-wide liquidity shortages,
impair the ability of companies to access near-term working capital needs, and create additional market and economic uncertainty. There
can be no assurance that future credit and financial market instability and a deterioration in confidence in economic conditions will
not occur. Our general business strategy may be adversely affected by any such economic downturn, liquidity shortages, volatile business
environment or continued unpredictable and unstable market conditions.</span> If the current equity and credit markets deteriorate, <span style="background-color: white">or
if adverse developments are experienced by financial institutions</span>, <span style="background-color: white">it may cause short-term
liquidity risk and also may</span> make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure
to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our operations, growth
strategy, financial performance and stock price and could require it to delay or abandon clinical development plans. In addition, there
is a risk that one or more of our current service providers may not survive an economic downturn, which could directly affect our ability
to attain our operating goals on schedule and on budget.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our
stock price and trading volume may decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our Class A common stock relies in part on the research and reports that industry or financial analysts publish about
us, our business, our markets and our competitors. We do not control these analysts. If securities analysts do not cover our Class A
common stock, the lack of research coverage may adversely affect the market price of our Class A common stock. Furthermore, if one or
more of the analysts who do cover us downgrade our stock or if those analysts issue other unfavorable commentary about us or our business,
our stock price would likely decline. If one or more of these analysts cease coverage of us or fails to regularly publish reports on
us, we could lose visibility in the market and interest in our stock could decrease, which in turn could cause our stock price or trading
volume to decline and may also impair our ability to grow our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
could be subject to securities class action litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock
price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s
attention and resources, which could harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Financial
reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management will be required to
devote substantial time to compliance matters.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a publicly traded company we incur significant additional legal, accounting and other expenses. The obligations of being a public company
in the U.S. require significant expenditures and place significant demands on our management and other personnel, including costs resulting
from public company reporting obligations under the Exchange Act and the rules and regulations regarding corporate governance practices,
including those under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, and The Nasdaq Capital Market.
These rules require the establishment and maintenance of effective disclosure and financial controls and procedures, internal control
over financial reporting and changes in corporate governance practices, among many other complex rules that are often difficult to implement,
monitor and maintain compliance with. Moreover, despite recent reforms made possible by the JOBS Act, the reporting requirements, rules,
and regulations will make some activities more time-consuming and costly, particularly after we are no longer a &#8220;smaller reporting
company.&#8221; Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all
of these requirements and to keep pace with new regulations, otherwise we may fall out of compliance and risk becoming subject to litigation
or being delisted, among other potential problems.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have material weaknesses in our internal control over financial reporting, which could adversely affect our business, financial condition
and operating results. </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
previously disclosed material weaknesses in our internal control over financial reporting. Specifically, we have insufficient resources
with the appropriate knowledge and expertise to design, implement, and operate effective internal controls over our financial reporting
process that contributed to other material weaknesses within our system of internal control over financial reporting at the control activity
level. If we are unable to remedy the current material weaknesses, or have additional material weaknesses or deficiencies in our internal
control over financial reporting in the future, our consolidated financial statements might contain material misstatements and we could
be required to restate our financial results. Moreover, failures in internal controls may also cause us to fail to meet reporting obligations,
negatively affect investor confidence in our management and the accuracy of our financial statements and disclosures, or result in adverse
publicity and concerns from investors, any of which could have a negative effect on the price of our common stock, subject us to regulatory
investigations and penalties or stockholder litigation, and adversely impact our business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="NA_001"></span>Item
1B. Unresolved Staff Comments. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="NA_002"></span>Item
1C. Cybersecurity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_981_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240101__20241231_gBFCRMPFAIAMT-R_zwbQmdhLhTle" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" continuedAt="ConU000052-01" escape="true" id="Fact000052" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate cybersecurity into our Enterprise Risk Management program. <span id="xdx_90F_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_z5pG55CGOOk" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000053" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">Our cybersecurity program <span id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zQQzNNHtbDQi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000054" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">incorporates</ix:nonNumeric></span> cybersecurity processes,
technologies, and controls designed to identify and manage potential material cyber risks including, but not limited to, operational
risk, intellectual property theft, fraud, harm to employees, patients, or third parties, and violation of privacy or security-related
laws or regulations.</ix:nonNumeric></span> Our cybersecurity program is designed to be aligned with applicable industry standards set by the Center for Internet
Security. Our cybersecurity program employs a range of tools and services, including regular network and endpoint monitoring, managed
detection and response, system patching, managed security services, server and endpoint scheduled backups, awareness training and testing,
periodic vulnerability assessment and penetration testing, to update <span id="xdx_908_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_z4Eu0iED4kRj" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000055" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">our ongoing risk identification and mitigation efforts and is assessed
periodically by independent <span id="xdx_908_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_z9bDmY6Vmzrf" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000056" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third parties</ix:nonNumeric></span>.</ix:nonNumeric></span></span></ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_C0A_gBFCRMPFAIAMT-R_zfSltLYv8pD8"><ix:continuation continuedAt="ConU000052-02" id="ConU000052-01"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></span></p>

<div id="xdx_C01_gBFCRMPFAIAMT-R_z2GMANeMQAxa"><ix:continuation id="ConU000052-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240101__20241231_zpmPgEsnMNn9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000057" name="cyd:CybersecurityRiskRoleOfManagementTextBlock">Our
cybersecurity program is managed by a vice president of global security and cybersecurity who reports to our Chief Executive Officer,
or CEO, providing routine security program updates and briefings</ix:nonNumeric></span>. <span id="xdx_90F_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zlMHrjVtZjxc" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000058" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">The current vice president of global security and cybersecurity has
more than 25 years of experience in cybersecurity, federal law enforcement, and cyber investigations, while possessing the required subject
matter expertise, skills, experience, and industry certifications expected of an individual assigned to these duties</ix:nonNumeric></span>. <span id="xdx_906_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_z4MyJI167cSd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000059" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">Our information
security team, which includes the vice president of global security and cybersecurity, as well as additional professionals, is responsible
for leading enterprise-wide cybersecurity strategy, policy, standards, and processes</ix:nonNumeric></span>. The vice president provides regular updates to
our CEO and other members of management. <span id="xdx_901_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240101__20241231_zXxLC73Ar6xg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000060" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock">Our board of directors has ultimate oversight of cybersecurity risk, which it manages as part
of our Enterprise Risk Management program</ix:nonNumeric></span>. <span id="xdx_90F_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zOdfSq1T0vNi" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000061" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">Cybersecurity periodically provides updates to our management on cyber risks and threats,
the status of projects to strengthen our information security systems, assessments of the information security program, and the emerging
threat landscape</ix:nonNumeric></span>. <span id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_zkCb9OSTkJx" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleantrue" id="Fact000062" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">Management</ix:nonNumeric></span> informs the audit committee or the board of directors of risks from cybersecurity threats as necessary or
advisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, we are <span id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_z7OP6zn0gMTa" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:booleanfalse" id="Fact000063" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">not</ix:nonNumeric></span> aware of any material cybersecurity incidents. While we have not, as of the date of this
annual report on Form 10-K, experienced a cybersecurity threat or incident resulting in a material adverse impact to our business or
operations, these threats are constantly evolving, thereby increasing the difficulty of successfully defending against them or implementing
adequate preventative measures. There can be no guarantee that we will not experience such an incident in the future. We maintain cybersecurity
insurance coverage that provides protection against losses arising from certain cybersecurity incidents. In addition, we seek to detect
and investigate unauthorized attempts and attacks against our network, products, and services, and to prevent their occurrence and recurrence
where practicable through changes or updates to our internal processes and tools and changes or updates to our products and services;
however, we remain potentially vulnerable to known or unknown threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</ix:continuation></div><!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="NA_003"></span>Item
2. Properties. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
occupy approximately 150,000 square feet of office, laboratory and manufacturing space in Florham Park, New Jersey under a lease expiring
in 2036, which we use as our principal place of business. We believe that our existing facilities will be sufficient for our needs for
the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="NA_004"></span>Item
3. Legal Proceedings.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal
proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business other than as described
below. Regardless of outcome, litigation can have an adverse impact because of defense and settlement costs, diversion of management
resources and other factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Arbitration
Demand from Palantir Technologies Inc.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 20, 2023, Palantir Technologies Inc., or Palantir, commenced an arbitration with JAMS Arbitration, or JAMS, asserting claims for
declaratory relief and breach of contract relating to the May 5, 2021 Master Subscription Agreement, or Palantir MSA, seeking damages
in an amount equal to the full value of the contract. We have responded to the arbitration demand and asserted counterclaims for breach
of contract, breach of warranty, fraudulent inducement, violation of California&#8217;s Unfair Competition Law, amongst others, in relation
to the Palantir MSA. On December 21, 2023, we entered into a settlement and release agreement as amended pursuant to the JAMS arbitration
proceeding asserting claims for declaratory relief and breach of contract relating to the Palantir MSA. Both parties agreed to dismiss
the arbitration proceeding and dispute and provide for mutual releases upon satisfaction of a settlement payment obligation. Through
June 3, 2024, we made total settlement payments of $3.5 million and issued Palantir an aggregate of 60,584 shares of our Class A common
stock as consideration for further amendments to the settlement and release agreement, and on June 4, 2024, the parties dismissed all
claims and counterclaims. The Palantir MSA has fully terminated and neither party has any further rights or obligations thereunder. The
shares of our Class A common stock issued to Palantir were issued with piggyback registration rights. Resale of such shares by Palantir
shall be included on any future registration statement we file.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Celularity
Inc. v. Evolution Biologyx, LLC, et al.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 17, 2023, we filed a complaint against Evolution Biologyx, LLC, Saleem S. Saab, individually, and Encyte, LLC, (collectively, &#8220;Evolution&#8221;),
in the U.S. District Court for the District of New Jersey to recover unpaid invoice amounts for the sale of our biomaterial products
in the amount of approximately $2.35 million, plus interest. In September 2021, we executed a distribution agreement with Evolution,
whereupon Evolution purchased biomaterial products from us for sale through Evolution&#8217;s distribution channels. We fulfilled Evolution&#8217;s
orders and otherwise performed each of our obligations under the distribution agreement. Despite attempts to recover the outstanding
invoices and Evolution&#8217;s promise to pay, Evolution has refused to pay any of the invoices and has materially breached its obligations
under the distribution agreement. Our complaint asserts claims of breach of contract, amongst others. On April 4, 2024, Evolution filed
a counter claim alleging damages in an amount to be determined resulting from alleged breach of contract, breach of warranty, quasi contract
and fraud. We believe Evolution&#8217;s counter claims are without any merit, and we intend to vigorously pursue the matter to recover
the outstanding payments owed by Evolution, including interest and associated attorney&#8217;s fees, as well as defend against Evolution&#8217;s
counterclaims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Civil
Investigative Demand</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
received a Civil Investigative Demand, or Demand, under the False Claims Act, 31 U.S.C. &#167; 3729, dated August 14, 2022, from the
U.S. Attorney&#8217;s Office for the Eastern District of Pennsylvania. The Demand requests documents and information relating to claims
submitted to Medicare, Medicaid, or other federal insurers for services or procedures involving injectable human tissue therapy products
derived from amniotic fluid or birth tissue and includes Interfyl. We are cooperating with the request and are engaged in an ongoing
dialogue with the Assistant U.S. Attorneys handling the Demand. The matter is still in preliminary stages and there is uncertainty as
to whether the Demand will result in any liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>TargetCW
v. Celularity Inc</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 27, 2024, WMBE Payrolling, Inc., dba TCWGlobal, filed a complaint in the United States District Court for the Southern
District of California alleging a breach of contract and account stated claims relating to a Master Services Agreement dated May 4,
2020, or the TCWGlobal MSA, for the provision of certain leased workers to perform services on our behalf. The complaint alleges
that we breached the TCWGlobal MSA by failing to make payments on certain invoices for the services of the leased workers. On May 7,
2024, we entered into a settlement agreement and mutual release with TCWGlobal pursuant to which we agreed to pay $516,127 in
tiered monthly installments, with the last payment due and payable on May 1, 2025, in exchange for a dismissal of the complaint and
full release of all claims. We defaulted on the payments in November 2024. On April 21, 2025, we were served with a motion by TCWGlobal to enforce
the settlement and enter judgment against us in the amount of $350,127.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Hackensack Meridian v. Celularity Inc</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March
27, 2025, Hackensack Meridian Health (&#8220;HUMC&#8221;) filed a complaint in the Superior Court of New Jersey seeking $947,576 allegedly
owed by Celularity for costs associated with clinical trials. The amounts claimed were part of a three-party arrangement with a contract
research organization (CRO), which we engaged to make payments on our behalf to HUMC. We have asserted that we believe there are improper
charges in the claim. The parties are attempting to agree on the actual amounts owed by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="NA_005"></span>Item
4. Mine Safety Disclosures.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="NA_006"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="NA_007"></span>Item
5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of our Class A common stock have traded on the Nasdaq Capital Market under the ticker symbol &#8220;CELU.&#8221; Our ticker symbol for
our warrants, which are each exercisable for one-tenth of a share of Class A common stock at an exercise price of $115.00 per share,
as adjusted for the reverse stock split, is &#8220;CELUW&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Holders
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 7, 2025, there were approximately 96 stockholders of record of our Class A common stock and four holders of record of our publicly
traded warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities
Authorized for Issuance under Equity Compensation Plans</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
about our equity compensation plans is incorporated herein by reference to Item 12 of Part III of this annual report on Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2024, we issued 20,000 shares of our Class A common stock to Palantir Technologies Inc., Palantir, pursuant to a Confidential
Letter Agreement by and among us and Palantir dated January 10, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 6, 2024, we issued 40,584 shares of our Class A common stock to Palantir pursuant to a Confidential Letter Amendment to the Palantir
Settlement Agreement by and among us and Palantir dated December 21, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
dates ranging from November 11, 2024 to November 14, 2024, we issued YA II PN. Ltd., or Yorkville, a total of 478,881 shares of our Class
A common stock in connection with the conversion of notes outstanding in the principal and interest amount of $1.3 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 18, 2024, we issued 59,176 shares of our Class A common stock to a former employee pursuant to a Confidential Settlement and
Release Agreement by and among us and the former employee with an effective date of November 18, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer
Purchases of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="NA_008"></span>Item
6. [Reserved] </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="NA_009"></span>Item
7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The
following discussion contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221; Such forward-looking statements, which
represent our intent, belief, or current expectations, involve risks and uncertainties and other factors that could cause actual results
and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. In
some cases you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221;
&#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221;
&#8220;believe,&#8221; &#8220;should&#8221; and similar expressions. Factors that could cause or contribute to differences in results
include, but are not limited to, those set forth under Item 1.B. &#8220;Risk Factors&#8221; and elsewhere in this annual report on Form
10-K. Except as required by law, we undertake no obligation to update these forward-looking statements to reflect events or circumstances
after the date of this report or to reflect actual outcomes.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a regenerative and cellular medicines company focused on addressing aging related and degenerative diseases. Our goal is to ensure
all individuals have the opportunity to live healthier longer. We develop off-the-shelf placental-derived allogeneic cell therapy product
candidates including mesenchymal-like adherent stromal cells, or MLASCs, for which we have clinical datasets from Phase I and Phase II
clinical studies and are prioritizing advanced stage programs in diabetic foot ulcer, or DFU, and Crohn&#8217;s Disease, or CD. It also
includes natural killer, or NK cells, product candidates for which we have clinical datasets from Phase I and Phase II clinical studies
and are currently investigating in preclinical studies as senoablatant candidates. We believe that by harnessing the placenta&#8217;s
unique biology and ready availability, we will be able to develop therapeutic solutions that address a significant unmet global need
for effective, accessible and affordable therapeutics. Our advanced biomaterials business today is comprised primarily of the sale of
Biovance 3L and Rebound product lines, directly or through our distribution network. Biovance 3L is a tri-layer decellularized, dehydrated
human amniotic membrane derived from the placenta of a healthy, full-term pregnancy. It is an intact, natural extracellular matrix that
provides a foundation for the wound regeneration process and acts as a scaffold for restoration of functional tissue. Rebound is a full
thickness extracellular matrix that contains amnion and chorion. We are developing new placental biomaterial products to deepen the biomaterials
commercial pipeline. We also plan to leverage our core expertise in cellular therapeutic development and manufacturing to generate revenues
by providing contract manufacturing and development services to third parties. The initial focus of this new service offering will be
to assist development stage cell therapy companies with the development and manufacturing of their therapeutic candidates for clinical
trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are working toward a set of milestones with respect to off-the-shelf placental-derived allogeneic biomaterial product candidates and
cell therapy product candidates, respectively. With respect to our biomaterial product candidate pipeline, we expect to submit a 510(k)
application for our Celularity Tendon Wrap, or CTW, in the second half of 2025. We expect to advance the development of our FUSE Bone
Void Filler, or FUSE, with the objective of a 510(k) filing in the second half of 2026, and to advance the development of our Celularity
Placental Matrix, or CPM, with the objective of a 510(k) filing in the second half of 2027. With respect to our MLASCs cell therapy product
candidate for DFU (PDA 002), we expect in the first half of 2025 to request an End of Phase 2, or EOP2, meeting with the FDA as part
of which we intend to discuss with the FDA our Phase 3 plan and protocols. In addition, with respect to our MLASCs cell therapy product
candidate (PDA 001), we expect to complete, in the first half of 2025, our safety and efficacy assessment of previously generated data
that is one factor in determining whether to progress our MLASCs cell therapy product candidate in CD to a Phase 3 clinical trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Celularity IMPACT manufacturing process is a seamless, fully integrated process designed to optimize speed and scalability from the sourcing
of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific
chemistry, manufacturing and controls, or CMC, advanced cell manufacturing and cryopreservation. The result is a suite of allogeneic
inventory-ready, on demand placental-derived cell therapy products. We also operate and manage a commercial biobanking business that
includes the collection, processing and cryogenic storage of certain birth byproducts for third-parties. A biobank is an organized collection
of biological human material and its associated information stored for future retrieval and use in research, regenerative medicine, and
innovation. We provide a fee-based biobanking service to expectant parents who contract with us to collect, process, cryogenically preserve
and store certain biomaterial, including umbilical cord blood and placenta derived cells and tissue. We receive a one-time fee for the
collection, processing, and cryogenic preservation of the biomaterials, and a storage fee to maintain the biomaterials in our biobank
payable annually generally over a period of 18 to 25 years. We intend to explore opportunities to diversify our biobanking business,
including adult cell banking.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current science is the product of the cumulative background and effort over two decades of our seasoned and experienced management team.
We have our roots in Anthrogenesis Corporation, or Anthrogenesis, a company founded under the name Lifebank in 1998 by Robert J. Hariri,
M.D., Ph.D., our founder and Chief Executive Officer, and acquired in 2002 by Celgene Corporation, or Celgene. The team continued to
hone their expertise in the field of placental-derived technology at Celgene through August 2017, when we acquired Anthrogenesis. We
have a robust global intellectual property portfolio comprised of over 300 patents and patent applications protecting our Celularity
IMPACT platform, our processes, technologies and cell therapy programs that we are actively developing or are seeking to out-license/find
a collaboration partner to develop. We believe this know-how, expertise and intellectual property will drive the rapid development and,
if approved, commercialization of these potentially lifesaving therapies for patients with unmet medical needs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Recent Developments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
October 9, 2024, we entered into an asset purchase agreement with Sequence LifeScience, Inc., or Sequence, pursuant to which we acquired
Sequence&#8217;s Rebound&#8482; full thickness placental-derived allograft matrix product, or the Product, and certain assets related
thereto, collectively the Asset. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will pay aggregate
consideration for the Asset of up to $5.5 million<span style="background-color: white">, which consists of (i) an upfront cash payment
of $1.0 million (ii) an aggregate of up to $4.0 million in monthly milestone payments, or the Milestone Payments, and (iii) a credit
of $0.5 million for the previous payment made by the Company to Sequence pursuant to that certain letter of intent between us and Sequence
dated August 16, 2024. Pursuant to the terms of the Asset Purchase Agreement, the Milestone Payments are calculated based on 20% of net
sales collected by us from our customers during the preceding calendar month, commencing the first full month after the closing of the
transaction. The closing of the transaction occurred on October 9, 2024. Concurrently with the execution of the Asset Purchase Agreement,
we entered into an exclusive supply agreement with Sequence for the manufacture and supply of the Product for a minimum period of six
months. We retain the right to manufacture the Product internally and intend to commence a technology transfer as soon as practicable.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On November 25, 2024, we
entered into a securities purchase agreement with an accredited investor pursuant to which we agreed to sell and issue to the investor
and other purchasers in a private placement transaction, in one or more closings, unsecured senior convertible notes (the &#8220;November
Notes&#8221;) and warrants (the &#8220;November Warrants&#8221;). As of the date of this annual report, we have issued and sold $0.75
million in aggregate principal amount of November Notes and related November Warrants. The November Notes bear interest at an annual rate
of 8% (increasing to 10% in the event of default as defined in the securities purchase agreement) and have a maturity date of one year
from the date of issuance. Upon an event of default, the November Notes are convertible at the holder&#8217;s option into shares of our
Class A common stock at a price per share equal to (i) $2.85 (adjusted for stock splits, reverse stock splits, stock dividends, or similar
transactions); or (ii) the offering price of a subsequent financing transaction with gross proceeds of $2.5 million or more, subject to
a floor price of $1.00 per share. The November Warrants entitle the holder thereof to purchase shares of Class A common stock equal to
the principal amount of November Notes purchased by such holder, divided by the exercise price of $2.85 per share. The exercise price,
and the number of shares of Class A common stock issuable under the November Warrants, are subject to a one-time reset upon the completion
of a subsequent financing transaction with gross proceeds of $2.5 million or more, subject to a floor price of $1.00 per share. The November
Warrants are immediately exercisable and have a five-year term. In connection with the transaction, we issued a five-year warrant to the
placement agent to purchase 52,500 shares of Class A common stock (the &#8220;Placement Agent Warrants&#8221;) at an exercise price equal
to 125% of the offering price, or $3.56. The Placement Agent Warrants are subject to the same one-time reset upon completion of a subsequent
financing transaction as the November Warrants, except that the reset price for the Placement Agent Warrants shall be 125% of the reset
price of the November Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On December 27, 2024, we
entered into a securities purchase agreement with an institutional investor for the issuance and sale in a private placement (the &#8220;December
Placement&#8221;) of (i) 1,263,157 shares of our Class A common stock and (ii) five-year warrants to purchase up to 1,263,157 shares of
our Class A common stock, at a purchase price of $2.375 per share of Class A common stock and accompanying warrant. Effective as of January
23, 2025, the December Placement was terminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 24, 2025, we agreed
with the holder of warrants dated January 16, 2024 to purchase 535,274 shares of Class A common stock (the &#8220;2024 Warrant&#8221;)
and warrants dated January 9, 2020, as amended, to purchase 652,981 shares of Class A common stock (the &#8220;2020 Warrant&#8221; and
together with the 2024 Warrants, the &#8220;Warrants&#8221;) to amend the exercise price of the Warrants to $2.07 per share from $2.49
per share. The holder agreed to exercise the Warrants for gross proceeds to us of approximately $2.46 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 29, 2025, Dr.
Robert Hariri, our CEO, extended the maturity date of his outstanding loans from December 31, 2024 to December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On February 12, 2025, we
entered into a binding term sheet with Resorts World Inc Pte Ltd, or RWI, pursuant to which RWI agreed to, among other things, an extension
of that certain second forbearance agreement dated as of March 13, 2024 whereby RWI has agreed not to exercise its rights and remedies
upon the occurrence of any default under certain loans owed to RWI and whereby the maturity date of the foregoing loans is extended to
February 15, 2026. Pursuant to the RWI binding term sheet, we agreed to (i) use a portion of the proceeds from our next registered public
offering to pay RWI approximately $1.3 million, representing cash interest through January 31, 2025 and (ii) issue to RWI, on July 24,
2025, a new five-year warrant to purchase up to 500,000 shares of our Class A common stock. In addition, we agreed to reprice certain
outstanding warrants held by RWI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40.5pt">On February 12, 2025, we
entered into a binding term sheet, with C.V. Starr &amp; Co., Inc., or Starr, pursuant to which Starr agreed to, among other things, an
extension of that certain forbearance agreement dated March 13, 2024 whereby Starr agreed not to exercise its rights and remedies upon
the occurrence of any default under certain loans owed to Starr and whereby the maturity date of the loan is extended to February 15,
2026. Pursuant to the Starr binding term sheet, we agreed to (i) use a portion of the proceeds from our next registered public offering
to pay Starr approximately $0.8 million, representing cash interest through January 31, 2025 and (ii) issue to Starr a new five-year warrant
to purchase up to 100,000 shares of our Class A common stock. In addition, we agreed to reprice certain outstanding warrants held by Starr.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40.5pt">On April 22, 2025, we
were notified by Nasdaq that we had not paid certain fees required by Listing Rule 5250(f) totalling $70,000, and as a result, we
will be delisted unless we appeal this determination. We paid the assessed fees on April 24, 2025, and Nasdaq informed us on April
30, 2025, that we were in compliance with Listing Rule 5250(f) and the matter is now closed. Additionally, on April 16, 2025, Nasdaq
provided formal notice to us that as a result of our failure to timely file this annual report on Form 10-K, we no longer complied
with the continued listing requirements under the timely filing criteria outlined in Nasdaq Listing Rule 5250(c)(1). Pursuant to
Listing Rule 5810(d)(2), this delinquency serves as an additional and separate basis for delisting, and as such, our common stock
will be suspended from trading on May 1, 2025, unless we appeal Nasdaq&#8217;s determination before a Hearing Panel. On April 29,
2025, we filed an appeal requesting an oral hearing with a Nasdaq Hearing Panel. There can be no assurance that the appeal will be
successful or that we will maintain compliance with the Nasdaq listing requirements. If relief is not granted by the Nasdaq Hearing
Panel or we are unable to regain compliance, our securities will be delisted from the Nasdaq.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i></i></p>

<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><b><i>Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In accordance with Accounting
Standards Update, or ASU, No. 2014-15, <i>Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern (Subtopic
205-40)</i>, or ASU 205-40, we evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial
doubt about our ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As a small clinical-stage
biotechnology company, we are subject to certain inherent risks and uncertainties associated with the development of an enterprise. In
this regard, since our inception, substantially all of management&#8217;s efforts have been devoted to making investments in research
and development including basic scientific research into placentally-derived allogeneic cells, pre-clinical studies to support our current
and future clinical programs in cellular therapeutics, and clinical development of our cell programs as well as facilities and selling,
general and administrative expenses that support our core business operations (collectively the &#8220;investments&#8221;), all at the
expense of our short-term profitability. We have historically funded these investments through limited revenues generated from our biobanking
and degenerative disease businesses and issuances of equity and debt securities to public and private investors (these issuances are collectively
referred to as &#8220;outside capital&#8221;). Notwithstanding these efforts, management can provide no assurance that our research and
development and commercialization efforts will be successfully completed, or that adequate protection of our intellectual property will
be adequately maintained. Even if these efforts are successful, it is uncertain when, if ever, we will generate significant sales or operate
in a profitable manner to sustain our operations without needing to continue to rely on outside capital. Continued decline in our share
price could result in further impairment of our goodwill or long-lived assets in a future period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of the date the accompanying
consolidated financial statements were issued, or the issuance date, management evaluated the significance of the following adverse conditions
and events in accordance with ASU 205-40:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since inception, we have incurred significant operating losses and used net cash from operations. For
the year ended December 31, 2024, we incurred an operating loss of $38.4 million and used net cash outflows in operations of $6.4 million.
As of December 31, 2024, we had an accumulated deficit of $899.7 million. We expect to continue to incur significant operating losses
and use net cash in operations for the foreseeable future.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">We expect to incur substantial expenditures to fund our investments for the foreseeable future. In order
to fund these investments, we will need to secure additional sources of outside capital. While we are actively seeking to secure additional
outside capital (and have historically been able to successfully secure such capital), as of the issuance date, no additional outside
capital has been secured or was deemed probable of being secured. In addition, management can provide no assurance that we will be able
to secure additional outside capital in the future or on terms that are acceptable to us. Absent an ability to secure additional outside
capital in the very near term, we will be unable to meet our obligations as they become due over the next 12 months beyond the issuance
date.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of the issuance date, we had approximately $43.3 million of principal debt outstanding, all of which
is currently due or due within one year of the issuance date. As disclosed in Note 10, substantially all of our outstanding debt is subject
to a forbearance agreement. In the event the terms of the forbearance agreements are not met and/or the outstanding borrowings are not
repaid, the lenders may, at their discretion, exercise all of their rights and remedies under the loan agreements which may include, among
other things, seizing our assets and/or forcing us into liquidation.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0">A<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s a result of our failure to timely
                                                                                                                                                                                                           file this annual report on Form 10-K, we no longer complied with the continued listing requirements under the timely filing criteria
                                                                                                                                                                                                           outlined in Nasdaq Listing Rule 5250(c)(1). Pursuant to Listing Rule 5810(d)(2), this delinquency serves as an additional and
                                                                                                                                                                                                           separate basis for delisting, and as such, our common stock will be suspended from trading on May 1, 2025, unless we appeal
                                                                                                                                                                                                           Nasdaq&#8217;s determination before a Hearing Panel. On April 29, 2025, we filed an appeal requesting an oral hearing with a Nasdaq
                                                                                                                                                                                                           Hearing Panel. There can be no assurance that the appeal will be successful or that we will maintain compliance with the Nasdaq
                                                                                                                                                                                                           listing requirements. If relief is not granted by the Nasdaq Hearing Panel or we are unable to regain compliance, our securities
                                                                                                                                                                                                           will be delisted from the Nasdaq, which such delisting could have a materially adverse effect on our ability to continue as a going
                                                                                                                                                                                                           concern. </span></p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event we are unable to secure additional outside capital to fund our obligations when they become
due, including repayment of our outstanding debt, over the next 12 months beyond the issuance date, management will be required to seek
other strategic alternatives, which may include, among others, a significant curtailment of our operations, a sale of certain of our assets,
a sale of our entire company to strategic or financial investors, and/or allowing us to become insolvent by filing for bankruptcy protection
under the provisions of the U.S. Bankruptcy Code.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">These uncertainties raise
substantial doubt about our ability to continue as a going concern. The accompanying consolidated financial statements have been prepared
on the basis that we will continue to operate as a going concern, which contemplates that we will be able to realize assets and settle
liabilities and commitments in the normal course of business for the foreseeable future. Accordingly, the accompanying consolidated financial
statements do not include any adjustments that may result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>Business Segments</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We manage our operations
through an evaluation of three distinct business segments: Cell Therapy, Degenerative Disease, and BioBanking. The reportable
segments were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers to
cellular therapies we are researching and developing. Therapies being researched are unproven and in various phases of development.
All of the cell therapy programs fall into the Cell Therapy segment. Degenerative Disease produces, sells and licenses products used
in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl and CentaFlex. We sell products in this segment using
independent sales representatives as well as distributors. We are developing additional tissue-based products for the Degenerative
Disease segment. BioBanking collects stem cells from umbilical cords and placentas and provides storage of such cells on behalf of
individuals for future use. We operate in the biobanking business primarily under the LifebankUSA brand. For more information about
our reportable business segments refer to Note 19, &#8220;<i>Segment Information</i>&#8221; of our audited consolidated financial
statements included elsewhere in this annual report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Celularity Inc., formerly
known as GX Acquisition Corp. (&#8220;GX&#8221;), was a blank check company incorporated in Delaware on August 24, 2018. The Company was
formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar
business combination with one or more businesses. On July 16, 2021 (the &#8220;Closing Date&#8221;), the Company consummated the previously
announced merger pursuant to the Merger Agreement and Plan of Reorganization, dated January 8, 2021 (the &#8220;Merger Agreement&#8221;),
by and among GX, Alpha First Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of GX (&#8220;First Merger
Sub&#8221;), Celularity LLC (f/k/a Alpha Second Merger Sub LLC), a Delaware limited liability company and a direct, wholly owned subsidiary
of GX (&#8220;Second Merger Sub&#8221;), and the entity formerly known as Celularity Inc., incorporated under the laws of the state of
Delaware on August 29, 2016 (&#8220;Legacy Celularity&#8221;). Upon completion of the merger transaction, GX changed its name to Celularity
Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 170 Park Avenue, Florham Park, New Jersey 07932, and our telephone number is (908) 768-2170. We maintain a website at <i>https://celularity.com/</i>
where general information about us is available. The information contained on our website is not incorporated by reference into this annual
report on Form 10-K, and you should not consider any information contained on, or that can be accessed through, our website as part of
this annual report or in deciding whether to purchase our securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>Components of Operating Results</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Net revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Net revenues include: (i)
sales of biomaterial products, including Biovance, Biovance 3L, Rebound<sup>TM</sup>, Interfyl, and CentaFlex of which our direct sales
are included in Product Sales while sales through our network of distribution partners are included in License, royalty and other; and
(ii) the collection, processing and storage of umbilical cord and placental blood and tissue after full-term pregnancies, collectively,
Services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Cost of revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Cost of revenues consists
of labor, material and overhead costs associated with our two existing commercial business segments, biobanking and degenerative disease.
Biobanking costs include the cost of storage and transportation kits for newly banked materials as well as tank and facility overhead
costs for cord blood and other units in storage. Degenerative disease costs include costs associated with procuring placentas, qualifying
the placental material and processing the placental tissue into a marketable product. Costs in the degenerative disease segment include
labor and overhead costs associated with the production of the Biovance, Biovance 3L, Interfyl and CentaFlex product lines. Cost of revenues
associated with direct sales are part of Product Sales while cost of revenues associated with sales through our network of distribution
partners are included in License, royalty and other.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 79 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Research and development expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our research and development
expenses primarily relate to basic scientific research into placentally derived allogeneic cells, pre-clinical studies to support our
current and future clinical programs in cellular medicine, clinical development of our NK cell programs and facilities, depreciation and
other direct and allocated expenses incurred as a result of research and development activities. We incur expenses for personnel expenses
for research scientists, specialized chemicals and reagents used to conduct biologic research, expense for third party testing and validation
and various overhead expenses including rent and facility maintenance expense. Basic research, research collaborations involving partners
and research designed to enable successful regulatory submissions is critical to our current and future success in cell therapy. The amount
of our research and development expenditures will depend on numerous factors, including the timing of clinical trials, preliminary evidence
of efficacy in clinical trials and the number of indications that we choose to pursue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Selling, general and administrative expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Selling, general and administrative
expense consists primarily of personnel costs including salaries, bonuses, stock compensation and benefits for specialized staff that
support our core business operations. Executive management, finance, legal, human resources and information technology are key components
of selling, general and administrative expense and those expenses are recognized when incurred. We expect that as a result of our reprioritization
efforts, we will see a decrease in our selling, general and administrative costs in the near term. The magnitude and timing of our selling,
general and administrative costs will depend on the progress of clinical trials, commercialization efforts for any approved therapies
including the release of new products within the degenerative disease portfolio, changes in the regulatory environment or staffing needs
to support our business strategy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Change in fair value of contingent consideration liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Because the acquisitions
of Anthrogenesis from Celgene and HLI CT were accounted for as business combinations, we recognized acquisition-related contingent
consideration on the balance sheets in accordance with the acquisition method of accounting. See Note 12, &#8220;<i>Commitments and
Contingencies</i>&#8221; for more information. The fair value of contingent consideration liability is determined based on a
probability-weighted income approach derived from revenue estimates and a probability assessment with respect to the likelihood of
achieving regulatory and commercial milestone obligations and royalty obligations. The fair value of acquisition related contingent
consideration is remeasured each reporting period with changes in fair value recorded in the consolidated statements of operations and comprehensive loss.
Changes in contingent consideration fair value estimates result in an increase or decrease in our contingent consideration
obligation and a corresponding charge or reduction to operating results. Key elements of the contingent consideration are regulatory
milestone payments, sales milestone payments and royalty payments. Regulatory payments are due on regulatory approval of certain
cell types in the United States and the European Union. Regulatory milestone payments are one time but are due prior to any
potential commercial success of a cell type in a specific indication. Royalty payments are a percentage of net sales. Sales
milestone payments are due when certain aggregate sales thresholds have been met. Management must use substantial judgment in
evaluating the value of the contingent consideration. Estimates used by management include but are not limited to: (i) the number
and type of clinical programs that we are likely to pursue based on the quality of our preclinical data, (ii) the time required to
conduct clinical trials, (iii) the odds of regulatory success in those trials, (iv) the potential number of patients treatable for
the indications in which we are successful and (v) the pricing of treatments that achieve commercial status. All of these areas
involve substantial judgment on the part of management and are inherently uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>Comparison of Year Ended December 31, 2024 to December
31, 2023</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">(in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Percent</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Change</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Change</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Revenues:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left">Product sales, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">35,336</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">13,149</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">22,187</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">168.7</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,140</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,441</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(301</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5.5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">License, royalty and other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,744</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,181</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,563</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">228.7</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Total revenues</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">54,220</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">22,771</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">31,449</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">138.1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Cost of revenues (excluding amortization of acquired <br/>intangible assets)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Product sales</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,924</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,628</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,704</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(42.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt">Services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,172</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,650</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(478</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(29.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">License, royalty and other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,893</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,738</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,155</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">55.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,386</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">30,465</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(13,079</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(42.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Selling, general and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">58,643</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">50,576</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,067</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Change in fair value of contingent consideration liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(193</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(104,339</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">104,146</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(99.8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Goodwill impairment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">112,347</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(112,347</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(100.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">IPR&amp;D impairment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">107,800</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(107,800</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(100.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Amortization of acquired intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,753</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,193</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(440</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(20.1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">92,578</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">215,058</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(122,480</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">(57.0</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(38,358</p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(192,287</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">153,929</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">(80.1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Page; Sequence: 80 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Net Revenues and Cost of Revenues </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Net revenues for the year
ended December 31, 2024 was $54.2 million, an increase of $31.4 million, or 138.1%, compared to the prior year period. The increase was
primarily due to a $22.2 million increase in product sales driven mainly by increased sales of Biovance 3L and Rebound and a $9.6 million
increase in license, royalty and other driven by Rebound distributor sales, which we started selling in the third quarter of 2024 through
an exclusive distribution agreement with Sequence. On October 9, 2024, we acquired Rebound in an asset purchase agreement with Sequence.
For more information about the Rebound asset purchase agreement, see Note 3, &#8220;<i>Asset Acquisition</i>&#8221; in our audited consolidated
financial statements included elsewhere in this annual report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Cost of revenues for the
year ended December 31, 2024 was $15.0 million, a decrease of $1.0 million, or 6.4%, compared to the prior year period. The decrease
was primarily due to a $3.7 million decrease in product sales costs, which was primarily related to lower inventory impairment
charges. Included in product sales costs in the current year were inventory impairment and obsolescence charges of $0.8 million,
compared to inventory impairment charges of $5.4 million in the prior year period due to lower of cost or market adjustments. The
decrease in product sales costs was partially offset by an increase of $3.2 million in licenses, royalty and other costs, primarily
driven by Rebound distributor sales. As a percentage of revenues, cost of revenues decreased to 28% for the year ended December 31,
2024 compared to 70% in the prior year period. This decrease was due to an increase in Biovance 3L and Rebound sales, which have a
higher gross profit margin than other biomaterial products and lower inventory impairment charges.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Research and Development Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Research and development
expenses for the year ended December 31, 2024 were $17.4 million, a decrease of $13.1 million, or 42.9%, compared to the prior year period.
The decrease was primarily due to: (i) $8.2 million decrease in outside services, driven by a $2.8 million decrease in clinical trial
costs, resulting from discontinuing certain clinical trials related to cell therapy candidates and $4.0 million included in the prior year period in connection with the Pulthera, LLC sublicense agreement for stem cells inventory to be
used in research and development; (ii) $3.6 million decrease in personnel costs, mainly due to a
reduction in force implemented in March 2023; and, (iii) $1.9 million decrease in corporate allocations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><i>Selling, General and Administrative Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Selling, general and administrative
expenses for the year ended December 31, 2024 were $58.6 million, an increase of $8.1 million, or 16.0%, compared to the prior year period.
The increase was primarily due to higher selling expenses, which were driven by an increase in biomaterial sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Change in Fair Value of Contingent
Consideration Liability</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The acquisition-related contingent
consideration liability decreased to $1.4 million as of December 31, 2024, compared to $1.6 million at December 31, 2023. This decrease,
resulting in a gain of $0.2 million for the year ended December 31, 2024, was driven by adjustments to market-based assumptions related
to future consideration payable in connection with the HLI Cellular Therapeutics acquisition. In 2023, we discontinued our cell therapy
clinical trials, which led to the full write-off the Anthrogenesis acquisition-related contingent consideration liability. As a result,
we recognized a gain of $104.3 million for the year ended December 31, 2023. For more information about changes in the fair value of contingent
consideration liability refer to Note 4, &#8220;<i>Fair Value of Financial Assets and Liabilities</i>&#8221; of our audited consolidated
financial statements included elsewhere in this annual report on Form 10-K).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 81 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Impairments</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">There were no impairment
charges for the year ended December 31, 2024. For the year ended December 31, 2023, we recorded goodwill and IPR&amp;D impairment charge
of $112.3 million and $107.8 million, respectively, due to the decline in future revenue projections in the Cell Therapy business driven
by discontinuation of clinical trials and changes in our strategy and pipeline.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Other Income (Expense)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">(in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Percent</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Change</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Change</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: left">Interest income</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">331</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">320</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">11</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">3.4</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(6,264</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,015</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,249</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">107.8</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of warrant liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">398</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,164</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,766</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(93.5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(492</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,177</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">685</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(58.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss on debt extinguishment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,908</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,908</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(100.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other expense, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(9,599</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(6,290</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,309</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">52.6</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total other expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(19,534</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,998</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(15,536</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">388.6</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2024, total other expense was $19.5 million compared to $4.0 million in the prior year period. The decrease was primarily due to changes
in the fair value of warrant liabilities of $5.8 million, a loss on debt extinguishment of $3.9 million and an increase in interest expense
of $3.2 million. Change in fair value of warrant liability for the year ended December 31, 2023, was a $6.2 million gain primarily due
to decreases in the price of our Class A common stock during the prior year period (see Note 4, &#8220;<i>Fair Value of Financial Assets
and Liabilities</i>&#8221; of our audited consolidated financial statements included elsewhere in this annual report on Form 10-K). Included
in the year ended December 31, 2024 was a $3.9 million loss on debt extinguishment recorded in connection with the January 12, 2024 RWI
Second Amended Bridge Loan (for more information about the RWI Second Amended Bridge Loan refer to Note 10, &#8220;<i>Debt</i>&#8221; in
our audited consolidated financial statements included elsewhere in this annual report on Form 10-K). The $3.2 million increase in interest
expense was primarily driven by interest on the January 12, 2024, RWI Second Amended Bridge Loan. Other expense, net increased $3.3 million
from the prior period primarily due to an accrual for liquidated damages resulting from our failure to satisfy certain public information
conditions pursuant to the securities purchase agreement dated May 18, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024,
we had $0.7 million of unrestricted cash and cash equivalents and an accumulated deficit of $899.7 million. Our primary sources of cash
are revenues generated through our biomaterials and biobanking commercial businesses, as well as financing activities. Our capital resources
are primarily used to fund our operating expenses, including: selling, general and administrative costs to operate our commercial businesses;
costs to maintain our GMP manufacturing and research and development facility; and, costs related to development of our advanced biomaterial
and cell therapy product candidates, along with cash used for debt repayment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On October 9, 2024, we entered
into an asset purchase agreement with Sequence LifeScience, Inc., or Sequence, pursuant to which we acquired Sequence&#8217;s Rebound&#8482;
full thickness placental-derived allograft matrix product, or the Product, and certain assets related thereto, collectively the Asset.
We will pay aggregate consideration for the Asset of up to $5.5 million, which consists of (i) an upfront cash payment of $1.0 million
(ii) an aggregate of up to $4.0 million in monthly milestone payments, or the Milestone Payments, and (iii) a credit of $0.5 million for
the previous payment made by us to Sequence pursuant to that certain letter of intent between us and Sequence dated August 16, 2024. Pursuant
to the terms of the Asset Purchase Agreement, the Milestone Payments are calculated based on 20% of net sales collected by us from our
customers during the preceding calendar month, commencing the first full month after the closing of the transaction. The closing of the
transaction occurred on October 9, 2024. Concurrently with the execution of the Asset Purchase Agreement, we entered into an exclusive
supply agreement with Sequence for the manufacture and supply of the Product for a minimum period of six months. We retain the right to
manufacture the Product internally and intend to commence a technology transfer as soon as practicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt"></p>

<!-- Field: Page; Sequence: 82 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On November 25, 2024, we
entered into a securities purchase agreement with an accredited investor pursuant to which we agreed to sell and issue to the investor
and other purchasers in a private placement transaction, in one or more closings, unsecured senior convertible notes (the &#8220;November
Notes&#8221;) and warrants (the &#8220;November Warrants&#8221;). As of the date of this annual report, we have issued and sold $0.75
million in aggregate principal amount of November Notes and related November Warrants. The November Notes bear interest at an annual rate
of 8% (increasing to 10% in the event of default as defined in the securities purchase agreement) and have a maturity date of one year
from the date of issuance. Upon an event of default, the November Notes are convertible at the holder&#8217;s option into shares of our
Class A common stock at a price per share equal to (i) $2.85 (adjusted for stock splits, reverse stock splits, stock dividends, or similar
transactions); or (ii) the offering price of a subsequent financing transaction with gross proceeds of $2.5 million or more, subject to
a floor price of $1.00 per share. The November Warrants entitle the holder thereof to purchase shares of Class A common stock equal to
the principal amount of November Notes purchased by such holder, divided by the exercise price of $2.85 per share. The exercise price,
and the number of shares of Class A common stock issuable under the November Warrants, are subject to a one-time reset upon the completion
of a subsequent financing transaction with gross proceeds of $2.5 million or more, subject to a floor price of $1.00 per share. The November
Warrants are immediately exercisable and have a five-year term. In connection with the transaction, we issued a five-year warrant to the
placement agent to purchase 52,500 shares of Class A common stock (the &#8220;Placement Agent Warrants&#8221;) at an exercise price equal
to 125% of the offering price, or $3.56. The Placement Agent Warrants are subject to the same one-time reset upon completion of a subsequent
financing transaction as the November Warrants, except that the reset price for the Placement Agent Warrants shall be 125% of the reset
price of the November Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 24, 2025, we agreed
with the holder of warrants dated January 16, 2024 to purchase 535,274 shares of Class A common stock (the &#8220;2024 Warrant&#8221;)
and warrants dated January 9, 2020, as amended, to purchase 652,981 shares of Class A common stock (the &#8220;2020 Warrant&#8221; and
together with the 2024 Warrants, the &#8220;Warrants&#8221;) to amend the exercise price of the Warrants to $2.07 per share from $2.49
per share. The holder agreed to exercise the Warrants for gross proceeds to us of approximately $2.46 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 29, 2025, Dr.
Robert Hariri, our CEO, extended the maturity date of his outstanding loans from December 31, 2024 to December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of the issuance date,
we had insufficient unrestricted cash and cash equivalents available to fund our operations and no available additional sources of outside
capital to sustain our operations for a period of 12 months beyond the issuance date. These uncertainties raise substantial doubt about
our ability to continue as a going concern. Refer to the Going Concern section above for further details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">To date, we have not had
any cellular therapeutics approved for sale and have not generated any revenues from the sale of our cellular therapeutics and we are
not actively developing any cellular therapeutics in our pipeline given our liquidity. We do not expect to generate any revenues from
cellular therapeutic product sales unless and until we successfully complete development and obtain regulatory approval for one or more
of our therapeutic candidates, which we expect will take a number of years. If we obtain regulatory approval for any of our therapeutic
candidates, we expect to incur significant commercialization expenses related to therapeutic sales, marketing, manufacturing and distribution
as our current commercialization efforts are limited to our biobanking and degenerative disease businesses. As a result, until such time,
if ever, as we can generate sufficient revenues to fund operations, we expect to finance our cash needs through equity offerings, debt
financings or other capital sources, including commercial sales of our biomaterials products, as well as potentially collaborations, licenses
and other similar arrangements for our cellular therapeutic candidates. We continue to explore licensing and collaboration arrangements
for our cellular therapeutics as well as distribution arrangements for our degenerative disease business. However, we may be unable to
raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Any failure to raise capital as
and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies.
Failure to obtain this necessary capital or address our liquidity needs may force us to delay, limit or terminate our operations, make
further reductions in our workforce, discontinue our commercialization efforts for our biomaterials products as well as other clinical
trial programs, liquidate all or a portion of our assets or pursue other strategic alternatives, and/or seek protection under the provisions
of the U.S. Bankruptcy Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We expect to incur substantial
expenses in the foreseeable future for the expansion of our degenerative disease business and ongoing internal research and development
programs. We will require substantial additional funding in the future to build the sales, marketing and distribution infrastructure that
will be necessary to commercialize our biomaterials products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">To date, inflation has not
had a significant impact on our business. However, any significant increase in inflation and interest rates could have a significant effect
on the economy in general and, thereby, could affect our future operating results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 83 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Cash Flows</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table
summarizes our cash flows for the periods indicated:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">(in thousands)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Change</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash (used in)/provided by</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 53%; text-align: left">Operating activities</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(6,401</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(38,685</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">32,284</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Investing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">514</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(4,048</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,562</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Financing activities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,701</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">24,094</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(17,393</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net change in cash, cash equivalents and restricted cash</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">814</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(18,639</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,453</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Operating Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We used $6.4 million of net
cash in operations for the year ended December 31, 2024 compared to $38.7 million for the year ended December 31, 2023. The decrease was
primarily due to higher net revenues driven mainly by increased sales of Biovance 3L and Rebound and lower operating expenses mainly due
to lower research and development costs resulting from discontinuation of certain clinical trials related to cell therapy candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Investing Activities </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Net cash provided by investing
activities was $0.5 million during the year ended December 31, 2024 compared to net cash used in investing activities of $4.0 million
during the year ended December 31, 2023. Net cash provided by investing activities for the year ended December 31, 2024 included $2.2
million settlement of a convertible note receivable from Sanuwave, offset by $1.5 million for the Rebound asset purchase and $0.2 million
of capital expenditures. Net cash used in investing activities for the year ended December 31, 2023, included $1.0 million of capital
expenditures and $3.0 million used to acquire in-process research and development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Financing Activities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities was $6.7 million for the year ended December 31, 2024, which consisted of $15.0 million from the RWI Second Amended Bridge
Loan entered into on January 12, 2024, $6.0 million from the January 2024 private placement with Dragasac and $3.6 million net proceeds
from convertible debt issuances, including $3.0 million from the March 13, 2024 convertible promissory note issued to Yorkville and $0.6
million from the November 2024 convertible promissory note issued to an accredited investor, partially offset by $17.4 million for the
payment in full of the Yorkville PPA. We generated $24.1 million of net cash from financing activities for the year ended December 31,
2023, which included: $11.6 million aggregate net cash proceeds from senior secured bridge loan and warrant agreements entered into with
Resorts World Inc Pte Ltd, in May 2023 and June 2023; $12.8 million in cash proceeds from PIPE financings, consisting of a $9.0 million
PIPE entered into in March 2023 and a $3.8 million PIPE entered into in May 2023; $5.0 million in proceeds from the issuance of a senior
secured bridge loan and warrants to C.V. Starr in March 2023; $8.2 million net proceeds from registered direct offerings, consisting of
net proceeds of $5.5 million from a registered direct offering in April 2023 and $2.7 million registered direct offering in July 2023;
and $3.0 million in proceeds from loan agreements entered into in August 2023, including a $1.0 million loan agreement with Dr. Robert
Hariri, our Chairman and Chief Executive Officer. Partially offsetting these sources was $16.8 million principal repayments of the PPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>Critical Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our significant accounting
policies are summarized in Note 2, &#8220;<i>Summary of Significant Accounting Policies</i>,&#8221; included in our consolidated financial
statements included elsewhere in this annual report on Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The preparation of our
consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated
financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions
reflected in these consolidated financial statements include, but are not limited to, assumptions related to goodwill and intangible
impairment assessment, the valuation of inventory, gross-to-net sales adjustments, contingent consideration, short-term debt, and
contingent stock consideration, determination of incremental borrowing rates, and the valuations of stock options and preferred
stock warrants. We based our estimates on historical experience, known trends and other market-specific or other relevant factors
that we believe to be reasonable under the circumstances. On an ongoing basis, management evaluates these estimates when there are
changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual
results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 84 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We recognize revenue
when control of the products and services is transferred to our customers in an amount that reflects the consideration we expect to receive
from our customers in exchange for those products and services. This process involves identifying the contract with a customer, determining
the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance
obligations in the contract, and recognizing revenue when the performance obligations have been satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A performance obligation
is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with
other resources that are readily available to the customer and is separately identified in the contract. We consider a performance obligation
satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain
the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with customers
and to the extent that the transaction price includes variable consideration, we estimate the amount of variable consideration that should
be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances, to
which we expect to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Products within our
Degenerative Disease segment generally do not contain multiple elements. We allow for a right of return for those products but to date
returns have been minimal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><b><i>Valuation of Goodwill and Intangible Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have acquired and
may continue to acquire significant intangible assets in connection with business combinations, which we record at fair value. The determination
of fair value requires the use of forecasts, estimates and assumptions, which requires significant judgment by management. Each of these
factors are subject to uncertainty and can significantly affect the value of the intangible asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Goodwill and indefinite-lived
intangible assets are reviewed for impairment annually or when an event occurs that could result in an impairment. The impairment analysis
requires the exercise of significant judgment by management and can involve both the assessment of qualitative factors (which are subject
to uncertainty and can change significantly from period to period), as well as a quantitative. For our quantitative impairment tests,
we use an estimated future cash flow approach that requires significant judgment with respect to future volume, revenue and expense growth
rates, the selection of an appropriate discount rate, asset groupings and other assumptions and estimates. The estimates and assumptions
used are subject to uncertainty. The use of alternative estimates and assumptions could increase or decrease the estimated fair value
of the assets and could potentially impact our results of operations. Actual results may differ from our estimates. For the year ended
December 31, 2023, we recognized goodwill impairment charges of $112.3 million and indefinite-lived intangible asset impairment charges
associated with IPR&amp;D of $107.8 million. For more information about the trigger events leading to the impairments refer to Note 2,
&#8220;<i>Summary of Significant Accounting Policies</i>&#8221; and Note 8, &#8220;Goodwill and Intangibles, Net&#8221; of our consolidated
financial statements included elsewhere in this annual report on Form 10-K).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Valuation of Inventory</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have disclosed our inventory
valuation policy in Note 2, &#8220;<i>Summary of Significant Accounting Policies</i>&#8221; of our consolidated financial statements included
elsewhere in this annual report on Form 10-K. We periodically analyze the inventory levels to determine whether there is any obsolete,
expired, or excess inventory. If any inventory is (i) expected to expire prior to being sold, (ii) has a cost basis in excess of its net
realizable value, (iii) is in excess of expected sales requirements as determined by internal sales forecasts, or (iv) fails to meet commercial
sale specifications, the inventory is written-down through a charge to cost of revenues. The determination of whether inventory costs
will be realizable requires estimates by management of future expected inventory requirements, based on sales forecasts. If actual market
conditions are less favorable than those projected by management, inventory write-downs may be required. Inventory, net of current portion
on our consolidated balance sheets includes inventory expected to remain on hand beyond one year. For the year ended December 31, 2024,
we recognized inventory impairment and obsolescence charges totaling $0.8 million. In comparison, for the year ended December 31, 2023,
we recorded inventory impairment charges of $5.4 million, consisting of lower of cost or net realizable value adjustments for finished goods and work
in progress of $2.1 million and $3.3 million, respectively. Both years&#8217; inventory impairment charges are reflected in cost of revenues
in our consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 85 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><b><i>Contingent Consideration</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have
acquisition-related contingent consideration, which consists of potential milestone and royalty obligations, which was recorded in
the consolidated balance sheets at our acquisition-date estimated fair value. We remeasure the fair value each reporting period,
with changes recorded in the consolidated statements of operations and comprehensive loss. The determination of fair value requires the exercise of
significant judgment and estimates by management. These include estimates and assumptions regarding the achievement and timing of
milestones, forecasted revenues and assumptions utilized in calculating a discount rate. If management&#8217;s assumptions prove to
be inaccurate, it could result in changes to the contingent consideration liability and have a material effect on our results of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><b><i>Warrant Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Accounting for liability
classified warrants requires management to exercise judgment and make estimates and assumptions regarding their fair value (for more
information about the material inputs and assumptions used to value the liability classified warrants refer to Note 4,
&#8220;<i>Fair Value of Financial Assets and Liabilities</i>&#8221; of our audited consolidated financial statements included
elsewhere in this annual report on Form 10-K). The warrant liabilities are initially recorded at fair value upon the date of
issuance and subsequently remeasured to fair value at each reporting date, with changes recognized in the consolidated statements of
operations and comprehensive loss. Changes in the fair value of the liability classified warrants will continue to be recognized until the warrants are
exercised, expire or qualify for equity classification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We recognize compensation
expense related to stock options granted to employees and nonemployees based on the estimated grant date fair value and recognize forfeitures
as they occur. We estimate the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing
model for service-based and performance-based awards. For awards with market conditions, we utilize a Monte-Carlo model to estimate the
fair value of those awards. The grant date fair value of the stock-based awards is recognized on a straight-line basis over the requisite
service period, which is typically the vesting period of the respective awards. The Black-Scholes option-pricing model and Monte-Carlo
model requires the use of highly subjective assumptions to determine the fair value of stock-based awards. See Note 14, &#8220;Stock-Based
Compensation&#8221; to our audited consolidated financial statements included elsewhere in this annual report on Form 10-K for information
concerning certain of the specific assumptions used in applying the Black-Scholes option-pricing model to determine the estimated fair
value of stock options granted during the years ended December 31, 2024 and 2023. Such assumptions involve inherent uncertainties and
the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions
or estimates, our stock-based compensation could be materially different.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Leases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We cannot readily determine
the interest rate implicit in the lease, therefore, we use our incremental borrowing rate, or IBR, to measure lease liabilities. The IBR
is the rate of interest that we would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain
an asset of a similar value to the right-of-use, or ROU, asset in a similar economic environment. The IBR therefore reflects what we &#8216;would
have to pay&#8217;, which requires estimation when no observable rates are available or when they need to be adjusted to reflect the terms
and conditions of the lease. We estimate the IBR using observable inputs (such as market interest rates) when available and are required
to make certain entity and asset-specific estimates. The IBR used in the calculation of the present value of lease payments in calculating
lease liabilities and the corresponding ROU requires the use of significant judgment by management.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Short-Term Debt</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We elected the fair value
option to account for the Yorkville PPA. Due to its short-term nature, as of December 31, 2023, the Yorkville PPA fair value approximated
the January 17, 2024 settlement amount. We also elected the fair value option to account for the Yorkville convertible promissory note,
issued on March 13, 2024, and the unsecured senior convertible notes, issued pursuant to the securities purchase agreement signed on November
25, 2024. The Yorkville convertible promissory note and the unsecured senior convertible notes are comprised of the debt host instruments
and embedded derivatives. The fair values of the Yorkville convertible promissory note and unsecured senior convertible notes are based
on valuations which employ a Monte Carlo model and a credit default model. The fair value measurement of the debt was determined using
Level 3 inputs and assumptions unobservable in the market. Changes in the fair value of debt that is accounted for at fair value, inclusive
of related accrued interest expense, are presented as gains or losses in the accompanying consolidated statements of operations and comprehensive
income (loss) under change in fair value of debt. The portion of total changes in fair value of debt attributable to changes in instrument-specific
credit risk are determined through specific measurement of periodic changes in the discount rate assumption exclusive of base market changes
and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements of operations and comprehensive
income (loss). The actual settlement of the short-term debt could differ from estimates based on the timing of when and if the investors
elect to convert amounts into common shares, potential cash repayment by us prior to maturity, and movements in our common share price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 86 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Recent Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">See Note 2, &#8220;<i>Summary
of Significant Accounting Policies</i>&#8221; to our consolidated financial statements included elsewhere in this annual report on Form
10-K for information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made
one, of their potential impact on our financial condition of results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><span id="a_001YV1"></span>Item 7A. Quantitative and Qualitative Disclosures About
Market Risk.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are exposed to market
risks in the ordinary course of business. These risks primarily include interest rate sensitivities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Interest Rate Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We had cash and cash
equivalents of $0.7 million as of December 31, 2024, which consists principally of cash held in commercial bank accounts and money market
funds having an original maturity of less than three months. At December 31, 2024, substantially all cash and cash equivalents were held
in either commercial bank accounts or money market funds. The primary objective of our investment activities is to preserve capital to
fund our operations. We also seek to maximize income from our investments without assuming significant risk. Because our investments are
primarily short-term in duration, we believe that our exposure to interest rate risk is not significant, and a 1% movement in market interest
rates would not have a significant impact on the total value of our portfolio. We have no variable interest debt outstanding as of December
31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Effects of Inflation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Inflation generally
affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our
results of operations during the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><span id="a_001YV2"></span>Item 8. Financial Statements and Supplementary Data. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 94%"/>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center"><span style="font-size: 10pt">Page</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="text-decoration: underline"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 120%"><a href="#a_001YVF3">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID No. <span id="xdx_90E_edei--AuditorFirmId_c20240101__20241231_zMv0UNthsDp7"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000064" name="dei:AuditorFirmId">274</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt; line-height: 120%">83</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 120%"><a href="#a_001YVF4">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID No. <span id="xdx_90C_edei--AuditorFirmId_c20230101__20231231_z9OriGhhy5db"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact000065" name="dei:AuditorFirmId">34</ix:nonNumeric></span>)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt; line-height: 120%">84</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><span style="text-decoration: underline"><a href="#a_001YVF5">Consolidated Balance Sheets</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt; line-height: 120%">85</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#a_001YVF6">Consolidated Statements of Operations and Comprehensive Loss</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt; line-height: 120%">86</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#a_001YVF7">Consolidated Statements of Stockholders&#8217; Equity</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt; line-height: 120%">87</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#a_001YVF8">Consolidated Statements of Cash Flow</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt; line-height: 120%">88</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt; line-height: 120%"><span style="text-decoration: underline"><a href="#a_001YVF9">Notes to Consolidated Financial Statements</a></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-size: 10pt; line-height: 120%">89</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 87 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b><span id="a_001YVF3"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">To the Board of Directors and Stockholders of
Celularity Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b>Opinion on
the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>&#160;</b></p>

<p id="xdx_988_edei--AuditorOpinionTextBlock_c20240101__20241231_zVX5tuiFiFD4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000066" name="dei:AuditorOpinionTextBlock">We
have audited the accompanying consolidated balance sheet of Celularity Inc. (the &#8220;Company&#8221;) as of December 31, 2024 and
the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the year
then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the
financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31,
2024, and the consolidated results of its operations and its cash flows for the year then ended, in conformity
with accounting principles generally accepted in the United States of America. </ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b>Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements,
the Company has suffered recurring losses and net cash outflows from operations and has outstanding debt that is currently due for which
the Company does not have sufficient liquidity to repay, which raises substantial doubt about its ability to continue as a going concern.
Management&#8217;s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments
that might result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b>Basis for
Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements
based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We conducted our audit
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our audit included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for
our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Critical Audit Matter</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The critical audit matter communicated
below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated
to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved
our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way
our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing
a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Accounting for Debt and Equity Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As described in Notes 10 and 13
to the financial statements, the Company entered into a series of debt and equity financing arrangements with both existing and new debt
and equity holders. The transactions were entered into at various times throughout 2024 and consisted of convertible notes, standby equity
purchase agreements, private placements, existing loan modifications and warrant agreements. The description of the transactions and accounting
implications are disclosed in Note 10 under the following captions: Yorkville Convertible Promissory Note, Unsecured Senior Convertible
Notes, Short-Term Debt-Related Parties &#8211; C.V. Starr and RWI; and Note 13 under January 2024 PIPE and Standby Equity Purchase Agreement.
Based on the specific terms in the agreements and the applicable authoritative guidance, the Company determined the appropriate debt and
equity classification for each transaction as well as the proper accounting treatment and valuation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We identified the assessment of
the appropriate accounting and balance sheet classification of the common stock warrants as equity or liability, as well as the accounting
and valuation of the various debt and equity instruments issued, as a critical audit matter due to the complexity in assessing the instruments&#8217;
features, which requires management to interpret the complex terms in the agreements and apply the appropriate accounting
authoritative guidance and apply judgement in the estimates and assumptions involved in the valuation. As such, there was a high
degree of auditor judgement and subjectivity, and significant audit effort was required in performing procedures to evaluate management&#8217;s
conclusions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Addressing the critical audit
matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements.
These&#160; procedures included, among others,&#160; (i) obtaining an understanding of and evaluating the design of controls related
to accounting over financial reporting, including complex transactions; (ii) obtaining the agreements, and evaluating the terms and conditions
of the agreements, and (iii) assessing the reasonableness of management&#8217;s interpretation and application of the appropriate authoritative
accounting guidance; and the appropriateness of conclusions reached by management which included (a) evaluating the underlying terms
of the agreements, (b) assessing the appropriateness of management&#8217;s application of the authoritative accounting guidance and (c)
evaluating the methodologies and assumptions used to estimate the fair value of the debt and equity instruments issued. Professionals
with specialized skill and knowledge were used to assist in evaluating (i) the appropriateness of the valuation model, and (ii) the reasonableness
and appropriateness of certain assumptions used in evaluating the reasonableness of the fair value of certain of the debt and equity
instruments issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt">/s/ <span id="xdx_90D_edei--AuditorName_c20240101__20241231_zm2RK3vWB6oe"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000067" name="dei:AuditorName">EisnerAmper LLP</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><span style="background-color: white">We have served as the Company&#8217;s
auditor since 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">EISNERAMPER LLP</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><span style="background-color: white"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><span id="xdx_90C_edei--AuditorLocation_c20240101__20241231_zNNnhwHrGGB8"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000068" name="dei:AuditorLocation">Iselin, New Jersey</ix:nonNumeric></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">May 8, 2025</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 88 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b><span id="a_001YVF4"></span>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">To the stockholders and the Board of Directors of Celularity Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b>Opinion on
the Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have audited the
accompanying consolidated balance sheet of Celularity Inc. (the &#8220;Company&#8221;) as of December 31, 2023, the related
consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity (deficit), and cash flows for the
year ended December 31, 2023, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and
the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with accounting principles
generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b>Going Concern</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements,
the Company has suffered recurring losses and net cash outflows from operations and has outstanding debt that is currently due for which
the Company does not have sufficient liquidity to repay, which raises substantial doubt about its ability to continue as a going concern.
Management&#8217;s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments
that might result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b>Basis for
Opinion</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements
based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We conducted our audit
in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our audit included
performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing
procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for
our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt">/s/ <span id="xdx_901_edei--AuditorName_c20230101__20231231_z48b7rOoO40c"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact000069" name="dei:AuditorName">Deloitte &amp; Touche LLP</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><span id="xdx_908_edei--AuditorLocation_c20230101__20231231_zuA1QAguIuTl"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact000070" name="dei:AuditorLocation">Morristown, New Jersey</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"></p>

<p style="font: 10pt Verdana, Helvetica, Sans-Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">July
30, 2024 (May 8, 2025, as to the effects of the adoption of ASU No. 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable
Segment Disclosures</i>, described in Note 2).</span></p>

<p style="font: 10pt Verdana, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Verdana, Helvetica, Sans-Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
began serving as the Company&#8217;s auditor in 2018. In 2024, we became the predecessor auditor.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><span style="background-color: white"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>


<!-- Field: Page; Sequence: 89 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b><span id="a_001YVF5"></span>CELULARITY INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>(In thousands, except share and per share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_305_111_pn3n3_zpUAdUsLUHje" summary="xdx: Statement - Consolidated Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20241231_zltw7Wlsrdq3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231_zxg9cmASzTJ" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AssetsAbstract_iB_znLH4WNfWpEa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrentAbstract_i01B_z4KDJj0ofhEd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Current assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzuq2_zCDfVe8jAo5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 68%; text-align: left">Cash and cash equivalents</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-12-31" id="Fact000078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">738</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000079" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">227</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsAndOtherReceivablesNetCurrent_i02I_maACzuq2_zWP6HWdRhcnc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Accounts receivable, net of allowance of $<span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20241231_zvlLC2gKYKR8" title="Accounts receivable, net of allowance"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2024-12-31" id="Fact000084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,294</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zhh8kW88V9bh" title="Accounts receivable, allowance"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2023-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,837</ix:nonFraction></span> as of December 31, 2024 and 2023, respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="AsOf2024-12-31" id="Fact000081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,557</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsAndOtherReceivablesNetCurrent" contextRef="AsOf2023-12-31" id="Fact000082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,046</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--PromissoryNotesReceivable_i02I_maACzuq2_zFyizOkJdrjk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Notes receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0088">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:PromissoryNotesReceivable" contextRef="AsOf2023-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,072</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryNet_i02I_maACzuq2_zV0tOk5RrE8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,409</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,753</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzuq2_z1RU8BtVwTif" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Prepaid expenses and other current assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">857</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,695</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrent_i02TI_mtACzuq2_maAzSdC_zywJ5T8ThR47" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Total current assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-12-31" id="Fact000097" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,561</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,793</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAzSdC_zl7wTsbtd9h7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61,600</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67,828</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--Goodwill_i01I_maAzSdC_zTtQWRHCiSXf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Goodwill</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,347</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,347</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maAzSdC_zhICCyniXHsk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact000106" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,248</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact000107" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,001</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAzSdC_zNEeYSaotIu8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Right-of-use assets - operating leases</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,830</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,990</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RestrictedCashNoncurrent_i01I_maAzSdC_zTZ7BISDUn4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Restricted cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2024-12-31" id="Fact000112" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,239</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2023-12-31" id="Fact000113" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,936</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InventoryNoncurrent_i01I_maAzSdC_zBobLsiKC7ng" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Inventory, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNoncurrent" contextRef="AsOf2024-12-31" id="Fact000115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,587</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNoncurrent" contextRef="AsOf2023-12-31" id="Fact000116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,657</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAssetsNoncurrent_i01I_maAzSdC_zhGan6VIzyd6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other long-term assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-12-31" id="Fact000118" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">270</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2023-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">337</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Assets_i01TI_mtAzSdC_zoiUUCj0pYHh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132,682</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">143,889</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zyeeQG633dkl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Stockholders&#8217; Equity</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrentAbstract_i01B_zGBIMrJ2AIt5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Current liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsPayableCurrent_i02I_maLCzfqQ_z5dvRaUWMeV6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-12-31" id="Fact000130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,296</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,144</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_i02I_maLCzfqQ_zdBDqxfLYu4j" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accrued expenses and other current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-12-31" id="Fact000133" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,842</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2023-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,580</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentSoftware_i02I_maLCzfqQ_zYE8EVIPb4E7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accrued R&amp;D software</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0136">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AccruedResearchAndDevelopmentSoftware" contextRef="AsOf2023-12-31" id="Fact000137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AssetAcquisitionContingentConsiderationLiabilityCurrent_i02I_maLCzfqQ_zaAr5CmUQS4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Acquisition-related contingent consideration</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">650</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0140">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShortTermBorrowings_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maLCzfqQ_zrg0GE9YkLhh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Short-term debt - unaffiliated (includes debt measured at fair value of $<span id="xdx_908_eus-gaap--ShorttermDebtFairValue_iI_c20241231_zVK8okABqxR6" title="Short-term debt, fair value"><ix:nonFraction name="us-gaap:ShorttermDebtFairValue" contextRef="AsOf2024-12-31" id="Fact000145" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,485</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ShorttermDebtFairValue_iI_c20231231_zWYBxvJgG3L5" title="Short-term debt, fair value"><ix:nonFraction name="us-gaap:ShorttermDebtFairValue" contextRef="AsOf2023-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,223</ix:nonFraction></span> as of December 31, 2024 and 2023, respectively)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact000142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact000143" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,331</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShortTermBorrowings_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzfqQ_zo5bePl4M5g8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Short-term debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000149" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,876</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,909</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShortTermBorrowings_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCzfqQ_zvLBLwGJ8LEk" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Short-term debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,876</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000153" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,909</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--ContractWithCustomerLiabilityCurrent_i02I_maLCzfqQ_ztyctj1Xct6h" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Deferred revenue</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2024-12-31" id="Fact000155" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,531</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,834</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzfqQ_maLzpls_zEUeZTdrBCL5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt; text-align: left">Total current liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact000158" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">53,680</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000159" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67,298</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ContractWithCustomerLiabilityNoncurrent_i01I_maLzpls_zvpw3KsFLOwi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred revenue, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000161" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,724</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000162" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,186</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetAcquisitionContingentConsiderationLiability_i01I_maLzpls_zckJ9GzEs794" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Acquisition-related contingent consideration, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="AsOf2024-12-31" id="Fact000164" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,413</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetAcquisitionContingentConsiderationLiability" contextRef="AsOf2023-12-31" id="Fact000165" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,606</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebtNoncurrent_i01I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLzpls_ztwMVhW618Mh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Long-term debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact000167" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,927</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0168">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maLzpls_zImzB6rSXq88" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Long-term lease liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-12-31" id="Fact000170" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,548</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000171" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,177</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--WarrantLiability_i01I_maLzpls_zrgVUOS82BYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiability" contextRef="AsOf2024-12-31" id="Fact000173" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,264</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiability" contextRef="AsOf2023-12-31" id="Fact000174" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,359</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredIncomeTaxLiabilitiesNet_i01I_maLzpls_z432mdIBeRP3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred income tax liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2024-12-31" id="Fact000176" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="AsOf2023-12-31" id="Fact000177" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherLiabilitiesNoncurrent_i01I_maLzpls_z1OKyeEjdeja" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2024-12-31" id="Fact000179" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">280</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000180" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">294</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Liabilities_i01TI_mtLzpls_maLASEzSAo_zR0A6cvmdY52" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-12-31" id="Fact000182" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">123,845</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000183" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">102,929</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CommitmentsAndContingencies_iI_maLASEzSAo_zdUs3Bb7EQD3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Commitments and Contingencies (Note 12)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0185">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0186">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_iB_zPCmJlR2KhHj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Stockholders&#8217; equity:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PreferredStockValue_i01I_maSEIPAzDGw_zJmIA5WQf4Jd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Preferred stock, $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20241231_zZJN5vSjGMM5" title="Preferred stock par value"><span id="xdx_905_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231_zp8ZgiZKjxIe" title="Preferred stock par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000194" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20241231_zxzz8qeUe5ek" title="Preferred stock, shares authorized"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_z5pcw8cWtrbf" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000198" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000200" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20241231_zQekrWg6wnvl" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20241231_zJqozWKmaZde" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_pid_dn_c20231231_znkiKhETNHqi" title="Preferred stock, shares issued"><span id="xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_pid_dn_c20231231_z2ZGgRS2aXT3" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000202" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000204" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000206" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000208" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding as of December 31, 2024 and 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0191">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0192">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockValue_i01I_maSEIPAzDGw_zKrnCKKR3Syc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Common stock, $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231_zuW95lmjig2i" title="Common stock, par value"><span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231_ziXErqMq3Xjb" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value, <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231_zG3yNU0Wb6Ba" title="Common stock, shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231_z83QyqEIRcMa" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact000217" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">730,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized, <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231_zCFkXl4TpJIe" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231_zimToHutTHRk" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact000223" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,546,671</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231_zbmTbJ0drHNe" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231_zy1eLAIffA09" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,378,192</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as of December 31, 2024 and 2023, respectively</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-12-31" id="Fact000210" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdditionalPaidInCapital_i01I_maSEIPAzDGw_zlhyQvjejij3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Additional paid-in capital</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2024-12-31" id="Fact000229" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">908,523</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">882,732</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maSEIPAzDGw_zVFywiAyDROi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Accumulated deficit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000232" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">899,683</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">841,791</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maSEIPAzDGw_zIxpnuyGnJNj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Accumulated other comprehensive loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-12-31" id="Fact000235" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockholdersEquity_i01TI_mtSEIPAzDGw_maLASEzSAo_zcZsD2aQXiLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000238" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,837</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,960</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzSAo_zSMxiBtWoMQ9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000241" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">132,682</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">143,889</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 90 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b><span id="a_001YVF6"></span>CELULARITY INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>(In thousands, except share and per share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_113_pn3n3_zRZZS3Rby6N7" summary="xdx: Statement - Consolidated Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zmQextqvSIn2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_z5obJDYOlUS5" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenuesAbstract_iB_zoFzhDV3Vtm4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">Revenues</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zLNAG4LxoVI5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left; padding-left: 24pt">Product sales, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_us-gaap_ProductMember" id="Fact000247" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,336</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_us-gaap_ProductMember" id="Fact000248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,149</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zBnfLqe4gmQg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 24pt">Services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_us-gaap_ServiceMember" id="Fact000250" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,140</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_us-gaap_ServiceMember" id="Fact000251" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,441</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_zf9LoRypIONl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 24pt">License, royalty and other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_LicenseRoyaltyAndOtherMember" id="Fact000253" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,744</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_LicenseRoyaltyAndOtherMember" id="Fact000254" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,181</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_maOILznAC_zCYXgi2thFal" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total net revenues</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact000256" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,220</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact000257" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,771</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingExpensesAbstract_iB_zsOCbP0j5im8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CostOfRevenueAbstract_i01B_zYAoHrvGtKfa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 12pt">Cost of revenues (excluding amortization of acquired intangible assets)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CostOfRevenue_i02_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_maOICAEzW9B_zP37Ob6pATV7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 24pt">Product sales</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_us-gaap_ProductMember" id="Fact000265" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,924</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-12-31_us-gaap_ProductMember" id="Fact000266" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,628</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CostOfRevenue_i02_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_maOICAEzW9B_zNhNo1nFvHz9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 24pt">Services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_us-gaap_ServiceMember" id="Fact000268" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,172</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-12-31_us-gaap_ServiceMember" id="Fact000269" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,650</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CostOfRevenue_i02_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_maOICAEzW9B_ztGMUB7qRuib" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 24pt">License, royalty and other</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_LicenseRoyaltyAndOtherMember" id="Fact000271" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,893</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-12-31_custom_LicenseRoyaltyAndOtherMember" id="Fact000272" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,738</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CostOfRevenue_i02_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_maOICAEzW9B_zpvJOtWMqvua" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 24pt">Cost of revenues</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_LicenseRoyaltyAndOtherMember" id="Fact000274" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,893</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-12-31_custom_LicenseRoyaltyAndOtherMember" id="Fact000275" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,738</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_i01_maOICAEzW9B_zmgnzG1Ht0Wg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 12pt">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000277" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,386</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-12-31" id="Fact000278" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,465</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maOICAEzW9B_zz2ZV8n6s2j8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 12pt">Selling, general and administrative</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000280" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58,643</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">50,576</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_i01_maOICAEzW9B_zEb9OGa0oWR" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 12pt">Change in fair value of contingent consideration liability</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2024-01-01to2024-12-31" id="Fact000283" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">193</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2023-01-012023-12-31" id="Fact000284" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">104,339</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--GoodwillImpairmentLoss_i01_maOICAEzW9B_zYBn5ZsNiI73" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 12pt">Goodwill impairment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0286">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-01-012023-12-31" id="Fact000287" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,347</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_i01_maOICAEzW9B_zwpci51Zqjil" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 12pt">IPR&amp;D impairment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-01-012023-12-31" id="Fact000290" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107,800</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AmortizationOfIntangibleAssets_i01_maOICAEzW9B_zn9ZJRBNCPlk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 12pt">Amortization of acquired intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000292" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,753</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact000293" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,193</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--OperatingIncomeCostsAndExpenses_i01T_msOILznAC_mtOICAEzW9B_zJBLqe4A520a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total operating expenses</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:OperatingIncomeCostsAndExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000295" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">92,578</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:OperatingIncomeCostsAndExpenses" contextRef="From2023-01-012023-12-31" id="Fact000296" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">215,058</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingIncomeLoss_iT_mtOILznAC_maILFCOzCvF_zq58ca2DYwi3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from operations</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000298" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,358</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000299" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">192,287</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherNonoperatingIncomeExpenseAbstract_iB_zphjjAkSQjW5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense):</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingIncome_i01_maNIEzLTi_zoeOYGWobYsc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 12pt">Interest income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2024-01-01to2024-12-31" id="Fact000304" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">331</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-01-012023-12-31" id="Fact000305" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">320</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherNonoperatingExpense_i01N_di_msNIEzLTi_z7yliQz9Tr22" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 12pt">Interest expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000307" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,264</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-01-012023-12-31" id="Fact000308" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,015</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msNIEzLTi_zOzxZRF72Yd7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 12pt">Change in fair value of warrant liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000310" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">398</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000311" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,164</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ChangeInFairValueOfDebt_i01N_di_msNIEzLTi_zOh8aEHUadN7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 12pt">Change in fair value of debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:ChangeInFairValueOfDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000313" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">492</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:ChangeInFairValueOfDebt" contextRef="From2023-01-012023-12-31" id="Fact000314" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,177</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEzLTi_zdTIugsRyEb3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 12pt">Loss on debt extinguishment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000316" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,908</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--OtherNonoperatingIncomeExpenses_i01_maNIEzLTi_ziTwQxtKT717" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 12pt">Other expense, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:OtherNonoperatingIncomeExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact000319" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">9,599</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:OtherNonoperatingIncomeExpenses" contextRef="From2023-01-012023-12-31" id="Fact000320" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,290</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpense_i01T_maILFCOzCvF_mtNIEzLTi_zLpwW5OTj2Ib" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Total other expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000322" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,534</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact000323" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,998</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzCvF_maNILzIeQ_zR8Ac4gJy3Ha" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss before income taxes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-12-31" id="Fact000325" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57,892</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact000326" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">196,285</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_msNILzIeQ_zXm1SgOl3MP5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Income tax expense</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact000329" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_iT_mtNILzIeQ_maCINOTzYCp_zGryekafzTs9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000331" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57,892</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000332" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">196,295</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_maOCILNz5aU_zLciG29eOJV5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 12pt">Change in fair value of debt due to change in credit risk, net of tax</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="From2024-01-01to2024-12-31" id="Fact000334" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" contextRef="From2023-01-012023-12-31" id="Fact000335" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">146</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_iT_mtOCILNz5aU_maCINOTzYCp_zRyMuf77ehO2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other comprehensive (loss) income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2024-01-01to2024-12-31" id="Fact000337" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="From2023-01-012023-12-31" id="Fact000338" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">146</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCINOTzYCp_znQTDVpn26n7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2024-01-01to2024-12-31" id="Fact000340" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57,897</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-01-012023-12-31" id="Fact000341" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">196,149</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 2.65pt">Share information:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net loss per share &#8211; basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--EarningsPerShareBasic_pid_c20240101__20241231_zUYyUIZ9g0rf" title="Net loss per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_909_eus-gaap--EarningsPerShareDiluted_pid_c20240101__20241231_zL4Wg3nlOAae" title="Net loss per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000343" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-01-01to2024-12-31" id="Fact000345" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.64</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pid_c20230101__20231231_zAOiYlFrHcNa" title="Net loss per share - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pid_c20230101__20231231_zHbgJQGUMaCd" title="Net loss per share - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-012023-12-31" id="Fact000347" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-012023-12-31" id="Fact000349" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">11.02</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 2.65pt">Weighted average shares outstanding &#8211; basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20240101__20241231_zjwRUPmmbFK" title="Weighted average shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20240101__20241231_zJTyFJJmcbs5" title="Weighted average shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-01-01to2024-12-31" id="Fact000351" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-01-01to2024-12-31" id="Fact000353" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,890,518</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20230101__20231231_zMmYRjPUOcb4" title="Weighted average shares outstanding - basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20230101__20231231_zBkfycfjRphd" title="Weighted average shares outstanding - diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucyBhbmQgQ29tcHJlaGVuc2l2ZSBMb3NzAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-012023-12-31" id="Fact000355" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-012023-12-31" id="Fact000357" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,813,044</ix:nonFraction></ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 91 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b><span id="a_001YVF7"></span>CELULARITY INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217;
EQUITY </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>(In thousands, except share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_304_114_pn3n3_zSzhRAljIoxc" summary="xdx: Statement - Consolidated Statements of Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zX8kjfzb5l5d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zhiqLCfZCNQg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z4LvoTKWnGx1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_z7ZJSSuMfS5i" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Income (Loss)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_4BF_zNK5wht3ZYo4" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Equity</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Common Stock</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>Additional</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>Paid-in </b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Accumulated</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">Accumulated Other Comprehensive</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>Total</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>Stockholders&#8217; </b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Capital</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Deficit</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Income (Loss)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Equity</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_438_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zGw1gGQjOOO6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 40%">Balances at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsvonzILIC6l" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000365" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,892,129</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000360" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">844,373</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000361" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">645,496</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000362" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000363" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">198,901</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_zmTfQtjofzg6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock in Registered Direct Offering, net of offering expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zDauWHeOG7Lh" title="Issuance of common stock in Registered Direct Offering, net of offering expenses, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000373" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,780,220</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000367" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000368" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,320</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0370">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000371" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,322</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension_z0YOvmas63r8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued pursuant to short-term debt maturity extension</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdYRhqlPUqT9" title="Common stock issued pursuant to short-term debt maturity extension, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000381" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">270,731</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000376" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">712</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" contextRef="From2023-01-012023-12-31" id="Fact000379" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">712</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zO2gZkbMvLTb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise of stock options</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmdnh9LyHyxc" title="Exercise of stock options, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000389" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">108,637</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000384" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">304</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0385">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2023-01-012023-12-31" id="Fact000387" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">304</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--FairValueOfWarrantModificationForProfessionalService_z1yvEqBi9lI3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Fair value of warrant modification for professional services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0391">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:FairValueOfWarrantModificationForProfessionalService" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000392" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">403</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:FairValueOfWarrantModificationForProfessionalService" contextRef="From2023-01-012023-12-31" id="Fact000395" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">403</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueOfResearchAndDevelopment_zYLbL6NGDl56" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock for stem-cells to be used in research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesOfResearchAndDevelopment_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_fKGl2KQ_____zIC193TKmRf2" title="Issuance of common stock for stem-cells to be used in research and development, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodSharesOfResearchAndDevelopment" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000403" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">169,492</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0397">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000398" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment" contextRef="From2023-01-012023-12-31" id="Fact000401" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zR25YrUumoFb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of warrants to RWI and C.V. Starr</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000406" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,290</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31" id="Fact000409" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,290</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zDmN5lMfNeF2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued pursuant to short-term debt conversion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuPQRATZT2h2" title="Common stock issued pursuant to short-term debt conversion, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000417" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">559,481</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000411" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000412" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,598</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000414" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">155</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2023-01-012023-12-31" id="Fact000415" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,444</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zpcWB2uXeEqc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vesting of restricted stock units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGtx85Dr0P4b" title="Vesting of restricted stock units, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000425" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">83,759</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0419">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" contextRef="From2023-01-012023-12-31" id="Fact000423" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_iN_di_zASVztcCTAO6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax withholding on vesting of restricted stock units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOH4bNffXWok" title="Tax withholding on vesting of restricted stock units, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000433" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">19,130</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000431" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_z5P3MzXFGzek" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000436" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,017</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0437">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2023-01-012023-12-31" id="Fact000439" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,017</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses_zUHKGjkdzqK1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock in PIPE Offering, net of offering expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zO2bdcoqXqa6" title="Issuance of common stock in PIPE Offering, net of offering expenses, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000447" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,519,579</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000441" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000442" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,680</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0444">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" contextRef="From2023-01-012023-12-31" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,681</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--StockIssuedDuringPeriodValueATMAgreement_zAyHj7wKAb9g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock under ATM Agreement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesATMAgreement_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zChOugKKP6m2" title="Issuance of common stock under ATM Agreement, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodSharesATMAgreement" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000455" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,296</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValueATMAgreement" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000450" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">136</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0451">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValueATMAgreement" contextRef="From2023-01-012023-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">136</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent_zmVdgogR9XQl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of debt due to change in credit risk, net of tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0457">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0458">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000460" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">146</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" contextRef="From2023-01-012023-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">146</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_zRDwWIBHfo1d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0463">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0464">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000465" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">196,295</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0466">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000467" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">196,295</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43C_c20240101__20241231_eus-gaap--StockholdersEquity_iS_zhlVkjjAS6p7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balances at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNjJS29mq6Q7" title="Balance, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000475" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,378,192</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000469" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000470" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">882,732</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000471" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">841,791</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000473" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,960</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_436_c20240101__20241231_eus-gaap--StockholdersEquity_iS_z5koxpoGDMC6" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Balances</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRU59DlFPL6" title="Balances, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000483" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,378,192</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000477" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000478" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">882,732</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000479" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">841,791</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000481" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,960</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zkeooS6xse5d" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock and warrants in PIPE Offering, net of offering expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvezWxqZ5E12" title="Issuance of common stock and warrants in PIPE Offering, net of offering expenses, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000491" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,141,098</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000486" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2024-01-01to2024-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee_zCqrahdzWUvg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock to Yorkville for debt extension and SEPA commitment fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbGzzdHj6hQ" title="Issuance of common stock to Yorkville for debt extension and SEPA commitment fee, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000499" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">116,964</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0493">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000494" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">317</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" contextRef="From2024-01-01to2024-12-31" id="Fact000497" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">317</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants_zszrkEPHziF7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance and modification of warrants to RWI and C.V. Starr</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000502" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,261</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0504">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000505" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,261</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zaCpZlyfwLx8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise of stock options</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeu1Wxk0Xz0f" title="Exercise of stock options, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000513" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,744</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000508" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact000511" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--StockRepurchasedAndRetiredDuringPeriodValue_iN_di_zfyi44s9HAM4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Retirement of shares in connection with reverse stock split</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--StockRepurchasedAndRetiredDuringPeriodShares_iN_pid_di_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTpwuPi0xzP7" title="Retirement of shares in connection with reverse stock split, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000521" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">191</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000515" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000516" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0518">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--StockIssuedDuringPeriodValueConsiderationForSettlementAgreement_zsiCCWHLKJh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock to Palantir as consideration for settlement agreement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOiRhOaZ7xLl" title="Issuance of common stock to Palantir as consideration for settlement agreement, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000529" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,584</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000524" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">175</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0525">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0526">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" contextRef="From2024-01-01to2024-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">175</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zQlhbkCsj4q9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0531">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000532" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,569</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="From2024-01-01to2024-12-31" id="Fact000535" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,569</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_za8hWsl9eKIk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Reclassification of warrants from liability classified to equity classified</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000538" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,970</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" contextRef="From2024-01-01to2024-12-31" id="Fact000541" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,970</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent_zDk5TFrLmXz6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Change in fair value of debt due to change in credit risk, net of tax</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0543">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0544">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000546" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" contextRef="From2024-01-01to2024-12-31" id="Fact000547" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_zxbQAN2BLNH9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vesting of restricted stock units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaqKvHeIGz41" title="Vesting of restricted stock units, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000555" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">401,013</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0549">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_iN_di_zayRysaZQeBb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax withholding on vesting of restricted stock units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharesPaidForTaxWithholdingForShareBasedCompensation_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgAbkkxKxQb9" title="Tax withholding on vesting of restricted stock units, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000563" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">109,790</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0557">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000558" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000561" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zQu6o8npuvkj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Common stock issued pursuant to short-term debt conversion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSGv4ntNzkUb" title="Common stock issued pursuant to short-term debt conversion, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000571" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">478,881</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000566" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0568">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2024-01-01to2024-12-31" id="Fact000569" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zkg06yO2fA11" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Issuance of common stock as compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zoaowoGuyN5k" title="Issuance of common stock as compensation expense, shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember" id="Fact000579" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,176</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0573">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000574" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0575">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0576">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000577" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zEKX1JaTn8wk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0581">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0582">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember" id="Fact000583" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57,892</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0584">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000585" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57,892</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_438_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zDkHrPxz4lhj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balances at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znTgGCuIREFl" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000593" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,546,671</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000587" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000588" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">908,523</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000589" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">899,683</ix:nonFraction> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000590" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000591" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,837</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_43B_c20240101__20241231_eus-gaap--StockholdersEquity_iE_zpt6MAM2bxQh" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balances</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_pid_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeOA246Gtdhd" title="Balances, shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000601" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,546,671</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_CommonStockMember" id="Fact000595" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000596" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">908,523</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember" id="Fact000597" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">899,683</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000598" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-12-31" id="Fact000599" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,837</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 92 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b><span id="a_001YVF8"></span>CELULARITY INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>(In thousands)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_pn3n3_z2dJBzTcZHse" summary="xdx: Statement - Consolidated Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_49C_20240101__20241231_z4GhcXMHe4Uf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_497_20230101__20231231_zeDoKt6NCb1c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zJDuwc8BOUId" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flow from operating activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetIncomeLoss_i01_maNCPBUzJiX_zs0LBXAl5g06" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; width: 68%; text-align: left">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000606" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57,892</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31" id="Fact000607" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">196,295</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zLnTQscbYvQ8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Adjustments to reconcile net loss to net cash used in operations:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DepreciationDepletionAndAmortization_i02_maNCPBUzJiX_zVSqvZrb4nf4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2024-01-01to2024-12-31" id="Fact000612" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,922</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-12-31" id="Fact000613" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,324</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--NonCashLeaseExpense_i02_maNCPBUzJiX_zCm9JMW4T768" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Non cash lease expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:NonCashLeaseExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000615" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">160</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:NonCashLeaseExpense" contextRef="From2023-01-012023-12-31" id="Fact000616" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--ProvisionForDoubtfulAccounts_i02_maNCPBUzJiX_zL7sfnGtgOzc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Provision for credit losses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2024-01-01to2024-12-31" id="Fact000618" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">457</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2023-01-012023-12-31" id="Fact000619" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,233</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ProvisionForInventoryObsolescence_i02_maNCPBUzJiX_zAJTA0bs17B6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Provision for inventory obsolescence</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:ProvisionForInventoryObsolescence" contextRef="From2024-01-01to2024-12-31" id="Fact000621" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">186</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ProvisionForInventoryObsolescence" contextRef="From2023-01-012023-12-31" id="Fact000622" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,328</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FairValueAdjustmentOfWarrants_i02_maNCPBUzJiX_zzWgJlgrjFV9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Change in fair value of warrant liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2024-01-01to2024-12-31" id="Fact000624" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">398</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31" id="Fact000625" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,164</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_408_ecustom--InventoryImpairmentCharge_i02I_maNCPBUzJiX_z1tFWPTadh8l" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Inventory impairment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryImpairmentCharge" contextRef="From2024-01-01to2024-12-31" id="Fact000627" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">466</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryImpairmentCharge" contextRef="From2023-01-012023-12-31" id="Fact000628" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,384</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GoodwillImpairmentLoss_i02_maNCPBUzJiX_zVnanjmNSZ7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Goodwill impairment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0630">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-01-012023-12-31" id="Fact000631" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,347</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_i02_maNCPBUzJiX_zYnMZ8WSKWu" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">IPR&amp;D impairment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0633">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-01-012023-12-31" id="Fact000634" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107,800</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_i02_maNCPBUzJiX_z0uWUN75ssw5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Stock-based compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000636" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,569</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000637" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,017</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_i02_maNCPBUzJiX_z85MB2RMotO1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Change in fair value of contingent consideration</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2024-01-01to2024-12-31" id="Fact000639" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">193</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2023-01-012023-12-31" id="Fact000640" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">104,339</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40F_ecustom--AcquiredInProcessResearchAndDevelopment_i02_maNCPBUzJiX_zvqE1DojlvVk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Acquired in-process research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0642">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AcquiredInProcessResearchAndDevelopment" contextRef="From2023-01-012023-12-31" id="Fact000643" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IssuanceOfCommonStockUsedInResearchAndDevelopment_i02_maNCPBUzJiX_zDX1gvx9TU19" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Issuance of common stock for stem-cells to be used in research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0645">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:IssuanceOfCommonStockUsedInResearchAndDevelopment" contextRef="From2023-01-012023-12-31" id="Fact000646" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--IssuanceOfCommonStockAsConsiderationForSettlementAgreement_i02_maNCPBUzJiX_zdj5k4F0N2s5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Issuance of common stock to Palantir as consideration for settlement agreement</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:IssuanceOfCommonStockAsConsiderationForSettlementAgreement" contextRef="From2024-01-01to2024-12-31" id="Fact000648" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">175</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0649">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee_i02_maNCPBUzJiX_zS3uSRNV25bi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Issuance of common stock to Yorkville for debt extension and SEPA commitment fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" contextRef="From2024-01-01to2024-12-31" id="Fact000651" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">317</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" contextRef="From2023-01-012023-12-31" id="Fact000652" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">712</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfCommonStockAsCompensationExpense_i02_maNCPBUzJiX_zEztCOGjAOQd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Issuance of common stock as compensation expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:IssuanceOfCommonStockAsCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000654" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">158</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0655">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DiscountsArisingFromLoanArrangementRelatedParty_i02_maNCPBUzJiX_zmcgV9VpGbM8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Discounts arising from RWI loan arrangement - related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:DiscountsArisingFromLoanArrangementRelatedParty" contextRef="From2023-01-012023-12-31" id="Fact000658" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,151</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--FairValueOfWarrantModificationForProfessionalServices_i02_maNCPBUzJiX_zzJaGKVgnoDh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Fair value of warrant modification for professional services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0660">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:FairValueOfWarrantModificationForProfessionalServices" contextRef="From2023-01-012023-12-31" id="Fact000661" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">403</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msNCPBUzJiX_zVCqlBBKcll9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Loss on debt extinguishment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000663" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,908</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0664">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--ChangeInFairValueOfDebt_i02_maNCPBUzJiX_zOV4Itm6HaSf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Change in fair value of debt</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ChangeInFairValueOfDebt" contextRef="From2024-01-01to2024-12-31" id="Fact000666" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">492</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ChangeInFairValueOfDebt" contextRef="From2023-01-012023-12-31" id="Fact000667" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,177</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ChangeInFairValueOfContingentStockConsideration_i02_maNCPBUzJiX_ziQUcWRLZso4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Change in fair value of contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0669">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:ChangeInFairValueOfContingentStockConsideration" contextRef="From2023-01-012023-12-31" id="Fact000670" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">159</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--NonCashInterestExpense_i02_maNCPBUzJiX_zj0JExfsH8m8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Non cash interest expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:NonCashInterestExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000672" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,144</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0673">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherOperatingCapitalNet_i02N_di_msNCPBUzJiX_zoZUnku0WBBd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Other, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="From2024-01-01to2024-12-31" id="Fact000675" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">300</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="From2023-01-012023-12-31" id="Fact000676" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,157</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zcroe75KIf85" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left">Changes in operating assets and liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUzJiX_zufkptI2CII9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt; text-align: left">Accounts receivable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-01-01to2024-12-31" id="Fact000681" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,968</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-12-31" id="Fact000682" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,827</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msNCPBUzJiX_zve8n8V8RCX6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-01-01to2024-12-31" id="Fact000684" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,284</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-012023-12-31" id="Fact000685" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">865</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzJiX_z04q8brMB8xh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt; text-align: left">Prepaid expenses and other assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000687" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">905</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-12-31" id="Fact000688" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,606</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzJiX_zv9mTWzFzIt4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt; text-align: left">Accounts payable</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2024-01-01to2024-12-31" id="Fact000690" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,239</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-12-31" id="Fact000691" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,497</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maNCPBUzJiX_znUMXNLg2Kzb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt; text-align: left">Accrued expenses and other liabilities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2024-01-01to2024-12-31" id="Fact000693" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,634</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2023-01-012023-12-31" id="Fact000694" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,128</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_409_ecustom--IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense_i03_maNCPBUzJiX_zhe4SiZubtx5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt; text-align: left">Accrued R&amp;D software</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000696" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" contextRef="From2023-01-012023-12-31" id="Fact000697" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,834</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i03_maNCPBUzJiX_zY5wbGTa0eN3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt; text-align: left">Lease liabilities - operating</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000699" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">371</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-12-31" id="Fact000700" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">275</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i03_maNCPBUzJiX_znYGU2feu9ba" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 40pt; text-align: left">Deferred revenue</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2024-01-01to2024-12-31" id="Fact000702" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">235</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2023-01-012023-12-31" id="Fact000703" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,528</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzJiX_maCCERCzbPj_zPi6DECmFduh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash used in operating activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000705" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,401</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-12-31" id="Fact000706" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,685</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zQVlRHP9tbWd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash flow from investing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUznAG_zfYw2uP2no8k" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Capital expenditures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-01-01to2024-12-31" id="Fact000711" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">161</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-12-31" id="Fact000712" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,048</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsToAcquireOtherProductiveAssets_i01N_di_msNCPBUznAG_z5Nnwn6VZNfl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Rebound asset acquisition</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="From2024-01-01to2024-12-31" id="Fact000714" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsToAcquireInProcessResearchAndDevelopment_i01N_di_msNCPBUznAG_zgb503G02d29" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Purchase of acquired in-process research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" contextRef="From2023-01-012023-12-31" id="Fact000718" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromConvertibleNote_i01N_di_msNCPBUznAG_zvPxePUvtImb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from Sanuwave convertible note</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ProceedsFromConvertibleNote" contextRef="From2024-01-01to2024-12-31" id="Fact000720" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,175</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUznAG_maCCERCzbPj_zPa629Mlz6j4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: -10pt; text-align: left">Net cash provided by (used in) investing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000723" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">514</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-12-31" id="Fact000724" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,048</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_z6Y5B16o14G" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: -10pt; text-align: left">Cash flow from financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--ProceedsFromWarrantsAndShortTermDebtRelatedParties_i01_maNCPBUzsOm_zLC08HWSvFql" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from warrants and short-term debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ProceedsFromWarrantsAndShortTermDebtRelatedParties" contextRef="From2024-01-01to2024-12-31" id="Fact000729" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ProceedsFromWarrantsAndShortTermDebtRelatedParties" contextRef="From2023-01-012023-12-31" id="Fact000730" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,369</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--RepaymentsOfShortTermDebtUnaffiliated_i01N_di_msNCPBUzsOm_zcampxL4RFcj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Repayments of short-term debt - unaffiliated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:RepaymentsOfShortTermDebtUnaffiliated" contextRef="From2024-01-01to2024-12-31" id="Fact000732" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,374</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:RepaymentsOfShortTermDebtUnaffiliated" contextRef="From2023-01-012023-12-31" id="Fact000733" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,811</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_406_ecustom--ProceedsFromTheSaleOfCommonStockInAtmOffering_i01_maNCPBUzsOm_zI2NQa3dZflk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from the sale of common stock in ATM offering</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0735">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ProceedsFromTheSaleOfCommonStockInAtmOffering" contextRef="From2023-01-012023-12-31" id="Fact000736" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">136</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromShortTermDebtUnaffiliated_i01_maNCPBUzsOm_zRuGV47dneU9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from issuance of short-term debt - unaffiliated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ProceedsFromShortTermDebtUnaffiliated" contextRef="From2024-01-01to2024-12-31" id="Fact000738" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,622</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ProceedsFromShortTermDebtUnaffiliated" contextRef="From2023-01-012023-12-31" id="Fact000739" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--PaymentOfSepaCommitmentFee_i01N_di_msNCPBUzsOm_zm9OI2TA19g5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Payment of SEPA commitment fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:PaymentOfSepaCommitmentFee" contextRef="From2024-01-01to2024-12-31" id="Fact000741" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">25</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RepaymentsOfShortTermDebtRelatedParty_i01N_di_msNCPBUzsOm_za1M8KGGZhd5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Repayments of short-term debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:RepaymentsOfShortTermDebtRelatedParty" contextRef="From2024-01-01to2024-12-31" id="Fact000744" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">146</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_maNCPBUzsOm_zxjRgDTUCVMa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from PIPE financing</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2024-01-01to2024-12-31" id="Fact000747" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-01-012023-12-31" id="Fact000748" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,750</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzsOm_zYD2cKiw8UIf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from the exercise of stock options</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2024-01-01to2024-12-31" id="Fact000750" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-01-012023-12-31" id="Fact000751" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">304</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsRelatedToTaxWithholdingForShareBasedCompensation_i01N_di_msNCPBUzsOm_zMX9g7iYKkl8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Tax withholding on vesting of restricted stock units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2024-01-01to2024-12-31" id="Fact000753" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">434</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact000754" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">101</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_i01_maNCPBUzsOm_zL8R9bT7MWXd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Proceeds from registered direct offering</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0756">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-01-012023-12-31" id="Fact000757" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_di_msNCPBUzsOm_zDuqs036r5Ma" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Payments of PIPE and other issuance costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0759">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2023-01-012023-12-31" id="Fact000760" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,553</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzsOm_maCCERCzbPj_zVb3ecoSI5Kj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Net cash provided by financing activities</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000762" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,701</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-12-31" id="Fact000763" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,094</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_mtCCERCzbPj_zWhWP5iLgAGh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Net increase (decrease) in cash, cash equivalents and restricted cash</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-01-01to2024-12-31" id="Fact000765" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">814</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-12-31" id="Fact000766" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">18,639</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zlUAhNkRu2Ck" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Cash, cash equivalents and restricted cash at beginning of year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000768" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,163</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-12-31" id="Fact000769" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,802</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zLUIevctlw9a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt; text-align: left">Cash, cash equivalents and restricted cash at end of year</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-12-31" id="Fact000771" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,977</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-12-31" id="Fact000772" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,163</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zNP5y2btbR68" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Supplemental disclosure of cash flow information:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPaidNet_i01_zWdAoquOUZ9g" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Cash paid for interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-01-01to2024-12-31" id="Fact000777" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">144</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-012023-12-31" id="Fact000778" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,073</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherNoncashInvestingAndFinancingItemsAbstract_iB_zD61zWZj5GWf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Supplemental non-cash investing and financing activities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CapitalExpendituresIncurredButNotYetPaid_i01N_di_z87sFdTowMDb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Property and equipment included in accounts payable and accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="From2024-01-01to2024-12-31" id="Fact000783" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="From2023-01-012023-12-31" id="Fact000784" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">223</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--ConversionOfStockAmountIssued1_i01_zv6HiUzugVFi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Common stock issued for short-term debt conversion</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2024-01-01to2024-12-31" id="Fact000786" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="From2023-01-012023-12-31" id="Fact000787" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,599</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--ModificationOfCVStarrWarrantsInConnectionWithForbearance_i01_z921ZDwixgqh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Modification of C.V. Starr warrants in connection with forbearance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ModificationOfCVStarrWarrantsInConnectionWithForbearance" contextRef="From2024-01-01to2024-12-31" id="Fact000789" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0790">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--IssuanceOfRwiWarrantsInConnectionWithForbearance_i01_zbOOlMe0x4A" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Issuance of RWI warrants in connection with forbearance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:IssuanceOfRwiWarrantsInConnectionWithForbearance" contextRef="From2024-01-01to2024-12-31" id="Fact000792" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,162</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0793">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--IssuanceOfWarrantsOnSeniorSecuredBridgeLoan_i01_zjgV7OXgFBbe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Issuance of warrants on senior secured bridge loan</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0795">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:IssuanceOfWarrantsOnSeniorSecuredBridgeLoan" contextRef="From2023-01-012023-12-31" id="Fact000796" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,002</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification_i01_zsM9befYCpIc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification" contextRef="From2023-01-012023-12-31" id="Fact000799" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,083</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--PIPERelatedCostsIncludedInAccruedExpenses_i01_zhaCuN9DfKl9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">PIPE related costs included in accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0801">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:PIPERelatedCostsIncludedInAccruedExpenses" contextRef="From2023-01-012023-12-31" id="Fact000802" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">69</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties_i01_zY5zpyAFyzue" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Interest accrued on senior secured loans within long-term debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties" contextRef="From2023-01-012023-12-31" id="Fact000805" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,770</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition_i01_zpHjHINhPYUl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Contingent consideration accrued in connection with Rebound asset acquisition</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition" contextRef="From2024-01-01to2024-12-31" id="Fact000807" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">650</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0808">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--InventoryAcquiredInConnectionWithReboundAssetAcquisition_i01_z4sx7evjM9dc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Inventory acquired in connection with Rebound asset acquisition</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryAcquiredInConnectionWithReboundAssetAcquisition" contextRef="From2024-01-01to2024-12-31" id="Fact000810" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,150</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0811">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_i01_zRHSM4Tb9voh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Reclassification of warrants from liability classified to equity classified</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" contextRef="From2024-01-01to2024-12-31" id="Fact000813" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,970</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0814">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--AssumptionOfShorttermDebtUnaffiliatedByRelatedParty_i01_zNGHbwq4dZQi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left">Assumption of short-term debt - unaffiliated by related party</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AssumptionOfShorttermDebtUnaffiliatedByRelatedParty" contextRef="From2024-01-01to2024-12-31" id="Fact000816" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,333</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0817">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">The accompanying notes are an integral part of these
consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>


<!-- Field: Page; Sequence: 93 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b><span id="a_001YVF9"></span>CELULARITY INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: center"><b>(In thousands, except share and per share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000819" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_80E_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zYuxJggu6Kn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b>1. <span id="xdx_825_zvCMjvWeGmob">Nature of Business</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Celularity Inc., (&#8220;Celularity&#8221;
or the &#8220;Company&#8221;), formerly known as GX Acquisition Corp. (&#8220;GX&#8221;), was a blank check company incorporated in Delaware
on <span id="xdx_902_edei--EntityIncorporationDateOfIncorporation_dd_c20240101__20241231_zuNcLjKQvCya" title="Date of incorporation"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt:datemonthdayyearen" id="Fact000821" name="dei:EntityIncorporationDateOfIncorporation">August 24, 2018</ix:nonNumeric></span>. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock
purchase, reorganization or other similar business combination with one or more businesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On July 16, 2021 (the &#8220;Closing
Date&#8221;), the Company consummated the previously announced merger pursuant to the Merger Agreement and Plan of Reorganization, dated
January 8, 2021 (the &#8220;Merger Agreement&#8221;), by and among GX, Alpha First Merger Sub, Inc., a Delaware corporation and a direct,
wholly owned subsidiary of GX (&#8220;First Merger Sub&#8221;), Celularity LLC (f/k/a Alpha Second Merger Sub LLC), a Delaware limited
liability company and a direct, wholly owned subsidiary of GX (&#8220;Second Merger Sub&#8221;), and the entity formerly known as Celularity
Inc., incorporated under the laws of the state of Delaware on August 29, 2016 (&#8220;Legacy Celularity&#8221;). Upon completion of the
merger transaction, GX changed its name to Celularity Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At the special meeting held
on February 22, 2024, the stockholders of Celularity approved an amendment to Celularity&#8217;s Second Amended and Restated Certificate
of Incorporation, as amended, to effect a reverse stock split of Celularity&#8217;s Class A common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240222__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zondG55V88O9" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-02-22_us-gaap_CommonClassAMember" id="Fact000823" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share,
at a ratio of <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20240222__20240222__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zaVQuXSXhhKi" title="Reverse stock split ratio"><ix:nonNumeric contextRef="From2024-02-222024-02-22_us-gaap_CommonClassAMember" id="Fact000825" name="us-gaap:StockholdersEquityReverseStockSplit">1-for-10</ix:nonNumeric></span>. Following the reverse stock split, each 10 shares of Celularity&#8217;s Class A common stock issued and outstanding
immediately prior thereto were combined into one new share of Class A common stock. Unless specifically provided otherwise herein, all
share and per share information has been adjusted to reflect the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Description of Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Celularity is a cell therapy
and regenerative medicine company focused on addressing aging related diseases including cancer and degenerative diseases. Celularity
is headquartered in Florham Park, NJ. Legacy Celularity acquired Anthrogenesis Corporation (&#8220;Anthrogenesis&#8221;) in August 2017
from Celgene Corporation (&#8220;Celgene&#8221;), a global biotechnology company that merged with Bristol Myers Squibb Company. Previously,
Anthrogenesis operated as Celgene Cellular Therapeutics, Celgene&#8217;s cell therapy division.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is subject to
risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors
of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations
and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant
additional approval prior to commercialization, including extensive preclinical and clinical testing and regulatory approval. These efforts
require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities.
Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant
revenue from cellular therapy product sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Going Concern </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has evaluated
whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability
to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As an emerging clinical-stage
biotechnology company, Celularity is subject to certain inherent risks and uncertainties associated with the development of an enterprise.
In this regard, since the Company&#8217;s inception, substantially all of management&#8217;s efforts have been devoted to making investments
in research and development including basic scientific research into placentally-derived allogeneic cells, pre-clinical studies to support
its current and future clinical programs in cellular therapeutics, and clinical development of its cell programs as well as facilities
and selling, general and administrative expenses that support its core business operations (collectively, the &#8220;investments&#8221;),
all at the expense of the Company&#8217;s short-term profitability. The Company has historically funded these investments through limited
revenues generated from its biobanking and degenerative disease businesses and issuances of equity and debt securities to public and private
investors (these issuances are collectively referred to as &#8220;outside capital&#8221;). Notwithstanding these efforts, management can
provide no assurance that the Company&#8217;s research and development and commercialization efforts will be successfully completed, or
that adequate protection of the Company&#8217;s intellectual property will be adequately maintained. Even if these efforts are successful,
it is uncertain when, if ever, the Company will generate significant sales or operate in a profitable manner to sustain the Company&#8217;s
operations without needing to continue to rely on outside capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 94 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">As of the date the accompanying
consolidated financial statements were issued, or the issuance date, management evaluated the significance of the following adverse conditions
and events in considering its ability to continue as a going concern:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since its inception, the Company has incurred significant operating losses and net cash used in operating
activities. For the year ended December 31, 2024, the Company incurred an operating loss of $<span id="xdx_901_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20240101__20241231_zBI0HyVmlHq9" title="Operating loss"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000827" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,358</ix:nonFraction></span> and net cash used in operating activities
of $<span id="xdx_905_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20241231_zjGCeCbYNwal" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-01-01to2024-12-31" id="Fact000829" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,401</ix:nonFraction></span>. As of December 31, 2024, the Company had an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20241231_zDCUPldZq8el" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-12-31" id="Fact000831" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">899,683</ix:nonFraction></span>. The Company expects to continue to incur significant
operating losses and use net cash for operations for the foreseeable future.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company expects to incur substantial expenditures to fund its investments for the foreseeable future.
In order to fund these investments, the Company will need to secure additional sources of outside capital. While the Company is actively
seeking to secure additional outside capital (and has historically been able to successfully secure such capital), as of the issuance
date, additional outside capital sufficient to fund operations for the next six months has not been secured or was deemed probable of
being secured. In addition, management can provide no assurance that the Company will be able to secure additional outside capital in
the future or on terms that are acceptable to the Company. Absent an ability to secure additional outside capital in the very near term,
the Company will be unable to meet its obligations as they become due over the next 12 months beyond the issuance date.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of the issuance date, the Company had approximately $<span id="xdx_906_eus-gaap--DebtInstrumentIssuedPrincipal_pn3n3_c20240101__20241231_zvdnnGv06CPf" title="Principal debt outstanding"><ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="From2024-01-01to2024-12-31" id="Fact000833" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">43,288</ix:nonFraction></span> of principal debt outstanding, all of which
is currently due or due within one year of the issuance date. As disclosed in Note 10, a substantial portion of the Company&#8217;s outstanding
debt is subject to forbearance agreements. In the event the terms of the forbearance agreements are not met and/or the outstanding borrowings
are not repaid, the lenders may, at their discretion, exercise all of their rights and remedies under the loan agreements which may include,
among other things, seizing the Company&#8217;s assets and/or forcing the Company into liquidation.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 22, 2025, the Company was notified by Nasdaq that it had not
                                                                                                                                                                                                           paid certain fees required by Listing Rule 5250(f) totalling $<span id="xdx_903_eus-gaap--PaymentForManagementFee_pn3n3_c20250422__20250422__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpm1pT0klGGi" title="Payment for fee"><ix:nonFraction name="us-gaap:PaymentForManagementFee" contextRef="From2025-04-222025-04-22_us-gaap_SubsequentEventMember" id="Fact000835" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">70,000</ix:nonFraction></span>, and as a result, the Company will be delisted unless it
                                                                                                                                                                                                           appeals this determination. The Company paid the assessed fees on April 24, 2025, and Nasdaq informed the Company on April 30, 2025,
                                                                                                                                                                                                           that it was in compliance with Listing Rule 5250(f) and the matter is now closed. Additionally, on April 16, 2025, Nasdaq provided
                                                                                                                                                                                                           formal notice to the Company that as a result of the Company&#8217;s failure to timely file this annual report on Form 10-K, it no
                                                                                                                                                                                                           longer complied with the continued listing requirements under the timely filing criteria outlined in Nasdaq Listing Rule 5250(c)(1).
                                                                                                                                                                                                           Pursuant to Listing Rule 5810(d)(2), this delinquency serves as an additional and separate basis for delisting, and as such, the
                                                                                                                                                                                                           Company&#8217;s common stock will be suspended from trading on May 1, 2025, unless it appeals Nasdaq&#8217;s determination before a
                                                                                                                                                                                                           Hearing Panel. On April 29, 2025, the Company filed an appeal requesting an oral hearing with a Nasdaq Hearing Panel. There can be
                                                                                                                                                                                                           no assurance that the appeal will be successful or that the Company will maintain compliance with the Nasdaq listing requirements.
                                                                                                                                                                                                           If relief is not granted by the Nasdaq Hearing Panel or the Company is unable to regain compliance, the Company&#8217;s securities
                                                                                                                                                                                                           will be delisted from the Nasdaq, which such delisting could have a materially adverse effect on the Company&#8217;s ability to
                                                                                                                                                                                                           continue as a going concern.</p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event the Company is unable to secure additional outside capital to fund the Company&#8217;s obligations
when they become due over the next 12 months beyond the issuance date, which includes the funds needed to repay the Company&#8217;s outstanding
debt, management will be required to seek other strategic alternatives, which may include, among others, a significant curtailment of
the Company&#8217;s operations, a sale of certain of the Company&#8217;s assets, a sale of the entire Company to strategic or financial
investors, and/or allowing the Company to become insolvent by filing for bankruptcy protection under the provisions of the U.S. Bankruptcy
Code.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">These uncertainties raise
substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements
have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates that the Company will
be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly,
the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000837" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zt50ofiaX3L4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b>2. <span id="xdx_821_zk911nBMBO35">Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000839" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zdyDETNzOD07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s
consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).
The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and
transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management,
is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000841" name="us-gaap:UseOfEstimates"><p id="xdx_845_eus-gaap--UseOfEstimates_zs3ze1DxCDi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The preparation of the
Company&#8217;s consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the
consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant
estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related
to the Company&#8217;s goodwill and intangible asset impairment assessments, determination of incremental borrowing rates, and the
valuations of inventory, gross-to-net sales adjustments, contingent consideration, short-term debt, stock options and stock
warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors
that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are
changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual
results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 95 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000843" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrCWIXAoDtD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Fair Value Measurements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain assets and
liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an
orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to
be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable
and the last is considered unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 &#8212; Quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 &#8212; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active
markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities,
or other inputs that are observable or can be corroborated by observable market data.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"/><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity that are significant
to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000845" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zYWQkJNKxIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Cash and cash equivalents
consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having a maturity when
acquired of less than three months. The Company considers all highly liquid investments with maturities of three months or less at
the date of acquisition to be cash equivalents. At December 31, 2024 and 2023, substantially all cash and cash equivalents were held
in either commercial bank accounts or money market funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000847" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_z1PgwfZPO0v2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Restricted Cash</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">As of December 31,
2024 and 2023, the Company maintained a letter of credit of $<span id="xdx_90C_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20241231__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zjoVwFqEBhq3" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2024-12-31_us-gaap_LetterOfCreditMember" id="Fact000849" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,239</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zczK3zS7p75k" title="Restricted cash"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2023-12-31_us-gaap_LetterOfCreditMember" id="Fact000851" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,936</ix:nonFraction></span>, respectively, for the benefit of the landlord of a leased
property, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000853" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJI8ZxNTfRj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Accounts Receivable</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Accounts receivable represent amounts due from customers, typically within 30 to 90 days from invoice date, arising from the Company&#8217;s revenue-generating activities. Accounts receivable are presented net of an allowance for credit losses. The
allowance for credit losses is determined based on a combination of the aging of receivables, and customer-specific information, including
historical loss experience, current economic conditions, forecasts of future economic conditions and other relevant risk factors. The
Company applies judgment in evaluating the collectability of accounts. Receivables are written off when all reasonable collection efforts
have been exhausted and the amounts are deemed uncollectible. Actual credit losses may differ from management&#8217;s estimates, and such
differences are recognized in the period in which they become known. The Company&#8217;s accounts receivable balance, net of allowance for credit losses, was $<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20241231_zeQQoLgBpzc9" title="Accounts receivable balance, net of allowance for credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-12-31" id="Fact000855" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,357</ix:nonFraction></span>, $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20231231_zcx3fNrMjZqd" title="Accounts receivable balance, net of allowance for credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-12-31" id="Fact000857" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,046</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231_zN2uiosrvhKc" title="Accounts receivable balance, net of allowance for credit losses"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2022-12-31" id="Fact000859" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,452</ix:nonFraction></span>
as of December 31, 2024, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000861" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_849_eus-gaap--InventoryPolicyTextBlock_zZCOVQRpq42a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Inventory</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Inventory is stated
at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. Prior to initial approval
from the FDA or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred.
After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product.
The Company continues to expense costs associated with clinical trial supply costs as research and development expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company periodically
analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i)
expected to expire prior to being sold, (ii) has a cost basis in excess of its net realizable value, (iii) is in excess of expected
sales requirements as determined by internal sales forecasts, or (iv) fails to meet commercial sale specifications, the inventory is
written-down through a charge to cost of revenues. The determination of whether inventory costs will be realizable requires
estimates by management of future expected inventory requirements, based on sales forecasts. If actual market conditions are less
favorable than those projected by management, additional inventory write-downs may be required. Inventory, net of current portion on
the Company&#8217;s consolidated balance sheets includes inventory expected to remain on hand beyond one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 96 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000863" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zirH0xyvqwPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Property and Equipment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000865" name="CELU:ScheduleOfEstimatedUsefulLivesTableTextBlock"><p id="xdx_89C_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zNuXmaECBYkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Property and equipment
are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line
method over the estimated useful life of each asset, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span id="xdx_8BB_zWqIoqbkfaU7" style="display: none">Schedule of Property and
Equipment Estimated Useful Life</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated Useful Life</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 69%">Building</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29%; text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zZlzOQlagac9" title="Property and equipment expected useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_BuildingMember" format="ixt-sec:duryear" id="Fact000867" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">26</ix:nonNumeric></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zB89FzWimrl3" title="Property and equipment expected useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000869" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> - <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zwDyWQvpt0Rd" title="Property and equipment expected useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000871" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Lab equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zSXMcDK2itY8" title="Property and equipment expected useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_EquipmentMember" format="ixt-sec:duryear" id="Fact000873" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ7S4NKtSWNd" title="Property and equipment expected useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" id="Fact000875" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Software</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zV3KFxImgR3a" title="Property and equipment expected useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_SoftwareDevelopmentMember" format="ixt-sec:duryear" id="Fact000877" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zdaZ6Eefrqd2" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0878">shorter of the estimated useful life or the lease term</span></span></td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zGGLuPyKsfA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Estimated useful lives are
periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When
assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are
eliminated from the consolidated balance sheets and any resulting gains or losses are included in the consolidated statements of
operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as
construction-in-progress and depreciated once placed into service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000880" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD7ahGB9k1gg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Impairment of Long-Lived Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Long-lived assets consist
of property, plant and equipment, operating right-of-use assets, and finite-lived intangible assets. Long-lived assets to be held and
used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets
may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant
underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes
or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability,
the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset
group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows
expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess
of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. Due to the goodwill
impairment recognized during the year ended December 31, 2023 as discussed below and in Note 8, the Company performed a recoverability
test on long-lived assets and concluded no additional impairment to be recognized as result of this test. The Company did not record any
impairment losses on long-lived assets during the years ended December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000882" name="CELU:AssetAcquisitionsPolicyTextBlock"><p id="xdx_848_ecustom--AssetAcquisitionsPolicyTextBlock_zwRrPSrKxFj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Asset Acquisitions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company measures
and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes
transaction costs. In an asset acquisition, the cost allocated to acquire IPR&amp;D with no alternative future use is charged to research
and development expense at the acquisition date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000884" name="us-gaap:InProcessResearchAndDevelopmentPolicy"><p id="xdx_841_eus-gaap--InProcessResearchAndDevelopmentPolicy_zO49g7Q62gg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>In-Process Research and Development</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of IPR&amp;D
acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of
the related research and development activities. When the related research and development is completed, the asset is reclassified to
a finite-lived asset and amortized over its estimated useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of an
IPR&amp;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to
be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability
of technical success, the projected costs to complete, expected market competition, and an assessment of the asset&#8217;s life-cycle.
The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated
with the cash flow streams.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 97 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Indefinite-lived IPR&amp;D
is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The
Company tests its indefinite-lived IPR&amp;D annually for impairment during the fourth quarter. In testing indefinite-lived
IPR&amp;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of
events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the
Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived IPR&amp;D without
performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or
economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess
qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived IPR&amp;D
is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived IPR&amp;D. Under either
approach, if the fair value of the indefinite-lived IPR&amp;D is less than its carrying amount, an impairment charge is recognized
in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2024, the Company did <span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_dxL_c20240101__20241231_zBVtE4RSkLYc" title="Indefinite-lived IPR&amp;D::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0886">no</span></span>t
recognize an impairment charge related to its indefinite-lived IPR&amp;D. During the year ended December 31, 2023, the Company
recognized an impairment charge related to its indefinite-lived IPR&amp;D of $<span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_c20230101__20231231_zRCobO66Fxgg" title="Indefinite-lived IPR&amp;D"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="From2023-01-012023-12-31" id="Fact000888" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107,800</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000890" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zVgnjKMbbyub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Goodwill</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Goodwill represents
the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets
acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if
there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company manages
its operations through an evaluation of <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_z6ccAPGLi27e" title="Operating segments"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2024-01-01to2024-12-31" id="Fact000892" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">three</ix:nonFraction></span> different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note
19). The Company determined that the operating segments represented the reporting units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In testing goodwill
for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances
would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, or the Company
can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances
considered in the Company&#8217;s qualitative assessment include, but are not limited to, a significant adverse change in legal or business
climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess qualitative factors and the
Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, the Company
would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit
to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, no
impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize
an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value, not to exceed the total
amount of goodwill allocated to the reporting unit. During the year ended December 31, 2024, the Company did <span id="xdx_903_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_do_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zrfBEylpfebh" title="Goodwill impairment"><ix:nonFraction name="us-gaap:GoodwillImpairmentLossNetOfTax" contextRef="From2024-01-012024-12-31_custom_CellTherapyMember" id="Fact000894" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD">no</ix:nonFraction></span>t recognize any goodwill
impairment. During the year ended December 31, 2023, the Company recognized goodwill impairment of $<span id="xdx_901_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zO7f9dSxunO7" title="Goodwill impairment"><ix:nonFraction name="us-gaap:GoodwillImpairmentLossNetOfTax" contextRef="From2023-01-012023-12-31_custom_CellTherapyMember" id="Fact000896" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,347</ix:nonFraction></span> relating to the Cell Therapy
reporting unit (see Note 8) in the Company&#8217;s consolidated statement of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000898" name="CELU:WarrantsLiabilitiesPolicyTextBlock"><p id="xdx_844_ecustom--WarrantsLiabilitiesPolicyTextBlock_zPm9aumjiLI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Warrant Liabilities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounts for
the public warrants, private placement warrants, registered direct warrants, May 2022 PIPE warrants, and November 2024 Purchaser
Warrants and Placement Agent Warrants (collectively, &#8220;Liability Warrants&#8221;) in accordance with the guidance contained in
Accounting Standards Codification (&#8220;ASC&#8221;) 815-40, <i>Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own
Equity</i>, under which the Liability Warrants do not meet the criteria for equity treatment and must be recorded as liabilities.
Accordingly, the Company classifies the Liability Warrants as liabilities at their fair value and adjusts to fair value at each
reporting period. These liabilities are subject to re-measurement at each balance sheet date until exercised or expired, and any change in
fair value is recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The Liability
Warrants, excluding the public warrants, were initially and subsequently valued using either a Black-Scholes or a Monte Carlo option
pricing model, which are considered to be Level 3 fair value measurements. The public warrants are valued based on the quoted market
price as of each relevant reporting date, which is considered to be a Level 1 fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 98 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000900" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_zB6GsSXh3MT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Leases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In accordance with
Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, <i>Leases (Topic 842)</i> (ASU 2016-02 or ASC 842), the Company classifies leases
at the lease commencement date. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease
based on the circumstances present. Leases with a term greater than one year will be recognized on the consolidated balance sheets as
right-of-use (&#8220;ROU&#8221;) assets, lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal
options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and
the corresponding ROU assets are recorded based on the present values of lease payments over the terms. The interest rate implicit in
lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which
are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a
similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liabilities and are
recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants.
Certain adjustments to ROU assets may be required for items such as initial direct costs paid, incentives received, or lease prepayments.
If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company
would reassess lease classification, remeasure the lease liabilities using revised inputs as of the reassessment date, and adjust the
ROU assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has elected
the &#8220;package of 3&#8221; practical expedients permitted under the transition guidance, which eliminates the requirements to reassess
prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy
which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of
exercising will not be included within the ROU assets and lease liabilities on its consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Refer to Note 11 for further information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000902" name="CELU:ShortTermDebtPolicyTextBlock"><p id="xdx_84A_ecustom--ShortTermDebtPolicyTextBlock_zJawFRlv44Sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Short-Term Debt - Yorkville and
Unsecured Senior Convertible Notes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company elected
the fair value option to account for its pre-paid advance agreement with YA II PN, Ltd (&#8220;Yorkville&#8221;) (see Note 10). As of
December 31, 2023, due to the short-term nature of the debt, the fair value approximated the settlement amount which was fully paid on
January 17, 2024. The Company also elected the fair value option to account for the Yorkville convertible promissory note signed on March
13, 2024 (see Note 10) and the unsecured senior convertible notes issued pursuant to the securities purchase agreement signed on November
25, 2024 (see Note 10). As of December 31, 2024, the estimate of the fair value of the Yorkville convertible promissory note and the unsecured
senior convertible notes was determined using a binomial lattice model and a credit default model. The fair value measurement of the debt
is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair value of debt that is accounted for
at fair value, inclusive of related accrued interest expense, are presented as gains or losses in the accompanying consolidated statements
of operations and comprehensive loss under change in fair value of debt. The portion of total changes in fair value of debt attributable
to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption
exclusive of base market changes and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements
of operations and comprehensive loss. The actual settlement of the short-term debt could differ from current estimates based on the timing
of when and if the investors elect to convert amounts into common shares, potential cash repayment by the Company prior to maturity, and
movements in the Company&#8217;s common share price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000904" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock"><p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zMzJP3CBwZOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company generates
revenue from its degenerative disease commercial operations (i.e., the sale of Biovance<sup>&#174;</sup>, Biovance 3L<sup>&#174;</sup>,
CentaFlex<sup>&#174;</sup>, Interfyl<sup>&#174;</sup> and Rebound<sup>TM</sup>), biobanking services (i.e., the collection, processing and
storage of umbilical cord and placental blood and tissue after full-term pregnancies), and license, royalty and other revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><i><span style="text-decoration: underline">Product sales</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><i><span style="text-decoration: underline">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Biovance, Biovance 3L, CentaFlex
and Rebound are decellularized, dehydrated human amniotic membrane products intended for use as a biological membrane covering that provides
the extracellular matrix while supporting the repair of damaged tissue. Interfyl is an allogeneic decellularized particulate human placental
connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use
in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. <span style="background-color: white">Rebound&#8482;
is a full thickness extracellular matrix that contains amnion and chorion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recognizes
revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects
to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer,
determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct
performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied. Sales and
other taxes collected on behalf of third parties are excluded from revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 99 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A performance obligation
is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with
other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance
obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use
and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with
customers and to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration
that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances,
to which the Company expects to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company offers
volume-based discounts, rebates and prompt pay discounts and other various incentives which are accounted for under the variable consideration
model. If sales incentives may be earned by a customer for purchasing a specified amount of product, the Company estimates whether such
incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction
is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company
considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to estimate what
levels of incentives will be earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company provides
for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore
does not record a provision for returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><i><span style="text-decoration: underline">Services</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company separately recognizes
revenues for services to expectant parents who contract with the Company to collect, process and store umbilical cord blood and placenta
derived cells and tissue for private use. The Company recognizes revenue from collection and processing fees at the point in time of the
successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period. Contracted
storage periods are generally <span id="xdx_90E_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z58qSIxTyhdb" title="Contracted storage periods"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000906" name="CELU:ContractedStoragePeriods">18</ix:nonNumeric></span> years and <span id="xdx_900_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zfUgtyGy5kj7" title="Contracted storage periods"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000908" name="CELU:ContractedStoragePeriods">25</ix:nonNumeric></span> years. Deferred revenue on the accompanying consolidated balance sheets includes the portion
of the 18- and the 25-year storage fees that are being recognized over the contractual storage period. The Company classifies deferred
revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">When determining the transaction
price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance,
resulting in a significant financing component. For all plans (annual, lifetime, <span id="xdx_90D_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zieb2Fryhruh"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000909" name="CELU:ContractedStoragePeriods">18</ix:nonNumeric></span>
years and <span id="xdx_90A_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z6PRk83KBTyh"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000910" name="CELU:ContractedStoragePeriods">25</ix:nonNumeric></span>
years), the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans
for customers to pay over time for a period of one
<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z6uayugqonI7" title="Over time for a period"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MinimumMember" format="ixt-sec:durmonth" id="Fact000912" name="CELU:PaymentPlansForCustomerToPayOverTimePeriod">1</ix:nonNumeric></span></span> to <span id="xdx_908_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zEGtPcJ7xRMe" title="Over time for a period"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MaximumMember" format="ixt-sec:durmonth" id="Fact000914" name="CELU:PaymentPlansForCustomerToPayOverTimePeriod">24</ix:nonNumeric></span>
months (over time plans). The Company concluded that a significant financing component is not present within either the prepaid or overtime
payment plans. The Company has determined that the prepaid plans do not include a significant financing component as the payment terms
were structured primarily for reasons other than the provision of financing and to maximize profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">When considered over
a <span id="xdx_908_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zyN5PDwPyEo7" title="Over time for a period"><ix:nonNumeric contextRef="From2024-01-012024-12-31_srt_MaximumMember" format="ixt-sec:durmonth" id="Fact000916" name="CELU:PaymentPlansForCustomerToPayOverTimePeriod">24</ix:nonNumeric></span>-month period for over time plans, the difference between the cash selling price and the consideration paid is nominal. As such, the
Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when
considered in the context of all contracts entered into nor are they significant at the individual contract level.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company offers
promotional discounts and other various incentives which are accounted for under the variable consideration model. The Company estimates
whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue
transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method,
the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to
estimate what levels of incentives will be earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
the Company&#8217;s processing and storage agreements contain multiple performance obligations, ASC 606, <i>Revenue from Contracts with
Customers,</i> requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised
services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the standalone
selling prices of the processing services and storage services and concluded that the published list price is the price that a customer
in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged
the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage</span><span style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><i><span style="text-decoration: underline">License, royalty and other</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under license agreements,
the Company assesses whether the related performance obligation is satisfied at a point in time or over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 100 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At the inception of
each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable
of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial,
and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved
in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period,
the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate
of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings
in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy
a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the
milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. See
Note 16 for further discussion of the Company&#8217;s license agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">While the Company&#8217;s
direct sales of degenerative disease products are included in product sales, sales through the Company&#8217;s network of distribution partners
are included in license, royalty and other revenues. For certain distribution agreements as described in Note 16, the Company will utilize
the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to
invoice so long as the consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue
upon invoicing for these agreements (subsequent to receipt of the related purchase order).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000918" name="us-gaap:CostOfSalesPolicyTextBlock"><p id="xdx_845_eus-gaap--CostOfSalesPolicyTextBlock_z35GVfzsFpM8" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Cost of Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Cost
of revenues consists of labor, material and overhead costs associated with the Company&#8217;s two existing commercial business segments,
biobanking and degenerative disease. Biobanking costs, which include the cost of storage and transportation kits for newly banked materials
as well as tank and facility overhead costs for cord blood and other units in storage, are included in services in cost of revenues. Degenerative
disease costs, which include costs associated with procuring placentas, qualifying the placental material and processing the placental
tissue into a marketable product, are included in product sales or license, royalty and other in cost of revenues depending on the class
of customer. Costs in the degenerative disease segment include labor and overhead costs associated with the production of the Biovance,
Biovance 3L, Interfyl and Rebound product lines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white"></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000920" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztoNo8vfpm03" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Research and Development Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has entered
into various research and development and other agreements with commercial firms, researchers, universities and others for provisions
of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expense
as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses,
depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside
vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical
trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. Nonrefundable advance
payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses.
Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or
when it is no longer expected that the goods will be delivered, or the services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upfront payments, milestone
payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000922" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zehqyqrWofT4" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Advertising and Marketing Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Advertising and marketing
costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were
$<span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20240101__20241231_zPHclHX0L6aa" title="Advertising and marketing costs"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2024-01-01to2024-12-31" id="Fact000924" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20230101__20231231_zFZsOBngTiul" title="Advertising and marketing costs"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2023-01-012023-12-31" id="Fact000926" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">44</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000928" name="CELU:GovernmentGrantsPolicyTextBlock"><p id="xdx_84F_ecustom--GovernmentGrantsPolicyTextBlock_zAOMqF8O9Nv1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Government Grants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">From time to time,
the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction
to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency.
The Company did <span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20240101__20241231_zPvnZyyuNW4" title="Grant monies"><span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20230101__20231231_z3b1OtFQdtV" title="Grant monies"><ix:nonFraction name="CELU:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" contextRef="From2024-01-01to2024-12-31" id="Fact000930" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="CELU:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" contextRef="From2023-01-012023-12-31" id="Fact000932" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t receive grant monies during the years ended December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 101 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000934" name="CELU:PatentCostsPolicyTextBlock"><p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zOVE1KisiZFb" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Patent Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">All patent-related
costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the
recovery of the expenditure. Amounts incurred are classified in selling, general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000936" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zO3jvgy1FGPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company measures
all stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation
expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company
typically issues stock-based awards with only service-based vesting conditions and records the expense for these awards using a straight-line
method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s
board of directors may also approve and award performance-based stock options. The performance-based stock options are earned based on
the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based awards over
the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability
of vesting at each reporting period for performance-based awards and adjusts expense accordingly on a cumulative basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of each
service-performance- and market-based stock option grant is estimated on the date of grant using an appropriate option pricing
model using inputs available as of the grant date. For awards with service-based vesting conditions only, the Company determines the
fair value of the award as of the grant date using the Black-Scholes option-pricing model. Prior to the merger, Legacy Celularity
was a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, the
Company estimates its expected stock price volatility using its volatility since the merger and the historical volatility of
publicly traded peer companies. The expected term of the Company&#8217;s stock options granted to employees is determined utilizing
the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock
options granted to non-employee consultants is equal to the contractual term of the option award or the Company&#8217;s estimated
term based on the underlying agreement. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in
effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected
dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay
any cash dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company classifies
stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award
recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. The Company elects
to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure
to satisfy a service or performance condition is generally reversed in the period of the forfeiture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000938" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zcClrkt8H3S1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Comprehensive Income (Loss)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Comprehensive income (loss)
refers to revenues, expenses, gains and losses that under GAAP are included in comprehensive income (loss) but are excluded from net income
(loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss). The Company&#8217;s only
component of other comprehensive income (loss) is comprised of the portion of the total change in fair value of debt accounted for under
the fair value option that is attributable to changes in instrument-specific credit risk. During the year ended December 31, 2024, the
Company recorded instrument-specific credit risk loss of $<span id="xdx_907_ecustom--InstrumentSpecificCreditRiskLoss_pn3n3_c20240101__20241231_zXuxthYZisj4" title="Instrument-specific credit risk loss"><ix:nonFraction name="CELU:InstrumentSpecificCreditRiskLoss" contextRef="From2024-01-01to2024-12-31" id="Fact000940" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></span>. During the year ended December 31, 2023, the Company recorded instrument-specific
credit risk income of $<span id="xdx_905_ecustom--InstrumentSpecificCreditRiskIncome_pn3n3_c20230101__20231231_zTIEM30L2NXa" title="Instrument-specific credit risk income"><ix:nonFraction name="CELU:InstrumentSpecificCreditRiskIncome" contextRef="From2023-01-012023-12-31" id="Fact000942" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">146</ix:nonFraction></span> and reclassified $<span id="xdx_904_ecustom--AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_pn3n3_c20230101__20231231_zaEvSgctPaZ1" title="Accumulated other comprehensive income"><ix:nonFraction name="CELU:AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion" contextRef="From2023-01-012023-12-31" id="Fact000944" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">155</ix:nonFraction></span> from accumulated other comprehensive loss to other expense, net on the consolidated statements
of operations and comprehensive loss upon short-term debt conversion. These amounts have been recorded as a separate component of stockholders&#8217;
equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000946" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zcM4XvGXdhs1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounts for
income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns.
Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and
liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets
and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will
be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely
than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge
to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and
considering prudent and feasible tax planning strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 102 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounts
for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount
of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based
on the technical merits of the position. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then
assessed to determine the amount of benefit to recognize in the consolidated financial statements. <span id="xdx_906_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zbOsqvgmw2Xf" title="Income tax examination likelihood settlement"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact000948" name="us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority</ix:nonNumeric></span>.
The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note
18).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000950" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zDCGXGQdLZZ3" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Net Loss per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Basic net loss per share
of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period.
Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such
as redeemable convertible preferred stock, convertible debt, stock options, restricted stock units and warrants, which would result in
the issuance of incremental shares of common stock. However, potential common shares are excluded if their effect is anti-dilutive. For
diluted net loss per share when the Company has a net loss, the weighted-average number of shares of common stock is the same as for basic
net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact
is anti-dilutive. All warrants are participating securities, as they participate on a one-for-one basis with Class A common stock in the
distribution of dividends, if and when declared by the Board of Directors. For the purposes of computing earnings per share, the warrants
are considered to participate with Class A common stock in earnings of the Company. Therefore, the Company computes earnings per share
using the two-class method, an earnings allocation method that determines net income (loss) per share (when there are earnings) for common
stock and participating securities. No income was allocated to the warrants for the years ended December 31, 2024 and 2023, as results
of operations were a loss for both periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000952" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgF07KC77J2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following potentially
dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common stock outstanding, prior
to the use of the two-class method, as they would be anti-dilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span id="xdx_8B6_zFS2Zb9yp5z4" style="display: none">Schedule of Potentially
Dilutive Securities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_zTLtiqSQNdm2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zcfC9dr3F2Ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zO4pWMMkDXGa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left">Stock options</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000954" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,006,525</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember" id="Fact000955" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,820,187</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG54qjzKR72f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Restricted stock units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000957" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">688,106</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000958" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">823,332</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpDgmRzbMwm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember" id="Fact000960" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,221,557</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember" id="Fact000961" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,070,627</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zngdWYOZ7SBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="Fact000963" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,126,496</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember" id="Fact000964" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">549,681</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zc76zzjiS1Tb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive
    securities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-01-01to2024-12-31" id="Fact000966" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,042,684</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31" id="Fact000967" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,263,827</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zSxqGmWvKgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000969" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze7191TVFkX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Segment Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Operating segments
are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company manages
its operations through an evaluation of <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_ztB8DCNcXN04" title="Number of operating segments"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2024-01-01to2024-12-31" id="Fact000971" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">three</ix:nonFraction></span> distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments
are presented for the years ended December 31, 2024 and 2023 in Note 19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000973" name="CELU:AllowanceForCreditLossesPolicyTextBlock"><p id="xdx_841_ecustom--AllowanceForCreditLossesPolicyTextBlock_zhEEiQk5NWE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Allowance for Credit Losses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">With the adoption of ASU
2016-13 <i>Financial Instruments &#8212; Credit Losses, </i>as noted below, the Company recognizes credit losses based on forward-looking
current expected credit losses. The Company makes estimates of expected credit losses based upon its assessment of various factors, including
historical collection experience, the age of accounts receivable balances, credit quality of its customers, current economic conditions,
reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000975" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_z2szKM6kK2K1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Concentrations of Credit Risk and
Significant Customers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Financial instruments that
potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, and
accounts receivable. The Company generally maintains cash balances in various operating accounts at financial institutions that management
believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses
related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the
normal credit risk associated with commercial banking relationships.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 103 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is subject to
credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts
receivables are a result from product sales and services performed in the United States. As of December 31, 2024, three of the Company&#8217;s
customers, each of which individually comprised at least 10%, represented an aggregate <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_z4PaOevwtynb" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember" id="Fact000977" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">46</ix:nonFraction></span>% of the Company&#8217;s outstanding gross accounts
receivable. As of December 31, 2023, two of the Company&#8217;s customers, each of which individually comprised at least 10%, represented an
aggregate <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zx2bmIlaY6N" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember" id="Fact000979" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">41</ix:nonFraction></span>% of the Company&#8217;s outstanding gross accounts receivable. During the year ended December 31, 2024, the Company had one
customer provide for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFlNmPzgrYt7" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000981" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>% of revenue and another customer provided for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zanEqKEWCkk7" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2024-01-012024-12-31_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000983" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>% of revenue. During the year ended December 31, 2023, the Company
had one customer provide for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmQz2erMMjnc" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000985" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>% of revenue and another customer provided for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zc4bGqHB5XBa" title="Concentration risk, percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000987" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13</ix:nonFraction></span>% of revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000989" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription"><p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zAzQwpXzibg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Reclassifications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain prior period amounts
have been reclassified to conform with current year presentation. On the consolidated balance sheets, short-term debt - Yorkville and
other short-term debt were reclassified to short-term debt - unaffiliated, and short-term debt - related party and short-term debt - related
parties - C.V. Starr and RWI were reclassified to short-term debt - related parties. See Note 10 for further information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000991" name="CELU:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"><p id="xdx_845_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zL3RHbbgw3o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Recently Adopted Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In June 2016, the Financial
Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, <i>Financial Instruments &#8212; Credit Losses</i> (&#8220;ASU 2016-13&#8221;),
which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types
of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale
debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual
periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption
permitted. The Company adopted ASU 2016-13 effective January 1, 2023. The standard did not have a material impact on the consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In November 2023, the FASB
issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>, which requires disclosure of
incremental segment information on an annual and interim basis. This ASU was effective for fiscal years beginning after December 15, 2023,
and interim periods within fiscal years beginning after December 15, 2024. The Company adopted the guidance in ASU 2023-07 for the year
ended December 31, 2024, and it is being applied retrospectively to its consolidated financial statement disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000993" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z20Svbe71ez6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Recently Issued Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In December 2023, the FASB
issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which expands the disclosures required for
income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should
be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this
pronouncement on its financial statement disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In November 2024, the FASB
issued ASU 2024-03, <i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses</i>, as subsequently amended by ASU 2025-01 to clarify the effective date,
which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee
compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of
operations and comprehensive loss. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within
fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively
to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods
presented in the consolidated financial statements. The Company is currently evaluating the effect of this pronouncement on its
consolidated financial statements and footnote disclosures.</p>

</ix:nonNumeric><p id="xdx_855_zCWYG4UIoI86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact000995" name="us-gaap:AssetAcquisitionTextBlock"><p id="xdx_800_eus-gaap--AssetAcquisitionTextBlock_zhxAhBhUhWNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b>3. <span id="xdx_822_zZ01t3MtGYU">Asset
Acquisition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
October 9, 2024, the Company entered into an asset purchase agreement with Sequence LifeScience, Inc. (&#8220;Sequence&#8221;) to acquire
Sequence&#8217;s Rebound&#8482; full thickness placental-derived allograft matrix product and certain related intangible assets. Rebound
adds to the Company&#8217;s portfolio of placental-derived advanced biomaterial products. The Company will pay aggregate consideration for
the assets of up to $<span id="xdx_90C_eus-gaap--AssetAcquisitionPriceOfAcquisitionExpected_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zJgwKjDGGuJg" title="Consideration for assets"><ix:nonFraction name="us-gaap:AssetAcquisitionPriceOfAcquisitionExpected" contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember" id="Fact000997" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,500</ix:nonFraction></span>, which consists of (i) an upfront cash payment of $<span id="xdx_90B_ecustom--UpfrontPayment_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zFhxnxo7W5n5" title="Upfront payment"><ix:nonFraction name="CELU:UpfrontPayment" contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember" id="Fact000999" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span> (ii) an aggregate of up to $<span id="xdx_906_ecustom--MonthlyMilestonePayments_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zpFxjdmJsUbe" title="Monthly milestone payments"><ix:nonFraction name="CELU:MonthlyMilestonePayments" contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember" id="Fact001001" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,000</ix:nonFraction></span> in monthly milestone
payments, and (iii) a credit of $<span id="xdx_90B_ecustom--PriorPaymentToRelatedParty_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zfl9ECv87zc8" title="Prior payment to related party"><ix:nonFraction name="CELU:PriorPaymentToRelatedParty" contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember" id="Fact001003" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> for the previous payment made by the Company to Sequence pursuant to a letter of intent between the
Company and Sequence dated August 16, 2024. Pursuant to the terms of the asset purchase agreement, the milestones are calculated based
on <span id="xdx_90E_ecustom--NetSalesPercentage_pid_dp_uPure_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zD4yQaSflqdk" title="Net sales percentage"><ix:nonFraction name="CELU:NetSalesPercentage" contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember" id="Fact001005" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of net sales collected by the Company from its customers during the preceding calendar month, commencing the first full month after
the closing of the transaction. Transaction costs incurred with in connection with the Rebound asset acquisition were de minimis. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 104 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Concurrently
with the execution of the asset purchase agreement, the Company entered into an exclusive supply agreement with Sequence for the manufacture
and supply of Rebound for a minimum period of six months. The Company retains the right to manufacture Rebound internally and intends
to commence a technology transfer as soon as practicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Company determined that this transaction represented an asset acquisition in accordance with ASC 805, <i>Business Combinations</i>, because
the acquired assets did not meet the definition of a business. As noted above, the purchase price consists of $<span id="xdx_906_ecustom--PurchasePriceContingentConsideration_iI_pn3n3_c20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifescienceIncMember_zCLr3nEPywra" title="Purchase price contingent consideration"><ix:nonFraction name="CELU:PurchasePriceContingentConsideration" contextRef="AsOf2024-10-09_custom_SequenceLifeScienceIncMember" id="Fact001007" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,000</ix:nonFraction></span> of contingent consideration
that is based on future collections of net sales of Rebound. The Company&#8217;s policy is to record contingent consideration when the contingency
is resolved and, therefore, it is generally excluded from the cost of the acquisition. Further, the contingent consideration comprising
monthly milestone payments does not meet the definition of a derivative and, therefore, is not required to be recorded at fair value.
The fair value of the net assets acquired exceeded the initial cash payments for the purchase, resulting in the write-down of the intangible
assets acquired and the recognition of a contingent consideration liability for the excess of the fair value of the inventory acquired
over the initial cash consideration. Future monthly milestone payments will reduce the contingent consideration liability until it has
been satisfied in full, and then will be recognized as a period cost when incurred. The Company incurred $<span id="xdx_906_ecustom--MilestonePayments_pn3n3_c20240101__20241231__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zRiN36SPa5T" title="Milestone payments"><ix:nonFraction name="CELU:MilestonePayments" contextRef="From2024-01-012024-12-31_custom_SequenceLifeScienceIncMember" id="Fact001009" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></span> of milestone payments based
on collections of net sales of Rebound for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001011" name="us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock"><p id="xdx_89C_eus-gaap--AssetAcquisitionContingentConsiderationTableTextBlock_zWprWttZeAY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
purchase price was allocated to the acquired assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span id="xdx_8B0_zhki8gkWMykj" style="display: none">Schedule of Purchase Price
Allocated to Acquired Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zhZC3kVIpmUd" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Consideration:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pn3n3_zTu4rAjBYes1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 81%; text-align: left">Cash payment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><ix:nonFraction name="us-gaap:PaymentsToAcquireOtherProductiveAssets" contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember" id="Fact001013" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_pn3n3_zL14qSuNb2r3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Contingent consideration</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember" id="Fact001015" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">650</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferred_iT_pn3n3_zpdDNHBxCcL8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total consideration</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetAcquisitionConsiderationTransferred" contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember" id="Fact001017" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,150</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Assets acquired:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iE_pn3n3_z30MMVIHKErb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" contextRef="AsOf2024-10-09_custom_SequenceLifeScienceIncMember" id="Fact001019" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,150</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iE_pn3n3_zbTaf1s3DQO8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets acquired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="AsOf2024-10-09_custom_SequenceLifeScienceIncMember" id="Fact001021" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,150</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zuJTYBOM6t42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 105 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001023" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_z6SiLsoMDCHh" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b>4. <span id="xdx_827_ztEHcNuV4JL4">Fair Value of Financial Assets and Liabilities</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001025" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmb9PfWUKqwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following tables present information about
the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value
hierarchy used to determine such fair values:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span id="xdx_8B0_zIQ9WZasChz3" style="display: none">Schedule of Financial Assets and Liabilities Measures at Fair Value</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzdSkuVcoJR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKzHQVU6Tj2h" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zApwOvikycBa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIXAcRbJ3x5d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements as of December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zdMFe61yvfVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zWYNCb0WUnu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001034" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,413</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001035" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,413</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zd4svOi91Nf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1037">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ContingentStockConsideration" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001039" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ContingentStockConsideration" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001040" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zwUGyLIeWUPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - Yorkville</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShorttermDebtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001044" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,865</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShorttermDebtFairValue" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001045" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,865</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ShorttermDebtUnsecuredSeniorConvertibleNotes_i01I_pn3n3_z0t3w7QzYWHl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - unsecured senior convertible notes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001049" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">620</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001050" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">620</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zUynWyqYoAzl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - July 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrantsTwo" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001054" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,115</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrantsTwo" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001055" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,115</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_zWEc9xjtmMs6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - April 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001059" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,022</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001060" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,022</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zUq07lyItO7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - May 2022 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001064" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">505</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">505</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--WarrantLiabilityPurchaserWarrants_i01I_pn3n3_z2PtyNiQlTp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - November 2024 Purchaser Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1068">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPurchaserWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">278</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPurchaserWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">278</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityPlacementAgentWarrants_i01I_pn3n3_zNBg7V0hk4Dh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - November 2024 Placement Agent Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1073">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPlacementAgentWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPlacementAgentWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_za5eSpLRTsAh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - Sponsor Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1077">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilitySponsorWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001079" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilitySponsorWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zKkeFd1iCppf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability - Public Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPublicWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="Fact001082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1083">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPublicWarrants" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001085" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zGTzThLR8fVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    fair value liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="Fact001087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">287</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1088">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,902</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,189</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 106 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuoNHfmxmcGg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_499_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj5R1lOBqXD3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsIIUtxsRVa2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBOWcqsAuqA1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zT3saKyHg636" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ReceivablesFairValueDisclosure_i01I_pn3n3_zIP15TdqERni" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt; width: 44%; text-align: left">Convertible note receivable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ReceivablesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,072</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ReceivablesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,072</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_i01TI_pn3n3_zsY9iNcyNuOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    fair value assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,072</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,072</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zDRifOTUMxqb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zqB1icF8FiQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001114" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,606</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001115" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,606</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zS4112ALhre2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ContingentStockConsideration" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001119" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ContingentStockConsideration" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zvY5jqAgnAgk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - Yorkville</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShorttermDebtFairValue" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001124" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,223</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShorttermDebtFairValue" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001125" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,223</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zmNieavx7vW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - July 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1127">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrantsTwo" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001129" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,529</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrantsTwo" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,529</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_ziPEtsdI1uv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - April 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1132">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,487</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityRegisteredDirectWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,487</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zhq8ZtQ6e1K1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - May 2022 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1137">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">708</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">708</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_zkMudQLWnIg6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - Sponsor Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1142">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1143">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilitySponsorWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilitySponsorWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001145" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">60</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zcieF696gda1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt; text-align: left">Warrant liability - Public Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPublicWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="Fact001147" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">575</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1148">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:WarrantLiabilityPublicWarrants" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001150" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">575</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zDNkMAT9gqOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    fair value liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" id="Fact001152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">575</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member" id="Fact001154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,640</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact001155" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,215</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zf4pa8jSTNo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the years ended December
31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The carrying values of other current
liabilities approximate fair value in the accompanying consolidated financial statements due to the short-term nature of those instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Valuation of Convertible Note Receivable</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The convertible note receivable
was received in connection with the disposition of the UltraMIST/MIST business in 2020. At any time on or after January 1, 2021, at the
sole discretion of the Company, amounts outstanding under the convertible note receivable (including accrued interest) may be converted
into Sanuwave common stock at a defined rate. The convertible note receivable was to be paid on or before August 6, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On December 18, 2023, the Company
entered into a forbearance agreement with Sanuwave (&#8220;Sanuwave Forbearance Agreement&#8221;). Per the Sanuwave Forbearance Agreement,
from the period from December 18, 2023 to the earliest of (i) February 28, 2024, (ii) the commencement of bankruptcy proceedings for Sanuwave
pursuant to the U.S. Bankruptcy Code, (iii) the occurrence of an event of default other than payment default, or (iv) the failure of Sanuwave
to comply with any term, condition or covenant set forth in the forbearance agreement, the Company agrees that it will not exercise any
remedy available to it under the convertible note receivable, excluding the right to increase the interest rate. As collateral for payments
owed to Palantir Technologies, Inc. (&#8220;Palantir&#8221;), the Company assigned to Palantir the Sanuwave convertible note receivable
in the event of default (see Note 12). On May 10, 2024, the Company entered into a letter agreement with Sanuwave to extend the forbearance
period from <span id="xdx_902_ecustom--ForbearanceExtendMaturityPeriod_dd_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zXnAEax64Pjb" title="Forbearance extend period"><ix:nonNumeric contextRef="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_srt_MinimumMember_custom_LetterAgreementMember" format="ixt:datemonthdayyearen" id="Fact001157" name="CELU:ForbearanceExtendMaturityPeriod">February 28, 2024</ix:nonNumeric></span> to <span id="xdx_90C_ecustom--ForbearanceExtendMaturityPeriod_dd_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zDmq86VPpjEd" title="Forbearance extend period"><ix:nonNumeric contextRef="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_srt_MaximumMember_custom_LetterAgreementMember" format="ixt:datemonthdayyearen" id="Fact001159" name="CELU:ForbearanceExtendMaturityPeriod">June 3, 2024</ix:nonNumeric></span>. The letter agreement increased the total note payments to $<span id="xdx_90A_ecustom--IncreasedNotePayments_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zlhdWpGFG3v3" title="Increased total note payments"><ix:nonFraction name="CELU:IncreasedNotePayments" contextRef="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_custom_LetterAgreementMember" id="Fact001161" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,175</ix:nonFraction></span>. Upon executing the letter
agreement, Sanuwave made an initial note payment of $<span id="xdx_90B_eus-gaap--RepaymentsOfNotesPayable_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zrJiqYunjp3e" title="Initial note payment"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_custom_LetterAgreementMember" id="Fact001163" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span> and on June 3, 2024, made a second note payment of $<span id="xdx_90F_eus-gaap--RepaymentsOfNotesPayable_pn3n3_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zQAlStmKJ8z6" title="Note payment"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2024-06-032024-06-03_custom_SanuwaveForbearanceAgreementMember_custom_LetterAgreementMember" id="Fact001165" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,075</ix:nonFraction></span>, fully discharging
all outstanding indebtedness under the note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001167" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z8ZzFNHpUFr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of the convertible note receivable measured on a recurring basis using Level 3 inputs for the year ended December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"><span id="xdx_8B9_zFErd4Rfj6ak" style="display: none">Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1, 2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of) </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Convertible note receivable</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ReceivablesFairValueDisclosure_iS_pn3n3_c20240101__20241231_zOLLVDccNtha" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ReceivablesFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact001169" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,072</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3n3_c20240101__20241231_zaj2eaLR5NPk" title="Net transfers into (out of) Level 3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231_z9GFUYXI1Ohb" title="Purchases, settlements and other net" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" contextRef="From2024-01-01to2024-12-31" id="Fact001173" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,072</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20240101__20241231_zVAfHEi1grW8" title="Fair value adjustments" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1175">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ReceivablesFairValueDisclosure_iE_pn3n3_c20240101__20241231_zqGG7pp5j9Qf" title="Ending balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1177">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zFfljS9cMqYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At December 31, 2023, the fair
value of this note was based on a bond valuation which employs a credit default model. The Company utilized Level 3 inputs on a probability
weighted model based on outcomes of a default, repayment and conversion of the note. The measurement was based upon unobservable inputs
supported by little or no market activity based on the Company&#8217;s own assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 107 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001179" name="CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock"><p id="xdx_89B_ecustom--ScheduleOfConvertibleNoteValuationModelTableTextBlock_z7EuHh2GNVD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the convertible
note valuation model were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zacK0CQDrUZ7" style="display: none">Schedule of Convertible
Note Valuation Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Face value</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FaceValueOfNotesReceivable_iI_pn3n3_c20231231_zmau9GTs49T6" title="Face value" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="CELU:FaceValueOfNotesReceivable" contextRef="AsOf2023-12-31" id="Fact001181" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Coupon rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20231231__20231231__srt--RangeAxis__srt--MinimumMember_zCS9azBSfThe" title="Coupon rate"><ix:nonFraction name="CELU:PercentageOfCouponRate" contextRef="From2023-12-312023-12-31_srt_MinimumMember" id="Fact001183" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.00</ix:nonFraction></span>% - <span id="xdx_90E_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20231231__20231231__srt--RangeAxis__srt--MaximumMember_zkO4ImOn8EX3" title="Coupon rate"><ix:nonFraction name="CELU:PercentageOfCouponRate" contextRef="From2023-12-312023-12-31_srt_MaximumMember" id="Fact001185" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17.00</ix:nonFraction></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231_zwuj6HzjR2aa" title="Stock price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31" id="Fact001187" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.2</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20231231__20231231__srt--RangeAxis__srt--MinimumMember_zDUEeNif64j5" title="Term (years)"><ix:nonNumeric contextRef="From2023-12-312023-12-31_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001189" name="CELU:ValuationInputForConvertiblePromissoryNoteTerm">0.51</ix:nonNumeric></span>-<span id="xdx_90B_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20231231__20231231__srt--RangeAxis__srt--MaximumMember_z4mH3Z1StVXc" title="Term (years)"><ix:nonNumeric contextRef="From2023-12-312023-12-31_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001191" name="CELU:ValuationInputForConvertiblePromissoryNoteTerm">2.45</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ValuationInputForConvertiblePromissoryNote_pid_dp_uPure_c20231231__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZA4dA31wVBa" title="Risk-free interest rate"><ix:nonFraction name="CELU:ValuationInputForConvertiblePromissoryNote" contextRef="From2023-12-312023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001193" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.47</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">n/a</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zdApwdr2DKp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Valuation of Contingent Consideration</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value measurement of
the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted income approach. The
measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s own assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember" escape="true" id="Fact001195" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_hus-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_z6CBmcdOyEgk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs for the years ended December
31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zHZbPLTYsDQe" style="display: none">Schedule
of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_134_zNw4XXVgHO08" summary="xdx: Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zYJsuLNyjdMk" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember" id="Fact001197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,606</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zDRjxdHhzJ88" title="Net transfers into (out of) Level 3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zmmUuDNaRxni" title="Purchases, settlements and other net" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1201">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zVEsLod7WOd" title="Fair value adjustments" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2024-01-012024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember" id="Fact001203" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">193</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zt8vlGcR6nXk" title="Ending balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember" id="Fact001205" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,413</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_134_zNC3CdBWLkj4" summary="xdx: Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zgKVqS6FHds4" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember" id="Fact001207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">105,945</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zh3XTRHRkxY3" title="Net transfers into (out of) Level 3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1209">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_z2ZvNt2EbTS3" title="Purchases, settlements and other net" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zSMQPI9PFEGc" title="Fair value adjustments" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember" id="Fact001213" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">104,339</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zN0pxvdHgzl" title="Ending balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember" id="Fact001215" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,606</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zWSf8A9lYiW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of the liability
to make potential future milestone and earn-out payments was estimated by the Company at each reporting date based, in part, on the results
of a third-party valuation using a discounted cash flow analysis based on various assumptions, including the probability of achieving
specified events, discount rates, and the period of time until earn-out payments are payable and the conditions triggering the milestone
payments are met. The actual settlement of contingent consideration could differ from current estimates based on the actual occurrence
of these specified events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At each reporting date, the Company
revalues the contingent consideration obligation to estimated fair value and records changes in fair value as income or expense in the
Company&#8217;s consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent consideration
obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in
probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations. The Company has
classified the contingent consideration as a long-term liability in the consolidated balance sheets as of December 31, 2024 and 2023.
See Note 12 for more information on contingent consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Valuation of Contingent Stock Consideration</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The contingent stock consideration
liability at December 31, 2024 and 2023 is comprised of the fair value of potential future issuance of Class A common stock to CariCord
participating shareholders pursuant to a settlement agreement signed during the year ended December 31, 2021. The fair value measurement
of the contingent stock consideration obligation is determined using Level 3 inputs and is based on a probability-weighted expected return
methodology (&#8220;PWERM&#8221;). The measurement is largely based upon unobservable inputs supported by little or no market activity
based on the Company&#8217;s own assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 108 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_ContingentStockConsiderationMember" escape="true" id="Fact001217" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_896_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_hus-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrgIdd6CCJ6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level 3 inputs for the years ended
December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zyurDf37iSEl" style="display: none">Schedule
of Reconciliation of  Contingent  Consideration Obligation Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_134_zW1PSCMU8oc9" summary="xdx: Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1, 2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of) </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zREGJY4dLpHc" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_custom_ContingentStockConsiderationMember" id="Fact001219" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zDZshqLpWFv5" title="Net transfers into (out of) Level 3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1221">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_za5rNgaSgQaf" title="Purchases, settlements and other net" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1223">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrSf4Fxc8xB1" title="Fair value adjustments" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1225">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zM7E2M5RFyVj" title="Ending balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2024-12-31_custom_ContingentStockConsiderationMember" id="Fact001227" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_134_zeyYDCS4uIO6" summary="xdx: Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1, 2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of) </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zeV8B7OeS81" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2022-12-31_custom_ContingentStockConsiderationMember" id="Fact001229" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">186</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrmPNoNkTqsk" title="Net transfers into (out of) Level 3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1231">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_z6uT9Pz8O09c" title="Purchases, settlements and other net" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1233">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zfkuwXI8oiMf" title="Fair value adjustments" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" contextRef="From2023-01-012023-12-31_custom_ContingentStockConsiderationMember" id="Fact001235" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">159</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zF6YQa9MfQzk" title="Ending balance" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="AsOf2023-12-31_custom_ContingentStockConsiderationMember" id="Fact001237" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_z9KCGkZoOW81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of the liability
to issue future shares of Class A common stock was estimated by the Company at each reporting date using a PWERM based on various inputs
and assumptions, including the Company&#8217;s common share price, discount rates, and the probability of achieving specified future operational
targets. The actual settlement of contingent stock consideration could differ from current estimates based on the actual achievement of
these specified targets and movements in the Company&#8217;s common share price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At each reporting date, the Company
revalues the contingent stock consideration obligation to estimated fair value and records changes in fair value as income or expense
in the Company&#8217;s consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent stock
consideration obligation may result from changes in discount rates, changes in the Company&#8217;s common share price, and changes in
probability assumptions with respect to the likelihood of achieving specified operational targets. The change in the fair value of the
contingent stock consideration obligation during the year ended December 31, 2024 was de minimis. The Company has classified the contingent
stock consideration as a current liability in the consolidated balance sheets as of December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Valuation of Short-Term Debt - Yorkville and
Unsecured Senior Convertible Notes </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company elected the fair value
option to account for the Yorkville PPA signed on September 15, 2022 (see Note 10). As of December 31, 2023, due to the short-term nature
of the debt, the fair value of the Yorkville PPA approximated the settlement amount, which was fully paid on January 17, 2024. The Company
also elected the fair value option to account for the Yorkville convertible promissory note signed on March 13, 2024 (see Note 10) and
the unsecured senior convertible notes issued pursuant to the securities purchase agreement signed on November 25, 2024 (see Note 10).
The fair value measurement of the debt is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair
value of debt that is accounted for at fair value, inclusive of related accrued interest expense, are presented as gains or losses in
the accompanying consolidated statements of operations and comprehensive loss under change in fair value of debt. The portion of total
changes in fair value of debt attributable to changes in instrument-specific credit risk are determined through specific measurement of
periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive loss
in the accompanying consolidated statements of operations and comprehensive loss. The actual settlement of the short-term debt could differ
from current estimates based on the timing of when and if the investors elect to convert amounts into common shares, potential cash repayment
by the Company prior to maturity, and movements in the Company&#8217;s common share price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 109 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001239" name="CELU:FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"><p id="xdx_89A_ecustom--FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zf0Q2VjZAwu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of short-term debt obligations measured on a recurring basis using Level 3 inputs for the years ended December 31, 2023
and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span id="xdx_8BE_zNNatWJYUOr5" style="display: none">Schedule of Reconciliation
of Short-term Debt Obligation Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zVKESrallsn9" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2022-12-31_custom_YorkvilleMember" id="Fact001241" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,603</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Conversion of debt into common shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zhvrNP5gY3L3" title="Conversion of debt into common shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember" id="Fact001243" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,599</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Principal repayments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zS1dpiGcM6gi" title="Principal repayments" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember" id="Fact001245" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">16,811</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of convertible promissory note</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4ULDL8Mjadd" title="Issuance of convertible promissory note" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" contextRef="From2024-01-012024-12-31_custom_YorkvilleMember" id="Fact001247" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,150</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of unsecured senior convertible notes, net of fair value adjustment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zeX9B9QAWsp8" title="Issuance of unsecured senior convertible notes, net of fair value adjustment" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" contextRef="From2024-01-012024-12-31_custom_YorkvilleMember" id="Fact001249" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Fair value adjustment through earnings</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueAdjustmentThroughEarnings_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zFZNR5QOZBYa" title="Fair value adjustment through earnings" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:FairValueAdjustmentThroughEarnings" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember" id="Fact001251" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">354</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Fair value adjustment through accumulated other comprehensive income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zhNjeaH9OFa5" title="Fair value adjustment through accumulated other comprehensive income" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember" id="Fact001253" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">146</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustment through interest accrual</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zLErIKWgnKOd" title="Fair value adjustment through interest accrual" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember" id="Fact001255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">822</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zqe7Y2DTYfic" title="Ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2023-12-31_custom_YorkvilleMember" id="Fact001257" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,223</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zGRO4GIysI72" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2023-12-31_custom_YorkvilleMember" id="Fact001259" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,223</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Principal repayments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zF9UaBSzflMi" title="Principal repayments" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="From2024-01-012024-12-31_custom_YorkvilleMember" id="Fact001261" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">17,374</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of convertible promissory note</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zFAaasce3Mwe" title="Issuance of convertible promissory note" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" contextRef="From2024-01-012024-12-31_custom_YorkvilleMember" id="Fact001263" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,150</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of unsecured senior convertible notes, net of fair value adjustment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zxqiZcy4m6dd" title="Issuance of unsecured senior convertible notes, net of fair value adjustment" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" contextRef="From2024-01-012024-12-31_custom_YorkvilleMember" id="Fact001265" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Conversion of debt into common shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zz2hQxzRVtKe" title="Conversion of debt into common shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" contextRef="From2024-01-012024-12-31_custom_YorkvilleMember" id="Fact001267" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Fair value adjustment through earnings</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--FairValueAdjustmentThroughEarnings_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4SqkTJzQf1" title="Fair value adjustment through earnings" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:FairValueAdjustmentThroughEarnings" contextRef="From2024-01-012024-12-31_custom_YorkvilleMember" id="Fact001269" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">492</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustment through accumulated other comprehensive income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zvPuDmokQ0b4" title="Fair value adjustment through accumulated other comprehensive income" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" contextRef="From2024-01-012024-12-31_custom_YorkvilleMember" id="Fact001271" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zbWbs4csl4Af" title="Ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-12-31_custom_YorkvilleMember" id="Fact001273" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zmIi29t9N328" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair values of the Yorkville
convertible promissory note and the unsecured senior convertible notes are based on valuations which employ a Monte Carlo model and a
credit default model. The Company utilized Level 3 inputs in a probability weighted model based on outcomes of a default, repayment and
conversion of the notes. The measurements are based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s
own assumptions. The fair value of the Yorkville convertible promissory note on March 13, 2024, the date of issuance, was $<span id="xdx_906_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn3n3_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_z71AsINP3rd" title="Maximum advance amount"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember" id="Fact001275" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,993</ix:nonFraction></span> and the
aggregate fair value of the unsecured senior convertible notes at the dates of issuance was $<span id="xdx_90B_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn3n3_c20241125__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zZOnHRxRc5gl" title="Fair value of notes"><ix:nonFraction name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="AsOf2024-11-25_custom_YorkvilleMember_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001277" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">689</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember" escape="true" id="Fact001279" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zfo8uakP2dzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the Yorkville
convertible promissory note valuation model were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"><span id="xdx_8B8_zRmKbrmT24b3" style="display: none">Schedule
of Yorkville Convertible Promissory Note Valuation Model</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_134_zOfiwpenfdxc" summary="xdx: Disclosure - Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 13, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zMqZRp1rMQYk" title="Common share price" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember" id="Fact001281" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.08</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zxs1LosLo8fc" title="Common share price" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.79</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Credit spread</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zLvvUhVDsDF6" title="Credit spread" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputCreditSpreadMember" id="Fact001285" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_z2IzhynUZUB2" title="Credit spread" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputCreditSpreadMember" id="Fact001287" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">8.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVV2H3Upm6yl" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001289" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_dp_uPure_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z6Ks0qa9vmYi" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001291" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtY_c20241231__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_ztu2y3fZZrcd" title="Term (years)"><ix:nonNumeric contextRef="From2024-12-312024-12-31_custom_ConvertiblePromissoryNotesMember" format="ixt-sec:duryear" id="Fact001293" name="us-gaap:DebtInstrumentTerm">0.20</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtY_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zs1dCz38dpKc" title="Term (years)"><ix:nonNumeric contextRef="From2024-03-132024-03-13_custom_ConvertiblePromissoryNotesMember" format="ixt-sec:duryear" id="Fact001295" name="us-gaap:DebtInstrumentTerm">1.00</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zemIL64A3Sa" title="Risk-free interest rate" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ConvertiblePromissoryNotesMember" id="Fact001297" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.30</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zZvfYkcT7fZa" title="Risk-free interest rate" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-03-13_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ConvertiblePromissoryNotesMember" id="Fact001299" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.90</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zdfWGeHfU5fc" title="Volatility" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ConvertiblePromissoryNotesMember" id="Fact001301" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">50.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_z2aDlnnw0YM2" title="Convertible promissory note valuation measurement" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-03-13_us-gaap_MeasurementInputPriceVolatilityMember_custom_ConvertiblePromissoryNotesMember" id="Fact001303" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">50.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zlQo6qILlvDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 110 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_UnsecuredSeniorConvertibleNotesMember" escape="true" id="Fact001305" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"><p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zTvux3YbDZIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the unsecured
senior convertible notes valuation model were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zk68lVch4AYc" style="display: none">Schedule of Convertible Notes Valuation Model</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_134_zKMHyYVPLnzg" summary="xdx: Disclosure - Schedule of Convertible Notes Valuation Model (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">November
    25, 2024 and December 3, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance) (1)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zZTqX6286Cd2" title="Common share price" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001307" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.08</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-size: 10pt">$<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zLdyZuROQD85" title="Common share price"><span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zxflIT1IHQzd" title="Common share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember" id="Fact001309" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember" id="Fact001311" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></ix:nonFraction></span></span> - $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zSgBqNNguSpi" title="Common share price"><span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zyuD3A9OV6wd" title="Common share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember" id="Fact001313" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember" id="Fact001315" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Credit spread</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zVDI4VzbsIQg" title="Credit spread" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember" id="Fact001317" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.6</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z2uQH62zK8ig" title="Credit spread"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zAh06WBCci26" title="Credit spread"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MinimumMember" id="Fact001319" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MinimumMember" id="Fact001321" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">6.9</ix:nonFraction></ix:nonFraction></span></span>% - <span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zhhrcNJelGa" title="Credit spread"><span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zEAsIfUYXqM8" title="Credit spread"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MaximumMember" id="Fact001323" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MaximumMember" id="Fact001325" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.2</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJd7tlAjGaLh" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001327" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zUGtc8ylboFa" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zkkpx6rrEkKj" title="Dividend yield"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentTerm_dtY_c20241231__20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zMbKtC0UigYg" title="Term (years)"><ix:nonNumeric contextRef="From2024-12-312024-12-31_custom_UnsecuredSeniorConvertibleNotesMember" format="ixt-sec:duryear" id="Fact001333" name="us-gaap:DebtInstrumentTerm">0.90</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z7jKIqN6Tg8" title="Term (years)"><span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_c20241203__20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zALKmgbTgC79" title="Term (years)"><ix:nonNumeric contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001335" name="us-gaap:DebtInstrumentTerm"><ix:nonNumeric contextRef="From2024-12-032024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001337" name="us-gaap:DebtInstrumentTerm">0.98</ix:nonNumeric></ix:nonNumeric></span></span> - <span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zRqleYV3qTCj" title="Term (years)"><span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20241203__20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zSRZYbnhzw84" title="Term (years)"><ix:nonNumeric contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001339" name="us-gaap:DebtInstrumentTerm"><ix:nonNumeric contextRef="From2024-12-032024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001341" name="us-gaap:DebtInstrumentTerm">1.00</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zMy7V7zPVt29" title="Risk-free interest rate" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001343" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.20</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zjoNobOYO79f" title="Risk-free interest rate"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zmpMbwWuLrza" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember" id="Fact001345" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-03_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember" id="Fact001347" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.30</ix:nonFraction></ix:nonFraction></span></span>% - <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zifSE1MeQCfg" title="Risk-free interest rate"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zMydr8j9YtB2" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-03_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember" id="Fact001351" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.40</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zvRQnJF2wXA" title="Volatility" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001353" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">50.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_fKDEp_zSsteMh4V2u4" title="Unsecured senior convertible notes valuation measurement" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zrJk7b2gmGN7" title="Unsecured senior convertible notes valuation measurement"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-11-25_us-gaap_MeasurementInputPriceVolatilityMember_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001355" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001357" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">50.0</ix:nonFraction></ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td id="xdx_F0A_zCJMq6KSn8i4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td>
  <td id="xdx_F1A_z0jldVQDcmsl" style="font: 10pt Times New Roman, Times, Serif"><ix:footnote id="Footnote001358" xml:lang="en-US">As discussed
in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.</ix:footnote></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A1_zwmcYL5ZJcT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Valuation of Warrant Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The warrant liability at December
31, 2024 is comprised of the fair value of warrants to purchase shares of Class A common stock. The Public Warrants are recorded at fair
value based on the period-end publicly stated close price, which is a Level 1 input. The January 2024 Bridge Loan - Tranche #2 Warrants
(prior to reclassification to equity classified) and November 2024 Purchaser Warrants and Placement Agent Warrants were recorded at fair
value based on a Monte Carlo simulation model and the Registered Direct, PIPE and Sponsor Warrants are recorded at their respective closing
date fair values based on a Black-Scholes option pricing model that utilizes inputs for: (i) the value of the underlying asset, (ii) the
exercise price, (iii) the risk-free rate, (iv) the volatility of the underlying asset, (v) the dividend yield of the underlying asset
and (vi) maturity, which are Level 3 inputs. The Black-Scholes option pricing model&#8217;s primary unobservable input utilized in determining
the fair values of the warrant liabilities is the expected volatility of the Class A common stock. Prior to the merger, Legacy Celularity
was a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, the Company
estimates its expected stock price volatility using its volatility since the merger and the historical volatility of publicly traded peer
companies. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal
to the estimated remaining term of the warrants. Inputs to the Monte Carlo and Black-Scholes option pricing models for the warrants are
updated each reporting period to reflect fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001360" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"><p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zjyFz6XDPKI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">The following table presents
a reconciliation of the warrant liabilities measured on a recurring basis using Level 3 inputs for the years ended December 31, 2024 and
2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"><span id="xdx_8B5_zcldbup38v16" style="display: none">Schedule
of Reconciliation of Warrant Liabilities Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueNetAssetLiability_iS_pn3n3_c20230101__20231231_zv83jol6Vrw8" title="Fair value, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2022-12-31" id="Fact001362" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,598</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">April 2023 Registered Direct warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--RegisteredDirectWarrantsIssuance_pn3n3_c20230101__20231231_zYQSGJmIAR0e" title="April 2023 Registered Direct warrant issuance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:RegisteredDirectWarrantsIssuance" contextRef="From2023-01-012023-12-31" id="Fact001364" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,280</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">July 2023 Registered Direct warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--RegisteredDirectWarrantIssuanceDuringJuly_pn3n3_c20230101__20231231_zNAbj1Ln54fc" title="July 2023 Registered Direct warrant issuance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:RegisteredDirectWarrantIssuanceDuringJuly" contextRef="From2023-01-012023-12-31" id="Fact001366" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,645</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">January 2024 Bridge Loan - Tranche #2 warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20241231_zzrHJqazzILl" title="January 2024 Bridge Loan - Tranche #2 warrant issuance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:BridgeLoanAndWarrantIssuanceTrancheTwo" contextRef="From2024-01-01to2024-12-31" id="Fact001368" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,858</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Purchaser warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--PurchaserWarrantIssuance_pn3n3_c20240101__20241231_zRQhynbDgJS7" title="November 2024 Purchaser warrant issuance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:PurchaserWarrantIssuance" contextRef="From2024-01-01to2024-12-31" id="Fact001370" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">354</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Placement Agent warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--PlacementAgentWarrantIssuance_pn3n3_c20240101__20241231_zQ8q8BnPHXC9" title="November 2024 Placement Agent warrant issuance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:PlacementAgentWarrantIssuance" contextRef="From2024-01-01to2024-12-31" id="Fact001372" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Gain recognized in earnings from change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20230101__20231231_zSfHqRBVumY4" title="Gain recognized in earnings from change in fair value" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:GainLossRecognizedInEarningsFromChangeInFairValues" contextRef="From2023-01-012023-12-31" id="Fact001374" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,164</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reclassification of warrants from liability classified to equity classified</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_iN_pn3n3_di_c20240101__20241231_zAYvgaG8wXdd" title="Reclassification of warrants from liability classified to equity classified" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" contextRef="From2024-01-01to2024-12-31" id="Fact001376" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,970</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iE_pn3n3_c20230101__20231231_zsJoXuGoalyj" title="Fair Value, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FairValueNetAssetLiability" contextRef="AsOf2023-12-31" id="Fact001378" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,359</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--FairValueNetAssetLiabilities_iS_pn3n3_c20240101__20241231_zupYiVyrn6Fh" title="Fair value, Beginning Balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="CELU:FairValueNetAssetLiabilities" contextRef="AsOf2023-12-31" id="Fact001380" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,784</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">January 2024 Bridge Loan - Tranche #2 warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20241231_zL4C51rZusf7" title="January 2024 Bridge Loan - Tranche #2 warrant issuance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:BridgeLoanAndWarrantIssuanceTrancheTwo" contextRef="From2024-01-01to2024-12-31" id="Fact001382" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,858</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Purchaser warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--PurchaserWarrantIssuance_pn3n3_c20240101__20241231_zYqRQrDzXBv6" title="November 2024 Purchaser warrant issuance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:PurchaserWarrantIssuance" contextRef="From2024-01-01to2024-12-31" id="Fact001384" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">354</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Placement Agent warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--PlacementAgentWarrantIssuance_pn3n3_c20240101__20241231_zm7Vjh1Xt2z4" title="November 2024 Placement Agent warrant issuance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:PlacementAgentWarrantIssuance" contextRef="From2024-01-01to2024-12-31" id="Fact001386" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Gain recognized in earnings from change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20240101__20241231_zzkmZsqcwQ4j" title="Gain recognized in earnings from change in fair value" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:GainLossRecognizedInEarningsFromChangeInFairValues" contextRef="From2024-01-01to2024-12-31" id="Fact001388" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">110</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reclassification of warrants from liability classified to equity classified</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_iN_pn3n3_di_c20240101__20241231_zofKHTbfU5sj" title="Reclassification of warrants from liability classified to equity classified" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" contextRef="From2024-01-01to2024-12-31" id="Fact001390" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,970</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_ecustom--FairValueNetAssetLiabilities_iE_pn3n3_c20240101__20241231_zFbzS9y3Xwj9" title="Fair Value, Ending Balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:FairValueNetAssetLiabilities" contextRef="AsOf2024-12-31" id="Fact001392" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,977</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_znYBXzYrM7dl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 111 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" escape="true" id="Fact001394" name="CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock"><p id="xdx_894_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z4HlKRmYDho4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the May
2022 PIPE Warrants and the 2023 Registered Direct Warrants were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BC_zoUjs92MHBnc" style="display: none">Schedule of May 2022 PIPE
Warrants and 2023 Registered Direct Warrants</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_134_zEHOvFR1Mwhi" summary="xdx: Disclosure - Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z6PG08ySPr5l" title="Common share price" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" id="Fact001396" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.08</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zCRK8jT4vjC4" title="Common share price" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" id="Fact001398" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.47</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zmEvPrAz9hM7" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember" id="Fact001400" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></span>
- $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zfUk6mHWWwNh" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember" id="Fact001402" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.50</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zrMGli18XHq9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember" id="Fact001404" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></span>
- $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zJWdhbVywlOe" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember" id="Fact001406" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.50</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxGV7EC1yBg3" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001408" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zEmedH3Yxuyi" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001410" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zqqmdDhqA1F1" title="Term (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001412" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.78</ix:nonNumeric></span> - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zAioW97a69J8" title="Term (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001414" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.09</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zcGSO7wcj1H1" title="Term (years)"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001416" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.03</ix:nonNumeric></span> - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zYPkZGeS1hv" title="Term (years)"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001418" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.34</ix:nonNumeric></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxzAXW7Iyqv5" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001420" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.3</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBP1NbAdcYS3" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001422" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.60</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zGKerOI6ie58" title="Warrant and right outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001424" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">98.5</ix:nonFraction></span>%
- <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zqXn656Hh2Rf" title="Warrant and right outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001426" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">98.8</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmDWrMaUJ0jg" title="Warrant and right outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001428" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">97.0</ix:nonFraction></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zOTYWDqRSdrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" escape="true" id="Fact001430" name="CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zTcYeIkClw3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the January
2024 Bridge Loan - Tranche #2 Warrants were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zZ0un3uuJzJ" style="display: none">Schedule
of January 2024 Bridge Loan</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_134_zfYZtbJYHUCe" summary="xdx: Disclosure - Schedule of January 20224 Bridge Loan (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">July 15, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">January 16, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(reclassification)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zAbhamf6yZW" title="Common share price" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" id="Fact001432" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.19</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_z64Ma4fo2Mof" title="Common share price" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" id="Fact001434" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term to initial exercise date (years) (1)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">N/A</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingTermToInitialExerciseDate_dtY_c20240116__20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_fKDEp_zcXnJ9apWTCk" title="Term to initial exercise date (years)"><ix:nonNumeric contextRef="From2024-01-162024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" format="ixt-sec:duryear" id="Fact001436" name="CELU:WarrantsAndRightsOutstandingTermToInitialExerciseDate">0.50</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z7VZpfBBKDAf" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001438" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zUspIO83bWra" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001440" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zTUh2p0IL1h4" title="Term (years)"><ix:nonNumeric contextRef="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" format="ixt-sec:duryear" id="Fact001442" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.0</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zmJhZgZn5kze" title="Term (years)"><ix:nonNumeric contextRef="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" format="ixt-sec:duryear" id="Fact001444" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.0</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zQtJ5evwm8fl" title="Risk-free interest rate" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001446" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zE6CO87NoSzj" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001448" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.90</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_za4iYSViZnu7" title="Warrant and right outstanding measurement input" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001450" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">112.5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxyeuyuk4Ic8" title="Warrants measurement input" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001452" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">107.5</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td id="xdx_F04_z71VMIls35L4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td>
  <td id="xdx_F13_zKhae20pVIZ5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:footnote id="Footnote001453" xml:lang="en-US">As discussed
further in Note 10, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July
15, 2024, the warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the
Company&#8217;s own stock. As such, the warrants were adjusted to fair value as of the initial exercise date and then reclassified from
liability classified to equity classified.</ix:footnote></td></tr>
</table>

</ix:nonNumeric><p id="xdx_8AC_zpGW3SKSXqB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" escape="true" id="Fact001455" name="CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zvnUoeoQ9v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the November
2024 Purchaser and Placement Agent Warrants were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_ztlx07gIa4l1" style="display: none">Schedule of November 2024
Purchaser and Placement Agent Warrants</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_134_zf71QPEgAjk3" summary="xdx: Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">November
    25, 2024 And December 3, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance) (1)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zfGGfYtsJZbc" title="Common share price" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" id="Fact001457" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.08</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z46kT17Xe09" title="Common share price"><span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zdPSTTIBsnPg" title="Common share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember" id="Fact001459" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember" id="Fact001461" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.00</ix:nonFraction></ix:nonFraction></span></span> - $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zUBNXIdNreje" title="Common share price"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zD6q4W4va4Ei" title="Common share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember" id="Fact001463" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember" id="Fact001465" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction></ix:nonFraction></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term to Subsequent Financing (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDEp_zWcgJBsQJeA1" title="Term to Subsequent Financing (years)"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact001467" name="CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing">0.1</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241125__20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zwMw4iO8pdL4" title="Term to Subsequent Financing (years)"><span id="xdx_90F_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241203__20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zsMAnpTzZCy9" title="Term to Subsequent Financing (years)"><ix:nonNumeric contextRef="From2024-11-252024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001469" name="CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing"><ix:nonNumeric contextRef="From2024-12-032024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001471" name="CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing">0.1</ix:nonNumeric></ix:nonNumeric></span></span> &#8211; <span id="xdx_90F_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241125__20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zaZtsaHXQC6i" title="Term to Subsequent Financing (years)"><span id="xdx_90B_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241203__20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_znGABSFOpMX3" title="Term to Subsequent Financing (years)"><ix:nonNumeric contextRef="From2024-11-252024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001473" name="CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing"><ix:nonNumeric contextRef="From2024-12-032024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001475" name="CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing">0.6</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_z2ubyhNq9aP1" title="Exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1477">-</span></span></span><span style="font-size: 10pt">(2)
                                            (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_zNuCSAwlQxbb" title="Exercise price"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_zTugOBVBSw2" title="Exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1479"><span style="-sec-ix-hidden: xdx2ixbrl1481">-</span></span></span></span></span><span style="font-size: 10pt">(2)
                                            (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zyra5DSUeNdi" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001483" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zqTqJDZCG9w8" title="Dividend yield" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zlYgUJDN3XN2" title="Dividend yield"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001485" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001487" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zrf14xqZGeQg" title="Term (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" format="ixt-sec:duryear" id="Fact001489" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.9</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zQM7oWhv7xg2" title="Term (years)"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zwLjgcQrbbj7" title="Term (years)"><ix:nonNumeric contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001491" name="us-gaap:WarrantsAndRightsOutstandingTerm"><ix:nonNumeric contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact001493" name="us-gaap:WarrantsAndRightsOutstandingTerm">4.9</ix:nonNumeric></ix:nonNumeric></span></span> - <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zJBWbv0TIhd8" title="Term (years)"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zn5pqv4KyjNf" title="Term (years)"><ix:nonNumeric contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001495" name="us-gaap:WarrantsAndRightsOutstandingTerm"><ix:nonNumeric contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact001497" name="us-gaap:WarrantsAndRightsOutstandingTerm">5.0</ix:nonNumeric></ix:nonNumeric></span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zjXhXlFf6lch" title="Risk-free interest rate" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001499" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z7kdEynBbjV4" title="Risk-free interest rate"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zYCIPq13Jt7l" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact001501" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact001503" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.00</ix:nonFraction></ix:nonFraction></span></span>% - <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zXs8IFU1i6Yc" title="Risk-free interest rate"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zrczjLQgNIc4" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact001505" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact001507" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.10</ix:nonFraction></ix:nonFraction></span></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z4DuF0GwDnq4" title="Warrant and right outstanding measurement input" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001509" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">50.0</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zHJJnU0FRPxd" title="Warrants measurement input" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zEtlV5c2Xc8d" title="Warrants measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001511" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001513" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">50.0</ix:nonFraction></ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zwHFDf6Kt7oc" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zaexGBibPay7" style="font-size: 10pt"><ix:footnote id="Footnote001514" xml:lang="en-US">As discussed in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0C_zo1gJoXsJVn6" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_z1UxLlq7Ve35" style="font-size: 10pt"><ix:footnote id="Footnote001515" xml:lang="en-US">The exercise price of the November 2024 Purchaser Warrants is based on the lesser of (i) $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zqWPryMPDFY" title="Exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zay0CNo8kkFc" title="Exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember" id="Fact001517" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember" id="Fact001519" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction></ix:nonFraction></span></span> or (ii) the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $<span id="xdx_906_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zHA1eE5Olt08" title="Floor price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_90B_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zJ5hleIJxI8l" title="Floor price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="CELU:FloorPrice" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember" id="Fact001521" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="CELU:FloorPrice" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember" id="Fact001523" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></ix:nonFraction></span></span>. </ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F04_zTvOtzIYoIMl" style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zZ0Nol6SrmT5" style="font-size: 10pt"><ix:footnote id="Footnote001524" xml:lang="en-US">The exercise price of the November 2024 Placement Agent Warrants is based on the lesser of (i) $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zO2jaDs7pQ78" title="Exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zCedlLw6AzQh" title="Exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" id="Fact001526" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" id="Fact001528" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.56</ix:nonFraction></ix:nonFraction></span></span> or (ii) <span id="xdx_900_ecustom--OfferingPricePercentage_iI_pid_dp_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z7jn9S0Q2kz4" title="Offering price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_90F_ecustom--OfferingPricePercentage_iI_pid_dp_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6z2KSFYOoUa" title="Offering price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="CELU:OfferingPricePercentage" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" id="Fact001530" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="CELU:OfferingPricePercentage" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" id="Fact001532" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125</ix:nonFraction></ix:nonFraction></span></span>% of the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $<span id="xdx_909_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6RlELFC2O76" title="Floor price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><span id="xdx_909_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zXObzrFkExgd" title="Floor price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"><ix:nonFraction name="CELU:FloorPrice" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" id="Fact001534" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="CELU:FloorPrice" contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" id="Fact001536" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></ix:nonFraction></span></span>.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A2_zrBWg2bfEe75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<ix:exclude><!-- Field: Page; Sequence: 112 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_GXSponsorWarrantsMember" escape="true" id="Fact001538" name="CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock"><p id="xdx_892_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--GXSponsorWarrantsMember_zGrSlJfF6DBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the Sponsor
Warrants are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zB0hiBDOJ4C7" style="display: none">Schedule
of Significant Inputs for  Warrants</span></p>

<table cellspacing="0" cellpadding="0" id="xdx_30D_134_zAdfdWkMttb7" summary="xdx: Disclosure - Schedule of Significant Inputs for Sponsor Warrants (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b>December 31,</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 68%; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td style="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b>2023</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Common share price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zdLpurqPp6A9" title="Common share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember" id="Fact001540" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.08</ix:nonFraction></span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zHrA3tQ4MLil" title="Common share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember" id="Fact001542" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.47</ix:nonFraction></span> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Exercise price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zIjzfAiMIA33" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember" id="Fact001544" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">115.00</ix:nonFraction></span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zDtY0m1KwlSk" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember" id="Fact001546" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">115.00</ix:nonFraction></span> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_znSj9p5G03x7" title="Dividend yield"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001548" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zkmoPeuCUJqa" title="Dividend yield"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001550" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Term (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 2.65pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zJG9hzzs3Ie9" title="Term (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember" format="ixt-sec:duryear" id="Fact001552" name="us-gaap:WarrantsAndRightsOutstandingTerm">1.5</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 2.65pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zzBfFK2s4on2" title="Term (years)"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember" format="ixt-sec:duryear" id="Fact001554" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.5</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zlL5PZSicnPh" title="Dividend yield"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001556" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.21</ix:nonFraction></span> %</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zLvpUZm4ACi" title="Dividend yield"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember" id="Fact001558" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4.12</ix:nonFraction></span> %</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zFdi7bi7MYG5" title="Warrant and right outstanding measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001560" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">111.4</ix:nonFraction></span> %</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zU0Uag68bPC4" title="Warrant measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001562" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">100.7</ix:nonFraction></span> %</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_z4Jr6QIPfAIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001564" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_802_eus-gaap--InventoryDisclosureTextBlock_zUj32syHQ38i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 9pt"><b>5. <span id="xdx_82C_zDfNpZ71Gtsl">Inventory</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001566" name="CELU:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_zbJGEZG537Ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s major classes
of inventories were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B2_zNXMLq17be14" style="display: none">Schedule of Major Classes of Inventories</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_z0oxNuQH6BM9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_z1Sy0CV749j8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryRawMaterialsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zhgsDZuCwOoa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Raw materials</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="CELU:InventoryRawMaterialsCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact001568" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="CELU:InventoryRawMaterialsCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact001569" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,081</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InventoryWorkInProgressCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zVB3cP12G5M3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Work in progress</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryWorkInProgressCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact001571" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,093</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryWorkInProgressCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact001572" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,696</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InventoryFinishedGoodsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zIJhOEWkJYhc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryFinishedGoodsCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact001574" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,964</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryFinishedGoodsCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact001575" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,922</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryGrossCurrentAndNoncurrent_iTI_pn3n3_mtIGCANzRGk_maINCANzn4U_zR9JoHVr99Fh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Inventory, gross</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryGrossCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact001577" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,099</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryGrossCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact001578" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,699</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryReserveCurrentAndNoncurrent_iNI_pn3n3_di_msINCANzn4U_zQKbRCaEbD27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: inventory reserves</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:InventoryReserveCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact001580" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,103</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:InventoryReserveCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact001581" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,289</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzn4U_zjOUTiYxcyBj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Inventory, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryNetCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact001583" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,996</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryNetCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact001584" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,410</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance sheet classification:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InventoryNet_iI_pn3n3_maINCANzRqB_zkUsypJ2wO8b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-12-31" id="Fact001586" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,409</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" id="Fact001587" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,753</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryNoncurrent_iI_pn3n3_maINCANzRqB_zYrOm4DbQWJl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Inventory, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNoncurrent" contextRef="AsOf2024-12-31" id="Fact001589" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,587</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InventoryNoncurrent" contextRef="AsOf2023-12-31" id="Fact001590" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,657</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzRqB_zUrrpmwh493i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory,
    net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryNetCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact001592" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,996</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryNetCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact001593" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,410</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zGCq0q5VkL9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Inventory, net of current portion
includes inventory expected to remain on-hand beyond one year from each balance sheet date presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recognized a $<span id="xdx_905_ecustom--InventoryImpairmentCharge_pn3n3_c20240101__20241231_zVK6lO0lri2f" title="Inventory impairment charge"><ix:nonFraction name="CELU:InventoryImpairmentCharge" contextRef="From2024-01-01to2024-12-31" id="Fact001595" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">466</ix:nonFraction></span>
inventory impairment charge during the year ended December 31, 2024 in the consolidated statements of operations and comprehensive loss
due to lower of cost or net realizable value adjustments for finished goods. The Company recognized a $<span id="xdx_903_ecustom--InventoryImpairmentCharge_pn3n3_c20230101__20231231_zSGpucAq6sT2" title="Inventory impairment charge"><ix:nonFraction name="CELU:InventoryImpairmentCharge" contextRef="From2023-01-012023-12-31" id="Fact001597" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,384</ix:nonFraction></span> inventory impairment charge during the
year ended December 31, 2023 in the consolidated statements of operations and comprehensive loss due to lower of cost or net realizable value adjustments
of $<span id="xdx_90D_ecustom--InventoryImpairmentCharge_pn3n3_c20230101__20231231__us-gaap--PublicUtilitiesInventoryAxis__custom--InventoryFinishedGoodsMember_znxgQfGZKCec" title="Inventory impairment charge"><ix:nonFraction name="CELU:InventoryImpairmentCharge" contextRef="From2023-01-012023-12-31_custom_InventoryFinishedGoodsMember" id="Fact001599" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,129</ix:nonFraction></span> for finished goods and $<span id="xdx_900_ecustom--InventoryImpairmentCharge_pn3n3_c20230101__20231231__us-gaap--PublicUtilitiesInventoryAxis__custom--InventoryWorkInProgressMember_zTbcT7fYNyu6" title="Inventory impairment charge"><ix:nonFraction name="CELU:InventoryImpairmentCharge" contextRef="From2023-01-012023-12-31_custom_InventoryWorkInProgressMember" id="Fact001601" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,255</ix:nonFraction></span> for work in progress.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001603" name="CELU:ScheduleOfActivityInInventoryReservesTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfActivityInInventoryReservesTableTextBlock_zoEC85ifNptj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A schedule of the activity in
the inventory reserves is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zt5KLN76Jir9" style="display: none">Schedule of Inventory Reserves</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20230101__20231231_zz06ao9xkpqk" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="CELU:InventoryReserveCurrentAndNoncurrent" contextRef="AsOf2022-12-31" id="Fact001605" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,099</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Provision for obsolete inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ProvisionForObsoleteInventory_pn3n3_c20230101__20231231_zPXHSsX6uZx8" title="Additions for obsolete inventory" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ProvisionForObsoleteInventory" contextRef="From2023-01-012023-12-31" id="Fact001607" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,627</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Write-offs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231_zJHTXS7zIXDd" title="Write-offs" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2023-01-012023-12-31" id="Fact001609" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,437</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20240101__20241231_zid77wqlTBR5" title="Beginning balance" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryReserveCurrentAndNoncurrent" contextRef="AsOf2023-12-31" id="Fact001611" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,289</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Provision for obsolete inventory</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ProvisionForObsoleteInventory_pn3n3_c20240101__20241231_zNYqVjdhWtic" title="Provision for obsolete inventory" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="CELU:ProvisionForObsoleteInventory" contextRef="From2024-01-01to2024-12-31" id="Fact001613" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">186</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_ecustom--InventoryReserveCurrentAndNoncurrent_iE_pn3n3_c20240101__20241231_z4Cf0d7yZPK9" title="Ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:InventoryReserveCurrentAndNoncurrent" contextRef="AsOf2024-12-31" id="Fact001615" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,103</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zQ9i1U1FuV17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 113 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001617" name="CELU:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock"><p id="xdx_80C_ecustom--PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_ztg47MUKmRcf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>6. <span id="xdx_82F_zjXVz5q2zpEa">Prepaid Expenses and Other Current Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001619" name="CELU:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqYfYW8Dbhuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Prepaid expenses and other current
assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4EEgadYQn07" style="display: none">Schedule of Prepaid Expenses and Other Current Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zi4ei7GVBExl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zsxUhxK2I4t8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidClinicalExpense_iI_pn3n3_maPEAOAzmHw_zomryCENgGJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Prepaid clinical expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="CELU:PrepaidClinicalExpense" contextRef="AsOf2024-12-31" id="Fact001621" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">221</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="CELU:PrepaidClinicalExpense" contextRef="AsOf2023-12-31" id="Fact001622" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">688</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzmHw_zs27gXEcEKtc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid insurance expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-12-31" id="Fact001624" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">375</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2023-12-31" id="Fact001625" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">678</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzmHw_zXnzH76PbSYf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-12-31" id="Fact001627" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">261</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2023-12-31" id="Fact001628" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">329</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzmHw_zVQJCjGAr3fb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-12-31" id="Fact001630" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">857</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact001631" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,695</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zEBOwtpqP2yj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001633" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_znGHWKsYKE52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>7. <span id="xdx_82F_zBclf8ZH9sA">Property and Equipment, Net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001635" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zrEB20Nhmw9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Property and equipment, net consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_zV1V4CvDzjj6" style="display: none">Schedule of Property and Equipment, Net</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zu1AF8La1y4c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zohzI8AJFkeg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zon6DKNLfu6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact001637" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73,211</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact001638" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73,211</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryAndProductionEquipmentMember_zVnagmLc6SSd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Laboratory and production equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_LaboratoryAndProductionEquipmentMember" id="Fact001640" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,093</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_LaboratoryAndProductionEquipmentMember" id="Fact001641" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,093</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryEquipmentAndFixturesMember_zoDb4Y1Ecrp8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Machinery, equipment and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31_custom_MachineryEquipmentAndFixturesMember" id="Fact001643" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,163</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_custom_MachineryEquipmentAndFixturesMember" id="Fact001644" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,781</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zgtMKGpgvAm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1646">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_ConstructionInProgressMember" id="Fact001647" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzl3Y_zaEDlb83rPW7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-12-31" id="Fact001649" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94,467</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact001650" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">95,106</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzl3Y_zsJCGdbHmB4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-12-31" id="Fact001652" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32,867</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact001653" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27,278</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzl3Y_znmECYxPwsa1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-12-31" id="Fact001655" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">61,600</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact001656" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">67,828</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zgb55HJm93u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Depreciation expense was $<span id="xdx_904_eus-gaap--Depreciation_pn3n3_c20240101__20241231_zrdyFlI62lVf" title="Depreciation"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-01-01to2024-12-31" id="Fact001658" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,169</ix:nonFraction></span>
and $<span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20230101__20231231_zrQCErHj6fHk" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-012023-12-31" id="Fact001660" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,131</ix:nonFraction></span> for the years ended December 31, 2024 and 2023 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001662" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_80B_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zB3CJnqs7h1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>8. <span id="xdx_82D_zil7g7Usjdz1">Goodwill and Intangible Assets, Net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Goodwill</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company tests its goodwill
for impairment on an annual basis in the fourth quarter of each year for all of its reporting units, or more frequently if events or circumstances
indicate a potential impairment. The Company manages its operations through an evaluation of <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zDWYYDbxvuej" title="Number of operating segments"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2024-01-01to2024-12-31" id="Fact001664" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">three</ix:nonFraction></span> different operating segments: Cell
Therapy, Degenerative Disease and BioBanking (see Note 19). The Company determined that the operating segments represented the reporting
units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During annual impairment tests
and for any period in which the Company identifies an impairment trigger, the Company&#8217;s methodology includes internally generated
separate cash flow projections for each reporting unit based on the different drivers that affect each reporting unit. The Company compares
the fair values of each of its reporting units to their respective carrying amounts. If the carrying value of a reporting unit exceeds
its estimated fair value, a goodwill impairment charge is recorded for the difference, with the impairment loss limited to the total amount
of goodwill allocated to that reporting unit. The fair values of each of the Company&#8217;s reporting units were derived using the income
approach, specifically the discounted cash flow method. The use of a discounted cash flow analysis requires significant judgment to estimate
the future cash flows and the period of time over which those cash flows will be realized, as well as to determine the appropriate discount
rate. The discounted cash flow model reflects management&#8217;s assumptions regarding revenue growth rates, risk-adjusted discount rates,
terminal period growth rates, economic and market trends, and other expectations about the anticipated operating results of the Company&#8217;s
reporting units. As part of the goodwill impairment test, the Company also considers its market capitalization in assessing the reasonableness
of the combined fair values estimated for its reporting units. Substantial changes in the cash flows assumptions of the different reporting
units may lead to a future impairment or may alter the implied distribution of value between the different reporting units. A material
decline in the Company&#8217;s stock price may affect the imputed discount rate and the distribution of value between the reporting units,
which may also lead to a future impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The carrying value of
goodwill, all of which was assigned to the Company&#8217;s BioBanking reporting unit, was $<span id="xdx_900_eus-gaap--Goodwill_iI_pn3n3_c20241231_zj9GkYnWr9f1" title="Goodwill"><span id="xdx_90E_eus-gaap--Goodwill_iI_pn3n3_c20231231_z5kOs5kI5W11" title="Goodwill"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-12-31" id="Fact001666" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-12-31" id="Fact001668" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,347</ix:nonFraction></ix:nonFraction></span></span>
at both December 31, 2024 and 2023. At December 31, 2024, the Company performed a qualitative assessment to determine whether the
existence of events or circumstances would indicate that it was more likely than not that the that the fair value of the reporting
unit is less than its carrying amount. Based on the assessment, there was <span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_dxL_c20240101__20241231_zFlxrRjfSlGj" title="Goodwill, impairment loss::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1670">no</span></span>
goodwill impairment recognized during the year ended December 31, 2024. At December 31, 2023, the estimated fair value of the
BioBanking reporting unit was substantially in excess of its book value. The relative stability of the expected cash flows of the
BioBanking reporting unit makes an impairment of goodwill in the future less likely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 114 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Degenerative Disease reporting unit goodwill was fully impaired as
of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For the year ended December 31,
2023, the Company recognized $<span id="xdx_908_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20231231_zEJ2KmV5UfQg" title="Goodwill, impairment loss"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-01-012023-12-31" id="Fact001672" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,347</ix:nonFraction></span> of goodwill impairment charges related to its Cell Therapy reporting unit, which resulted in full
impairment of the reporting unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the first quarter 2023,
as a result of a sustained decrease in its stock price and market capitalization, and its decision to cease recruitment in its GBM and
HER2+ gastric trials, the Company tested for impairment due to these triggering events. Based on the results of the impairment analysis,
the carrying value exceeded the fair value on the Cell Therapy reporting unit. The Company recognized a $<span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20230331__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zIZ52k3ea8cb" title="Goodwill impairment"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-01-012023-03-31_custom_CellTherapyMember" id="Fact001674" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">29,633</ix:nonFraction></span> goodwill impairment charge
during the first quarter of 2023 in its consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the second quarter of 2023,
the Company&#8217;s stock price and market capitalization continued to decline, and the Company also determined to cease active recruitment
in its AML trial and halted all NK programs. The AML trial was the Company&#8217;s most advanced clinical program with a relatively large
addressable patient population given the high unmet medical need in relapsed and refractory AML. After the Company ceased recruitment,
it removed all associated cash flows relating to that program including all other NK related programs as well. As a result of these triggering
events, the Company fully impaired the IPR&amp;D assets associated with these product candidates, and performed a goodwill impairment
test on its Cell Therapy reporting unit. At June 30, 2023, the estimated fair value of the Cell Therapy reporting unit was determined
to be at breakeven compared to the carrying value using a discount rate commensurate with the risks associated with the cash flows for
preclinical product candidates. The Company also performed a reconciliation of the aggregate fair value of each reporting unit to the
market capitalization of the Company. The analysis showed the fair value of the reporting units approximated the Company&#8217;s market
capitalization, indicating an insignificant control premium. Based on the results of the impairment analysis, the Company did not recognize
a goodwill impairment charge during the second quarter of 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the third quarter of 2023,
the Company&#8217;s stock price and market capitalization continued to further decline. The Company also elected to terminate development
of CYCART-19 for B-cell malignancies during the quarter, as well as paused development in exosomes. Therefore, the Company tested for
impairment due to these triggering events. Based on the results of the impairment analysis, the carrying value exceeded the fair value
on the Cell Therapy reporting unit. The Company recognized a goodwill impairment charge for the remaining goodwill balance on the Cell
Therapy reporting unit of $<span id="xdx_90A_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_z2e9ZkJw5FF3" title="Goodwill impairment"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-07-012023-09-30_custom_CellTherapyMember" id="Fact001676" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82,714</ix:nonFraction></span> during the third quarter of 2023 in its consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 115 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Intangible Assets, Net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001678" name="CELU:ScheduleOfIntangibleAssetsNetTableTextBlock"><p id="xdx_89A_ecustom--ScheduleOfIntangibleAssetsNetTableTextBlock_zp9R0cz9cBoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Intangible assets, net consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;<span id="xdx_8BD_zEI0baKYzh72" style="display: none">Schedule of Intangible Assets, Net</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center">Estimated Useful</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lives</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortizable intangible assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left">Developed technology</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zk4Hg6LIWdI" title="Amortizable intangible assets" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_us-gaap_DevelopedTechnologyRightsMember" id="Fact001680" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,810</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z8DV7ILVQOCl" title="Amortizable intangible assets" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_DevelopedTechnologyRightsMember" id="Fact001682" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,810</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%; text-align: center"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zKomfhsDWbX8" title="Estimated useful lives"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zKeqrOcyApE7" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear" id="Fact001684" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear" id="Fact001686" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">11</ix:nonNumeric></ix:nonNumeric></span></span> &#8211; <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zE7O61tLP2jg" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zGZ8JDgOKlt8" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear" id="Fact001688" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear" id="Fact001690" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">16</ix:nonNumeric></ix:nonNumeric></span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Customer relationships</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpey0st8Psof" title="Amortizable intangible assets" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_us-gaap_CustomerRelationshipsMember" id="Fact001692" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,413</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zt79MvYyhrrd" title="Amortizable intangible assets" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember" id="Fact001694" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,413</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZNRm9GWyzOe" title="Estimated useful lives"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_znA3YFipl42k" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_us-gaap_CustomerRelationshipsMember" format="ixt-sec:duryear" id="Fact001696" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember" format="ixt-sec:duryear" id="Fact001698" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric></ix:nonNumeric></span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Trade names &amp; trademarks</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zQtE0ZjLJ3Td" title="Amortizable intangible assets" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_us-gaap_TrademarksAndTradeNamesMember" id="Fact001700" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">570</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z1K0sSPuLrpk" title="Amortizable intangible assets" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_TrademarksAndTradeNamesMember" id="Fact001702" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">570</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zypKiA9HYaJ3" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zLJ6nI2dRzFj" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_TrademarksAndTradeNamesMember" format="ixt-sec:duryear" id="Fact001704" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MinimumMember_us-gaap_TrademarksAndTradeNamesMember" format="ixt-sec:duryear" id="Fact001706" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric></ix:nonNumeric></span></span> &#8211; <span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zmxkha5Nynoh" title="Estimated useful lives"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zT5gbhQv4yma" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_TrademarksAndTradeNamesMember" format="ixt-sec:duryear" id="Fact001708" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife"><ix:nonNumeric contextRef="AsOf2023-12-31_srt_MaximumMember_us-gaap_TrademarksAndTradeNamesMember" format="ixt-sec:duryear" id="Fact001710" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">13</ix:nonNumeric></ix:nonNumeric></span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reacquired rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zCOBGXONR1Xe" title="Amortizable intangible assets" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31_custom_ReacquiredRightsMember" id="Fact001712" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,200</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z0Q6d4BviyFj" title="Amortizable intangible assets" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_custom_ReacquiredRightsMember" id="Fact001714" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,200</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zRVXc399vNK2" title="Estimated useful lives"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zuPFnsfYBbJk" title="Estimated useful lives"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_ReacquiredRightsMember" format="ixt-sec:duryear" id="Fact001716" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_ReacquiredRightsMember" format="ixt-sec:duryear" id="Fact001718" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">6</ix:nonNumeric></ix:nonNumeric></span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231_zMysKLxwjrM3" title="Amortizable intangible assets" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-12-31" id="Fact001720" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,993</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zKntFN5eObw7" title="Amortizable intangible assets" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31" id="Fact001722" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">23,993</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: accumulated amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Developed technology</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zuIiJvpDIE76" title="Less: Accumulated amortization" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_us-gaap_DevelopedTechnologyRightsMember" id="Fact001724" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">8,895</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zYggwKni2n4c" title="Less: Accumulated amortization" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_DevelopedTechnologyRightsMember" id="Fact001726" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">7,722</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Customer relationships</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMJutBLF2Gzc" title="Less: Accumulated amortization" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_us-gaap_CustomerRelationshipsMember" id="Fact001728" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,965</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zm0AIZpePhp1" title="Less: Accumulated amortization" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember" id="Fact001730" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Trade names &amp; trademarks</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zRf3C91RYWL4" title="Less: Accumulated amortization" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_us-gaap_TrademarksAndTradeNamesMember" id="Fact001732" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">385</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zq7vyMKCivQe" title="Less: Accumulated amortization" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_us-gaap_TrademarksAndTradeNamesMember" id="Fact001734" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">330</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reacquired rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zYQCEH6iTGwe" title="Less: Accumulated amortization" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31_custom_ReacquiredRightsMember" id="Fact001736" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,200</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z6rGmCBUzS85" title="Less: Accumulated amortization" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31_custom_ReacquiredRightsMember" id="Fact001738" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,940</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231_zCO8uBdZSHg1" title="Less: Accumulated amortization" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-12-31" id="Fact001740" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15,445</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zsoXmgHUdaga" title="Less: Accumulated amortization" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" id="Fact001742" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">13,692</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortizable intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20241231_zeAQLZlamwXb" title="Amortizable intangible assets, net" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact001744" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,548</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zH0T6eOSvxK1" title="Amortizable intangible assets, net" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact001746" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,301</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-amortized intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Acquired IPR&amp;D product rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pn3n3_c20241231_zCwQlrHnCual" title="Acquired IPR&amp;D product rights" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact001748" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pn3n3_c20231231_zD6WkEBB7u58" title="Acquired IPR&amp;D product rights" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact001750" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">700</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"><span id="xdx_90D_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20240101__20241231_zJ8NLo7eOplc" title="Estimated useful lives"><span id="xdx_903_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231_zJRToTbP3Oi3" title="Estimated useful lives"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact001752" name="CELU:IndefiniteLivedIntangibleAssetsAmortizationMethod"><ix:nonNumeric contextRef="From2023-01-012023-12-31" id="Fact001754" name="CELU:IndefiniteLivedIntangibleAssetsAmortizationMethod">indefinite</ix:nonNumeric></ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zN9HH3HOXyC4" title="Intangible assets, net" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-12-31" id="Fact001756" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,248</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231_zw7IsKKgInCa" title="Intangible assets, net" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-12-31" id="Fact001758" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,001</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zwoZkJnhaoif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Amortization expense for intangible
assets was $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231_zI6DDFjYdW57" title="Amortization expense for intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-12-31" id="Fact001760" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,753</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231_zQFQQ2n3b448" title="Amortization expense for intangible assets"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact001762" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,193</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20240101__20241231_zeYPlweYr5cl" title="Impairment of intangible assets"><span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20230101__20231231_zJXdRaeuQqsd" title="Impairment of intangible assets"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2024-01-01to2024-12-31" id="Fact001764" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" contextRef="From2023-01-012023-12-31" id="Fact001766" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">No</ix:nonFraction></ix:nonFraction></span></span> impairment charges were recorded
on intangible assets for the year ended December 31, 2024. During the year ended December 31, 2023, the Company discontinued its unmodified
NK cell and AML Cell Therapy clinical trials and as a result recorded an IPR&amp;D impairment of $<span id="xdx_903_eus-gaap--OtherAssetImpairmentCharges_pn3n3_c20230101__20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zS5kM6D0Kj4a" title="Impairment of intangible assets"><ix:nonFraction name="us-gaap:OtherAssetImpairmentCharges" contextRef="From2023-01-012023-12-31_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact001768" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107,800</ix:nonFraction></span> on its CYNK-001 and GMNK intangible
assets acquired from the Anthrogenesis acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001770" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zsnhUmgIjgEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Aggregate amortization expense
for each of the five succeeding years and thereafter related to intangible assets held as of December 31, 2024 is estimated as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zIfmSuNTef3g" style="display: none">Schedule of Aggregate Amortization Expense Related to Intangible Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_499_20241231_z5US2EjNLEja" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANziI0_z0mTudr8y395" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact001772" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,493</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANziI0_z1YnuRaZCey1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2024-12-31" id="Fact001774" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,356</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANziI0_zYCmO88Xjf94" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2024-12-31" id="Fact001776" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,258</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANziI0_zOZP3u3m1stl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2024-12-31" id="Fact001778" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,208</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANziI0_zvMflM025v27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2029</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2024-12-31" id="Fact001780" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,155</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANziI0_zpwNfqesTSr3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2024-12-31" id="Fact001782" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,078</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANziI0_zM1f7lQIOgtf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-12-31" id="Fact001784" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,548</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z9KRpM8JBAV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 116 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001786" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_803_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zTmJ9voyBuPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>9. <span id="xdx_822_z6IxIn0Sz2r8">Accrued Expenses and Other Current Liabilities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001788" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zoX30kvD2mj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Accrued expenses and other current
liabilities consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zIUy5zgunx62" style="display: none">Schedule of Accrued Expenses and Other Current Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zUAi0bF2i42i" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zuwPaF1q9IUd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedClinicalTrialExpense_iI_pn3n3_maALCzZ4Y_zzAhWduSOoRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Accrued clinical trial expense</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="CELU:AccruedClinicalTrialExpense" contextRef="AsOf2024-12-31" id="Fact001790" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="CELU:AccruedClinicalTrialExpense" contextRef="AsOf2023-12-31" id="Fact001791" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">189</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZ4Y_zJ6XaJr5vRmc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued professional fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2024-12-31" id="Fact001793" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">691</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2023-12-31" id="Fact001794" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">573</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_zrvXYFNqhztb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued wages, bonuses, commissions and vacation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001796" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,797</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001797" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,011</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccrualsForConstructionInProgress_iI_pn3n3_maALCzZ4Y_zn9pm8Seomub" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accruals for construction in progress</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AccrualsForConstructionInProgress" contextRef="AsOf2024-12-31" id="Fact001799" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">135</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AccrualsForConstructionInProgress" contextRef="AsOf2023-12-31" id="Fact001800" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">214</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzZ4Y_zppufrkn0l51" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2024-12-31" id="Fact001802" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,798</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1803">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccruedComplianceFee_iI_pn3n3_maALCzZ4Y_zTcBA7RcvQ1f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued compliance fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AccruedComplianceFee" contextRef="AsOf2024-12-31" id="Fact001805" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,277</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:AccruedComplianceFee" contextRef="AsOf2023-12-31" id="Fact001806" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,145</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_z2OK4PmAx5Bc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001808" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">955</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001809" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,448</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZ4Y_zaLHpancMSKc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    accrued expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2024-12-31" id="Fact001811" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,842</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001812" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,580</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zgkgdF1r8Jhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001814" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80D_eus-gaap--DebtDisclosureTextBlock_zW9jjYQNoCx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>10. <span id="xdx_820_zR5uKsA7BlNe">Debt</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact001816" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zK6Q9XSMaC9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Debt consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zvoiRhCYEAuh" style="display: none">Schedule
of Debt</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zHu7pAPGbOW" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zZqnJOOrQPv2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Debt - unaffiliated:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zyA9YHtaLfJi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Yorkville - PPA (measured at fair value)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1818">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtUnaffiliated" contextRef="AsOf2023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001819" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,223</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--ConvertiblePromissoryNotesMember_zqsGDZKzQrz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Yorkville - convertible promissory note (measured at fair value)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtUnaffiliated" contextRef="AsOf2024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember" id="Fact001821" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,865</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1822">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--CreditFacilityAxis__custom--UnsecuredSeniorConvertibleNoteMember_zHs57v3UQFL3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Unsecured senior convertible notes (measured at fair value)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtUnaffiliated" contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNoteMember" id="Fact001824" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">620</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1825">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OtherShortTermDebt_iI_pn3n3_zVEapbxVD6wh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Short-term debt - other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1827">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:OtherShortTermDebt" contextRef="AsOf2023-12-31" id="Fact001828" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,108</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_zvnBk4RyqYTb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total debt - unaffiliated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtUnaffiliated" contextRef="AsOf2024-12-31" id="Fact001830" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtUnaffiliated" contextRef="AsOf2023-12-31" id="Fact001831" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,331</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Debt - related parties:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CVStarrBridgeLoanNetOfDiscountMember_zB6V0cUxTM8i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">C.V. Starr Bridge Loan, net of discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtRelatedParty" contextRef="AsOf2024-12-31_custom_CVStarrBridgeLoanNetOfDiscountMember" id="Fact001833" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,652</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtRelatedParty" contextRef="AsOf2023-12-31_custom_CVStarrBridgeLoanNetOfDiscountMember" id="Fact001834" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,523</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--RWIBridgeLoanNetOfDiscountMember_zqMwMDQu5Axb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">RWI Bridge Loan, net of discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtRelatedParty" contextRef="AsOf2024-12-31_custom_RWIBridgeLoanNetOfDiscountMember" id="Fact001836" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,275</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtRelatedParty" contextRef="AsOf2023-12-31_custom_RWIBridgeLoanNetOfDiscountMember" id="Fact001837" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,967</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zy480WSqLQo9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">CEO promissory note</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtRelatedParty" contextRef="AsOf2024-12-31_custom_CEOPromissoryNoteMember" id="Fact001839" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,876</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtRelatedParty" contextRef="AsOf2023-12-31_custom_CEOPromissoryNoteMember" id="Fact001840" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,419</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_zH425rxDLV0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtRelatedParty" contextRef="AsOf2024-12-31" id="Fact001842" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,803</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ShortTermDebtRelatedParty" contextRef="AsOf2023-12-31" id="Fact001843" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,909</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--Debt_iTI_pn3n3_zyvhxlDi9rCl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total debt</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:Debt" contextRef="AsOf2024-12-31" id="Fact001845" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,288</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:Debt" contextRef="AsOf2023-12-31" id="Fact001846" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance sheet classification:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShortTermBorrowings_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z8IP16kNtQU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - unaffiliated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember" id="Fact001848" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact001849" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,331</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2FkvjdwenYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001851" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,876</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact001852" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19,909</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4DEWC6mnYVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Long-term debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember" id="Fact001854" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,927</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1855">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--Debt_iTI_pn3n3_znK7NZGmPrz7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:Debt" contextRef="AsOf2024-12-31" id="Fact001857" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">42,288</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:Debt" contextRef="AsOf2023-12-31" id="Fact001858" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,240</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zovKF4TJKJr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>


<ix:exclude><!-- Field: Page; Sequence: 117 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Yorkville PPA</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On September 15, 2022, the Company
entered into a Pre-Paid Advance Agreement (&#8220;PPA&#8221;) with Yorkville, pursuant to which the Company could request advances of
up to $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zEu36Cn8rZZ4" title="Maximum advance amount"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001860" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,000</ix:nonFraction></span> in cash from Yorkville (or such greater amount that the parties may mutually agree) (each, a &#8220;Pre-Paid Advance&#8221;)
over an <span id="xdx_90F_ecustom--PrePaidAdvancePeriod_dtM_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zjdBAdOMizHh" title="Pre-paid advance period"><ix:nonNumeric contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" format="ixt-sec:durmonth" id="Fact001862" name="CELU:PrePaidAdvancePeriod">18</ix:nonNumeric></span>-month period, with an aggregate limitation of $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zNU7m9JN3l48" title="Line of credit aggregate limitation amount"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001864" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150,000</ix:nonFraction></span>. Pre-Paid Advances were issued at a <span id="xdx_906_ecustom--PrePaidAdvanceIssuedDiscountPercentage_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zuAVveHPnX2l" title="Pre-paid advance issued discount percentage"><ix:nonFraction name="CELU:PrePaidAdvanceIssuedDiscountPercentage" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001866" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.0</ix:nonFraction></span>% discount, bore interest at
an annual rate equal to <span id="xdx_90B_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zXEYolPefsEf" title="Annual interest rate"><ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001868" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.0</ix:nonFraction></span>% (increased to <span id="xdx_902_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zOPAPeOsIVR3" title="Line of credit increase in interest rate during period in event of default"><ix:nonFraction name="CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001870" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>% in the event of default as described in the PPA) and could have been offset by the issuance
of shares of common stock, at Yorkville&#8217;s option, at a price per share calculated pursuant to the PPA, which in no event would be
less than $<span id="xdx_909_ecustom--IssuanceOfCommonStockMinimumOptionPricePerShare_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zdxBo79pJM2g" title="Issuance of common stock minimum option price per share"><ix:nonFraction name="CELU:IssuanceOfCommonStockMinimumOptionPricePerShare" contextRef="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001872" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.50</ix:nonFraction></span> per share. The issuance of the shares under the PPA was subject to certain limitations, including that the aggregate number
of shares of common stock issued pursuant to the PPA could not exceed <span id="xdx_908_ecustom--MaximumPercentageOfCommonStockIssued_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zxeqPc6HgnM9" title="Maximum percentage of common stock issued"><ix:nonFraction name="CELU:MaximumPercentageOfCommonStockIssued" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001874" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.9</ix:nonFraction></span>% of the Company&#8217;s outstanding stock as of September 15,
2022, as well as a beneficial ownership limitation of <span id="xdx_90B_ecustom--PercentageOfBeneficialOwnershipLimitation_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z4JSxLC1JxJd" title="Percentage of beneficial ownership limitation"><ix:nonFraction name="CELU:PercentageOfBeneficialOwnershipLimitation" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001876" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>%. Further, Yorkville agreed not to purchase any shares of common stock for
60 days following entry into the PPA, nor could Yorkville purchase more than $<span id="xdx_905_ecustom--MinimumNumberOfSharesOfCommonStockPurchase_pid_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zqBfNCeMMWh5" title="Minimum number of shares of common stock purchase"><ix:nonFraction name="CELU:MinimumNumberOfSharesOfCommonStockPurchase" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001878" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000</ix:nonFraction></span> of shares of common stock during a 30-day period,
in each case at a price per share less than the Fixed Price, as defined in the PPA. In the event the daily volume weighted average price
(&#8220;VWAP&#8221;) of the Class A common stock was below $<span id="xdx_907_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z5868LZc4olf" title="Minimum required daily volume weighted average price"><ix:nonFraction name="CELU:MinimumRequiredDailyVolumeWeightedAveragePrice" contextRef="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001880" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.50</ix:nonFraction></span> (the &#8220;floor price&#8221;) for any five of seven consecutive trading
days, the Company would pay Yorkville a monthly cash payment of $<span id="xdx_908_ecustom--RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_ztiTq3RYLZMk" title="Required monthly payment if daily volume weighted average price is below $0.75 for any five of seven trading days"><ix:nonFraction name="CELU:RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001882" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></span>, plus any accrued and unpaid interest along with a <span id="xdx_90A_ecustom--RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zrY1S51BJFB7" title="Redemption premium percentage if volume weighted average price is less than $0.75"><ix:nonFraction name="CELU:RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001884" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>% redemption
premium until such time as the daily VWAP for five consecutive trading days immediately prior to the due date of the next monthly payment
was at least <span id="xdx_908_ecustom--RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z4KPhPfgJXPb" title="Redemption premium percentage if volume weighted average price more than $0.75"><ix:nonFraction name="CELU:RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001886" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.0</ix:nonFraction></span>% greater than $<span id="xdx_908_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zDOoDdpW6Etg" title="Minimum required daily volume weighted average price"><ix:nonFraction name="CELU:MinimumRequiredDailyVolumeWeightedAveragePrice" contextRef="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001888" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.50</ix:nonFraction></span>. In connection with the Company&#8217;s 2023 annual stockholder meeting held in June 2023, the Company
and Yorkville agreed to lower the floor price to $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20230630__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zAkvFJXVaxKe" title="Share price per share"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-06-30_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001890" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span> (the &#8220;amended floor price&#8221;). The Company also received stockholder
approval of the proposal for the issuance of more than <span id="xdx_901_ecustom--IssuancePricePercentage_iI_pid_dp_uPure_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zn3DIIExglQ2" title="Issuance price percentage"><ix:nonFraction name="CELU:IssuancePricePercentage" contextRef="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember_us-gaap_CommonClassAMember" id="Fact001892" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20.0</ix:nonFraction></span>% of its pre-transaction Class A common stock outstanding at a price below
the minimum price pursuant to the PPA. Further, absent prior written consent from Yorkville, the Company agreed it would not increase
the size or amount borrowed under the C.V. Starr loan facility nor would it incur other borrowings or liens of any kind as long as any
amounts were due and remained outstanding to Yorkville until paid in full. The Company agreed that all obligations due and owing to Yorkville
would become secured obligations upon any violation under the PPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the entry into
the PPA, the Company received the initial Pre-Paid Advance of $<span id="xdx_902_ecustom--ProceedsFromLinesOfCreditGross_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zyXhcZG3pGNg" title="Proceeds from pre-paid advance gross"><ix:nonFraction name="CELU:ProceedsFromLinesOfCreditGross" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001894" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,000</ix:nonFraction></span> gross or $<span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zV57Yp2XMaW6" title="Proceeds from pre-paid advance"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001896" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,200</ix:nonFraction></span> net of discount. Each Pre-Paid Advance had a maturity
of <span id="xdx_90B_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zAMXcGH2nLZ5" title="Pre-paid advance maturity period"><ix:nonNumeric contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" format="ixt-sec:durmonth" id="Fact001898" name="us-gaap:LineOfCreditFacilityExpirationPeriod">12</ix:nonNumeric></span> months. Further Pre-Paid Advances would be based upon the mutual agreement of the parties. Direct costs and fees related to the
PPA were recognized in earnings. At issuance, the Company concluded that certain features of the PPA would be considered a derivative
that would require bifurcation. In lieu of bifurcation, the Company elected the fair value option for this financial instrument and records
changes in fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. Under
the fair value option, upon derecognition the Company will include in net loss the cumulative amount of the gain or loss on the debt that
resulted from changes in instrument-specific credit risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, Yorkville elected to convert $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zdbfoAHDf6ta"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001899" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,889</ix:nonFraction>
</span>of principal and $<span id="xdx_90A_ecustom--DebtConversionOriginalDebtAccruedInterestAmount_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z40lQakk2ia4"><ix:nonFraction name="CELU:DebtConversionOriginalDebtAccruedInterestAmount" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001900" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">400</ix:nonFraction>
</span>of accrued interest into <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z2DWO6oszANe"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001901" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">559,481</ix:nonFraction>
</span>shares of common stock. Further, during the year December 31, 2023, total repayments to Yorkville were $<span id="xdx_907_ecustom--DebtInstrumentPayment_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zAcYv2w8Pqgb"><ix:nonFraction name="CELU:DebtInstrumentPayment" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001902" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">18,724</ix:nonFraction>
</span>which consisted of (i) $<span id="xdx_901_eus-gaap--RepaymentsOfShortTermDebt_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zlvW8W8khUld"><ix:nonFraction name="us-gaap:RepaymentsOfShortTermDebt" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001903" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,811</ix:nonFraction>
</span>applied to the principal amount; (ii) $<span id="xdx_902_ecustom--DebtInstrumentAccruedInterest_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zx86s29SeOO"><ix:nonFraction name="CELU:DebtInstrumentAccruedInterest" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001904" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,073</ix:nonFraction>
</span>towards accrued interest; and (iii) $<span id="xdx_903_ecustom--DebtInstrumentRedemptionPremium_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zlkSuENUM6y8"><ix:nonFraction name="CELU:DebtInstrumentRedemptionPremium" contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001905" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">840</ix:nonFraction>
</span>of redemption premium. As of December 31, 2023, the fair value of the debt was $<span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zb3wzGbR7Hc6"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001906" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,223</ix:nonFraction>
</span>and the principal balance was $<span id="xdx_90E_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zjBE2fAXjuR8"><ix:nonFraction name="us-gaap:DebtDefaultShorttermDebtAmount" contextRef="AsOf2023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001907" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,623</ix:nonFraction></span>.
Refer to Note 4 for additional details regarding the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 12, 2024, the Company
and Yorkville entered into a forbearance agreement (&#8220;Forbearance Agreement&#8221;), pursuant to which Yorkville agreed to restrain
from enforcing its rights and remedies as a result of the event of default during the forbearance period. The forbearance period was to
continue until the earlier of January 19, 2024 or the date the Company fully repaid all amounts outstanding under the PPA (&#8220;Forbearance
Period&#8221;). During the Forbearance Period, interest accrued at <span id="xdx_907_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zKCOjTBLX1Mf" title="Annual interest rate"><ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="From2024-01-122024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001909" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>% per annum. In addition, the Company was to make a cash payment
of $<span id="xdx_90D_eus-gaap--RepaymentsOfDebt_pn3n3_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z0irwK5bUMnk" title="Cash payment"><ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2024-01-122024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001911" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,348</ix:nonFraction></span> plus per diem interest of $<span id="xdx_909_ecustom--DebtInstrumentPerDiemInterestAmount_pn3n3_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zq6ivEPVgGpf" title="Diem interest payment for each day"><ix:nonFraction name="CELU:DebtInstrumentPerDiemInterestAmount" contextRef="From2024-01-122024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001913" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7</ix:nonFraction></span> for each day after January 12, 2024 until payment was made and was required to issue Yorkville
a total of <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zUz68o3Bi3T" title="Issue of common stock"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001915" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of its common stock. On January 12, 2024, the Company issued Yorkville <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zRjl56beh1zi" title="Issue of common stock"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember" id="Fact001917" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> of its common stock in connection
with the extension of the maturity date of the PPA. The PPA was repaid in full on January 17, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 13, 2024, the Company
entered into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) with Yorkville (see Note 13).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Yorkville Convertible Promissory Note</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upon entry into the SEPA, the
Company issued Yorkville a $<span id="xdx_90E_eus-gaap--DebtInstrumentIssuedPrincipal_pn3n3_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zqRuDAcD9oRd" title="Debt issued"><ix:nonFraction name="us-gaap:DebtInstrumentIssuedPrincipal" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001919" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,150</ix:nonFraction></span> convertible promissory note for $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3n3_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zumzYzeIuaSe" title="Maximum advance amount"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001921" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,993</ix:nonFraction></span> in cash (after a <span id="xdx_90E_ecustom--ConvertiblePromissoryNoteDiscountPercentage_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zNNe1uAB2fuk" title="Original issue discount"><ix:nonFraction name="CELU:ConvertiblePromissoryNoteDiscountPercentage" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001923" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>% original issue discount). The note bears
interest at an annual rate equal to <span id="xdx_902_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_z9uR9tgy4oue" title="Annual interest rate"><ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001925" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span>% (increased to <span id="xdx_907_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zJoqJA3cJsO1" title="Line of credit increase in interest rate during period in event of default"><ix:nonFraction name="CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001927" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.0</ix:nonFraction></span>% in the event of default as provided in the note) and was scheduled to mature
on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_ddp_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zPX3slQ313a5" title="Maturity date"><ix:nonNumeric contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" format="ixt:datemonthdayyearen" id="Fact001929" name="us-gaap:DebtInstrumentMaturityDate">March 13, 2025</ix:nonNumeric></span>. The note was initially convertible into common stock at a price per share equal to $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zwwcRG4MXMc1" title="Conversion price per share"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001931" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.3171</ix:nonFraction></span>, provided however, the conversion
price was subject to reset on the earlier of (a) the fifth trading day following the effective date of the resale shelf, or (b) the six-month
anniversary of the issuance date of the convertible note (i.e., September 13, 2024). The conversion price was reset to $<span id="xdx_90E_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20240913__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zrCDfmFiJEAf" title="Minimum required daily volume weighted average price"><ix:nonFraction name="CELU:MinimumRequiredDailyVolumeWeightedAveragePrice" contextRef="AsOf2024-09-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001933" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.7546</ix:nonFraction></span> on September
13, 2024. Upon the occurrence and during the continuation of an event of default (as defined in the note), the note (including accrued
interest) may become immediately due and payable. The issuance of the common stock upon conversion of the note and otherwise under the
SEPA is capped at <span id="xdx_90F_ecustom--PercentageOfConversionOnOutstandingCommonStock_iI_pid_dp_uPure_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zYJvwSu2mJxg" title="Percentage of conversion on outstanding common stock"><ix:nonFraction name="CELU:PercentageOfConversionOnOutstandingCommonStock" contextRef="AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001935" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">19.9</ix:nonFraction></span>% of the outstanding common stock as of March 13, 2024. Further, the note and SEPA include a beneficial ownership
blocker for Yorkville such that Yorkville may not be deemed the beneficial owner of more than <span id="xdx_909_ecustom--PercentageOfBeneficialOwnershipLimitation_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zJB78gIBqVle" title="Percentage of beneficial ownership limitation"><ix:nonFraction name="CELU:PercentageOfBeneficialOwnershipLimitation" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001937" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.99</ix:nonFraction></span>% of the Company&#8217;s common stock.
As a result of the Company&#8217;s failure to file its 2023 Form 10-K by April 30, 2024 (i.e., a deemed Event of Default under the convertible
promissory note), the Company began accruing interest at the default rate of <span id="xdx_901_ecustom--DebtInstrumentDefaultInterestRate_iI_pid_dp_uPure_c20240501__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zvYpcemlyPJ6" title="Debt instrument default interest rate"><ix:nonFraction name="CELU:DebtInstrumentDefaultInterestRate" contextRef="AsOf2024-05-01_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001939" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.0</ix:nonFraction></span>% as of May 1, 2024. A further event of default occurred
as a result of the Company&#8217;s failure to file a registration statement with the SEC for the resale by Yorkville of the shares of
common stock issuable under the SEPA by May 3, 2024 (see Note 13).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 118 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company determined that
the convertible promissory note included embedded derivatives that would otherwise require bifurcation as derivative liabilities, and
neither the debt instrument nor the embedded features are required to be classified as equity. Therefore, at inception, the Company elected
to carry the convertible promissory note comprised of the debt host and the embedded derivative liabilities at fair value on a recurring
basis as permitted under ASC 825, <i>Financial Instruments</i>. Changes in fair value caused by changes in the instrument-specific credit
risk are reported in other comprehensive income, and the remaining change in fair value is reported in earnings (i.e., as a component
of other income/expense). Interest expense is a component of the change in fair value of the convertible promissory note and, therefore,
is not separately recorded. As a result of the fair value election, the original issue discount of $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zF8BAQKqJNSg"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2024-01-012024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001940" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">157</ix:nonFraction>
</span>was recorded to other expense in the consolidated statements of operations and comprehensive loss. In November 2024, Yorkville
elected to convert $<span id="xdx_908_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20241101__20241130__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zbLAEPypdqoi"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2024-11-012024-11-30_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001941" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,150</ix:nonFraction>
</span>of principal and $<span id="xdx_900_ecustom--DebtConversionOriginalDebtAccruedInterestAmount_pn3n3_c20241101__20241130__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_z2kKqmPSaKnb"><ix:nonFraction name="CELU:DebtConversionOriginalDebtAccruedInterestAmount" contextRef="From2024-11-012024-11-30_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001942" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169</ix:nonFraction>
</span>of accrued interest into <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20241101__20241130__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zOArtWavtwlb"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2024-11-012024-11-30_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001943" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">478,881</ix:nonFraction>
</span>shares of common stock. As of December 31, 2024, the fair value of the debt was $<span id="xdx_901_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zIaMp8qW1hde"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="AsOf2024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001944" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,865</ix:nonFraction>
</span>and the principal balance was $<span id="xdx_903_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_znp6F7xHbnKe"><ix:nonFraction name="us-gaap:DebtDefaultShorttermDebtAmount" contextRef="AsOf2024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact001945" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></span>.
Refer to Note 4 for additional details regarding the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 17, 2025, the Company
entered into a letter agreement with Yorkville to extend the maturity date of the convertible promissory note from <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_ddp_c20250316__20250316__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwfaYR1XLZz3" title="Maturity date"><ix:nonNumeric contextRef="From2025-03-162025-03-16_custom_YorkvilleMember_us-gaap_SubsequentEventMember" format="ixt:datemonthdayyearen" id="Fact001947" name="us-gaap:DebtInstrumentMaturityDate">March 13, 2025</ix:nonNumeric></span> to <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_ddp_c20250317__20250317__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zu81ZUjT0toh" title="Maturity date"><ix:nonNumeric contextRef="From2025-03-172025-03-17_custom_YorkvilleMember_us-gaap_SubsequentEventMember" format="ixt:datemonthdayyearen" id="Fact001949" name="us-gaap:DebtInstrumentMaturityDate">May
12, 2025</ix:nonNumeric></span>. In addition, Yorkville agreed not to declare an event of default until May 12, 2025 (the &#8220;Forbearance&#8221;). In connection
with the maturity date extension and Forbearance, the Company agreed to issue Yorkville <span id="xdx_90E_eus-gaap--SharesIssued_iI_pid_c20250317__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zx6GQLqCx0vc" title="Common stock issued pursuant to short-term debt maturity extension, shares"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2025-03-17_custom_YorkvilleMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember" id="Fact001951" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares of its Class A common stock. The
shares of Class A common stock were issued with piggyback registration rights such that the resale of such shares by Yorkville are to
be included on any such registration statement filed by the Company following the issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Unsecured Senior Convertible Notes </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On November 25, 2024, the Company
entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an accredited investor, pursuant to which the
Company agreed to sell and issue, in one or more closings, to the investor and other purchasers in a private placement transaction, unsecured
senior convertible notes and warrants for an aggregate original principal amount of up to $<span id="xdx_905_ecustom--NotesAndPurchaserWarrantsPrincipalAmount_iI_pn3n3_c20241125__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zqaokJSO2pog" title="Notes and purchaser warrants principal amount"><ix:nonFraction name="CELU:NotesAndPurchaserWarrantsPrincipalAmount" contextRef="AsOf2024-11-25_srt_MaximumMember_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001953" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span>. The Company issued and sold $<span id="xdx_90C_ecustom--ProceedsFromNotesAndPurchaserWarrants_pn3n3_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_z0IQx2QS1rh7" title="Proceeds from notes and purchaser warrants"><ix:nonFraction name="CELU:ProceedsFromNotesAndPurchaserWarrants" contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001955" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></span> unsecured
senior convertible notes and warrants to acquire up to an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zzUAAFz4iTCk" title="Notes and purchaser warrant share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001957" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">263,156</ix:nonFraction></span> shares of Class A common stock (the &#8220;November 2024
Purchaser Warrants&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The unsecured senior convertible
notes bear interest at an annual rate of <span id="xdx_909_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zYxt2iPbeio8" title="Bearing interest"><ix:nonFraction name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001959" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.0</ix:nonFraction></span>% (increasing to <span id="xdx_905_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zBdu5baJ7N6h" title="Increase in bearing interest"><ix:nonFraction name="CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001961" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.0</ix:nonFraction></span>% in the event of default as defined in the Purchase Agreement) and have
a maturity date of one year from the date of issuance. Upon an event of default, the notes are convertible at the purchasers&#8217; option
into shares of the Company&#8217;s Class A common stock at a price per share equal to (i) $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zi0JEwZs3O88" title="Stock price per share"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001963" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction></span> (adjusted for stock splits, reverse stock
splits, stock dividends, or similar transactions); or (ii) the offering price of a subsequent financing transaction with gross proceeds
of $<span id="xdx_90F_ecustom--MinimumGrossProceeds_pn3n3_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zhhbz5TvXbD8" title="Gross proceeds"><ix:nonFraction name="CELU:MinimumGrossProceeds" contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001965" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USDPShares">2,500</ix:nonFraction></span> or more (a &#8220;Subsequent Financing&#8221;), subject to a floor price of $<span id="xdx_90A_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zZgHf43ynl4b" title="Floor price"><ix:nonFraction name="CELU:FloorPrice" contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember" id="Fact001967" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share. The unsecured senior convertible
notes include customary negative covenants restricting the Company&#8217;s ability to incur other indebtedness other than as permitted,
pay dividends to stockholders, grant or suffer to exist a security interest in any of the Company&#8217;s assets, other than as permitted,
amongst others. In addition, the unsecured senior convertible notes include customary events of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The November 2024 Purchaser Warrants
entitle the investors to purchase shares of common stock equal to each purchaser&#8217;s subscription amount divided by the exercise price
of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125_zWFBf91CgRbl" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-11-25" id="Fact001969" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction></span> per share. The exercise price, and the number of shares of common stock issuable under the November 2024 Purchaser Warrants,
are subject to a one-time reset upon the completion of a Subsequent Financing, subject to a floor price of $<span id="xdx_906_ecustom--FloorPrice_iI_pid_c20241125_zjCfAPiEvHRg" title="Floor price"><ix:nonFraction name="CELU:FloorPrice" contextRef="AsOf2024-11-25" id="Fact001971" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.00</ix:nonFraction></span> per share. The Purchaser
Warrants are immediately exercisable and have a <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125_zGMYRS7Phzpg" title="Warrant outstanding term"><ix:nonNumeric contextRef="AsOf2024-11-25" format="ixt-sec:duryear" id="Fact001973" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span>-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the transaction,
the Company agreed to issue a <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125_zuS67AQUxVBl" title="Warrant outstanding term"><ix:nonNumeric contextRef="AsOf2024-11-25" format="ixt-sec:duryear" id="Fact001975" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span>-year warrant to purchase a number of shares of common stock equal to <span id="xdx_90F_ecustom--PercentageOfCashFeeEqualToAggregateProceeds_pid_dp_uPure_c20241125__20241125_zrDzroq94yb4" title="Percentage of cash fee equal to aggregate proceeds"><ix:nonFraction name="CELU:PercentageOfCashFeeEqualToAggregateProceeds" contextRef="From2024-11-252024-11-25" id="Fact001977" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></span>% of the proceeds of the transaction
(the &#8220;November 2024 Placement Agent Warrants&#8221;), at an exercise price equal to <span id="xdx_905_ecustom--PercentageOfExercisePriceEqualToOfferingPrice_pid_dp_uPure_c20241125__20241125_z8GFkK9M0PJi" title="Percentage of exercise price equal to offering price"><ix:nonFraction name="CELU:PercentageOfExercisePriceEqualToOfferingPrice" contextRef="From2024-11-252024-11-25" id="Fact001979" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125</ix:nonFraction></span>% of the offering price. The November 2024
Placement Agent Warrants are subject to the same one-time exercise price adjustment provision as the November 2024 Purchaser Warrants
in connection with a Subsequent Financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company determined
that the unsecured senior convertible notes included embedded derivatives that would otherwise require bifurcation as derivative
liabilities, and neither the debt instrument nor the embedded features are required to be classified as equity. Therefore, at
inception, the Company elected to carry the unsecured senior convertibles note comprised of the debt host and the embedded
derivative liabilities at fair value on a recurring basis as permitted under ASC 825, <i>Financial Instruments</i>. Changes in fair
value caused by changes in the instrument-specific credit risk are reported in other comprehensive income, and the remaining change
in fair value is reported in earnings (i.e., as a component of other income/expense). Interest expense is a component of the change
in fair value of the unsecured senior convertible notes and, therefore, is not separately recorded. The November 2024 Purchaser and
Placement Agent Warrants are classified as liabilities since the exercise price was not determined at issuance and may be
subsequently adjusted in connection with a Subsequent Financing. The fair value of the November 2024 Placement Agent Warrants has
been treated as a transaction cost and was reduced from the cash proceeds to arrive at the net proceeds from the transaction. As a
result of the fair value election, a charge of $<span id="xdx_90A_eus-gaap--OtherExpenses_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zczTZ41mF9m9" title="Other expenses"><ix:nonFraction name="us-gaap:OtherExpenses" contextRef="From2024-01-012024-12-31_custom_UnsecuredSeniorConvertibleNotesMember15557562" id="Fact001981" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">478</ix:nonFraction></span>
was recorded to other expense in the consolidated statements of operations and comprehensive loss for the difference between the net
proceeds from the transaction and the aggregate fair value of the unsecured senior convertible notes and November 2024 Purchaser and
Placement Agent Warrants at issuance. As of December 31, 2024, the fair value of the debt was $<span id="xdx_908_ecustom--ShorttermDebtUnsecuredSeniorConvertibleNotes_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_z3vKcOwv2cOk" title="Fair value of debt"><ix:nonFraction name="CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes" contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember15557609" id="Fact001983" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">620</ix:nonFraction></span>
and the principal balance was $<span id="xdx_900_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zXsdSvxB7f36" title="Short-term debt, unpaid principal balance"><ix:nonFraction name="us-gaap:DebtDefaultShorttermDebtAmount" contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember15557609" id="Fact001985" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></span>.
Refer to Note 4 for additional details regarding the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 119 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Short-Term Debt - Other and CEO Promissory Note</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On August 21, 2023, the Company
entered into a loan agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri, and two unaffiliated lenders, providing
for a loan in the aggregate principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zbdjUEhRr5h3" title="Principal amont"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember" id="Fact001987" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span> (of which Dr. Hariri contributed $<span id="xdx_901_ecustom--DebtInstrumentContributionAmount_iI_pn3n3_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zqW02L1sOXX3" title="Debt instrument contribution amount"><ix:nonFraction name="CELU:DebtInstrumentContributionAmount" contextRef="AsOf2023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember" id="Fact001989" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span>), or the &#8220;Loan.&#8221; The Loan bears
interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_z69gi4gmear2" title="Loan interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember" id="Fact001991" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>% per year, with the first year of interest being paid in kind on the last day of each month and matured on
<span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20230821__20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zotw7jUCBqid" title="Maturity date"><ix:nonNumeric contextRef="From2023-08-212023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember" format="ixt:datemonthdayyearen" id="Fact001993" name="us-gaap:DebtInstrumentMaturityDate">August 21, 2024</ix:nonNumeric></span>. Pursuant to the terms of the Loan, the Company is required to apply the net proceeds from a subsequent transaction (as
defined) in which the Company receives gross proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromOtherShortTermDebt_pn3n3_c20230821__20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zjuKWyn9npXe" title="Gross proceeds"><ix:nonFraction name="us-gaap:ProceedsFromOtherShortTermDebt" contextRef="From2023-08-212023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember" id="Fact001995" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,500</ix:nonFraction></span> or more to repay the Loan. The Company did not repay the Loan upon receipt
of the letter of credit funds in connection with signing the lease amendment (see Note 11) or the January 2024 PIPE (see Note 13), both
of which were defined as subsequent transactions. The lenders agreed to a loan amendment whereby the loan maturity date was extended to
December 31, 2024, and on September 30, 2024, Dr. Hariri and the two unaffiliated lenders entered into an assignment agreement whereby
Dr. Hariri assumed the full loan in exchange for repayment of the other lenders&#8217; respective principal loan amount, plus accrued
interest. As a result, the loan was reclassified from short-term debt - unaffiliated to short-term debt - related parties. On January
29, 2025, Dr. Hariri extended the maturity date of the Loan from December 31, 2024 to December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On October 12, 2023, in order
to further address the Company&#8217;s immediate working capital requirements, Dr. Hariri and the Company signed a promissory note for
$<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zcMYknctZn67" title="Principal amont"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember" id="Fact001997" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">285</ix:nonFraction></span> which bears interest at a rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20231012__20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zoBuhnrs4wAd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-10-122023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember" id="Fact001999" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>% per year. The note matures together with the outstanding principal amount and accrued and
unpaid interest upon the earlier of <span id="xdx_90B_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20231012__20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_z4REyKsAH5M7" title="Pre-paid advance maturity period"><ix:nonNumeric contextRef="From2023-10-122023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember" format="ixt-sec:durmonth" id="Fact002001" name="us-gaap:LineOfCreditFacilityExpirationPeriod">12</ix:nonNumeric></span> months from the date of the note or upon a change of control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, there
was no other short-term debt and the carrying value of the CEO promissory note inclusive of accrued interest was $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20241231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zXsNFuI8eAF8" title="Carrying value of short-term debt"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-12-31_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember" id="Fact002003" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,876</ix:nonFraction></span>. As of December
31, 2023, the carrying value of the other short-term debt and the CEO promissory note inclusive of accrued interest was $<span id="xdx_902_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20231231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zIqfjHOFdT37" title="Carrying value of short-term debt"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2023-12-31_custom_ChairmanAndChiefExecutiveOfficerMember" id="Fact002005" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,108</ix:nonFraction></span> and $<span id="xdx_90F_ecustom--OtherShortTermDebtDueToRelatedParty_iI_pn3n3_c20231231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zIoN2C7pvr7b" title="Other short term debt due to related party"><ix:nonFraction name="CELU:OtherShortTermDebtDueToRelatedParty" contextRef="AsOf2023-12-31_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember" id="Fact002007" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,419</ix:nonFraction></span>,
respectively. At December 31, 2024 and 2023, the carrying amounts of the loans were deemed to approximate fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Short-Term Debt &#8211; Related Parties - C.V.
Starr and RWI</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>C.V. Starr &amp; Co., Inc</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 17, 2023, the Company
entered into a loan agreement (the &#8220;Starr Bridge Loan&#8221;) with C.V. Starr &amp; Co., Inc. (&#8220;C.V. Starr&#8221;), a stockholder
of the Company, for an aggregate principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zoyjRRhSaYB5"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember" id="Fact002008" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction>
</span>net of an original issue discount of $<span id="xdx_90A_ecustom--DebtInstrumentOriginalIssueDiscount_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z9whcFx8iuN4"><ix:nonFraction name="CELU:DebtInstrumentOriginalIssueDiscount" contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember" id="Fact002009" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">100</ix:nonFraction></span>.
The loan bears interest at a rate equal to <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z03A3essdUH5"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember" id="Fact002010" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.0</ix:nonFraction></span>%
per year or <span id="xdx_900_ecustom--DebtInstrumentInterestRateEffectivePercentageInEventOfDefault_iI_pid_dp_uPure_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zRCD2cA2zgL2" title="Effective percentage in event of default"><ix:nonFraction name="CELU:DebtInstrumentInterestRateEffectivePercentageInEventOfDefault" contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember" id="Fact002012" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>%
in the event of default, with the first year of interest being paid in kind on the last day of each month, and was scheduled to mature
on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20230317__20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zEwur4td2ZOd"><ix:nonNumeric contextRef="From2023-03-172023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember" format="ixt:datemonthdayyearen" id="Fact002013" name="us-gaap:DebtInstrumentMaturityDate">March
17, 2025</ix:nonNumeric></span>. In addition, the parties entered into a warrant agreement to acquire up to an aggregate <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_dd_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zzCLqSRPRt65"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember" id="Fact002014" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction>
</span>shares of Class A common stock (&#8220;Starr Warrant&#8221;), at a purchase price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zqTtew2C4tK7"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember" id="Fact002015" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.25</ix:nonFraction>
</span>per whole share underlying the Starr Warrant or $<span id="xdx_90E_ecustom--ShareIssuedPurchasedPrice_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zqiFSRFEmZb" title="Share issued purchased price"><ix:nonFraction name="CELU:ShareIssuedPurchasedPrice" contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember" id="Fact002017" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">94</ix:nonFraction></span>.
The Starr Warrant has a five<span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zSjWof9RusY4" style="display: none"><ix:nonNumeric contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember" format="ixt-sec:duryear" id="Fact002018" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span>-year
term and had an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zEBymEqYunn3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember" id="Fact002019" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.10</ix:nonFraction>
</span>per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In June 2023, in connection with
the Amended RWI Loan (as defined below), the Company granted C.V. Starr additional warrants to acquire up to an aggregate <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zhYRS7YIp159" title="Warrants to purchase Class A common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-30_us-gaap_WarrantMember_custom_LoanAgreementMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember" id="Fact002021" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares
of its Class A common stock (&#8220;Starr Additional Warrant&#8221; and in combination with Starr Warrant, &#8220;Starr Warrants&#8221;),
which additional warrants have a <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_znZKBAhBmZ82" title="Warrants to purchase Class A common stock"><ix:nonNumeric contextRef="AsOf2023-06-30_us-gaap_WarrantMember_custom_LoanAgreementMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember" format="ixt-sec:duryear" id="Fact002023" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span>-year term and had an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zsBKavssXCXd" title="Exercise per share price (in Dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-30_us-gaap_WarrantMember_custom_LoanAgreementMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember" id="Fact002025" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.10</ix:nonFraction></span> per share. The Company applied the guidance for this transaction
in accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i> and ASC 815, <i>Derivatives and Hedging</i>. The net proceeds
of the Starr Bridge Loan and Starr Additional Warrant were recorded at fair value. The fair value of the Starr Additional Warrant was
determined using a Black-Scholes option pricing model. The Starr Warrants met the requirements for a derivative scope exception under
ASC 815-10-15--74(a) for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the terms of the Starr Bridge
Loan, the Company agreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends to stockholders,
repay or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of the Company&#8217;s
assets, other than as permitted, or hold cash and cash equivalents less than $<span id="xdx_90D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230630__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z8lQ0awJMlya" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-06-30_custom_LoanAgreementMember_custom_CVStarrCoIncMember" id="Fact002027" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span> for more than five consecutive business days. During
the year ended December 31, 2023, the Company&#8217;s cash and cash equivalents fell below the $<span id="xdx_904_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zkZLrsnBPfG7" title="Fall in cash and cash equivalents"><ix:nonFraction name="CELU:FallInCashAndCashEquivalents" contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_CVStarrCoIncMember" id="Fact002029" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span> minimum liquidity covenant, which
per the terms of the loan agreement caused an event of default. Therefore, the Company reclassified the loan as a current liability reflected
within short-term debt - related parties on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 12, 2024, the Company
entered into an amendment which terminated the minimum $<span id="xdx_907_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zL4u0X3gMAu8" title="Fall in cash and cash equivalents"><ix:nonFraction name="CELU:FallInCashAndCashEquivalents" contextRef="AsOf2024-01-12_custom_LoanAgreementMember_custom_CVStarrCoIncMember" id="Fact002031" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span> liquidity covenant requirement. In addition to the negative covenants in
the Starr Bridge Loan, the Starr Bridge Loan includes customary events of default and the Company granted C.V. Starr a senior security
interest in all of its assets, pari passu with RWI (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 120 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 13, 2024, the Company
and C.V. Starr entered into a forbearance agreement (&#8220;Starr Forbearance Agreement&#8221;) with respect to the Starr Bridge Loan.
Under the Starr Forbearance Agreement, (i) C.V. Starr agreed not to exercise its rights and remedies upon the occurrence of any default
under the Starr Bridge Loan until the Company&#8217;s obligations in respect of the Yorkville convertible promissory note have been indefeasibly
paid in full, (ii) C.V. Starr consented to the Company&#8217;s incurrence of indebtedness under the Yorkville convertible promissory note,
(iii) C.V. Starr consented to cash payments required to be made under the SEPA and the Yorkville convertible promissory note, (iv) the
Company agreed to increase the interest rate on the loan outstanding under the Starr Bridge Loan by <span id="xdx_905_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zvUVpCNfamv5" title="Increase interest rate on loan outstanding by basis points"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember" id="Fact002033" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span> basis points and (v) the Company
agreed to amend the exercise price of (x) that certain warrant to acquire <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zc4aEW9vqFef" title="Warrants to purchase Class A common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember" id="Fact002035" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> shares of the Company&#8217;s common stock for $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z9NFnBki9O2i" title="Purchase price of per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember" id="Fact002037" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.10</ix:nonFraction></span>
per share, expiring <span id="xdx_90A_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_za9yhXBQjITk" title="Warrant expiration date"><ix:nonNumeric contextRef="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember" format="ixt:datemonthdayyearen" id="Fact002039" name="CELU:ClassOfWarrantOrRighstExpirationDate">March 17, 2028</ix:nonNumeric></span>, and (y) that certain warrant to acquire <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_z4jmsNlTHxCh" title="Warrants to purchase Class A common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember_custom_TrancheTwoWarrantMember" id="Fact002041" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> shares of common stock for $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_zc7GI4BOhWbf" title="Purchase price of per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember_custom_TrancheTwoWarrantMember" id="Fact002043" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.10</ix:nonFraction></span> per share expiring
<span id="xdx_907_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_zLnSiS0CjKUj" title="Warrant expiration date"><ix:nonNumeric contextRef="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember_custom_TrancheTwoWarrantMember" format="ixt:datemonthdayyearen" id="Fact002045" name="CELU:ClassOfWarrantOrRighstExpirationDate">June 20, 2028</ix:nonNumeric></span>, each of which are held by C.V. Starr, such that the exercise price of each such warrant in (x) and (y) is $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zaO6xlAVgH06" title="Warrants to purchase Class A common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember" id="Fact002047" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.895</ix:nonFraction></span> per share.
In addition, the interest rate of the Starr Bridge Loan was increased to <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zESUbTSpiFSk" title="Loan interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember" id="Fact002049" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13.0</ix:nonFraction></span>% per annum. The Starr Forbearance Agreement resulted in
a modification of the Starr Bridge Loan, since the change in cash flows was determined to be less than <span id="xdx_90E_ecustom--PercentageOfChangesInCashFlow_pid_dp_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zP8dfQpo2LS7" title="Percentage of changes in cash flow"><ix:nonFraction name="CELU:PercentageOfChangesInCashFlow" contextRef="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember" id="Fact002051" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%. Accordingly, no gain or loss
was recorded and the change in fair value of the Starr Warrants of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zcHgusK9am0a" title="Debt instrument, unamortized discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_CVStarrCoIncMember" id="Fact002053" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">51</ix:nonFraction></span> was recorded as a debt discount and will be amortized based on
the new effective interest rate over the term of the Starr Bridge Loan. Due to the Company&#8217;s failure to make certain interest payments
when due, the Company began accruing interest at the default rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240415__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z5gWzIfkNRY8" title="Default rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2024-04-15_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember" id="Fact002055" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16.0</ix:nonFraction></span>% as of April 5, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On February 12, 2025, the Company
entered into a binding term sheet with C.V. Starr, pursuant to which C.V. Starr agreed to, among other things, an extension of the Starr
Forbearance Agreement whereby C.V. Starr agreed not to exercise its rights and remedies upon the occurrence of any default under the Starr
Bridge Loan and whereby the maturity date of the Starr Bridge Loan has been extended to <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znq7wJDeH5Ce" title="Debt instrument maturity date"><ix:nonNumeric contextRef="From2025-02-122025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember" format="ixt:datemonthdayyearen" id="Fact002057" name="us-gaap:DebtInstrumentMaturityDate">February 15, 2026</ix:nonNumeric></span>. Pursuant to the binding term
sheet, the Company agreed to (i) use a portion of the proceeds from its next registered public offering to pay C.V. Starr approximately
$<span id="xdx_90A_eus-gaap--RepaymentsOfOtherDebt_pn3n3_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zr3kEed3T92" title="Payment of debt"><ix:nonFraction name="us-gaap:RepaymentsOfOtherDebt" contextRef="From2025-02-122025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember" id="Fact002059" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">800</ix:nonFraction></span>, representing cash interest through January 31, 2025 and (ii) issue to C.V. Starr a new five<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zriDK47dH1q2" title="Warrant term" style="display: none"><ix:nonNumeric contextRef="AsOf2025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember" format="ixt-sec:duryear" id="Fact002061" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span>-year warrant to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTFpUgkYn8Bf" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember" id="Fact002063" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span>
shares of its Class A common stock. In addition, the Company agreed to reprice certain outstanding warrants held by C.V. Starr.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024 and 2023,
the carrying value of Starr Bridge Loan, inclusive of accrued interest and net of discount, was $<span id="xdx_907_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zfGcje90qJM4" title="Short-term debt - related parties"><ix:nonFraction name="CELU:ShortTermDebtRelatedParties" contextRef="AsOf2024-12-31_custom_LoanAgreementMember_custom_CVStarrCoIncMember" id="Fact002065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,652</ix:nonFraction></span> and $<span id="xdx_904_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z6uH0OOCWMRj" title="Short-term debt - related parties"><ix:nonFraction name="CELU:ShortTermDebtRelatedParties" contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_CVStarrCoIncMember" id="Fact002067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,523</ix:nonFraction></span>, respectively. The carrying
amounts of the Starr Bridge Loan were deemed to approximate fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Resorts World Inc Pte Ltd</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On May 16, 2023, with written
consent provided by Yorkville, the Company entered into a senior secured loan agreement (&#8220;RWI Bridge Loan&#8221;) with Resorts World
Inc Pte Ltd, (&#8220;RWI&#8221;) providing for an initial loan in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zTgQBRo1Syd8" title="Principal amont"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember" id="Fact002069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></span> net of an original issue discount
of $<span id="xdx_90E_ecustom--DebtInstrumentDiscount_iI_pn3n3_c20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zyaRxZoBaHl2" title="Discount"><ix:nonFraction name="CELU:DebtInstrumentDiscount" contextRef="AsOf2023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember" id="Fact002071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">120</ix:nonFraction></span>, which bears interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zRoB7Q0TNbb6" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-05-162023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember" id="Fact002073" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% per year or <span id="xdx_908_ecustom--DebtInstrumentInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zECKK1IiNIw6" title="Interest rate during period in event of default"><ix:nonFraction name="CELU:DebtInstrumentInterestRateDuringPeriodInEventOfDefault" contextRef="From2023-05-162023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember" id="Fact002075" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.5</ix:nonFraction></span>% in the event of default, with the first year of interest being paid
in kind on the last day of each month, and matured on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zUKZuv4HB4V2" title="Maturity date"><ix:nonNumeric contextRef="From2023-05-162023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember" format="ixt:datemonthdayyearen" id="Fact002077" name="us-gaap:DebtInstrumentMaturityDate">June 14, 2023</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On June 21, 2023, the Company
closed on an amended and restated senior secured loan agreement (&#8220;Amended RWI Loan&#8221;), to amend and restate the previous senior
secured loan agreement, in its entirety. The Amended RWI Loan provided for an additional loan in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdXZBrm2lARk"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" id="Fact002078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></span>
net of an original issue discount of $<span id="xdx_90F_ecustom--DebtInstrumentDiscount_iI_pn3n3_c20230621__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zCXxZWt6Ezr6"><ix:nonFraction name="CELU:DebtInstrumentDiscount" contextRef="AsOf2023-06-21_us-gaap_BridgeLoanMember_custom_InitialLoanMember" id="Fact002079" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">678</ix:nonFraction></span>,
which bears interest at a rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zUIsEOrQd1I7"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-06-212023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" id="Fact002080" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>%
per year or <span id="xdx_90A_ecustom--DebtInstrumentInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdVlKpZJul2l"><ix:nonFraction name="CELU:DebtInstrumentInterestRateDuringPeriodInEventOfDefault" contextRef="From2023-06-212023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" id="Fact002081" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.5</ix:nonFraction></span>%
in the event of default, with the first year of interest being paid in kind on the last day of each month, and was schedule to mature
on <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_ddp_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zawp11OqPaS4"><ix:nonNumeric contextRef="From2023-06-212023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" format="ixt:datemonthdayyearen" id="Fact002082" name="us-gaap:DebtInstrumentMaturityDate">March
17, 2025</ix:nonNumeric></span>. The Amended RWI Loan extended the maturity date of the initial loan to March 17, 2025. In addition, the Amended RWI
Loan provided for the issuance of warrants to acquire up to an aggregate <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zyP4srljLJf4"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" id="Fact002083" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span>
shares of the Company&#8217;s Class A common stock (&#8220;RWI Warrant&#8221;), at a purchase price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zW0rrs5fgJF5"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" id="Fact002084" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.25</ix:nonFraction></span>
per whole share underlying the RWI Warrant (or an aggregate purchase price of $<span id="xdx_90D_ecustom--ShareIssuedPurchasedPrice_iI_pn3n3_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zC7nwY3FxHl8" title="Share issued purchase price"><ix:nonFraction name="CELU:ShareIssuedPurchasedPrice" contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" id="Fact002086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">375</ix:nonFraction></span>).
The RWI Warrant has a <span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"></span>five<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zrWErKGQkTbi" title="Warrant term (years)" style="display: none"><ix:nonNumeric contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" format="ixt-sec:duryear" id="Fact002088" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span>-year term and an exercise
price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zidNSrUCfNof" title="Exercise per share price (in Dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" id="Fact002090" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.10</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the Amended
RWI Loan, the Company was required to apply the net proceeds to the trigger payments due to Yorkville pursuant to the PPA. In addition,
the Company agreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends to stockholders, repay
or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of its assets, other than as
permitted, or hold cash and cash equivalents of less than $<span id="xdx_904_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230914__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zCVkeFF9B6L" title="Cash and cash equivalents"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-14_us-gaap_BridgeLoanMember" id="Fact002092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span> for more than five consecutive business days, and includes customary
events of default. The Company granted RWI a senior security interest in all of its assets, pari passu with C.V. Starr pursuant to the
Starr Bridge Loan. The Company and RWI signed a forbearance agreement on September 14, 2023, whereby RWI agreed to forebear any action
under the terms of the Amended RWI Loan in relation to the minimum $<span id="xdx_902_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20230914__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z6nRumKmOxie" title="Fall in cash and cash equivalents"><ix:nonFraction name="CELU:FallInCashAndCashEquivalents" contextRef="AsOf2023-09-14_us-gaap_BridgeLoanMember" id="Fact002094" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span> liquidity covenant and with respect to any potential default
in relation to the Company&#8217;s outstanding debt owed to Yorkville until December 31, 2023. The Company reclassified the loan as a
current liability reflected within short-term debt - related parties on the consolidated balance sheets. Pursuant to the amendment on
January 12, 2024, see below, the minimum $<span id="xdx_907_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z3jtfnxBxGO3" title="Fall in cash and cash equivalents"><ix:nonFraction name="CELU:FallInCashAndCashEquivalents" contextRef="AsOf2024-01-12_us-gaap_BridgeLoanMember" id="Fact002096" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span> liquidity covenant requirement was terminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounted for the
Amended RWI Loan in accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i> and ASC 815, <i>Derivatives and Hedging</i>.
The net proceeds of the Amended RWI Loan and RWI Warrant were recorded at fair value, which resulted in a total discount of $<span id="xdx_908_ecustom--DiscountOnWarrantAmount_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zBbBGCNLt10c" title="Discount on warrant amount"><ix:nonFraction name="CELU:DiscountOnWarrantAmount" contextRef="AsOf2024-01-12_us-gaap_BridgeLoanMember" id="Fact002098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,151</ix:nonFraction></span> based
on the difference between the proceeds and fair value which were recorded as a loss within other income (expense) on the consolidated
statements of operations and comprehensive loss. The fair value of the RWI Warrant was determined using a Black-Scholes option pricing
model. The RWI Warrant met the requirements for a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed
to an entity&#8217;s own stock and classified in stockholders&#8217; equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 121 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 12, 2024, the Company
entered into a second amended and restated senior secured loan agreement (&#8220;RWI Second Amended Bridge Loan&#8221;), to amend and
restate the previously announced senior secured loan agreement with RWI dated as of May 16, 2023, as amended on June 20, 2023, in its
entirety. The RWI Second Amended Bridge Loan provided for an additional loan in the aggregate principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zzEllrog4Ii8" title="Principal amont"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" id="Fact002100" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,000</ix:nonFraction></span> net of an original
issue discount of $<span id="xdx_90D_ecustom--DebtInstrumentOriginalIssueDiscount_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdytJFBLvMA5" title="Original issue discount"><ix:nonFraction name="CELU:DebtInstrumentOriginalIssueDiscount" contextRef="AsOf2024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" id="Fact002102" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,750</ix:nonFraction></span>, which bears interest at a rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240112__20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zyksgdLle4p" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2024-01-122024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" id="Fact002104" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% per year, with the first year of interest being paid in kind on the
last day of each month, and matures on <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20240112__20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zgLGuu7uN392" title="Maturity date"><ix:nonNumeric contextRef="From2024-01-122024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" format="ixt:datemonthdayyearen" id="Fact002106" name="us-gaap:DebtInstrumentMaturityDate">July 16, 2025</ix:nonNumeric></span>. In addition, the RWI Second Amended Bridge Loan provides for the issuance of a <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zIcHd3biS7cf" title="Term (years)"><ix:nonNumeric contextRef="AsOf2024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember" format="ixt-sec:duryear" id="Fact002108" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span>-year
immediately exercisable warrant to acquire up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember_zLaVUFeQN3z6" title="Warrants to purchase Class A common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-01-12_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember_custom_AdditionalLoanMember" id="Fact002110" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,650,000</ix:nonFraction></span> shares of Class A common stock (&#8220;Tranche #1 Warrant&#8221;), and a warrant
to acquire up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_znnXJkv2AU7a" title="Warrants to purchase Class A common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-01-12_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember" id="Fact002112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,350,000</ix:nonFraction></span> shares of Class A common stock, which would only be exercisable upon the later of (x) stockholder approval
for Nasdaq purposes of its exercise price, (y) CFIUS clearance and (z) six months from issuance date (&#8220;Tranche #2 Warrant&#8221;)
and will expire <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zGWRpWRxv7q" title="Term (years)"><ix:nonNumeric contextRef="AsOf2024-01-12_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember" format="ixt-sec:duryear" id="Fact002114" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span> years after it becomes exercisable. The Tranche #1 Warrant and Tranche #2 Warrant were each issued on January 16, 2024
in conjunction with the close of the RWI Second Amended Bridge Loan. The Tranche #1 Warrant has an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240116__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zKffveNuw6z2" title="Exercise per share price (in Dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-16_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember" id="Fact002116" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.4898</ix:nonFraction></span> per share.
The Tranche #2 Warrant became exercisable on July 15, 2024 and has an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240715__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zILL7YPzKjzf" title="Exercise per share price (in Dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-07-15_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember" id="Fact002118" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.988</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the RWI
Second Amended Bridge Loan, the Company was required to apply the proceeds of the additional loan (i) to the payment in full of all outstanding
amounts owed to Yorkville under the PPA, (ii) to the payment of invoices of certain critical vendors, (iii) to the first settlement payment
owed to Palantir (see Note 12), and (iv) for working capital and other purposes pre-approved by RWI. Pursuant to the terms of the RWI
Second Amended Bridge Loan, the Company agreed to customary negative covenants restricting its ability to pay dividends to stockholders,
repay or incur other indebtedness other than as permitted, or grant or suffer to exist a security interest in any of the Company&#8217;s
assets, other than as permitted. In addition, the Company agreed to apply net revenues received through the sale of its products/provision
of services in connection with or related to its distribution and manufacturing agreement with Genting Innovation Pte Ltd (&#8220;Genting
Innovation&#8221;), a related party, as a prepayment towards the loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The RWI Second Amended Bridge
Loan resulted in an extinguishment of the Amended RWI Loan, since the change in cash flows exceeded 10%. As a result, the Company record
a loss on extinguishment equal to the difference between (i) the fair values of the new loan and Tranche #1 and Tranche #2 Warrants and
(ii) the previous carrying amount of the Amended RWI Loan, or $<span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zvlAExeNruhg" title="Short-term debt"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-01-12_us-gaap_BridgeLoanMember" id="Fact002120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,908</ix:nonFraction></span>. The Company has not elected to carry the RWI Second Amended Bridge
Loan at fair value, as permitted under ASC 815, <i>Derivatives and Hedging</i> and ASC 825, <i>Fair Value Option for Financial Instruments</i>.
The Tranche #1 Warrant has been classified in stockholders&#8217; equity, since it is exercisable into a fixed number of the Company&#8217;s
own shares at a known exercise price, and therefore is not required to be classified as a liability under ASC 480, <i>Distinguishing Liabilities
from Equity</i>. The Tranche #2 Warrant was initially classified as a liability, since the exercise price (i.e., Minimum Price) was not
determined at issuance and may have been subsequently adjusted. As of July 15, 2024, the Tranche #2 Warrant became exercisable and no
longer contains adjustment provisions to the exercise price that are not indexed to the Company&#8217;s own stock, resulting in the reclassification
from liability to equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company and RWI also entered
into an investor rights agreement dated as of January 12, 2024. The investor rights agreement provides RWI certain information and audit
rights, as well as registration rights with respect to the shares underlying the Tranche #1 Warrant and Tranche #2 Warrant, including
both the undertaking to file a registration statement within 45 days of filing of the 2023 Form 10-K, &#8220;piggyback&#8221; registration
rights, as well as the right to request up to three demand rights for underwritten offerings per year; in each case subject to customary
&#8220;underwriter cutback&#8221; language as well as any objections raised by the Securities and Exchange Commission to inclusion of
securities. If the initial registration statement was not filed on or prior to May 15, 2024, the investor rights agreement provided for
partial liquidating damages equal to <span id="xdx_90F_ecustom--PercentageOfPartialLiquidatingDamagesOnPurchasePrice_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember_zx1nUieJ1XQh" title="Percentage of partial liquidating damages on purchase price"><ix:nonFraction name="CELU:PercentageOfPartialLiquidatingDamagesOnPurchasePrice" contextRef="AsOf2024-01-12_custom_InitialAndSecondTrancheMember" id="Fact002122" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span>% of the purchase price of the Tranche #1 and Tranche #2 Warrants amount each month, up to a maximum
of <span id="xdx_905_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember__srt--RangeAxis__srt--MaximumMember_zADvUSH5nhY8" title="Percentage of partial liquidating damages on subscription amount"><ix:nonFraction name="CELU:PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" contextRef="AsOf2024-01-12_custom_InitialAndSecondTrancheMember_srt_MaximumMember" id="Fact002124" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.0</ix:nonFraction></span>%, plus interest thereon accruing daily at a rate of <span id="xdx_908_ecustom--DailyInterestAccruingRate_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember_zEuxq7KRqyOd" title="Daily interest accruing rate"><ix:nonFraction name="CELU:DailyInterestAccruingRate" contextRef="AsOf2024-01-12_custom_InitialAndSecondTrancheMember" id="Fact002126" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.0</ix:nonFraction></span>% per annum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 13, 2024, the Company
and RWI entered into a second forbearance agreement (&#8220;RWI 2nd Forbearance Agreement&#8221;). Under the RWI 2nd Forbearance Agreement,
(i) RWI agreed not to exercise its rights and remedies upon the occurrence of any default under the RWI Second Amended Bridge Loan until
the Company&#8217;s obligations in respect of the Yorkville convertible promissory note have been indefeasibly paid in full or March 13,
2025, whichever occurs first, (ii) RWI consented to the Company&#8217;s incurrence of indebtedness under the Yorkville convertible promissory
note, (iii) RWI consented to cash payments required to be made under the SEPA and the Yorkville convertible promissory note, (iv) the
Company agreed to increase the interest rate on the loan outstanding under the RWI Loan Agreement by <span id="xdx_90C_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z4U5BpqXOaCe" title="Increase interest rate on loan outstanding by basis points"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2024-03-132024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember" id="Fact002128" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span> basis points, or from <span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDeDFfe9AsAl" title="Variable interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2024-03-132024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember" id="Fact002130" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% to
<span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zsP2Ah3UhUo7" title="Variable interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2024-03-132024-03-13_us-gaap_BridgeLoanMember_us-gaap_WarrantMember_srt_MaximumMember" id="Fact002132" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13.5</ix:nonFraction></span>% per annum, and (v) the Company agreed to issue RWI a warrant to acquire up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zt7mFgp7IfIg" title="Warrants to purchase Class A common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember" id="Fact002134" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span> shares of common stock (&#8220;RWI New Warrant&#8221;),
which expires June 20, 2028 and has an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zbc9z0r8ODi8" title="Exercise per share price (in Dollars per share)"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember" id="Fact002136" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.895</ix:nonFraction></span> per share. The RWI 2nd Forbearance Agreement resulted in a modification
of the RWI Second Amended Bridge Loan, since the change in cash flows was less than <span id="xdx_904_ecustom--PercentageOfChangesInCashFlow_pid_dp_uPure_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zMAdKWp0k9wf" title="Percentage of changes in cash flow"><ix:nonFraction name="CELU:PercentageOfChangesInCashFlow" contextRef="From2024-03-132024-03-13_us-gaap_BridgeLoanMember_us-gaap_WarrantMember_srt_MaximumMember" id="Fact002138" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%. Accordingly, no gain or loss was recorded, and
the fair value of the RWI New Warrant of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqXtRNoTm315" title="Debt instrument, unamortized discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember15559390" id="Fact002140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,162</ix:nonFraction></span> was recorded as debt discount and will be amortized based on the new effective interest
rate over the term of the RWI Second Amended Bridge Loan. Due to the Company&#8217;s failure to make certain interest payments when due,
the Company began accruing interest on the Amended RWI Loan balance of approximately $<span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20240805__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRXqGRYwEYZ" title="Short-term debt"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-08-05_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember" id="Fact002142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,700</ix:nonFraction></span> at the default rate of <span id="xdx_90C_ecustom--DebtInstrumentDefaultInterestRate_iI_pid_dp_uPure_c20240805__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember_zN4itdkarbyd" title="Debt instrument default interest rate"><ix:nonFraction name="CELU:DebtInstrumentDefaultInterestRate" contextRef="AsOf2024-08-05_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember" id="Fact002144" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16.5</ix:nonFraction></span>% as of August
5, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 122 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On February 12, 2025, the Company
entered into a binding term sheet with RWI, pursuant to which RWI agreed to, among other things, an extension of the RWI 2nd Forbearance
Agreement whereby RWI has agreed not to exercise its rights and remedies upon the occurrence of any default under certain loans owed to
RWI and whereby the maturity date of the foregoing loans is extended to <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4ZxmFLG2mYk" title="Debt instrument maturity date"><ix:nonNumeric contextRef="From2025-02-122025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember" format="ixt:datemonthdayyearen" id="Fact002146" name="us-gaap:DebtInstrumentMaturityDate">February 15, 2026</ix:nonNumeric></span>. Pursuant to the RWI binding term sheet, the
Company agreed to (i) use a portion of the proceeds from its next registered public offering to pay RWI approximately $<span id="xdx_90D_eus-gaap--RepaymentsOfOtherDebt_pn3n3_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcNg3ZK1tYOk" title="Payment for debt"><ix:nonFraction name="us-gaap:RepaymentsOfOtherDebt" contextRef="From2025-02-122025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember" id="Fact002148" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,300</ix:nonFraction></span>, representing
cash interest through January 31, 2025 and (ii) issue to RWI, on July 24, 2025, a new five<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znRNUkUF9wpk" title="Warrant term (years)" style="display: none"><ix:nonNumeric contextRef="AsOf2025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember" format="ixt-sec:duryear" id="Fact002150" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span>-year warrant to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkBa73YxmTe1" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember" id="Fact002152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares
of its Class A common stock. In addition, the Company agreed to reprice certain outstanding warrants held by RWI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024 and 2023,
the carrying values of the RWI Second Amended Bridge Loan and Amended RWI Loan, inclusive of interest and net of discount was $<span id="xdx_909_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zOoCz7iI2ha" title="Short-term debt - related parties"><ix:nonFraction name="CELU:ShortTermDebtRelatedParties" contextRef="AsOf2024-12-31_us-gaap_BridgeLoanMember" id="Fact002154" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">30,275</ix:nonFraction></span>
and $<span id="xdx_902_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zU8pYDoUxsY4" title="Short-term debt - related parties"><ix:nonFraction name="CELU:ShortTermDebtRelatedParties" contextRef="AsOf2023-12-31_us-gaap_BridgeLoanMember" id="Fact002156" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,967</ix:nonFraction></span>, respectively. The carrying amounts of the RWI Second Amended Bridge Loan and Amended RWI Loan were deemed to approximate
fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40.8pt"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002158" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_805_eus-gaap--LesseeOperatingLeasesTextBlock_zk9BJsnCoqMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>11. <span id="xdx_82C_zapz0rYJQL0g">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">ROU assets represent the Company&#8217;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments
arising from the lease. The Company&#8217;s lease ROU assets and liabilities are recognized at the lease commencement date based on the
present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses its incremental
borrowing rate (&#8220;IBR&#8221;) based on the information available at the lease commencement date to determine the appropriate discount
rate by multiple asset classes. Variable lease payments that are not based on an index or that result from changes to an index subsequent
to the initial measurement of the corresponding lease liability are not included in the measurement of lease ROU assets or liabilities
and instead are recognized in earnings in the period in which the obligation for those payments is incurred. Lease terms may include options
to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. Lease expense is recognized
on a straight-line basis over the expected lease term. Rent expense was $<span id="xdx_90F_ecustom--OperatingLeasesRentExpense_pn3n3_c20240101__20241231_zKsdObsX78n2" title="Rent expense"><ix:nonFraction name="CELU:OperatingLeasesRentExpense" contextRef="From2024-01-01to2024-12-31" id="Fact002160" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,444</ix:nonFraction></span> and $<span id="xdx_90A_ecustom--OperatingLeasesRentExpense_pn3n3_c20230101__20231231_ze6GsLJzISk7" title="Rent expense"><ix:nonFraction name="CELU:OperatingLeasesRentExpense" contextRef="From2023-01-012023-12-31" id="Fact002162" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,750</ix:nonFraction></span> for the years ended December 31, 2024 and 2023,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 13, 2019, Legacy Celularity
entered into a lease agreement for a <span id="xdx_90D_ecustom--AreaOfBuilding_usqft_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_z60z2WxQP3Lj" title="Area of building"><ix:nonFraction name="CELU:AreaOfBuilding" contextRef="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember" id="Fact002164" format="ixt:numdotdecimal" decimals="INF" unitRef="sqft">147,215</ix:nonFraction>
</span>square foot facility consisting of office, manufacturing and laboratory space in Florham Park, New Jersey, which expires in <span id="xdx_900_ecustom--OperatingLeaseExpiryYear_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zhWbVzqOWcuf" title="Operating lease expiry year"><ix:nonNumeric contextRef="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember" id="Fact002166" name="CELU:OperatingLeaseExpiryYear">2036</ix:nonNumeric></span>.
The Company has the <span id="xdx_900_eus-gaap--LesseeOperatingLeaseOptionToExtend_dtY_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zmrWpUdFmIZ4" title="Option to renew lease term period."><ix:nonNumeric contextRef="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember" id="Fact002168" name="us-gaap:LesseeOperatingLeaseOptionToExtend">option to renew the term of the lease for two additional five-year terms</ix:nonNumeric></span> so long as the lease is then in full force
and effect; both option periods have been included in determining the lease term
used in recognizing the ROU assets and lease liability. The lease term commenced on <span id="xdx_900_ecustom--OperatingLeaseCommencementDate_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zCO9QgObL3z5" title="Operating lease commencement date"><ix:nonNumeric contextRef="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember" format="ixt:datemonthdayyearen" id="Fact002170" name="CELU:OperatingLeaseCommencementDate">March
1, 2020</ix:nonNumeric></span> subject to an abatement of the fixed rent for the first 13 months following the lease commencement date. The initial monthly
base rent was approximately $<span id="xdx_902_ecustom--InitialMonthlyBaseRent_pn3n3_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zfNcRCna5Uvb" title="Initial monthly base rent"><ix:nonFraction name="CELU:InitialMonthlyBaseRent" contextRef="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember" id="Fact002172" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">230</ix:nonFraction>
</span>and will increase annually. The Company is obligated to pay real estate taxes and costs related to the premises, including costs
of operations, maintenance, repair, replacement and management of the new leased premises. In connection with entering into this lease
agreement, Legacy Celularity issued a letter of credit of $<span id="xdx_902_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zlXDWUXcZpVe"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="AsOf2023-12-31_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember" id="Fact002173" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,722</ix:nonFraction></span>.
The lease agreement allows for a landlord provided tenant improvement allowance of $<span id="xdx_90F_eus-gaap--TenantImprovements_iI_pn3n3_c20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zQSRmTAtBdok"><ix:nonFraction name="us-gaap:TenantImprovements" contextRef="AsOf2019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember" id="Fact002174" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,722</ix:nonFraction>
</span>to be applied to the costs of the construction of the leasehold improvements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On September 14, 2023, the Company
entered into a lease amendment on the Company&#8217;s Florham Park, New Jersey facility to reduce the letter of credit by approximately
$<span id="xdx_90F_ecustom--ReductionInLineOfCredit_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zhi0VebCiCX6" title="Reduction in line of credit"><ix:nonFraction name="CELU:ReductionInLineOfCredit" contextRef="AsOf2023-09-14_custom_FlorhamParkNewJerseyMember" id="Fact002176" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,900</ix:nonFraction></span> for a new letter of credit in the amount of $<span id="xdx_905_ecustom--NewLineOfCredit_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zZSwrEwEM3n" title="New line of credit"><ix:nonFraction name="CELU:NewLineOfCredit" contextRef="AsOf2023-09-14_custom_FlorhamParkNewJerseyMember" id="Fact002178" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,883</ix:nonFraction></span> in exchange for higher base rental payments of approximately $<span id="xdx_909_ecustom--BaseRentalPayments_pn3n3_c20230914__20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zF8BZUGPiF54" title="Base rental payments"><ix:nonFraction name="CELU:BaseRentalPayments" contextRef="From2023-09-142023-09-14_custom_FlorhamParkNewJerseyMember" id="Fact002180" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">400</ix:nonFraction></span> per year,
effective October 1, 2023. The letter of credit, inclusive of interest earned on the account, is classified as restricted cash (non-current)
on the consolidated balance sheets. The Company evaluates changes to the terms and conditions of a lease contract to determine if they
result in a new lease or a modification of an existing lease. The Company accounted for the lease amendment as a modification since the
change in lease payments did not represent additional ROU assets. The Company reassessed the IBR, and remeasured the lease liability and
ROU asset on the modification date of September 14, 2023. As a result, the Company recorded a decrease to the ROU asset and related lease
liability in the amount of $<span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zr2b0RFxZ1w8" title="Operating lease liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-09-14_custom_FlorhamParkNewJerseyMember" id="Fact002182" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,083</ix:nonFraction></span> on the consolidated balance sheets reflecting a higher IBR due to lower Company credit rating.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002184" name="us-gaap:LeaseCostTableTextBlock"><p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zzZwHVMfDS09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The components of the Company&#8217;s
lease costs are classified on its consolidated statements of operations and comprehensive loss as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BC_zEvjVtPLhjy8" style="display: none">Schedule of Lease Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_z01c7OEiLum6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zr2OEtetPtNe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzz3O_zQPvpqJHDyz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact002186" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,911</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact002187" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,256</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--VariableLeaseCost_maLCzz3O_z2Dke0KHhmwj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact002189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,348</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="From2023-01-012023-12-31" id="Fact002190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,132</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LeaseCost_iT_mtLCzz3O_z3dA7Ic5ESs5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2024-01-01to2024-12-31" id="Fact002192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,259</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="From2023-01-012023-12-31" id="Fact002193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,388</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zjRS8CHezIHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002195" name="CELU:CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock"><p id="xdx_89B_ecustom--CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_zUyVx6kQYK87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The table below shows the cash
activity related to the Company&#8217;s lease liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zxKbWd3fK01l" style="display: none">Schedule of Cash Activity
Related to the lease Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_z4ONtJT2joai" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zFFb7eV4Du76" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash paid related to lease liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zIwRZpFFzHBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Operating cash flows from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2024-01-01to2024-12-31" id="Fact002197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,378</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2023-01-012023-12-31" id="Fact002198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,995</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_z1WuKGegbIji" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 123 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002200" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zeGRIeMXVnHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, the maturities
of the Company&#8217;s operating lease liabilities were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zKzb7mbioMVc" style="display: none">Schedule
of Future Minimum Payments under Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_493_20241231_zt7xViQDUVO" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPznn8_zAFNfB3fXeLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2024-12-31" id="Fact002202" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,452</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPznn8_zBDPk29rFmHh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-12-31" id="Fact002204" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,526</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPznn8_zH75YC2c8TZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-12-31" id="Fact002206" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,599</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPznn8_zkdyi0jYyBp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-12-31" id="Fact002208" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,673</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPznn8_zRyx60139Kuk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2029</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2024-12-31" id="Fact002210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,746</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPznn8_zkGgZuJvQkG7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2024-12-31" id="Fact002212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,821</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznn8_zpq5tiEUlcw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-12-31" id="Fact002214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,817</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zbxAJ1eTPXng" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-12-31" id="Fact002216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,269</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_z8mDX89PLs0c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-12-31" id="Fact002218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,548</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zPgp2hykfyS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, the weighted
average remaining lease term of the Company&#8217;s operating lease was <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zYNNJYgasNvl" title="Weighted average remaining lease term"><ix:nonNumeric contextRef="AsOf2024-12-31" format="ixt-sec:duryear" id="Fact002220" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">21.3</ix:nonNumeric></span> years, and the weighted average discount rate used to determine
the lease liability for the operating lease was <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_zEA7EkRXyJth" title="Weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-12-31" id="Fact002222" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14.24</ix:nonFraction></span>%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002224" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHn1dBx817ye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>12. <span id="xdx_821_za5rrymlh6ie">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Contingent Consideration Related to Business
Combinations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with Legacy Celularity&#8217;s
acquisition in 2017 of HLI Cellular Therapeutics, LLC and Anthrogenesis, the Company has agreed to pay future consideration to the sellers
upon the achievement of certain regulatory and commercial milestones. As a result, the Company recorded $<span id="xdx_90D_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HLICellularTherapeuticsLLCAndAnthrogenesisMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularitysMember_zO2zVmIlaPbl" title="Contingent consideration"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2024-12-31_custom_HLICellularTherapeuticsLLCAndAnthrogenesisMember_custom_LegacyCelularitysMember" id="Fact002226" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,413</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HLICellularTherapeuticsLLCAndAnthrogenesisMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularitysMember_zolUcu0OmSI9" title="Contingent consideration"><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="AsOf2023-12-31_custom_HLICellularTherapeuticsLLCAndAnthrogenesisMember_custom_LegacyCelularitysMember" id="Fact002228" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,606</ix:nonFraction></span> as contingent
consideration as of December 31, 2024 and 2023, respectively. During 2023, the Company discontinued its unmodified NK cell and AML Cell
Therapy clinical trials subject to the contingent consideration agreement under the Anthrogenesis acquisition and, as a result, the fair
value of the contingent consideration obligation decreased significantly as of December 31, 2023. Due to the contingent nature of these
milestone and royalty payments, there is a high degree of judgment in the management estimates that determine the fair value of the contingent
consideration. See Note 4 for further discussion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Indemnification Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In the ordinary course of business,
the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect
to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement
claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors
and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise
by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required
to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs
as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities
related to such obligations in its consolidated financial statements as of December 31, 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Agreement with Palantir Technologies Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On May 5, 2021, Legacy Celularity
executed a Master Subscription Agreement (the &#8220;Palantir MSA&#8221;) with Palantir under which it agreed to pay $<span id="xdx_90D_ecustom--PaymentsForMasterSubscriptionAgreement_pn3n3_c20210505__20210505__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--TypeOfArrangementAxis__custom--MasterSubscriptionAgreementMember_zx0KAVOYOD46" title="Payments for master subscription agreement"><ix:nonFraction name="CELU:PaymentsForMasterSubscriptionAgreement" contextRef="From2021-05-052021-05-05_custom_PalantirTechnologiesIncMember_custom_MasterSubscriptionAgreementMember" id="Fact002230" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,000</ix:nonFraction></span> over <span id="xdx_90E_ecustom--PaymentSubscriptionPeriod_dc_c20210505__20210505__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--TypeOfArrangementAxis__custom--MasterSubscriptionAgreementMember_zWtaR8iTPIqa" title="Payment subscription period"><ix:nonNumeric contextRef="From2021-05-052021-05-05_custom_PalantirTechnologiesIncMember_custom_MasterSubscriptionAgreementMember" format="ixt-sec:durwordsen" id="Fact002232" name="CELU:PaymentSubscriptionPeriod">five
years</ix:nonNumeric></span> for access to Palantir&#8217;s Foundry platform along with certain professional services. The Company intended to utilize Palantir&#8217;s
Foundry platform to secure deeper insights into data obtained from the Company&#8217;s discovery and process development, as well as manufacturing
and biorepository operations. In January 2023, the Company ceased use of the software and provided a notice of dispute to Palantir on
the basis that the software had not performed as promised and that Palantir had failed to provide the Company with the professional services
necessary to successfully implement, integrate and enable the Foundry platform. As a result, in accordance with ASC 420, <i>Exit or Disposal
Costs</i>, during the quarter ended March 31, 2023, the Company recognized the remaining related cease-use costs liability estimated based
on the discounted future cash flows of contract payments for $<span id="xdx_900_eus-gaap--BusinessExitCosts1_pn3n3_c20230101__20230331__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--IncomeStatementLocationAxis__custom--SoftwareCeaseUseCostsMember_z1e8f410E072" title="Exit or disposal costs"><ix:nonFraction name="us-gaap:BusinessExitCosts1" contextRef="From2023-01-012023-03-31_custom_PalantirTechnologiesIncMember_custom_SoftwareCeaseUseCostsMember" id="Fact002234" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">24,402</ix:nonFraction></span> which was included as software cease-use costs in the consolidated
statements of operations and comprehensive loss. On December 21, 2023, the Company entered into a settlement and release agreement with
Palantir (the &#8220;Palantir Settlement Agreement&#8221;), which was subsequently amended on January 10, 2024 and May 6, 2024, whereupon
the parties agreed that if the Company paid Palantir the settlement fees of $<span id="xdx_90E_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240110__20240110__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember_zaRZoMPdxI11" title="Agreed to pay settlement payment"><span id="xdx_908_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240506__20240506__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember_zR3lwXVXtcUa" title="Agreed to pay settlement payment"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2024-01-102024-01-10_custom_PalantirTechnologiesIncMember" id="Fact002236" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2024-05-062024-05-06_custom_PalantirTechnologiesIncMember" id="Fact002238" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,500</ix:nonFraction></ix:nonFraction></span></span>, less any amounts previously paid, and issued shares
as discussed in the <i>Arbitration Demand</i> section below no later than June 3, 2024, the parties would cease the arbitration and deem
the original Palantir MSA terminated. The Company made the required payments prior to June 3, 2024, and on June 4, 2024, the parties dismissed
all claims and counterclaims. Accordingly, at December 31, 2023, the Company reversed previously recognized costs in excess of the final
settlement amount. The Company had <span id="xdx_90F_ecustom--AccruedResearchAndDevelopmentSoftware_iI_dxL_c20241231_z8AyrJbCfvp1" title="Accrued research and development software::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2240">no</span></span> liability as of December 31, 2024 and a current liability of $<span id="xdx_906_ecustom--AccruedResearchAndDevelopmentSoftware_iI_pn3n3_c20231231_zt6oUP1d7sR8" title="Accrued research and development software"><ix:nonFraction name="CELU:AccruedResearchAndDevelopmentSoftware" contextRef="AsOf2023-12-31" id="Fact002242" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,500</ix:nonFraction></span> as of December 31, 2023, respectively,
for accrued R&amp;D software on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 124 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Sirion License Agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In December 2021, the Company
entered into a license agreement (&#8220;Sirion License&#8221;) with Sirion Biotech GmbH (&#8220;Sirion&#8221;). Under the Sirion License,
Sirion granted the Company a license related to patent rights and know-how associated with poloxamers (&#8220;Licensed Product&#8221;).
As part of the Sirion License, the Company paid Sirion $<span id="xdx_90A_ecustom--UpfrontFee_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zxjQOZJfa7Oh" title="Upfront fee"><ix:nonFraction name="CELU:UpfrontFee" contextRef="From2021-12-012021-12-31_custom_LicenseAgreementMember" id="Fact002244" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">136</ix:nonFraction></span> as an upfront fee, a $<span id="xdx_900_ecustom--AnnualMaintenanceFee_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zf23AZAPacRg" title="Annual maintenance fee"><ix:nonFraction name="CELU:AnnualMaintenanceFee" contextRef="From2021-12-012021-12-31_custom_LicenseAgreementMember" id="Fact002246" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">113</ix:nonFraction></span> annual maintenance fee and may owe up to $<span id="xdx_90B_ecustom--ClinicalAndRegulatoryMilestones_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zIEPMjSvUaK3" title="Clinical and regulatory milestones"><ix:nonFraction name="CELU:ClinicalAndRegulatoryMilestones" contextRef="From2021-12-012021-12-31_custom_LicenseAgreementMember" id="Fact002248" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,099</ix:nonFraction></span>
related to clinical and regulatory milestones for each Licensed Product during the term. The Company also agreed to pay Sirion low-single
digit royalties on net sales on a Licensed Product-by-Licensed Product and country-by-country basis and until the later of: (i) expiration
of the last to expire valid claim of the patents covering such Licensed Product, and (ii) <span id="xdx_900_eus-gaap--LongtermPurchaseCommitmentPeriod_dtY_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zzsBGGpBl9Fa" title="License agreement period"><ix:nonNumeric contextRef="From2021-12-012021-12-31_custom_LicenseAgreementMember" format="ixt-sec:duryear" id="Fact002250" name="us-gaap:LongtermPurchaseCommitmentPeriod">10</ix:nonNumeric></span> years after first Commercial Sale of a Licensed
Product. In addition, the Sirion License is subject to termination rights including for termination for material breach and by the Company
for convenience upon <span id="xdx_90A_ecustom--LicenseAgreementNoticePeriod_dtD_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zb44zc04qRwi" title="License agreement period"><ix:nonNumeric contextRef="From2021-12-012021-12-31_custom_LicenseAgreementMember" format="ixt-sec:durday" id="Fact002252" name="CELU:LicenseAgreementNoticePeriod">30</ix:nonNumeric></span> days written notice. During the years ended December 31, 2024 and 2023, no milestones have been achieved and no
royalties have been earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Legal Proceedings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At each reporting date, the Company
evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions
of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such
legal proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Civil Investigative Demand</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company received a Civil Investigative
Demand (the &#8220;Demand&#8221;) under the False Claims Act, 31 U.S.C. &#167; 3729, dated August 14, 2022, from the U.S. Attorney&#8217;s
Office for the Eastern District of Pennsylvania. The Demand requests documents and information relating to claims submitted to Medicare,
Medicaid, or other federal insurers for services or procedures involving injectable human tissue therapy products derived from amniotic
fluid or birth tissue and includes Interfyl, a biomaterials product. The Company is cooperating with the request and is engaged in an
ongoing dialogue with the Assistant U.S. Attorneys handling the Demand. The matter is still in preliminary stages and there is uncertainty
as to whether the Demand will result in any liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Arbitration Demand from Palantir Technologies Inc.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On April 20, 2023, Palantir commenced
an arbitration with JAMS Arbitration asserting claims for declaratory relief and breach of contract relating to the Palantir MSA, seeking
damages in an amount equal to the full value of the contract. The Company responded to the arbitration demand and asserted counterclaims
for breach of contract, breach of warranty, fraudulent inducement, violation of California&#8217;s Unfair Competition Law, amongst others,
in relation to the Palantir MSA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On December 21, 2023, the Company
and Palantir entered into the Palantir Settlement Agreement to resolve the JAMS Arbitration. The Palantir Settlement Agreement was subsequently
amended on January 10, 2024 and May 6, 2024. Both parties agreed to dismiss the arbitration proceeding and dispute and provide for mutual
releases upon the Company&#8217;s satisfaction of a settlement payment obligation. Through June 3, 2024, the Company made total settlement
payments of $<span id="xdx_90F_eus-gaap--PaymentsForLegalSettlements_pn5n6_c20231221__20240603__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_zALaKV4zO3D9" title="Settlement payment"><ix:nonFraction name="us-gaap:PaymentsForLegalSettlements" contextRef="From2023-12-212024-06-03_custom_SettlementAndReleaseAgreementMember" id="Fact002254" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3,500</ix:nonFraction></span> and issued Palantir an aggregate of <span id="xdx_90C_ecustom--NumberOfSharesIssuedForPiggybackRegistrationRights_pid_c20231221__20240603__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_zc8MPuma22H3" title="Shares issued for piggyback registration rights"><ix:nonFraction name="CELU:NumberOfSharesIssuedForPiggybackRegistrationRights" contextRef="From2023-12-212024-06-03_us-gaap_CommonClassAMember_custom_SettlementAndReleaseAgreementMember" id="Fact002256" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,584</ix:nonFraction></span> shares of the Company&#8217;s Class A common stock as consideration for
further amendments to the Palantir Settlement Agreement. On June 4, 2024, the parties dismissed all claims and counterclaims. The Palantir
MSA is now fully terminated and neither party has any further rights or obligations thereunder. The shares of the Company&#8217;s Class
A common stock issued to Palantir were issued with piggyback registration rights. Resale of such shares by Palantir shall be included
on any future registration statement filed by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Celularity Inc. v. Evolution Biologyx, LLC, et
al.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On April 17, 2023, the
Company filed a complaint against Evolution Biologyx, LLC, Saleem S. Saab, individually, and Encyte, LLC (collectively,
&#8220;Evolution&#8221;) in the United States District Court for the District of New Jersey to recover unpaid invoice amounts for
the sale of its biomaterial products in the amount of approximately $<span id="xdx_90E_ecustom--SaleOfBiomaterialProductsAmount_pn3n3_c20230417__20230417__srt--LitigationCaseAxis__custom--EvolutionMember_zj67dzFHRaQl" title="Sale of biomaterial products amount"><ix:nonFraction name="CELU:SaleOfBiomaterialProductsAmount" contextRef="From2023-04-172023-04-17_custom_EvolutionMember" id="Fact002258" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,350</ix:nonFraction></span>,
plus interest. In September 2021, the Company executed a distribution agreement with Evolution, whereupon Evolution purchased
biomaterial products from the Company for sale through Evolution&#8217;s distribution channels. The Company fulfilled
Evolution&#8217;s orders and otherwise performed each of its obligations under the distribution agreement. Despite attempts to
recover the outstanding invoices and Evolution&#8217;s promise to pay, Evolution has refused to pay any of the invoices and has
materially breached its obligations under the distribution agreement. The Company&#8217;s complaint asserts claims of breach of
contract and fraudulent inducement, amongst others. On April 4, 2024, Evolution filed a counter claim alleging damages in an amount
to be determined resulting from alleged breach of contract, breach of warranty, quasi contract and fraud. The Company believes
Evolution&#8217;s counter claims are without any merit, and the Company intends to vigorously pursue the matter to recover the outstanding
payments owed by Evolution, including interest and associated attorney&#8217;s fees, as well as defend against Evolution&#8217;s
counterclaims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 125 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>TargetCW v. Celularity Inc.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 27, 2024, WMBE Payrolling,
Inc., dba TCWGlobal, filed a complaint in the United States District Court for the Southern District of California alleging a breach
of contract and account stated claims relating to a Master Services Agreement dated May 4, 2020, or the TCWGlobal MSA, for the provision
of certain leased workers to perform services on the Company&#8217;s behalf. The complaint alleges that the Company breached the TCWGlobal
MSA by failing to make payments on certain invoices for the services of the leased workers. On May 7, 2024, the Company entered into
a settlement agreement and mutual release with TCWGlobal whereupon the Company agreed to pay $<span id="xdx_909_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240507__20240507__srt--LitigationCaseAxis__custom--EvolutionMember_z1PI9jEe0ge3"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2024-05-072024-05-07_custom_EvolutionMember" id="Fact002259" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">516</ix:nonFraction></span>
in tiered monthly installments, with the last payment due and payable on May 1, 2025, in exchange for a dismissal of the complaint
and full release of all claims. The Company defaulted on the payments in November 2024. On April 21, 2025, the Company was served with a motion by
TCWGlobal to enforce the settlement and enter judgment against the Company in the amount of $<span id="xdx_900_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20250421__20250421__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znCxXqvPxlu9" title="Payments for legal settlements"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2025-04-212025-04-21_us-gaap_SubsequentEventMember" id="Fact002261" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">350</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Hackensack Meridian v. Celularity Inc</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 27, 2025,
Hackensack Meridian Health (&#8220;HUMC&#8221;) filed a complaint in the Superior Court of New Jersey seeking $<span id="xdx_90C_eus-gaap--AffiliateCosts_pn3n3_c20250327__20250327__dei--LegalEntityAxis__custom--HackensackMeridianHealthMember_zRwEeSLzZ0O6" title="Affiliate costs"><ix:nonFraction name="us-gaap:AffiliateCosts" contextRef="From2025-03-272025-03-27_custom_HackensackMeridianHealthMember" id="Fact002263" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">946</ix:nonFraction></span>
allegedly owed by Celularity for costs associated with clinical trials. The amounts claimed were part of a three-party arrangement
with a contract research organization (CRO), which the Company engaged to make payments on behalf of the Company to HUMC. The
Company has asserted that it believes there are improper charges in the claim. The parties are attempting to agree on the actual
amounts owed by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002265" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1AgSkNrKyvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>13. <span id="xdx_82E_zpoHaW1MBjyf">Equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024 and 2023,
the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zzP46tktkF21" title="Common stock, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zngpxZf0Dl7h" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact002267" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact002269" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">730,000,000</ix:nonFraction></ix:nonFraction></span></span> shares of $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zz2jOAbkxrR" title="Common stock, par value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zcBIpKkDLQUj" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact002271" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact002273" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span>
par value Class A common stock. As of December 31, 2024 and 2023, shares of Class A common stock issued and outstanding were <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zffNudoe2Wzc" title="Common stock shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zCc7uYAiYQk8" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact002275" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact002277" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">22,546,671</ix:nonFraction></ix:nonFraction></span></span>
and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zp3OXOlt9rih" title="Common stock shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zABHH19CG8Eh" title="Common stock shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact002279" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember" id="Fact002281" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,378,192</ix:nonFraction></ix:nonFraction></span></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Voting Power</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Except as otherwise required by
law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess
all voting power for the election of the Company&#8217;s directors and all other matters requiring stockholder action. Holders of <span id="xdx_908_eus-gaap--CommonStockVotingRights_c20240101__20241231_zOfJh576ymZ" title="Common stock, voting rights"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" id="Fact002283" name="us-gaap:CommonStockVotingRights">common
stock are entitled to one vote per share</ix:nonNumeric></span> on matters to be voted on by stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Dividends</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Holders of Class A common stock
will be entitled to receive such dividends, if any, as may be declared from time to time by the Company&#8217;s board of directors in
its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock
be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Liquidation, Dissolution and Winding Up</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In the event of the Company&#8217;s
voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled
to receive an equal amount per share of all of the Company&#8217;s assets of whatever kind available for distribution to stockholders,
after the rights of the holders of the preferred stock have been satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Preemptive or Other Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s stockholders
have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Election of Directors</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s board of directors
is divided into three classes, Class I, Class II and Class III, with only one class of directors being elected in each year and each class
serving a three-year term, except with respect to the election of directors at the special meeting held in connection with the merger
with GX, Class I directors are elected to an initial one-year term (and three-year terms subsequently), the Class II directors are elected
to an initial two-year term (and three-year terms subsequently) and the Class III directors are elected to an initial three-year term
(and three-year terms subsequently). There is no cumulative voting with respect to the election of directors, with the result that the
holders of more than <span id="xdx_907_ecustom--PercentageOfSharesRequiredForVoting_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--RangeAxis__srt--MinimumMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_z7BtHAhb1u0g" title="Percentage of shares required for voting"><ix:nonFraction name="CELU:PercentageOfSharesRequiredForVoting" contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_srt_MinimumMember_custom_LegacyCelularityMember" id="Fact002285" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>% of the shares voted for the election of directors can elect all of the directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s Certificate
of Incorporation authorized <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zMPMSSRnujr" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-12-31" id="Fact002287" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span> shares of preferred stock and provides that shares of preferred stock may be issued from time to
time in one or more series. The Company&#8217;s board of directors is authorized to fix the voting rights, if any, designations, powers
and preferences, the relative, participating, optional or other special rights, and any qualifications, limitations and restrictions thereof,
applicable to the shares of each series of preferred stock. The Company&#8217;s board of directors is able to, without stockholder approval,
issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common
stock and could have anti-takeover effects. The ability of the Company&#8217;s board of directors to issue preferred stock without stockholder
approval could have the effect of delaying, deferring or preventing a change of control of Celularity or the removal of existing management.
As of December 31, 2024 and 2023, the Company did <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_zDOurdQhr3Q5" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20231231_zup0S26onVL8" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-12-31" id="Fact002289" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact002291" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span></span>t have any outstanding preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>


<ix:exclude><!-- Field: Page; Sequence: 126 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>ATM Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On September 8, 2022, the Company
entered into an At-the-Market Sales Agreement (the &#8220;ATM Agreement&#8221;) with BTIG, LLC, Oppenheimer &amp; Co. Inc. and B. Riley
Securities, Inc., acting as sales agents and/or principals, pursuant to which the Company may offer and sell, from time to time in its
sole discretion, shares of its common stock, having an aggregate offering price of up to $<span id="xdx_909_ecustom--AggregateOfferingPrice_pn3n3_c20220908__20220908__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zD6ESkPAXEbk" title="Aggregate offering price"><ix:nonFraction name="CELU:AggregateOfferingPrice" contextRef="From2022-09-082022-09-08_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember" id="Fact002293" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">150,000</ix:nonFraction></span>, subject to certain limitations as set
forth in the ATM Agreement. The Company is not obligated to make any sales of shares under the ATM Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Any shares offered and sold in
the at-the-market offering will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 and the related prospectus
supplement. Under the ATM Agreement, the sales agents may sell shares of common stock by any method permitted by law deemed to be an &#8220;at
the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act of 1933. The Company will pay the sales agents a commission
rate of up to <span id="xdx_905_ecustom--MaximumPercentageOfSalesCommissionFromGrossSalesProceeds_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_zdO9IkuS93f9" title="Sales agents commission rate"><ix:nonFraction name="CELU:MaximumPercentageOfSalesCommissionFromGrossSalesProceeds" contextRef="From2024-01-012024-12-31_custom_AtTheMarketSalesAgreementMember" id="Fact002295" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% of the gross sales proceeds of any shares sold and has agreed to provide the sales agents with customary indemnification,
contribution and reimbursement rights. The ATM Agreement contains customary representations and warranties and conditions to the placements
of the shares pursuant thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, the Company received gross and net proceeds of $<span id="xdx_90C_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_z7Ifc1hiRyL4" title="Gross proceeds from issuance of common stock"><ix:nonFraction name="CELU:GrossProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31_custom_AtTheMarketSalesAgreementMember" id="Fact002297" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">141</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_z7mqmJ7afdyi" title="Net proceeds from sale of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-12-31_custom_AtTheMarketSalesAgreementMember" id="Fact002299" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">136</ix:nonFraction></span>, respectively, from the sale of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zaR0ZLiUtpta" title="Purchase and sale of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember" id="Fact002301" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,296</ix:nonFraction></span> shares of its common stock
at an average price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zIYKuW2yGU4i" title="Average price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2023-12-31_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember" id="Fact002303" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.60</ix:nonFraction></span> per share under the ATM Agreement. No shares were issued under the ATM Agreement during the year ended December
31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>March 2023 PIPE</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 20, 2023, the Company
entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief Executive Officer, Dr. Robert
Hariri, providing for the private placement of (i) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zK3ykL2gkUj8" title="Purchase and sale of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember" id="Fact002305" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">938,183</ix:nonFraction></span> shares of its Class A common stock, and (ii) accompanying warrants to purchase
up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230320__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoZcbsY43TCa" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-03-20_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_srt_MaximumMember_us-gaap_PrivatePlacementMember" id="Fact002307" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">938,183</ix:nonFraction></span> shares of Class A common stock (the &#8220;March 2023 PIPE Warrants&#8221;), for $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230320__srt--RangeAxis__srt--MaximumMember_z5gfR1FtFkmf" title="Purchase price of per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-03-20_srt_MaximumMember" id="Fact002309" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.34</ix:nonFraction></span> per share and $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230320__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z8TnFe7dODY7" title="Purchase price of per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-03-20_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_PrivatePlacementMember" id="Fact002311" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.25</ix:nonFraction></span> per accompanying
March 2023 PIPE Warrant, for an aggregate purchase price of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zcVg0HpFPsg1" title="Proceeds from PIPE financings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002313" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,000</ix:nonFraction></span> (of which Dr. Hariri subscribed for $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zjfYZQdKVF46" title="Proceeds from PIPE financings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_ChairmanAndChiefExecutiveOfficerMember_us-gaap_PrivatePlacementMember" id="Fact002315" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></span>). The closing of the private
placement occurred on March 27, 2023. Each March 2023 PIPE Warrant had an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zsyIHdhlRZF3" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002317" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></span> per share, is immediately exercisable,
will expire on <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zfL3kXj8747e" title="Expiration dateity"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002319" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 27, 2028</ix:nonNumeric></span> (<span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zp35YvnYCo76" title="Term (years)"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" format="ixt-sec:durwordsen" id="Fact002321" name="us-gaap:WarrantsAndRightsOutstandingTerm">five years</ix:nonNumeric></span> from the date of issuance), and is subject to customary adjustments for certain transactions
affecting the Company&#8217;s capitalization. The March 2023 PIPE Warrants may not be exercised if the aggregate number of shares of Class
A common stock beneficially owned by the holder thereof (together with its affiliates) would exceed the specified percentage cap provided
therein (which may be adjusted upon <span id="xdx_900_ecustom--AdjustedAdvanceNoticePeriod_dtD_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zRVFHUCoz1Fh" title="Adjusted advance notice period"><ix:nonNumeric contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" format="ixt-sec:durday" id="Fact002323" name="CELU:AdjustedAdvanceNoticePeriod">61</ix:nonNumeric></span> days advance notice) immediately after exercise thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounted for the
March 2023 PIPE Warrants and common stock as a single non-arm&#8217;s length transaction. The Company applied the guidance for this transaction
in accordance with ASU 2020-06, <i>(Subtopic 470-20): Debt - Debt with Conversion and Other Options, ASC 815 Derivatives and Hedging,
</i>and <i>ASC 480 Distinguishing Liabilities from Equity</i>. Accordingly, the net proceeds were allocated between common stock and the
March 2023 PIPE warrants at their respective fair value, which resulted in a net premium of $<span id="xdx_90E_ecustom--PremiumPaidForPrivatePlacementPurchase_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zeezlJFGJPU3" title="Premium paid for private placement purchase"><ix:nonFraction name="CELU:PremiumPaidForPrivatePlacementPurchase" contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002325" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,650</ix:nonFraction></span> based on the difference between the
proceeds and fair value of the common stock and March 2023 PIPE warrants, which was recorded as additional paid-in capital within stockholders&#8217;
equity on the consolidated balance sheets. The fair value of the March 2023 PIPE Warrants was determined using a Black-Scholes option
pricing model and the common stock based on closing date share price. The Company evaluated the March 2023 PIPE warrants under ASC 815
and determined that they did not require liability classification and met the requirements for a derivative scope exception under ASC
815-10-15-74(a) for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity. The
warrants were recorded in additional paid-in capital within stockholders&#8217; equity on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On September 14, 2023, the Company
entered into a warrant amendment on the March 2023 PIPE Warrants with the unaffiliated investor to reduce the exercise price from $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230914__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zLCkFRXrdeu9" title="Purchase price of per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-09-14_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002327" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></span>
per share to $<span id="xdx_907_ecustom--ReducedExercisePrice_pid_c20230314__20230314__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zXSK6B6aw8cb" title="Reduced exercise price"><ix:nonFraction name="CELU:ReducedExercisePrice" contextRef="From2023-03-142023-03-14_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002329" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share for warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230914__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z9RDuUMosfV5" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-09-14_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002331" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">729,698</ix:nonFraction></span> shares of Class A common stock. The warrant amendment was executed as consideration
for professional services rendered to the Company. As a result, the Company accounted for the transaction in accordance with ASC 718,
<i>Stock-Based Compensation,</i> and based on the calculated incremental fair value attributable to the modified warrant compared to the
original warrant immediately prior to the modification, recognized an expense of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pn3n3_c20230101__20231231_zOy4dfKxKBn" title="Fair value of modified warrant, incremental expense"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2023-01-012023-12-31" id="Fact002333" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">402</ix:nonFraction></span> within selling, general and administrative on the
consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 127 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Registered Direct Offerings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On April 10, 2023, the Company
closed on a registered direct offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230410__20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zwUmyepiUhzc" title="Purchase and sale of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-102023-04-10_us-gaap_CommonClassAMember" id="Fact002335" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">923,076</ix:nonFraction></span> shares of its Class A common stock together with warrants (&#8220;Registered Direct
Warrants&#8221;) to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhkBnS8qbxIi" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-04-10_us-gaap_CommonClassAMember" id="Fact002337" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">923,076</ix:nonFraction></span> shares of its Class A common stock at a combined purchase price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zztqIc7PO2hj" title="Purchase price of per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-04-10_us-gaap_CommonClassAMember" id="Fact002339" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.50</ix:nonFraction></span> per share and accompanying
warrant, resulting in total gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230410__20230410_zGluPZdW76k4" title="Proceeds from the exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-04-102023-04-10" id="Fact002341" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></span> before deducting placement agent commissions and other estimated offering
expenses. The Registered Direct Warrants had an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230410_z31MTntvPOoi" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-04-10" id="Fact002343" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.50</ix:nonFraction></span>, became exercisable beginning six months after the date of issuance
and will expire <span id="xdx_90C_ecustom--WarrantExpirationTerm_pid_c20230410__20230410_zYXkG0vtmhAe" title="Warrant term"><ix:nonNumeric contextRef="From2023-04-102023-04-10" format="ixt-sec:durwordsen" id="Fact002345" name="CELU:WarrantExpirationTerm">five years</ix:nonNumeric></span> thereafter. The Company used the $<span id="xdx_901_ecustom--DebtInstrumentPayment_pn3n3_c20230410__20230410_zPp8EQfAXuT4" title="Debt instrument payment"><ix:nonFraction name="CELU:DebtInstrumentPayment" contextRef="From2023-04-102023-04-10" id="Fact002347" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,505</ix:nonFraction></span> net proceeds from the offering to repay its obligations to Yorkville
under the PPA. The Company considered the appropriate accounting guidance and concluded that the Registered Direct Warrants qualified
for liability treatment, and therefore, recorded the warrant liability at fair value $<span id="xdx_907_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20230410_ztrGXk6yLaql" title="Fair value of the warrant liability"><ix:nonFraction name="CELU:FairValueNetAssetsLiability" contextRef="AsOf2023-04-10" id="Fact002349" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,280</ix:nonFraction></span> which was based on a Black-Scholes option
pricing model. The remainder of the net proceeds were allocated to the Class A common stock issued and recorded as a component of equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upon the closing of the registered
direct offering on April 10, 2023, the Company amended the existing May 2022 PIPE Warrants, to reduce the exercise price from $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220518__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zGrnJRVLD608" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-05-18_srt_MaximumMember_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember" id="Fact002351" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">82.50</ix:nonFraction></span> to
$<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220518__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zCELkqsrdzHk" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-05-18_srt_MinimumMember_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember" id="Fact002353" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.50</ix:nonFraction></span> per share and extended the expiration <span id="xdx_901_ecustom--AmendedTerminationDateDescription_c20230410__20230410__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember_zcTecCUbCKe7" title="Amended termination date description"><ix:nonNumeric contextRef="From2023-04-102023-04-10_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember" id="Fact002355" name="CELU:AmendedTerminationDateDescription">date to five and one-half years following the closing of the offering</ix:nonNumeric></span> or October 10, 2028.
The modification resulted in the recognition of additional warrant liability of $<span id="xdx_90C_ecustom--AdditionalWarrantLiability_iI_pn3n3_c20230410_zGMsvzy7DaQ3" title="Additional warrant liability"><ix:nonFraction name="CELU:AdditionalWarrantLiability" contextRef="AsOf2023-04-10" id="Fact002357" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,389</ix:nonFraction></span> based on the Black-Scholes option pricing model
as of the modification date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On July 31, 2023, the Company
closed on a registered direct offering of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230731__20230731_z97b5JcdWJjf" title="Purchase and sale of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-07-312023-07-31" id="Fact002359" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">857,142</ix:nonFraction></span> shares of its Class A common stock together with warrants (&#8220;July 2023 Registered
Direct Warrants&#8221;) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230731__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zWcY2JCiJ0bf" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-31_us-gaap_CommonClassAMember" id="Fact002361" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">857,142</ix:nonFraction></span> shares of its Class A common stock at a combined purchase price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230731__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zKJNpgRDRJ2c" title="Purchase price of per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-07-31_us-gaap_CommonClassAMember" id="Fact002363" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></span> per share and
accompanying warrant, resulting in total gross proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230731__20230731_zX8t6hhn1Li6" title="Proceeds from the exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2023-07-312023-07-31" id="Fact002365" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span> before deducting placement agent commissions and other
estimated offering expenses. The July 2023 Registered Direct Warrants have an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230731__srt--RangeAxis__srt--MinimumMember_zmmdIsfhFQxg" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-31_srt_MinimumMember" id="Fact002367" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></span>, will be exercisable beginning six
months after the date of issuance and will expire <span id="xdx_903_ecustom--WarrantExpirationTerm_c20230731__20230731_z07eBOkj6o1j" title="Warrant term"><ix:nonNumeric contextRef="From2023-07-312023-07-31" format="ixt-sec:durwordsen" id="Fact002369" name="CELU:WarrantExpirationTerm">five years</ix:nonNumeric></span> thereafter. The Company used the $<span id="xdx_90F_ecustom--DebtInstrumentPayment_pn3n3_c20230731__20230731_ztBPn20dwIO6" title="Debt instrument payment"><ix:nonFraction name="CELU:DebtInstrumentPayment" contextRef="From2023-07-312023-07-31" id="Fact002371" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,740</ix:nonFraction></span> net proceeds for working capital
and general corporate purposes. The Company considered the appropriate accounting guidance and concluded that the July 2023 Registered
Direct Warrants qualified for liability treatment, and therefore, recorded the warrant liability at fair value $<span id="xdx_90B_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20230731_zl4YeRxKLODi" title="Fair value of the warrant liability"><ix:nonFraction name="CELU:FairValueNetAssetsLiability" contextRef="AsOf2023-07-31" id="Fact002373" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,645</ix:nonFraction></span> which was based
on a Black-Scholes option pricing model. The remainder of the net proceeds were allocated to the Class A common stock issued and recorded
as a component of equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the July 31,
2023 registered direct offering described above, the Company also entered into an amendment to certain existing warrants to purchase up
to an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230731__srt--RangeAxis__srt--MaximumMember_zMsM43C6hZdc" title="Warrants to purchase class A common stock"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-07-31_srt_MaximumMember" id="Fact002375" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">892,856</ix:nonFraction></span> shares at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230731_zbPoZKRZzIWj" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-07-31" id="Fact002377" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.50</ix:nonFraction></span> (consisting of all the May 2022 PIPE Warrants and a portion of the Registered
Direct Warrants issued in April 2023), and such amended warrants have a reduced exercise price of $<span id="xdx_907_ecustom--ReducedExercisePrice_pid_c20230731__20230731_zmFbXSS0NRPb" title="Reduced exercise price"><ix:nonFraction name="CELU:ReducedExercisePrice" contextRef="From2023-07-312023-07-31" id="Fact002379" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></span> per share. As noted above, the
modification resulted in an increase to the warrant liability of $<span id="xdx_90A_ecustom--WarrantLiability_iI_pn3n3_c20230731_z6vCgBkY7lwh" title="Warrant liabilities"><ix:nonFraction name="CELU:WarrantLiability" contextRef="AsOf2023-07-31" id="Fact002381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">511</ix:nonFraction></span> based on the Black-Scholes option pricing model as of the July 31,
2023 modification date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>May 2023 PIPE</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On May 18, 2023, the Company closed
on a securities purchase agreement with a group of accredited investors, providing for the private placement of an aggregate (i) <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230518__20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zB97X1Rtinuj" title="Purchase and sale of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-05-182023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002383" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">581,394</ix:nonFraction></span>
shares of its Class A common stock and (ii) accompanying warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zKYoNmWrCRG" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002385" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">581,394</ix:nonFraction></span> shares of Class A common stock (the &#8220;May
2023 PIPE Warrants&#8221;), for $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zMwKBz0fhIQi" title="Purchase price of per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002387" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.20</ix:nonFraction></span> per share and $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsZV7NXXM2sf" title="Purchase price of per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_PrivatePlacementMember" id="Fact002389" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.25</ix:nonFraction></span> per accompanying May 2023 PIPE Warrant, for an aggregate gross purchase price
of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230518__20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zOKEFWvqbl44" title="Proceeds from PIPE financings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-05-182023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002391" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,750</ix:nonFraction></span>. Each May 2023 PIPE Warrant has an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zJVpUs9ia6ja" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002393" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per share, is immediately exercisable, will expire on <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z9oF7VthUw6c" title="Warrants and rights outstanding, expire date"><ix:nonNumeric contextRef="AsOf2023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002395" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 17, 2028</ix:nonNumeric></span>,
and is subject to customary adjustments for certain transactions affecting the Company&#8217;s capitalization. The May 2023 PIPE Warrants
may not be exercised if the aggregate number of shares of Class A common stock beneficially owned by the holder thereof (together with
its affiliates) would exceed the specified percentage cap provided therein (which may be adjusted upon <span id="xdx_904_ecustom--AdjustedAdvanceNoticePeriod_dtD_c20230518__20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zEwTiSCUUkNj" title="Adjusted advance notice period"><ix:nonNumeric contextRef="From2023-05-182023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" format="ixt-sec:durday" id="Fact002397" name="CELU:AdjustedAdvanceNoticePeriod">61</ix:nonNumeric></span> days advance notice) immediately
after exercise thereof. The Company evaluated the May 2023 PIPE Warrants under ASC 815 and determined that they did not require liability
classification and met the requirements for a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed
to an entity&#8217;s own stock and classified in stockholders&#8217; equity. Accordingly, the proceeds were allocated between common stock
and the May 2023 PIPE Warrants at their respective relative fair value basis to stockholders&#8217; equity on the consolidated balance
sheets. The fair value of the May 2023 PIPE Warrants was determined using a Black-Scholes option pricing model and the common stock based
on the closing date share price and were recorded in additional paid-in capital within stockholders&#8217; equity on the consolidated
balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>January 2024 PIPE</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 12, 2024, the Company
entered into a securities purchase agreement with an existing investor, Dragasac Limited (&#8220;Dragasac&#8221;), providing for the private
placement of (i) <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240112__20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zVumiEmKFrIh" title="Purchase and sale of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-122024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002399" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,141,098</ix:nonFraction></span> shares of its Class A common stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zfYMSMtMZoF" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002401" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share, or the Class A common stock, and (ii) accompanying
warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zv4Clk7iU4yk" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember_srt_MaximumMember" id="Fact002403" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">535,274</ix:nonFraction></span> shares of Class A common stock (&#8220;January 2024 PIPE Warrant&#8221;), for $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zW64YVJ4iIu9" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002405" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.4898</ix:nonFraction></span> per share and
$<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240112__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zxNERNQXYr16" title="Purchase price of per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2024-01-12_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002407" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.25</ix:nonFraction></span> per accompanying January 2024 PIPE Warrant, for an aggregate purchase price of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20240112__20240112__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zr1UDANRGaKg" title="Aggregate purchase price"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2024-01-122024-01-12_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002409" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,000</ix:nonFraction></span>. The closing of the private
placement occurred on <span id="xdx_903_ecustom--WarrantsAndRightsIssuedClosingDate_c20240112__20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_znP3dpZ8rWg7" title="Warrants and rights issued closing date"><ix:nonNumeric contextRef="From2024-01-122024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002411" name="CELU:WarrantsAndRightsIssuedClosingDate">January 16, 2024</ix:nonNumeric></span>. The securities were issued pursuant to an exemption from registration provided under Section 4(a)(2)
of the Securities Act and Regulation D promulgated thereunder. The offer and sale of the shares and January 2024 PIPE Warrant (including
the shares underlying the January 2024 PIPE Warrant) has not been registered under the Act or any state securities laws. The securities
may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Each January
2024 PIPE Warrant had an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zp56Yzz1qWqe" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002413" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.4898</ix:nonFraction></span> per share, is immediately exercisable, and will expire on <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zgcjS8Aqm85d" title="Warrants and rights outstanding, expire date"><ix:nonNumeric contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002415" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">January 16, 2029</ix:nonNumeric></span> (five<span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zsflcWEiRANd" title="Term (years)" style="display: none"><ix:nonNumeric contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" format="ixt-sec:duryear" id="Fact002417" name="us-gaap:WarrantsAndRightsOutstandingTerm">5</ix:nonNumeric></span> years
from the date of issuance).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 128 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounted for the
January 2024 PIPE Warrant and common stock as a single non-arm&#8217;s length transaction recognized in equity. The Company applied the
guidance for this transaction in accordance with ASU 2020-06, <i>(Subtopic 470-20): Debt - Debt with Conversion and Other Options, ASC
815 Derivatives and Hedging, </i>and <i>ASC 480 Distinguishing Liabilities from Equity</i>. Accordingly, the net proceeds were allocated
between common stock and the January 2024 PIPE Warrant at their respective fair values, which resulted in proceeds of $<span id="xdx_90D_ecustom--ProceedsFromPrivatePlacements_pn3n3_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zdQkTf053Oti" title="Proceeds from private placements"><ix:nonFraction name="CELU:ProceedsFromPrivatePlacements" contextRef="From2024-01-122024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002419" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">909</ix:nonFraction></span> allocated to
the January 2024 PIPE Warrant and the balance of the proceeds allocated to the common stock. The fair value of the January 2024 PIPE Warrant
was determined using a Black-Scholes option pricing model and the common stock based on closing date share price. The Company evaluated
the January 2024 PIPE warrant under ASC 815 and determined that it did not require liability classification and met the requirements for
a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed to an entity&#8217;s own stock and classified
in stockholders&#8217; equity. The warrants were recorded in additional paid-in capital within stockholders&#8217; equity on the consolidated
balance sheets. Also in connection with the January 2024 PIPE transaction, the Company repriced legacy warrants held by Dragasac to purchase
<span id="xdx_902_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_z8xcTaqW9Cc5" title="Number Of warrants repriced"><ix:nonFraction name="CELU:NumberOfWarrantsRepriced" contextRef="AsOf2024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002421" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">652,981</ix:nonFraction></span> shares of common stock with a previous exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_z305bCEZgp9i" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002423" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">67.70</ix:nonFraction></span> per share to a new exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zM2WcHcid9tf" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember" id="Fact002425" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.4898</ix:nonFraction></span> per share. The modification
of warrants resulted in incremental fair value of $<span id="xdx_90A_ecustom--FairValueOfWarrantModificationIncrementalForEquityIssuanceCost_pn3n3_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zDX9Y1DZcBK6" title="Fair value of warrant modification"><ix:nonFraction name="CELU:FairValueOfWarrantModificationIncrementalForEquityIssuanceCost" contextRef="From2024-01-122024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002427" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">524</ix:nonFraction></span>, which has been recognized as an equity issuance cost and had no net impact on
stockholders&#8217; equity as the warrants remain equity-classified after the modification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the execution
of the securities purchase agreement, the Company also entered into an investor rights agreement with Dragasac dated as of January 12,
2024. The investor rights agreement provides Dragasac certain information and audit rights, as well as registration rights with respect
to the shares (and shares underlying the January 2024 PIPE Warrant), including both the undertaking to file a registration statement within
45 days of filing of the 2023 Form 10-K, &#8220;piggyback&#8221; registration rights, as well as the right to request up to three demand
rights for underwritten offerings per year; in each case subject to customary &#8220;underwriter cutback&#8221; language as well as any
objections raised by the SEC to inclusion of securities. If the initial registration statement was not filed on or prior to May 15, 2024,
the investor rights agreement provides for partial liquidating damages equal to <span id="xdx_908_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--InvestorRightsAgreementMember__srt--CounterpartyNameAxis__custom--DragasacLimitedMember_zZajXYhPwtjc" title="Percentage of partial liquidating damages"><ix:nonFraction name="CELU:PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" contextRef="AsOf2024-01-12_srt_MinimumMember_custom_InvestorRightsAgreementMember_custom_DragasacLimitedMember" id="Fact002429" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span>% of the subscription amount each month, up to a maximum
of <span id="xdx_904_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--InvestorRightsAgreementMember__srt--CounterpartyNameAxis__custom--DragasacLimitedMember_zaMhrDSfYPJe" title="Percentage of partial liquidating damages"><ix:nonFraction name="CELU:PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" contextRef="AsOf2024-01-12_srt_MaximumMember_custom_InvestorRightsAgreementMember_custom_DragasacLimitedMember" id="Fact002431" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.0</ix:nonFraction></span>%, plus interest thereon accruing daily at a rate of <span id="xdx_90C_ecustom--DailyInterestAccruingRate_iI_pid_dp_uPure_c20240112_zbXo20ukgOSi" title="Daily interest accruing rate"><ix:nonFraction name="CELU:DailyInterestAccruingRate" contextRef="AsOf2024-01-12" id="Fact002433" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.0</ix:nonFraction></span>% per annum. The Company began to accrue partial liquidating damages and
interest as of May 22, 2024. As a condition to closing, the Company entered into an amendment to an amended and restated distribution
and manufacturing agreement with an affiliate of Dragasac to add cell therapy products in clinical development, investigational stage
and/or in near-term commercial use to the list of products under the scope of the exclusive distribution and manufacturing licenses (including
unmodified natural killer cells (such as CYNK-001) for aging and other non-oncology indications, PSC-100, PDA-001, PDA-002, pEXO and APPL-001
for regenerative indications).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Effective February 16, 2024, in
order to comply with Section 4.15(a) of the securities purchase agreement, the Company entered into an amended employment agreement with
its Chief Administrative Officer (&#8220;CAO&#8221;), whereby the CAO agreed to decrease his base salary from $<span id="xdx_909_ecustom--RelatedPartyBaseSalary_pn3n3_c20240216__20240216__srt--TitleOfIndividualAxis__custom--ChiefAdministrativeOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--AmendedEmploymentAgreementMember_zbbHV3NbmJe7" title="Base salary"><ix:nonFraction name="CELU:RelatedPartyBaseSalary" contextRef="From2024-02-162024-02-16_custom_ChiefAdministrativeOfficerMember_custom_AmendedEmploymentAgreementMember" id="Fact002435" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">500</ix:nonFraction></span> to $<span id="xdx_90E_ecustom--RelatedPartyBaseSalary_pn3n3_c20240216__20240216__srt--TitleOfIndividualAxis__custom--ChiefAdministrativeOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--AmendedEmploymentAgreementMember__srt--RangeAxis__srt--MinimumMember_zeV1eDFu5Akf" title="Base salary"><ix:nonFraction name="CELU:RelatedPartyBaseSalary" contextRef="From2024-02-162024-02-16_custom_ChiefAdministrativeOfficerMember_custom_AmendedEmploymentAgreementMember_srt_MinimumMember" id="Fact002437" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">425</ix:nonFraction></span> per year through
December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Warrant Modifications</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 12, 2024, in connection
with the January 2024 PIPE, the Company agreed to amend the exercise price of legacy warrants held by Dragasac to purchase <span id="xdx_90E_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zFCusVhahAEd" title="Number of warrants repriced"><ix:nonFraction name="CELU:NumberOfWarrantsRepriced" contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember" id="Fact002439" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">652,981</ix:nonFraction></span> shares
of common stock, which expired <span id="xdx_90A_ecustom--ClassOfWarrantOrRighstExpirationDate_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zWT8tw3Gisde" title="Warrant expiration date"><ix:nonNumeric contextRef="From2024-01-122024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember" format="ixt:datemonthdayyearen" id="Fact002441" name="CELU:ClassOfWarrantOrRighstExpirationDate">March 16, 2025</ix:nonNumeric></span>, from $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zVYwpQnpNtl8" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_CommonClassAMember" id="Fact002443" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">67.70</ix:nonFraction></span> per share to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zg8XKimAshxc" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember" id="Fact002445" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.4898</ix:nonFraction></span> per share. On January 24, 2025, the Company agreed to
reduce the exercise price of both the January 2024 PIPE Warrant and legacy warrants held by Dragasac from $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_z1poJw3q6s93" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_srt_MaximumMember" id="Fact002447" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.4898</ix:nonFraction></span> per share to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_z92lFZYHPcKl" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_srt_MinimumMember" id="Fact002449" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.07</ix:nonFraction></span> per
share. See Warrants section below for additional information. On March 13, 2024, in connection with the RWI Forbearance Agreement (see
Note 10), the Company agreed to issue RWI a warrant to acquire up to <span id="xdx_908_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSKeJ2LN7H21" title="Number of warrants repriced"><ix:nonFraction name="CELU:NumberOfWarrantsRepriced" contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_custom_RwiForbearanceAgreementMember_us-gaap_WarrantMember_srt_MaximumMember" id="Fact002451" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></span> shares of common stock, which expires <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240313__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrNMxVQS955" title="Warrants and rights outstanding, expire date"><ix:nonNumeric contextRef="AsOf2024-03-13_custom_RwiForbearanceAgreementMember_us-gaap_WarrantMember_us-gaap_CommonStockMember" format="ixt:datemonthdayyearen" id="Fact002453" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">June 20, 2028</ix:nonNumeric></span> and has
an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_z5Sjbby3oO6k" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-03-13_custom_RwiForbearanceAgreementMember_us-gaap_WarrantMember_us-gaap_CommonStockMember" id="Fact002455" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.895</ix:nonFraction></span> per share. Additionally, on March 13, 2024, in connection with the Starr Forbearance Agreement (see Note 10),
the Company agreed to amend the exercise price of the <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zZZJdsMCtTSc" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember" id="Fact002457" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> March 2023 Loan Warrants expiring <span id="xdx_90B_ecustom--ClassOfWarrantOrRighstExpirationDate_c20240313__20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zobszqjG8aF" title="Warrant expiration date"><ix:nonNumeric contextRef="From2024-03-132024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002459" name="CELU:ClassOfWarrantOrRighstExpirationDate">March 17, 2028</ix:nonNumeric></span> from $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240312__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zqGvLWEpkxZd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-03-12_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember" id="Fact002461" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.10</ix:nonFraction></span> per share to
$<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zIfevTWfKf7a" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember" id="Fact002463" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.895</ix:nonFraction></span> per share (the &#8220;Minimum Price&#8221; as determined pursuant to Nasdaq 5635(d) on March 13, 2024) and the <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_z1LcfNkglVZf" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember" id="Fact002465" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> June 2023
Warrants expiring <span id="xdx_90F_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zvxc5pNAp7Ef" title="Warrant expiration date"><ix:nonNumeric contextRef="From2024-03-132024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002467" name="CELU:ClassOfWarrantOrRighstExpirationDate">June 20, 2028</ix:nonNumeric></span> from $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zb7tOaqwWeZ5" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember" id="Fact002469" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.10</ix:nonFraction></span> per share to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zE8mefiFdKR" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember" id="Fact002471" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.895</ix:nonFraction></span> per share, each of which are held by C.V. Starr.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Standby Equity Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 13, 2024, the Company
and Yorkville entered into a SEPA. Under the SEPA, the Company has the right to sell to Yorkville up to $<span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zHm3cP8anGna" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-03-13_custom_YorkvilleMember_us-gaap_CommonClassAMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002473" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> of its Class A common
stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zIiDz8rMAhFh" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-03-13_custom_YorkvilleMember_us-gaap_CommonClassAMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002475" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share subject to certain limitations and conditions set forth in the SEPA, from time to time, over a 36-month
period. Sales of the common stock to Yorkville under the SEPA, and the timing of any such sales, are at the Company&#8217;s option, and
the Company is under no obligation to sell any shares of common stock to Yorkville under the SEPA except in connection with notices that
may be submitted by Yorkville, in certain circumstances as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upon the satisfaction of the conditions
precedent in the SEPA, which include having a resale shelf for shares of common stock issued to Yorkville declared effective, the Company
has the right to direct Yorkville to purchase a specified number of shares of common stock by delivering written notice (&#8220;Advance&#8221;).
An Advance may not exceed <span id="xdx_909_ecustom--SaleOfStockMaximumAverageDailyTradedAmountPercentage_iI_dp_uPure_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_z3CINtoAGEK7" title="Sale of stock, maximum average daily traded amount (in percent)"><ix:nonFraction name="CELU:SaleOfStockMaximumAverageDailyTradedAmountPercentage" contextRef="AsOf2024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002477" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>% of the average of the daily trading volume of the common stock on Nasdaq, during the <span id="xdx_907_ecustom--SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays_pid_dc_uInteger_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zAxLxSh7pZVe" title="Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days"><ix:nonFraction name="CELU:SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002479" format="ixt-sec:numwordsen" decimals="INF" unitRef="Integer">five</ix:nonFraction></span> consecutive trading
days immediately preceding the written notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 129 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Yorkville will generally purchase
shares pursuant to an Advance at a price per share equal to <span id="xdx_905_ecustom--SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice_iI_dp_uPure_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zqXzvyuHVZP7" title="Sale of stock, percentage based on volume weighted average price"><ix:nonFraction name="CELU:SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice" contextRef="AsOf2024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002481" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">97</ix:nonFraction></span>% of the VWAP, on Nasdaq during the three consecutive trading days commencing
on the date of the delivery of the written notice (unless the Company specifies a minimum acceptable price or there is no VWAP on the
subject trading day).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The SEPA will automatically terminate
on the earliest to occur of (i) the first day of the month next following the 36-month anniversary of the date of the SEPA or (ii) the
date on which Yorkville shall have made payment for shares of common stock equal to $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zPqKiPWctZOj" title="Consideration shares of common stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_us-gaap_CommonClassAMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002483" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10,000</ix:nonFraction></span>. The Company has the right to terminate the
SEPA at no cost or penalty upon five trading days&#8217; prior written notice to Yorkville, provided that there are no outstanding advances
for which shares of common stock need to be issued and the Yorkville convertible promissory note (the &#8220;Initial Advance&#8221;) (see
Note 10) has been paid in full. The Company and Yorkville may also agree to terminate the SEPA by mutual written consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As consideration for Yorkville&#8217;s
commitment to purchase the shares of common stock pursuant to the SEPA, the Company paid Yorkville a $<span id="xdx_908_ecustom--SaleOfStockConsiderationCashDueDiligenceFee_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zIqR9onD240h" title="Cash due diligence fee"><ix:nonFraction name="CELU:SaleOfStockConsiderationCashDueDiligenceFee" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002485" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">25</ix:nonFraction></span> cash due diligence fee and a
commitment fee equal to <span id="xdx_90B_ecustom--SaleOfStockConsiderationCommitmentFeeInShares_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zBJBNQUMgIqh" title="Commitment fee in shares"><ix:nonFraction name="CELU:SaleOfStockConsiderationCommitmentFeeInShares" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002487" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,964</ix:nonFraction></span> shares of common stock. The Company recorded direct issuance costs of $<span id="xdx_901_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zYf40Wn1Nbkd" title="Payments of stock issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember" id="Fact002489" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125</ix:nonFraction></span> inclusive of the commitment
shares as other expense in the consolidated statements of operations and other comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the entry into
the SEPA, on March 13, 2024, the Company entered into a registration rights agreement with Yorkville, pursuant to which the Company agreed
to file with the SEC no later than May 3, 2024, a registration statement for the resale by Yorkville of the shares of common stock issued
under the SEPA (including the commitment fee shares). The Company agreed to use commercially reasonable efforts to have such registration
statement declared effective within 45 days of such filing and to maintain the effectiveness of such registration statement during the
36-month commitment period. The Company will not have the ability to request any Advances under the SEPA (nor may Yorkville convert the
Initial Advance into common stock) until such resale registration statement is declared effective by the SEC. The Company has not yet
filed a registration statement with the SEC for the resale by Yorkville of the shares of common stock issued under the SEPA, which is
deemed an event of default under the SEPA and as a result, the interest rate on the on the Yorkville convertible promissory note (see
Note 10) increased to <span id="xdx_908_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zENZycd17X28" title="Line of credit percentage"><ix:nonFraction name="CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember15564515" id="Fact002491" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18.0</ix:nonFraction></span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company determined that the
SEPA should be accounted for as a derivative measured at fair value, with changes in the fair value recognized in earnings. Because the
Company has not yet filed a registration statement and no shares can currently be issued under the SEPA, the SEPA is deemed to have no
value as of the issuance date and as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 130 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, the Company
had outstanding warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z5BOd94ACYgc" title="Warrants to purchase aggregate shares"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember" id="Fact002493" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,221,557</ix:nonFraction></span> shares of Class A common stock. A summary of the warrants is as follows:</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002495" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zqDAMexY9Ui5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;<span id="xdx_8B8_zKad2K7DCD7" style="display: none">Summary of the Warrants</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>shares</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>price</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Expiration</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>date</b></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left">Dragasac Warrants (1) (4)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____z0ajEyNc7Gri" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_DragasacWarrantMember" id="Fact002497" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">652,981</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____z8rfYtZnGm0c" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_DragasacWarrantMember" id="Fact002499" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.4898</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____zinEqo0yyrj2" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_DragasacWarrantMember" format="ixt:datemonthdayyearen" id="Fact002501" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 16, 2025</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Public Warrants (2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zD7zdoffSM62" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_PublicWarrantsMember" id="Fact002503" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,437,447</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zB5PsoNJXGE8" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_PublicWarrantsMember" id="Fact002505" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">115.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zbLI7oxrz5Ye" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_PublicWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002507" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">July 16, 2026</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sponsor Warrants (2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zOETGiKL24Af" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_SponsorWarrantsMember" id="Fact002509" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">849,999</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zG7kLfJ7pqBa" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SponsorWarrantsMember" id="Fact002511" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">115.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zw7uGCgnGvxd" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_SponsorWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002513" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">July 16, 2026</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">May 2022 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zNBLwgk4u2M6" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" id="Fact002515" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">405,405</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zYnIQ2JKWm62" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" id="Fact002517" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_z9aJUtHsiila" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002519" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">October 10, 2028</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">March 2023 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zUxz96duCA9h" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002521" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">208,485</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zrAr8lT7pT7b" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002523" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zbMTTbD0VWKc" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002525" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 27, 2028</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">March 2023 PIPE Warrants (modified)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zP7VnzVPnA1g" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" id="Fact002527" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">729,698</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zB4FeFTE49ka" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" id="Fact002529" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zTinxyaSs7C4" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" format="ixt:datemonthdayyearen" id="Fact002531" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 27, 2028</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">March 2023 Loan Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_znGDbJamzLb2" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember" id="Fact002533" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_zuYOPZJcdbu5" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember" id="Fact002535" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.8950</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_z8mn0HGHCDu2" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002537" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">March 17, 2028</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">April 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKOrvgR95rk7" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" id="Fact002539" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">435,625</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_z5ana1gABy3f" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" id="Fact002541" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zJKCZ8wAHof9" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002543" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">October 10, 2028</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">April 2023 Registered Direct Warrants (modified)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zq37NcuNL3a8" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" id="Fact002545" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">487,451</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zDignA4wcAh9" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" id="Fact002547" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_z3dbEpyhwLI5" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" format="ixt:datemonthdayyearen" id="Fact002549" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">October 10, 2028</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">May 2023 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zI4rOAiVvCij" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002551" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">581,394</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zvM8PcQRmBAi" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" id="Fact002553" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zd5RNva34Wxe" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002555" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 17, 2028</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">June 2023 Warrants (3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zeCpcQOTjk6f" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeWarrantsMember" id="Fact002557" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zdMvnGprRZpf" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeWarrantsMember" id="Fact002559" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.8950</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zBVhMP3jdaTi" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002561" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">June 20, 2028</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">June 2023 Loan Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zQQc2iOSUeJ9" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember" id="Fact002563" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_z77BMZWgNc9f" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember" id="Fact002565" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.10</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_ztf6Zdk7HOP3" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002567" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">June 20, 2028</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">July 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zFxWian5umj6" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" id="Fact002569" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">857,142</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zhUxE7E1J034" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" id="Fact002571" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.50</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKAC9gfv4dya" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002573" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">January 31, 2029</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">January 2024 PIPE Warrants (4)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_zyfcgBb1FFFj" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002575" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">535,274</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_z5X4MytO6C6g" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" id="Fact002577" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.4898</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_zu80bN8I5Ofk" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002579" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">January 16, 2029</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">January 2024 Bridge Loan - Tranche #1 Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zE6EeyOX72B" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" id="Fact002581" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,650,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zXUvDttoFB0b" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" id="Fact002583" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.4898</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_z7usxMXNNxQg" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002585" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">January 16, 2029</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">January 2024 Bridge Loan - Tranche #2 Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zOZ7yCW1h3Tg" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" id="Fact002587" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,350,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zqSWqzySTfn6" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" id="Fact002589" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.9880</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zgQ38ONYpxVg" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002591" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">July 15, 2029</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">March 2024 RWI Forbearance Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_ziSrMKBgY6n6" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" id="Fact002593" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">300,000</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zYFg60Zj7Nq" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" id="Fact002595" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.8958</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zz6eqvfyOVsk" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" format="ixt:datemonthdayyearen" id="Fact002597" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">June 20, 2028</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">November 2024 Purchaser Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember_zaMPNsvijBw9" title="Number of shares" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember" id="Fact002599" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">263,156</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember_zlIGAKCCmTri" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember" id="Fact002601" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.85</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember__srt--RangeAxis__srt--MinimumMember_zemQZleBalsi" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_srt_MinimumMember" format="ixt:datemonthdayyearen" id="Fact002603" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">November 25, 2029</ix:nonNumeric></span> - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember__srt--RangeAxis__srt--MaximumMember_zFdB8Lo57Zge" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_srt_MaximumMember" format="ixt:datemonthdayyearen" id="Fact002605" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">December 3, 2029</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">November 2024 Placement Agent Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_ztFSS2vs3ty9" title="Number of shares" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember15565437" id="Fact002607" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,500</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zFUgq2fTDmKl" title="Exercise price" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember15565437" id="Fact002609" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.56</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_z9H1KcEEjrv1" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_srt_MinimumMember" format="ixt:datemonthdayyearen" id="Fact002611" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">November 25, 2029</ix:nonNumeric></span> - <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_z6Q7qsYVDzna" title="Expiration date"><ix:nonNumeric contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_srt_MaximumMember" format="ixt:datemonthdayyearen" id="Fact002613" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">December 3, 2029</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zmqvCnSL8DGb" title="Number of shares" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2024-12-31" id="Fact002615" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,221,557</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td id="xdx_F01_zaUWrq4ZJf36" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zU7ufP8Z2xui" style="font-size: 10pt"><ix:footnote id="Footnote002616" xml:lang="en-US">In connection with the execution of the January 2024 PIPE described above, the Company agreed to reprice <span id="xdx_909_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_z0CxQy6hgMJh" title="Number of warrants repriced" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="CELU:NumberOfWarrantsRepriced" contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember" id="Fact002618" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">652,981</ix:nonFraction></span> legacy warrants held by Dragasac with a previous exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zJ7gS6haRbBc" title="Exercise price per share or per unit of warrants or rights outstanding" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember_custom_DragasacWarrantMember" id="Fact002620" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">67.70</ix:nonFraction></span> to a new exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zYVzxB4PfIah" title="Exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember" id="Fact002622" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.4898</ix:nonFraction></span>. The term of the warrants was unchanged.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F02_zpkmujJUSn29" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zsXTc6rGNjph" style="font-size: 10pt"><ix:footnote id="Footnote002623" xml:lang="en-US">The number of Public Warrants
and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are <span id="xdx_903_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_zHSrw9l6fBM" title="Warrants outstanding" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="CELU:WarrantsOutstanding" contextRef="AsOf2024-12-31_custom_PublicWarrantsMember" id="Fact002625" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,374,478</ix:nonFraction></span> Public Warrants and <span id="xdx_90B_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zhb8lpf7vX1c" title="Warrants outstanding" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="CELU:WarrantsOutstanding" contextRef="AsOf2024-12-31_custom_SponsorWarrantsMember" id="Fact002627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,499,999</ix:nonFraction></span> Sponsor
Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant
is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfdpdBsJpoed" title="Exercise per share price (in Dollars per share)" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-12-31_custom_SponsorWarrantsMember_us-gaap_CommonClassAMember" id="Fact002629" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">115.00</ix:nonFraction></span> as a result
of the split.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F07_zYFMOuFpTkL1" style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zmEyC4kJiPda" style="font-size: 10pt"><ix:footnote id="Footnote002630" xml:lang="en-US">In connection with the execution
of the Starr Forbearance Agreement on March 13, 2024, described above under Warrant Modification and further in Note 10, the Company
agreed to reprice <span id="xdx_903_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zNKnX4iQB39l" title="Number of warrants repriced" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="CELU:NumberOfWarrantsRepriced" contextRef="AsOf2024-03-13_custom_StarrForbearanceAgreementMember" id="Fact002632" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction></span> warrants with a previous exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zB4Cdrckei1h" title="Exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-03-13_custom_StarrForbearanceAgreementMember" id="Fact002634" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.10</ix:nonFraction></span> and <span id="xdx_904_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zGIhzk4KHX5l" title="Number of warrants repriced" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="CELU:NumberOfWarrantsRepriced" contextRef="AsOf2024-03-13_custom_CVStarrCoIncMember" id="Fact002636" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">50,000</ix:nonFraction></span> warrants with a previous exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313_ztdMSGu7CCBf" title="Exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-03-13" id="Fact002638" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.10</ix:nonFraction></span>
held by C.V. Starr to a new exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zYKfrX5dCT29" title="Exercise price" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-03-13_custom_CVStarrCoIncMember" id="Fact002640" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.895</ix:nonFraction></span>. The term of the warrants was unchanged.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F04_zDR8Xy7PCx4h" style="font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zWd9mgsl4eQl" style="font-size: 10pt"><ix:footnote id="Footnote002641" xml:lang="en-US">On January 24, 2025, the
Company agreed to reduce the exercise price of the Dragasac warrants and the January 2024 PIPE warrants from $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zDOZqY4vlhF5" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-24_custom_JanuaryTwoThousandTwentyFourPIPEWarrantMember_us-gaap_SubsequentEventMember_srt_MinimumMember" id="Fact002643" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.49</ix:nonFraction></span> per share to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zfw8z5NDCiqh" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2025-01-24_custom_JanuaryTwoThousandTwentyFourPIPEWarrantMember_us-gaap_SubsequentEventMember_srt_MaximumMember" id="Fact002645" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.07</ix:nonFraction></span>
per share. As a result of the price reduction, the holder agreed to immediately exercise the warrants in full and to purchase an aggregate
<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zs0kpvh31E5b" title="Aggregate shares" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember" id="Fact002647" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,188,255</ix:nonFraction></span> shares of the Company&#8217;s Class A common stock for gross proceeds to the Company of approximately $<span id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250124__20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJKjoIgtMeje" title="Proceeds from the exercise of warrants" class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2025-01-242025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember" id="Fact002649" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million<i>.</i></ix:footnote></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002651" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z0NGXDvd3URc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>14. <span id="xdx_822_zWTRJlARrpBc">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>2021 Equity Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In July 2021, the Company&#8217;s
board of directors adopted, and the Company&#8217;s stockholders approved the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;).
The 2021 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;) to employees and for the grant of nonstatutory stock
options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and
other forms of stock awards to employees, directors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 131 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The number of shares of Class
A Common Stock initially reserved for issuance under the 2021 Plan is <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20210731__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQtlAGgt2VK4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-07-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember" id="Fact002652" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,091,528</ix:nonFraction></span>.
As of December 31, 2024, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zc3pCPWh7Mqh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember" id="Fact002653" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">330,391</ix:nonFraction>
</span>shares were reserved for issuance and those shares remain available for future grant under the 2021 Plan. The number of shares
reserved for issuance will automatically increase on January 1 of each year, for a period of <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zmA2bGuNGDeb"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember" format="ixt-sec:duryear" id="Fact002654" name="CELU:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod">10</ix:nonNumeric>
</span>years, from January 1, 2022 through January 1, 2031, by <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zjF5fDVKnRdf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember" id="Fact002655" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.0</ix:nonFraction></span>%
of the total number of shares of Celularity common stock outstanding on December 31 of the preceding calendar year, or a lesser number
of shares as may be determined by the Company&#8217;s board of directors. On January 1, 2025, the number of shares reserved for issuance
increased to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250101__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyZH2dar6LRj" title="Number of shares reserved for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-01-01_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember_us-gaap_SubsequentEventMember" id="Fact002657" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,229,890</ix:nonFraction></span> and those shares remain available for future grant under the 2021 Plan. The shares added to the 2021 Plan on
January 1, 2025, remain subject to an effective registration statement on Form S-8. Shares subject to stock awards granted under the
2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce
the number of shares available for issuance under the 2021 Plan. Additionally, shares issued pursuant to stock awards under the 2021
Plan that are repurchased or forfeited, as well as shares that are reacquired as consideration for the exercise or purchase price of
a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2021
Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The 2021 Plan is administered
by the Company&#8217;s board of directors. The Company&#8217;s board of directors, or a duly authorized committee thereof, may delegate
to one or more officers the authority to (i) designate employees other than officers to receive specified stock awards and (ii) determine
the number of shares to be subject to such stock awards. Subject to the terms of the 2021 Plan, the plan administrator has the authority
to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any, the number of shares
subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together with any vesting
acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms and conditions of
the award agreements for use under the 2021 Plan. The plan administrator has the power to modify outstanding awards under the 2021 Plan.
Subject to the terms of the 2021 Plan and in connection with a corporate transaction or capitalization adjustment, the plan administrator
may not reprice or cancel and regrant any award at a lower exercise price, strike price or purchase price or cancel any award with an
exercise price, strike price or purchase price in exchange for cash, property or other awards without first obtaining the approval of
the Company&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>2017 Equity Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The 2017 Equity Incentive Plan
(the &#8220;2017 Plan&#8221;) adopted by Legacy Celularity&#8217;s board of directors and approved by Legacy Celularity&#8217;s stockholders
provided for Legacy Celularity to grant stock options to employees, directors and consultants of Legacy Celularity. In connection with
the closing of the merger and effectiveness of the 2021 Plan, no further grants were made under the 2017 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The total number of stock options
that could have been issued under the 2017 Plan was <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember_ziF5CSSxU6q4" title="Number of shares remaining available for future grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002659" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,234,204</ix:nonFraction></span>. Shares that expired, forfeited, canceled or otherwise terminated without
having been fully exercised were available for future grant under the 2017 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The 2017 Plan is
administered by the Company&#8217;s board of directors or, at the discretion of the Company&#8217;s board of directors, by a
committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of Legacy
Celularity&#8217;s board of directors, or its committee if so delegated, except that the exercise price per share of stock options
could not be less than <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember_z5Eb2iTmkd29" title="Percentage of fair market value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002661" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span>%
of the fair market value of the share of common stock on the date of grant and the term of stock option could not be greater than <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zbP0wfLWFZGl" title="Stock option, expiration period"><ix:nonNumeric contextRef="From2024-01-012024-09-30_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MaximumMember" format="ixt-sec:durwordsen" id="Fact002663" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">ten
years</ix:nonNumeric></span>. Stock options granted to employees, officers, members of the board of directors and consultants typically vested over
a three<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zKNd1ARCEp5b" style="display: none"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact002664" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">3</ix:nonNumeric></span> or four<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zbhMpSrZRHX2" title="Options vesting period" style="display: none"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact002666" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">4</ix:nonNumeric></span>
year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Stock Option Valuation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span style="text-decoration: underline">Awards with Service Conditions</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of each option
is estimated on the date of grant using a Black-Scholes option pricing model that takes into account inputs such as the exercise price,
the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest
rate, and dividend yield. The fair value of each grant of stock options was determined by the Company using the methods and assumptions
discussed below. Certain of these inputs are subjective and generally require judgment to determine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data. The expected term of non-employee options is equal to the contractual term or its estimated term based on the underlying agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The expected stock price
volatility is based on historical volatilities of comparable public entities within the Company&#8217;s industry.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The risk-free interest rate
is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with
the respective expected term or contractual term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The expected dividend yield
is <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dpxL_uPure_c20240101__20241231_zw9j1ThKW2Z1" title="Expected dividend yield::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2668">0</span></span>% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common
stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 132 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002670" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zHSi7VNtimMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents,
on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of
stock options granted during the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zYZqiUnPXdY6" style="display: none">Schedule
of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_z2potn9roIG5" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-01to2024-12-31" id="Fact002672" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.4</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zHl1CZ2pHpVh" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31" id="Fact002674" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.1</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zkwd3rGxq8T2" title="Expected term (in years)"><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" format="ixt-sec:duryear" id="Fact002676" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.7</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_z9cm5bOa8hn7" title="Expected term (in years)"><ix:nonNumeric contextRef="From2023-01-012023-12-31" format="ixt-sec:duryear" id="Fact002678" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.6</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_z4S89HLms7e6" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-01-01to2024-12-31" id="Fact002680" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">104.9</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zAbmS7zcuBj2" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31" id="Fact002682" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">86.5</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zplEkoymBS58" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl2684">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zbEOdeV1aY8b" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl2686">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A1_zadLJXErc7ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The weighted average grant-date
fair value per share of stock options granted during the years ended December 31, 2024 and 2023 was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zWZaSb40nqD" title="Weighted average grant-date fair value of stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-01to2024-12-31" id="Fact002688" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.66</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_z8rsPSk2yGY8" title="Weighted average grant-date fair value of stock options granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-01-012023-12-31" id="Fact002690" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.35</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002692" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zbJRYdYPlJFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table summarizes
option activity with service conditions under the 2021 Plan and the 2017 Plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zG2i2ti5NyG7" style="display: none">Schedule of Stock Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Options</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Exercise Price</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Contract Term</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>(years)</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Intrinsic</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Value</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Outstanding at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zF3IYl6nrHu7" title="Options beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002694" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,820,187</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zoyox20ifwRb" title="Weighted Average Exercise Price, beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002696" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">40.16</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zXdRJbXwnUFh" title="Weighted Average Contract Term" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact002698" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.6</ix:nonNumeric></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zCES6e24mm3i" title="Aggregate Intrinsic Value" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2700">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zHBRRWhxZNU8" title="Options Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002702" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,503,394</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z9wP3RaRS9J7" title="Weighted Average Exercise Price, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002704" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.26</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zM79G07533W7" title="Options Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002706" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,744</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zJMc6pjrZmz2" title="Weighted Average Exercise Price, Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002708" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.80</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Forfeited/Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zEN22apL8W43" title="Options  Forfeited/Expired" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002710" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">341,312</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zGwGKKQKXEGa" title="Weighted Average Exercise Price, Forfeited/Expired" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002712" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">29.51</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding at December 31, 2024*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____ziiElOR6ieD1" title="Options ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002714" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,961,525</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zCXYjC5bYQ96" title="Weighted Average Exercise Price, ending balance" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002716" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.27</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zzU2IuFCZSPi" title="Weighted Average Contract Term" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact002718" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.4</ix:nonNumeric></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____z2g25bNo2c86" title="Aggregate Intrinsic Value" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002720" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vested and expected to vest at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z4DWpWCjrpp6" title="Options Vested and expected to vest" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002722" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,961,525</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z6uGximBcL7e" title="Weighted Average Exercise Price, Vested and expected to vest" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002724" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">27.27</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zG1uF8gKqDjb" title="Weighted Average Contract Term, Vested and expected to vest" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact002726" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">6.4</ix:nonNumeric></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zwzPVArM19v2" title="Aggregate Intrinsic Value Vested and expected to vest" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002728" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercisable at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zueTC5c1bAi9" title="Options Exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002730" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,586,561</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zI8ItzR1OnB8" title="Weighted Average Exercise Price, Exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" id="Fact002732" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">37.49</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zku2lDcJSgTg" title="Weighted Average Contract Term Exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" format="ixt-sec:duryear" id="Fact002734" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.9</ix:nonNumeric></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zUGFYOScdgS" title="Aggregate Intrinsic Value Exercisable" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2736">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0F_zB4AoTlKrtr2" style="width: 15pt; text-align: right">*</td><td id="xdx_F1D_zLXerFXny1Wc" style="text-align: justify"><ix:footnote id="Footnote002737" xml:lang="en-US">Options outstanding at December 31, 2024 under the 2021 Plan and 2017 Plan were <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zJXOtNTlcnPg" title="Options outstanding" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-12-31_custom_TwoThousandTwentyOnePlanMember" id="Fact002739" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,569,029</ix:nonFraction></span> and
                                                                             <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zBXUGuFGvff8" title="Options outstanding" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2024-12-31_custom_TwoThousandSeventeenPlanMember" id="Fact002741" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,437,496</ix:nonFraction></span>, respectively. Options outstanding at December 31, 2024 under the 2021 Plan include <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_z1vLdctHuub8" title="Options outstanding including awards" class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyOnePlanMember" id="Fact002743" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,000</ix:nonFraction></span> awards with performance
                                                                             conditions (see below).</ix:footnote></td>
</tr></table>

</ix:nonNumeric><p id="xdx_8A9_zbWkmUhL99Bl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The aggregate intrinsic value
of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s Class
A common stock for those options that had exercise prices lower than the fair value of Class A common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recorded stock-based
compensation expense relating to option awards with service conditions of $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVoTZaTbQlz9" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember15566546" id="Fact002745" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,336</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAidfgl5l4R3" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember15566546" id="Fact002747" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,293</ix:nonFraction></span> for the years ended December 31, 2024 and
2023, respectively. During the years ended December 31, 2024 and 2023, the aggregate intrinsic value was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20240101__20241231_z2qlZRNPNFm8" title="Aggregate intrinsic value, stock option exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2024-01-01to2024-12-31" id="Fact002749" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20230101__20231231_ziIVqEioo094" title="Aggregate intrinsic value, stock option exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2023-01-012023-12-31" id="Fact002751" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span>, respectively, for
the stock options exercised. As of December 31, 2024, unrecognized compensation cost for options issued with service conditions was $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr5a2gDZWsub" title="Unrecognized compensation cost for options issued"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember" id="Fact002753" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,129</ix:nonFraction></span>
and will be recognized over an estimated weighted-average amortization period of <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmasEAcJvBre" title="Estimated weighted-average amortization period"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember15566546" format="ixt-sec:duryear" id="Fact002755" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.09</ix:nonNumeric></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i><span style="text-decoration: underline">Awards with Performance Conditions</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the advisory
agreement signed with Robin L. Smith, MD (see Note 20), the Company awarded options under the 2021 Plan to acquire a total of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zDU1UinCtXA9" title="Vested options to acquire shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-08-162022-08-16_custom_AwardsWithPerformanceConditionsMember" id="Fact002757" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">105,000</ix:nonFraction>
</span>shares with an exercise price of $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_ztfIXeIU6hld" title="Vested options to acquire per share"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="From2022-08-162022-08-16_custom_AwardsWithPerformanceConditionsMember" id="Fact002759" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">29.90</ix:nonFraction>
</span>to Dr. Smith, a former member of the Company&#8217;s board of directors. The initial tranche of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember__us-gaap--VestingAxis__custom--InitialTrancheMember_zXZvvIfxBOu1" title="Vested options to acquire shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-08-162022-08-16_custom_AwardsWithPerformanceConditionsMember_custom_InitialTrancheMember" id="Fact002761" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction>
</span>stock options vested upon execution of the advisory agreement on August 16, 2022. The remaining <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zPEeCOAp7SR2" title="Stock option vesting"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-08-16_custom_AwardsWithPerformanceConditionsMember" id="Fact002763" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80,000</ix:nonFraction>
</span>stock options are subject to vesting upon achievement of certain predefined milestones in relation to the expansion of the degenerative
disease business. On November 1, 2022, the second tranche of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20221101__20221101__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember__us-gaap--VestingAxis__custom--SecondTrancheMember_zHNDKY5vzIG7" title="Vested options to acquire shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-11-012022-11-01_custom_AwardsWithPerformanceConditionsMember_custom_SecondTrancheMember" id="Fact002765" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction>
</span>stock options vested upon achievement of the first milestone. The fair value of the award was determined based on a Black-Scholes
option-pricing model. The Company&#8217;s grant date fair value assumptions were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221101__20221101__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zfDLt0ldrHIc" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-11-012022-11-01_custom_AwardsWithPerformanceConditionsMember" id="Fact002767" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">79.9</ix:nonFraction></span>%
expected volatility, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_z4qecaMATcBh" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-01-012024-12-31_custom_AwardsWithPerformanceConditionsMember" id="Fact002769" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.95</ix:nonFraction></span>%
risk-free interest rate, five<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zstFfh2JjH52" title="Expected term (in years)" style="display: none"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_AwardsWithPerformanceConditionsMember" format="ixt-sec:duryear" id="Fact002771" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span>-year
expected term, and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zJNQsvrJPNX7" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-01-012024-12-31_custom_AwardsWithPerformanceConditionsMember" id="Fact002773" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%
expected dividend yield. The remaining <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230816__20230816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zVJoatRXjjz4" title="Remaining stock options forfeited upon termination of the advisory agreement"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-08-162023-08-16_custom_AwardsWithPerformanceConditionsMember" id="Fact002775" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">60,000</ix:nonFraction>
</span>stock options were forfeited on August 16, 2023 upon termination of the advisory agreement. There were no milestones achieved
or probable of being achieved and accordingly there was <span id="xdx_901_eus-gaap--ShareBasedCompensation_do_c20230101__20231231_zcCv8Tx1Slq6" title="Stock based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-12-31" id="Fact002777" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span> stock-based compensation expense recorded during the year ended December 31,
2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>


<ix:exclude><!-- Field: Page; Sequence: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Restricted Stock Units</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company issues restricted
stock units (&#8220;RSUs&#8221;) to employees that generally vest over a four<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDcQ3FA3Ugv4" style="display: none"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843" format="ixt-sec:duryear" id="Fact002778" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">4</ix:nonNumeric></span>-year
period, with <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zXzUpGs5YaOf" title="Vesting percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" id="Fact002780" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>%
vesting on the anniversary of the grant date, and the remainder vesting in equal annual installments thereafter so that the RSUs are
vested in full on the four-year anniversary of the grant date. At times, the board of directors may approve exceptions to the standard
RSU vesting terms. Any unvested shares will be forfeited upon termination of services. The fair value of an RSU is equal to the fair
market value price of the Company&#8217;s common stock on the date of grant. RSU expense is amortized straight-line over the vesting
period. There are no RSUs outstanding under the 2017 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002782" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zqTyDgwas09a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table summarizes
activity related to RSU stock-based payment awards under the 2021 Plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BC_zSXrC3ysNlUj" style="display: none">Schedule
of Activity Related to RSU Stock-Based Payment Awards</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Number of</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Shares</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Grant Date Fair Value</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Outstanding at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNALfbpj75qb" title="Number of Shares, Outstanding beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002784" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">823,332</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zytdOBicjFqk" title="Weighted Average Grant Date Fair Value,Outstanding beginning balance" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002786" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.77</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPpuztLsUrMk" title="Number of Shares, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843" id="Fact002788" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">337,080</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqSxsnwAFd6a" title="Weighted Average Grant Date Fair Value, Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843" id="Fact002790" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.23</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Released</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb9ccMxJtKmc" title="Number of Shares, Released" style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843" id="Fact002792" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">400,996</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaMY8zj0UKFe" title="Weighted Average Grant Date Fair Value, Released" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843" id="Fact002794" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.58</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXrulQsvRS1b" title="Number of Shares, Forfeited" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843" id="Fact002796" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">99,977</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z09oFjThdPM6" title="Weighted Average Grant Date Fair Value, Forfeited" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843" id="Fact002798" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.24</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTMssxfDjrkd" title="Number of Shares, Outstanding ending balance" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002800" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">659,439</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfIVN9J5UJud" title="Weighted Average Grant Date Fair Value, Outstanding ending balance" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002802" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.29</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zkivrNzpp2f4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recorded stock-based
compensation expense of $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGMsTsOX3Re6" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843" id="Fact002804" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,022</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgxjToMJNQFi" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember15566875" id="Fact002806" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,724</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively, related to RSUs. As of December
31, 2024, the total unrecognized expense related to all RSUs was $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2Jw3T2Wx3s7" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember" id="Fact002808" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,136</ix:nonFraction></span>, which the Company expects to recognize over a weighted-average
period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zO7nJ4XsE9y8" title="Estimated weighted-average amortization period"><ix:nonNumeric contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843" format="ixt-sec:duryear" id="Fact002810" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.44</ix:nonNumeric></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Stock Units with Market Condition Vesting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In July 2023, the Company granted
<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zGQAA9vfK7gg" title="Number of shares granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember" id="Fact002812" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">174,500</ix:nonFraction>
</span>market condition stock unit awards (&#8220;MCUs&#8221;) under the 2021 Plan to certain members of management. The awards are scheduled
to vest over a period of one<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember__srt--RangeAxis__srt--MinimumMember_zcNthJVudLQf" style="display: none"><ix:nonNumeric contextRef="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact002813" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">1</ix:nonNumeric></span>
to three<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember__srt--RangeAxis__srt--MaximumMember_zdiw7pywvJMd" style="display: none"><ix:nonNumeric contextRef="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact002814" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">3</ix:nonNumeric></span>
years from the grant date based on continuous employment and specified market conditions based on the Company&#8217;s stock price
at the time of vest. As of December 31, 2024, <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zXY3Uc9m9Gs5"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2024-12-31_custom_MarketConditionStockUnitMember" id="Fact002815" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">145,833</ix:nonFraction>
</span>of the MCUs were forfeited as a result of the participant&#8217;s termination of continuous service. Stock-based compensation
expense for the remaining <span id="xdx_90A_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zGZS0NtUWivf"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_MarketConditionStockUnitMember" id="Fact002816" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,667</ix:nonFraction>
</span>MCUs is being recognized over the requisite service period based on the award&#8217;s fair value on the grant date, which was
determined based on the Company&#8217;s closing stock price on the date of grant of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_z1eHeYU75zlh" title="Grant date fair value of units granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-01-012024-12-31_custom_MarketConditionStockUnitMember" id="Fact002818" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.00</ix:nonFraction></span>,
further discounted to reflect the effects of the market condition of the award. The Company recorded stock-based compensation expense
relating to MCUs of $<span id="xdx_90D_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_z5dzjiq4qnAk" title="Stock based compensation expense"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="From2024-01-012024-12-31_custom_MarketConditionStockUnitMember" id="Fact002820" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">211</ix:nonFraction>
</span>for the year ended December 31, 2024. Stock-based compensation expense relating to MCUs for the year ended December 31, 2023 was
de minimis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Stock-Based Compensation Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002822" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zFenUch6J8Pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recorded stock-based
compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_zGrfAobJxpB1" style="display: none">Schedule
of Stock-based Compensation Expense</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zpCCS3OARQOk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zlS3CHNW0iY7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zBJyVCyCdy3a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Cost of revenues</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_CostOfSalesMember" id="Fact002824" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">450</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_CostOfSalesMember" id="Fact002825" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">580</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4xEVC9YXIW4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact002827" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,287</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact002828" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,832</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zdpAFtrQkOKi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-012024-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" id="Fact002830" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,832</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember" id="Fact002831" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,605</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z5JTi4sY6kU1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2024-01-01to2024-12-31" id="Fact002833" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,569</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31" id="Fact002834" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,017</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zNA8pyrQr0Sb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 134 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002836" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_800_eus-gaap--RevenueFromContractWithCustomerTextBlock_z9mChV1hdOsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>15. <span id="xdx_82D_zCp4DW6FVf7b">Revenue Recognition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002838" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_zROoRw6VM9Xh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table provides information
about disaggregated revenue by product and services:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zt6RnZ0QmU8g" style="display: none">Schedule
of Disaggregated Revenue by Product and Services</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zdrQC8CKc5xl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zLt4mVa3r0qe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zEW9OaK2KmO9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Product sales, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_us-gaap_ProductMember" id="Fact002840" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">35,336</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_us-gaap_ProductMember" id="Fact002841" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,149</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zCj0kf6Hgt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_us-gaap_ServiceMember" id="Fact002843" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,140</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_us-gaap_ServiceMember" id="Fact002844" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,441</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_zH04zl1TXRIh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">License, royalty and other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_LicenseRoyaltyAndOtherMember" id="Fact002846" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,744</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_LicenseRoyaltyAndOtherMember" id="Fact002847" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,181</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zPX4N7a5iaJl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact002849" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,220</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact002850" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,771</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zHlJ8wyJqCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Net revenues include: (i) sales
of biomaterial products, including Biovance, Biovance 3L, Rebound, Interfyl, and CentaFlex, of which our direct sales are included in
Product Sales while sales through our network of distribution partners are included in License, royalty and other; and (ii) the collection,
processing and storage of umbilical cord and placental blood and tissue after full-term pregnancies, collectively, Services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002852" name="us-gaap:DeferredRevenueByArrangementDisclosureTextBlock"><p id="xdx_891_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zxrUfkApAj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table provides changes
in deferred revenue from contract liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span id="xdx_8B0_z6sEHbgyCuyb" style="display: none">Schedule of Changes in Deferred Revenue from Contract Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zgcH59FHu7Hf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_z0aJk7FE0jFl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zpdE3pR8daW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Balance at January 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2023-12-31" id="Fact002854" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,020</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2022-12-31" id="Fact002855" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,492</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zKWnLp2hTeXe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Beginning Balance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2023-12-31" id="Fact002857" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,020</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2022-12-31" id="Fact002858" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,492</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_pn3n3_z9cqP8P7KSz8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Deferral of revenue <span id="xdx_F44_zlYoFHsrAbjb">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" contextRef="From2024-01-01to2024-12-31" id="Fact002860" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,731</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="CELU:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" contextRef="From2023-01-012023-12-31" id="Fact002861" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,266</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn3n3_zIryK7iBJilg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Recognition of unearned revenue <span id="xdx_F49_z9a1Na1pz1L">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="From2024-01-01to2024-12-31" id="Fact002863" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,496</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" contextRef="From2023-01-012023-12-31" id="Fact002864" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,738</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zchUp2VJK0P9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2024-12-31" id="Fact002866" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,255</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2023-12-31" id="Fact002867" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,020</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zRUhVhWBte6d" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Ending Balance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2024-12-31" id="Fact002869" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,255</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" contextRef="AsOf2023-12-31" id="Fact002870" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,020</ix:nonFraction></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zR7xVvRdZReb" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zvoy2DxJ072b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002871" xml:lang="en-US">Deferral
    of revenue includes $<span id="xdx_908_eus-gaap--DeferredRevenue_iI_pn3n3_c20241231_zbtl13DKTSt6" class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2024-12-31" id="Fact002872" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,061</ix:nonFraction></span> in 2024 resulting from payments received in advance of performance under the biobanking services storage
    contracts that are recognized as revenue under the contract as performance is completed.</ix:footnote></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F00_z2KygN5bQh7d" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zil4UEkHihvf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:footnote id="Footnote002873" xml:lang="en-US">Recognition
    of unearned revenue includes $<span id="xdx_907_ecustom--UnearnedRevenue_iI_pn3n3_c20241231_zQdD2DbYPnl6" class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"><ix:nonFraction name="CELU:UnearnedRevenue" contextRef="AsOf2024-12-31" id="Fact002874" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,561</ix:nonFraction></span> that was included in the beginning deferred revenue balance at January 1, 2024.</ix:footnote></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AA_zBrwprJACCh5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 135 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002876" name="CELU:LicenseAndDistributionAgreementsTextBlock"><p id="xdx_806_ecustom--LicenseAndDistributionAgreementsTextBlock_zdTgqvdlL5Mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>16. <span id="xdx_827_z0FFb1lSaFL6">License and Distribution Agreements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Sequence LifeScience, Inc. Independent Distribution
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On August 23, 2024, the Company
entered into an Independent Distributor Agreement (the &#8220;Distribution Agreement&#8221;) with Sequence LifeScience, Inc. (&#8220;Sequence&#8221;),
which provided the Company exclusive rights to market, sell and distribute Rebound<sup>TM</sup>, a full thickness placental-derived allograft
matrix product, in the U.S. for a period of ninety (90) days. Under the terms of the Distribution Agreement, Sequence made Rebound available
for purchase to the Company at a fixed price consistent with market terms. The Distribution Agreement was intended to be a bridge to allow
the parties to cooperatively market the product prior to consummating an asset purchase agreement. The Company acquired Rebound on October
9, 2024, through an asset purchase agreement with Sequence. See Note 3 for more information about the Rebound asset purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Regeneron Research Collaboration Services Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On August 25, 2023, the Company
entered into a multi-year research collaboration services agreement with Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;), pursuant
to which the Company will support the research effort of Regeneron&#8217;s allogeneic cell therapy candidates (the &#8220;Regeneron Services
Agreement&#8221;). The Regeneron Services Agreement&#8217;s initial focus is the research on a targeted allogeneic gamma delta chimeric
antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. Payments
to the Company under the Regeneron Services Agreement included a non-refundable up-front payment of $<span id="xdx_900_ecustom--NonrefundableUpfrontPayment_pn3n3_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_zrVgzXoUiyc6" title="Nonrefundable up-front payment"><ix:nonFraction name="CELU:NonrefundableUpfrontPayment" contextRef="From2023-08-252023-08-25_custom_RegeneronResearchCollaborationServicesAgreementMember" id="Fact002878" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">750</ix:nonFraction></span> and payments based upon the achievement
of defined milestones according to written statements of work. The Regeneron Services Agreement will expire <span id="xdx_904_ecustom--ServiceAgreementTerm_dc_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_z3OGOBmFS3J9" title="Service agreement term"><ix:nonNumeric contextRef="From2023-08-252023-08-25_custom_RegeneronResearchCollaborationServicesAgreementMember" format="ixt-sec:durwordsen" id="Fact002880" name="CELU:ServiceAgreementTerm">five years</ix:nonNumeric></span> from the effective
date and may be terminated immediately by either party for the uncured material breach, bankruptcy, or insolvency of the other party.
Regeneron may also terminate for convenience upon <span id="xdx_901_ecustom--LicenseAgreementNoticePeriod_dtD_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_zTGlJd6Q5vib" title="License agreement notice period"><ix:nonNumeric contextRef="From2023-08-252023-08-25_custom_RegeneronResearchCollaborationServicesAgreementMember" format="ixt-sec:durday" id="Fact002882" name="CELU:LicenseAgreementNoticePeriod">30</ix:nonNumeric></span> days&#8217; written notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 136 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Regeneron Services Agreement
grants Regeneron a royalty-free, fully-paid up, worldwide, non-exclusive license, with the right to grant sublicenses, to the Company&#8217;s
intellectual property (&#8220;IP&#8221;) to the extent that any such license is necessary for Regeneron to fully use the Company&#8217;s
research services. The Company determined that the (1) research licenses and (2) the research activities performed by the Company represent
a single combined performance obligation under the Regeneron Services Agreement. The Company determined that Regeneron cannot benefit
from the licenses separately from the research activities because these services are specialized and rely on the Company&#8217;s expertise
such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent
one combined performance obligation and the entire transaction price was allocated to that single combined performance obligation. The
performance obligation will be satisfied over the research term as the Company performs the research activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, the Company
received payments totaling $<span id="xdx_905_eus-gaap--DeferredRevenueRevenueRecognized1_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--RegeneronServicesAgreementMember_zCERV8PWfpuf" title="Received payments"><ix:nonFraction name="us-gaap:DeferredRevenueRevenueRecognized1" contextRef="From2024-01-012024-12-31_custom_RegeneronServicesAgreementMember" id="Fact002884" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,325</ix:nonFraction></span> under the Regeneron Services Agreement, of which $<span id="xdx_90A_eus-gaap--Revenues_pn3n3_c20241001__20241231__us-gaap--TypeOfArrangementAxis__custom--RegeneronServicesAgreementMember_z1gJR610XnPa" title="Revenues"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-10-012024-12-31_custom_RegeneronServicesAgreementMember" id="Fact002886" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">688</ix:nonFraction></span> was recognized in revenue during the fourth quarter
of 2024 based on achievement of defined milestones. As of December 31, 2024, the remaining $<span id="xdx_90E_eus-gaap--DeferredRevenue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--RegeneronServicesAgreementMember_zghB0gSjHUHe" title="Deferred Revenue"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2024-12-31_custom_RegeneronServicesAgreementMember" id="Fact002888" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">637</ix:nonFraction></span> was recorded as deferred revenue to be
recognized based on satisfaction of future performance obligations. The Company recognizes revenue using the cost-to-cost method, which
it believes best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards
completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified
performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent
of progress towards completion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Sorrento Therapeutics, Inc. License and Transfer
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company and Sorrento Therapeutics,
Inc. (&#8220;Sorrento&#8221;), a related party through September 30, 2023, are party to a License and Transfer Agreement for the exclusive
worldwide license to CD19 CAR-T constructs for use in placenta-derived cells and/or cord blood-derived cells for the treatment of any
disease or disorder (the &#8220;2020 Sorrento License Agreement&#8221;). The Company retains the right to sublicense the rights granted
under the agreement with Sorrento&#8217;s prior written consent. As consideration for the license, the Company is obligated to pay Sorrento
a royalty equal to low single-digit percentage of net sales (as defined within the agreement) and a royalty equal to low double-digit
percentage of all sublicensing revenues (as defined within the agreement). The 2020 Sorrento License Agreement will remain in effect until
terminated by either the Company or Sorrento for uncured material breach upon 90 days written notice or, after the first anniversary of
the effective date of the 2020 Sorrento License Agreement, by the Company for convenience upon six months&#8217; written notice to Sorrento.
On October 19, 2023, Sorrento filed a Plan of Reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court
for the Southern District of Texas which plan contemplates a liquidation of the debtor. If the Plan is confirmed by the Bankruptcy Court,
the Company believes that Sorrento will not be able to perform under the license and that any rights the Company might have under the
license would be unenforceable. After assessing the status of the IND to determine an optional path forward for the program, the Company
elected to terminate development of CYCART-19 for B-cell malignancies during the third quarter of 2023. The Company may continue pre-clinical
development of other T-cell candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Genting Innovation PTE LTD Distribution Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On May 4, 2018, concurrently with
Dragasac&#8217;s equity investment in Legacy Celularity, Legacy Celularity entered into a distribution agreement with Genting Innovation
PTE LTD (&#8220;Genting Innovation&#8221;) pursuant to which Genting Innovation was granted supply and distribution rights to certain
Company products in select Asia markets (the &#8220;Genting Agreement&#8221;). The Genting Agreement granted Genting Innovation limited
distribution rights to the Company&#8217;s then-current portfolio of degenerative disease products and provides for the automatic rights
to future products developed by or on behalf of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The term of the Genting Agreement
was renewed on January 31, 2023, and automatically renews for successive 12 month terms unless: Genting provides written notice of its
intention not to renew at least three months prior to a renewal term or the Genting Agreement is otherwise terminated by either party
for cause.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Genting Innovation and Dragasac
are both direct subsidiaries of Genting Berhad, a public limited liability company incorporated and domiciled in Malaysia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On June 14, 2023, the Genting
Agreement was amended and restated to include manufacturing rights in the territories covered under the agreement, expansion to two new
countries, and a commitment by the Company to provide technology transfer pursuant to the plan established by a Joint Steering Committee.
On January 17, 2024, the Company further amended the Genting Agreement to include distribution and manufacturing rights to certain of
the Company&#8217;s cell therapy products, including PSC-100, PDA-001, PDA-002, pEXO-001, APPL-001 and CYNK-001. As of December 31, 2024,
the Company has not recognized any revenue under the Genting Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 137 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Celgene
Corporation License Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is party to a license agreement with Celgene (the &#8220;Celgene Agreement&#8221;) pursuant to which the Company granted Celgene
two separate licenses to certain intellectual property. The Celgene Agreement grants Celgene a royalty-free, fully-paid up, worldwide,
non-exclusive license to the certain intellectual property (&#8220;IP&#8221;) for pre-clinical research purposes in all fields and a
royalty-free, fully-paid up, worldwide license, with the right to grant sublicenses, for the development, manufacture, commercialization
and exploitation of products in the field of the construction of any CAR, the modification of any T-lymphocyte or NK cell to express
such a CAR, and/or the use of such CARs or T-lymphocytes or NK cells for any purpose, including prophylactic, diagnostic, and/or therapeutic
uses thereof. The Celgene Agreement will remain in effect until its termination by either party for cause</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pulthera,
LLC Binding Term Sheet</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with the entry into the securities purchase agreement for the March 2023 private placement described in Note 13 above, the Company executed
a binding term sheet to negotiate and enter into a sublicense agreement of certain assets from an affiliate of Pulthera, LLC (the &#8220;sublicensor&#8221;).
Pursuant to the binding term sheet, the Company paid the sublicensor a $<span id="xdx_901_ecustom--PaymentOfOptionFeeInCash_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember_zp0MPzqwCgZc" title="Payment of option fee in cash"><ix:nonFraction name="CELU:PaymentOfOptionFeeInCash" contextRef="From2023-01-012023-12-31_custom_PultheraLLCBindingTermSheetMember" id="Fact002890" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span> option fee in cash and issued $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzcLYNEd0blj" title="Issuance of common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_custom_PultheraLLCBindingTermSheetMember_us-gaap_CommonStockMember" id="Fact002892" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span> of shares of its Class
A common stock (<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230317__20230317__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcvKqHcxYuJ4" title="Purchase and sale of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-03-172023-03-17_custom_PultheraLLCBindingTermSheetMember_us-gaap_CommonStockMember" id="Fact002894" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">169,492</ix:nonFraction></span> shares based on the closing price on March 17, 2023) as consideration for stem-cells inventory to be used in
research and development. The option fee paid by the Company will be applied towards an initial license fee as outlined in the sublicense
agreement. The Company is required to use diligent and reasonable efforts to develop and obtain regulatory approval to market at least
one licensed product contingent upon a firm written commitment to provide further financing to the Company. The $<span id="xdx_905_ecustom--OptionFeeExpense_pn3n3_c20230317__20230317__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zPNvr80kRnhj" title="Option fee expense"><ix:nonFraction name="CELU:OptionFeeExpense" contextRef="From2023-03-172023-03-17_custom_PultheraLLCBindingTermSheetMember_us-gaap_ResearchAndDevelopmentExpenseMember" id="Fact002896" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,000</ix:nonFraction></span> option fee was
recorded as acquired IPR&amp;D expense included in research and development expense on the consolidated statements of operations and
comprehensive loss for the year ended December 31, 2023, as the acquired IPR&amp;D had no alternative future use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>License
Agreement with BioCellgraft, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 11, 2023, the Company and BioCellgraft, Inc. (&#8220;BioCellgraft&#8221;) entered into a license agreement whereby the
Company granted an exclusive license to BioCellgraft, with the right to sublicense, to develop and commercialize certain licensed
products to the dental market in the United States over an initial four<span id="xdx_90F_ecustom--CommercialLicenseToDentalProductsAgreementPeriod_dtY_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zVuYnNlGRql8" title="Commercial license" style="display: none"><ix:nonNumeric contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember" format="ixt-sec:duryear" id="Fact002898" name="CELU:CommercialLicenseToDentalProductsAgreementPeriod">4</ix:nonNumeric></span>
year term and it will automatically renew for an additional <span id="xdx_905_ecustom--CommercialLicenseToDentalProductsAgreementRenewalTerm_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_z5dDGyQAJHN" title="Commercial license to dental products agreement renewal term"><ix:nonNumeric contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember" format="ixt-sec:durwordsen" id="Fact002900" name="CELU:CommercialLicenseToDentalProductsAgreementRenewalTerm">two
years</ix:nonNumeric></span> unless either party provides written notice of termination. BioCellgraft will pay to the Company total license fees of
$<span id="xdx_901_ecustom--LicenseFeeExpense_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zDf81aDSIRik" title="License fee expense"><ix:nonFraction name="CELU:LicenseFeeExpense" contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember" id="Fact002902" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction></span>
over a <span id="xdx_909_ecustom--LicenseFeesPaymentPeriod_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_z9jRDWxxAdMk" title="License fees payment period"><ix:nonNumeric contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember" format="ixt-sec:durwordsen" id="Fact002904" name="CELU:LicenseFeesPaymentPeriod">two
year</ix:nonNumeric></span> period, as defined. Upon execution of the agreement, the Company received a $<span id="xdx_902_ecustom--LicenseFeePayment_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zI7buGLLxO5f" title="License fee payment"><ix:nonFraction name="CELU:LicenseFeePayment" contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember" id="Fact002906" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></span>
payment towards the first year payment. To date, the Company has not received any additional consideration beyond the $<span id="xdx_904_ecustom--AdditionalLicenseFee_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zavzXl2EEc2b" title="Additional license fee"><ix:nonFraction name="CELU:AdditionalLicenseFee" contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember" id="Fact002908" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">300</ix:nonFraction></span> license payment under the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 138; Options: NewSection; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002910" name="us-gaap:DefinedBenefitPlanTextBlock"><p id="xdx_80A_eus-gaap--DefinedBenefitPlanTextBlock_zXS3pxKshPif" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_827_zNftIQHdsuC7">Benefit Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers all
employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a
pre-tax basis. Matching contributions to the plan may be made at the discretion of the Company&#8217;s board of directors. During
the years ended December 31, 2024 and 2023, the Company made contributions of <span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20240101__20241231_zdfqdFxpxFPc" title="Contributions made to the plan">$<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2024-01-01to2024-12-31" id="Fact002912" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">139</ix:nonFraction></span>
and $<span id="xdx_906_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20230101__20231231_zAkawPEAlzq4" title="Contributions made to the plan"><ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="From2023-01-012023-12-31" id="Fact002914" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">198</ix:nonFraction></span>,
respectively. During the year ended December 31, 2022, the Company accrued $1,159 but
has not made the matching contribution to the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002916" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zDQcziwyEVpe" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.
<span id="xdx_821_zblnKLZ3FlZ7">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002918" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z3M0NuN8Cwh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s current and deferred tax provision is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BC_zsHdMHqJd9v2" style="display: none">Schedule
of Current and Deferred Tax Provision</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_z0e9IhQQ7L64" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zhtwx24pxe87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current income tax expense:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzRNM_zI2maAw2fDNb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2920">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2921">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzRNM_zK6Vep8cO504" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; width: 62%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2923">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 15%; text-align: right"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact002924" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzRNM_maITEBzV7j_zQ0IhocEGkLb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current income tax expense</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2926">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact002927" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income tax expense
    (benefit):</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDFSALzhM1_zmBbGExPym8b" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact002929" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact002930" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDFSALzhM1_zvr8Jt4Pjd1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2024-01-01to2024-12-31" id="Fact002932" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact002933" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_pn3n3_mtDFSALzhM1_maITEBzV7j_zjJeOyoGOYj3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax expense</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2935">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2936">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzV7j_z7w27h2KP5Cb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    income tax expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2938">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-01-012023-12-31" id="Fact002939" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zfLXsvzyS3R5" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 139; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002941" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUgOlIqXjr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BD_zsLPthYADiCf" style="display: none">Schedule
of Reconciliation of the U.S &#160;federal statutory income tax</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zIdyspTUrI7e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zPxflrFiO1yk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zOJd785Svxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-01-01to2024-12-31" id="Fact002943" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-012023-12-31" id="Fact002944" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zy0opPxbvWu3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">State income taxes, net of federal benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-01-01to2024-12-31" id="Fact002946" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.3</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-012023-12-31" id="Fact002947" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.4</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_pid_dp_uPure_maABC_zkQCKuYaPwfl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Interest accretion expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" contextRef="From2024-01-01to2024-12-31" id="Fact002949" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.1</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" contextRef="From2023-01-012023-12-31" id="Fact002950" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11.0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zyWyox63eEFh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-01-01to2024-12-31" id="Fact002952" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">20.1</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-012023-12-31" id="Fact002953" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">20.0</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_pid_dp_uPure_maABC_zmnevfawRT1f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Mark to market warrant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2955">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" contextRef="From2023-01-012023-12-31" id="Fact002956" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.5</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueUp_pid_dp_uPure_maABC_z2aTJcj9tgo9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELU:EffectiveIncomeTaxRateReconciliationDeferredTrueUp" contextRef="From2024-01-01to2024-12-31" id="Fact002958" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.1</ix:nonFraction></td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELU:EffectiveIncomeTaxRateReconciliationDeferredTrueUp" contextRef="From2023-01-012023-12-31" id="Fact002959" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">2.4</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_maABC_zY4hNHLT3E3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt">Impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2961">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" contextRef="From2023-01-012023-12-31" id="Fact002962" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">12.0</ix:nonFraction></td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maABC_zfCjhXbNEKsd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt">Other permanent items</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2024-01-01to2024-12-31" id="Fact002964" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.4</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2023-01-012023-12-31" id="Fact002965" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.5</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_zeWtlL2hemk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2967">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2968">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zlAHjbUu4jy" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact002970" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zi4QXOddxo86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
deferred income tax liabilities as of December 31, 2024 and 2023 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BB_zds472WMQSuh" style="display: none">Schedule
of Deferred tax assets and liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_z9xT3qbgUaR" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_zHCNmkSzn9u7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzt0C_zhpy46YqYn3d" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; width: 62%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-12-31" id="Fact002972" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121,804</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact002973" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109,544</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_iI_pn3n3_maDTAGzt0C_zk5UBaetBOUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact002975" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,674</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact002976" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,674</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzt0C_zm4MVrbOMqyc" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-12-31" id="Fact002978" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact002979" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxAssetsStartupCosts_iI_pn3n3_maDTAGzt0C_z0NT2rqjyJ6e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Startup costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsStartupCosts" contextRef="AsOf2024-12-31" id="Fact002981" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">431</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsStartupCosts" contextRef="AsOf2023-12-31" id="Fact002982" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">498</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzt0C_z1UrxDPPExS1" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2024-12-31" id="Fact002984" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,028</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2023-12-31" id="Fact002985" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,442</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_maDTAGzt0C_z91X2XbqNxc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="AsOf2024-12-31" id="Fact002987" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,469</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="AsOf2023-12-31" id="Fact002988" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,441</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxAssetsUnicap_iI_pn3n3_maDTAGzt0C_zLqVzXBNyxwk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt">Unicap</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsUnicap" contextRef="AsOf2024-12-31" id="Fact002990" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsUnicap" contextRef="AsOf2023-12-31" id="Fact002991" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsImputedInterestOnContingentPayments_iI_pn3n3_maDTAGzt0C_zVlS9nBr0tni" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Imputed interest on contingent payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsImputedInterestOnContingentPayments" contextRef="AsOf2024-12-31" id="Fact002993" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">97</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsImputedInterestOnContingentPayments" contextRef="AsOf2023-12-31" id="Fact002994" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">110</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_iI_pn3n3_maDTAGzt0C_ztssh3ZI7SO9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Legal fee capitalization and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" contextRef="AsOf2024-12-31" id="Fact002996" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,053</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" contextRef="AsOf2023-12-31" id="Fact002997" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,171</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopment_iI_pn3n3_maDTAGzt0C_zFYvavF3XMna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsCapitalizedResearchAndDevelopment" contextRef="AsOf2024-12-31" id="Fact002999" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,903</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELU:DeferredTaxAssetsCapitalizedResearchAndDevelopment" contextRef="AsOf2023-12-31" id="Fact003000" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">26,613</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsIrcSectionInterest_iI_pn3n3_maDTAGzt0C_ztuSB1QKAfYf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">IRC Section 163j interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="CELU:DeferredTaxAssetsIrcSectionInterest" contextRef="AsOf2024-12-31" id="Fact003002" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,471</ix:nonFraction></p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl3003">&#8212;</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzt0C_zT1EZe8s2U0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2024-12-31" id="Fact003005" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,755</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="AsOf2023-12-31" id="Fact003006" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,751</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzt0C_msDTLz2tA_zsDbjdal1e1a" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-12-31" id="Fact003008" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">181,407</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2023-12-31" id="Fact003009" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169,788</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLz2tA_zyXNPfWiCFPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-12-31" id="Fact003011" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">181,416</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact003012" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">169,797</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_mtDTLz2tA_z7zamQdTwQEf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2024-12-31" id="Fact003014" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilities" contextRef="AsOf2023-12-31" id="Fact003015" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_z5fwHJ1DgCy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact003017" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zPIXQ5CkpcV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span id="xdx_8B5_z1hwNIxNUSgd" style="display: none">Schedule
of Unrecognized Tax&#160;Benefits</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrecognized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax Benefits</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 81%">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20230101__20231231_zBSXdntP5td8" title="Balance beginning" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2022-12-31" id="Fact003019" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,028</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt">Decrease related to current year tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_iN_pn3n3_di_c20230101__20231231_zmnL1nNWgZej" title="Decrease related to current year tax provisions" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3021">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20240101__20241231_zXIYdJT8wvY1" title="Balance beginning" style="text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-12-31" id="Fact003023" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,028</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt">Decrease related to current year tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_pn3n3_c20240101__20241231_zonEQghkWPml" title="Decrease related to current year tax provisions" style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3025">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20240101__20241231_zDdvDxShsZVe" title="Balance ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-12-31" id="Fact003027" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,028</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_ziaga27DDco7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the Company had U.S. federal and state net operating loss carryforwards of $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_ziDmdJeQCBY2" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-12-31_custom_UnitedStatesFederalAndStateMember" id="Fact003029" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">121,804</ix:nonFraction></span></span> and $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zVXgNipR6lu1" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2023-12-31_custom_UnitedStatesFederalAndStateMember" id="Fact003031" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109,544</ix:nonFraction></span>, respectively,
which may be available to offset future taxable income and begin to expire in <span id="xdx_906_ecustom--OperatingLossCarryforwardsExpirationYear_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zUSFUR0TXuD6" title="Operating loss carryforwards expiration year"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_UnitedStatesFederalAndStateMember" id="Fact003033" name="CELU:OperatingLossCarryforwardsExpirationYear">2040</ix:nonNumeric></span>. As of December 31, 2024 and 2023, the Company also
had U.S. federal and state research and development tax credit carryforwards of $<span id="xdx_90D_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zIgos4UtZTj5" title="Tax credit carryforwards"><span id="xdx_90E_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zz64ZTRvZZc3" title="Tax credit carryforwards"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2024-12-31_custom_UnitedStatesFederalAndStateMember" id="Fact003035" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2023-12-31_custom_UnitedStatesFederalAndStateMember" id="Fact003037" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,674</ix:nonFraction></ix:nonFraction></span></span>, which may be available to offset future tax liabilities
and begin to expire in <span id="xdx_901_ecustom--TaxCreditCarryforwardsExpirationYear_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zpFztl0uagQc" title="Tax credit carryforwards expiration year"><ix:nonNumeric contextRef="From2024-01-012024-12-31_custom_UnitedStatesFederalAndStateMember" id="Fact003039" name="CELU:TaxCreditCarryforwardsExpirationYear">2032</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 140; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilization
of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to
an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due
to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of
carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined
by Section 382, results from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than
50% over a three-year period. A corporation that experiences an ownership change is subject to an annual limitation under Section 382,
which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable
long-term tax-exempt rate subject to additional adjustments, as required. The Company experienced an ownership change on August 15, 2017.
The annual limitation from the ownership change is not expected to result in the expiration of net operating losses or research and development
credits before utilization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
realization of deferred tax assets is dependent upon the Company&#8217;s ability to generate taxable income in future years. ASC 740-10,
<i>Income Taxes,</i> requires a valuation allowance to be applied against deferred tax assets when it is considered &#8220;more likely
than not&#8221; that some or all of the gross deferred tax assets will not be realized. The Company considers all available positive
and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies,
and recent financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, based upon the weight of available evidence, the Company concluded that it is not more likely than not that the
benefits of the federal and state deferred tax assets will be realized. Accordingly, the Company has recorded a valuation allowance
against its federal and state gross deferred tax assets. The valuation allowance increased by $<span id="xdx_909_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20240101__20241231_zfhL2wkih1p2" title="Valuation allowance increased amount"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2024-01-01to2024-12-31" id="Fact003041" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11,619</ix:nonFraction></span>
and $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20230101__20231231_zXaeuFAfY6E" title="Valuation allowance increased amount"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-01-012023-12-31" id="Fact003043" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">39,272</ix:nonFraction></span> during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact of an uncertain income tax position is recognized at the largest amount that is &#8220;more likely than not&#8221; to be sustained
upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of
being sustained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the Company had gross unrecognized tax benefits of $<span id="xdx_908_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_c20241231_zfS5TTMtMjm" title="Unrecognized tax benefits"><span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_c20231231_zJ4oHnG87CG6" title="Unrecognized tax benefits"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2024-12-31" id="Fact003045" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="AsOf2023-12-31" id="Fact003047" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,028</ix:nonFraction></ix:nonFraction></span></span>. The Company does not expect that there will
be a significant change in the unrecognized tax benefits over the next 12 months. The Company&#8217;s policy is to record interest and
penalties related to income taxes as part of its income tax provision. As of December 31, 2024 and 2023, the Company had <span id="xdx_90E_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20241231_zprHYbbMtRI3" title="Interest accrued"><span id="xdx_904_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20231231_zbdimWnO0gbl" title="Interest accrued"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="AsOf2024-12-31" id="Fact003049" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="AsOf2023-12-31" id="Fact003051" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> accrued interest
or penalties related to uncertain tax positions and no amounts had been recognized in the Company&#8217;s consolidated statements of
operations and comprehensive loss. The Company files income tax returns in the U.S. and numerous states, as prescribed by the tax laws
of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state
jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under
statute from 2019 to the present; however, carryforward attributes that were acquired may still be adjusted upon examination by federal,
state or local tax authorities if they either have been or will be used in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact003053" name="us-gaap:SegmentReportingDisclosureTextBlock"><p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_zmQtIdTxCWbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.
<span id="xdx_821_zo88cKvPnDl2">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. The
Company manages its operations through an evaluation of <span id="xdx_904_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zlCMeSBJwb6i" title="Number of operating segments"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="From2024-01-01to2024-12-31" id="Fact003055" format="ixt-sec:numwordsen" decimals="INF" unitRef="Segment">three</ix:nonFraction></span>
distinct operating segments: Cell Therapy, Degenerative Disease, and BioBanking. The chief operating decision maker, who is the
Company&#8217;s chief executive officer, uses the actual segment contribution results compared to budgets, among other factors, for
performance evaluation and resource allocation among these segments. The segment contribution is calculated as net revenues less the cost of
revenues (excluding amortization of acquired intangible assets) and direct expenses. Direct expenses in the Cell Therapy operating segment
consist of research and development costs, and direct expenses in the Degenerative Disease and Biobanking operating segments consist
mainly of selling, general, and administrative costs. The CODM assesses actual results against budgets and forecasts, and uses this information
to make decisions about strategic investment into the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reportable segments, which are the same as the operating segments, were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers
to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development.
Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. BioBanking collects stem cells from
umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not
regularly review any asset information or related income statement effects by operating segment and, accordingly, asset information is
not reported by reportable segment. Refer to the Consolidated Balance Sheet for information about total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 141; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact003057" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7MsvFz8HyC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
information by segment is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4dnuEopRayj" style="display: none">Schedule
of Financial Information by Segment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zaJeG6QuIika" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zRdiwc27IrG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zmWAsGw2FLTl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zdNVWlpmDQZ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zFlxIwfO1ZLa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_CellTherapyMember" id="Fact003059" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">688</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_BiobankingMember" id="Fact003060" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,140</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-012024-12-31_custom_DegenerativeDiseaseMember" id="Fact003061" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">48,392</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-01-01to2024-12-31" id="Fact003062" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54,220</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_z6oD0O66Pp32" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3064">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_BiobankingMember" id="Fact003065" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,172</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-012024-12-31_custom_DegenerativeDiseaseMember" id="Fact003066" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,817</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2024-01-01to2024-12-31" id="Fact003067" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,989</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zsn5f4L3Lfq1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DirectOperatingCosts" contextRef="From2024-01-012024-12-31_custom_CellTherapyMember" id="Fact003069" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,807</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DirectOperatingCosts" contextRef="From2024-01-012024-12-31_custom_BiobankingMember" id="Fact003070" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,673</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DirectOperatingCosts" contextRef="From2024-01-012024-12-31_custom_DegenerativeDiseaseMember" id="Fact003071" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20,846</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DirectOperatingCosts" contextRef="From2024-01-01to2024-12-31" id="Fact003072" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">38,326</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zKp3SXBNZjTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="CELU:SegmentContribution" contextRef="From2024-01-012024-12-31_custom_CellTherapyMember" id="Fact003074" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">15,119</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELU:SegmentContribution" contextRef="From2024-01-012024-12-31_custom_BiobankingMember" id="Fact003075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,295</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELU:SegmentContribution" contextRef="From2024-01-012024-12-31_custom_DegenerativeDiseaseMember" id="Fact003076" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,729</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELU:SegmentContribution" contextRef="From2024-01-01to2024-12-31" id="Fact003077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">905</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left"/></tr>
  <tr id="xdx_403_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zvokvZw8jKPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact003082" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">37,703</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_z9YmKl0Zm4y9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CELU:IndirectExpenses" contextRef="From2024-01-01to2024-12-31" id="Fact003087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,560</ix:nonFraction></td><td style="text-align: left">(a)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_zy9Ir4UQXRgj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss from operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2024-01-01to2024-12-31" id="Fact003092" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">38,358</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NonoperatingIncomeExpense_pn3n3_zM86SXyYRgT5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact003097" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">19,534</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zbYRBRQML3ub" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-01-01to2024-12-31" id="Fact003102" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">57,892</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">(a) Components of indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_pn3n3_zU5qMoswLhw6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of contingent consideration liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2024-01-01to2024-12-31" id="Fact003107" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">193</ix:nonFraction></p></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--GoodwillImpairmentLoss_pn3n3_zaPW4LNidUte" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_zvsVRcpDXuek" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">-</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_zuBp989h8Zcl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2024-01-01to2024-12-31" id="Fact003122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,753</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zHvY1GYh1Vg2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Total other</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2024-01-01to2024-12-31" id="Fact003127" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,560</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zkkFar7V0Ty" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zK8GvaIWaIsa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zFKHznCBYLIk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zzI6AJoePq4b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zflaTG577tNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3129">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_BiobankingMember" id="Fact003130" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,441</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_DegenerativeDiseaseMember" id="Fact003131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17,330</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31" id="Fact003132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22,771</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_zPC8oVzarJK3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3134">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-12-31_custom_BiobankingMember" id="Fact003135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,650</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-12-31_custom_DegenerativeDiseaseMember" id="Fact003136" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,366</ix:nonFraction></td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="From2023-01-012023-12-31" id="Fact003137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">16,016</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zG4Cj5FVOJdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DirectOperatingCosts" contextRef="From2023-01-012023-12-31_custom_CellTherapyMember" id="Fact003139" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">28,694</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DirectOperatingCosts" contextRef="From2023-01-012023-12-31_custom_BiobankingMember" id="Fact003140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,752</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DirectOperatingCosts" contextRef="From2023-01-012023-12-31_custom_DegenerativeDiseaseMember" id="Fact003141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,720</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DirectOperatingCosts" contextRef="From2023-01-012023-12-31" id="Fact003142" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,166</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zHkcP6fon5J8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="CELU:SegmentContribution" contextRef="From2023-01-012023-12-31_custom_CellTherapyMember" id="Fact003144" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">28,694</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="CELU:SegmentContribution" contextRef="From2023-01-012023-12-31_custom_BiobankingMember" id="Fact003145" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,039</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="CELU:SegmentContribution" contextRef="From2023-01-012023-12-31_custom_DegenerativeDiseaseMember" id="Fact003146" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">6,756</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="CELU:SegmentContribution" contextRef="From2023-01-012023-12-31" id="Fact003147" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">33,411</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zp1Kw2Vt6bXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:OtherGeneralAndAdministrativeExpense" contextRef="From2023-01-012023-12-31" id="Fact003152" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">40,876</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zTB24HnD9AM5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CELU:IndirectExpenses" contextRef="From2023-01-012023-12-31" id="Fact003157" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118,001</ix:nonFraction></td><td style="text-align: left">(a)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z5dCtCMTfXre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="From2023-01-012023-12-31" id="Fact003162" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">192,287</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_pn3n3_zMhWuZqxowS3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact003167" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,998</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zWhYAfDaejy8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-01-012023-12-31" id="Fact003172" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">196,285</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">(a) Components of indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_pn3n3_zsoqlzgUqxrh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of contingent consideration liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="From2023-01-012023-12-31" id="Fact003177" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">104,339</ix:nonFraction></p></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--GoodwillImpairmentLoss_pn3n3_zH1R7OOaPDg3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" contextRef="From2023-01-012023-12-31" id="Fact003182" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">112,347</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_zjf98iY3BuJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">IPR&amp;D impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="CELU:InProcessResearchAndDevelopmentImpairment" contextRef="From2023-01-012023-12-31" id="Fact003187" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">107,800</ix:nonFraction></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_zX4hqGkHilGh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-012023-12-31" id="Fact003192" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,193</ix:nonFraction></p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zCmpparvduik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Total other</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-12-31" id="Fact003197" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">118,001</ix:nonFraction></p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_z18RdlWjc1W3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact003199" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zumD8rrpiVr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><b>20. <span id="xdx_827_z8jnspUMxdpf">Related
Party Transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amended and Restated Employment Agreement with
Dr. Robert Hariri</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2023, in order to address the Company&#8217;s current working capital requirements, Robert Hariri, M.D., Ph.D., the Company&#8217;s
Chairman and Chief Executive Officer, agreed to temporarily reduce payment of his salary pursuant to his employment agreement to minimum
wage level with the remaining salary deferred until December 31, 2023. As of December 31, 2024, $<span id="xdx_90C_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20241231__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember_zCQej8C0bARi" title="Accrued expenses"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" contextRef="AsOf2024-12-31_custom_DrRobertHaririMember" id="Fact003201" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,274</ix:nonFraction></span> was recorded to accrued expenses
on the consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with the Securities Purchase Agreement dated <span id="xdx_90E_ecustom--SecuritiesPurchaseAgreementDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember_zQHu6YsW1vS5" title="Securities purchase agreement date"><ix:nonNumeric contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember" format="ixt:datemonthdayyearen" id="Fact003203" name="CELU:SecuritiesPurchaseAgreementDate">January 12, 2024</ix:nonNumeric></span> with Dragasac Limited, Dr. Hariri is not to be paid the
$<span id="xdx_901_ecustom--UnpaidBaseSalary_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWuovfOGLzji" title="Unpaid base salary"><ix:nonFraction name="CELU:UnpaidBaseSalary" contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember" id="Fact003205" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,088</ix:nonFraction></span> in base salary that was otherwise due to him for the 2023 calendar year unless the Company raises additional cash through offerings
of equity securities with aggregate net proceeds equal or greater to $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zAbPi7EMMWD7" title="Net proceeds from offerings of equity securities"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember" id="Fact003207" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">21,000</ix:nonFraction></span> at a valuation at least equal to the valuation, cost per
security or exercise/conversion price, as applicable, of the Class A common stock and January 2024 PIPE Warrant purchased by Dragasac
Limited in January 2024. In compliance with the requirements of Internal Revenue Code Section 409A, the compensation committee of the
Company&#8217;s board of directors approved a cash bonus program, or bonus program, effective <span id="xdx_90A_ecustom--BonusProgramEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--AmendedAndRestatedEmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrRobertHaririMember_zuyD7XAVMZyd" title="Bonus program effective date"><ix:nonNumeric contextRef="From2023-01-252023-01-25_custom_AmendedAndRestatedEmploymentAgreementMember_custom_DrRobertHaririMember" format="ixt:datemonthdayyearen" id="Fact003209" name="CELU:BonusProgramEffectiveDate">February 16, 2024</ix:nonNumeric></span>, pursuant to which Dr.
Hariri will be paid <span id="xdx_90B_ecustom--PercentageOfUnpaidBaseSalary_pid_dp_uPure_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdptatZHHLX6" title="Percentage of unpaid base salary"><ix:nonFraction name="CELU:PercentageOfUnpaidBaseSalary" contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember" id="Fact003211" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">125</ix:nonFraction></span>% of his unpaid base salary upon the satisfaction of the foregoing performance conditions. Accordingly, the Company
entered into a second amendment to Dr. Hariri&#8217;s employment agreement implementing the <span id="xdx_903_ecustom--PercentageOfBaseSalary_pid_dp_uPure_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYwaxCPxxmpb" title="Percentage of base salary"><ix:nonFraction name="CELU:PercentageOfBaseSalary" contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember" id="Fact003213" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">85</ix:nonFraction></span>% base salary reduction effective as of
<span id="xdx_90F_ecustom--BonusProgramEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcPSW2mToMK2" title="Bonus program effective date"><ix:nonNumeric contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:datemonthdayyearen" id="Fact003215" name="CELU:BonusProgramEffectiveDate">February 16, 2024</ix:nonNumeric></span> and documenting the bonus program. As a result of the reduction, Dr. Hariri&#8217;s annual rate of base salary for
the 2024 year will be $<span id="xdx_90C_ecustom--AnnualRateOfBaseSalary_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z44GM73MMXJ5" title="Annual rate of base salary"><ix:nonFraction name="CELU:AnnualRateOfBaseSalary" contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember" id="Fact003217" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">180</ix:nonFraction></span>. Payment of Dr. Hariri&#8217;s base salary at the rate in effect prior to the reduction will resume on <span id="xdx_90D_ecustom--BaseSalaryEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zm7D7HqGLhyh" title="Bonus program effective date"><ix:nonNumeric contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember" format="ixt:datemonthdayyearen" id="Fact003219" name="CELU:BaseSalaryEffectiveDate">January
1, 2025</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 142; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>March
2023 PIPE</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 20, 2023, the Company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief
Executive Officer, Dr. Robert Hariri, for an aggregate purchase price of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DrRobertHaririMember_zsZ8mMXEu9fl" title="Proceeds from PIPE financings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_SecuritiesPurchaseAgreementMember_custom_DrRobertHaririMember" id="Fact003221" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,000</ix:nonFraction></span> (of which Dr. Hariri subscribed for $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--TitleOfIndividualAxis__custom--DrHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztjRMGwjsXva" title="Proceeds from PIPE financings"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_DrHaririMember_custom_SecuritiesPurchaseAgreementMember" id="Fact003223" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,000</ix:nonFraction></span>). See Note
13 under March 2023 PIPE caption for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan
Agreement with Dr. Robert Hariri</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2023, the Company entered into a $<span id="xdx_908_ecustom--DebtInstrumentContributionAmount_iI_pn3n3_c20030821__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zvRQjfj7J3dd" title="Debt instrument contribution amount"><ix:nonFraction name="CELU:DebtInstrumentContributionAmount" contextRef="AsOf2003-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember" id="Fact003225" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,000</ix:nonFraction></span> loan agreement with Dr. Robert Hariri, M.D., Ph.D., the Company&#8217;s Chairman and
Chief Executive Officer, which bears interest at a rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20030821__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_z59R2Q8O24w1" title="Loan interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2003-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember" id="Fact003227" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>% per year, with the first year of interest being paid in kind on the
last day of each month and was scheduled to mature on August 21, 2024. The loan maturity date was subsequently extended to December 31,
2024. On September 30, 2024, Dr. Hariri assumed the loans of two unaffiliated lenders who were parties to an August 21, 2023 loan agreement.
On January 29, 2025, Dr. Hariri extended the maturity date of the loan to December 31, 2025. See Note 10, Short-Term Debt - Other and
CEO Promissory Note, for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2023, in order to further address the Company&#8217;s immediate working capital requirements, Dr. Hariri and the Company
signed a promissory note (&#8220;CEO Promissory Note&#8221;) for $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zNn7sVaR62Rg" title="Principal amont"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember" id="Fact003229" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">285</ix:nonFraction></span> which bears interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20231012__20231012__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zAs2q4x8Ryjf" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-10-122023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember" id="Fact003231" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span>% per year (Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting
&amp; Advisory Agreements with Dr. Andrew Pecora</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--RelatedPartyTransactionTermsAndMannerOfSettlement_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zpms6Azy9Lsf" title="Related party description"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ConsultingAgreementMember_custom_DrAndrewPecoraMember" id="Fact003233" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement">On
August 31, 2022, Dr. Pecora resigned as the Company&#8217;s President, and subsequently entered into a consulting agreement with the
Company dated September 21, 2022, to receive a $<span id="xdx_905_ecustom--ReceiveForMonth_pn3n3_c20220901__20220921__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_z5Q1XgESzH3" title="Receive for month"><ix:nonFraction name="CELU:ReceiveForMonth" contextRef="From2022-09-012022-09-21_custom_ConsultingAgreementMember_custom_DrAndrewPecoraMember" id="Fact003235" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></span> monthly fee for an initial six-month term and which would be automatically renewed
for one additional six- month term if either party did not provide notice of non-renewal.</ix:nonNumeric></span> Simultaneously, the Company entered into a
scientific and clinical advisor agreement (the &#8220;SAB Agreement&#8221;), effective as of September 1, 2022, whereby Dr. Pecora agreed
to serve as co-chair of the Company&#8217;s scientific and clinical advisory board for a $<span id="xdx_908_ecustom--ReceiveForMonth_pn3n3_c20220901__20220901__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zVCJNmEtNcPe" title="Receive for month"><ix:nonFraction name="CELU:ReceiveForMonth" contextRef="From2022-09-012022-09-01_custom_ScientificAndClinicalAdvisorAgreementMember_custom_DrAndrewPecoraMember" id="Fact003237" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">10</ix:nonFraction></span> monthly fee and a one-time grant of RSUs
having a value of $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn3n3_c20220901__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zn9M3ZvmbV4g" title="RSUs one-time grant value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2022-09-01_custom_ScientificAndClinicalAdvisorAgreementMember_us-gaap_RestrictedStockUnitsRSUMember" id="Fact003239" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">125</ix:nonFraction></span> on the grant date and which vest equally over <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220901__20220901__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zvNByTqAupFk" title="Options vesting period"><ix:nonNumeric contextRef="From2022-09-012022-09-01_us-gaap_RestrictedStockUnitsRSUMember_custom_ScientificAndClinicalAdvisorAgreementMember_custom_DrAndrewPecoraMember" format="ixt-sec:durwordsen" id="Fact003241" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">four years</ix:nonNumeric></span>. The SAB Agreement had a one-year term and may be renewed
for successive one-year terms upon mutual agreement of both parties. The consulting agreement was early terminated effective January
14, 2023. As of August 8, 2024, Dr. Pecora no longer serves on the Company&#8217;s scientific and clinical advisory board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advisory
Agreement with Robin L. Smith MD</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2022, the Company entered into an advisory agreement with Robin L. Smith, MD, a then member of the Company&#8217;s board of
directors, to receive $<span id="xdx_90D_ecustom--ReceiveForMonth_pn3n3_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zhFvxGFY3Aoe" title="Receive for month"><ix:nonFraction name="CELU:ReceiveForMonth" contextRef="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember" id="Fact003243" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></span> per month for advisory fees, an equity grant for a total amount of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_ze9FhPN6M83" title="Vested options to acquire shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember" id="Fact003245" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">105,000</ix:nonFraction></span> stock options with the initial tranche
of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--VestingAxis__custom--InitialTrancheMember_z7Z6vWabPqwj" title="Vested options to acquire shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember_custom_InitialTrancheMember" id="Fact003247" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span> stock options vesting upon execution of the advisory agreement and the remaining shares subject to vesting upon achievement
of certain predefined milestones. On November 1, 2022, the second tranche of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220901__20220901__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zSAdhf9MvmF" title="Vested options to acquire shares"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-09-012022-09-01_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact003249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,000</ix:nonFraction></span> stock options vested upon achievement of the milestone.
The agreement also provided for a one-time cash bonus of $<span id="xdx_901_ecustom--RelatedPartyCashBonus_pn3n3_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zgWDh8JLzM67" title="One-time cash bonus"><ix:nonFraction name="CELU:RelatedPartyCashBonus" contextRef="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember" id="Fact003251" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,500</ix:nonFraction></span> upon the successful achievement of the trigger event, as defined in the
agreement. The Company paid advisory fees of $<span id="xdx_904_ecustom--PaymentsToRelatedParty_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_z5AMetMKU4Jh" title="Amount paid"><ix:nonFraction name="CELU:PaymentsToRelatedParty" contextRef="From2024-01-012024-12-31_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember" id="Fact003253" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_904_ecustom--PaymentsToRelatedParty_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_z48DEbWUbSGc" title="Amount paid"><ix:nonFraction name="CELU:PaymentsToRelatedParty" contextRef="From2023-01-012023-12-31_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember" id="Fact003255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">20</ix:nonFraction></span> for the years ended December 31, 2024 and 2023, respectively. The advisory agreement
expired pursuant to the terms of the agreement on August 16, 2023 and was not renewed for an additional term. Dr. Smith resigned from
the Company&#8217;s board effective December 24, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COTA,
Inc</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, Legacy Celularity and COTA, Inc. (&#8220;COTA&#8221;) entered into an Order Schedule (the &#8220;Order Schedule No. 2&#8221;),
to the Master Data License Agreement between Legacy Celularity and COTA, dated October 29, 2018, pursuant to which COTA will provide
the licensed data in connection with AML patients. The COTA Order Schedule No. 2 will terminate on the one-year anniversary following
the final licensed data deliverable described therein. Andrew Pecora, M.D., Celularity&#8217;s former President, is the Founder and Chairman
of the Board of COTA and Dr. Robin L. Smith, a former member of the Company&#8217;s board of directors, is an investor in COTA. The Company
did <span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_do_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--COTAIncMember_zACmZrmRqpnj" title="Contribution made"><span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_do_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--COTAIncMember_zQED0LyNLbhf" title="Contribution made"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_COTAIncMember" id="Fact003257" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-012023-12-31_custom_COTAIncMember" id="Fact003259" format="ixt-sec:numwordsen" decimals="-3" scale="3" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t make any payments to COTA during either of the years ended December 31, 2024 and 2023. As of August 8, 2024, Dr. Pecora no longer
serves on the Company&#8217;s scientific and clinical advisory board and therefore, COTA is no longer a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 143; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cryoport
Systems, Inc</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company made payments totaling $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CryoportSystemsIncMember_zXvS4XjsfdRi" title="Contribution made"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2024-01-012024-12-31_custom_CryoportSystemsIncMember" id="Fact003261" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CryoportSystemsIncMember_z5BLWuaBKlF2" title="Contribution made"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-012023-12-31_custom_CryoportSystemsIncMember" id="Fact003263" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">33</ix:nonFraction></span>, respectively, to Cryoport Systems, Inc (&#8220;Cryoport&#8221;)
for transportation of cryopreserved materials. The Company&#8217;s Chief Executive Officer and director, Dr. Robert Hariri, M.D, Ph.D.,
has served on Cryoport&#8217;s board of directors since September 2015.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>C.V.
Starr Loan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2023 the Company entered into a $<span id="xdx_909_ecustom--LoanAgreement_iI_pn3n3_c20230317__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember_zLVcKK4AVDqi"><ix:nonFraction name="CELU:LoanAgreement" contextRef="AsOf2023-03-17_custom_CVStarLoanMember" id="Fact003264" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loan agreement with C.V. Starr. C.V. Starr is
an investor in the Company, beneficially owning <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zeD0gMf4MF1l"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_CVStarLoanMember_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember" id="Fact003265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">125,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to purchase Class A common stock and
<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zzAMWNQfcDa3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_CVStarLoanMember_us-gaap_CommonClassAMember" id="Fact003266" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,528,138</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Class A common stock as of December
31, 2024. See Note 10, Short-Term Debt &#8211; Related Parties &#8211; C.V. Starr and RWI for more information.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Resorts World Inc Pte
Ltd</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On May 16, 2023, the Company entered
into a $<span id="xdx_90F_ecustom--LoanAgreement_iI_pn3n3_c20230316__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember_z5LOP61EL9pc" title="Loan agreement"><ix:nonFraction name="CELU:LoanAgreement" contextRef="AsOf2023-03-16_custom_ResortsWorldIncPteLtdMember" id="Fact003268" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,000</ix:nonFraction></span> loan agreement, as amended on June 21, 2023, with RWI. On January 12, 2024, the Company entered into a $<span id="xdx_90C_ecustom--SecondLoanAgreement_iI_pn3n3_c20240112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember_zVKlXukmp0v8" title="Second loan agreement"><ix:nonFraction name="CELU:SecondLoanAgreement" contextRef="AsOf2024-01-12_custom_ResortsWorldIncPteLtdMember" id="Fact003270" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">15,000</ix:nonFraction></span> second loan
agreement with RWI. RWI is affiliated with Lim Kok Thay, a significant stockholder and former member of the Company's board of directors,
beneficially owning <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230316__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zKJfDRqxF7ml" title="Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-03-16_custom_ResortsWorldIncPteLtdMember_us-gaap_CommonClassAMember" id="Fact003272" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,600,000</ix:nonFraction></span> warrants to purchase Class A common stock and <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zYRUYP8oMIKa" title="Warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2024-12-31_custom_ResortsWorldIncPteLtdMember_us-gaap_CommonClassAMember" id="Fact003274" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,338,161</ix:nonFraction></span> shares of Class A common stock as of December 31,
2024. See Note 10, Short-Term Debt &#8211; Related Parties &#8211; C.V. Starr and RWI for more information.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
of an Immediate Family Member </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexandra
Hariri, the daughter of Robert J. Hariri, M.D., Ph.D., Celularity&#8217;s Chairman and Chief Executive Officer, is employed by the Company
as an Executive Director, Corporate Strategy &amp; Business Development. Ms. Hariri&#8217;s annual base salary for 2024 and 2023 was
$<span id="xdx_90C_ecustom--RelatedPartyBaseSalary_pn3n3_c20240101__20241231__srt--CounterpartyNameAxis__custom--MsHaririMember__us-gaap--RelatedPartyTransactionAxis__custom--EmploymentOfImmediateFamilyMemberMember_z5svl5zpKhH1" title="Base salary"><span id="xdx_90D_ecustom--RelatedPartyBaseSalary_pn3n3_c20230101__20231231__srt--CounterpartyNameAxis__custom--MsHaririMember__us-gaap--RelatedPartyTransactionAxis__custom--EmploymentOfImmediateFamilyMemberMember_zZXcnQgQ0fC3" title="Base salary"><ix:nonFraction name="CELU:RelatedPartyBaseSalary" contextRef="From2024-01-012024-12-31_custom_MsHaririMember_custom_EmploymentOfImmediateFamilyMemberMember" id="Fact003276" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD"><ix:nonFraction name="CELU:RelatedPartyBaseSalary" contextRef="From2023-01-012023-12-31_custom_MsHaririMember_custom_EmploymentOfImmediateFamilyMemberMember" id="Fact003278" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">265</ix:nonFraction></ix:nonFraction></span></span>. Ms. Hariri has received and continues to be eligible to receive a bonus, equity awards and benefits on the same general terms and
conditions as applicable to unrelated employees in similar positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fountain
Life Management LLC </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 46.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2024, the Company entered into a Technology Services Agreement with Fountain Life Management LLC (&#8220;Fountain Life&#8221;),
under which the Company agreed to process and store mononuclear cells isolated from blood samples collected by Fountain Life or its authorized
representatives in accordance with the Company&#8217;s adult banking enrollment processes. In consideration of the services, Fountain
Life will pay the Company a one-time fee of two thousand five hundred dollars per sample collected and stored. The initial term of the
agreement is one year and the term automatically extends for one-year periods unless earlier terminated by either party. The Company&#8217;s
Chairman and Chief Executive Officer, Dr. Robert Hariri, M.D, Ph.D., and director, Peter Diamandis, M.D., are founding partners of Fountain
Life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-01-01to2024-12-31" escape="true" id="Fact003280" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zB8PstfAYygj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>21.
<span id="xdx_825_z0MZfQGUNV3i">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2025, the
Company executed a cash advance agreement to sell $<span id="xdx_908_eus-gaap--AccountsReceivableNet_iI_pn3n3_c20250501__dei--LegalEntityAxis__custom--GenesisEquityGroupFundingLlcMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAbA5qMzLSU4" title="Accounts receivable"><ix:nonFraction name="us-gaap:AccountsReceivableNet" contextRef="AsOf2025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember" id="Fact003282" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">990</ix:nonFraction></span>
of accounts receivable to Genesis Equity Group Funding LLC (&#8220;GEG&#8221;) to provide incremental funding to address immediate
cash needs. Net funds, after applicable fees, were $<span id="xdx_90C_ecustom--ApplicableFees_iI_pn3n3_c20250501__dei--LegalEntityAxis__custom--GenesisEquityGroupFundingLlcMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpGhJPCAcdx6" title="Applicable fees"><ix:nonFraction name="CELU:ApplicableFees" contextRef="AsOf2025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember" id="Fact003284" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">594</ix:nonFraction></span>.
The amount GEG will collect from the Company towards the receivables purchased amount is capped at $<span id="xdx_900_eus-gaap--InterestIncomePurchasedReceivables_pn3n3_c20250501__20250501__dei--LegalEntityAxis__custom--GenesisEquityGroupFundingLlcMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWUZPooueIql" title="Receivables purchased"><ix:nonFraction name="us-gaap:InterestIncomePurchasedReceivables" contextRef="From2025-05-012025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember" id="Fact003286" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">47</ix:nonFraction></span>
for twenty-one (21) weeks.</p>

</ix:nonNumeric><p id="xdx_81F_zFnAW4Z0DJ04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 144; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_001"></span>Item
9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_002"></span>Item
9A. Controls and Procedures. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Evaluation
of Disclosure Controls and Procedures</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &#8220;disclosure controls and procedures&#8221;, as defined under Rules 13a-15(e) and 15d-15(e) under the Exchange Act or the Act,
means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by an issuer in
the reports that it files or submits under the Act is recorded, processed, summarized and reported, within the time periods specified
in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed
to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act is accumulated
and communicated to the issuer&#8217;s management, including its principal executive and principal financial officers, or persons performing
similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management, with the participation of our Principal Executive Officer and Principal Financial Officer, evaluated the effectiveness of
our disclosure controls and procedures as of December 31, 2024. Based on that evaluation, management concluded that such disclosure controls
and procedures were not effective, at the reasonable assurance level, as of December 31, 2024, as a result of the material weaknesses
in internal control over financial reporting discussed below as well as our inability to timely file our quarterly reports on Form 10-Q
for all quarters in the year ended December 31, 2024, and this annual report on Form 10-K for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Internal
Control Over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control system
was designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation
of published financial statements. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even
those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.
An internal control material weakness is a significant deficiency, or aggregation of deficiencies, that does not reduce to a relatively
low level the risk that material misstatements in financial statements will be prevented or detected on a timely basis by employees in
the normal course of their work. An internal control significant deficiency, or aggregation of deficiencies, is one that could result
in a misstatement of the financial statements that is more than inconsequential. In making its assessment of internal control over financial
reporting management used the criteria issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal
Control&#8201;&#8212;&#8201;Integrated Framework (2013). Our management assessed the effectiveness of our internal control over financial
reporting as of December 31, 2024, and determined that our internal control over financial reporting was not effective at a reasonable
assurance level due to the material weaknesses previously disclosed in our Form 10-K for the fiscal year ended December 31, 2023 and
our quarterly reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Material
Weaknesses in Internal Control Over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our annual report on Form 10-K for the year ended December 31, 2023, we previously disclosed material weaknesses in our internal control
over financial reporting. Specifically, we had insufficient resources with the appropriate knowledge and expertise to design, implement,
and operate effective internal controls over our financial reporting process that contributed to other material weaknesses within our
system of internal control over financial reporting at the control activity level. In addition, we failed to timely file our quarterly
reports on Form 10-Q for all quarters in the year ended December 31, 2024, and this annual report on Form 10-K for the year ended December
31, 2024. As a result, we have identified the following material weaknesses as of December 31, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt; text-align: justify; text-indent: -24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">i.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Control
    Environment</i>: We failed to demonstrate a commitment to attract, develop, and retain competent and sufficient qualified resources
    with an appropriate level of knowledge, experience, and training in certain areas around our financial reporting process. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">ii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risk
    Assessment:</i> We failed to design and implement certain risk assessment activities related to identifying and analyzing risks to
    achieve objectives and identifying and assessing changes in the business that could impact our system of internal controls.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">iii.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Control
    Activities:</i> We failed to design and implement certain control activities that address relevant risks and retain sufficient evidence
    of the performance of control activities. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">iv.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Information
    and Communication:</i> We failed to design and implement certain information and communication activities related to obtaining or
    generating and using relevant quality information to support the functioning of internal control. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">v.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Monitoring:</i>
    We failed to design and implement certain monitoring activities to ascertain whether the components of internal control are present
    and functioning. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 145; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Plans for Remediation of Material Weaknesses </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently implementing
our remediation plan to address the material weaknesses identified above. Such measures include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hiring
    additional accounting personnel to ensure timely reporting of significant matters.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designing
    and implementing controls to formalize roles and review responsibilities to align with our team&#8217;s skills and experience and
    designing and implementing formalized controls to operate at a level of precision to identify all potentially material errors.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designing
    and implementing procedures to identify and evaluate changes in our business and the impact on our internal controls in order to
    plan and perform more timely and thorough monitoring activities and risk assessment analyses.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designing
    and implementing formal processes, policies and procedures supporting our financial close process.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engaging
    an outside firm to assist with the documentation, design and implementation of our internal control environment. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">R<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">emediation
of the identified material weaknesses and strengthening our internal control environment will require a substantial effort throughout
2025 and beyond, as necessary. We will test the ongoing operating effectiveness of the new and existing controls in future periods. The
material weaknesses cannot be considered completely remediated until the applicable controls have operated for a sufficient period of
time and management has concluded, through testing, that these controls are operating effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Changes
in Internal Control over Financial Reporting</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for the identified material weaknesses described above and related remediation efforts to date, there have been no changes in our internal
control over financial reporting that occurred during the quarter ended December 31, 2024 that materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="m_003"></span>Item 9B. Other Information. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Rule 10b5-1 Trading Plans</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the three months ended
December 31, 2024, none of our directors or executive officers <span id="xdx_90D_eecd--Rule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zCMKSAeL15ae" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90F_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20241001__20241231_zcPat6SpagF7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact003287" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact003288" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_90D_eecd--Rule10b51ArrTrmntdFlag_dbF_c20241001__20241231_znZ3WlO3QdNl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_90F_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20241001__20241231_zOYFyXfswsya" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact003289" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2024-10-012024-12-31" format="ixt:booleanfalse" id="Fact003290" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> any contract, instruction or written plan for the
purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any &#8220;non-Rule
10b5-1 trading arrangement.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="m_004"></span>Item 9C. Disclosure Regarding Foreign Jurisdictions
that Prevent Inspections.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">&#160;</p>


<!-- Field: Page; Sequence: 146; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="m_005"></span>PART III </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
required by the following items is incorporated by reference to our Definitive Proxy Statement, expected to be filed within 120 days
of our fiscal year end:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="m_006"></span>Item
10. Directors, Executive Officers and Corporate Governance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="m_007"></span>Item
11. Executive Compensation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="m_008"></span>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="m_009"></span>Item
13. Certain Relationships and Related Transactions, and Director Independence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="m_010"></span>Item
14. Principal Accounting Fees and Services</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_011"></span>PART
IV </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_012"></span>Item
15. Exhibits, Financial Statement Schedules. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as part of this report</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.25pt; text-align: justify; text-indent: -24.75pt"><i>&#160;</i></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt"><i>(1)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Statements &#8211; See Index to Consolidated Financial Statements in Item 8.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><i>(2)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financial
    Statement Schedules</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    other schedules are omitted because they are not required or the required information is included in the financial statements or
    notes thereto</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><i>(3)</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exhibits</i></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; text-align: left; font: 10pt Times New Roman, Times, Serif; width: 0.75in; vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Exhibit</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Number</b></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in; text-align: left"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">2.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021001040/ea132952ex2-1_gxacquisit.htm" style="-sec-extract: exhibit">Merger Agreement and Plan of Reorganization by and among GX Acquisition Corp., Alpha First Merger Sub, Inc., Alpha Second Merger Sub, LLC, and Celularity Inc. (incorporated by reference to Exhibit 2.1 to the current report on Form 8-K, filed with the Commission on January 8, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex3-1_celularity.htm" style="-sec-extract: exhibit">Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1752828/000095017023028627/celu-20230614.htm" style="-sec-extract: exhibit">Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation of Celularity Inc. (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the Commission on June 16, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1752828/000149315224007848/form8-k.htm" style="-sec-extract: exhibit">Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation of Celularity Inc. (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the Commission on February 26, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex3-2_celularity.htm" style="-sec-extract: exhibit">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex4-1_celularity.htm" style="-sec-extract: exhibit">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<!-- Field: Page; Sequence: 147; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex10-3_celularity.htm" style="-sec-extract: exhibit">Amended and Restated Registration Rights Agreement (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1752828/000119312522156126/d349292d8k.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated May 18, 2022, between Celularity Inc. and the holder party thereto (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the Commission on May 20, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1752828/000095017023009338/celu-20230317.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, among Celularity Inc. and the holder party thereto (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the Commission on March 23, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1752828/000095017023023264/celu-20230516.htm" style="-sec-extract: exhibit">Form of Registration Rights Agreement, dated May 18, 2023, among Celularity Inc. and the holder party thereto (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed with the Commission on May 19, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1752828/000149315224010134/form8-k.htm" style="-sec-extract: exhibit">Registration Rights Agreement, dated March 13, 2024, between Celularity, Inc. and YA II PN, Ltd. (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed on March 15, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex10-4_celularity.htm" style="-sec-extract: exhibit">Vesting Agreement dated as of July 16, 2021 by and among GX Sponsor LLC, Celularity Inc. (f/k/a GX Acquisition Corp.), and each of the other Persons set forth on the signature pages thereto (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390019009582/f8k052019ex4-1_gxacq.htm" style="-sec-extract: exhibit">Warrant Agreement, dated May 20, 2019, by and between GX Acquisition Corp. and Continental Stock Transfer &amp; Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to the current report on Form 8-K, filed with the Commission on May 24, 2019).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex4-2_celularity.htm" style="-sec-extract: exhibit">Specimen Warrant Certificate (incorporated by reference to Exhibit 4.2 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">10.9#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1ex10-9_gxacq.htm" style="-sec-extract: exhibit">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.9 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">10.10#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-10_gxacquisition.htm" style="-sec-extract: exhibit">Celularity Inc. Amended and Restated 2017 Equity Incentive Plan (incorporated by reference to Exhibit 10.10 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">10.11#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-11_gxacquisition.htm" style="-sec-extract: exhibit">Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2017 Stock Incentive Plan (incorporated by reference to Exhibit 10.11 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">10.12#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000101376221000108/ea147925ex99-3_celularity.htm" style="-sec-extract: exhibit">Celularity Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 99.3 to the registration statement on Form S-8 (File No. 333-260025), filed with the Commission on October 4, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.13#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000101376221000108/ea147925ex99-4_celularity.htm" style="-sec-extract: exhibit">Forms of Stock Option Grant Notice, Option Agreement, Notice of Exercise, RSU Award Grant Notice and Award Agreement under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 99.4 to the registration statement on Form S-8 (File No. 333-260025), filed with the Commission on October 4, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">10.14#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000101376221000108/ea147925ex99-5_celularity.htm" style="-sec-extract: exhibit">Celularity 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.5 to the registration statement on Form S-8 (File No. 333-260025), filed with the Commission on October 4, 2021.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">10.15#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-14_gxacquisition.htm" style="-sec-extract: exhibit">Celularity Inc. 2018 Annual Incentive Plan (incorporated by reference to Exhibit 10.14 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 148; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-15_gxacquisition.htm" style="-sec-extract: exhibit">Amended and Restated Employment Agreement by and between Celularity and Robert J. Hariri, dated as of January 7, 2021 (incorporated by reference to Exhibit 10.15 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017023011440/celu-ex10_14.htm" style="-sec-extract: exhibit">Amendment to the Employment Agreement, as of January 25, 2023, by and between Celularity Inc. and Robert J. Hariri. (incorporated by reference to Exhibit 10.14 to the annual report on Form 10-K, filed with the Commission on March 31, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224007505/ex10-1.htm" style="-sec-extract: exhibit">Second Amendment dated February 16, 2024 to the Amended and Restated Employment Agreement dated January 7, 2021 by and between Celularity Inc. and Robert J. Hariri, MD PhD (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed on February 22, 2024.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017022024523/celu-ex10_7.htm" style="-sec-extract: exhibit">Employment Agreement, as of April 1, 2022, by and between Celularity Inc. and David C. Beers (incorporated by reference to Exhibit 10.7 to the quarterly report on Form 10-Q filed with the Commission on November 10, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224007505/ex10-2.htm" style="-sec-extract: exhibit">Amendment dated February 16, 2024 to the Amended and Restated Employment Agreement dated as of April 1, 2022 by and between Celularity Inc. and David Beers (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed on February 22, 2024.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017022024523/celu-ex10_6.htm" style="-sec-extract: exhibit">Employment Agreement, as of April 1, 2022, by and between Celularity Inc. and Stephen A. Brigido (incorporated by reference to Exhibit 10.6 to the quarterly report on Form 10-Q filed with the Commission on November 10, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224007505/ex10-3.htm" style="-sec-extract: exhibit">Amendment dated February 16, 2024 to the Amended and Restated Employment Agreement dated as of April 1, 2022 by and between Celularity Inc. and Stephen Brigido (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed on February 22, 2024.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021048256/ea147489ex10-1_celularityinc.htm" style="-sec-extract: exhibit">Employment Agreement, as of April 1, 2022, by and between Celularity Inc. and John R. Haines (incorporated by reference to Exhibit 10.8 to the quarterly report on Form 10-Q filed with the Commission on November 10, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24#</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224007505/ex10-4.htm" style="-sec-extract: exhibit">Amendment dated February 16, 2024 to the Amended and Restated Employment Agreement dated as of April 1, 2022 by and between Celularity Inc. and John Haines (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed on February 22, 2024.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021004069/fs42021ex10-32_gxacquisition.htm" style="-sec-extract: exhibit">Lease Agreement, dated March 13, 2019, by and between LSREF4 Turtle, LLC and Celularity Inc (incorporated by reference to Exhibit 10.32 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"/>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024000474/celu-ex10_7.htm" style="-sec-extract: exhibit">Second Amendment to the Lease Agreement originally entered on March 13, 2019, by and between Celularity Inc. and LPIT 170 Park Avenue, LLC, dated on September 14, 2023 (incorporated by reference to Exhibit 10.7 to the current report on Form 10-Q, filed with the Commission on January 3, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024087886/celu-ex10_32.htm" style="-sec-extract: exhibit">Lease Amendment, dated September 14, 2023, by and between LSREF4 Turtle, LLC and Celularity Inc. (incorporated by reference to Exhibit 10.32 to the annual report on Form 10-K, filed with the Commission on July 30, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28&#165;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1ex10-22_gxacq.htm" style="-sec-extract: exhibit">License Agreement, dated August 15, 2017, by and between Celgene Corporation and Anthrogenesis Corp. (incorporated by reference to Exhibit 10.23 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29&#165;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1ex10-24_gxacq.htm" style="-sec-extract: exhibit">Contingent Value Rights Agreement, dated August 15, 2017, by and between Celularity Inc. and the Holders named therein, as amended by Amendment No. 1 to the Contingent Value Rights Agreement, dated March 4, 2021 (incorporated by reference to Exhibit 10.25 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Page; Sequence: 149; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024005029/celu-ex10_3.htm" style="-sec-extract: exhibit">Investors Rights Agreement, between Celularity Inc. and Dragasac Limited, dated as of January 12, 2024 (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K, filed on January 17, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024005029/celu-ex10_8.htm" style="-sec-extract: exhibit">Investor Rights Agreement dated as of January 12, 2024, between Celularity Inc. and Resorts World Inc Pte Ltd (incorporated by reference to Exhibit 10.8 to the current report on Form 8-K, filed on January 17, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32&#165;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021018114/fs42021a1ex10-27_gxacq.htm" style="-sec-extract: exhibit">Agreement and Plan of Merger, dated August 22, 2018, by and among Celularity Inc., CariCord Inc, CC Subsidiary, Inc. and Gregory L. Andrews, as amended by the First Amendment to the Agreement and Plan of Merger, dated September 30, 2018 and the Second Amendment to the Agreement and Plan of Merger, dated June 24, 2020 (incorporated by reference to Exhibit 10.28 to the registration statement on Form S-4 (File No. 333-252402), filed with the Commission on June 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000119312523197738/d472066dex104.htm" style="-sec-extract: exhibit">Amendment to certain warrants issued on May 20, 2022 and April 4, 2023, dated as of July 27, 2023, by and between Celularity Inc. and the holder party thereto (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed with the Commission on July 28, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017023009338/celu-ex10_5.htm" style="-sec-extract: exhibit">Form of Starr Warrant issued on March 17, 2023 (incorporated by reference to Exhibit 10.5 to the current report on Form 8-K, filed with the Commission on March 23, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000119312523094337/d494893dex102.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the Commission on April 7, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017023029159/celu-ex10_2.htm" style="-sec-extract: exhibit">Form of RWI Warrant (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the Commission on June 21, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000119312523197738/d472066dex102.htm" style="-sec-extract: exhibit">Form of Common Stock Purchase Warrant issued on July 31, 2023 (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the Commission on July 28, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017023042544/celu-ex10_11.htm" style="-sec-extract: exhibit">Form of Additional Starr Warrant dated as of June 20, 2023, by and between Celularity Inc. and C.V. Starr &amp; Co., Inc. (incorporated by reference to Exhibit 10.11 to the quarterly report on Form 10-Q, filed with the Commission on August 14, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024005029/celu-ex10_4.htm" style="-sec-extract: exhibit">Amended and Restated Warrant, between Celularity Inc. and Dragasac Limited, dated as of January 16, 2024 (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed on January 17, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024005029/celu-ex10_6.htm" style="-sec-extract: exhibit">Tranche 1 Warrant issued to RWI, dated as of January 16, 2024 (incorporated by reference to Exhibit 10.6 to the current report on Form 8-K, filed on January 17, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.42</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024005029/celu-ex10_7.htm" style="-sec-extract: exhibit">Tranche 2 Warrant issued to RWI, dated as of January 16, 2024 (incorporated by reference to Exhibit 10.7 to the current report on Form 8-K, filed on January 17, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.43</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224010134/ex10-6.htm" style="-sec-extract: exhibit">Warrant issued to Resorts World Inc Pte Ltd, dated as of March 13, 2024 (incorporated by reference to Exhibit 10.6 to the current report on Form 8-K, filed on March 15, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.44</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000119312522240629/d364568dex11.htm" style="-sec-extract: exhibit">At-the-Market Sales Agreement, dated September 8, 2022, by and among the Celularity Inc., BTIG, LLC, Oppenheimer &amp; Co. Inc. and B. Riley Securities, Inc. (incorporated by reference to Exhibit 1.1 to the current report on Form 8-K, filed with the Commission on September 8, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.45</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017023009338/celu-ex10_1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated March 20, 2023, among Celularity Inc. and the purchaser party thereto (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on March 23, 2023).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 150; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.46</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000119312523094337/d494893dex101.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, dated as of April 4, 2023, by and between Celularity Inc. and the investors party thereto (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on April 7, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.47</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017023023264/celu-ex10_1.htm" style="-sec-extract: exhibit">Form of Securities Purchase Agreement, dated May 17, 2023, among Celularity Inc. and the purchaser party thereto (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on May 19, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.48</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000119312523197738/d472066dex101.htm" style="-sec-extract: exhibit">Securities Purchase Agreement dated as of July 27, 2023, by and between Celularity Inc. and the investors party thereto (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on July 28, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.49+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024005029/celu-ex10_1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement, between Celularity Inc. and Dragasac Limited, dated as of January 12, 2024 (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed on January 17, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017023009338/celu-ex10_4.htm" style="-sec-extract: exhibit">Secured Loan Agreement, dated as of March 17, 2023, among Celularity Inc. and the lender party thereto (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed with the Commission on March 23, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017023022503/celu-ex10_1.htm" style="-sec-extract: exhibit">Secured Loan Agreement, dated as of May 16, 2023, among Celularity Inc. and the lender party thereto (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on May 16, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.52</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017023029159/celu-ex10_1.htm" style="-sec-extract: exhibit">Form of Amended and Restated Secured Loan Agreement, dated as of June 20, 2023, by and between Celularity Inc. and the lender party thereto (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on June 21, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.53&#165;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000119312523221469/d531828dex101.htm" style="-sec-extract: exhibit">Loan Agreement, dated as of August 21, 2023, among Celularity Inc. and the lenders thereto (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on August 25, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024005029/celu-ex10_5.htm" style="-sec-extract: exhibit">Second Amended and Restated Loan Agreement, among Celularity Inc., Celularity LLC and Resorts World Inc Pte Ltd dated as of January 12, 2024 (incorporated by reference to Exhibit 10.5 to the current report on Form 8-K, filed on January 17, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000119312523221469/d531828dex101.htm" style="-sec-extract: exhibit">Supplemental Letter Agreement to Pre-Paid Advance dated as of September 15, 2022, by and between Celularity Inc. and YA II PN, Ltd. dated on September 18, 2023 (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on August 25, 2023).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.56</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024005029/celu-ex10_9.htm" style="-sec-extract: exhibit">Support Agreement, dated as of January 12, 2024 (incorporated by reference to Exhibit 10.9 to the current report on Form 8-K, filed on January 17, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.57</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224010134/ex10-1.htm" style="-sec-extract: exhibit">Standby Equity Purchase Agreement, dated March 13, 2024, between Celularity, Inc. and YA II PN, Ltd. (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed on March 15, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.58</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224010134/ex10-2.htm" style="-sec-extract: exhibit">Form of convertible promissory note (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed on March 15, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.59</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224010134/ex10-4.htm" style="-sec-extract: exhibit">Forbearance Agreement, dated March 13, 2024, between Celularity Inc. and Resorts World Inc Pte Ltd. (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K, filed on March 15, 2024).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.60</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224010134/ex10-5.htm" style="-sec-extract: exhibit">Forbearance Agreement, dated March 13, 2024, between Celularity Inc. and C.V. Starr &amp; Co. Inc. (incorporated by reference to Exhibit 10.5 to the current report on Form 8-K, filed on March 15, 2024).</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 151; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in; text-align: justify"><span style="font-size: 10pt">10.61</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.1in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000119312522156126/d349292dex102.htm" style="-sec-extract: exhibit">Form of PIPE Warrant (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the Commission on May 20, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000119312522245623/d385403dex101.htm" style="-sec-extract: exhibit">Pre-Paid Advance Agreement, dated September 15, 2022, by and between Celularity Inc. and YA II PN, Ltd. (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on September 15, 2022).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.63</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024115082/celu-ex10_22.htm" style="-sec-extract: exhibit">Amendment dated August 16, 2024 to the Loan Agreement dated August 21, 2023 by and between Celularity Inc. and the lender parties thereto (incorporated by reference to Exhibit 10.22 to the quarterly report on Form 10-Q filed with the Commission on October 16, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.64</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224048330/ex10-1.htm" style="-sec-extract: exhibit">Securities Purchase Agreement dated as of November 25, 2024, by and between Celularity Inc. and the investor parties thereto (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K filed with the Commission on December 2, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.65</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224048330/ex10-2.htm" style="-sec-extract: exhibit">Form of Unsecured Bridge Note (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K filed with the Commission on December 2, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224048330/ex10-3.htm" style="-sec-extract: exhibit">Form of Purchaser Warrant (incorporated by reference to Exhibit 10.3 to the current report on Form 8-K filed with the Commission on December 2, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224048330/ex10-4.htm" style="-sec-extract: exhibit">Form of Placement Agent Warrant (incorporated by reference to Exhibit 10.4 to the current report on Form 8-K filed with the Commission on December 2, 2024)</a></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315225006219/ex10-68.htm" style="-sec-extract: exhibit">Binding Term Sheet by and between the Company and Resorts World Inc Pte Ltd dated February 12, 2025 (incorporated by reference to Exhibit 10.1 to the current report on Form 8-K, filed with the Commission on February 18, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">10.69</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315225006219/ex10-69.htm" style="-sec-extract: exhibit">Binding Term Sheet by and between the Company and C.V. Starr &amp; Co., Inc. dated February 12, 2025 (incorporated by reference to Exhibit 10.2 to the current report on Form 8-K, filed with the Commission on February 18, 2025).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">16.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000149315224030288/ex16-1.htm" style="-sec-extract: exhibit">Letter from Deloitte &amp; Touche LLP dated August 5, 2024 (incorporated by reference to Exhibit 16.1 to the current report on Form 8-K filed with the Commission on August 5, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">19.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex19-1.htm">Insider Trading Policy</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000121390021038102/ea144415ex3-1_celularity.htm" style="-sec-extract: exhibit">List of Subsidiaries (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the Commission on July 22, 2021).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-1.htm">Consent of Deloitte &amp; Touche LLP.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">23.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex23-2.htm">Consent of EisnerAmper LLP</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">24.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="#poa_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on the signature page).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">32.1&#8224;&#8224;&#8224;*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">97.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017024087886/celu-ex97_1.htm" style="-sec-extract: exhibit">Compensation Recovery Policy (incorporated by reference to Exhibit 97.1 to the annual report on Form 10-K, filed with the Commission on July 30, 2024)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1752828/000095017023011440/celu-ex99_1.htm" style="-sec-extract: exhibit">Order of the Chancery Court of the State of Delaware (incorporated by reference to Exhibit 99.1 to the annual report on Form 10-K, filed with the Commission on March 31, 2023)</a></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-size: 10pt">101.INS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: justify"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">101.SCH</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">101.CAL</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">101.DEF</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">101.LAB</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">101.PRE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#
Indicates a management contract or any compensatory plan, contract or arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+
Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. We agree to furnish supplementally a copy of any
omitted schedule or exhibit to the SEC upon request.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#165;
Certain portions of this exhibit are omitted because they are not material and are the type that the registrant treats as private or
confidential.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;&#8224;&#8224;
These certifications will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act or otherwise subject to the
liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities
Act or the Exchange Act except to the extent specifically incorporated by reference into such filing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="m_013"></span>Item
16. Form 10-K Summary</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NA</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 152; Value: 133 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report
to be signed on its behalf by the undersigned, thereunto duly authorized<b>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celularity
    Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    May 8, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert J. Hariri</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Robert
    J. Hariri, M.D., Ph.D.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief
    Executive Officer</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="poa_001"></span>KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Robert J. Hariri, M.D.,
Ph.D. and David C. Beers, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution
and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments
to this annual report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the
Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do
and perform each and every act and thing requisite and necessary to be done, as fully for all intents and purposes as he or she might
or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or his or her substitute or
substitutes may lawfully do or cause to be done by virtue hereof</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on
behalf of the Registrant in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Robert J. Hariri</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Chairman of the Board of Directors (Principal Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Robert
    J. Hariri, M.D., Ph.D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    David C. Beers</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial and Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>David
    C. Beers</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Dean C. Kehler</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dean
    C. Kehler</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Diane Parks</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Diane
    Parks</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Geoffrey Ling M.D.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geoffrey
    Ling, M.D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Peter Diamandis</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peter
    Diamandis, M.D.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>


<!-- Field: Page; Sequence: 153; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJyFkdFqwjAUhp/AdzgUL0XTbo7RO1eqjOksTtxuYz2dwTannESnj7S3XJoqwiYsBEKS/z/ff5Ig6AUTGqsSGT6eFlNYYlWX0iIssEBGnaNTJM8vMbh1gZ/KWJba+u3FmJDzoPM89MXanXvlQRncxCDuB+JxEA1BhPGdgGwWdJr7hHShNqitkiVIvYGMqWaFVvKprbCUR9JUnTxphWwU6RjCvmivvyESYQSvdJBfxDsD02kSdHp+dIIJ0752qvRoUTdOSEusHM607uv0afK9sVTF75Kb3kwq8216RM6VkesSx8RzjW9byTgvklIa4xquSL9Zyncje1Zixip3gjAcZshePcNqjezqhyKKQjE6R79geoAOBHglQUEMpBFMYwcqwONgBLkngmmQIK17sosPoW7Ajbjr2FC7D/H2Gw3+Dp9JXslyj6IvhAj/iX0rSg9qyXBoakC3rfI3wA8Bsb5y -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>ex19-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
19.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: .25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Purpose</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: -22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the course of your relationship with Celularity Inc. (including its subsidiaries and affiliates, collectively the &ldquo;Company&rdquo;),
you may receive material information that is not yet public (&ldquo;<B><I>Material Nonpublic Information</I></B>&rdquo;) about the Company
or about other publicly traded companies with which the Company has business relationships. Material Nonpublic Information may give you,
or someone you pass that information on to, a leg up over others when deciding whether to buy, sell or otherwise transact in the Company&rsquo;s
securities or the securities of another publicly traded company. This Insider Trading Policy (this &ldquo;<B><I>Policy</I></B>&rdquo;)
sets forth guidelines with respect to transactions in the Company&rsquo;s securities by our directors, officers, other employees and
consultants who are advised that they are subject to this Policy and who may become aware of Material Nonpublic Information and the other
persons subject to this Policy as described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anyone
who engages in insider trading or otherwise violates this Policy may be subject to both civil liability and criminal penalties. Violators
also risk disciplinary action by the Company, up to and including termination of employment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; width: .25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scope</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: -22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Policy applies to all transactions in securities issued by the Company, as well as derivative securities that are not issued by the
    Company, such as exchange-traded put or call options or swaps relating to the Company&rsquo;s securities. Accordingly, for purposes
    of this Policy, the terms &ldquo;<B><I>trade</I></B>,&rdquo; &ldquo;<B><I>trading</I></B>,&rdquo; and &ldquo;<B><I>transactions</I></B>&rdquo;
    include not only purchases and sales of the Company&rsquo;s common stock in the public market but also any other purchases, sales,
    transfers, or other acquisitions and dispositions of common or preferred equity, options, warrants, and other securities (including
    debt securities) and other arrangements or transactions that affect economic exposure to changes in the prices of these securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.55in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Policy applies to all employees, directors, officers and designated consultants (collectively, &ldquo;<B><I>Colleagues</I></B>&rdquo;)
    of the Company and its subsidiaries. This Policy also applies to immediate family members, persons with whom you share a household,
    persons who are your economic dependents, and any other individuals or entities whose transactions in securities you influence, direct,
    or control (including, e.g., a venture or other investment fund, if you influence, direct, or control transactions by the fund).
    The foregoing persons who are deemed subject to this Policy are referred to in this Policy as &ldquo;<B><I>Related Persons</I></B>.&rdquo;
    You are responsible for making sure that your Related Persons comply with this Policy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.55in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Policy does not apply to any entity that invests in securities in the ordinary course of its business (e.g., a venture or other investment
    fund) if (and only if) such entity has established and certified to the Company that it has its own insider trading controls and
    procedures in compliance with applicable securities laws with respect to trading in the Company&rsquo;s securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.55in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Policy continues to apply to transactions in the Company&rsquo;s securities or the securities of other public companies engaged in
    business transactions with the Company even after your relationship with the Company has ended. If you are aware of Material Nonpublic
    Information when your relationship with the Company ends, you may not trade the Company&rsquo;s securities or the securities of other
    applicable companies until the Material Nonpublic Information has been publicly disseminated or is no longer material. Further, if
    you leave the Company during a trading blackout period (as discussed below), then you may not trade in the Company&rsquo;s securities
    or the securities of other applicable companies until the trading blackout period has ended.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Responsibility</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: -22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    Colleagues have ethical and legal obligations to maintain the confidentiality of information about the Company and to not engage
    in transactions in the Company&rsquo;s securities while aware of Material Nonpublic Information.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.55in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designated
    Persons (defined below) are required to obtain pre-clearance from the Company&rsquo;s General Counsel or his/her designee of any
    transaction in the Company&rsquo;s securities, even during an open trading window, including the purchase or sale in the open market,
    loan or other transfer of beneficial ownership.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.55in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every
    Colleague is responsible for making sure that he or she complies with this Policy, and that any family member, household member,
    or other person or entity whose transactions are subject to this Policy, also comply with this Policy. In all cases, the responsibility
    for determining whether an individual is aware of Material Nonpublic Information rests with that individual, and any action on the
    part of the Company or any employee or director of the Company pursuant to this Policy (or otherwise) does not in any way constitute
    legal advice or insulate an individual from liability under applicable securities laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.55in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
    could be subject to severe legal penalties and disciplinary action by the Company, up to and including termination of employment,
    for any conduct prohibited by this Policy or applicable securities laws.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Policy</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 22.5pt; text-align: justify; text-indent: -22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
    Policy Statement and Definition of Material Nonpublic Information</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.55in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statement
    of Policy Prohibiting Insider Trading and Tipping</B>. Any Colleague who is aware of Material Nonpublic Information relating to the
    Company may not, directly or indirectly:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">engage
    in any transactions in the Company&rsquo;s securities, except as otherwise specified under the heading &ldquo;Exceptions to this
    Policy&rdquo; below;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 94.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommend
    to another person that they buy, hold, or sell the Company&rsquo;s securities at any time; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 94.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
    Material Nonpublic Information to persons within the Company whose jobs do not require them to have that information, or outside
    of the Company to other persons, such as family, friends, business associates, and investors, unless the disclosure is made in accordance
    with the Company&rsquo;s policies regarding the protection or authorized external disclosure of information regarding the Company;
    or assist anyone engaged in the above activities (also known as &ldquo;<B><I>tipping</I></B>&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 94.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    prohibition against insider trading is absolute. It applies even if the decision to trade is not based on such Material Nonpublic
    Information. It also applies to transactions that may be necessary or justifiable for independent reasons (such as the need to raise
    money for an emergency expenditure) and to very small transactions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.1.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, no Colleague who, in the course of working for the Company, learns of or is otherwise aware of Material Nonpublic Information
    about another publicly traded company with which the Company does business, including a supplier, partner or collaborator of the
    Company, may trade in that company&rsquo;s securities until the information becomes public or is no longer material.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Understanding
    Material Nonpublic Information</B>. It is not always easy to figure out whether you are aware of Material Nonpublic Information.
    But there is one important factor to determine whether nonpublic information you know about a public company is material: whether
    the information could be expected to affect the market price of that company&rsquo;s securities or to be considered important by
    investors who are considering trading that company&rsquo;s securities. If the information makes you want to trade, it would probably
    have the same effect on others. Keep in mind that both positive and negative information can be material. There is no bright-line
    standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances and is often
    evaluated by relevant enforcement authorities with the benefit of hindsight. If you possess Material Nonpublic Information, you may
    not trade in a company&rsquo;s stock, advise anyone else to do so or communicate the information to anyone else until you know that
    the information has been publicly disseminated, as described below. This means that in some circumstances, you may have to forego
    a proposed transaction in a company&rsquo;s securities even if you planned to execute the transaction prior to learning of the inside
    information and even though you believe you may suffer an economic loss or sacrifice an anticipated profit by waiting. &ldquo;Trading&rdquo;
    includes engaging in short sales, transactions in put or call options, hedging transactions and other inherently speculative transactions
    (all of which are prohibited by this Policy).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    may not participate in &ldquo;chat rooms&rdquo; or other electronic discussion groups or contribute to blogs, bulletin boards or
    social media forums on the internet concerning the activities of the Company or other companies with which the Company does business,
    even if you do so anonymously, unless doing so is part of your job responsibilities and you have explicit authorization from the
    General Counsel or his/her designee.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
    by no means an all-inclusive list, information about the following items may be considered to be Material Nonpublic Information until
    it is publicly disseminated:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    results or forecasts;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">status
    of product or product candidate development or regulatory approvals;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
    data relating to products or product candidates, both marketed and investigational;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">timelines
    for pre-clinical studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquisitions
    or dispositions of assets, divisions or companies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">public
    or private sales of debt or equity securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">stock
    splits, dividends or changes in dividend Policy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    establishment of a repurchase program for the Company&rsquo;s securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gain
    or loss of a significant licensor, licensee or supplier;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in or new partner relationships, collaborations or grants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">notice
    of issuance or denial of patents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    developments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">management
    or control changes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee
    layoffs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    disruption in the Company&rsquo;s operations or breach or unauthorized access of its property or assets, including its facilities
    and information technology infrastructure;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tender
    offers or proxy fights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accounting
    restatements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation
    or settlements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impending
    bankruptcy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 148.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>When
    Information Becomes Public:</B> The prohibition on trading when you have Material Nonpublic Information lifts once that information
    becomes publicly disseminated. But for information to be considered publicly disseminated, it must be widely disseminated through
    a press release, a filing with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;), or other widely disseminated
    announcement. Once information is publicly disseminated, it is still necessary to afford the investing public with sufficient time
    to absorb the information. Information will be considered publicly disseminated for purposes of this Policy only after two (2) full
    trading days have elapsed since the information was publicly disclosed. For example, if we announce Material Nonpublic Information
    before trading begins on Wednesday, then you may execute a transaction in our securities on Friday; if we announce Material Nonpublic
    Information after trading ends on Wednesday, then you may execute a transaction in our securities on Monday (in each case subject
    to any pre-clearance requirements set forth in this Policy). Depending on the particular circumstances, the Company may determine
    that a longer or shorter waiting period should apply to the release of specific Material Nonpublic Information.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Procedures
    to Aid in the Prevention of Insider Trading</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.55in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Clearance
    and Notice of Transactions for Designated Persons.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Clearance
    by Designated Persons. Designated Persons are required to notify and receive approval from the Company&rsquo;s General Counsel or
    his/her designee prior to engaging in transactions in the Company&rsquo;s securities (even during an open trading window) and observe
    other restrictions designed to minimize the risk of apparent or actual insider trading. Designated Persons are required to complete
    and submit a Pre-Clearance From attached as Exhibit A to the Company&rsquo;s General Counsel. The following individuals are considered
    Designated Persons:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Members
    of the Board of Directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    Officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees
    at the level of Vice President and above;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees
    in the Finance department;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees
    in the Legal and Compliance department;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees
    in the Clinical Development department;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees
    in the Regulatory department; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive
    assistants who support Executive Officers.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 148.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company may also require that certain additional persons limit their transactions in the Company&rsquo;s securities to certain trading
window periods as described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
General Counsel or his/her designee shall have sole discretion to decide whether to clear any contemplated transaction (the Chief Financial
Officer or his/her designee (other than the General Counsel) shall have sole discretion to decide whether to clear transactions by the
General Counsel or persons or entities subject to this Policy as a result of their relationship with the General Counsel).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
trades that are pre-cleared must be effected within five (5) business days of receipt of the preclearance unless a specific exception
has been granted by the Company&rsquo;s General Counsel or his/her designee. A pre-cleared trade (or any portion of a pre-cleared trade)
that has not been effected during the five (5) business day-period must be pre-cleared again prior to execution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.1.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Post-Transaction
    Notification by Designated Persons.</U> Each Designed Person covered under the Company&rsquo;s Section 16 Compliance Program (applicable
    only to Officers and Directors) is required to notify the General Counsel or his/her designee of the occurrence of any transaction
    of the Company&rsquo;s securities as soon as possible, but in any event on the same day as the trade, or, with respect to transactions
    effected pursuant to a Rule 10b5-1 trading plan, on the day the Designated Person is advised of the terms of the transaction.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Window Period and Trading Blackout Period</B>. The Company has established periods during which Colleagues and their Related Persons&mdash;regardless
    of whether they are aware of Material Nonpublic Information or not&mdash;may not conduct any trades in Company securities. Such period
    when trading is allowed is referred to as a <B>&ldquo;<I>trading window period</I>&rdquo; </B>and such period when trading is not
    allowed is referred to as a <B>&ldquo;<I>trading blackout period</I>&rdquo;</B>, including <B>&ldquo;<I>quarterly trading blackout
    periods</I>&rdquo; </B>and <B>&ldquo;<I>event-specific trading blackout periods</I>&rdquo;</B> described below. This means that,
    except as described in this Policy, all Company employees, directors, designated consultants and their Related Persons will be able
    to trade in Company securities only during limited open trading window periods that generally will begin after two (2) full trading
    days have elapsed after the public dissemination of the Company&rsquo;s annual or quarterly financial results and end at the beginning
    of the next quarterly trading blackout period. Of course, even during an open trading window period, you may not (unless an exception
    applies) conduct any trades in Company securities if you are otherwise in possession of Material Nonpublic Information.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.2.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quarterly
    Trading Blackout Periods. Each &ldquo;<B><I>quarterly trading blackout period</I></B>&rdquo; will generally begin at the end of the
    day that is two (2) weeks before the end of each fiscal quarter and end after two (2) full trading days have elapsed after the public
    dissemination of the Company&rsquo;s annual or quarterly financial results. Please note that the quarterly trading blackout period
    may commence early or may be extended if, in the judgment of the Compliance Officer, there exists undisclosed information that would
    make trades inappropriate. It is important to note that the fact that the quarterly trading blackout period has commenced early or
    has been extended should be considered Material Nonpublic Information that should not be communicated to any other person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Colleague who believes that special circumstances require him or her to trade during a closing trading window should consult with the
Compliance Officer. Permission to trade during a closed trading window will be granted only where the circumstances are extenuating and
there appears to be no significant risk that the trade may subsequently be questioned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2.2.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Event-Specific
    Trading Blackout Periods. From time to time, an event may occur that is material to the Company is known by only a few Colleagues.
    So long as the event remains material and nonpublic, persons designated by the Company&rsquo;s General Counsel may not trade in the
    Company&rsquo;s securities. In that situation, the Company&rsquo;s General Counsel or designee will notify the designated individuals
    that neither they nor their Related Persons may trade in the Company&rsquo;s securities, an &ldquo;<B><I>event-specific trading blackout
    period</I></B>.&rdquo; The existence of an event-specific trading blackout period should also be considered Material Nonpublic Information
    and should not be communicated to any other person. Even if you have not been designated as a person who should not trade due to
    an event-specific trading blackout period, you should not trade while aware of Material Nonpublic Information. Exceptions will not
    be granted during an event-specific trading blackout.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 121.5pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Special
    and Prohibited Transactions</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.55in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inherently
    Speculative Transactions</B>. No Colleague may engage in short sales, transactions in put options, call options, or other derivative
    securities on an exchange or in any other organized market, or in any other inherently speculative transactions with respect to the
    Company&rsquo;s stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hedging
    Transactions</B>. Hedging or monetization transactions can be accomplished through a number of possible mechanisms, including through
    the use of financial instruments such as prepaid variable forwards, equity swaps, collars, and exchange funds. Such hedging transactions
    may permit a Colleague to continue to own the Company&rsquo;s securities obtained through employee benefit plans or otherwise, but
    without the full risks and rewards of ownership. When that occurs, the Colleague may no longer have the same objectives as the Company&rsquo;s
    other stockholders. Therefore, Colleagues are prohibited from engaging in any such transactions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Margin
    Accounts and Pledged Securities</B>. Securities held in a margin account as collateral for a margin loan may be sold by the broker
    without the customer&rsquo;s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated)
    as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale
    may occur at a time when the pledgor is aware of Material Nonpublic Information or otherwise is not permitted to trade in the Company&rsquo;s
    securities, Colleagues are prohibited from holding securities of the Company in a margin account or otherwise pledging the Company&rsquo;s
    securities as collateral for a loan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Standing
    and Limit Orders</B>. Standing and limit orders (except standing and limit orders under approved Trading Plans as discussed in Section
    4.5 below) create heightened risks for insider trading violations similar to the use of margin accounts. There is no control over
    the timing of purchases or sales that result from standing instructions to a broker, and as a result the broker could execute a transaction
    when Colleague is in possession of Material Nonpublic Information. The Company therefore discourages placing standing or limit orders
    on the Company&rsquo;s securities. If a person subject to this Policy determines that they must use a standing order or limit order
    (other than under an approved Trading Plan as discussed in Section 4.5 below), the order should be limited to short duration and
    the person using such standing order or limit order is required to cancel such instructions immediately in the event restrictions
    are imposed on their ability to trade pursuant to this Policy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Additional
    Requirements and Restrictions for Directors and Executive Officers</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.55in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Short-Swing
    Trading, Control Stock and Section 16 Reports</B>. Officers and directors subject to the reporting obligations under Section 16 of
    the Securities Exchange Act of 1934, as amended (&ldquo;<I>Exchange Act</I>&rdquo;) should take care to avoid short-swing transactions
    (within the meaning of Section 16(b) of the Exchange Act) and the restrictions on sales by control persons (Rule 144 under the Securities
    Act of 1933, as amended), and should file all appropriate Section 16(a) reports (Forms 3, 4, and 5), which are described in the Company&rsquo;s
    Section 16 Compliance Program, and any notices of sale required by Rule 144.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prohibition
    of Trading During Pension Plan Blackouts</B>. No director or executive officer of the Company may, directly or indirectly, purchase,
    sell or otherwise transfer any equity security of the Company (other than an exempt security) during any &ldquo;blackout period&rsquo;&rsquo;
    (as defined in Regulation BTR under the Exchange Act) if a director or executive officer acquires or previously acquired such equity
    security in connection with his or her service or employment as a director or executive officer. This prohibition does not apply
    to any transactions that are specifically exempted, including but not limited to, purchases or sales of the Company&rsquo;s securities
    made pursuant to, and in compliance with, a Trading Plan (as defined in Section 4.5); compensatory grants or awards of equity securities
    pursuant to a plan that, by its terms, permits executive officers and directors to receive automatic grants or awards and specifies
    the terms of the grants and awards; or acquisitions or dispositions of equity securities involving a <I>bona fide</I> gift or by
    will or the laws of descent or pursuant to a domestic relations order. The Company will notify each director and executive officer
    of any blackout periods in accordance with the provisions of Regulation BTR. Because Regulation BTR is very complex, no director
    or executive officer of the Company should engage in any transactions in the Company&rsquo;s securities, even if believed to be exempt
    from Regulation BTR, without first consulting with the Company&rsquo;s General Counsel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exceptions
    to this Policy</B>. This Policy does not apply in the case of the following transactions, except as specifically noted:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.55in; text-align: justify; text-indent: -0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option
    Exercises</B>. This Policy does not apply to the exercise of options granted under the Company&rsquo;s equity compensation plans
    for cash or, where permitted under the option, by a net exercise transaction with the Company or by delivery to the Company of already-owned
    stock of the Company. This Policy does, however, apply to any sale of stock as part of a broker-assisted cashless exercise or any
    other market sale, whether or not for the purpose of generating the cash needed to pay the exercise price or pay taxes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tax
    Withholding Transactions</B>. This Policy does not apply to the surrender of shares directly to the Company to satisfy tax withholding
    obligations as a result of the issuance of shares upon vesting or exercise of restricted stock units, options, or other equity awards
    granted under the Company&rsquo;s equity compensation plans. Of course, any market sale of the stock received upon exercise or vesting
    of any such equity awards remains subject to all provisions of this Policy whether or not for the purpose of generating the cash
    needed to pay the exercise price or pay taxes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ESPP</B>.
    This Policy does not apply to the purchase of stock by employees under the Company&rsquo;s Employee Stock Purchase Plan (<B>&ldquo;<I>ESPP</I>&rdquo;</B>)
    on periodic designated dates in accordance with the ESPP. This Policy does, however, apply to a Colleague&rsquo;s initial election
    to participate in the ESPP, changes to a Colleague&rsquo;s election to participate in the ESPP for any enrollment period, or to the
    subsequent sale of the stock acquired pursuant to the ESPP.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10b5-1
    Automatic Trading Programs</B>. Under Rule 10b5-1 the Exchange Act, Colleagues may establish a trading plan under which a broker
    is instructed to buy and sell Company securities based on pre-determined criteria (a <B>&ldquo;<I>Trading Plan</I>&rdquo;</B>). So
    long as a Trading Plan is properly established, purchases and sales of Company securities pursuant to that Trading Plan are not subject
    to this Policy. To be properly established, a Colleague&rsquo;s Trading Plan must be established in compliance with the requirements
    of Rule 10b5-1 of the Exchange Act and any applicable 10b5-1 trading plan guidelines of the Company at a time when they were unaware
    of any Material Nonpublic Information relating the Company and when the Company was not otherwise in a trading blackout period. Moreover,
    all Trading Plans must be reviewed and approved by the Company before being established to confirm that the Trading Plan complies
    with all pertinent company policies and applicable securities laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gifts</B>.
    This Policy does not apply to <I>bona fide</I> gifts of Company securities that have been pre-cleared by the General Counsel or his/her
    designee. Whether a gift is truly <I>bona fide </I>will depend on the facts and circumstances surrounding each gift. Pre-clearance
    must be obtained at least two (2) business days in advance of the proposed gift, and pre-cleared gifts not completed within five
    (5) business days will require new pre-clearance. The Company may choose to shorten this period. Pre-clearance will not be given
    for gifts occurring during a blackout period if the recipient could reasonably be expected to sell Company securities into the public
    market during the trading blackout period during which the gift is made (e.g., a donation to a charitable organization).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitations
    on Liability</B>. None of the Company, the General Counsel or the Company&rsquo;s other directors, officers or employees will have
    any liability for any delay in reviewing, or refusal of, a request to allow a pledge submitted, a request for pre-clearance or a
    trading plan submitted for review or approval. Notwithstanding any preclearance of a transaction, none of the company, the General
    Counsel or the Company&rsquo;s other directors, officers or employees assumes any liability for the legality or consequences of such
    transaction or trading plan to the person engaging in or adopting such transaction or trading plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related
    Documents</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 27pt; text-align: justify; text-indent: -27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GLB-FRM-5985:
    Request for Pre-Clearance of Stock Transaction (CORP-FORM-0006).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>References</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
    16 Compliance Program (applicable only to Directors and Officers)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 76.5pt; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Definitions/Abbreviations</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definition</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Designated
    Persons</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    directors, executive officers and certain other employees who by virtue of their function may have access to Material Non-public
    Information, including: (i) all employees at the Vice President level and above, (ii) all members of the Company&rsquo;s Legal and
    Compliance department, (iii) all members of the Company&rsquo;s Finance department, (iv) all members of the Company&rsquo;s Clinical
    Development department, (v) all members of the Company&rsquo;s Regulatory department, and (vi) all Executive Assistants to executive
    officers of the Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Material
    Nonpublic Information</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Material
    nonpublic information is any information that is not known to persons outside the Company that could be relied upon or considered
    significant to an investor making a decision to buy or sell Celularity securities. Information that should be considered sensitive
    and nonpublic material includes, but is not limited to, the following:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.85in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    results;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
    Earnings or Losses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">News
    of a pending or proposed sale, merger or acquisition;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acquisitions,
    Mergers or Divestitures;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impending
    bankruptcy or financial liquidity problems;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Major
    changes in senior management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    dividends or splits;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    equity or debt offerings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    contracts in a pending status or in discussion.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related
    Persons</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immediate
    family members, persons with whom you share a household, persons who are your economic dependents, and any other individuals or entities
    whose transactions in securities you influence, direct, or control (including, e.g., a venture or other investment fund, if you influence,
    direct, or control transactions by the fund)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quarterly
    Trading Blackout Periods</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    period in which Colleagues are precluded from trading the Company&rsquo;s securities beginning at the end of the day that is two
    (2) weeks before the end of each fiscal quarter and end after two (2) full trading days have elapsed after the public dissemination
    of the Company&rsquo;s annual or quarterly financial results. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 23.1</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt">We consent to the
incorporation by reference in Registration Statements Nos. 333-258600 and 333-265191 on Form S-1, Registration Nos. 333-266786 and
333-272198 on Form S-3 and Registration Statements Nos. 333-260025 and 333-266783 on Form S-8 of our report dated July 30, 2024 (May
8, 2025, as to the effects of the adoption of ASU No. 2023-07, <I>Segment Reporting (Topic 280): Improvements to Reportable Segment
Disclosures</I>, described in Note 2), relating to the financial statements of Celularity, Inc. appearing in this Annual Report on
Form 10-K of Celularity Inc., for the year ended December 31, 2024.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
DELOITTE &amp; TOUCHE LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morristown,
New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin: 0pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ex23-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements of Celularity, Inc. on Form S-1 (Nos. 333-258600 and 333-265191),
Form S-3 (Nos. 333-266786 and 333-272198) and Form S-8 (Nos. 333-260025 and 333-266783) of our report dated May 8, 2025, on our audit
of the financial statements as of December 31, 2024 and for the year then ended, which report is included in this Annual Report on Form
10-K to be filed on or about May 8, 2025. Our report includes an explanatory paragraph about the existence of substantial doubt concerning
the Company's ability to continue as a going concern.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
EisnerAmper LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">EISNERAMPER LLP</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Iselin,
New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RULES
13a-14(a) and 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Robert J. Hariri, certify that:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual Report on Form 10-K of Celularity Inc.;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and
                                            maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
                                            and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
                                            Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant, including its consolidated subsidiaries, is made known to us by others within
                                            those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such internal control over financial reporting, or caused such internal control over financial
                                            reporting to be designed under our supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.5pt; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert J. Hariri</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Robert
    J. Hariri, M.D., Ph.D.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
                                            Executive Officer</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RULES
13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AS
ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
David C. Beers, certify that:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
                                            have reviewed this Annual Report on Form 10-K of Celularity Inc.;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, this report does not contain any untrue statement of a material fact or
                                            omit to state a material fact necessary to make the statements made, in light of the circumstances
                                            under which such statements were made, not misleading with respect to the period covered
                                            by this report;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
                                            on my knowledge, the financial statements, and other financial information included in this
                                            report, fairly present in all material respects the financial condition, results of operations
                                            and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and
                                            maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
                                            and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
                                            Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such disclosure controls and procedures, or caused such disclosure controls and procedures
                                            to be designed under our supervision, to ensure that material information relating to the
                                            registrant, including its consolidated subsidiaries, is made known to us by others within
                                            those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
                                            such internal control over financial reporting, or caused such internal control over financial
                                            reporting to be designed under our supervision, to provide reasonable assurance regarding
                                            the reliability of financial reporting and the preparation of financial statements for external
                                            purposes in accordance with generally accepted accounting principles;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
                                            the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
                                            in this report our conclusions about the effectiveness of the disclosure controls and procedures,
                                            as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
                                            in this report any change in the registrant&rsquo;s internal control over financial reporting
                                            that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
                                            fourth fiscal quarter in the case of an annual report) that has materially affected, or is
                                            reasonably likely to materially affect, the registrant&rsquo;s internal control over financial
                                            reporting; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
                                            evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
                                            and the audit committee of the registrant&rsquo;s board of directors (or persons performing
                                            the equivalent functions):</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
                                            significant deficiencies and material weaknesses in the design or operation of internal control
                                            over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
                                            ability to record, process, summarize and report financial information; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
                                            fraud, whether or not material, that involves management or other employees who have a significant
                                            role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David C. Beers</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
    C. Beers</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
                                            Financial Officer</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report of Celularity Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the period ending December 31, 2024
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), we certify, pursuant to 18 U.S.C.
&sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange
                                            Act of 1934; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            information contained in the Report fairly presents, in all material respects, the financial
                                            condition and results of operations of the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 24.5pt; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Robert J. Hariri</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Robert
    J. Hariri</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
    Executive Officer</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 8, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    David C. Beers</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>David
    C. Beers</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
    Financial Officer</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not
to be incorporated by reference into any filing of the Company. under the Securities Act of 1933, as amended, or the Exchange Act (whether
made before or after the date of the Report), irrespective of any general incorporation language contained in such filing. A signed original
of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained
by the Company and furnished to the Securities and Exchange Commission or its staff upon request</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'L!&@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 'PW^%']OZ7_ ,_0_P"^&_PH TJ*S?[?TO\ Y^A_WPW^%']OZ7_S]#_OAO\
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M]]K_ /$T?\*QTG_GZO?^^U_^)H^LTP_LC$]E]YY317JW_"L=)_Y^KW_OM?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)FES0 449HS
M0 449HS0 449HS0 44F:-PH 6BDS2YH **,T9H **,T9H **,T9H **,T9H
M**3-&: %HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS1F@ HHS
M1F@ HHS2;A0 M%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T %%&:,T
M %%&:,T %%&:,T %%&:,T %%&:,T %%&:3(H 6BC-&: "BC-&: "BC-&: "B
MC-&: "BC-&: "BC-&: "BC-&: "BDR*7- !11FC- !11FC- !11FC- !11FC
M- !11FC- !11FC- !11FC- !11FC- !129%&: %HHS1F@ HHS1F@ HHS1F@
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M'\3_ //\/^^!1_PL?Q/_ ,_P_P"^!7*457U>E_*@Y(]CJ_\ A8_B?_G^'_?
MH_X6/XG_ .?X?]\"N4HJ?84OY4')'L=9_P +(\3_ //Z/^^!1_PLCQ/_ ,_H
M_P"^!7)T4_84OY4')'L=\WCWQ"/#D5V+P"9KIXR=@^Z%4_UK,_X6/XF_Y_5_
M[X%9C_\ (H0_]?K_ /H"UCUG"A3U]T2A'L=9_P +(\3_ //Z/^^!1_PLCQ/_
M ,_H_P"^!7)T5I["E_*A\D>QU?\ PL?Q/_S_  _[X%'_  L?Q/\ \_P_[X%<
MI12]A2_E0<D>QU?_  L?Q/\ \_P_[X%'_"Q_$_\ S_#_ +X%<I11["E_*@Y(
M]CK/^%D>)_\ G]'_ 'P*/^%D>)_^?T?]\"N3HI^PI?RH.2/8ZO\ X6/XG_Y_
MA_WP*/\ A8_B?_G^'_? KE**?U>E_*@Y(]CK/^%D>)_^?T?]\"C_ (61XG_Y
M_1_WP*Y.BE["E_*@Y(]CK/\ A9'B?_G]'_? H_X61XG_ .?T?]\"N3HH]A2_
ME0<D>QU?_"Q_$_\ S_#_ +X%+_PL;Q-_S_#_ +X%<G11]7I?RH.2/8^AO FJ
M7>L>&8KN]DWS,Q!(&*ZBN+^&/_(FP?[[5VE?.54E4:1YLU:3%HHHK,D****
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M_O@T?V3J/_/E/_WP:^D:*/K\OY0^L/L?-W]DZC_SY3_]\&M;1-,ODCU'?:3
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M@T?V3J/_ #Y3_P#?!KZ?V+Z"C:OH/RH_M*7\H?67V/G71M,ODMM3#6<P+6S
M?(>365_9.H?\^5Q_W[-?3Q5<CIUI=B^@_*DLPDG?E%]8?8^8/[)U'_GQN/\
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M']D:C_SXW'_?!I/[(U'_ )\;C_O@U]0;%]!1L7T%']I2_E#ZR^Q\P?V3J/\
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MFFNDCO9+YXYXY=1D;='DC8+;;M7 Z-^M%PN>H7M_!I\"S7#$!G6-0HW%F)P
M /\ /%9M_P"*M.L+N2V9;J>6)=TWV:W:40C_ &RH^7\:KZYF3Q7X=B< P[IY
M>>GF!0%_':SUG:%J=CHD^NVVK3PVUP+R2<F9@OFQM]TC/WN.*&,["WGANK>*
MXMY%DAE4.CJ<AE(R"#Z4YW6.-I&/RJ"2:X 2#4/%%H+1+RTLUT=;F"R21H%#
M[WVED0@=,<'\16?I=[.;O298-2NKB^O%N%U.WDN&=8U".0=A.(\,% P!G/?-
M%P/1M-U&VU;3K>_M&+6]P@>,L-I(/L:L2RK#!),^2L:ESM&3@>@KR;PZ)M)T
MSPO);7EWB^L)?/C:X=D^6/*[5)PN/8"KOAU)HKGPG+)>WMR=4M;A+Q;JY>5)
M0 I'R,2HQTX R"<T7 ])M;F.[M8[B+/ER*&7<,'\J9;:A;W5Q<P1LPEMGV2H
MPP0< CZ@@CFO/O$UV^G>(9[DWLDD%MY1CM[>^>WE@QU58L%)@?0CVKIP2GQ"
M;RQM\W34,HZ='?:2/7D_E0!;U;Q-INBSI#>22!F3S&\N,N(TR!O<C[JY(Y-;
M (89'0\BO*_'$GVC6;VYDDBBBL(TBEL2Y634868%E!SS]W@ 9)X)P:] \.ZL
MNN:#::BD(A$R9\K?N*?[).!R.]%P-2I(/]:M1U)#_K10P+M%5KV^M].M)+JZ
MD6.&,99C6'I'CC1-:O/LEK.ZS'.U9%V[L>E2HMJZ0K-G344F:,U(A:*3-&:
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M[<DMI(I+1(TCB,4+HY,LC#:=S(>BAN,=C6A:^.8)9UC%L7B;>J.LH:1BH[H
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ME$4BR*I]#C@46FM:5?6DUS9ZE9SV\!(EEAF5DCP,G)!P..:\_P!8+VZZJ-/
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MV5%<0R7HM%F)/E-.%W<#)P3Z 9K&T75?#MWKMW-9^(-/O[^ZP D,Z,RQJ.%
M!)P.3GU-4]18W.OZ\9 2+/3@D0[#>-Q/UXQ6==K$OPD\/R?*+M+:Q-NP'S>9
MM0<?\!S0,Z34/$'A.WU#R]1U31H[R _=N9X@\9Z_Q'(/>M6TNM/E9X;*:W<J
M [)$RY&[D$@>O7WKBM"CUM_$GB,V4FG+']M7S!<PNS$[!T(8"M72AY7C_P 0
M>85&^*!A[@( 3^E%P.@BU.QG=$AO;>1W9D55E!+,OW@/<=_2KT/^M%>8VBE/
M MQJ"-B2'66N(''?,X0X^JEA^->F6IWF-L8)&:+@9/C;1[K6O#4UI9G]]N#A
M<XW8[5Y9H/@/7;[4U2>WN+")#\T[+@CZ>M>\=J3&*NG7E3BXH<9N*LCSS_A6
M$W_0RWW_ 'R?_BJ/^%83?]#+??\ ?)_^*KT3 HI>WGW%SR/._P#A5\W_ $,M
M]_WR?_BJ/^%7S?\ 0RWW_?)_^*KT2BCVT^X<\CSO_A5\W_0RWW_?)_\ BJ/^
M%7S?]#+??]\G_P"*KT2BCVT^X<\CSO\ X5?-_P!#+??]\G_XJC_A5\W_ $,M
M]_WR?_BJ]$HH]M/N'/(\[_X5?-_T,M]_WR?_ (JC_A5\W_0RWW_?)_\ BJ]$
MHH]M/N'/(\[_ .%7S?\ 0RWW_?)_^*H_X5?-_P!#+??]\G_XJO1**/;3[ASR
M/.C\,)AC_BI+[_OD_P#Q5+_PK";_ *&2^_[Y/_Q5>A-U7ZTZCVT^X^>1YW_P
MJ^;_ *&6^_[Y/_Q5'_"KYO\ H9;[_OD__%5Z)11[:?<7/(\[_P"%7S?]#+??
M]\G_ .*H_P"%7S?]#+??]\G_ .*KT2BCVT^X<\CSO_A5\W_0RWW_ 'R?_BJ/
M^%7S?]#+??\ ?)_^*KT2BCVT^X<\CSO_ (5?-_T,M]_WR?\ XJC_ (5?-_T,
MM]_WR?\ XJO1**/;3[ASR/._^%7S?]#+??\ ?)_^*H_X5?-_T,M]_P!\G_XJ
MO1**/;3[ASR/._\ A5\W_0RWW_?)_P#BJ/\ A5\W_0RWW_?)_P#BJ]$HH]M/
MN'/(\[_X5?-_T,M]_P!\G_XJC_A5\W_0RWW_ 'R?_BJ]$HH]M/N'/(\[_P"%
M7S?]#+??]\G_ .*H_P"%7S?]#+??]\G_ .*KT2BCVT^X<\CSH_"^;('_  DM
M]^1_^*I?^%7S?]#+??\ ?)_^*KT(_P"L7Z&G4>VGW#GD>=_\*OF_Z&6^_P"^
M3_\ %4?\*OF_Z&6^_P"^3_\ %5Z)11[:?<.>1YW_ ,*OF_Z&6^_[Y/\ \51_
MPJ^;_H9;[_OD_P#Q5>B44>VGW#GD>=_\*OF_Z&6^_P"^3_\ %4?\*OF_Z&6^
M_P"^3_\ %5Z)11[:?<.>1YW_ ,*OF_Z&6^_[Y/\ \51_PJ^;_H9;[_OD_P#Q
M5>B44>VGW#GD>=_\*OF_Z&6^_P"^3_\ %4?\*OF_Z&6^_P"^3_\ %5Z)11[:
M?<.>1YY_PJ^7_H9+[_OD_P#Q5/@^&LMO<QS?\)%>N(W#[2IYP<X^]7H.*3%+
MVT^X<[/(? T=O-X]U+^TPK7BEO+#]<Y[?A7HNO>'K'Q#I[6MT@'.5D4?,OTK
MFO%?P_;5;_\ M32;G[+?=6YP&/KD=#57P[X5\66VM17VJ:N62(;2AE,FY?3G
MI6\Y1G::E9]A,Z'1[[1K"1?#UO*SM O_ "U[GTR:?XO2T;P[<M<JH(7Y">H;
MMBJWB/P@NJ3B\LI?L]XO\0X#?_7K$B\&:WJ$R+J]^QA0]/,+?EZ5G'E;YKGE
M5IUWS4W"]]F;?@'S&\-H'SM$C!/IQ_\ 7K<&E6PU9M3.XW+1B/D_*!["IK*T
MBL;>.W@4+'&N% KF=>NUEUR2&X -IIUJ;MD/1WZ#/TZU#?-)M'?0ING34'T-
MB[\/6%[->2S>;ONXEBD(?&%4\ >E5'\&Z4URLP,Z@21R&-7PA9/NDC%<A8Z7
M?V6C6.KII\,4UNCW4EP'#23E^0" ,@<_I5H>)]<%H5CE:26X\E+>66%%VR,W
M*X'48]>>*ODE]EF]F=/'X/TQ)2\AGF^5E599-P4-UQQFK6DZ#:Z.6^SR2ME0
MH5RIVCVP!7*KXAUA+F6S?4(]C7OV=;IHE&P ?-QC'7UK$M]2F.J75W+/%<[Y
M99#(\2GY(4PK 8P,LPY'I3]G-K5A9GH%EX7M=/U.;48+BZ\Z9MT@:0$-^E3W
MVB0WMQ),;F[A,B".189,*XYZC!]:XJ3Q-K]A'OEG6=Q9>?+&8E C)/R]!GZU
MMZ%J6I7/B.>RDU%+RVM[=&D=8U'[QAG&0.U1*$OB;"S+MQX-TN<2J3/'') (
M'CCDP"HZ=J4^$--,=RLDES*]QMW2/)EAMZ8..*P++3'U[7M3U)X+">V$PA3[
M7"7("]=O.!UK+_T2[TV[U-!$VIW5^3:E,&1%#8&.X&!5<LMK@=G#X1TZ&Z%R
MTMS--YRS%I9,[F4$#/'8$TT>#M-0R[6G2.3<=BN %)[@XR/SKD-=U*YU#58-
M0"W!L=.N(XTD1?W;MN D)/MP!72>.)_-TJSL4>-3?7")F0_*!U.?:DXRNE?<
M#9TK0K7299Y8'EDEGQYDDK D@=!P!5:3PKITDS.S3^4TOFO;[_W3-ZD8KG+Z
MTCLHK.!?[.M[6[N1'=36$?E@J!D*QR>I-4]4EATQ]971T"636BV^V+A#,[ #
M&.,X)H4&W>X6.O?PKISWLEPQFVO+YS0A_P!V7_O8]:(O"NG1^1M\[, E"9?O
M)]YOK7.66FZCH$]OJ%OH8(C@$+06L@+RGN[' %1:E);:QXKM;>RA$>H(\4MU
M<2R9,('/EK[G)!Q349-Z,#6C\$1&_E+W$D=F(%@B2&3#%>^XXYS6B_A+27CN
M$,3J)RAX;[FP87;Z8%9_B;6-0M-1CMK&Z$"1VSSSL8U8@#IU%8;^)=?M8F9I
MQ.XM(7E40J!%)(3C&!SQSSW-"C.23N&IUD?A>R2:WD6:X\RV<LC!E!.1@@X'
M3_&I=,\-6&D7'FVS2@#(6-B"JY].,_K7)?\ "3:U&8[=WF$<L^T77DIYFP*2
M1M^[G(J!M6U*>^MKB^NWC:TLVF>(!0&;) )'3G@T>SF]V%F>F[A2D^U>8C6M
M9M=/N6MKF&V2UMXF98X$^>>1B0,8]",U9O?$NL;;MH[^*"XBG2VBMQ&IWD]6
MY&:E49,7*>B[LG%+7*^$#(TNLLS%X_MS!6QU(50V/QS75=JSDK.PFA:***0!
M1110!4NOOBH*L7'+CZ5!BK0T)12XHQ3&)12XHQ0 E%+BC% "4HZT8I0.:0#:
M*7%&*8&;J>A:;K#Q-?VHE:+(0AV4X..#@C(X'!XINH^'M*U81"]M%D\I=BX8
MKA?[O!&1['BM3%&* *MYI]IJ%H+6Z@62 $$)R ".G2E6PM4:Y80*3=?Z[/(?
MC'.?;BK.*,4@,NP\/Z5ID4\5I9JB3C$@9F?<.F/F)X]NE01^$M#BTVXT];'_
M $:XV^:AE<EL8P,YR ,# !Q6WBC% &9IN@Z?I+L]E%*A9=IWW$CC'L&8XK2I
M<48H 2E/6C%!!S0(2BEQ1BF,2BEQ1B@!**7%&* $HI<48H 2BEQ1B@!**7%&
M* $HI<48H 2BEQ1B@!*=_#^-)BEQ\OXT 9&I>&]*U:[CNKRW=KB-"BR),\9"
MG!(^5AD9 IP\/:4-)?2_L2&S?EHR2<GU)SG/OG-:F*,4@.:U#PO!'H4]EI%G
M:%Y95D=+N20B7&.LF2ZG &#SC'2JF@>"X;6QU&+5;:V/VZ82-!#*\BQ[?NXD
M;#%O]K@UV&*,4 8]OX8T>UCB2*R4"*?[0I9V9O,_O$DY)Y[YIT_AO2+F"XAE
MLT9+B83R89@3(,88$'(/ Z$5K8HQ0!E6_AS2+58!#9JOD2F:,EV9@YZDDG)/
MUS4-QX2T*ZO);N>P#S2R+*Y\QPI=<8;:#@-\HYQFMO%&* ,IO#FD/>M>-9@S
MF59RV]O]8O1L9QFK,.EV-O>W=Y%;(MQ=[?/?J7P,#/X5<Q1B@#(L?#.CZ;>F
M\M+,1SX(5B[,$!/.T$D+GV IVJ>'=+UBZBN;VW9YHE*)(DSQD*>WRD5JXHQ0
M!E1^'=)AL(K)+-?L\4PG52S$^8.0Q).2?J:;;>&-&L[_ .VP602?)8?O&*J3
MU*J3M7\!6OBC% &-;>%=$L[QKJ"P196W_P ;%5W'+;5)PN?8"FVOA'0K*=)X
M-/42(&"EG9P P(8 ,2,$$\=*V\48H QK+POHVGB46]D )4\MA)(\GR_W1N)P
M/85+I?A[2M&E>6QM?+D=0A9G9R%'0 L3@>PP*U,48H QKG1VDUT7J>6T$\!@
MNXG8C*]0PP.3V[<5'9>$-#TZ6"2VLF!@ $2O/)(J8&!A68@8'M6[BC% %6UL
M+6SGN9K>$))<OYDS9)WMC&:JZEX?TO5Y5EO;8O*J[0Z2O&V/0E2,CV-:F*,4
MP,/4="6YL[#3;9(H--AE626,$@D(=RJ/JV"23V[YK?A $J\<4S%20\2"DP+M
M%-WCT/Y4;QZ'\J@D=13=X]#^5&\>A_*@!U%-WCT/Y4;QZ'\J '44W>/0_E1O
M'H?RH =13=X]#^5&\>A_*@!U%-WCT/Y4;QZ'\J '44W>/0_E1O'H?RH &ZK]
M:=4;,,KP>OI3MX]#^5 #J*;O'H?RHWCT/Y4 .HIN\>A_*C>/0_E0 ZBF[QZ'
M\J-X]#^5 #J*;O'H?RHWCT/Y4 .HIN\>A_*C>/0_E0 ZBF[QZ'\J-X]#^5 #
MJ*;O'H?RHWCT/Y4 .HIN\>A_*C>/0_E0 A_UB_0T^HRPW@X/3TIV\>A_*@!U
M%-WCT/Y4;QZ'\J '44W>/0_E1O'H?RH =13=X]#^5&\>A_*@!U%-WCT/Y4;Q
MZ'\J '44W>/0_E1O'H?RH =13=X]#^5&\>A_*@!2*,4F\>A_*C>/0_E0 N*,
M4F\>A_*C>/0_E0 F/G_"J#Z/:R:D]\Z[I'B\ET;!5ESGD8J]N'F=#T]*=O'H
M?RHO8!HB4)Y85=F,;<<8JM'I=A"=T5E;(0=V5B4<^O2K>\>A_*C>/0_E0!6?
M3[-XRCVENT9;<5,8()]<8ZTBZ98HFU;.W5=NW B4#'ITZ5:WCT/Y4;QZ'\J+
ML"A>:7#=PR(I\EI%"M)$J[BH[9(/'X5!HWA^ST03_9B[/,VYW?;D_@H 'Y5K
M;QZ'\J-X]#^5.[M8"..WBA0I%$B G)"K@$U!'I5A#)YD5E;1OTW)$H/\JM[Q
MZ'\J-X]#^5("#[';"W^SBWB$/_//8-O7/3IUI)[&UNE5;BVAF"_=$D88#Z9J
MQO'H?RHWCT/Y4 55TVR2!H5M+=86.6C$2[2?4C%.&GVBPB%;6 1AMP01C /K
MBK&\>A_*C>/0_E0 ;<=*J_V78^=Y_P!BM_.SN\SREW9^N*M;QZ'\J-X]#^5
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M44 %%%% #6[?6G4UNJ_6G4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]CTB W\S2W3C>Y(Z9[#V%:E8O0D**** &C_6'Z4ZFC_6'Z4Z@ HHHH ****
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M!(4444 %%%% !1110 4444 %%%% !1110 UNJ_6G4UNJ_6G4 %%%% !1110
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M3: 1>E+110 4444 -'^L/TIU-'^L/TIU !1110 4444 %%%% !1110 4444
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M5]4BT;3GO9HWDC5@N$QDY..]6KAS%;2R#JB%AGV%8?BKPI9>)[+RYK>V:Z7
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MX]#1QZ&@ I>Q^M)D>AIW&#QWI -HI>/2DR/0TP"BCCT-''H: "BCCT-''H:
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M^\/RH =13</_ 'A^5&'_ +P_*@!U%-P_]X?E1A_[P_*@!U%-P_\ >'Y48?\
MO#\J '44W#_WA^5&'_O#\J '44W#_P!X?E1A_P"\/RH =13</_>'Y48?^\/R
MH 1OOK]#3ZC(;>.1^5.PW]X?E0 ZBFX?^\/RHP_]X?E0 ZBFX?\ O#\J,/\
MWA^5 #J*;A_[P_*C#_WA^5 #J*;A_P"\/RHP_P#>'Y4 .HIN'_O#\J,/_>'Y
M4 .HIN'_ +P_*C#_ -X?E0 ZBFX?^\/RHP_]X?E0 ZBFX?\ O#\J,-_>'Y4
M'\?X4ZHP&\SJ.GI3L/\ WA^5 #J*;A_[P_*C#_WA^5 #J*;A_P"\/RHP_P#>
M'Y4 .HIN'_O#\J,/_>'Y4 .HIN'_ +P_*C#_ -X?E0 ZBFX?^\/RHP_]X?E0
M ZBFX?\ O#\J,/\ WA^5 #J*;A_[P_*C#_WA^5 #J*;A_P"\/RHP_P#>'Y4
M ^\U.IB@Y;)I] !1110 4444 %%%% !1110!4N?OBH*GNOOBH*N.PT%%%%,8
M4444 %%%% !2CK24HZT,!**** "BBB@ HHHH **** "BBB@ H/6BE/6A@)17
M'6ME'XHU_6_[1EF\FPN%M+>".9H]G[I'+G:1DDL>OH*3Q'<C2?#UCI%YK*(]
M[,+<WDKB(K%U<EL\':" <]<4K@=E17F%_K<5[X LU:^>X-IJ$=G<RVKLQD"D
MC(*9)W !N,]:T_#\UG+XT">'C>BPAMG&H)<B90LA*F+ E^;.-_0=/PHN!WE%
M<WXP\3CPYIV^-96N6P5Q:RR)C.#EE7 /L36LE_#?Z1+=6_G*C1OM\V%XFR!_
M=< C\J=P+U%>2Z2\-SH&ER:9'JSZ^TZ%IF2X\KB3YBS-^[*[<]#717?Q%M[7
M5KBW(LQ;6UV+20/>!;EGZ%EBQRH/'4'VI7 [BBN.F\9WT=MJMZ-+A-E8W'V7
MS#.V[?E<LP"'" -DG)(QTJ"7Q$U^-(GFBB9C?^6#IU^)8G]\@98?[)"T7 [B
MBN%@\:7VJZ=J1M;:PCECM)I8U6]!FA9"1B6,J&1N_ 89'7H3##XYNK/3=*M[
MG^SFU">U-Q))>7OD1;1P,,5Y8DC@#\:+@>@45Q*^.KK4#;G1],AF2;3A?EKF
MX,>T98%/E5LGY>HX/K5J'Q;>ZE]GCT;3(YYWLA=RK/.8@H)P$4A3EB0>N!QR
M13N%SK**XC5_B$FFZC<6WD6:_9(T:Y2YO5BE);G;$F#O('N!75RZG;0:8E_(
M)F@95<>5"\C8/3Y5!)_"BX%RG?P_C7,^#_$X\1Z=OD247(+%LVLD:$!L##,,
M$^P.:Z;^'\: &T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !4D'^M%1U)!_K128%VC(]:S-:UNRT&Q-W?2[(\X  R6/H!6=X
M?\9:3XBD>*U:1)U&XQ2K@X]?2I4)-72T%9VN=+12;A1N'K2$+12;AZT;AZT
M+12;AZT;AZT +2&C</6D)'K0 9HR*\\\7:[JM[X@A\-:$_E3LH:>7/W0>>OI
MC^=94]CXL\$O#?\ VQ]3M&<":++-U^O/Y5K&A=7;LWT*L>KDC% /%<MK6EZG
MKR6L]E>R6<+QAGC;*L#U_.LO2M0U70-?ATG4Y?M$,_\ JI<]#_G^=2H76CU.
M*>(<)\LHZ=SOFZK]:=36_A^M.J#K"BBB@ HHHH **** "BBB@ HHHH ****
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M+MU['816,UP(Q$LTK2*&7<H.[;U8<]15R#Q+)=ZD\-KI=Q/9Q7'V>2Z1QA7
MR?EZD#(YK,O_  3<7TL*R:A:M GE@.]D#<1A0.(Y0PV@XSR&ZFKUOX=U*POY
M!8ZPL&FS7/VF2$VVZ7<<959"V IP.JD\G!Z$ &-X=\672Z!81>1/J>HR1O,X
M\P J@)&23^6*T9?',#-9BQL9+DW%L+K'F",JFXJ0 ?O,"#D#^M06G@B[TNWM
M#INJ11WD,+P22RVQ=)(V.?NAQ@@]\GZ4Z\\#R2Z9::=;WMH]M! 82M]9"<AC
MRTD; J48Y]QP...34"SJOC6'3KJ:&.RDN!:P"XNR)%0Q*>< 'ECC/ ]*J>(?
M%TC:=J,>D6TUQY%LLLEU'(%\K< 5P.I."#QZTR^^'RRW/GVES:;WMEMYGO[%
M;I_E& Z%B-K=>H8=.*L:CX-N97O5TW5$M(;^%(KE7M@Y)50H9,%0IP .A'L*
M-0.@T:62?0["65R\CVT;.Q.225!R?UJ^>M5K"U-CIUM:;P_D1)'NQC=M &<?
MA5D]: ,"]\.2/J4]_IFJ3:=-<J%G\N-763 P#ANC =Q[>E%AX4L[&\@G6228
M0PM&J2X8%F(+.3W8XK>HIV YN]\'6EUJ$]REQ)"DTT4[11J-N^/C/XC'Y5H3
M:(C^((-8AN'@F6,Q3(H&V=.H#>X/(/O[UJ446 J:EIUMJMDUK=*S1$@D!B#P
M>*L2QB:%XR<!U*T^LCQ/=7UEX>N9]-1GN5VXVKN95+ ,P'<@9('\Z +&BZ6F
MBZ/;Z=%(TB0*5#N,$Y)/]:RF\)*NISW-OJ$]O;W%Q]IFMT1?F?OA_O $\X%9
M>G:W<1+>3V6MR:S##;L\EO=1I'<QR <80*F5/?/YU9TOQN)]!TFYNM/NY+^\
MLQ<R6]LB_*N.7Y?[IY(YSCM2 THO#0@L;^WM[^XA>ZNS=&5, JQ"_+CH5^4<
M'KDU3@\$P1W"7,M_/)<BZ%R\@14W,!@# X''I5J[\6V<%A%>06E]>P/ UP6M
MHU_=HO4L691D>@R>*YK7/&]]875]>:<INK5;&&>")HP5!9L9/(/3WH W8_!R
MO<B:]U*>\$<,L,(>-0R+)@'+#EC@#DU&?!82.S:VU26*ZMH3;^?Y*-OC)SM*
MD8X('/6J2>,YK'7]92_MK^2R@-N0J1I_H@=1G>=P[GG&[&#7;(ZR(KH<JP!!
M]118#"B\+01W0N#=SR/]@^PDR')(RQW$^OS&JR>#OLD=N=-U2XM)X[7[(\RQ
MJQDCSD<'@$'."/6NHHIV YBY\'*][)<6NIW-L9XU2X(57:7:,!MQY!QW%=*B
M".-4!)"@ 9//YTZB@"IIVFVVEV:VMHK+""6 8DG).35W^'\:;3OX?QH ;111
M0 5R?C*]O':UTC3;_P"Q7<X:8S!PI54&1^!; _&NMK!?PO97NMW6HZK#:WXD
M54@BFMU80J.N-V<Y./3I0P(K+Q;;7D.@LD+,=51B"K<1,H&X'Z$X_"LEO&=]
M>>(=%M[&R(M+FZGM[C<ZY/EJ3D'MC&?PQWJ3_A!IK26.32M1AM?L]Y+<VD3V
MI:.)9 "Z;0XXW9(P1C.,&GV/@FXL7TR9=2CDN+.\EN79[?Y9%D4JR@!N.IP>
M?H:6H$L/C6*[:(FRGBLKO>EI>;P1*0/3J,]LUG6'C9K;2[>"&QO-1E6P:^DE
MEF56\M78')/4C:,#O^%7;7P3-;M:VKZFLFF63N]I"(")%)&!O?<0P'LJTVQ\
M"M9QLO\ :(;.EOI^?)Q]YF;?U_VNGZT:@/B\>1F-I9]+N(8FLGOK=F<$RHO4
M8_A/UJ,>.[AI?*7P_<^8UF+Z,&9,-"<\D_PGC[IYJ2Y\$-<6]M%_: 7R=.DL
M<^5UW#[_ %[>E6E\)E;J.;[8#MTH:=M\KKC/S]??I^M&H#K7QC:W1E\JWDVQ
MZ=]OW9'*_P!WZ\50?QZ6YM=&GG"V:7DI\U5\M&^O4^U1GP->P1Q+8:Q%$6T\
MZ?=&6U+[T)^\GS#:PYZ[A[59L_!1M8IT_M /YNG)8Y\G&-HQO^]W]/UHU 2\
M\>6T+J+6TDND6S2]G82JGE1ODKU^\<!N!Z59\5ZHQ^'^HZGI]P\9-FTD4L9P
MPXR"#VK)N?AV'DMI;:YL#*MC%93M>Z>MQD1@A7C#-\C<G.=PZ<<<]%J^@_VE
MX3N=#CN!#YUN8!-Y0(7C&=HP,>PQ0!B7,-SX=72+^WU*_N$GG2&XANKEI0P=
M>HW="".WK573O&9MK"&&&WN]1NI6N)%^T3(C%4?! )X)YX'7%;$7AW5+JYL6
MUG5+6XMK%O,B@M;1H=S@8!8M(^<#/ QUK//@6Z72X[&._L)XPTK&._TX3Q@N
MV=RC>K*PSC.XCD\4 :&I^,8[&Y2V@L)+B9;<7$R&18S$A]=W4^PJ/4_&T5GI
M\.H6UA)=V;VHNGF\U8PJ=@-WWCUX%4;KX>(QM'M;BUDEAM5M9'U*R%WN"]&&
M6&UO?D>U-U;X=G496*7UJ$>P6S8SV*R-'C=\\6"JH3NYPOITHU T9?&D?]I+
M9VNGRW $<<DC+(JD*_0A3RWX4FH>.+:QU&ZMUM&EMK.1(KJX$JKY;L <!3RV
M RYQZU4U'P+=:C##;OJ-FT*0K$7EL TT6.IAD# H3UYW<T7G@!9=:N;VVGL4
MBNGCDF^TZ>D\RLH"GRY&/R@A1P0W))&,\ '9HRR(KJ<JP!%.IJ*$14'11C_.
M*=3 *DA_UHJ.I(/]:*3 Y?XB^'[S7M*M_L(WRP.6,?\ >!'_ -:N*\-_#C4[
MZ=FU$36$(7&1PY/T]*]J%%7"O.,.1#4VE8\[_P"%3VO_ $&;W\A1_P *HM?^
M@S>_D*]$HI>VJ=Q<\CSO_A5%K_T&;W\A1_PJBU_Z#-[^0KT7%&*/;5.X<[/.
MO^%46O\ T&;W\A1_PJBU_P"@S>_D*]%Q1BCVU3N'.SSK_A5%K_T&;W\A0?A1
M:_\ 09OOR%>BXHQ1[:IW#G9Y/K=C=^"_%%GKEO%)=6?V=()FQS\JA>?<A0:Z
M71/'^G:_JB:?;VTREU)#NO&X<XKKI$25"DBAD/!##(-06^GV=D2;6T@@)Z^5
M&%S^0H=6,H^\M4*]SC#XEU#P_JUQ!K"/- [%HI%' 'M5>WFG\7>*;2ZC@:.R
MM#NW,/O=_P">*[Z:U@NDVSQ)*OHZ@BG1010($B144= HP*/:+HM3SGA9R=I2
MO&]R1NJ_6GTUNJ_6G5D>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 P_ZQ?H:?3#_K%^AI] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 -'^L/TIU-'^L/TIU !1110 4444 %%%% !1110 4444 %%%% !1110
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8?]8OT-/IC??7Z&GT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T?ZP_2G4W^,_2G4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 T?>:G4T??-.H ****
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M[/<_G1L]S^=.HH ;L&<\T;?<TZB@!NSW/YT;/<_G3J* &[/<_G1L]S^=.HH
M;L]S^=&SW/YTZB@!NSW/YT;/<_G3J* &[/<_G1L]S^=.HH ;L]S^=&SW/YTZ
MB@!NSW/YT;/<_G3J* &[/<_G1M]S3J* &[!G/-&SW/YTZB@!NSW/YT;/<_G3
MJ* &[/<_G1L]S^=.HH ;L]S^=&SW/YTZB@!NSW/YT;/<_G3J* &[/<_G1L]S
M^=.HH ;L]S^=&SW/YTZB@!NSW/YT;/<_G3J* &[/<_G1L'J:=10 T*!TIU%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )_!&@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8/X5W/A74=0U+1$EU2SDM+M6*.DB%2V,?-@]N:RE3Y5>]Q-&[1114""BBB@
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M76C07=NNI/:K<'_5&8 G\,]*\WOO ?B?P_J<MSX9G+PR'A4D56 ]PW!I^E>
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M/_H%2?\ ?T?X4?5*W8.5GJ.:,UY=_P +BC_Z!4G_ ']'^%'_  N*/_H%2?\
M?T?X4?5*W8.5GJ.:,UY=_P +BC_Z!4G_ ']'^%'_  N*/_H%2?\ ?T?X4?5*
MW8.5GJ.:,UY=_P +BC_Z!4G_ ']'^%'_  N*/_H%2?\ ?T?X4?5*W8.5GJ.:
M,UY=_P +BC_Z!4G_ ']'^%'_  N*/_H%2?\ ?T?X4?5*W8.5GJ.:,UY=_P +
MBC_Z!4G_ ']'^%'_  N*/_H%2?\ ?T?X4?5*W8.5GJ.:,UY=_P +BC_Z!4G_
M ']'^%'_  N*/_H%2?\ ?T?X4?5*W8.5GJ.:,UY=_P +BC_Z!4G_ ']'^%'_
M  N*/_H%2?\ ?T?X4?5*W8.5GJ.:,UY=_P +BC_Z!4G_ ']'^%'_  N*/_H%
M2?\ ?T?X4?5*W8.5GJ.:,UY=_P +BC_Z!4G_ ']'^%'_  N*/_H%2?\ ?T?X
M4?5*W8.5GJ.:,UY=_P +BC_Z!4G_ ']'^%'_  N*/_H%2?\ ?T?X4?5*W8.5
MGJ.:,UY=_P +BC_Z!4G_ ']'^%'_  N*/_H%2?\ ?T?X4?5*W8.5GJ.:,UY=
M_P +BC_Z!4G_ ']'^%'_  N*/_H%2?\ ?T?X4?5*W8.5GJ.:,UY=_P +BC_Z
M!4G_ ']'^%'_  N*/_H%2?\ ?T?X4?5*W8.5GJ.:,UY=_P +BC_Z!4G_ ']'
M^%'_  N*/_H%2?\ ?T?X4?5*W8.5GJ.:,UY=_P +BC_Z!4G_ ']'^%'_  N*
M/_H%2?\ ?T?X4?5*W8.5GJ.:,UY=_P +BC_Z!4G_ ']'^%'_  N*/_H%2?\
M?T?X4?5*W8.5GJ.:,UY=_P +BC_Z!4G_ ']'^%'_  N*/_H%2?\ ?T?X4?5*
MW8.5GJ6:0L!7EO\ PN*/_H$O_P!_!2K\8(V8+_93\G_GH*/JM7L'*SU'-&:\
MWU+XJ)IVJ7=B=-9S;RM'N$F,X.,U5_X7#'_T"I/^_@_PI+"U6KI!RL]2S1FO
M+O\ A<4?_0*D_P"_H_PH_P"%Q1_] J3_ +^C_"G]4K=@Y6>HYHS7EW_"XH_^
M@5)_W]'^%'_"XH_^@5)_W]'^%'U2MV#E9ZCFC->7?\+BC_Z!4G_?T?X4?\+B
MC_Z!4G_?T?X4?5*W8.5GJ.:,UY=_PN*/_H%2?]_1_A1_PN*/_H%2?]_1_A1]
M4K=@Y6>HYHS7EW_"XH_^@5)_W]'^%'_"XH_^@5)_W]'^%'U2MV#E9ZCFC->7
M?\+BC_Z!4G_?T?X4?\+BC_Z!4G_?T?X4?5*W8.5GJ.:,UY=_PN*/_H%2?]_1
M_A1_PN*/_H%2?]_1_A1]4K=@Y6>HYHS7EW_"XH_^@5)_W]'^%'_"XH_^@5)_
MW]'^%'U2MV#E9ZCFC->6_P#"XH_^@5)_W\'^%'_"XH_^@3)_W\'^%'U2MV#E
M9ZEFC-><:C\4DL)(%_LUG\V%9?\ 68QG/'Z53_X7%'_T"I/^_@_PI+"UFM@Y
M6>IYHS7EW_"XH_\ H%2?]_1_A1_PN*/_ *!4G_?T?X4_JE;L'*SU'-&:\N_X
M7%'_ - J3_OZ/\*/^%Q1_P#0*D_[^C_"CZI6[!RL]1S1FO+O^%Q1_P#0*D_[
M^C_"C_A<4?\ T"I/^_H_PH^J5NP<K/4<T9KR[_A<4?\ T"I/^_H_PH_X7%'_
M - J3_OZ/\*/JE;L'*SU'-&:\N_X7%'_ - J3_OZ/\*/^%Q1_P#0*D_[^C_"
MCZI6[!RL]1S1FO+O^%Q1_P#0*D_[^C_"C_A<4?\ T"I/^_H_PH^J5NP<K/4<
MT9KR[_A<4?\ T"I/^_H_PI/^%Q1_] E_^_@H^J5NP<K/4LT9KRS_ (7%'_T"
MY/\ OX/\*GL_BQ'>7L-O_9C+YC!=WF=*3PM9= Y6>FYHS7F-Q\7([:ZF@.EN
M3&[+GS!S@XJ+_A<4?_0*D_[^C_"G]5J]@Y6>I9HS7EW_  N*/_H%2?\ ?T?X
M4?\ "XH_^@5)_P!_1_A1]4K=@Y6>HYHS7EW_  N*/_H%2?\ ?T?X4?\ "XH_
M^@5)_P!_1_A1]4K=@Y6>HYHS7EW_  N*/_H%2?\ ?T?X4?\ "XH_^@5)_P!_
M1_A1]4K=@Y6>HYHS7EW_  N*/_H%2?\ ?T?X4?\ "XH_^@5)_P!_1_A1]4K=
M@Y6>HYHS7EW_  N*/_H%2?\ ?T?X4?\ "XH_^@5)_P!_1_A1]4K=@Y6>HYHS
M7EW_  N*/_H%2?\ ?T?X4?\ "XH_^@5)_P!_1_A1]4K=@Y6>HYHS7EW_  N*
M/_H%2?\ ?T?X4?\ "XH_^@5)_P!_1_A1]4K=@Y6>HYHS7EW_  N*/_H%2?\
M?T?X4?\ "XH_^@5)_P!_1_A1]4K=@Y6>HYHS7EW_  N*/_H%2?\ ?T?X4?\
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MYC/S'T%/VD>X71FT5:;3;U(9IFM95BA?RY6*G"-Z'T-5:M.^P!1113 ****
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M]W:2B6"0H5=>APB@]?<&L&@4M=,(\L5'L,2BEHJP$HI:3M28&SXB_P!?9?\
M7G'_ #-8U;/B+_7V7_7G'_,UCU%/X0$HI:*T EM'6.\@=SA5D4D^@S7?7.HZ
M7%XW;Q&-3MI+>%-R0IN,DC;-H&, #KU]J\[HKGJ4>=WN#/0[/Q+:06&AF*^A
MAN(IY&E$D9=4# _> QQSVJR/$.A07^FSF9$E:*5)EMI7:"%FQAD5ON]SQBO,
MZ*R^J1ON*QW.C:G8Z#J\#SZV;R*3S$41[BML6R _/?GG Z$TU->MM#T?3[2&
MXBN[J&[,Y>(G;&I/3)'4]ZXBBJ^K1;U86/3+KQ9HUIXATB.R?=IL3R3S.O\
MSTD)Z_[O]:;;Z_IMGJ>EQ?:[%;6*[>=C )3LR",EG8]<] *\UHJ?J<>X6/1_
M"E[:ZCX@UJRGS-8SR-=*V. 5.=WY5Q.O:@=4UV\O"01+*=N/[HX'Z"HK35;Z
MP@E@M;AHHYAM<+CD?7K5.M*='EFY!8**6BND8E7]%_Y#5G_UU%4*OZ+_ ,AJ
MS_ZZBIE\+ BU/_D*WG_79_YFJM6]3_Y"MY_UW?\ F:JTX[(!**6BF E%+10
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MF9Y-_P *EU#_ *"-O_WR:/\ A4NH?]!&W_[Y->LT4?7:W<.9GDW_  J74/\
MH(V__?)H_P"%2ZA_T$;?_ODUZS11]=K=PYF>3?\ "I=0_P"@C;_]\FC_ (5+
MJ'_01M_^^37K-%'UVMW#F9Y-_P *EU#_ *"-O_WR:/\ A4NH?]!&W_[Y->LT
M4?7:W<.9GDW_  J74/\ H(V__?)H_P"%2ZA_T$;?_ODUZS11]=K=PYF>3?\
M"I=0_P"@C;_]\FC_ (5+J'_01M_^^37K-%'UVMW#F9Y-_P *EU#_ *"-O_WR
M:/\ A4NH?]!&W_[Y->LT4?7:W<.9GDW_  J74/\ H(V__?)H_P"%2ZA_T$;?
M_ODUZS11]=K=PYF>3?\ "I=0_P"@C;_]\FC_ (5+J'_01M_^^37K-%'UVMW#
MF9Y-_P *EU#_ *"-O_WR:/\ A4NH?]!&W_[Y->LT4?7:W<.9GDW_  J74/\
MH(V__?)H_P"%2ZA_T$;?_ODUZS11]=K=PYF>3?\ "I=0_P"@C;_]\FC_ (5+
MJ'_01M_^^37K-%'UVMW#F9Y-_P *EU#_ *"-O_WR:/\ A4NH?]!&W_[Y->LT
M4?7:W<.9GDW_  J74/\ H(V__?)H_P"%2ZA_T$;?_ODUZS11]=K=PYF>3?\
M"I=0_P"@C;_]\FC_ (5+J'_01M_^^37K-%'UVMW#F9Y-_P *EU#_ *"-O_WR
M:/\ A4NH?]!&W_[Y->LT4?7:W<.9GDW_  J74/\ H(V__?)I4^$VH*X/]I6_
M!_NFO6*.]+ZY5?4.9GF6K_#&^U#5[V\2_MU6>9Y I4Y&3FJ?_"I=0_Z"-M_W
MR:];?[[?6FT+&54K)AS,\F_X5+J'_01M_P#ODT?\*EU#_H(V_P#WR:]9HI_7
M:W<.9GDW_"I=0_Z"-O\ ]\FC_A4NH?\ 01M_^^37K-%'UVMW#F9Y-_PJ74/^
M@C;_ /?)H_X5+J'_ $$;?_ODUZS11]=K=PYF>3?\*EU#_H(V_P#WR:/^%2ZA
M_P!!&W_[Y->LT4?7:W<.9GDW_"I=0_Z"-O\ ]\FC_A4NH?\ 01M_^^37K-%'
MUVMW#F9Y-_PJ74/^@C;_ /?)H_X5+J'_ $$;?_ODUZS11]=K=PYF>3?\*EU#
M_H(V_P#WR:/^%2ZA_P!!&W_[Y->LT4?7:W<.9GDW_"I=0_Z"-O\ ]\FC_A4N
MH?\ 01M_^^37K-%'UVMW#F9Y-_PJ74/^@C;_ /?)H_X5+J'_ $$;?_ODUZS1
M1]=K=PYF>;:G\+[^_DMW2^@7RX%B.5/.,_XU1_X5!J?_ $$;?_ODU[$GW!]*
M=26,JK2X<S/&_P#A3^I_]!&W_P"^31_PI_4_^@C;_P#?)KV2BCZ[6[AS,\;_
M .%/ZG_T$;?_ +Y-'_"G]3_Z"-O_ -\FO9**/KM;N',SQO\ X4_J?_01M_\
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M_P!!&W_[Y-'_  I_4_\ H(V__?)KV2BCZ[6[AS,\;_X5!J?_ $$;?_ODT?\
M"H-3_P"@C;_]\FO9**?UVMW#F9XW_P *?U/_ *"-O_WR:/\ A3^I_P#01M_^
M^37LE%+Z[6[AS,\;_P"%/ZG_ -!&W_[Y-'_"G]3_ .@C;_\ ?)KV2BCZ[6[A
MS,\;_P"%0:G_ -!&W_[X-'_"H-3_ .@C;_\ ?)KV2BCZ[6[AS,\;_P"%/ZG_
M -!&W_[Y-'_"G]3_ .@C;_\ ?)KV2BCZ[6[AS,\;_P"%/ZG_ -!&W_[Y-'_"
MG]3_ .@C;_\ ?)KV2BCZ[6[AS,\;_P"%/ZG_ -!&W_[Y-'_"G]3_ .@C;_\
M?)KV2BCZ[6[AS,\;_P"%/ZG_ -!&W_[Y-'_"G]3_ .@C;_\ ?)KV2BCZ[6[A
MS,\;_P"%/ZG_ -!&W_[Y-'_"H-3_ .@C;_\ ?!KV2BG]=K=PYF>4Q_"_4$T:
M>Q-] 7DE60-M.!@51_X5!J?_ $$;?_O@U[$?OBG4OKE5=0YF>-_\*?U/_H(V
M_P#WR:/^%/ZG_P!!&W_[Y->R44?7:W<.9GC?_"G]3_Z"-O\ ]\FC_A3^I_\
M01M_^^37L=%'UVMW#F9XY_PI_4_^@C;_ /?)H_X4_J?_ $$;?_ODU[)11]=K
M=PYF>-_\*?U/_H(V_P#WR:/^%/ZG_P!!&W_[Y->R44?7:W<.9GC?_"G]3_Z"
M-O\ ]\FC_A3^I_\ 01M_^^37LE%'UVMW#F9XW_PI_4_^@C;_ /?)H_X4_J?_
M $$;?_ODU[)11]=K=PYF>-_\*?U/_H(V_P#WR:/^%/ZG_P!!&W_[Y->R44?7
M:W<.9GC?_"H-3_Z"-O\ ]\FC_A4&IC_F(6__ 'R:]DHH^NUNX<S,;PSI,FB:
M#;:?+(LCPJ0648!YK9[445R-MN[)"BBB@ HHHH **** *DGWVIM)=2I;QRS2
M'"1J68^P&37,>$/&EOXL-VL=K);/;D85VSYB'.&'MQ346TWV%=7L=1150:II
M_P#S_6I[_P"M7I^=2?;K3R%F^U0>4S;5D\P;2?0&BS"Z)Z*R=7UM;#2'O[.%
M;_:X7RXIE'4XZGCBK\EY:PRK#+<1)*W1&< GZ"CE871/16/<^)=.AU"ZTZ*5
M)=0M[=IS & )P.%R>YJ:QUB*?2K6]O/+L6N%#>7+*ORGTST/X4W%A=&E15'5
MM332M%N=2V><D$1EVJ?O#V-<@?BC9#P2WB+[!)N680_9/,&[=D=\>G/3M3C3
ME+5(3DEN=[167IFNVM_HNGZE*\=J+V!)DCEE (W ''OUJW-?V=NVV:[@C.,X
M>0 XJ;,=T6:*J-J5KY<S13Q3-$A9D20$\5G^&O$UIXDT:VOTV023J6^SM*&=
M0#C^GI3Y7:X71MT57&H63%PMW;G8NYL2CY1ZGGBA;^S:$SK=P-"#@N)!MSZ9
MS2LPNBQ14,5W;3*[17$4BI]\JX(7Z^E+!=6]R"UO/'*!P3&X;'Y46"Z):*Y;
MQ7XVMO"UY96TMK)</<\OL8#RDSC<>.F:NZGXEAT[6-%T\0-*-49PD@? 0*N[
M..^:KDD+F1N45A>'O$]MKNA_VI(BV<7FO%B608RIQUXK7-W;+;BX-Q"(#TD+
MC;^=2TT.Z9-15<7]F8VD%U 8U(#-Y@P">F3FFG4K$1K(;VV",2%8RK@GV.>:
M+,=T6J*YK5O&%MINOV>DQI%-)/$TTCM.(UB08Y[YSG./:M72-:L-=M#<Z?.)
M8@Q0D'N*;A)*[0E)/0T****D84444 %%%% !1110 4444 %%%% !1110 4#K
M10.M #G^^WUIM.?[[?6FT %%%% !117/W/BF.TAUMYK5E.EX)4/DR@J&!'''
M6@#H**YZ'Q4D]MHDD=HYDU.0QF+>,P%0V_)QS@KC\:VH[VUE:18[F%S'RX60
M$K]?2@">BHOM5OA3Y\6&7>IWCD>H]1[TV"]M+IBMO=0RL!DK'(&('KQ0!/16
M,WB2T/B"TTF QSM<([&2.4$)M&<$"C5]=>QOK;3K&R:^U"=3((?,"*B#@LS8
M.!G@<=C0!LT5E:9K/VRVN'O+<V$UJVR=)7RH]P_ (]ZNC4+(P>>+RW,.<>9Y
MHVY^O2@"Q15<W]FKQJ;N -*,Q@R %Q[>M6* "BBB@ HHHH M)]P?2G=*1/N#
MZ5ROC/QSIW@NSCEO%>6:4D1PIP6_'L*:3D[(3:6K.KH_"N'\)?$W1?%4<P#?
M8IXL%H[AP,@^A[]*ZG^VM+_Z"5G_ -_U_P :<H2B[-"4D]F:%%9_]M:9_P!!
M*S_[_K_C1_;6F?\ 02L_^_Z_XTK,=T:%%9_]M:9_T$K/_O\ K_C1_;6F?]!*
MS_[_ *_XT6871H45G_VUIG_02L_^_P"O^-']M:9_T$K/_O\ K_C19A=&A16?
M_;6F?]!*S_[_ *_XT?VUIG_02L_^_P"O^-%F%T:%%9_]M:9_T$K/_O\ K_C1
M_;6F?]!*S_[_ *_XT6871H45G_VUIG_02L_^_P"O^-']M:9_T$K/_O\ K_C1
M9A=&A2-]TU0_MK3/^@E9_P#?]?\ &@ZSIA4_\3*S_P"_Z_XT6871>7[H^E.K
M/&LZ9@?\3*S_ ._Z_P"-']M:9_T$K/\ [_K_ (T6871H45G_ -M:9_T$K/\
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MS"Z-"BL_^VM,_P"@E9_]_P!?\:/[:TS_ *"5G_W_ %_QHLPNC0HK/_MK3/\
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ME_SUU+_O^O\ \37IU%3[6IW'[./8\Q_X43X2_P">NI?]_P!?_B:/^%$^$O\
MGKJ7_?\ 7_XFO3J*/:U.X>SCV/,?^%$^$O\ GKJ7_?\ 7_XFC_A1/A+_ )ZZ
ME_W_ %_^)KTZBCVM3N'LX]CS'_A1/A+_ )ZZE_W_ %_^)H_X43X2_P">NI?]
M_P!?_B:].HH]K4[A[./8\Q_X43X2_P">NI?]_P!?_B:/^%$^$O\ GKJ7_?\
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MZ !_OM]:;3V4ER<CKZTFP^H_.@!M%.V'U'YT;#ZC\Z &T4[8?4?G1L/J/SH
M;13MA]1^=&P^H_.@!M%.V'U'YT;#ZC\Z &T4[8?4?G1L/J/SH ;13MA]1^=&
MP^H_.@!M%.V'U'YT;#ZC\Z &T4[8?4?G1L/J/SH ;13MA]1^=&P^H_.@"RGW
M!]*=35^Z*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %(WW32TC?=-
M  OW1]*6D7[HI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :?]8/I3J:1\XIU
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %23_6-3:=)]]J;0 4444 %%%% !1110 4444 %%%% !11^%% !1110
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M+H_X4]X&_P"@*?\ P*F_^+H_=>8>^:__  G_ (2_Z&33/_ E?\:/^$_\)?\
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M  GWA+_H8],_\"%_QH_X3[PE_P!#'IG_ ($+_C61_P *>\#_ /0&;_P*F_\
MBZ/^%/>!O^@*?_ J;_XNK_=>9/OFO_PG_A+_ *&33/\ P)7_ !H_X3_PE_T,
MFF?^!*_XUD?\*>\#?] 4_P#@5-_\71_PI[P-_P! 4_\ @5-_\71^Z\P]\U_^
M$_\ "7_0R:9_X$K_ (T?\)_X2_Z&33/_  )7_&LC_A3W@;_H"G_P*F_^+H_X
M4]X&_P"@*?\ P*F_^+H_=>8>^:__  G_ (2_Z&33/_ E?\:/^$_\)?\ 0R:9
M_P"!*_XUD?\ "GO W_0%/_@5-_\ %T?\*>\#?] 4_P#@5-_\71^Z\P]\U_\
MA/\ PE_T,FF?^!*_XT?\)_X2_P"ADTS_ ,"5_P :R/\ A3W@;_H"G_P*F_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML;^Z:-C?W329/K1D^M "[&_NFC8W]TTF3ZT9/K0 NQO[IHV-_=-)D^M&3ZT
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MBBB@ HH_2B@ HH/ )/ '<U7M+ZTOT9[.Z@N%5MK-#(' /H<=Z +%%'';FB@
MHJ&XN[:SC$EU<10(6"AI'"@D]!D]ZFHL 44R66.")Y99$CB12S.QP% ZDD\
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M12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC%
M"44N*,4 )12XHQ0 E%+BC% "44N*,4 )0.M+BD[T .?[[?6FTY_OM]:3% "4
M4N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0
ME%+BDQ0!;3[@^E.IJ?<'TIU !1110 4444 %%%% !1110 4444 %%%% !111
M0 4C?=-+2-]TT "_='TI:1?NCZ4M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD60%K)/%I,%Q,][=^47R@X3(.YCUK0G^(MU+/,--TR&6*+3!J1>><H=N2"N
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MJAA9VE8(T3'.,]""!C]:)4G&-V)33=CJJ***S+"BBB@ HHHH **** "BBB@
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M+N_N"\^QWO\ ;ND?]!6Q_P# A/\ &C^W=(_Z"MC_ .!"?XUP7_"C?"7KJ/\
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M@K8_^!"?XT?V[I'_ $%;'_P(3_&N"_X4;X2]=1_\"!_\31_PHWPEZZC_ .!
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M (4;X2_O:C_X$#_XFC_A1OA+UU'_ ,"!_P#$T[4N[^X5Y]CO?[=TC_H*V/\
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M*Z:]95+%XV!7Y<;=O'3&*C@\"6\<C2R:C<S2/?1WSLP49D4>PX!]!T[5UM%
M'-7OA$7&JW5]::G<6(O"ANHX54^:5X!#$94D8!QC@"NC1=B!02<#&2<FG44
M%%%% !1110!;3[@^E.IJ?<'TIU !1110 4444@"BBB@ HHHH **** "BBB@
MHHHH *1ONFEI&^Z:8 OW1]*6D7[H^E+0 4444@"BBB@ HHHH **** "BBB@
MHHHH ****8!1110 4E+10 4444 )12T4 %%%% !1112 **** "BBB@ HHHH
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M[X^E.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH J2??:FTZ3_6-3: "B@44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44?6B@ HHHH *
M*** "BBB@ H[T4#K0 Y_OM]:;3G^^WUIM !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% %M/N#Z4ZFI]P?2C=0 ZBDW4HY% !1110 4444
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MABG@'GZLEPLW/ER*A!.TXY'8&M[Q-X)U36=3O9H+FS:WNK5;<+<ELP'&"R
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M_OPO_P 77H?]CZ;_ - ZT_[\K_A1_8^F_P#0.M/^_*_X5E>GV?WCM/N>>?\
M"]O"?_/'4_\ OPO_ ,71_P +V\)_\\=3_P"_"_\ Q=>A_P!CZ;_T#K3_ +\K
M_A1_8^F_] ZT_P"_*_X47I]G]X6GW///^%[>$_\ GCJ?_?A?_BZ/^%[>$_\
MGCJ?_?A?_BZ]#_L?3?\ H'6G_?E?\*/['TW_ *!UI_WY7_"B]/L_O"T^YYY_
MPO;PG_SQU/\ [\+_ /%T?\+V\)_\\=3_ ._"_P#Q=>A_V/IO_0.M/^_*_P"%
M']CZ;_T#K3_ORO\ A1>GV?WA:?<\\_X7MX3_ .>.I_\ ?A?_ (NC_A>WA/\
MYXZG_P!^%_\ BZ]#_L?3?^@=:?\ ?E?\*/['TW_H'6G_ 'Y7_"B]/L_O"T^Y
MYY_PO;PG_P \=3_[\+_\71_PO;PG_P \=3_[\+_\77H?]CZ;_P! ZT_[\K_A
M1_8^F_\ 0.M/^_*_X47I]G]X6GW///\ A>WA/_GCJ?\ WX7_ .+I/^%Z^$R#
M^YU/_OPO_P 77HG]CZ;_ - ZT_[\K_A2'1]-P?\ B76G_?E?\*+T^S^\+3[G
MGO\ PO7PF /W.I_]^%_^+H_X7MX3_P">.I_]^%_^+KT(:/IN!_Q+K3_ORO\
MA2_V/IO_ $#K3_ORO^%%Z?9_>%I]SSS_ (7MX3_YXZG_ -^%_P#BZ/\ A>WA
M/_GCJ?\ WX7_ .+KT/\ L?3?^@=:?]^5_P */['TW_H'6G_?E?\ "B]/L_O"
MT^YYY_PO;PG_ ,\=3_[\+_\ %T?\+V\)_P#/'4_^_"__ !=>A_V/IO\ T#K3
M_ORO^%']CZ;_ - ZT_[\K_A1>GV?WA:?<\\_X7MX3_YXZG_WX7_XNC_A>WA/
M_GCJ?_?A?_BZ]#_L?3?^@=:?]^5_PH_L?3?^@=:?]^5_PHO3[/[PM/N>>?\
M"]O"?_/'4_\ OPO_ ,71_P +V\)_\\=3_P"_"_\ Q=>A_P!CZ;_T#K3_ +\K
M_A1_8^F_] ZT_P"_*_X47I]G]X6GW///^%[>$_\ GCJ?_?A?_BZ/^%[>$_\
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ME?\ "B]/L_O%:?<\\_X7MX3_ .>.I_\ ?A?_ (NC_A>WA/\ YXZG_P!^%_\
MBZ]#_L?3?^@=:?\ ?E?\*/['TW_H'6G_ 'Y7_"B]/L_O"T^YYY_PO;PG_P \
M=3_[\+_\71_PO;PG_P \=3_[\+_\77H?]CZ;_P! ZT_[\K_A1_8^F_\ 0.M/
M^_*_X47I]G]X6GW///\ A>WA/_GCJ?\ WX7_ .+H_P"%[>$_^>.I_P#?A?\
MXNO0_P"Q]-_Z!UI_WY7_  H_L?3?^@=:?]^5_P *+T^S^\+3[GGG_"]O"?\
MSQU/_OPO_P 71_PO;PG_ ,\=3_[\+_\ %UZ'_8^F_P#0.M/^_*_X4?V/IO\
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M^-'_  KGX@?]%!N/^^Y/\:/9Q_F7XAS/L>MYHS7DG_"N?B!_T4&X_P"^Y/\
M&C_A7/Q _P"B@W'_ 'W)_C1[./\ ,OQ#F?8];S1FO)/^%<_$#_HH-Q_WW)_C
M1_PKGX@?]%!N/^^Y/\:/9Q_F7XAS/L>MYI">#7DW_"N?B!_T4"X_[[D_QII^
M'/C_ !_R/]S_ -]R_P"-'LX_S+\0YGV/6P?E%+FO)!\.?'^/^2@7/_?<O^-+
M_P *Y^('_10+C_ON3_&CV<?YE^(<S['K6:,UY)_PKGX@?]%!N/\ ON3_ !H_
MX5S\0/\ HH-Q_P!]R?XT>SC_ #+\0YGV/6\T9KR3_A7/Q _Z*#<?]]R?XT?\
M*Y^('_10;C_ON3_&CV<?YE^(<S['K>:,UY)_PKGX@?\ 10;C_ON3_&C_ (5S
M\0/^B@W'_?<G^-'LX_S+\0YGV/6\T9KR3_A7/Q _Z*#<?]]R?XT?\*Y^('_1
M0;C_ +[D_P :/9Q_F7XAS/L>MYHS7DG_  KGX@?]%!N/^^Y/\:/^%<_$#_HH
M-Q_WW)_C1[./\R_$.9]CUSBCBO(_^%=>/_\ HH%Q_P!]R?XT?\*Z\?\ _10+
MG_ON7_&CDC_,@YGV/6QS5>^O(-/LY;NZD$<$2EG<CH*\TTWP%XWM-5L[FZ\<
MW%Q;Q3I)+"7DQ(H8$KR>X!%>CZC/+;6$TT-JUU(JY$*, 7]AFI<4G9.Y2;:,
MF+QEHDVGS7R7+[(I!$T9A<2[R 0!&1N)(.1@<BGMXNT./2(M5DOE2TFD$2%T
M8,7)QMVD;L^V.*X*ZT+5;Z6YOX["_@LAJ45R(\%;MAY95R#U(!( YZ9Q5G4_
M#>I:GX&AFN[*>YU6"X06WF\S)#YJGYO]K .3UQ5\D;K4GFD>AZGJUEH]D+N^
MD,4)=4W!"W)X' %02^(=+M[R\MIKQ8GLX1/.7!540YP=QX['BLGQ]IUUJGA7
M[+:02RRF>(E8_O  \G\*Y?4_!^I/JNO)9K>31R6ULT4ES,S^:T<NYDW,3V'3
MWI1C%K5C<FGHCM8?&.DS^8(VO/,C7>86LIED9?54*[F'N :33?&&CZM%<2VC
MW1BMPQEDDLY8T7;U&64#(].M/TO59[Z;R3H]W;(D7,UPFSYO[H'4_6N:TC2=
M4M_"-]8/9S1S76J2G!7I&TI;=]"!^M+E5M0NS;?Q[X?2=XWN;@"-TCDE-I+Y
M49?&W<^W:N=PZFNH4AE!!R".M>;6_@R[U/5O$5O>3W-II5Q>1.(5C7%PB!3P
MQ&0,C'!KMM9LKJ\T*ZLK"Z-I<R1&.*<$YC/8\<TFDM$.+?4U.*.*\C'PZ\?X
M_P"2@7'_ 'W+_C1_PKKQ_P#]% N/^^Y/\:KDC_,B>9]CUO-&:\D_X5S\0/\
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M?A/[_P"E&$_O_I0 RBGX3^_^E&$_O_I0 RBGX3^_^E&$_O\ Z4 ,HI^$_O\
MZ483^_\ I0 RBGX3^_\ I1A/[_Z4 ,HI^$_O_I1A/[_Z4 ,HI^$_O_I1A/[_
M .E #**?A/[_ .E&$_O_ *4 ,HI^$_O_ *483^_^E #**?A/[_Z483^_^E #
M**?A/[_Z483^_P#I0 RBGX3^_P#I1A/[_P"E #**?A/[_P"E&$_O_I0 R@=:
M?A/[_P"E)A>S'\J !_OM]:;3V"[CEN<^E&$_O_I0 RBGX3^_^E&$_O\ Z4 ,
MHI^$_O\ Z483^_\ I0 RBGX3^_\ I1A/[_Z4 ,HI^$_O_I1A/[_Z4 ,HI^$_
MO_I1A/[_ .E #**?A/[_ .E&$_O_ *4 ,HI^$_O_ *483^_^E #**?A/[_Z4
M83^_^E #**?A/[_Z4F$_O?I0!93[@^E.I@)"C R,=:7+_P!W]: '44W+_P!W
M]:,O_=_6@!U%-R_]W]:,O_=_6@!U%-R_]W]:,O\ W?UH =13<O\ W?UHR_\
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MEF(!* =L9 _.E\$Z;=V;ZS>7-L]K%?7C306\@PR+[CMFN5L=#N=2TSQ=ID8
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M2E4=.7-8B<>96/G?P#X1\>7.D23Z1J[:/:N^0DVX>8<?> P?:NN_X0GXH_\
M0[0_]]-_\17K6,=J4=*J5>4G>R)5-)6N>2?\(3\4/^AVA_[Z;_XBC_A"?BA_
MT.T/_?3?_$5ZY12]M+LON'[-'D?_  A/Q0_Z':'_ +Z;_P"(H_X0GXH?]#M#
M_P!]-_\ $5ZY11[:79?<'LT>1_\ "$_%#_H=H?\ OIO_ (BC_A"?BA_T.T/_
M 'TW_P 17KE%'MI=E]P>S1Y'_P (3\4/^AVA_P"^F_\ B*/^$)^*'_0[0_\
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M/RFGTC?=- #0W ^4TN__ &32K]T?2EH ;O\ ]DT;_P#9-.HH ;O_ -DT;_\
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MFG44 -W_ .R:-_\ LFG44 -W_P"R:3=_LM^5/HH 0'/:EHHH **** "BBB@
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MSS?_ (4CX._YXWO_ ($'_"C_ (4CX._YXWO_ ($'_"O2**KVM3N+V<>QYO\
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MK&QO2C8WI0!3CTRPB@,$5E;)"6#&-8E"DCD'&,9R!3Y+.UE\SS+>%_- $FY
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H%%
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M5=6N?"/BO4IM4F<V<[PPPLD;1@9&,@KSCW_6G6T&K7'BS6WL]4NHKE-)AD@
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MA&T5L"['8K !AR><X'7-6M-TNUTBS6TLD=(%)*J\C/MSU +$G'MTH MT444
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MZA0#^5/V]*=1*?,.,;"T445!04444 )VJIJ&FVNJV3VMY")(G&"IJY12O;5
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M =GWHS[TW8O]T4;%_NB@!V?>C/O3=B_W11L7^Z* '9]Z,^]-V+_=%&Q?[HH
M=GWHS[TW8O\ =%&Q?[HH =GWHS[TW8O]T4;%_NB@!V?>C/O3=B_W11L7^Z*
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AH =GWHS3=B_W11L7^Z* '44@ '04M !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_003.jpg
<TEXT>
begin 644 form10-k_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Q \\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#,_M;_IE^M']K?],OUK,HH T_[6_P"F7ZT?VM_TR_6L
MRB@#3_M;_IE^M']K?],OUK,HH T_[6_Z9?K1_:W_ $R_6LSG% ]* -/^UO\
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M;_OFCV<@^LT^YZ%_:W_3+]:/[6_Z9?K7GO\ PLW0/2;_ +YH_P"%FZ!Z3?\
M?-'LY!]8I]ST+^UO^F1H_M;_ *95Y[_PLW0/[LW_ 'S1_P +-T#^[-_WS1[.
M0?6*?<]"_M;_ *9?K1_:W_3+]:\]_P"%FZ!Z3?\ ?-'_  LW0/2;_OFCV<@^
ML4^YZ%_:W_3+]:/[6_Z95Y[_ ,+-T#^[-_WS1_PLW0/2;_OFCV<@^L4^YZ%_
M:W_3+]:/[6_Z9?K7GO\ PLW0/2;_ +YH_P"%FZ!Z3?\ ?-'LY!]8I]ST+^UO
M^F7ZT?VK_P!,OUKSW_A9N@>DW_?-'_"S= ])O^^:/9R!XFFNIZ%_:W_3(T?V
MK_TR_6O/?^%FZ!Z3?]\FC_A9N@>DW_?)H]G(/K-/N>A?VM_TR_6C^UO^F7ZU
MY[_PLW0/2;_OFC_A9N@>DW_?-'LY!]9I]ST+^UO^F1H_M;_IE^M>>_\ "S=
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M5JB@"'[':[<&V0C&W!':BVLK2R#"U@2+=RVT8S4U% !1110 4444 %%%'\J
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MZ=J\3^*EP=3^)#PJ=P4I&!^-?4OAJT6R\-:=;JNT) N1[XH UA2TW'%'^30
MZBF]:!C- #J*;S1G(S0 ZBFC)[8H/'..: '44F>>*3)% #J*:<CIS[44 .HI
MISU[^E.'2@!#TKA_BOH*:YX#O4\O?- OF1^V*[DU4OX1<Z?<P$9$D3+C\* /
MB_PM<&*[D@?^(8Q[UVNFP)<:K:6\GW))0K?2N)EA;2O&-S;G@I.R_K78PS-;
MSQSQ_P"L0[A]:]O!2<J?*=M!WA8]!N? ]C%<%8W+0.X59.PKF?$^E0:+=0VE
ML-Z_\]^S?2JO_"2:F(3#YQ*;MY^IJK<ZE<WEM';SMN2(Y0]Q6\:=1/5FJ3-6
M\LK.PFMK%H6D>0*3*/4U:U72;/R]16&/RVL<$'^^".]8O]LW1@6-MC,HPLA'
M('I2WNMW=[&T;[4$G^L*CEJKEDY:#LRYH>GVVJV,\'EL;I1N0^OL*T-0\)^7
M:Z3%:N/M-T2)6;@*?2L"UU:ZL[8PVY5/1Q]X4MQK5_<V\,4L[E83E"#SFB4)
M\V@6=R>VT1O^$A&EW# 88[F4YSBK$.EKK>IR65C$+=H7*M(W3 [UC1W,\=PM
MPLK><IR'[FKPUV[2X$T86,_Q!?X_7-.<9]!M,W;+PFL+2QWK+(X;Y'3H156R
MT&&].J1)\LD,@2(GH,UF+KU\CN4?:'.<?W:BBU>\A\_8^//8,_N14J%2Y-I&
MO+X*O;>5XIKN,*IQYFW()(SBII?"+O;V4$;K'<R+F1S]T\UF'Q/J3,2S@I_<
M/0'UI$\2ZE&5)<.%&W!'44<M7N%IFU%X*:W;;<SJ9ED9-HZ' S5 ^#[MF4+/
M&)7P53'(!-53XGU+>SLZDDELGMGBF?\ "1:B$5?,&5QA^^!VI<M;N%IC]9\.
M3:+ DDDZ3(TA0[1C#"L?.>O)]:NWNK7=_#Y4[[EWE_Q-4JZ()I>]N:J_4***
M*L HHHH **** "BBB@ HHHH **** "@=:.U !/ J9245J2VNHX.2NT^O6NUF
ME_L.PTQ;+2UNA<H3*VW.[VKC=H"XK4L_$>I6%N((9=R#[@89V?2OG,1.,I^Z
M>?4MS:'6:?%%_P (TUW^XL)GF.?,B+8'I61J-LDO@^:Y2,2S^?CS8TQD?2LJ
M'Q+J,$30L4D1FW$.,\UJ>&KW5=9OCID$L4,,A+,S+\JFN<R*DUDO_"O+686[
M&<RX+!>:Q]&NY++5X&$*MO8*RN.U=EI_]IF34[6XOX+:UL&^=VCW!O<"LQ_"
MMQ>W@O;34(Y8G0S0RJN-Q';% '0W,%KJ%]K%A*D%I#';ADFV<(?6G:)H6FP6
M&G;)8+T%FS.J<=/2N:@L=8U"V:ZDN4C>_?[,R,.2!WJYI^DZSI^NVOA^SOX\
M;2\4N/E;CI0!=LHX;CQ1:P2W-M=19<E4A*A<#O2>(=.3^Q),B"[>XG$=O+;I
MCR^>0:I26FO+YMP/*BN89C#M5<$D\9S4<=I<Z3:7$5KKD,MPD@::U88V-[&@
M#7USPVB:';+'9QJUJ8]S(P+/G[V12ZY<Z)IGGQW4ML_^CJ8;9(\,K8[FLBXT
MZ719I9YO$+F[N4#M%Y)(Y[9J+4/"0O+Z,W&M1-JD\(9(/+ZC' S0!:U";2K?
MPHNNPV@^UW2^3LQPA]:/A[I]JUO<7.H0ADE.V)BN=S>E<?=7=VEL=*GXA@<_
M)[BIM.\0:AI=NT%K+^Z)R%/\)]10!-XHTR?2]?GBFMOLZN=T<9["L;J,'O5W
M4=5O=8G$]_.TT@& S>E4J .N\&^,IM#G6SNV+V;''/\ #7L,,T5S D\#!HW&
M00<U\WG!'-=AX.\93:'.MI=L7LW..?X* /8Z*9#-%<P+/;N'C89!%/\ ;K0
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M;(\4Z;-<)# 6;=D;V3[I%-LO%%A.\@N#L=,D-MX(% '-6KZU<7K275U.\*R
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MD6%5: VV3D>],GU/P\^I6FNB]G:6UB""'RC@L!ZULR01?:([<+'<J;1V6[V
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MG X)Q7H!TAM39EO[N.&T^T;43 &Y>V#2-X:T>"[E,FPA(R0N[@\\&H]HA7.
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M]*Z:=!)W&D=EX#\=-:F/2M5ES$>(Y#VKU<$,H="&5N0PZ$5\PXY!]^/:O1_
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MQHERVU+OE-QZ,.U>XE4D4QR &-UVL#WKYE\<:-=^!?'0O+52D9D\Z!ATZ]*
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MUAANQI".</2F&I[B!X)"CC@=#4!H 8>M-IQZTV@!AIIIQIIH 91110 4444
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M3** '>;+VE<?0T&65L[IG;/7)ZTVB@!RR2HNU975?[H/%'FR\?OGP.@S3:*
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M.?\ N4?8Y_[E $%%3_8Y_P"Y1]CG_N4 045/]CG_ +E'V.?^Y0!!14_V.?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!#TXJK?6:7UI);R$A7&,@\@U;HI ?/?C/3=<\):AAKJ=[*0YBE#''T-<C
M+JTT[^9+*TC^K'-?46K:3::U8265[$LD,@QSU!]17SGXT\&7GA+4"I4R6,AS
M%,!^AKOP]2.S*3,;^T&]:/M[>M4?PHSCVKOY4AFE#K%Q:Y,$SQ%NI4XS7?>
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MQZ?I,VYKF2/S-[<Y7ZT =OSV-.IO)XIU !1110 4444 %%%% !1110 4444
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M?E5\=_6@<T 9]YH]E?2"2XAWMTXX!^M2?V79^0D)MX_+C^ZN.!5S/7%&<=J
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MA=>(=2>"*1DL8FP%!^_7)X ' 'T]*1?NC]:6OHJ5-1C9%A^-%%%:7&%%%%,
MHHHH ****8!1112 **** "BBB@ HHHH **** "BBB@ HHHI7 ****8!1112N
M 4444P"BBB@ HXHHI@)Q2T4O;I4W 2BBBBX!BC% Z]*,47 ,48H%'K1H,***
M,9IZ""BBB@ HHHH **** "BBBA, HHHI@'X9%%%%+4 HHHH ****  X;K75>
M"?&%SX<U*.&61GL9#AE8_=]ZY6D894X_.LJD%.+3!H^J+>9+B))HV#1NH92*
MFKC/AIJ;:AX5B1V+/ =F37:&OG91Y9-&;"BBBD 4444 %%%% !1110 4444
M%%%% !7@/CO_ ).#TC_KE%7OU> ^._\ DX/2/^N45 'OU%%% !1110 4444
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M% !1110 4444 %%%% !1110 5X#X[_Y.#TC_ *Y15[]7@/CO_DX/2,?\\HJ
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M#=6^DR:Y:W5M%%+8^7Y;;2 0?6F7-A:V%C>21NDTDA&QT8 @"N 5W485V ]
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MU&<I)%&!GV-<]X$^"$?AO6X]6U*\%P\/,48' /J: /2?%DTUOX3U*>WD*2I
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M UO:CX+2^\/:;IZW9BN].VFWN@.05[XKE_$W@B]M?"VI7#3RZIK-TRAIE3!
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M_*&T_5:F\'^"T\+?:IFN?/NKILR,J[%_ #I0!U@IU,48X[4^@ HHHH ****
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M$V?_ %TK;#_Q$"W/'Z,9HHKZ(T-K3/%&H:9"ENC!X@>C=JW]<\7W-O#;&TC
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M3Q=,OAQKN2,>?OVKCH:]!\4::OB/PGM7&XH) ?0XKQ35KB+]W96X_=0#!/\
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MN0X->+5HN+4"6C;\4<^%]0(/_+)B#6%X+U*VU'P*L<\R;HXV60,>@J_>$O\
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M$AP?7FNG\?W%O_PD#W&E7Q:.=<R")N,^]<A_6O9PM/E]Y]2T%%%%=PPHHHH
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MH-4QGL?P=_Y =Y_UV->E]Z\T^#O_ " [S_KL:]+[U\]7_B,AA1116(@HHHH
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M_H?_ "'[+_KJ/YU0J_H?_(?LO^NH_G6=3X&![/\ %#_D3C_OK5ZX_P"2=_\
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MG7O^0_>_]=#_ #K/^M:&O_\ (P7O_70_SK/KW*2]Q%#X%!N[?(!PXQ7O'B
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M#XR\<:?X@M;:*VC8-%(&.?2KNL?$+3+_ ,,OIL<;"4QA>:\PP!_B*, ?P_\
MUJYEA8*U@L"C P>M+1THKLM884444 %%%% !5G39UM-2M[E_NQ2 D56H^OYU
M$E=6 ]*\8>/M-U_0?L-LCB3<#R/2K,GQ%TN3PK_9@1_.\CR^G?%>68 'I[B@
M 9Z8-<OU2"2%8!W]Z***Z]-AEK3+A;+5+:Z<$K$X)Q7=^,O'6G>(-$6RMD?S
M ZMS[5YUV]Z0 #H,#U]*QG1C-IL1Z?=_$+3)_"ITM8V$Q@$>3ZUY@.GXT8&<
MTN/TZ4Z5)4]@"BBBMQA1110 4444 26\@ANH92,A'#&O3=<^(>F:EX:DTZ*-
M_->,+DCO7EW/:CZ5A5HQFTV(]1T'XAZ9IOAF/3ID?SE0IQTKS&=Q)=SR#[KN
M6%,^F#12IT8TVV@L%3V$RVVHV]P_*QN&/X5!1UX/2MI*ZL!Z1XL\>Z=KGA\V
M,$;"0D'\JF7XAZ8/"_\ 9IC;S?)\O/X5YCCV^F*,#/8@US+"PM8 /WF/J<T4
M#IS172MAA1115 %%%% !2$9X_&EH[_R-0^P'J:_$;2QX5_LS8_G?9_+SVSBJ
MO@_Q_IN@Z"+&Y1S)DG(Z<UYMC/8>]'X<URO"0:8K%K4[E+S5+BY0'9(Y855H
MQV_6BNJ*44D@'1-LFC<]%8&O3-3^(6F7GA=M-2-Q*8MF>V:\QI, ?2LZE)3M
M?H58]-\-_$'3=(\,QZ=-&YE52"?K7F\[B2[FE' DD9A^-1D ]1FC^?>BE1C!
MMHD****U0PH_R:*='$\\R0Q*6DD.U0/6DY)(1[%\'$*Z#=DCK,<5Z37.^"]$
M.A>'8+9UQ,PW2?6NC-?.U9*4VT0PHHHK, HHHH **** "BBB@ HHHH ****
M ]*Q[_PWH^K7'VB_T^&XEQMW.N3@5L4F* .?_P"$'\,G_F#6O_?%.C\&>'(P
M0NCVO_? K?Q10!B?\(AX>_Z!%I_W[%'_  A_A[_H$6G_ '[%;>*,4 8X\+:"
MHP-)M/\ OV*7_A&=#&?^)5:?]^Q6O2$>] 'E_CGX-Z7XI>.YL2NGW*#!$:@*
MU6_AU\+++P-)+=O,;F]D7&\C[@]!7HN#1MH 3/0UR=EX'MK>/68Y9WECU0DN
M#_!FNL(YK'\1^(+?PUI1U"YBEFC#A-D2Y/- '/Z3\.TM996U34)-03R3;P*X
M_P!6A[4:)\/5T[4X[F^OY;V&W4I;0R#B-3VKL+6Y6\L8KI%95E3> W4<5RT.
MMWO_  C]I=239D:\9&/JH)XH W9M#LSI5U8VD,=M%<J0YC7')[U@W'@**7PK
MI^D1WDD=QIY+6UU_$K9ZTW_A-;A+%[N6S78RDPJ#R><<U//XMDM[%C.D<5TK
M8(/*XQF@"FGPXMVT*:VGO9)-1EE\XWO\0?L:@_X5DEQ;JUYJ4D]\9UEFG8??
M"G(%:=EXN>_D<PPH(8X!*\C>IXXK(N?&=U<F:&WE6.6!"[M&, C\: -JX\&I
M_P )G#XCL+M[60)Y<\*#Y9A[UC:]\-[S5/$4VKV'B"YL'F7:Z1CM4T?CAI]-
MBDCY+(%+ ?,&]3[58MO'">88W'F+"N)CCYB?:@!D?PTT^#PU'IT-Q(+N.3SE
MO#]_S/6I+'P(\-O>37>I27.JW0 :[8<@#H,5:T76K[4=?=95"6;Q[H5%7-:U
MY],N8T545/XW<$Y'MB@#G+#X7VRQZ@VI7C7,]VNW>!@(/I5C3/ -Q:6LT4^J
MO,=FR!@H'EBMNQU^2_=YXH5^P(O^L)YS6)-XSEDU**QC9!([%@4!'RCUS0!3
MM?A<BR7$]YJ4DMQ/M5F50HV@Y Q70Q^$;5?%+ZU*5FW6RP")U!"@=ZQ=2\:S
MFWN8;-H_M "F)EZ\G'-2W_BR[@AM+=P(;UI-C;>AH TM=\&6^N:K;7DD[Q1P
MPO%Y2# (88K!TSX7FSU"SGGU:6:&SR(82HP%/8U:TWQ5J5Q?W)V))9V[8D)^
M\/4UU>E:FFKPM<08,&<(WK0!R</P[EBNFA769QHYD:3[$.!D]:;I_P .6L'F
M@_M-WL2&\J#:/DSWS7?XH(H XC_A7L)TO1K(WTFW3)C(&_YZ9/0U1N/A@TJ7
MD<>L31PRS_:(DQ_JWKT7:*,4 <GX4\'2>'+Z]O)K][J:[QOW# S76+1C\Z,<
MT +1110 4444 %%%% !1110 4444 (:3WQG-.I,<T </XM^'EEX@<W<!^SWF
M.JCAOK7G-S\,_$=O(56%)!V*5[[CFEQ713Q-2"T'<^>_^%=^)/\ GT%'_"O/
M$G_/H*^A:2M?KM0+GSW_ ,*\\2?\^HH_X5YXD_Y]17T)2T?7:@7/GK_A7GB7
M_GU%'_"O/$G_ #ZBOH6BCZ[4"Y\]?\*\\2?\^@H_X5YXD_Y]!7T+24?7:@7/
MGO\ X5WXD_Y]!1_PKSQ+_P ^@KZ$HI?79A<^>_\ A7?B3_GT%'_"O/$G_/H*
M^A:*?UVH%SYZ_P"%>>)/^?04?\*\\2?\^@KZ%HH^NU N?/7_  KSQ)_SZ"C_
M (5YXD_Y]!7T+11]=J!<^>O^%>>)/^?04?\ "N_$G_/H*^A:2CZ[4"Y\]_\
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M/^?05]"T4?7:@7/GK_A7GB3_ )]!1_PKSQ)_SZ"OH6BCZ[4"Y\]?\*\\2?\
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M1%S>=B1POTKNJ,5C/$U)Z,+B#K3J04M8""BBB@ HHHH **** "BBB@ HHHH
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MC3(K.%0 @YQTSWK1P,YI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHI6 ****+ %%%%%@"DI:*+ )12T460"4M%%%@"BBBB
MP!11118 I*6BBP"44M%%D E%+119 )2T446 ****+ %%%%%@"BBBBP!11118
M I*6BBP"44M%%D 44446 ****+ %%%%%@"BBBBP!11118 HHHHL 4E+118!*
M6BBBP!11118 HHHHL 4444 %%%%, HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>celu-20241231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaWN+bP9z5Z8eekhvWBxbTkKLyUj/OiQby46duymgXQM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:CELU="http://celularity.com/20241231" elementFormDefault="qualified" targetNamespace="http://celularity.com/20241231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://celularity.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
          <link:definition>00000005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/NatureOfBusiness" id="NatureOfBusiness">
          <link:definition>999014 - Disclosure - Nature of Business</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999015 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/AssetAcquisition" id="AssetAcquisition">
          <link:definition>999016 - Disclosure - Asset Acquisition</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilities" id="FairValueOfFinancialAssetsAndLiabilities">
          <link:definition>999017 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/Inventory" id="Inventory">
          <link:definition>999018 - Disclosure - Inventory</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
          <link:definition>999019 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
          <link:definition>999020 - Disclosure - Property and Equipment, Net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNet" id="GoodwillAndIntangibleAssetsNet">
          <link:definition>999021 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
          <link:definition>999022 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/Debt" id="Debt">
          <link:definition>999023 - Disclosure - Debt</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/Leases" id="Leases">
          <link:definition>999024 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999025 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/Equity" id="Equity">
          <link:definition>999026 - Disclosure - Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999027 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/RevenueRecognition" id="RevenueRecognition">
          <link:definition>999028 - Disclosure - Revenue Recognition</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/LicenseAndDistributionAgreements" id="LicenseAndDistributionAgreements">
          <link:definition>999029 - Disclosure - License and Distribution Agreements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/BenefitPlan" id="BenefitPlan">
          <link:definition>999030 - Disclosure - Benefit Plan</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999031 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/SegmentInformation" id="SegmentInformation">
          <link:definition>999032 - Disclosure - Segment Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>999033 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>999034 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999035 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999036 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/AssetAcquisitionTables" id="AssetAcquisitionTables">
          <link:definition>999037 - Disclosure - Asset Acquisition (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" id="FairValueOfFinancialAssetsAndLiabilitiesTables">
          <link:definition>999038 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/InventoryTables" id="InventoryTables">
          <link:definition>999039 - Disclosure - Inventory (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
          <link:definition>999040 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
          <link:definition>999041 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables" id="GoodwillAndIntangibleAssetsNetTables">
          <link:definition>999042 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
          <link:definition>999043 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/DebtTables" id="DebtTables">
          <link:definition>999044 - Disclosure - Debt (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999045 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/EquityTables" id="EquityTables">
          <link:definition>999046 - Disclosure - Equity (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999047 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/RevenueRecognitionTables" id="RevenueRecognitionTables">
          <link:definition>999048 - Disclosure - Revenue Recognition (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999049 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/SegmentInformationTables" id="SegmentInformationTables">
          <link:definition>999050 - Disclosure - Segment Information (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/NatureOfBusinessDetailsNarrative" id="NatureOfBusinessDetailsNarrative">
          <link:definition>999051 - Disclosure - Nature of Business (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" id="ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails">
          <link:definition>999052 - Disclosure - Schedule of Property and Equipment Estimated Useful Life (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" id="ScheduleOfPotentiallyDilutiveSecuritiesDetails">
          <link:definition>999053 - Disclosure - Schedule of Potentially Dilutive Securities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails" id="ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails">
          <link:definition>999055 - Disclosure - Schedule of Purchase Price Allocated to Acquired Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/AssetAcquisitionDetailsNarrative" id="AssetAcquisitionDetailsNarrative">
          <link:definition>999056 - Disclosure - Asset Acquisition (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails" id="ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails">
          <link:definition>999057 - Disclosure - Schedule of Financial Assets and Liabilities Measures at Fair Value (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails" id="ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails">
          <link:definition>999058 - Disclosure - Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails" id="ScheduleOfConvertibleNoteValuationModelDetails">
          <link:definition>999059 - Disclosure - Schedule of Convertible Note Valuation Model (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" id="ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails">
          <link:definition>999060 - Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails" id="ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails">
          <link:definition>999061 - Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails" id="ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails">
          <link:definition>999062 - Disclosure - Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails" id="ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails">
          <link:definition>999063 - Disclosure - Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails" id="ScheduleOfConvertibleNotesValuationModelDetails">
          <link:definition>999064 - Disclosure - Schedule of Convertible Notes Valuation Model (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails" id="ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails">
          <link:definition>999065 - Disclosure - Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails" id="ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails">
          <link:definition>999066 - Disclosure - Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails" id="ScheduleOfJanuary20224BridgeLoanDetails">
          <link:definition>999067 - Disclosure - Schedule of January 20224 Bridge Loan (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails" id="ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails">
          <link:definition>999068 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical" id="ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical">
          <link:definition>999069 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails" id="ScheduleOfSignificantInputsForSponsorWarrantsDetails">
          <link:definition>999070 - Disclosure - Schedule of Significant Inputs for Sponsor Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative" id="FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative">
          <link:definition>999071 - Disclosure - Fair Value of Financial Assets and Liabilities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails" id="ScheduleOfMajorClassesOfInventoriesDetails">
          <link:definition>999072 - Disclosure - Schedule of Major Classes of Inventories (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfInventoryReservesDetails" id="ScheduleOfInventoryReservesDetails">
          <link:definition>999073 - Disclosure - Schedule of Inventory Reserves (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/InventoryDetailsNarrative" id="InventoryDetailsNarrative">
          <link:definition>999074 - Disclosure - Inventory (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:definition>999075 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails" id="ScheduleOfPropertyAndEquipmentNetDetails">
          <link:definition>999076 - Disclosure - Schedule of Property and Equipment, Net (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/PropertyAndEquipmentNetDetailsNarrative" id="PropertyAndEquipmentNetDetailsNarrative">
          <link:definition>999077 - Disclosure - Property and Equipment, Net (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails" id="ScheduleOfIntangibleAssetsNetDetails">
          <link:definition>999078 - Disclosure - Schedule of Intangible Assets, Net (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" id="ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails">
          <link:definition>999079 - Disclosure - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" id="GoodwillAndIntangibleAssetsNetDetailsNarrative">
          <link:definition>999080 - Disclosure - Goodwill and Intangible Assets, Net (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:definition>999081 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfDebtDetails" id="ScheduleOfDebtDetails">
          <link:definition>999082 - Disclosure - Schedule of Debt (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>999083 - Disclosure - Debt (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfLeaseCostsDetails" id="ScheduleOfLeaseCostsDetails">
          <link:definition>999084 - Disclosure - Schedule of Lease Costs (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails" id="ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails">
          <link:definition>999085 - Disclosure - Schedule of Cash Activity Related to the lease Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" id="ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails">
          <link:definition>999086 - Disclosure - Schedule of Future Minimum Payments under Operating Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>999087 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999088 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/SummaryOfWarrantsDetails" id="SummaryOfWarrantsDetails">
          <link:definition>999089 - Disclosure - Summary of the Warrants (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical" id="SummaryOfWarrantsDetailsParenthetical">
          <link:definition>999090 - Disclosure - Summary of the Warrants (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/EquityDetailsNarrative" id="EquityDetailsNarrative">
          <link:definition>999091 - Disclosure - Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails" id="ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails">
          <link:definition>999092 - Disclosure - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>999093 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical" id="ScheduleOfStockOptionActivityDetailsParenthetical">
          <link:definition>999094 - Disclosure - Schedule of Stock Option Activity (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails" id="ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails">
          <link:definition>999095 - Disclosure - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
          <link:definition>999096 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999097 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails" id="ScheduleOfDisaggregatedRevenueByProductAndServicesDetails">
          <link:definition>999098 - Disclosure - Schedule of Disaggregated Revenue by Product and Services (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" id="ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails">
          <link:definition>999099 - Disclosure - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical" id="ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical">
          <link:definition>999100 - Disclosure -  Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative" id="LicenseAndDistributionAgreementsDetailsNarrative">
          <link:definition>999101 - Disclosure - License and Distribution Agreements (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/BenefitPlanDetailsNarrative" id="BenefitPlanDetailsNarrative">
          <link:definition>999102 - Disclosure - Benefit Plan (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails" id="ScheduleOfCurrentAndDeferredTaxProvisionDetails">
          <link:definition>999103 - Disclosure - Schedule of Current and Deferred Tax Provision (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails" id="ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails">
          <link:definition>999104 - Disclosure - Schedule of Reconciliation of the U.S federal statutory income tax (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
          <link:definition>999105 - Disclosure - Schedule of Deferred tax assets and liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" id="ScheduleOfUnrecognizedTaxBenefitsDetails">
          <link:definition>999106 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999107 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails" id="ScheduleOfFinancialInformationBySegmentDetails">
          <link:definition>999108 - Disclosure - Schedule of Financial Information by Segment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/SegmentInformationDetailsNarrative" id="SegmentInformationDetailsNarrative">
          <link:definition>999109 - Disclosure - Segment Information (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>999110 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://celularity.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>999111 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="celu-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="celu-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="celu-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="celu-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="CELU_ClassCommonStockParValue0.0001PerShareMember" name="ClassCommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" name="WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LicenseRoyaltyAndOtherMember" name="LicenseRoyaltyAndOtherMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_CellTherapyMember" name="CellTherapyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ThreeCustomersMember" name="ThreeCustomersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_TwoCustomersMember" name="TwoCustomersMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_CustomerTwoMember" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SequenceLifeScienceIncMember" name="SequenceLifeScienceIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AcquisitionRelatedContingentConsiderationObligationsMember" name="AcquisitionRelatedContingentConsiderationObligationsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ContingentStockConsiderationMember" name="ContingentStockConsiderationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ConvertiblePromissoryNotesMember" name="ConvertiblePromissoryNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_UnsecuredSeniorConvertibleNotesMember" name="UnsecuredSeniorConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" name="MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" name="JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" name="NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_GXSponsorWarrantsMember" name="GXSponsorWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SanuwaveForbearanceAgreementMember" name="SanuwaveForbearanceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LetterAgreementMember" name="LetterAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_YorkvilleMember" name="YorkvilleMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember" name="NovemberTwoThousandTwentyFourPurchaserWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" name="NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SponsorsWarrantsMember" name="SponsorsWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InventoryFinishedGoodsMember" name="InventoryFinishedGoodsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InventoryWorkInProgressMember" name="InventoryWorkInProgressMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LaboratoryAndProductionEquipmentMember" name="LaboratoryAndProductionEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MachineryEquipmentAndFixturesMember" name="MachineryEquipmentAndFixturesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ReacquiredRightsMember" name="ReacquiredRightsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PrePaidAdvanceAgreementMember" name="PrePaidAdvanceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_UnsecuredSeniorConvertibleNoteMember" name="UnsecuredSeniorConvertibleNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_CVStarrBridgeLoanNetOfDiscountMember" name="CVStarrBridgeLoanNetOfDiscountMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RWIBridgeLoanNetOfDiscountMember" name="RWIBridgeLoanNetOfDiscountMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_CEOPromissoryNoteMember" name="CEOPromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StandbyEquityPurchaseAgreementMember" name="StandbyEquityPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ChairmanAndChiefExecutiveOfficerMember" name="ChairmanAndChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_CVStarrCoIncMember" name="CVStarrCoIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ForbearanceAgreementMember" name="ForbearanceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_TrancheTwoWarrantMember" name="TrancheTwoWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InitialLoanMember" name="InitialLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AdditionalLoanMember" name="AdditionalLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_TrancheOneWarrantMember" name="TrancheOneWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InitialAndSecondTrancheMember" name="InitialAndSecondTrancheMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ResortsWorldIncPteLtdMember" name="ResortsWorldIncPteLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OfficeManufacturingAndLaboratorySpaceMember" name="OfficeManufacturingAndLaboratorySpaceMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FlorhamParkNewJerseyMember" name="FlorhamParkNewJerseyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LegacyCelularityMember" name="LegacyCelularityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember" name="HLICellularTherapeuticsLLCAndAnthrogenesisMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LegacyCelularitysMember" name="LegacyCelularitysMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PalantirTechnologiesIncMember" name="PalantirTechnologiesIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MasterSubscriptionAgreementMember" name="MasterSubscriptionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SoftwareCeaseUseCostsMember" name="SoftwareCeaseUseCostsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SettlementAndReleaseAgreementMember" name="SettlementAndReleaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_EvolutionMember" name="EvolutionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_HackensackMeridianHealthMember" name="HackensackMeridianHealthMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AtTheMarketSalesAgreementMember" name="AtTheMarketSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" name="MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" name="MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember" name="MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" name="MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember" name="JanuaryTwoThousandTwentyFourPipeWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_TwoThousandTwentyFourWarrantRepricingMember" name="TwoThousandTwentyFourWarrantRepricingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InvestorRightsAgreementMember" name="InvestorRightsAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DragasacLimitedMember" name="DragasacLimitedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ChiefAdministrativeOfficerMember" name="ChiefAdministrativeOfficerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AmendedEmploymentAgreementMember" name="AmendedEmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RwiForbearanceAgreementMember" name="RwiForbearanceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember" name="MarchTwoThousandTwentyThreeLoanWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember" name="JuneTwoThousandTwentyThreeLoanWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DragasacWarrantMember" name="DragasacWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PublicWarrantsMember" name="PublicWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SponsorWarrantsMember" name="SponsorWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" name="MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" name="AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" name="AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_JuneTwoThousandTwentyThreeWarrantsMember" name="JuneTwoThousandTwentyThreeWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" name="JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" name="JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" name="MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember" name="NovemberTwoThousandTwentyFourPurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember" name="JanuaryTwoThousandTwentyFourPIPEWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StarrForbearanceAgreementMember" name="StarrForbearanceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember" name="TwoThousandAndTwentyOneEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_TwoThousandAndSeventeenEquityIncentivePlanMember" name="TwoThousandAndSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AwardsWithPerformanceConditionsMember" name="AwardsWithPerformanceConditionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InitialTrancheMember" name="InitialTrancheMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SecondTrancheMember" name="SecondTrancheMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MarketConditionStockUnitMember" name="MarketConditionStockUnitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" name="TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_TwoThousandTwentyOnePlanMember" name="TwoThousandTwentyOnePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_TwoThousandSeventeenPlanMember" name="TwoThousandSeventeenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RegeneronResearchCollaborationServicesAgreementMember" name="RegeneronResearchCollaborationServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RegeneronServicesAgreementMember" name="RegeneronServicesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PultheraLLCBindingTermSheetMember" name="PultheraLLCBindingTermSheetMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LicenseAgreementWithBiocellgraftIncMember" name="LicenseAgreementWithBiocellgraftIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_UnitedStatesFederalAndStateMember" name="UnitedStatesFederalAndStateMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_BiobankingMember" name="BiobankingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DegenerativeDiseaseMember" name="DegenerativeDiseaseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DrRobertHaririMember" name="DrRobertHaririMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AmendedAndRestatedEmploymentAgreementMember" name="AmendedAndRestatedEmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DrHaririMember" name="DrHaririMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ConsultingAgreementMember" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DrAndrewPecoraMember" name="DrAndrewPecoraMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ScientificAndClinicalAdvisorAgreementMember" name="ScientificAndClinicalAdvisorAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RobinLSmithMdMember" name="RobinLSmithMdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AdvisoryAgreementMember" name="AdvisoryAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_COTAIncMember" name="COTAIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_CryoportSystemsIncMember" name="CryoportSystemsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_CVStarLoanMember" name="CVStarLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MsHaririMember" name="MsHaririMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_EmploymentOfImmediateFamilyMemberMember" name="EmploymentOfImmediateFamilyMemberMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_GenesisEquityGroupFundingLlcMember" name="GenesisEquityGroupFundingLlcMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PromissoryNotesReceivable" name="PromissoryNotesReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AccruedResearchAndDevelopmentSoftware" name="AccruedResearchAndDevelopmentSoftware" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantLiability" name="WarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OperatingIncomeCostsAndExpenses" name="OperatingIncomeCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ChangeInFairValueOfDebt" name="ChangeInFairValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OtherNonoperatingIncomeExpenses" name="OtherNonoperatingIncomeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" name="StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" name="StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" name="StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension" name="StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FairValueOfWarrantModificationForProfessionalService" name="FairValueOfWarrantModificationForProfessionalService" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment" name="StockIssuedDuringPeriodValueOfResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment" name="StockIssuedDuringPeriodSharesOfResearchAndDevelopment" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" name="StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses" name="StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodValueATMAgreement" name="StockIssuedDuringPeriodValueATMAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodSharesATMAgreement" name="StockIssuedDuringPeriodSharesATMAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" name="StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee" name="StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" name="AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" name="StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement" name="StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" name="AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NonCashLeaseExpense" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ProvisionForInventoryObsolescence" name="ProvisionForInventoryObsolescence" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InventoryImpairmentCharge" name="InventoryImpairmentCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AcquiredInProcessResearchAndDevelopment" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment" name="IssuanceOfCommonStockUsedInResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement" name="IssuanceOfCommonStockAsConsiderationForSettlementAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" name="IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IssuanceOfCommonStockAsCompensationExpense" name="IssuanceOfCommonStockAsCompensationExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DiscountsArisingFromLoanArrangementRelatedParty" name="DiscountsArisingFromLoanArrangementRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FairValueOfWarrantModificationForProfessionalServices" name="FairValueOfWarrantModificationForProfessionalServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ChangeInFairValueOfContingentStockConsideration" name="ChangeInFairValueOfContingentStockConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NonCashInterestExpense" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" name="IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ProceedsFromConvertibleNote" name="ProceedsFromConvertibleNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties" name="ProceedsFromWarrantsAndShortTermDebtRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RepaymentsOfShortTermDebtUnaffiliated" name="RepaymentsOfShortTermDebtUnaffiliated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering" name="ProceedsFromTheSaleOfCommonStockInAtmOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ProceedsFromShortTermDebtUnaffiliated" name="ProceedsFromShortTermDebtUnaffiliated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PaymentOfSepaCommitmentFee" name="PaymentOfSepaCommitmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RepaymentsOfShortTermDebtRelatedParty" name="RepaymentsOfShortTermDebtRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance" name="ModificationOfCVStarrWarrantsInConnectionWithForbearance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance" name="IssuanceOfRwiWarrantsInConnectionWithForbearance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan" name="IssuanceOfWarrantsOnSeniorSecuredBridgeLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification" name="ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PIPERelatedCostsIncludedInAccruedExpenses" name="PIPERelatedCostsIncludedInAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties" name="InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition" name="ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition" name="InventoryAcquiredInConnectionWithReboundAssetAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" name="ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty" name="AssumptionOfShorttermDebtUnaffiliatedByRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" name="DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DisclosureLicenseAndDistributionAgreementsAbstract" name="DisclosureLicenseAndDistributionAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LicenseAndDistributionAgreementsTextBlock" name="LicenseAndDistributionAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AssetAcquisitionsPolicyTextBlock" name="AssetAcquisitionsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantsLiabilitiesPolicyTextBlock" name="WarrantsLiabilitiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ShortTermDebtPolicyTextBlock" name="ShortTermDebtPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_GovernmentGrantsPolicyTextBlock" name="GovernmentGrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AllowanceForCreditLossesPolicyTextBlock" name="AllowanceForCreditLossesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock" name="ScheduleOfEstimatedUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock" name="ScheduleOfConvertibleNoteValuationModelTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" name="FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" name="ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" name="ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ScheduleOfActivityInInventoryReservesTableTextBlock" name="ScheduleOfActivityInInventoryReservesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ScheduleOfIntangibleAssetsNetTableTextBlock" name="ScheduleOfIntangibleAssetsNetTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock" name="CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ContractedStoragePeriods" name="ContractedStoragePeriods" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PaymentPlansForCustomerToPayOverTimePeriod" name="PaymentPlansForCustomerToPayOverTimePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" name="ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InstrumentSpecificCreditRiskLoss" name="InstrumentSpecificCreditRiskLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InstrumentSpecificCreditRiskIncome" name="InstrumentSpecificCreditRiskIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion" name="AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" name="AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" name="AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_UpfrontPayment" name="UpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MonthlyMilestonePayments" name="MonthlyMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PriorPaymentToRelatedParty" name="PriorPaymentToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NetSalesPercentage" name="NetSalesPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PurchasePriceContingentConsideration" name="PurchasePriceContingentConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MilestonePayments" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ContingentStockConsideration" name="ContingentStockConsideration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes" name="ShorttermDebtUnsecuredSeniorConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantLiabilityRegisteredDirectWarrantsTwo" name="WarrantLiabilityRegisteredDirectWarrantsTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantLiabilityRegisteredDirectWarrants" name="WarrantLiabilityRegisteredDirectWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" name="WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantLiabilityPurchaserWarrants" name="WarrantLiabilityPurchaserWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantLiabilityPlacementAgentWarrants" name="WarrantLiabilityPlacementAgentWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantLiabilitySponsorWarrants" name="WarrantLiabilitySponsorWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantLiabilityPublicWarrants" name="WarrantLiabilityPublicWarrants" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FaceValueOfNotesReceivable" name="FaceValueOfNotesReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PercentageOfCouponRate" name="PercentageOfCouponRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ValuationInputForConvertiblePromissoryNoteTerm" name="ValuationInputForConvertiblePromissoryNoteTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ValuationInputForConvertiblePromissoryNote" name="ValuationInputForConvertiblePromissoryNote" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" name="FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" name="FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" name="IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FairValueAdjustmentThroughEarnings" name="FairValueAdjustmentThroughEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" name="FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual" name="FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RegisteredDirectWarrantsIssuance" name="RegisteredDirectWarrantsIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RegisteredDirectWarrantIssuanceDuringJuly" name="RegisteredDirectWarrantIssuanceDuringJuly" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_BridgeLoanAndWarrantIssuanceTrancheTwo" name="BridgeLoanAndWarrantIssuanceTrancheTwo" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PurchaserWarrantIssuance" name="PurchaserWarrantIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PlacementAgentWarrantIssuance" name="PlacementAgentWarrantIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_GainLossRecognizedInEarningsFromChangeInFairValues" name="GainLossRecognizedInEarningsFromChangeInFairValues" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FairValueNetAssetLiabilities" name="FairValueNetAssetLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate" name="WarrantsAndRightsOutstandingTermToInitialExerciseDate" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing" name="WarrantsAndRightsOutstandingTermToSubsequentFinancing" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FloorPrice" name="FloorPrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OfferingPricePercentage" name="OfferingPricePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ForbearanceExtendMaturityPeriod" name="ForbearanceExtendMaturityPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IncreasedNotePayments" name="IncreasedNotePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InventoryRawMaterialsCurrentAndNoncurrent" name="InventoryRawMaterialsCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InventoryWorkInProgressCurrentAndNoncurrent" name="InventoryWorkInProgressCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InventoryFinishedGoodsCurrentAndNoncurrent" name="InventoryFinishedGoodsCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InventoryGrossCurrentAndNoncurrent" name="InventoryGrossCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InventoryReserveCurrentAndNoncurrent" name="InventoryReserveCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InventoryNetCurrentAndNoncurrent" name="InventoryNetCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ProvisionForObsoleteInventory" name="ProvisionForObsoleteInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PrepaidClinicalExpense" name="PrepaidClinicalExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod" name="IndefiniteLivedIntangibleAssetsAmortizationMethod" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AccruedClinicalTrialExpense" name="AccruedClinicalTrialExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AccrualsForConstructionInProgress" name="AccrualsForConstructionInProgress" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AccruedComplianceFee" name="AccruedComplianceFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ShortTermDebtUnaffiliated" name="ShortTermDebtUnaffiliated" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OtherShortTermDebt" name="OtherShortTermDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ShortTermDebtRelatedParty" name="ShortTermDebtRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_Debt" name="Debt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PrePaidAdvancePeriod" name="PrePaidAdvancePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PrePaidAdvanceIssuedDiscountPercentage" name="PrePaidAdvanceIssuedDiscountPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" name="LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IssuanceOfCommonStockMinimumOptionPricePerShare" name="IssuanceOfCommonStockMinimumOptionPricePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MaximumPercentageOfCommonStockIssued" name="MaximumPercentageOfCommonStockIssued" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PercentageOfBeneficialOwnershipLimitation" name="PercentageOfBeneficialOwnershipLimitation" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MinimumNumberOfSharesOfCommonStockPurchase" name="MinimumNumberOfSharesOfCommonStockPurchase" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MinimumRequiredDailyVolumeWeightedAveragePrice" name="MinimumRequiredDailyVolumeWeightedAveragePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice" name="RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice" name="RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice" name="RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IssuancePricePercentage" name="IssuancePricePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ProceedsFromLinesOfCreditGross" name="ProceedsFromLinesOfCreditGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DebtConversionOriginalDebtAccruedInterestAmount" name="DebtConversionOriginalDebtAccruedInterestAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DebtInstrumentPayment" name="DebtInstrumentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DebtInstrumentAccruedInterest" name="DebtInstrumentAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DebtInstrumentRedemptionPremium" name="DebtInstrumentRedemptionPremium" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DebtInstrumentPerDiemInterestAmount" name="DebtInstrumentPerDiemInterestAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ConvertiblePromissoryNoteDiscountPercentage" name="ConvertiblePromissoryNoteDiscountPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PercentageOfConversionOnOutstandingCommonStock" name="PercentageOfConversionOnOutstandingCommonStock" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DebtInstrumentDefaultInterestRate" name="DebtInstrumentDefaultInterestRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NotesAndPurchaserWarrantsPrincipalAmount" name="NotesAndPurchaserWarrantsPrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ProceedsFromNotesAndPurchaserWarrants" name="ProceedsFromNotesAndPurchaserWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MinimumGrossProceeds" name="MinimumGrossProceeds" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PercentageOfCashFeeEqualToAggregateProceeds" name="PercentageOfCashFeeEqualToAggregateProceeds" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PercentageOfExercisePriceEqualToOfferingPrice" name="PercentageOfExercisePriceEqualToOfferingPrice" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DebtInstrumentContributionAmount" name="DebtInstrumentContributionAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OtherShortTermDebtDueToRelatedParty" name="OtherShortTermDebtDueToRelatedParty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DebtInstrumentOriginalIssueDiscount" name="DebtInstrumentOriginalIssueDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault" name="DebtInstrumentInterestRateEffectivePercentageInEventOfDefault" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ShareIssuedPurchasedPrice" name="ShareIssuedPurchasedPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FallInCashAndCashEquivalents" name="FallInCashAndCashEquivalents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ClassOfWarrantOrRighstExpirationDate" name="ClassOfWarrantOrRighstExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PercentageOfChangesInCashFlow" name="PercentageOfChangesInCashFlow" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ShortTermDebtRelatedParties" name="ShortTermDebtRelatedParties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DebtInstrumentDiscount" name="DebtInstrumentDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault" name="DebtInstrumentInterestRateDuringPeriodInEventOfDefault" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DiscountOnWarrantAmount" name="DiscountOnWarrantAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice" name="PercentageOfPartialLiquidatingDamagesOnPurchasePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" name="PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DailyInterestAccruingRate" name="DailyInterestAccruingRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OperatingLeasesRentExpense" name="OperatingLeasesRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AreaOfBuilding" name="AreaOfBuilding" nillable="true" xbrli:periodType="duration" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OperatingLeaseExpiryYear" name="OperatingLeaseExpiryYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OperatingLeaseCommencementDate" name="OperatingLeaseCommencementDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InitialMonthlyBaseRent" name="InitialMonthlyBaseRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ReductionInLineOfCredit" name="ReductionInLineOfCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NewLineOfCredit" name="NewLineOfCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_BaseRentalPayments" name="BaseRentalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PaymentsForMasterSubscriptionAgreement" name="PaymentsForMasterSubscriptionAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PaymentSubscriptionPeriod" name="PaymentSubscriptionPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_UpfrontFee" name="UpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AnnualMaintenanceFee" name="AnnualMaintenanceFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ClinicalAndRegulatoryMilestones" name="ClinicalAndRegulatoryMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LicenseAgreementNoticePeriod" name="LicenseAgreementNoticePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NumberOfSharesIssuedForPiggybackRegistrationRights" name="NumberOfSharesIssuedForPiggybackRegistrationRights" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SaleOfBiomaterialProductsAmount" name="SaleOfBiomaterialProductsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NumberOfWarrantsRepriced" name="NumberOfWarrantsRepriced" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantsOutstanding" name="WarrantsOutstanding" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PercentageOfSharesRequiredForVoting" name="PercentageOfSharesRequiredForVoting" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AggregateOfferingPrice" name="AggregateOfferingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds" name="MaximumPercentageOfSalesCommissionFromGrossSalesProceeds" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AdjustedAdvanceNoticePeriod" name="AdjustedAdvanceNoticePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PremiumPaidForPrivatePlacementPurchase" name="PremiumPaidForPrivatePlacementPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ReducedExercisePrice" name="ReducedExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantExpirationTerm" name="WarrantExpirationTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FairValueNetAssetsLiability" name="FairValueNetAssetsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AmendedTerminationDateDescription" name="AmendedTerminationDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AdditionalWarrantLiability" name="AdditionalWarrantLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_WarrantsAndRightsIssuedClosingDate" name="WarrantsAndRightsIssuedClosingDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ProceedsFromPrivatePlacements" name="ProceedsFromPrivatePlacements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost" name="FairValueOfWarrantModificationIncrementalForEquityIssuanceCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RelatedPartyBaseSalary" name="RelatedPartyBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage" name="SaleOfStockMaximumAverageDailyTradedAmountPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays" name="SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice" name="SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SaleOfStockConsiderationCashDueDiligenceFee" name="SaleOfStockConsiderationCashDueDiligenceFee" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SaleOfStockConsiderationCommitmentFeeInShares" name="SaleOfStockConsiderationCommitmentFeeInShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" name="ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_UnearnedRevenue" name="UnearnedRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_NonrefundableUpfrontPayment" name="NonrefundableUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ServiceAgreementTerm" name="ServiceAgreementTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PaymentOfOptionFeeInCash" name="PaymentOfOptionFeeInCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OptionFeeExpense" name="OptionFeeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_CommercialLicenseToDentalProductsAgreementPeriod" name="CommercialLicenseToDentalProductsAgreementPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm" name="CommercialLicenseToDentalProductsAgreementRenewalTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LicenseFeeExpense" name="LicenseFeeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LicenseFeesPaymentPeriod" name="LicenseFeesPaymentPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LicenseFeePayment" name="LicenseFeePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AdditionalLicenseFee" name="AdditionalLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" name="EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" name="EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp" name="EffectiveIncomeTaxRateReconciliationDeferredTrueUp" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DeferredTaxAssetsStartupCosts" name="DeferredTaxAssetsStartupCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DeferredTaxAssetsUnicap" name="DeferredTaxAssetsUnicap" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DeferredTaxAssetsImputedInterestOnContingentPayments" name="DeferredTaxAssetsImputedInterestOnContingentPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" name="DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_DeferredTaxAssetsIrcSectionInterest" name="DeferredTaxAssetsIrcSectionInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_TaxCreditCarryforwardsExpirationYear" name="TaxCreditCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SegmentContribution" name="SegmentContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_IndirectExpenses" name="IndirectExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_InProcessResearchAndDevelopmentImpairment" name="InProcessResearchAndDevelopmentImpairment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SecuritiesPurchaseAgreementDate" name="SecuritiesPurchaseAgreementDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_UnpaidBaseSalary" name="UnpaidBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_BonusProgramEffectiveDate" name="BonusProgramEffectiveDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PercentageOfUnpaidBaseSalary" name="PercentageOfUnpaidBaseSalary" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PercentageOfBaseSalary" name="PercentageOfBaseSalary" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_AnnualRateOfBaseSalary" name="AnnualRateOfBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_BaseSalaryEffectiveDate" name="BaseSalaryEffectiveDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ReceiveForMonth" name="ReceiveForMonth" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_RelatedPartyCashBonus" name="RelatedPartyCashBonus" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_PaymentsToRelatedParty" name="PaymentsToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_LoanAgreement" name="LoanAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_SecondLoanAgreement" name="SecondLoanAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ApplicableFees" name="ApplicableFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_ChangeInFairValueOfContingentConsiderationLiability" name="ChangeInFairValueOfContingentConsiderationLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELU_OtherMember" name="OtherMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>celu-20241231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celularity.com/role/Cover" xlink:href="celu-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BalanceSheets" xlink:href="celu-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BalanceSheetsParenthetical" xlink:href="celu-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="celu-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/StatementsOfStockholdersEquity" xlink:href="celu-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/StatementsOfCashFlows" xlink:href="celu-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/NatureOfBusiness" xlink:href="celu-20241231.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AssetAcquisition" xlink:href="celu-20241231.xsd#AssetAcquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilities" xlink:href="celu-20241231.xsd#FairValueOfFinancialAssetsAndLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Inventory" xlink:href="celu-20241231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="celu-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PropertyAndEquipmentNet" xlink:href="celu-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNet" xlink:href="celu-20241231.xsd#GoodwillAndIntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="celu-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Debt" xlink:href="celu-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Leases" xlink:href="celu-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/CommitmentsAndContingencies" xlink:href="celu-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Equity" xlink:href="celu-20241231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Stock-basedCompensation" xlink:href="celu-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RevenueRecognition" xlink:href="celu-20241231.xsd#RevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LicenseAndDistributionAgreements" xlink:href="celu-20241231.xsd#LicenseAndDistributionAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BenefitPlan" xlink:href="celu-20241231.xsd#BenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/IncomeTaxes" xlink:href="celu-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SegmentInformation" xlink:href="celu-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RelatedPartyTransactions" xlink:href="celu-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SubsequentEvents" xlink:href="celu-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AssetAcquisitionTables" xlink:href="celu-20241231.xsd#AssetAcquisitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:href="celu-20241231.xsd#FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/InventoryTables" xlink:href="celu-20241231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="celu-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PropertyAndEquipmentNetTables" xlink:href="celu-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables" xlink:href="celu-20241231.xsd#GoodwillAndIntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="celu-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/DebtTables" xlink:href="celu-20241231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LeasesTables" xlink:href="celu-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/EquityTables" xlink:href="celu-20241231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Stock-basedCompensationTables" xlink:href="celu-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RevenueRecognitionTables" xlink:href="celu-20241231.xsd#RevenueRecognitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/IncomeTaxesTables" xlink:href="celu-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SegmentInformationTables" xlink:href="celu-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/NatureOfBusinessDetailsNarrative" xlink:href="celu-20241231.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:href="celu-20241231.xsd#ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails" xlink:href="celu-20241231.xsd#ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AssetAcquisitionDetailsNarrative" xlink:href="celu-20241231.xsd#AssetAcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails" xlink:href="celu-20241231.xsd#ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfConvertibleNoteValuationModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfConvertibleNotesValuationModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails" xlink:href="celu-20241231.xsd#ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails" xlink:href="celu-20241231.xsd#ScheduleOfJanuary20224BridgeLoanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails" xlink:href="celu-20241231.xsd#ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical" xlink:href="celu-20241231.xsd#ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails" xlink:href="celu-20241231.xsd#ScheduleOfSignificantInputsForSponsorWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative" xlink:href="celu-20241231.xsd#FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails" xlink:href="celu-20241231.xsd#ScheduleOfMajorClassesOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfInventoryReservesDetails" xlink:href="celu-20241231.xsd#ScheduleOfInventoryReservesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/InventoryDetailsNarrative" xlink:href="celu-20241231.xsd#InventoryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="celu-20241231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="celu-20241231.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="celu-20241231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="celu-20241231.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" xlink:href="celu-20241231.xsd#ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" xlink:href="celu-20241231.xsd#GoodwillAndIntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfDebtDetails" xlink:href="celu-20241231.xsd#ScheduleOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/DebtDetailsNarrative" xlink:href="celu-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfLeaseCostsDetails" xlink:href="celu-20241231.xsd#ScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:href="celu-20241231.xsd#ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LeasesDetailsNarrative" xlink:href="celu-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="celu-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfWarrantsDetails" xlink:href="celu-20241231.xsd#SummaryOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical" xlink:href="celu-20241231.xsd#SummaryOfWarrantsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/EquityDetailsNarrative" xlink:href="celu-20241231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="celu-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical" xlink:href="celu-20241231.xsd#ScheduleOfStockOptionActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails" xlink:href="celu-20241231.xsd#ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="celu-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="celu-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:href="celu-20241231.xsd#ScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical" xlink:href="celu-20241231.xsd#ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative" xlink:href="celu-20241231.xsd#LicenseAndDistributionAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BenefitPlanDetailsNarrative" xlink:href="celu-20241231.xsd#BenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:href="celu-20241231.xsd#ScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="celu-20241231.xsd#ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/IncomeTaxesDetailsNarrative" xlink:href="celu-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails" xlink:href="celu-20241231.xsd#ScheduleOfFinancialInformationBySegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SegmentInformationDetailsNarrative" xlink:href="celu-20241231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="celu-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SubsequentEventsDetailsNarrative" xlink:href="celu-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PromissoryNotesReceivable" xlink:label="loc_CELUPromissoryNotesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_CELUPromissoryNotesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaapInventoryNoncurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapInventoryNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedResearchAndDevelopmentSoftware" xlink:label="loc_CELUAccruedResearchAndDevelopmentSoftware" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_CELUAccruedResearchAndDevelopmentSoftware" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapContractWithCustomerLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiability" xlink:label="loc_CELUWarrantLiability" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_CELUWarrantLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingIncomeCostsAndExpenses" xlink:label="loc_CELUOperatingIncomeCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUOperatingIncomeCostsAndExpenses" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUOperatingIncomeCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUOperatingIncomeCostsAndExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUOperatingIncomeCostsAndExpenses" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUOperatingIncomeCostsAndExpenses" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUOperatingIncomeCostsAndExpenses" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUOperatingIncomeCostsAndExpenses" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_CELUOperatingIncomeCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChangeInFairValueOfDebt" xlink:label="loc_CELUChangeInFairValueOfDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_CELUChangeInFairValueOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OtherNonoperatingIncomeExpenses" xlink:label="loc_CELUOtherNonoperatingIncomeExpenses" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_CELUOtherNonoperatingIncomeExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NonCashLeaseExpense" xlink:label="loc_CELUNonCashLeaseExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUNonCashLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProvisionForInventoryObsolescence" xlink:label="loc_CELUProvisionForInventoryObsolescence" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUProvisionForInventoryObsolescence" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryImpairmentCharge" xlink:label="loc_CELUInventoryImpairmentCharge" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUInventoryImpairmentCharge" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_CELUAcquiredInProcessResearchAndDevelopment" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUAcquiredInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment" xlink:label="loc_CELUIssuanceOfCommonStockUsedInResearchAndDevelopment" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUIssuanceOfCommonStockUsedInResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement" xlink:label="loc_CELUIssuanceOfCommonStockAsConsiderationForSettlementAgreement" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUIssuanceOfCommonStockAsConsiderationForSettlementAgreement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" xlink:label="loc_CELUIssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUIssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockAsCompensationExpense" xlink:label="loc_CELUIssuanceOfCommonStockAsCompensationExpense" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUIssuanceOfCommonStockAsCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DiscountsArisingFromLoanArrangementRelatedParty" xlink:label="loc_CELUDiscountsArisingFromLoanArrangementRelatedParty" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUDiscountsArisingFromLoanArrangementRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueOfWarrantModificationForProfessionalServices" xlink:label="loc_CELUFairValueOfWarrantModificationForProfessionalServices" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUFairValueOfWarrantModificationForProfessionalServices" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChangeInFairValueOfDebt" xlink:label="loc_CELUChangeInFairValueOfDebt" />
      <link:calculationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUChangeInFairValueOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChangeInFairValueOfContingentStockConsideration" xlink:label="loc_CELUChangeInFairValueOfContingentStockConsideration" />
      <link:calculationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUChangeInFairValueOfContingentStockConsideration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NonCashInterestExpense" xlink:label="loc_CELUNonCashInterestExpense" />
      <link:calculationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUNonCashInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingCapitalNet" />
      <link:calculationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" xlink:label="loc_CELUIncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" />
      <link:calculationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELUIncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromConvertibleNote" xlink:label="loc_CELUProceedsFromConvertibleNote" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_CELUProceedsFromConvertibleNote" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties" xlink:label="loc_CELUProceedsFromWarrantsAndShortTermDebtRelatedParties" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELUProceedsFromWarrantsAndShortTermDebtRelatedParties" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RepaymentsOfShortTermDebtUnaffiliated" xlink:label="loc_CELURepaymentsOfShortTermDebtUnaffiliated" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELURepaymentsOfShortTermDebtUnaffiliated" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering" xlink:label="loc_CELUProceedsFromTheSaleOfCommonStockInAtmOffering" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELUProceedsFromTheSaleOfCommonStockInAtmOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromShortTermDebtUnaffiliated" xlink:label="loc_CELUProceedsFromShortTermDebtUnaffiliated" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELUProceedsFromShortTermDebtUnaffiliated" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentOfSepaCommitmentFee" xlink:label="loc_CELUPaymentOfSepaCommitmentFee" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELUPaymentOfSepaCommitmentFee" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RepaymentsOfShortTermDebtRelatedParty" xlink:label="loc_CELURepaymentsOfShortTermDebtRelatedParty" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELURepaymentsOfShortTermDebtRelatedParty" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/NatureOfBusiness" xlink:title="999014 - Disclosure - Nature of Business" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/AssetAcquisition" xlink:title="999016 - Disclosure - Asset Acquisition" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilities" xlink:title="999017 - Disclosure - Fair Value of Financial Assets and Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/Inventory" xlink:title="999018 - Disclosure - Inventory" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999019 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/PropertyAndEquipmentNet" xlink:title="999020 - Disclosure - Property and Equipment, Net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/GoodwillAndIntangibleAssetsNet" xlink:title="999021 - Disclosure - Goodwill and Intangible Assets, Net" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999022 - Disclosure - Accrued Expenses and Other Current Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/Debt" xlink:title="999023 - Disclosure - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/Leases" xlink:title="999024 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/Equity" xlink:title="999026 - Disclosure - Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/Stock-basedCompensation" xlink:title="999027 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/RevenueRecognition" xlink:title="999028 - Disclosure - Revenue Recognition" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/LicenseAndDistributionAgreements" xlink:title="999029 - Disclosure - License and Distribution Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/BenefitPlan" xlink:title="999030 - Disclosure - Benefit Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/IncomeTaxes" xlink:title="999031 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/SegmentInformation" xlink:title="999032 - Disclosure - Segment Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/RelatedPartyTransactions" xlink:title="999033 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/SubsequentEvents" xlink:title="999034 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999035 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999036 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/AssetAcquisitionTables" xlink:title="999037 - Disclosure - Asset Acquisition (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:title="999038 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/InventoryTables" xlink:title="999039 - Disclosure - Inventory (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999040 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/PropertyAndEquipmentNetTables" xlink:title="999041 - Disclosure - Property and Equipment, Net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables" xlink:title="999042 - Disclosure - Goodwill and Intangible Assets, Net (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999043 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/DebtTables" xlink:title="999044 - Disclosure - Debt (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/LeasesTables" xlink:title="999045 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/EquityTables" xlink:title="999046 - Disclosure - Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/Stock-basedCompensationTables" xlink:title="999047 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/RevenueRecognitionTables" xlink:title="999048 - Disclosure - Revenue Recognition (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/IncomeTaxesTables" xlink:title="999049 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/SegmentInformationTables" xlink:title="999050 - Disclosure - Segment Information (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/NatureOfBusinessDetailsNarrative" xlink:title="999051 - Disclosure - Nature of Business (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:title="999052 - Disclosure - Schedule of Property and Equipment Estimated Useful Life (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999053 - Disclosure - Schedule of Potentially Dilutive Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails" xlink:title="999055 - Disclosure - Schedule of Purchase Price Allocated to Acquired Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/AssetAcquisitionDetailsNarrative" xlink:title="999056 - Disclosure - Asset Acquisition (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails" xlink:title="999057 - Disclosure - Schedule of Financial Assets and Liabilities Measures at Fair Value (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails" xlink:title="999058 - Disclosure - Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails" xlink:title="999059 - Disclosure - Schedule of Convertible Note Valuation Model (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" xlink:title="999060 - Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails" xlink:title="999061 - Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails" xlink:title="999062 - Disclosure - Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails" xlink:title="999063 - Disclosure - Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails" xlink:title="999064 - Disclosure - Schedule of Convertible Notes Valuation Model (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999065 - Disclosure - Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails" xlink:title="999066 - Disclosure - Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails" xlink:title="999067 - Disclosure - Schedule of January 20224 Bridge Loan (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails" xlink:title="999068 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical" xlink:title="999069 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails" xlink:title="999070 - Disclosure - Schedule of Significant Inputs for Sponsor Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative" xlink:title="999071 - Disclosure - Fair Value of Financial Assets and Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails" xlink:title="999072 - Disclosure - Schedule of Major Classes of Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryGrossCurrentAndNoncurrent" xlink:label="loc_CELUInventoryGrossCurrentAndNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryRawMaterialsCurrentAndNoncurrent" xlink:label="loc_CELUInventoryRawMaterialsCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUInventoryGrossCurrentAndNoncurrent" xlink:to="loc_CELUInventoryRawMaterialsCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryWorkInProgressCurrentAndNoncurrent" xlink:label="loc_CELUInventoryWorkInProgressCurrentAndNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUInventoryGrossCurrentAndNoncurrent" xlink:to="loc_CELUInventoryWorkInProgressCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:label="loc_CELUInventoryFinishedGoodsCurrentAndNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUInventoryGrossCurrentAndNoncurrent" xlink:to="loc_CELUInventoryFinishedGoodsCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryNetCurrentAndNoncurrent" xlink:label="loc_CELUInventoryNetCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUInventoryNetCurrentAndNoncurrent" xlink:to="loc_CELUInventoryGrossCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryReserveCurrentAndNoncurrent" xlink:label="loc_CELUInventoryReserveCurrentAndNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CELUInventoryNetCurrentAndNoncurrent" xlink:to="loc_CELUInventoryReserveCurrentAndNoncurrent" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfInventoryReservesDetails" xlink:title="999073 - Disclosure - Schedule of Inventory Reserves (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/InventoryDetailsNarrative" xlink:title="999074 - Disclosure - Inventory (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999075 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrepaidClinicalExpense" xlink:label="loc_CELUPrepaidClinicalExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_CELUPrepaidClinicalExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="999076 - Disclosure - Schedule of Property and Equipment, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="999077 - Disclosure - Property and Equipment, Net (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="999078 - Disclosure - Schedule of Intangible Assets, Net (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" xlink:title="999079 - Disclosure - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" xlink:title="999080 - Disclosure - Goodwill and Intangible Assets, Net (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999081 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedClinicalTrialExpense" xlink:label="loc_CELUAccruedClinicalTrialExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_CELUAccruedClinicalTrialExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccrualsForConstructionInProgress" xlink:label="loc_CELUAccrualsForConstructionInProgress" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_CELUAccrualsForConstructionInProgress" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedComplianceFee" xlink:label="loc_CELUAccruedComplianceFee" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_CELUAccruedComplianceFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfDebtDetails" xlink:title="999082 - Disclosure - Schedule of Debt (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/DebtDetailsNarrative" xlink:title="999083 - Disclosure - Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfLeaseCostsDetails" xlink:title="999084 - Disclosure - Schedule of Lease Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLeaseCost" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails" xlink:title="999085 - Disclosure - Schedule of Cash Activity Related to the lease Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:title="999086 - Disclosure - Schedule of Future Minimum Payments under Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/LeasesDetailsNarrative" xlink:title="999087 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999088 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfWarrantsDetails" xlink:title="999089 - Disclosure - Summary of the Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical" xlink:title="999090 - Disclosure - Summary of the Warrants (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/EquityDetailsNarrative" xlink:title="999091 - Disclosure - Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails" xlink:title="999092 - Disclosure - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999093 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical" xlink:title="999094 - Disclosure - Schedule of Stock Option Activity (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails" xlink:title="999095 - Disclosure - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999096 - Disclosure - Schedule of Stock-based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999097 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:title="999098 - Disclosure - Schedule of Disaggregated Revenue by Product and Services (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" xlink:title="999099 - Disclosure - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical" xlink:title="999100 - Disclosure -  Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative" xlink:title="999101 - Disclosure - License and Distribution Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/BenefitPlanDetailsNarrative" xlink:title="999102 - Disclosure - Benefit Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:title="999103 - Disclosure - Schedule of Current and Deferred Tax Provision (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails" xlink:title="999104 - Disclosure - Schedule of Reconciliation of the U.S federal statutory income tax (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" xlink:label="loc_CELUEffectiveIncomeTaxRateReconciliationInterestAccretionExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CELUEffectiveIncomeTaxRateReconciliationInterestAccretionExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" xlink:label="loc_CELUEffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CELUEffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp" xlink:label="loc_CELUEffectiveIncomeTaxRateReconciliationDeferredTrueUp" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_CELUEffectiveIncomeTaxRateReconciliationDeferredTrueUp" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999105 - Disclosure - Schedule of Deferred tax assets and liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="loc_CELUDeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CELUDeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsStartupCosts" xlink:label="loc_CELUDeferredTaxAssetsStartupCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CELUDeferredTaxAssetsStartupCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsUnicap" xlink:label="loc_CELUDeferredTaxAssetsUnicap" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CELUDeferredTaxAssetsUnicap" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsImputedInterestOnContingentPayments" xlink:label="loc_CELUDeferredTaxAssetsImputedInterestOnContingentPayments" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CELUDeferredTaxAssetsImputedInterestOnContingentPayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" xlink:label="loc_CELUDeferredTaxAssetsLegalFeeCapitalizationAndAmortization" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CELUDeferredTaxAssetsLegalFeeCapitalizationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="loc_CELUDeferredTaxAssetsCapitalizedResearchAndDevelopment" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CELUDeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsIrcSectionInterest" xlink:label="loc_CELUDeferredTaxAssetsIrcSectionInterest" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_CELUDeferredTaxAssetsIrcSectionInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:title="999106 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/IncomeTaxesDetailsNarrative" xlink:title="999107 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails" xlink:title="999108 - Disclosure - Schedule of Financial Information by Segment (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/SegmentInformationDetailsNarrative" xlink:title="999109 - Disclosure - Segment Information (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999110 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celularity.com/role/SubsequentEventsDetailsNarrative" xlink:title="999111 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>celu-20241231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celularity.com/role/Cover" xlink:href="celu-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BalanceSheets" xlink:href="celu-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BalanceSheetsParenthetical" xlink:href="celu-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="celu-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/StatementsOfStockholdersEquity" xlink:href="celu-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/StatementsOfCashFlows" xlink:href="celu-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/NatureOfBusiness" xlink:href="celu-20241231.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AssetAcquisition" xlink:href="celu-20241231.xsd#AssetAcquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilities" xlink:href="celu-20241231.xsd#FairValueOfFinancialAssetsAndLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Inventory" xlink:href="celu-20241231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="celu-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PropertyAndEquipmentNet" xlink:href="celu-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNet" xlink:href="celu-20241231.xsd#GoodwillAndIntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="celu-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Debt" xlink:href="celu-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Leases" xlink:href="celu-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/CommitmentsAndContingencies" xlink:href="celu-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Equity" xlink:href="celu-20241231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Stock-basedCompensation" xlink:href="celu-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RevenueRecognition" xlink:href="celu-20241231.xsd#RevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LicenseAndDistributionAgreements" xlink:href="celu-20241231.xsd#LicenseAndDistributionAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BenefitPlan" xlink:href="celu-20241231.xsd#BenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/IncomeTaxes" xlink:href="celu-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SegmentInformation" xlink:href="celu-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RelatedPartyTransactions" xlink:href="celu-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SubsequentEvents" xlink:href="celu-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AssetAcquisitionTables" xlink:href="celu-20241231.xsd#AssetAcquisitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:href="celu-20241231.xsd#FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/InventoryTables" xlink:href="celu-20241231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="celu-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PropertyAndEquipmentNetTables" xlink:href="celu-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables" xlink:href="celu-20241231.xsd#GoodwillAndIntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="celu-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/DebtTables" xlink:href="celu-20241231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LeasesTables" xlink:href="celu-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/EquityTables" xlink:href="celu-20241231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Stock-basedCompensationTables" xlink:href="celu-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RevenueRecognitionTables" xlink:href="celu-20241231.xsd#RevenueRecognitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/IncomeTaxesTables" xlink:href="celu-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SegmentInformationTables" xlink:href="celu-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/NatureOfBusinessDetailsNarrative" xlink:href="celu-20241231.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:href="celu-20241231.xsd#ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails" xlink:href="celu-20241231.xsd#ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AssetAcquisitionDetailsNarrative" xlink:href="celu-20241231.xsd#AssetAcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails" xlink:href="celu-20241231.xsd#ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfConvertibleNoteValuationModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfConvertibleNotesValuationModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails" xlink:href="celu-20241231.xsd#ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails" xlink:href="celu-20241231.xsd#ScheduleOfJanuary20224BridgeLoanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails" xlink:href="celu-20241231.xsd#ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical" xlink:href="celu-20241231.xsd#ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails" xlink:href="celu-20241231.xsd#ScheduleOfSignificantInputsForSponsorWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative" xlink:href="celu-20241231.xsd#FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails" xlink:href="celu-20241231.xsd#ScheduleOfMajorClassesOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfInventoryReservesDetails" xlink:href="celu-20241231.xsd#ScheduleOfInventoryReservesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/InventoryDetailsNarrative" xlink:href="celu-20241231.xsd#InventoryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="celu-20241231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="celu-20241231.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="celu-20241231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="celu-20241231.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" xlink:href="celu-20241231.xsd#ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" xlink:href="celu-20241231.xsd#GoodwillAndIntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfDebtDetails" xlink:href="celu-20241231.xsd#ScheduleOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/DebtDetailsNarrative" xlink:href="celu-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfLeaseCostsDetails" xlink:href="celu-20241231.xsd#ScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:href="celu-20241231.xsd#ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LeasesDetailsNarrative" xlink:href="celu-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="celu-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfWarrantsDetails" xlink:href="celu-20241231.xsd#SummaryOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical" xlink:href="celu-20241231.xsd#SummaryOfWarrantsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/EquityDetailsNarrative" xlink:href="celu-20241231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="celu-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical" xlink:href="celu-20241231.xsd#ScheduleOfStockOptionActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails" xlink:href="celu-20241231.xsd#ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="celu-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="celu-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:href="celu-20241231.xsd#ScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical" xlink:href="celu-20241231.xsd#ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative" xlink:href="celu-20241231.xsd#LicenseAndDistributionAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BenefitPlanDetailsNarrative" xlink:href="celu-20241231.xsd#BenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:href="celu-20241231.xsd#ScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="celu-20241231.xsd#ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/IncomeTaxesDetailsNarrative" xlink:href="celu-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails" xlink:href="celu-20241231.xsd#ScheduleOfFinancialInformationBySegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SegmentInformationDetailsNarrative" xlink:href="celu-20241231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="celu-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SubsequentEventsDetailsNarrative" xlink:href="celu-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ClassCommonStockParValue0.0001PerShareMember" xlink:label="loc_CELUClassCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CELUClassCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" xlink:label="loc_CELUWarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CELUWarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_70" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_70" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_70" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_70" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_70" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_70" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_70" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_70" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_70" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_70" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_70" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_70" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_70" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_70" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_70" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_70" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_70" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_70" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_70" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_70" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_70" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_70" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag_70" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag_70" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId_70" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorOpinionTextBlock_70" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName_70" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation_70" xlink:type="arc" order="63" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssetsCurrentAbstract_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PromissoryNotesReceivable" xlink:label="loc_CELUPromissoryNotesReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_CELUPromissoryNotesReceivable_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapInventoryNet_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_70" xlink:to="loc_us-gaapAssetsCurrent_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapGoodwill_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapRestrictedCashNoncurrent_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaapInventoryNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapInventoryNoncurrent_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapOtherAssetsNoncurrent_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_70" xlink:to="loc_us-gaapAssets_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccountsPayableCurrent_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedResearchAndDevelopmentSoftware" xlink:label="loc_CELUAccruedResearchAndDevelopmentSoftware_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_CELUAccruedResearchAndDevelopmentSoftware_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapShortTermBorrowings_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_70" xlink:to="loc_us-gaapLiabilitiesCurrent_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapContractWithCustomerLiabilityNoncurrent_70" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiability_70" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLongTermDebtNoncurrent_70" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_70" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiability" xlink:label="loc_CELUWarrantLiability_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_CELUWarrantLiability_70" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet_70" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent_70" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilities_70" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies_70" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_70" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapPreferredStockValue_70" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapCommonStockValue_70" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAdditionalPaidInCapital_70" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_70" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_70" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_70" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_70" xlink:type="arc" order="41" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseRoyaltyAndOtherMember" xlink:label="loc_CELULicenseRoyaltyAndOtherMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_CELULicenseRoyaltyAndOtherMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRevenuesAbstract_90" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="loc_us-gaapCostOfRevenueAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapCostOfRevenueAbstract_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCostOfRevenueAbstract_90" xlink:to="loc_us-gaapCostOfRevenue_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapGoodwillImpairmentLoss_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingIncomeCostsAndExpenses" xlink:label="loc_CELUOperatingIncomeCostsAndExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_90" xlink:to="loc_CELUOperatingIncomeCostsAndExpenses_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapOtherNonoperatingIncome_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapOtherNonoperatingExpense_90" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_90" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChangeInFairValueOfDebt" xlink:label="loc_CELUChangeInFairValueOfDebt_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_CELUChangeInFairValueOfDebt_90" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_90" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OtherNonoperatingIncomeExpenses" xlink:label="loc_CELUOtherNonoperatingIncomeExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_CELUOtherNonoperatingIncomeExpenses_90" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract_90" xlink:to="loc_us-gaapNonoperatingIncomeExpense_90" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_90" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_90" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_90" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_90" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax_90" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic_90" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted_90" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic_90" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding_90" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:label="loc_CELUStockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:label="loc_CELUStockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" xlink:label="loc_CELUStockIssuedDuringPeriodValuesShortTermDebtMaturityExtension_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValuesShortTermDebtMaturityExtension_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension" xlink:label="loc_CELUStockIssuedDuringPeriodSharesShortTermDebtMaturityExtension_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesShortTermDebtMaturityExtension_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueOfWarrantModificationForProfessionalService" xlink:label="loc_CELUFairValueOfWarrantModificationForProfessionalService_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUFairValueOfWarrantModificationForProfessionalService_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment" xlink:label="loc_CELUStockIssuedDuringPeriodValueOfResearchAndDevelopment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValueOfResearchAndDevelopment_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment" xlink:label="loc_CELUStockIssuedDuringPeriodSharesOfResearchAndDevelopment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesOfResearchAndDevelopment_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" xlink:label="loc_CELUStockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses" xlink:label="loc_CELUStockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueATMAgreement" xlink:label="loc_CELUStockIssuedDuringPeriodValueATMAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValueATMAgreement_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesATMAgreement" xlink:label="loc_CELUStockIssuedDuringPeriodSharesATMAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesATMAgreement_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent_60" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" xlink:label="loc_CELUStockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee_60" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee" xlink:label="loc_CELUStockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee_60" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" xlink:label="loc_CELUAdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUAdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants_60" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue_60" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_60" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" xlink:label="loc_CELUStockIssuedDuringPeriodValueConsiderationForSettlementAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValueConsiderationForSettlementAgreement_60" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement" xlink:label="loc_CELUStockIssuedDuringPeriodSharesConsiderationForSettlementAgreement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesConsiderationForSettlementAgreement_60" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:label="loc_CELUAdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUAdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_60" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/NatureOfBusiness" xlink:title="999014 - Disclosure - Nature of Business" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/AssetAcquisition" xlink:title="999016 - Disclosure - Asset Acquisition" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilities" xlink:title="999017 - Disclosure - Fair Value of Financial Assets and Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/Inventory" xlink:title="999018 - Disclosure - Inventory" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999019 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/PropertyAndEquipmentNet" xlink:title="999020 - Disclosure - Property and Equipment, Net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/GoodwillAndIntangibleAssetsNet" xlink:title="999021 - Disclosure - Goodwill and Intangible Assets, Net" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999022 - Disclosure - Accrued Expenses and Other Current Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/Debt" xlink:title="999023 - Disclosure - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/Leases" xlink:title="999024 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/Equity" xlink:title="999026 - Disclosure - Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/Stock-basedCompensation" xlink:title="999027 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/RevenueRecognition" xlink:title="999028 - Disclosure - Revenue Recognition" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/LicenseAndDistributionAgreements" xlink:title="999029 - Disclosure - License and Distribution Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/BenefitPlan" xlink:title="999030 - Disclosure - Benefit Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/IncomeTaxes" xlink:title="999031 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/SegmentInformation" xlink:title="999032 - Disclosure - Segment Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/RelatedPartyTransactions" xlink:title="999033 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/SubsequentEvents" xlink:title="999034 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999035 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999036 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/AssetAcquisitionTables" xlink:title="999037 - Disclosure - Asset Acquisition (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:title="999038 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AcquisitionRelatedContingentConsiderationObligationsMember" xlink:label="loc_CELUAcquisitionRelatedContingentConsiderationObligationsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CELUAcquisitionRelatedContingentConsiderationObligationsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContingentStockConsiderationMember" xlink:label="loc_CELUContingentStockConsiderationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CELUContingentStockConsiderationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNotesMember" xlink:label="loc_CELUUnsecuredSeniorConvertibleNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUUnsecuredSeniorConvertibleNotesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" xlink:label="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GXSponsorWarrantsMember" xlink:label="loc_CELUGXSponsorWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUGXSponsorWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock" xlink:label="loc_CELUScheduleOfConvertibleNoteValuationModelTableTextBlock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_CELUScheduleOfConvertibleNoteValuationModelTableTextBlock_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_CELUFairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_CELUFairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" xlink:label="loc_CELUScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_CELUScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_100" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/InventoryTables" xlink:title="999039 - Disclosure - Inventory (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999040 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/PropertyAndEquipmentNetTables" xlink:title="999041 - Disclosure - Property and Equipment, Net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables" xlink:title="999042 - Disclosure - Goodwill and Intangible Assets, Net (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999043 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/DebtTables" xlink:title="999044 - Disclosure - Debt (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/LeasesTables" xlink:title="999045 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/EquityTables" xlink:title="999046 - Disclosure - Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/Stock-basedCompensationTables" xlink:title="999047 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/RevenueRecognitionTables" xlink:title="999048 - Disclosure - Revenue Recognition (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/IncomeTaxesTables" xlink:title="999049 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/SegmentInformationTables" xlink:title="999050 - Disclosure - Segment Information (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/NatureOfBusinessDetailsNarrative" xlink:title="999051 - Disclosure - Nature of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_deiEntityIncorporationDateOfIncorporation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationDateOfIncorporation_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForManagementFee" xlink:label="loc_us-gaapPaymentForManagementFee_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentForManagementFee_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:title="999052 - Disclosure - Schedule of Property and Equipment Estimated Useful Life (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaapSoftwareDevelopmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareDevelopmentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_80" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999053 - Disclosure - Schedule of Potentially Dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeAxis" xlink:label="loc_us-gaapPledgingPurposeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapPledgingPurposeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeDomain" xlink:label="loc_us-gaapPledgingPurposeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPledgingPurposeAxis" xlink:to="loc_us-gaapPledgingPurposeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeDomain" xlink:label="loc_us-gaapPledgingPurposeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPledgingPurposeAxis" xlink:to="loc_us-gaapPledgingPurposeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaapLetterOfCreditMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPledgingPurposeDomain" xlink:to="loc_us-gaapLetterOfCreditMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CellTherapyMember" xlink:label="loc_CELUCellTherapyMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CELUCellTherapyMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ThreeCustomersMember" xlink:label="loc_CELUThreeCustomersMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_CELUThreeCustomersMember_110" xlink:type="arc" order="113" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoCustomersMember" xlink:label="loc_CELUTwoCustomersMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_CELUTwoCustomersMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CustomerOneMember" xlink:label="loc_CELUCustomerOneMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_CELUCustomerOneMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CustomerTwoMember" xlink:label="loc_CELUCustomerTwoMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_CELUCustomerTwoMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRestrictedCashNoncurrent_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLossNetOfTax" xlink:label="loc_us-gaapGoodwillImpairmentLossNetOfTax_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLossNetOfTax_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContractedStoragePeriods" xlink:label="loc_CELUContractedStoragePeriods_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUContractedStoragePeriods_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentPlansForCustomerToPayOverTimePeriod" xlink:label="loc_CELUPaymentPlansForCustomerToPayOverTimePeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUPaymentPlansForCustomerToPayOverTimePeriod_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" xlink:label="loc_CELUReductionOfResearchAndDevelopmentExpenseResultingFromGrant_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUReductionOfResearchAndDevelopmentExpenseResultingFromGrant_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InstrumentSpecificCreditRiskLoss" xlink:label="loc_CELUInstrumentSpecificCreditRiskLoss_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUInstrumentSpecificCreditRiskLoss_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InstrumentSpecificCreditRiskIncome" xlink:label="loc_CELUInstrumentSpecificCreditRiskIncome_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUInstrumentSpecificCreditRiskIncome_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion" xlink:label="loc_CELUAccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUAccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_180" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails" xlink:title="999055 - Disclosure - Schedule of Purchase Price Allocated to Acquired Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SequenceLifeScienceIncMember" xlink:label="loc_CELUSequenceLifeScienceIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_CELUSequenceLifeScienceIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_CELUAssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUAssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_CELUAssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUAssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/AssetAcquisitionDetailsNarrative" xlink:title="999056 - Disclosure - Asset Acquisition (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SequenceLifeScienceIncMember" xlink:label="loc_CELUSequenceLifeScienceIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_CELUSequenceLifeScienceIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:label="loc_us-gaapAssetAcquisitionPriceOfAcquisitionExpected_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionPriceOfAcquisitionExpected_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UpfrontPayment" xlink:label="loc_CELUUpfrontPayment_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUUpfrontPayment_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MonthlyMilestonePayments" xlink:label="loc_CELUMonthlyMilestonePayments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUMonthlyMilestonePayments_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PriorPaymentToRelatedParty" xlink:label="loc_CELUPriorPaymentToRelatedParty_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUPriorPaymentToRelatedParty_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NetSalesPercentage" xlink:label="loc_CELUNetSalesPercentage_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUNetSalesPercentage_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PurchasePriceContingentConsideration" xlink:label="loc_CELUPurchasePriceContingentConsideration_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUPurchasePriceContingentConsideration_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MilestonePayments" xlink:label="loc_CELUMilestonePayments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUMilestonePayments_40" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails" xlink:title="999057 - Disclosure - Schedule of Financial Assets and Liabilities Measures at Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContingentStockConsideration" xlink:label="loc_CELUContingentStockConsideration_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_CELUContingentStockConsideration_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtFairValue" xlink:label="loc_us-gaapShorttermDebtFairValue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_us-gaapShorttermDebtFairValue_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes" xlink:label="loc_CELUShorttermDebtUnsecuredSeniorConvertibleNotes_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_CELUShorttermDebtUnsecuredSeniorConvertibleNotes_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityRegisteredDirectWarrantsTwo" xlink:label="loc_CELUWarrantLiabilityRegisteredDirectWarrantsTwo_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_CELUWarrantLiabilityRegisteredDirectWarrantsTwo_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityRegisteredDirectWarrants" xlink:label="loc_CELUWarrantLiabilityRegisteredDirectWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_CELUWarrantLiabilityRegisteredDirectWarrants_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" xlink:label="loc_CELUWarrantLiabilityPrivateInvestmentInPublicEquityWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_CELUWarrantLiabilityPrivateInvestmentInPublicEquityWarrants_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPurchaserWarrants" xlink:label="loc_CELUWarrantLiabilityPurchaserWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_CELUWarrantLiabilityPurchaserWarrants_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPlacementAgentWarrants" xlink:label="loc_CELUWarrantLiabilityPlacementAgentWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_CELUWarrantLiabilityPlacementAgentWarrants_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilitySponsorWarrants" xlink:label="loc_CELUWarrantLiabilitySponsorWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_CELUWarrantLiabilitySponsorWarrants_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPublicWarrants" xlink:label="loc_CELUWarrantLiabilityPublicWarrants_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_CELUWarrantLiabilityPublicWarrants_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract_90" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaapAssetsFairValueDisclosureAbstract_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosureAbstract_90" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFairValueDisclosure" xlink:label="loc_us-gaapReceivablesFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsFairValueDisclosureAbstract_90" xlink:to="loc_us-gaapReceivablesFairValueDisclosure_90" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsFairValueDisclosureAbstract_90" xlink:to="loc_us-gaapAssetsFairValueDisclosure_90" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails" xlink:title="999058 - Disclosure - Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails" xlink:title="999059 - Disclosure - Schedule of Convertible Note Valuation Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FaceValueOfNotesReceivable" xlink:label="loc_CELUFaceValueOfNotesReceivable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUFaceValueOfNotesReceivable_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfCouponRate" xlink:label="loc_CELUPercentageOfCouponRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUPercentageOfCouponRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ValuationInputForConvertiblePromissoryNoteTerm" xlink:label="loc_CELUValuationInputForConvertiblePromissoryNoteTerm_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUValuationInputForConvertiblePromissoryNoteTerm_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ValuationInputForConvertiblePromissoryNote" xlink:label="loc_CELUValuationInputForConvertiblePromissoryNote_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUValuationInputForConvertiblePromissoryNote_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" xlink:title="999060 - Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AcquisitionRelatedContingentConsiderationObligationsMember" xlink:label="loc_CELUAcquisitionRelatedContingentConsiderationObligationsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CELUAcquisitionRelatedContingentConsiderationObligationsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails" xlink:title="999061 - Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContingentStockConsiderationMember" xlink:label="loc_CELUContingentStockConsiderationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CELUContingentStockConsiderationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails" xlink:title="999062 - Disclosure - Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_YorkvilleMember" xlink:label="loc_CELUYorkvilleMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUYorkvilleMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermBorrowings_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" xlink:label="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" xlink:label="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" xlink:label="loc_CELUIssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUIssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueAdjustmentThroughEarnings" xlink:label="loc_CELUFairValueAdjustmentThroughEarnings_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFairValueAdjustmentThroughEarnings_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" xlink:label="loc_CELUFairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual" xlink:label="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails" xlink:title="999063 - Disclosure - Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputCreditSpreadMember" xlink:label="loc_us-gaapMeasurementInputCreditSpreadMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputCreditSpreadMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails" xlink:title="999064 - Disclosure - Schedule of Convertible Notes Valuation Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNotesMember" xlink:label="loc_CELUUnsecuredSeniorConvertibleNotesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUUnsecuredSeniorConvertibleNotesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputCreditSpreadMember" xlink:label="loc_us-gaapMeasurementInputCreditSpreadMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputCreditSpreadMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_270" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput_270" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_270" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999065 - Disclosure - Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails" xlink:title="999066 - Disclosure - Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" xlink:label="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_140" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails" xlink:title="999067 - Disclosure - Schedule of January 20224 Bridge Loan (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate" xlink:label="loc_CELUWarrantsAndRightsOutstandingTermToInitialExerciseDate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUWarrantsAndRightsOutstandingTermToInitialExerciseDate_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_100" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails" xlink:title="999068 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing" xlink:label="loc_CELUWarrantsAndRightsOutstandingTermToSubsequentFinancing_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUWarrantsAndRightsOutstandingTermToSubsequentFinancing_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_240" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical" xlink:title="999069 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPurchaserWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPurchaserWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FloorPrice" xlink:label="loc_CELUFloorPrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELUFloorPrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OfferingPricePercentage" xlink:label="loc_CELUOfferingPricePercentage_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELUOfferingPricePercentage_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails" xlink:title="999070 - Disclosure - Schedule of Significant Inputs for Sponsor Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SponsorsWarrantsMember" xlink:label="loc_CELUSponsorsWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUSponsorsWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_90" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative" xlink:title="999071 - Disclosure - Fair Value of Financial Assets and Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SanuwaveForbearanceAgreementMember" xlink:label="loc_CELUSanuwaveForbearanceAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUSanuwaveForbearanceAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LetterAgreementMember" xlink:label="loc_CELULetterAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELULetterAgreementMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_YorkvilleMember" xlink:label="loc_CELUYorkvilleMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUYorkvilleMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNotesMember" xlink:label="loc_CELUUnsecuredSeniorConvertibleNotesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUUnsecuredSeniorConvertibleNotesMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ForbearanceExtendMaturityPeriod" xlink:label="loc_CELUForbearanceExtendMaturityPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUForbearanceExtendMaturityPeriod_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IncreasedNotePayments" xlink:label="loc_CELUIncreasedNotePayments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUIncreasedNotePayments_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaapConvertibleDebtFairValueDisclosures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapConvertibleDebtFairValueDisclosures_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails" xlink:title="999072 - Disclosure - Schedule of Major Classes of Inventories (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfInventoryReservesDetails" xlink:title="999073 - Disclosure - Schedule of Inventory Reserves (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/InventoryDetailsNarrative" xlink:title="999074 - Disclosure - Inventory (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaapInventoryLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaapInventoryCurrentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInventoryLineItems" xlink:to="loc_us-gaapInventoryCurrentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaapPublicUtilitiesInventoryAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapInventoryCurrentTable" xlink:to="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaapPublicUtilitiesInventoryTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:to="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaapPublicUtilitiesInventoryTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:to="loc_us-gaapPublicUtilitiesInventoryTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryFinishedGoodsMember" xlink:label="loc_CELUInventoryFinishedGoodsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:to="loc_CELUInventoryFinishedGoodsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryWorkInProgressMember" xlink:label="loc_CELUInventoryWorkInProgressMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:to="loc_CELUInventoryWorkInProgressMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryImpairmentCharge" xlink:label="loc_CELUInventoryImpairmentCharge_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInventoryLineItems" xlink:to="loc_CELUInventoryImpairmentCharge_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999075 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="999076 - Disclosure - Schedule of Property and Equipment, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LaboratoryAndProductionEquipmentMember" xlink:label="loc_CELULaboratoryAndProductionEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CELULaboratoryAndProductionEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MachineryEquipmentAndFixturesMember" xlink:label="loc_CELUMachineryEquipmentAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CELUMachineryEquipmentAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="999077 - Disclosure - Property and Equipment, Net (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="999078 - Disclosure - Schedule of Intangible Assets, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaapDevelopedTechnologyRightsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapDevelopedTechnologyRightsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaapTrademarksAndTradeNamesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksAndTradeNamesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReacquiredRightsMember" xlink:label="loc_CELUReacquiredRightsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_CELUReacquiredRightsMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_210" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_210" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_210" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_210" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_210" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="loc_CELUIndefiniteLivedIntangibleAssetsAmortizationMethod_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_CELUIndefiniteLivedIntangibleAssetsAmortizationMethod_210" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_210" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" xlink:title="999079 - Disclosure - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" xlink:title="999080 - Disclosure - Goodwill and Intangible Assets, Net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CellTherapyMember" xlink:label="loc_CELUCellTherapyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CELUCellTherapyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapGoodwill_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaapOtherAssetImpairmentCharges_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapOtherAssetImpairmentCharges_80" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999081 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfDebtDetails" xlink:title="999082 - Disclosure - Schedule of Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_YorkvilleMember" xlink:label="loc_CELUYorkvilleMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUYorkvilleMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrePaidAdvanceAgreementMember" xlink:label="loc_CELUPrePaidAdvanceAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUPrePaidAdvanceAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNoteMember" xlink:label="loc_CELUUnsecuredSeniorConvertibleNoteMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUUnsecuredSeniorConvertibleNoteMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarrBridgeLoanNetOfDiscountMember" xlink:label="loc_CELUCVStarrBridgeLoanNetOfDiscountMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUCVStarrBridgeLoanNetOfDiscountMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RWIBridgeLoanNetOfDiscountMember" xlink:label="loc_CELURWIBridgeLoanNetOfDiscountMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELURWIBridgeLoanNetOfDiscountMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CEOPromissoryNoteMember" xlink:label="loc_CELUCEOPromissoryNoteMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUCEOPromissoryNoteMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShortTermDebtUnaffiliated" xlink:label="loc_CELUShortTermDebtUnaffiliated_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUShortTermDebtUnaffiliated_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OtherShortTermDebt" xlink:label="loc_CELUOtherShortTermDebt_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUOtherShortTermDebt_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShortTermDebtRelatedParty" xlink:label="loc_CELUShortTermDebtRelatedParty_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUShortTermDebtRelatedParty_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_Debt" xlink:label="loc_CELUDebt_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebt_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermBorrowings_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent_190" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/DebtDetailsNarrative" xlink:title="999083 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_YorkvilleMember" xlink:label="loc_CELUYorkvilleMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUYorkvilleMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarrCoIncMember" xlink:label="loc_CELUCVStarrCoIncMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUCVStarrCoIncMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ResortsWorldIncPteLtdMember" xlink:label="loc_CELUResortsWorldIncPteLtdMember_700" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUResortsWorldIncPteLtdMember_700" xlink:type="arc" order="702" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrePaidAdvanceAgreementMember" xlink:label="loc_CELUPrePaidAdvanceAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUPrePaidAdvanceAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StandbyEquityPurchaseAgreementMember" xlink:label="loc_CELUStandbyEquityPurchaseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUStandbyEquityPurchaseAgreementMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ForbearanceAgreementMember" xlink:label="loc_CELUForbearanceAgreementMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUForbearanceAgreementMember_390" xlink:type="arc" order="392" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_670" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapWarrantMember_670" xlink:type="arc" order="673" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CEOPromissoryNoteMember" xlink:label="loc_CELUCEOPromissoryNoteMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUCEOPromissoryNoteMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaapBridgeLoanMember_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapBridgeLoanMember_480" xlink:type="arc" order="481" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNotesMember" xlink:label="loc_CELUUnsecuredSeniorConvertibleNotesMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELUUnsecuredSeniorConvertibleNotesMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LoanAgreementMember" xlink:label="loc_CELULoanAgreementMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELULoanAgreementMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialLoanMember" xlink:label="loc_CELUInitialLoanMember_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELUInitialLoanMember_480" xlink:type="arc" order="482" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdditionalLoanMember" xlink:label="loc_CELUAdditionalLoanMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELUAdditionalLoanMember_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChairmanAndChiefExecutiveOfficerMember" xlink:label="loc_CELUChairmanAndChiefExecutiveOfficerMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUChairmanAndChiefExecutiveOfficerMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_340" xlink:type="arc" order="343" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TrancheTwoWarrantMember" xlink:label="loc_CELUTrancheTwoWarrantMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUTrancheTwoWarrantMember_410" xlink:type="arc" order="414" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TrancheOneWarrantMember" xlink:label="loc_CELUTrancheOneWarrantMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUTrancheOneWarrantMember_570" xlink:type="arc" order="571" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialAndSecondTrancheMember" xlink:label="loc_CELUInitialAndSecondTrancheMember_610" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUInitialAndSecondTrancheMember_610" xlink:type="arc" order="611" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_750" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrePaidAdvancePeriod" xlink:label="loc_CELUPrePaidAdvancePeriod_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPrePaidAdvancePeriod_750" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_750" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrePaidAdvanceIssuedDiscountPercentage" xlink:label="loc_CELUPrePaidAdvanceIssuedDiscountPercentage_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPrePaidAdvanceIssuedDiscountPercentage_750" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod_750" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" xlink:label="loc_CELULineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELULineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_750" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockMinimumOptionPricePerShare" xlink:label="loc_CELUIssuanceOfCommonStockMinimumOptionPricePerShare_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUIssuanceOfCommonStockMinimumOptionPricePerShare_750" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MaximumPercentageOfCommonStockIssued" xlink:label="loc_CELUMaximumPercentageOfCommonStockIssued_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUMaximumPercentageOfCommonStockIssued_750" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfBeneficialOwnershipLimitation" xlink:label="loc_CELUPercentageOfBeneficialOwnershipLimitation_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfBeneficialOwnershipLimitation_750" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MinimumNumberOfSharesOfCommonStockPurchase" xlink:label="loc_CELUMinimumNumberOfSharesOfCommonStockPurchase_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUMinimumNumberOfSharesOfCommonStockPurchase_750" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MinimumRequiredDailyVolumeWeightedAveragePrice" xlink:label="loc_CELUMinimumRequiredDailyVolumeWeightedAveragePrice_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUMinimumRequiredDailyVolumeWeightedAveragePrice_750" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice" xlink:label="loc_CELURequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELURequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice_750" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice" xlink:label="loc_CELURedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELURedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice_750" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice" xlink:label="loc_CELURedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELURedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice_750" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapSharePrice_750" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuancePricePercentage" xlink:label="loc_CELUIssuancePricePercentage_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUIssuancePricePercentage_750" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromLinesOfCreditGross" xlink:label="loc_CELUProceedsFromLinesOfCreditGross_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUProceedsFromLinesOfCreditGross_750" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit_750" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationPeriod_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationPeriod_750" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1_750" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtConversionOriginalDebtAccruedInterestAmount" xlink:label="loc_CELUDebtConversionOriginalDebtAccruedInterestAmount_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtConversionOriginalDebtAccruedInterestAmount_750" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_750" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentPayment" xlink:label="loc_CELUDebtInstrumentPayment_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentPayment_750" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfShortTermDebt_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapRepaymentsOfShortTermDebt_750" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentAccruedInterest" xlink:label="loc_CELUDebtInstrumentAccruedInterest_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentAccruedInterest_750" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentRedemptionPremium" xlink:label="loc_CELUDebtInstrumentRedemptionPremium_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentRedemptionPremium_750" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue_750" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultShorttermDebtAmount" xlink:label="loc_us-gaapDebtDefaultShorttermDebtAmount_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtDefaultShorttermDebtAmount_750" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt_750" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentPerDiemInterestAmount" xlink:label="loc_CELUDebtInstrumentPerDiemInterestAmount_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentPerDiemInterestAmount_750" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_750" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal_750" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNoteDiscountPercentage" xlink:label="loc_CELUConvertiblePromissoryNoteDiscountPercentage_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUConvertiblePromissoryNoteDiscountPercentage_750" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_750" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_750" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfConversionOnOutstandingCommonStock" xlink:label="loc_CELUPercentageOfConversionOnOutstandingCommonStock_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfConversionOnOutstandingCommonStock_750" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentDefaultInterestRate" xlink:label="loc_CELUDebtInstrumentDefaultInterestRate_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentDefaultInterestRate_750" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium_750" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapSharesIssued_750" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NotesAndPurchaserWarrantsPrincipalAmount" xlink:label="loc_CELUNotesAndPurchaserWarrantsPrincipalAmount_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUNotesAndPurchaserWarrantsPrincipalAmount_750" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromNotesAndPurchaserWarrants" xlink:label="loc_CELUProceedsFromNotesAndPurchaserWarrants_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUProceedsFromNotesAndPurchaserWarrants_750" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_750" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_750" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MinimumGrossProceeds" xlink:label="loc_CELUMinimumGrossProceeds_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUMinimumGrossProceeds_750" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FloorPrice" xlink:label="loc_CELUFloorPrice_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFloorPrice_750" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_750" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfCashFeeEqualToAggregateProceeds" xlink:label="loc_CELUPercentageOfCashFeeEqualToAggregateProceeds_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfCashFeeEqualToAggregateProceeds_750" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfExercisePriceEqualToOfferingPrice" xlink:label="loc_CELUPercentageOfExercisePriceEqualToOfferingPrice_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfExercisePriceEqualToOfferingPrice_750" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapOtherExpenses_750" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes" xlink:label="loc_CELUShorttermDebtUnsecuredSeniorConvertibleNotes_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUShorttermDebtUnsecuredSeniorConvertibleNotes_750" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_750" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentContributionAmount" xlink:label="loc_CELUDebtInstrumentContributionAmount_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentContributionAmount_750" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_750" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaapProceedsFromOtherShortTermDebt_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapProceedsFromOtherShortTermDebt_750" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_750" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermBorrowings_750" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OtherShortTermDebtDueToRelatedParty" xlink:label="loc_CELUOtherShortTermDebtDueToRelatedParty_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUOtherShortTermDebtDueToRelatedParty_750" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentOriginalIssueDiscount" xlink:label="loc_CELUDebtInstrumentOriginalIssueDiscount_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentOriginalIssueDiscount_750" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault" xlink:label="loc_CELUDebtInstrumentInterestRateEffectivePercentageInEventOfDefault_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentInterestRateEffectivePercentageInEventOfDefault_750" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_750" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShareIssuedPurchasedPrice" xlink:label="loc_CELUShareIssuedPurchasedPrice_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUShareIssuedPurchasedPrice_750" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_750" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FallInCashAndCashEquivalents" xlink:label="loc_CELUFallInCashAndCashEquivalents_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFallInCashAndCashEquivalents_750" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_750" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ClassOfWarrantOrRighstExpirationDate" xlink:label="loc_CELUClassOfWarrantOrRighstExpirationDate_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUClassOfWarrantOrRighstExpirationDate_750" xlink:type="arc" order="64" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfChangesInCashFlow" xlink:label="loc_CELUPercentageOfChangesInCashFlow_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfChangesInCashFlow_750" xlink:type="arc" order="65" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_750" xlink:type="arc" order="66" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaapRepaymentsOfOtherDebt_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapRepaymentsOfOtherDebt_750" xlink:type="arc" order="67" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShortTermDebtRelatedParties" xlink:label="loc_CELUShortTermDebtRelatedParties_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUShortTermDebtRelatedParties_750" xlink:type="arc" order="68" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentDiscount" xlink:label="loc_CELUDebtInstrumentDiscount_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentDiscount_750" xlink:type="arc" order="69" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault" xlink:label="loc_CELUDebtInstrumentInterestRateDuringPeriodInEventOfDefault_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentInterestRateDuringPeriodInEventOfDefault_750" xlink:type="arc" order="70" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DiscountOnWarrantAmount" xlink:label="loc_CELUDiscountOnWarrantAmount_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDiscountOnWarrantAmount_750" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice" xlink:label="loc_CELUPercentageOfPartialLiquidatingDamagesOnPurchasePrice_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfPartialLiquidatingDamagesOnPurchasePrice_750" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" xlink:label="loc_CELUPercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_750" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DailyInterestAccruingRate" xlink:label="loc_CELUDailyInterestAccruingRate_750" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDailyInterestAccruingRate_750" xlink:type="arc" order="74" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfLeaseCostsDetails" xlink:title="999084 - Disclosure - Schedule of Lease Costs (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails" xlink:title="999085 - Disclosure - Schedule of Cash Activity Related to the lease Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:title="999086 - Disclosure - Schedule of Future Minimum Payments under Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/LeasesDetailsNarrative" xlink:title="999087 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OfficeManufacturingAndLaboratorySpaceMember" xlink:label="loc_CELUOfficeManufacturingAndLaboratorySpaceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CELUOfficeManufacturingAndLaboratorySpaceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FlorhamParkNewJerseyMember" xlink:label="loc_CELUFlorhamParkNewJerseyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CELUFlorhamParkNewJerseyMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LegacyCelularityMember" xlink:label="loc_CELULegacyCelularityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CELULegacyCelularityMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLeasesRentExpense" xlink:label="loc_CELUOperatingLeasesRentExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUOperatingLeasesRentExpense_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AreaOfBuilding" xlink:label="loc_CELUAreaOfBuilding_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUAreaOfBuilding_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLeaseExpiryYear" xlink:label="loc_CELUOperatingLeaseExpiryYear_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUOperatingLeaseExpiryYear_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLeaseCommencementDate" xlink:label="loc_CELUOperatingLeaseCommencementDate_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUOperatingLeaseCommencementDate_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialMonthlyBaseRent" xlink:label="loc_CELUInitialMonthlyBaseRent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUInitialMonthlyBaseRent_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRestrictedCashNoncurrent_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements" xlink:label="loc_us-gaapTenantImprovements_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapTenantImprovements_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReductionInLineOfCredit" xlink:label="loc_CELUReductionInLineOfCredit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUReductionInLineOfCredit_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NewLineOfCredit" xlink:label="loc_CELUNewLineOfCredit_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUNewLineOfCredit_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BaseRentalPayments" xlink:label="loc_CELUBaseRentalPayments_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUBaseRentalPayments_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent_90" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999088 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember" xlink:label="loc_CELUHLICellularTherapeuticsLLCAndAnthrogenesisMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUHLICellularTherapeuticsLLCAndAnthrogenesisMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LegacyCelularitysMember" xlink:label="loc_CELULegacyCelularitysMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CELULegacyCelularitysMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PalantirTechnologiesIncMember" xlink:label="loc_CELUPalantirTechnologiesIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CELUPalantirTechnologiesIncMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MasterSubscriptionAgreementMember" xlink:label="loc_CELUMasterSubscriptionAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUMasterSubscriptionAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAgreementMember" xlink:label="loc_CELULicenseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELULicenseAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SettlementAndReleaseAgreementMember" xlink:label="loc_CELUSettlementAndReleaseAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUSettlementAndReleaseAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SoftwareCeaseUseCostsMember" xlink:label="loc_CELUSoftwareCeaseUseCostsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_CELUSoftwareCeaseUseCostsMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EvolutionMember" xlink:label="loc_CELUEvolutionMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_CELUEvolutionMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_HackensackMeridianHealthMember" xlink:label="loc_CELUHackensackMeridianHealthMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CELUHackensackMeridianHealthMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentsForMasterSubscriptionAgreement" xlink:label="loc_CELUPaymentsForMasterSubscriptionAgreement_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUPaymentsForMasterSubscriptionAgreement_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentSubscriptionPeriod" xlink:label="loc_CELUPaymentSubscriptionPeriod_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUPaymentSubscriptionPeriod_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaapBusinessExitCosts1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessExitCosts1_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedResearchAndDevelopmentSoftware" xlink:label="loc_CELUAccruedResearchAndDevelopmentSoftware_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUAccruedResearchAndDevelopmentSoftware_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UpfrontFee" xlink:label="loc_CELUUpfrontFee_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUUpfrontFee_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AnnualMaintenanceFee" xlink:label="loc_CELUAnnualMaintenanceFee_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUAnnualMaintenanceFee_160" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ClinicalAndRegulatoryMilestones" xlink:label="loc_CELUClinicalAndRegulatoryMilestones_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUClinicalAndRegulatoryMilestones_160" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaapLongtermPurchaseCommitmentPeriod_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLongtermPurchaseCommitmentPeriod_160" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAgreementNoticePeriod" xlink:label="loc_CELULicenseAgreementNoticePeriod_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELULicenseAgreementNoticePeriod_160" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements_160" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NumberOfSharesIssuedForPiggybackRegistrationRights" xlink:label="loc_CELUNumberOfSharesIssuedForPiggybackRegistrationRights_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUNumberOfSharesIssuedForPiggybackRegistrationRights_160" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfBiomaterialProductsAmount" xlink:label="loc_CELUSaleOfBiomaterialProductsAmount_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUSaleOfBiomaterialProductsAmount_160" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AffiliateCosts" xlink:label="loc_us-gaapAffiliateCosts_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAffiliateCosts_160" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfWarrantsDetails" xlink:title="999089 - Disclosure - Summary of the Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DragasacWarrantMember" xlink:label="loc_CELUDragasacWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUDragasacWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PublicWarrantsMember" xlink:label="loc_CELUPublicWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUPublicWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SponsorWarrantsMember" xlink:label="loc_CELUSponsorWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUSponsorWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:label="loc_CELUAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" xlink:label="loc_CELUAprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUAprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JuneTwoThousandTwentyThreeWarrantsMember" xlink:label="loc_CELUJuneTwoThousandTwentyThreeWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJuneTwoThousandTwentyThreeWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="loc_CELUJuneTwoThousandTwentyThreeLoanWarrantsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJuneTwoThousandTwentyThreeLoanWarrantsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:label="loc_CELUJulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourPipeWarrantsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourPipeWarrantsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPurchaseWarrantsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPurchaseWarrantsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourPIPEWarrantMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourPIPEWarrantMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_270" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_270" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_270" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical" xlink:title="999090 - Disclosure - Summary of the Warrants (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandTwentyFourWarrantRepricingMember" xlink:label="loc_CELUTwoThousandTwentyFourWarrantRepricingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUTwoThousandTwentyFourWarrantRepricingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DragasacWarrantMember" xlink:label="loc_CELUDragasacWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUDragasacWarrantMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PublicWarrantsMember" xlink:label="loc_CELUPublicWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUPublicWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SponsorWarrantsMember" xlink:label="loc_CELUSponsorWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUSponsorWarrantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StarrForbearanceAgreementMember" xlink:label="loc_CELUStarrForbearanceAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUStarrForbearanceAgreementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarrCoIncMember" xlink:label="loc_CELUCVStarrCoIncMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUCVStarrCoIncMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NumberOfWarrantsRepriced" xlink:label="loc_CELUNumberOfWarrantsRepriced_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELUNumberOfWarrantsRepriced_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsOutstanding" xlink:label="loc_CELUWarrantsOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELUWarrantsOutstanding_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_110" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/EquityDetailsNarrative" xlink:title="999091 - Disclosure - Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AtTheMarketSalesAgreementMember" xlink:label="loc_CELUAtTheMarketSalesAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUAtTheMarketSalesAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_250" xlink:type="arc" order="252" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember" xlink:label="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_550" xlink:type="arc" order="551" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StandbyEquityPurchaseAgreementMember" xlink:label="loc_CELUStandbyEquityPurchaseAgreementMember_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUStandbyEquityPurchaseAgreementMember_630" xlink:type="arc" order="633" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LegacyCelularityMember" xlink:label="loc_CELULegacyCelularityMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CELULegacyCelularityMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_120" xlink:type="arc" order="124" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapWarrantMember_550" xlink:type="arc" order="553" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChairmanAndChiefExecutiveOfficerMember" xlink:label="loc_CELUChairmanAndChiefExecutiveOfficerMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUChairmanAndChiefExecutiveOfficerMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChiefAdministrativeOfficerMember" xlink:label="loc_CELUChiefAdministrativeOfficerMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUChiefAdministrativeOfficerMember_490" xlink:type="arc" order="491" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourPipeWarrantsMember_380" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourPipeWarrantsMember_380" xlink:type="arc" order="383" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandTwentyFourWarrantRepricingMember" xlink:label="loc_CELUTwoThousandTwentyFourWarrantRepricingMember_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUTwoThousandTwentyFourWarrantRepricingMember_450" xlink:type="arc" order="451" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember_570" xlink:type="arc" order="576" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="loc_CELUJuneTwoThousandTwentyThreeLoanWarrantsMember_600" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUJuneTwoThousandTwentyThreeLoanWarrantsMember_600" xlink:type="arc" order="606" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InvestorRightsAgreementMember" xlink:label="loc_CELUInvestorRightsAgreementMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUInvestorRightsAgreementMember_460" xlink:type="arc" order="462" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RwiForbearanceAgreementMember" xlink:label="loc_CELURwiForbearanceAgreementMember_550" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELURwiForbearanceAgreementMember_550" xlink:type="arc" order="552" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ForbearanceAgreementMember" xlink:label="loc_CELUForbearanceAgreementMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUForbearanceAgreementMember_570" xlink:type="arc" order="572" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DragasacLimitedMember" xlink:label="loc_CELUDragasacLimitedMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CELUDragasacLimitedMember_460" xlink:type="arc" order="463" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_YorkvilleMember" xlink:label="loc_CELUYorkvilleMember_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CELUYorkvilleMember_630" xlink:type="arc" order="631" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AmendedEmploymentAgreementMember" xlink:label="loc_CELUAmendedEmploymentAgreementMember_490" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CELUAmendedEmploymentAgreementMember_490" xlink:type="arc" order="492" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_530" xlink:type="arc" order="532" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LoanAgreementMember" xlink:label="loc_CELULoanAgreementMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELULoanAgreementMember_570" xlink:type="arc" order="574" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarrCoIncMember" xlink:label="loc_CELUCVStarrCoIncMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUCVStarrCoIncMember_570" xlink:type="arc" order="575" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember_670" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember_670" xlink:type="arc" order="672" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_690" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_690" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_690" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_690" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockVotingRights_690" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfSharesRequiredForVoting" xlink:label="loc_CELUPercentageOfSharesRequiredForVoting_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUPercentageOfSharesRequiredForVoting_690" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_690" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_690" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AggregateOfferingPrice" xlink:label="loc_CELUAggregateOfferingPrice_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUAggregateOfferingPrice_690" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds" xlink:label="loc_CELUMaximumPercentageOfSalesCommissionFromGrossSalesProceeds_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUMaximumPercentageOfSalesCommissionFromGrossSalesProceeds_690" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_CELUGrossProceedsFromIssuanceOfCommonStock_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUGrossProceedsFromIssuanceOfCommonStock_690" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_690" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_690" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_690" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_690" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_690" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_690" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_690" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_690" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_690" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdjustedAdvanceNoticePeriod" xlink:label="loc_CELUAdjustedAdvanceNoticePeriod_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUAdjustedAdvanceNoticePeriod_690" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PremiumPaidForPrivatePlacementPurchase" xlink:label="loc_CELUPremiumPaidForPrivatePlacementPurchase_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUPremiumPaidForPrivatePlacementPurchase_690" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReducedExercisePrice" xlink:label="loc_CELUReducedExercisePrice_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUReducedExercisePrice_690" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_690" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_690" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantExpirationTerm" xlink:label="loc_CELUWarrantExpirationTerm_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUWarrantExpirationTerm_690" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentPayment" xlink:label="loc_CELUDebtInstrumentPayment_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUDebtInstrumentPayment_690" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueNetAssetsLiability" xlink:label="loc_CELUFairValueNetAssetsLiability_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUFairValueNetAssetsLiability_690" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AmendedTerminationDateDescription" xlink:label="loc_CELUAmendedTerminationDateDescription_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUAmendedTerminationDateDescription_690" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdditionalWarrantLiability" xlink:label="loc_CELUAdditionalWarrantLiability_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUAdditionalWarrantLiability_690" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiability" xlink:label="loc_CELUWarrantLiability_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUWarrantLiability_690" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsAndRightsIssuedClosingDate" xlink:label="loc_CELUWarrantsAndRightsIssuedClosingDate_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUWarrantsAndRightsIssuedClosingDate_690" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromPrivatePlacements" xlink:label="loc_CELUProceedsFromPrivatePlacements_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUProceedsFromPrivatePlacements_690" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NumberOfWarrantsRepriced" xlink:label="loc_CELUNumberOfWarrantsRepriced_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUNumberOfWarrantsRepriced_690" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost" xlink:label="loc_CELUFairValueOfWarrantModificationIncrementalForEquityIssuanceCost_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUFairValueOfWarrantModificationIncrementalForEquityIssuanceCost_690" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" xlink:label="loc_CELUPercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUPercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_690" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DailyInterestAccruingRate" xlink:label="loc_CELUDailyInterestAccruingRate_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUDailyInterestAccruingRate_690" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RelatedPartyBaseSalary" xlink:label="loc_CELURelatedPartyBaseSalary_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELURelatedPartyBaseSalary_690" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ClassOfWarrantOrRighstExpirationDate" xlink:label="loc_CELUClassOfWarrantOrRighstExpirationDate_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUClassOfWarrantOrRighstExpirationDate_690" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_690" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage" xlink:label="loc_CELUSaleOfStockMaximumAverageDailyTradedAmountPercentage_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUSaleOfStockMaximumAverageDailyTradedAmountPercentage_690" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays" xlink:label="loc_CELUSaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUSaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays_690" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice" xlink:label="loc_CELUSaleOfStockPercentageBasedOnVolumeWeightedAveragePrice_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUSaleOfStockPercentageBasedOnVolumeWeightedAveragePrice_690" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_690" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockConsiderationCashDueDiligenceFee" xlink:label="loc_CELUSaleOfStockConsiderationCashDueDiligenceFee_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUSaleOfStockConsiderationCashDueDiligenceFee_690" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockConsiderationCommitmentFeeInShares" xlink:label="loc_CELUSaleOfStockConsiderationCommitmentFeeInShares_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUSaleOfStockConsiderationCommitmentFeeInShares_690" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_690" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" xlink:label="loc_CELULineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_690" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELULineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_690" xlink:type="arc" order="47" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails" xlink:title="999092 - Disclosure - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999093 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="loc_CELUTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELUTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_50" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical" xlink:title="999094 - Disclosure - Schedule of Stock Option Activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandTwentyOnePlanMember" xlink:label="loc_CELUTwoThousandTwentyOnePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELUTwoThousandTwentyOnePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandSeventeenPlanMember" xlink:label="loc_CELUTwoThousandSeventeenPlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELUTwoThousandSeventeenPlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails" xlink:title="999095 - Disclosure - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999096 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999097 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="loc_CELUTwoThousandAndTwentyOneEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELUTwoThousandAndTwentyOneEquityIncentivePlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="loc_CELUTwoThousandAndSeventeenEquityIncentivePlanMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELUTwoThousandAndSeventeenEquityIncentivePlanMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AwardsWithPerformanceConditionsMember" xlink:label="loc_CELUAwardsWithPerformanceConditionsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELUAwardsWithPerformanceConditionsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarketConditionStockUnitMember" xlink:label="loc_CELUMarketConditionStockUnitMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELUMarketConditionStockUnitMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialTrancheMember" xlink:label="loc_CELUInitialTrancheMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUInitialTrancheMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecondTrancheMember" xlink:label="loc_CELUSecondTrancheMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUSecondTrancheMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_230" xlink:type="arc" order="232" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" xlink:label="loc_CELUShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELUShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_320" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_320" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_320" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_320" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_320" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_320" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_320" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_320" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_320" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_320" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_320" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_320" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_320" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation_320" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:title="999098 - Disclosure - Schedule of Disaggregated Revenue by Product and Services (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseRoyaltyAndOtherMember" xlink:label="loc_CELULicenseRoyaltyAndOtherMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_CELULicenseRoyaltyAndOtherMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" xlink:title="999099 - Disclosure - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical" xlink:title="999100 - Disclosure -  Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative" xlink:title="999101 - Disclosure - License and Distribution Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RegeneronResearchCollaborationServicesAgreementMember" xlink:label="loc_CELURegeneronResearchCollaborationServicesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELURegeneronResearchCollaborationServicesAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RegeneronServicesAgreementMember" xlink:label="loc_CELURegeneronServicesAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELURegeneronServicesAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PultheraLLCBindingTermSheetMember" xlink:label="loc_CELUPultheraLLCBindingTermSheetMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUPultheraLLCBindingTermSheetMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAgreementWithBiocellgraftIncMember" xlink:label="loc_CELULicenseAgreementWithBiocellgraftIncMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELULicenseAgreementWithBiocellgraftIncMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NonrefundableUpfrontPayment" xlink:label="loc_CELUNonrefundableUpfrontPayment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUNonrefundableUpfrontPayment_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ServiceAgreementTerm" xlink:label="loc_CELUServiceAgreementTerm_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUServiceAgreementTerm_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAgreementNoticePeriod" xlink:label="loc_CELULicenseAgreementNoticePeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELULicenseAgreementNoticePeriod_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaapDeferredRevenueRevenueRecognized1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenueRevenueRecognized1_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenue_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentOfOptionFeeInCash" xlink:label="loc_CELUPaymentOfOptionFeeInCash_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUPaymentOfOptionFeeInCash_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OptionFeeExpense" xlink:label="loc_CELUOptionFeeExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUOptionFeeExpense_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CommercialLicenseToDentalProductsAgreementPeriod" xlink:label="loc_CELUCommercialLicenseToDentalProductsAgreementPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUCommercialLicenseToDentalProductsAgreementPeriod_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm" xlink:label="loc_CELUCommercialLicenseToDentalProductsAgreementRenewalTerm_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUCommercialLicenseToDentalProductsAgreementRenewalTerm_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseFeeExpense" xlink:label="loc_CELULicenseFeeExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELULicenseFeeExpense_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseFeesPaymentPeriod" xlink:label="loc_CELULicenseFeesPaymentPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELULicenseFeesPaymentPeriod_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseFeePayment" xlink:label="loc_CELULicenseFeePayment_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELULicenseFeePayment_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdditionalLicenseFee" xlink:label="loc_CELUAdditionalLicenseFee_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUAdditionalLicenseFee_100" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/BenefitPlanDetailsNarrative" xlink:title="999102 - Disclosure - Benefit Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:title="999103 - Disclosure - Schedule of Current and Deferred Tax Provision (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails" xlink:title="999104 - Disclosure - Schedule of Reconciliation of the U.S federal statutory income tax (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999105 - Disclosure - Schedule of Deferred tax assets and liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:title="999106 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/IncomeTaxesDetailsNarrative" xlink:title="999107 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnitedStatesFederalAndStateMember" xlink:label="loc_CELUUnitedStatesFederalAndStateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CELUUnitedStatesFederalAndStateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_CELUOperatingLossCarryforwardsExpirationYear_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CELUOperatingLossCarryforwardsExpirationYear_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TaxCreditCarryforwardsExpirationYear" xlink:label="loc_CELUTaxCreditCarryforwardsExpirationYear_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CELUTaxCreditCarryforwardsExpirationYear_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_80" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails" xlink:title="999108 - Disclosure - Schedule of Financial Information by Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CellTherapyMember" xlink:label="loc_CELUCellTherapyMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CELUCellTherapyMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BiobankingMember" xlink:label="loc_CELUBiobankingMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CELUBiobankingMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DegenerativeDiseaseMember" xlink:label="loc_CELUDegenerativeDiseaseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CELUDegenerativeDiseaseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfRevenue_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts" xlink:label="loc_us-gaapDirectOperatingCosts_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDirectOperatingCosts_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SegmentContribution" xlink:label="loc_CELUSegmentContribution_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_CELUSegmentContribution_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IndirectExpenses" xlink:label="loc_CELUIndirectExpenses_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_CELUIndirectExpenses_90" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaapIncomeLossFromContinuingOperations_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperations_90" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense_90" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_90" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss_90" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InProcessResearchAndDevelopmentImpairment" xlink:label="loc_CELUInProcessResearchAndDevelopmentImpairment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_CELUInProcessResearchAndDevelopmentImpairment_90" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_90" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_90" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/SegmentInformationDetailsNarrative" xlink:title="999109 - Disclosure - Segment Information (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999110 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrRobertHaririMember" xlink:label="loc_CELUDrRobertHaririMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CELUDrRobertHaririMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AmendedAndRestatedEmploymentAgreementMember" xlink:label="loc_CELUAmendedAndRestatedEmploymentAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CELUAmendedAndRestatedEmploymentAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EmploymentOfImmediateFamilyMemberMember" xlink:label="loc_CELUEmploymentOfImmediateFamilyMemberMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CELUEmploymentOfImmediateFamilyMemberMember_300" xlink:type="arc" order="302" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecuritiesPurchaseAgreementMember" xlink:label="loc_CELUSecuritiesPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUSecuritiesPurchaseAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LoanAgreementMember" xlink:label="loc_CELULoanAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELULoanAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConsultingAgreementMember" xlink:label="loc_CELUConsultingAgreementMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUConsultingAgreementMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScientificAndClinicalAdvisorAgreementMember" xlink:label="loc_CELUScientificAndClinicalAdvisorAgreementMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUScientificAndClinicalAdvisorAgreementMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdvisoryAgreementMember" xlink:label="loc_CELUAdvisoryAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUAdvisoryAgreementMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrRobertHaririMember" xlink:label="loc_CELUDrRobertHaririMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUDrRobertHaririMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrAndrewPecoraMember" xlink:label="loc_CELUDrAndrewPecoraMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUDrAndrewPecoraMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RobinLSmithMdMember" xlink:label="loc_CELURobinLSmithMdMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELURobinLSmithMdMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_COTAIncMember" xlink:label="loc_CELUCOTAIncMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUCOTAIncMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CryoportSystemsIncMember" xlink:label="loc_CELUCryoportSystemsIncMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUCryoportSystemsIncMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarLoanMember" xlink:label="loc_CELUCVStarLoanMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUCVStarLoanMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ResortsWorldIncPteLtdMember" xlink:label="loc_CELUResortsWorldIncPteLtdMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUResortsWorldIncPteLtdMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember_240" xlink:type="arc" order="243" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrRobertHaririMember" xlink:label="loc_CELUDrRobertHaririMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUDrRobertHaririMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrHaririMember" xlink:label="loc_CELUDrHaririMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUDrHaririMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChairmanAndChiefExecutiveOfficerMember" xlink:label="loc_CELUChairmanAndChiefExecutiveOfficerMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUChairmanAndChiefExecutiveOfficerMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CEOPromissoryNoteMember" xlink:label="loc_CELUCEOPromissoryNoteMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUCEOPromissoryNoteMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialTrancheMember" xlink:label="loc_CELUInitialTrancheMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUInitialTrancheMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MsHaririMember" xlink:label="loc_CELUMsHaririMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CELUMsHaririMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities_330" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecuritiesPurchaseAgreementDate" xlink:label="loc_CELUSecuritiesPurchaseAgreementDate_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUSecuritiesPurchaseAgreementDate_330" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnpaidBaseSalary" xlink:label="loc_CELUUnpaidBaseSalary_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUUnpaidBaseSalary_330" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_330" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BonusProgramEffectiveDate" xlink:label="loc_CELUBonusProgramEffectiveDate_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUBonusProgramEffectiveDate_330" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfUnpaidBaseSalary" xlink:label="loc_CELUPercentageOfUnpaidBaseSalary_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUPercentageOfUnpaidBaseSalary_330" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfBaseSalary" xlink:label="loc_CELUPercentageOfBaseSalary_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUPercentageOfBaseSalary_330" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AnnualRateOfBaseSalary" xlink:label="loc_CELUAnnualRateOfBaseSalary_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUAnnualRateOfBaseSalary_330" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BaseSalaryEffectiveDate" xlink:label="loc_CELUBaseSalaryEffectiveDate_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUBaseSalaryEffectiveDate_330" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_330" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentContributionAmount" xlink:label="loc_CELUDebtInstrumentContributionAmount_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUDebtInstrumentContributionAmount_330" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_330" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_330" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_330" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement_330" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReceiveForMonth" xlink:label="loc_CELUReceiveForMonth_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUReceiveForMonth_330" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_330" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_330" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_330" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RelatedPartyCashBonus" xlink:label="loc_CELURelatedPartyCashBonus_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELURelatedPartyCashBonus_330" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentsToRelatedParty" xlink:label="loc_CELUPaymentsToRelatedParty_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUPaymentsToRelatedParty_330" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_330" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LoanAgreement" xlink:label="loc_CELULoanAgreement_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELULoanAgreement_330" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_330" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecondLoanAgreement" xlink:label="loc_CELUSecondLoanAgreement_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUSecondLoanAgreement_330" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RelatedPartyBaseSalary" xlink:label="loc_CELURelatedPartyBaseSalary_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELURelatedPartyBaseSalary_330" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celularity.com/role/SubsequentEventsDetailsNarrative" xlink:title="999111 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GenesisEquityGroupFundingLlcMember" xlink:label="loc_CELUGenesisEquityGroupFundingLlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CELUGenesisEquityGroupFundingLlcMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAccountsReceivableNet_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ApplicableFees" xlink:label="loc_CELUApplicableFees_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CELUApplicableFees_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomePurchasedReceivables" xlink:label="loc_us-gaapInterestIncomePurchasedReceivables_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInterestIncomePurchasedReceivables_30" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AwardsWithPerformanceConditionsMember" xlink:label="loc_CELUAwardsWithPerformanceConditionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELUAwardsWithPerformanceConditionsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarketConditionStockUnitMember" xlink:label="loc_CELUMarketConditionStockUnitMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELUMarketConditionStockUnitMember" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>celu-20241231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ClassCommonStockParValue0.0001PerShareMember" xlink:label="CELU_ClassCommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ClassCommonStockParValue0.0001PerShareMember" xlink:to="CELU_ClassCommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ClassCommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Class A common stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" xlink:label="CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" xlink:to="CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember_lbl" xml:lang="en-US">Warrants, each exercisable for one share of Class A common stock at an exercise price of $115 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseRoyaltyAndOtherMember" xlink:label="CELU_LicenseRoyaltyAndOtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseRoyaltyAndOtherMember" xlink:to="CELU_LicenseRoyaltyAndOtherMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LicenseRoyaltyAndOtherMember_lbl" xml:lang="en-US">License Royalty and Other [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Common Class A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeAxis" xlink:label="us-gaap_PledgingPurposeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PledgingPurposeAxis_lbl" xml:lang="en-US">Pledging Purpose [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US">Letter of Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CellTherapyMember" xlink:label="CELU_CellTherapyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CellTherapyMember" xlink:to="CELU_CellTherapyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_CellTherapyMember_lbl" xml:lang="en-US">Cell Therapy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ThreeCustomersMember" xlink:label="CELU_ThreeCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ThreeCustomersMember" xlink:to="CELU_ThreeCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ThreeCustomersMember_lbl" xml:lang="en-US">Three Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoCustomersMember" xlink:label="CELU_TwoCustomersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoCustomersMember" xlink:to="CELU_TwoCustomersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_TwoCustomersMember_lbl" xml:lang="en-US">Two Customers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CustomerOneMember" xlink:label="CELU_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CustomerOneMember" xlink:to="CELU_CustomerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_CustomerOneMember_lbl" xml:lang="en-US">Customer One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CustomerTwoMember" xlink:label="CELU_CustomerTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CustomerTwoMember" xlink:to="CELU_CustomerTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_CustomerTwoMember_lbl" xml:lang="en-US">Customer Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingMember_lbl" xml:lang="en-US">Building [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xml:lang="en-US">Software Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SequenceLifeScienceIncMember" xlink:label="CELU_SequenceLifeScienceIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SequenceLifeScienceIncMember" xlink:to="CELU_SequenceLifeScienceIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SequenceLifeScienceIncMember_lbl" xml:lang="en-US">Sequence LifeScience Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AcquisitionRelatedContingentConsiderationObligationsMember" xlink:label="CELU_AcquisitionRelatedContingentConsiderationObligationsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AcquisitionRelatedContingentConsiderationObligationsMember" xlink:to="CELU_AcquisitionRelatedContingentConsiderationObligationsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AcquisitionRelatedContingentConsiderationObligationsMember_lbl" xml:lang="en-US">Acquisition - Related Contingent Consideration Obligations [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContingentStockConsiderationMember" xlink:label="CELU_ContingentStockConsiderationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ContingentStockConsiderationMember" xlink:to="CELU_ContingentStockConsiderationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ContingentStockConsiderationMember_lbl" xml:lang="en-US">Contingent Stock Consideration [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="CELU_ConvertiblePromissoryNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ConvertiblePromissoryNotesMember" xlink:to="CELU_ConvertiblePromissoryNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ConvertiblePromissoryNotesMember_lbl" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNotesMember" xlink:label="CELU_UnsecuredSeniorConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UnsecuredSeniorConvertibleNotesMember" xlink:to="CELU_UnsecuredSeniorConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_UnsecuredSeniorConvertibleNotesMember_lbl" xml:lang="en-US">Unsecured Senior Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" xlink:label="CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" xlink:to="CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_lbl" xml:lang="en-US">May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:label="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:to="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_lbl" xml:lang="en-US">January 2024 Bridge Loan - Tranche #2 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" xlink:label="CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" xlink:to="CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_lbl" xml:lang="en-US">November 2024 Purchaser and Placement Agent Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GXSponsorWarrantsMember" xlink:label="CELU_GXSponsorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_GXSponsorWarrantsMember" xlink:to="CELU_GXSponsorWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_GXSponsorWarrantsMember_lbl" xml:lang="en-US">GX Sponsor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SanuwaveForbearanceAgreementMember" xlink:label="CELU_SanuwaveForbearanceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SanuwaveForbearanceAgreementMember" xlink:to="CELU_SanuwaveForbearanceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SanuwaveForbearanceAgreementMember_lbl" xml:lang="en-US">Sanuwave Forbearance Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LetterAgreementMember" xlink:label="CELU_LetterAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LetterAgreementMember" xlink:to="CELU_LetterAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LetterAgreementMember_lbl" xml:lang="en-US">Letter Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US">Lender Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_YorkvilleMember" xlink:label="CELU_YorkvilleMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_YorkvilleMember" xlink:to="CELU_YorkvilleMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_YorkvilleMember_lbl" xml:lang="en-US">Yorkville [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputCreditSpreadMember" xlink:label="us-gaap_MeasurementInputCreditSpreadMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputCreditSpreadMember" xlink:to="us-gaap_MeasurementInputCreditSpreadMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputCreditSpreadMember_lbl" xml:lang="en-US">Measurement Input, Credit Spread [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember" xlink:label="CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember" xlink:to="CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember_lbl" xml:lang="en-US">November 2024 Purchaser Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:to="CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_lbl" xml:lang="en-US">November 2024 Placement Agent Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SponsorsWarrantsMember" xlink:label="CELU_SponsorsWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SponsorsWarrantsMember" xlink:to="CELU_SponsorsWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SponsorsWarrantsMember_lbl" xml:lang="en-US">Sponsors Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="us-gaap_PublicUtilitiesInventoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_lbl" xml:lang="en-US">Inventory [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryFinishedGoodsMember" xlink:label="CELU_InventoryFinishedGoodsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryFinishedGoodsMember" xlink:to="CELU_InventoryFinishedGoodsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InventoryFinishedGoodsMember_lbl" xml:lang="en-US">Inventory Finished Goods [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryWorkInProgressMember" xlink:label="CELU_InventoryWorkInProgressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryWorkInProgressMember" xlink:to="CELU_InventoryWorkInProgressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InventoryWorkInProgressMember_lbl" xml:lang="en-US">Inventory Work in Progress [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LaboratoryAndProductionEquipmentMember" xlink:label="CELU_LaboratoryAndProductionEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LaboratoryAndProductionEquipmentMember" xlink:to="CELU_LaboratoryAndProductionEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LaboratoryAndProductionEquipmentMember_lbl" xml:lang="en-US">Laboratory and Production Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MachineryEquipmentAndFixturesMember" xlink:label="CELU_MachineryEquipmentAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MachineryEquipmentAndFixturesMember" xlink:to="CELU_MachineryEquipmentAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MachineryEquipmentAndFixturesMember_lbl" xml:lang="en-US">Machinery, Equipment and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Progress [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US">In Process Research and Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="us-gaap_TrademarksAndTradeNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksAndTradeNamesMember" xlink:to="us-gaap_TrademarksAndTradeNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksAndTradeNamesMember_lbl" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReacquiredRightsMember" xlink:label="CELU_ReacquiredRightsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReacquiredRightsMember" xlink:to="CELU_ReacquiredRightsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ReacquiredRightsMember_lbl" xml:lang="en-US">Reacquired Rights [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrePaidAdvanceAgreementMember" xlink:label="CELU_PrePaidAdvanceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PrePaidAdvanceAgreementMember" xlink:to="CELU_PrePaidAdvanceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PrePaidAdvanceAgreementMember_lbl" xml:lang="en-US">Pre Paid Advance Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNoteMember" xlink:label="CELU_UnsecuredSeniorConvertibleNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UnsecuredSeniorConvertibleNoteMember" xlink:to="CELU_UnsecuredSeniorConvertibleNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_UnsecuredSeniorConvertibleNoteMember_lbl" xml:lang="en-US">Unsecured Senior Convertible Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarrBridgeLoanNetOfDiscountMember" xlink:label="CELU_CVStarrBridgeLoanNetOfDiscountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CVStarrBridgeLoanNetOfDiscountMember" xlink:to="CELU_CVStarrBridgeLoanNetOfDiscountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_CVStarrBridgeLoanNetOfDiscountMember_lbl" xml:lang="en-US">CV Starr Bridge Loan Net of Discount [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RWIBridgeLoanNetOfDiscountMember" xlink:label="CELU_RWIBridgeLoanNetOfDiscountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RWIBridgeLoanNetOfDiscountMember" xlink:to="CELU_RWIBridgeLoanNetOfDiscountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RWIBridgeLoanNetOfDiscountMember_lbl" xml:lang="en-US">RWI Bridge Loan Net of Discount [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CEOPromissoryNoteMember" xlink:label="CELU_CEOPromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CEOPromissoryNoteMember" xlink:to="CELU_CEOPromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_CEOPromissoryNoteMember_lbl" xml:lang="en-US">CEO Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StandbyEquityPurchaseAgreementMember" xlink:label="CELU_StandbyEquityPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StandbyEquityPurchaseAgreementMember" xlink:to="CELU_StandbyEquityPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StandbyEquityPurchaseAgreementMember_lbl" xml:lang="en-US">Equity Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LoanAgreementMember" xlink:label="CELU_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LoanAgreementMember" xlink:to="CELU_LoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChairmanAndChiefExecutiveOfficerMember" xlink:label="CELU_ChairmanAndChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ChairmanAndChiefExecutiveOfficerMember" xlink:to="CELU_ChairmanAndChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ChairmanAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chairman and Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarrCoIncMember" xlink:label="CELU_CVStarrCoIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CVStarrCoIncMember" xlink:to="CELU_CVStarrCoIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_CVStarrCoIncMember_lbl" xml:lang="en-US">C.V. Starr Co Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ForbearanceAgreementMember" xlink:label="CELU_ForbearanceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ForbearanceAgreementMember" xlink:to="CELU_ForbearanceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ForbearanceAgreementMember_lbl" xml:lang="en-US">Forbearance Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TrancheTwoWarrantMember" xlink:label="CELU_TrancheTwoWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TrancheTwoWarrantMember" xlink:to="CELU_TrancheTwoWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_TrancheTwoWarrantMember_lbl" xml:lang="en-US">Tranche Two Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoanMember" xlink:to="us-gaap_BridgeLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BridgeLoanMember_lbl" xml:lang="en-US">Bridge Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialLoanMember" xlink:label="CELU_InitialLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InitialLoanMember" xlink:to="CELU_InitialLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InitialLoanMember_lbl" xml:lang="en-US">Initial Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdditionalLoanMember" xlink:label="CELU_AdditionalLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdditionalLoanMember" xlink:to="CELU_AdditionalLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AdditionalLoanMember_lbl" xml:lang="en-US">Additional Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TrancheOneWarrantMember" xlink:label="CELU_TrancheOneWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TrancheOneWarrantMember" xlink:to="CELU_TrancheOneWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_TrancheOneWarrantMember_lbl" xml:lang="en-US">Tranche One Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialAndSecondTrancheMember" xlink:label="CELU_InitialAndSecondTrancheMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InitialAndSecondTrancheMember" xlink:to="CELU_InitialAndSecondTrancheMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InitialAndSecondTrancheMember_lbl" xml:lang="en-US">Initial and Second Tranche [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ResortsWorldIncPteLtdMember" xlink:label="CELU_ResortsWorldIncPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ResortsWorldIncPteLtdMember" xlink:to="CELU_ResortsWorldIncPteLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ResortsWorldIncPteLtdMember_lbl" xml:lang="en-US">Resorts World Inc Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OfficeManufacturingAndLaboratorySpaceMember" xlink:label="CELU_OfficeManufacturingAndLaboratorySpaceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OfficeManufacturingAndLaboratorySpaceMember" xlink:to="CELU_OfficeManufacturingAndLaboratorySpaceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_OfficeManufacturingAndLaboratorySpaceMember_lbl" xml:lang="en-US">Office Manufacturing and Laboratory Space [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FlorhamParkNewJerseyMember" xlink:label="CELU_FlorhamParkNewJerseyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FlorhamParkNewJerseyMember" xlink:to="CELU_FlorhamParkNewJerseyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FlorhamParkNewJerseyMember_lbl" xml:lang="en-US">Florham Park New Jersey [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LegacyCelularityMember" xlink:label="CELU_LegacyCelularityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LegacyCelularityMember" xlink:to="CELU_LegacyCelularityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LegacyCelularityMember_lbl" xml:lang="en-US">Legacy Celularity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember" xlink:label="CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember" xlink:to="CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember_lbl" xml:lang="en-US">HLI Cellular Therapeutics LLC and Anthrogenesis [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LegacyCelularitysMember" xlink:label="CELU_LegacyCelularitysMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LegacyCelularitysMember" xlink:to="CELU_LegacyCelularitysMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LegacyCelularitysMember_lbl" xml:lang="en-US">Legacy Celularitys [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PalantirTechnologiesIncMember" xlink:label="CELU_PalantirTechnologiesIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PalantirTechnologiesIncMember" xlink:to="CELU_PalantirTechnologiesIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PalantirTechnologiesIncMember_lbl" xml:lang="en-US">Palantir Technologies Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MasterSubscriptionAgreementMember" xlink:label="CELU_MasterSubscriptionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MasterSubscriptionAgreementMember" xlink:to="CELU_MasterSubscriptionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MasterSubscriptionAgreementMember_lbl" xml:lang="en-US">Master Subscription Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SoftwareCeaseUseCostsMember" xlink:label="CELU_SoftwareCeaseUseCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SoftwareCeaseUseCostsMember" xlink:to="CELU_SoftwareCeaseUseCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SoftwareCeaseUseCostsMember_lbl" xml:lang="en-US">Software Cease Use Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAgreementMember" xlink:label="CELU_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseAgreementMember" xlink:to="CELU_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SettlementAndReleaseAgreementMember" xlink:label="CELU_SettlementAndReleaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SettlementAndReleaseAgreementMember" xlink:to="CELU_SettlementAndReleaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SettlementAndReleaseAgreementMember_lbl" xml:lang="en-US">Settlement and Release Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EvolutionMember" xlink:label="CELU_EvolutionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_EvolutionMember" xlink:to="CELU_EvolutionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_EvolutionMember_lbl" xml:lang="en-US">Evolution [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_HackensackMeridianHealthMember" xlink:label="CELU_HackensackMeridianHealthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_HackensackMeridianHealthMember" xlink:to="CELU_HackensackMeridianHealthMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_HackensackMeridianHealthMember_lbl" xml:lang="en-US">Hackensack Meridian Health [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AtTheMarketSalesAgreementMember" xlink:label="CELU_AtTheMarketSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AtTheMarketSalesAgreementMember" xlink:to="CELU_AtTheMarketSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AtTheMarketSalesAgreementMember_lbl" xml:lang="en-US">At the Market Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:to="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_lbl" xml:lang="en-US">March 2023 Private Investment in Public Equity Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" xlink:label="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" xlink:to="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_lbl" xml:lang="en-US">May 2022 Private Investment in Public Equity Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember" xlink:label="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember" xlink:to="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember_lbl" xml:lang="en-US">May 2022 Private Investment in Public Equity Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:to="CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_lbl" xml:lang="en-US">May 2023 Private Investment in Public Equity Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember" xlink:label="CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember" xlink:to="CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember_lbl" xml:lang="en-US">January 2024 PIPE Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandTwentyFourWarrantRepricingMember" xlink:label="CELU_TwoThousandTwentyFourWarrantRepricingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandTwentyFourWarrantRepricingMember" xlink:to="CELU_TwoThousandTwentyFourWarrantRepricingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_TwoThousandTwentyFourWarrantRepricingMember_lbl" xml:lang="en-US">2024 Warrant Repricing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InvestorRightsAgreementMember" xlink:label="CELU_InvestorRightsAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InvestorRightsAgreementMember" xlink:to="CELU_InvestorRightsAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InvestorRightsAgreementMember_lbl" xml:lang="en-US">Investor Rights Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DragasacLimitedMember" xlink:label="CELU_DragasacLimitedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DragasacLimitedMember" xlink:to="CELU_DragasacLimitedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DragasacLimitedMember_lbl" xml:lang="en-US">Dragasac Limited [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChiefAdministrativeOfficerMember" xlink:label="CELU_ChiefAdministrativeOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ChiefAdministrativeOfficerMember" xlink:to="CELU_ChiefAdministrativeOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ChiefAdministrativeOfficerMember_lbl" xml:lang="en-US">Chief Administrative Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AmendedEmploymentAgreementMember" xlink:label="CELU_AmendedEmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AmendedEmploymentAgreementMember" xlink:to="CELU_AmendedEmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AmendedEmploymentAgreementMember_lbl" xml:lang="en-US">Amended Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RwiForbearanceAgreementMember" xlink:label="CELU_RwiForbearanceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RwiForbearanceAgreementMember" xlink:to="CELU_RwiForbearanceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RwiForbearanceAgreementMember_lbl" xml:lang="en-US">RWI Forbearance Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:to="CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember_lbl" xml:lang="en-US">March 2023 Loan Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember" xlink:to="CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember_lbl" xml:lang="en-US">June 2023 Loan Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DragasacWarrantMember" xlink:label="CELU_DragasacWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DragasacWarrantMember" xlink:to="CELU_DragasacWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DragasacWarrantMember_lbl" xml:lang="en-US">Dragasac Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PublicWarrantsMember" xlink:label="CELU_PublicWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PublicWarrantsMember" xlink:to="CELU_PublicWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PublicWarrantsMember_lbl" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SponsorWarrantsMember" xlink:label="CELU_SponsorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SponsorWarrantsMember" xlink:to="CELU_SponsorWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SponsorWarrantsMember_lbl" xml:lang="en-US">Sponsor Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" xlink:label="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" xlink:to="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_lbl" xml:lang="en-US">March 2023 Private Investment in Public Equity Warrants, Modified [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:label="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:to="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_lbl" xml:lang="en-US">April 2023 Registered Direct Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" xlink:label="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" xlink:to="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_lbl" xml:lang="en-US">April 2023 Registered Direct Warrants Modified [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JuneTwoThousandTwentyThreeWarrantsMember" xlink:label="CELU_JuneTwoThousandTwentyThreeWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JuneTwoThousandTwentyThreeWarrantsMember" xlink:to="CELU_JuneTwoThousandTwentyThreeWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_JuneTwoThousandTwentyThreeWarrantsMember_lbl" xml:lang="en-US">June 2023 Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:label="CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:to="CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_lbl" xml:lang="en-US">July 2023 Registered Direct Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" xlink:label="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" xlink:to="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_lbl" xml:lang="en-US">January 2024 Bridge Loan Tranche One Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" xlink:label="CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" xlink:to="CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_lbl" xml:lang="en-US">March 2024 RWI Forbearance Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember" xlink:label="CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember" xlink:to="CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_lbl" xml:lang="en-US">November 2024 Purchaser Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember" xlink:label="CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember" xlink:to="CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember_lbl" xml:lang="en-US">January 2024 PIPE Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StarrForbearanceAgreementMember" xlink:label="CELU_StarrForbearanceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StarrForbearanceAgreementMember" xlink:to="CELU_StarrForbearanceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StarrForbearanceAgreementMember_lbl" xml:lang="en-US">Starr Forbearance Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:to="CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember_lbl" xml:lang="en-US">2021 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="CELU_TwoThousandAndSeventeenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:to="CELU_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_TwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xml:lang="en-US">2017 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AwardsWithPerformanceConditionsMember" xlink:label="CELU_AwardsWithPerformanceConditionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AwardsWithPerformanceConditionsMember" xlink:to="CELU_AwardsWithPerformanceConditionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AwardsWithPerformanceConditionsMember_lbl" xml:lang="en-US">Awards With Performance Conditions [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialTrancheMember" xlink:label="CELU_InitialTrancheMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InitialTrancheMember" xlink:to="CELU_InitialTrancheMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InitialTrancheMember_lbl" xml:lang="en-US">Initial Tranche [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecondTrancheMember" xlink:label="CELU_SecondTrancheMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SecondTrancheMember" xlink:to="CELU_SecondTrancheMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SecondTrancheMember_lbl" xml:lang="en-US">Second Tranche [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarketConditionStockUnitMember" xlink:label="CELU_MarketConditionStockUnitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MarketConditionStockUnitMember" xlink:to="CELU_MarketConditionStockUnitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MarketConditionStockUnitMember_lbl" xml:lang="en-US">Market Condition Stock Unit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" xlink:to="CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_lbl" xml:lang="en-US">2021 and 2017 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandTwentyOnePlanMember" xlink:label="CELU_TwoThousandTwentyOnePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandTwentyOnePlanMember" xlink:to="CELU_TwoThousandTwentyOnePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_TwoThousandTwentyOnePlanMember_lbl" xml:lang="en-US">2021 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandSeventeenPlanMember" xlink:label="CELU_TwoThousandSeventeenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandSeventeenPlanMember" xlink:to="CELU_TwoThousandSeventeenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_TwoThousandSeventeenPlanMember_lbl" xml:lang="en-US">2017 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RegeneronResearchCollaborationServicesAgreementMember" xlink:label="CELU_RegeneronResearchCollaborationServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RegeneronResearchCollaborationServicesAgreementMember" xlink:to="CELU_RegeneronResearchCollaborationServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RegeneronResearchCollaborationServicesAgreementMember_lbl" xml:lang="en-US">Regeneron Research Collaboration Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RegeneronServicesAgreementMember" xlink:label="CELU_RegeneronServicesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RegeneronServicesAgreementMember" xlink:to="CELU_RegeneronServicesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RegeneronServicesAgreementMember_lbl" xml:lang="en-US">Regeneron Services Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PultheraLLCBindingTermSheetMember" xlink:label="CELU_PultheraLLCBindingTermSheetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PultheraLLCBindingTermSheetMember" xlink:to="CELU_PultheraLLCBindingTermSheetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PultheraLLCBindingTermSheetMember_lbl" xml:lang="en-US">Pulthera LLC Binding Term Sheet [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAgreementWithBiocellgraftIncMember" xlink:label="CELU_LicenseAgreementWithBiocellgraftIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseAgreementWithBiocellgraftIncMember" xlink:to="CELU_LicenseAgreementWithBiocellgraftIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LicenseAgreementWithBiocellgraftIncMember_lbl" xml:lang="en-US">License Agreement With Biocellgraft Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnitedStatesFederalAndStateMember" xlink:label="CELU_UnitedStatesFederalAndStateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UnitedStatesFederalAndStateMember" xlink:to="CELU_UnitedStatesFederalAndStateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_UnitedStatesFederalAndStateMember_lbl" xml:lang="en-US">United States Federal and State [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BiobankingMember" xlink:label="CELU_BiobankingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_BiobankingMember" xlink:to="CELU_BiobankingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_BiobankingMember_lbl" xml:lang="en-US">Biobanking [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DegenerativeDiseaseMember" xlink:label="CELU_DegenerativeDiseaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DegenerativeDiseaseMember" xlink:to="CELU_DegenerativeDiseaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DegenerativeDiseaseMember_lbl" xml:lang="en-US">Degenerative Disease [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrRobertHaririMember" xlink:label="CELU_DrRobertHaririMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DrRobertHaririMember" xlink:to="CELU_DrRobertHaririMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DrRobertHaririMember_lbl" xml:lang="en-US">Dr Robert Hariri [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecuritiesPurchaseAgreementMember" xlink:label="CELU_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SecuritiesPurchaseAgreementMember" xlink:to="CELU_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AmendedAndRestatedEmploymentAgreementMember" xlink:label="CELU_AmendedAndRestatedEmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AmendedAndRestatedEmploymentAgreementMember" xlink:to="CELU_AmendedAndRestatedEmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AmendedAndRestatedEmploymentAgreementMember_lbl" xml:lang="en-US">Amended and Restated Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrHaririMember" xlink:label="CELU_DrHaririMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DrHaririMember" xlink:to="CELU_DrHaririMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DrHaririMember_lbl" xml:lang="en-US">Dr Hariri [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConsultingAgreementMember" xlink:label="CELU_ConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ConsultingAgreementMember" xlink:to="CELU_ConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrAndrewPecoraMember" xlink:label="CELU_DrAndrewPecoraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DrAndrewPecoraMember" xlink:to="CELU_DrAndrewPecoraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DrAndrewPecoraMember_lbl" xml:lang="en-US">Dr Andrew Pecora [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScientificAndClinicalAdvisorAgreementMember" xlink:label="CELU_ScientificAndClinicalAdvisorAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScientificAndClinicalAdvisorAgreementMember" xlink:to="CELU_ScientificAndClinicalAdvisorAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ScientificAndClinicalAdvisorAgreementMember_lbl" xml:lang="en-US">Scientific and Clinical Advisor Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RobinLSmithMdMember" xlink:label="CELU_RobinLSmithMdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RobinLSmithMdMember" xlink:to="CELU_RobinLSmithMdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RobinLSmithMdMember_lbl" xml:lang="en-US">Robin L Smith Md [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdvisoryAgreementMember" xlink:label="CELU_AdvisoryAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdvisoryAgreementMember" xlink:to="CELU_AdvisoryAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AdvisoryAgreementMember_lbl" xml:lang="en-US">Advisory Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_COTAIncMember" xlink:label="CELU_COTAIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_COTAIncMember" xlink:to="CELU_COTAIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_COTAIncMember_lbl" xml:lang="en-US">COTA Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CryoportSystemsIncMember" xlink:label="CELU_CryoportSystemsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CryoportSystemsIncMember" xlink:to="CELU_CryoportSystemsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_CryoportSystemsIncMember_lbl" xml:lang="en-US">Cryoport Systems Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarLoanMember" xlink:label="CELU_CVStarLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CVStarLoanMember" xlink:to="CELU_CVStarLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_CVStarLoanMember_lbl" xml:lang="en-US">CV Star Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MsHaririMember" xlink:label="CELU_MsHaririMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MsHaririMember" xlink:to="CELU_MsHaririMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MsHaririMember_lbl" xml:lang="en-US">Ms Hariri [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EmploymentOfImmediateFamilyMemberMember" xlink:label="CELU_EmploymentOfImmediateFamilyMemberMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_EmploymentOfImmediateFamilyMemberMember" xlink:to="CELU_EmploymentOfImmediateFamilyMemberMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_EmploymentOfImmediateFamilyMemberMember_lbl" xml:lang="en-US">Employment of Immediate Family Member [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GenesisEquityGroupFundingLlcMember" xlink:label="CELU_GenesisEquityGroupFundingLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_GenesisEquityGroupFundingLlcMember" xlink:to="CELU_GenesisEquityGroupFundingLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_GenesisEquityGroupFundingLlcMember_lbl" xml:lang="en-US">Genesis Equity Group Funding LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorOpinionTextBlock_lbl" xml:lang="en-US">Auditor Opinion [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Defined Benefit Plan [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance of $6,294 and $5,837 as of December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PromissoryNotesReceivable" xlink:label="CELU_PromissoryNotesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PromissoryNotesReceivable" xlink:to="CELU_PromissoryNotesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PromissoryNotesReceivable_lbl" xml:lang="en-US">Notes receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets - operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNoncurrent_lbl" xml:lang="en-US">Inventory, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other long-term assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedResearchAndDevelopmentSoftware" xlink:label="CELU_AccruedResearchAndDevelopmentSoftware" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AccruedResearchAndDevelopmentSoftware" xlink:to="CELU_AccruedResearchAndDevelopmentSoftware_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AccruedResearchAndDevelopmentSoftware_lbl" xml:lang="en-US">Accrued R&amp;D software</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xml:lang="en-US">Acquisition-related contingent consideration, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiability" xlink:label="CELU_WarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiability" xlink:to="CELU_WarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantLiability_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US">Deferred income tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding as of December 31, 2024 and 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value, 730,000,000 shares authorized, 22,546,671 and 19,378,192 issued and outstanding as of December 31, 2024 and 2023, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Accounts receivable, allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtFairValue" xlink:label="us-gaap_ShorttermDebtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtFairValue" xlink:to="us-gaap_ShorttermDebtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShorttermDebtFairValue_lbl" xml:lang="en-US">Short-term debt, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total net revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="us-gaap_CostOfRevenueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenueAbstract" xlink:to="us-gaap_CostOfRevenueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenueAbstract_lbl" xml:lang="en-US">Cost of revenues (excluding amortization of acquired intangible assets)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xml:lang="en-US">Change in fair value of contingent consideration liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Goodwill impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">IPR&amp;D impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingIncomeCostsAndExpenses" xlink:label="CELU_OperatingIncomeCostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OperatingIncomeCostsAndExpenses" xlink:to="CELU_OperatingIncomeCostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="CELU_OperatingIncomeCostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChangeInFairValueOfDebt" xlink:label="CELU_ChangeInFairValueOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ChangeInFairValueOfDebt" xlink:to="CELU_ChangeInFairValueOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELU_ChangeInFairValueOfDebt_lbl" xml:lang="en-US">Change in fair value of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OtherNonoperatingIncomeExpenses" xlink:label="CELU_OtherNonoperatingIncomeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OtherNonoperatingIncomeExpenses" xlink:to="CELU_OtherNonoperatingIncomeExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_OtherNonoperatingIncomeExpenses_lbl" xml:lang="en-US">Other expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent_lbl" xml:lang="en-US">Change in fair value of debt due to change in credit risk, net of tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Other comprehensive (loss) income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share - diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding - basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares outstanding - diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balances, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:label="CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:to="CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_lbl" xml:lang="en-US">Issuance of common stock in Registered Direct Offering, net of offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:label="CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:to="CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_lbl" xml:lang="en-US">Issuance of common stock in Registered Direct Offering, net of offering expenses, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" xlink:label="CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" xlink:to="CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension_lbl" xml:lang="en-US">Common stock issued pursuant to short-term debt maturity extension</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension" xlink:label="CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension" xlink:to="CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension_lbl" xml:lang="en-US">Common stock issued pursuant to short-term debt maturity extension, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueOfWarrantModificationForProfessionalService" xlink:label="CELU_FairValueOfWarrantModificationForProfessionalService" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueOfWarrantModificationForProfessionalService" xlink:to="CELU_FairValueOfWarrantModificationForProfessionalService_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FairValueOfWarrantModificationForProfessionalService_lbl" xml:lang="en-US">Fair value of warrant modification for professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment" xlink:label="CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment" xlink:to="CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment_lbl" xml:lang="en-US">Issuance of common stock for stem-cells to be used in research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment" xlink:label="CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment" xlink:to="CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment_lbl" xml:lang="en-US">Issuance of common stock for stem-cells to be used in research and development, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of warrants to RWI and C.V. Starr</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued pursuant to short-term debt conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued pursuant to short-term debt conversion, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Vesting of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Vesting of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Tax withholding on vesting of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Tax withholding on vesting of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" xlink:label="CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" xlink:to="CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses_lbl" xml:lang="en-US">Issuance of common stock in PIPE Offering, net of offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses" xlink:label="CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses" xlink:to="CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses_lbl" xml:lang="en-US">Issuance of common stock in PIPE Offering, net of offering expenses, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueATMAgreement" xlink:label="CELU_StockIssuedDuringPeriodValueATMAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValueATMAgreement" xlink:to="CELU_StockIssuedDuringPeriodValueATMAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodValueATMAgreement_lbl" xml:lang="en-US">Issuance of common stock under ATM Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesATMAgreement" xlink:label="CELU_StockIssuedDuringPeriodSharesATMAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesATMAgreement" xlink:to="CELU_StockIssuedDuringPeriodSharesATMAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodSharesATMAgreement_lbl" xml:lang="en-US">Issuance of common stock under ATM Agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent_lbl" xml:lang="en-US">Change in fair value of debt due to change in credit risk, net of tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock and warrants in PIPE Offering, net of offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock and warrants in PIPE Offering, net of offering expenses, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" xlink:label="CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" xlink:to="CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee_lbl" xml:lang="en-US">Issuance of common stock to Yorkville for debt extension and SEPA commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee" xlink:label="CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee" xlink:to="CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee_lbl" xml:lang="en-US">Issuance of common stock to Yorkville for debt extension and SEPA commitment fee, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" xlink:label="CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" xlink:to="CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants_lbl" xml:lang="en-US">Issuance and modification of warrants to RWI and C.V. Starr</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xml:lang="en-US">Retirement of shares in connection with reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US">Retirement of shares in connection with reverse stock split, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" xlink:label="CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" xlink:to="CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement_lbl" xml:lang="en-US">Issuance of common stock to Palantir as consideration for settlement agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement" xlink:label="CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement" xlink:to="CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement_lbl" xml:lang="en-US">Issuance of common stock to Palantir as consideration for settlement agreement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:label="CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:to="CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_lbl" xml:lang="en-US">Reclassification of warrants from liability classified to equity classified</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Issuance of common stock as compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Issuance of common stock as compensation expense, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balances</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balances, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flow from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NonCashLeaseExpense" xlink:label="CELU_NonCashLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NonCashLeaseExpense" xlink:to="CELU_NonCashLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NonCashLeaseExpense_lbl" xml:lang="en-US">Non cash lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProvisionForInventoryObsolescence" xlink:label="CELU_ProvisionForInventoryObsolescence" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProvisionForInventoryObsolescence" xlink:to="CELU_ProvisionForInventoryObsolescence_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ProvisionForInventoryObsolescence_lbl" xml:lang="en-US">Provision for inventory obsolescence</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryImpairmentCharge" xlink:label="CELU_InventoryImpairmentCharge" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryImpairmentCharge" xlink:to="CELU_InventoryImpairmentCharge_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InventoryImpairmentCharge_lbl" xml:lang="en-US">Inventory impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_2_lbl" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AcquiredInProcessResearchAndDevelopment" xlink:label="CELU_AcquiredInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AcquiredInProcessResearchAndDevelopment" xlink:to="CELU_AcquiredInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AcquiredInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Acquired in-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment" xlink:label="CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment" xlink:to="CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment_lbl" xml:lang="en-US">Issuance of common stock for stem-cells to be used in research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement" xlink:label="CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement" xlink:to="CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement_lbl" xml:lang="en-US">Issuance of common stock to Palantir as consideration for settlement agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" xlink:label="CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" xlink:to="CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee_lbl" xml:lang="en-US">Issuance of common stock to Yorkville for debt extension and SEPA commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockAsCompensationExpense" xlink:label="CELU_IssuanceOfCommonStockAsCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockAsCompensationExpense" xlink:to="CELU_IssuanceOfCommonStockAsCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_IssuanceOfCommonStockAsCompensationExpense_lbl" xml:lang="en-US">Issuance of common stock as compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DiscountsArisingFromLoanArrangementRelatedParty" xlink:label="CELU_DiscountsArisingFromLoanArrangementRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DiscountsArisingFromLoanArrangementRelatedParty" xlink:to="CELU_DiscountsArisingFromLoanArrangementRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DiscountsArisingFromLoanArrangementRelatedParty_lbl" xml:lang="en-US">Discounts arising from RWI loan arrangement - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueOfWarrantModificationForProfessionalServices" xlink:label="CELU_FairValueOfWarrantModificationForProfessionalServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueOfWarrantModificationForProfessionalServices" xlink:to="CELU_FairValueOfWarrantModificationForProfessionalServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_FairValueOfWarrantModificationForProfessionalServices_lbl" xml:lang="en-US">Fair value of warrant modification for professional services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on debt extinguishment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ChangeInFairValueOfDebt" xlink:to="CELU_ChangeInFairValueOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ChangeInFairValueOfDebt_2_lbl" xml:lang="en-US">Change in fair value of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChangeInFairValueOfContingentStockConsideration" xlink:label="CELU_ChangeInFairValueOfContingentStockConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ChangeInFairValueOfContingentStockConsideration" xlink:to="CELU_ChangeInFairValueOfContingentStockConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ChangeInFairValueOfContingentStockConsideration_lbl" xml:lang="en-US">Change in fair value of contingent stock consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NonCashInterestExpense" xlink:label="CELU_NonCashInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NonCashInterestExpense" xlink:to="CELU_NonCashInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NonCashInterestExpense_lbl" xml:lang="en-US">Non cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_lbl" xml:lang="en-US">Other, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" xlink:label="CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" xlink:to="CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense_lbl" xml:lang="en-US">Accrued R&amp;D software</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liabilities - operating</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flow from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Capital expenditures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_lbl" xml:lang="en-US">Rebound asset acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Purchase of acquired in-process research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromConvertibleNote" xlink:label="CELU_ProceedsFromConvertibleNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromConvertibleNote" xlink:to="CELU_ProceedsFromConvertibleNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELU_ProceedsFromConvertibleNote_lbl" xml:lang="en-US">Proceeds from Sanuwave convertible note</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flow from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties" xlink:label="CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties" xlink:to="CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties_lbl" xml:lang="en-US">Proceeds from warrants and short-term debt - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RepaymentsOfShortTermDebtUnaffiliated" xlink:label="CELU_RepaymentsOfShortTermDebtUnaffiliated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RepaymentsOfShortTermDebtUnaffiliated" xlink:to="CELU_RepaymentsOfShortTermDebtUnaffiliated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELU_RepaymentsOfShortTermDebtUnaffiliated_lbl" xml:lang="en-US">Repayments of short-term debt - unaffiliated</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering" xlink:label="CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering" xlink:to="CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering_lbl" xml:lang="en-US">Proceeds from the sale of common stock in ATM offering</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromShortTermDebtUnaffiliated" xlink:label="CELU_ProceedsFromShortTermDebtUnaffiliated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromShortTermDebtUnaffiliated" xlink:to="CELU_ProceedsFromShortTermDebtUnaffiliated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ProceedsFromShortTermDebtUnaffiliated_lbl" xml:lang="en-US">Proceeds from issuance of short-term debt - unaffiliated</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentOfSepaCommitmentFee" xlink:label="CELU_PaymentOfSepaCommitmentFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentOfSepaCommitmentFee" xlink:to="CELU_PaymentOfSepaCommitmentFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELU_PaymentOfSepaCommitmentFee_lbl" xml:lang="en-US">Payment of SEPA commitment fee</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RepaymentsOfShortTermDebtRelatedParty" xlink:label="CELU_RepaymentsOfShortTermDebtRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RepaymentsOfShortTermDebtRelatedParty" xlink:to="CELU_RepaymentsOfShortTermDebtRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELU_RepaymentsOfShortTermDebtRelatedParty_lbl" xml:lang="en-US">Repayments of short-term debt - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from PIPE financing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US">Tax withholding on vesting of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from registered direct offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments of PIPE and other issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Property and equipment included in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Common stock issued for short-term debt conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance" xlink:label="CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance" xlink:to="CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance_lbl" xml:lang="en-US">Modification of C.V. Starr warrants in connection with forbearance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance" xlink:label="CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance" xlink:to="CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance_lbl" xml:lang="en-US">Issuance of RWI warrants in connection with forbearance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan" xlink:label="CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan" xlink:to="CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan_lbl" xml:lang="en-US">Issuance of warrants on senior secured bridge loan</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification" xlink:label="CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification" xlink:to="CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification_lbl" xml:lang="en-US">Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PIPERelatedCostsIncludedInAccruedExpenses" xlink:label="CELU_PIPERelatedCostsIncludedInAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PIPERelatedCostsIncludedInAccruedExpenses" xlink:to="CELU_PIPERelatedCostsIncludedInAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PIPERelatedCostsIncludedInAccruedExpenses_lbl" xml:lang="en-US">PIPE related costs included in accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties" xlink:label="CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties" xlink:to="CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties_lbl" xml:lang="en-US">Interest accrued on senior secured loans within long-term debt - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition" xlink:label="CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition" xlink:to="CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition_lbl" xml:lang="en-US">Contingent consideration accrued in connection with Rebound asset acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition" xlink:label="CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition" xlink:to="CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition_lbl" xml:lang="en-US">Inventory acquired in connection with Rebound asset acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:label="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:to="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_lbl" xml:lang="en-US">Reclassification of warrants from liability classified to equity classified</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty" xlink:label="CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty" xlink:to="CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty_lbl" xml:lang="en-US">Assumption of short-term debt - unaffiliated by related party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xml:lang="en-US">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="cyd_MaterialCybersecurityIncidentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentAbstract" xlink:to="cyd_MaterialCybersecurityIncidentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentAbstract_lbl" xml:lang="en-US">Material Cybersecurity Incident [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentNatureTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Nature [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentScopeTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Scope [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentTimingTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Timing [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:to="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock_lbl" xml:lang="en-US">Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Nature of Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_lbl" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xml:lang="en-US">Asset Acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:to="CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosureLeasesAbstract" xlink:label="CELU_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DisclosureLeasesAbstract" xlink:to="CELU_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosureLicenseAndDistributionAgreementsAbstract" xlink:label="CELU_DisclosureLicenseAndDistributionAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DisclosureLicenseAndDistributionAgreementsAbstract" xlink:to="CELU_DisclosureLicenseAndDistributionAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DisclosureLicenseAndDistributionAgreementsAbstract_lbl" xml:lang="en-US">License And Distribution Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAndDistributionAgreementsTextBlock" xlink:label="CELU_LicenseAndDistributionAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseAndDistributionAgreementsTextBlock" xlink:to="CELU_LicenseAndDistributionAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LicenseAndDistributionAgreementsTextBlock_lbl" xml:lang="en-US">License and Distribution Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="us-gaap_DefinedBenefitPlanTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanTextBlock" xlink:to="us-gaap_DefinedBenefitPlanTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanTextBlock_lbl" xml:lang="en-US">Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AssetAcquisitionsPolicyTextBlock" xlink:label="CELU_AssetAcquisitionsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AssetAcquisitionsPolicyTextBlock" xlink:to="CELU_AssetAcquisitionsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AssetAcquisitionsPolicyTextBlock_lbl" xml:lang="en-US">Asset Acquisitions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US">In-Process Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsLiabilitiesPolicyTextBlock" xlink:label="CELU_WarrantsLiabilitiesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsLiabilitiesPolicyTextBlock" xlink:to="CELU_WarrantsLiabilitiesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantsLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShortTermDebtPolicyTextBlock" xlink:label="CELU_ShortTermDebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShortTermDebtPolicyTextBlock" xlink:to="CELU_ShortTermDebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ShortTermDebtPolicyTextBlock_lbl" xml:lang="en-US">Short-Term Debt - Yorkville and Unsecured Senior Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising and Marketing Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GovernmentGrantsPolicyTextBlock" xlink:label="CELU_GovernmentGrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_GovernmentGrantsPolicyTextBlock" xlink:to="CELU_GovernmentGrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_GovernmentGrantsPolicyTextBlock_lbl" xml:lang="en-US">Government Grants</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PatentCostsPolicyTextBlock" xlink:label="CELU_PatentCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PatentCostsPolicyTextBlock" xlink:to="CELU_PatentCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US">Patent Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AllowanceForCreditLossesPolicyTextBlock" xlink:label="CELU_AllowanceForCreditLossesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AllowanceForCreditLossesPolicyTextBlock" xlink:to="CELU_AllowanceForCreditLossesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AllowanceForCreditLossesPolicyTextBlock_lbl" xml:lang="en-US">Allowance for Credit Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk and Significant Customers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock" xlink:label="CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock" xlink:to="CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment Estimated Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock_lbl" xml:lang="en-US">Schedule of Purchase Price Allocated to Acquired Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_lbl" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="us-gaap_BusinessAcquisitionContingentConsiderationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionContingentConsiderationLineItems_lbl" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measures at Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock" xlink:label="CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock" xlink:to="CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Note Valuation Model</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Contingent Consideration Obligation Measured on a Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Notes Valuation Model</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" xlink:label="CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" xlink:to="CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_lbl" xml:lang="en-US">Schedule of Significant Inputs for Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:label="CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:to="CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Major Classes of Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfActivityInInventoryReservesTableTextBlock" xlink:label="CELU_ScheduleOfActivityInInventoryReservesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfActivityInInventoryReservesTableTextBlock" xlink:to="CELU_ScheduleOfActivityInInventoryReservesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ScheduleOfActivityInInventoryReservesTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory Reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfIntangibleAssetsNetTableTextBlock" xlink:label="CELU_ScheduleOfIntangibleAssetsNetTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfIntangibleAssetsNetTableTextBlock" xlink:to="CELU_ScheduleOfIntangibleAssetsNetTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ScheduleOfIntangibleAssetsNetTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Aggregate Amortization Expense Related to Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock" xlink:label="CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock" xlink:to="CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash Activity Related to the lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Payments under Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Summary of the Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Activity Related to RSU Stock-Based Payment Awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Disaggregated Revenue by Product and Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:to="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueByArrangementDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Deferred Revenue from Contract Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Current and Deferred Tax Provision</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of the U.S federal statutory income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US">Schedule of Financial Information by Segment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US">Date of incorporation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse stock split ratio</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Principal debt outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForManagementFee" xlink:label="us-gaap_PaymentForManagementFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentForManagementFee" xlink:to="us-gaap_PaymentForManagementFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentForManagementFee_lbl" xml:lang="en-US">Payment for fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment expected useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable balance, net of allowance for credit losses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Indefinite-lived IPR&amp;D</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLossNetOfTax" xlink:label="us-gaap_GoodwillImpairmentLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLossNetOfTax" xlink:to="us-gaap_GoodwillImpairmentLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillImpairmentLossNetOfTax_lbl" xml:lang="en-US">Goodwill impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContractedStoragePeriods" xlink:label="CELU_ContractedStoragePeriods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ContractedStoragePeriods" xlink:to="CELU_ContractedStoragePeriods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ContractedStoragePeriods_lbl" xml:lang="en-US">Contracted storage periods</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentPlansForCustomerToPayOverTimePeriod" xlink:label="CELU_PaymentPlansForCustomerToPayOverTimePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentPlansForCustomerToPayOverTimePeriod" xlink:to="CELU_PaymentPlansForCustomerToPayOverTimePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PaymentPlansForCustomerToPayOverTimePeriod_lbl" xml:lang="en-US">Over time for a period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="us-gaap_MarketingAndAdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xml:lang="en-US">Advertising and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" xlink:label="CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" xlink:to="CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_lbl" xml:lang="en-US">Grant monies</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InstrumentSpecificCreditRiskLoss" xlink:label="CELU_InstrumentSpecificCreditRiskLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InstrumentSpecificCreditRiskLoss" xlink:to="CELU_InstrumentSpecificCreditRiskLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InstrumentSpecificCreditRiskLoss_lbl" xml:lang="en-US">Instrument-specific credit risk loss</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InstrumentSpecificCreditRiskIncome" xlink:label="CELU_InstrumentSpecificCreditRiskIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InstrumentSpecificCreditRiskIncome" xlink:to="CELU_InstrumentSpecificCreditRiskIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InstrumentSpecificCreditRiskIncome_lbl" xml:lang="en-US">Instrument-specific credit risk income</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion" xlink:label="CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion" xlink:to="CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:to="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_lbl" xml:lang="en-US">Income tax examination likelihood settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US">Asset Acquisition [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireOtherProductiveAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireOtherProductiveAssets_2_lbl" xml:lang="en-US">Cash payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_lbl" xml:lang="en-US">Contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Total consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:to="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_lbl" xml:lang="en-US">Consideration for assets</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UpfrontPayment" xlink:label="CELU_UpfrontPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UpfrontPayment" xlink:to="CELU_UpfrontPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_UpfrontPayment_lbl" xml:lang="en-US">Upfront payment</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MonthlyMilestonePayments" xlink:label="CELU_MonthlyMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MonthlyMilestonePayments" xlink:to="CELU_MonthlyMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MonthlyMilestonePayments_lbl" xml:lang="en-US">Monthly milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PriorPaymentToRelatedParty" xlink:label="CELU_PriorPaymentToRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PriorPaymentToRelatedParty" xlink:to="CELU_PriorPaymentToRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PriorPaymentToRelatedParty_lbl" xml:lang="en-US">Prior payment to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NetSalesPercentage" xlink:label="CELU_NetSalesPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NetSalesPercentage" xlink:to="CELU_NetSalesPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NetSalesPercentage_lbl" xml:lang="en-US">Net sales percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PurchasePriceContingentConsideration" xlink:label="CELU_PurchasePriceContingentConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PurchasePriceContingentConsideration" xlink:to="CELU_PurchasePriceContingentConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PurchasePriceContingentConsideration_lbl" xml:lang="en-US">Purchase price contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MilestonePayments" xlink:label="CELU_MilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MilestonePayments" xlink:to="CELU_MilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MilestonePayments_lbl" xml:lang="en-US">Milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US">Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Acquisition-related contingent consideration obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContingentStockConsideration" xlink:label="CELU_ContingentStockConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ContingentStockConsideration" xlink:to="CELU_ContingentStockConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ContingentStockConsideration_lbl" xml:lang="en-US">Contingent stock consideration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtFairValue" xlink:to="us-gaap_ShorttermDebtFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShorttermDebtFairValue_2_lbl" xml:lang="en-US">Short-term debt - Yorkville</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes" xlink:label="CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes" xlink:to="CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes_lbl" xml:lang="en-US">Short-term debt - unsecured senior convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityRegisteredDirectWarrantsTwo" xlink:label="CELU_WarrantLiabilityRegisteredDirectWarrantsTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityRegisteredDirectWarrantsTwo" xlink:to="CELU_WarrantLiabilityRegisteredDirectWarrantsTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantLiabilityRegisteredDirectWarrantsTwo_lbl" xml:lang="en-US">Warrant liability - July 2023 Registered Direct Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityRegisteredDirectWarrants" xlink:label="CELU_WarrantLiabilityRegisteredDirectWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityRegisteredDirectWarrants" xlink:to="CELU_WarrantLiabilityRegisteredDirectWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantLiabilityRegisteredDirectWarrants_lbl" xml:lang="en-US">Warrant liability - April 2023 Registered Direct Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" xlink:label="CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" xlink:to="CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_lbl" xml:lang="en-US">Warrant liability - May 2022 PIPE Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPurchaserWarrants" xlink:label="CELU_WarrantLiabilityPurchaserWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityPurchaserWarrants" xlink:to="CELU_WarrantLiabilityPurchaserWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantLiabilityPurchaserWarrants_lbl" xml:lang="en-US">Warrant liability - November 2024 Purchaser Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPlacementAgentWarrants" xlink:label="CELU_WarrantLiabilityPlacementAgentWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityPlacementAgentWarrants" xlink:to="CELU_WarrantLiabilityPlacementAgentWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantLiabilityPlacementAgentWarrants_lbl" xml:lang="en-US">Warrant liability - November 2024 Placement Agent Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilitySponsorWarrants" xlink:label="CELU_WarrantLiabilitySponsorWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilitySponsorWarrants" xlink:to="CELU_WarrantLiabilitySponsorWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantLiabilitySponsorWarrants_lbl" xml:lang="en-US">Warrant liability - Sponsor Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPublicWarrants" xlink:label="CELU_WarrantLiabilityPublicWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityPublicWarrants" xlink:to="CELU_WarrantLiabilityPublicWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantLiabilityPublicWarrants_lbl" xml:lang="en-US">Warrant liability - Public Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total fair value liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US">Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFairValueDisclosure" xlink:label="us-gaap_ReceivablesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFairValueDisclosure" xlink:to="us-gaap_ReceivablesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesFairValueDisclosure_lbl" xml:lang="en-US">Convertible note receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Total fair value assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFairValueDisclosure" xlink:to="us-gaap_ReceivablesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ReceivablesFairValueDisclosure_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US">Net transfers into (out of) Level 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_lbl" xml:lang="en-US">Purchases, settlements and other net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xml:lang="en-US">Fair value adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFairValueDisclosure" xlink:to="us-gaap_ReceivablesFairValueDisclosure_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ReceivablesFairValueDisclosure_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FaceValueOfNotesReceivable" xlink:label="CELU_FaceValueOfNotesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FaceValueOfNotesReceivable" xlink:to="CELU_FaceValueOfNotesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FaceValueOfNotesReceivable_lbl" xml:lang="en-US">Face value</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfCouponRate" xlink:label="CELU_PercentageOfCouponRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfCouponRate" xlink:to="CELU_PercentageOfCouponRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PercentageOfCouponRate_lbl" xml:lang="en-US">Coupon rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ValuationInputForConvertiblePromissoryNoteTerm" xlink:label="CELU_ValuationInputForConvertiblePromissoryNoteTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ValuationInputForConvertiblePromissoryNoteTerm" xlink:to="CELU_ValuationInputForConvertiblePromissoryNoteTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ValuationInputForConvertiblePromissoryNoteTerm_lbl" xml:lang="en-US">Term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ValuationInputForConvertiblePromissoryNote" xlink:label="CELU_ValuationInputForConvertiblePromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ValuationInputForConvertiblePromissoryNote" xlink:to="CELU_ValuationInputForConvertiblePromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ValuationInputForConvertiblePromissoryNote_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_lbl" xml:lang="en-US">Net transfers into (out of) Level 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_lbl" xml:lang="en-US">Purchases, settlements and other net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Fair value adjustments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="us-gaap_LineOfCreditFacilityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="us-gaap_LineOfCreditFacilityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShortTermBorrowings_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" xlink:label="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" xlink:to="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_lbl" xml:lang="en-US">Conversion of debt into common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US">Principal repayments</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" xlink:label="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" xlink:to="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_lbl" xml:lang="en-US">Issuance of convertible promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" xlink:label="CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" xlink:to="CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_lbl" xml:lang="en-US">Issuance of unsecured senior convertible notes, net of fair value adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueAdjustmentThroughEarnings" xlink:label="CELU_FairValueAdjustmentThroughEarnings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueAdjustmentThroughEarnings" xlink:to="CELU_FairValueAdjustmentThroughEarnings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FairValueAdjustmentThroughEarnings_lbl" xml:lang="en-US">Fair value adjustment through earnings</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" xlink:label="CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" xlink:to="CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US">Fair value adjustment through accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual" xlink:label="CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual" xlink:to="CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_lbl" xml:lang="en-US">Fair value adjustment through interest accrual</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShortTermBorrowings_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Common share price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Convertible promissory note valuation measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Term (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMeasurementInput_2_lbl" xml:lang="en-US">Unsecured senior convertible notes valuation measurement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Fair value, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RegisteredDirectWarrantsIssuance" xlink:label="CELU_RegisteredDirectWarrantsIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RegisteredDirectWarrantsIssuance" xlink:to="CELU_RegisteredDirectWarrantsIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RegisteredDirectWarrantsIssuance_lbl" xml:lang="en-US">April 2023 Registered Direct warrant issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RegisteredDirectWarrantIssuanceDuringJuly" xlink:label="CELU_RegisteredDirectWarrantIssuanceDuringJuly" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RegisteredDirectWarrantIssuanceDuringJuly" xlink:to="CELU_RegisteredDirectWarrantIssuanceDuringJuly_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RegisteredDirectWarrantIssuanceDuringJuly_lbl" xml:lang="en-US">July 2023 Registered Direct warrant issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BridgeLoanAndWarrantIssuanceTrancheTwo" xlink:label="CELU_BridgeLoanAndWarrantIssuanceTrancheTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_BridgeLoanAndWarrantIssuanceTrancheTwo" xlink:to="CELU_BridgeLoanAndWarrantIssuanceTrancheTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_BridgeLoanAndWarrantIssuanceTrancheTwo_lbl" xml:lang="en-US">January 2024 Bridge Loan - Tranche #2 warrant issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PurchaserWarrantIssuance" xlink:label="CELU_PurchaserWarrantIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PurchaserWarrantIssuance" xlink:to="CELU_PurchaserWarrantIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PurchaserWarrantIssuance_lbl" xml:lang="en-US">November 2024 Purchaser warrant issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PlacementAgentWarrantIssuance" xlink:label="CELU_PlacementAgentWarrantIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PlacementAgentWarrantIssuance" xlink:to="CELU_PlacementAgentWarrantIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PlacementAgentWarrantIssuance_lbl" xml:lang="en-US">November 2024 Placement Agent warrant issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GainLossRecognizedInEarningsFromChangeInFairValues" xlink:label="CELU_GainLossRecognizedInEarningsFromChangeInFairValues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_GainLossRecognizedInEarningsFromChangeInFairValues" xlink:to="CELU_GainLossRecognizedInEarningsFromChangeInFairValues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_GainLossRecognizedInEarningsFromChangeInFairValues_lbl" xml:lang="en-US">Gain recognized in earnings from change in fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:to="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_2_lbl" xml:lang="en-US">Reclassification of warrants from liability classified to equity classified</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueNetAssetLiability_2_lbl" xml:lang="en-US">Fair Value, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueNetAssetLiabilities" xlink:label="CELU_FairValueNetAssetLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueNetAssetLiabilities" xlink:to="CELU_FairValueNetAssetLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="CELU_FairValueNetAssetLiabilities_lbl" xml:lang="en-US">Fair value, Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueNetAssetLiabilities" xlink:to="CELU_FairValueNetAssetLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CELU_FairValueNetAssetLiabilities_2_lbl" xml:lang="en-US">Fair Value, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrant and right outstanding measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate" xlink:label="CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate" xlink:to="CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate_lbl" xml:lang="en-US">Term to initial exercise date (years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2_lbl" xml:lang="en-US">Warrants measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing" xlink:label="CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing" xlink:to="CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing_lbl" xml:lang="en-US">Term to Subsequent Financing (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FloorPrice" xlink:label="CELU_FloorPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FloorPrice" xlink:to="CELU_FloorPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FloorPrice_lbl" xml:lang="en-US">Floor price</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OfferingPricePercentage" xlink:label="CELU_OfferingPricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OfferingPricePercentage" xlink:to="CELU_OfferingPricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_OfferingPricePercentage_lbl" xml:lang="en-US">Offering price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_3_lbl" xml:lang="en-US">Warrant measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ForbearanceExtendMaturityPeriod" xlink:label="CELU_ForbearanceExtendMaturityPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ForbearanceExtendMaturityPeriod" xlink:to="CELU_ForbearanceExtendMaturityPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ForbearanceExtendMaturityPeriod_lbl" xml:lang="en-US">Forbearance extend period</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IncreasedNotePayments" xlink:label="CELU_IncreasedNotePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IncreasedNotePayments" xlink:to="CELU_IncreasedNotePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IncreasedNotePayments_lbl" xml:lang="en-US">Increased total note payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Note payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Fair value of notes</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryRawMaterialsCurrentAndNoncurrent" xlink:label="CELU_InventoryRawMaterialsCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryRawMaterialsCurrentAndNoncurrent" xlink:to="CELU_InventoryRawMaterialsCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InventoryRawMaterialsCurrentAndNoncurrent_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryWorkInProgressCurrentAndNoncurrent" xlink:label="CELU_InventoryWorkInProgressCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryWorkInProgressCurrentAndNoncurrent" xlink:to="CELU_InventoryWorkInProgressCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InventoryWorkInProgressCurrentAndNoncurrent_lbl" xml:lang="en-US">Work in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:label="CELU_InventoryFinishedGoodsCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:to="CELU_InventoryFinishedGoodsCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InventoryFinishedGoodsCurrentAndNoncurrent_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryGrossCurrentAndNoncurrent" xlink:label="CELU_InventoryGrossCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryGrossCurrentAndNoncurrent" xlink:to="CELU_InventoryGrossCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="CELU_InventoryGrossCurrentAndNoncurrent_lbl" xml:lang="en-US">Inventory, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryReserveCurrentAndNoncurrent" xlink:label="CELU_InventoryReserveCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryReserveCurrentAndNoncurrent" xlink:to="CELU_InventoryReserveCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELU_InventoryReserveCurrentAndNoncurrent_lbl" xml:lang="en-US">Less: inventory reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryNetCurrentAndNoncurrent" xlink:label="CELU_InventoryNetCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryNetCurrentAndNoncurrent" xlink:to="CELU_InventoryNetCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="CELU_InventoryNetCurrentAndNoncurrent_lbl" xml:lang="en-US">Inventory, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryReserveCurrentAndNoncurrent" xlink:to="CELU_InventoryReserveCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="CELU_InventoryReserveCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProvisionForObsoleteInventory" xlink:label="CELU_ProvisionForObsoleteInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProvisionForObsoleteInventory" xlink:to="CELU_ProvisionForObsoleteInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ProvisionForObsoleteInventory_lbl" xml:lang="en-US">Provision for obsolete inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Write-offs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryReserveCurrentAndNoncurrent" xlink:to="CELU_InventoryReserveCurrentAndNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="CELU_InventoryReserveCurrentAndNoncurrent_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US">Inventory, Current [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US">Inventory [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryImpairmentCharge" xlink:to="CELU_InventoryImpairmentCharge_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_InventoryImpairmentCharge_2_lbl" xml:lang="en-US">Inventory impairment charge</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_2_lbl" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrepaidClinicalExpense" xlink:label="CELU_PrepaidClinicalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PrepaidClinicalExpense" xlink:to="CELU_PrepaidClinicalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PrepaidClinicalExpense_lbl" xml:lang="en-US">Prepaid clinical expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Amortizable intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Amortizable intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Acquired IPR&amp;D product rights</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod" xlink:to="CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense for intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="us-gaap_OtherAssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedClinicalTrialExpense" xlink:label="CELU_AccruedClinicalTrialExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AccruedClinicalTrialExpense" xlink:to="CELU_AccruedClinicalTrialExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AccruedClinicalTrialExpense_lbl" xml:lang="en-US">Accrued clinical trial expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued wages, bonuses, commissions and vacation</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccrualsForConstructionInProgress" xlink:label="CELU_AccrualsForConstructionInProgress" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AccrualsForConstructionInProgress" xlink:to="CELU_AccrualsForConstructionInProgress_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AccrualsForConstructionInProgress_lbl" xml:lang="en-US">Accruals for construction in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedComplianceFee" xlink:label="CELU_AccruedComplianceFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AccruedComplianceFee" xlink:to="CELU_AccruedComplianceFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AccruedComplianceFee_lbl" xml:lang="en-US">Accrued compliance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShortTermDebtUnaffiliated" xlink:label="CELU_ShortTermDebtUnaffiliated" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShortTermDebtUnaffiliated" xlink:to="CELU_ShortTermDebtUnaffiliated_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ShortTermDebtUnaffiliated_lbl" xml:lang="en-US">Total debt - unaffiliated</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OtherShortTermDebt" xlink:label="CELU_OtherShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OtherShortTermDebt" xlink:to="CELU_OtherShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_OtherShortTermDebt_lbl" xml:lang="en-US">Short-term debt - other</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShortTermDebtRelatedParty" xlink:label="CELU_ShortTermDebtRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShortTermDebtRelatedParty" xlink:to="CELU_ShortTermDebtRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ShortTermDebtRelatedParty_lbl" xml:lang="en-US">Total debt - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_Debt" xlink:label="CELU_Debt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_Debt" xlink:to="CELU_Debt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="CELU_Debt_lbl" xml:lang="en-US">Total debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBorrowings_4_lbl" xml:lang="en-US">Short-term debt - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_lbl" xml:lang="en-US">Maximum advance amount</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrePaidAdvancePeriod" xlink:label="CELU_PrePaidAdvancePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PrePaidAdvancePeriod" xlink:to="CELU_PrePaidAdvancePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PrePaidAdvancePeriod_lbl" xml:lang="en-US">Pre-paid advance period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of credit aggregate limitation amount</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrePaidAdvanceIssuedDiscountPercentage" xlink:label="CELU_PrePaidAdvanceIssuedDiscountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PrePaidAdvanceIssuedDiscountPercentage" xlink:to="CELU_PrePaidAdvanceIssuedDiscountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PrePaidAdvanceIssuedDiscountPercentage_lbl" xml:lang="en-US">Pre-paid advance issued discount percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_lbl" xml:lang="en-US">Bearing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" xlink:label="CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" xlink:to="CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_lbl" xml:lang="en-US">Increase in bearing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockMinimumOptionPricePerShare" xlink:label="CELU_IssuanceOfCommonStockMinimumOptionPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockMinimumOptionPricePerShare" xlink:to="CELU_IssuanceOfCommonStockMinimumOptionPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IssuanceOfCommonStockMinimumOptionPricePerShare_lbl" xml:lang="en-US">Issuance of common stock minimum option price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MaximumPercentageOfCommonStockIssued" xlink:label="CELU_MaximumPercentageOfCommonStockIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MaximumPercentageOfCommonStockIssued" xlink:to="CELU_MaximumPercentageOfCommonStockIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MaximumPercentageOfCommonStockIssued_lbl" xml:lang="en-US">Maximum percentage of common stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfBeneficialOwnershipLimitation" xlink:label="CELU_PercentageOfBeneficialOwnershipLimitation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfBeneficialOwnershipLimitation" xlink:to="CELU_PercentageOfBeneficialOwnershipLimitation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PercentageOfBeneficialOwnershipLimitation_lbl" xml:lang="en-US">Percentage of beneficial ownership limitation</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MinimumNumberOfSharesOfCommonStockPurchase" xlink:label="CELU_MinimumNumberOfSharesOfCommonStockPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MinimumNumberOfSharesOfCommonStockPurchase" xlink:to="CELU_MinimumNumberOfSharesOfCommonStockPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MinimumNumberOfSharesOfCommonStockPurchase_lbl" xml:lang="en-US">Minimum number of shares of common stock purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MinimumRequiredDailyVolumeWeightedAveragePrice" xlink:label="CELU_MinimumRequiredDailyVolumeWeightedAveragePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MinimumRequiredDailyVolumeWeightedAveragePrice" xlink:to="CELU_MinimumRequiredDailyVolumeWeightedAveragePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MinimumRequiredDailyVolumeWeightedAveragePrice_lbl" xml:lang="en-US">Minimum required daily volume weighted average price</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice" xlink:label="CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice" xlink:to="CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice_lbl" xml:lang="en-US">Required monthly payment if daily volume weighted average price is below $0.75 for any five of seven trading days</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice" xlink:label="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice" xlink:to="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice_lbl" xml:lang="en-US">Redemption premium percentage if volume weighted average price is less than $0.75</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice" xlink:label="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice" xlink:to="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice_lbl" xml:lang="en-US">Redemption premium percentage if volume weighted average price more than $0.75</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_3_lbl" xml:lang="en-US">Share price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuancePricePercentage" xlink:label="CELU_IssuancePricePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuancePricePercentage" xlink:to="CELU_IssuancePricePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IssuancePricePercentage_lbl" xml:lang="en-US">Issuance price percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromLinesOfCreditGross" xlink:label="CELU_ProceedsFromLinesOfCreditGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromLinesOfCreditGross" xlink:to="CELU_ProceedsFromLinesOfCreditGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ProceedsFromLinesOfCreditGross_lbl" xml:lang="en-US">Proceeds from pre-paid advance gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from pre-paid advance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityExpirationPeriod_lbl" xml:lang="en-US">Pre-paid advance maturity period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtConversionOriginalDebtAccruedInterestAmount" xlink:label="CELU_DebtConversionOriginalDebtAccruedInterestAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtConversionOriginalDebtAccruedInterestAmount" xlink:to="CELU_DebtConversionOriginalDebtAccruedInterestAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DebtConversionOriginalDebtAccruedInterestAmount_lbl" xml:lang="en-US">[custom:DebtConversionOriginalDebtAccruedInterestAmount]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentPayment" xlink:label="CELU_DebtInstrumentPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentPayment" xlink:to="CELU_DebtInstrumentPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DebtInstrumentPayment_lbl" xml:lang="en-US">[custom:DebtInstrumentPayment]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentAccruedInterest" xlink:label="CELU_DebtInstrumentAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentAccruedInterest" xlink:to="CELU_DebtInstrumentAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DebtInstrumentAccruedInterest_lbl" xml:lang="en-US">[custom:DebtInstrumentAccruedInterest]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentRedemptionPremium" xlink:label="CELU_DebtInstrumentRedemptionPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentRedemptionPremium" xlink:to="CELU_DebtInstrumentRedemptionPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DebtInstrumentRedemptionPremium_lbl" xml:lang="en-US">[custom:DebtInstrumentRedemptionPremium]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultShorttermDebtAmount" xlink:label="us-gaap_DebtDefaultShorttermDebtAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDefaultShorttermDebtAmount" xlink:to="us-gaap_DebtDefaultShorttermDebtAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDefaultShorttermDebtAmount_lbl" xml:lang="en-US">Short-term debt, unpaid principal balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Cash payment</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentPerDiemInterestAmount" xlink:label="CELU_DebtInstrumentPerDiemInterestAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentPerDiemInterestAmount" xlink:to="CELU_DebtInstrumentPerDiemInterestAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DebtInstrumentPerDiemInterestAmount_lbl" xml:lang="en-US">Diem interest payment for each day</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Issue of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_2_lbl" xml:lang="en-US">Debt issued</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNoteDiscountPercentage" xlink:label="CELU_ConvertiblePromissoryNoteDiscountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ConvertiblePromissoryNoteDiscountPercentage" xlink:to="CELU_ConvertiblePromissoryNoteDiscountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ConvertiblePromissoryNoteDiscountPercentage_lbl" xml:lang="en-US">Original issue discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt instrument maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfConversionOnOutstandingCommonStock" xlink:label="CELU_PercentageOfConversionOnOutstandingCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfConversionOnOutstandingCommonStock" xlink:to="CELU_PercentageOfConversionOnOutstandingCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PercentageOfConversionOnOutstandingCommonStock_lbl" xml:lang="en-US">Percentage of conversion on outstanding common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentDefaultInterestRate" xlink:label="CELU_DebtInstrumentDefaultInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentDefaultInterestRate" xlink:to="CELU_DebtInstrumentDefaultInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DebtInstrumentDefaultInterestRate_lbl" xml:lang="en-US">Debt instrument default interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Common stock issued pursuant to short-term debt maturity extension, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NotesAndPurchaserWarrantsPrincipalAmount" xlink:label="CELU_NotesAndPurchaserWarrantsPrincipalAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NotesAndPurchaserWarrantsPrincipalAmount" xlink:to="CELU_NotesAndPurchaserWarrantsPrincipalAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NotesAndPurchaserWarrantsPrincipalAmount_lbl" xml:lang="en-US">Notes and purchaser warrants principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromNotesAndPurchaserWarrants" xlink:label="CELU_ProceedsFromNotesAndPurchaserWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromNotesAndPurchaserWarrants" xlink:to="CELU_ProceedsFromNotesAndPurchaserWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ProceedsFromNotesAndPurchaserWarrants_lbl" xml:lang="en-US">Proceeds from notes and purchaser warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase aggregate shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise per share price (in Dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MinimumGrossProceeds" xlink:label="CELU_MinimumGrossProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MinimumGrossProceeds" xlink:to="CELU_MinimumGrossProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MinimumGrossProceeds_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrant term (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfCashFeeEqualToAggregateProceeds" xlink:label="CELU_PercentageOfCashFeeEqualToAggregateProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfCashFeeEqualToAggregateProceeds" xlink:to="CELU_PercentageOfCashFeeEqualToAggregateProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PercentageOfCashFeeEqualToAggregateProceeds_lbl" xml:lang="en-US">Percentage of cash fee equal to aggregate proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfExercisePriceEqualToOfferingPrice" xlink:label="CELU_PercentageOfExercisePriceEqualToOfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfExercisePriceEqualToOfferingPrice" xlink:to="CELU_PercentageOfExercisePriceEqualToOfferingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PercentageOfExercisePriceEqualToOfferingPrice_lbl" xml:lang="en-US">Percentage of exercise price equal to offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="us-gaap_OtherExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes" xlink:to="CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes_2_lbl" xml:lang="en-US">Fair value of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amont</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentContributionAmount" xlink:label="CELU_DebtInstrumentContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentContributionAmount" xlink:to="CELU_DebtInstrumentContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DebtInstrumentContributionAmount_lbl" xml:lang="en-US">Debt instrument contribution amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Default rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherShortTermDebt" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xml:lang="en-US">Gross proceeds</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OtherShortTermDebtDueToRelatedParty" xlink:label="CELU_OtherShortTermDebtDueToRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OtherShortTermDebtDueToRelatedParty" xlink:to="CELU_OtherShortTermDebtDueToRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_OtherShortTermDebtDueToRelatedParty_lbl" xml:lang="en-US">Other short term debt due to related party</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentOriginalIssueDiscount" xlink:label="CELU_DebtInstrumentOriginalIssueDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentOriginalIssueDiscount" xlink:to="CELU_DebtInstrumentOriginalIssueDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_DebtInstrumentOriginalIssueDiscount_lbl" xml:lang="en-US">Original issue discount</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault" xlink:label="CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault" xlink:to="CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault_lbl" xml:lang="en-US">Effective percentage in event of default</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Purchase price of per share</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShareIssuedPurchasedPrice" xlink:label="CELU_ShareIssuedPurchasedPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShareIssuedPurchasedPrice" xlink:to="CELU_ShareIssuedPurchasedPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ShareIssuedPurchasedPrice_lbl" xml:lang="en-US">Share issued purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FallInCashAndCashEquivalents" xlink:label="CELU_FallInCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FallInCashAndCashEquivalents" xlink:to="CELU_FallInCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FallInCashAndCashEquivalents_lbl" xml:lang="en-US">Fall in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Variable interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ClassOfWarrantOrRighstExpirationDate" xlink:label="CELU_ClassOfWarrantOrRighstExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ClassOfWarrantOrRighstExpirationDate" xlink:to="CELU_ClassOfWarrantOrRighstExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ClassOfWarrantOrRighstExpirationDate_lbl" xml:lang="en-US">Warrant expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfChangesInCashFlow" xlink:label="CELU_PercentageOfChangesInCashFlow" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfChangesInCashFlow" xlink:to="CELU_PercentageOfChangesInCashFlow_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PercentageOfChangesInCashFlow_lbl" xml:lang="en-US">Percentage of changes in cash flow</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="us-gaap_RepaymentsOfOtherDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherDebt" xlink:to="us-gaap_RepaymentsOfOtherDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherDebt_lbl" xml:lang="en-US">Payment for debt</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShortTermDebtRelatedParties" xlink:label="CELU_ShortTermDebtRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShortTermDebtRelatedParties" xlink:to="CELU_ShortTermDebtRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ShortTermDebtRelatedParties_lbl" xml:lang="en-US">Short-term debt - related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentDiscount" xlink:label="CELU_DebtInstrumentDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentDiscount" xlink:to="CELU_DebtInstrumentDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DebtInstrumentDiscount_lbl" xml:lang="en-US">Discount</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault" xlink:label="CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault" xlink:to="CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault_lbl" xml:lang="en-US">Interest rate during period in event of default</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DiscountOnWarrantAmount" xlink:label="CELU_DiscountOnWarrantAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DiscountOnWarrantAmount" xlink:to="CELU_DiscountOnWarrantAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DiscountOnWarrantAmount_lbl" xml:lang="en-US">Discount on warrant amount</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice" xlink:label="CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice" xlink:to="CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice_lbl" xml:lang="en-US">Percentage of partial liquidating damages on purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" xlink:label="CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" xlink:to="CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_lbl" xml:lang="en-US">Percentage of partial liquidating damages on subscription amount</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DailyInterestAccruingRate" xlink:label="CELU_DailyInterestAccruingRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DailyInterestAccruingRate" xlink:to="CELU_DailyInterestAccruingRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DailyInterestAccruingRate_lbl" xml:lang="en-US">Daily interest accruing rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DisclosureLeasesAbstract" xlink:to="CELU_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Lease Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US">Variable lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total operating lease cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DisclosureLeasesAbstract" xlink:to="CELU_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="CELU_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Cash Activity Related To Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLeasesRentExpense" xlink:label="CELU_OperatingLeasesRentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OperatingLeasesRentExpense" xlink:to="CELU_OperatingLeasesRentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_OperatingLeasesRentExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AreaOfBuilding" xlink:label="CELU_AreaOfBuilding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AreaOfBuilding" xlink:to="CELU_AreaOfBuilding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AreaOfBuilding_lbl" xml:lang="en-US">Area of building</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLeaseExpiryYear" xlink:label="CELU_OperatingLeaseExpiryYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OperatingLeaseExpiryYear" xlink:to="CELU_OperatingLeaseExpiryYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_OperatingLeaseExpiryYear_lbl" xml:lang="en-US">Operating lease expiry year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Option to renew lease term period.</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLeaseCommencementDate" xlink:label="CELU_OperatingLeaseCommencementDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OperatingLeaseCommencementDate" xlink:to="CELU_OperatingLeaseCommencementDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_OperatingLeaseCommencementDate_lbl" xml:lang="en-US">Operating lease commencement date</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialMonthlyBaseRent" xlink:label="CELU_InitialMonthlyBaseRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InitialMonthlyBaseRent" xlink:to="CELU_InitialMonthlyBaseRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InitialMonthlyBaseRent_lbl" xml:lang="en-US">Initial monthly base rent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_2_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Tenant Improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReductionInLineOfCredit" xlink:label="CELU_ReductionInLineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReductionInLineOfCredit" xlink:to="CELU_ReductionInLineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ReductionInLineOfCredit_lbl" xml:lang="en-US">Reduction in line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NewLineOfCredit" xlink:label="CELU_NewLineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NewLineOfCredit" xlink:to="CELU_NewLineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NewLineOfCredit_lbl" xml:lang="en-US">New line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BaseRentalPayments" xlink:label="CELU_BaseRentalPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_BaseRentalPayments" xlink:to="CELU_BaseRentalPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_BaseRentalPayments_lbl" xml:lang="en-US">Base rental payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_2_lbl" xml:lang="en-US">Contingent consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentsForMasterSubscriptionAgreement" xlink:label="CELU_PaymentsForMasterSubscriptionAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentsForMasterSubscriptionAgreement" xlink:to="CELU_PaymentsForMasterSubscriptionAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PaymentsForMasterSubscriptionAgreement_lbl" xml:lang="en-US">Payments for master subscription agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentSubscriptionPeriod" xlink:label="CELU_PaymentSubscriptionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentSubscriptionPeriod" xlink:to="CELU_PaymentSubscriptionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PaymentSubscriptionPeriod_lbl" xml:lang="en-US">Payment subscription period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1" xlink:label="us-gaap_BusinessExitCosts1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessExitCosts1" xlink:to="us-gaap_BusinessExitCosts1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessExitCosts1_lbl" xml:lang="en-US">Exit or disposal costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US">Payments for legal settlements</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AccruedResearchAndDevelopmentSoftware" xlink:to="CELU_AccruedResearchAndDevelopmentSoftware_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_AccruedResearchAndDevelopmentSoftware_2_lbl" xml:lang="en-US">Accrued research and development software</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UpfrontFee" xlink:label="CELU_UpfrontFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UpfrontFee" xlink:to="CELU_UpfrontFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_UpfrontFee_lbl" xml:lang="en-US">Upfront fee</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AnnualMaintenanceFee" xlink:label="CELU_AnnualMaintenanceFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AnnualMaintenanceFee" xlink:to="CELU_AnnualMaintenanceFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AnnualMaintenanceFee_lbl" xml:lang="en-US">Annual maintenance fee</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ClinicalAndRegulatoryMilestones" xlink:label="CELU_ClinicalAndRegulatoryMilestones" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ClinicalAndRegulatoryMilestones" xlink:to="CELU_ClinicalAndRegulatoryMilestones_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ClinicalAndRegulatoryMilestones_lbl" xml:lang="en-US">Clinical and regulatory milestones</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xml:lang="en-US">License agreement period</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAgreementNoticePeriod" xlink:label="CELU_LicenseAgreementNoticePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseAgreementNoticePeriod" xlink:to="CELU_LicenseAgreementNoticePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_LicenseAgreementNoticePeriod_lbl" xml:lang="en-US">License agreement period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="us-gaap_PaymentsForLegalSettlements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US">Settlement payment</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NumberOfSharesIssuedForPiggybackRegistrationRights" xlink:label="CELU_NumberOfSharesIssuedForPiggybackRegistrationRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NumberOfSharesIssuedForPiggybackRegistrationRights" xlink:to="CELU_NumberOfSharesIssuedForPiggybackRegistrationRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NumberOfSharesIssuedForPiggybackRegistrationRights_lbl" xml:lang="en-US">Shares issued for piggyback registration rights</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfBiomaterialProductsAmount" xlink:label="CELU_SaleOfBiomaterialProductsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfBiomaterialProductsAmount" xlink:to="CELU_SaleOfBiomaterialProductsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SaleOfBiomaterialProductsAmount_lbl" xml:lang="en-US">Sale of biomaterial products amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AffiliateCosts" xlink:label="us-gaap_AffiliateCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AffiliateCosts" xlink:to="us-gaap_AffiliateCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AffiliateCosts_lbl" xml:lang="en-US">Affiliate costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NumberOfWarrantsRepriced" xlink:label="CELU_NumberOfWarrantsRepriced" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NumberOfWarrantsRepriced" xlink:to="CELU_NumberOfWarrantsRepriced_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NumberOfWarrantsRepriced_lbl" xml:lang="en-US">Number of warrants repriced</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsOutstanding" xlink:label="CELU_WarrantsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsOutstanding" xlink:to="CELU_WarrantsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Aggregate shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from the exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_3_lbl" xml:lang="en-US">Common stock shares issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockVotingRights_lbl" xml:lang="en-US">Common stock, voting rights</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfSharesRequiredForVoting" xlink:label="CELU_PercentageOfSharesRequiredForVoting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfSharesRequiredForVoting" xlink:to="CELU_PercentageOfSharesRequiredForVoting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PercentageOfSharesRequiredForVoting_lbl" xml:lang="en-US">Percentage of shares required for voting</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AggregateOfferingPrice" xlink:label="CELU_AggregateOfferingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AggregateOfferingPrice" xlink:to="CELU_AggregateOfferingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AggregateOfferingPrice_lbl" xml:lang="en-US">Aggregate offering price</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds" xlink:label="CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds" xlink:to="CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds_lbl" xml:lang="en-US">Sales agents commission rate</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GrossProceedsFromIssuanceOfCommonStock" xlink:label="CELU_GrossProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_GrossProceedsFromIssuanceOfCommonStock" xlink:to="CELU_GrossProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from sale of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Purchase and sale of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Average price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_2_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xml:lang="en-US">Warrants and rights outstanding, expire date</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdjustedAdvanceNoticePeriod" xlink:label="CELU_AdjustedAdvanceNoticePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdjustedAdvanceNoticePeriod" xlink:to="CELU_AdjustedAdvanceNoticePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AdjustedAdvanceNoticePeriod_lbl" xml:lang="en-US">Adjusted advance notice period</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PremiumPaidForPrivatePlacementPurchase" xlink:label="CELU_PremiumPaidForPrivatePlacementPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PremiumPaidForPrivatePlacementPurchase" xlink:to="CELU_PremiumPaidForPrivatePlacementPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PremiumPaidForPrivatePlacementPurchase_lbl" xml:lang="en-US">Premium paid for private placement purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReducedExercisePrice" xlink:label="CELU_ReducedExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReducedExercisePrice" xlink:to="CELU_ReducedExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ReducedExercisePrice_lbl" xml:lang="en-US">Reduced exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US">Fair value of modified warrant, incremental expense</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantExpirationTerm" xlink:label="CELU_WarrantExpirationTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantExpirationTerm" xlink:to="CELU_WarrantExpirationTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantExpirationTerm_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentPayment" xlink:to="CELU_DebtInstrumentPayment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_DebtInstrumentPayment_2_lbl" xml:lang="en-US">Debt instrument payment</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueNetAssetsLiability" xlink:label="CELU_FairValueNetAssetsLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueNetAssetsLiability" xlink:to="CELU_FairValueNetAssetsLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FairValueNetAssetsLiability_lbl" xml:lang="en-US">Fair value of the warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AmendedTerminationDateDescription" xlink:label="CELU_AmendedTerminationDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AmendedTerminationDateDescription" xlink:to="CELU_AmendedTerminationDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AmendedTerminationDateDescription_lbl" xml:lang="en-US">Amended termination date description</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdditionalWarrantLiability" xlink:label="CELU_AdditionalWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdditionalWarrantLiability" xlink:to="CELU_AdditionalWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AdditionalWarrantLiability_lbl" xml:lang="en-US">Additional warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsAndRightsIssuedClosingDate" xlink:label="CELU_WarrantsAndRightsIssuedClosingDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsAndRightsIssuedClosingDate" xlink:to="CELU_WarrantsAndRightsIssuedClosingDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_WarrantsAndRightsIssuedClosingDate_lbl" xml:lang="en-US">Warrants and rights issued closing date</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromPrivatePlacements" xlink:label="CELU_ProceedsFromPrivatePlacements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromPrivatePlacements" xlink:to="CELU_ProceedsFromPrivatePlacements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ProceedsFromPrivatePlacements_lbl" xml:lang="en-US">Proceeds from private placements</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost" xlink:label="CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost" xlink:to="CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost_lbl" xml:lang="en-US">Fair value of warrant modification</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" xlink:to="CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_2_lbl" xml:lang="en-US">Percentage of partial liquidating damages</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RelatedPartyBaseSalary" xlink:label="CELU_RelatedPartyBaseSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RelatedPartyBaseSalary" xlink:to="CELU_RelatedPartyBaseSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RelatedPartyBaseSalary_lbl" xml:lang="en-US">Base salary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants to purchase aggregate shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage" xlink:label="CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage" xlink:to="CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage_lbl" xml:lang="en-US">Sale of stock, maximum average daily traded amount (in percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays" xlink:label="CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays" xlink:to="CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays_lbl" xml:lang="en-US">Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice" xlink:label="CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice" xlink:to="CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice_lbl" xml:lang="en-US">Sale of stock, percentage based on volume weighted average price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Consideration shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockConsiderationCashDueDiligenceFee" xlink:label="CELU_SaleOfStockConsiderationCashDueDiligenceFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfStockConsiderationCashDueDiligenceFee" xlink:to="CELU_SaleOfStockConsiderationCashDueDiligenceFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SaleOfStockConsiderationCashDueDiligenceFee_lbl" xml:lang="en-US">Cash due diligence fee</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockConsiderationCommitmentFeeInShares" xlink:label="CELU_SaleOfStockConsiderationCommitmentFeeInShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfStockConsiderationCommitmentFeeInShares" xlink:to="CELU_SaleOfStockConsiderationCommitmentFeeInShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SaleOfStockConsiderationCommitmentFeeInShares_lbl" xml:lang="en-US">Commitment fee in shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of stock issuance costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" xlink:to="CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_2_lbl" xml:lang="en-US">Line of credit percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Contract Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited/Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Options Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Contract Term, Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Contract Term Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Options outstanding including awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value,Outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of Shares, Released</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Released</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of Shares, Outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Outstanding ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of shares remaining available for future grant</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" xlink:label="CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" xlink:to="CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_lbl" xml:lang="en-US">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Percentage of fair market value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock option, expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Options vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant-date fair value of stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value, stock option exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Estimated weighted-average amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested options to acquire shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested options to acquire per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Stock option vesting</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Remaining stock options forfeited upon termination of the advisory agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of shares granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Grant date fair value of units granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_2_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" xlink:label="CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" xlink:to="CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_lbl" xml:lang="en-US">Deferral of revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_lbl" xml:lang="en-US">Recognition of unearned revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiability_2_lbl" xml:lang="en-US">Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnearnedRevenue" xlink:label="CELU_UnearnedRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UnearnedRevenue" xlink:to="CELU_UnearnedRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_UnearnedRevenue_lbl" xml:lang="en-US">[custom:UnearnedRevenue-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NonrefundableUpfrontPayment" xlink:label="CELU_NonrefundableUpfrontPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NonrefundableUpfrontPayment" xlink:to="CELU_NonrefundableUpfrontPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NonrefundableUpfrontPayment_lbl" xml:lang="en-US">Nonrefundable up-front payment</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ServiceAgreementTerm" xlink:label="CELU_ServiceAgreementTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ServiceAgreementTerm" xlink:to="CELU_ServiceAgreementTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ServiceAgreementTerm_lbl" xml:lang="en-US">Service agreement term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseAgreementNoticePeriod" xlink:to="CELU_LicenseAgreementNoticePeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LicenseAgreementNoticePeriod_2_lbl" xml:lang="en-US">License agreement notice period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xml:lang="en-US">Received payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentOfOptionFeeInCash" xlink:label="CELU_PaymentOfOptionFeeInCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentOfOptionFeeInCash" xlink:to="CELU_PaymentOfOptionFeeInCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PaymentOfOptionFeeInCash_lbl" xml:lang="en-US">Payment of option fee in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OptionFeeExpense" xlink:label="CELU_OptionFeeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OptionFeeExpense" xlink:to="CELU_OptionFeeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_OptionFeeExpense_lbl" xml:lang="en-US">Option fee expense</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CommercialLicenseToDentalProductsAgreementPeriod" xlink:label="CELU_CommercialLicenseToDentalProductsAgreementPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CommercialLicenseToDentalProductsAgreementPeriod" xlink:to="CELU_CommercialLicenseToDentalProductsAgreementPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_CommercialLicenseToDentalProductsAgreementPeriod_lbl" xml:lang="en-US">Commercial license</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm" xlink:label="CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm" xlink:to="CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm_lbl" xml:lang="en-US">Commercial license to dental products agreement renewal term</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseFeeExpense" xlink:label="CELU_LicenseFeeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseFeeExpense" xlink:to="CELU_LicenseFeeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LicenseFeeExpense_lbl" xml:lang="en-US">License fee expense</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseFeesPaymentPeriod" xlink:label="CELU_LicenseFeesPaymentPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseFeesPaymentPeriod" xlink:to="CELU_LicenseFeesPaymentPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LicenseFeesPaymentPeriod_lbl" xml:lang="en-US">License fees payment period</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseFeePayment" xlink:label="CELU_LicenseFeePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseFeePayment" xlink:to="CELU_LicenseFeePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LicenseFeePayment_lbl" xml:lang="en-US">License fee payment</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdditionalLicenseFee" xlink:label="CELU_AdditionalLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdditionalLicenseFee" xlink:to="CELU_AdditionalLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AdditionalLicenseFee_lbl" xml:lang="en-US">Additional license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US">Contributions made to the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred tax expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Total income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" xlink:label="CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" xlink:to="CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_lbl" xml:lang="en-US">Interest accretion expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" xlink:label="CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" xlink:to="CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_lbl" xml:lang="en-US">Mark to market warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp" xlink:label="CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp" xlink:to="CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp_lbl" xml:lang="en-US">Deferred true-up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xml:lang="en-US">Impairment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Other permanent items</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:to="CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsStartupCosts" xlink:label="CELU_DeferredTaxAssetsStartupCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsStartupCosts" xlink:to="CELU_DeferredTaxAssetsStartupCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DeferredTaxAssetsStartupCosts_lbl" xml:lang="en-US">Startup costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsUnicap" xlink:label="CELU_DeferredTaxAssetsUnicap" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsUnicap" xlink:to="CELU_DeferredTaxAssetsUnicap_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DeferredTaxAssetsUnicap_lbl" xml:lang="en-US">Unicap</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsImputedInterestOnContingentPayments" xlink:label="CELU_DeferredTaxAssetsImputedInterestOnContingentPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsImputedInterestOnContingentPayments" xlink:to="CELU_DeferredTaxAssetsImputedInterestOnContingentPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DeferredTaxAssetsImputedInterestOnContingentPayments_lbl" xml:lang="en-US">Imputed interest on contingent payments</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" xlink:label="CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" xlink:to="CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_lbl" xml:lang="en-US">Legal fee capitalization and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsIrcSectionInterest" xlink:label="CELU_DeferredTaxAssetsIrcSectionInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsIrcSectionInterest" xlink:to="CELU_DeferredTaxAssetsIrcSectionInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DeferredTaxAssetsIrcSectionInterest_lbl" xml:lang="en-US">IRC Section 163j interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US">Net deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Balance beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US">Decrease related to current year tax provisions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_2_lbl" xml:lang="en-US">Decrease related to current year tax provisions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_2_lbl" xml:lang="en-US">Balance ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLossCarryforwardsExpirationYear" xlink:label="CELU_OperatingLossCarryforwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OperatingLossCarryforwardsExpirationYear" xlink:to="CELU_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_OperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carryforwards expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TaxCreditCarryforwardsExpirationYear" xlink:label="CELU_TaxCreditCarryforwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TaxCreditCarryforwardsExpirationYear" xlink:to="CELU_TaxCreditCarryforwardsExpirationYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_TaxCreditCarryforwardsExpirationYear_lbl" xml:lang="en-US">Tax credit carryforwards expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance increased amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_3_lbl" xml:lang="en-US">Unrecognized tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Interest accrued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Net revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfRevenue_2_lbl" xml:lang="en-US">Cost of revenues (excluding amortization of acquired intangible assets)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts" xlink:label="us-gaap_DirectOperatingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectOperatingCosts" xlink:to="us-gaap_DirectOperatingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectOperatingCosts_lbl" xml:lang="en-US">Direct expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SegmentContribution" xlink:label="CELU_SegmentContribution" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SegmentContribution" xlink:to="CELU_SegmentContribution_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SegmentContribution_lbl" xml:lang="en-US">Segment contribution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Other general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IndirectExpenses" xlink:label="CELU_IndirectExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IndirectExpenses" xlink:to="CELU_IndirectExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IndirectExpenses_lbl" xml:lang="en-US">Indirect expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InProcessResearchAndDevelopmentImpairment" xlink:label="CELU_InProcessResearchAndDevelopmentImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InProcessResearchAndDevelopmentImpairment" xlink:to="CELU_InProcessResearchAndDevelopmentImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_InProcessResearchAndDevelopmentImpairment_lbl" xml:lang="en-US">IPR&amp;D impairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_3_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_2_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecuritiesPurchaseAgreementDate" xlink:label="CELU_SecuritiesPurchaseAgreementDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SecuritiesPurchaseAgreementDate" xlink:to="CELU_SecuritiesPurchaseAgreementDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SecuritiesPurchaseAgreementDate_lbl" xml:lang="en-US">Securities purchase agreement date</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnpaidBaseSalary" xlink:label="CELU_UnpaidBaseSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UnpaidBaseSalary" xlink:to="CELU_UnpaidBaseSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_UnpaidBaseSalary_lbl" xml:lang="en-US">Unpaid base salary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Net proceeds from offerings of equity securities</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BonusProgramEffectiveDate" xlink:label="CELU_BonusProgramEffectiveDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_BonusProgramEffectiveDate" xlink:to="CELU_BonusProgramEffectiveDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_BonusProgramEffectiveDate_lbl" xml:lang="en-US">Bonus program effective date</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfUnpaidBaseSalary" xlink:label="CELU_PercentageOfUnpaidBaseSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfUnpaidBaseSalary" xlink:to="CELU_PercentageOfUnpaidBaseSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PercentageOfUnpaidBaseSalary_lbl" xml:lang="en-US">Percentage of unpaid base salary</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfBaseSalary" xlink:label="CELU_PercentageOfBaseSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfBaseSalary" xlink:to="CELU_PercentageOfBaseSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PercentageOfBaseSalary_lbl" xml:lang="en-US">Percentage of base salary</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AnnualRateOfBaseSalary" xlink:label="CELU_AnnualRateOfBaseSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AnnualRateOfBaseSalary" xlink:to="CELU_AnnualRateOfBaseSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AnnualRateOfBaseSalary_lbl" xml:lang="en-US">Annual rate of base salary</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BaseSalaryEffectiveDate" xlink:label="CELU_BaseSalaryEffectiveDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_BaseSalaryEffectiveDate" xlink:to="CELU_BaseSalaryEffectiveDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELU_BaseSalaryEffectiveDate_lbl" xml:lang="en-US">Bonus program effective date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_3_lbl" xml:lang="en-US">Proceeds from PIPE financings</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_2_lbl" xml:lang="en-US">Loan interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xml:lang="en-US">Related party description</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReceiveForMonth" xlink:label="CELU_ReceiveForMonth" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReceiveForMonth" xlink:to="CELU_ReceiveForMonth_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ReceiveForMonth_lbl" xml:lang="en-US">Receive for month</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">RSUs one-time grant value</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RelatedPartyCashBonus" xlink:label="CELU_RelatedPartyCashBonus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RelatedPartyCashBonus" xlink:to="CELU_RelatedPartyCashBonus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RelatedPartyCashBonus_lbl" xml:lang="en-US">One-time cash bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentsToRelatedParty" xlink:label="CELU_PaymentsToRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentsToRelatedParty" xlink:to="CELU_PaymentsToRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PaymentsToRelatedParty_lbl" xml:lang="en-US">Amount paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Contribution made</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LoanAgreement" xlink:label="CELU_LoanAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LoanAgreement" xlink:to="CELU_LoanAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_LoanAgreement_lbl" xml:lang="en-US">Loan agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecondLoanAgreement" xlink:label="CELU_SecondLoanAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SecondLoanAgreement" xlink:to="CELU_SecondLoanAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_SecondLoanAgreement_lbl" xml:lang="en-US">Second loan agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ApplicableFees" xlink:label="CELU_ApplicableFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ApplicableFees" xlink:to="CELU_ApplicableFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ApplicableFees_lbl" xml:lang="en-US">Applicable fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomePurchasedReceivables" xlink:label="us-gaap_InterestIncomePurchasedReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomePurchasedReceivables" xlink:to="us-gaap_InterestIncomePurchasedReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomePurchasedReceivables_lbl" xml:lang="en-US">Receivables purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" xlink:to="CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember_doc" xml:lang="en-US">Warrants, each exercisable for one share of Class A common stock at an exercise price of $115 per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ClassCommonStockParValue0.0001PerShareMember" xlink:to="CELU_ClassCommonStockParValue0.0001PerShareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ClassCommonStockParValue0.0001PerShareMember_doc" xml:lang="en-US">Class A common stock, par value $0.0001 per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ContingentStockConsideration" xlink:to="CELU_ContingentStockConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ContingentStockConsideration_doc" xml:lang="en-US">Contingent stock consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityRegisteredDirectWarrantsTwo" xlink:to="CELU_WarrantLiabilityRegisteredDirectWarrantsTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantLiabilityRegisteredDirectWarrantsTwo_doc" xml:lang="en-US">Warrant liability registered direct warrants two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityRegisteredDirectWarrants" xlink:to="CELU_WarrantLiabilityRegisteredDirectWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantLiabilityRegisteredDirectWarrants_doc" xml:lang="en-US">Warrant liability registered direct warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" xlink:to="CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_doc" xml:lang="en-US">Warrant liability private investment in public equity warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilitySponsorWarrants" xlink:to="CELU_WarrantLiabilitySponsorWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantLiabilitySponsorWarrants_doc" xml:lang="en-US">Warrant liability sponsor warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityPublicWarrants" xlink:to="CELU_WarrantLiabilityPublicWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantLiabilityPublicWarrants_doc" xml:lang="en-US">Warrant liability public warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityPurchaserWarrants" xlink:to="CELU_WarrantLiabilityPurchaserWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantLiabilityPurchaserWarrants_doc" xml:lang="en-US">Warrant liability purchaser warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiabilityPlacementAgentWarrants" xlink:to="CELU_WarrantLiabilityPlacementAgentWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantLiabilityPlacementAgentWarrants_doc" xml:lang="en-US">Warrant liability placement agent warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes" xlink:to="CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes_doc" xml:lang="en-US">Short-term debt unsecured senior convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ForbearanceExtendMaturityPeriod" xlink:to="CELU_ForbearanceExtendMaturityPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ForbearanceExtendMaturityPeriod_doc" xml:lang="en-US">Forbearance extend maturity period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SanuwaveForbearanceAgreementMember" xlink:to="CELU_SanuwaveForbearanceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SanuwaveForbearanceAgreementMember_doc" xml:lang="en-US">Sanuwave Forbearance Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LetterAgreementMember" xlink:to="CELU_LetterAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LetterAgreementMember_doc" xml:lang="en-US">Letter Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IncreasedNotePayments" xlink:to="CELU_IncreasedNotePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IncreasedNotePayments_doc" xml:lang="en-US">Increased total note payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock" xlink:to="CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock_doc" xml:lang="en-US">Schedule Of Convertible Note Valuation Model Table [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FaceValueOfNotesReceivable" xlink:to="CELU_FaceValueOfNotesReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FaceValueOfNotesReceivable_doc" xml:lang="en-US">Face Value Of Notes Receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfCouponRate" xlink:to="CELU_PercentageOfCouponRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PercentageOfCouponRate_doc" xml:lang="en-US">Percentage of coupon rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ValuationInputForConvertiblePromissoryNoteTerm" xlink:to="CELU_ValuationInputForConvertiblePromissoryNoteTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ValuationInputForConvertiblePromissoryNoteTerm_doc" xml:lang="en-US">Valuation input for a convertible promissory note term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ValuationInputForConvertiblePromissoryNote" xlink:to="CELU_ValuationInputForConvertiblePromissoryNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ValuationInputForConvertiblePromissoryNote_doc" xml:lang="en-US">Valuation input for a convertible promissory note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PromissoryNotesReceivable" xlink:to="CELU_PromissoryNotesReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PromissoryNotesReceivable_doc" xml:lang="en-US">Promissory notes receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AccruedResearchAndDevelopmentSoftware" xlink:to="CELU_AccruedResearchAndDevelopmentSoftware_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AccruedResearchAndDevelopmentSoftware_doc" xml:lang="en-US">Accrued research and development software.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShortTermDebtRelatedParty" xlink:to="CELU_ShortTermDebtRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ShortTermDebtRelatedParty_doc" xml:lang="en-US">Short-term debt - related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShortTermDebtUnaffiliated" xlink:to="CELU_ShortTermDebtUnaffiliated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ShortTermDebtUnaffiliated_doc" xml:lang="en-US">Short term debt unaffiliated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantLiability" xlink:to="CELU_WarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantLiability_doc" xml:lang="en-US">Warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ContingentStockConsiderationMember" xlink:to="CELU_ContingentStockConsiderationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ContingentStockConsiderationMember_doc" xml:lang="en-US">Contingent Stock Consideration [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ChangeInFairValueOfContingentStockConsideration" xlink:to="CELU_ChangeInFairValueOfContingentStockConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ChangeInFairValueOfContingentStockConsideration_doc" xml:lang="en-US">Change in fair value of contingent stock consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_doc" xml:lang="en-US">Fair Value Assets Of Yorkville Debt Measured On Recurring Basis Unobservable Input Reconciliation [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_YorkvilleMember" xlink:to="CELU_YorkvilleMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_YorkvilleMember_doc" xml:lang="en-US">Yorkville [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" xlink:to="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation convertible promissory note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" xlink:to="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation conversion of debt into common shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" xlink:to="CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_doc" xml:lang="en-US">Issuance of unsecured senior convertible notes, net of fair value adjustment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual" xlink:to="CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_doc" xml:lang="en-US">Fair value measurement with unobservable inputs reconciliation fair value adjustment through interest accrual.</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChangeInFairValueOfContingentConsiderationLiability" xlink:label="CELU_ChangeInFairValueOfContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ChangeInFairValueOfContingentConsiderationLiability" xlink:to="CELU_ChangeInFairValueOfContingentConsiderationLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ChangeInFairValueOfContingentConsiderationLiability_doc" xml:lang="en-US">Change in fair value of contingent consideration liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InProcessResearchAndDevelopmentImpairment" xlink:to="CELU_InProcessResearchAndDevelopmentImpairment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InProcessResearchAndDevelopmentImpairment_doc" xml:lang="en-US">In process research and development impairment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OperatingIncomeCostsAndExpenses" xlink:to="CELU_OperatingIncomeCostsAndExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OperatingIncomeCostsAndExpenses_doc" xml:lang="en-US">Operating income costs and expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ChangeInFairValueOfDebt" xlink:to="CELU_ChangeInFairValueOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ChangeInFairValueOfDebt_doc" xml:lang="en-US">Change in fair value of debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OtherNonoperatingIncomeExpenses" xlink:to="CELU_OtherNonoperatingIncomeExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OtherNonoperatingIncomeExpenses_doc" xml:lang="en-US">Other nonoperating income expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ConvertiblePromissoryNotesMember" xlink:to="CELU_ConvertiblePromissoryNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ConvertiblePromissoryNotesMember_doc" xml:lang="en-US">Convertible Promissory Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StandbyEquityPurchaseAgreementMember" xlink:to="CELU_StandbyEquityPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StandbyEquityPurchaseAgreementMember_doc" xml:lang="en-US">Equity Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:to="CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_doc" xml:lang="en-US">Stock issued during period value of common stock in registered direct offering net of offering expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:to="CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses_doc" xml:lang="en-US">Stock issued during period shares of common stock in registered direct offering net of offering expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueOfWarrantModificationForProfessionalService" xlink:to="CELU_FairValueOfWarrantModificationForProfessionalService_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FairValueOfWarrantModificationForProfessionalService_doc" xml:lang="en-US">Fair Value Of Warrant Modification For Professional Services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment" xlink:to="CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment_doc" xml:lang="en-US">Stock issued during period value of research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment" xlink:to="CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment_doc" xml:lang="en-US">Stock issued during period shares of research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" xlink:to="CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants_doc" xml:lang="en-US">Adjustments to additional paid in capital issuance and modification of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:to="CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_doc" xml:lang="en-US">Adjustments to additional paid in capital reclassification of warrants from liability classified to equity classified.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UnsecuredSeniorConvertibleNotesMember" xlink:to="CELU_UnsecuredSeniorConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_UnsecuredSeniorConvertibleNotesMember_doc" xml:lang="en-US">Unsecured Senior Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NonCashLeaseExpense" xlink:to="CELU_NonCashLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NonCashLeaseExpense_doc" xml:lang="en-US">Non cash lease expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProvisionForInventoryObsolescence" xlink:to="CELU_ProvisionForInventoryObsolescence_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ProvisionForInventoryObsolescence_doc" xml:lang="en-US">Provision for Inventory Obsolescence.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AcquiredInProcessResearchAndDevelopment" xlink:to="CELU_AcquiredInProcessResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AcquiredInProcessResearchAndDevelopment_doc" xml:lang="en-US">Acquired In-process Research And Development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" xlink:to="CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee_doc" xml:lang="en-US">Issuance of common stock relating to debt extension and commitment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockAsCompensationExpense" xlink:to="CELU_IssuanceOfCommonStockAsCompensationExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IssuanceOfCommonStockAsCompensationExpense_doc" xml:lang="en-US">Issuance of common stock as compensation expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment" xlink:to="CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment_doc" xml:lang="en-US">Issuance of common stock used in research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement" xlink:to="CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement_doc" xml:lang="en-US">Issuance of common stock as consideration for settlement agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DiscountsArisingFromLoanArrangementRelatedParty" xlink:to="CELU_DiscountsArisingFromLoanArrangementRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DiscountsArisingFromLoanArrangementRelatedParty_doc" xml:lang="en-US">Discounts arising from loan arrangement related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueNetAssetsLiability" xlink:to="CELU_FairValueNetAssetsLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FairValueNetAssetsLiability_doc" xml:lang="en-US">Fair value net assets liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RegisteredDirectWarrantsIssuance" xlink:to="CELU_RegisteredDirectWarrantsIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RegisteredDirectWarrantsIssuance_doc" xml:lang="en-US">Registered direct warrants issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RegisteredDirectWarrantIssuanceDuringJuly" xlink:to="CELU_RegisteredDirectWarrantIssuanceDuringJuly_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RegisteredDirectWarrantIssuanceDuringJuly_doc" xml:lang="en-US">Registered Direct Warrant Issuance During July.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_GainLossRecognizedInEarningsFromChangeInFairValues" xlink:to="CELU_GainLossRecognizedInEarningsFromChangeInFairValues_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_GainLossRecognizedInEarningsFromChangeInFairValues_doc" xml:lang="en-US">Gain loss recognized in earnings from change in fair values.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueOfWarrantModificationForProfessionalServices" xlink:to="CELU_FairValueOfWarrantModificationForProfessionalServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FairValueOfWarrantModificationForProfessionalServices_doc" xml:lang="en-US">Fair Value Of Warrant Modification For Professional Services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_BridgeLoanAndWarrantIssuanceTrancheTwo" xlink:to="CELU_BridgeLoanAndWarrantIssuanceTrancheTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_BridgeLoanAndWarrantIssuanceTrancheTwo_doc" xml:lang="en-US">Bridge loan and warrant issuance tranche two.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NonCashInterestExpense" xlink:to="CELU_NonCashInterestExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NonCashInterestExpense_doc" xml:lang="en-US">Non cash interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:to="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_doc" xml:lang="en-US">Reclassification of warrants from liability classified to equity classified.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromConvertibleNote" xlink:to="CELU_ProceedsFromConvertibleNote_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ProceedsFromConvertibleNote_doc" xml:lang="en-US">Proceeds from convertible note.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PurchaserWarrantIssuance" xlink:to="CELU_PurchaserWarrantIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PurchaserWarrantIssuance_doc" xml:lang="en-US">November 2024 Purchaser warrant issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PlacementAgentWarrantIssuance" xlink:to="CELU_PlacementAgentWarrantIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PlacementAgentWarrantIssuance_doc" xml:lang="en-US">November 2024 Placement Agent warrant issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties" xlink:to="CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties_doc" xml:lang="en-US">Proceeds from warrants and short term debt related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RepaymentsOfShortTermDebtRelatedParty" xlink:to="CELU_RepaymentsOfShortTermDebtRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RepaymentsOfShortTermDebtRelatedParty_doc" xml:lang="en-US">Repayments of short term debt related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering" xlink:to="CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering_doc" xml:lang="en-US">Proceeds from the sale of common stock in Atm offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" xlink:to="CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_doc" xml:lang="en-US">May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromShortTermDebtUnaffiliated" xlink:to="CELU_ProceedsFromShortTermDebtUnaffiliated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ProceedsFromShortTermDebtUnaffiliated_doc" xml:lang="en-US">Proceeds from short term debt unaffiliated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentOfSepaCommitmentFee" xlink:to="CELU_PaymentOfSepaCommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PaymentOfSepaCommitmentFee_doc" xml:lang="en-US">Payment of sepa commitment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" xlink:to="CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_doc" xml:lang="en-US">Schedule Of Fair Value Significant Inputs For Warrants Issued [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RepaymentsOfShortTermDebtUnaffiliated" xlink:to="CELU_RepaymentsOfShortTermDebtUnaffiliated_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RepaymentsOfShortTermDebtUnaffiliated_doc" xml:lang="en-US">Repayments of short term debt unaffiliated.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance" xlink:to="CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance_doc" xml:lang="en-US">Modification of CV starr warrants in connection with forbearance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification" xlink:to="CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification_doc" xml:lang="en-US">Reduction of right of use assets and associated lease liability due to lease modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance" xlink:to="CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance_doc" xml:lang="en-US">Issuance of rwi warrants in connection with for bearance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan" xlink:to="CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan_doc" xml:lang="en-US">Issuance of warrants on senior secured bridge loan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PIPERelatedCostsIncludedInAccruedExpenses" xlink:to="CELU_PIPERelatedCostsIncludedInAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PIPERelatedCostsIncludedInAccruedExpenses_doc" xml:lang="en-US">PIPE related costs included in accrued expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties" xlink:to="CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties_doc" xml:lang="en-US">Interest accrued on senior secured loans within long term debt related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:to="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_doc" xml:lang="en-US">January 2024 Bridge Loan - Tranche #2 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate" xlink:to="CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate_doc" xml:lang="en-US">Warrants and rights outstanding term to initial exercise date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition" xlink:to="CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition_doc" xml:lang="en-US">Contingent consideration accrued in connection with Rebound asset acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition" xlink:to="CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition_doc" xml:lang="en-US">Inventory acquired in connection with Rebound asset acquisition.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty" xlink:to="CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty_doc" xml:lang="en-US">Assumption of short-term debt - unaffiliated by related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_Debt" xlink:to="CELU_Debt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_Debt_doc" xml:lang="en-US">Debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" xlink:to="CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_doc" xml:lang="en-US">November 2024 Purchaser and Placement Agent Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock" xlink:to="CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock_doc" xml:lang="en-US">Schedule of Estimated Useful Lives [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing" xlink:to="CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing_doc" xml:lang="en-US">Warrants and rights outstanding term to subsequent financing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AssetAcquisitionsPolicyTextBlock" xlink:to="CELU_AssetAcquisitionsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AssetAcquisitionsPolicyTextBlock_doc" xml:lang="en-US">Asset Acquisitions [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CellTherapyMember" xlink:to="CELU_CellTherapyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_CellTherapyMember_doc" xml:lang="en-US">Cell Therapy [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsLiabilitiesPolicyTextBlock" xlink:to="CELU_WarrantsLiabilitiesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantsLiabilitiesPolicyTextBlock_doc" xml:lang="en-US">Warrants Liabilities [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShortTermDebtPolicyTextBlock" xlink:to="CELU_ShortTermDebtPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ShortTermDebtPolicyTextBlock_doc" xml:lang="en-US">Short Term Debt [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ContractedStoragePeriods" xlink:to="CELU_ContractedStoragePeriods_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ContractedStoragePeriods_doc" xml:lang="en-US">Contracted storage periods.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentPlansForCustomerToPayOverTimePeriod" xlink:to="CELU_PaymentPlansForCustomerToPayOverTimePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PaymentPlansForCustomerToPayOverTimePeriod_doc" xml:lang="en-US">Payment plans for customer to pay over time period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_GovernmentGrantsPolicyTextBlock" xlink:to="CELU_GovernmentGrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_GovernmentGrantsPolicyTextBlock_doc" xml:lang="en-US">Government Grants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" xlink:to="CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_doc" xml:lang="en-US">Reduction of research and development expense resulting from grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PatentCostsPolicyTextBlock" xlink:to="CELU_PatentCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PatentCostsPolicyTextBlock_doc" xml:lang="en-US">Patent Costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember" xlink:to="CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember_doc" xml:lang="en-US">November 2024 Purchaser Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion" xlink:to="CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_doc" xml:lang="en-US">Accumulated other comprehensive income to other expense upon short term debt conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FloorPrice" xlink:to="CELU_FloorPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FloorPrice_doc" xml:lang="en-US">Floor price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InstrumentSpecificCreditRiskIncome" xlink:to="CELU_InstrumentSpecificCreditRiskIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InstrumentSpecificCreditRiskIncome_doc" xml:lang="en-US">Instrument specific credit risk income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InstrumentSpecificCreditRiskLoss" xlink:to="CELU_InstrumentSpecificCreditRiskLoss_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InstrumentSpecificCreditRiskLoss_doc" xml:lang="en-US">Instrument specific credit risk loss.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:to="CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_doc" xml:lang="en-US">November 2024 Placement Agent Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OfferingPricePercentage" xlink:to="CELU_OfferingPricePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OfferingPricePercentage_doc" xml:lang="en-US">Offering price percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CustomerTwoMember" xlink:to="CELU_CustomerTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_CustomerTwoMember_doc" xml:lang="en-US">Customer Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SponsorsWarrantsMember" xlink:to="CELU_SponsorsWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SponsorsWarrantsMember_doc" xml:lang="en-US">Sponsors Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_doc" xml:lang="en-US">Recently Adopted Accounting Pronouncements [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CustomerOneMember" xlink:to="CELU_CustomerOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_CustomerOneMember_doc" xml:lang="en-US">Customer One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UpfrontPayment" xlink:to="CELU_UpfrontPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_UpfrontPayment_doc" xml:lang="en-US">Upfront payment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MonthlyMilestonePayments" xlink:to="CELU_MonthlyMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MonthlyMilestonePayments_doc" xml:lang="en-US">Monthly milestone payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PriorPaymentToRelatedParty" xlink:to="CELU_PriorPaymentToRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PriorPaymentToRelatedParty_doc" xml:lang="en-US">Prior payment to related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NetSalesPercentage" xlink:to="CELU_NetSalesPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NetSalesPercentage_doc" xml:lang="en-US">Net sales percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:to="CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_doc" xml:lang="en-US">Schedule Of Inventory Current And Noncurrent [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryRawMaterialsCurrentAndNoncurrent" xlink:to="CELU_InventoryRawMaterialsCurrentAndNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InventoryRawMaterialsCurrentAndNoncurrent_doc" xml:lang="en-US">Inventory raw materials current and noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryWorkInProgressCurrentAndNoncurrent" xlink:to="CELU_InventoryWorkInProgressCurrentAndNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InventoryWorkInProgressCurrentAndNoncurrent_doc" xml:lang="en-US">Inventory work in progress current and noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:to="CELU_InventoryFinishedGoodsCurrentAndNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InventoryFinishedGoodsCurrentAndNoncurrent_doc" xml:lang="en-US">Inventory finished goods current and noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryGrossCurrentAndNoncurrent" xlink:to="CELU_InventoryGrossCurrentAndNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InventoryGrossCurrentAndNoncurrent_doc" xml:lang="en-US">Inventory gross current and noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryReserveCurrentAndNoncurrent" xlink:to="CELU_InventoryReserveCurrentAndNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InventoryReserveCurrentAndNoncurrent_doc" xml:lang="en-US">Inventory reserve current and noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryNetCurrentAndNoncurrent" xlink:to="CELU_InventoryNetCurrentAndNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InventoryNetCurrentAndNoncurrent_doc" xml:lang="en-US">Inventory net current and noncurrent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryImpairmentCharge" xlink:to="CELU_InventoryImpairmentCharge_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InventoryImpairmentCharge_doc" xml:lang="en-US">Inventory Impairment Charge.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfActivityInInventoryReservesTableTextBlock" xlink:to="CELU_ScheduleOfActivityInInventoryReservesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ScheduleOfActivityInInventoryReservesTableTextBlock_doc" xml:lang="en-US">Schedule Of Activity In Inventory Reserves [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:to="CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_doc" xml:lang="en-US">Prepaid Expenses And Other Current Assets Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PrepaidClinicalExpense" xlink:to="CELU_PrepaidClinicalExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PrepaidClinicalExpense_doc" xml:lang="en-US">Prepaid clinical expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PurchasePriceContingentConsideration" xlink:to="CELU_PurchasePriceContingentConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PurchasePriceContingentConsideration_doc" xml:lang="en-US">Purchase price contingent consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MilestonePayments" xlink:to="CELU_MilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MilestonePayments_doc" xml:lang="en-US">Milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LegacyCelularitysMember" xlink:to="CELU_LegacyCelularitysMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LegacyCelularitysMember_doc" xml:lang="en-US">Legacy Celularitys [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentsForMasterSubscriptionAgreement" xlink:to="CELU_PaymentsForMasterSubscriptionAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PaymentsForMasterSubscriptionAgreement_doc" xml:lang="en-US">Payments for master subscription agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PalantirTechnologiesIncMember" xlink:to="CELU_PalantirTechnologiesIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PalantirTechnologiesIncMember_doc" xml:lang="en-US">Palantir Technologies Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MasterSubscriptionAgreementMember" xlink:to="CELU_MasterSubscriptionAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MasterSubscriptionAgreementMember_doc" xml:lang="en-US">Master Subscription Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentSubscriptionPeriod" xlink:to="CELU_PaymentSubscriptionPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PaymentSubscriptionPeriod_doc" xml:lang="en-US">Payment subscription period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SoftwareCeaseUseCostsMember" xlink:to="CELU_SoftwareCeaseUseCostsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SoftwareCeaseUseCostsMember_doc" xml:lang="en-US">Software Cease Use Costs [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ClinicalAndRegulatoryMilestones" xlink:to="CELU_ClinicalAndRegulatoryMilestones_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ClinicalAndRegulatoryMilestones_doc" xml:lang="en-US">Clinical and regulatory milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseAgreementMember" xlink:to="CELU_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UpfrontFee" xlink:to="CELU_UpfrontFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_UpfrontFee_doc" xml:lang="en-US">Upfront fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AnnualMaintenanceFee" xlink:to="CELU_AnnualMaintenanceFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AnnualMaintenanceFee_doc" xml:lang="en-US">Annual maintenance fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseAgreementNoticePeriod" xlink:to="CELU_LicenseAgreementNoticePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LicenseAgreementNoticePeriod_doc" xml:lang="en-US">License agreement notice period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NumberOfSharesIssuedForPiggybackRegistrationRights" xlink:to="CELU_NumberOfSharesIssuedForPiggybackRegistrationRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NumberOfSharesIssuedForPiggybackRegistrationRights_doc" xml:lang="en-US">Number of shares issued for piggy back registration rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SettlementAndReleaseAgreementMember" xlink:to="CELU_SettlementAndReleaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SettlementAndReleaseAgreementMember_doc" xml:lang="en-US">Settlement and Release Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfBiomaterialProductsAmount" xlink:to="CELU_SaleOfBiomaterialProductsAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SaleOfBiomaterialProductsAmount_doc" xml:lang="en-US">Sale of biomaterial products amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_EvolutionMember" xlink:to="CELU_EvolutionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_EvolutionMember_doc" xml:lang="en-US">Evolution [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfSharesRequiredForVoting" xlink:to="CELU_PercentageOfSharesRequiredForVoting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PercentageOfSharesRequiredForVoting_doc" xml:lang="en-US">Percentage of shares required for voting.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LegacyCelularityMember" xlink:to="CELU_LegacyCelularityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LegacyCelularityMember_doc" xml:lang="en-US">Legacy Celularity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OtherMember" xlink:label="CELU_OtherMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OtherMember" xlink:to="CELU_OtherMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OtherMember_doc" xml:lang="en-US">Other [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AggregateOfferingPrice" xlink:to="CELU_AggregateOfferingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AggregateOfferingPrice_doc" xml:lang="en-US">Aggregate offering price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AtTheMarketSalesAgreementMember" xlink:to="CELU_AtTheMarketSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AtTheMarketSalesAgreementMember_doc" xml:lang="en-US">At the Market Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds" xlink:to="CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds_doc" xml:lang="en-US">Maximum percentage of sales commission from gross sales proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScheduleOfIntangibleAssetsNetTableTextBlock" xlink:to="CELU_ScheduleOfIntangibleAssetsNetTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ScheduleOfIntangibleAssetsNetTableTextBlock_doc" xml:lang="en-US">Schedule Of Intangible Assets Net [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_GrossProceedsFromIssuanceOfCommonStock" xlink:to="CELU_GrossProceedsFromIssuanceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_GrossProceedsFromIssuanceOfCommonStock_doc" xml:lang="en-US">Gross proceeds from issuance of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:to="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_doc" xml:lang="en-US">March 2023 Private Investment in Public Equity Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReacquiredRightsMember" xlink:to="CELU_ReacquiredRightsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ReacquiredRightsMember_doc" xml:lang="en-US">Reacquired Rights [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ChairmanAndChiefExecutiveOfficerMember" xlink:to="CELU_ChairmanAndChiefExecutiveOfficerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ChairmanAndChiefExecutiveOfficerMember_doc" xml:lang="en-US">Chairman and Chief Executive Officer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdjustedAdvanceNoticePeriod" xlink:to="CELU_AdjustedAdvanceNoticePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AdjustedAdvanceNoticePeriod_doc" xml:lang="en-US">Adjusted advance notice period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PremiumPaidForPrivatePlacementPurchase" xlink:to="CELU_PremiumPaidForPrivatePlacementPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PremiumPaidForPrivatePlacementPurchase_doc" xml:lang="en-US">Premium Paid For Private Placement Purchase.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReducedExercisePrice" xlink:to="CELU_ReducedExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ReducedExercisePrice_doc" xml:lang="en-US">Reduced exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentPayment" xlink:to="CELU_DebtInstrumentPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DebtInstrumentPayment_doc" xml:lang="en-US">Debt instrument payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantExpirationTerm" xlink:to="CELU_WarrantExpirationTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantExpirationTerm_doc" xml:lang="en-US">Warrant expiration term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" xlink:to="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_doc" xml:lang="en-US">May 2022 Private Investment in Public Equity Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AmendedTerminationDateDescription" xlink:to="CELU_AmendedTerminationDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AmendedTerminationDateDescription_doc" xml:lang="en-US">Amended termination date description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember" xlink:to="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember_doc" xml:lang="en-US">May 2022 Private Investment in Public Equity Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdditionalWarrantLiability" xlink:to="CELU_AdditionalWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AdditionalWarrantLiability_doc" xml:lang="en-US">Additional warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:to="CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_doc" xml:lang="en-US">May 2023 Private Investment in Public Equity Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod" xlink:to="CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod_doc" xml:lang="en-US">Indefinite lived intangible assets amortization method.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember" xlink:to="CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember_doc" xml:lang="en-US">January 2024 PIPE Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsAndRightsIssuedClosingDate" xlink:to="CELU_WarrantsAndRightsIssuedClosingDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantsAndRightsIssuedClosingDate_doc" xml:lang="en-US">Warrants and rights issued closing date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromPrivatePlacements" xlink:to="CELU_ProceedsFromPrivatePlacements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ProceedsFromPrivatePlacements_doc" xml:lang="en-US">Proceeds from private placements.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NumberOfWarrantsRepriced" xlink:to="CELU_NumberOfWarrantsRepriced_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NumberOfWarrantsRepriced_doc" xml:lang="en-US">Number Of Warrants Repriced.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandTwentyFourWarrantRepricingMember" xlink:to="CELU_TwoThousandTwentyFourWarrantRepricingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_TwoThousandTwentyFourWarrantRepricingMember_doc" xml:lang="en-US">2024 Warrant Repricing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost" xlink:to="CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost_doc" xml:lang="en-US">Fair Value Of Warrant Modification Incremental For Equity Issuance Cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" xlink:to="CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_doc" xml:lang="en-US">Percentage of partial liquidating damages on subscription amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InvestorRightsAgreementMember" xlink:to="CELU_InvestorRightsAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InvestorRightsAgreementMember_doc" xml:lang="en-US">Investor Rights Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DragasacLimitedMember" xlink:to="CELU_DragasacLimitedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DragasacLimitedMember_doc" xml:lang="en-US">Dragasac Limited [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DailyInterestAccruingRate" xlink:to="CELU_DailyInterestAccruingRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DailyInterestAccruingRate_doc" xml:lang="en-US">Daily Interest Accruing Rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RelatedPartyBaseSalary" xlink:to="CELU_RelatedPartyBaseSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RelatedPartyBaseSalary_doc" xml:lang="en-US">Related Party Base Salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ChiefAdministrativeOfficerMember" xlink:to="CELU_ChiefAdministrativeOfficerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ChiefAdministrativeOfficerMember_doc" xml:lang="en-US">Chief Administrative Officer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AmendedEmploymentAgreementMember" xlink:to="CELU_AmendedEmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AmendedEmploymentAgreementMember_doc" xml:lang="en-US">Amended Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ClassOfWarrantOrRighstExpirationDate" xlink:to="CELU_ClassOfWarrantOrRighstExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ClassOfWarrantOrRighstExpirationDate_doc" xml:lang="en-US">Class of warrant or righst expiration date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RwiForbearanceAgreementMember" xlink:to="CELU_RwiForbearanceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RwiForbearanceAgreementMember_doc" xml:lang="en-US">RWI Forbearance Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ForbearanceAgreementMember" xlink:to="CELU_ForbearanceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ForbearanceAgreementMember_doc" xml:lang="en-US">Forbearance Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LoanAgreementMember" xlink:to="CELU_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LoanAgreementMember_doc" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CVStarrCoIncMember" xlink:to="CELU_CVStarrCoIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_CVStarrCoIncMember_doc" xml:lang="en-US">C.V. Starr Co Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:to="CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember_doc" xml:lang="en-US">March 2023 Loan Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember" xlink:to="CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember_doc" xml:lang="en-US">June 2023 Loan Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AccruedClinicalTrialExpense" xlink:to="CELU_AccruedClinicalTrialExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AccruedClinicalTrialExpense_doc" xml:lang="en-US">Accrued clinical trial expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AccrualsForConstructionInProgress" xlink:to="CELU_AccrualsForConstructionInProgress_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AccrualsForConstructionInProgress_doc" xml:lang="en-US">Accruals for construction in progress.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AccruedComplianceFee" xlink:to="CELU_AccruedComplianceFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AccruedComplianceFee_doc" xml:lang="en-US">Accrued compliance fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage" xlink:to="CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage_doc" xml:lang="en-US">Sale of stock maximum average daily traded amount percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays" xlink:to="CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays_doc" xml:lang="en-US">Sale of stock maximum average dailyTradedAmountThresholdConsecutiveTradingDays</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice" xlink:to="CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice_doc" xml:lang="en-US">Sale of stock percentage based on volume weighted average price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfStockConsiderationCommitmentFeeInShares" xlink:to="CELU_SaleOfStockConsiderationCommitmentFeeInShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SaleOfStockConsiderationCommitmentFeeInShares_doc" xml:lang="en-US">Sale of stock consideration commitment fee in shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SaleOfStockConsiderationCashDueDiligenceFee" xlink:to="CELU_SaleOfStockConsiderationCashDueDiligenceFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SaleOfStockConsiderationCashDueDiligenceFee_doc" xml:lang="en-US">Sale of stock consideration cash due diligence fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" xlink:to="CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_doc" xml:lang="en-US">Line of credit increase in interest rate during period in event of default.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DragasacWarrantMember" xlink:to="CELU_DragasacWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DragasacWarrantMember_doc" xml:lang="en-US">Dragasac Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PublicWarrantsMember" xlink:to="CELU_PublicWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PublicWarrantsMember_doc" xml:lang="en-US">Public Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SponsorWarrantsMember" xlink:to="CELU_SponsorWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SponsorWarrantsMember_doc" xml:lang="en-US">Sponsor Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" xlink:to="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_doc" xml:lang="en-US">March 2023 Private Investment in Public Equity Warrants, Modified [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:to="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_doc" xml:lang="en-US">April 2023 Registered Direct Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" xlink:to="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_doc" xml:lang="en-US">April 2023 Registered Direct Warrants Modified [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JuneTwoThousandTwentyThreeWarrantsMember" xlink:to="CELU_JuneTwoThousandTwentyThreeWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_JuneTwoThousandTwentyThreeWarrantsMember_doc" xml:lang="en-US">June 2023 Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:to="CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_doc" xml:lang="en-US">July 2023 Registered Direct Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" xlink:to="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_doc" xml:lang="en-US">January 2024 Bridge Loan Tranche One Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" xlink:to="CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_doc" xml:lang="en-US">March 2024 RWI Forbearance Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OtherShortTermDebt" xlink:to="CELU_OtherShortTermDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OtherShortTermDebt_doc" xml:lang="en-US">Other short term debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember" xlink:to="CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_doc" xml:lang="en-US">November 2024 Purchaser Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_WarrantsOutstanding" xlink:to="CELU_WarrantsOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_WarrantsOutstanding_doc" xml:lang="en-US">Warrants Outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StarrForbearanceAgreementMember" xlink:to="CELU_StarrForbearanceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StarrForbearanceAgreementMember_doc" xml:lang="en-US">Starr Forbearance Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PrePaidAdvanceAgreementMember" xlink:to="CELU_PrePaidAdvanceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PrePaidAdvanceAgreementMember_doc" xml:lang="en-US">Pre Paid Advance Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PrePaidAdvancePeriod" xlink:to="CELU_PrePaidAdvancePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PrePaidAdvancePeriod_doc" xml:lang="en-US">Pre paid advance period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PrePaidAdvanceIssuedDiscountPercentage" xlink:to="CELU_PrePaidAdvanceIssuedDiscountPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PrePaidAdvanceIssuedDiscountPercentage_doc" xml:lang="en-US">Pre paid advance issued discount percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockMinimumOptionPricePerShare" xlink:to="CELU_IssuanceOfCommonStockMinimumOptionPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IssuanceOfCommonStockMinimumOptionPricePerShare_doc" xml:lang="en-US">Issuance of common stock minimum option price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MaximumPercentageOfCommonStockIssued" xlink:to="CELU_MaximumPercentageOfCommonStockIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MaximumPercentageOfCommonStockIssued_doc" xml:lang="en-US">Maximum percentage of common stock issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfBeneficialOwnershipLimitation" xlink:to="CELU_PercentageOfBeneficialOwnershipLimitation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PercentageOfBeneficialOwnershipLimitation_doc" xml:lang="en-US">Percentage of beneficial ownership limitation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MinimumNumberOfSharesOfCommonStockPurchase" xlink:to="CELU_MinimumNumberOfSharesOfCommonStockPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MinimumNumberOfSharesOfCommonStockPurchase_doc" xml:lang="en-US">Minimum number of shares of common stock purchase.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MinimumRequiredDailyVolumeWeightedAveragePrice" xlink:to="CELU_MinimumRequiredDailyVolumeWeightedAveragePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MinimumRequiredDailyVolumeWeightedAveragePrice_doc" xml:lang="en-US">Minimum required daily volume weighted average price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice" xlink:to="CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice_doc" xml:lang="en-US">Required monthly payment if daily volume weighted average price is below stated price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice" xlink:to="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice_doc" xml:lang="en-US">Redemption premium percentage if volume weighted average price is less than stated price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice" xlink:to="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice_doc" xml:lang="en-US">Redemption premium percentage if volume weighted average price more than stated price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuancePricePercentage" xlink:to="CELU_IssuancePricePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IssuancePricePercentage_doc" xml:lang="en-US">Issuance Price Percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromLinesOfCreditGross" xlink:to="CELU_ProceedsFromLinesOfCreditGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ProceedsFromLinesOfCreditGross_doc" xml:lang="en-US">Proceeds from lines of credit gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtConversionOriginalDebtAccruedInterestAmount" xlink:to="CELU_DebtConversionOriginalDebtAccruedInterestAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DebtConversionOriginalDebtAccruedInterestAmount_doc" xml:lang="en-US">Debt conversion original debt accrued interest amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentAccruedInterest" xlink:to="CELU_DebtInstrumentAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DebtInstrumentAccruedInterest_doc" xml:lang="en-US">Debt instrument accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentRedemptionPremium" xlink:to="CELU_DebtInstrumentRedemptionPremium_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DebtInstrumentRedemptionPremium_doc" xml:lang="en-US">Debt instrument redemption premium.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentPerDiemInterestAmount" xlink:to="CELU_DebtInstrumentPerDiemInterestAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DebtInstrumentPerDiemInterestAmount_doc" xml:lang="en-US">Debt Instrument Per Diem Interest Amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:to="CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember_doc" xml:lang="en-US">2021 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ConvertiblePromissoryNoteDiscountPercentage" xlink:to="CELU_ConvertiblePromissoryNoteDiscountPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ConvertiblePromissoryNoteDiscountPercentage_doc" xml:lang="en-US">Convertible Promissory Note Discount Percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" xlink:to="CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares issued for future issuance automatic increase period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfConversionOnOutstandingCommonStock" xlink:to="CELU_PercentageOfConversionOnOutstandingCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PercentageOfConversionOnOutstandingCommonStock_doc" xml:lang="en-US">Percentage of conversion on outstanding common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:to="CELU_TwoThousandAndSeventeenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_TwoThousandAndSeventeenEquityIncentivePlanMember_doc" xml:lang="en-US">2017 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentDefaultInterestRate" xlink:to="CELU_DebtInstrumentDefaultInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DebtInstrumentDefaultInterestRate_doc" xml:lang="en-US">Debt instrument default interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" xlink:to="CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_doc" xml:lang="en-US">2021 and 2017 Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AwardsWithPerformanceConditionsMember" xlink:to="CELU_AwardsWithPerformanceConditionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AwardsWithPerformanceConditionsMember_doc" xml:lang="en-US">Awards With Performance Conditions [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InitialTrancheMember" xlink:to="CELU_InitialTrancheMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InitialTrancheMember_doc" xml:lang="en-US">Initial Tranche [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SecondTrancheMember" xlink:to="CELU_SecondTrancheMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SecondTrancheMember_doc" xml:lang="en-US">Second Tranche [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension" xlink:to="CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension_doc" xml:lang="en-US">Stock issued during period shares short term debt maturity extension.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdditionalLoanMember" xlink:to="CELU_AdditionalLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AdditionalLoanMember_doc" xml:lang="en-US">Additional Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MarketConditionStockUnitMember" xlink:to="CELU_MarketConditionStockUnitMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MarketConditionStockUnitMember_doc" xml:lang="en-US">Market Condition Stock Unit [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NotesAndPurchaserWarrantsPrincipalAmount" xlink:to="CELU_NotesAndPurchaserWarrantsPrincipalAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NotesAndPurchaserWarrantsPrincipalAmount_doc" xml:lang="en-US">Notes and purchaser warrants principal amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromNotesAndPurchaserWarrants" xlink:to="CELU_ProceedsFromNotesAndPurchaserWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ProceedsFromNotesAndPurchaserWarrants_doc" xml:lang="en-US">Proceeds from notes and purchaser warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MinimumGrossProceeds" xlink:to="CELU_MinimumGrossProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MinimumGrossProceeds_doc" xml:lang="en-US">Minimum gross proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" xlink:to="CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_doc" xml:lang="en-US">Contract with customer liability increase decrease for contract from business combination and deferred revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfCashFeeEqualToAggregateProceeds" xlink:to="CELU_PercentageOfCashFeeEqualToAggregateProceeds_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PercentageOfCashFeeEqualToAggregateProceeds_doc" xml:lang="en-US">Percentage of cash fee equal to aggregate proceeds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfExercisePriceEqualToOfferingPrice" xlink:to="CELU_PercentageOfExercisePriceEqualToOfferingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PercentageOfExercisePriceEqualToOfferingPrice_doc" xml:lang="en-US">Percentage of exercise price equal to pffering price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UnearnedRevenue" xlink:to="CELU_UnearnedRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_UnearnedRevenue_doc" xml:lang="en-US">Unearned revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseAndDistributionAgreementsTextBlock" xlink:to="CELU_LicenseAndDistributionAgreementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LicenseAndDistributionAgreementsTextBlock_doc" xml:lang="en-US">License And Distribution Agreements [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ServiceAgreementTerm" xlink:to="CELU_ServiceAgreementTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ServiceAgreementTerm_doc" xml:lang="en-US">Service agreement term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RegeneronResearchCollaborationServicesAgreementMember" xlink:to="CELU_RegeneronResearchCollaborationServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RegeneronResearchCollaborationServicesAgreementMember_doc" xml:lang="en-US">Regeneron Research Collaboration Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NonrefundableUpfrontPayment" xlink:to="CELU_NonrefundableUpfrontPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NonrefundableUpfrontPayment_doc" xml:lang="en-US">Nonrefundable up-front payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RegeneronServicesAgreementMember" xlink:to="CELU_RegeneronServicesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RegeneronServicesAgreementMember_doc" xml:lang="en-US">Regeneron Services Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentOfOptionFeeInCash" xlink:to="CELU_PaymentOfOptionFeeInCash_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PaymentOfOptionFeeInCash_doc" xml:lang="en-US">Payment Of Option Fee In Cash.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PultheraLLCBindingTermSheetMember" xlink:to="CELU_PultheraLLCBindingTermSheetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PultheraLLCBindingTermSheetMember_doc" xml:lang="en-US">Pulthera LLC Binding Term Sheet [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OptionFeeExpense" xlink:to="CELU_OptionFeeExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OptionFeeExpense_doc" xml:lang="en-US">Option fee expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm" xlink:to="CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm_doc" xml:lang="en-US">Commercial license to dental products agreement renewal term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseAgreementWithBiocellgraftIncMember" xlink:to="CELU_LicenseAgreementWithBiocellgraftIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LicenseAgreementWithBiocellgraftIncMember_doc" xml:lang="en-US">License Agreement With Biocellgraft Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseFeesPaymentPeriod" xlink:to="CELU_LicenseFeesPaymentPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LicenseFeesPaymentPeriod_doc" xml:lang="en-US">License fees payment period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseFeeExpense" xlink:to="CELU_LicenseFeeExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LicenseFeeExpense_doc" xml:lang="en-US">License fee expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseFeePayment" xlink:to="CELU_LicenseFeePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LicenseFeePayment_doc" xml:lang="en-US">License fee payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" xlink:to="CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_doc" xml:lang="en-US">Effective income tax rate reconciliation interest accretion expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" xlink:to="CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_doc" xml:lang="en-US">Effective income tax rate reconciliation mark to market warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp" xlink:to="CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp_doc" xml:lang="en-US">Effective income tax rate reconciliation deferred true up.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentContributionAmount" xlink:to="CELU_DebtInstrumentContributionAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DebtInstrumentContributionAmount_doc" xml:lang="en-US">Debt Instrument, Contribution Amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CEOPromissoryNoteMember" xlink:to="CELU_CEOPromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_CEOPromissoryNoteMember_doc" xml:lang="en-US">CEO Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OtherShortTermDebtDueToRelatedParty" xlink:to="CELU_OtherShortTermDebtDueToRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OtherShortTermDebtDueToRelatedParty_doc" xml:lang="en-US">Other short term debt due to related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:to="CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_doc" xml:lang="en-US">Deferred tax assets tax credit carryforwards research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsStartupCosts" xlink:to="CELU_DeferredTaxAssetsStartupCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DeferredTaxAssetsStartupCosts_doc" xml:lang="en-US">Deferred tax assets startup costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsUnicap" xlink:to="CELU_DeferredTaxAssetsUnicap_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DeferredTaxAssetsUnicap_doc" xml:lang="en-US">Deferred tax assets unicap.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsImputedInterestOnContingentPayments" xlink:to="CELU_DeferredTaxAssetsImputedInterestOnContingentPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DeferredTaxAssetsImputedInterestOnContingentPayments_doc" xml:lang="en-US">Deferred tax assets imputed interest on contingent payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" xlink:to="CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_doc" xml:lang="en-US">Deferred tax assets legal fee capitalization and amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment_doc" xml:lang="en-US">Deferred tax assets capitalized research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault" xlink:to="CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault_doc" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage in Event of Default.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentOriginalIssueDiscount" xlink:to="CELU_DebtInstrumentOriginalIssueDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DebtInstrumentOriginalIssueDiscount_doc" xml:lang="en-US">Debt Instrument Original Issue Discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShareIssuedPurchasedPrice" xlink:to="CELU_ShareIssuedPurchasedPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ShareIssuedPurchasedPrice_doc" xml:lang="en-US">Share Issued Purchased Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UnitedStatesFederalAndStateMember" xlink:to="CELU_UnitedStatesFederalAndStateMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_UnitedStatesFederalAndStateMember_doc" xml:lang="en-US">United States Federal and State [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OperatingLossCarryforwardsExpirationYear" xlink:to="CELU_OperatingLossCarryforwardsExpirationYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OperatingLossCarryforwardsExpirationYear_doc" xml:lang="en-US">Operating loss carryforwards expiration year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TaxCreditCarryforwardsExpirationYear" xlink:to="CELU_TaxCreditCarryforwardsExpirationYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_TaxCreditCarryforwardsExpirationYear_doc" xml:lang="en-US">Tax credit carryforwards expiration year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FallInCashAndCashEquivalents" xlink:to="CELU_FallInCashAndCashEquivalents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FallInCashAndCashEquivalents_doc" xml:lang="en-US">Fall In Cash And Cash Equivalents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_BiobankingMember" xlink:to="CELU_BiobankingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_BiobankingMember_doc" xml:lang="en-US">Biobanking [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DegenerativeDiseaseMember" xlink:to="CELU_DegenerativeDiseaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DegenerativeDiseaseMember_doc" xml:lang="en-US">Degenerative Disease [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SegmentContribution" xlink:to="CELU_SegmentContribution_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SegmentContribution_doc" xml:lang="en-US">Segment contribution.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IndirectExpenses" xlink:to="CELU_IndirectExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IndirectExpenses_doc" xml:lang="en-US">Indirect expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TrancheTwoWarrantMember" xlink:to="CELU_TrancheTwoWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_TrancheTwoWarrantMember_doc" xml:lang="en-US">Tranche Two Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfChangesInCashFlow" xlink:to="CELU_PercentageOfChangesInCashFlow_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PercentageOfChangesInCashFlow_doc" xml:lang="en-US">Percentage of changes in cash flow.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DrRobertHaririMember" xlink:to="CELU_DrRobertHaririMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DrRobertHaririMember_doc" xml:lang="en-US">Dr Robert Hariri [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SecuritiesPurchaseAgreementDate" xlink:to="CELU_SecuritiesPurchaseAgreementDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SecuritiesPurchaseAgreementDate_doc" xml:lang="en-US">Securities Purchase Agreement Date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SecuritiesPurchaseAgreementMember" xlink:to="CELU_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UnpaidBaseSalary" xlink:to="CELU_UnpaidBaseSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_UnpaidBaseSalary_doc" xml:lang="en-US">Unpaid base salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfUnpaidBaseSalary" xlink:to="CELU_PercentageOfUnpaidBaseSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PercentageOfUnpaidBaseSalary_doc" xml:lang="en-US">Percentage of unpaid base salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfBaseSalary" xlink:to="CELU_PercentageOfBaseSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PercentageOfBaseSalary_doc" xml:lang="en-US">Percentage Of Base Salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_BonusProgramEffectiveDate" xlink:to="CELU_BonusProgramEffectiveDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_BonusProgramEffectiveDate_doc" xml:lang="en-US">Bonus program effective date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AnnualRateOfBaseSalary" xlink:to="CELU_AnnualRateOfBaseSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AnnualRateOfBaseSalary_doc" xml:lang="en-US">Annual Rate Of Base Salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_BaseSalaryEffectiveDate" xlink:to="CELU_BaseSalaryEffectiveDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_BaseSalaryEffectiveDate_doc" xml:lang="en-US">Base salary effective date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DrHaririMember" xlink:to="CELU_DrHaririMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DrHaririMember_doc" xml:lang="en-US">Dr Hariri [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ConsultingAgreementMember" xlink:to="CELU_ConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ConsultingAgreementMember_doc" xml:lang="en-US">Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DrAndrewPecoraMember" xlink:to="CELU_DrAndrewPecoraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DrAndrewPecoraMember_doc" xml:lang="en-US">Dr Andrew Pecora [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReceiveForMonth" xlink:to="CELU_ReceiveForMonth_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ReceiveForMonth_doc" xml:lang="en-US">Receive For Month.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ScientificAndClinicalAdvisorAgreementMember" xlink:to="CELU_ScientificAndClinicalAdvisorAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ScientificAndClinicalAdvisorAgreementMember_doc" xml:lang="en-US">Scientific and Clinical Advisor Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RobinLSmithMdMember" xlink:to="CELU_RobinLSmithMdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RobinLSmithMdMember_doc" xml:lang="en-US">Robin L Smith Md [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdvisoryAgreementMember" xlink:to="CELU_AdvisoryAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AdvisoryAgreementMember_doc" xml:lang="en-US">Advisory Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RelatedPartyCashBonus" xlink:to="CELU_RelatedPartyCashBonus_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RelatedPartyCashBonus_doc" xml:lang="en-US">Related party cash bonus.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentsToRelatedParty" xlink:to="CELU_PaymentsToRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PaymentsToRelatedParty_doc" xml:lang="en-US">Payments To Related Party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_COTAIncMember" xlink:to="CELU_COTAIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_COTAIncMember_doc" xml:lang="en-US">COTA Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CryoportSystemsIncMember" xlink:to="CELU_CryoportSystemsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_CryoportSystemsIncMember_doc" xml:lang="en-US">Cryoport Systems Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LoanAgreement" xlink:to="CELU_LoanAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LoanAgreement_doc" xml:lang="en-US">Loan agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CVStarLoanMember" xlink:to="CELU_CVStarLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_CVStarLoanMember_doc" xml:lang="en-US">CV Star Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MsHaririMember" xlink:to="CELU_MsHaririMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MsHaririMember_doc" xml:lang="en-US">Ms Hariri [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_EmploymentOfImmediateFamilyMemberMember" xlink:to="CELU_EmploymentOfImmediateFamilyMemberMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_EmploymentOfImmediateFamilyMemberMember_doc" xml:lang="en-US">Employment of Immediate Family Member [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ShortTermDebtRelatedParties" xlink:to="CELU_ShortTermDebtRelatedParties_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ShortTermDebtRelatedParties_doc" xml:lang="en-US">Short term debt related parties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InitialLoanMember" xlink:to="CELU_InitialLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InitialLoanMember_doc" xml:lang="en-US">Initial Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentDiscount" xlink:to="CELU_DebtInstrumentDiscount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DebtInstrumentDiscount_doc" xml:lang="en-US">Debt instrument discount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault" xlink:to="CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault_doc" xml:lang="en-US">Debt instrument interest rate during period in event of default.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DiscountOnWarrantAmount" xlink:to="CELU_DiscountOnWarrantAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DiscountOnWarrantAmount_doc" xml:lang="en-US">Discount on warrant amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TrancheOneWarrantMember" xlink:to="CELU_TrancheOneWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_TrancheOneWarrantMember_doc" xml:lang="en-US">Tranche One Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice" xlink:to="CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice_doc" xml:lang="en-US">Percentage Of Partial Liquidating Damages On Purchase Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InitialAndSecondTrancheMember" xlink:to="CELU_InitialAndSecondTrancheMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InitialAndSecondTrancheMember_doc" xml:lang="en-US">Initial and Second Tranche [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ResortsWorldIncPteLtdMember" xlink:to="CELU_ResortsWorldIncPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ResortsWorldIncPteLtdMember_doc" xml:lang="en-US">Resorts World Inc Pte Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OperatingLeasesRentExpense" xlink:to="CELU_OperatingLeasesRentExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OperatingLeasesRentExpense_doc" xml:lang="en-US">Operating leases rent expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AreaOfBuilding" xlink:to="CELU_AreaOfBuilding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AreaOfBuilding_doc" xml:lang="en-US">Area of building.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OfficeManufacturingAndLaboratorySpaceMember" xlink:to="CELU_OfficeManufacturingAndLaboratorySpaceMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OfficeManufacturingAndLaboratorySpaceMember_doc" xml:lang="en-US">Office Manufacturing and Laboratory Space [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FlorhamParkNewJerseyMember" xlink:to="CELU_FlorhamParkNewJerseyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FlorhamParkNewJerseyMember_doc" xml:lang="en-US">Florham Park New Jersey [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OperatingLeaseExpiryYear" xlink:to="CELU_OperatingLeaseExpiryYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OperatingLeaseExpiryYear_doc" xml:lang="en-US">Operating lease expiry year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OperatingLeaseCommencementDate" xlink:to="CELU_OperatingLeaseCommencementDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_OperatingLeaseCommencementDate_doc" xml:lang="en-US">Operating lease commencement date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InitialMonthlyBaseRent" xlink:to="CELU_InitialMonthlyBaseRent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InitialMonthlyBaseRent_doc" xml:lang="en-US">Initial monthly base rent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReductionInLineOfCredit" xlink:to="CELU_ReductionInLineOfCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ReductionInLineOfCredit_doc" xml:lang="en-US">Reduction in line of credit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NewLineOfCredit" xlink:to="CELU_NewLineOfCredit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_NewLineOfCredit_doc" xml:lang="en-US">New line of credit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_BaseRentalPayments" xlink:to="CELU_BaseRentalPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_BaseRentalPayments_doc" xml:lang="en-US">Base rental payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock" xlink:to="CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_doc" xml:lang="en-US">Cash And Non Cash Activity Related To Lease Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueAdjustmentThroughEarnings" xlink:to="CELU_FairValueAdjustmentThroughEarnings_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FairValueAdjustmentThroughEarnings_doc" xml:lang="en-US">Fair value adjustment through earnings.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" xlink:to="CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_doc" xml:lang="en-US">Fair value adjustment through accumulated other comprehensive income.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RWIBridgeLoanNetOfDiscountMember" xlink:to="CELU_RWIBridgeLoanNetOfDiscountMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_RWIBridgeLoanNetOfDiscountMember_doc" xml:lang="en-US">RWI Bridge Loan Net of Discount [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CVStarrBridgeLoanNetOfDiscountMember" xlink:to="CELU_CVStarrBridgeLoanNetOfDiscountMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_CVStarrBridgeLoanNetOfDiscountMember_doc" xml:lang="en-US">CV Starr Bridge Loan Net of Discount [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_MachineryEquipmentAndFixturesMember" xlink:to="CELU_MachineryEquipmentAndFixturesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_MachineryEquipmentAndFixturesMember_doc" xml:lang="en-US">Machinery, Equipment and Fixtures [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LaboratoryAndProductionEquipmentMember" xlink:to="CELU_LaboratoryAndProductionEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LaboratoryAndProductionEquipmentMember_doc" xml:lang="en-US">Laboratory and Production Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_GXSponsorWarrantsMember" xlink:to="CELU_GXSponsorWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_GXSponsorWarrantsMember_doc" xml:lang="en-US">GX Sponsor Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_LicenseRoyaltyAndOtherMember" xlink:to="CELU_LicenseRoyaltyAndOtherMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_LicenseRoyaltyAndOtherMember_doc" xml:lang="en-US">License Royalty and Other [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandSeventeenPlanMember" xlink:to="CELU_TwoThousandSeventeenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_TwoThousandSeventeenPlanMember_doc" xml:lang="en-US">2017 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoThousandTwentyOnePlanMember" xlink:to="CELU_TwoThousandTwentyOnePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_TwoThousandTwentyOnePlanMember_doc" xml:lang="en-US">2021 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" xlink:to="CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension_doc" xml:lang="en-US">Stock issued during period value short term debt maturity extension.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" xlink:to="CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses_doc" xml:lang="en-US">Stock issued during period value PIPE offering net of offering expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses" xlink:to="CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses_doc" xml:lang="en-US">Stock issued during period shares PIPE offering net of offering expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValueATMAgreement" xlink:to="CELU_StockIssuedDuringPeriodValueATMAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodValueATMAgreement_doc" xml:lang="en-US">Stock issued during period value for ATM agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesATMAgreement" xlink:to="CELU_StockIssuedDuringPeriodSharesATMAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodSharesATMAgreement_doc" xml:lang="en-US">Stock issued during period shares for ATM agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" xlink:to="CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement_doc" xml:lang="en-US">Stock issued during period value for consideration for settlement agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement" xlink:to="CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement_doc" xml:lang="en-US">Stock issued during period shares for consideration for settlement agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" xlink:to="CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee_doc" xml:lang="en-US">Stock issued during period value for debt extension and commitment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee" xlink:to="CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee_doc" xml:lang="en-US">Stock issued during period shares for debt extension and commitment fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" xlink:to="CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense_doc" xml:lang="en-US">Increase decrease in accrued research development software expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ThreeCustomersMember" xlink:to="CELU_ThreeCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ThreeCustomersMember_doc" xml:lang="en-US">Three Customers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_TwoCustomersMember" xlink:to="CELU_TwoCustomersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_TwoCustomersMember_doc" xml:lang="en-US">Two Customers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SequenceLifeScienceIncMember" xlink:to="CELU_SequenceLifeScienceIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SequenceLifeScienceIncMember_doc" xml:lang="en-US">Sequence LifeScience Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_doc" xml:lang="en-US">Asset acquisition recognized identifiable assets acquired and liabilities assumed inventory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_doc" xml:lang="en-US">Asset acquisition recognized identifiable assets acquired and liabilities assumed inventory assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AcquisitionRelatedContingentConsiderationObligationsMember" xlink:to="CELU_AcquisitionRelatedContingentConsiderationObligationsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AcquisitionRelatedContingentConsiderationObligationsMember_doc" xml:lang="en-US">Acquisition - Related Contingent Consideration Obligations [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryWorkInProgressMember" xlink:to="CELU_InventoryWorkInProgressMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InventoryWorkInProgressMember_doc" xml:lang="en-US">Inventory Work in Progress [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryFinishedGoodsMember" xlink:to="CELU_InventoryFinishedGoodsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_InventoryFinishedGoodsMember_doc" xml:lang="en-US">Inventory Finished Goods [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_CommercialLicenseToDentalProductsAgreementPeriod" xlink:to="CELU_CommercialLicenseToDentalProductsAgreementPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_CommercialLicenseToDentalProductsAgreementPeriod_doc" xml:lang="en-US">Commercial license to dental products agreement period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProvisionForObsoleteInventory" xlink:to="CELU_ProvisionForObsoleteInventory_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ProvisionForObsoleteInventory_doc" xml:lang="en-US">Provision for obsolete inventory.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AllowanceForCreditLossesPolicyTextBlock" xlink:to="CELU_AllowanceForCreditLossesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AllowanceForCreditLossesPolicyTextBlock_doc" xml:lang="en-US">Disclosure of accounting policy related to allowance for credit losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember" xlink:to="CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember_doc" xml:lang="en-US">January 2024 PIPE Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember" xlink:to="CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember_doc" xml:lang="en-US">HLI Cellular Therapeutics LLC and Anthrogenesis [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AmendedAndRestatedEmploymentAgreementMember" xlink:to="CELU_AmendedAndRestatedEmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AmendedAndRestatedEmploymentAgreementMember_doc" xml:lang="en-US">Amended and Restated Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_UnsecuredSeniorConvertibleNoteMember" xlink:to="CELU_UnsecuredSeniorConvertibleNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_UnsecuredSeniorConvertibleNoteMember_doc" xml:lang="en-US">Unsecured Senior Convertible Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AdditionalLicenseFee" xlink:to="CELU_AdditionalLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_AdditionalLicenseFee_doc" xml:lang="en-US">Additional license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DeferredTaxAssetsIrcSectionInterest" xlink:to="CELU_DeferredTaxAssetsIrcSectionInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_DeferredTaxAssetsIrcSectionInterest_doc" xml:lang="en-US">Deferred tax assets irc section interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueNetAssetLiabilities" xlink:to="CELU_FairValueNetAssetLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_FairValueNetAssetLiabilities_doc" xml:lang="en-US">Fair value net asset liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_SecondLoanAgreement" xlink:to="CELU_SecondLoanAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_SecondLoanAgreement_doc" xml:lang="en-US">Second loan agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_GenesisEquityGroupFundingLlcMember" xlink:to="CELU_GenesisEquityGroupFundingLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_GenesisEquityGroupFundingLlcMember_doc" xml:lang="en-US">Genesis Equity Group Funding LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ApplicableFees" xlink:to="CELU_ApplicableFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELU_ApplicableFees_doc" xml:lang="en-US">Applicable fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:to="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember_lbl" xml:lang="en-US">Useful Life, Shorter of Lease Term or Asset Utility [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember" xlink:to="CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_3_lbl" xml:lang="en-US">November 2024 Purchaser Warrants [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_OperatingIncomeCostsAndExpenses" xlink:to="CELU_OperatingIncomeCostsAndExpenses_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_OperatingIncomeCostsAndExpenses_3_lbl" xml:lang="en-US">OperatingIncomeCostsAndExpenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_3_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_2_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_3_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, before Tax, after Reclassification Adjustment, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_2_lbl" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2_lbl" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment" xlink:to="CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment_3_lbl" xml:lang="en-US">IssuanceOfCommonStockUsedInResearchAndDevelopment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement" xlink:to="CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement_3_lbl" xml:lang="en-US">IssuanceOfCommonStockAsConsiderationForSettlementAgreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" xlink:to="CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee_3_lbl" xml:lang="en-US">IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IssuanceOfCommonStockAsCompensationExpense" xlink:to="CELU_IssuanceOfCommonStockAsCompensationExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IssuanceOfCommonStockAsCompensationExpense_3_lbl" xml:lang="en-US">IssuanceOfCommonStockAsCompensationExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueOfWarrantModificationForProfessionalServices" xlink:to="CELU_FairValueOfWarrantModificationForProfessionalServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FairValueOfWarrantModificationForProfessionalServices_3_lbl" xml:lang="en-US">FairValueOfWarrantModificationForProfessionalServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" xlink:to="CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense_3_lbl" xml:lang="en-US">IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_2_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_2_lbl" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ProceedsFromConvertibleNote" xlink:to="CELU_ProceedsFromConvertibleNote_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ProceedsFromConvertibleNote_3_lbl" xml:lang="en-US">ProceedsFromConvertibleNote</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RepaymentsOfShortTermDebtUnaffiliated" xlink:to="CELU_RepaymentsOfShortTermDebtUnaffiliated_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RepaymentsOfShortTermDebtUnaffiliated_3_lbl" xml:lang="en-US">RepaymentsOfShortTermDebtUnaffiliated</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_PaymentOfSepaCommitmentFee" xlink:to="CELU_PaymentOfSepaCommitmentFee_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_PaymentOfSepaCommitmentFee_3_lbl" xml:lang="en-US">PaymentOfSepaCommitmentFee</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_RepaymentsOfShortTermDebtRelatedParty" xlink:to="CELU_RepaymentsOfShortTermDebtRelatedParty_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_RepaymentsOfShortTermDebtRelatedParty_3_lbl" xml:lang="en-US">RepaymentsOfShortTermDebtRelatedParty</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_lbl" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_2_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:to="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_4_lbl" xml:lang="en-US">ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_2_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_2_lbl" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_2_lbl" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_2_lbl" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLossNetOfTax" xlink:to="us-gaap_GoodwillImpairmentLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLossNetOfTax_2_lbl" xml:lang="en-US">Goodwill, Impairment Loss, Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_2_lbl" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_3_lbl" xml:lang="en-US">AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_3_lbl" xml:lang="en-US">AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_2_lbl" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_2_lbl" xml:lang="en-US">Debt Instrument, Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_3_lbl" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_FairValueNetAssetLiabilities" xlink:to="CELU_FairValueNetAssetLiabilities_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_FairValueNetAssetLiabilities_4_lbl" xml:lang="en-US">Fair value net asset liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryGrossCurrentAndNoncurrent" xlink:to="CELU_InventoryGrossCurrentAndNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InventoryGrossCurrentAndNoncurrent_3_lbl" xml:lang="en-US">InventoryGrossCurrentAndNoncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryReserveCurrentAndNoncurrent" xlink:to="CELU_InventoryReserveCurrentAndNoncurrent_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InventoryReserveCurrentAndNoncurrent_5_lbl" xml:lang="en-US">InventoryReserveCurrentAndNoncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InventoryNetCurrentAndNoncurrent" xlink:to="CELU_InventoryNetCurrentAndNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InventoryNetCurrentAndNoncurrent_3_lbl" xml:lang="en-US">InventoryNetCurrentAndNoncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod" xlink:to="CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod_3_lbl" xml:lang="en-US">IndefiniteLivedIntangibleAssetsAmortizationMethod</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetImpairmentCharges" xlink:to="us-gaap_OtherAssetImpairmentCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetImpairmentCharges_2_lbl" xml:lang="en-US">Other Asset Impairment Charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_Debt" xlink:to="CELU_Debt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_Debt_3_lbl" xml:lang="en-US">Debt [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_2_lbl" xml:lang="en-US">Repayments of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_2_lbl" xml:lang="en-US">Shares, Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherShortTermDebt" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt_2_lbl" xml:lang="en-US">Proceeds from Other Short-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_DebtInstrumentOriginalIssueDiscount" xlink:to="CELU_DebtInstrumentOriginalIssueDiscount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_DebtInstrumentOriginalIssueDiscount_3_lbl" xml:lang="en-US">DebtInstrumentOriginalIssueDiscount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_2_lbl" xml:lang="en-US">Lease, Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_3_lbl" xml:lang="en-US">Contract with Customer, Liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_2_lbl" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_2_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_InProcessResearchAndDevelopmentImpairment" xlink:to="CELU_InProcessResearchAndDevelopmentImpairment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_InProcessResearchAndDevelopmentImpairment_3_lbl" xml:lang="en-US">InProcessResearchAndDevelopmentImpairment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELU_BaseSalaryEffectiveDate" xlink:to="CELU_BaseSalaryEffectiveDate_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELU_BaseSalaryEffectiveDate_3_lbl" xml:lang="en-US">BaseSalaryEffectiveDate</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>celu-20241231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celularity.com/role/Cover" xlink:href="celu-20241231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BalanceSheets" xlink:href="celu-20241231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BalanceSheetsParenthetical" xlink:href="celu-20241231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="celu-20241231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/StatementsOfStockholdersEquity" xlink:href="celu-20241231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/StatementsOfCashFlows" xlink:href="celu-20241231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#MaterialCybersecurityIncidentDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/NatureOfBusiness" xlink:href="celu-20241231.xsd#NatureOfBusiness" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AssetAcquisition" xlink:href="celu-20241231.xsd#AssetAcquisition" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilities" xlink:href="celu-20241231.xsd#FairValueOfFinancialAssetsAndLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Inventory" xlink:href="celu-20241231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="celu-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PropertyAndEquipmentNet" xlink:href="celu-20241231.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNet" xlink:href="celu-20241231.xsd#GoodwillAndIntangibleAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="celu-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Debt" xlink:href="celu-20241231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Leases" xlink:href="celu-20241231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/CommitmentsAndContingencies" xlink:href="celu-20241231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Equity" xlink:href="celu-20241231.xsd#Equity" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Stock-basedCompensation" xlink:href="celu-20241231.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RevenueRecognition" xlink:href="celu-20241231.xsd#RevenueRecognition" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LicenseAndDistributionAgreements" xlink:href="celu-20241231.xsd#LicenseAndDistributionAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BenefitPlan" xlink:href="celu-20241231.xsd#BenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/IncomeTaxes" xlink:href="celu-20241231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SegmentInformation" xlink:href="celu-20241231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RelatedPartyTransactions" xlink:href="celu-20241231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SubsequentEvents" xlink:href="celu-20241231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AssetAcquisitionTables" xlink:href="celu-20241231.xsd#AssetAcquisitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:href="celu-20241231.xsd#FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/InventoryTables" xlink:href="celu-20241231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="celu-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PropertyAndEquipmentNetTables" xlink:href="celu-20241231.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables" xlink:href="celu-20241231.xsd#GoodwillAndIntangibleAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="celu-20241231.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/DebtTables" xlink:href="celu-20241231.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LeasesTables" xlink:href="celu-20241231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/EquityTables" xlink:href="celu-20241231.xsd#EquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Stock-basedCompensationTables" xlink:href="celu-20241231.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RevenueRecognitionTables" xlink:href="celu-20241231.xsd#RevenueRecognitionTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/IncomeTaxesTables" xlink:href="celu-20241231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SegmentInformationTables" xlink:href="celu-20241231.xsd#SegmentInformationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/NatureOfBusinessDetailsNarrative" xlink:href="celu-20241231.xsd#NatureOfBusinessDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:href="celu-20241231.xsd#ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="celu-20241231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails" xlink:href="celu-20241231.xsd#ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/AssetAcquisitionDetailsNarrative" xlink:href="celu-20241231.xsd#AssetAcquisitionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails" xlink:href="celu-20241231.xsd#ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfConvertibleNoteValuationModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfConvertibleNotesValuationModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails" xlink:href="celu-20241231.xsd#ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails" xlink:href="celu-20241231.xsd#ScheduleOfJanuary20224BridgeLoanDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails" xlink:href="celu-20241231.xsd#ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical" xlink:href="celu-20241231.xsd#ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails" xlink:href="celu-20241231.xsd#ScheduleOfSignificantInputsForSponsorWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative" xlink:href="celu-20241231.xsd#FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails" xlink:href="celu-20241231.xsd#ScheduleOfMajorClassesOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfInventoryReservesDetails" xlink:href="celu-20241231.xsd#ScheduleOfInventoryReservesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/InventoryDetailsNarrative" xlink:href="celu-20241231.xsd#InventoryDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="celu-20241231.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:href="celu-20241231.xsd#ScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="celu-20241231.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:href="celu-20241231.xsd#ScheduleOfIntangibleAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" xlink:href="celu-20241231.xsd#ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" xlink:href="celu-20241231.xsd#GoodwillAndIntangibleAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfDebtDetails" xlink:href="celu-20241231.xsd#ScheduleOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/DebtDetailsNarrative" xlink:href="celu-20241231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfLeaseCostsDetails" xlink:href="celu-20241231.xsd#ScheduleOfLeaseCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:href="celu-20241231.xsd#ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LeasesDetailsNarrative" xlink:href="celu-20241231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="celu-20241231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfWarrantsDetails" xlink:href="celu-20241231.xsd#SummaryOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical" xlink:href="celu-20241231.xsd#SummaryOfWarrantsDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/EquityDetailsNarrative" xlink:href="celu-20241231.xsd#EquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails" xlink:href="celu-20241231.xsd#ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="celu-20241231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical" xlink:href="celu-20241231.xsd#ScheduleOfStockOptionActivityDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails" xlink:href="celu-20241231.xsd#ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="celu-20241231.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="celu-20241231.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:href="celu-20241231.xsd#ScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical" xlink:href="celu-20241231.xsd#ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative" xlink:href="celu-20241231.xsd#LicenseAndDistributionAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/BenefitPlanDetailsNarrative" xlink:href="celu-20241231.xsd#BenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:href="celu-20241231.xsd#ScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails" xlink:href="celu-20241231.xsd#ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="celu-20241231.xsd#ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="celu-20241231.xsd#ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/IncomeTaxesDetailsNarrative" xlink:href="celu-20241231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails" xlink:href="celu-20241231.xsd#ScheduleOfFinancialInformationBySegmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SegmentInformationDetailsNarrative" xlink:href="celu-20241231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="celu-20241231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celularity.com/role/SubsequentEventsDetailsNarrative" xlink:href="celu-20241231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ClassCommonStockParValue0.0001PerShareMember" xlink:label="loc_CELUClassCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CELUClassCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" xlink:label="loc_CELUWarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_CELUWarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorOpinionTextBlock" xlink:label="loc_deiAuditorOpinionTextBlock" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorOpinionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsAndOtherReceivablesNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PromissoryNotesReceivable" xlink:label="loc_CELUPromissoryNotesReceivable" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_CELUPromissoryNotesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaapInventoryNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapInventoryNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedResearchAndDevelopmentSoftware" xlink:label="loc_CELUAccruedResearchAndDevelopmentSoftware" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_CELUAccruedResearchAndDevelopmentSoftware" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityNoncurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationLiability" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiability" xlink:label="loc_CELUWarrantLiability" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_CELUWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilitiesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefinedBenefitPlanDisclosureLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtFairValue" xlink:label="loc_us-gaapShorttermDebtFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapShorttermDebtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseRoyaltyAndOtherMember" xlink:label="loc_CELULicenseRoyaltyAndOtherMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_CELULicenseRoyaltyAndOtherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenueAbstract" xlink:label="loc_us-gaapCostOfRevenueAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapCostOfRevenueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCostOfRevenueAbstract" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingIncomeCostsAndExpenses" xlink:label="loc_CELUOperatingIncomeCostsAndExpenses" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_CELUOperatingIncomeCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChangeInFairValueOfDebt" xlink:label="loc_CELUChangeInFairValueOfDebt" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_CELUChangeInFairValueOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OtherNonoperatingIncomeExpenses" xlink:label="loc_CELUOtherNonoperatingIncomeExpenses" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_CELUOtherNonoperatingIncomeExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:label="loc_CELUStockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:label="loc_CELUStockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" xlink:label="loc_CELUStockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValuesShortTermDebtMaturityExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension" xlink:label="loc_CELUStockIssuedDuringPeriodSharesShortTermDebtMaturityExtension" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesShortTermDebtMaturityExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueOfWarrantModificationForProfessionalService" xlink:label="loc_CELUFairValueOfWarrantModificationForProfessionalService" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUFairValueOfWarrantModificationForProfessionalService" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment" xlink:label="loc_CELUStockIssuedDuringPeriodValueOfResearchAndDevelopment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValueOfResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment" xlink:label="loc_CELUStockIssuedDuringPeriodSharesOfResearchAndDevelopment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesOfResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" xlink:label="loc_CELUStockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses" xlink:label="loc_CELUStockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueATMAgreement" xlink:label="loc_CELUStockIssuedDuringPeriodValueATMAgreement" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValueATMAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesATMAgreement" xlink:label="loc_CELUStockIssuedDuringPeriodSharesATMAgreement" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesATMAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" xlink:label="loc_CELUStockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee" xlink:label="loc_CELUStockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" xlink:label="loc_CELUAdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUAdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement" xlink:label="loc_CELUStockIssuedDuringPeriodValueConsiderationForSettlementAgreement" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodValueConsiderationForSettlementAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement" xlink:label="loc_CELUStockIssuedDuringPeriodSharesConsiderationForSettlementAgreement" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUStockIssuedDuringPeriodSharesConsiderationForSettlementAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:label="loc_CELUAdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUAdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NonCashLeaseExpense" xlink:label="loc_CELUNonCashLeaseExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUNonCashLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProvisionForInventoryObsolescence" xlink:label="loc_CELUProvisionForInventoryObsolescence" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUProvisionForInventoryObsolescence" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryImpairmentCharge" xlink:label="loc_CELUInventoryImpairmentCharge" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUInventoryImpairmentCharge" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AcquiredInProcessResearchAndDevelopment" xlink:label="loc_CELUAcquiredInProcessResearchAndDevelopment" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUAcquiredInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment" xlink:label="loc_CELUIssuanceOfCommonStockUsedInResearchAndDevelopment" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUIssuanceOfCommonStockUsedInResearchAndDevelopment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement" xlink:label="loc_CELUIssuanceOfCommonStockAsConsiderationForSettlementAgreement" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUIssuanceOfCommonStockAsConsiderationForSettlementAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" xlink:label="loc_CELUIssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUIssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockAsCompensationExpense" xlink:label="loc_CELUIssuanceOfCommonStockAsCompensationExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUIssuanceOfCommonStockAsCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DiscountsArisingFromLoanArrangementRelatedParty" xlink:label="loc_CELUDiscountsArisingFromLoanArrangementRelatedParty" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUDiscountsArisingFromLoanArrangementRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueOfWarrantModificationForProfessionalServices" xlink:label="loc_CELUFairValueOfWarrantModificationForProfessionalServices" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUFairValueOfWarrantModificationForProfessionalServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChangeInFairValueOfDebt" xlink:label="loc_CELUChangeInFairValueOfDebt" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUChangeInFairValueOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChangeInFairValueOfContingentStockConsideration" xlink:label="loc_CELUChangeInFairValueOfContingentStockConsideration" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUChangeInFairValueOfContingentStockConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NonCashInterestExpense" xlink:label="loc_CELUNonCashInterestExpense" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELUNonCashInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingCapitalNet" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" xlink:label="loc_CELUIncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_CELUIncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromConvertibleNote" xlink:label="loc_CELUProceedsFromConvertibleNote" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_CELUProceedsFromConvertibleNote" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties" xlink:label="loc_CELUProceedsFromWarrantsAndShortTermDebtRelatedParties" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELUProceedsFromWarrantsAndShortTermDebtRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RepaymentsOfShortTermDebtUnaffiliated" xlink:label="loc_CELURepaymentsOfShortTermDebtUnaffiliated" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELURepaymentsOfShortTermDebtUnaffiliated" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering" xlink:label="loc_CELUProceedsFromTheSaleOfCommonStockInAtmOffering" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELUProceedsFromTheSaleOfCommonStockInAtmOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromShortTermDebtUnaffiliated" xlink:label="loc_CELUProceedsFromShortTermDebtUnaffiliated" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELUProceedsFromShortTermDebtUnaffiliated" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentOfSepaCommitmentFee" xlink:label="loc_CELUPaymentOfSepaCommitmentFee" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELUPaymentOfSepaCommitmentFee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RepaymentsOfShortTermDebtRelatedParty" xlink:label="loc_CELURepaymentsOfShortTermDebtRelatedParty" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELURepaymentsOfShortTermDebtRelatedParty" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaapConversionOfStockAmountIssued1" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapConversionOfStockAmountIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance" xlink:label="loc_CELUModificationOfCVStarrWarrantsInConnectionWithForbearance" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CELUModificationOfCVStarrWarrantsInConnectionWithForbearance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance" xlink:label="loc_CELUIssuanceOfRwiWarrantsInConnectionWithForbearance" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CELUIssuanceOfRwiWarrantsInConnectionWithForbearance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan" xlink:label="loc_CELUIssuanceOfWarrantsOnSeniorSecuredBridgeLoan" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CELUIssuanceOfWarrantsOnSeniorSecuredBridgeLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification" xlink:label="loc_CELUReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CELUReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PIPERelatedCostsIncludedInAccruedExpenses" xlink:label="loc_CELUPIPERelatedCostsIncludedInAccruedExpenses" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CELUPIPERelatedCostsIncludedInAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties" xlink:label="loc_CELUInterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties" />
      <link:presentationArc order="670" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CELUInterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition" xlink:label="loc_CELUContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CELUContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition" xlink:label="loc_CELUInventoryAcquiredInConnectionWithReboundAssetAcquisition" />
      <link:presentationArc order="690" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CELUInventoryAcquiredInConnectionWithReboundAssetAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:label="loc_CELUReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" />
      <link:presentationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CELUReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty" xlink:label="loc_CELUAssumptionOfShorttermDebtUnaffiliatedByRelatedParty" />
      <link:presentationArc order="710" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_CELUAssumptionOfShorttermDebtUnaffiliatedByRelatedParty" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="00000012 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" xlink:title="00000013 - Disclosure - Material Cybersecurity Incident Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentAbstract" xlink:label="loc_cydMaterialCybersecurityIncidentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentNatureTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentNatureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentNatureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentScopeTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentScopeTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentScopeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentTimingTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentTimingTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentTimingTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:label="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydMaterialCybersecurityIncidentAbstract" xlink:to="loc_cydMaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/NatureOfBusiness" xlink:title="999014 - Disclosure - Nature of Business">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999015 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/AssetAcquisition" xlink:title="999016 - Disclosure - Asset Acquisition">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="loc_us-gaapAssetAcquisitionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapAssetAcquisitionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilities" xlink:title="999017 - Disclosure - Fair Value of Financial Assets and Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/Inventory" xlink:title="999018 - Disclosure - Inventory">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999019 - Disclosure - Prepaid Expenses and Other Current Assets">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_CELUDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:label="loc_CELUPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_CELUPrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/PropertyAndEquipmentNet" xlink:title="999020 - Disclosure - Property and Equipment, Net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/GoodwillAndIntangibleAssetsNet" xlink:title="999021 - Disclosure - Goodwill and Intangible Assets, Net">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999022 - Disclosure - Accrued Expenses and Other Current Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/Debt" xlink:title="999023 - Disclosure - Debt">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/Leases" xlink:title="999024 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosureLeasesAbstract" xlink:label="loc_CELUDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/CommitmentsAndContingencies" xlink:title="999025 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/Equity" xlink:title="999026 - Disclosure - Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/Stock-basedCompensation" xlink:title="999027 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/RevenueRecognition" xlink:title="999028 - Disclosure - Revenue Recognition">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/LicenseAndDistributionAgreements" xlink:title="999029 - Disclosure - License and Distribution Agreements">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosureLicenseAndDistributionAgreementsAbstract" xlink:label="loc_CELUDisclosureLicenseAndDistributionAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAndDistributionAgreementsTextBlock" xlink:label="loc_CELULicenseAndDistributionAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLicenseAndDistributionAgreementsAbstract" xlink:to="loc_CELULicenseAndDistributionAgreementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/BenefitPlan" xlink:title="999030 - Disclosure - Benefit Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanTextBlock" xlink:label="loc_us-gaapDefinedBenefitPlanTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedBenefitPlanTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/IncomeTaxes" xlink:title="999031 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/SegmentInformation" xlink:title="999032 - Disclosure - Segment Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/RelatedPartyTransactions" xlink:title="999033 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/SubsequentEvents" xlink:title="999034 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999035 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AssetAcquisitionsPolicyTextBlock" xlink:label="loc_CELUAssetAcquisitionsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELUAssetAcquisitionsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentPolicy" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsLiabilitiesPolicyTextBlock" xlink:label="loc_CELUWarrantsLiabilitiesPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELUWarrantsLiabilitiesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShortTermDebtPolicyTextBlock" xlink:label="loc_CELUShortTermDebtPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELUShortTermDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GovernmentGrantsPolicyTextBlock" xlink:label="loc_CELUGovernmentGrantsPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELUGovernmentGrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PatentCostsPolicyTextBlock" xlink:label="loc_CELUPatentCostsPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELUPatentCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AllowanceForCreditLossesPolicyTextBlock" xlink:label="loc_CELUAllowanceForCreditLossesPolicyTextBlock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELUAllowanceForCreditLossesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_CELURecentlyAdoptedAccountingPronouncementsPolicyTextBlock" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELURecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999036 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock" xlink:label="loc_CELUScheduleOfEstimatedUsefulLivesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELUScheduleOfEstimatedUsefulLivesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/AssetAcquisitionTables" xlink:title="999037 - Disclosure - Asset Acquisition (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock" xlink:label="loc_us-gaapAssetAcquisitionContingentConsiderationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapAssetAcquisitionContingentConsiderationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" xlink:title="999038 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AcquisitionRelatedContingentConsiderationObligationsMember" xlink:label="loc_CELUAcquisitionRelatedContingentConsiderationObligationsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CELUAcquisitionRelatedContingentConsiderationObligationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContingentStockConsiderationMember" xlink:label="loc_CELUContingentStockConsiderationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CELUContingentStockConsiderationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNotesMember" xlink:label="loc_CELUUnsecuredSeniorConvertibleNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUUnsecuredSeniorConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" xlink:label="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GXSponsorWarrantsMember" xlink:label="loc_CELUGXSponsorWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUGXSponsorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock" xlink:label="loc_CELUScheduleOfConvertibleNoteValuationModelTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_CELUScheduleOfConvertibleNoteValuationModelTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:label="loc_CELUFairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_CELUFairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" xlink:label="loc_CELUScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_CELUScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/InventoryTables" xlink:title="999039 - Disclosure - Inventory (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:label="loc_CELUScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_CELUScheduleOfInventoryCurrentAndNoncurrentTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfActivityInInventoryReservesTableTextBlock" xlink:label="loc_CELUScheduleOfActivityInInventoryReservesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_CELUScheduleOfActivityInInventoryReservesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999040 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_CELUDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_CELUScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_CELUScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/PropertyAndEquipmentNetTables" xlink:title="999041 - Disclosure - Property and Equipment, Net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables" xlink:title="999042 - Disclosure - Goodwill and Intangible Assets, Net (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScheduleOfIntangibleAssetsNetTableTextBlock" xlink:label="loc_CELUScheduleOfIntangibleAssetsNetTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_CELUScheduleOfIntangibleAssetsNetTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999043 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/DebtTables" xlink:title="999044 - Disclosure - Debt (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/LeasesTables" xlink:title="999045 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosureLeasesAbstract" xlink:label="loc_CELUDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock" xlink:label="loc_CELUCashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_CELUCashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/EquityTables" xlink:title="999046 - Disclosure - Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/Stock-basedCompensationTables" xlink:title="999047 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/RevenueRecognitionTables" xlink:title="999048 - Disclosure - Revenue Recognition (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueByArrangementDisclosureTextBlock" xlink:label="loc_us-gaapDeferredRevenueByArrangementDisclosureTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDeferredRevenueByArrangementDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/IncomeTaxesTables" xlink:title="999049 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/SegmentInformationTables" xlink:title="999050 - Disclosure - Segment Information (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/NatureOfBusinessDetailsNarrative" xlink:title="999051 - Disclosure - Nature of Business (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_deiEntityIncorporationDateOfIncorporation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationDateOfIncorporation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaapStockholdersEquityReverseStockSplit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityReverseStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentForManagementFee" xlink:label="loc_us-gaapPaymentForManagementFee" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentForManagementFee" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:title="999052 - Disclosure - Schedule of Property and Equipment Estimated Useful Life (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaapBuildingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapBuildingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaapSoftwareDevelopmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails" xlink:title="999053 - Disclosure - Schedule of Potentially Dilutive Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaapConvertibleDebtSecuritiesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapConvertibleDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeAxis" xlink:label="loc_us-gaapPledgingPurposeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapPledgingPurposeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PledgingPurposeDomain" xlink:label="loc_us-gaapPledgingPurposeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPledgingPurposeAxis" xlink:to="loc_us-gaapPledgingPurposeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LetterOfCreditMember" xlink:label="loc_us-gaapLetterOfCreditMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPledgingPurposeDomain" xlink:to="loc_us-gaapLetterOfCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CellTherapyMember" xlink:label="loc_CELUCellTherapyMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CELUCellTherapyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ThreeCustomersMember" xlink:label="loc_CELUThreeCustomersMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_CELUThreeCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoCustomersMember" xlink:label="loc_CELUTwoCustomersMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_CELUTwoCustomersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CustomerOneMember" xlink:label="loc_CELUCustomerOneMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_CELUCustomerOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CustomerTwoMember" xlink:label="loc_CELUCustomerTwoMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_CELUCustomerTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLossNetOfTax" xlink:label="loc_us-gaapGoodwillImpairmentLossNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContractedStoragePeriods" xlink:label="loc_CELUContractedStoragePeriods" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUContractedStoragePeriods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentPlansForCustomerToPayOverTimePeriod" xlink:label="loc_CELUPaymentPlansForCustomerToPayOverTimePeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUPaymentPlansForCustomerToPayOverTimePeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant" xlink:label="loc_CELUReductionOfResearchAndDevelopmentExpenseResultingFromGrant" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUReductionOfResearchAndDevelopmentExpenseResultingFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InstrumentSpecificCreditRiskLoss" xlink:label="loc_CELUInstrumentSpecificCreditRiskLoss" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUInstrumentSpecificCreditRiskLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InstrumentSpecificCreditRiskIncome" xlink:label="loc_CELUInstrumentSpecificCreditRiskIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUInstrumentSpecificCreditRiskIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion" xlink:label="loc_CELUAccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_CELUAccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:label="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationLikelihoodOfUnfavorableSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails" xlink:title="999055 - Disclosure - Schedule of Purchase Price Allocated to Acquired Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapAssetAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SequenceLifeScienceIncMember" xlink:label="loc_CELUSequenceLifeScienceIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_CELUSequenceLifeScienceIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapPaymentsToAcquireOtherProductiveAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="loc_us-gaapAssetAcquisitionConsiderationTransferred" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionConsiderationTransferred" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_CELUAssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUAssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_CELUAssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUAssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/AssetAcquisitionDetailsNarrative" xlink:title="999056 - Disclosure - Asset Acquisition (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable" xlink:label="loc_us-gaapAssetAcquisitionTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationAndAssetAcquisitionAbstract" xlink:to="loc_us-gaapAssetAcquisitionTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="loc_us-gaapAssetAcquisitionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="loc_us-gaapAssetAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionTable" xlink:to="loc_us-gaapAssetAcquisitionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="loc_us-gaapAssetAcquisitionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionAxis" xlink:to="loc_us-gaapAssetAcquisitionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SequenceLifeScienceIncMember" xlink:label="loc_CELUSequenceLifeScienceIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionDomain" xlink:to="loc_CELUSequenceLifeScienceIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:label="loc_us-gaapAssetAcquisitionPriceOfAcquisitionExpected" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_us-gaapAssetAcquisitionPriceOfAcquisitionExpected" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UpfrontPayment" xlink:label="loc_CELUUpfrontPayment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUUpfrontPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MonthlyMilestonePayments" xlink:label="loc_CELUMonthlyMilestonePayments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUMonthlyMilestonePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PriorPaymentToRelatedParty" xlink:label="loc_CELUPriorPaymentToRelatedParty" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUPriorPaymentToRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NetSalesPercentage" xlink:label="loc_CELUNetSalesPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUNetSalesPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PurchasePriceContingentConsideration" xlink:label="loc_CELUPurchasePriceContingentConsideration" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUPurchasePriceContingentConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MilestonePayments" xlink:label="loc_CELUMilestonePayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetAcquisitionLineItems" xlink:to="loc_CELUMilestonePayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails" xlink:title="999057 - Disclosure - Schedule of Financial Assets and Liabilities Measures at Fair Value (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContingentStockConsideration" xlink:label="loc_CELUContingentStockConsideration" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_CELUContingentStockConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShorttermDebtFairValue" xlink:label="loc_us-gaapShorttermDebtFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_us-gaapShorttermDebtFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes" xlink:label="loc_CELUShorttermDebtUnsecuredSeniorConvertibleNotes" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_CELUShorttermDebtUnsecuredSeniorConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityRegisteredDirectWarrantsTwo" xlink:label="loc_CELUWarrantLiabilityRegisteredDirectWarrantsTwo" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_CELUWarrantLiabilityRegisteredDirectWarrantsTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityRegisteredDirectWarrants" xlink:label="loc_CELUWarrantLiabilityRegisteredDirectWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_CELUWarrantLiabilityRegisteredDirectWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants" xlink:label="loc_CELUWarrantLiabilityPrivateInvestmentInPublicEquityWarrants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_CELUWarrantLiabilityPrivateInvestmentInPublicEquityWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPurchaserWarrants" xlink:label="loc_CELUWarrantLiabilityPurchaserWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_CELUWarrantLiabilityPurchaserWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPlacementAgentWarrants" xlink:label="loc_CELUWarrantLiabilityPlacementAgentWarrants" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_CELUWarrantLiabilityPlacementAgentWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilitySponsorWarrants" xlink:label="loc_CELUWarrantLiabilitySponsorWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_CELUWarrantLiabilitySponsorWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiabilityPublicWarrants" xlink:label="loc_CELUWarrantLiabilityPublicWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_CELUWarrantLiabilityPublicWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosureAbstract" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaapAssetsFairValueDisclosureAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFairValueDisclosure" xlink:label="loc_us-gaapReceivablesFairValueDisclosure" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsFairValueDisclosureAbstract" xlink:to="loc_us-gaapReceivablesFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsFairValueDisclosureAbstract" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails" xlink:title="999058 - Disclosure - Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFairValueDisclosure" xlink:label="loc_us-gaapReceivablesFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapReceivablesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesFairValueDisclosure" xlink:label="loc_us-gaapReceivablesFairValueDisclosure_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapReceivablesFairValueDisclosure_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails" xlink:title="999059 - Disclosure - Schedule of Convertible Note Valuation Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FaceValueOfNotesReceivable" xlink:label="loc_CELUFaceValueOfNotesReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUFaceValueOfNotesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfCouponRate" xlink:label="loc_CELUPercentageOfCouponRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUPercentageOfCouponRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ValuationInputForConvertiblePromissoryNoteTerm" xlink:label="loc_CELUValuationInputForConvertiblePromissoryNoteTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUValuationInputForConvertiblePromissoryNoteTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ValuationInputForConvertiblePromissoryNote" xlink:label="loc_CELUValuationInputForConvertiblePromissoryNote" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUValuationInputForConvertiblePromissoryNote" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails" xlink:title="999060 - Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AcquisitionRelatedContingentConsiderationObligationsMember" xlink:label="loc_CELUAcquisitionRelatedContingentConsiderationObligationsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CELUAcquisitionRelatedContingentConsiderationObligationsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails" xlink:title="999061 - Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaapContingentConsiderationByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="loc_us-gaapContingentConsiderationByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaapContingentConsiderationTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationByTypeAxis" xlink:to="loc_us-gaapContingentConsiderationTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContingentStockConsiderationMember" xlink:label="loc_CELUContingentStockConsiderationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContingentConsiderationTypeDomain" xlink:to="loc_CELUContingentStockConsiderationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionContingentConsiderationLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails" xlink:title="999062 - Disclosure - Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_YorkvilleMember" xlink:label="loc_CELUYorkvilleMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUYorkvilleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" xlink:label="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" xlink:label="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" xlink:label="loc_CELUIssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUIssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueAdjustmentThroughEarnings" xlink:label="loc_CELUFairValueAdjustmentThroughEarnings" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFairValueAdjustmentThroughEarnings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" xlink:label="loc_CELUFairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual" xlink:label="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermBorrowings_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails" xlink:title="999063 - Disclosure - Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputCreditSpreadMember" xlink:label="loc_us-gaapMeasurementInputCreditSpreadMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputCreditSpreadMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails" xlink:title="999064 - Disclosure - Schedule of Convertible Notes Valuation Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNotesMember" xlink:label="loc_CELUUnsecuredSeniorConvertibleNotesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUUnsecuredSeniorConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputCreditSpreadMember" xlink:label="loc_us-gaapMeasurementInputCreditSpreadMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputCreditSpreadMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaapDebtInstrumentMeasurementInput" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="999065 - Disclosure - Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueNetAssetLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RegisteredDirectWarrantsIssuance" xlink:label="loc_CELURegisteredDirectWarrantsIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CELURegisteredDirectWarrantsIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RegisteredDirectWarrantIssuanceDuringJuly" xlink:label="loc_CELURegisteredDirectWarrantIssuanceDuringJuly" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CELURegisteredDirectWarrantIssuanceDuringJuly" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BridgeLoanAndWarrantIssuanceTrancheTwo" xlink:label="loc_CELUBridgeLoanAndWarrantIssuanceTrancheTwo" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CELUBridgeLoanAndWarrantIssuanceTrancheTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PurchaserWarrantIssuance" xlink:label="loc_CELUPurchaserWarrantIssuance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CELUPurchaserWarrantIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PlacementAgentWarrantIssuance" xlink:label="loc_CELUPlacementAgentWarrantIssuance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CELUPlacementAgentWarrantIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GainLossRecognizedInEarningsFromChangeInFairValues" xlink:label="loc_CELUGainLossRecognizedInEarningsFromChangeInFairValues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CELUGainLossRecognizedInEarningsFromChangeInFairValues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:label="loc_CELUReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CELUReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueNetAssetLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueNetAssetLiabilities" xlink:label="loc_CELUFairValueNetAssetLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CELUFairValueNetAssetLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueNetAssetLiabilities" xlink:label="loc_CELUFairValueNetAssetLiabilities_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_CELUFairValueNetAssetLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails" xlink:title="999066 - Disclosure - Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" xlink:label="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails" xlink:title="999067 - Disclosure - Schedule of January 20224 Bridge Loan (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate" xlink:label="loc_CELUWarrantsAndRightsOutstandingTermToInitialExerciseDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUWarrantsAndRightsOutstandingTermToInitialExerciseDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails" xlink:title="999068 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing" xlink:label="loc_CELUWarrantsAndRightsOutstandingTermToSubsequentFinancing" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUWarrantsAndRightsOutstandingTermToSubsequentFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical" xlink:title="999069 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPurchaserWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPurchaserWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FloorPrice" xlink:label="loc_CELUFloorPrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELUFloorPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OfferingPricePercentage" xlink:label="loc_CELUOfferingPricePercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELUOfferingPricePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails" xlink:title="999070 - Disclosure - Schedule of Significant Inputs for Sponsor Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SponsorsWarrantsMember" xlink:label="loc_CELUSponsorsWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUSponsorsWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative" xlink:title="999071 - Disclosure - Fair Value of Financial Assets and Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SanuwaveForbearanceAgreementMember" xlink:label="loc_CELUSanuwaveForbearanceAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUSanuwaveForbearanceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LetterAgreementMember" xlink:label="loc_CELULetterAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELULetterAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_YorkvilleMember" xlink:label="loc_CELUYorkvilleMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUYorkvilleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNotesMember" xlink:label="loc_CELUUnsecuredSeniorConvertibleNotesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUUnsecuredSeniorConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ForbearanceExtendMaturityPeriod" xlink:label="loc_CELUForbearanceExtendMaturityPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUForbearanceExtendMaturityPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IncreasedNotePayments" xlink:label="loc_CELUIncreasedNotePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_CELUIncreasedNotePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaapConvertibleDebtFairValueDisclosures" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapConvertibleDebtFairValueDisclosures" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails" xlink:title="999072 - Disclosure - Schedule of Major Classes of Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryRawMaterialsCurrentAndNoncurrent" xlink:label="loc_CELUInventoryRawMaterialsCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_CELUInventoryRawMaterialsCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryWorkInProgressCurrentAndNoncurrent" xlink:label="loc_CELUInventoryWorkInProgressCurrentAndNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_CELUInventoryWorkInProgressCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryFinishedGoodsCurrentAndNoncurrent" xlink:label="loc_CELUInventoryFinishedGoodsCurrentAndNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_CELUInventoryFinishedGoodsCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryGrossCurrentAndNoncurrent" xlink:label="loc_CELUInventoryGrossCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_CELUInventoryGrossCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryReserveCurrentAndNoncurrent" xlink:label="loc_CELUInventoryReserveCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_CELUInventoryReserveCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryNetCurrentAndNoncurrent" xlink:label="loc_CELUInventoryNetCurrentAndNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_CELUInventoryNetCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaapInventoryNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfInventoryReservesDetails" xlink:title="999073 - Disclosure - Schedule of Inventory Reserves (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryReserveCurrentAndNoncurrent" xlink:label="loc_CELUInventoryReserveCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_CELUInventoryReserveCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProvisionForObsoleteInventory" xlink:label="loc_CELUProvisionForObsoleteInventory" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_CELUProvisionForObsoleteInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryReserveCurrentAndNoncurrent" xlink:label="loc_CELUInventoryReserveCurrentAndNoncurrent_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_CELUInventoryReserveCurrentAndNoncurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/InventoryDetailsNarrative" xlink:title="999074 - Disclosure - Inventory (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaapInventoryCurrentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryCurrentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaapInventoryLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryCurrentTable" xlink:to="loc_us-gaapInventoryLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="loc_us-gaapPublicUtilitiesInventoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryCurrentTable" xlink:to="loc_us-gaapPublicUtilitiesInventoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="loc_us-gaapPublicUtilitiesInventoryTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPublicUtilitiesInventoryAxis" xlink:to="loc_us-gaapPublicUtilitiesInventoryTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryFinishedGoodsMember" xlink:label="loc_CELUInventoryFinishedGoodsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:to="loc_CELUInventoryFinishedGoodsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryWorkInProgressMember" xlink:label="loc_CELUInventoryWorkInProgressMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPublicUtilitiesInventoryTypeDomain" xlink:to="loc_CELUInventoryWorkInProgressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InventoryImpairmentCharge" xlink:label="loc_CELUInventoryImpairmentCharge" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryLineItems" xlink:to="loc_CELUInventoryImpairmentCharge" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999075 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_CELUDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrepaidClinicalExpense" xlink:label="loc_CELUPrepaidClinicalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_CELUPrepaidClinicalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails" xlink:title="999076 - Disclosure - Schedule of Property and Equipment, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LaboratoryAndProductionEquipmentMember" xlink:label="loc_CELULaboratoryAndProductionEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CELULaboratoryAndProductionEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MachineryEquipmentAndFixturesMember" xlink:label="loc_CELUMachineryEquipmentAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CELUMachineryEquipmentAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="999077 - Disclosure - Property and Equipment, Net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails" xlink:title="999078 - Disclosure - Schedule of Intangible Assets, Net (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaapDevelopedTechnologyRightsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapDevelopedTechnologyRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaapTrademarksAndTradeNamesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksAndTradeNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReacquiredRightsMember" xlink:label="loc_CELUReacquiredRightsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_CELUReacquiredRightsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="loc_CELUIndefiniteLivedIntangibleAssetsAmortizationMethod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_CELUIndefiniteLivedIntangibleAssetsAmortizationMethod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails" xlink:title="999079 - Disclosure - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative" xlink:title="999080 - Disclosure - Goodwill and Intangible Assets, Net (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CellTherapyMember" xlink:label="loc_CELUCellTherapyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CELUCellTherapyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaapInProcessResearchAndDevelopmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInProcessResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetImpairmentCharges" xlink:label="loc_us-gaapOtherAssetImpairmentCharges" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="loc_us-gaapOtherAssetImpairmentCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999081 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedClinicalTrialExpense" xlink:label="loc_CELUAccruedClinicalTrialExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CELUAccruedClinicalTrialExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccrualsForConstructionInProgress" xlink:label="loc_CELUAccrualsForConstructionInProgress" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CELUAccrualsForConstructionInProgress" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedComplianceFee" xlink:label="loc_CELUAccruedComplianceFee" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CELUAccruedComplianceFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfDebtDetails" xlink:title="999082 - Disclosure - Schedule of Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_YorkvilleMember" xlink:label="loc_CELUYorkvilleMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUYorkvilleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrePaidAdvanceAgreementMember" xlink:label="loc_CELUPrePaidAdvanceAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUPrePaidAdvanceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNoteMember" xlink:label="loc_CELUUnsecuredSeniorConvertibleNoteMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUUnsecuredSeniorConvertibleNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarrBridgeLoanNetOfDiscountMember" xlink:label="loc_CELUCVStarrBridgeLoanNetOfDiscountMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUCVStarrBridgeLoanNetOfDiscountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RWIBridgeLoanNetOfDiscountMember" xlink:label="loc_CELURWIBridgeLoanNetOfDiscountMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELURWIBridgeLoanNetOfDiscountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CEOPromissoryNoteMember" xlink:label="loc_CELUCEOPromissoryNoteMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUCEOPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShortTermDebtUnaffiliated" xlink:label="loc_CELUShortTermDebtUnaffiliated" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUShortTermDebtUnaffiliated" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OtherShortTermDebt" xlink:label="loc_CELUOtherShortTermDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUOtherShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShortTermDebtRelatedParty" xlink:label="loc_CELUShortTermDebtRelatedParty" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUShortTermDebtRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_Debt" xlink:label="loc_CELUDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/DebtDetailsNarrative" xlink:title="999083 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaapLineOfCreditFacilityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLineOfCreditFacilityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaapLineOfCreditFacilityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_YorkvilleMember" xlink:label="loc_CELUYorkvilleMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUYorkvilleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarrCoIncMember" xlink:label="loc_CELUCVStarrCoIncMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUCVStarrCoIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ResortsWorldIncPteLtdMember" xlink:label="loc_CELUResortsWorldIncPteLtdMember" />
      <link:presentationArc order="710" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUResortsWorldIncPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrePaidAdvanceAgreementMember" xlink:label="loc_CELUPrePaidAdvanceAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUPrePaidAdvanceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StandbyEquityPurchaseAgreementMember" xlink:label="loc_CELUStandbyEquityPurchaseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUStandbyEquityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ForbearanceAgreementMember" xlink:label="loc_CELUForbearanceAgreementMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_CELUForbearanceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CEOPromissoryNoteMember" xlink:label="loc_CELUCEOPromissoryNoteMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUCEOPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaapBridgeLoanMember" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapBridgeLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnsecuredSeniorConvertibleNotesMember" xlink:label="loc_CELUUnsecuredSeniorConvertibleNotesMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELUUnsecuredSeniorConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LoanAgreementMember" xlink:label="loc_CELULoanAgreementMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELULoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialLoanMember" xlink:label="loc_CELUInitialLoanMember" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELUInitialLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdditionalLoanMember" xlink:label="loc_CELUAdditionalLoanMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELUAdditionalLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_srtTitleOfIndividualAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChairmanAndChiefExecutiveOfficerMember" xlink:label="loc_CELUChairmanAndChiefExecutiveOfficerMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUChairmanAndChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_2" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityTable" xlink:to="loc_us-gaapVestingAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TrancheTwoWarrantMember" xlink:label="loc_CELUTrancheTwoWarrantMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUTrancheTwoWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TrancheOneWarrantMember" xlink:label="loc_CELUTrancheOneWarrantMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUTrancheOneWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialAndSecondTrancheMember" xlink:label="loc_CELUInitialAndSecondTrancheMember" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUInitialAndSecondTrancheMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrePaidAdvancePeriod" xlink:label="loc_CELUPrePaidAdvancePeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPrePaidAdvancePeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PrePaidAdvanceIssuedDiscountPercentage" xlink:label="loc_CELUPrePaidAdvanceIssuedDiscountPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPrePaidAdvanceIssuedDiscountPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" xlink:label="loc_CELULineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELULineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuanceOfCommonStockMinimumOptionPricePerShare" xlink:label="loc_CELUIssuanceOfCommonStockMinimumOptionPricePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUIssuanceOfCommonStockMinimumOptionPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MaximumPercentageOfCommonStockIssued" xlink:label="loc_CELUMaximumPercentageOfCommonStockIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUMaximumPercentageOfCommonStockIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfBeneficialOwnershipLimitation" xlink:label="loc_CELUPercentageOfBeneficialOwnershipLimitation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfBeneficialOwnershipLimitation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MinimumNumberOfSharesOfCommonStockPurchase" xlink:label="loc_CELUMinimumNumberOfSharesOfCommonStockPurchase" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUMinimumNumberOfSharesOfCommonStockPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MinimumRequiredDailyVolumeWeightedAveragePrice" xlink:label="loc_CELUMinimumRequiredDailyVolumeWeightedAveragePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUMinimumRequiredDailyVolumeWeightedAveragePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice" xlink:label="loc_CELURequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELURequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice" xlink:label="loc_CELURedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELURedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice" xlink:label="loc_CELURedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELURedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IssuancePricePercentage" xlink:label="loc_CELUIssuancePricePercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUIssuancePricePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromLinesOfCreditGross" xlink:label="loc_CELUProceedsFromLinesOfCreditGross" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUProceedsFromLinesOfCreditGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaapLineOfCreditFacilityExpirationPeriod" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtConversionOriginalDebtAccruedInterestAmount" xlink:label="loc_CELUDebtConversionOriginalDebtAccruedInterestAmount" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtConversionOriginalDebtAccruedInterestAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentPayment" xlink:label="loc_CELUDebtInstrumentPayment" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfShortTermDebt" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapRepaymentsOfShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentAccruedInterest" xlink:label="loc_CELUDebtInstrumentAccruedInterest" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentRedemptionPremium" xlink:label="loc_CELUDebtInstrumentRedemptionPremium" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentRedemptionPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaapDebtInstrumentFairValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDefaultShorttermDebtAmount" xlink:label="loc_us-gaapDebtDefaultShorttermDebtAmount" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtDefaultShorttermDebtAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentPerDiemInterestAmount" xlink:label="loc_CELUDebtInstrumentPerDiemInterestAmount" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentPerDiemInterestAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentIssuedPrincipal" xlink:label="loc_us-gaapDebtInstrumentIssuedPrincipal" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentIssuedPrincipal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNoteDiscountPercentage" xlink:label="loc_CELUConvertiblePromissoryNoteDiscountPercentage" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUConvertiblePromissoryNoteDiscountPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfConversionOnOutstandingCommonStock" xlink:label="loc_CELUPercentageOfConversionOnOutstandingCommonStock" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfConversionOnOutstandingCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentDefaultInterestRate" xlink:label="loc_CELUDebtInstrumentDefaultInterestRate" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentDefaultInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NotesAndPurchaserWarrantsPrincipalAmount" xlink:label="loc_CELUNotesAndPurchaserWarrantsPrincipalAmount" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUNotesAndPurchaserWarrantsPrincipalAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromNotesAndPurchaserWarrants" xlink:label="loc_CELUProceedsFromNotesAndPurchaserWarrants" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUProceedsFromNotesAndPurchaserWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MinimumGrossProceeds" xlink:label="loc_CELUMinimumGrossProceeds" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUMinimumGrossProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FloorPrice" xlink:label="loc_CELUFloorPrice" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFloorPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfCashFeeEqualToAggregateProceeds" xlink:label="loc_CELUPercentageOfCashFeeEqualToAggregateProceeds" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfCashFeeEqualToAggregateProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfExercisePriceEqualToOfferingPrice" xlink:label="loc_CELUPercentageOfExercisePriceEqualToOfferingPrice" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfExercisePriceEqualToOfferingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherExpenses" xlink:label="loc_us-gaapOtherExpenses" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapOtherExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes" xlink:label="loc_CELUShorttermDebtUnsecuredSeniorConvertibleNotes" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUShorttermDebtUnsecuredSeniorConvertibleNotes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentContributionAmount" xlink:label="loc_CELUDebtInstrumentContributionAmount" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentContributionAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromOtherShortTermDebt" xlink:label="loc_us-gaapProceedsFromOtherShortTermDebt" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapProceedsFromOtherShortTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OtherShortTermDebtDueToRelatedParty" xlink:label="loc_CELUOtherShortTermDebtDueToRelatedParty" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUOtherShortTermDebtDueToRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentOriginalIssueDiscount" xlink:label="loc_CELUDebtInstrumentOriginalIssueDiscount" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentOriginalIssueDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault" xlink:label="loc_CELUDebtInstrumentInterestRateEffectivePercentageInEventOfDefault" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentInterestRateEffectivePercentageInEventOfDefault" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShareIssuedPurchasedPrice" xlink:label="loc_CELUShareIssuedPurchasedPrice" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUShareIssuedPurchasedPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FallInCashAndCashEquivalents" xlink:label="loc_CELUFallInCashAndCashEquivalents" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUFallInCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ClassOfWarrantOrRighstExpirationDate" xlink:label="loc_CELUClassOfWarrantOrRighstExpirationDate" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUClassOfWarrantOrRighstExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfChangesInCashFlow" xlink:label="loc_CELUPercentageOfChangesInCashFlow" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfChangesInCashFlow" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherDebt" xlink:label="loc_us-gaapRepaymentsOfOtherDebt" />
      <link:presentationArc order="670" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_us-gaapRepaymentsOfOtherDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShortTermDebtRelatedParties" xlink:label="loc_CELUShortTermDebtRelatedParties" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUShortTermDebtRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentDiscount" xlink:label="loc_CELUDebtInstrumentDiscount" />
      <link:presentationArc order="690" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault" xlink:label="loc_CELUDebtInstrumentInterestRateDuringPeriodInEventOfDefault" />
      <link:presentationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDebtInstrumentInterestRateDuringPeriodInEventOfDefault" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DiscountOnWarrantAmount" xlink:label="loc_CELUDiscountOnWarrantAmount" />
      <link:presentationArc order="710" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDiscountOnWarrantAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice" xlink:label="loc_CELUPercentageOfPartialLiquidatingDamagesOnPurchasePrice" />
      <link:presentationArc order="720" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfPartialLiquidatingDamagesOnPurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" xlink:label="loc_CELUPercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" />
      <link:presentationArc order="730" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUPercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DailyInterestAccruingRate" xlink:label="loc_CELUDailyInterestAccruingRate" />
      <link:presentationArc order="740" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLineItems" xlink:to="loc_CELUDailyInterestAccruingRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfLeaseCostsDetails" xlink:title="999084 - Disclosure - Schedule of Lease Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosureLeasesAbstract" xlink:label="loc_CELUDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaapVariableLeaseCost" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapVariableLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaapLeaseCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLeaseCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails" xlink:title="999085 - Disclosure - Schedule of Cash Activity Related to the lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosureLeasesAbstract" xlink:label="loc_CELUDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails" xlink:title="999086 - Disclosure - Schedule of Future Minimum Payments under Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosureLeasesAbstract" xlink:label="loc_CELUDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/LeasesDetailsNarrative" xlink:title="999087 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosureLeasesAbstract" xlink:label="loc_CELUDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLeasesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OfficeManufacturingAndLaboratorySpaceMember" xlink:label="loc_CELUOfficeManufacturingAndLaboratorySpaceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CELUOfficeManufacturingAndLaboratorySpaceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FlorhamParkNewJerseyMember" xlink:label="loc_CELUFlorhamParkNewJerseyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_CELUFlorhamParkNewJerseyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LegacyCelularityMember" xlink:label="loc_CELULegacyCelularityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CELULegacyCelularityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLeasesRentExpense" xlink:label="loc_CELUOperatingLeasesRentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUOperatingLeasesRentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AreaOfBuilding" xlink:label="loc_CELUAreaOfBuilding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUAreaOfBuilding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLeaseExpiryYear" xlink:label="loc_CELUOperatingLeaseExpiryYear" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUOperatingLeaseExpiryYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaapLesseeOperatingLeaseOptionToExtend" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseOptionToExtend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLeaseCommencementDate" xlink:label="loc_CELUOperatingLeaseCommencementDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUOperatingLeaseCommencementDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialMonthlyBaseRent" xlink:label="loc_CELUInitialMonthlyBaseRent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUInitialMonthlyBaseRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaapRestrictedCashNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapRestrictedCashNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TenantImprovements" xlink:label="loc_us-gaapTenantImprovements" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapTenantImprovements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReductionInLineOfCredit" xlink:label="loc_CELUReductionInLineOfCredit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUReductionInLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NewLineOfCredit" xlink:label="loc_CELUNewLineOfCredit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUNewLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BaseRentalPayments" xlink:label="loc_CELUBaseRentalPayments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CELUBaseRentalPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999088 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember" xlink:label="loc_CELUHLICellularTherapeuticsLLCAndAnthrogenesisMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUHLICellularTherapeuticsLLCAndAnthrogenesisMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LegacyCelularitysMember" xlink:label="loc_CELULegacyCelularitysMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CELULegacyCelularitysMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtCounterpartyNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PalantirTechnologiesIncMember" xlink:label="loc_CELUPalantirTechnologiesIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CELUPalantirTechnologiesIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MasterSubscriptionAgreementMember" xlink:label="loc_CELUMasterSubscriptionAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUMasterSubscriptionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAgreementMember" xlink:label="loc_CELULicenseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELULicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SettlementAndReleaseAgreementMember" xlink:label="loc_CELUSettlementAndReleaseAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUSettlementAndReleaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SoftwareCeaseUseCostsMember" xlink:label="loc_CELUSoftwareCeaseUseCostsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_CELUSoftwareCeaseUseCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis" xlink:label="loc_srtLitigationCaseAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_srtLitigationCaseAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srtLitigationCaseTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseAxis" xlink:to="loc_srtLitigationCaseTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EvolutionMember" xlink:label="loc_CELUEvolutionMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtLitigationCaseTypeDomain" xlink:to="loc_CELUEvolutionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_deiLegalEntityAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_HackensackMeridianHealthMember" xlink:label="loc_CELUHackensackMeridianHealthMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CELUHackensackMeridianHealthMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentsForMasterSubscriptionAgreement" xlink:label="loc_CELUPaymentsForMasterSubscriptionAgreement" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUPaymentsForMasterSubscriptionAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentSubscriptionPeriod" xlink:label="loc_CELUPaymentSubscriptionPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUPaymentSubscriptionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaapBusinessExitCosts1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapBusinessExitCosts1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AccruedResearchAndDevelopmentSoftware" xlink:label="loc_CELUAccruedResearchAndDevelopmentSoftware" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUAccruedResearchAndDevelopmentSoftware" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UpfrontFee" xlink:label="loc_CELUUpfrontFee" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUUpfrontFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AnnualMaintenanceFee" xlink:label="loc_CELUAnnualMaintenanceFee" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUAnnualMaintenanceFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ClinicalAndRegulatoryMilestones" xlink:label="loc_CELUClinicalAndRegulatoryMilestones" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUClinicalAndRegulatoryMilestones" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="loc_us-gaapLongtermPurchaseCommitmentPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLongtermPurchaseCommitmentPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAgreementNoticePeriod" xlink:label="loc_CELULicenseAgreementNoticePeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELULicenseAgreementNoticePeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements" xlink:label="loc_us-gaapPaymentsForLegalSettlements" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapPaymentsForLegalSettlements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NumberOfSharesIssuedForPiggybackRegistrationRights" xlink:label="loc_CELUNumberOfSharesIssuedForPiggybackRegistrationRights" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUNumberOfSharesIssuedForPiggybackRegistrationRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfBiomaterialProductsAmount" xlink:label="loc_CELUSaleOfBiomaterialProductsAmount" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_CELUSaleOfBiomaterialProductsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AffiliateCosts" xlink:label="loc_us-gaapAffiliateCosts" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAffiliateCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfWarrantsDetails" xlink:title="999089 - Disclosure - Summary of the Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DragasacWarrantMember" xlink:label="loc_CELUDragasacWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUDragasacWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PublicWarrantsMember" xlink:label="loc_CELUPublicWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SponsorWarrantsMember" xlink:label="loc_CELUSponsorWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUSponsorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:label="loc_CELUAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUAprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" xlink:label="loc_CELUAprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUAprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JuneTwoThousandTwentyThreeWarrantsMember" xlink:label="loc_CELUJuneTwoThousandTwentyThreeWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJuneTwoThousandTwentyThreeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="loc_CELUJuneTwoThousandTwentyThreeLoanWarrantsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJuneTwoThousandTwentyThreeLoanWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:label="loc_CELUJulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourPipeWarrantsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourPipeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyFourRwiForbearanceWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPurchaseWarrantsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPurchaseWarrantsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:label="loc_CELUNovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUNovemberTwoThousandTwentyFourPlacementAgentWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourPIPEWarrantMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourPIPEWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical" xlink:title="999090 - Disclosure - Summary of the Warrants (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandTwentyFourWarrantRepricingMember" xlink:label="loc_CELUTwoThousandTwentyFourWarrantRepricingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUTwoThousandTwentyFourWarrantRepricingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DragasacWarrantMember" xlink:label="loc_CELUDragasacWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUDragasacWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PublicWarrantsMember" xlink:label="loc_CELUPublicWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUPublicWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SponsorWarrantsMember" xlink:label="loc_CELUSponsorWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUSponsorWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StarrForbearanceAgreementMember" xlink:label="loc_CELUStarrForbearanceAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUStarrForbearanceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarrCoIncMember" xlink:label="loc_CELUCVStarrCoIncMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUCVStarrCoIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NumberOfWarrantsRepriced" xlink:label="loc_CELUNumberOfWarrantsRepriced" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELUNumberOfWarrantsRepriced" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsOutstanding" xlink:label="loc_CELUWarrantsOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CELUWarrantsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/EquityDetailsNarrative" xlink:title="999091 - Disclosure - Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AtTheMarketSalesAgreementMember" xlink:label="loc_CELUAtTheMarketSalesAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUAtTheMarketSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember" xlink:label="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_2" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_StandbyEquityPurchaseAgreementMember" xlink:label="loc_CELUStandbyEquityPurchaseAgreementMember" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUStandbyEquityPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaapBusinessAcquisitionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapBusinessAcquisitionAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaapBusinessAcquisitionAcquireeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAxis" xlink:to="loc_us-gaapBusinessAcquisitionAcquireeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LegacyCelularityMember" xlink:label="loc_CELULegacyCelularityMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessAcquisitionAcquireeDomain" xlink:to="loc_CELULegacyCelularityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChairmanAndChiefExecutiveOfficerMember" xlink:label="loc_CELUChairmanAndChiefExecutiveOfficerMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUChairmanAndChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChiefAdministrativeOfficerMember" xlink:label="loc_CELUChiefAdministrativeOfficerMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUChiefAdministrativeOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember" xlink:label="loc_CELUJanuaryTwoThousandTwentyFourPipeWarrantsMember" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUJanuaryTwoThousandTwentyFourPipeWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandTwentyFourWarrantRepricingMember" xlink:label="loc_CELUTwoThousandTwentyFourWarrantRepricingMember" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUTwoThousandTwentyFourWarrantRepricingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="loc_CELUJuneTwoThousandTwentyThreeLoanWarrantsMember" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_CELUJuneTwoThousandTwentyThreeLoanWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InvestorRightsAgreementMember" xlink:label="loc_CELUInvestorRightsAgreementMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUInvestorRightsAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RwiForbearanceAgreementMember" xlink:label="loc_CELURwiForbearanceAgreementMember" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELURwiForbearanceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ForbearanceAgreementMember" xlink:label="loc_CELUForbearanceAgreementMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUForbearanceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtCounterpartyNameAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DragasacLimitedMember" xlink:label="loc_CELUDragasacLimitedMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CELUDragasacLimitedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_YorkvilleMember" xlink:label="loc_CELUYorkvilleMember" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CELUYorkvilleMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AmendedEmploymentAgreementMember" xlink:label="loc_CELUAmendedEmploymentAgreementMember" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CELUAmendedEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="110" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="120" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LoanAgreementMember" xlink:label="loc_CELULoanAgreementMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELULoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="130" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarrCoIncMember" xlink:label="loc_CELUCVStarrCoIncMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_CELUCVStarrCoIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="140" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConvertiblePromissoryNotesMember" xlink:label="loc_CELUConvertiblePromissoryNotesMember" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUConvertiblePromissoryNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaapCommonStockVotingRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockVotingRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfSharesRequiredForVoting" xlink:label="loc_CELUPercentageOfSharesRequiredForVoting" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUPercentageOfSharesRequiredForVoting" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AggregateOfferingPrice" xlink:label="loc_CELUAggregateOfferingPrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUAggregateOfferingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds" xlink:label="loc_CELUMaximumPercentageOfSalesCommissionFromGrossSalesProceeds" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUMaximumPercentageOfSalesCommissionFromGrossSalesProceeds" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_CELUGrossProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUGrossProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdjustedAdvanceNoticePeriod" xlink:label="loc_CELUAdjustedAdvanceNoticePeriod" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUAdjustedAdvanceNoticePeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PremiumPaidForPrivatePlacementPurchase" xlink:label="loc_CELUPremiumPaidForPrivatePlacementPurchase" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUPremiumPaidForPrivatePlacementPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReducedExercisePrice" xlink:label="loc_CELUReducedExercisePrice" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUReducedExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantExpirationTerm" xlink:label="loc_CELUWarrantExpirationTerm" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUWarrantExpirationTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentPayment" xlink:label="loc_CELUDebtInstrumentPayment" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUDebtInstrumentPayment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueNetAssetsLiability" xlink:label="loc_CELUFairValueNetAssetsLiability" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUFairValueNetAssetsLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AmendedTerminationDateDescription" xlink:label="loc_CELUAmendedTerminationDateDescription" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUAmendedTerminationDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdditionalWarrantLiability" xlink:label="loc_CELUAdditionalWarrantLiability" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUAdditionalWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantLiability" xlink:label="loc_CELUWarrantLiability" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_WarrantsAndRightsIssuedClosingDate" xlink:label="loc_CELUWarrantsAndRightsIssuedClosingDate" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUWarrantsAndRightsIssuedClosingDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ProceedsFromPrivatePlacements" xlink:label="loc_CELUProceedsFromPrivatePlacements" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUProceedsFromPrivatePlacements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NumberOfWarrantsRepriced" xlink:label="loc_CELUNumberOfWarrantsRepriced" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUNumberOfWarrantsRepriced" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost" xlink:label="loc_CELUFairValueOfWarrantModificationIncrementalForEquityIssuanceCost" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUFairValueOfWarrantModificationIncrementalForEquityIssuanceCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" xlink:label="loc_CELUPercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUPercentageOfPartialLiquidatingDamagesOnSubscriptionAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DailyInterestAccruingRate" xlink:label="loc_CELUDailyInterestAccruingRate" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUDailyInterestAccruingRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RelatedPartyBaseSalary" xlink:label="loc_CELURelatedPartyBaseSalary" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELURelatedPartyBaseSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ClassOfWarrantOrRighstExpirationDate" xlink:label="loc_CELUClassOfWarrantOrRighstExpirationDate" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUClassOfWarrantOrRighstExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage" xlink:label="loc_CELUSaleOfStockMaximumAverageDailyTradedAmountPercentage" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUSaleOfStockMaximumAverageDailyTradedAmountPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays" xlink:label="loc_CELUSaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUSaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice" xlink:label="loc_CELUSaleOfStockPercentageBasedOnVolumeWeightedAveragePrice" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUSaleOfStockPercentageBasedOnVolumeWeightedAveragePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockConsiderationCashDueDiligenceFee" xlink:label="loc_CELUSaleOfStockConsiderationCashDueDiligenceFee" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUSaleOfStockConsiderationCashDueDiligenceFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SaleOfStockConsiderationCommitmentFeeInShares" xlink:label="loc_CELUSaleOfStockConsiderationCommitmentFeeInShares" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELUSaleOfStockConsiderationCommitmentFeeInShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" xlink:label="loc_CELULineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_CELULineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails" xlink:title="999092 - Disclosure - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="999093 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="loc_CELUTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELUTwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical" xlink:title="999094 - Disclosure - Schedule of Stock Option Activity (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandTwentyOnePlanMember" xlink:label="loc_CELUTwoThousandTwentyOnePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELUTwoThousandTwentyOnePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandSeventeenPlanMember" xlink:label="loc_CELUTwoThousandSeventeenPlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELUTwoThousandSeventeenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails" xlink:title="999095 - Disclosure - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="999096 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaapCostOfSalesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapCostOfSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999097 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:label="loc_CELUTwoThousandAndTwentyOneEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELUTwoThousandAndTwentyOneEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TwoThousandAndSeventeenEquityIncentivePlanMember" xlink:label="loc_CELUTwoThousandAndSeventeenEquityIncentivePlanMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELUTwoThousandAndSeventeenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AwardsWithPerformanceConditionsMember" xlink:label="loc_CELUAwardsWithPerformanceConditionsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELUAwardsWithPerformanceConditionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarketConditionStockUnitMember" xlink:label="loc_CELUMarketConditionStockUnitMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELUMarketConditionStockUnitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialTrancheMember" xlink:label="loc_CELUInitialTrancheMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUInitialTrancheMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecondTrancheMember" xlink:label="loc_CELUSecondTrancheMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUSecondTrancheMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" xlink:label="loc_CELUShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELUShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeBenefitsAndShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails" xlink:title="999098 - Disclosure - Schedule of Disaggregated Revenue by Product and Services (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseRoyaltyAndOtherMember" xlink:label="loc_CELULicenseRoyaltyAndOtherMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_CELULicenseRoyaltyAndOtherMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails" xlink:title="999099 - Disclosure - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaapContractWithCustomerLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" xlink:label="loc_CELUContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_CELUContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaapContractWithCustomerLiability_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapContractWithCustomerLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical" xlink:title="999100 - Disclosure -  Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnearnedRevenue" xlink:label="loc_CELUUnearnedRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_CELUUnearnedRevenue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative" xlink:title="999101 - Disclosure - License and Distribution Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DisclosureLicenseAndDistributionAgreementsAbstract" xlink:label="loc_CELUDisclosureLicenseAndDistributionAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELUDisclosureLicenseAndDistributionAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RegeneronResearchCollaborationServicesAgreementMember" xlink:label="loc_CELURegeneronResearchCollaborationServicesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELURegeneronResearchCollaborationServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RegeneronServicesAgreementMember" xlink:label="loc_CELURegeneronServicesAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELURegeneronServicesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PultheraLLCBindingTermSheetMember" xlink:label="loc_CELUPultheraLLCBindingTermSheetMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUPultheraLLCBindingTermSheetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAgreementWithBiocellgraftIncMember" xlink:label="loc_CELULicenseAgreementWithBiocellgraftIncMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELULicenseAgreementWithBiocellgraftIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_NonrefundableUpfrontPayment" xlink:label="loc_CELUNonrefundableUpfrontPayment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUNonrefundableUpfrontPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ServiceAgreementTerm" xlink:label="loc_CELUServiceAgreementTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUServiceAgreementTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseAgreementNoticePeriod" xlink:label="loc_CELULicenseAgreementNoticePeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELULicenseAgreementNoticePeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="loc_us-gaapDeferredRevenueRevenueRecognized1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenueRevenueRecognized1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentOfOptionFeeInCash" xlink:label="loc_CELUPaymentOfOptionFeeInCash" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUPaymentOfOptionFeeInCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OptionFeeExpense" xlink:label="loc_CELUOptionFeeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUOptionFeeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CommercialLicenseToDentalProductsAgreementPeriod" xlink:label="loc_CELUCommercialLicenseToDentalProductsAgreementPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUCommercialLicenseToDentalProductsAgreementPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm" xlink:label="loc_CELUCommercialLicenseToDentalProductsAgreementRenewalTerm" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUCommercialLicenseToDentalProductsAgreementRenewalTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseFeeExpense" xlink:label="loc_CELULicenseFeeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELULicenseFeeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseFeesPaymentPeriod" xlink:label="loc_CELULicenseFeesPaymentPeriod" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELULicenseFeesPaymentPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LicenseFeePayment" xlink:label="loc_CELULicenseFeePayment" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELULicenseFeePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdditionalLicenseFee" xlink:label="loc_CELUAdditionalLicenseFee" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELUAdditionalLicenseFee" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/BenefitPlanDetailsNarrative" xlink:title="999102 - Disclosure - Benefit Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails" xlink:title="999103 - Disclosure - Schedule of Current and Deferred Tax Provision (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails" xlink:title="999104 - Disclosure - Schedule of Reconciliation of the U.S federal statutory income tax (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense" xlink:label="loc_CELUEffectiveIncomeTaxRateReconciliationInterestAccretionExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELUEffectiveIncomeTaxRateReconciliationInterestAccretionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" xlink:label="loc_CELUEffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELUEffectiveIncomeTaxRateReconciliationMarkToMarketWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp" xlink:label="loc_CELUEffectiveIncomeTaxRateReconciliationDeferredTrueUp" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELUEffectiveIncomeTaxRateReconciliationDeferredTrueUp" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="999105 - Disclosure - Schedule of Deferred tax assets and liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="loc_CELUDeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELUDeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsStartupCosts" xlink:label="loc_CELUDeferredTaxAssetsStartupCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELUDeferredTaxAssetsStartupCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaapDeferredTaxAssetsDeferredIncome" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsDeferredIncome" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsUnicap" xlink:label="loc_CELUDeferredTaxAssetsUnicap" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELUDeferredTaxAssetsUnicap" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsImputedInterestOnContingentPayments" xlink:label="loc_CELUDeferredTaxAssetsImputedInterestOnContingentPayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELUDeferredTaxAssetsImputedInterestOnContingentPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization" xlink:label="loc_CELUDeferredTaxAssetsLegalFeeCapitalizationAndAmortization" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELUDeferredTaxAssetsLegalFeeCapitalizationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="loc_CELUDeferredTaxAssetsCapitalizedResearchAndDevelopment" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELUDeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DeferredTaxAssetsIrcSectionInterest" xlink:label="loc_CELUDeferredTaxAssetsIrcSectionInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CELUDeferredTaxAssetsIrcSectionInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaapDeferredTaxLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails" xlink:title="999106 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapUnrecognizedTaxBenefits_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/IncomeTaxesDetailsNarrative" xlink:title="999107 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnitedStatesFederalAndStateMember" xlink:label="loc_CELUUnitedStatesFederalAndStateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CELUUnitedStatesFederalAndStateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_OperatingLossCarryforwardsExpirationYear" xlink:label="loc_CELUOperatingLossCarryforwardsExpirationYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CELUOperatingLossCarryforwardsExpirationYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_TaxCreditCarryforwardsExpirationYear" xlink:label="loc_CELUTaxCreditCarryforwardsExpirationYear" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_CELUTaxCreditCarryforwardsExpirationYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaapUnrecognizedTaxBenefits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapUnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails" xlink:title="999108 - Disclosure - Schedule of Financial Information by Segment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaapSegmentReportingInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapSegmentReportingInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CellTherapyMember" xlink:label="loc_CELUCellTherapyMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CELUCellTherapyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BiobankingMember" xlink:label="loc_CELUBiobankingMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CELUBiobankingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DegenerativeDiseaseMember" xlink:label="loc_CELUDegenerativeDiseaseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_CELUDegenerativeDiseaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaapCostOfRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapCostOfRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DirectOperatingCosts" xlink:label="loc_us-gaapDirectOperatingCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapDirectOperatingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SegmentContribution" xlink:label="loc_CELUSegmentContribution" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_CELUSegmentContribution" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_IndirectExpenses" xlink:label="loc_CELUIndirectExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_CELUIndirectExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaapIncomeLossFromContinuingOperations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaapGoodwillImpairmentLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapGoodwillImpairmentLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InProcessResearchAndDevelopmentImpairment" xlink:label="loc_CELUInProcessResearchAndDevelopmentImpairment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_CELUInProcessResearchAndDevelopmentImpairment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingInformationLineItems" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/SegmentInformationDetailsNarrative" xlink:title="999109 - Disclosure - Segment Information (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="999110 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrRobertHaririMember" xlink:label="loc_CELUDrRobertHaririMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CELUDrRobertHaririMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AmendedAndRestatedEmploymentAgreementMember" xlink:label="loc_CELUAmendedAndRestatedEmploymentAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CELUAmendedAndRestatedEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_EmploymentOfImmediateFamilyMemberMember" xlink:label="loc_CELUEmploymentOfImmediateFamilyMemberMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CELUEmploymentOfImmediateFamilyMemberMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecuritiesPurchaseAgreementMember" xlink:label="loc_CELUSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LoanAgreementMember" xlink:label="loc_CELULoanAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELULoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ConsultingAgreementMember" xlink:label="loc_CELUConsultingAgreementMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ScientificAndClinicalAdvisorAgreementMember" xlink:label="loc_CELUScientificAndClinicalAdvisorAgreementMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUScientificAndClinicalAdvisorAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AdvisoryAgreementMember" xlink:label="loc_CELUAdvisoryAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELUAdvisoryAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrRobertHaririMember" xlink:label="loc_CELUDrRobertHaririMember_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUDrRobertHaririMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrAndrewPecoraMember" xlink:label="loc_CELUDrAndrewPecoraMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUDrAndrewPecoraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RobinLSmithMdMember" xlink:label="loc_CELURobinLSmithMdMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELURobinLSmithMdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_COTAIncMember" xlink:label="loc_CELUCOTAIncMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUCOTAIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CryoportSystemsIncMember" xlink:label="loc_CELUCryoportSystemsIncMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUCryoportSystemsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CVStarLoanMember" xlink:label="loc_CELUCVStarLoanMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUCVStarLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ResortsWorldIncPteLtdMember" xlink:label="loc_CELUResortsWorldIncPteLtdMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELUResortsWorldIncPteLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:label="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CELUMarchTwoThousandTwentyThreeLoanWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrRobertHaririMember" xlink:label="loc_CELUDrRobertHaririMember_3" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUDrRobertHaririMember_3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DrHaririMember" xlink:label="loc_CELUDrHaririMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUDrHaririMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ChairmanAndChiefExecutiveOfficerMember" xlink:label="loc_CELUChairmanAndChiefExecutiveOfficerMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELUChairmanAndChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_CEOPromissoryNoteMember" xlink:label="loc_CELUCEOPromissoryNoteMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_CELUCEOPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapVestingAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_InitialTrancheMember" xlink:label="loc_CELUInitialTrancheMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_CELUInitialTrancheMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtCounterpartyNameAxis" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_MsHaririMember" xlink:label="loc_CELUMsHaririMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_CELUMsHaririMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecuritiesPurchaseAgreementDate" xlink:label="loc_CELUSecuritiesPurchaseAgreementDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUSecuritiesPurchaseAgreementDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_UnpaidBaseSalary" xlink:label="loc_CELUUnpaidBaseSalary" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUUnpaidBaseSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BonusProgramEffectiveDate" xlink:label="loc_CELUBonusProgramEffectiveDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUBonusProgramEffectiveDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfUnpaidBaseSalary" xlink:label="loc_CELUPercentageOfUnpaidBaseSalary" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUPercentageOfUnpaidBaseSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PercentageOfBaseSalary" xlink:label="loc_CELUPercentageOfBaseSalary" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUPercentageOfBaseSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_AnnualRateOfBaseSalary" xlink:label="loc_CELUAnnualRateOfBaseSalary" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUAnnualRateOfBaseSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_BaseSalaryEffectiveDate" xlink:label="loc_CELUBaseSalaryEffectiveDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUBaseSalaryEffectiveDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_DebtInstrumentContributionAmount" xlink:label="loc_CELUDebtInstrumentContributionAmount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUDebtInstrumentContributionAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ReceiveForMonth" xlink:label="loc_CELUReceiveForMonth" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUReceiveForMonth" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RelatedPartyCashBonus" xlink:label="loc_CELURelatedPartyCashBonus" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELURelatedPartyCashBonus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_PaymentsToRelatedParty" xlink:label="loc_CELUPaymentsToRelatedParty" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUPaymentsToRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_LoanAgreement" xlink:label="loc_CELULoanAgreement" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELULoanAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_SecondLoanAgreement" xlink:label="loc_CELUSecondLoanAgreement" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELUSecondLoanAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_RelatedPartyBaseSalary" xlink:label="loc_CELURelatedPartyBaseSalary" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CELURelatedPartyBaseSalary" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celularity.com/role/SubsequentEventsDetailsNarrative" xlink:title="999111 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_GenesisEquityGroupFundingLlcMember" xlink:label="loc_CELUGenesisEquityGroupFundingLlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CELUGenesisEquityGroupFundingLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapAccountsReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celu-20241231.xsd#CELU_ApplicableFees" xlink:label="loc_CELUApplicableFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_CELUApplicableFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomePurchasedReceivables" xlink:label="loc_us-gaapInterestIncomePurchasedReceivables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapInterestIncomePurchasedReceivables" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 06, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Celularity Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001752828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1702591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">170 Park Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Florham Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">768-2170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,949,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">None<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">274<span></span>
</td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text">We
have audited the accompanying consolidated balance sheet of Celularity Inc. (the &#8220;Company&#8221;) as of December 31, 2024 and
the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the year
then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the
financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31,
2024, and the consolidated results of its operations and its cash flows for the year then ended, in conformity
with accounting principles generally accepted in the United States of America. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EisnerAmper LLP<span></span>
</td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin, New Jersey<span></span>
</td>
<td class="text">Morristown, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CELU_ClassCommonStockParValue0.0001PerShareMember', window );">Class A common stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CELU<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember', window );">Warrants, each exercisable for one share of Class A common stock at an exercise price of $115 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, each exercisable
    for one share of Class A common stock at an exercise price of $115 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CELUW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CELU_ClassCommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CELU_ClassCommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 738<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Accounts receivable, net of allowance of $6,294 and $5,837 as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">13,557<span></span>
</td>
<td class="nump">10,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PromissoryNotesReceivable', window );">Notes receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">5,409<span></span>
</td>
<td class="nump">5,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">857<span></span>
</td>
<td class="nump">1,695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">20,561<span></span>
</td>
<td class="nump">19,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">61,600<span></span>
</td>
<td class="nump">67,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">7,347<span></span>
</td>
<td class="nump">7,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">9,248<span></span>
</td>
<td class="nump">11,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating leases</a></td>
<td class="nump">10,830<span></span>
</td>
<td class="nump">10,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">10,239<span></span>
</td>
<td class="nump">9,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, net of current portion</a></td>
<td class="nump">12,587<span></span>
</td>
<td class="nump">16,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">132,682<span></span>
</td>
<td class="nump">143,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">23,296<span></span>
</td>
<td class="nump">14,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">19,842<span></span>
</td>
<td class="nump">7,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AccruedResearchAndDevelopmentSoftware', window );">Accrued R&amp;D software</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">650<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">3,531<span></span>
</td>
<td class="nump">2,834<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">53,680<span></span>
</td>
<td class="nump">67,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">2,724<span></span>
</td>
<td class="nump">3,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Acquisition-related contingent consideration, net of current portion</a></td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">26,548<span></span>
</td>
<td class="nump">26,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiability', window );">Warrant liabilities</a></td>
<td class="nump">3,264<span></span>
</td>
<td class="nump">4,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">123,845<span></span>
</td>
<td class="nump">102,929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding as of December 31, 2024 and 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 730,000,000 shares authorized, 22,546,671 and 19,378,192 issued and outstanding as of December 31, 2024 and 2023, respectively</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">908,523<span></span>
</td>
<td class="nump">882,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(899,683)<span></span>
</td>
<td class="num">(841,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">8,837<span></span>
</td>
<td class="nump">40,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">132,682<span></span>
</td>
<td class="nump">143,889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">19,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">3,876<span></span>
</td>
<td class="nump">19,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt - related parties</a></td>
<td class="nump">$ 35,927<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AccruedResearchAndDevelopmentSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AccruedResearchAndDevelopmentSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PromissoryNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Promissory notes receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PromissoryNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance</a></td>
<td class="nump">$ 6,294<span></span>
</td>
<td class="nump">$ 5,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term debt, fair value</a></td>
<td class="nump">$ 2,485<span></span>
</td>
<td class="nump">$ 17,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">730,000,000<span></span>
</td>
<td class="nump">730,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">22,546,671<span></span>
</td>
<td class="nump">19,378,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">22,546,671<span></span>
</td>
<td class="nump">19,378,192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 54,220<span></span>
</td>
<td class="nump">$ 22,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenues (excluding amortization of acquired intangible assets)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">14,989<span></span>
</td>
<td class="nump">16,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">17,386<span></span>
</td>
<td class="nump">30,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">58,643<span></span>
</td>
<td class="nump">50,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration liability</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(104,339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">112,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">IPR&amp;D impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">107,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">1,753<span></span>
</td>
<td class="nump">2,193<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_OperatingIncomeCostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">92,578<span></span>
</td>
<td class="nump">215,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(38,358)<span></span>
</td>
<td class="num">(192,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Interest expense</a></td>
<td class="num">(6,264)<span></span>
</td>
<td class="num">(3,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">6,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ChangeInFairValueOfDebt', window );">Change in fair value of debt</a></td>
<td class="num">(492)<span></span>
</td>
<td class="num">(1,177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="num">(3,908)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_OtherNonoperatingIncomeExpenses', window );">Other expense, net</a></td>
<td class="num">(9,599)<span></span>
</td>
<td class="num">(6,290)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(19,534)<span></span>
</td>
<td class="num">(3,998)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(57,892)<span></span>
</td>
<td class="num">(196,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(57,892)<span></span>
</td>
<td class="num">(196,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent', window );">Change in fair value of debt due to change in credit risk, net of tax</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (57,897)<span></span>
</td>
<td class="num">$ (196,149)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (11.02)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (11.02)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic</a></td>
<td class="nump">21,890,518<span></span>
</td>
<td class="nump">17,813,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted</a></td>
<td class="nump">21,890,518<span></span>
</td>
<td class="nump">17,813,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 35,336<span></span>
</td>
<td class="nump">$ 13,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenues (excluding amortization of acquired intangible assets)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">4,924<span></span>
</td>
<td class="nump">8,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">5,140<span></span>
</td>
<td class="nump">5,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenues (excluding amortization of acquired intangible assets)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=CELU_LicenseRoyaltyAndOtherMember', window );">License Royalty and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">13,744<span></span>
</td>
<td class="nump">4,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenueAbstract', window );"><strong>Cost of revenues (excluding amortization of acquired intangible assets)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">$ 8,893<span></span>
</td>
<td class="nump">$ 5,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ChangeInFairValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ChangeInFairValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_OperatingIncomeCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating income costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_OperatingIncomeCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_OtherNonoperatingIncomeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_OtherNonoperatingIncomeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=CELU_LicenseRoyaltyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=CELU_LicenseRoyaltyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2022</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 844,373<span></span>
</td>
<td class="num">$ (645,496)<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 198,901<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, shares at Dec. 31, 2022</a></td>
<td class="nump">14,892,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses', window );">Issuance of common stock in Registered Direct Offering, net of offering expenses</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,320<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses', window );">Issuance of common stock in Registered Direct Offering, net of offering expenses, shares</a></td>
<td class="nump">1,780,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension', window );">Common stock issued pursuant to short-term debt maturity extension</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension', window );">Common stock issued pursuant to short-term debt maturity extension, shares</a></td>
<td class="nump">270,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">108,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueOfWarrantModificationForProfessionalService', window );">Fair value of warrant modification for professional services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment', window );">Issuance of common stock for stem-cells to be used in research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment', window );">Issuance of common stock for stem-cells to be used in research and development, shares</a></td>
<td class="nump">169,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants to RWI and C.V. Starr</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,290<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued pursuant to short-term debt conversion</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,598<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="nump">4,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued pursuant to short-term debt conversion, shares</a></td>
<td class="nump">559,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">83,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding on vesting of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Tax withholding on vesting of restricted stock units, shares</a></td>
<td class="num">(19,130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">15,017<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">15,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses', window );">Issuance of common stock in PIPE Offering, net of offering expenses</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">12,680<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">12,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses', window );">Issuance of common stock in PIPE Offering, net of offering expenses, shares</a></td>
<td class="nump">1,519,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodValueATMAgreement', window );">Issuance of common stock under ATM Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodSharesATMAgreement', window );">Issuance of common stock under ATM Agreement, shares</a></td>
<td class="nump">13,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent', window );">Change in fair value of debt due to change in credit risk, net of tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(196,295)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(196,295)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2023</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">882,732<span></span>
</td>
<td class="num">(841,791)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40,960<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, shares at Dec. 31, 2023</a></td>
<td class="nump">19,378,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">20,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued pursuant to short-term debt conversion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued pursuant to short-term debt conversion, shares</a></td>
<td class="nump">478,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">401,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding on vesting of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(434)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Tax withholding on vesting of restricted stock units, shares</a></td>
<td class="num">(109,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,569<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent', window );">Change in fair value of debt due to change in credit risk, net of tax</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(57,892)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(57,892)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and warrants in PIPE Offering, net of offering expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and warrants in PIPE Offering, net of offering expenses, shares</a></td>
<td class="nump">2,141,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee', window );">Issuance of common stock to Yorkville for debt extension and SEPA commitment fee</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee', window );">Issuance of common stock to Yorkville for debt extension and SEPA commitment fee, shares</a></td>
<td class="nump">116,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants', window );">Issuance and modification of warrants to RWI and C.V. Starr</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,261<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of shares in connection with reverse stock split</a></td>
<td class="num">$ (17)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of shares in connection with reverse stock split, shares</a></td>
<td class="num">(191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement', window );">Issuance of common stock to Palantir as consideration for settlement agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement', window );">Issuance of common stock to Palantir as consideration for settlement agreement, shares</a></td>
<td class="nump">60,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified', window );">Reclassification of warrants from liability classified to equity classified</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,970<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,970<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock as compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock as compensation expense, shares</a></td>
<td class="nump">59,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2024</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 908,523<span></span>
</td>
<td class="num">$ (899,683)<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="nump">$ 8,837<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balances, shares at Dec. 31, 2024</a></td>
<td class="nump">22,546,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital issuance and modification of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital reclassification of warrants from liability classified to equity classified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FairValueOfWarrantModificationForProfessionalService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrant Modification For Professional Services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FairValueOfWarrantModificationForProfessionalService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodSharesATMAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares for ATM agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodSharesATMAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares for consideration for settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares for debt extension and commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares of common stock in registered direct offering net of offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares of research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares PIPE offering net of offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares short term debt maturity extension.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodValueATMAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value for ATM agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodValueATMAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value for consideration for settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value for debt extension and commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value of common stock in registered direct offering net of offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value of research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value PIPE offering net of offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value short term debt maturity extension.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (57,892)<span></span>
</td>
<td class="num">$ (196,295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,922<span></span>
</td>
<td class="nump">9,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NonCashLeaseExpense', window );">Non cash lease expense</a></td>
<td class="nump">160<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ProvisionForInventoryObsolescence', window );">Provision for inventory obsolescence</a></td>
<td class="num">(186)<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(398)<span></span>
</td>
<td class="num">(6,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryImpairmentCharge', window );">Inventory impairment</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">5,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">112,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">IPR&amp;D impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">107,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">11,569<span></span>
</td>
<td class="nump">15,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(104,339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment', window );">Issuance of common stock for stem-cells to be used in research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement', window );">Issuance of common stock to Palantir as consideration for settlement agreement</a></td>
<td class="nump">175<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee', window );">Issuance of common stock to Yorkville for debt extension and SEPA commitment fee</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IssuanceOfCommonStockAsCompensationExpense', window );">Issuance of common stock as compensation expense</a></td>
<td class="nump">158<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DiscountsArisingFromLoanArrangementRelatedParty', window );">Discounts arising from RWI loan arrangement - related party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueOfWarrantModificationForProfessionalServices', window );">Fair value of warrant modification for professional services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on debt extinguishment</a></td>
<td class="nump">3,908<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ChangeInFairValueOfDebt', window );">Change in fair value of debt</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ChangeInFairValueOfContingentStockConsideration', window );">Change in fair value of contingent stock consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NonCashInterestExpense', window );">Non cash interest expense</a></td>
<td class="nump">4,144<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other, net</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">4,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(3,968)<span></span>
</td>
<td class="num">(6,827)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">6,284<span></span>
</td>
<td class="num">(865)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">5,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">9,239<span></span>
</td>
<td class="nump">8,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">12,634<span></span>
</td>
<td class="num">(1,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense', window );">Accrued R&amp;D software</a></td>
<td class="num">(3,500)<span></span>
</td>
<td class="num">(3,834)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities - operating</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(6,401)<span></span>
</td>
<td class="num">(38,685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(1,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Rebound asset acquisition</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Purchase of acquired in-process research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ProceedsFromConvertibleNote', window );">Proceeds from Sanuwave convertible note</a></td>
<td class="nump">2,175<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">514<span></span>
</td>
<td class="num">(4,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties', window );">Proceeds from warrants and short-term debt - related parties</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">18,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RepaymentsOfShortTermDebtUnaffiliated', window );">Repayments of short-term debt - unaffiliated</a></td>
<td class="num">(17,374)<span></span>
</td>
<td class="num">(16,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering', window );">Proceeds from the sale of common stock in ATM offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ProceedsFromShortTermDebtUnaffiliated', window );">Proceeds from issuance of short-term debt - unaffiliated</a></td>
<td class="nump">3,622<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PaymentOfSepaCommitmentFee', window );">Payment of SEPA commitment fee</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RepaymentsOfShortTermDebtRelatedParty', window );">Repayments of short-term debt - related parties</a></td>
<td class="num">(146)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from PIPE financing</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">12,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding on vesting of restricted stock units</a></td>
<td class="num">(434)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from registered direct offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of PIPE and other issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,553)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,701<span></span>
</td>
<td class="nump">24,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">814<span></span>
</td>
<td class="num">(18,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">10,163<span></span>
</td>
<td class="nump">28,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">10,977<span></span>
</td>
<td class="nump">10,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in accounts payable and accrued expenses</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Common stock issued for short-term debt conversion</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">4,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance', window );">Modification of C.V. Starr warrants in connection with forbearance</a></td>
<td class="nump">51<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance', window );">Issuance of RWI warrants in connection with forbearance</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan', window );">Issuance of warrants on senior secured bridge loan</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification', window );">Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,083)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PIPERelatedCostsIncludedInAccruedExpenses', window );">PIPE related costs included in accrued expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties', window );">Interest accrued on senior secured loans within long-term debt - related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition', window );">Contingent consideration accrued in connection with Rebound asset acquisition</a></td>
<td class="nump">650<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition', window );">Inventory acquired in connection with Rebound asset acquisition</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified', window );">Reclassification of warrants from liability classified to equity classified</a></td>
<td class="nump">2,970<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty', window );">Assumption of short-term debt - unaffiliated by related party</a></td>
<td class="nump">$ 2,333<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired In-process Research And Development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumption of short-term debt - unaffiliated by related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ChangeInFairValueOfContingentStockConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent stock consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ChangeInFairValueOfContingentStockConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ChangeInFairValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ChangeInFairValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration accrued in connection with Rebound asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DiscountsArisingFromLoanArrangementRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discounts arising from loan arrangement related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DiscountsArisingFromLoanArrangementRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FairValueOfWarrantModificationForProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrant Modification For Professional Services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FairValueOfWarrantModificationForProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accrued research development software expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest accrued on senior secured loans within long term debt related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory acquired in connection with Rebound asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InventoryImpairmentCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Impairment Charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InventoryImpairmentCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IssuanceOfCommonStockAsCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock as compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IssuanceOfCommonStockAsCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock as consideration for settlement agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock relating to debt extension and commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock used in research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of rwi warrants in connection with for bearance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of warrants on senior secured bridge loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modification of CV starr warrants in connection with forbearance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PIPERelatedCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PIPE related costs included in accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PIPERelatedCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PaymentOfSepaCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of sepa commitment fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PaymentOfSepaCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ProceedsFromConvertibleNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from convertible note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ProceedsFromConvertibleNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ProceedsFromShortTermDebtUnaffiliated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from short term debt unaffiliated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ProceedsFromShortTermDebtUnaffiliated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the sale of common stock in Atm offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from warrants and short term debt related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ProvisionForInventoryObsolescence">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for Inventory Obsolescence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ProvisionForInventoryObsolescence</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrants from liability classified to equity classified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction of right of use assets and associated lease liability due to lease modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_RepaymentsOfShortTermDebtRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of short term debt related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_RepaymentsOfShortTermDebtRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_RepaymentsOfShortTermDebtUnaffiliated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayments of short term debt unaffiliated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_RepaymentsOfShortTermDebtUnaffiliated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (57,892)<span></span>
</td>
<td class="num">$ (196,295)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporate cybersecurity into our Enterprise Risk Management program. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_z5pG55CGOOk">Our cybersecurity program <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zQQzNNHtbDQi">incorporates</span> cybersecurity processes,
technologies, and controls designed to identify and manage potential material cyber risks including, but not limited to, operational
risk, intellectual property theft, fraud, harm to employees, patients, or third parties, and violation of privacy or security-related
laws or regulations.</span> Our cybersecurity program is designed to be aligned with applicable industry standards set by the Center for Internet
Security. Our cybersecurity program employs a range of tools and services, including regular network and endpoint monitoring, managed
detection and response, system patching, managed security services, server and endpoint scheduled backups, awareness training and testing,
periodic vulnerability assessment and penetration testing, to update <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_z4Eu0iED4kRj">our ongoing risk identification and mitigation efforts and is assessed
periodically by independent <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_z9bDmY6Vmzrf">third parties</span>.</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240101__20241231_zpmPgEsnMNn9">Our
cybersecurity program is managed by a vice president of global security and cybersecurity who reports to our Chief Executive Officer,
or CEO, providing routine security program updates and briefings</span>. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zlMHrjVtZjxc">The current vice president of global security and cybersecurity has
more than 25 years of experience in cybersecurity, federal law enforcement, and cyber investigations, while possessing the required subject
matter expertise, skills, experience, and industry certifications expected of an individual assigned to these duties</span>. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_z4MyJI167cSd">Our information
security team, which includes the vice president of global security and cybersecurity, as well as additional professionals, is responsible
for leading enterprise-wide cybersecurity strategy, policy, standards, and processes</span>. The vice president provides regular updates to
our CEO and other members of management. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240101__20241231_zXxLC73Ar6xg">Our board of directors has ultimate oversight of cybersecurity risk, which it manages as part
of our Enterprise Risk Management program</span>. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zOdfSq1T0vNi">Cybersecurity periodically provides updates to our management on cyber risks and threats,
the status of projects to strengthen our information security systems, assessments of the information security program, and the emerging
threat landscape</span>. <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_zkCb9OSTkJx">Management</span> informs the audit committee or the board of directors of risks from cybersecurity threats as necessary or
advisable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2024, we are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_z7OP6zn0gMTa">not</span> aware of any material cybersecurity incidents. While we have not, as of the date of this
annual report on Form 10-K, experienced a cybersecurity threat or incident resulting in a material adverse impact to our business or
operations, these threats are constantly evolving, thereby increasing the difficulty of successfully defending against them or implementing
adequate preventative measures. There can be no guarantee that we will not experience such an incident in the future. We maintain cybersecurity
insurance coverage that provides protection against losses arising from certain cybersecurity incidents. In addition, we seek to detect
and investigate unauthorized attempts and attacks against our network, products, and services, and to prevent their occurrence and recurrence
where practicable through changes or updates to our internal processes and tools and changes or updates to our products and services;
however, we remain potentially vulnerable to known or unknown threats.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our cybersecurity program <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zQQzNNHtbDQi">incorporates</span> cybersecurity processes,
technologies, and controls designed to identify and manage potential material cyber risks including, but not limited to, operational
risk, intellectual property theft, fraud, harm to employees, patients, or third parties, and violation of privacy or security-related
laws or regulations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">Our board of directors has ultimate oversight of cybersecurity risk, which it manages as part
of our Enterprise Risk Management program<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Our
cybersecurity program is managed by a vice president of global security and cybersecurity who reports to our Chief Executive Officer,
or CEO, providing routine security program updates and briefings<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our information
security team, which includes the vice president of global security and cybersecurity, as well as additional professionals, is responsible
for leading enterprise-wide cybersecurity strategy, policy, standards, and processes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">The current vice president of global security and cybersecurity has
more than 25 years of experience in cybersecurity, federal law enforcement, and cyber investigations, while possessing the required subject
matter expertise, skills, experience, and industry certifications expected of an individual assigned to these duties<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Cybersecurity periodically provides updates to our management on cyber risks and threats,
the status of projects to strengthen our information security systems, assessments of the information security program, and the emerging
threat landscape<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zYuxJggu6Kn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b>1. <span id="xdx_825_zvCMjvWeGmob">Nature of Business</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Celularity Inc., (&#8220;Celularity&#8221;
or the &#8220;Company&#8221;), formerly known as GX Acquisition Corp. (&#8220;GX&#8221;), was a blank check company incorporated in Delaware
on <span id="xdx_902_edei--EntityIncorporationDateOfIncorporation_dd_c20240101__20241231_zuNcLjKQvCya" title="Date of incorporation">August 24, 2018</span>. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock
purchase, reorganization or other similar business combination with one or more businesses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On July 16, 2021 (the &#8220;Closing
Date&#8221;), the Company consummated the previously announced merger pursuant to the Merger Agreement and Plan of Reorganization, dated
January 8, 2021 (the &#8220;Merger Agreement&#8221;), by and among GX, Alpha First Merger Sub, Inc., a Delaware corporation and a direct,
wholly owned subsidiary of GX (&#8220;First Merger Sub&#8221;), Celularity LLC (f/k/a Alpha Second Merger Sub LLC), a Delaware limited
liability company and a direct, wholly owned subsidiary of GX (&#8220;Second Merger Sub&#8221;), and the entity formerly known as Celularity
Inc., incorporated under the laws of the state of Delaware on August 29, 2016 (&#8220;Legacy Celularity&#8221;). Upon completion of the
merger transaction, GX changed its name to Celularity Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At the special meeting held
on February 22, 2024, the stockholders of Celularity approved an amendment to Celularity&#8217;s Second Amended and Restated Certificate
of Incorporation, as amended, to effect a reverse stock split of Celularity&#8217;s Class A common stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240222__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zondG55V88O9" title="Common stock, par value">0.0001</span> per share,
at a ratio of <span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20240222__20240222__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zaVQuXSXhhKi" title="Reverse stock split ratio">1-for-10</span>. Following the reverse stock split, each 10 shares of Celularity&#8217;s Class A common stock issued and outstanding
immediately prior thereto were combined into one new share of Class A common stock. Unless specifically provided otherwise herein, all
share and per share information has been adjusted to reflect the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Description of Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Celularity is a cell therapy
and regenerative medicine company focused on addressing aging related diseases including cancer and degenerative diseases. Celularity
is headquartered in Florham Park, NJ. Legacy Celularity acquired Anthrogenesis Corporation (&#8220;Anthrogenesis&#8221;) in August 2017
from Celgene Corporation (&#8220;Celgene&#8221;), a global biotechnology company that merged with Bristol Myers Squibb Company. Previously,
Anthrogenesis operated as Celgene Cellular Therapeutics, Celgene&#8217;s cell therapy division.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is subject to
risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors
of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations
and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant
additional approval prior to commercialization, including extensive preclinical and clinical testing and regulatory approval. These efforts
require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities.
Even if the Company&#8217;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant
revenue from cellular therapy product sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Going Concern </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has evaluated
whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability
to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As an emerging clinical-stage
biotechnology company, Celularity is subject to certain inherent risks and uncertainties associated with the development of an enterprise.
In this regard, since the Company&#8217;s inception, substantially all of management&#8217;s efforts have been devoted to making investments
in research and development including basic scientific research into placentally-derived allogeneic cells, pre-clinical studies to support
its current and future clinical programs in cellular therapeutics, and clinical development of its cell programs as well as facilities
and selling, general and administrative expenses that support its core business operations (collectively, the &#8220;investments&#8221;),
all at the expense of the Company&#8217;s short-term profitability. The Company has historically funded these investments through limited
revenues generated from its biobanking and degenerative disease businesses and issuances of equity and debt securities to public and private
investors (these issuances are collectively referred to as &#8220;outside capital&#8221;). Notwithstanding these efforts, management can
provide no assurance that the Company&#8217;s research and development and commercialization efforts will be successfully completed, or
that adequate protection of the Company&#8217;s intellectual property will be adequately maintained. Even if these efforts are successful,
it is uncertain when, if ever, the Company will generate significant sales or operate in a profitable manner to sustain the Company&#8217;s
operations without needing to continue to rely on outside capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">As of the date the accompanying
consolidated financial statements were issued, or the issuance date, management evaluated the significance of the following adverse conditions
and events in considering its ability to continue as a going concern:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since its inception, the Company has incurred significant operating losses and net cash used in operating
activities. For the year ended December 31, 2024, the Company incurred an operating loss of $<span id="xdx_901_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20240101__20241231_zBI0HyVmlHq9" title="Operating loss">38,358</span> and net cash used in operating activities
of $<span id="xdx_905_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20241231_zjGCeCbYNwal" title="Net cash used in operating activities">6,401</span>. As of December 31, 2024, the Company had an accumulated deficit of $<span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20241231_zDCUPldZq8el" title="Accumulated deficit">899,683</span>. The Company expects to continue to incur significant
operating losses and use net cash for operations for the foreseeable future.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company expects to incur substantial expenditures to fund its investments for the foreseeable future.
In order to fund these investments, the Company will need to secure additional sources of outside capital. While the Company is actively
seeking to secure additional outside capital (and has historically been able to successfully secure such capital), as of the issuance
date, additional outside capital sufficient to fund operations for the next six months has not been secured or was deemed probable of
being secured. In addition, management can provide no assurance that the Company will be able to secure additional outside capital in
the future or on terms that are acceptable to the Company. Absent an ability to secure additional outside capital in the very near term,
the Company will be unable to meet its obligations as they become due over the next 12 months beyond the issuance date.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of the issuance date, the Company had approximately $<span id="xdx_906_eus-gaap--DebtInstrumentIssuedPrincipal_pn3n3_c20240101__20241231_zvdnnGv06CPf" title="Principal debt outstanding">43,288</span> of principal debt outstanding, all of which
is currently due or due within one year of the issuance date. As disclosed in Note 10, a substantial portion of the Company&#8217;s outstanding
debt is subject to forbearance agreements. In the event the terms of the forbearance agreements are not met and/or the outstanding borrowings
are not repaid, the lenders may, at their discretion, exercise all of their rights and remedies under the loan agreements which may include,
among other things, seizing the Company&#8217;s assets and/or forcing the Company into liquidation.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On April 22, 2025, the Company was notified by Nasdaq that it had not
                                                                                                                                                                                                           paid certain fees required by Listing Rule 5250(f) totalling $<span id="xdx_903_eus-gaap--PaymentForManagementFee_pn3n3_c20250422__20250422__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpm1pT0klGGi" title="Payment for fee">70,000</span>, and as a result, the Company will be delisted unless it
                                                                                                                                                                                                           appeals this determination. The Company paid the assessed fees on April 24, 2025, and Nasdaq informed the Company on April 30, 2025,
                                                                                                                                                                                                           that it was in compliance with Listing Rule 5250(f) and the matter is now closed. Additionally, on April 16, 2025, Nasdaq provided
                                                                                                                                                                                                           formal notice to the Company that as a result of the Company&#8217;s failure to timely file this annual report on Form 10-K, it no
                                                                                                                                                                                                           longer complied with the continued listing requirements under the timely filing criteria outlined in Nasdaq Listing Rule 5250(c)(1).
                                                                                                                                                                                                           Pursuant to Listing Rule 5810(d)(2), this delinquency serves as an additional and separate basis for delisting, and as such, the
                                                                                                                                                                                                           Company&#8217;s common stock will be suspended from trading on May 1, 2025, unless it appeals Nasdaq&#8217;s determination before a
                                                                                                                                                                                                           Hearing Panel. On April 29, 2025, the Company filed an appeal requesting an oral hearing with a Nasdaq Hearing Panel. There can be
                                                                                                                                                                                                           no assurance that the appeal will be successful or that the Company will maintain compliance with the Nasdaq listing requirements.
                                                                                                                                                                                                           If relief is not granted by the Nasdaq Hearing Panel or the Company is unable to regain compliance, the Company&#8217;s securities
                                                                                                                                                                                                           will be delisted from the Nasdaq, which such delisting could have a materially adverse effect on the Company&#8217;s ability to
                                                                                                                                                                                                           continue as a going concern.</p></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In the event the Company is unable to secure additional outside capital to fund the Company&#8217;s obligations
when they become due over the next 12 months beyond the issuance date, which includes the funds needed to repay the Company&#8217;s outstanding
debt, management will be required to seek other strategic alternatives, which may include, among others, a significant curtailment of
the Company&#8217;s operations, a sale of certain of the Company&#8217;s assets, a sale of the entire Company to strategic or financial
investors, and/or allowing the Company to become insolvent by filing for bankruptcy protection under the provisions of the U.S. Bankruptcy
Code.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">These uncertainties raise
substantial doubt about the Company&#8217;s ability to continue as a going concern. The accompanying consolidated financial statements
have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates that the Company will
be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly,
the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zt50ofiaX3L4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b>2. <span id="xdx_821_zk911nBMBO35">Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>&#160;</b></p>

<p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zdyDETNzOD07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s
consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).
The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and
transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management,
is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_845_eus-gaap--UseOfEstimates_zs3ze1DxCDi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The preparation of the
Company&#8217;s consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the
consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant
estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related
to the Company&#8217;s goodwill and intangible asset impairment assessments, determination of incremental borrowing rates, and the
valuations of inventory, gross-to-net sales adjustments, contingent consideration, short-term debt, stock options and stock
warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors
that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are
changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual
results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrCWIXAoDtD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Fair Value Measurements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain assets and
liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an
orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to
be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable
and the last is considered unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 &#8212; Quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 &#8212; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active
markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities,
or other inputs that are observable or can be corroborated by observable market data.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity that are significant
to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zYWQkJNKxIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Cash and cash equivalents
consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having a maturity when
acquired of less than three months. The Company considers all highly liquid investments with maturities of three months or less at
the date of acquisition to be cash equivalents. At December 31, 2024 and 2023, substantially all cash and cash equivalents were held
in either commercial bank accounts or money market funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_z1PgwfZPO0v2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Restricted Cash</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">As of December 31,
2024 and 2023, the Company maintained a letter of credit of $<span id="xdx_90C_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20241231__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zjoVwFqEBhq3" title="Restricted cash">10,239</span> and $<span id="xdx_90E_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zczK3zS7p75k" title="Restricted cash">9,936</span>, respectively, for the benefit of the landlord of a leased
property, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJI8ZxNTfRj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Accounts Receivable</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Accounts receivable represent amounts due from customers, typically within 30 to 90 days from invoice date, arising from the Company&#8217;s revenue-generating activities. Accounts receivable are presented net of an allowance for credit losses. The
allowance for credit losses is determined based on a combination of the aging of receivables, and customer-specific information, including
historical loss experience, current economic conditions, forecasts of future economic conditions and other relevant risk factors. The
Company applies judgment in evaluating the collectability of accounts. Receivables are written off when all reasonable collection efforts
have been exhausted and the amounts are deemed uncollectible. Actual credit losses may differ from management&#8217;s estimates, and such
differences are recognized in the period in which they become known. The Company&#8217;s accounts receivable balance, net of allowance for credit losses, was $<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20241231_zeQQoLgBpzc9" title="Accounts receivable balance, net of allowance for credit losses">13,357</span>, $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20231231_zcx3fNrMjZqd" title="Accounts receivable balance, net of allowance for credit losses">10,046</span> and $<span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231_zN2uiosrvhKc" title="Accounts receivable balance, net of allowance for credit losses">4,452</span>
as of December 31, 2024, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_849_eus-gaap--InventoryPolicyTextBlock_zZCOVQRpq42a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Inventory</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Inventory is stated
at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. Prior to initial approval
from the FDA or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred.
After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product.
The Company continues to expense costs associated with clinical trial supply costs as research and development expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company periodically
analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i)
expected to expire prior to being sold, (ii) has a cost basis in excess of its net realizable value, (iii) is in excess of expected
sales requirements as determined by internal sales forecasts, or (iv) fails to meet commercial sale specifications, the inventory is
written-down through a charge to cost of revenues. The determination of whether inventory costs will be realizable requires
estimates by management of future expected inventory requirements, based on sales forecasts. If actual market conditions are less
favorable than those projected by management, additional inventory write-downs may be required. Inventory, net of current portion on
the Company&#8217;s consolidated balance sheets includes inventory expected to remain on hand beyond one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zirH0xyvqwPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Property and Equipment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p id="xdx_89C_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zNuXmaECBYkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Property and equipment
are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line
method over the estimated useful life of each asset, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span id="xdx_8BB_zWqIoqbkfaU7" style="display: none">Schedule of Property and
Equipment Estimated Useful Life</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated Useful Life</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 69%">Building</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29%; text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zZlzOQlagac9" title="Property and equipment expected useful lives">26</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zB89FzWimrl3" title="Property and equipment expected useful lives">5</span> - <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zwDyWQvpt0Rd" title="Property and equipment expected useful lives">7</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Lab equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zSXMcDK2itY8" title="Property and equipment expected useful lives">5</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ7S4NKtSWNd" title="Property and equipment expected useful lives">3</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Software</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zV3KFxImgR3a" title="Property and equipment expected useful lives">3</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zdaZ6Eefrqd2" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0878">shorter of the estimated useful life or the lease term</span></span></td></tr>
  </table>

<p id="xdx_8A3_zGGLuPyKsfA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Estimated useful lives are
periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When
assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are
eliminated from the consolidated balance sheets and any resulting gains or losses are included in the consolidated statements of
operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as
construction-in-progress and depreciated once placed into service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD7ahGB9k1gg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Impairment of Long-Lived Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Long-lived assets consist
of property, plant and equipment, operating right-of-use assets, and finite-lived intangible assets. Long-lived assets to be held and
used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets
may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant
underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes
or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability,
the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset
group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows
expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess
of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. Due to the goodwill
impairment recognized during the year ended December 31, 2023 as discussed below and in Note 8, the Company performed a recoverability
test on long-lived assets and concluded no additional impairment to be recognized as result of this test. The Company did not record any
impairment losses on long-lived assets during the years ended December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_848_ecustom--AssetAcquisitionsPolicyTextBlock_zwRrPSrKxFj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Asset Acquisitions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company measures
and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes
transaction costs. In an asset acquisition, the cost allocated to acquire IPR&amp;D with no alternative future use is charged to research
and development expense at the acquisition date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_841_eus-gaap--InProcessResearchAndDevelopmentPolicy_zO49g7Q62gg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>In-Process Research and Development</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of IPR&amp;D
acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of
the related research and development activities. When the related research and development is completed, the asset is reclassified to
a finite-lived asset and amortized over its estimated useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of an
IPR&amp;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to
be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability
of technical success, the projected costs to complete, expected market competition, and an assessment of the asset&#8217;s life-cycle.
The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated
with the cash flow streams.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Indefinite-lived IPR&amp;D
is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The
Company tests its indefinite-lived IPR&amp;D annually for impairment during the fourth quarter. In testing indefinite-lived
IPR&amp;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of
events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the
Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived IPR&amp;D without
performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or
economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess
qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived IPR&amp;D
is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived IPR&amp;D. Under either
approach, if the fair value of the indefinite-lived IPR&amp;D is less than its carrying amount, an impairment charge is recognized
in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2024, the Company did <span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_dxL_c20240101__20241231_zBVtE4RSkLYc" title="Indefinite-lived IPR&amp;D::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0886">no</span></span>t
recognize an impairment charge related to its indefinite-lived IPR&amp;D. During the year ended December 31, 2023, the Company
recognized an impairment charge related to its indefinite-lived IPR&amp;D of $<span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_c20230101__20231231_zRCobO66Fxgg" title="Indefinite-lived IPR&amp;D">107,800</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zVgnjKMbbyub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Goodwill</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Goodwill represents
the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets
acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if
there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company manages
its operations through an evaluation of <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_z6ccAPGLi27e" title="Operating segments">three</span> different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note
19). The Company determined that the operating segments represented the reporting units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In testing goodwill
for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances
would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, or the Company
can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances
considered in the Company&#8217;s qualitative assessment include, but are not limited to, a significant adverse change in legal or business
climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess qualitative factors and the
Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, the Company
would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit
to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, no
impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize
an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value, not to exceed the total
amount of goodwill allocated to the reporting unit. During the year ended December 31, 2024, the Company did <span id="xdx_903_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_do_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zrfBEylpfebh" title="Goodwill impairment">no</span>t recognize any goodwill
impairment. During the year ended December 31, 2023, the Company recognized goodwill impairment of $<span id="xdx_901_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zO7f9dSxunO7" title="Goodwill impairment">112,347</span> relating to the Cell Therapy
reporting unit (see Note 8) in the Company&#8217;s consolidated statement of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_844_ecustom--WarrantsLiabilitiesPolicyTextBlock_zPm9aumjiLI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Warrant Liabilities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounts for
the public warrants, private placement warrants, registered direct warrants, May 2022 PIPE warrants, and November 2024 Purchaser
Warrants and Placement Agent Warrants (collectively, &#8220;Liability Warrants&#8221;) in accordance with the guidance contained in
Accounting Standards Codification (&#8220;ASC&#8221;) 815-40, <i>Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own
Equity</i>, under which the Liability Warrants do not meet the criteria for equity treatment and must be recorded as liabilities.
Accordingly, the Company classifies the Liability Warrants as liabilities at their fair value and adjusts to fair value at each
reporting period. These liabilities are subject to re-measurement at each balance sheet date until exercised or expired, and any change in
fair value is recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The Liability
Warrants, excluding the public warrants, were initially and subsequently valued using either a Black-Scholes or a Monte Carlo option
pricing model, which are considered to be Level 3 fair value measurements. The public warrants are valued based on the quoted market
price as of each relevant reporting date, which is considered to be a Level 1 fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_zB6GsSXh3MT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Leases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In accordance with
Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, <i>Leases (Topic 842)</i> (ASU 2016-02 or ASC 842), the Company classifies leases
at the lease commencement date. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease
based on the circumstances present. Leases with a term greater than one year will be recognized on the consolidated balance sheets as
right-of-use (&#8220;ROU&#8221;) assets, lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal
options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and
the corresponding ROU assets are recorded based on the present values of lease payments over the terms. The interest rate implicit in
lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which
are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a
similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liabilities and are
recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants.
Certain adjustments to ROU assets may be required for items such as initial direct costs paid, incentives received, or lease prepayments.
If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company
would reassess lease classification, remeasure the lease liabilities using revised inputs as of the reassessment date, and adjust the
ROU assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has elected
the &#8220;package of 3&#8221; practical expedients permitted under the transition guidance, which eliminates the requirements to reassess
prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy
which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of
exercising will not be included within the ROU assets and lease liabilities on its consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Refer to Note 11 for further information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p id="xdx_84A_ecustom--ShortTermDebtPolicyTextBlock_zJawFRlv44Sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Short-Term Debt - Yorkville and
Unsecured Senior Convertible Notes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company elected
the fair value option to account for its pre-paid advance agreement with YA II PN, Ltd (&#8220;Yorkville&#8221;) (see Note 10). As of
December 31, 2023, due to the short-term nature of the debt, the fair value approximated the settlement amount which was fully paid on
January 17, 2024. The Company also elected the fair value option to account for the Yorkville convertible promissory note signed on March
13, 2024 (see Note 10) and the unsecured senior convertible notes issued pursuant to the securities purchase agreement signed on November
25, 2024 (see Note 10). As of December 31, 2024, the estimate of the fair value of the Yorkville convertible promissory note and the unsecured
senior convertible notes was determined using a binomial lattice model and a credit default model. The fair value measurement of the debt
is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair value of debt that is accounted for
at fair value, inclusive of related accrued interest expense, are presented as gains or losses in the accompanying consolidated statements
of operations and comprehensive loss under change in fair value of debt. The portion of total changes in fair value of debt attributable
to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption
exclusive of base market changes and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements
of operations and comprehensive loss. The actual settlement of the short-term debt could differ from current estimates based on the timing
of when and if the investors elect to convert amounts into common shares, potential cash repayment by the Company prior to maturity, and
movements in the Company&#8217;s common share price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zMzJP3CBwZOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company generates
revenue from its degenerative disease commercial operations (i.e., the sale of Biovance<sup>&#174;</sup>, Biovance 3L<sup>&#174;</sup>,
CentaFlex<sup>&#174;</sup>, Interfyl<sup>&#174;</sup> and Rebound<sup>TM</sup>), biobanking services (i.e., the collection, processing and
storage of umbilical cord and placental blood and tissue after full-term pregnancies), and license, royalty and other revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><i><span style="text-decoration: underline">Product sales</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><i><span style="text-decoration: underline">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Biovance, Biovance 3L, CentaFlex
and Rebound are decellularized, dehydrated human amniotic membrane products intended for use as a biological membrane covering that provides
the extracellular matrix while supporting the repair of damaged tissue. Interfyl is an allogeneic decellularized particulate human placental
connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use
in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. <span style="background-color: white">Rebound&#8482;
is a full thickness extracellular matrix that contains amnion and chorion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recognizes
revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects
to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer,
determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct
performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied. Sales and
other taxes collected on behalf of third parties are excluded from revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A performance obligation
is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with
other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance
obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use
and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with
customers and to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration
that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances,
to which the Company expects to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company offers
volume-based discounts, rebates and prompt pay discounts and other various incentives which are accounted for under the variable consideration
model. If sales incentives may be earned by a customer for purchasing a specified amount of product, the Company estimates whether such
incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction
is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company
considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to estimate what
levels of incentives will be earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company provides
for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore
does not record a provision for returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><i><span style="text-decoration: underline">Services</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company separately recognizes
revenues for services to expectant parents who contract with the Company to collect, process and store umbilical cord blood and placenta
derived cells and tissue for private use. The Company recognizes revenue from collection and processing fees at the point in time of the
successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period. Contracted
storage periods are generally <span id="xdx_90E_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z58qSIxTyhdb" title="Contracted storage periods">18</span> years and <span id="xdx_900_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zfUgtyGy5kj7" title="Contracted storage periods">25</span> years. Deferred revenue on the accompanying consolidated balance sheets includes the portion
of the 18- and the 25-year storage fees that are being recognized over the contractual storage period. The Company classifies deferred
revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">When determining the transaction
price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance,
resulting in a significant financing component. For all plans (annual, lifetime, <span id="xdx_90D_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zieb2Fryhruh">18</span>
years and <span id="xdx_90A_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z6PRk83KBTyh">25</span>
years), the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans
for customers to pay over time for a period of one
<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z6uayugqonI7" title="Over time for a period">1</span></span> to <span id="xdx_908_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zEGtPcJ7xRMe" title="Over time for a period">24</span>
months (over time plans). The Company concluded that a significant financing component is not present within either the prepaid or overtime
payment plans. The Company has determined that the prepaid plans do not include a significant financing component as the payment terms
were structured primarily for reasons other than the provision of financing and to maximize profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">When considered over
a <span id="xdx_908_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zyN5PDwPyEo7" title="Over time for a period">24</span>-month period for over time plans, the difference between the cash selling price and the consideration paid is nominal. As such, the
Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when
considered in the context of all contracts entered into nor are they significant at the individual contract level.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company offers
promotional discounts and other various incentives which are accounted for under the variable consideration model. The Company estimates
whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue
transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method,
the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to
estimate what levels of incentives will be earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
the Company&#8217;s processing and storage agreements contain multiple performance obligations, ASC 606, <i>Revenue from Contracts with
Customers,</i> requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised
services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the standalone
selling prices of the processing services and storage services and concluded that the published list price is the price that a customer
in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged
the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage</span><span style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><i><span style="text-decoration: underline">License, royalty and other</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under license agreements,
the Company assesses whether the related performance obligation is satisfied at a point in time or over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At the inception of
each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable
of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial,
and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved
in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period,
the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate
of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings
in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy
a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the
milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. See
Note 16 for further discussion of the Company&#8217;s license agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">While the Company&#8217;s
direct sales of degenerative disease products are included in product sales, sales through the Company&#8217;s network of distribution partners
are included in license, royalty and other revenues. For certain distribution agreements as described in Note 16, the Company will utilize
the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to
invoice so long as the consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue
upon invoicing for these agreements (subsequent to receipt of the related purchase order).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_845_eus-gaap--CostOfSalesPolicyTextBlock_z35GVfzsFpM8" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Cost of Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Cost
of revenues consists of labor, material and overhead costs associated with the Company&#8217;s two existing commercial business segments,
biobanking and degenerative disease. Biobanking costs, which include the cost of storage and transportation kits for newly banked materials
as well as tank and facility overhead costs for cord blood and other units in storage, are included in services in cost of revenues. Degenerative
disease costs, which include costs associated with procuring placentas, qualifying the placental material and processing the placental
tissue into a marketable product, are included in product sales or license, royalty and other in cost of revenues depending on the class
of customer. Costs in the degenerative disease segment include labor and overhead costs associated with the production of the Biovance,
Biovance 3L, Interfyl and Rebound product lines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white"></span></p>

<p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztoNo8vfpm03" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Research and Development Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has entered
into various research and development and other agreements with commercial firms, researchers, universities and others for provisions
of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expense
as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses,
depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside
vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical
trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. Nonrefundable advance
payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses.
Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or
when it is no longer expected that the goods will be delivered, or the services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upfront payments, milestone
payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zehqyqrWofT4" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Advertising and Marketing Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Advertising and marketing
costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were
$<span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20240101__20241231_zPHclHX0L6aa" title="Advertising and marketing costs">23</span> and $<span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20230101__20231231_zFZsOBngTiul" title="Advertising and marketing costs">44</span> for the years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_84F_ecustom--GovernmentGrantsPolicyTextBlock_zAOMqF8O9Nv1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Government Grants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">From time to time,
the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction
to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency.
The Company did <span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20240101__20241231_zPvnZyyuNW4" title="Grant monies"><span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20230101__20231231_z3b1OtFQdtV" title="Grant monies">no</span></span>t receive grant monies during the years ended December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zOVE1KisiZFb" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Patent Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">All patent-related
costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the
recovery of the expenditure. Amounts incurred are classified in selling, general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zO3jvgy1FGPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company measures
all stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation
expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company
typically issues stock-based awards with only service-based vesting conditions and records the expense for these awards using a straight-line
method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s
board of directors may also approve and award performance-based stock options. The performance-based stock options are earned based on
the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based awards over
the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability
of vesting at each reporting period for performance-based awards and adjusts expense accordingly on a cumulative basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of each
service-performance- and market-based stock option grant is estimated on the date of grant using an appropriate option pricing
model using inputs available as of the grant date. For awards with service-based vesting conditions only, the Company determines the
fair value of the award as of the grant date using the Black-Scholes option-pricing model. Prior to the merger, Legacy Celularity
was a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, the
Company estimates its expected stock price volatility using its volatility since the merger and the historical volatility of
publicly traded peer companies. The expected term of the Company&#8217;s stock options granted to employees is determined utilizing
the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock
options granted to non-employee consultants is equal to the contractual term of the option award or the Company&#8217;s estimated
term based on the underlying agreement. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in
effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected
dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay
any cash dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company classifies
stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award
recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. The Company elects
to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure
to satisfy a service or performance condition is generally reversed in the period of the forfeiture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zcClrkt8H3S1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Comprehensive Income (Loss)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Comprehensive income (loss)
refers to revenues, expenses, gains and losses that under GAAP are included in comprehensive income (loss) but are excluded from net income
(loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss). The Company&#8217;s only
component of other comprehensive income (loss) is comprised of the portion of the total change in fair value of debt accounted for under
the fair value option that is attributable to changes in instrument-specific credit risk. During the year ended December 31, 2024, the
Company recorded instrument-specific credit risk loss of $<span id="xdx_907_ecustom--InstrumentSpecificCreditRiskLoss_pn3n3_c20240101__20241231_zXuxthYZisj4" title="Instrument-specific credit risk loss">5</span>. During the year ended December 31, 2023, the Company recorded instrument-specific
credit risk income of $<span id="xdx_905_ecustom--InstrumentSpecificCreditRiskIncome_pn3n3_c20230101__20231231_zTIEM30L2NXa" title="Instrument-specific credit risk income">146</span> and reclassified $<span id="xdx_904_ecustom--AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_pn3n3_c20230101__20231231_zaEvSgctPaZ1" title="Accumulated other comprehensive income">155</span> from accumulated other comprehensive loss to other expense, net on the consolidated statements
of operations and comprehensive loss upon short-term debt conversion. These amounts have been recorded as a separate component of stockholders&#8217;
equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zcM4XvGXdhs1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounts for
income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns.
Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and
liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets
and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will
be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely
than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge
to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and
considering prudent and feasible tax planning strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounts
for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount
of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based
on the technical merits of the position. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then
assessed to determine the amount of benefit to recognize in the consolidated financial statements. <span id="xdx_906_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zbOsqvgmw2Xf" title="Income tax examination likelihood settlement">The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority</span>.
The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note
18).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zDCGXGQdLZZ3" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Net Loss per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Basic net loss per share
of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period.
Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such
as redeemable convertible preferred stock, convertible debt, stock options, restricted stock units and warrants, which would result in
the issuance of incremental shares of common stock. However, potential common shares are excluded if their effect is anti-dilutive. For
diluted net loss per share when the Company has a net loss, the weighted-average number of shares of common stock is the same as for basic
net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact
is anti-dilutive. All warrants are participating securities, as they participate on a one-for-one basis with Class A common stock in the
distribution of dividends, if and when declared by the Board of Directors. For the purposes of computing earnings per share, the warrants
are considered to participate with Class A common stock in earnings of the Company. Therefore, the Company computes earnings per share
using the two-class method, an earnings allocation method that determines net income (loss) per share (when there are earnings) for common
stock and participating securities. No income was allocated to the warrants for the years ended December 31, 2024 and 2023, as results
of operations were a loss for both periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgF07KC77J2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following potentially
dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common stock outstanding, prior
to the use of the two-class method, as they would be anti-dilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span id="xdx_8B6_zFS2Zb9yp5z4" style="display: none">Schedule of Potentially
Dilutive Securities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_zTLtiqSQNdm2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zcfC9dr3F2Ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zO4pWMMkDXGa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left">Stock options</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">4,006,525</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">2,820,187</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG54qjzKR72f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Restricted stock units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">688,106</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">823,332</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpDgmRzbMwm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,221,557</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,070,627</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zngdWYOZ7SBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,126,496</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">549,681</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zc76zzjiS1Tb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive
    securities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,042,684</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">11,263,827</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zSxqGmWvKgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze7191TVFkX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Segment Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Operating segments
are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company manages
its operations through an evaluation of <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_ztB8DCNcXN04" title="Number of operating segments">three</span> distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments
are presented for the years ended December 31, 2024 and 2023 in Note 19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p id="xdx_841_ecustom--AllowanceForCreditLossesPolicyTextBlock_zhEEiQk5NWE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Allowance for Credit Losses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">With the adoption of ASU
2016-13 <i>Financial Instruments &#8212; Credit Losses, </i>as noted below, the Company recognizes credit losses based on forward-looking
current expected credit losses. The Company makes estimates of expected credit losses based upon its assessment of various factors, including
historical collection experience, the age of accounts receivable balances, credit quality of its customers, current economic conditions,
reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_z2szKM6kK2K1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Concentrations of Credit Risk and
Significant Customers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Financial instruments that
potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, and
accounts receivable. The Company generally maintains cash balances in various operating accounts at financial institutions that management
believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses
related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the
normal credit risk associated with commercial banking relationships.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is subject to
credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts
receivables are a result from product sales and services performed in the United States. As of December 31, 2024, three of the Company&#8217;s
customers, each of which individually comprised at least 10%, represented an aggregate <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_z4PaOevwtynb" title="Concentration risk, percentage">46</span>% of the Company&#8217;s outstanding gross accounts
receivable. As of December 31, 2023, two of the Company&#8217;s customers, each of which individually comprised at least 10%, represented an
aggregate <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zx2bmIlaY6N" title="Concentration risk, percentage">41</span>% of the Company&#8217;s outstanding gross accounts receivable. During the year ended December 31, 2024, the Company had one
customer provide for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFlNmPzgrYt7" title="Concentration risk, percentage">17</span>% of revenue and another customer provided for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zanEqKEWCkk7" title="Concentration risk, percentage">16</span>% of revenue. During the year ended December 31, 2023, the Company
had one customer provide for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmQz2erMMjnc" title="Concentration risk, percentage">14</span>% of revenue and another customer provided for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zc4bGqHB5XBa" title="Concentration risk, percentage">13</span>% of revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zAzQwpXzibg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Reclassifications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain prior period amounts
have been reclassified to conform with current year presentation. On the consolidated balance sheets, short-term debt - Yorkville and
other short-term debt were reclassified to short-term debt - unaffiliated, and short-term debt - related party and short-term debt - related
parties - C.V. Starr and RWI were reclassified to short-term debt - related parties. See Note 10 for further information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_845_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zL3RHbbgw3o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Recently Adopted Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In June 2016, the Financial
Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, <i>Financial Instruments &#8212; Credit Losses</i> (&#8220;ASU 2016-13&#8221;),
which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types
of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale
debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual
periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption
permitted. The Company adopted ASU 2016-13 effective January 1, 2023. The standard did not have a material impact on the consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In November 2023, the FASB
issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>, which requires disclosure of
incremental segment information on an annual and interim basis. This ASU was effective for fiscal years beginning after December 15, 2023,
and interim periods within fiscal years beginning after December 15, 2024. The Company adopted the guidance in ASU 2023-07 for the year
ended December 31, 2024, and it is being applied retrospectively to its consolidated financial statement disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z20Svbe71ez6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Recently Issued Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In December 2023, the FASB
issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which expands the disclosures required for
income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should
be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this
pronouncement on its financial statement disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In November 2024, the FASB
issued ASU 2024-03, <i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses</i>, as subsequently amended by ASU 2025-01 to clarify the effective date,
which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee
compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of
operations and comprehensive loss. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within
fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively
to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods
presented in the consolidated financial statements. The Company is currently evaluating the effect of this pronouncement on its
consolidated financial statements and footnote disclosures.</p>

<p id="xdx_855_zCWYG4UIoI86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Asset Acquisition</a></td>
<td class="text"><p id="xdx_800_eus-gaap--AssetAcquisitionTextBlock_zhxAhBhUhWNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b>3. <span id="xdx_822_zZ01t3MtGYU">Asset
Acquisition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">On
October 9, 2024, the Company entered into an asset purchase agreement with Sequence LifeScience, Inc. (&#8220;Sequence&#8221;) to acquire
Sequence&#8217;s Rebound&#8482; full thickness placental-derived allograft matrix product and certain related intangible assets. Rebound
adds to the Company&#8217;s portfolio of placental-derived advanced biomaterial products. The Company will pay aggregate consideration for
the assets of up to $<span id="xdx_90C_eus-gaap--AssetAcquisitionPriceOfAcquisitionExpected_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zJgwKjDGGuJg" title="Consideration for assets">5,500</span>, which consists of (i) an upfront cash payment of $<span id="xdx_90B_ecustom--UpfrontPayment_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zFhxnxo7W5n5" title="Upfront payment">1,000</span> (ii) an aggregate of up to $<span id="xdx_906_ecustom--MonthlyMilestonePayments_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zpFxjdmJsUbe" title="Monthly milestone payments">4,000</span> in monthly milestone
payments, and (iii) a credit of $<span id="xdx_90B_ecustom--PriorPaymentToRelatedParty_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zfl9ECv87zc8" title="Prior payment to related party">500</span> for the previous payment made by the Company to Sequence pursuant to a letter of intent between the
Company and Sequence dated August 16, 2024. Pursuant to the terms of the asset purchase agreement, the milestones are calculated based
on <span id="xdx_90E_ecustom--NetSalesPercentage_pid_dp_uPure_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zD4yQaSflqdk" title="Net sales percentage">20</span>% of net sales collected by the Company from its customers during the preceding calendar month, commencing the first full month after
the closing of the transaction. Transaction costs incurred with in connection with the Rebound asset acquisition were de minimis. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Concurrently
with the execution of the asset purchase agreement, the Company entered into an exclusive supply agreement with Sequence for the manufacture
and supply of Rebound for a minimum period of six months. The Company retains the right to manufacture Rebound internally and intends
to commence a technology transfer as soon as practicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
Company determined that this transaction represented an asset acquisition in accordance with ASC 805, <i>Business Combinations</i>, because
the acquired assets did not meet the definition of a business. As noted above, the purchase price consists of $<span id="xdx_906_ecustom--PurchasePriceContingentConsideration_iI_pn3n3_c20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifescienceIncMember_zCLr3nEPywra" title="Purchase price contingent consideration">4,000</span> of contingent consideration
that is based on future collections of net sales of Rebound. The Company&#8217;s policy is to record contingent consideration when the contingency
is resolved and, therefore, it is generally excluded from the cost of the acquisition. Further, the contingent consideration comprising
monthly milestone payments does not meet the definition of a derivative and, therefore, is not required to be recorded at fair value.
The fair value of the net assets acquired exceeded the initial cash payments for the purchase, resulting in the write-down of the intangible
assets acquired and the recognition of a contingent consideration liability for the excess of the fair value of the inventory acquired
over the initial cash consideration. Future monthly milestone payments will reduce the contingent consideration liability until it has
been satisfied in full, and then will be recognized as a period cost when incurred. The Company incurred $<span id="xdx_906_ecustom--MilestonePayments_pn3n3_c20240101__20241231__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zRiN36SPa5T" title="Milestone payments">135</span> of milestone payments based
on collections of net sales of Rebound for the year ended December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_89C_eus-gaap--AssetAcquisitionContingentConsiderationTableTextBlock_zWprWttZeAY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
purchase price was allocated to the acquired assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span id="xdx_8B0_zhki8gkWMykj" style="display: none">Schedule of Purchase Price
Allocated to Acquired Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zhZC3kVIpmUd" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Consideration:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pn3n3_zTu4rAjBYes1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 81%; text-align: left">Cash payment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">1,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_pn3n3_zL14qSuNb2r3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Contingent consideration</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">650</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferred_iT_pn3n3_zpdDNHBxCcL8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total consideration</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,150</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Assets acquired:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iE_pn3n3_z30MMVIHKErb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,150</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iE_pn3n3_zbTaf1s3DQO8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets acquired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,150</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A6_zuJTYBOM6t42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_z6SiLsoMDCHh" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b>4. <span id="xdx_827_ztEHcNuV4JL4">Fair Value of Financial Assets and Liabilities</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b>&#160;</b></p>

<p id="xdx_899_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmb9PfWUKqwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following tables present information about
the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value
hierarchy used to determine such fair values:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span id="xdx_8B0_zIQ9WZasChz3" style="display: none">Schedule of Financial Assets and Liabilities Measures at Fair Value</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzdSkuVcoJR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKzHQVU6Tj2h" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zApwOvikycBa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIXAcRbJ3x5d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements as of December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zdMFe61yvfVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zWYNCb0WUnu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1,413</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1,413</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zd4svOi91Nf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1037">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zwUGyLIeWUPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - Yorkville</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,865</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,865</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ShorttermDebtUnsecuredSeniorConvertibleNotes_i01I_pn3n3_z0t3w7QzYWHl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - unsecured senior convertible notes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">620</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">620</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zUynWyqYoAzl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - July 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,115</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,115</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_zWEc9xjtmMs6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - April 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zUq07lyItO7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - May 2022 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">505</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">505</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--WarrantLiabilityPurchaserWarrants_i01I_pn3n3_z2PtyNiQlTp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - November 2024 Purchaser Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1068">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">278</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">278</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityPlacementAgentWarrants_i01I_pn3n3_zNBg7V0hk4Dh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - November 2024 Placement Agent Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1073">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_za5eSpLRTsAh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - Sponsor Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1077">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zKkeFd1iCppf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability - Public Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">287</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1083">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">287</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zGTzThLR8fVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    fair value liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">287</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1088">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,902</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,189</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuoNHfmxmcGg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_499_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj5R1lOBqXD3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsIIUtxsRVa2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBOWcqsAuqA1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zT3saKyHg636" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ReceivablesFairValueDisclosure_i01I_pn3n3_zIP15TdqERni" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt; width: 44%; text-align: left">Convertible note receivable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,072</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,072</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_i01TI_pn3n3_zsY9iNcyNuOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    fair value assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,072</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,072</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zDRifOTUMxqb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zqB1icF8FiQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,606</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,606</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zS4112ALhre2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zvY5jqAgnAgk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - Yorkville</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,223</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,223</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zmNieavx7vW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - July 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1127">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,529</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,529</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_ziPEtsdI1uv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - April 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1132">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,487</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,487</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zhq8ZtQ6e1K1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - May 2022 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1137">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">708</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">708</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_zkMudQLWnIg6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - Sponsor Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1142">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1143">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zcieF696gda1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt; text-align: left">Warrant liability - Public Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">575</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1148">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">575</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zDNkMAT9gqOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    fair value liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">575</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,640</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">23,215</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zf4pa8jSTNo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the years ended December
31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The carrying values of other current
liabilities approximate fair value in the accompanying consolidated financial statements due to the short-term nature of those instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Valuation of Convertible Note Receivable</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The convertible note receivable
was received in connection with the disposition of the UltraMIST/MIST business in 2020. At any time on or after January 1, 2021, at the
sole discretion of the Company, amounts outstanding under the convertible note receivable (including accrued interest) may be converted
into Sanuwave common stock at a defined rate. The convertible note receivable was to be paid on or before August 6, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On December 18, 2023, the Company
entered into a forbearance agreement with Sanuwave (&#8220;Sanuwave Forbearance Agreement&#8221;). Per the Sanuwave Forbearance Agreement,
from the period from December 18, 2023 to the earliest of (i) February 28, 2024, (ii) the commencement of bankruptcy proceedings for Sanuwave
pursuant to the U.S. Bankruptcy Code, (iii) the occurrence of an event of default other than payment default, or (iv) the failure of Sanuwave
to comply with any term, condition or covenant set forth in the forbearance agreement, the Company agrees that it will not exercise any
remedy available to it under the convertible note receivable, excluding the right to increase the interest rate. As collateral for payments
owed to Palantir Technologies, Inc. (&#8220;Palantir&#8221;), the Company assigned to Palantir the Sanuwave convertible note receivable
in the event of default (see Note 12). On May 10, 2024, the Company entered into a letter agreement with Sanuwave to extend the forbearance
period from <span id="xdx_902_ecustom--ForbearanceExtendMaturityPeriod_dd_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zXnAEax64Pjb" title="Forbearance extend period">February 28, 2024</span> to <span id="xdx_90C_ecustom--ForbearanceExtendMaturityPeriod_dd_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zDmq86VPpjEd" title="Forbearance extend period">June 3, 2024</span>. The letter agreement increased the total note payments to $<span id="xdx_90A_ecustom--IncreasedNotePayments_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zlhdWpGFG3v3" title="Increased total note payments">2,175</span>. Upon executing the letter
agreement, Sanuwave made an initial note payment of $<span id="xdx_90B_eus-gaap--RepaymentsOfNotesPayable_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zrJiqYunjp3e" title="Initial note payment">100</span> and on June 3, 2024, made a second note payment of $<span id="xdx_90F_eus-gaap--RepaymentsOfNotesPayable_pn3n3_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zQAlStmKJ8z6" title="Note payment">2,075</span>, fully discharging
all outstanding indebtedness under the note.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z8ZzFNHpUFr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of the convertible note receivable measured on a recurring basis using Level 3 inputs for the year ended December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"><span id="xdx_8B9_zFErd4Rfj6ak" style="display: none">Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1, 2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of) </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Convertible note receivable</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ReceivablesFairValueDisclosure_iS_pn3n3_c20240101__20241231_zOLLVDccNtha" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">2,072</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3n3_c20240101__20241231_zaj2eaLR5NPk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231_z9GFUYXI1Ohb" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net">(2,072</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20240101__20241231_zVAfHEi1grW8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"><span style="-sec-ix-hidden: xdx2ixbrl1175">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ReceivablesFairValueDisclosure_iE_pn3n3_c20240101__20241231_zqGG7pp5j9Qf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1177">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zFfljS9cMqYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At December 31, 2023, the fair
value of this note was based on a bond valuation which employs a credit default model. The Company utilized Level 3 inputs on a probability
weighted model based on outcomes of a default, repayment and conversion of the note. The measurement was based upon unobservable inputs
supported by little or no market activity based on the Company&#8217;s own assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p id="xdx_89B_ecustom--ScheduleOfConvertibleNoteValuationModelTableTextBlock_z7EuHh2GNVD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the convertible
note valuation model were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zacK0CQDrUZ7" style="display: none">Schedule of Convertible
Note Valuation Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Face value</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FaceValueOfNotesReceivable_iI_pn3n3_c20231231_zmau9GTs49T6" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Face value">4,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Coupon rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20231231__20231231__srt--RangeAxis__srt--MinimumMember_zCS9azBSfThe" title="Coupon rate">12.00</span>% - <span id="xdx_90E_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20231231__20231231__srt--RangeAxis__srt--MaximumMember_zkO4ImOn8EX3" title="Coupon rate">17.00</span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231_zwuj6HzjR2aa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock price">0.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20231231__20231231__srt--RangeAxis__srt--MinimumMember_zDUEeNif64j5" title="Term (years)">0.51</span>-<span id="xdx_90B_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20231231__20231231__srt--RangeAxis__srt--MaximumMember_z4mH3Z1StVXc" title="Term (years)">2.45</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ValuationInputForConvertiblePromissoryNote_pid_dp_uPure_c20231231__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZA4dA31wVBa" title="Risk-free interest rate">5.47</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">n/a</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zdApwdr2DKp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Valuation of Contingent Consideration</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value measurement of
the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted income approach. The
measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s own assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_hus-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_z6CBmcdOyEgk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs for the years ended December
31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zHZbPLTYsDQe" style="display: none">Schedule
of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_134_zNw4XXVgHO08" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zYJsuLNyjdMk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">1,606</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zDRjxdHhzJ88" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zmmUuDNaRxni" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl1201">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zVEsLod7WOd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments">(193</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zt8vlGcR6nXk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance">1,413</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_134_zNC3CdBWLkj4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zgKVqS6FHds4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">105,945</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zh3XTRHRkxY3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1209">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_z2ZvNt2EbTS3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zSMQPI9PFEGc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments">(104,339</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zN0pxvdHgzl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance">1,606</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zWSf8A9lYiW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of the liability
to make potential future milestone and earn-out payments was estimated by the Company at each reporting date based, in part, on the results
of a third-party valuation using a discounted cash flow analysis based on various assumptions, including the probability of achieving
specified events, discount rates, and the period of time until earn-out payments are payable and the conditions triggering the milestone
payments are met. The actual settlement of contingent consideration could differ from current estimates based on the actual occurrence
of these specified events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At each reporting date, the Company
revalues the contingent consideration obligation to estimated fair value and records changes in fair value as income or expense in the
Company&#8217;s consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent consideration
obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in
probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations. The Company has
classified the contingent consideration as a long-term liability in the consolidated balance sheets as of December 31, 2024 and 2023.
See Note 12 for more information on contingent consideration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Valuation of Contingent Stock Consideration</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The contingent stock consideration
liability at December 31, 2024 and 2023 is comprised of the fair value of potential future issuance of Class A common stock to CariCord
participating shareholders pursuant to a settlement agreement signed during the year ended December 31, 2021. The fair value measurement
of the contingent stock consideration obligation is determined using Level 3 inputs and is based on a probability-weighted expected return
methodology (&#8220;PWERM&#8221;). The measurement is largely based upon unobservable inputs supported by little or no market activity
based on the Company&#8217;s own assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p id="xdx_896_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_hus-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrgIdd6CCJ6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level 3 inputs for the years ended
December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zyurDf37iSEl" style="display: none">Schedule
of Reconciliation of  Contingent  Consideration Obligation Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_134_zW1PSCMU8oc9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1, 2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of) </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zREGJY4dLpHc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">27</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zDZshqLpWFv5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1221">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_za5rNgaSgQaf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1223">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrSf4Fxc8xB1" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1225">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zM7E2M5RFyVj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance">27</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_134_zeyYDCS4uIO6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1, 2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of) </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zeV8B7OeS81" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrmPNoNkTqsk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1231">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_z6uT9Pz8O09c" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1233">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zfkuwXI8oiMf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments">(159</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zF6YQa9MfQzk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance">27</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_z9KCGkZoOW81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of the liability
to issue future shares of Class A common stock was estimated by the Company at each reporting date using a PWERM based on various inputs
and assumptions, including the Company&#8217;s common share price, discount rates, and the probability of achieving specified future operational
targets. The actual settlement of contingent stock consideration could differ from current estimates based on the actual achievement of
these specified targets and movements in the Company&#8217;s common share price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At each reporting date, the Company
revalues the contingent stock consideration obligation to estimated fair value and records changes in fair value as income or expense
in the Company&#8217;s consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent stock
consideration obligation may result from changes in discount rates, changes in the Company&#8217;s common share price, and changes in
probability assumptions with respect to the likelihood of achieving specified operational targets. The change in the fair value of the
contingent stock consideration obligation during the year ended December 31, 2024 was de minimis. The Company has classified the contingent
stock consideration as a current liability in the consolidated balance sheets as of December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Valuation of Short-Term Debt - Yorkville and
Unsecured Senior Convertible Notes </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company elected the fair value
option to account for the Yorkville PPA signed on September 15, 2022 (see Note 10). As of December 31, 2023, due to the short-term nature
of the debt, the fair value of the Yorkville PPA approximated the settlement amount, which was fully paid on January 17, 2024. The Company
also elected the fair value option to account for the Yorkville convertible promissory note signed on March 13, 2024 (see Note 10) and
the unsecured senior convertible notes issued pursuant to the securities purchase agreement signed on November 25, 2024 (see Note 10).
The fair value measurement of the debt is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair
value of debt that is accounted for at fair value, inclusive of related accrued interest expense, are presented as gains or losses in
the accompanying consolidated statements of operations and comprehensive loss under change in fair value of debt. The portion of total
changes in fair value of debt attributable to changes in instrument-specific credit risk are determined through specific measurement of
periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive loss
in the accompanying consolidated statements of operations and comprehensive loss. The actual settlement of the short-term debt could differ
from current estimates based on the timing of when and if the investors elect to convert amounts into common shares, potential cash repayment
by the Company prior to maturity, and movements in the Company&#8217;s common share price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_89A_ecustom--FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zf0Q2VjZAwu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of short-term debt obligations measured on a recurring basis using Level 3 inputs for the years ended December 31, 2023
and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span id="xdx_8BE_zNNatWJYUOr5" style="display: none">Schedule of Reconciliation
of Short-term Debt Obligation Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zVKESrallsn9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance">37,603</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Conversion of debt into common shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zhvrNP5gY3L3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion of debt into common shares">(4,599</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Principal repayments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zS1dpiGcM6gi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Principal repayments">(16,811</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of convertible promissory note</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4ULDL8Mjadd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of convertible promissory note">3,150</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of unsecured senior convertible notes, net of fair value adjustment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zeX9B9QAWsp8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of unsecured senior convertible notes, net of fair value adjustment">689</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Fair value adjustment through earnings</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueAdjustmentThroughEarnings_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zFZNR5QOZBYa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through earnings">354</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Fair value adjustment through accumulated other comprehensive income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zhNjeaH9OFa5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through accumulated other comprehensive income">(146</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustment through interest accrual</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zLErIKWgnKOd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through interest accrual">822</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zqe7Y2DTYfic" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">17,223</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zGRO4GIysI72" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance">17,223</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Principal repayments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zF9UaBSzflMi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Principal repayments">(17,374</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of convertible promissory note</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zFAaasce3Mwe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of convertible promissory note">3,150</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of unsecured senior convertible notes, net of fair value adjustment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zxqiZcy4m6dd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of unsecured senior convertible notes, net of fair value adjustment">689</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Conversion of debt into common shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zz2hQxzRVtKe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion of debt into common shares">(1,700</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Fair value adjustment through earnings</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--FairValueAdjustmentThroughEarnings_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4SqkTJzQf1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through earnings">492</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustment through accumulated other comprehensive income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zvPuDmokQ0b4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through accumulated other comprehensive income">5</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zbWbs4csl4Af" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">2,485</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zmIi29t9N328" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair values of the Yorkville
convertible promissory note and the unsecured senior convertible notes are based on valuations which employ a Monte Carlo model and a
credit default model. The Company utilized Level 3 inputs in a probability weighted model based on outcomes of a default, repayment and
conversion of the notes. The measurements are based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s
own assumptions. The fair value of the Yorkville convertible promissory note on March 13, 2024, the date of issuance, was $<span id="xdx_906_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn3n3_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_z71AsINP3rd" title="Maximum advance amount">2,993</span> and the
aggregate fair value of the unsecured senior convertible notes at the dates of issuance was $<span id="xdx_90B_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn3n3_c20241125__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zZOnHRxRc5gl" title="Fair value of notes">689</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zfo8uakP2dzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the Yorkville
convertible promissory note valuation model were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"><span id="xdx_8B8_zRmKbrmT24b3" style="display: none">Schedule
of Yorkville Convertible Promissory Note Valuation Model</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_134_zOfiwpenfdxc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 13, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zMqZRp1rMQYk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zxs1LosLo8fc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">5.79</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Credit spread</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zLvvUhVDsDF6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread">7.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_z2IzhynUZUB2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread">8.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVV2H3Upm6yl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_dp_uPure_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z6Ks0qa9vmYi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtY_c20241231__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_ztu2y3fZZrcd" title="Term (years)">0.20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtY_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zs1dCz38dpKc" title="Term (years)">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zemIL64A3Sa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate">4.30</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zZvfYkcT7fZa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate">4.90</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zdfWGeHfU5fc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility">50.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_z2aDlnnw0YM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible promissory note valuation measurement">50.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A4_zlQo6qILlvDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zTvux3YbDZIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the unsecured
senior convertible notes valuation model were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zk68lVch4AYc" style="display: none">Schedule of Convertible Notes Valuation Model</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_134_zKMHyYVPLnzg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Convertible Notes Valuation Model (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">November
    25, 2024 and December 3, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance) (1)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zZTqX6286Cd2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-size: 10pt">$<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zLdyZuROQD85" title="Common share price"><span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zxflIT1IHQzd" title="Common share price">2.00</span></span> - $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zSgBqNNguSpi" title="Common share price"><span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zyuD3A9OV6wd" title="Common share price">3.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Credit spread</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zVDI4VzbsIQg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread">7.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z2uQH62zK8ig" title="Credit spread"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zAh06WBCci26" title="Credit spread">6.9</span></span>% - <span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zhhrcNJelGa" title="Credit spread"><span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zEAsIfUYXqM8" title="Credit spread">7.2</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJd7tlAjGaLh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zUGtc8ylboFa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zkkpx6rrEkKj" title="Dividend yield">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentTerm_dtY_c20241231__20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zMbKtC0UigYg" title="Term (years)">0.90</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z7jKIqN6Tg8" title="Term (years)"><span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_c20241203__20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zALKmgbTgC79" title="Term (years)">0.98</span></span> - <span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zRqleYV3qTCj" title="Term (years)"><span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20241203__20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zSRZYbnhzw84" title="Term (years)">1.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zMy7V7zPVt29" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate">4.20</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zjoNobOYO79f" title="Risk-free interest rate"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zmpMbwWuLrza" title="Risk-free interest rate">4.30</span></span>% - <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zifSE1MeQCfg" title="Risk-free interest rate"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zMydr8j9YtB2" title="Risk-free interest rate">4.40</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zvRQnJF2wXA" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility">50.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_fKDEp_zSsteMh4V2u4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unsecured senior convertible notes valuation measurement"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zrJk7b2gmGN7" title="Unsecured senior convertible notes valuation measurement">50.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td id="xdx_F0A_zCJMq6KSn8i4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td>
  <td id="xdx_F1A_z0jldVQDcmsl" style="font: 10pt Times New Roman, Times, Serif">As discussed
in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.</td></tr>
</table>

<p id="xdx_8A1_zwmcYL5ZJcT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Valuation of Warrant Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The warrant liability at December
31, 2024 is comprised of the fair value of warrants to purchase shares of Class A common stock. The Public Warrants are recorded at fair
value based on the period-end publicly stated close price, which is a Level 1 input. The January 2024 Bridge Loan - Tranche #2 Warrants
(prior to reclassification to equity classified) and November 2024 Purchaser Warrants and Placement Agent Warrants were recorded at fair
value based on a Monte Carlo simulation model and the Registered Direct, PIPE and Sponsor Warrants are recorded at their respective closing
date fair values based on a Black-Scholes option pricing model that utilizes inputs for: (i) the value of the underlying asset, (ii) the
exercise price, (iii) the risk-free rate, (iv) the volatility of the underlying asset, (v) the dividend yield of the underlying asset
and (vi) maturity, which are Level 3 inputs. The Black-Scholes option pricing model&#8217;s primary unobservable input utilized in determining
the fair values of the warrant liabilities is the expected volatility of the Class A common stock. Prior to the merger, Legacy Celularity
was a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, the Company
estimates its expected stock price volatility using its volatility since the merger and the historical volatility of publicly traded peer
companies. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal
to the estimated remaining term of the warrants. Inputs to the Monte Carlo and Black-Scholes option pricing models for the warrants are
updated each reporting period to reflect fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">&#160;</p>

<p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zjyFz6XDPKI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">The following table presents
a reconciliation of the warrant liabilities measured on a recurring basis using Level 3 inputs for the years ended December 31, 2024 and
2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"><span id="xdx_8B5_zcldbup38v16" style="display: none">Schedule
of Reconciliation of Warrant Liabilities Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueNetAssetLiability_iS_pn3n3_c20230101__20231231_zv83jol6Vrw8" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Fair value, Beginning Balance">3,598</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">April 2023 Registered Direct warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--RegisteredDirectWarrantsIssuance_pn3n3_c20230101__20231231_zYQSGJmIAR0e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="April 2023 Registered Direct warrant issuance">4,280</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">July 2023 Registered Direct warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--RegisteredDirectWarrantIssuanceDuringJuly_pn3n3_c20230101__20231231_zNAbj1Ln54fc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="July 2023 Registered Direct warrant issuance">2,645</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">January 2024 Bridge Loan - Tranche #2 warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20241231_zzrHJqazzILl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="January 2024 Bridge Loan - Tranche #2 warrant issuance">1,858</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Purchaser warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--PurchaserWarrantIssuance_pn3n3_c20240101__20241231_zRQhynbDgJS7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Purchaser warrant issuance">354</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Placement Agent warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--PlacementAgentWarrantIssuance_pn3n3_c20240101__20241231_zQ8q8BnPHXC9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Placement Agent warrant issuance">61</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Gain recognized in earnings from change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20230101__20231231_zSfHqRBVumY4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain recognized in earnings from change in fair value">(6,164</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reclassification of warrants from liability classified to equity classified</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_iN_pn3n3_di_c20240101__20241231_zAYvgaG8wXdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassification of warrants from liability classified to equity classified">(2,970</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iE_pn3n3_c20230101__20231231_zsJoXuGoalyj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value, Ending Balance">4,359</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--FairValueNetAssetLiabilities_iS_pn3n3_c20240101__20241231_zupYiVyrn6Fh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Fair value, Beginning Balance">3,784</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">January 2024 Bridge Loan - Tranche #2 warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20241231_zL4C51rZusf7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="January 2024 Bridge Loan - Tranche #2 warrant issuance">1,858</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Purchaser warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--PurchaserWarrantIssuance_pn3n3_c20240101__20241231_zYqRQrDzXBv6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Purchaser warrant issuance">354</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Placement Agent warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--PlacementAgentWarrantIssuance_pn3n3_c20240101__20241231_zm7Vjh1Xt2z4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Placement Agent warrant issuance">61</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Gain recognized in earnings from change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20240101__20241231_zzkmZsqcwQ4j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain recognized in earnings from change in fair value">(110</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reclassification of warrants from liability classified to equity classified</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_iN_pn3n3_di_c20240101__20241231_zofKHTbfU5sj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassification of warrants from liability classified to equity classified">(2,970</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_ecustom--FairValueNetAssetLiabilities_iE_pn3n3_c20240101__20241231_zFbzS9y3Xwj9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value, Ending Balance">2,977</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_znYBXzYrM7dl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p id="xdx_894_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z4HlKRmYDho4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the May
2022 PIPE Warrants and the 2023 Registered Direct Warrants were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BC_zoUjs92MHBnc" style="display: none">Schedule of May 2022 PIPE
Warrants and 2023 Registered Direct Warrants</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_134_zEHOvFR1Mwhi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z6PG08ySPr5l" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zCRK8jT4vjC4" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.47</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zmEvPrAz9hM7" title="Exercise price">3.50</span>
- $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zfUk6mHWWwNh" title="Exercise price">7.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zrMGli18XHq9" title="Exercise price">3.50</span>
- $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zJWdhbVywlOe" title="Exercise price">7.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxGV7EC1yBg3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zEmedH3Yxuyi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zqqmdDhqA1F1" title="Term (years)">3.78</span> - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zAioW97a69J8" title="Term (years)">4.09</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zcGSO7wcj1H1" title="Term (years)">5.03</span> - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zYPkZGeS1hv" title="Term (years)">5.34</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxzAXW7Iyqv5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">4.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBP1NbAdcYS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">4.60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zGKerOI6ie58" title="Warrant and right outstanding measurement input">98.5</span>%
- <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zqXn656Hh2Rf" title="Warrant and right outstanding measurement input">98.8</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmDWrMaUJ0jg" title="Warrant and right outstanding measurement input">97.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AD_zOTYWDqRSdrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p id="xdx_899_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zTcYeIkClw3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the January
2024 Bridge Loan - Tranche #2 Warrants were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zZ0un3uuJzJ" style="display: none">Schedule
of January 2024 Bridge Loan</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_134_zfYZtbJYHUCe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of January 20224 Bridge Loan (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">July 15, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">January 16, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(reclassification)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zAbhamf6yZW" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">3.19</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_z64Ma4fo2Mof" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term to initial exercise date (years) (1)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">N/A</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingTermToInitialExerciseDate_dtY_c20240116__20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_fKDEp_zcXnJ9apWTCk" title="Term to initial exercise date (years)">0.50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z7VZpfBBKDAf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zUspIO83bWra" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zTUh2p0IL1h4" title="Term (years)">5.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zmJhZgZn5kze" title="Term (years)">5.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zQtJ5evwm8fl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate">4.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zE6CO87NoSzj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">3.90</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_za4iYSViZnu7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant and right outstanding measurement input">112.5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxyeuyuk4Ic8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants measurement input">107.5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td id="xdx_F04_z71VMIls35L4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td>
  <td id="xdx_F13_zKhae20pVIZ5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As discussed
further in Note 10, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July
15, 2024, the warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the
Company&#8217;s own stock. As such, the warrants were adjusted to fair value as of the initial exercise date and then reclassified from
liability classified to equity classified.</td></tr>
</table>

<p id="xdx_8AC_zpGW3SKSXqB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<p id="xdx_892_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zvnUoeoQ9v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the November
2024 Purchaser and Placement Agent Warrants were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_ztlx07gIa4l1" style="display: none">Schedule of November 2024
Purchaser and Placement Agent Warrants</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_134_zf71QPEgAjk3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">November
    25, 2024 And December 3, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance) (1)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zfGGfYtsJZbc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z46kT17Xe09" title="Common share price"><span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zdPSTTIBsnPg" title="Common share price">2.00</span></span> - $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zUBNXIdNreje" title="Common share price"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zD6q4W4va4Ei" title="Common share price">3.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term to Subsequent Financing (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDEp_zWcgJBsQJeA1" title="Term to Subsequent Financing (years)">0.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241125__20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zwMw4iO8pdL4" title="Term to Subsequent Financing (years)"><span id="xdx_90F_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241203__20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zsMAnpTzZCy9" title="Term to Subsequent Financing (years)">0.1</span></span> &#8211; <span id="xdx_90F_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241125__20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zaZtsaHXQC6i" title="Term to Subsequent Financing (years)"><span id="xdx_90B_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241203__20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_znGABSFOpMX3" title="Term to Subsequent Financing (years)">0.6</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_z2ubyhNq9aP1" title="Exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1477">-</span></span></span><span style="font-size: 10pt">(2)
                                            (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_zNuCSAwlQxbb" title="Exercise price"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_zTugOBVBSw2" title="Exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1479"><span style="-sec-ix-hidden: xdx2ixbrl1481">-</span></span></span></span></span><span style="font-size: 10pt">(2)
                                            (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zyra5DSUeNdi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zqTqJDZCG9w8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zlYgUJDN3XN2" title="Dividend yield">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zrf14xqZGeQg" title="Term (years)">4.9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zQM7oWhv7xg2" title="Term (years)"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zwLjgcQrbbj7" title="Term (years)">4.9</span></span> - <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zJBWbv0TIhd8" title="Term (years)"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zn5pqv4KyjNf" title="Term (years)">5.0</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zjXhXlFf6lch" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate">4.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z7kdEynBbjV4" title="Risk-free interest rate"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zYCIPq13Jt7l" title="Risk-free interest rate">4.00</span></span>% - <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zXs8IFU1i6Yc" title="Risk-free interest rate"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zrczjLQgNIc4" title="Risk-free interest rate">4.10</span></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z4DuF0GwDnq4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant and right outstanding measurement input">50.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zHJJnU0FRPxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants measurement input"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zEtlV5c2Xc8d" title="Warrants measurement input">50.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zwHFDf6Kt7oc" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zaexGBibPay7" style="font-size: 10pt">As discussed in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0C_zo1gJoXsJVn6" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_z1UxLlq7Ve35" style="font-size: 10pt">The exercise price of the November 2024 Purchaser Warrants is based on the lesser of (i) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zqWPryMPDFY" title="Exercise price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zay0CNo8kkFc" title="Exercise price">2.85</span></span> or (ii) the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zHA1eE5Olt08" title="Floor price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zJ5hleIJxI8l" title="Floor price">1.00</span></span>. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F04_zTvOtzIYoIMl" style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zZ0Nol6SrmT5" style="font-size: 10pt">The exercise price of the November 2024 Placement Agent Warrants is based on the lesser of (i) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zO2jaDs7pQ78" title="Exercise price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zCedlLw6AzQh" title="Exercise price">3.56</span></span> or (ii) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_ecustom--OfferingPricePercentage_iI_pid_dp_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z7jn9S0Q2kz4" title="Offering price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--OfferingPricePercentage_iI_pid_dp_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6z2KSFYOoUa" title="Offering price">125</span></span>% of the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6RlELFC2O76" title="Floor price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zXObzrFkExgd" title="Floor price">1.00</span></span>.</span></td></tr>
  </table>
<p id="xdx_8A2_zrBWg2bfEe75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_892_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--GXSponsorWarrantsMember_zGrSlJfF6DBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the Sponsor
Warrants are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zB0hiBDOJ4C7" style="display: none">Schedule
of Significant Inputs for  Warrants</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_134_zAdfdWkMttb7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Schedule of Significant Inputs for Sponsor Warrants (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b>December 31,</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 68%; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td style="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b>2023</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Common share price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zdLpurqPp6A9" title="Common share price">2.08</span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zHrA3tQ4MLil" title="Common share price">2.47</span> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Exercise price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zIjzfAiMIA33" title="Exercise price">115.00</span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zDtY0m1KwlSk" title="Exercise price">115.00</span> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_znSj9p5G03x7" title="Dividend yield">0</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zkmoPeuCUJqa" title="Dividend yield">0</span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Term (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 2.65pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zJG9hzzs3Ie9" title="Term (years)">1.5</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 2.65pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zzBfFK2s4on2" title="Term (years)">2.5</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zlL5PZSicnPh" title="Dividend yield">4.21</span> %</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zLvpUZm4ACi" title="Dividend yield">4.12</span> %</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zFdi7bi7MYG5" title="Warrant and right outstanding measurement input">111.4</span> %</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zU0Uag68bPC4" title="Warrant measurement input">100.7</span> %</span></td></tr>
  </table>
<p id="xdx_8A6_z4Jr6QIPfAIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p id="xdx_802_eus-gaap--InventoryDisclosureTextBlock_zUj32syHQ38i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 9pt"><b>5. <span id="xdx_82C_zDfNpZ71Gtsl">Inventory</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_899_ecustom--ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_zbJGEZG537Ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s major classes
of inventories were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B2_zNXMLq17be14" style="display: none">Schedule of Major Classes of Inventories</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_z0oxNuQH6BM9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_z1Sy0CV749j8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryRawMaterialsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zhgsDZuCwOoa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Raw materials</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">42</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,081</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InventoryWorkInProgressCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zVB3cP12G5M3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Work in progress</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,093</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,696</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InventoryFinishedGoodsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zIJhOEWkJYhc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,964</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,922</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryGrossCurrentAndNoncurrent_iTI_pn3n3_mtIGCANzRGk_maINCANzn4U_zR9JoHVr99Fh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Inventory, gross</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,099</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">24,699</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryReserveCurrentAndNoncurrent_iNI_pn3n3_di_msINCANzn4U_zQKbRCaEbD27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: inventory reserves</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,103</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,289</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzn4U_zjOUTiYxcyBj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Inventory, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,996</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,410</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance sheet classification:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InventoryNet_iI_pn3n3_maINCANzRqB_zkUsypJ2wO8b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,753</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryNoncurrent_iI_pn3n3_maINCANzRqB_zYrOm4DbQWJl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Inventory, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,587</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,657</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzRqB_zUrrpmwh493i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory,
    net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,996</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,410</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zGCq0q5VkL9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Inventory, net of current portion
includes inventory expected to remain on-hand beyond one year from each balance sheet date presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recognized a $<span id="xdx_905_ecustom--InventoryImpairmentCharge_pn3n3_c20240101__20241231_zVK6lO0lri2f" title="Inventory impairment charge">466</span>
inventory impairment charge during the year ended December 31, 2024 in the consolidated statements of operations and comprehensive loss
due to lower of cost or net realizable value adjustments for finished goods. The Company recognized a $<span id="xdx_903_ecustom--InventoryImpairmentCharge_pn3n3_c20230101__20231231_zSGpucAq6sT2" title="Inventory impairment charge">5,384</span> inventory impairment charge during the
year ended December 31, 2023 in the consolidated statements of operations and comprehensive loss due to lower of cost or net realizable value adjustments
of $<span id="xdx_90D_ecustom--InventoryImpairmentCharge_pn3n3_c20230101__20231231__us-gaap--PublicUtilitiesInventoryAxis__custom--InventoryFinishedGoodsMember_znxgQfGZKCec" title="Inventory impairment charge">2,129</span> for finished goods and $<span id="xdx_900_ecustom--InventoryImpairmentCharge_pn3n3_c20230101__20231231__us-gaap--PublicUtilitiesInventoryAxis__custom--InventoryWorkInProgressMember_zTbcT7fYNyu6" title="Inventory impairment charge">3,255</span> for work in progress.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_891_ecustom--ScheduleOfActivityInInventoryReservesTableTextBlock_zoEC85ifNptj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A schedule of the activity in
the inventory reserves is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zt5KLN76Jir9" style="display: none">Schedule of Inventory Reserves</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20230101__20231231_zz06ao9xkpqk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance">1,099</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Provision for obsolete inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ProvisionForObsoleteInventory_pn3n3_c20230101__20231231_zPXHSsX6uZx8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions for obsolete inventory">7,627</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Write-offs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231_zJHTXS7zIXDd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-offs">(6,437</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20240101__20241231_zid77wqlTBR5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">2,289</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Provision for obsolete inventory</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ProvisionForObsoleteInventory_pn3n3_c20240101__20241231_zNYqVjdhWtic" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Provision for obsolete inventory">(186</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_ecustom--InventoryReserveCurrentAndNoncurrent_iE_pn3n3_c20240101__20241231_z4Cf0d7yZPK9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">2,103</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zQ9i1U1FuV17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_80C_ecustom--PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_ztg47MUKmRcf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>6. <span id="xdx_82F_zjXVz5q2zpEa">Prepaid Expenses and Other Current Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_898_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqYfYW8Dbhuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Prepaid expenses and other current
assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4EEgadYQn07" style="display: none">Schedule of Prepaid Expenses and Other Current Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zi4ei7GVBExl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zsxUhxK2I4t8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidClinicalExpense_iI_pn3n3_maPEAOAzmHw_zomryCENgGJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Prepaid clinical expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">221</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">688</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzmHw_zs27gXEcEKtc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid insurance expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">678</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzmHw_zXnzH76PbSYf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">261</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">329</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzmHw_zVQJCjGAr3fb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">857</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,695</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zEBOwtpqP2yj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses And Other Current Assets Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_znGHWKsYKE52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>7. <span id="xdx_82F_zBclf8ZH9sA">Property and Equipment, Net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zrEB20Nhmw9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Property and equipment, net consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_zV1V4CvDzjj6" style="display: none">Schedule of Property and Equipment, Net</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zu1AF8La1y4c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zohzI8AJFkeg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zon6DKNLfu6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">73,211</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">73,211</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryAndProductionEquipmentMember_zVnagmLc6SSd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Laboratory and production equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,093</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,093</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryEquipmentAndFixturesMember_zoDb4Y1Ecrp8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Machinery, equipment and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,163</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,781</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zgtMKGpgvAm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1646">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzl3Y_zaEDlb83rPW7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94,467</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">95,106</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzl3Y_zsJCGdbHmB4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(32,867</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(27,278</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzl3Y_znmECYxPwsa1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">61,600</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">67,828</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zgb55HJm93u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Depreciation expense was $<span id="xdx_904_eus-gaap--Depreciation_pn3n3_c20240101__20241231_zrdyFlI62lVf" title="Depreciation">6,169</span>
and $<span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20230101__20231231_zrQCErHj6fHk" title="Depreciation expense">7,131</span> for the years ended December 31, 2024 and 2023 respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zB3CJnqs7h1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>8. <span id="xdx_82D_zil7g7Usjdz1">Goodwill and Intangible Assets, Net</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Goodwill</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company tests its goodwill
for impairment on an annual basis in the fourth quarter of each year for all of its reporting units, or more frequently if events or circumstances
indicate a potential impairment. The Company manages its operations through an evaluation of <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zDWYYDbxvuej" title="Number of operating segments">three</span> different operating segments: Cell
Therapy, Degenerative Disease and BioBanking (see Note 19). The Company determined that the operating segments represented the reporting
units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During annual impairment tests
and for any period in which the Company identifies an impairment trigger, the Company&#8217;s methodology includes internally generated
separate cash flow projections for each reporting unit based on the different drivers that affect each reporting unit. The Company compares
the fair values of each of its reporting units to their respective carrying amounts. If the carrying value of a reporting unit exceeds
its estimated fair value, a goodwill impairment charge is recorded for the difference, with the impairment loss limited to the total amount
of goodwill allocated to that reporting unit. The fair values of each of the Company&#8217;s reporting units were derived using the income
approach, specifically the discounted cash flow method. The use of a discounted cash flow analysis requires significant judgment to estimate
the future cash flows and the period of time over which those cash flows will be realized, as well as to determine the appropriate discount
rate. The discounted cash flow model reflects management&#8217;s assumptions regarding revenue growth rates, risk-adjusted discount rates,
terminal period growth rates, economic and market trends, and other expectations about the anticipated operating results of the Company&#8217;s
reporting units. As part of the goodwill impairment test, the Company also considers its market capitalization in assessing the reasonableness
of the combined fair values estimated for its reporting units. Substantial changes in the cash flows assumptions of the different reporting
units may lead to a future impairment or may alter the implied distribution of value between the different reporting units. A material
decline in the Company&#8217;s stock price may affect the imputed discount rate and the distribution of value between the reporting units,
which may also lead to a future impairment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The carrying value of
goodwill, all of which was assigned to the Company&#8217;s BioBanking reporting unit, was $<span id="xdx_900_eus-gaap--Goodwill_iI_pn3n3_c20241231_zj9GkYnWr9f1" title="Goodwill"><span id="xdx_90E_eus-gaap--Goodwill_iI_pn3n3_c20231231_z5kOs5kI5W11" title="Goodwill">7,347</span></span>
at both December 31, 2024 and 2023. At December 31, 2024, the Company performed a qualitative assessment to determine whether the
existence of events or circumstances would indicate that it was more likely than not that the that the fair value of the reporting
unit is less than its carrying amount. Based on the assessment, there was <span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_dxL_c20240101__20241231_zFlxrRjfSlGj" title="Goodwill, impairment loss::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1670">no</span></span>
goodwill impairment recognized during the year ended December 31, 2024. At December 31, 2023, the estimated fair value of the
BioBanking reporting unit was substantially in excess of its book value. The relative stability of the expected cash flows of the
BioBanking reporting unit makes an impairment of goodwill in the future less likely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Degenerative Disease reporting unit goodwill was fully impaired as
of December 31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">For the year ended December 31,
2023, the Company recognized $<span id="xdx_908_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20231231_zEJ2KmV5UfQg" title="Goodwill, impairment loss">112,347</span> of goodwill impairment charges related to its Cell Therapy reporting unit, which resulted in full
impairment of the reporting unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the first quarter 2023,
as a result of a sustained decrease in its stock price and market capitalization, and its decision to cease recruitment in its GBM and
HER2+ gastric trials, the Company tested for impairment due to these triggering events. Based on the results of the impairment analysis,
the carrying value exceeded the fair value on the Cell Therapy reporting unit. The Company recognized a $<span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20230331__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zIZ52k3ea8cb" title="Goodwill impairment">29,633</span> goodwill impairment charge
during the first quarter of 2023 in its consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the second quarter of 2023,
the Company&#8217;s stock price and market capitalization continued to decline, and the Company also determined to cease active recruitment
in its AML trial and halted all NK programs. The AML trial was the Company&#8217;s most advanced clinical program with a relatively large
addressable patient population given the high unmet medical need in relapsed and refractory AML. After the Company ceased recruitment,
it removed all associated cash flows relating to that program including all other NK related programs as well. As a result of these triggering
events, the Company fully impaired the IPR&amp;D assets associated with these product candidates, and performed a goodwill impairment
test on its Cell Therapy reporting unit. At June 30, 2023, the estimated fair value of the Cell Therapy reporting unit was determined
to be at breakeven compared to the carrying value using a discount rate commensurate with the risks associated with the cash flows for
preclinical product candidates. The Company also performed a reconciliation of the aggregate fair value of each reporting unit to the
market capitalization of the Company. The analysis showed the fair value of the reporting units approximated the Company&#8217;s market
capitalization, indicating an insignificant control premium. Based on the results of the impairment analysis, the Company did not recognize
a goodwill impairment charge during the second quarter of 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the third quarter of 2023,
the Company&#8217;s stock price and market capitalization continued to further decline. The Company also elected to terminate development
of CYCART-19 for B-cell malignancies during the quarter, as well as paused development in exosomes. Therefore, the Company tested for
impairment due to these triggering events. Based on the results of the impairment analysis, the carrying value exceeded the fair value
on the Cell Therapy reporting unit. The Company recognized a goodwill impairment charge for the remaining goodwill balance on the Cell
Therapy reporting unit of $<span id="xdx_90A_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_z2e9ZkJw5FF3" title="Goodwill impairment">82,714</span> during the third quarter of 2023 in its consolidated statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Intangible Assets, Net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_89A_ecustom--ScheduleOfIntangibleAssetsNetTableTextBlock_zp9R0cz9cBoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Intangible assets, net consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;<span id="xdx_8BD_zEI0baKYzh72" style="display: none">Schedule of Intangible Assets, Net</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center">Estimated Useful</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lives</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortizable intangible assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left">Developed technology</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zk4Hg6LIWdI" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z8DV7ILVQOCl" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%; text-align: center"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zKomfhsDWbX8" title="Estimated useful lives"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zKeqrOcyApE7" title="Estimated useful lives">11</span></span> &#8211; <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zE7O61tLP2jg" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zGZ8JDgOKlt8" title="Estimated useful lives">16</span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Customer relationships</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpey0st8Psof" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">2,413</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zt79MvYyhrrd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">2,413</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZNRm9GWyzOe" title="Estimated useful lives"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_znA3YFipl42k" title="Estimated useful lives">10</span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Trade names &amp; trademarks</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zQtE0ZjLJ3Td" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">570</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z1K0sSPuLrpk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">570</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zypKiA9HYaJ3" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zLJ6nI2dRzFj" title="Estimated useful lives">10</span></span> &#8211; <span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zmxkha5Nynoh" title="Estimated useful lives"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zT5gbhQv4yma" title="Estimated useful lives">13</span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reacquired rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zCOBGXONR1Xe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">4,200</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z0Q6d4BviyFj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">4,200</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zRVXc399vNK2" title="Estimated useful lives"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zuPFnsfYBbJk" title="Estimated useful lives">6</span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231_zMysKLxwjrM3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">23,993</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zKntFN5eObw7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">23,993</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: accumulated amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Developed technology</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zuIiJvpDIE76" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(8,895</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zYggwKni2n4c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(7,722</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Customer relationships</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMJutBLF2Gzc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(1,965</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zm0AIZpePhp1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(1,700</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Trade names &amp; trademarks</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zRf3C91RYWL4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(385</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zq7vyMKCivQe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(330</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reacquired rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zYQCEH6iTGwe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(4,200</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z6rGmCBUzS85" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(3,940</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231_zCO8uBdZSHg1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(15,445</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zsoXmgHUdaga" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(13,692</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortizable intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20241231_zeAQLZlamwXb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets, net">8,548</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zH0T6eOSvxK1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets, net">10,301</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-amortized intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Acquired IPR&amp;D product rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pn3n3_c20241231_zCwQlrHnCual" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Acquired IPR&amp;D product rights">700</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pn3n3_c20231231_zD6WkEBB7u58" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Acquired IPR&amp;D product rights">700</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"><span id="xdx_90D_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20240101__20241231_zJ8NLo7eOplc" title="Estimated useful lives"><span id="xdx_903_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231_zJRToTbP3Oi3" title="Estimated useful lives">indefinite</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zN9HH3HOXyC4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Intangible assets, net">9,248</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231_zw7IsKKgInCa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Intangible assets, net">11,001</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zwoZkJnhaoif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Amortization expense for intangible
assets was $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231_zI6DDFjYdW57" title="Amortization expense for intangible assets">1,753</span> and $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231_zQFQQ2n3b448" title="Amortization expense for intangible assets">2,193</span> for the years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20240101__20241231_zeYPlweYr5cl" title="Impairment of intangible assets"><span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20230101__20231231_zJXdRaeuQqsd" title="Impairment of intangible assets">No</span></span> impairment charges were recorded
on intangible assets for the year ended December 31, 2024. During the year ended December 31, 2023, the Company discontinued its unmodified
NK cell and AML Cell Therapy clinical trials and as a result recorded an IPR&amp;D impairment of $<span id="xdx_903_eus-gaap--OtherAssetImpairmentCharges_pn3n3_c20230101__20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zS5kM6D0Kj4a" title="Impairment of intangible assets">107,800</span> on its CYNK-001 and GMNK intangible
assets acquired from the Anthrogenesis acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zsnhUmgIjgEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Aggregate amortization expense
for each of the five succeeding years and thereafter related to intangible assets held as of December 31, 2024 is estimated as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zIfmSuNTef3g" style="display: none">Schedule of Aggregate Amortization Expense Related to Intangible Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_499_20241231_z5US2EjNLEja" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANziI0_z0mTudr8y395" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,493</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANziI0_z1YnuRaZCey1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,356</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANziI0_zYCmO88Xjf94" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,258</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANziI0_zOZP3u3m1stl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,208</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANziI0_zvMflM025v27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2029</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,155</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANziI0_zpwNfqesTSr3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,078</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANziI0_zM1f7lQIOgtf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,548</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z9KRpM8JBAV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p id="xdx_803_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zTmJ9voyBuPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>9. <span id="xdx_822_z6IxIn0Sz2r8">Accrued Expenses and Other Current Liabilities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zoX30kvD2mj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Accrued expenses and other current
liabilities consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zIUy5zgunx62" style="display: none">Schedule of Accrued Expenses and Other Current Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zUAi0bF2i42i" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zuwPaF1q9IUd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedClinicalTrialExpense_iI_pn3n3_maALCzZ4Y_zzAhWduSOoRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Accrued clinical trial expense</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">189</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">189</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZ4Y_zJ6XaJr5vRmc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued professional fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">691</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">573</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_zrvXYFNqhztb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued wages, bonuses, commissions and vacation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,797</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,011</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccrualsForConstructionInProgress_iI_pn3n3_maALCzZ4Y_zn9pm8Seomub" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accruals for construction in progress</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">135</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">214</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzZ4Y_zppufrkn0l51" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,798</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1803">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccruedComplianceFee_iI_pn3n3_maALCzZ4Y_zTcBA7RcvQ1f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued compliance fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,277</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,145</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_z2OK4PmAx5Bc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">955</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,448</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZ4Y_zaLHpancMSKc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    accrued expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,842</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,580</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zgkgdF1r8Jhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--DebtDisclosureTextBlock_zW9jjYQNoCx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>10. <span id="xdx_820_zR5uKsA7BlNe">Debt</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zK6Q9XSMaC9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Debt consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zvoiRhCYEAuh" style="display: none">Schedule
of Debt</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zHu7pAPGbOW" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zZqnJOOrQPv2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Debt - unaffiliated:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zyA9YHtaLfJi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Yorkville - PPA (measured at fair value)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1818">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">17,223</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--ConvertiblePromissoryNotesMember_zqsGDZKzQrz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Yorkville - convertible promissory note (measured at fair value)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,865</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1822">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--CreditFacilityAxis__custom--UnsecuredSeniorConvertibleNoteMember_zHs57v3UQFL3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Unsecured senior convertible notes (measured at fair value)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">620</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1825">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OtherShortTermDebt_iI_pn3n3_zVEapbxVD6wh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Short-term debt - other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1827">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,108</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_zvnBk4RyqYTb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total debt - unaffiliated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,485</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,331</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Debt - related parties:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CVStarrBridgeLoanNetOfDiscountMember_zB6V0cUxTM8i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">C.V. Starr Bridge Loan, net of discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,652</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,523</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--RWIBridgeLoanNetOfDiscountMember_zqMwMDQu5Axb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">RWI Bridge Loan, net of discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">30,275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,967</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zy480WSqLQo9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">CEO promissory note</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,876</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,419</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_zH425rxDLV0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">39,803</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,909</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--Debt_iTI_pn3n3_zyvhxlDi9rCl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total debt</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">42,288</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">39,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance sheet classification:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShortTermBorrowings_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z8IP16kNtQU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - unaffiliated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,485</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19,331</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2FkvjdwenYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,876</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19,909</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4DEWC6mnYVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Long-term debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">35,927</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1855">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--Debt_iTI_pn3n3_znK7NZGmPrz7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">42,288</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">39,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zovKF4TJKJr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Yorkville PPA</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On September 15, 2022, the Company
entered into a Pre-Paid Advance Agreement (&#8220;PPA&#8221;) with Yorkville, pursuant to which the Company could request advances of
up to $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zEu36Cn8rZZ4" title="Maximum advance amount">40,000</span> in cash from Yorkville (or such greater amount that the parties may mutually agree) (each, a &#8220;Pre-Paid Advance&#8221;)
over an <span id="xdx_90F_ecustom--PrePaidAdvancePeriod_dtM_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zjdBAdOMizHh" title="Pre-paid advance period">18</span>-month period, with an aggregate limitation of $<span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zNU7m9JN3l48" title="Line of credit aggregate limitation amount">150,000</span>. Pre-Paid Advances were issued at a <span id="xdx_906_ecustom--PrePaidAdvanceIssuedDiscountPercentage_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zuAVveHPnX2l" title="Pre-paid advance issued discount percentage">2.0</span>% discount, bore interest at
an annual rate equal to <span id="xdx_90B_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zXEYolPefsEf" title="Annual interest rate">6.0</span>% (increased to <span id="xdx_902_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zOPAPeOsIVR3" title="Line of credit increase in interest rate during period in event of default">15.0</span>% in the event of default as described in the PPA) and could have been offset by the issuance
of shares of common stock, at Yorkville&#8217;s option, at a price per share calculated pursuant to the PPA, which in no event would be
less than $<span id="xdx_909_ecustom--IssuanceOfCommonStockMinimumOptionPricePerShare_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zdxBo79pJM2g" title="Issuance of common stock minimum option price per share">7.50</span> per share. The issuance of the shares under the PPA was subject to certain limitations, including that the aggregate number
of shares of common stock issued pursuant to the PPA could not exceed <span id="xdx_908_ecustom--MaximumPercentageOfCommonStockIssued_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zxeqPc6HgnM9" title="Maximum percentage of common stock issued">19.9</span>% of the Company&#8217;s outstanding stock as of September 15,
2022, as well as a beneficial ownership limitation of <span id="xdx_90B_ecustom--PercentageOfBeneficialOwnershipLimitation_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z4JSxLC1JxJd" title="Percentage of beneficial ownership limitation">4.99</span>%. Further, Yorkville agreed not to purchase any shares of common stock for
60 days following entry into the PPA, nor could Yorkville purchase more than $<span id="xdx_905_ecustom--MinimumNumberOfSharesOfCommonStockPurchase_pid_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zqBfNCeMMWh5" title="Minimum number of shares of common stock purchase">6,000</span> of shares of common stock during a 30-day period,
in each case at a price per share less than the Fixed Price, as defined in the PPA. In the event the daily volume weighted average price
(&#8220;VWAP&#8221;) of the Class A common stock was below $<span id="xdx_907_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z5868LZc4olf" title="Minimum required daily volume weighted average price">7.50</span> (the &#8220;floor price&#8221;) for any five of seven consecutive trading
days, the Company would pay Yorkville a monthly cash payment of $<span id="xdx_908_ecustom--RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_ztiTq3RYLZMk" title="Required monthly payment if daily volume weighted average price is below $0.75 for any five of seven trading days">6,000</span>, plus any accrued and unpaid interest along with a <span id="xdx_90A_ecustom--RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zrY1S51BJFB7" title="Redemption premium percentage if volume weighted average price is less than $0.75">5.0</span>% redemption
premium until such time as the daily VWAP for five consecutive trading days immediately prior to the due date of the next monthly payment
was at least <span id="xdx_908_ecustom--RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z4KPhPfgJXPb" title="Redemption premium percentage if volume weighted average price more than $0.75">10.0</span>% greater than $<span id="xdx_908_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zDOoDdpW6Etg" title="Minimum required daily volume weighted average price">7.50</span>. In connection with the Company&#8217;s 2023 annual stockholder meeting held in June 2023, the Company
and Yorkville agreed to lower the floor price to $<span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20230630__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zAkvFJXVaxKe" title="Share price per share">0.50</span> (the &#8220;amended floor price&#8221;). The Company also received stockholder
approval of the proposal for the issuance of more than <span id="xdx_901_ecustom--IssuancePricePercentage_iI_pid_dp_uPure_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zn3DIIExglQ2" title="Issuance price percentage">20.0</span>% of its pre-transaction Class A common stock outstanding at a price below
the minimum price pursuant to the PPA. Further, absent prior written consent from Yorkville, the Company agreed it would not increase
the size or amount borrowed under the C.V. Starr loan facility nor would it incur other borrowings or liens of any kind as long as any
amounts were due and remained outstanding to Yorkville until paid in full. The Company agreed that all obligations due and owing to Yorkville
would become secured obligations upon any violation under the PPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the entry into
the PPA, the Company received the initial Pre-Paid Advance of $<span id="xdx_902_ecustom--ProceedsFromLinesOfCreditGross_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zyXhcZG3pGNg" title="Proceeds from pre-paid advance gross">40,000</span> gross or $<span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zV57Yp2XMaW6" title="Proceeds from pre-paid advance">39,200</span> net of discount. Each Pre-Paid Advance had a maturity
of <span id="xdx_90B_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zAMXcGH2nLZ5" title="Pre-paid advance maturity period">12</span> months. Further Pre-Paid Advances would be based upon the mutual agreement of the parties. Direct costs and fees related to the
PPA were recognized in earnings. At issuance, the Company concluded that certain features of the PPA would be considered a derivative
that would require bifurcation. In lieu of bifurcation, the Company elected the fair value option for this financial instrument and records
changes in fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. Under
the fair value option, upon derecognition the Company will include in net loss the cumulative amount of the gain or loss on the debt that
resulted from changes in instrument-specific credit risk.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, Yorkville elected to convert $<span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zdbfoAHDf6ta">3,889
</span>of principal and $<span id="xdx_90A_ecustom--DebtConversionOriginalDebtAccruedInterestAmount_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z40lQakk2ia4">400
</span>of accrued interest into <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z2DWO6oszANe">559,481
</span>shares of common stock. Further, during the year December 31, 2023, total repayments to Yorkville were $<span id="xdx_907_ecustom--DebtInstrumentPayment_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zAcYv2w8Pqgb">18,724
</span>which consisted of (i) $<span id="xdx_901_eus-gaap--RepaymentsOfShortTermDebt_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zlvW8W8khUld">16,811
</span>applied to the principal amount; (ii) $<span id="xdx_902_ecustom--DebtInstrumentAccruedInterest_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zx86s29SeOO">1,073
</span>towards accrued interest; and (iii) $<span id="xdx_903_ecustom--DebtInstrumentRedemptionPremium_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zlkSuENUM6y8">840
</span>of redemption premium. As of December 31, 2023, the fair value of the debt was $<span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zb3wzGbR7Hc6">17,223
</span>and the principal balance was $<span id="xdx_90E_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zjBE2fAXjuR8">16,623</span>.
Refer to Note 4 for additional details regarding the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 12, 2024, the Company
and Yorkville entered into a forbearance agreement (&#8220;Forbearance Agreement&#8221;), pursuant to which Yorkville agreed to restrain
from enforcing its rights and remedies as a result of the event of default during the forbearance period. The forbearance period was to
continue until the earlier of January 19, 2024 or the date the Company fully repaid all amounts outstanding under the PPA (&#8220;Forbearance
Period&#8221;). During the Forbearance Period, interest accrued at <span id="xdx_907_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zKCOjTBLX1Mf" title="Annual interest rate">15.0</span>% per annum. In addition, the Company was to make a cash payment
of $<span id="xdx_90D_eus-gaap--RepaymentsOfDebt_pn3n3_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z0irwK5bUMnk" title="Cash payment">17,348</span> plus per diem interest of $<span id="xdx_909_ecustom--DebtInstrumentPerDiemInterestAmount_pn3n3_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zq6ivEPVgGpf" title="Diem interest payment for each day">7</span> for each day after January 12, 2024 until payment was made and was required to issue Yorkville
a total of <span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zUz68o3Bi3T" title="Issue of common stock">100,000</span> shares of its common stock. On January 12, 2024, the Company issued Yorkville <span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zRjl56beh1zi" title="Issue of common stock">100,000</span> of its common stock in connection
with the extension of the maturity date of the PPA. The PPA was repaid in full on January 17, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 13, 2024, the Company
entered into a Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) with Yorkville (see Note 13).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Yorkville Convertible Promissory Note</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upon entry into the SEPA, the
Company issued Yorkville a $<span id="xdx_90E_eus-gaap--DebtInstrumentIssuedPrincipal_pn3n3_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zqRuDAcD9oRd" title="Debt issued">3,150</span> convertible promissory note for $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3n3_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zumzYzeIuaSe" title="Maximum advance amount">2,993</span> in cash (after a <span id="xdx_90E_ecustom--ConvertiblePromissoryNoteDiscountPercentage_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zNNe1uAB2fuk" title="Original issue discount">5.0</span>% original issue discount). The note bears
interest at an annual rate equal to <span id="xdx_902_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_z9uR9tgy4oue" title="Annual interest rate">8.0</span>% (increased to <span id="xdx_907_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zJoqJA3cJsO1" title="Line of credit increase in interest rate during period in event of default">18.0</span>% in the event of default as provided in the note) and was scheduled to mature
on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_ddp_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zPX3slQ313a5" title="Maturity date">March 13, 2025</span>. The note was initially convertible into common stock at a price per share equal to $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zwwcRG4MXMc1" title="Conversion price per share">6.3171</span>, provided however, the conversion
price was subject to reset on the earlier of (a) the fifth trading day following the effective date of the resale shelf, or (b) the six-month
anniversary of the issuance date of the convertible note (i.e., September 13, 2024). The conversion price was reset to $<span id="xdx_90E_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20240913__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zrCDfmFiJEAf" title="Minimum required daily volume weighted average price">2.7546</span> on September
13, 2024. Upon the occurrence and during the continuation of an event of default (as defined in the note), the note (including accrued
interest) may become immediately due and payable. The issuance of the common stock upon conversion of the note and otherwise under the
SEPA is capped at <span id="xdx_90F_ecustom--PercentageOfConversionOnOutstandingCommonStock_iI_pid_dp_uPure_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zYJvwSu2mJxg" title="Percentage of conversion on outstanding common stock">19.9</span>% of the outstanding common stock as of March 13, 2024. Further, the note and SEPA include a beneficial ownership
blocker for Yorkville such that Yorkville may not be deemed the beneficial owner of more than <span id="xdx_909_ecustom--PercentageOfBeneficialOwnershipLimitation_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zJB78gIBqVle" title="Percentage of beneficial ownership limitation">4.99</span>% of the Company&#8217;s common stock.
As a result of the Company&#8217;s failure to file its 2023 Form 10-K by April 30, 2024 (i.e., a deemed Event of Default under the convertible
promissory note), the Company began accruing interest at the default rate of <span id="xdx_901_ecustom--DebtInstrumentDefaultInterestRate_iI_pid_dp_uPure_c20240501__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zvYpcemlyPJ6" title="Debt instrument default interest rate">18.0</span>% as of May 1, 2024. A further event of default occurred
as a result of the Company&#8217;s failure to file a registration statement with the SEC for the resale by Yorkville of the shares of
common stock issuable under the SEPA by May 3, 2024 (see Note 13).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company determined that
the convertible promissory note included embedded derivatives that would otherwise require bifurcation as derivative liabilities, and
neither the debt instrument nor the embedded features are required to be classified as equity. Therefore, at inception, the Company elected
to carry the convertible promissory note comprised of the debt host and the embedded derivative liabilities at fair value on a recurring
basis as permitted under ASC 825, <i>Financial Instruments</i>. Changes in fair value caused by changes in the instrument-specific credit
risk are reported in other comprehensive income, and the remaining change in fair value is reported in earnings (i.e., as a component
of other income/expense). Interest expense is a component of the change in fair value of the convertible promissory note and, therefore,
is not separately recorded. As a result of the fair value election, the original issue discount of $<span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zF8BAQKqJNSg">157
</span>was recorded to other expense in the consolidated statements of operations and comprehensive loss. In November 2024, Yorkville
elected to convert $<span id="xdx_908_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20241101__20241130__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zbLAEPypdqoi">1,150
</span>of principal and $<span id="xdx_900_ecustom--DebtConversionOriginalDebtAccruedInterestAmount_pn3n3_c20241101__20241130__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_z2kKqmPSaKnb">169
</span>of accrued interest into <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20241101__20241130__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zOArtWavtwlb">478,881
</span>shares of common stock. As of December 31, 2024, the fair value of the debt was $<span id="xdx_901_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zIaMp8qW1hde">1,865
</span>and the principal balance was $<span id="xdx_903_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_znp6F7xHbnKe">2,000</span>.
Refer to Note 4 for additional details regarding the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 17, 2025, the Company
entered into a letter agreement with Yorkville to extend the maturity date of the convertible promissory note from <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_ddp_c20250316__20250316__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwfaYR1XLZz3" title="Maturity date">March 13, 2025</span> to <span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_ddp_c20250317__20250317__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zu81ZUjT0toh" title="Maturity date">May
12, 2025</span>. In addition, Yorkville agreed not to declare an event of default until May 12, 2025 (the &#8220;Forbearance&#8221;). In connection
with the maturity date extension and Forbearance, the Company agreed to issue Yorkville <span id="xdx_90E_eus-gaap--SharesIssued_iI_pid_c20250317__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zx6GQLqCx0vc" title="Common stock issued pursuant to short-term debt maturity extension, shares">100,000</span> shares of its Class A common stock. The
shares of Class A common stock were issued with piggyback registration rights such that the resale of such shares by Yorkville are to
be included on any such registration statement filed by the Company following the issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Unsecured Senior Convertible Notes </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On November 25, 2024, the Company
entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with an accredited investor, pursuant to which the
Company agreed to sell and issue, in one or more closings, to the investor and other purchasers in a private placement transaction, unsecured
senior convertible notes and warrants for an aggregate original principal amount of up to $<span id="xdx_905_ecustom--NotesAndPurchaserWarrantsPrincipalAmount_iI_pn3n3_c20241125__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zqaokJSO2pog" title="Notes and purchaser warrants principal amount">1,000</span>. The Company issued and sold $<span id="xdx_90C_ecustom--ProceedsFromNotesAndPurchaserWarrants_pn3n3_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_z0IQx2QS1rh7" title="Proceeds from notes and purchaser warrants">750</span> unsecured
senior convertible notes and warrants to acquire up to an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zzUAAFz4iTCk" title="Notes and purchaser warrant share">263,156</span> shares of Class A common stock (the &#8220;November 2024
Purchaser Warrants&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The unsecured senior convertible
notes bear interest at an annual rate of <span id="xdx_909_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zYxt2iPbeio8" title="Bearing interest">8.0</span>% (increasing to <span id="xdx_905_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zBdu5baJ7N6h" title="Increase in bearing interest">10.0</span>% in the event of default as defined in the Purchase Agreement) and have
a maturity date of one year from the date of issuance. Upon an event of default, the notes are convertible at the purchasers&#8217; option
into shares of the Company&#8217;s Class A common stock at a price per share equal to (i) $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zi0JEwZs3O88" title="Stock price per share">2.85</span> (adjusted for stock splits, reverse stock
splits, stock dividends, or similar transactions); or (ii) the offering price of a subsequent financing transaction with gross proceeds
of $<span id="xdx_90F_ecustom--MinimumGrossProceeds_pn3n3_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zhhbz5TvXbD8" title="Gross proceeds">2,500</span> or more (a &#8220;Subsequent Financing&#8221;), subject to a floor price of $<span id="xdx_90A_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zZgHf43ynl4b" title="Floor price">1.00</span> per share. The unsecured senior convertible
notes include customary negative covenants restricting the Company&#8217;s ability to incur other indebtedness other than as permitted,
pay dividends to stockholders, grant or suffer to exist a security interest in any of the Company&#8217;s assets, other than as permitted,
amongst others. In addition, the unsecured senior convertible notes include customary events of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The November 2024 Purchaser Warrants
entitle the investors to purchase shares of common stock equal to each purchaser&#8217;s subscription amount divided by the exercise price
of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125_zWFBf91CgRbl" title="Exercise price">2.85</span> per share. The exercise price, and the number of shares of common stock issuable under the November 2024 Purchaser Warrants,
are subject to a one-time reset upon the completion of a Subsequent Financing, subject to a floor price of $<span id="xdx_906_ecustom--FloorPrice_iI_pid_c20241125_zjCfAPiEvHRg" title="Floor price">1.00</span> per share. The Purchaser
Warrants are immediately exercisable and have a <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125_zGMYRS7Phzpg" title="Warrant outstanding term">5</span>-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the transaction,
the Company agreed to issue a <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125_zuS67AQUxVBl" title="Warrant outstanding term">5</span>-year warrant to purchase a number of shares of common stock equal to <span id="xdx_90F_ecustom--PercentageOfCashFeeEqualToAggregateProceeds_pid_dp_uPure_c20241125__20241125_zrDzroq94yb4" title="Percentage of cash fee equal to aggregate proceeds">7</span>% of the proceeds of the transaction
(the &#8220;November 2024 Placement Agent Warrants&#8221;), at an exercise price equal to <span id="xdx_905_ecustom--PercentageOfExercisePriceEqualToOfferingPrice_pid_dp_uPure_c20241125__20241125_z8GFkK9M0PJi" title="Percentage of exercise price equal to offering price">125</span>% of the offering price. The November 2024
Placement Agent Warrants are subject to the same one-time exercise price adjustment provision as the November 2024 Purchaser Warrants
in connection with a Subsequent Financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company determined
that the unsecured senior convertible notes included embedded derivatives that would otherwise require bifurcation as derivative
liabilities, and neither the debt instrument nor the embedded features are required to be classified as equity. Therefore, at
inception, the Company elected to carry the unsecured senior convertibles note comprised of the debt host and the embedded
derivative liabilities at fair value on a recurring basis as permitted under ASC 825, <i>Financial Instruments</i>. Changes in fair
value caused by changes in the instrument-specific credit risk are reported in other comprehensive income, and the remaining change
in fair value is reported in earnings (i.e., as a component of other income/expense). Interest expense is a component of the change
in fair value of the unsecured senior convertible notes and, therefore, is not separately recorded. The November 2024 Purchaser and
Placement Agent Warrants are classified as liabilities since the exercise price was not determined at issuance and may be
subsequently adjusted in connection with a Subsequent Financing. The fair value of the November 2024 Placement Agent Warrants has
been treated as a transaction cost and was reduced from the cash proceeds to arrive at the net proceeds from the transaction. As a
result of the fair value election, a charge of $<span id="xdx_90A_eus-gaap--OtherExpenses_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zczTZ41mF9m9" title="Other expenses">478</span>
was recorded to other expense in the consolidated statements of operations and comprehensive loss for the difference between the net
proceeds from the transaction and the aggregate fair value of the unsecured senior convertible notes and November 2024 Purchaser and
Placement Agent Warrants at issuance. As of December 31, 2024, the fair value of the debt was $<span id="xdx_908_ecustom--ShorttermDebtUnsecuredSeniorConvertibleNotes_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_z3vKcOwv2cOk" title="Fair value of debt">620</span>
and the principal balance was $<span id="xdx_900_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zXsdSvxB7f36" title="Short-term debt, unpaid principal balance">750</span>.
Refer to Note 4 for additional details regarding the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Short-Term Debt - Other and CEO Promissory Note</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On August 21, 2023, the Company
entered into a loan agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri, and two unaffiliated lenders, providing
for a loan in the aggregate principal amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zbdjUEhRr5h3" title="Principal amont">3,000</span> (of which Dr. Hariri contributed $<span id="xdx_901_ecustom--DebtInstrumentContributionAmount_iI_pn3n3_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zqW02L1sOXX3" title="Debt instrument contribution amount">1,000</span>), or the &#8220;Loan.&#8221; The Loan bears
interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_z69gi4gmear2" title="Loan interest rate">15.0</span>% per year, with the first year of interest being paid in kind on the last day of each month and matured on
<span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20230821__20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zotw7jUCBqid" title="Maturity date">August 21, 2024</span>. Pursuant to the terms of the Loan, the Company is required to apply the net proceeds from a subsequent transaction (as
defined) in which the Company receives gross proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromOtherShortTermDebt_pn3n3_c20230821__20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zjuKWyn9npXe" title="Gross proceeds">4,500</span> or more to repay the Loan. The Company did not repay the Loan upon receipt
of the letter of credit funds in connection with signing the lease amendment (see Note 11) or the January 2024 PIPE (see Note 13), both
of which were defined as subsequent transactions. The lenders agreed to a loan amendment whereby the loan maturity date was extended to
December 31, 2024, and on September 30, 2024, Dr. Hariri and the two unaffiliated lenders entered into an assignment agreement whereby
Dr. Hariri assumed the full loan in exchange for repayment of the other lenders&#8217; respective principal loan amount, plus accrued
interest. As a result, the loan was reclassified from short-term debt - unaffiliated to short-term debt - related parties. On January
29, 2025, Dr. Hariri extended the maturity date of the Loan from December 31, 2024 to December 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On October 12, 2023, in order
to further address the Company&#8217;s immediate working capital requirements, Dr. Hariri and the Company signed a promissory note for
$<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zcMYknctZn67" title="Principal amont">285</span> which bears interest at a rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20231012__20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zoBuhnrs4wAd" title="Interest rate">15.0</span>% per year. The note matures together with the outstanding principal amount and accrued and
unpaid interest upon the earlier of <span id="xdx_90B_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20231012__20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_z4REyKsAH5M7" title="Pre-paid advance maturity period">12</span> months from the date of the note or upon a change of control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, there
was no other short-term debt and the carrying value of the CEO promissory note inclusive of accrued interest was $<span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20241231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zXsNFuI8eAF8" title="Carrying value of short-term debt">3,876</span>. As of December
31, 2023, the carrying value of the other short-term debt and the CEO promissory note inclusive of accrued interest was $<span id="xdx_902_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20231231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zIqfjHOFdT37" title="Carrying value of short-term debt">2,108</span> and $<span id="xdx_90F_ecustom--OtherShortTermDebtDueToRelatedParty_iI_pn3n3_c20231231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zIoN2C7pvr7b" title="Other short term debt due to related party">1,419</span>,
respectively. At December 31, 2024 and 2023, the carrying amounts of the loans were deemed to approximate fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Short-Term Debt &#8211; Related Parties - C.V.
Starr and RWI</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>C.V. Starr &amp; Co., Inc</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 17, 2023, the Company
entered into a loan agreement (the &#8220;Starr Bridge Loan&#8221;) with C.V. Starr &amp; Co., Inc. (&#8220;C.V. Starr&#8221;), a stockholder
of the Company, for an aggregate principal amount of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zoyjRRhSaYB5">5,000
</span>net of an original issue discount of $<span id="xdx_90A_ecustom--DebtInstrumentOriginalIssueDiscount_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z9whcFx8iuN4">100</span>.
The loan bears interest at a rate equal to <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z03A3essdUH5">12.0</span>%
per year or <span id="xdx_900_ecustom--DebtInstrumentInterestRateEffectivePercentageInEventOfDefault_iI_pid_dp_uPure_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zRCD2cA2zgL2" title="Effective percentage in event of default">15.0</span>%
in the event of default, with the first year of interest being paid in kind on the last day of each month, and was scheduled to mature
on <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20230317__20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zEwur4td2ZOd">March
17, 2025</span>. In addition, the parties entered into a warrant agreement to acquire up to an aggregate <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_dd_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zzCLqSRPRt65">75,000
</span>shares of Class A common stock (&#8220;Starr Warrant&#8221;), at a purchase price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zqTtew2C4tK7">1.25
</span>per whole share underlying the Starr Warrant or $<span id="xdx_90E_ecustom--ShareIssuedPurchasedPrice_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zqiFSRFEmZb" title="Share issued purchased price">94</span>.
The Starr Warrant has a five<span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zSjWof9RusY4" style="display: none">5</span>-year
term and had an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zEBymEqYunn3">7.10
</span>per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In June 2023, in connection with
the Amended RWI Loan (as defined below), the Company granted C.V. Starr additional warrants to acquire up to an aggregate <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zhYRS7YIp159" title="Warrants to purchase Class A common stock">50,000</span> shares
of its Class A common stock (&#8220;Starr Additional Warrant&#8221; and in combination with Starr Warrant, &#8220;Starr Warrants&#8221;),
which additional warrants have a <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_znZKBAhBmZ82" title="Warrants to purchase Class A common stock">5</span>-year term and had an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zsBKavssXCXd" title="Exercise per share price (in Dollars per share)">8.10</span> per share. The Company applied the guidance for this transaction
in accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i> and ASC 815, <i>Derivatives and Hedging</i>. The net proceeds
of the Starr Bridge Loan and Starr Additional Warrant were recorded at fair value. The fair value of the Starr Additional Warrant was
determined using a Black-Scholes option pricing model. The Starr Warrants met the requirements for a derivative scope exception under
ASC 815-10-15--74(a) for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under the terms of the Starr Bridge
Loan, the Company agreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends to stockholders,
repay or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of the Company&#8217;s
assets, other than as permitted, or hold cash and cash equivalents less than $<span id="xdx_90D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230630__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z8lQ0awJMlya" title="Cash and cash equivalents">3,000</span> for more than five consecutive business days. During
the year ended December 31, 2023, the Company&#8217;s cash and cash equivalents fell below the $<span id="xdx_904_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zkZLrsnBPfG7" title="Fall in cash and cash equivalents">3,000</span> minimum liquidity covenant, which
per the terms of the loan agreement caused an event of default. Therefore, the Company reclassified the loan as a current liability reflected
within short-term debt - related parties on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 12, 2024, the Company
entered into an amendment which terminated the minimum $<span id="xdx_907_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zL4u0X3gMAu8" title="Fall in cash and cash equivalents">3,000</span> liquidity covenant requirement. In addition to the negative covenants in
the Starr Bridge Loan, the Starr Bridge Loan includes customary events of default and the Company granted C.V. Starr a senior security
interest in all of its assets, pari passu with RWI (as defined below).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 13, 2024, the Company
and C.V. Starr entered into a forbearance agreement (&#8220;Starr Forbearance Agreement&#8221;) with respect to the Starr Bridge Loan.
Under the Starr Forbearance Agreement, (i) C.V. Starr agreed not to exercise its rights and remedies upon the occurrence of any default
under the Starr Bridge Loan until the Company&#8217;s obligations in respect of the Yorkville convertible promissory note have been indefeasibly
paid in full, (ii) C.V. Starr consented to the Company&#8217;s incurrence of indebtedness under the Yorkville convertible promissory note,
(iii) C.V. Starr consented to cash payments required to be made under the SEPA and the Yorkville convertible promissory note, (iv) the
Company agreed to increase the interest rate on the loan outstanding under the Starr Bridge Loan by <span id="xdx_905_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zvUVpCNfamv5" title="Increase interest rate on loan outstanding by basis points">100</span> basis points and (v) the Company
agreed to amend the exercise price of (x) that certain warrant to acquire <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zc4aEW9vqFef" title="Warrants to purchase Class A common stock">75,000</span> shares of the Company&#8217;s common stock for $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z9NFnBki9O2i" title="Purchase price of per share">7.10</span>
per share, expiring <span id="xdx_90A_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_za9yhXBQjITk" title="Warrant expiration date">March 17, 2028</span>, and (y) that certain warrant to acquire <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_z4jmsNlTHxCh" title="Warrants to purchase Class A common stock">50,000</span> shares of common stock for $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_zc7GI4BOhWbf" title="Purchase price of per share">8.10</span> per share expiring
<span id="xdx_907_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_zLnSiS0CjKUj" title="Warrant expiration date">June 20, 2028</span>, each of which are held by C.V. Starr, such that the exercise price of each such warrant in (x) and (y) is $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zaO6xlAVgH06" title="Warrants to purchase Class A common stock">5.895</span> per share.
In addition, the interest rate of the Starr Bridge Loan was increased to <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zESUbTSpiFSk" title="Loan interest rate">13.0</span>% per annum. The Starr Forbearance Agreement resulted in
a modification of the Starr Bridge Loan, since the change in cash flows was determined to be less than <span id="xdx_90E_ecustom--PercentageOfChangesInCashFlow_pid_dp_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zP8dfQpo2LS7" title="Percentage of changes in cash flow">10</span>%. Accordingly, no gain or loss
was recorded and the change in fair value of the Starr Warrants of $<span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zcHgusK9am0a" title="Debt instrument, unamortized discount">51</span> was recorded as a debt discount and will be amortized based on
the new effective interest rate over the term of the Starr Bridge Loan. Due to the Company&#8217;s failure to make certain interest payments
when due, the Company began accruing interest at the default rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240415__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z5gWzIfkNRY8" title="Default rate">16.0</span>% as of April 5, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On February 12, 2025, the Company
entered into a binding term sheet with C.V. Starr, pursuant to which C.V. Starr agreed to, among other things, an extension of the Starr
Forbearance Agreement whereby C.V. Starr agreed not to exercise its rights and remedies upon the occurrence of any default under the Starr
Bridge Loan and whereby the maturity date of the Starr Bridge Loan has been extended to <span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znq7wJDeH5Ce" title="Debt instrument maturity date">February 15, 2026</span>. Pursuant to the binding term
sheet, the Company agreed to (i) use a portion of the proceeds from its next registered public offering to pay C.V. Starr approximately
$<span id="xdx_90A_eus-gaap--RepaymentsOfOtherDebt_pn3n3_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zr3kEed3T92" title="Payment of debt">800</span>, representing cash interest through January 31, 2025 and (ii) issue to C.V. Starr a new five<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zriDK47dH1q2" style="display: none" title="Warrant term">5</span>-year warrant to purchase up to <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTFpUgkYn8Bf" title="Warrants to purchase aggregate shares">100,000</span>
shares of its Class A common stock. In addition, the Company agreed to reprice certain outstanding warrants held by C.V. Starr.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024 and 2023,
the carrying value of Starr Bridge Loan, inclusive of accrued interest and net of discount, was $<span id="xdx_907_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zfGcje90qJM4" title="Short-term debt - related parties">5,652</span> and $<span id="xdx_904_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z6uH0OOCWMRj" title="Short-term debt - related parties">5,523</span>, respectively. The carrying
amounts of the Starr Bridge Loan were deemed to approximate fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Resorts World Inc Pte Ltd</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On May 16, 2023, with written
consent provided by Yorkville, the Company entered into a senior secured loan agreement (&#8220;RWI Bridge Loan&#8221;) with Resorts World
Inc Pte Ltd, (&#8220;RWI&#8221;) providing for an initial loan in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zTgQBRo1Syd8" title="Principal amont">6,000</span> net of an original issue discount
of $<span id="xdx_90E_ecustom--DebtInstrumentDiscount_iI_pn3n3_c20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zyaRxZoBaHl2" title="Discount">120</span>, which bears interest at a rate of <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zRoB7Q0TNbb6" title="Interest rate">12.5</span>% per year or <span id="xdx_908_ecustom--DebtInstrumentInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zECKK1IiNIw6" title="Interest rate during period in event of default">15.5</span>% in the event of default, with the first year of interest being paid
in kind on the last day of each month, and matured on <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zUKZuv4HB4V2" title="Maturity date">June 14, 2023</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On June 21, 2023, the Company
closed on an amended and restated senior secured loan agreement (&#8220;Amended RWI Loan&#8221;), to amend and restate the previous senior
secured loan agreement, in its entirety. The Amended RWI Loan provided for an additional loan in the aggregate principal amount of $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdXZBrm2lARk">6,000</span>
net of an original issue discount of $<span id="xdx_90F_ecustom--DebtInstrumentDiscount_iI_pn3n3_c20230621__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zCXxZWt6Ezr6">678</span>,
which bears interest at a rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zUIsEOrQd1I7">12.5</span>%
per year or <span id="xdx_90A_ecustom--DebtInstrumentInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdVlKpZJul2l">15.5</span>%
in the event of default, with the first year of interest being paid in kind on the last day of each month, and was schedule to mature
on <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_ddp_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zawp11OqPaS4">March
17, 2025</span>. The Amended RWI Loan extended the maturity date of the initial loan to March 17, 2025. In addition, the Amended RWI
Loan provided for the issuance of warrants to acquire up to an aggregate <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zyP4srljLJf4">300,000</span>
shares of the Company&#8217;s Class A common stock (&#8220;RWI Warrant&#8221;), at a purchase price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zW0rrs5fgJF5">1.25</span>
per whole share underlying the RWI Warrant (or an aggregate purchase price of $<span id="xdx_90D_ecustom--ShareIssuedPurchasedPrice_iI_pn3n3_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zC7nwY3FxHl8" title="Share issued purchase price">375</span>).
The RWI Warrant has a <span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"></span>five<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zrWErKGQkTbi" style="display: none" title="Warrant term (years)">5</span>-year term and an exercise
price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zidNSrUCfNof" title="Exercise per share price (in Dollars per share)">8.10</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the Amended
RWI Loan, the Company was required to apply the net proceeds to the trigger payments due to Yorkville pursuant to the PPA. In addition,
the Company agreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends to stockholders, repay
or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of its assets, other than as
permitted, or hold cash and cash equivalents of less than $<span id="xdx_904_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230914__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zCVkeFF9B6L" title="Cash and cash equivalents">3,000</span> for more than five consecutive business days, and includes customary
events of default. The Company granted RWI a senior security interest in all of its assets, pari passu with C.V. Starr pursuant to the
Starr Bridge Loan. The Company and RWI signed a forbearance agreement on September 14, 2023, whereby RWI agreed to forebear any action
under the terms of the Amended RWI Loan in relation to the minimum $<span id="xdx_902_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20230914__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z6nRumKmOxie" title="Fall in cash and cash equivalents">3,000</span> liquidity covenant and with respect to any potential default
in relation to the Company&#8217;s outstanding debt owed to Yorkville until December 31, 2023. The Company reclassified the loan as a
current liability reflected within short-term debt - related parties on the consolidated balance sheets. Pursuant to the amendment on
January 12, 2024, see below, the minimum $<span id="xdx_907_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z3jtfnxBxGO3" title="Fall in cash and cash equivalents">3,000</span> liquidity covenant requirement was terminated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounted for the
Amended RWI Loan in accordance with ASC 470-20, <i>Debt with Conversion and Other Options</i> and ASC 815, <i>Derivatives and Hedging</i>.
The net proceeds of the Amended RWI Loan and RWI Warrant were recorded at fair value, which resulted in a total discount of $<span id="xdx_908_ecustom--DiscountOnWarrantAmount_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zBbBGCNLt10c" title="Discount on warrant amount">2,151</span> based
on the difference between the proceeds and fair value which were recorded as a loss within other income (expense) on the consolidated
statements of operations and comprehensive loss. The fair value of the RWI Warrant was determined using a Black-Scholes option pricing
model. The RWI Warrant met the requirements for a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed
to an entity&#8217;s own stock and classified in stockholders&#8217; equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 12, 2024, the Company
entered into a second amended and restated senior secured loan agreement (&#8220;RWI Second Amended Bridge Loan&#8221;), to amend and
restate the previously announced senior secured loan agreement with RWI dated as of May 16, 2023, as amended on June 20, 2023, in its
entirety. The RWI Second Amended Bridge Loan provided for an additional loan in the aggregate principal amount of $<span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zzEllrog4Ii8" title="Principal amont">15,000</span> net of an original
issue discount of $<span id="xdx_90D_ecustom--DebtInstrumentOriginalIssueDiscount_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdytJFBLvMA5" title="Original issue discount">3,750</span>, which bears interest at a rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240112__20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zyksgdLle4p" title="Interest rate">12.5</span>% per year, with the first year of interest being paid in kind on the
last day of each month, and matures on <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20240112__20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zgLGuu7uN392" title="Maturity date">July 16, 2025</span>. In addition, the RWI Second Amended Bridge Loan provides for the issuance of a <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zIcHd3biS7cf" title="Term (years)">5</span>-year
immediately exercisable warrant to acquire up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember_zLaVUFeQN3z6" title="Warrants to purchase Class A common stock">1,650,000</span> shares of Class A common stock (&#8220;Tranche #1 Warrant&#8221;), and a warrant
to acquire up to <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_znnXJkv2AU7a" title="Warrants to purchase Class A common stock">1,350,000</span> shares of Class A common stock, which would only be exercisable upon the later of (x) stockholder approval
for Nasdaq purposes of its exercise price, (y) CFIUS clearance and (z) six months from issuance date (&#8220;Tranche #2 Warrant&#8221;)
and will expire <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zGWRpWRxv7q" title="Term (years)">5</span> years after it becomes exercisable. The Tranche #1 Warrant and Tranche #2 Warrant were each issued on January 16, 2024
in conjunction with the close of the RWI Second Amended Bridge Loan. The Tranche #1 Warrant has an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240116__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zKffveNuw6z2" title="Exercise per share price (in Dollars per share)">2.4898</span> per share.
The Tranche #2 Warrant became exercisable on July 15, 2024 and has an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240715__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zILL7YPzKjzf" title="Exercise per share price (in Dollars per share)">2.988</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to the terms of the RWI
Second Amended Bridge Loan, the Company was required to apply the proceeds of the additional loan (i) to the payment in full of all outstanding
amounts owed to Yorkville under the PPA, (ii) to the payment of invoices of certain critical vendors, (iii) to the first settlement payment
owed to Palantir (see Note 12), and (iv) for working capital and other purposes pre-approved by RWI. Pursuant to the terms of the RWI
Second Amended Bridge Loan, the Company agreed to customary negative covenants restricting its ability to pay dividends to stockholders,
repay or incur other indebtedness other than as permitted, or grant or suffer to exist a security interest in any of the Company&#8217;s
assets, other than as permitted. In addition, the Company agreed to apply net revenues received through the sale of its products/provision
of services in connection with or related to its distribution and manufacturing agreement with Genting Innovation Pte Ltd (&#8220;Genting
Innovation&#8221;), a related party, as a prepayment towards the loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The RWI Second Amended Bridge
Loan resulted in an extinguishment of the Amended RWI Loan, since the change in cash flows exceeded 10%. As a result, the Company record
a loss on extinguishment equal to the difference between (i) the fair values of the new loan and Tranche #1 and Tranche #2 Warrants and
(ii) the previous carrying amount of the Amended RWI Loan, or $<span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zvlAExeNruhg" title="Short-term debt">3,908</span>. The Company has not elected to carry the RWI Second Amended Bridge
Loan at fair value, as permitted under ASC 815, <i>Derivatives and Hedging</i> and ASC 825, <i>Fair Value Option for Financial Instruments</i>.
The Tranche #1 Warrant has been classified in stockholders&#8217; equity, since it is exercisable into a fixed number of the Company&#8217;s
own shares at a known exercise price, and therefore is not required to be classified as a liability under ASC 480, <i>Distinguishing Liabilities
from Equity</i>. The Tranche #2 Warrant was initially classified as a liability, since the exercise price (i.e., Minimum Price) was not
determined at issuance and may have been subsequently adjusted. As of July 15, 2024, the Tranche #2 Warrant became exercisable and no
longer contains adjustment provisions to the exercise price that are not indexed to the Company&#8217;s own stock, resulting in the reclassification
from liability to equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company and RWI also entered
into an investor rights agreement dated as of January 12, 2024. The investor rights agreement provides RWI certain information and audit
rights, as well as registration rights with respect to the shares underlying the Tranche #1 Warrant and Tranche #2 Warrant, including
both the undertaking to file a registration statement within 45 days of filing of the 2023 Form 10-K, &#8220;piggyback&#8221; registration
rights, as well as the right to request up to three demand rights for underwritten offerings per year; in each case subject to customary
&#8220;underwriter cutback&#8221; language as well as any objections raised by the Securities and Exchange Commission to inclusion of
securities. If the initial registration statement was not filed on or prior to May 15, 2024, the investor rights agreement provided for
partial liquidating damages equal to <span id="xdx_90F_ecustom--PercentageOfPartialLiquidatingDamagesOnPurchasePrice_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember_zx1nUieJ1XQh" title="Percentage of partial liquidating damages on purchase price">1.0</span>% of the purchase price of the Tranche #1 and Tranche #2 Warrants amount each month, up to a maximum
of <span id="xdx_905_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember__srt--RangeAxis__srt--MaximumMember_zADvUSH5nhY8" title="Percentage of partial liquidating damages on subscription amount">6.0</span>%, plus interest thereon accruing daily at a rate of <span id="xdx_908_ecustom--DailyInterestAccruingRate_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember_zEuxq7KRqyOd" title="Daily interest accruing rate">18.0</span>% per annum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 13, 2024, the Company
and RWI entered into a second forbearance agreement (&#8220;RWI 2nd Forbearance Agreement&#8221;). Under the RWI 2nd Forbearance Agreement,
(i) RWI agreed not to exercise its rights and remedies upon the occurrence of any default under the RWI Second Amended Bridge Loan until
the Company&#8217;s obligations in respect of the Yorkville convertible promissory note have been indefeasibly paid in full or March 13,
2025, whichever occurs first, (ii) RWI consented to the Company&#8217;s incurrence of indebtedness under the Yorkville convertible promissory
note, (iii) RWI consented to cash payments required to be made under the SEPA and the Yorkville convertible promissory note, (iv) the
Company agreed to increase the interest rate on the loan outstanding under the RWI Loan Agreement by <span id="xdx_90C_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z4U5BpqXOaCe" title="Increase interest rate on loan outstanding by basis points">100</span> basis points, or from <span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDeDFfe9AsAl" title="Variable interest rate">12.5</span>% to
<span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zsP2Ah3UhUo7" title="Variable interest rate">13.5</span>% per annum, and (v) the Company agreed to issue RWI a warrant to acquire up to <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zt7mFgp7IfIg" title="Warrants to purchase Class A common stock">300,000</span> shares of common stock (&#8220;RWI New Warrant&#8221;),
which expires June 20, 2028 and has an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zbc9z0r8ODi8" title="Exercise per share price (in Dollars per share)">5.895</span> per share. The RWI 2nd Forbearance Agreement resulted in a modification
of the RWI Second Amended Bridge Loan, since the change in cash flows was less than <span id="xdx_904_ecustom--PercentageOfChangesInCashFlow_pid_dp_uPure_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zMAdKWp0k9wf" title="Percentage of changes in cash flow">10</span>%. Accordingly, no gain or loss was recorded, and
the fair value of the RWI New Warrant of $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqXtRNoTm315" title="Debt instrument, unamortized discount">1,162</span> was recorded as debt discount and will be amortized based on the new effective interest
rate over the term of the RWI Second Amended Bridge Loan. Due to the Company&#8217;s failure to make certain interest payments when due,
the Company began accruing interest on the Amended RWI Loan balance of approximately $<span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20240805__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRXqGRYwEYZ" title="Short-term debt">13,700</span> at the default rate of <span id="xdx_90C_ecustom--DebtInstrumentDefaultInterestRate_iI_pid_dp_uPure_c20240805__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember_zN4itdkarbyd" title="Debt instrument default interest rate">16.5</span>% as of August
5, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On February 12, 2025, the Company
entered into a binding term sheet with RWI, pursuant to which RWI agreed to, among other things, an extension of the RWI 2nd Forbearance
Agreement whereby RWI has agreed not to exercise its rights and remedies upon the occurrence of any default under certain loans owed to
RWI and whereby the maturity date of the foregoing loans is extended to <span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4ZxmFLG2mYk" title="Debt instrument maturity date">February 15, 2026</span>. Pursuant to the RWI binding term sheet, the
Company agreed to (i) use a portion of the proceeds from its next registered public offering to pay RWI approximately $<span id="xdx_90D_eus-gaap--RepaymentsOfOtherDebt_pn3n3_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcNg3ZK1tYOk" title="Payment for debt">1,300</span>, representing
cash interest through January 31, 2025 and (ii) issue to RWI, on July 24, 2025, a new five<span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znRNUkUF9wpk" style="display: none" title="Warrant term (years)">5</span>-year warrant to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkBa73YxmTe1" title="Warrants to purchase aggregate shares">500,000</span> shares
of its Class A common stock. In addition, the Company agreed to reprice certain outstanding warrants held by RWI.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024 and 2023,
the carrying values of the RWI Second Amended Bridge Loan and Amended RWI Loan, inclusive of interest and net of discount was $<span id="xdx_909_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zOoCz7iI2ha" title="Short-term debt - related parties">30,275</span>
and $<span id="xdx_902_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zU8pYDoUxsY4" title="Short-term debt - related parties">12,967</span>, respectively. The carrying amounts of the RWI Second Amended Bridge Loan and Amended RWI Loan were deemed to approximate
fair value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40.8pt"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_805_eus-gaap--LesseeOperatingLeasesTextBlock_zk9BJsnCoqMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>11. <span id="xdx_82C_zapz0rYJQL0g">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">ROU assets represent the Company&#8217;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments
arising from the lease. The Company&#8217;s lease ROU assets and liabilities are recognized at the lease commencement date based on the
present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses its incremental
borrowing rate (&#8220;IBR&#8221;) based on the information available at the lease commencement date to determine the appropriate discount
rate by multiple asset classes. Variable lease payments that are not based on an index or that result from changes to an index subsequent
to the initial measurement of the corresponding lease liability are not included in the measurement of lease ROU assets or liabilities
and instead are recognized in earnings in the period in which the obligation for those payments is incurred. Lease terms may include options
to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. Lease expense is recognized
on a straight-line basis over the expected lease term. Rent expense was $<span id="xdx_90F_ecustom--OperatingLeasesRentExpense_pn3n3_c20240101__20241231_zKsdObsX78n2" title="Rent expense">4,444</span> and $<span id="xdx_90A_ecustom--OperatingLeasesRentExpense_pn3n3_c20230101__20231231_ze6GsLJzISk7" title="Rent expense">3,750</span> for the years ended December 31, 2024 and 2023,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 13, 2019, Legacy Celularity
entered into a lease agreement for a <span id="xdx_90D_ecustom--AreaOfBuilding_usqft_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_z60z2WxQP3Lj" title="Area of building">147,215
</span>square foot facility consisting of office, manufacturing and laboratory space in Florham Park, New Jersey, which expires in <span id="xdx_900_ecustom--OperatingLeaseExpiryYear_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zhWbVzqOWcuf" title="Operating lease expiry year">2036</span>.
The Company has the <span id="xdx_900_eus-gaap--LesseeOperatingLeaseOptionToExtend_dtY_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zmrWpUdFmIZ4" title="Option to renew lease term period.">option to renew the term of the lease for two additional five-year terms</span> so long as the lease is then in full force
and effect; both option periods have been included in determining the lease term
used in recognizing the ROU assets and lease liability. The lease term commenced on <span id="xdx_900_ecustom--OperatingLeaseCommencementDate_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zCO9QgObL3z5" title="Operating lease commencement date">March
1, 2020</span> subject to an abatement of the fixed rent for the first 13 months following the lease commencement date. The initial monthly
base rent was approximately $<span id="xdx_902_ecustom--InitialMonthlyBaseRent_pn3n3_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zfNcRCna5Uvb" title="Initial monthly base rent">230
</span>and will increase annually. The Company is obligated to pay real estate taxes and costs related to the premises, including costs
of operations, maintenance, repair, replacement and management of the new leased premises. In connection with entering into this lease
agreement, Legacy Celularity issued a letter of credit of $<span id="xdx_902_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zlXDWUXcZpVe">14,722</span>.
The lease agreement allows for a landlord provided tenant improvement allowance of $<span id="xdx_90F_eus-gaap--TenantImprovements_iI_pn3n3_c20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zQSRmTAtBdok">14,722
</span>to be applied to the costs of the construction of the leasehold improvements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On September 14, 2023, the Company
entered into a lease amendment on the Company&#8217;s Florham Park, New Jersey facility to reduce the letter of credit by approximately
$<span id="xdx_90F_ecustom--ReductionInLineOfCredit_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zhi0VebCiCX6" title="Reduction in line of credit">4,900</span> for a new letter of credit in the amount of $<span id="xdx_905_ecustom--NewLineOfCredit_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zZSwrEwEM3n" title="New line of credit">9,883</span> in exchange for higher base rental payments of approximately $<span id="xdx_909_ecustom--BaseRentalPayments_pn3n3_c20230914__20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zF8BZUGPiF54" title="Base rental payments">400</span> per year,
effective October 1, 2023. The letter of credit, inclusive of interest earned on the account, is classified as restricted cash (non-current)
on the consolidated balance sheets. The Company evaluates changes to the terms and conditions of a lease contract to determine if they
result in a new lease or a modification of an existing lease. The Company accounted for the lease amendment as a modification since the
change in lease payments did not represent additional ROU assets. The Company reassessed the IBR, and remeasured the lease liability and
ROU asset on the modification date of September 14, 2023. As a result, the Company recorded a decrease to the ROU asset and related lease
liability in the amount of $<span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zr2b0RFxZ1w8" title="Operating lease liability">2,083</span> on the consolidated balance sheets reflecting a higher IBR due to lower Company credit rating.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zzZwHVMfDS09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The components of the Company&#8217;s
lease costs are classified on its consolidated statements of operations and comprehensive loss as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BC_zEvjVtPLhjy8" style="display: none">Schedule of Lease Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_z01c7OEiLum6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zr2OEtetPtNe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzz3O_zQPvpqJHDyz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,911</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,256</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--VariableLeaseCost_maLCzz3O_z2Dke0KHhmwj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,348</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,132</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LeaseCost_iT_mtLCzz3O_z3dA7Ic5ESs5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,259</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,388</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zjRS8CHezIHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_89B_ecustom--CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_zUyVx6kQYK87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The table below shows the cash
activity related to the Company&#8217;s lease liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zxKbWd3fK01l" style="display: none">Schedule of Cash Activity
Related to the lease Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_z4ONtJT2joai" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zFFb7eV4Du76" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash paid related to lease liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zIwRZpFFzHBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Operating cash flows from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,378</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">2,995</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_z1WuKGegbIji" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zeGRIeMXVnHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, the maturities
of the Company&#8217;s operating lease liabilities were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zKzb7mbioMVc" style="display: none">Schedule
of Future Minimum Payments under Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_493_20241231_zt7xViQDUVO" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPznn8_zAFNfB3fXeLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,452</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPznn8_zBDPk29rFmHh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,526</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPznn8_zH75YC2c8TZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,599</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPznn8_zkdyi0jYyBp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,673</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPznn8_zRyx60139Kuk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2029</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,746</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPznn8_zkGgZuJvQkG7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">80,821</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznn8_zpq5tiEUlcw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">98,817</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zbxAJ1eTPXng" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(72,269</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_z8mDX89PLs0c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26,548</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zPgp2hykfyS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, the weighted
average remaining lease term of the Company&#8217;s operating lease was <span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zYNNJYgasNvl" title="Weighted average remaining lease term">21.3</span> years, and the weighted average discount rate used to determine
the lease liability for the operating lease was <span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_zEA7EkRXyJth" title="Weighted average discount rate">14.24</span>%.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHn1dBx817ye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>12. <span id="xdx_821_za5rrymlh6ie">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Contingent Consideration Related to Business
Combinations</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with Legacy Celularity&#8217;s
acquisition in 2017 of HLI Cellular Therapeutics, LLC and Anthrogenesis, the Company has agreed to pay future consideration to the sellers
upon the achievement of certain regulatory and commercial milestones. As a result, the Company recorded $<span id="xdx_90D_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HLICellularTherapeuticsLLCAndAnthrogenesisMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularitysMember_zO2zVmIlaPbl" title="Contingent consideration">1,413</span> and $<span id="xdx_904_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HLICellularTherapeuticsLLCAndAnthrogenesisMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularitysMember_zolUcu0OmSI9" title="Contingent consideration">1,606</span> as contingent
consideration as of December 31, 2024 and 2023, respectively. During 2023, the Company discontinued its unmodified NK cell and AML Cell
Therapy clinical trials subject to the contingent consideration agreement under the Anthrogenesis acquisition and, as a result, the fair
value of the contingent consideration obligation decreased significantly as of December 31, 2023. Due to the contingent nature of these
milestone and royalty payments, there is a high degree of judgment in the management estimates that determine the fair value of the contingent
consideration. See Note 4 for further discussion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Indemnification Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In the ordinary course of business,
the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect
to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement
claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors
and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise
by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required
to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs
as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities
related to such obligations in its consolidated financial statements as of December 31, 2024 or 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Agreement with Palantir Technologies Inc.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On May 5, 2021, Legacy Celularity
executed a Master Subscription Agreement (the &#8220;Palantir MSA&#8221;) with Palantir under which it agreed to pay $<span id="xdx_90D_ecustom--PaymentsForMasterSubscriptionAgreement_pn3n3_c20210505__20210505__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--TypeOfArrangementAxis__custom--MasterSubscriptionAgreementMember_zx0KAVOYOD46" title="Payments for master subscription agreement">40,000</span> over <span id="xdx_90E_ecustom--PaymentSubscriptionPeriod_dc_c20210505__20210505__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--TypeOfArrangementAxis__custom--MasterSubscriptionAgreementMember_zWtaR8iTPIqa" title="Payment subscription period">five
years</span> for access to Palantir&#8217;s Foundry platform along with certain professional services. The Company intended to utilize Palantir&#8217;s
Foundry platform to secure deeper insights into data obtained from the Company&#8217;s discovery and process development, as well as manufacturing
and biorepository operations. In January 2023, the Company ceased use of the software and provided a notice of dispute to Palantir on
the basis that the software had not performed as promised and that Palantir had failed to provide the Company with the professional services
necessary to successfully implement, integrate and enable the Foundry platform. As a result, in accordance with ASC 420, <i>Exit or Disposal
Costs</i>, during the quarter ended March 31, 2023, the Company recognized the remaining related cease-use costs liability estimated based
on the discounted future cash flows of contract payments for $<span id="xdx_900_eus-gaap--BusinessExitCosts1_pn3n3_c20230101__20230331__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--IncomeStatementLocationAxis__custom--SoftwareCeaseUseCostsMember_z1e8f410E072" title="Exit or disposal costs">24,402</span> which was included as software cease-use costs in the consolidated
statements of operations and comprehensive loss. On December 21, 2023, the Company entered into a settlement and release agreement with
Palantir (the &#8220;Palantir Settlement Agreement&#8221;), which was subsequently amended on January 10, 2024 and May 6, 2024, whereupon
the parties agreed that if the Company paid Palantir the settlement fees of $<span id="xdx_90E_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240110__20240110__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember_zaRZoMPdxI11" title="Agreed to pay settlement payment"><span id="xdx_908_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240506__20240506__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember_zR3lwXVXtcUa" title="Agreed to pay settlement payment">3,500</span></span>, less any amounts previously paid, and issued shares
as discussed in the <i>Arbitration Demand</i> section below no later than June 3, 2024, the parties would cease the arbitration and deem
the original Palantir MSA terminated. The Company made the required payments prior to June 3, 2024, and on June 4, 2024, the parties dismissed
all claims and counterclaims. Accordingly, at December 31, 2023, the Company reversed previously recognized costs in excess of the final
settlement amount. The Company had <span id="xdx_90F_ecustom--AccruedResearchAndDevelopmentSoftware_iI_dxL_c20241231_z8AyrJbCfvp1" title="Accrued research and development software::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2240">no</span></span> liability as of December 31, 2024 and a current liability of $<span id="xdx_906_ecustom--AccruedResearchAndDevelopmentSoftware_iI_pn3n3_c20231231_zt6oUP1d7sR8" title="Accrued research and development software">3,500</span> as of December 31, 2023, respectively,
for accrued R&amp;D software on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Sirion License Agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In December 2021, the Company
entered into a license agreement (&#8220;Sirion License&#8221;) with Sirion Biotech GmbH (&#8220;Sirion&#8221;). Under the Sirion License,
Sirion granted the Company a license related to patent rights and know-how associated with poloxamers (&#8220;Licensed Product&#8221;).
As part of the Sirion License, the Company paid Sirion $<span id="xdx_90A_ecustom--UpfrontFee_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zxjQOZJfa7Oh" title="Upfront fee">136</span> as an upfront fee, a $<span id="xdx_900_ecustom--AnnualMaintenanceFee_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zf23AZAPacRg" title="Annual maintenance fee">113</span> annual maintenance fee and may owe up to $<span id="xdx_90B_ecustom--ClinicalAndRegulatoryMilestones_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zIEPMjSvUaK3" title="Clinical and regulatory milestones">5,099</span>
related to clinical and regulatory milestones for each Licensed Product during the term. The Company also agreed to pay Sirion low-single
digit royalties on net sales on a Licensed Product-by-Licensed Product and country-by-country basis and until the later of: (i) expiration
of the last to expire valid claim of the patents covering such Licensed Product, and (ii) <span id="xdx_900_eus-gaap--LongtermPurchaseCommitmentPeriod_dtY_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zzsBGGpBl9Fa" title="License agreement period">10</span> years after first Commercial Sale of a Licensed
Product. In addition, the Sirion License is subject to termination rights including for termination for material breach and by the Company
for convenience upon <span id="xdx_90A_ecustom--LicenseAgreementNoticePeriod_dtD_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zb44zc04qRwi" title="License agreement period">30</span> days written notice. During the years ended December 31, 2024 and 2023, no milestones have been achieved and no
royalties have been earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Legal Proceedings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At each reporting date, the Company
evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions
of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such
legal proceedings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Civil Investigative Demand</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company received a Civil Investigative
Demand (the &#8220;Demand&#8221;) under the False Claims Act, 31 U.S.C. &#167; 3729, dated August 14, 2022, from the U.S. Attorney&#8217;s
Office for the Eastern District of Pennsylvania. The Demand requests documents and information relating to claims submitted to Medicare,
Medicaid, or other federal insurers for services or procedures involving injectable human tissue therapy products derived from amniotic
fluid or birth tissue and includes Interfyl, a biomaterials product. The Company is cooperating with the request and is engaged in an
ongoing dialogue with the Assistant U.S. Attorneys handling the Demand. The matter is still in preliminary stages and there is uncertainty
as to whether the Demand will result in any liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Arbitration Demand from Palantir Technologies Inc.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On April 20, 2023, Palantir commenced
an arbitration with JAMS Arbitration asserting claims for declaratory relief and breach of contract relating to the Palantir MSA, seeking
damages in an amount equal to the full value of the contract. The Company responded to the arbitration demand and asserted counterclaims
for breach of contract, breach of warranty, fraudulent inducement, violation of California&#8217;s Unfair Competition Law, amongst others,
in relation to the Palantir MSA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On December 21, 2023, the Company
and Palantir entered into the Palantir Settlement Agreement to resolve the JAMS Arbitration. The Palantir Settlement Agreement was subsequently
amended on January 10, 2024 and May 6, 2024. Both parties agreed to dismiss the arbitration proceeding and dispute and provide for mutual
releases upon the Company&#8217;s satisfaction of a settlement payment obligation. Through June 3, 2024, the Company made total settlement
payments of $<span id="xdx_90F_eus-gaap--PaymentsForLegalSettlements_pn5n6_c20231221__20240603__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_zALaKV4zO3D9" title="Settlement payment">3,500</span> and issued Palantir an aggregate of <span id="xdx_90C_ecustom--NumberOfSharesIssuedForPiggybackRegistrationRights_pid_c20231221__20240603__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_zc8MPuma22H3" title="Shares issued for piggyback registration rights">60,584</span> shares of the Company&#8217;s Class A common stock as consideration for
further amendments to the Palantir Settlement Agreement. On June 4, 2024, the parties dismissed all claims and counterclaims. The Palantir
MSA is now fully terminated and neither party has any further rights or obligations thereunder. The shares of the Company&#8217;s Class
A common stock issued to Palantir were issued with piggyback registration rights. Resale of such shares by Palantir shall be included
on any future registration statement filed by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>Celularity Inc. v. Evolution Biologyx, LLC, et
al.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On April 17, 2023, the
Company filed a complaint against Evolution Biologyx, LLC, Saleem S. Saab, individually, and Encyte, LLC (collectively,
&#8220;Evolution&#8221;) in the United States District Court for the District of New Jersey to recover unpaid invoice amounts for
the sale of its biomaterial products in the amount of approximately $<span id="xdx_90E_ecustom--SaleOfBiomaterialProductsAmount_pn3n3_c20230417__20230417__srt--LitigationCaseAxis__custom--EvolutionMember_zj67dzFHRaQl" title="Sale of biomaterial products amount">2,350</span>,
plus interest. In September 2021, the Company executed a distribution agreement with Evolution, whereupon Evolution purchased
biomaterial products from the Company for sale through Evolution&#8217;s distribution channels. The Company fulfilled
Evolution&#8217;s orders and otherwise performed each of its obligations under the distribution agreement. Despite attempts to
recover the outstanding invoices and Evolution&#8217;s promise to pay, Evolution has refused to pay any of the invoices and has
materially breached its obligations under the distribution agreement. The Company&#8217;s complaint asserts claims of breach of
contract and fraudulent inducement, amongst others. On April 4, 2024, Evolution filed a counter claim alleging damages in an amount
to be determined resulting from alleged breach of contract, breach of warranty, quasi contract and fraud. The Company believes
Evolution&#8217;s counter claims are without any merit, and the Company intends to vigorously pursue the matter to recover the outstanding
payments owed by Evolution, including interest and associated attorney&#8217;s fees, as well as defend against Evolution&#8217;s
counterclaims.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i>TargetCW v. Celularity Inc.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 27, 2024, WMBE Payrolling,
Inc., dba TCWGlobal, filed a complaint in the United States District Court for the Southern District of California alleging a breach
of contract and account stated claims relating to a Master Services Agreement dated May 4, 2020, or the TCWGlobal MSA, for the provision
of certain leased workers to perform services on the Company&#8217;s behalf. The complaint alleges that the Company breached the TCWGlobal
MSA by failing to make payments on certain invoices for the services of the leased workers. On May 7, 2024, the Company entered into
a settlement agreement and mutual release with TCWGlobal whereupon the Company agreed to pay $<span id="xdx_909_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240507__20240507__srt--LitigationCaseAxis__custom--EvolutionMember_z1PI9jEe0ge3">516</span>
in tiered monthly installments, with the last payment due and payable on May 1, 2025, in exchange for a dismissal of the complaint
and full release of all claims. The Company defaulted on the payments in November 2024. On April 21, 2025, the Company was served with a motion by
TCWGlobal to enforce the settlement and enter judgment against the Company in the amount of $<span id="xdx_900_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20250421__20250421__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znCxXqvPxlu9" title="Payments for legal settlements">350</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Hackensack Meridian v. Celularity Inc</i>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 27, 2025,
Hackensack Meridian Health (&#8220;HUMC&#8221;) filed a complaint in the Superior Court of New Jersey seeking $<span id="xdx_90C_eus-gaap--AffiliateCosts_pn3n3_c20250327__20250327__dei--LegalEntityAxis__custom--HackensackMeridianHealthMember_zRwEeSLzZ0O6" title="Affiliate costs">946</span>
allegedly owed by Celularity for costs associated with clinical trials. The amounts claimed were part of a three-party arrangement
with a contract research organization (CRO), which the Company engaged to make payments on behalf of the Company to HUMC. The
Company has asserted that it believes there are improper charges in the claim. The parties are attempting to agree on the actual
amounts owed by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1AgSkNrKyvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>13. <span id="xdx_82E_zpoHaW1MBjyf">Equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024 and 2023,
the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zzP46tktkF21" title="Common stock, shares authorized"><span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zngpxZf0Dl7h" title="Common stock, shares authorized">730,000,000</span></span> shares of $<span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zz2jOAbkxrR" title="Common stock, par value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zcBIpKkDLQUj" title="Common stock, par value">0.0001</span></span>
par value Class A common stock. As of December 31, 2024 and 2023, shares of Class A common stock issued and outstanding were <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zffNudoe2Wzc" title="Common stock shares issued"><span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zCc7uYAiYQk8" title="Common stock shares outstanding">22,546,671</span></span>
and <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zp3OXOlt9rih" title="Common stock shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zABHH19CG8Eh" title="Common stock shares outstanding">19,378,192</span></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Voting Power</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Except as otherwise required by
law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess
all voting power for the election of the Company&#8217;s directors and all other matters requiring stockholder action. Holders of <span id="xdx_908_eus-gaap--CommonStockVotingRights_c20240101__20241231_zOfJh576ymZ" title="Common stock, voting rights">common
stock are entitled to one vote per share</span> on matters to be voted on by stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Dividends</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Holders of Class A common stock
will be entitled to receive such dividends, if any, as may be declared from time to time by the Company&#8217;s board of directors in
its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock
be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Liquidation, Dissolution and Winding Up</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In the event of the Company&#8217;s
voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled
to receive an equal amount per share of all of the Company&#8217;s assets of whatever kind available for distribution to stockholders,
after the rights of the holders of the preferred stock have been satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Preemptive or Other Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s stockholders
have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Election of Directors</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s board of directors
is divided into three classes, Class I, Class II and Class III, with only one class of directors being elected in each year and each class
serving a three-year term, except with respect to the election of directors at the special meeting held in connection with the merger
with GX, Class I directors are elected to an initial one-year term (and three-year terms subsequently), the Class II directors are elected
to an initial two-year term (and three-year terms subsequently) and the Class III directors are elected to an initial three-year term
(and three-year terms subsequently). There is no cumulative voting with respect to the election of directors, with the result that the
holders of more than <span id="xdx_907_ecustom--PercentageOfSharesRequiredForVoting_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--RangeAxis__srt--MinimumMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_z7BtHAhb1u0g" title="Percentage of shares required for voting">50</span>% of the shares voted for the election of directors can elect all of the directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s Certificate
of Incorporation authorized <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zMPMSSRnujr" title="Preferred stock, shares authorized">10,000,000</span> shares of preferred stock and provides that shares of preferred stock may be issued from time to
time in one or more series. The Company&#8217;s board of directors is authorized to fix the voting rights, if any, designations, powers
and preferences, the relative, participating, optional or other special rights, and any qualifications, limitations and restrictions thereof,
applicable to the shares of each series of preferred stock. The Company&#8217;s board of directors is able to, without stockholder approval,
issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common
stock and could have anti-takeover effects. The ability of the Company&#8217;s board of directors to issue preferred stock without stockholder
approval could have the effect of delaying, deferring or preventing a change of control of Celularity or the removal of existing management.
As of December 31, 2024 and 2023, the Company did <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_zDOurdQhr3Q5" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20231231_zup0S26onVL8" title="Preferred stock, shares outstanding">no</span></span>t have any outstanding preferred stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>ATM Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On September 8, 2022, the Company
entered into an At-the-Market Sales Agreement (the &#8220;ATM Agreement&#8221;) with BTIG, LLC, Oppenheimer &amp; Co. Inc. and B. Riley
Securities, Inc., acting as sales agents and/or principals, pursuant to which the Company may offer and sell, from time to time in its
sole discretion, shares of its common stock, having an aggregate offering price of up to $<span id="xdx_909_ecustom--AggregateOfferingPrice_pn3n3_c20220908__20220908__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zD6ESkPAXEbk" title="Aggregate offering price">150,000</span>, subject to certain limitations as set
forth in the ATM Agreement. The Company is not obligated to make any sales of shares under the ATM Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Any shares offered and sold in
the at-the-market offering will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 and the related prospectus
supplement. Under the ATM Agreement, the sales agents may sell shares of common stock by any method permitted by law deemed to be an &#8220;at
the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act of 1933. The Company will pay the sales agents a commission
rate of up to <span id="xdx_905_ecustom--MaximumPercentageOfSalesCommissionFromGrossSalesProceeds_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_zdO9IkuS93f9" title="Sales agents commission rate">3.0</span>% of the gross sales proceeds of any shares sold and has agreed to provide the sales agents with customary indemnification,
contribution and reimbursement rights. The ATM Agreement contains customary representations and warranties and conditions to the placements
of the shares pursuant thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">During the year ended December
31, 2023, the Company received gross and net proceeds of $<span id="xdx_90C_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_z7Ifc1hiRyL4" title="Gross proceeds from issuance of common stock">141</span> and $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_z7mqmJ7afdyi" title="Net proceeds from sale of common stock">136</span>, respectively, from the sale of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zaR0ZLiUtpta" title="Purchase and sale of shares">13,296</span> shares of its common stock
at an average price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zIYKuW2yGU4i" title="Average price per share">10.60</span> per share under the ATM Agreement. No shares were issued under the ATM Agreement during the year ended December
31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>March 2023 PIPE</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 20, 2023, the Company
entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief Executive Officer, Dr. Robert
Hariri, providing for the private placement of (i) <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zK3ykL2gkUj8" title="Purchase and sale of shares">938,183</span> shares of its Class A common stock, and (ii) accompanying warrants to purchase
up to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230320__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoZcbsY43TCa" title="Warrants to purchase aggregate shares">938,183</span> shares of Class A common stock (the &#8220;March 2023 PIPE Warrants&#8221;), for $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230320__srt--RangeAxis__srt--MaximumMember_z5gfR1FtFkmf" title="Purchase price of per share">8.34</span> per share and $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230320__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z8TnFe7dODY7" title="Purchase price of per share">1.25</span> per accompanying
March 2023 PIPE Warrant, for an aggregate purchase price of $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zcVg0HpFPsg1" title="Proceeds from PIPE financings">9,000</span> (of which Dr. Hariri subscribed for $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zjfYZQdKVF46" title="Proceeds from PIPE financings">2,000</span>). The closing of the private
placement occurred on March 27, 2023. Each March 2023 PIPE Warrant had an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zsyIHdhlRZF3" title="Exercise price">30.00</span> per share, is immediately exercisable,
will expire on <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zfL3kXj8747e" title="Expiration dateity">March 27, 2028</span> (<span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zp35YvnYCo76" title="Term (years)">five years</span> from the date of issuance), and is subject to customary adjustments for certain transactions
affecting the Company&#8217;s capitalization. The March 2023 PIPE Warrants may not be exercised if the aggregate number of shares of Class
A common stock beneficially owned by the holder thereof (together with its affiliates) would exceed the specified percentage cap provided
therein (which may be adjusted upon <span id="xdx_900_ecustom--AdjustedAdvanceNoticePeriod_dtD_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zRVFHUCoz1Fh" title="Adjusted advance notice period">61</span> days advance notice) immediately after exercise thereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounted for the
March 2023 PIPE Warrants and common stock as a single non-arm&#8217;s length transaction. The Company applied the guidance for this transaction
in accordance with ASU 2020-06, <i>(Subtopic 470-20): Debt - Debt with Conversion and Other Options, ASC 815 Derivatives and Hedging,
</i>and <i>ASC 480 Distinguishing Liabilities from Equity</i>. Accordingly, the net proceeds were allocated between common stock and the
March 2023 PIPE warrants at their respective fair value, which resulted in a net premium of $<span id="xdx_90E_ecustom--PremiumPaidForPrivatePlacementPurchase_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zeezlJFGJPU3" title="Premium paid for private placement purchase">1,650</span> based on the difference between the
proceeds and fair value of the common stock and March 2023 PIPE warrants, which was recorded as additional paid-in capital within stockholders&#8217;
equity on the consolidated balance sheets. The fair value of the March 2023 PIPE Warrants was determined using a Black-Scholes option
pricing model and the common stock based on closing date share price. The Company evaluated the March 2023 PIPE warrants under ASC 815
and determined that they did not require liability classification and met the requirements for a derivative scope exception under ASC
815-10-15-74(a) for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity. The
warrants were recorded in additional paid-in capital within stockholders&#8217; equity on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On September 14, 2023, the Company
entered into a warrant amendment on the March 2023 PIPE Warrants with the unaffiliated investor to reduce the exercise price from $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230914__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zLCkFRXrdeu9" title="Purchase price of per share">30.00</span>
per share to $<span id="xdx_907_ecustom--ReducedExercisePrice_pid_c20230314__20230314__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zXSK6B6aw8cb" title="Reduced exercise price">10.00</span> per share for warrants to purchase <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230914__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z9RDuUMosfV5" title="Warrants to purchase aggregate shares">729,698</span> shares of Class A common stock. The warrant amendment was executed as consideration
for professional services rendered to the Company. As a result, the Company accounted for the transaction in accordance with ASC 718,
<i>Stock-Based Compensation,</i> and based on the calculated incremental fair value attributable to the modified warrant compared to the
original warrant immediately prior to the modification, recognized an expense of $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pn3n3_c20230101__20231231_zOy4dfKxKBn" title="Fair value of modified warrant, incremental expense">402</span> within selling, general and administrative on the
consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Registered Direct Offerings</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On April 10, 2023, the Company
closed on a registered direct offering of <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230410__20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zwUmyepiUhzc" title="Purchase and sale of shares">923,076</span> shares of its Class A common stock together with warrants (&#8220;Registered Direct
Warrants&#8221;) to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhkBnS8qbxIi" title="Warrants to purchase aggregate shares">923,076</span> shares of its Class A common stock at a combined purchase price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zztqIc7PO2hj" title="Purchase price of per share">6.50</span> per share and accompanying
warrant, resulting in total gross proceeds of approximately $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230410__20230410_zGluPZdW76k4" title="Proceeds from the exercise of warrants">6,000</span> before deducting placement agent commissions and other estimated offering
expenses. The Registered Direct Warrants had an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230410_z31MTntvPOoi" title="Exercise price">7.50</span>, became exercisable beginning six months after the date of issuance
and will expire <span id="xdx_90C_ecustom--WarrantExpirationTerm_pid_c20230410__20230410_zYXkG0vtmhAe" title="Warrant term">five years</span> thereafter. The Company used the $<span id="xdx_901_ecustom--DebtInstrumentPayment_pn3n3_c20230410__20230410_zPp8EQfAXuT4" title="Debt instrument payment">5,505</span> net proceeds from the offering to repay its obligations to Yorkville
under the PPA. The Company considered the appropriate accounting guidance and concluded that the Registered Direct Warrants qualified
for liability treatment, and therefore, recorded the warrant liability at fair value $<span id="xdx_907_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20230410_ztrGXk6yLaql" title="Fair value of the warrant liability">4,280</span> which was based on a Black-Scholes option
pricing model. The remainder of the net proceeds were allocated to the Class A common stock issued and recorded as a component of equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upon the closing of the registered
direct offering on April 10, 2023, the Company amended the existing May 2022 PIPE Warrants, to reduce the exercise price from $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220518__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zGrnJRVLD608" title="Shares issued price per share">82.50</span> to
$<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220518__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zCELkqsrdzHk" title="Shares issued price per share">7.50</span> per share and extended the expiration <span id="xdx_901_ecustom--AmendedTerminationDateDescription_c20230410__20230410__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember_zcTecCUbCKe7" title="Amended termination date description">date to five and one-half years following the closing of the offering</span> or October 10, 2028.
The modification resulted in the recognition of additional warrant liability of $<span id="xdx_90C_ecustom--AdditionalWarrantLiability_iI_pn3n3_c20230410_zGMsvzy7DaQ3" title="Additional warrant liability">1,389</span> based on the Black-Scholes option pricing model
as of the modification date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On July 31, 2023, the Company
closed on a registered direct offering of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230731__20230731_z97b5JcdWJjf" title="Purchase and sale of shares">857,142</span> shares of its Class A common stock together with warrants (&#8220;July 2023 Registered
Direct Warrants&#8221;) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230731__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zWcY2JCiJ0bf" title="Warrants to purchase aggregate shares">857,142</span> shares of its Class A common stock at a combined purchase price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230731__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zKJNpgRDRJ2c" title="Purchase price of per share">3.50</span> per share and
accompanying warrant, resulting in total gross proceeds of approximately $<span id="xdx_900_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230731__20230731_zX8t6hhn1Li6" title="Proceeds from the exercise of warrants">3,000</span> before deducting placement agent commissions and other
estimated offering expenses. The July 2023 Registered Direct Warrants have an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230731__srt--RangeAxis__srt--MinimumMember_zmmdIsfhFQxg" title="Exercise price">3.50</span>, will be exercisable beginning six
months after the date of issuance and will expire <span id="xdx_903_ecustom--WarrantExpirationTerm_c20230731__20230731_z07eBOkj6o1j" title="Warrant term">five years</span> thereafter. The Company used the $<span id="xdx_90F_ecustom--DebtInstrumentPayment_pn3n3_c20230731__20230731_ztBPn20dwIO6" title="Debt instrument payment">2,740</span> net proceeds for working capital
and general corporate purposes. The Company considered the appropriate accounting guidance and concluded that the July 2023 Registered
Direct Warrants qualified for liability treatment, and therefore, recorded the warrant liability at fair value $<span id="xdx_90B_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20230731_zl4YeRxKLODi" title="Fair value of the warrant liability">2,645</span> which was based
on a Black-Scholes option pricing model. The remainder of the net proceeds were allocated to the Class A common stock issued and recorded
as a component of equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the July 31,
2023 registered direct offering described above, the Company also entered into an amendment to certain existing warrants to purchase up
to an aggregate of <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230731__srt--RangeAxis__srt--MaximumMember_zMsM43C6hZdc" title="Warrants to purchase class A common stock">892,856</span> shares at an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230731_zbPoZKRZzIWj" title="Exercise price">7.50</span> (consisting of all the May 2022 PIPE Warrants and a portion of the Registered
Direct Warrants issued in April 2023), and such amended warrants have a reduced exercise price of $<span id="xdx_907_ecustom--ReducedExercisePrice_pid_c20230731__20230731_zmFbXSS0NRPb" title="Reduced exercise price">3.50</span> per share. As noted above, the
modification resulted in an increase to the warrant liability of $<span id="xdx_90A_ecustom--WarrantLiability_iI_pn3n3_c20230731_z6vCgBkY7lwh" title="Warrant liabilities">511</span> based on the Black-Scholes option pricing model as of the July 31,
2023 modification date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>May 2023 PIPE</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On May 18, 2023, the Company closed
on a securities purchase agreement with a group of accredited investors, providing for the private placement of an aggregate (i) <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230518__20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zB97X1Rtinuj" title="Purchase and sale of shares">581,394</span>
shares of its Class A common stock and (ii) accompanying warrants to purchase up to <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zKYoNmWrCRG" title="Warrants to purchase aggregate shares">581,394</span> shares of Class A common stock (the &#8220;May
2023 PIPE Warrants&#8221;), for $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zMwKBz0fhIQi" title="Purchase price of per share">5.20</span> per share and $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsZV7NXXM2sf" title="Purchase price of per share">1.25</span> per accompanying May 2023 PIPE Warrant, for an aggregate gross purchase price
of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230518__20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zOKEFWvqbl44" title="Proceeds from PIPE financings">3,750</span>. Each May 2023 PIPE Warrant has an exercise price of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zJVpUs9ia6ja" title="Exercise price">10.00</span> per share, is immediately exercisable, will expire on <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z9oF7VthUw6c" title="Warrants and rights outstanding, expire date">May 17, 2028</span>,
and is subject to customary adjustments for certain transactions affecting the Company&#8217;s capitalization. The May 2023 PIPE Warrants
may not be exercised if the aggregate number of shares of Class A common stock beneficially owned by the holder thereof (together with
its affiliates) would exceed the specified percentage cap provided therein (which may be adjusted upon <span id="xdx_904_ecustom--AdjustedAdvanceNoticePeriod_dtD_c20230518__20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zEwTiSCUUkNj" title="Adjusted advance notice period">61</span> days advance notice) immediately
after exercise thereof. The Company evaluated the May 2023 PIPE Warrants under ASC 815 and determined that they did not require liability
classification and met the requirements for a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed
to an entity&#8217;s own stock and classified in stockholders&#8217; equity. Accordingly, the proceeds were allocated between common stock
and the May 2023 PIPE Warrants at their respective relative fair value basis to stockholders&#8217; equity on the consolidated balance
sheets. The fair value of the May 2023 PIPE Warrants was determined using a Black-Scholes option pricing model and the common stock based
on the closing date share price and were recorded in additional paid-in capital within stockholders&#8217; equity on the consolidated
balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>January 2024 PIPE</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 12, 2024, the Company
entered into a securities purchase agreement with an existing investor, Dragasac Limited (&#8220;Dragasac&#8221;), providing for the private
placement of (i) <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240112__20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zVumiEmKFrIh" title="Purchase and sale of shares">2,141,098</span> shares of its Class A common stock, par value $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zfYMSMtMZoF" title="Common stock, par value">0.0001</span> per share, or the Class A common stock, and (ii) accompanying
warrants to purchase up to <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zv4Clk7iU4yk" title="Warrants to purchase aggregate shares">535,274</span> shares of Class A common stock (&#8220;January 2024 PIPE Warrant&#8221;), for $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zW64YVJ4iIu9" title="Exercise price">2.4898</span> per share and
$<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240112__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zxNERNQXYr16" title="Purchase price of per share">1.25</span> per accompanying January 2024 PIPE Warrant, for an aggregate purchase price of approximately $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20240112__20240112__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zr1UDANRGaKg" title="Aggregate purchase price">6,000</span>. The closing of the private
placement occurred on <span id="xdx_903_ecustom--WarrantsAndRightsIssuedClosingDate_c20240112__20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_znP3dpZ8rWg7" title="Warrants and rights issued closing date">January 16, 2024</span>. The securities were issued pursuant to an exemption from registration provided under Section 4(a)(2)
of the Securities Act and Regulation D promulgated thereunder. The offer and sale of the shares and January 2024 PIPE Warrant (including
the shares underlying the January 2024 PIPE Warrant) has not been registered under the Act or any state securities laws. The securities
may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Each January
2024 PIPE Warrant had an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zp56Yzz1qWqe" title="Exercise price">2.4898</span> per share, is immediately exercisable, and will expire on <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zgcjS8Aqm85d" title="Warrants and rights outstanding, expire date">January 16, 2029</span> (five<span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zsflcWEiRANd" style="display: none" title="Term (years)">5</span> years
from the date of issuance).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounted for the
January 2024 PIPE Warrant and common stock as a single non-arm&#8217;s length transaction recognized in equity. The Company applied the
guidance for this transaction in accordance with ASU 2020-06, <i>(Subtopic 470-20): Debt - Debt with Conversion and Other Options, ASC
815 Derivatives and Hedging, </i>and <i>ASC 480 Distinguishing Liabilities from Equity</i>. Accordingly, the net proceeds were allocated
between common stock and the January 2024 PIPE Warrant at their respective fair values, which resulted in proceeds of $<span id="xdx_90D_ecustom--ProceedsFromPrivatePlacements_pn3n3_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zdQkTf053Oti" title="Proceeds from private placements">909</span> allocated to
the January 2024 PIPE Warrant and the balance of the proceeds allocated to the common stock. The fair value of the January 2024 PIPE Warrant
was determined using a Black-Scholes option pricing model and the common stock based on closing date share price. The Company evaluated
the January 2024 PIPE warrant under ASC 815 and determined that it did not require liability classification and met the requirements for
a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed to an entity&#8217;s own stock and classified
in stockholders&#8217; equity. The warrants were recorded in additional paid-in capital within stockholders&#8217; equity on the consolidated
balance sheets. Also in connection with the January 2024 PIPE transaction, the Company repriced legacy warrants held by Dragasac to purchase
<span id="xdx_902_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_z8xcTaqW9Cc5" title="Number Of warrants repriced">652,981</span> shares of common stock with a previous exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_z305bCEZgp9i" title="Exercise price">67.70</span> per share to a new exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zM2WcHcid9tf" title="Exercise price">2.4898</span> per share. The modification
of warrants resulted in incremental fair value of $<span id="xdx_90A_ecustom--FairValueOfWarrantModificationIncrementalForEquityIssuanceCost_pn3n3_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zDX9Y1DZcBK6" title="Fair value of warrant modification">524</span>, which has been recognized as an equity issuance cost and had no net impact on
stockholders&#8217; equity as the warrants remain equity-classified after the modification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the execution
of the securities purchase agreement, the Company also entered into an investor rights agreement with Dragasac dated as of January 12,
2024. The investor rights agreement provides Dragasac certain information and audit rights, as well as registration rights with respect
to the shares (and shares underlying the January 2024 PIPE Warrant), including both the undertaking to file a registration statement within
45 days of filing of the 2023 Form 10-K, &#8220;piggyback&#8221; registration rights, as well as the right to request up to three demand
rights for underwritten offerings per year; in each case subject to customary &#8220;underwriter cutback&#8221; language as well as any
objections raised by the SEC to inclusion of securities. If the initial registration statement was not filed on or prior to May 15, 2024,
the investor rights agreement provides for partial liquidating damages equal to <span id="xdx_908_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--InvestorRightsAgreementMember__srt--CounterpartyNameAxis__custom--DragasacLimitedMember_zZajXYhPwtjc" title="Percentage of partial liquidating damages">1.0</span>% of the subscription amount each month, up to a maximum
of <span id="xdx_904_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--InvestorRightsAgreementMember__srt--CounterpartyNameAxis__custom--DragasacLimitedMember_zaMhrDSfYPJe" title="Percentage of partial liquidating damages">6.0</span>%, plus interest thereon accruing daily at a rate of <span id="xdx_90C_ecustom--DailyInterestAccruingRate_iI_pid_dp_uPure_c20240112_zbXo20ukgOSi" title="Daily interest accruing rate">18.0</span>% per annum. The Company began to accrue partial liquidating damages and
interest as of May 22, 2024. As a condition to closing, the Company entered into an amendment to an amended and restated distribution
and manufacturing agreement with an affiliate of Dragasac to add cell therapy products in clinical development, investigational stage
and/or in near-term commercial use to the list of products under the scope of the exclusive distribution and manufacturing licenses (including
unmodified natural killer cells (such as CYNK-001) for aging and other non-oncology indications, PSC-100, PDA-001, PDA-002, pEXO and APPL-001
for regenerative indications).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Effective February 16, 2024, in
order to comply with Section 4.15(a) of the securities purchase agreement, the Company entered into an amended employment agreement with
its Chief Administrative Officer (&#8220;CAO&#8221;), whereby the CAO agreed to decrease his base salary from $<span id="xdx_909_ecustom--RelatedPartyBaseSalary_pn3n3_c20240216__20240216__srt--TitleOfIndividualAxis__custom--ChiefAdministrativeOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--AmendedEmploymentAgreementMember_zbbHV3NbmJe7" title="Base salary">500</span> to $<span id="xdx_90E_ecustom--RelatedPartyBaseSalary_pn3n3_c20240216__20240216__srt--TitleOfIndividualAxis__custom--ChiefAdministrativeOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--AmendedEmploymentAgreementMember__srt--RangeAxis__srt--MinimumMember_zeV1eDFu5Akf" title="Base salary">425</span> per year through
December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Warrant Modifications</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On January 12, 2024, in connection
with the January 2024 PIPE, the Company agreed to amend the exercise price of legacy warrants held by Dragasac to purchase <span id="xdx_90E_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zFCusVhahAEd" title="Number of warrants repriced">652,981</span> shares
of common stock, which expired <span id="xdx_90A_ecustom--ClassOfWarrantOrRighstExpirationDate_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zWT8tw3Gisde" title="Warrant expiration date">March 16, 2025</span>, from $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zVYwpQnpNtl8" title="Exercise price">67.70</span> per share to $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zg8XKimAshxc" title="Exercise price">2.4898</span> per share. On January 24, 2025, the Company agreed to
reduce the exercise price of both the January 2024 PIPE Warrant and legacy warrants held by Dragasac from $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_z1poJw3q6s93" title="Exercise price">2.4898</span> per share to $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_z92lFZYHPcKl" title="Exercise price">2.07</span> per
share. See Warrants section below for additional information. On March 13, 2024, in connection with the RWI Forbearance Agreement (see
Note 10), the Company agreed to issue RWI a warrant to acquire up to <span id="xdx_908_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSKeJ2LN7H21" title="Number of warrants repriced">300,000</span> shares of common stock, which expires <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240313__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrNMxVQS955" title="Warrants and rights outstanding, expire date">June 20, 2028</span> and has
an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_z5Sjbby3oO6k" title="Exercise price">5.895</span> per share. Additionally, on March 13, 2024, in connection with the Starr Forbearance Agreement (see Note 10),
the Company agreed to amend the exercise price of the <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zZZJdsMCtTSc" title="Warrants to purchase aggregate shares">75,000</span> March 2023 Loan Warrants expiring <span id="xdx_90B_ecustom--ClassOfWarrantOrRighstExpirationDate_c20240313__20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zobszqjG8aF" title="Warrant expiration date">March 17, 2028</span> from $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240312__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zqGvLWEpkxZd" title="Exercise price">7.10</span> per share to
$<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zIfevTWfKf7a" title="Exercise price">5.895</span> per share (the &#8220;Minimum Price&#8221; as determined pursuant to Nasdaq 5635(d) on March 13, 2024) and the <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_z1LcfNkglVZf" title="Warrants to purchase aggregate shares">50,000</span> June 2023
Warrants expiring <span id="xdx_90F_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zvxc5pNAp7Ef" title="Warrant expiration date">June 20, 2028</span> from $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zb7tOaqwWeZ5" title="Exercise price">8.10</span> per share to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zE8mefiFdKR" title="Exercise price">5.895</span> per share, each of which are held by C.V. Starr.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Standby Equity Purchase Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On March 13, 2024, the Company
and Yorkville entered into a SEPA. Under the SEPA, the Company has the right to sell to Yorkville up to $<span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zHm3cP8anGna" title="Common stock, shares authorized">10,000</span> of its Class A common
stock, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zIiDz8rMAhFh" title="Common stock, par value">0.0001</span> per share subject to certain limitations and conditions set forth in the SEPA, from time to time, over a 36-month
period. Sales of the common stock to Yorkville under the SEPA, and the timing of any such sales, are at the Company&#8217;s option, and
the Company is under no obligation to sell any shares of common stock to Yorkville under the SEPA except in connection with notices that
may be submitted by Yorkville, in certain circumstances as described below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upon the satisfaction of the conditions
precedent in the SEPA, which include having a resale shelf for shares of common stock issued to Yorkville declared effective, the Company
has the right to direct Yorkville to purchase a specified number of shares of common stock by delivering written notice (&#8220;Advance&#8221;).
An Advance may not exceed <span id="xdx_909_ecustom--SaleOfStockMaximumAverageDailyTradedAmountPercentage_iI_dp_uPure_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_z3CINtoAGEK7" title="Sale of stock, maximum average daily traded amount (in percent)">100</span>% of the average of the daily trading volume of the common stock on Nasdaq, during the <span id="xdx_907_ecustom--SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays_pid_dc_uInteger_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zAxLxSh7pZVe" title="Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days">five</span> consecutive trading
days immediately preceding the written notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Yorkville will generally purchase
shares pursuant to an Advance at a price per share equal to <span id="xdx_905_ecustom--SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice_iI_dp_uPure_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zqXzvyuHVZP7" title="Sale of stock, percentage based on volume weighted average price">97</span>% of the VWAP, on Nasdaq during the three consecutive trading days commencing
on the date of the delivery of the written notice (unless the Company specifies a minimum acceptable price or there is no VWAP on the
subject trading day).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The SEPA will automatically terminate
on the earliest to occur of (i) the first day of the month next following the 36-month anniversary of the date of the SEPA or (ii) the
date on which Yorkville shall have made payment for shares of common stock equal to $<span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zPqKiPWctZOj" title="Consideration shares of common stock">10,000</span>. The Company has the right to terminate the
SEPA at no cost or penalty upon five trading days&#8217; prior written notice to Yorkville, provided that there are no outstanding advances
for which shares of common stock need to be issued and the Yorkville convertible promissory note (the &#8220;Initial Advance&#8221;) (see
Note 10) has been paid in full. The Company and Yorkville may also agree to terminate the SEPA by mutual written consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As consideration for Yorkville&#8217;s
commitment to purchase the shares of common stock pursuant to the SEPA, the Company paid Yorkville a $<span id="xdx_908_ecustom--SaleOfStockConsiderationCashDueDiligenceFee_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zIqR9onD240h" title="Cash due diligence fee">25</span> cash due diligence fee and a
commitment fee equal to <span id="xdx_90B_ecustom--SaleOfStockConsiderationCommitmentFeeInShares_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zBJBNQUMgIqh" title="Commitment fee in shares">16,964</span> shares of common stock. The Company recorded direct issuance costs of $<span id="xdx_901_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zYf40Wn1Nbkd" title="Payments of stock issuance costs">125</span> inclusive of the commitment
shares as other expense in the consolidated statements of operations and other comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the entry into
the SEPA, on March 13, 2024, the Company entered into a registration rights agreement with Yorkville, pursuant to which the Company agreed
to file with the SEC no later than May 3, 2024, a registration statement for the resale by Yorkville of the shares of common stock issued
under the SEPA (including the commitment fee shares). The Company agreed to use commercially reasonable efforts to have such registration
statement declared effective within 45 days of such filing and to maintain the effectiveness of such registration statement during the
36-month commitment period. The Company will not have the ability to request any Advances under the SEPA (nor may Yorkville convert the
Initial Advance into common stock) until such resale registration statement is declared effective by the SEC. The Company has not yet
filed a registration statement with the SEC for the resale by Yorkville of the shares of common stock issued under the SEPA, which is
deemed an event of default under the SEPA and as a result, the interest rate on the on the Yorkville convertible promissory note (see
Note 10) increased to <span id="xdx_908_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zENZycd17X28" title="Line of credit percentage">18.0</span>%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company determined that the
SEPA should be accounted for as a derivative measured at fair value, with changes in the fair value recognized in earnings. Because the
Company has not yet filed a registration statement and no shares can currently be issued under the SEPA, the SEPA is deemed to have no
value as of the issuance date and as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, the Company
had outstanding warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z5BOd94ACYgc" title="Warrants to purchase aggregate shares">11,221,557</span> shares of Class A common stock. A summary of the warrants is as follows:</p>

<p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zqDAMexY9Ui5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;<span id="xdx_8B8_zKad2K7DCD7" style="display: none">Summary of the Warrants</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>shares</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>price</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Expiration</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>date</b></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left">Dragasac Warrants (1) (4)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____z0ajEyNc7Gri" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of shares">652,981</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____z8rfYtZnGm0c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise price">2.4898</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____zinEqo0yyrj2" title="Expiration date">March 16, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Public Warrants (2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zD7zdoffSM62" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">1,437,447</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zB5PsoNJXGE8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">115.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zbLI7oxrz5Ye" title="Expiration date">July 16, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sponsor Warrants (2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zOETGiKL24Af" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">849,999</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zG7kLfJ7pqBa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">115.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zw7uGCgnGvxd" title="Expiration date">July 16, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">May 2022 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zNBLwgk4u2M6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">405,405</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zYnIQ2JKWm62" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">3.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_z9aJUtHsiila" title="Expiration date">October 10, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">March 2023 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zUxz96duCA9h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">208,485</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zrAr8lT7pT7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">30.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zbMTTbD0VWKc" title="Expiration date">March 27, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">March 2023 PIPE Warrants (modified)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zP7VnzVPnA1g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">729,698</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zB4FeFTE49ka" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zTinxyaSs7C4" title="Expiration date">March 27, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">March 2023 Loan Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_znGDbJamzLb2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">75,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_zuYOPZJcdbu5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">5.8950</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_z8mn0HGHCDu2" title="Expiration date">March 17, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">April 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKOrvgR95rk7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">435,625</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_z5ana1gABy3f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">7.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zJKCZ8wAHof9" title="Expiration date">October 10, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">April 2023 Registered Direct Warrants (modified)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zq37NcuNL3a8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">487,451</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zDignA4wcAh9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">3.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_z3dbEpyhwLI5" title="Expiration date">October 10, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">May 2023 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zI4rOAiVvCij" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">581,394</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zvM8PcQRmBAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zd5RNva34Wxe" title="Expiration date">May 17, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">June 2023 Warrants (3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zeCpcQOTjk6f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zdMvnGprRZpf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">5.8950</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zBVhMP3jdaTi" title="Expiration date">June 20, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">June 2023 Loan Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zQQc2iOSUeJ9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">300,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_z77BMZWgNc9f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">8.10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_ztf6Zdk7HOP3" title="Expiration date">June 20, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">July 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zFxWian5umj6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">857,142</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zhUxE7E1J034" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">3.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKAC9gfv4dya" title="Expiration date">January 31, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">January 2024 PIPE Warrants (4)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_zyfcgBb1FFFj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">535,274</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_z5X4MytO6C6g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.4898</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_zu80bN8I5Ofk" title="Expiration date">January 16, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">January 2024 Bridge Loan - Tranche #1 Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zE6EeyOX72B" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">1,650,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zXUvDttoFB0b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.4898</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_z7usxMXNNxQg" title="Expiration date">January 16, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">January 2024 Bridge Loan - Tranche #2 Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zOZ7yCW1h3Tg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">1,350,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zqSWqzySTfn6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.9880</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zgQ38ONYpxVg" title="Expiration date">July 15, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">March 2024 RWI Forbearance Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_ziSrMKBgY6n6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">300,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zYFg60Zj7Nq" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">5.8958</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zz6eqvfyOVsk" title="Expiration date">June 20, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">November 2024 Purchaser Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember_zaMPNsvijBw9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">263,156</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember_zlIGAKCCmTri" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.85</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember__srt--RangeAxis__srt--MinimumMember_zemQZleBalsi" title="Expiration date">November 25, 2029</span> - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember__srt--RangeAxis__srt--MaximumMember_zFdB8Lo57Zge" title="Expiration date">December 3, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">November 2024 Placement Agent Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_ztFSS2vs3ty9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">52,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zFUgq2fTDmKl" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Exercise price">3.56</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_z9H1KcEEjrv1" title="Expiration date">November 25, 2029</span> - <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_z6Q7qsYVDzna" title="Expiration date">December 3, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zmqvCnSL8DGb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">11,221,557</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td id="xdx_F01_zaUWrq4ZJf36" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zU7ufP8Z2xui" style="font-size: 10pt">In connection with the execution of the January 2024 PIPE described above, the Company agreed to reprice <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_z0CxQy6hgMJh" title="Number of warrants repriced">652,981</span> legacy warrants held by Dragasac with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zJ7gS6haRbBc" title="Exercise price per share or per unit of warrants or rights outstanding">67.70</span> to a new exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zYVzxB4PfIah" title="Exercise price">2.4898</span>. The term of the warrants was unchanged.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F02_zpkmujJUSn29" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zsXTc6rGNjph" style="font-size: 10pt">The number of Public Warrants
and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_zHSrw9l6fBM" title="Warrants outstanding">14,374,478</span> Public Warrants and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zhb8lpf7vX1c" title="Warrants outstanding">8,499,999</span> Sponsor
Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant
is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfdpdBsJpoed" title="Exercise per share price (in Dollars per share)">115.00</span> as a result
of the split.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F07_zYFMOuFpTkL1" style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zmEyC4kJiPda" style="font-size: 10pt">In connection with the execution
of the Starr Forbearance Agreement on March 13, 2024, described above under Warrant Modification and further in Note 10, the Company
agreed to reprice <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zNKnX4iQB39l" title="Number of warrants repriced">75,000</span> warrants with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zB4Cdrckei1h" title="Exercise price">7.10</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zGIhzk4KHX5l" title="Number of warrants repriced">50,000</span> warrants with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313_ztdMSGu7CCBf" title="Exercise price">8.10</span>
held by C.V. Starr to a new exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zYKfrX5dCT29" title="Exercise price">5.895</span>. The term of the warrants was unchanged.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F04_zDR8Xy7PCx4h" style="font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zWd9mgsl4eQl" style="font-size: 10pt">On January 24, 2025, the
Company agreed to reduce the exercise price of the Dragasac warrants and the January 2024 PIPE warrants from $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zDOZqY4vlhF5" title="Exercise price">2.49</span> per share to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zfw8z5NDCiqh" title="Exercise price">2.07</span>
per share. As a result of the price reduction, the holder agreed to immediately exercise the warrants in full and to purchase an aggregate
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zs0kpvh31E5b" title="Aggregate shares">1,188,255</span> shares of the Company&#8217;s Class A common stock for gross proceeds to the Company of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250124__20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJKjoIgtMeje" title="Proceeds from the exercise of warrants">2.5</span> million<i>.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z0NGXDvd3URc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>14. <span id="xdx_822_zWTRJlARrpBc">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>2021 Equity Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In July 2021, the Company&#8217;s
board of directors adopted, and the Company&#8217;s stockholders approved the 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;).
The 2021 Plan provides for the grant of incentive stock options (&#8220;ISOs&#8221;) to employees and for the grant of nonstatutory stock
options (&#8220;NSOs&#8221;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and
other forms of stock awards to employees, directors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The number of shares of Class
A Common Stock initially reserved for issuance under the 2021 Plan is <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20210731__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQtlAGgt2VK4">2,091,528</span>.
As of December 31, 2024, <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zc3pCPWh7Mqh">330,391
</span>shares were reserved for issuance and those shares remain available for future grant under the 2021 Plan. The number of shares
reserved for issuance will automatically increase on January 1 of each year, for a period of <span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zmA2bGuNGDeb">10
</span>years, from January 1, 2022 through January 1, 2031, by <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zjF5fDVKnRdf">4.0</span>%
of the total number of shares of Celularity common stock outstanding on December 31 of the preceding calendar year, or a lesser number
of shares as may be determined by the Company&#8217;s board of directors. On January 1, 2025, the number of shares reserved for issuance
increased to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250101__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyZH2dar6LRj" title="Number of shares reserved for issuance">1,229,890</span> and those shares remain available for future grant under the 2021 Plan. The shares added to the 2021 Plan on
January 1, 2025, remain subject to an effective registration statement on Form S-8. Shares subject to stock awards granted under the
2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce
the number of shares available for issuance under the 2021 Plan. Additionally, shares issued pursuant to stock awards under the 2021
Plan that are repurchased or forfeited, as well as shares that are reacquired as consideration for the exercise or purchase price of
a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2021
Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The 2021 Plan is administered
by the Company&#8217;s board of directors. The Company&#8217;s board of directors, or a duly authorized committee thereof, may delegate
to one or more officers the authority to (i) designate employees other than officers to receive specified stock awards and (ii) determine
the number of shares to be subject to such stock awards. Subject to the terms of the 2021 Plan, the plan administrator has the authority
to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any, the number of shares
subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together with any vesting
acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms and conditions of
the award agreements for use under the 2021 Plan. The plan administrator has the power to modify outstanding awards under the 2021 Plan.
Subject to the terms of the 2021 Plan and in connection with a corporate transaction or capitalization adjustment, the plan administrator
may not reprice or cancel and regrant any award at a lower exercise price, strike price or purchase price or cancel any award with an
exercise price, strike price or purchase price in exchange for cash, property or other awards without first obtaining the approval of
the Company&#8217;s stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>2017 Equity Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The 2017 Equity Incentive Plan
(the &#8220;2017 Plan&#8221;) adopted by Legacy Celularity&#8217;s board of directors and approved by Legacy Celularity&#8217;s stockholders
provided for Legacy Celularity to grant stock options to employees, directors and consultants of Legacy Celularity. In connection with
the closing of the merger and effectiveness of the 2021 Plan, no further grants were made under the 2017 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The total number of stock options
that could have been issued under the 2017 Plan was <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember_ziF5CSSxU6q4" title="Number of shares remaining available for future grant">3,234,204</span>. Shares that expired, forfeited, canceled or otherwise terminated without
having been fully exercised were available for future grant under the 2017 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The 2017 Plan is
administered by the Company&#8217;s board of directors or, at the discretion of the Company&#8217;s board of directors, by a
committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of Legacy
Celularity&#8217;s board of directors, or its committee if so delegated, except that the exercise price per share of stock options
could not be less than <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember_z5Eb2iTmkd29" title="Percentage of fair market value">100</span>%
of the fair market value of the share of common stock on the date of grant and the term of stock option could not be greater than <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zbP0wfLWFZGl" title="Stock option, expiration period">ten
years</span>. Stock options granted to employees, officers, members of the board of directors and consultants typically vested over
a three<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zKNd1ARCEp5b" style="display: none">3</span> or four<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zbhMpSrZRHX2" style="display: none" title="Options vesting period">4</span>
year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Stock Option Valuation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span style="text-decoration: underline">Awards with Service Conditions</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of each option
is estimated on the date of grant using a Black-Scholes option pricing model that takes into account inputs such as the exercise price,
the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest
rate, and dividend yield. The fair value of each grant of stock options was determined by the Company using the methods and assumptions
discussed below. Certain of these inputs are subjective and generally require judgment to determine.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"><span style="font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The expected term of employee stock options with service-based vesting is determined using the &#8220;simplified&#8221; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#8217;s lack of sufficient historical data. The expected term of non-employee options is equal to the contractual term or its estimated term based on the underlying agreement.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The expected stock price
volatility is based on historical volatilities of comparable public entities within the Company&#8217;s industry.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-size: 10pt"></span>&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The risk-free interest rate
is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with
the respective expected term or contractual term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">The expected dividend yield
is <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dpxL_uPure_c20240101__20241231_zw9j1ThKW2Z1" title="Expected dividend yield::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl2668">0</span></span>% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common
stock.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zHSi7VNtimMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents,
on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of
stock options granted during the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zYZqiUnPXdY6" style="display: none">Schedule
of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_z2potn9roIG5" title="Risk-free interest rate">4.4</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zHl1CZ2pHpVh" title="Risk-free interest rate">4.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zkwd3rGxq8T2" title="Expected term (in years)">5.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_z9cm5bOa8hn7" title="Expected term (in years)">5.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_z4S89HLms7e6" title="Expected volatility">104.9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zAbmS7zcuBj2" title="Expected volatility">86.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zplEkoymBS58" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl2684">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zbEOdeV1aY8b" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl2686">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A1_zadLJXErc7ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The weighted average grant-date
fair value per share of stock options granted during the years ended December 31, 2024 and 2023 was $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zWZaSb40nqD" title="Weighted average grant-date fair value of stock options granted">2.66</span> and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_z8rsPSk2yGY8" title="Weighted average grant-date fair value of stock options granted">5.35</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zbJRYdYPlJFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table summarizes
option activity with service conditions under the 2021 Plan and the 2017 Plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zG2i2ti5NyG7" style="display: none">Schedule of Stock Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Options</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Exercise Price</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Contract Term</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>(years)</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Intrinsic</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Value</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Outstanding at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zF3IYl6nrHu7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options beginning balance">2,820,187</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zoyox20ifwRb" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, beginning balance">40.16</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zXdRJbXwnUFh" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Contract Term">5.6</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zCES6e24mm3i" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2700">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zHBRRWhxZNU8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Granted">1,503,394</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z9wP3RaRS9J7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted">3.26</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zM79G07533W7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Exercised">(20,744</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zJMc6pjrZmz2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised">2.80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Forfeited/Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zEN22apL8W43" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options  Forfeited/Expired">(341,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zGwGKKQKXEGa" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited/Expired">29.51</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding at December 31, 2024*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____ziiElOR6ieD1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options ending balance">3,961,525</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zCXYjC5bYQ96" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, ending balance">27.27</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zzU2IuFCZSPi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Contract Term">6.4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____z2g25bNo2c86" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value">16</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vested and expected to vest at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z4DWpWCjrpp6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Vested and expected to vest">3,961,525</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z6uGximBcL7e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Vested and expected to vest">27.27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zG1uF8gKqDjb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Contract Term, Vested and expected to vest">6.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zwzPVArM19v2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Vested and expected to vest">16</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercisable at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zueTC5c1bAi9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Exercisable">2,586,561</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zI8ItzR1OnB8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable">37.49</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zku2lDcJSgTg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Contract Term Exercisable">4.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zUGFYOScdgS" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2736">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0F_zB4AoTlKrtr2" style="width: 15pt; text-align: right">*</td><td id="xdx_F1D_zLXerFXny1Wc" style="text-align: justify">Options outstanding at December 31, 2024 under the 2021 Plan and 2017 Plan were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zJXOtNTlcnPg" title="Options outstanding">2,569,029</span> and
                                                                             <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zBXUGuFGvff8" title="Options outstanding">1,437,496</span>, respectively. Options outstanding at December 31, 2024 under the 2021 Plan include <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_z1vLdctHuub8" title="Options outstanding including awards">45,000</span> awards with performance
                                                                             conditions (see below).</td>
</tr></table>

<p id="xdx_8A9_zbWkmUhL99Bl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The aggregate intrinsic value
of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#8217;s Class
A common stock for those options that had exercise prices lower than the fair value of Class A common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recorded stock-based
compensation expense relating to option awards with service conditions of $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVoTZaTbQlz9" title="Stock-based compensation expense">8,336</span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAidfgl5l4R3" title="Stock-based compensation expense">9,293</span> for the years ended December 31, 2024 and
2023, respectively. During the years ended December 31, 2024 and 2023, the aggregate intrinsic value was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20240101__20241231_z2qlZRNPNFm8" title="Aggregate intrinsic value, stock option exercised">8</span> and $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20230101__20231231_ziIVqEioo094" title="Aggregate intrinsic value, stock option exercised">0</span>, respectively, for
the stock options exercised. As of December 31, 2024, unrecognized compensation cost for options issued with service conditions was $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr5a2gDZWsub" title="Unrecognized compensation cost for options issued">7,129</span>
and will be recognized over an estimated weighted-average amortization period of <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmasEAcJvBre" title="Estimated weighted-average amortization period">2.09</span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><i><span style="text-decoration: underline">Awards with Performance Conditions</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In connection with the advisory
agreement signed with Robin L. Smith, MD (see Note 20), the Company awarded options under the 2021 Plan to acquire a total of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zDU1UinCtXA9" title="Vested options to acquire shares">105,000
</span>shares with an exercise price of $<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_ztfIXeIU6hld" title="Vested options to acquire per share">29.90
</span>to Dr. Smith, a former member of the Company&#8217;s board of directors. The initial tranche of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember__us-gaap--VestingAxis__custom--InitialTrancheMember_zXZvvIfxBOu1" title="Vested options to acquire shares">25,000
</span>stock options vested upon execution of the advisory agreement on August 16, 2022. The remaining <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zPEeCOAp7SR2" title="Stock option vesting">80,000
</span>stock options are subject to vesting upon achievement of certain predefined milestones in relation to the expansion of the degenerative
disease business. On November 1, 2022, the second tranche of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20221101__20221101__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember__us-gaap--VestingAxis__custom--SecondTrancheMember_zHNDKY5vzIG7" title="Vested options to acquire shares">20,000
</span>stock options vested upon achievement of the first milestone. The fair value of the award was determined based on a Black-Scholes
option-pricing model. The Company&#8217;s grant date fair value assumptions were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221101__20221101__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zfDLt0ldrHIc" title="Expected volatility">79.9</span>%
expected volatility, <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_z4qecaMATcBh" title="Risk-free interest rate">2.95</span>%
risk-free interest rate, five<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zstFfh2JjH52" style="display: none" title="Expected term (in years)">5</span>-year
expected term, and <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zJNQsvrJPNX7" title="Expected dividend yield">0</span>%
expected dividend yield. The remaining <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230816__20230816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zVJoatRXjjz4" title="Remaining stock options forfeited upon termination of the advisory agreement">60,000
</span>stock options were forfeited on August 16, 2023 upon termination of the advisory agreement. There were no milestones achieved
or probable of being achieved and accordingly there was <span id="xdx_901_eus-gaap--ShareBasedCompensation_do_c20230101__20231231_zcCv8Tx1Slq6" title="Stock based compensation">no</span> stock-based compensation expense recorded during the year ended December 31,
2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Restricted Stock Units</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company issues restricted
stock units (&#8220;RSUs&#8221;) to employees that generally vest over a four<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDcQ3FA3Ugv4" style="display: none">4</span>-year
period, with <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zXzUpGs5YaOf" title="Vesting percentage">25</span>%
vesting on the anniversary of the grant date, and the remainder vesting in equal annual installments thereafter so that the RSUs are
vested in full on the four-year anniversary of the grant date. At times, the board of directors may approve exceptions to the standard
RSU vesting terms. Any unvested shares will be forfeited upon termination of services. The fair value of an RSU is equal to the fair
market value price of the Company&#8217;s common stock on the date of grant. RSU expense is amortized straight-line over the vesting
period. There are no RSUs outstanding under the 2017 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zqTyDgwas09a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table summarizes
activity related to RSU stock-based payment awards under the 2021 Plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BC_zSXrC3ysNlUj" style="display: none">Schedule
of Activity Related to RSU Stock-Based Payment Awards</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Number of</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Shares</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Grant Date Fair Value</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Outstanding at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNALfbpj75qb" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of Shares, Outstanding beginning balance">823,332</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zytdOBicjFqk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value,Outstanding beginning balance">13.77</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPpuztLsUrMk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted">337,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqSxsnwAFd6a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted">2.23</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Released</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb9ccMxJtKmc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Released">(400,996</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaMY8zj0UKFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Released">11.58</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXrulQsvRS1b" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited">(99,977</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z09oFjThdPM6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">13.24</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTMssxfDjrkd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Outstanding ending balance">659,439</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfIVN9J5UJud" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding ending balance">9.29</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zkivrNzpp2f4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recorded stock-based
compensation expense of $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGMsTsOX3Re6" title="Stock-based compensation expense">3,022</span> and $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgxjToMJNQFi" title="Stock-based compensation expense">5,724</span> for the years ended December 31, 2024 and 2023, respectively, related to RSUs. As of December
31, 2024, the total unrecognized expense related to all RSUs was $<span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2Jw3T2Wx3s7" title="Stock-based compensation expense">4,136</span>, which the Company expects to recognize over a weighted-average
period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zO7nJ4XsE9y8" title="Estimated weighted-average amortization period">1.44</span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Stock Units with Market Condition Vesting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In July 2023, the Company granted
<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zGQAA9vfK7gg" title="Number of shares granted">174,500
</span>market condition stock unit awards (&#8220;MCUs&#8221;) under the 2021 Plan to certain members of management. The awards are scheduled
to vest over a period of one<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember__srt--RangeAxis__srt--MinimumMember_zcNthJVudLQf" style="display: none">1</span>
to three<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember__srt--RangeAxis__srt--MaximumMember_zdiw7pywvJMd" style="display: none">3</span>
years from the grant date based on continuous employment and specified market conditions based on the Company&#8217;s stock price
at the time of vest. As of December 31, 2024, <span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zXY3Uc9m9Gs5">145,833
</span>of the MCUs were forfeited as a result of the participant&#8217;s termination of continuous service. Stock-based compensation
expense for the remaining <span id="xdx_90A_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zGZS0NtUWivf">28,667
</span>MCUs is being recognized over the requisite service period based on the award&#8217;s fair value on the grant date, which was
determined based on the Company&#8217;s closing stock price on the date of grant of $<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_z1eHeYU75zlh" title="Grant date fair value of units granted">5.00</span>,
further discounted to reflect the effects of the market condition of the award. The Company recorded stock-based compensation expense
relating to MCUs of $<span id="xdx_90D_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_z5dzjiq4qnAk" title="Stock based compensation expense">211
</span>for the year ended December 31, 2024. Stock-based compensation expense relating to MCUs for the year ended December 31, 2023 was
de minimis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Stock-Based Compensation Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zFenUch6J8Pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recorded stock-based
compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_zGrfAobJxpB1" style="display: none">Schedule
of Stock-based Compensation Expense</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zpCCS3OARQOk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zlS3CHNW0iY7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zBJyVCyCdy3a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Cost of revenues</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">450</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">580</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4xEVC9YXIW4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,287</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,832</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zdpAFtrQkOKi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,832</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,605</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z5JTi4sY6kU1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">11,569</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15,017</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zNA8pyrQr0Sb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_800_eus-gaap--RevenueFromContractWithCustomerTextBlock_z9mChV1hdOsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>15. <span id="xdx_82D_zCp4DW6FVf7b">Revenue Recognition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_zROoRw6VM9Xh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table provides information
about disaggregated revenue by product and services:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zt6RnZ0QmU8g" style="display: none">Schedule
of Disaggregated Revenue by Product and Services</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zdrQC8CKc5xl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zLt4mVa3r0qe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zEW9OaK2KmO9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Product sales, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">35,336</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">13,149</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zCj0kf6Hgt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,140</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,441</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_zH04zl1TXRIh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">License, royalty and other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,744</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,181</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zPX4N7a5iaJl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">54,220</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,771</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zHlJ8wyJqCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Net revenues include: (i) sales
of biomaterial products, including Biovance, Biovance 3L, Rebound, Interfyl, and CentaFlex, of which our direct sales are included in
Product Sales while sales through our network of distribution partners are included in License, royalty and other; and (ii) the collection,
processing and storage of umbilical cord and placental blood and tissue after full-term pregnancies, collectively, Services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p id="xdx_891_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zxrUfkApAj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table provides changes
in deferred revenue from contract liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span id="xdx_8B0_z6sEHbgyCuyb" style="display: none">Schedule of Changes in Deferred Revenue from Contract Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zgcH59FHu7Hf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_z0aJk7FE0jFl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zpdE3pR8daW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Balance at January 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">6,020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4,492</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zKWnLp2hTeXe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Beginning Balance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,020</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,492</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_pn3n3_z9cqP8P7KSz8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Deferral of revenue <span id="xdx_F44_zlYoFHsrAbjb">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,731</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,266</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn3n3_zIryK7iBJilg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Recognition of unearned revenue <span id="xdx_F49_z9a1Na1pz1L">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,496</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,738</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zchUp2VJK0P9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,255</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zRUhVhWBte6d" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Ending Balance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,255</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zR7xVvRdZReb" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zvoy2DxJ072b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferral
    of revenue includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DeferredRevenue_iI_pn3n3_c20241231_zbtl13DKTSt6">5,061</span> in 2024 resulting from payments received in advance of performance under the biobanking services storage
    contracts that are recognized as revenue under the contract as performance is completed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F00_z2KygN5bQh7d" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zil4UEkHihvf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition
    of unearned revenue includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_ecustom--UnearnedRevenue_iI_pn3n3_c20241231_zQdD2DbYPnl6">2,561</span> that was included in the beginning deferred revenue balance at January 1, 2024.</span></td></tr>
  </table>
<p id="xdx_8AA_zBrwprJACCh5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Distribution Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DisclosureLicenseAndDistributionAgreementsAbstract', window );"><strong>License And Distribution Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LicenseAndDistributionAgreementsTextBlock', window );">License and Distribution Agreements</a></td>
<td class="text"><p id="xdx_806_ecustom--LicenseAndDistributionAgreementsTextBlock_zdTgqvdlL5Mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b>16. <span id="xdx_827_z0FFb1lSaFL6">License and Distribution Agreements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Sequence LifeScience, Inc. Independent Distribution
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On August 23, 2024, the Company
entered into an Independent Distributor Agreement (the &#8220;Distribution Agreement&#8221;) with Sequence LifeScience, Inc. (&#8220;Sequence&#8221;),
which provided the Company exclusive rights to market, sell and distribute Rebound<sup>TM</sup>, a full thickness placental-derived allograft
matrix product, in the U.S. for a period of ninety (90) days. Under the terms of the Distribution Agreement, Sequence made Rebound available
for purchase to the Company at a fixed price consistent with market terms. The Distribution Agreement was intended to be a bridge to allow
the parties to cooperatively market the product prior to consummating an asset purchase agreement. The Company acquired Rebound on October
9, 2024, through an asset purchase agreement with Sequence. See Note 3 for more information about the Rebound asset purchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Regeneron Research Collaboration Services Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On August 25, 2023, the Company
entered into a multi-year research collaboration services agreement with Regeneron Pharmaceuticals, Inc. (&#8220;Regeneron&#8221;), pursuant
to which the Company will support the research effort of Regeneron&#8217;s allogeneic cell therapy candidates (the &#8220;Regeneron Services
Agreement&#8221;). The Regeneron Services Agreement&#8217;s initial focus is the research on a targeted allogeneic gamma delta chimeric
antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. Payments
to the Company under the Regeneron Services Agreement included a non-refundable up-front payment of $<span id="xdx_900_ecustom--NonrefundableUpfrontPayment_pn3n3_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_zrVgzXoUiyc6" title="Nonrefundable up-front payment">750</span> and payments based upon the achievement
of defined milestones according to written statements of work. The Regeneron Services Agreement will expire <span id="xdx_904_ecustom--ServiceAgreementTerm_dc_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_z3OGOBmFS3J9" title="Service agreement term">five years</span> from the effective
date and may be terminated immediately by either party for the uncured material breach, bankruptcy, or insolvency of the other party.
Regeneron may also terminate for convenience upon <span id="xdx_901_ecustom--LicenseAgreementNoticePeriod_dtD_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_zTGlJd6Q5vib" title="License agreement notice period">30</span> days&#8217; written notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Regeneron Services Agreement
grants Regeneron a royalty-free, fully-paid up, worldwide, non-exclusive license, with the right to grant sublicenses, to the Company&#8217;s
intellectual property (&#8220;IP&#8221;) to the extent that any such license is necessary for Regeneron to fully use the Company&#8217;s
research services. The Company determined that the (1) research licenses and (2) the research activities performed by the Company represent
a single combined performance obligation under the Regeneron Services Agreement. The Company determined that Regeneron cannot benefit
from the licenses separately from the research activities because these services are specialized and rely on the Company&#8217;s expertise
such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent
one combined performance obligation and the entire transaction price was allocated to that single combined performance obligation. The
performance obligation will be satisfied over the research term as the Company performs the research activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, the Company
received payments totaling $<span id="xdx_905_eus-gaap--DeferredRevenueRevenueRecognized1_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--RegeneronServicesAgreementMember_zCERV8PWfpuf" title="Received payments">1,325</span> under the Regeneron Services Agreement, of which $<span id="xdx_90A_eus-gaap--Revenues_pn3n3_c20241001__20241231__us-gaap--TypeOfArrangementAxis__custom--RegeneronServicesAgreementMember_z1gJR610XnPa" title="Revenues">688</span> was recognized in revenue during the fourth quarter
of 2024 based on achievement of defined milestones. As of December 31, 2024, the remaining $<span id="xdx_90E_eus-gaap--DeferredRevenue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--RegeneronServicesAgreementMember_zghB0gSjHUHe" title="Deferred Revenue">637</span> was recorded as deferred revenue to be
recognized based on satisfaction of future performance obligations. The Company recognizes revenue using the cost-to-cost method, which
it believes best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards
completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified
performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent
of progress towards completion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Sorrento Therapeutics, Inc. License and Transfer
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company and Sorrento Therapeutics,
Inc. (&#8220;Sorrento&#8221;), a related party through September 30, 2023, are party to a License and Transfer Agreement for the exclusive
worldwide license to CD19 CAR-T constructs for use in placenta-derived cells and/or cord blood-derived cells for the treatment of any
disease or disorder (the &#8220;2020 Sorrento License Agreement&#8221;). The Company retains the right to sublicense the rights granted
under the agreement with Sorrento&#8217;s prior written consent. As consideration for the license, the Company is obligated to pay Sorrento
a royalty equal to low single-digit percentage of net sales (as defined within the agreement) and a royalty equal to low double-digit
percentage of all sublicensing revenues (as defined within the agreement). The 2020 Sorrento License Agreement will remain in effect until
terminated by either the Company or Sorrento for uncured material breach upon 90 days written notice or, after the first anniversary of
the effective date of the 2020 Sorrento License Agreement, by the Company for convenience upon six months&#8217; written notice to Sorrento.
On October 19, 2023, Sorrento filed a Plan of Reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court
for the Southern District of Texas which plan contemplates a liquidation of the debtor. If the Plan is confirmed by the Bankruptcy Court,
the Company believes that Sorrento will not be able to perform under the license and that any rights the Company might have under the
license would be unenforceable. After assessing the status of the IND to determine an optional path forward for the program, the Company
elected to terminate development of CYCART-19 for B-cell malignancies during the third quarter of 2023. The Company may continue pre-clinical
development of other T-cell candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><b><i>Genting Innovation PTE LTD Distribution Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On May 4, 2018, concurrently with
Dragasac&#8217;s equity investment in Legacy Celularity, Legacy Celularity entered into a distribution agreement with Genting Innovation
PTE LTD (&#8220;Genting Innovation&#8221;) pursuant to which Genting Innovation was granted supply and distribution rights to certain
Company products in select Asia markets (the &#8220;Genting Agreement&#8221;). The Genting Agreement granted Genting Innovation limited
distribution rights to the Company&#8217;s then-current portfolio of degenerative disease products and provides for the automatic rights
to future products developed by or on behalf of the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The term of the Genting Agreement
was renewed on January 31, 2023, and automatically renews for successive 12 month terms unless: Genting provides written notice of its
intention not to renew at least three months prior to a renewal term or the Genting Agreement is otherwise terminated by either party
for cause.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Genting Innovation and Dragasac
are both direct subsidiaries of Genting Berhad, a public limited liability company incorporated and domiciled in Malaysia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On June 14, 2023, the Genting
Agreement was amended and restated to include manufacturing rights in the territories covered under the agreement, expansion to two new
countries, and a commitment by the Company to provide technology transfer pursuant to the plan established by a Joint Steering Committee.
On January 17, 2024, the Company further amended the Genting Agreement to include distribution and manufacturing rights to certain of
the Company&#8217;s cell therapy products, including PSC-100, PDA-001, PDA-002, pEXO-001, APPL-001 and CYNK-001. As of December 31, 2024,
the Company has not recognized any revenue under the Genting Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Celgene
Corporation License Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is party to a license agreement with Celgene (the &#8220;Celgene Agreement&#8221;) pursuant to which the Company granted Celgene
two separate licenses to certain intellectual property. The Celgene Agreement grants Celgene a royalty-free, fully-paid up, worldwide,
non-exclusive license to the certain intellectual property (&#8220;IP&#8221;) for pre-clinical research purposes in all fields and a
royalty-free, fully-paid up, worldwide license, with the right to grant sublicenses, for the development, manufacture, commercialization
and exploitation of products in the field of the construction of any CAR, the modification of any T-lymphocyte or NK cell to express
such a CAR, and/or the use of such CARs or T-lymphocytes or NK cells for any purpose, including prophylactic, diagnostic, and/or therapeutic
uses thereof. The Celgene Agreement will remain in effect until its termination by either party for cause</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pulthera,
LLC Binding Term Sheet</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with the entry into the securities purchase agreement for the March 2023 private placement described in Note 13 above, the Company executed
a binding term sheet to negotiate and enter into a sublicense agreement of certain assets from an affiliate of Pulthera, LLC (the &#8220;sublicensor&#8221;).
Pursuant to the binding term sheet, the Company paid the sublicensor a $<span id="xdx_901_ecustom--PaymentOfOptionFeeInCash_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember_zp0MPzqwCgZc" title="Payment of option fee in cash">3,000</span> option fee in cash and issued $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzcLYNEd0blj" title="Issuance of common stock">1,000</span> of shares of its Class
A common stock (<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230317__20230317__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcvKqHcxYuJ4" title="Purchase and sale of shares">169,492</span> shares based on the closing price on March 17, 2023) as consideration for stem-cells inventory to be used in
research and development. The option fee paid by the Company will be applied towards an initial license fee as outlined in the sublicense
agreement. The Company is required to use diligent and reasonable efforts to develop and obtain regulatory approval to market at least
one licensed product contingent upon a firm written commitment to provide further financing to the Company. The $<span id="xdx_905_ecustom--OptionFeeExpense_pn3n3_c20230317__20230317__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zPNvr80kRnhj" title="Option fee expense">3,000</span> option fee was
recorded as acquired IPR&amp;D expense included in research and development expense on the consolidated statements of operations and
comprehensive loss for the year ended December 31, 2023, as the acquired IPR&amp;D had no alternative future use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>License
Agreement with BioCellgraft, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 11, 2023, the Company and BioCellgraft, Inc. (&#8220;BioCellgraft&#8221;) entered into a license agreement whereby the
Company granted an exclusive license to BioCellgraft, with the right to sublicense, to develop and commercialize certain licensed
products to the dental market in the United States over an initial four<span id="xdx_90F_ecustom--CommercialLicenseToDentalProductsAgreementPeriod_dtY_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zVuYnNlGRql8" style="display: none" title="Commercial license">4</span>
year term and it will automatically renew for an additional <span id="xdx_905_ecustom--CommercialLicenseToDentalProductsAgreementRenewalTerm_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_z5dDGyQAJHN" title="Commercial license to dental products agreement renewal term">two
years</span> unless either party provides written notice of termination. BioCellgraft will pay to the Company total license fees of
$<span id="xdx_901_ecustom--LicenseFeeExpense_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zDf81aDSIRik" title="License fee expense">5,000</span>
over a <span id="xdx_909_ecustom--LicenseFeesPaymentPeriod_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_z9jRDWxxAdMk" title="License fees payment period">two
year</span> period, as defined. Upon execution of the agreement, the Company received a $<span id="xdx_902_ecustom--LicenseFeePayment_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zI7buGLLxO5f" title="License fee payment">300</span>
payment towards the first year payment. To date, the Company has not received any additional consideration beyond the $<span id="xdx_904_ecustom--AdditionalLicenseFee_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zavzXl2EEc2b" title="Additional license fee">300</span> license payment under the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DisclosureLicenseAndDistributionAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DisclosureLicenseAndDistributionAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_LicenseAndDistributionAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License And Distribution Agreements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_LicenseAndDistributionAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTextBlock', window );">Benefit Plan</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--DefinedBenefitPlanTextBlock_zXS3pxKshPif" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_827_zNftIQHdsuC7">Benefit Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers all
employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a
pre-tax basis. Matching contributions to the plan may be made at the discretion of the Company&#8217;s board of directors. During
the years ended December 31, 2024 and 2023, the Company made contributions of <span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20240101__20241231_zdfqdFxpxFPc" title="Contributions made to the plan">$139</span>
and $<span id="xdx_906_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20230101__20231231_zAkawPEAlzq4" title="Contributions made to the plan">198</span>,
respectively. During the year ended December 31, 2022, the Company accrued $1,159 but
has not made the matching contribution to the plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 715<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477317/912-715-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zDQcziwyEVpe" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.
<span id="xdx_821_zblnKLZ3FlZ7">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z3M0NuN8Cwh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s current and deferred tax provision is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BC_zsHdMHqJd9v2" style="display: none">Schedule
of Current and Deferred Tax Provision</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_z0e9IhQQ7L64" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zhtwx24pxe87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current income tax expense:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzRNM_zI2maAw2fDNb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2920">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2921">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzRNM_zK6Vep8cO504" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; width: 62%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2923">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 15%; text-align: right">10</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzRNM_maITEBzV7j_zQ0IhocEGkLb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current income tax expense</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2926">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income tax expense
    (benefit):</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDFSALzhM1_zmBbGExPym8b" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDFSALzhM1_zvr8Jt4Pjd1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_pn3n3_mtDFSALzhM1_maITEBzV7j_zjJeOyoGOYj3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax expense</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2935">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2936">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzV7j_z7w27h2KP5Cb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    income tax expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2938">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zfLXsvzyS3R5" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUgOlIqXjr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BD_zsLPthYADiCf" style="display: none">Schedule
of Reconciliation of the U.S &#160;federal statutory income tax</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zIdyspTUrI7e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zPxflrFiO1yk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zOJd785Svxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zy0opPxbvWu3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">State income taxes, net of federal benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_pid_dp_uPure_maABC_zkQCKuYaPwfl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Interest accretion expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.0</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zyWyox63eEFh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_pid_dp_uPure_maABC_zmnevfawRT1f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Mark to market warrant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2955">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueUp_pid_dp_uPure_maABC_z2aTJcj9tgo9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.4</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_maABC_zY4hNHLT3E3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt">Impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2961">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maABC_zfCjhXbNEKsd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt">Other permanent items</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.4</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.5</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_zeWtlL2hemk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2967">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2968">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<p id="xdx_8A0_zlAHjbUu4jy" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zi4QXOddxo86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
deferred income tax liabilities as of December 31, 2024 and 2023 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BB_zds472WMQSuh" style="display: none">Schedule
of Deferred tax assets and liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_z9xT3qbgUaR" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_zHCNmkSzn9u7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzt0C_zhpy46YqYn3d" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; width: 62%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">121,804</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">109,544</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_iI_pn3n3_maDTAGzt0C_zk5UBaetBOUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,674</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzt0C_zm4MVrbOMqyc" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,539</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxAssetsStartupCosts_iI_pn3n3_maDTAGzt0C_z0NT2rqjyJ6e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Startup costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzt0C_z1UrxDPPExS1" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,028</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,442</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_maDTAGzt0C_z91X2XbqNxc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,441</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxAssetsUnicap_iI_pn3n3_maDTAGzt0C_zLqVzXBNyxwk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt">Unicap</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsImputedInterestOnContingentPayments_iI_pn3n3_maDTAGzt0C_zVlS9nBr0tni" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Imputed interest on contingent payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_iI_pn3n3_maDTAGzt0C_ztssh3ZI7SO9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Legal fee capitalization and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,171</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopment_iI_pn3n3_maDTAGzt0C_zFYvavF3XMna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,903</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,613</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsIrcSectionInterest_iI_pn3n3_maDTAGzt0C_ztuSB1QKAfYf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">IRC Section 163j interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1,471</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl3003">&#8212;</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzt0C_zT1EZe8s2U0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,755</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,751</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzt0C_msDTLz2tA_zsDbjdal1e1a" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,407</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,788</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLz2tA_zyXNPfWiCFPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(181,416</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(169,797</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_mtDTLz2tA_z7zamQdTwQEf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AD_z5fwHJ1DgCy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zPIXQ5CkpcV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span id="xdx_8B5_z1hwNIxNUSgd" style="display: none">Schedule
of Unrecognized Tax&#160;Benefits</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrecognized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax Benefits</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 81%">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20230101__20231231_zBSXdntP5td8" style="width: 15%; text-align: right" title="Balance beginning">1,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt">Decrease related to current year tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_iN_pn3n3_di_c20230101__20231231_zmnL1nNWgZej" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions"><span style="-sec-ix-hidden: xdx2ixbrl3021">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20240101__20241231_zXIYdJT8wvY1" style="text-align: right" title="Balance beginning">1,028</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt">Decrease related to current year tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_pn3n3_c20240101__20241231_zonEQghkWPml" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions"><span style="-sec-ix-hidden: xdx2ixbrl3025">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20240101__20241231_zDdvDxShsZVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending">1,028</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_ziaga27DDco7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the Company had U.S. federal and state net operating loss carryforwards of $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_ziDmdJeQCBY2" title="Net operating loss carryforwards">121,804</span></span> and $<span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zVXgNipR6lu1" title="Net operating loss carryforwards">109,544</span>, respectively,
which may be available to offset future taxable income and begin to expire in <span id="xdx_906_ecustom--OperatingLossCarryforwardsExpirationYear_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zUSFUR0TXuD6" title="Operating loss carryforwards expiration year">2040</span>. As of December 31, 2024 and 2023, the Company also
had U.S. federal and state research and development tax credit carryforwards of $<span id="xdx_90D_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zIgos4UtZTj5" title="Tax credit carryforwards"><span id="xdx_90E_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zz64ZTRvZZc3" title="Tax credit carryforwards">5,674</span></span>, which may be available to offset future tax liabilities
and begin to expire in <span id="xdx_901_ecustom--TaxCreditCarryforwardsExpirationYear_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zpFztl0uagQc" title="Tax credit carryforwards expiration year">2032</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Utilization
of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to
an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due
to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of
carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined
by Section 382, results from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than
50% over a three-year period. A corporation that experiences an ownership change is subject to an annual limitation under Section 382,
which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable
long-term tax-exempt rate subject to additional adjustments, as required. The Company experienced an ownership change on August 15, 2017.
The annual limitation from the ownership change is not expected to result in the expiration of net operating losses or research and development
credits before utilization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
realization of deferred tax assets is dependent upon the Company&#8217;s ability to generate taxable income in future years. ASC 740-10,
<i>Income Taxes,</i> requires a valuation allowance to be applied against deferred tax assets when it is considered &#8220;more likely
than not&#8221; that some or all of the gross deferred tax assets will not be realized. The Company considers all available positive
and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies,
and recent financial performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2024, based upon the weight of available evidence, the Company concluded that it is not more likely than not that the
benefits of the federal and state deferred tax assets will be realized. Accordingly, the Company has recorded a valuation allowance
against its federal and state gross deferred tax assets. The valuation allowance increased by $<span id="xdx_909_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20240101__20241231_zfhL2wkih1p2" title="Valuation allowance increased amount">11,619</span>
and $<span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20230101__20231231_zXaeuFAfY6E" title="Valuation allowance increased amount">39,272</span> during the years ended December 31, 2024 and 2023, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact of an uncertain income tax position is recognized at the largest amount that is &#8220;more likely than not&#8221; to be sustained
upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of
being sustained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2024 and 2023, the Company had gross unrecognized tax benefits of $<span id="xdx_908_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_c20241231_zfS5TTMtMjm" title="Unrecognized tax benefits"><span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_c20231231_zJ4oHnG87CG6" title="Unrecognized tax benefits">1,028</span></span>. The Company does not expect that there will
be a significant change in the unrecognized tax benefits over the next 12 months. The Company&#8217;s policy is to record interest and
penalties related to income taxes as part of its income tax provision. As of December 31, 2024 and 2023, the Company had <span id="xdx_90E_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20241231_zprHYbbMtRI3" title="Interest accrued"><span id="xdx_904_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20231231_zbdimWnO0gbl" title="Interest accrued">no</span></span> accrued interest
or penalties related to uncertain tax positions and no amounts had been recognized in the Company&#8217;s consolidated statements of
operations and comprehensive loss. The Company files income tax returns in the U.S. and numerous states, as prescribed by the tax laws
of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state
jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under
statute from 2019 to the present; however, carryforward attributes that were acquired may still be adjusted upon examination by federal,
state or local tax authorities if they either have been or will be used in a future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_zmQtIdTxCWbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.
<span id="xdx_821_zo88cKvPnDl2">Segment Information</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. The
Company manages its operations through an evaluation of <span id="xdx_904_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zlCMeSBJwb6i" title="Number of operating segments">three</span>
distinct operating segments: Cell Therapy, Degenerative Disease, and BioBanking. The chief operating decision maker, who is the
Company&#8217;s chief executive officer, uses the actual segment contribution results compared to budgets, among other factors, for
performance evaluation and resource allocation among these segments. The segment contribution is calculated as net revenues less the cost of
revenues (excluding amortization of acquired intangible assets) and direct expenses. Direct expenses in the Cell Therapy operating segment
consist of research and development costs, and direct expenses in the Degenerative Disease and Biobanking operating segments consist
mainly of selling, general, and administrative costs. The CODM assesses actual results against budgets and forecasts, and uses this information
to make decisions about strategic investment into the Company&#8217;s operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
reportable segments, which are the same as the operating segments, were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers
to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development.
Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. BioBanking collects stem cells from
umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not
regularly review any asset information or related income statement effects by operating segment and, accordingly, asset information is
not reported by reportable segment. Refer to the Consolidated Balance Sheet for information about total assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7MsvFz8HyC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
information by segment is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4dnuEopRayj" style="display: none">Schedule
of Financial Information by Segment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zaJeG6QuIika" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zRdiwc27IrG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zmWAsGw2FLTl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zdNVWlpmDQZ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zFlxIwfO1ZLa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">688</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,140</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">48,392</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">54,220</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_z6oD0O66Pp32" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3064">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,817</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,989</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zsn5f4L3Lfq1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,807</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,673</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">20,846</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">38,326</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zKp3SXBNZjTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,119</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,295</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,729</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">905</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr>
  <tr id="xdx_403_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zvokvZw8jKPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">37,703</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_z9YmKl0Zm4y9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,560</td><td style="text-align: left">(a)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_zy9Ir4UQXRgj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss from operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">(38,358</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NonoperatingIncomeExpense_pn3n3_zM86SXyYRgT5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(19,534</p></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zbYRBRQML3ub" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(57,892</p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">(a) Components of indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_pn3n3_zU5qMoswLhw6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of contingent consideration liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(193</p></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--GoodwillImpairmentLoss_pn3n3_zaPW4LNidUte" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_zvsVRcpDXuek" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">-</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_zuBp989h8Zcl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;1,753</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zHvY1GYh1Vg2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Total other</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1,560</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zkkFar7V0Ty" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zK8GvaIWaIsa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zFKHznCBYLIk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zzI6AJoePq4b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zflaTG577tNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3129">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,441</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">17,330</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">22,771</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_zPC8oVzarJK3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3134">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,366</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,016</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zG4Cj5FVOJdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">28,694</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,752</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,720</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40,166</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zHkcP6fon5J8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(28,694</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,039</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,756</td><td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(33,411</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zp1Kw2Vt6bXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">40,876</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zTB24HnD9AM5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">118,001</td><td style="text-align: left">(a)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z5dCtCMTfXre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(192,287</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_pn3n3_zMhWuZqxowS3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(3,998</p></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zWhYAfDaejy8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(196,285</p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">(a) Components of indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_pn3n3_zsoqlzgUqxrh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of contingent consideration liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(104,339</p></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--GoodwillImpairmentLoss_pn3n3_zH1R7OOaPDg3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">112,347</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_zjf98iY3BuJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">IPR&amp;D impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">107,800</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_zX4hqGkHilGh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,193</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zCmpparvduik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Total other</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">118,001</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_z18RdlWjc1W3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zumD8rrpiVr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"><b>20. <span id="xdx_827_z8jnspUMxdpf">Related
Party Transactions</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Amended and Restated Employment Agreement with
Dr. Robert Hariri</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 25, 2023, in order to address the Company&#8217;s current working capital requirements, Robert Hariri, M.D., Ph.D., the Company&#8217;s
Chairman and Chief Executive Officer, agreed to temporarily reduce payment of his salary pursuant to his employment agreement to minimum
wage level with the remaining salary deferred until December 31, 2023. As of December 31, 2024, $<span id="xdx_90C_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20241231__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember_zCQej8C0bARi" title="Accrued expenses">1,274</span> was recorded to accrued expenses
on the consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to comply with the Securities Purchase Agreement dated <span id="xdx_90E_ecustom--SecuritiesPurchaseAgreementDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember_zQHu6YsW1vS5" title="Securities purchase agreement date">January 12, 2024</span> with Dragasac Limited, Dr. Hariri is not to be paid the
$<span id="xdx_901_ecustom--UnpaidBaseSalary_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWuovfOGLzji" title="Unpaid base salary">1,088</span> in base salary that was otherwise due to him for the 2023 calendar year unless the Company raises additional cash through offerings
of equity securities with aggregate net proceeds equal or greater to $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zAbPi7EMMWD7" title="Net proceeds from offerings of equity securities">21,000</span> at a valuation at least equal to the valuation, cost per
security or exercise/conversion price, as applicable, of the Class A common stock and January 2024 PIPE Warrant purchased by Dragasac
Limited in January 2024. In compliance with the requirements of Internal Revenue Code Section 409A, the compensation committee of the
Company&#8217;s board of directors approved a cash bonus program, or bonus program, effective <span id="xdx_90A_ecustom--BonusProgramEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--AmendedAndRestatedEmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrRobertHaririMember_zuyD7XAVMZyd" title="Bonus program effective date">February 16, 2024</span>, pursuant to which Dr.
Hariri will be paid <span id="xdx_90B_ecustom--PercentageOfUnpaidBaseSalary_pid_dp_uPure_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdptatZHHLX6" title="Percentage of unpaid base salary">125</span>% of his unpaid base salary upon the satisfaction of the foregoing performance conditions. Accordingly, the Company
entered into a second amendment to Dr. Hariri&#8217;s employment agreement implementing the <span id="xdx_903_ecustom--PercentageOfBaseSalary_pid_dp_uPure_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYwaxCPxxmpb" title="Percentage of base salary">85</span>% base salary reduction effective as of
<span id="xdx_90F_ecustom--BonusProgramEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcPSW2mToMK2" title="Bonus program effective date">February 16, 2024</span> and documenting the bonus program. As a result of the reduction, Dr. Hariri&#8217;s annual rate of base salary for
the 2024 year will be $<span id="xdx_90C_ecustom--AnnualRateOfBaseSalary_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z44GM73MMXJ5" title="Annual rate of base salary">180</span>. Payment of Dr. Hariri&#8217;s base salary at the rate in effect prior to the reduction will resume on <span id="xdx_90D_ecustom--BaseSalaryEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zm7D7HqGLhyh" title="Bonus program effective date">January
1, 2025</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>March
2023 PIPE</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 20, 2023, the Company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief
Executive Officer, Dr. Robert Hariri, for an aggregate purchase price of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DrRobertHaririMember_zsZ8mMXEu9fl" title="Proceeds from PIPE financings">9,000</span> (of which Dr. Hariri subscribed for $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--TitleOfIndividualAxis__custom--DrHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztjRMGwjsXva" title="Proceeds from PIPE financings">2,000</span>). See Note
13 under March 2023 PIPE caption for further details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Loan
Agreement with Dr. Robert Hariri</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2023, the Company entered into a $<span id="xdx_908_ecustom--DebtInstrumentContributionAmount_iI_pn3n3_c20030821__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zvRQjfj7J3dd" title="Debt instrument contribution amount">1,000</span> loan agreement with Dr. Robert Hariri, M.D., Ph.D., the Company&#8217;s Chairman and
Chief Executive Officer, which bears interest at a rate of <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20030821__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_z59R2Q8O24w1" title="Loan interest rate">15.0</span>% per year, with the first year of interest being paid in kind on the
last day of each month and was scheduled to mature on August 21, 2024. The loan maturity date was subsequently extended to December 31,
2024. On September 30, 2024, Dr. Hariri assumed the loans of two unaffiliated lenders who were parties to an August 21, 2023 loan agreement.
On January 29, 2025, Dr. Hariri extended the maturity date of the loan to December 31, 2025. See Note 10, Short-Term Debt - Other and
CEO Promissory Note, for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2023, in order to further address the Company&#8217;s immediate working capital requirements, Dr. Hariri and the Company
signed a promissory note (&#8220;CEO Promissory Note&#8221;) for $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zNn7sVaR62Rg" title="Principal amont">285</span> which bears interest at a rate of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20231012__20231012__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zAs2q4x8Ryjf" title="Interest rate">15.0</span>% per year (Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Consulting
&amp; Advisory Agreements with Dr. Andrew Pecora</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--RelatedPartyTransactionTermsAndMannerOfSettlement_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zpms6Azy9Lsf" title="Related party description">On
August 31, 2022, Dr. Pecora resigned as the Company&#8217;s President, and subsequently entered into a consulting agreement with the
Company dated September 21, 2022, to receive a $<span id="xdx_905_ecustom--ReceiveForMonth_pn3n3_c20220901__20220921__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_z5Q1XgESzH3" title="Receive for month">10</span> monthly fee for an initial six-month term and which would be automatically renewed
for one additional six- month term if either party did not provide notice of non-renewal.</span> Simultaneously, the Company entered into a
scientific and clinical advisor agreement (the &#8220;SAB Agreement&#8221;), effective as of September 1, 2022, whereby Dr. Pecora agreed
to serve as co-chair of the Company&#8217;s scientific and clinical advisory board for a $<span id="xdx_908_ecustom--ReceiveForMonth_pn3n3_c20220901__20220901__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zVCJNmEtNcPe" title="Receive for month">10</span> monthly fee and a one-time grant of RSUs
having a value of $<span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn3n3_c20220901__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zn9M3ZvmbV4g" title="RSUs one-time grant value">125</span> on the grant date and which vest equally over <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220901__20220901__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zvNByTqAupFk" title="Options vesting period">four years</span>. The SAB Agreement had a one-year term and may be renewed
for successive one-year terms upon mutual agreement of both parties. The consulting agreement was early terminated effective January
14, 2023. As of August 8, 2024, Dr. Pecora no longer serves on the Company&#8217;s scientific and clinical advisory board.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Advisory
Agreement with Robin L. Smith MD</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 16, 2022, the Company entered into an advisory agreement with Robin L. Smith, MD, a then member of the Company&#8217;s board of
directors, to receive $<span id="xdx_90D_ecustom--ReceiveForMonth_pn3n3_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zhFvxGFY3Aoe" title="Receive for month">20</span> per month for advisory fees, an equity grant for a total amount of <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_ze9FhPN6M83" title="Vested options to acquire shares">105,000</span> stock options with the initial tranche
of <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--VestingAxis__custom--InitialTrancheMember_z7Z6vWabPqwj" title="Vested options to acquire shares">25,000</span> stock options vesting upon execution of the advisory agreement and the remaining shares subject to vesting upon achievement
of certain predefined milestones. On November 1, 2022, the second tranche of <span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220901__20220901__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zSAdhf9MvmF" title="Vested options to acquire shares">20,000</span> stock options vested upon achievement of the milestone.
The agreement also provided for a one-time cash bonus of $<span id="xdx_901_ecustom--RelatedPartyCashBonus_pn3n3_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zgWDh8JLzM67" title="One-time cash bonus">1,500</span> upon the successful achievement of the trigger event, as defined in the
agreement. The Company paid advisory fees of $<span id="xdx_904_ecustom--PaymentsToRelatedParty_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_z5AMetMKU4Jh" title="Amount paid">0</span> and $<span id="xdx_904_ecustom--PaymentsToRelatedParty_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_z48DEbWUbSGc" title="Amount paid">20</span> for the years ended December 31, 2024 and 2023, respectively. The advisory agreement
expired pursuant to the terms of the agreement on August 16, 2023 and was not renewed for an additional term. Dr. Smith resigned from
the Company&#8217;s board effective December 24, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>COTA,
Inc</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2020, Legacy Celularity and COTA, Inc. (&#8220;COTA&#8221;) entered into an Order Schedule (the &#8220;Order Schedule No. 2&#8221;),
to the Master Data License Agreement between Legacy Celularity and COTA, dated October 29, 2018, pursuant to which COTA will provide
the licensed data in connection with AML patients. The COTA Order Schedule No. 2 will terminate on the one-year anniversary following
the final licensed data deliverable described therein. Andrew Pecora, M.D., Celularity&#8217;s former President, is the Founder and Chairman
of the Board of COTA and Dr. Robin L. Smith, a former member of the Company&#8217;s board of directors, is an investor in COTA. The Company
did <span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_do_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--COTAIncMember_zACmZrmRqpnj" title="Contribution made"><span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_do_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--COTAIncMember_zQED0LyNLbhf" title="Contribution made">no</span></span>t make any payments to COTA during either of the years ended December 31, 2024 and 2023. As of August 8, 2024, Dr. Pecora no longer
serves on the Company&#8217;s scientific and clinical advisory board and therefore, COTA is no longer a related party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cryoport
Systems, Inc</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2024 and 2023, the Company made payments totaling $<span id="xdx_90A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CryoportSystemsIncMember_zXvS4XjsfdRi" title="Contribution made">2</span> and $<span id="xdx_90E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CryoportSystemsIncMember_z5BLWuaBKlF2" title="Contribution made">33</span>, respectively, to Cryoport Systems, Inc (&#8220;Cryoport&#8221;)
for transportation of cryopreserved materials. The Company&#8217;s Chief Executive Officer and director, Dr. Robert Hariri, M.D, Ph.D.,
has served on Cryoport&#8217;s board of directors since September 2015.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>C.V.
Starr Loan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 17, 2023 the Company entered into a $<span id="xdx_909_ecustom--LoanAgreement_iI_pn3n3_c20230317__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember_zLVcKK4AVDqi">5,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loan agreement with C.V. Starr. C.V. Starr is
an investor in the Company, beneficially owning <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zeD0gMf4MF1l">125,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to purchase Class A common stock and
<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zzAMWNQfcDa3">1,528,138
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Class A common stock as of December
31, 2024. See Note 10, Short-Term Debt &#8211; Related Parties &#8211; C.V. Starr and RWI for more information.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Resorts World Inc Pte
Ltd</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On May 16, 2023, the Company entered
into a $<span id="xdx_90F_ecustom--LoanAgreement_iI_pn3n3_c20230316__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember_z5LOP61EL9pc" title="Loan agreement">12,000</span> loan agreement, as amended on June 21, 2023, with RWI. On January 12, 2024, the Company entered into a $<span id="xdx_90C_ecustom--SecondLoanAgreement_iI_pn3n3_c20240112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember_zVKlXukmp0v8" title="Second loan agreement">15,000</span> second loan
agreement with RWI. RWI is affiliated with Lim Kok Thay, a significant stockholder and former member of the Company's board of directors,
beneficially owning <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230316__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zKJfDRqxF7ml" title="Warrants">3,600,000</span> warrants to purchase Class A common stock and <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zYRUYP8oMIKa" title="Warrants">6,338,161</span> shares of Class A common stock as of December 31,
2024. See Note 10, Short-Term Debt &#8211; Related Parties &#8211; C.V. Starr and RWI for more information.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employment
of an Immediate Family Member </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexandra
Hariri, the daughter of Robert J. Hariri, M.D., Ph.D., Celularity&#8217;s Chairman and Chief Executive Officer, is employed by the Company
as an Executive Director, Corporate Strategy &amp; Business Development. Ms. Hariri&#8217;s annual base salary for 2024 and 2023 was
$<span id="xdx_90C_ecustom--RelatedPartyBaseSalary_pn3n3_c20240101__20241231__srt--CounterpartyNameAxis__custom--MsHaririMember__us-gaap--RelatedPartyTransactionAxis__custom--EmploymentOfImmediateFamilyMemberMember_z5svl5zpKhH1" title="Base salary"><span id="xdx_90D_ecustom--RelatedPartyBaseSalary_pn3n3_c20230101__20231231__srt--CounterpartyNameAxis__custom--MsHaririMember__us-gaap--RelatedPartyTransactionAxis__custom--EmploymentOfImmediateFamilyMemberMember_zZXcnQgQ0fC3" title="Base salary">265</span></span>. Ms. Hariri has received and continues to be eligible to receive a bonus, equity awards and benefits on the same general terms and
conditions as applicable to unrelated employees in similar positions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Fountain
Life Management LLC </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 46.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 7, 2024, the Company entered into a Technology Services Agreement with Fountain Life Management LLC (&#8220;Fountain Life&#8221;),
under which the Company agreed to process and store mononuclear cells isolated from blood samples collected by Fountain Life or its authorized
representatives in accordance with the Company&#8217;s adult banking enrollment processes. In consideration of the services, Fountain
Life will pay the Company a one-time fee of two thousand five hundred dollars per sample collected and stored. The initial term of the
agreement is one year and the term automatically extends for one-year periods unless earlier terminated by either party. The Company&#8217;s
Chairman and Chief Executive Officer, Dr. Robert Hariri, M.D, Ph.D., and director, Peter Diamandis, M.D., are founding partners of Fountain
Life.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zB8PstfAYygj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>21.
<span id="xdx_825_z0MZfQGUNV3i">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span>&#160;</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2025, the
Company executed a cash advance agreement to sell $<span id="xdx_908_eus-gaap--AccountsReceivableNet_iI_pn3n3_c20250501__dei--LegalEntityAxis__custom--GenesisEquityGroupFundingLlcMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAbA5qMzLSU4" title="Accounts receivable">990</span>
of accounts receivable to Genesis Equity Group Funding LLC (&#8220;GEG&#8221;) to provide incremental funding to address immediate
cash needs. Net funds, after applicable fees, were $<span id="xdx_90C_ecustom--ApplicableFees_iI_pn3n3_c20250501__dei--LegalEntityAxis__custom--GenesisEquityGroupFundingLlcMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpGhJPCAcdx6" title="Applicable fees">594</span>.
The amount GEG will collect from the Company towards the receivables purchased amount is capped at $<span id="xdx_900_eus-gaap--InterestIncomePurchasedReceivables_pn3n3_c20250501__20250501__dei--LegalEntityAxis__custom--GenesisEquityGroupFundingLlcMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWUZPooueIql" title="Receivables purchased">47</span>
for twenty-one (21) weeks.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zdyDETNzOD07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s
consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).
The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and
transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management,
is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_845_eus-gaap--UseOfEstimates_zs3ze1DxCDi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The preparation of the
Company&#8217;s consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the
consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant
estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related
to the Company&#8217;s goodwill and intangible asset impairment assessments, determination of incremental borrowing rates, and the
valuations of inventory, gross-to-net sales adjustments, contingent consideration, short-term debt, stock options and stock
warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors
that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are
changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual
results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrCWIXAoDtD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Fair Value Measurements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain assets and
liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an
orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to
be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable
and the last is considered unobservable:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 &#8212; Quoted prices in active markets for identical assets or liabilities.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 &#8212; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active
markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities,
or other inputs that are observable or can be corroborated by observable market data.</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 &#8212; Unobservable inputs that are supported by little or no market activity that are significant
to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zYWQkJNKxIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Cash and cash equivalents
consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having a maturity when
acquired of less than three months. The Company considers all highly liquid investments with maturities of three months or less at
the date of acquisition to be cash equivalents. At December 31, 2024 and 2023, substantially all cash and cash equivalents were held
in either commercial bank accounts or money market funds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_z1PgwfZPO0v2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Restricted Cash</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">As of December 31,
2024 and 2023, the Company maintained a letter of credit of $<span id="xdx_90C_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20241231__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zjoVwFqEBhq3" title="Restricted cash">10,239</span> and $<span id="xdx_90E_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zczK3zS7p75k" title="Restricted cash">9,936</span>, respectively, for the benefit of the landlord of a leased
property, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJI8ZxNTfRj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Accounts Receivable</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">Accounts receivable represent amounts due from customers, typically within 30 to 90 days from invoice date, arising from the Company&#8217;s revenue-generating activities. Accounts receivable are presented net of an allowance for credit losses. The
allowance for credit losses is determined based on a combination of the aging of receivables, and customer-specific information, including
historical loss experience, current economic conditions, forecasts of future economic conditions and other relevant risk factors. The
Company applies judgment in evaluating the collectability of accounts. Receivables are written off when all reasonable collection efforts
have been exhausted and the amounts are deemed uncollectible. Actual credit losses may differ from management&#8217;s estimates, and such
differences are recognized in the period in which they become known. The Company&#8217;s accounts receivable balance, net of allowance for credit losses, was $<span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20241231_zeQQoLgBpzc9" title="Accounts receivable balance, net of allowance for credit losses">13,357</span>, $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20231231_zcx3fNrMjZqd" title="Accounts receivable balance, net of allowance for credit losses">10,046</span> and $<span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231_zN2uiosrvhKc" title="Accounts receivable balance, net of allowance for credit losses">4,452</span>
as of December 31, 2024, 2023 and 2022, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p id="xdx_849_eus-gaap--InventoryPolicyTextBlock_zZCOVQRpq42a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Inventory</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Inventory is stated
at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. Prior to initial approval
from the FDA or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred.
After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product.
The Company continues to expense costs associated with clinical trial supply costs as research and development expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company periodically
analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i)
expected to expire prior to being sold, (ii) has a cost basis in excess of its net realizable value, (iii) is in excess of expected
sales requirements as determined by internal sales forecasts, or (iv) fails to meet commercial sale specifications, the inventory is
written-down through a charge to cost of revenues. The determination of whether inventory costs will be realizable requires
estimates by management of future expected inventory requirements, based on sales forecasts. If actual market conditions are less
favorable than those projected by management, additional inventory write-downs may be required. Inventory, net of current portion on
the Company&#8217;s consolidated balance sheets includes inventory expected to remain on hand beyond one year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zirH0xyvqwPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Property and Equipment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p id="xdx_89C_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zNuXmaECBYkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Property and equipment
are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line
method over the estimated useful life of each asset, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span id="xdx_8BB_zWqIoqbkfaU7" style="display: none">Schedule of Property and
Equipment Estimated Useful Life</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated Useful Life</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 69%">Building</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29%; text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zZlzOQlagac9" title="Property and equipment expected useful lives">26</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zB89FzWimrl3" title="Property and equipment expected useful lives">5</span> - <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zwDyWQvpt0Rd" title="Property and equipment expected useful lives">7</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Lab equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zSXMcDK2itY8" title="Property and equipment expected useful lives">5</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ7S4NKtSWNd" title="Property and equipment expected useful lives">3</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Software</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zV3KFxImgR3a" title="Property and equipment expected useful lives">3</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zdaZ6Eefrqd2" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0878">shorter of the estimated useful life or the lease term</span></span></td></tr>
  </table>

<p id="xdx_8A3_zGGLuPyKsfA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Estimated useful lives are
periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When
assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are
eliminated from the consolidated balance sheets and any resulting gains or losses are included in the consolidated statements of
operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as
construction-in-progress and depreciated once placed into service.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD7ahGB9k1gg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Impairment of Long-Lived Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Long-lived assets consist
of property, plant and equipment, operating right-of-use assets, and finite-lived intangible assets. Long-lived assets to be held and
used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets
may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant
underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes
or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability,
the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset
group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows
expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess
of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. Due to the goodwill
impairment recognized during the year ended December 31, 2023 as discussed below and in Note 8, the Company performed a recoverability
test on long-lived assets and concluded no additional impairment to be recognized as result of this test. The Company did not record any
impairment losses on long-lived assets during the years ended December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AssetAcquisitionsPolicyTextBlock', window );">Asset Acquisitions</a></td>
<td class="text"><p id="xdx_848_ecustom--AssetAcquisitionsPolicyTextBlock_zwRrPSrKxFj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Asset Acquisitions</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company measures
and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes
transaction costs. In an asset acquisition, the cost allocated to acquire IPR&amp;D with no alternative future use is charged to research
and development expense at the acquisition date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research and Development</a></td>
<td class="text"><p id="xdx_841_eus-gaap--InProcessResearchAndDevelopmentPolicy_zO49g7Q62gg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>In-Process Research and Development</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of IPR&amp;D
acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of
the related research and development activities. When the related research and development is completed, the asset is reclassified to
a finite-lived asset and amortized over its estimated useful life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of an
IPR&amp;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to
be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability
of technical success, the projected costs to complete, expected market competition, and an assessment of the asset&#8217;s life-cycle.
The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated
with the cash flow streams.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Indefinite-lived IPR&amp;D
is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The
Company tests its indefinite-lived IPR&amp;D annually for impairment during the fourth quarter. In testing indefinite-lived
IPR&amp;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of
events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the
Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived IPR&amp;D without
performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or
economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess
qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived IPR&amp;D
is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived IPR&amp;D. Under either
approach, if the fair value of the indefinite-lived IPR&amp;D is less than its carrying amount, an impairment charge is recognized
in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2024, the Company did <span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_dxL_c20240101__20241231_zBVtE4RSkLYc" title="Indefinite-lived IPR&amp;D::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0886">no</span></span>t
recognize an impairment charge related to its indefinite-lived IPR&amp;D. During the year ended December 31, 2023, the Company
recognized an impairment charge related to its indefinite-lived IPR&amp;D of $<span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_c20230101__20231231_zRCobO66Fxgg" title="Indefinite-lived IPR&amp;D">107,800</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zVgnjKMbbyub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Goodwill</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Goodwill represents
the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets
acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if
there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company manages
its operations through an evaluation of <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_z6ccAPGLi27e" title="Operating segments">three</span> different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note
19). The Company determined that the operating segments represented the reporting units.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In testing goodwill
for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances
would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, or the Company
can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances
considered in the Company&#8217;s qualitative assessment include, but are not limited to, a significant adverse change in legal or business
climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess qualitative factors and the
Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, the Company
would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit
to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, no
impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize
an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value, not to exceed the total
amount of goodwill allocated to the reporting unit. During the year ended December 31, 2024, the Company did <span id="xdx_903_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_do_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zrfBEylpfebh" title="Goodwill impairment">no</span>t recognize any goodwill
impairment. During the year ended December 31, 2023, the Company recognized goodwill impairment of $<span id="xdx_901_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zO7f9dSxunO7" title="Goodwill impairment">112,347</span> relating to the Cell Therapy
reporting unit (see Note 8) in the Company&#8217;s consolidated statement of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantsLiabilitiesPolicyTextBlock', window );">Warrant Liabilities</a></td>
<td class="text"><p id="xdx_844_ecustom--WarrantsLiabilitiesPolicyTextBlock_zPm9aumjiLI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Warrant Liabilities</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounts for
the public warrants, private placement warrants, registered direct warrants, May 2022 PIPE warrants, and November 2024 Purchaser
Warrants and Placement Agent Warrants (collectively, &#8220;Liability Warrants&#8221;) in accordance with the guidance contained in
Accounting Standards Codification (&#8220;ASC&#8221;) 815-40, <i>Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own
Equity</i>, under which the Liability Warrants do not meet the criteria for equity treatment and must be recorded as liabilities.
Accordingly, the Company classifies the Liability Warrants as liabilities at their fair value and adjusts to fair value at each
reporting period. These liabilities are subject to re-measurement at each balance sheet date until exercised or expired, and any change in
fair value is recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The Liability
Warrants, excluding the public warrants, were initially and subsequently valued using either a Black-Scholes or a Monte Carlo option
pricing model, which are considered to be Level 3 fair value measurements. The public warrants are valued based on the quoted market
price as of each relevant reporting date, which is considered to be a Level 1 fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_zB6GsSXh3MT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Leases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In accordance with
Accounting Standards Update (&#8220;ASU&#8221;) 2016-02, <i>Leases (Topic 842)</i> (ASU 2016-02 or ASC 842), the Company classifies leases
at the lease commencement date. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease
based on the circumstances present. Leases with a term greater than one year will be recognized on the consolidated balance sheets as
right-of-use (&#8220;ROU&#8221;) assets, lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal
options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and
the corresponding ROU assets are recorded based on the present values of lease payments over the terms. The interest rate implicit in
lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which
are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a
similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liabilities and are
recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants.
Certain adjustments to ROU assets may be required for items such as initial direct costs paid, incentives received, or lease prepayments.
If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company
would reassess lease classification, remeasure the lease liabilities using revised inputs as of the reassessment date, and adjust the
ROU assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has elected
the &#8220;package of 3&#8221; practical expedients permitted under the transition guidance, which eliminates the requirements to reassess
prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy
which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of
exercising will not be included within the ROU assets and lease liabilities on its consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Refer to Note 11 for further information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShortTermDebtPolicyTextBlock', window );">Short-Term Debt - Yorkville and Unsecured Senior Convertible Notes</a></td>
<td class="text"><p id="xdx_84A_ecustom--ShortTermDebtPolicyTextBlock_zJawFRlv44Sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Short-Term Debt - Yorkville and
Unsecured Senior Convertible Notes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company elected
the fair value option to account for its pre-paid advance agreement with YA II PN, Ltd (&#8220;Yorkville&#8221;) (see Note 10). As of
December 31, 2023, due to the short-term nature of the debt, the fair value approximated the settlement amount which was fully paid on
January 17, 2024. The Company also elected the fair value option to account for the Yorkville convertible promissory note signed on March
13, 2024 (see Note 10) and the unsecured senior convertible notes issued pursuant to the securities purchase agreement signed on November
25, 2024 (see Note 10). As of December 31, 2024, the estimate of the fair value of the Yorkville convertible promissory note and the unsecured
senior convertible notes was determined using a binomial lattice model and a credit default model. The fair value measurement of the debt
is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair value of debt that is accounted for
at fair value, inclusive of related accrued interest expense, are presented as gains or losses in the accompanying consolidated statements
of operations and comprehensive loss under change in fair value of debt. The portion of total changes in fair value of debt attributable
to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption
exclusive of base market changes and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements
of operations and comprehensive loss. The actual settlement of the short-term debt could differ from current estimates based on the timing
of when and if the investors elect to convert amounts into common shares, potential cash repayment by the Company prior to maturity, and
movements in the Company&#8217;s common share price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zMzJP3CBwZOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company generates
revenue from its degenerative disease commercial operations (i.e., the sale of Biovance<sup>&#174;</sup>, Biovance 3L<sup>&#174;</sup>,
CentaFlex<sup>&#174;</sup>, Interfyl<sup>&#174;</sup> and Rebound<sup>TM</sup>), biobanking services (i.e., the collection, processing and
storage of umbilical cord and placental blood and tissue after full-term pregnancies), and license, royalty and other revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><i><span style="text-decoration: underline">Product sales</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><i><span style="text-decoration: underline">&#160;</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Biovance, Biovance 3L, CentaFlex
and Rebound are decellularized, dehydrated human amniotic membrane products intended for use as a biological membrane covering that provides
the extracellular matrix while supporting the repair of damaged tissue. Interfyl is an allogeneic decellularized particulate human placental
connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use
in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. <span style="background-color: white">Rebound&#8482;
is a full thickness extracellular matrix that contains amnion and chorion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recognizes
revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects
to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer,
determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct
performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied. Sales and
other taxes collected on behalf of third parties are excluded from revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A performance obligation
is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with
other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance
obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use
and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with
customers and to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration
that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances,
to which the Company expects to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company offers
volume-based discounts, rebates and prompt pay discounts and other various incentives which are accounted for under the variable consideration
model. If sales incentives may be earned by a customer for purchasing a specified amount of product, the Company estimates whether such
incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction
is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company
considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to estimate what
levels of incentives will be earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company provides
for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore
does not record a provision for returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><i><span style="text-decoration: underline">Services</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company separately recognizes
revenues for services to expectant parents who contract with the Company to collect, process and store umbilical cord blood and placenta
derived cells and tissue for private use. The Company recognizes revenue from collection and processing fees at the point in time of the
successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period. Contracted
storage periods are generally <span id="xdx_90E_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z58qSIxTyhdb" title="Contracted storage periods">18</span> years and <span id="xdx_900_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zfUgtyGy5kj7" title="Contracted storage periods">25</span> years. Deferred revenue on the accompanying consolidated balance sheets includes the portion
of the 18- and the 25-year storage fees that are being recognized over the contractual storage period. The Company classifies deferred
revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">When determining the transaction
price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance,
resulting in a significant financing component. For all plans (annual, lifetime, <span id="xdx_90D_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zieb2Fryhruh">18</span>
years and <span id="xdx_90A_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z6PRk83KBTyh">25</span>
years), the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans
for customers to pay over time for a period of one
<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z6uayugqonI7" title="Over time for a period">1</span></span> to <span id="xdx_908_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zEGtPcJ7xRMe" title="Over time for a period">24</span>
months (over time plans). The Company concluded that a significant financing component is not present within either the prepaid or overtime
payment plans. The Company has determined that the prepaid plans do not include a significant financing component as the payment terms
were structured primarily for reasons other than the provision of financing and to maximize profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">When considered over
a <span id="xdx_908_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zyN5PDwPyEo7" title="Over time for a period">24</span>-month period for over time plans, the difference between the cash selling price and the consideration paid is nominal. As such, the
Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when
considered in the context of all contracts entered into nor are they significant at the individual contract level.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company offers
promotional discounts and other various incentives which are accounted for under the variable consideration model. The Company estimates
whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue
transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method,
the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to
estimate what levels of incentives will be earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">As
the Company&#8217;s processing and storage agreements contain multiple performance obligations, ASC 606, <i>Revenue from Contracts with
Customers,</i> requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised
services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the standalone
selling prices of the processing services and storage services and concluded that the published list price is the price that a customer
in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged
the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage</span><span style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt">.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"><i><span style="text-decoration: underline">License, royalty and other</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Under license agreements,
the Company assesses whether the related performance obligation is satisfied at a point in time or over time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">At the inception of
each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable
of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial,
and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved
in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period,
the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate
of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings
in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy
a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the
milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. See
Note 16 for further discussion of the Company&#8217;s license agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">While the Company&#8217;s
direct sales of degenerative disease products are included in product sales, sales through the Company&#8217;s network of distribution partners
are included in license, royalty and other revenues. For certain distribution agreements as described in Note 16, the Company will utilize
the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to
invoice so long as the consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue
upon invoicing for these agreements (subsequent to receipt of the related purchase order).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Revenues</a></td>
<td class="text"><p id="xdx_845_eus-gaap--CostOfSalesPolicyTextBlock_z35GVfzsFpM8" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Cost of Revenues</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Cost
of revenues consists of labor, material and overhead costs associated with the Company&#8217;s two existing commercial business segments,
biobanking and degenerative disease. Biobanking costs, which include the cost of storage and transportation kits for newly banked materials
as well as tank and facility overhead costs for cord blood and other units in storage, are included in services in cost of revenues. Degenerative
disease costs, which include costs associated with procuring placentas, qualifying the placental material and processing the placental
tissue into a marketable product, are included in product sales or license, royalty and other in cost of revenues depending on the class
of customer. Costs in the degenerative disease segment include labor and overhead costs associated with the production of the Biovance,
Biovance 3L, Interfyl and Rebound product lines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="background-color: white"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztoNo8vfpm03" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Research and Development Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company has entered
into various research and development and other agreements with commercial firms, researchers, universities and others for provisions
of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expense
as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses,
depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside
vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical
trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. Nonrefundable advance
payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses.
Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or
when it is no longer expected that the goods will be delivered, or the services rendered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upfront payments, milestone
payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Costs</a></td>
<td class="text"><p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zehqyqrWofT4" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Advertising and Marketing Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Advertising and marketing
costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were
$<span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20240101__20241231_zPHclHX0L6aa" title="Advertising and marketing costs">23</span> and $<span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20230101__20231231_zFZsOBngTiul" title="Advertising and marketing costs">44</span> for the years ended December 31, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_GovernmentGrantsPolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><p id="xdx_84F_ecustom--GovernmentGrantsPolicyTextBlock_zAOMqF8O9Nv1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Government Grants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">From time to time,
the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction
to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency.
The Company did <span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20240101__20241231_zPvnZyyuNW4" title="Grant monies"><span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20230101__20231231_z3b1OtFQdtV" title="Grant monies">no</span></span>t receive grant monies during the years ended December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zOVE1KisiZFb" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Patent Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">All patent-related
costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the
recovery of the expenditure. Amounts incurred are classified in selling, general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zO3jvgy1FGPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company measures
all stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation
expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company
typically issues stock-based awards with only service-based vesting conditions and records the expense for these awards using a straight-line
method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s
board of directors may also approve and award performance-based stock options. The performance-based stock options are earned based on
the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based awards over
the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability
of vesting at each reporting period for performance-based awards and adjusts expense accordingly on a cumulative basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The fair value of each
service-performance- and market-based stock option grant is estimated on the date of grant using an appropriate option pricing
model using inputs available as of the grant date. For awards with service-based vesting conditions only, the Company determines the
fair value of the award as of the grant date using the Black-Scholes option-pricing model. Prior to the merger, Legacy Celularity
was a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, the
Company estimates its expected stock price volatility using its volatility since the merger and the historical volatility of
publicly traded peer companies. The expected term of the Company&#8217;s stock options granted to employees is determined utilizing
the &#8220;simplified&#8221; method for awards that qualify as &#8220;plain-vanilla&#8221; options. The expected term of stock
options granted to non-employee consultants is equal to the contractual term of the option award or the Company&#8217;s estimated
term based on the underlying agreement. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in
effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected
dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay
any cash dividends in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company classifies
stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award
recipient&#8217;s payroll costs are classified or in which the award recipient&#8217;s service payments are classified. The Company elects
to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure
to satisfy a service or performance condition is generally reversed in the period of the forfeiture.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zcClrkt8H3S1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><b><i>Comprehensive Income (Loss)</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Comprehensive income (loss)
refers to revenues, expenses, gains and losses that under GAAP are included in comprehensive income (loss) but are excluded from net income
(loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss). The Company&#8217;s only
component of other comprehensive income (loss) is comprised of the portion of the total change in fair value of debt accounted for under
the fair value option that is attributable to changes in instrument-specific credit risk. During the year ended December 31, 2024, the
Company recorded instrument-specific credit risk loss of $<span id="xdx_907_ecustom--InstrumentSpecificCreditRiskLoss_pn3n3_c20240101__20241231_zXuxthYZisj4" title="Instrument-specific credit risk loss">5</span>. During the year ended December 31, 2023, the Company recorded instrument-specific
credit risk income of $<span id="xdx_905_ecustom--InstrumentSpecificCreditRiskIncome_pn3n3_c20230101__20231231_zTIEM30L2NXa" title="Instrument-specific credit risk income">146</span> and reclassified $<span id="xdx_904_ecustom--AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_pn3n3_c20230101__20231231_zaEvSgctPaZ1" title="Accumulated other comprehensive income">155</span> from accumulated other comprehensive loss to other expense, net on the consolidated statements
of operations and comprehensive loss upon short-term debt conversion. These amounts have been recorded as a separate component of stockholders&#8217;
equity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zcM4XvGXdhs1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounts for
income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#8217;s tax returns.
Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and
liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets
and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will
be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely
than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge
to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and
considering prudent and feasible tax planning strategies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company accounts
for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount
of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based
on the technical merits of the position. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then
assessed to determine the amount of benefit to recognize in the consolidated financial statements. <span id="xdx_906_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zbOsqvgmw2Xf" title="Income tax examination likelihood settlement">The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority</span>.
The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note
18).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zDCGXGQdLZZ3" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"><b><i>Net Loss per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Basic net loss per share
of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period.
Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such
as redeemable convertible preferred stock, convertible debt, stock options, restricted stock units and warrants, which would result in
the issuance of incremental shares of common stock. However, potential common shares are excluded if their effect is anti-dilutive. For
diluted net loss per share when the Company has a net loss, the weighted-average number of shares of common stock is the same as for basic
net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact
is anti-dilutive. All warrants are participating securities, as they participate on a one-for-one basis with Class A common stock in the
distribution of dividends, if and when declared by the Board of Directors. For the purposes of computing earnings per share, the warrants
are considered to participate with Class A common stock in earnings of the Company. Therefore, the Company computes earnings per share
using the two-class method, an earnings allocation method that determines net income (loss) per share (when there are earnings) for common
stock and participating securities. No income was allocated to the warrants for the years ended December 31, 2024 and 2023, as results
of operations were a loss for both periods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgF07KC77J2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following potentially
dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common stock outstanding, prior
to the use of the two-class method, as they would be anti-dilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span id="xdx_8B6_zFS2Zb9yp5z4" style="display: none">Schedule of Potentially
Dilutive Securities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_zTLtiqSQNdm2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zcfC9dr3F2Ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zO4pWMMkDXGa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left">Stock options</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">4,006,525</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">2,820,187</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG54qjzKR72f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Restricted stock units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">688,106</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">823,332</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpDgmRzbMwm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,221,557</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,070,627</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zngdWYOZ7SBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,126,496</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">549,681</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zc76zzjiS1Tb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive
    securities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,042,684</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">11,263,827</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zSxqGmWvKgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze7191TVFkX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Segment Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Operating segments
are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company manages
its operations through an evaluation of <span id="xdx_906_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_ztB8DCNcXN04" title="Number of operating segments">three</span> distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments
are presented for the years ended December 31, 2024 and 2023 in Note 19.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AllowanceForCreditLossesPolicyTextBlock', window );">Allowance for Credit Losses</a></td>
<td class="text"><p id="xdx_841_ecustom--AllowanceForCreditLossesPolicyTextBlock_zhEEiQk5NWE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Allowance for Credit Losses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">With the adoption of ASU
2016-13 <i>Financial Instruments &#8212; Credit Losses, </i>as noted below, the Company recognizes credit losses based on forward-looking
current expected credit losses. The Company makes estimates of expected credit losses based upon its assessment of various factors, including
historical collection experience, the age of accounts receivable balances, credit quality of its customers, current economic conditions,
reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Significant Customers</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_z2szKM6kK2K1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Concentrations of Credit Risk and
Significant Customers</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Financial instruments that
potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, and
accounts receivable. The Company generally maintains cash balances in various operating accounts at financial institutions that management
believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses
related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the
normal credit risk associated with commercial banking relationships.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company is subject to
credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts
receivables are a result from product sales and services performed in the United States. As of December 31, 2024, three of the Company&#8217;s
customers, each of which individually comprised at least 10%, represented an aggregate <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_z4PaOevwtynb" title="Concentration risk, percentage">46</span>% of the Company&#8217;s outstanding gross accounts
receivable. As of December 31, 2023, two of the Company&#8217;s customers, each of which individually comprised at least 10%, represented an
aggregate <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zx2bmIlaY6N" title="Concentration risk, percentage">41</span>% of the Company&#8217;s outstanding gross accounts receivable. During the year ended December 31, 2024, the Company had one
customer provide for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFlNmPzgrYt7" title="Concentration risk, percentage">17</span>% of revenue and another customer provided for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zanEqKEWCkk7" title="Concentration risk, percentage">16</span>% of revenue. During the year ended December 31, 2023, the Company
had one customer provide for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmQz2erMMjnc" title="Concentration risk, percentage">14</span>% of revenue and another customer provided for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zc4bGqHB5XBa" title="Concentration risk, percentage">13</span>% of revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zAzQwpXzibg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Reclassifications</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Certain prior period amounts
have been reclassified to conform with current year presentation. On the consolidated balance sheets, short-term debt - Yorkville and
other short-term debt were reclassified to short-term debt - unaffiliated, and short-term debt - related party and short-term debt - related
parties - C.V. Starr and RWI were reclassified to short-term debt - related parties. See Note 10 for further information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zL3RHbbgw3o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Recently Adopted Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In June 2016, the Financial
Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2016-13, <i>Financial Instruments &#8212; Credit Losses</i> (&#8220;ASU 2016-13&#8221;),
which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types
of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale
debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual
periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption
permitted. The Company adopted ASU 2016-13 effective January 1, 2023. The standard did not have a material impact on the consolidated
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In November 2023, the FASB
issued ASU 2023-07, <i>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</i>, which requires disclosure of
incremental segment information on an annual and interim basis. This ASU was effective for fiscal years beginning after December 15, 2023,
and interim periods within fiscal years beginning after December 15, 2024. The Company adopted the guidance in ASU 2023-07 for the year
ended December 31, 2024, and it is being applied retrospectively to its consolidated financial statement disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z20Svbe71ez6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"><b><i>Recently Issued Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In December 2023, the FASB
issued ASU 2023-09, <i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>, which expands the disclosures required for
income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should
be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this
pronouncement on its financial statement disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">In November 2024, the FASB
issued ASU 2024-03, <i>Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses</i>, as subsequently amended by ASU 2025-01 to clarify the effective date,
which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee
compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of
operations and comprehensive loss. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within
fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively
to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods
presented in the consolidated financial statements. The Company is currently evaluating the effect of this pronouncement on its
consolidated financial statements and footnote disclosures.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AllowanceForCreditLossesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AllowanceForCreditLossesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AssetAcquisitionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisitions [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AssetAcquisitionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_GovernmentGrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Grants [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_GovernmentGrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recently Adopted Accounting Pronouncements [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ShortTermDebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short Term Debt [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ShortTermDebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantsLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantsLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock', window );">Schedule of Property and Equipment Estimated Useful Life</a></td>
<td class="text"><p id="xdx_89C_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zNuXmaECBYkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Property and equipment
are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line
method over the estimated useful life of each asset, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span id="xdx_8BB_zWqIoqbkfaU7" style="display: none">Schedule of Property and
Equipment Estimated Useful Life</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Estimated Useful Life</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 69%">Building</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 29%; text-align: center"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zZlzOQlagac9" title="Property and equipment expected useful lives">26</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Furniture and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zB89FzWimrl3" title="Property and equipment expected useful lives">5</span> - <span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zwDyWQvpt0Rd" title="Property and equipment expected useful lives">7</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Lab equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zSXMcDK2itY8" title="Property and equipment expected useful lives">5</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Computer equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ7S4NKtSWNd" title="Property and equipment expected useful lives">3</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Software</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zV3KFxImgR3a" title="Property and equipment expected useful lives">3</span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zdaZ6Eefrqd2" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"><span style="-sec-ix-hidden: xdx2ixbrl0878">shorter of the estimated useful life or the lease term</span></span></td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgF07KC77J2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following potentially
dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common stock outstanding, prior
to the use of the two-class method, as they would be anti-dilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span id="xdx_8B6_zFS2Zb9yp5z4" style="display: none">Schedule of Potentially
Dilutive Securities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_zTLtiqSQNdm2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20230101__20231231_zcfC9dr3F2Ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zO4pWMMkDXGa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left">Stock options</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">4,006,525</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">2,820,187</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG54qjzKR72f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Restricted stock units</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">688,106</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">823,332</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpDgmRzbMwm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">11,221,557</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,070,627</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zngdWYOZ7SBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,126,496</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">549,681</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zc76zzjiS1Tb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-dilutive
    securities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,042,684</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">11,263,827</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Estimated Useful Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock', window );">Schedule of Purchase Price Allocated to Acquired Assets</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--AssetAcquisitionContingentConsiderationTableTextBlock_zWprWttZeAY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="background-color: white">The
purchase price was allocated to the acquired assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span id="xdx_8B0_zhki8gkWMykj" style="display: none">Schedule of Purchase Price
Allocated to Acquired Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" id="xdx_498_20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zhZC3kVIpmUd" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Consideration:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pn3n3_zTu4rAjBYes1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 81%; text-align: left">Cash payment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right">1,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_pn3n3_zL14qSuNb2r3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Contingent consideration</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">650</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferred_iT_pn3n3_zpdDNHBxCcL8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total consideration</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,150</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Assets acquired:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iE_pn3n3_z30MMVIHKErb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,150</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iE_pn3n3_zbTaf1s3DQO8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets acquired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,150</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measures at Fair Value</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmb9PfWUKqwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following tables present information about
the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value
hierarchy used to determine such fair values:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><span id="xdx_8B0_zIQ9WZasChz3" style="display: none">Schedule of Financial Assets and Liabilities Measures at Fair Value</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzdSkuVcoJR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKzHQVU6Tj2h" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zApwOvikycBa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIXAcRbJ3x5d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements as of December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zdMFe61yvfVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zWYNCb0WUnu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1032">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1033">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1,413</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">1,413</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zd4svOi91Nf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1037">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zwUGyLIeWUPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - Yorkville</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1042">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,865</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,865</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--ShorttermDebtUnsecuredSeniorConvertibleNotes_i01I_pn3n3_z0t3w7QzYWHl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - unsecured senior convertible notes</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1047">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">620</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">620</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zUynWyqYoAzl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - July 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1053">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,115</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,115</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_zWEc9xjtmMs6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - April 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1057">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,022</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zUq07lyItO7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - May 2022 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1062">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1063">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">505</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">505</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--WarrantLiabilityPurchaserWarrants_i01I_pn3n3_z2PtyNiQlTp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - November 2024 Purchaser Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1067">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1068">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">278</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">278</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilityPlacementAgentWarrants_i01I_pn3n3_zNBg7V0hk4Dh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - November 2024 Placement Agent Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1072">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1073">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">48</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_za5eSpLRTsAh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - Sponsor Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1077">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1078">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zKkeFd1iCppf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Warrant liability - Public Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">287</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1083">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1084">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">287</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zGTzThLR8fVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    fair value liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">287</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1088">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,902</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,189</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuoNHfmxmcGg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_499_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj5R1lOBqXD3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsIIUtxsRVa2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBOWcqsAuqA1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fair Value Measurements as of December 31, 2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 1</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 2</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Level 3</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Total</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zT3saKyHg636" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ReceivablesFairValueDisclosure_i01I_pn3n3_zIP15TdqERni" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt; width: 44%; text-align: left">Convertible note receivable</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,072</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,072</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_i01TI_pn3n3_zsY9iNcyNuOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    fair value assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1103">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,072</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,072</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zDRifOTUMxqb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zqB1icF8FiQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1112">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1113">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,606</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,606</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zS4112ALhre2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1117">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1118">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zvY5jqAgnAgk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - Yorkville</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,223</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">17,223</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zmNieavx7vW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - July 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1127">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1128">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,529</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,529</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_ziPEtsdI1uv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - April 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1132">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,487</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,487</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zhq8ZtQ6e1K1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - May 2022 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1137">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1138">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">708</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">708</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_zkMudQLWnIg6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Warrant liability - Sponsor Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1142">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1143">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zcieF696gda1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt; text-align: left">Warrant liability - Public Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">575</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1148">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">575</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zDNkMAT9gqOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    fair value liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">575</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1153">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,640</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">23,215</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis</a></td>
<td class="text"><p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z8ZzFNHpUFr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of the convertible note receivable measured on a recurring basis using Level 3 inputs for the year ended December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"><span id="xdx_8B9_zFErd4Rfj6ak" style="display: none">Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1, 2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of) </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Convertible note receivable</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ReceivablesFairValueDisclosure_iS_pn3n3_c20240101__20241231_zOLLVDccNtha" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">2,072</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3n3_c20240101__20241231_zaj2eaLR5NPk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1171">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231_z9GFUYXI1Ohb" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net">(2,072</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20240101__20241231_zVAfHEi1grW8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"><span style="-sec-ix-hidden: xdx2ixbrl1175">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ReceivablesFairValueDisclosure_iE_pn3n3_c20240101__20241231_zqGG7pp5j9Qf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1177">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock', window );">Schedule of Convertible Note Valuation Model</a></td>
<td class="text"><p id="xdx_89B_ecustom--ScheduleOfConvertibleNoteValuationModelTableTextBlock_z7EuHh2GNVD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the convertible
note valuation model were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zacK0CQDrUZ7" style="display: none">Schedule of Convertible
Note Valuation Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Face value</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--FaceValueOfNotesReceivable_iI_pn3n3_c20231231_zmau9GTs49T6" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Face value">4,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Coupon rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20231231__20231231__srt--RangeAxis__srt--MinimumMember_zCS9azBSfThe" title="Coupon rate">12.00</span>% - <span id="xdx_90E_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20231231__20231231__srt--RangeAxis__srt--MaximumMember_zkO4ImOn8EX3" title="Coupon rate">17.00</span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Stock price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231_zwuj6HzjR2aa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock price">0.2</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20231231__20231231__srt--RangeAxis__srt--MinimumMember_zDUEeNif64j5" title="Term (years)">0.51</span>-<span id="xdx_90B_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20231231__20231231__srt--RangeAxis__srt--MaximumMember_z4mH3Z1StVXc" title="Term (years)">2.45</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--ValuationInputForConvertiblePromissoryNote_pid_dp_uPure_c20231231__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZA4dA31wVBa" title="Risk-free interest rate">5.47</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">n/a</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis</a></td>
<td class="text"><p id="xdx_89A_ecustom--FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zf0Q2VjZAwu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of short-term debt obligations measured on a recurring basis using Level 3 inputs for the years ended December 31, 2023
and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span id="xdx_8BE_zNNatWJYUOr5" style="display: none">Schedule of Reconciliation
of Short-term Debt Obligation Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zVKESrallsn9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance">37,603</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Conversion of debt into common shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zhvrNP5gY3L3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion of debt into common shares">(4,599</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Principal repayments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zS1dpiGcM6gi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Principal repayments">(16,811</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of convertible promissory note</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4ULDL8Mjadd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of convertible promissory note">3,150</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of unsecured senior convertible notes, net of fair value adjustment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_ecustom--IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zeX9B9QAWsp8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of unsecured senior convertible notes, net of fair value adjustment">689</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Fair value adjustment through earnings</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueAdjustmentThroughEarnings_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zFZNR5QOZBYa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through earnings">354</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Fair value adjustment through accumulated other comprehensive income</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zhNjeaH9OFa5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through accumulated other comprehensive income">(146</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustment through interest accrual</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zLErIKWgnKOd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through interest accrual">822</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zqe7Y2DTYfic" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">17,223</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zGRO4GIysI72" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance">17,223</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Principal repayments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zF9UaBSzflMi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Principal repayments">(17,374</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of convertible promissory note</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zFAaasce3Mwe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of convertible promissory note">3,150</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Issuance of unsecured senior convertible notes, net of fair value adjustment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_ecustom--IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zxqiZcy4m6dd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of unsecured senior convertible notes, net of fair value adjustment">689</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Conversion of debt into common shares</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zz2hQxzRVtKe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion of debt into common shares">(1,700</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Fair value adjustment through earnings</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_ecustom--FairValueAdjustmentThroughEarnings_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4SqkTJzQf1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through earnings">492</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Fair value adjustment through accumulated other comprehensive income</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zvPuDmokQ0b4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through accumulated other comprehensive income">5</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zbWbs4csl4Af" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">2,485</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zjyFz6XDPKI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">The following table presents
a reconciliation of the warrant liabilities measured on a recurring basis using Level 3 inputs for the years ended December 31, 2024 and
2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"><span id="xdx_8B5_zcldbup38v16" style="display: none">Schedule
of Reconciliation of Warrant Liabilities Measured on Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueNetAssetLiability_iS_pn3n3_c20230101__20231231_zv83jol6Vrw8" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Fair value, Beginning Balance">3,598</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">April 2023 Registered Direct warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--RegisteredDirectWarrantsIssuance_pn3n3_c20230101__20231231_zYQSGJmIAR0e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="April 2023 Registered Direct warrant issuance">4,280</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">July 2023 Registered Direct warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_ecustom--RegisteredDirectWarrantIssuanceDuringJuly_pn3n3_c20230101__20231231_zNAbj1Ln54fc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="July 2023 Registered Direct warrant issuance">2,645</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">January 2024 Bridge Loan - Tranche #2 warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20241231_zzrHJqazzILl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="January 2024 Bridge Loan - Tranche #2 warrant issuance">1,858</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Purchaser warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--PurchaserWarrantIssuance_pn3n3_c20240101__20241231_zRQhynbDgJS7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Purchaser warrant issuance">354</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Placement Agent warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--PlacementAgentWarrantIssuance_pn3n3_c20240101__20241231_zQ8q8BnPHXC9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Placement Agent warrant issuance">61</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Gain recognized in earnings from change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20230101__20231231_zSfHqRBVumY4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain recognized in earnings from change in fair value">(6,164</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reclassification of warrants from liability classified to equity classified</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_iN_pn3n3_di_c20240101__20241231_zAYvgaG8wXdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassification of warrants from liability classified to equity classified">(2,970</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iE_pn3n3_c20230101__20231231_zsJoXuGoalyj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value, Ending Balance">4,359</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance as of January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--FairValueNetAssetLiabilities_iS_pn3n3_c20240101__20241231_zupYiVyrn6Fh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Fair value, Beginning Balance">3,784</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">January 2024 Bridge Loan - Tranche #2 warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20241231_zL4C51rZusf7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="January 2024 Bridge Loan - Tranche #2 warrant issuance">1,858</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Purchaser warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--PurchaserWarrantIssuance_pn3n3_c20240101__20241231_zYqRQrDzXBv6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Purchaser warrant issuance">354</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">November 2024 Placement Agent warrant issuance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--PlacementAgentWarrantIssuance_pn3n3_c20240101__20241231_zm7Vjh1Xt2z4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Placement Agent warrant issuance">61</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Gain recognized in earnings from change in fair value</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20240101__20241231_zzkmZsqcwQ4j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain recognized in earnings from change in fair value">(110</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reclassification of warrants from liability classified to equity classified</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_iN_pn3n3_di_c20240101__20241231_zofKHTbfU5sj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassification of warrants from liability classified to equity classified">(2,970</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance as of December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_ecustom--FairValueNetAssetLiabilities_iE_pn3n3_c20240101__20241231_zFbzS9y3Xwj9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value, Ending Balance">2,977</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember', window );">May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock', window );">Schedule of Significant Inputs for Warrants</a></td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z4HlKRmYDho4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the May
2022 PIPE Warrants and the 2023 Registered Direct Warrants were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BC_zoUjs92MHBnc" style="display: none">Schedule of May 2022 PIPE
Warrants and 2023 Registered Direct Warrants</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_134_zEHOvFR1Mwhi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z6PG08ySPr5l" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zCRK8jT4vjC4" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.47</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zmEvPrAz9hM7" title="Exercise price">3.50</span>
- $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zfUk6mHWWwNh" title="Exercise price">7.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zrMGli18XHq9" title="Exercise price">3.50</span>
- $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zJWdhbVywlOe" title="Exercise price">7.50</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxGV7EC1yBg3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zEmedH3Yxuyi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zqqmdDhqA1F1" title="Term (years)">3.78</span> - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zAioW97a69J8" title="Term (years)">4.09</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zcGSO7wcj1H1" title="Term (years)">5.03</span> - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zYPkZGeS1hv" title="Term (years)">5.34</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxzAXW7Iyqv5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">4.3</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBP1NbAdcYS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">4.60</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zGKerOI6ie58" title="Warrant and right outstanding measurement input">98.5</span>%
- <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zqXn656Hh2Rf" title="Warrant and right outstanding measurement input">98.8</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmDWrMaUJ0jg" title="Warrant and right outstanding measurement input">97.0</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember', window );">January 2024 Bridge Loan - Tranche #2 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock', window );">Schedule of Significant Inputs for Warrants</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zTcYeIkClw3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the January
2024 Bridge Loan - Tranche #2 Warrants were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zZ0un3uuJzJ" style="display: none">Schedule
of January 2024 Bridge Loan</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_134_zfYZtbJYHUCe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of January 20224 Bridge Loan (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">July 15, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">January 16, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(reclassification)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zAbhamf6yZW" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">3.19</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_z64Ma4fo2Mof" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term to initial exercise date (years) (1)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt">N/A</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingTermToInitialExerciseDate_dtY_c20240116__20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_fKDEp_zcXnJ9apWTCk" title="Term to initial exercise date (years)">0.50</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z7VZpfBBKDAf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zUspIO83bWra" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zTUh2p0IL1h4" title="Term (years)">5.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zmJhZgZn5kze" title="Term (years)">5.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zQtJ5evwm8fl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate">4.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zE6CO87NoSzj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">3.90</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_za4iYSViZnu7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant and right outstanding measurement input">112.5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxyeuyuk4Ic8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants measurement input">107.5</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td id="xdx_F04_z71VMIls35L4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td>
  <td id="xdx_F13_zKhae20pVIZ5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As discussed
further in Note 10, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July
15, 2024, the warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the
Company&#8217;s own stock. As such, the warrants were adjusted to fair value as of the initial exercise date and then reclassified from
liability classified to equity classified.</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember', window );">November 2024 Purchaser and Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock', window );">Schedule of Significant Inputs for Warrants</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zvnUoeoQ9v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the November
2024 Purchaser and Placement Agent Warrants were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_ztlx07gIa4l1" style="display: none">Schedule of November 2024
Purchaser and Placement Agent Warrants</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_134_zf71QPEgAjk3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">November
    25, 2024 And December 3, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance) (1)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zfGGfYtsJZbc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-size: 10pt">$<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z46kT17Xe09" title="Common share price"><span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zdPSTTIBsnPg" title="Common share price">2.00</span></span> - $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zUBNXIdNreje" title="Common share price"><span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zD6q4W4va4Ei" title="Common share price">3.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term to Subsequent Financing (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_902_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDEp_zWcgJBsQJeA1" title="Term to Subsequent Financing (years)">0.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241125__20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zwMw4iO8pdL4" title="Term to Subsequent Financing (years)"><span id="xdx_90F_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241203__20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zsMAnpTzZCy9" title="Term to Subsequent Financing (years)">0.1</span></span> &#8211; <span id="xdx_90F_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241125__20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zaZtsaHXQC6i" title="Term to Subsequent Financing (years)"><span id="xdx_90B_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241203__20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_znGABSFOpMX3" title="Term to Subsequent Financing (years)">0.6</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_z2ubyhNq9aP1" title="Exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1477">-</span></span></span><span style="font-size: 10pt">(2)
                                            (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_zNuCSAwlQxbb" title="Exercise price"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_zTugOBVBSw2" title="Exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1479"><span style="-sec-ix-hidden: xdx2ixbrl1481">-</span></span></span></span></span><span style="font-size: 10pt">(2)
                                            (3)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zyra5DSUeNdi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zqTqJDZCG9w8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zlYgUJDN3XN2" title="Dividend yield">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zrf14xqZGeQg" title="Term (years)">4.9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zQM7oWhv7xg2" title="Term (years)"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zwLjgcQrbbj7" title="Term (years)">4.9</span></span> - <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zJBWbv0TIhd8" title="Term (years)"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zn5pqv4KyjNf" title="Term (years)">5.0</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zjXhXlFf6lch" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate">4.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z7kdEynBbjV4" title="Risk-free interest rate"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zYCIPq13Jt7l" title="Risk-free interest rate">4.00</span></span>% - <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zXs8IFU1i6Yc" title="Risk-free interest rate"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zrczjLQgNIc4" title="Risk-free interest rate">4.10</span></span>%</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z4DuF0GwDnq4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant and right outstanding measurement input">50.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zHJJnU0FRPxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants measurement input"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zEtlV5c2Xc8d" title="Warrants measurement input">50.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zwHFDf6Kt7oc" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zaexGBibPay7" style="font-size: 10pt">As discussed in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F0C_zo1gJoXsJVn6" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F15_z1UxLlq7Ve35" style="font-size: 10pt">The exercise price of the November 2024 Purchaser Warrants is based on the lesser of (i) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zqWPryMPDFY" title="Exercise price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zay0CNo8kkFc" title="Exercise price">2.85</span></span> or (ii) the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zHA1eE5Olt08" title="Floor price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zJ5hleIJxI8l" title="Floor price">1.00</span></span>. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F04_zTvOtzIYoIMl" style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zZ0Nol6SrmT5" style="font-size: 10pt">The exercise price of the November 2024 Placement Agent Warrants is based on the lesser of (i) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zO2jaDs7pQ78" title="Exercise price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zCedlLw6AzQh" title="Exercise price">3.56</span></span> or (ii) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_ecustom--OfferingPricePercentage_iI_pid_dp_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z7jn9S0Q2kz4" title="Offering price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--OfferingPricePercentage_iI_pid_dp_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6z2KSFYOoUa" title="Offering price">125</span></span>% of the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6RlELFC2O76" title="Floor price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zXObzrFkExgd" title="Floor price">1.00</span></span>.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_GXSponsorWarrantsMember', window );">GX Sponsor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock', window );">Schedule of Significant Inputs for Warrants</a></td>
<td class="text"><p id="xdx_892_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--GXSponsorWarrantsMember_zGrSlJfF6DBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the Sponsor
Warrants are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BB_zB0hiBDOJ4C7" style="display: none">Schedule
of Significant Inputs for  Warrants</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30D_134_zAdfdWkMttb7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Schedule of Significant Inputs for Sponsor Warrants (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b>December 31,</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 68%; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b>2024</b></span></td>
    <td style="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="border-top: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"><span style="font-size: 10pt"><b>2023</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Common share price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zdLpurqPp6A9" title="Common share price">2.08</span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zHrA3tQ4MLil" title="Common share price">2.47</span> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Exercise price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zIjzfAiMIA33" title="Exercise price">115.00</span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">$ <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zDtY0m1KwlSk" title="Exercise price">115.00</span> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_znSj9p5G03x7" title="Dividend yield">0</span>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zkmoPeuCUJqa" title="Dividend yield">0</span>%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Term (years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 2.65pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zJG9hzzs3Ie9" title="Term (years)">1.5</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 2.65pt; text-align: right"><span style="font-size: 10pt"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zzBfFK2s4on2" title="Term (years)">2.5</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Risk-free interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zlL5PZSicnPh" title="Dividend yield">4.21</span> %</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zLvpUZm4ACi" title="Dividend yield">4.12</span> %</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"><span style="font-size: 10pt">Volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zFdi7bi7MYG5" title="Warrant and right outstanding measurement input">111.4</span> %</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"><span style="font-size: 10pt">&#160;<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zU0Uag68bPC4" title="Warrant measurement input">100.7</span> %</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Convertible Notes Valuation Model</a></td>
<td class="text"><p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zfo8uakP2dzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the Yorkville
convertible promissory note valuation model were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"><span id="xdx_8B8_zRmKbrmT24b3" style="display: none">Schedule
of Yorkville Convertible Promissory Note Valuation Model</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_134_zOfiwpenfdxc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">March 13, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zMqZRp1rMQYk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zxs1LosLo8fc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">5.79</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Credit spread</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zLvvUhVDsDF6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread">7.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_z2IzhynUZUB2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread">8.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVV2H3Upm6yl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_dp_uPure_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z6Ks0qa9vmYi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtY_c20241231__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_ztu2y3fZZrcd" title="Term (years)">0.20</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtY_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zs1dCz38dpKc" title="Term (years)">1.00</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zemIL64A3Sa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate">4.30</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zZvfYkcT7fZa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate">4.90</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zdfWGeHfU5fc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility">50.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_z2aDlnnw0YM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible promissory note valuation measurement">50.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Convertible Notes Valuation Model</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zTvux3YbDZIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Significant inputs for the unsecured
senior convertible notes valuation model were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BD_zk68lVch4AYc" style="display: none">Schedule of Convertible Notes Valuation Model</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_134_zKMHyYVPLnzg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Convertible Notes Valuation Model (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">November
    25, 2024 and December 3, 2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><b>(issuance) (1)</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Common share price</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zZTqX6286Cd2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price">2.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-size: 10pt">$<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zLdyZuROQD85" title="Common share price"><span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zxflIT1IHQzd" title="Common share price">2.00</span></span> - $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zSgBqNNguSpi" title="Common share price"><span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zyuD3A9OV6wd" title="Common share price">3.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Credit spread</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zVDI4VzbsIQg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread">7.6</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z2uQH62zK8ig" title="Credit spread"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zAh06WBCci26" title="Credit spread">6.9</span></span>% - <span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zhhrcNJelGa" title="Credit spread"><span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zEAsIfUYXqM8" title="Credit spread">7.2</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJd7tlAjGaLh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zUGtc8ylboFa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"><span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zkkpx6rrEkKj" title="Dividend yield">0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Term (years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentTerm_dtY_c20241231__20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zMbKtC0UigYg" title="Term (years)">0.90</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z7jKIqN6Tg8" title="Term (years)"><span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_c20241203__20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zALKmgbTgC79" title="Term (years)">0.98</span></span> - <span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zRqleYV3qTCj" title="Term (years)"><span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20241203__20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zSRZYbnhzw84" title="Term (years)">1.00</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zMy7V7zPVt29" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate">4.20</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zjoNobOYO79f" title="Risk-free interest rate"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zmpMbwWuLrza" title="Risk-free interest rate">4.30</span></span>% - <span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zifSE1MeQCfg" title="Risk-free interest rate"><span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zMydr8j9YtB2" title="Risk-free interest rate">4.40</span></span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zvRQnJF2wXA" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility">50.0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_fKDEp_zSsteMh4V2u4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unsecured senior convertible notes valuation measurement"><span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zrJk7b2gmGN7" title="Unsecured senior convertible notes valuation measurement">50.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
  <td id="xdx_F0A_zCJMq6KSn8i4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td>
  <td id="xdx_F1A_z0jldVQDcmsl" style="font: 10pt Times New Roman, Times, Serif">As discussed
in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.</td></tr>
</table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=CELU_AcquisitionRelatedContingentConsiderationObligationsMember', window );">Acquisition - Related Contingent Consideration Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Contingent Consideration Obligation Measured on a Recurring Basis</a></td>
<td class="text"><p id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_hus-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_z6CBmcdOyEgk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs for the years ended December
31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BA_zHZbPLTYsDQe" style="display: none">Schedule
of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_134_zNw4XXVgHO08" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zYJsuLNyjdMk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">1,606</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zDRjxdHhzJ88" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1199">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zmmUuDNaRxni" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl1201">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zVEsLod7WOd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments">(193</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zt8vlGcR6nXk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance">1,413</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_301_134_zNC3CdBWLkj4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of)</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Acquisition-related contingent consideration obligations</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zgKVqS6FHds4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">105,945</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zh3XTRHRkxY3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"><span style="-sec-ix-hidden: xdx2ixbrl1209">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_z2ZvNt2EbTS3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"><span style="-sec-ix-hidden: xdx2ixbrl1211">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zSMQPI9PFEGc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments">(104,339</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zN0pxvdHgzl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance">1,606</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=CELU_ContingentStockConsiderationMember', window );">Contingent Stock Consideration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Contingent Consideration Obligation Measured on a Recurring Basis</a></td>
<td class="text"><p id="xdx_896_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_hus-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrgIdd6CCJ6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents a
reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level 3 inputs for the years ended
December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zyurDf37iSEl" style="display: none">Schedule
of Reconciliation of  Contingent  Consideration Obligation Measured on a Recurring Basis</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_134_zW1PSCMU8oc9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1, 2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of) </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2024</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zREGJY4dLpHc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">27</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zDZshqLpWFv5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1221">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_za5rNgaSgQaf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1223">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrSf4Fxc8xB1" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments">&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1225">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zM7E2M5RFyVj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance">27</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_305_134_zeyYDCS4uIO6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>January 1, 2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Net</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>transfers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>in to (out of) </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Level 3</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Purchases,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>settlements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>and other</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>net</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Fair value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>adjustments</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Balance as of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>December 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>2023</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left">Contingent stock consideration</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zeV8B7OeS81" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance">186</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrmPNoNkTqsk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3">&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1231">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_z6uT9Pz8O09c" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl1233">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zfkuwXI8oiMf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments">(159</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zF6YQa9MfQzk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance">27</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Assets Of Yorkville Debt Measured On Recurring Basis Unobservable Input Reconciliation [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Convertible Note Valuation Model Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Fair Value Significant Inputs For Warrants Issued [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_GXSponsorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_GXSponsorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=CELU_AcquisitionRelatedContingentConsiderationObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=CELU_AcquisitionRelatedContingentConsiderationObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=CELU_ContingentStockConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=CELU_ContingentStockConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock', window );">Schedule of Major Classes of Inventories</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_zbJGEZG537Ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company&#8217;s major classes
of inventories were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B2_zNXMLq17be14" style="display: none">Schedule of Major Classes of Inventories</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20241231_z0oxNuQH6BM9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_z1Sy0CV749j8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryRawMaterialsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zhgsDZuCwOoa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Raw materials</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">42</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,081</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InventoryWorkInProgressCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zVB3cP12G5M3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Work in progress</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">8,093</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,696</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--InventoryFinishedGoodsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zIJhOEWkJYhc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Finished goods</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11,964</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,922</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryGrossCurrentAndNoncurrent_iTI_pn3n3_mtIGCANzRGk_maINCANzn4U_zR9JoHVr99Fh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Inventory, gross</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">20,099</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">24,699</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--InventoryReserveCurrentAndNoncurrent_iNI_pn3n3_di_msINCANzn4U_zQKbRCaEbD27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: inventory reserves</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,103</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,289</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzn4U_zjOUTiYxcyBj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Inventory, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,996</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,410</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance sheet classification:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InventoryNet_iI_pn3n3_maINCANzRqB_zkUsypJ2wO8b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,409</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,753</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InventoryNoncurrent_iI_pn3n3_maINCANzRqB_zYrOm4DbQWJl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Inventory, net of current portion</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,587</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,657</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzRqB_zUrrpmwh493i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory,
    net</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">17,996</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,410</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ScheduleOfActivityInInventoryReservesTableTextBlock', window );">Schedule of Inventory Reserves</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfActivityInInventoryReservesTableTextBlock_zoEC85ifNptj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A schedule of the activity in
the inventory reserves is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B6_zt5KLN76Jir9" style="display: none">Schedule of Inventory Reserves</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%">Balance at January 1, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20230101__20231231_zz06ao9xkpqk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance">1,099</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Provision for obsolete inventory</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ProvisionForObsoleteInventory_pn3n3_c20230101__20231231_zPXHSsX6uZx8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions for obsolete inventory">7,627</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Write-offs</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231_zJHTXS7zIXDd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-offs">(6,437</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20240101__20241231_zid77wqlTBR5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance">2,289</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Provision for obsolete inventory</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_ecustom--ProvisionForObsoleteInventory_pn3n3_c20240101__20241231_zNYqVjdhWtic" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Provision for obsolete inventory">(186</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_ecustom--InventoryReserveCurrentAndNoncurrent_iE_pn3n3_c20240101__20241231_z4Cf0d7yZPK9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance">2,103</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ScheduleOfActivityInInventoryReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Activity In Inventory Reserves [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ScheduleOfActivityInInventoryReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Inventory Current And Noncurrent [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqYfYW8Dbhuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Prepaid expenses and other current
assets consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4EEgadYQn07" style="display: none">Schedule of Prepaid Expenses and Other Current Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20241231_zi4ei7GVBExl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zsxUhxK2I4t8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidClinicalExpense_iI_pn3n3_maPEAOAzmHw_zomryCENgGJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Prepaid clinical expenses</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">221</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">688</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzmHw_zs27gXEcEKtc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Prepaid insurance expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">375</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">678</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzmHw_zXnzH76PbSYf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">261</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">329</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzmHw_zVQJCjGAr3fb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">857</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,695</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zrEB20Nhmw9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Property and equipment, net consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B0_zV1V4CvDzjj6" style="display: none">Schedule of Property and Equipment, Net</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zu1AF8La1y4c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zohzI8AJFkeg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zon6DKNLfu6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Leasehold improvements</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">73,211</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">73,211</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryAndProductionEquipmentMember_zVnagmLc6SSd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Laboratory and production equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,093</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">14,093</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryEquipmentAndFixturesMember_zoDb4Y1Ecrp8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Machinery, equipment and fixtures</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,163</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">7,781</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zgtMKGpgvAm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Construction in progress</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1646">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">21</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzl3Y_zaEDlb83rPW7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Property and equipment</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">94,467</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">95,106</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzl3Y_zsJCGdbHmB4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less: Accumulated depreciation and amortization</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(32,867</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(27,278</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzl3Y_znmECYxPwsa1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">61,600</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">67,828</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ScheduleOfIntangibleAssetsNetTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><p id="xdx_89A_ecustom--ScheduleOfIntangibleAssetsNetTableTextBlock_zp9R0cz9cBoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Intangible assets, net consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;<span id="xdx_8BD_zEI0baKYzh72" style="display: none">Schedule of Intangible Assets, Net</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center">Estimated Useful</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Lives</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortizable intangible assets:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left">Developed technology</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zk4Hg6LIWdI" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z8DV7ILVQOCl" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Amortizable intangible assets">16,810</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%; text-align: center"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zKomfhsDWbX8" title="Estimated useful lives"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zKeqrOcyApE7" title="Estimated useful lives">11</span></span> &#8211; <span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zE7O61tLP2jg" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zGZ8JDgOKlt8" title="Estimated useful lives">16</span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Customer relationships</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpey0st8Psof" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">2,413</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zt79MvYyhrrd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">2,413</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZNRm9GWyzOe" title="Estimated useful lives"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_znA3YFipl42k" title="Estimated useful lives">10</span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Trade names &amp; trademarks</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zQtE0ZjLJ3Td" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">570</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z1K0sSPuLrpk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">570</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zypKiA9HYaJ3" title="Estimated useful lives"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zLJ6nI2dRzFj" title="Estimated useful lives">10</span></span> &#8211; <span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zmxkha5Nynoh" title="Estimated useful lives"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zT5gbhQv4yma" title="Estimated useful lives">13</span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reacquired rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zCOBGXONR1Xe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">4,200</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z0Q6d4BviyFj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">4,200</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zRVXc399vNK2" title="Estimated useful lives"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zuPFnsfYBbJk" title="Estimated useful lives">6</span></span> years</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231_zMysKLxwjrM3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">23,993</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zKntFN5eObw7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets">23,993</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Less: accumulated amortization</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Developed technology</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zuIiJvpDIE76" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(8,895</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zYggwKni2n4c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(7,722</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Customer relationships</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMJutBLF2Gzc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(1,965</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zm0AIZpePhp1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(1,700</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Trade names &amp; trademarks</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zRf3C91RYWL4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(385</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zq7vyMKCivQe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(330</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Reacquired rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zYQCEH6iTGwe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(4,200</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z6rGmCBUzS85" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(3,940</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231_zCO8uBdZSHg1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(15,445</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zsoXmgHUdaga" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization">(13,692</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Amortizable intangible assets, net</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20241231_zeAQLZlamwXb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets, net">8,548</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zH0T6eOSvxK1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets, net">10,301</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-amortized intangible assets</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Acquired IPR&amp;D product rights</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pn3n3_c20241231_zCwQlrHnCual" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Acquired IPR&amp;D product rights">700</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pn3n3_c20231231_zD6WkEBB7u58" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Acquired IPR&amp;D product rights">700</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"><span id="xdx_90D_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20240101__20241231_zJ8NLo7eOplc" title="Estimated useful lives"><span id="xdx_903_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231_zJRToTbP3Oi3" title="Estimated useful lives">indefinite</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zN9HH3HOXyC4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Intangible assets, net">9,248</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231_zw7IsKKgInCa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Intangible assets, net">11,001</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Aggregate Amortization Expense Related to Intangible Assets</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zsnhUmgIjgEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Aggregate amortization expense
for each of the five succeeding years and thereafter related to intangible assets held as of December 31, 2024 is estimated as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zIfmSuNTef3g" style="display: none">Schedule of Aggregate Amortization Expense Related to Intangible Assets</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_499_20241231_z5US2EjNLEja" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANziI0_z0mTudr8y395" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">1,493</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANziI0_z1YnuRaZCey1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,356</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANziI0_zYCmO88Xjf94" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,258</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANziI0_zOZP3u3m1stl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,208</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANziI0_zvMflM025v27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2029</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,155</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANziI0_zpwNfqesTSr3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,078</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANziI0_zM1f7lQIOgtf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
    expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">8,548</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ScheduleOfIntangibleAssetsNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Intangible Assets Net [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ScheduleOfIntangibleAssetsNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zoX30kvD2mj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Accrued expenses and other current
liabilities consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zIUy5zgunx62" style="display: none">Schedule of Accrued Expenses and Other Current Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20241231_zUAi0bF2i42i" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20231231_zuwPaF1q9IUd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedClinicalTrialExpense_iI_pn3n3_maALCzZ4Y_zzAhWduSOoRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Accrued clinical trial expense</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">189</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">189</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZ4Y_zJ6XaJr5vRmc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued professional fees</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">691</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">573</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_zrvXYFNqhztb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued wages, bonuses, commissions and vacation</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,797</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,011</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccrualsForConstructionInProgress_iI_pn3n3_maALCzZ4Y_zn9pm8Seomub" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accruals for construction in progress</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">135</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">214</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzZ4Y_zppufrkn0l51" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued interest</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,798</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1803">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccruedComplianceFee_iI_pn3n3_maALCzZ4Y_zTcBA7RcvQ1f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Accrued compliance fee</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">10,277</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,145</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_z2OK4PmAx5Bc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">955</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,448</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZ4Y_zaLHpancMSKc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    accrued expenses and other current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,842</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,580</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zK6Q9XSMaC9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Debt consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B4_zvoiRhCYEAuh" style="display: none">Schedule
of Debt</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20241231_zHu7pAPGbOW" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20231231_zZqnJOOrQPv2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Debt - unaffiliated:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zyA9YHtaLfJi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left">Yorkville - PPA (measured at fair value)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1818">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">17,223</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--ConvertiblePromissoryNotesMember_zqsGDZKzQrz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Yorkville - convertible promissory note (measured at fair value)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,865</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1822">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--CreditFacilityAxis__custom--UnsecuredSeniorConvertibleNoteMember_zHs57v3UQFL3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Unsecured senior convertible notes (measured at fair value)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">620</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1825">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--OtherShortTermDebt_iI_pn3n3_zVEapbxVD6wh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Short-term debt - other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1827">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,108</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_zvnBk4RyqYTb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total debt - unaffiliated</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,485</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,331</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Debt - related parties:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CVStarrBridgeLoanNetOfDiscountMember_zB6V0cUxTM8i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">C.V. Starr Bridge Loan, net of discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,652</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,523</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--RWIBridgeLoanNetOfDiscountMember_zqMwMDQu5Axb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">RWI Bridge Loan, net of discount</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">30,275</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">12,967</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zy480WSqLQo9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">CEO promissory note</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,876</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,419</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_zH425rxDLV0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">39,803</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">19,909</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--Debt_iTI_pn3n3_zyvhxlDi9rCl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 2.5pt">Total debt</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">42,288</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">39,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Balance sheet classification:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShortTermBorrowings_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z8IP16kNtQU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - unaffiliated</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,485</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19,331</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2FkvjdwenYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Short-term debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,876</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">19,909</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4DEWC6mnYVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt">Long-term debt - related parties</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">35,927</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1855">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--Debt_iTI_pn3n3_znK7NZGmPrz7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    debt</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">42,288</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">39,240</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Costs</a></td>
<td class="text"><p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zzZwHVMfDS09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The components of the Company&#8217;s
lease costs are classified on its consolidated statements of operations and comprehensive loss as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8BC_zEvjVtPLhjy8" style="display: none">Schedule of Lease Costs</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_492_20240101__20241231_z01c7OEiLum6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zr2OEtetPtNe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzz3O_zQPvpqJHDyz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,911</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,256</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--VariableLeaseCost_maLCzz3O_z2Dke0KHhmwj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Variable lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,348</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,132</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LeaseCost_iT_mtLCzz3O_z3dA7Ic5ESs5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total operating lease cost</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,259</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">4,388</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock', window );">Schedule of Cash Activity Related to the lease Liabilities</a></td>
<td class="text"><p id="xdx_89B_ecustom--CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_zUyVx6kQYK87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The table below shows the cash
activity related to the Company&#8217;s lease liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B3_zxKbWd3fK01l" style="display: none">Schedule of Cash Activity
Related to the lease Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20240101__20241231_z4ONtJT2joai" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231_zFFb7eV4Du76" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash paid related to lease liabilities:</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeasePayments_zIwRZpFFzHBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Operating cash flows from operating leases</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,378</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">2,995</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments under Operating Leases</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zeGRIeMXVnHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">As of December 31, 2024, the maturities
of the Company&#8217;s operating lease liabilities were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="xdx_8B0_zKzb7mbioMVc" style="display: none">Schedule
of Future Minimum Payments under Operating Leases</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_493_20241231_zt7xViQDUVO" style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPznn8_zAFNfB3fXeLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left">2025</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">3,452</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPznn8_zBDPk29rFmHh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2026</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,526</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPznn8_zH75YC2c8TZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2027</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,599</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPznn8_zkdyi0jYyBp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2028</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,673</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPznn8_zRyx60139Kuk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">2029</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,746</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPznn8_zkGgZuJvQkG7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Thereafter</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">80,821</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznn8_zpq5tiEUlcw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Total lease payments</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">98,817</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zbxAJ1eTPXng" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less imputed interest</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(72,269</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_z8mDX89PLs0c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26,548</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Non Cash Activity Related To Lease Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of the Warrants</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zqDAMexY9Ui5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;<span id="xdx_8B8_zKad2K7DCD7" style="display: none">Summary of the Warrants</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>shares</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>price</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Expiration</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>date</b></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left">Dragasac Warrants (1) (4)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____z0ajEyNc7Gri" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of shares">652,981</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____z8rfYtZnGm0c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise price">2.4898</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____zinEqo0yyrj2" title="Expiration date">March 16, 2025</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Public Warrants (2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zD7zdoffSM62" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">1,437,447</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zB5PsoNJXGE8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">115.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zbLI7oxrz5Ye" title="Expiration date">July 16, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Sponsor Warrants (2)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zOETGiKL24Af" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">849,999</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zG7kLfJ7pqBa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">115.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zw7uGCgnGvxd" title="Expiration date">July 16, 2026</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">May 2022 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zNBLwgk4u2M6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">405,405</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zYnIQ2JKWm62" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">3.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_z9aJUtHsiila" title="Expiration date">October 10, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">March 2023 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zUxz96duCA9h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">208,485</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zrAr8lT7pT7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">30.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zbMTTbD0VWKc" title="Expiration date">March 27, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">March 2023 PIPE Warrants (modified)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zP7VnzVPnA1g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">729,698</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zB4FeFTE49ka" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zTinxyaSs7C4" title="Expiration date">March 27, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">March 2023 Loan Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_znGDbJamzLb2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">75,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_zuYOPZJcdbu5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">5.8950</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_z8mn0HGHCDu2" title="Expiration date">March 17, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">April 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKOrvgR95rk7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">435,625</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_z5ana1gABy3f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">7.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zJKCZ8wAHof9" title="Expiration date">October 10, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">April 2023 Registered Direct Warrants (modified)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zq37NcuNL3a8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">487,451</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zDignA4wcAh9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">3.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_z3dbEpyhwLI5" title="Expiration date">October 10, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">May 2023 PIPE Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zI4rOAiVvCij" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">581,394</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zvM8PcQRmBAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">10.00</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zd5RNva34Wxe" title="Expiration date">May 17, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">June 2023 Warrants (3)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zeCpcQOTjk6f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">50,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zdMvnGprRZpf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">5.8950</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zBVhMP3jdaTi" title="Expiration date">June 20, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">June 2023 Loan Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zQQc2iOSUeJ9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">300,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_z77BMZWgNc9f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">8.10</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_ztf6Zdk7HOP3" title="Expiration date">June 20, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">July 2023 Registered Direct Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zFxWian5umj6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">857,142</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zhUxE7E1J034" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">3.50</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKAC9gfv4dya" title="Expiration date">January 31, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">January 2024 PIPE Warrants (4)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_zyfcgBb1FFFj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">535,274</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_z5X4MytO6C6g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.4898</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_zu80bN8I5Ofk" title="Expiration date">January 16, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">January 2024 Bridge Loan - Tranche #1 Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zE6EeyOX72B" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">1,650,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zXUvDttoFB0b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.4898</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_z7usxMXNNxQg" title="Expiration date">January 16, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">January 2024 Bridge Loan - Tranche #2 Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zOZ7yCW1h3Tg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">1,350,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zqSWqzySTfn6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.9880</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zgQ38ONYpxVg" title="Expiration date">July 15, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">March 2024 RWI Forbearance Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_ziSrMKBgY6n6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">300,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zYFg60Zj7Nq" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">5.8958</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zz6eqvfyOVsk" title="Expiration date">June 20, 2028</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">November 2024 Purchaser Warrants</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember_zaMPNsvijBw9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">263,156</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember_zlIGAKCCmTri" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price">2.85</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember__srt--RangeAxis__srt--MinimumMember_zemQZleBalsi" title="Expiration date">November 25, 2029</span> - <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember__srt--RangeAxis__srt--MaximumMember_zFdB8Lo57Zge" title="Expiration date">December 3, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">November 2024 Placement Agent Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_ztFSS2vs3ty9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">52,500</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zFUgq2fTDmKl" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Exercise price">3.56</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"><span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_z9H1KcEEjrv1" title="Expiration date">November 25, 2029</span> - <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_z6Q7qsYVDzna" title="Expiration date">December 3, 2029</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zmqvCnSL8DGb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares">11,221,557</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>&#160;</i></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td id="xdx_F01_zaUWrq4ZJf36" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F10_zU7ufP8Z2xui" style="font-size: 10pt">In connection with the execution of the January 2024 PIPE described above, the Company agreed to reprice <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_z0CxQy6hgMJh" title="Number of warrants repriced">652,981</span> legacy warrants held by Dragasac with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zJ7gS6haRbBc" title="Exercise price per share or per unit of warrants or rights outstanding">67.70</span> to a new exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zYVzxB4PfIah" title="Exercise price">2.4898</span>. The term of the warrants was unchanged.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F02_zpkmujJUSn29" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1D_zsXTc6rGNjph" style="font-size: 10pt">The number of Public Warrants
and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_zHSrw9l6fBM" title="Warrants outstanding">14,374,478</span> Public Warrants and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zhb8lpf7vX1c" title="Warrants outstanding">8,499,999</span> Sponsor
Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant
is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfdpdBsJpoed" title="Exercise per share price (in Dollars per share)">115.00</span> as a result
of the split.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F07_zYFMOuFpTkL1" style="font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zmEyC4kJiPda" style="font-size: 10pt">In connection with the execution
of the Starr Forbearance Agreement on March 13, 2024, described above under Warrant Modification and further in Note 10, the Company
agreed to reprice <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zNKnX4iQB39l" title="Number of warrants repriced">75,000</span> warrants with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zB4Cdrckei1h" title="Exercise price">7.10</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zGIhzk4KHX5l" title="Number of warrants repriced">50,000</span> warrants with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313_ztdMSGu7CCBf" title="Exercise price">8.10</span>
held by C.V. Starr to a new exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zYKfrX5dCT29" title="Exercise price">5.895</span>. The term of the warrants was unchanged.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F04_zDR8Xy7PCx4h" style="font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zWd9mgsl4eQl" style="font-size: 10pt">On January 24, 2025, the
Company agreed to reduce the exercise price of the Dragasac warrants and the January 2024 PIPE warrants from $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zDOZqY4vlhF5" title="Exercise price">2.49</span> per share to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zfw8z5NDCiqh" title="Exercise price">2.07</span>
per share. As a result of the price reduction, the holder agreed to immediately exercise the warrants in full and to purchase an aggregate
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zs0kpvh31E5b" title="Aggregate shares">1,188,255</span> shares of the Company&#8217;s Class A common stock for gross proceeds to the Company of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250124__20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJKjoIgtMeje" title="Proceeds from the exercise of warrants">2.5</span> million<i>.</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zHSi7VNtimMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table presents,
on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of
stock options granted during the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BE_zYZqiUnPXdY6" style="display: none">Schedule
of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_z2potn9roIG5" title="Risk-free interest rate">4.4</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zHl1CZ2pHpVh" title="Risk-free interest rate">4.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected term (in years)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zkwd3rGxq8T2" title="Expected term (in years)">5.7</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_z9cm5bOa8hn7" title="Expected term (in years)">5.6</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_z4S89HLms7e6" title="Expected volatility">104.9</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zAbmS7zcuBj2" title="Expected volatility">86.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zplEkoymBS58" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl2684">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zbEOdeV1aY8b" title="Expected dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl2686">&#8212;</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zbJRYdYPlJFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table summarizes
option activity with service conditions under the 2021 Plan and the 2017 Plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B7_zG2i2ti5NyG7" style="display: none">Schedule of Stock Option Activity</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Options</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Exercise Price</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Contract Term</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>(years)</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Aggregate</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Intrinsic</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Value</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%">Outstanding at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zF3IYl6nrHu7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options beginning balance">2,820,187</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zoyox20ifwRb" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, beginning balance">40.16</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zXdRJbXwnUFh" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Contract Term">5.6</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zCES6e24mm3i" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl2700">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zHBRRWhxZNU8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Granted">1,503,394</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z9wP3RaRS9J7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted">3.26</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zM79G07533W7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Exercised">(20,744</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zJMc6pjrZmz2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised">2.80</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Forfeited/Expired</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zEN22apL8W43" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options  Forfeited/Expired">(341,312</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zGwGKKQKXEGa" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited/Expired">29.51</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding at December 31, 2024*</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____ziiElOR6ieD1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options ending balance">3,961,525</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zCXYjC5bYQ96" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, ending balance">27.27</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zzU2IuFCZSPi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Contract Term">6.4</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____z2g25bNo2c86" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value">16</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Vested and expected to vest at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z4DWpWCjrpp6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Vested and expected to vest">3,961,525</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z6uGximBcL7e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Vested and expected to vest">27.27</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zG1uF8gKqDjb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Contract Term, Vested and expected to vest">6.4</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zwzPVArM19v2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Vested and expected to vest">16</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Exercisable at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zueTC5c1bAi9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Exercisable">2,586,561</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zI8ItzR1OnB8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable">37.49</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zku2lDcJSgTg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Contract Term Exercisable">4.9</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zUGFYOScdgS" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2736">&#8212;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td id="xdx_F0F_zB4AoTlKrtr2" style="width: 15pt; text-align: right">*</td><td id="xdx_F1D_zLXerFXny1Wc" style="text-align: justify">Options outstanding at December 31, 2024 under the 2021 Plan and 2017 Plan were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zJXOtNTlcnPg" title="Options outstanding">2,569,029</span> and
                                                                             <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zBXUGuFGvff8" title="Options outstanding">1,437,496</span>, respectively. Options outstanding at December 31, 2024 under the 2021 Plan include <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_z1vLdctHuub8" title="Options outstanding including awards">45,000</span> awards with performance
                                                                             conditions (see below).</td>
</tr></table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Activity Related to RSU Stock-Based Payment Awards</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zqTyDgwas09a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table summarizes
activity related to RSU stock-based payment awards under the 2021 Plan:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BC_zSXrC3ysNlUj" style="display: none">Schedule
of Activity Related to RSU Stock-Based Payment Awards</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Number of</p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Shares</p></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>Grant Date Fair Value</b></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Outstanding at January 1, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNALfbpj75qb" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of Shares, Outstanding beginning balance">823,332</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zytdOBicjFqk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value,Outstanding beginning balance">13.77</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Granted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPpuztLsUrMk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted">337,080</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqSxsnwAFd6a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted">2.23</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt">Released</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb9ccMxJtKmc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Released">(400,996</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaMY8zj0UKFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Released">11.58</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt">Forfeited</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXrulQsvRS1b" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited">(99,977</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z09oFjThdPM6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited">13.24</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding at December 31, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTMssxfDjrkd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Outstanding ending balance">659,439</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfIVN9J5UJud" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding ending balance">9.29</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zFenUch6J8Pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The Company recorded stock-based
compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8B8_zGrfAobJxpB1" style="display: none">Schedule
of Stock-based Compensation Expense</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231_zpCCS3OARQOk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zlS3CHNW0iY7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zBJyVCyCdy3a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Cost of revenues</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">450</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">580</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4xEVC9YXIW4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Research and development</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,287</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,832</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zdpAFtrQkOKi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9,832</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,605</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z5JTi4sY6kU1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
    compensation expense</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">11,569</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15,017</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue by Product and Services</a></td>
<td class="text"><p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_zROoRw6VM9Xh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table provides information
about disaggregated revenue by product and services:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span id="xdx_8BF_zt6RnZ0QmU8g" style="display: none">Schedule
of Disaggregated Revenue by Product and Services</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zdrQC8CKc5xl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230101__20231231_zLt4mVa3r0qe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended December 31,</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zEW9OaK2KmO9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Product sales, net</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">35,336</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">13,149</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zCj0kf6Hgt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Services</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,140</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,441</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_zH04zl1TXRIh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">License, royalty and other</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,744</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,181</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zPX4N7a5iaJl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenues</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">54,220</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">22,771</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock', window );">Schedule of Changes in Deferred Revenue from Contract Liabilities</a></td>
<td class="text"><p id="xdx_891_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zxrUfkApAj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The following table provides changes
in deferred revenue from contract liabilities:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"><span id="xdx_8B0_z6sEHbgyCuyb" style="display: none">Schedule of Changes in Deferred Revenue from Contract Liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20240101__20241231_zgcH59FHu7Hf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2024</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_z0aJk7FE0jFl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zpdE3pR8daW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Balance at January 1</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">6,020</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">4,492</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zKWnLp2hTeXe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Beginning Balance</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,020</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">4,492</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_ecustom--ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_pn3n3_z9cqP8P7KSz8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">Deferral of revenue <span id="xdx_F44_zlYoFHsrAbjb">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,731</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,266</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn3n3_zIryK7iBJilg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Recognition of unearned revenue <span id="xdx_F49_z9a1Na1pz1L">(2)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,496</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,738</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zchUp2VJK0P9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at December 31</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,255</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zRUhVhWBte6d" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Ending Balance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,255</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,020</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F06_zR7xVvRdZReb" style="font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F14_zvoy2DxJ072b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferral
    of revenue includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DeferredRevenue_iI_pn3n3_c20241231_zbtl13DKTSt6">5,061</span> in 2024 resulting from payments received in advance of performance under the biobanking services storage
    contracts that are recognized as revenue under the contract as performance is completed.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F00_z2KygN5bQh7d" style="font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1B_zil4UEkHihvf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition
    of unearned revenue includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_ecustom--UnearnedRevenue_iI_pn3n3_c20241231_zQdD2DbYPnl6">2,561</span> that was included in the beginning deferred revenue balance at January 1, 2024.</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueByArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueByArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Current and Deferred Tax Provision</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z3M0NuN8Cwh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the Company&#8217;s current and deferred tax provision is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8BC_zsHdMHqJd9v2" style="display: none">Schedule
of Current and Deferred Tax Provision</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49A_20240101__20241231_z0e9IhQQ7L64" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20230101__20231231_zhtwx24pxe87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current income tax expense:</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzRNM_zI2maAw2fDNb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2920">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2921">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzRNM_zK6Vep8cO504" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; width: 62%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 15%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2923">&#8212;</span></td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; width: 15%; text-align: right">10</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzRNM_maITEBzV7j_zQ0IhocEGkLb" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current income tax expense</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2926">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income tax expense
    (benefit):</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDFSALzhM1_zmBbGExPym8b" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDFSALzhM1_zvr8Jt4Pjd1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_pn3n3_mtDFSALzhM1_maITEBzV7j_zjJeOyoGOYj3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    deferred tax expense</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2935">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2936">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzV7j_z7w27h2KP5Cb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    income tax expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2938">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of the U.S federal statutory income tax</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUgOlIqXjr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BD_zsLPthYADiCf" style="display: none">Schedule
of Reconciliation of the U.S &#160;federal statutory income tax</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20240101__20241231_zIdyspTUrI7e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_zPxflrFiO1yk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zOJd785Svxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 62%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 15%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zy0opPxbvWu3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">State income taxes, net of federal benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1.3</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.4</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_pid_dp_uPure_maABC_zkQCKuYaPwfl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Interest accretion expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.0</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zyWyox63eEFh" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Change in valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_pid_dp_uPure_maABC_zmnevfawRT1f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Mark to market warrant</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2955">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.5</td><td style="text-align: left">%</td></tr>
  <tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueUp_pid_dp_uPure_maABC_z2aTJcj9tgo9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Deferred true-up</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(0.1</td><td style="text-align: left">)%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.4</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_maABC_zY4hNHLT3E3a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt">Impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2961">&#8212;</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12.0</td><td style="text-align: left">)%</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maABC_zfCjhXbNEKsd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt">Other permanent items</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.4</td><td style="padding-bottom: 1pt; text-align: left">%</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0.5</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_zeWtlL2hemk7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2967">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2968">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred tax assets and liabilities</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zi4QXOddxo86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
deferred income tax liabilities as of December 31, 2024 and 2023 consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8BB_zds472WMQSuh" style="display: none">Schedule
of Deferred tax assets and liabilities</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20241231_z9xT3qbgUaR" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231_zHCNmkSzn9u7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzt0C_zhpy46YqYn3d" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; width: 62%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">121,804</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">109,544</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_iI_pn3n3_maDTAGzt0C_zk5UBaetBOUl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,674</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,674</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzt0C_zm4MVrbOMqyc" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,539</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxAssetsStartupCosts_iI_pn3n3_maDTAGzt0C_z0NT2rqjyJ6e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Startup costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">431</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">498</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzt0C_z1UrxDPPExS1" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,028</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,442</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_maDTAGzt0C_z91X2XbqNxc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,469</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,441</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxAssetsUnicap_iI_pn3n3_maDTAGzt0C_zLqVzXBNyxwk" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt">Unicap</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--DeferredTaxAssetsImputedInterestOnContingentPayments_iI_pn3n3_maDTAGzt0C_zVlS9nBr0tni" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Imputed interest on contingent payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">97</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">110</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_iI_pn3n3_maDTAGzt0C_ztssh3ZI7SO9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">Legal fee capitalization and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,053</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,171</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopment_iI_pn3n3_maDTAGzt0C_zFYvavF3XMna" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; text-align: left">Capitalized research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,903</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">26,613</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredTaxAssetsIrcSectionInterest_iI_pn3n3_maDTAGzt0C_ztuSB1QKAfYf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left">IRC Section 163j interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1,471</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl3003">&#8212;</span></p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzt0C_zT1EZe8s2U0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,755</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">4,751</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzt0C_msDTLz2tA_zsDbjdal1e1a" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left">Total deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">181,407</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,788</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLz2tA_zyXNPfWiCFPf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(181,416</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(169,797</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_mtDTLz2tA_z7zamQdTwQEf" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 20pt; text-align: left; padding-bottom: 2.5pt">Net deferred tax liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zPIXQ5CkpcV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span id="xdx_8B5_z1hwNIxNUSgd" style="display: none">Schedule
of Unrecognized Tax&#160;Benefits</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unrecognized</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Tax Benefits</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 81%">Balance at January 1, 2023</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20230101__20231231_zBSXdntP5td8" style="width: 15%; text-align: right" title="Balance beginning">1,028</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt">Decrease related to current year tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_iN_pn3n3_di_c20230101__20231231_zmnL1nNWgZej" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions"><span style="-sec-ix-hidden: xdx2ixbrl3021">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at December 31, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20240101__20241231_zXIYdJT8wvY1" style="text-align: right" title="Balance beginning">1,028</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt">Decrease related to current year tax provision</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_pn3n3_c20240101__20241231_zonEQghkWPml" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions"><span style="-sec-ix-hidden: xdx2ixbrl3025">&#8212;</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Balance at December 31, 2024</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20240101__20241231_zDdvDxShsZVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending">1,028</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Financial Information by Segment</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7MsvFz8HyC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
information by segment is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span id="xdx_8B5_z4dnuEopRayj" style="display: none">Schedule
of Financial Information by Segment</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zaJeG6QuIika" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zRdiwc27IrG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zmWAsGw2FLTl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_499_20240101__20241231_zdNVWlpmDQZ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zFlxIwfO1ZLa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">688</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,140</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">48,392</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">54,220</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_z6oD0O66Pp32" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3064">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,172</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,817</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,989</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zsn5f4L3Lfq1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">15,807</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,673</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">20,846</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">38,326</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zKp3SXBNZjTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(15,119</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,295</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,729</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">905</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr>
  <tr id="xdx_403_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zvokvZw8jKPh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">37,703</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_z9YmKl0Zm4y9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,560</td><td style="text-align: left">(a)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_zy9Ir4UQXRgj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss from operations</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right">(38,358</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--NonoperatingIncomeExpense_pn3n3_zM86SXyYRgT5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(19,534</p></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zbYRBRQML3ub" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(57,892</p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">(a) Components of indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_pn3n3_zU5qMoswLhw6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of contingent consideration liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(193</p></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--GoodwillImpairmentLoss_pn3n3_zaPW4LNidUte" style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_zvsVRcpDXuek" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">-</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_zuBp989h8Zcl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;1,753</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zHvY1GYh1Vg2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Total other</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">1,560</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zkkFar7V0Ty" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zK8GvaIWaIsa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zFKHznCBYLIk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20230101__20231231_zzI6AJoePq4b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended December 31, 2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cell</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Therapy</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">BioBanking</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Degenerative Disease</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zflaTG577tNd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3129">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">5,441</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">17,330</td><td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">22,771</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_zPC8oVzarJK3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cost of revenues (excluding amortization of acquired intangible assets)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl3134">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">14,366</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,016</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zG4Cj5FVOJdk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Direct expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">28,694</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,752</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,720</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">40,166</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zHkcP6fon5J8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Segment contribution</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(28,694</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,039</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,756</td><td style="padding-bottom: 2.5pt; text-align: left">)</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(33,411</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zp1Kw2Vt6bXj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">40,876</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zTB24HnD9AM5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">118,001</td><td style="text-align: left">(a)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z5dCtCMTfXre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(192,287</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_pn3n3_zMhWuZqxowS3" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left">Other expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(3,998</p></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zWhYAfDaejy8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Loss before income taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(196,285</p></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">(a) Components of indirect expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_pn3n3_zsoqlzgUqxrh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of contingent consideration liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">(104,339</p></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--GoodwillImpairmentLoss_pn3n3_zH1R7OOaPDg3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Goodwill impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">112,347</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_zjf98iY3BuJe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">IPR&amp;D impairment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">107,800</p></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_zX4hqGkHilGh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">2,193</p></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zCmpparvduik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Total other</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">118,001</p></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 22, 2025</div></th>
<th class="th"><div>Feb. 22, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Date of incorporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 24,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,358<span></span>
</td>
<td class="nump">$ 192,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,401<span></span>
</td>
<td class="nump">38,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899,683<span></span>
</td>
<td class="nump">$ 841,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForManagementFee', window );">Payment for fee</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForManagementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForManagementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property and Equipment Estimated Useful Life (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment expected useful lives</a></td>
<td class="text">26 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment expected useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment expected useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment expected useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment expected useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment expected useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Useful Life, Shorter of Lease Term or Asset Utility [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Potentially Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">17,042,684<span></span>
</td>
<td class="nump">11,263,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">4,006,525<span></span>
</td>
<td class="nump">2,820,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">688,106<span></span>
</td>
<td class="nump">823,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">11,221,557<span></span>
</td>
<td class="nump">7,070,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
<td class="nump">1,126,496<span></span>
</td>
<td class="nump">549,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 10,239,000<span></span>
</td>
<td class="nump">$ 9,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts receivable balance, net of allowance for credit losses</a></td>
<td class="nump">13,357,000<span></span>
</td>
<td class="nump">10,046,000<span></span>
</td>
<td class="nump">$ 4,452,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived IPR&amp;D</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">107,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Advertising and marketing costs</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant', window );">Grant monies</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InstrumentSpecificCreditRiskLoss', window );">Instrument-specific credit risk loss</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InstrumentSpecificCreditRiskIncome', window );">Instrument-specific credit risk income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion', window );">Accumulated other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement', window );">Income tax examination likelihood settlement</a></td>
<td class="text">The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ContractedStoragePeriods', window );">Contracted storage periods</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PaymentPlansForCustomerToPayOverTimePeriod', window );">Over time for a period</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ContractedStoragePeriods', window );">Contracted storage periods</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PaymentPlansForCustomerToPayOverTimePeriod', window );">Over time for a period</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=CELU_CellTherapyMember', window );">Cell Therapy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLossNetOfTax', window );">Goodwill impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 112,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 10,239,000<span></span>
</td>
<td class="nump">$ 9,936,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated other comprehensive income to other expense upon short term debt conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ContractedStoragePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contracted storage periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ContractedStoragePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InstrumentSpecificCreditRiskIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Instrument specific credit risk income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InstrumentSpecificCreditRiskIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InstrumentSpecificCreditRiskLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Instrument specific credit risk loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InstrumentSpecificCreditRiskLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PaymentPlansForCustomerToPayOverTimePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment plans for customer to pay over time period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PaymentPlansForCustomerToPayOverTimePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction of research and development expense resulting from grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=CELU_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=CELU_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=CELU_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=CELU_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=CELU_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=CELU_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=CELU_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=CELU_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=CELU_CellTherapyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=CELU_CellTherapyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Purchase Price Allocated to Acquired Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=CELU_SequenceLifeScienceIncMember', window );">Sequence LifeScience Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Cash payment</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent consideration</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total consideration</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="nump">2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">$ 2,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition recognized identifiable assets acquired and liabilities assumed inventory assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition recognized identifiable assets acquired and liabilities assumed inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=CELU_SequenceLifeScienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=CELU_SequenceLifeScienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition (Details Narrative) - Sequence LifeScience Inc [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 09, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected', window );">Consideration for assets</a></td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_UpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_MonthlyMilestonePayments', window );">Monthly milestone payments</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PriorPaymentToRelatedParty', window );">Prior payment to related party</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NetSalesPercentage', window );">Net sales percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PurchasePriceContingentConsideration', window );">Purchase price contingent consideration</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_MonthlyMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monthly milestone payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_MonthlyMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_NetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net sales percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_NetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PriorPaymentToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prior payment to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PriorPaymentToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PurchasePriceContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PurchasePriceContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionPriceOfAcquisitionExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=CELU_SequenceLifeScienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=CELU_SequenceLifeScienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Financial Assets and Liabilities Measures at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term debt - Yorkville</a></td>
<td class="nump">$ 2,485<span></span>
</td>
<td class="nump">$ 17,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Convertible note receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration obligations</a></td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ContingentStockConsideration', window );">Contingent stock consideration</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term debt - Yorkville</a></td>
<td class="nump">1,865<span></span>
</td>
<td class="nump">17,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes', window );">Short-term debt - unsecured senior convertible notes</a></td>
<td class="nump">620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityRegisteredDirectWarrantsTwo', window );">Warrant liability - July 2023 Registered Direct Warrants</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">1,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityRegisteredDirectWarrants', window );">Warrant liability - April 2023 Registered Direct Warrants</a></td>
<td class="nump">1,022<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants', window );">Warrant liability - May 2022 PIPE Warrants</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPurchaserWarrants', window );">Warrant liability - November 2024 Purchaser Warrants</a></td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPlacementAgentWarrants', window );">Warrant liability - November 2024 Placement Agent Warrants</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilitySponsorWarrants', window );">Warrant liability - Sponsor Warrants</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPublicWarrants', window );">Warrant liability - Public Warrants</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value liabilities</a></td>
<td class="nump">7,189<span></span>
</td>
<td class="nump">23,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Convertible note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration obligations</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ContingentStockConsideration', window );">Contingent stock consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term debt - Yorkville</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes', window );">Short-term debt - unsecured senior convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityRegisteredDirectWarrantsTwo', window );">Warrant liability - July 2023 Registered Direct Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityRegisteredDirectWarrants', window );">Warrant liability - April 2023 Registered Direct Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants', window );">Warrant liability - May 2022 PIPE Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPurchaserWarrants', window );">Warrant liability - November 2024 Purchaser Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPlacementAgentWarrants', window );">Warrant liability - November 2024 Placement Agent Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilitySponsorWarrants', window );">Warrant liability - Sponsor Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPublicWarrants', window );">Warrant liability - Public Warrants</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value liabilities</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Convertible note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration obligations</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ContingentStockConsideration', window );">Contingent stock consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term debt - Yorkville</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes', window );">Short-term debt - unsecured senior convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityRegisteredDirectWarrantsTwo', window );">Warrant liability - July 2023 Registered Direct Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityRegisteredDirectWarrants', window );">Warrant liability - April 2023 Registered Direct Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants', window );">Warrant liability - May 2022 PIPE Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPurchaserWarrants', window );">Warrant liability - November 2024 Purchaser Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPlacementAgentWarrants', window );">Warrant liability - November 2024 Placement Agent Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilitySponsorWarrants', window );">Warrant liability - Sponsor Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPublicWarrants', window );">Warrant liability - Public Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Convertible note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Acquisition-related contingent consideration obligations</a></td>
<td class="nump">1,413<span></span>
</td>
<td class="nump">1,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ContingentStockConsideration', window );">Contingent stock consideration</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtFairValue', window );">Short-term debt - Yorkville</a></td>
<td class="nump">1,865<span></span>
</td>
<td class="nump">17,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes', window );">Short-term debt - unsecured senior convertible notes</a></td>
<td class="nump">620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityRegisteredDirectWarrantsTwo', window );">Warrant liability - July 2023 Registered Direct Warrants</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">1,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityRegisteredDirectWarrants', window );">Warrant liability - April 2023 Registered Direct Warrants</a></td>
<td class="nump">1,022<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants', window );">Warrant liability - May 2022 PIPE Warrants</a></td>
<td class="nump">505<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPurchaserWarrants', window );">Warrant liability - November 2024 Purchaser Warrants</a></td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPlacementAgentWarrants', window );">Warrant liability - November 2024 Placement Agent Warrants</a></td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilitySponsorWarrants', window );">Warrant liability - Sponsor Warrants</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiabilityPublicWarrants', window );">Warrant liability - Public Warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value liabilities</a></td>
<td class="nump">$ 6,902<span></span>
</td>
<td class="nump">22,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Convertible note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,072<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ContingentStockConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent stock consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ContingentStockConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term debt unsecured senior convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantLiabilityPlacementAgentWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability placement agent warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantLiabilityPlacementAgentWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability private investment in public equity warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantLiabilityPublicWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability public warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantLiabilityPublicWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantLiabilityPurchaserWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability purchaser warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantLiabilityPurchaserWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantLiabilityRegisteredDirectWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability registered direct warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantLiabilityRegisteredDirectWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantLiabilityRegisteredDirectWarrantsTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability registered direct warrants two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantLiabilityRegisteredDirectWarrantsTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantLiabilitySponsorWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability sponsor warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantLiabilitySponsorWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Beginning balance</a></td>
<td class="nump">$ 2,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Net transfers into (out of) Level 3</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements', window );">Purchases, settlements and other net</a></td>
<td class="num">(2,072)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Fair value adjustments</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesFairValueDisclosure', window );">Ending balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Convertible Note Valuation Model (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FaceValueOfNotesReceivable', window );">Face value | $</a></td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price | $ / shares</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ValuationInputForConvertiblePromissoryNote', window );">Risk-free interest rate</a></td>
<td class="nump">5.47%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfCouponRate', window );">Coupon rate</a></td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ValuationInputForConvertiblePromissoryNoteTerm', window );">Term (years)</a></td>
<td class="text">6 months 3 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfCouponRate', window );">Coupon rate</a></td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ValuationInputForConvertiblePromissoryNoteTerm', window );">Term (years)</a></td>
<td class="text">2 years 5 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FaceValueOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face Value Of Notes Receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FaceValueOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfCouponRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of coupon rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfCouponRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ValuationInputForConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation input for a convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ValuationInputForConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ValuationInputForConvertiblePromissoryNoteTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation input for a convertible promissory note term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ValuationInputForConvertiblePromissoryNoteTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details) - Acquisition - Related Contingent Consideration Obligations [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 1,606<span></span>
</td>
<td class="nump">$ 105,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Net transfers into (out of) Level 3</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Purchases, settlements and other net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Fair value adjustments</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(104,339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 1,413<span></span>
</td>
<td class="nump">$ 1,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=CELU_AcquisitionRelatedContingentConsiderationObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=CELU_AcquisitionRelatedContingentConsiderationObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details) - Contingent Stock Consideration [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Net transfers into (out of) Level 3</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Purchases, settlements and other net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Fair value adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=CELU_ContingentStockConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=CELU_ContingentStockConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis (Details) - Yorkville [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Beginning balance</a></td>
<td class="nump">$ 17,223<span></span>
</td>
<td class="nump">$ 37,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares', window );">Conversion of debt into common shares</a></td>
<td class="num">(1,700)<span></span>
</td>
<td class="num">(4,599)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Principal repayments</a></td>
<td class="num">(17,374)<span></span>
</td>
<td class="num">(16,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote', window );">Issuance of convertible promissory note</a></td>
<td class="nump">3,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment', window );">Issuance of unsecured senior convertible notes, net of fair value adjustment</a></td>
<td class="nump">689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueAdjustmentThroughEarnings', window );">Fair value adjustment through earnings</a></td>
<td class="nump">492<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome', window );">Fair value adjustment through accumulated other comprehensive income</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(146)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual', window );">Fair value adjustment through interest accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Ending balance</a></td>
<td class="nump">$ 2,485<span></span>
</td>
<td class="nump">$ 17,223<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment through accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FairValueAdjustmentThroughEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value adjustment through earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FairValueAdjustmentThroughEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation conversion of debt into common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs reconciliation fair value adjustment through interest accrual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of unsecured senior convertible notes, net of fair value adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 13, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term (years)</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member] | Measurement Input, Credit Spread [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible promissory note valuation measurement</a></td>
<td class="nump">7.50<span></span>
</td>
<td class="nump">8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible promissory note valuation measurement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible promissory note valuation measurement</a></td>
<td class="nump">4.30<span></span>
</td>
<td class="nump">4.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Convertible promissory note valuation measurement</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCreditSpreadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCreditSpreadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of Convertible Notes Valuation Model (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th" colspan="2">
<div>Dec. 03, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th" colspan="2">
<div>Nov. 25, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member] | Measurement Input, Credit Spread [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Unsecured senior convertible notes valuation measurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Unsecured senior convertible notes valuation measurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Unsecured senior convertible notes valuation measurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Unsecured senior convertible notes valuation measurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">50.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 months 23 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">11 months 23 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member] | Minimum [Member] | Measurement Input, Credit Spread [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Unsecured senior convertible notes valuation measurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Unsecured senior convertible notes valuation measurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4.30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">1 year<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member] | Maximum [Member] | Measurement Input, Credit Spread [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Unsecured senior convertible notes valuation measurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Unsecured senior convertible notes valuation measurement</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4.40<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As discussed
in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCreditSpreadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputCreditSpreadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Beginning Balance</a></td>
<td class="nump">$ 4,359<span></span>
</td>
<td class="nump">$ 3,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RegisteredDirectWarrantsIssuance', window );">April 2023 Registered Direct warrant issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RegisteredDirectWarrantIssuanceDuringJuly', window );">July 2023 Registered Direct warrant issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_BridgeLoanAndWarrantIssuanceTrancheTwo', window );">January 2024 Bridge Loan - Tranche #2 warrant issuance</a></td>
<td class="nump">1,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PurchaserWarrantIssuance', window );">November 2024 Purchaser warrant issuance</a></td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PlacementAgentWarrantIssuance', window );">November 2024 Placement Agent warrant issuance</a></td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_GainLossRecognizedInEarningsFromChangeInFairValues', window );">Gain recognized in earnings from change in fair value</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(6,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified', window );">Reclassification of warrants from liability classified to equity classified</a></td>
<td class="num">(2,970)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair Value, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueNetAssetLiabilities', window );">Fair value, Beginning Balance</a></td>
<td class="nump">3,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueNetAssetLiabilities', window );">Fair Value, Ending Balance</a></td>
<td class="nump">$ 2,977<span></span>
</td>
<td class="nump">$ 3,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_BridgeLoanAndWarrantIssuanceTrancheTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bridge loan and warrant issuance tranche two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_BridgeLoanAndWarrantIssuanceTrancheTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FairValueNetAssetLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value net asset liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FairValueNetAssetLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_GainLossRecognizedInEarningsFromChangeInFairValues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss recognized in earnings from change in fair values.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_GainLossRecognizedInEarningsFromChangeInFairValues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PlacementAgentWarrantIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>November 2024 Placement Agent warrant issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PlacementAgentWarrantIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PurchaserWarrantIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>November 2024 Purchaser warrant issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PurchaserWarrantIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrants from liability classified to equity classified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_RegisteredDirectWarrantIssuanceDuringJuly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registered Direct Warrant Issuance During July.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_RegisteredDirectWarrantIssuanceDuringJuly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_RegisteredDirectWarrantsIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Registered direct warrants issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_RegisteredDirectWarrantsIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 13, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 10, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember', window );">May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember', window );">May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant and right outstanding measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember', window );">May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant and right outstanding measurement input</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember', window );">May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="text">3 years 9 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember', window );">May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member] | Minimum [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant and right outstanding measurement input</a></td>
<td class="nump">98.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember', window );">May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="text">4 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember', window );">May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member] | Maximum [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant and right outstanding measurement input</a></td>
<td class="nump">98.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Schedule of January 20224 Bridge Loan (Details)<br></strong></div></th>
<th class="th">
<div>Jan. 16, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th">
<div>Jul. 15, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember', window );">January 2024 Bridge Loan - Tranche #2 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate', window );">Term to initial exercise date (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember', window );">January 2024 Bridge Loan - Tranche #2 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember', window );">January 2024 Bridge Loan - Tranche #2 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember', window );">January 2024 Bridge Loan - Tranche #2 Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As discussed
further in Note 10, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July
15, 2024, the warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the
Company&#8217;s own stock. As such, the warrants were adjusted to fair value as of the initial exercise date and then reclassified from
liability classified to equity classified.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants and rights outstanding term to initial exercise date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Dec. 03, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th" colspan="2">
<div>Nov. 25, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 13, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 10, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember', window );">November 2024 Purchaser and Placement Agent Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing', window );">Term to Subsequent Financing (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember', window );">November 2024 Purchaser and Placement Agent Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember', window );">November 2024 Purchaser and Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember', window );">November 2024 Purchaser and Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">50.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember', window );">November 2024 Purchaser and Placement Agent Warrants [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing', window );">Term to Subsequent Financing (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember', window );">November 2024 Purchaser and Placement Agent Warrants [Member] | Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember', window );">November 2024 Purchaser and Placement Agent Warrants [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing', window );">Term to Subsequent Financing (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember', window );">November 2024 Purchaser and Placement Agent Warrants [Member] | Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants measurement input</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="10"></td></tr>
<tr><td colspan="10"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As discussed in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">The exercise price of the November 2024 Placement Agent Warrants is based on the lesser of (i) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zO2jaDs7pQ78" title="Exercise price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zCedlLw6AzQh" title="Exercise price">3.56</span></span> or (ii) <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_ecustom--OfferingPricePercentage_iI_pid_dp_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z7jn9S0Q2kz4" title="Offering price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--OfferingPricePercentage_iI_pid_dp_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6z2KSFYOoUa" title="Offering price">125</span></span>% of the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6RlELFC2O76" title="Floor price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zXObzrFkExgd" title="Floor price">1.00</span></span>.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The exercise price of the November 2024 Purchaser Warrants is based on the lesser of (i) $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zqWPryMPDFY" title="Exercise price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zay0CNo8kkFc" title="Exercise price">2.85</span></span> or (ii) the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zHA1eE5Olt08" title="Floor price"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zJ5hleIJxI8l" title="Floor price">1.00</span></span>.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants and rights outstanding term to subsequent financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of November 2024 Purchaser and Placement Agent Warrants (Details) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Mar. 13, 2024</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Apr. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FloorPrice', window );">Floor price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember', window );">November 2024 Purchaser Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FloorPrice', window );">Floor price</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember', window );">November 2024 Placement Agent Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">3.56<span></span>
</td>
<td class="nump">3.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FloorPrice', window );">Floor price</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_OfferingPricePercentage', window );">Offering price</a></td>
<td class="nump">125.00%<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floor price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_OfferingPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering price percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_OfferingPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Significant Inputs for Sponsor Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 13, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 10, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_SponsorsWarrantsMember', window );">Sponsors Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common share price</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 115.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_SponsorsWarrantsMember', window );">Sponsors Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_SponsorsWarrantsMember', window );">Sponsors Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">4.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_SponsorsWarrantsMember', window );">Sponsors Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrant measurement input</a></td>
<td class="nump">111.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_SponsorsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_SponsorsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 03, 2024</div></th>
<th class="th"><div>May 10, 2024</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Mar. 13, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember', window );">Yorkville [Member] | Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,993<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember', window );">Yorkville [Member] | Unsecured Senior Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_SanuwaveForbearanceAgreementMember', window );">Sanuwave Forbearance Agreement [Member] | Letter Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IncreasedNotePayments', window );">Increased total note payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Note payment</a></td>
<td class="nump">$ 2,075<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_SanuwaveForbearanceAgreementMember', window );">Sanuwave Forbearance Agreement [Member] | Minimum [Member] | Letter Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ForbearanceExtendMaturityPeriod', window );">Forbearance extend period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 28,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_SanuwaveForbearanceAgreementMember', window );">Sanuwave Forbearance Agreement [Member] | Maximum [Member] | Letter Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ForbearanceExtendMaturityPeriod', window );">Forbearance extend period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  03,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ForbearanceExtendMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Forbearance extend maturity period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ForbearanceExtendMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IncreasedNotePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increased total note payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IncreasedNotePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_UnsecuredSeniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_SanuwaveForbearanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_SanuwaveForbearanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=CELU_LetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=CELU_LetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Major Classes of Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryRawMaterialsCurrentAndNoncurrent', window );">Raw materials</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 3,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryWorkInProgressCurrentAndNoncurrent', window );">Work in progress</a></td>
<td class="nump">8,093<span></span>
</td>
<td class="nump">10,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryFinishedGoodsCurrentAndNoncurrent', window );">Finished goods</a></td>
<td class="nump">11,964<span></span>
</td>
<td class="nump">10,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryGrossCurrentAndNoncurrent', window );">Inventory, gross</a></td>
<td class="nump">20,099<span></span>
</td>
<td class="nump">24,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryReserveCurrentAndNoncurrent', window );">Less: inventory reserves</a></td>
<td class="num">(2,103)<span></span>
</td>
<td class="num">(2,289)<span></span>
</td>
<td class="num">$ (1,099)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryNetCurrentAndNoncurrent', window );">Inventory, net</a></td>
<td class="nump">17,996<span></span>
</td>
<td class="nump">22,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">5,409<span></span>
</td>
<td class="nump">5,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, net of current portion</a></td>
<td class="nump">$ 12,587<span></span>
</td>
<td class="nump">$ 16,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InventoryFinishedGoodsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory finished goods current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InventoryFinishedGoodsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InventoryGrossCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory gross current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InventoryGrossCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory net current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InventoryRawMaterialsCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory raw materials current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InventoryRawMaterialsCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InventoryReserveCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory reserve current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InventoryReserveCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InventoryWorkInProgressCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory work in progress current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InventoryWorkInProgressCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Inventory Reserves (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryReserveCurrentAndNoncurrent', window );">Beginning balance</a></td>
<td class="nump">$ 2,289<span></span>
</td>
<td class="nump">$ 1,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ProvisionForObsoleteInventory', window );">Provision for obsolete inventory</a></td>
<td class="num">(186)<span></span>
</td>
<td class="nump">7,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-offs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryReserveCurrentAndNoncurrent', window );">Ending balance</a></td>
<td class="nump">$ 2,103<span></span>
</td>
<td class="nump">$ 2,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InventoryReserveCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory reserve current and noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InventoryReserveCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ProvisionForObsoleteInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Provision for obsolete inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ProvisionForObsoleteInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryImpairmentCharge', window );">Inventory impairment charge</a></td>
<td class="nump">$ 466<span></span>
</td>
<td class="nump">$ 5,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=CELU_InventoryFinishedGoodsMember', window );">Inventory Finished Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryImpairmentCharge', window );">Inventory impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=CELU_InventoryWorkInProgressMember', window );">Inventory Work in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InventoryImpairmentCharge', window );">Inventory impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InventoryImpairmentCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory Impairment Charge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InventoryImpairmentCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=CELU_InventoryFinishedGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=CELU_InventoryFinishedGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=CELU_InventoryWorkInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=CELU_InventoryWorkInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PrepaidClinicalExpense', window );">Prepaid clinical expenses</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance expense</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">329<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 857<span></span>
</td>
<td class="nump">$ 1,695<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PrepaidClinicalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid clinical expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PrepaidClinicalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 94,467<span></span>
</td>
<td class="nump">$ 95,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(32,867)<span></span>
</td>
<td class="num">(27,278)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">61,600<span></span>
</td>
<td class="nump">67,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">73,211<span></span>
</td>
<td class="nump">73,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CELU_LaboratoryAndProductionEquipmentMember', window );">Laboratory and Production Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">14,093<span></span>
</td>
<td class="nump">14,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CELU_MachineryEquipmentAndFixturesMember', window );">Machinery, Equipment and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">7,163<span></span>
</td>
<td class="nump">7,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CELU_LaboratoryAndProductionEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CELU_LaboratoryAndProductionEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CELU_MachineryEquipmentAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CELU_MachineryEquipmentAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 6,169<span></span>
</td>
<td class="nump">$ 7,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets</a></td>
<td class="nump">$ 23,993<span></span>
</td>
<td class="nump">$ 23,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(15,445)<span></span>
</td>
<td class="num">(13,692)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Amortizable intangible assets, net</a></td>
<td class="nump">8,548<span></span>
</td>
<td class="nump">10,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Acquired IPR&amp;D product rights</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod', window );">Estimated useful lives</a></td>
<td class="text">indefinite<span></span>
</td>
<td class="text">indefinite<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">$ 9,248<span></span>
</td>
<td class="nump">$ 11,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets</a></td>
<td class="nump">16,810<span></span>
</td>
<td class="nump">16,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (8,895)<span></span>
</td>
<td class="num">$ (7,722)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets</a></td>
<td class="nump">$ 2,413<span></span>
</td>
<td class="nump">$ 2,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (1,965)<span></span>
</td>
<td class="num">$ (1,700)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (385)<span></span>
</td>
<td class="num">$ (330)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">13 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=CELU_ReacquiredRightsMember', window );">Reacquired Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (4,200)<span></span>
</td>
<td class="num">$ (3,940)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets amortization method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=CELU_ReacquiredRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=CELU_ReacquiredRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">1,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">1,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">1,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">1,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Amortization expense</a></td>
<td class="nump">$ 8,548<span></span>
</td>
<td class="nump">$ 10,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,347,000<span></span>
</td>
<td class="nump">$ 7,347,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">112,347,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753,000<span></span>
</td>
<td class="nump">2,193,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=CELU_CellTherapyMember', window );">Cell Therapy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 82,714,000<span></span>
</td>
<td class="nump">$ 29,633,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=CELU_CellTherapyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=CELU_CellTherapyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AccruedClinicalTrialExpense', window );">Accrued clinical trial expense</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">691<span></span>
</td>
<td class="nump">573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued wages, bonuses, commissions and vacation</a></td>
<td class="nump">5,797<span></span>
</td>
<td class="nump">3,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AccrualsForConstructionInProgress', window );">Accruals for construction in progress</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AccruedComplianceFee', window );">Accrued compliance fee</a></td>
<td class="nump">10,277<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">955<span></span>
</td>
<td class="nump">2,448<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 19,842<span></span>
</td>
<td class="nump">$ 7,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AccrualsForConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accruals for construction in progress.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AccrualsForConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AccruedComplianceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compliance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AccruedComplianceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShortTermDebtUnaffiliated', window );">Total debt - unaffiliated</a></td>
<td class="nump">$ 2,485<span></span>
</td>
<td class="nump">$ 19,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_OtherShortTermDebt', window );">Short-term debt - other</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShortTermDebtRelatedParty', window );">Total debt - related parties</a></td>
<td class="nump">39,803<span></span>
</td>
<td class="nump">19,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_Debt', window );">Total debt</a></td>
<td class="nump">42,288<span></span>
</td>
<td class="nump">39,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt - related parties</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">19,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt - related parties</a></td>
<td class="nump">3,876<span></span>
</td>
<td class="nump">19,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt - related parties</a></td>
<td class="nump">35,927<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_CVStarrBridgeLoanNetOfDiscountMember', window );">CV Starr Bridge Loan Net of Discount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShortTermDebtRelatedParty', window );">Total debt - related parties</a></td>
<td class="nump">5,652<span></span>
</td>
<td class="nump">5,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_RWIBridgeLoanNetOfDiscountMember', window );">RWI Bridge Loan Net of Discount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShortTermDebtRelatedParty', window );">Total debt - related parties</a></td>
<td class="nump">30,275<span></span>
</td>
<td class="nump">12,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_CEOPromissoryNoteMember', window );">CEO Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShortTermDebtRelatedParty', window );">Total debt - related parties</a></td>
<td class="nump">3,876<span></span>
</td>
<td class="nump">1,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=CELU_UnsecuredSeniorConvertibleNoteMember', window );">Unsecured Senior Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShortTermDebtUnaffiliated', window );">Total debt - unaffiliated</a></td>
<td class="nump">620<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember', window );">Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt - related parties</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">17,223<span></span>
</td>
<td class="nump">$ 37,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember', window );">Yorkville [Member] | Pre Paid Advance Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShortTermDebtUnaffiliated', window );">Total debt - unaffiliated</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">17,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember', window );">Yorkville [Member] | Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShortTermDebtUnaffiliated', window );">Total debt - unaffiliated</a></td>
<td class="nump">$ 1,865<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_Debt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_Debt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_OtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other short term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_OtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ShortTermDebtRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term debt - related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ShortTermDebtRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ShortTermDebtUnaffiliated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term debt unaffiliated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ShortTermDebtUnaffiliated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_CVStarrBridgeLoanNetOfDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_CVStarrBridgeLoanNetOfDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_RWIBridgeLoanNetOfDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_RWIBridgeLoanNetOfDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_CEOPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_CEOPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=CELU_UnsecuredSeniorConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=CELU_UnsecuredSeniorConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=CELU_PrePaidAdvanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=CELU_PrePaidAdvanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=CELU_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=CELU_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 17, 2025</div></th>
<th class="th"><div>Mar. 16, 2025</div></th>
<th class="th"><div>Feb. 12, 2025</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Mar. 13, 2024</div></th>
<th class="th"><div>Jan. 12, 2024</div></th>
<th class="th"><div>Oct. 12, 2023</div></th>
<th class="th"><div>Aug. 21, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Jun. 21, 2023</div></th>
<th class="th"><div>May 16, 2023</div></th>
<th class="th"><div>Apr. 10, 2023</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 13, 2024</div></th>
<th class="th"><div>Aug. 05, 2024</div></th>
<th class="th"><div>Jul. 15, 2024</div></th>
<th class="th"><div>May 01, 2024</div></th>
<th class="th"><div>Apr. 15, 2024</div></th>
<th class="th"><div>Jan. 16, 2024</div></th>
<th class="th"><div>Sep. 14, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 20, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentPayment', window );">[custom:DebtInstrumentPayment]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issue of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,546,671<span></span>
</td>
<td class="nump">19,378,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Debt issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise per share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FloorPrice', window );">Floor price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfCashFeeEqualToAggregateProceeds', window );">Percentage of cash fee equal to aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfExercisePriceEqualToOfferingPrice', window );">Percentage of exercise price equal to offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">738<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DailyInterestAccruingRate', window );">Daily interest accruing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=CELU_InitialAndSecondTrancheMember', window );">Initial and Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice', window );">Percentage of partial liquidating damages on purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DailyInterestAccruingRate', window );">Daily interest accruing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=CELU_ChairmanAndChiefExecutiveOfficerMember', window );">Chairman and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amont</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CELU_UnsecuredSeniorConvertibleNotesMember', window );">Unsecured Senior Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Bearing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault', window );">Increase in bearing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDefaultShorttermDebtAmount', window );">Short-term debt, unpaid principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ProceedsFromNotesAndPurchaserWarrants', window );">Proceeds from notes and purchaser warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise per share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_MinimumGrossProceeds', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FloorPrice', window );">Floor price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes', window );">Fair value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CELU_LoanAgreementMember', window );">Loan Agreement [Member] | Chairman and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 21,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amont</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentContributionAmount', window );">Debt instrument contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Default rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherShortTermDebt', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">892,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Initial and Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount', window );">Percentage of partial liquidating damages on subscription amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Unsecured Senior Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NotesAndPurchaserWarrantsPrincipalAmount', window );">Notes and purchaser warrants principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember', window );">Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=CELU_CEOPromissoryNoteMember', window );">CEO Promissory Note [Member] | Chairman and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Pre-paid advance maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amont</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_OtherShortTermDebtDueToRelatedParty', window );">Other short term debt due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FallInCashAndCashEquivalents', window );">Fall in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShortTermDebtRelatedParties', window );">Short-term debt - related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,275<span></span>
</td>
<td class="nump">$ 12,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DiscountOnWarrantAmount', window );">Discount on warrant amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan [Member] | Initial Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 14,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amont</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentDiscount', window );">Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 678<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault', window );">Interest rate during period in event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan [Member] | Additional Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 17,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise per share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amont</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentOriginalIssueDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShareIssuedPurchasedPrice', window );">Share issued purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault', window );">Interest rate during period in event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan [Member] | Maximum [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfChangesInCashFlow', window );">Percentage of changes in cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issue of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,546,671<span></span>
</td>
<td class="nump">19,378,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,221,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Bridge Loan [Member] | Tranche One Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise per share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Bridge Loan [Member] | Additional Loan [Member] | Tranche One Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=CELU_ForbearanceAgreementMember', window );">Forbearance Agreement [Member] | Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=CELU_ForbearanceAgreementMember', window );">Forbearance Agreement [Member] | Bridge Loan [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentDefaultInterestRate', window );">Debt instrument default interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=CELU_ForbearanceAgreementMember', window );">Forbearance Agreement [Member] | Warrant [Member] | Bridge Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise per share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember', window );">Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,485<span></span>
</td>
<td class="nump">$ 17,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember', window );">Yorkville [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">May 12,  2025<span></span>
</td>
<td class="text">Mar. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember', window );">Yorkville [Member] | Common Class A [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common stock issued pursuant to short-term debt maturity extension, shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember', window );">Yorkville [Member] | Pre Paid Advance Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod', window );">Maximum advance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PrePaidAdvancePeriod', window );">Pre-paid advance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit aggregate limitation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PrePaidAdvanceIssuedDiscountPercentage', window );">Pre-paid advance issued discount percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Bearing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault', window );">Increase in bearing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IssuanceOfCommonStockMinimumOptionPricePerShare', window );">Issuance of common stock minimum option price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_MaximumPercentageOfCommonStockIssued', window );">Maximum percentage of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfBeneficialOwnershipLimitation', window );">Percentage of beneficial ownership limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_MinimumNumberOfSharesOfCommonStockPurchase', window );">Minimum number of shares of common stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_MinimumRequiredDailyVolumeWeightedAveragePrice', window );">Minimum required daily volume weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice', window );">Required monthly payment if daily volume weighted average price is below $0.75 for any five of seven trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice', window );">Redemption premium percentage if volume weighted average price is less than $0.75</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice', window );">Redemption premium percentage if volume weighted average price more than $0.75</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ProceedsFromLinesOfCreditGross', window );">Proceeds from pre-paid advance gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from pre-paid advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Pre-paid advance maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtConversionOriginalDebtAccruedInterestAmount', window );">[custom:DebtConversionOriginalDebtAccruedInterestAmount]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentPayment', window );">[custom:DebtInstrumentPayment]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of Short-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentAccruedInterest', window );">[custom:DebtInstrumentAccruedInterest]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentRedemptionPremium', window );">[custom:DebtInstrumentRedemptionPremium]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDefaultShorttermDebtAmount', window );">Short-term debt, unpaid principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentPerDiemInterestAmount', window );">Diem interest payment for each day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issue of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember', window );">Yorkville [Member] | Pre Paid Advance Agreement [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IssuancePricePercentage', window );">Issuance price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember', window );">Yorkville [Member] | Equity Purchase Agreement [Member] | Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod', window );">Maximum advance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Bearing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault', window );">Increase in bearing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfBeneficialOwnershipLimitation', window );">Percentage of beneficial ownership limitation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_MinimumRequiredDailyVolumeWeightedAveragePrice', window );">Minimum required daily volume weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtConversionOriginalDebtAccruedInterestAmount', window );">[custom:DebtConversionOriginalDebtAccruedInterestAmount]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt Instrument, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDefaultShorttermDebtAmount', window );">Short-term debt, unpaid principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Debt issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ConvertiblePromissoryNoteDiscountPercentage', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.3171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfConversionOnOutstandingCommonStock', window );">Percentage of conversion on outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentDefaultInterestRate', window );">Debt instrument default interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember', window );">C.V. Starr Co Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise per share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember', window );">C.V. Starr Co Inc [Member] | Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 17,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amont</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Default rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentOriginalIssueDiscount', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault', window );">Effective percentage in event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FallInCashAndCashEquivalents', window );">Fall in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShortTermDebtRelatedParties', window );">Short-term debt - related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,652<span></span>
</td>
<td class="nump">$ 5,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember', window );">C.V. Starr Co Inc [Member] | Common Class A [Member] | Loan Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise per share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShareIssuedPurchasedPrice', window );">Share issued purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember', window );">C.V. Starr Co Inc [Member] | Common Class A [Member] | Subsequent Event [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Payment for debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember', window );">C.V. Starr Co Inc [Member] | Forbearance Agreement [Member] | Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise per share price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Default rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ClassOfWarrantOrRighstExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 17,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfChangesInCashFlow', window );">Percentage of changes in cash flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember', window );">C.V. Starr Co Inc [Member] | Forbearance Agreement [Member] | Loan Agreement [Member] | Tranche Two Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ClassOfWarrantOrRighstExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_ResortsWorldIncPteLtdMember', window );">Resorts World Inc Pte Ltd [Member] | Subsequent Event [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherDebt', window );">Payment for debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ClassOfWarrantOrRighstExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or righst expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ClassOfWarrantOrRighstExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ConvertiblePromissoryNoteDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Promissory Note Discount Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ConvertiblePromissoryNoteDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DailyInterestAccruingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Daily Interest Accruing Rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DailyInterestAccruingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtConversionOriginalDebtAccruedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt conversion original debt accrued interest amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtConversionOriginalDebtAccruedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Contribution Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument default interest rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest rate during period in event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Interest Rate, Effective Percentage in Event of Default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentOriginalIssueDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Original Issue Discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentOriginalIssueDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentPerDiemInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Per Diem Interest Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentPerDiemInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentRedemptionPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument redemption premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentRedemptionPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DiscountOnWarrantAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount on warrant amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DiscountOnWarrantAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FallInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fall In Cash And Cash Equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FallInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Floor price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IssuanceOfCommonStockMinimumOptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock minimum option price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IssuanceOfCommonStockMinimumOptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IssuancePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Price Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IssuancePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit increase in interest rate during period in event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_MaximumPercentageOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_MaximumPercentageOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_MinimumGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_MinimumGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_MinimumNumberOfSharesOfCommonStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum number of shares of common stock purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_MinimumNumberOfSharesOfCommonStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_MinimumRequiredDailyVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum required daily volume weighted average price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_MinimumRequiredDailyVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_NotesAndPurchaserWarrantsPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes and purchaser warrants principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_NotesAndPurchaserWarrantsPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_OtherShortTermDebtDueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other short term debt due to related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_OtherShortTermDebtDueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfBeneficialOwnershipLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of beneficial ownership limitation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfBeneficialOwnershipLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfCashFeeEqualToAggregateProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of cash fee equal to aggregate proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfCashFeeEqualToAggregateProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfChangesInCashFlow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of changes in cash flow.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfChangesInCashFlow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfConversionOnOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of conversion on outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfConversionOnOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfExercisePriceEqualToOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of exercise price equal to pffering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfExercisePriceEqualToOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Partial Liquidating Damages On Purchase Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of partial liquidating damages on subscription amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PrePaidAdvanceIssuedDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre paid advance issued discount percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PrePaidAdvanceIssuedDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PrePaidAdvancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pre paid advance period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PrePaidAdvancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ProceedsFromLinesOfCreditGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from lines of credit gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ProceedsFromLinesOfCreditGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ProceedsFromNotesAndPurchaserWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from notes and purchaser warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ProceedsFromNotesAndPurchaserWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption premium percentage if volume weighted average price is less than stated price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption premium percentage if volume weighted average price more than stated price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Required monthly payment if daily volume weighted average price is below stated price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ShareIssuedPurchasedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issued Purchased Price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ShareIssuedPurchasedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ShortTermDebtRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term debt related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ShortTermDebtRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-term debt unsecured senior convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultShorttermDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding short-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultShorttermDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount borrowed under the credit facility at any time during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from short-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=CELU_InitialAndSecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=CELU_InitialAndSecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CELU_ChairmanAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CELU_ChairmanAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELU_UnsecuredSeniorConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELU_UnsecuredSeniorConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELU_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELU_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_CEOPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_CEOPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELU_InitialLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELU_InitialLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELU_AdditionalLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELU_AdditionalLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=CELU_TrancheOneWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=CELU_TrancheOneWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=CELU_ForbearanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=CELU_ForbearanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=CELU_YorkvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=CELU_PrePaidAdvanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=CELU_PrePaidAdvanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=CELU_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=CELU_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=CELU_TrancheTwoWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=CELU_TrancheTwoWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=CELU_ResortsWorldIncPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=CELU_ResortsWorldIncPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Lease Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 3,911<span></span>
</td>
<td class="nump">$ 3,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,348<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 5,259<span></span>
</td>
<td class="nump">$ 4,388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Cash Activity Related to the lease Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 3,378<span></span>
</td>
<td class="nump">$ 2,995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Payments under Operating Leases (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 3,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">3,526<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">3,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">3,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">3,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">80,821<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">98,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(72,269)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 26,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 14, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 13, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_OperatingLeasesRentExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,444,000<span></span>
</td>
<td class="nump">$ 3,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted Cash, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,239,000<span></span>
</td>
<td class="nump">9,936,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=CELU_FlorhamParkNewJerseyMember', window );">Florham Park New Jersey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ReductionInLineOfCredit', window );">Reduction in line of credit</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NewLineOfCredit', window );">New line of credit</a></td>
<td class="nump">9,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_BaseRentalPayments', window );">Base rental payments</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 2,083,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CELU_OfficeManufacturingAndLaboratorySpaceMember', window );">Office Manufacturing and Laboratory Space [Member] | Florham Park New Jersey [Member] | Legacy Celularity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AreaOfBuilding', window );">Area of building | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_OperatingLeaseExpiryYear', window );">Operating lease expiry year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to renew lease term period.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to renew the term of the lease for two additional five-year terms<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_OperatingLeaseCommencementDate', window );">Operating lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InitialMonthlyBaseRent', window );">Initial monthly base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted Cash, Noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,722,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AreaOfBuilding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of building.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AreaOfBuilding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_BaseRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base rental payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_BaseRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InitialMonthlyBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial monthly base rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InitialMonthlyBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_NewLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>New line of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_NewLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_OperatingLeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease commencement date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_OperatingLeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_OperatingLeaseExpiryYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease expiry year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_OperatingLeaseExpiryYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_OperatingLeasesRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases rent expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_OperatingLeasesRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ReductionInLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in line of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ReductionInLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=CELU_FlorhamParkNewJerseyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=CELU_FlorhamParkNewJerseyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CELU_OfficeManufacturingAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CELU_OfficeManufacturingAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=CELU_LegacyCelularityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=CELU_LegacyCelularityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2025</div></th>
<th class="th"><div>Mar. 27, 2025</div></th>
<th class="th"><div>May 07, 2024</div></th>
<th class="th"><div>May 06, 2024</div></th>
<th class="th"><div>Jan. 10, 2024</div></th>
<th class="th"><div>Apr. 17, 2023</div></th>
<th class="th"><div>May 05, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 03, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AccruedResearchAndDevelopmentSoftware', window );">Accrued research and development software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=CELU_HackensackMeridianHealthMember', window );">Hackensack Meridian Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AffiliateCosts', window );">Affiliate costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Payments for legal settlements</a></td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=CELU_EvolutionMember', window );">Evolution [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SaleOfBiomaterialProductsAmount', window );">Sale of biomaterial products amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_UpfrontFee', window );">Upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AnnualMaintenanceFee', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ClinicalAndRegulatoryMilestones', window );">Clinical and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">License agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LicenseAgreementNoticePeriod', window );">License agreement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_SettlementAndReleaseAgreementMember', window );">Settlement and Release Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_SettlementAndReleaseAgreementMember', window );">Settlement and Release Agreement [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NumberOfSharesIssuedForPiggybackRegistrationRights', window );">Shares issued for piggyback registration rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=CELU_PalantirTechnologiesIncMember', window );">Palantir Technologies Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=CELU_PalantirTechnologiesIncMember', window );">Palantir Technologies Inc [Member] | Software Cease Use Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit or disposal costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=CELU_PalantirTechnologiesIncMember', window );">Palantir Technologies Inc [Member] | Master Subscription Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PaymentsForMasterSubscriptionAgreement', window );">Payments for master subscription agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PaymentSubscriptionPeriod', window );">Payment subscription period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember', window );">HLI Cellular Therapeutics LLC and Anthrogenesis [Member] | Legacy Celularitys [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,413<span></span>
</td>
<td class="nump">$ 1,606<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AccruedResearchAndDevelopmentSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AccruedResearchAndDevelopmentSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AnnualMaintenanceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual maintenance fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AnnualMaintenanceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ClinicalAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical and regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ClinicalAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_LicenseAgreementNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_LicenseAgreementNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_NumberOfSharesIssuedForPiggybackRegistrationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for piggy back registration rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_NumberOfSharesIssuedForPiggybackRegistrationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PaymentSubscriptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment subscription period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PaymentSubscriptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PaymentsForMasterSubscriptionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for master subscription agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PaymentsForMasterSubscriptionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_SaleOfBiomaterialProductsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of biomaterial products amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_SaleOfBiomaterialProductsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AffiliateCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs associated with revenues arising from an entity that is an affiliate of the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AffiliateCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CELU_HackensackMeridianHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CELU_HackensackMeridianHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=CELU_EvolutionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=CELU_EvolutionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_SettlementAndReleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_SettlementAndReleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=CELU_PalantirTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=CELU_PalantirTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=CELU_SoftwareCeaseUseCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=CELU_SoftwareCeaseUseCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_MasterSubscriptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_MasterSubscriptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=CELU_LegacyCelularitysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=CELU_LegacyCelularitysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Summary of the Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jan. 24, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Mar. 13, 2024</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>May 18, 2023</div></th>
<th class="th"><div>Apr. 10, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,221,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | January 2024 PIPE Warrant [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | January 2024 PIPE Warrant [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_DragasacWarrantMember', window );">Dragasac Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">652,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,437,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 16,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_SponsorWarrantsMember', window );">Sponsor Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 16,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember', window );">May 2022 Private Investment in Public Equity Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 10,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember', window );">March 2023 Private Investment in Public Equity Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 27,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember', window );">March 2023 Private Investment in Public Equity Warrants, Modified [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 27,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember', window );">March 2023 Loan Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 17,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember', window );">April 2023 Registered Direct Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 10,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember', window );">April 2023 Registered Direct Warrants Modified [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 10,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember', window );">May 2023 Private Investment in Public Equity Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">581,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 17,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 17,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_JuneTwoThousandTwentyThreeWarrantsMember', window );">June 2023 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember', window );">June 2023 Loan Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember', window );">July 2023 Registered Direct Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember', window );">January 2024 PIPE Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 16,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember', window );">January 2024 Bridge Loan Tranche One Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 16,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember', window );">January 2024 Bridge Loan - Tranche #2 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember', window );">March 2024 RWI Forbearance Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember', window );">November 2024 Purchaser Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember', window );">November 2024 Purchaser Warrants [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 25,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember', window );">November 2024 Purchaser Warrants [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  03,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember', window );">November 2024 Placement Agent Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember', window );">November 2024 Placement Agent Warrants [Member] | Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 25,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember', window );">November 2024 Placement Agent Warrants [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec.  03,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In connection with the execution of the January 2024 PIPE described above, the Company agreed to reprice <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_z0CxQy6hgMJh" title="Number of warrants repriced">652,981</span> legacy warrants held by Dragasac with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zJ7gS6haRbBc" title="Exercise price per share or per unit of warrants or rights outstanding">67.70</span> to a new exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zYVzxB4PfIah" title="Exercise price">2.4898</span>. The term of the warrants was unchanged.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On January 24, 2025, the
Company agreed to reduce the exercise price of the Dragasac warrants and the January 2024 PIPE warrants from $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zDOZqY4vlhF5" title="Exercise price">2.49</span> per share to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zfw8z5NDCiqh" title="Exercise price">2.07</span>
per share. As a result of the price reduction, the holder agreed to immediately exercise the warrants in full and to purchase an aggregate
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zs0kpvh31E5b" title="Aggregate shares">1,188,255</span> shares of the Company&#8217;s Class A common stock for gross proceeds to the Company of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250124__20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJKjoIgtMeje" title="Proceeds from the exercise of warrants">2.5</span> million<i>.</i></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The number of Public Warrants
and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_zHSrw9l6fBM" title="Warrants outstanding">14,374,478</span> Public Warrants and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zhb8lpf7vX1c" title="Warrants outstanding">8,499,999</span> Sponsor
Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant
is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfdpdBsJpoed" title="Exercise per share price (in Dollars per share)">115.00</span> as a result
of the split.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">In connection with the execution
of the Starr Forbearance Agreement on March 13, 2024, described above under Warrant Modification and further in Note 10, the Company
agreed to reprice <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zNKnX4iQB39l" title="Number of warrants repriced">75,000</span> warrants with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zB4Cdrckei1h" title="Exercise price">7.10</span> and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zGIhzk4KHX5l" title="Number of warrants repriced">50,000</span> warrants with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313_ztdMSGu7CCBf" title="Exercise price">8.10</span>
held by C.V. Starr to a new exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zYKfrX5dCT29" title="Exercise price">5.895</span>. The term of the warrants was unchanged.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_DragasacWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_DragasacWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_SponsorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_SponsorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_JuneTwoThousandTwentyThreeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_JuneTwoThousandTwentyThreeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Summary of the Warrants (Details) (Parenthetical) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 24, 2025</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Apr. 10, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 25, 2024</div></th>
<th class="th"><div>Mar. 13, 2024</div></th>
<th class="th"><div>Jan. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_StarrForbearanceAgreementMember', window );">Starr Forbearance Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NumberOfWarrantsRepriced', window );">Number of warrants repriced</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember', window );">C.V. Starr Co Inc [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NumberOfWarrantsRepriced', window );">Number of warrants repriced</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_DragasacWarrantMember', window );">Dragasac Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,374,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_SponsorWarrantsMember', window );">Sponsor Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,499,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,142<span></span>
</td>
<td class="nump">923,076<span></span>
</td>
<td class="nump">11,221,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Dragasac Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Sponsor Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_TwoThousandTwentyFourWarrantRepricingMember', window );">2024 Warrant Repricing [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NumberOfWarrantsRepriced', window );">Number of warrants repriced</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">652,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_TwoThousandTwentyFourWarrantRepricingMember', window );">2024 Warrant Repricing [Member] | Common Class A [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_TwoThousandTwentyFourWarrantRepricingMember', window );">2024 Warrant Repricing [Member] | Common Class A [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Aggregate shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,188,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In connection with the execution of the January 2024 PIPE described above, the Company agreed to reprice <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_z0CxQy6hgMJh" title="Number of warrants repriced">652,981</span> legacy warrants held by Dragasac with a previous exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zJ7gS6haRbBc" title="Exercise price per share or per unit of warrants or rights outstanding">67.70</span> to a new exercise price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zYVzxB4PfIah" title="Exercise price">2.4898</span>. The term of the warrants was unchanged.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">On January 24, 2025, the
Company agreed to reduce the exercise price of the Dragasac warrants and the January 2024 PIPE warrants from $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zDOZqY4vlhF5" title="Exercise price">2.49</span> per share to $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zfw8z5NDCiqh" title="Exercise price">2.07</span>
per share. As a result of the price reduction, the holder agreed to immediately exercise the warrants in full and to purchase an aggregate
<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zs0kpvh31E5b" title="Aggregate shares">1,188,255</span> shares of the Company&#8217;s Class A common stock for gross proceeds to the Company of approximately $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250124__20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJKjoIgtMeje" title="Proceeds from the exercise of warrants">2.5</span> million<i>.</i></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">The number of Public Warrants
and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_zHSrw9l6fBM" title="Warrants outstanding">14,374,478</span> Public Warrants and <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zhb8lpf7vX1c" title="Warrants outstanding">8,499,999</span> Sponsor
Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant
is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfdpdBsJpoed" title="Exercise per share price (in Dollars per share)">115.00</span> as a result
of the split.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_NumberOfWarrantsRepriced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Repriced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_NumberOfWarrantsRepriced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=CELU_StarrForbearanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=CELU_StarrForbearanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_DragasacWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_DragasacWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_SponsorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_SponsorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_TwoThousandTwentyFourWarrantRepricingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_TwoThousandTwentyFourWarrantRepricingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Narrative)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 24, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 13, 2024 </div>
<div>USD ($) </div>
<div>Integer </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 12, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 18, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 10, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 20, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 14, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 08, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 25, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 12, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 22, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 14, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 18, 2022 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730,000,000<span></span>
</td>
<td class="nump">730,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,546,671<span></span>
</td>
<td class="nump">19,378,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,546,671<span></span>
</td>
<td class="nump">19,378,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">common
stock are entitled to one vote per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase and sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 12,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ReducedExercisePrice', window );">Reduced exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Fair value of modified warrant, incremental expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantExpirationTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentPayment', window );">Debt instrument payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueNetAssetsLiability', window );">Fair value of the warrant liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AdditionalWarrantLiability', window );">Additional warrant liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantLiability', window );">Warrant liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,264<span></span>
</td>
<td class="nump">4,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DailyInterestAccruingRate', window );">Daily interest accruing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,221,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember', window );">C.V. Starr Co Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NumberOfWarrantsRepriced', window );">Number of warrants repriced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember', window );">January 2024 PIPE Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ProceedsFromPrivatePlacements', window );">Proceeds from private placements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NumberOfWarrantsRepriced', window );">Number of warrants repriced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">652,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost', window );">Fair value of warrant modification | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_TwoThousandTwentyFourWarrantRepricingMember', window );">2024 Warrant Repricing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NumberOfWarrantsRepriced', window );">Number of warrants repriced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">652,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ClassOfWarrantOrRighstExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=CELU_ChiefAdministrativeOfficerMember', window );">Chief Administrative Officer [Member] | Amended Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RelatedPartyBaseSalary', window );">Base salary | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | January 2024 PIPE Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Investor Rights Agreement [Member] | Dragasac Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount', window );">Percentage of partial liquidating damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | 2024 Warrant Repricing [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Chief Administrative Officer [Member] | Amended Employment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RelatedPartyBaseSalary', window );">Base salary | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">892,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Investor Rights Agreement [Member] | Dragasac Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount', window );">Percentage of partial liquidating damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | 2024 Warrant Repricing [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 2.4898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Minimum [Member] | Legacy Celularity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfSharesRequiredForVoting', window );">Percentage of shares required for voting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_AtTheMarketSalesAgreementMember', window );">At the Market Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds', window );">Sales agents commission rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember', window );">March 2023 Private Investment in Public Equity Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and rights outstanding, expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 27,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AdjustedAdvanceNoticePeriod', window );">Adjusted advance notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PremiumPaidForPrivatePlacementPurchase', window );">Premium paid for private placement purchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ReducedExercisePrice', window );">Reduced exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember', window );">March 2023 Private Investment in Public Equity Warrants [Member] | Private Placement [Member] | Chairman and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember', window );">May 2022 Private Investment in Public Equity Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and rights outstanding, expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 10,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember', window );">May 2022 Private Investment in Public Equity Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AmendedTerminationDateDescription', window );">Amended termination date description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">date to five and one-half years following the closing of the offering<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember', window );">May 2023 Private Investment in Public Equity Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate purchase price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and rights outstanding, expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 17,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 17,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AdjustedAdvanceNoticePeriod', window );">Adjusted advance notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">61 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">581,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase and sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant [Member] | RWI Forbearance Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and rights outstanding, expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant [Member] | March 2023 Loan Warrants [Member] | Loan Agreement [Member] | C.V. Starr Co Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant [Member] | March 2023 Loan Warrants [Member] | Forbearance Agreement [Member] | Loan Agreement [Member] | C.V. Starr Co Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ClassOfWarrantOrRighstExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 17,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant [Member] | June 2023 Loan Warrants [Member] | Forbearance Agreement [Member] | Loan Agreement [Member] | C.V. Starr Co Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ClassOfWarrantOrRighstExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Maximum [Member] | Warrant [Member] | RWI Forbearance Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NumberOfWarrantsRepriced', window );">Number of warrants repriced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_StandbyEquityPurchaseAgreementMember', window );">Equity Purchase Agreement [Member] | Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage', window );">Sale of stock, maximum average daily traded amount (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays', window );">Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days | Integer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice', window );">Sale of stock, percentage based on volume weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SaleOfStockConsiderationCashDueDiligenceFee', window );">Cash due diligence fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SaleOfStockConsiderationCommitmentFeeInShares', window );">Commitment fee in shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_StandbyEquityPurchaseAgreementMember', window );">Equity Purchase Agreement [Member] | Yorkville [Member] | Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault', window );">Line of credit percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730,000,000<span></span>
</td>
<td class="nump">730,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,546,671<span></span>
</td>
<td class="nump">19,378,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,546,671<span></span>
</td>
<td class="nump">19,378,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase and sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,221,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | 2024 Warrant Repricing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | 2024 Warrant Repricing [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="nump">1,188,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of warrants | $</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Private Placement [Member] | January 2024 PIPE Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase and sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants and rights outstanding, expire date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 16,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_WarrantsAndRightsIssuedClosingDate', window );">Warrants and rights issued closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 16,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Maximum [Member] | Private Placement [Member] | January 2024 PIPE Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | March 2023 Private Investment in Public Equity Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase and sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | March 2023 Private Investment in Public Equity Warrants [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | March 2023 Private Investment in Public Equity Warrants [Member] | Maximum [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">938,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | May 2022 Private Investment in Public Equity Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | May 2022 Private Investment in Public Equity Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | May 2023 Private Investment in Public Equity Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase and sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">581,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">581,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | May 2023 Private Investment in Public Equity Warrants [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price of per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Equity Purchase Agreement [Member] | Yorkville [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration shares of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | At the Market Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AggregateOfferingPrice', window );">Aggregate offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase and sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Average price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AdditionalWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AdditionalWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AdjustedAdvanceNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted advance notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AdjustedAdvanceNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AmendedTerminationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amended termination date description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AmendedTerminationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ClassOfWarrantOrRighstExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or righst expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ClassOfWarrantOrRighstExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DailyInterestAccruingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Daily Interest Accruing Rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DailyInterestAccruingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FairValueNetAssetsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value net assets liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FairValueNetAssetsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Warrant Modification Incremental For Equity Issuance Cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line of credit increase in interest rate during period in event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of sales commission from gross sales proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_NumberOfWarrantsRepriced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Repriced.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_NumberOfWarrantsRepriced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of partial liquidating damages on subscription amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfSharesRequiredForVoting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares required for voting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfSharesRequiredForVoting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PremiumPaidForPrivatePlacementPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Premium Paid For Private Placement Purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PremiumPaidForPrivatePlacementPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ProceedsFromPrivatePlacements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from private placements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ProceedsFromPrivatePlacements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ReducedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduced exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ReducedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_RelatedPartyBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Base Salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_RelatedPartyBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_SaleOfStockConsiderationCashDueDiligenceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration cash due diligence fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_SaleOfStockConsiderationCashDueDiligenceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_SaleOfStockConsiderationCommitmentFeeInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration commitment fee in shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_SaleOfStockConsiderationCommitmentFeeInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock maximum average daily traded amount percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock maximum average dailyTradedAmountThresholdConsecutiveTradingDays</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock percentage based on volume weighted average price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant expiration term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_WarrantsAndRightsIssuedClosingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants and rights issued closing date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_WarrantsAndRightsIssuedClosingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=CELU_CVStarrCoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_TwoThousandTwentyFourWarrantRepricingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_TwoThousandTwentyFourWarrantRepricingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CELU_ChiefAdministrativeOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CELU_ChiefAdministrativeOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=CELU_AmendedEmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=CELU_AmendedEmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_InvestorRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_InvestorRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=CELU_DragasacLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=CELU_DragasacLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=CELU_LegacyCelularityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=CELU_LegacyCelularityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_AtTheMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_AtTheMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CELU_ChairmanAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CELU_ChairmanAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_RwiForbearanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_RwiForbearanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELU_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELU_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_ForbearanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_ForbearanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_StandbyEquityPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_StandbyEquityPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=CELU_YorkvilleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=CELU_YorkvilleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_ConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">104.90%<span></span>
</td>
<td class="nump">86.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - 2021 and 2017 Equity Incentive Plan [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options beginning balance</a></td>
<td class="nump">2,820,187<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, beginning balance</a></td>
<td class="nump">$ 40.16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contract Term</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,503,394<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 3.26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(20,744)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited/Expired</a></td>
<td class="num">(341,312)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/Expired</a></td>
<td class="nump">$ 29.51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options ending balance</a></td>
<td class="nump">3,961,525<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,820,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, ending balance</a></td>
<td class="nump">$ 27.27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 40.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options Vested and expected to vest</a></td>
<td class="nump">3,961,525<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest</a></td>
<td class="nump">$ 27.27<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contract Term, Vested and expected to vest</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Vested and expected to vest</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">2,586,561<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 37.49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contract Term Exercisable</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Options outstanding at December 31, 2024 under the 2021 Plan and 2017 Plan were <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zJXOtNTlcnPg" title="Options outstanding">2,569,029</span> and
                                                                             <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zBXUGuFGvff8" title="Options outstanding">1,437,496</span>, respectively. Options outstanding at December 31, 2024 under the 2021 Plan include <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_z1vLdctHuub8" title="Options outstanding including awards">45,000</span> awards with performance
                                                                             conditions (see below).</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELU_TwoThousandTwentyOnePlanMember', window );">2021 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Options outstanding</a></td>
<td class="nump">2,569,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options outstanding including awards</a></td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELU_TwoThousandSeventeenPlanMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Options outstanding</a></td>
<td class="nump">1,437,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELU_TwoThousandTwentyOnePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELU_TwoThousandTwentyOnePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELU_TwoThousandSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELU_TwoThousandSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Activity Related to RSU Stock-Based Payment Awards (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding beginning balance | shares</a></td>
<td class="nump">823,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value,Outstanding beginning balance | $ / shares</a></td>
<td class="nump">$ 13.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">337,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">$ 2.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Released | shares</a></td>
<td class="num">(400,996)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Released | $ / shares</a></td>
<td class="nump">$ 11.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited | shares</a></td>
<td class="num">(99,977)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">$ 13.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Outstanding ending balance | shares</a></td>
<td class="nump">659,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Outstanding ending balance | $ / shares</a></td>
<td class="nump">$ 9.29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 11,569<span></span>
</td>
<td class="nump">$ 15,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">1,287<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,832<span></span>
</td>
<td class="nump">$ 12,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 16, 2023</div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Aug. 16, 2022</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="nump">$ 5.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,569,000<span></span>
</td>
<td class="nump">$ 15,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value, stock option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.90%<span></span>
</td>
<td class="nump">86.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,569,000<span></span>
</td>
<td class="nump">15,017,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,336,000<span></span>
</td>
<td class="nump">9,293,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CELU_AwardsWithPerformanceConditionsMember', window );">Awards With Performance Conditions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested options to acquire per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Remaining stock options forfeited upon termination of the advisory agreement</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CELU_AwardsWithPerformanceConditionsMember', window );">Awards With Performance Conditions [Member] | Initial Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CELU_AwardsWithPerformanceConditionsMember', window );">Awards With Performance Conditions [Member] | Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,022,000<span></span>
</td>
<td class="nump">$ 5,724,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value of units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CELU_MarketConditionStockUnitMember', window );">Market Condition Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value of units granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Market Condition Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Market Condition Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remaining available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,091,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod', window );">[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember', window );">2021 Equity Incentive Plan [Member] | Common Class A [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remaining available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,229,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELU_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares remaining available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,234,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELU_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELU_TwoThousandAndSeventeenEquityIncentivePlanMember', window );">2017 Equity Incentive Plan [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares issued for future issuance automatic increase period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CELU_AwardsWithPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CELU_AwardsWithPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=CELU_InitialTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=CELU_InitialTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=CELU_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=CELU_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CELU_MarketConditionStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CELU_MarketConditionStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELU_TwoThousandAndSeventeenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELU_TwoThousandAndSeventeenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Disaggregated Revenue by Product and Services (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 54,220<span></span>
</td>
<td class="nump">$ 22,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">35,336<span></span>
</td>
<td class="nump">13,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">5,140<span></span>
</td>
<td class="nump">5,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=CELU_LicenseRoyaltyAndOtherMember', window );">License Royalty and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 13,744<span></span>
</td>
<td class="nump">$ 4,181<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=CELU_LicenseRoyaltyAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=CELU_LicenseRoyaltyAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,020<span></span>
</td>
<td class="nump">$ 4,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue', window );">Deferral of revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,731<span></span>
</td>
<td class="nump">6,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized', window );">Recognition of unearned revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(5,496)<span></span>
</td>
<td class="num">(4,738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,255<span></span>
</td>
<td class="nump">$ 6,020<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Deferral
    of revenue includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DeferredRevenue_iI_pn3n3_c20241231_zbtl13DKTSt6">5,061</span> in 2024 resulting from payments received in advance of performance under the biobanking services storage
    contracts that are recognized as revenue under the contract as performance is completed.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Recognition
    of unearned revenue includes $<span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_ecustom--UnearnedRevenue_iI_pn3n3_c20241231_zQdD2DbYPnl6">2,561</span> that was included in the beginning deferred revenue balance at January 1, 2024.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability increase decrease for contract from business combination and deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong> Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="nump">$ 5,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_UnearnedRevenue', window );">[custom:UnearnedRevenue-0]</a></td>
<td class="nump">$ 2,561<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_UnearnedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_UnearnedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Distribution Agreements (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 11, 2023</div></th>
<th class="th"><div>Aug. 25, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,061<span></span>
</td>
<td class="nump">$ 5,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase and sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase and sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,141,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_RegeneronResearchCollaborationServicesAgreementMember', window );">Regeneron Research Collaboration Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_NonrefundableUpfrontPayment', window );">Nonrefundable up-front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ServiceAgreementTerm', window );">Service agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LicenseAgreementNoticePeriod', window );">License agreement notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_RegeneronServicesAgreementMember', window );">Regeneron Services Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Received payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 637<span></span>
</td>
<td class="nump">$ 637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_PultheraLLCBindingTermSheetMember', window );">Pulthera LLC Binding Term Sheet [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PaymentOfOptionFeeInCash', window );">Payment of option fee in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_PultheraLLCBindingTermSheetMember', window );">Pulthera LLC Binding Term Sheet [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_OptionFeeExpense', window );">Option fee expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_PultheraLLCBindingTermSheetMember', window );">Pulthera LLC Binding Term Sheet [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase and sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_LicenseAgreementWithBiocellgraftIncMember', window );">License Agreement With Biocellgraft Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_CommercialLicenseToDentalProductsAgreementPeriod', window );">Commercial license</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm', window );">Commercial license to dental products agreement renewal term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LicenseFeeExpense', window );">License fee expense</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LicenseFeesPaymentPeriod', window );">License fees payment period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LicenseFeePayment', window );">License fee payment</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AdditionalLicenseFee', window );">Additional license fee</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AdditionalLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AdditionalLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_CommercialLicenseToDentalProductsAgreementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial license to dental products agreement period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_CommercialLicenseToDentalProductsAgreementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial license to dental products agreement renewal term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_LicenseAgreementNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement notice period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_LicenseAgreementNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_LicenseFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fee expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_LicenseFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_LicenseFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_LicenseFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_LicenseFeesPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fees payment period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_LicenseFeesPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_NonrefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable up-front payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_NonrefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_OptionFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option fee expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_OptionFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PaymentOfOptionFeeInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Option Fee In Cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PaymentOfOptionFeeInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ServiceAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Service agreement term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ServiceAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_RegeneronResearchCollaborationServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_RegeneronResearchCollaborationServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_RegeneronServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_RegeneronServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_PultheraLLCBindingTermSheetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_PultheraLLCBindingTermSheetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_LicenseAgreementWithBiocellgraftIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_LicenseAgreementWithBiocellgraftIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Benefit Plan (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contributions made to the plan</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Current and Deferred Tax Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Total deferred tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of the U.S federal statutory income tax (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefits</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense', window );">Interest accretion expense</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(20.10%)<span></span>
</td>
<td class="num">(20.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant', window );">Mark to market warrant</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp', window );">Deferred true-up</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Impairment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(12.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other permanent items</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation deferred true up.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation interest accretion expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation mark to market warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred tax assets and liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 121,804<span></span>
</td>
<td class="nump">$ 109,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">5,674<span></span>
</td>
<td class="nump">5,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">17,717<span></span>
</td>
<td class="nump">16,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DeferredTaxAssetsStartupCosts', window );">Startup costs</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">3,028<span></span>
</td>
<td class="nump">3,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,469<span></span>
</td>
<td class="nump">1,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DeferredTaxAssetsUnicap', window );">Unicap</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DeferredTaxAssetsImputedInterestOnContingentPayments', window );">Imputed interest on contingent payments</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization', window );">Legal fee capitalization and amortization</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">22,903<span></span>
</td>
<td class="nump">26,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DeferredTaxAssetsIrcSectionInterest', window );">IRC Section 163j interest</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">5,755<span></span>
</td>
<td class="nump">4,751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">181,407<span></span>
</td>
<td class="nump">169,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(181,416)<span></span>
</td>
<td class="num">(169,797)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DeferredTaxAssetsImputedInterestOnContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets imputed interest on contingent payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DeferredTaxAssetsImputedInterestOnContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DeferredTaxAssetsIrcSectionInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets irc section interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DeferredTaxAssetsIrcSectionInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets legal fee capitalization and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DeferredTaxAssetsStartupCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets startup costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DeferredTaxAssetsStartupCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DeferredTaxAssetsUnicap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets unicap.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DeferredTaxAssetsUnicap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance beginning</a></td>
<td class="nump">$ 1,028<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Decrease related to current year tax provisions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Decrease related to current year tax provisions</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance ending</a></td>
<td class="nump">$ 1,028<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increased amount</a></td>
<td class="nump">$ 11,619,000<span></span>
</td>
<td class="nump">$ 39,272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">1,028,000<span></span>
</td>
<td class="nump">1,028,000<span></span>
</td>
<td class="nump">$ 1,028,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest accrued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CELU_UnitedStatesFederalAndStateMember', window );">United States Federal and State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 121,804,000<span></span>
</td>
<td class="nump">109,544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 5,674,000<span></span>
</td>
<td class="nump">$ 5,674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_TaxCreditCarryforwardsExpirationYear', window );">Tax credit carryforwards expiration year</a></td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_TaxCreditCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_TaxCreditCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=CELU_UnitedStatesFederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=CELU_UnitedStatesFederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Financial Information by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,220<span></span>
</td>
<td class="nump">$ 22,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues (excluding amortization of acquired intangible assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,989<span></span>
</td>
<td class="nump">16,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,326<span></span>
</td>
<td class="nump">40,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SegmentContribution', window );">Segment contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">905<span></span>
</td>
<td class="num">(33,411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">Other general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,703<span></span>
</td>
<td class="nump">40,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_IndirectExpenses', window );">Indirect expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">118,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,358)<span></span>
</td>
<td class="num">(192,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,534)<span></span>
</td>
<td class="num">(3,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(57,892)<span></span>
</td>
<td class="num">(196,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">(104,339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">112,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_InProcessResearchAndDevelopmentImpairment', window );">IPR&amp;D impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753<span></span>
</td>
<td class="nump">2,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
<td class="nump">118,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=CELU_CellTherapyMember', window );">Cell Therapy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues (excluding amortization of acquired intangible assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,807<span></span>
</td>
<td class="nump">28,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SegmentContribution', window );">Segment contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,119)<span></span>
</td>
<td class="num">(28,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="nump">$ 82,714<span></span>
</td>
<td class="nump">$ 29,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=CELU_BiobankingMember', window );">Biobanking [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,140<span></span>
</td>
<td class="nump">5,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues (excluding amortization of acquired intangible assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">1,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
<td class="nump">1,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SegmentContribution', window );">Segment contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,295<span></span>
</td>
<td class="nump">2,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=CELU_DegenerativeDiseaseMember', window );">Degenerative Disease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,392<span></span>
</td>
<td class="nump">17,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues (excluding amortization of acquired intangible assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,817<span></span>
</td>
<td class="nump">14,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DirectOperatingCosts', window );">Direct expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,846<span></span>
</td>
<td class="nump">9,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SegmentContribution', window );">Segment contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,729<span></span>
</td>
<td class="num">$ (6,756)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_InProcessResearchAndDevelopmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In process research and development impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_InProcessResearchAndDevelopmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_IndirectExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indirect expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_IndirectExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_SegmentContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment contribution.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_SegmentContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DirectOperatingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate direct operating costs incurred during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DirectOperatingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=CELU_CellTherapyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=CELU_CellTherapyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=CELU_BiobankingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=CELU_BiobankingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=CELU_DegenerativeDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=CELU_DegenerativeDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2023</div></th>
<th class="th"><div>Mar. 20, 2023</div></th>
<th class="th"><div>Jan. 25, 2023</div></th>
<th class="th"><div>Sep. 01, 2022</div></th>
<th class="th"><div>Aug. 16, 2022</div></th>
<th class="th"><div>Sep. 21, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 12, 2024</div></th>
<th class="th"><div>Sep. 14, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Apr. 10, 2023</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>Mar. 16, 2023</div></th>
<th class="th"><div>Aug. 21, 2003</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,842,000<span></span>
</td>
<td class="nump">$ 7,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from PIPE financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="nump">12,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,221,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,142<span></span>
</td>
<td class="nump">923,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=CELU_ChairmanAndChiefExecutiveOfficerMember', window );">Chairman and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amont</a></td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=CELU_ChairmanAndChiefExecutiveOfficerMember', window );">Chairman and Chief Executive Officer [Member] | CEO Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amont</a></td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember', window );">March 2023 Private Investment in Public Equity Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from PIPE financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember', window );">March 2023 Private Investment in Public Equity Warrants [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_COTAIncMember', window );">COTA Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Contribution made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_CryoportSystemsIncMember', window );">Cryoport Systems Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Contribution made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_CVStarLoanMember', window );">CV Star Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LoanAgreement', window );">Loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_CVStarLoanMember', window );">CV Star Loan [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,528,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_CVStarLoanMember', window );">CV Star Loan [Member] | March 2023 Loan Warrants [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_ResortsWorldIncPteLtdMember', window );">Resorts World Inc Pte Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_LoanAgreement', window );">Loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SecondLoanAgreement', window );">Second loan agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_ResortsWorldIncPteLtdMember', window );">Resorts World Inc Pte Ltd [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,338,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | March 2023 Private Investment in Public Equity Warrants [Member] | Dr Robert Hariri [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from PIPE financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | March 2023 Private Investment in Public Equity Warrants [Member] | Dr Hariri [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from PIPE financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_LoanAgreementMember', window );">Loan Agreement [Member] | Chairman and Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_DebtInstrumentContributionAmount', window );">Debt instrument contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Loan interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Dr Andrew Pecora [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Related party description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On
August 31, 2022, Dr. Pecora resigned as the Company&#8217;s President, and subsequently entered into a consulting agreement with the
Company dated September 21, 2022, to receive a $10 monthly fee for an initial six-month term and which would be automatically renewed
for one additional six- month term if either party did not provide notice of non-renewal.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ReceiveForMonth', window );">Receive for month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_ScientificAndClinicalAdvisorAgreementMember', window );">Scientific and Clinical Advisor Agreement [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">RSUs one-time grant value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_ScientificAndClinicalAdvisorAgreementMember', window );">Scientific and Clinical Advisor Agreement [Member] | Dr Andrew Pecora [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ReceiveForMonth', window );">Receive for month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_ScientificAndClinicalAdvisorAgreementMember', window );">Scientific and Clinical Advisor Agreement [Member] | Dr Andrew Pecora [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_AdvisoryAgreementMember', window );">Advisory Agreement [Member] | Robin L Smith Md [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ReceiveForMonth', window );">Receive for month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RelatedPartyCashBonus', window );">One-time cash bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PaymentsToRelatedParty', window );">Amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_AdvisoryAgreementMember', window );">Advisory Agreement [Member] | Robin L Smith Md [Member] | Initial Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELU_AdvisoryAgreementMember', window );">Advisory Agreement [Member] | Robin L Smith Md [Member] | Share-Based Payment Arrangement, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested options to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=CELU_DrRobertHaririMember', window );">Dr Robert Hariri [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_SecuritiesPurchaseAgreementDate', window );">Securities purchase agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 12,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=CELU_DrRobertHaririMember', window );">Dr Robert Hariri [Member] | Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_UnpaidBaseSalary', window );">Unpaid base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,088,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from offerings of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_BonusProgramEffectiveDate', window );">Bonus program effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 16,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfUnpaidBaseSalary', window );">Percentage of unpaid base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_PercentageOfBaseSalary', window );">Percentage of base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_AnnualRateOfBaseSalary', window );">Annual rate of base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_BaseSalaryEffectiveDate', window );">Bonus program effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=CELU_AmendedAndRestatedEmploymentAgreementMember', window );">Amended and Restated Employment Agreement [Member] | Dr Robert Hariri [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_BonusProgramEffectiveDate', window );">Bonus program effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 16,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=CELU_EmploymentOfImmediateFamilyMemberMember', window );">Employment of Immediate Family Member [Member] | Ms Hariri [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_RelatedPartyBaseSalary', window );">Base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_AnnualRateOfBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Rate Of Base Salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_AnnualRateOfBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_BaseSalaryEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base salary effective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_BaseSalaryEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_BonusProgramEffectiveDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bonus program effective date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_BonusProgramEffectiveDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_DebtInstrumentContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Contribution Amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_DebtInstrumentContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_LoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_LoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PaymentsToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Related Party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PaymentsToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Base Salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_PercentageOfUnpaidBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of unpaid base salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_PercentageOfUnpaidBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ReceiveForMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receive For Month.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ReceiveForMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_RelatedPartyBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Base Salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_RelatedPartyBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_RelatedPartyCashBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party cash bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_RelatedPartyCashBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_SecondLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Second loan agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_SecondLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_SecuritiesPurchaseAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities Purchase Agreement Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_SecuritiesPurchaseAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_UnpaidBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid base salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_UnpaidBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the terms and manner of settlement of the related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CELU_ChairmanAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CELU_ChairmanAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=CELU_CEOPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=CELU_CEOPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_COTAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_COTAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_CryoportSystemsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_CryoportSystemsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_CVStarLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_CVStarLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_ResortsWorldIncPteLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_ResortsWorldIncPteLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CELU_DrRobertHaririMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CELU_DrRobertHaririMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CELU_DrHaririMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CELU_DrHaririMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_DrAndrewPecoraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_DrAndrewPecoraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_ScientificAndClinicalAdvisorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_ScientificAndClinicalAdvisorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELU_AdvisoryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELU_AdvisoryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_RobinLSmithMdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_RobinLSmithMdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=CELU_InitialTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=CELU_InitialTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=CELU_DrRobertHaririMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=CELU_DrRobertHaririMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=CELU_AmendedAndRestatedEmploymentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=CELU_AmendedAndRestatedEmploymentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_DrRobertHaririMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELU_DrRobertHaririMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=CELU_EmploymentOfImmediateFamilyMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=CELU_EmploymentOfImmediateFamilyMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=CELU_MsHaririMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=CELU_MsHaririMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - Genesis Equity Group Funding LLC [Member] - Subsequent Event [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>May 01, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELU_ApplicableFees', window );">Applicable fees</a></td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomePurchasedReceivables', window );">Receivables purchased</a></td>
<td class="nump">$ 47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELU_ApplicableFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Applicable fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELU_ApplicableFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELU_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomePurchasedReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest earned from receivables purchased; for instance, receivables purchased through a factoring arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomePurchasedReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CELU_GenesisEquityGroupFundingLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CELU_GenesisEquityGroupFundingLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>124
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )*+J%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( )*+J%J:O>_&\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( )*+J%J>7%PV@PH  +!*   8
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MC3(03=)JO+FH5ML#>7JW2A.+%CM:B_K4&WAPJ(*7"B3Z3U,%O:F%5;+.*IP
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M +]/A<B77_0!5B^I.O\_4$L#!!0    ( )*+J%J6W1N.V@<   DF   8
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M6EQ,D@G(V9RN"G4M[G]B+:'0^,M$(9N_X+ZU#28@6TDERG:P1E#R:O-)']I
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MPZI=>UWT0\58M6U?;FC&UWRB /]^757LVQMQ _7I$O2;_P%02P,$%     @
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M!6D#S/U:"+TS;()6H>/?4$L#!!0    ( )*+J%I(PJ 90P(  ) &   8
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MUP;ZIV<,G:EX.#2WLMCQ(D.>J%XQO9 V I6&R8DTT7UX[D[;QD.B- 8(RO$
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MW5[AX,:"=\<Y.&"F)!'WEJV,1WSHD?#;8C^+V+]'LV_*4G/'<6!4ZCQM, ,
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M='KYP_(]Z?F>I=,AMZ8D0XV%Q+:XP5D+>F7 9P?6CUE1LE5;86<R/JQ0N@B
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MVPS,+9&2=U41JAN;@0TPL!VV]E6=4<%)C!WE,R'D=#+$T0\P5!F_F:CLJ(;
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MP31)V&B0X.\D_-(X31!;B]I:Y*0.4<@) < +B#I (D:/>"*-YY,/+T)A[>T
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MQZW)Y8=IW(BP&WA3A;MY8SS>].&SP*<56#+ ]=P8WPWH@/ZQMOP'4$L#!!0
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MI60BW8FSMW_[P9NXKWH('I4$C_I&?P:1]8[?3?UHP+]N7OYY+?@JB<#J9?S
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M-H8SW<R[/X5_['Z=I/DELANXOLCY)?\O\.H[&0&'FST\9S89J]>.?D6<H0;
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M3P DV#.K]#H.<O C"LHD&8X-T+6@'@/R-=K<5MSV$[^@G_A4^0E:V6$_PI[
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M582QK-AN$PSK?+$'"(I21M<+ '$3I(\@7RH?([0M2>RJ6"5/,;J=8K.EK&;
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M]A;Z6;6VH)WI5%0C+"/-E&2\S8U>?-)RZ3+#\I"J]MP@Y_EUO;0'\KX!>=Z
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MZ.-:0 *>8@/X?I6 !>@_<(+RIS??_C]02P,$%     @ DHNH6FO4'X&_ P
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MJNRH+(#V<RE-/[$)AG]%\@=02P,$%     @ DHNH6AYNP_8" P  S08  !D
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MDBT'D^/!,HLGXQG"%8_Z@^B3*MX$G]UHM+,CNJJMV$P.=2\+=I%K] ="%PN
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MLJ@C=[G"R5]H6H#G"Z5L_844-+]?7OX'4$L#!!0    ( )*+J%KIFO*9_P(
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M[(%K%'"[QK8\COR03>4_E1]<T^#:-0T>2^K/"-N?(>&H]=)JV7ROMKNG,-+
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M>TIAR3?5(=]IE\O_<X:MLXIPTM8K86I8%FVYD2_7I4*,MV1E0.?5F)UFBF]
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M:0'>;QPFMN:&#NA^YKK^'U!+ P04    " "2BZA:[K*5L402  !:-   &0
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MP1?;?&<<O!Z:J3:OB*F2J-'(4/&TU(T@]6OO;^F !_5>FK%+X]$C=J?U9H=
MI]3.<<)3D7&H#M#C UTD4DJ(#-)[U?,<%356<$6;NEDV9G*^!_%*,V &Z@'T
MA3/X"Q;P[SVHE<Z)V=_$6G7 %WW+ W 2RDQ*B^RH'?C!A/AT1,TL^_-Q/5@\
MX!$ ;"*/)%@WJCW=U6$CMTKVH%RMTZ:;<[GJ=O6Q25,'G*;90Y?51TV4NOA$
M0*I'#A&4U^1 /$/Q35D803J:0F*R>>-7F>C!%[G$8$KNC$.]IN;J1V\/XAQ+
MI(2A2A7TB^<]\;$IHVC^"H(Y>&K751:A=9]B[!EU =N]C.?0<^@IT"]U+FRK
M#I ^6BPC-H_HDB%EZY3Y*!B;&Z*AM8OF^@,>]0"G)H/<6R8[ T%#?C)4W2 N
M_ENJKX]IEHF>YT TWJ_:4R#\W-7OK@\^- 2"UX:FFX9U3FI=[Z(/.'CG4!,,
M#;"/ON 5."_!XRIT@(8'/?33\"S<6 [!GV?"S,$P9D^,H\P\K<.G.X<3-FJ[
MFGHBJJGJ&PIM+^%ZJ(\G-RROJ2U&*#LY'4M$!COJH9\!94 P]$\;>JOD$2L9
M&WXC;P6]G/Z.QF\(>'@ 00-BT[HTO-&0:RMRH>@4T/+I&8[:DT7>T.6 %"9,
MFE,SAW7+.>5YM(@Y"JTQ,YB319K XXFG\(RI(:U [5;2)C(&.+-%+%[<I JN
M)#2ZU0<=^$ (R\6WJM<:3F;7^AK/<]192>>->E%BVASK*8C\EZG>PM,7<^,\
MC6Y +&">CLCH +;@&B3/.)#3@?/K%<Z*\Q*RA6J>!'![N!-2&BA6MI-S[G+F
M<+<_]'T:A 5/VT',@2D )$"FY6P*"'JR7P4F0',8ZUY#6)[%BSY"#)5AO8K1
M,?:]L;W&:L\658Y-K ERR7!2K?1Y"J9PQ]W)XLOV3@84(,@:'=FD>@X>O+H#
M?.!'KAJTY\_&DAMA25WUNA67?NI2K\#40]&!^5'F=%0*@".5[M[)">DAB+90
M7B/44Y0R129K%9E$P%2:-.J7#)^HHPJ;#&_7YJ)L%IQ08^*FW)Z+O);L@ NI
M3 8FZHA') Z=;U##<VR7IWBCP1E3D[=4G=/#$&V+Q=2*Z4.V.U/^69@B9VQ;
M\ H(5FEFY2+[GQ /3Y:?ZK0I1[N2[4QE>125IZO+L[6_\]^_ZHL]!;D$6'KF
MZ 1G#O;)#/,885^IU$^5.DO"9=]4TAC/8 YEP)&F;?KEB?)3]%:HB?%(1"I*
M.9"?2B&\W_!=,+["E$R5'SD=%<%M]25")P5JX,V)*?%6[F2--9?HC1N(W\3U
MUVP/M&LZ0(.HXZEBCSRKA3F/!2C-L1@W7MY<[\\5N,JQV1FQMR+FM89?;\#$
M[#LFIL,;:2T7@PT@J2DZ;&Z=VO5-YPQ"KF</OLP3&IYFF+M'0Y (.3EE+V/#
MH8?P1LVD_,1C>OUZ)ND\+#0X1 P"'ZH-/XKF[$$_:&OYLIMYO_6KF_?=^OK]
MMR(UFD,1/%=4.W8O@RN&9W:VLGYAZ^=NB>W=U^LL;:\+KUC@3R=S?SJ=8R8.
MHA$5RYGKLV;> Q2:X*S=58OITE\NEZ?6#$^\V70<^?"'YP@X./T85Y*..TQ=
M?OHP*1PO_.DB<@<0W0.KT^LN]]07B>3*G5:\<(/-4R0^2/!#1\)T&"]TO]!O
M-3Q]&$#KGIYT-()/(G\6(O_S0<&?1Z4ES70!-HN",YH\#NG#SGI?#$QW/=,C
MP:)FQ\F5[:"< CJM5&M15VVV:7NAFZW^HNSX76GMD8(1T?:I)A:7IX>H)<6"
M'>.^.#6E[1)XJ])D*[00U^QWH!-#C/X0-$3IG,[(]%=(AFV2DQ;)Y6)AXR@R
M])Q73MFG+W<XZ%H#]A*:#6B:#+3HZ?HW^:A!3.O)X%(KG,/9Q ^B&;$ (=;<
M;YAHP:#AJD?23=17>.C?<K;0CX@OL-_L.70;K/00T;XWL+5 ^M01SA\/N9)2
M"0VP0R-C#U$.,V_3>_;0DSK_)^#830@Z$?+D/W79FO_#QMAUB?8CKO;1*NP/
M@ZD_F4_]Z7S! /:6&FDUSGH8D<^=9#]4P%7':9JIQD"7TM.:2;M#$R;*HIM:
MT30?Z@%3O/0&(T_T;*!43V>TTS:3& ^#MC6X"O49>.1W:HLVT5,GIT9ZER9=
M7K8/[3QU&'>+&:^!#RSU\"GP@\7"#Z,(/D9LQ(9^:'#3^KT'/5V(OVK!;A;*
M,/W3#_>M^^',2O]>I+E=_^H&;+)-<SS:V<#2\6@>7>BNT'ZH9$&_'EG+JI)[
M>KL3T',KO &N;R38PGS #=S/B=[\'U!+ P04    " "2BZA:+TX@VNL,   8
M(P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R=6MF2V[82?>=7H"9+
MC5,TAXM6;U7C)5O%L<MC.W7KUGV 2$A"3!$R0,Y$^?I[&@ I4LO8R<.,1!)H
M]'+Z= /4DSNE/YFU$#7[:U-6YNG%NJZWCZZN3+X6&VXBM145GBR5WO :EWIU
M9;9:\,).VI17:1Q/KC9<5A?/GMA[;_6S)ZJI2UF)MYJ99K/A>O=<E.KNZ45R
MT=YX)U?KFFY</7NRY2MQ(^H/V[<:5U>=E$)N1&6DJI@6RZ<7U\FCYR,:;P=\
ME.+.]+XSLF2AU">Z^*5X>A&30J(4>4T2.#YNQ0M1EB0(:GSV,B^Z)6EB_WLK
M_4=K.VQ9<"->J/(/6=3KIQ>S"U:()6_*^IVZ^UEX>\8D+U>EL?_9G1L[RBY8
MWIA:;?QD:+"1E?OD?WD_]";,XC,34C\AM7J[A:R6+WG-GSW1ZHYI&@UI],6:
M:F=#.5E14&YJC:<2\^IG-[7*/SU\#KL*]D)M$&O#R5U/KFI(IS%7N9?TW$E*
MSTA*4O9:5?7:L%=5(8JA@"NHU>F6MKH]3^^5^%+D$<N2D*5Q.KI'7M;9FEEY
MDW.VKKD6WM:W? =HU>Q::UZMA/W^W^N%J35P\K]3UCO9V6G9E#N/S);GXND%
MDL,(?2LNGGW_33*)']^C^:C3?'2?]'\4I7LEG=8S&47LW!+D_(2]^MS(>L=^
MJ7(X"FG$WI:\PB7[M2EW=DC(ZK6P,WFU^_Z;69I,'YM@H;@NF%JR0FKDH=*&
M\4)M:U&$C%?%J3G,D"9K51:"1F^W6MT*-_(>52[I.8E(X\=V&-VUU\GC!U'P
MOIUM!Y-(60C#0&I6\ H@J$E-V4FU6C"H"A\8=NE%_W+SQK126:V8V&Q+M1,0
M1=8<B:LPM^9U \-W3F)P*/'WGL30KTI&BUPZ_VOB%1." 0%.F<-U[:@[^/;4
M@Z:2=?=T*[2E;ACF[Y&J@8*>FA3>&%*T+W%@5]B/'$S,H3L(#_:9B)%7JV:S
M@"220>EEI;THN3'!-45V PLLM.!:64M> BX>=\Y?TIC&*M> -?0^S#90TK T
MC.=).$YG+,OB,)LG01('HRAF29BF\W VC]G[PSF\ %-*4PLMBF"Q.XFR8V0Z
M>[X\+F10F[."D,^;>JVT_%N09S8;6=="T'):J&4(GMZA0I1BQ6L1P*NJ$C1W
MHS0^ETN9$\)).2\&L,:H2_D LXQ<59C60Y@+6;V&C?O)"M[,A07L%I!9R@-X
MV*!=2BL2_H!?H,FIL$'2 D*:Q9^PDJY,DZ\'HL 1^Z<D@^39> ^"YHA@2Z%H
MXZ Y_,;6_,!8<DFGU5!BBU[D8]D4LEJ1F7(KD9S&+2#^$CJ7!BL!^]:ME 6?
MNNOE099("*UV;NZA\4'/;,&'9KL92RX1-ZX_H4VZY65C%^!NNAMQBRPD/:EM
M C0$)7$I<[[ 5^^O5I5:K82-Y9VLUZ15.SG@>0ZX:)OX?F%D**U%>0?*:A^U
MUFSYSJ[0;)%GG4O(&:*N2U?6?(!Z-G74Z_SM\[J0CIG4,NBT97REA17CR+(Q
M)Q/5I<X],=^J.YJC@/U"+G<,[2&(L;*1]4 ])3;X*L19 V1%-E2^V7.>Q1V]
M59K2"/J@H+F'T"OG6UGS4O[M.)87?Z+5(C//H3>@7*Y4#1QV@,N)MTJ[NA:.
M\RF8WG&X8*4U>PC5\ "HFFT;G<-1O3N=Y%::1TKP#T5) @5NH,.QX<NY68=4
M_E 50#:XXTC%AX!606384FH#W"QJ-/44(0L'6XAYV<+COJH=(3;)]$RE=FQ]
M[G$P+.08UB_D;?/ 0.J_@5;S'4-#WY2<Z.0>RK8QZEJ)>R?W[0A\H^ JU=$<
M0J4+^[!9^,KZ21H>R8RHJ3H LO5W7BI#L?#@WPB]HL!!I%@NA=W;5,*<HN-*
ML66C;9RMMH@SZA/8K!CFLO>UR^5:(3WZ1-FW$ H!WKEJR@(9CL@MA*AL)8>K
M3HAD=Z"!+$RS49C&HST"?+T.^O6:?76]!GQ#2C,:74B3:^&R>_F5\T-:B@?[
MNNUGGNL,AKF'Z2WE4Q!<'K6MF(6!]7)7WXK3JCH !%^%8MMX2,1OKS+J@%%=
MCX%BA7076UK(KW90)I'WKF@=Q]2%DR@.?4!)4+*M1A+'H-TJV D.EV=LY-NY
M-W8:^XABZ#CT>L\A[ ;]'2WW8E]5WK=5M"N?MM*ZU0,T;>3,#1F!-LDYBG@;
MXUR*-1;]G#TO.?8I-SE2E'HBIP491X]174";SGC^"<]EA61$554-1,AJB[+C
M&AM?EP[XU&;:7I&AOO3,@KO<T5JY:VY]6:V]FJ0T10'-&$F@X/<NW6 7BEM5
MPG$E0HX67II/#Y>: EI1%I@ZT%800:N0Q$'XLI.B+*)SGNPV'4,RHM3K@7"8
M7=ZKCE# _;Y?1/?>;#PL"*Z-H5WA@DYP(G"5IKK@/6)$ZU8"E>^CB,Q)S@J4
MI'W+#[+'@#^;8F6;DG[KY[9G Y]9JSR''AI$ #,.8 \7=K_:)J(<F+JWS9<3
M(R'1MLB^GGBC0W9'';MW3:<'AN+J<\-+W[<B/=>8(7,&SM-\U:&B7=]JWO96
M:'%7L@*)@LWMJ0($=;;9 0Z[1=,UB(><15"W$6VHWZ?FEZU!DY"<0Q:@QEMF
M.G =]IT/._>UCJ,<^VR5<*L=Z^7898]_>]>YV.=D#_]=9Q@%WW\SGTSGCX>Z
M]+ >[+%.6G02>\9T(Z3;0N;D"FU[VVVS0"/-J$FP3PD LCKI,%D5Z./TSB'J
M.*L895705X&D#)YV+34>?HANX& MN&EH_R[R1CL5J*^R5;<E=7BLQU5+NT$$
MUTI5.#:2CK0%BK]=I"OK6'?K,^8@BOHH0&<</>0'LLYMB9>J1,):7#H_TKZ;
M]D\!=;PH3W2P0'7)@QD^D7YSU2, :OEM=TWW3Y'OPP/R/=S369<\M&0^8*U@
MF-9V&%D#'_NT=25'T&DB>XE=KNU%VO- FV?XDCUB-W[+%2  ?[1677NK?K(1
M^9%6_MCR9;^"&<\30]/>#$U[3:8%_X$^[G!SH$Y@U2%5@G>G$<=&T8A]A_\)
M^RYX-0CS)3QK[7S QM$4?Y/]@%[6)/$HFD/$;!*-^S*&L;=$EZ2/NT^"P5&<
M]P$)>@$YWQG\^]#8XO,M2Z/)!)9EXY.P=*\#Y-_8AGM&M"?U9'6?ZOL[U%-'
M12WM=HWE'A>'(6?7?H&@A< 1:EZU?<%;6ZN/GK_PJ<G>VR#Z"%ZOP(G4B*&)
M1Q^('7ON0!>\Z>]W:_8KKQH.2FD=EH:S- Z3V13>&L510NZ:X+N/8_"3CT 2
MCN,LS.8CED4I(<5I6;!+3)^.1NP!G#V+@Q^57@J)&5= BJ2N^C(;)6&6I#1B
M'HV30XV.@O@#&O;YA$[>QA3":91.V00P_I8ED^ CD"W<,<*>M92M@R>%W2?+
M&V&Q<')N&HYGDW \23 ^FT:C.:-<V#OGARZ3U1=L.@N<WDZ%FG:L.)F'<3J'
MPT?9-!S-)VPT#N/8$2OOPBR[,-LD(@+J55O4M1Q=O?64\;T_JH86=-RY$/4=
M[9I.G67U#VQ:>2V^CWO2PR+8GKX.&E1W-*W,OAVP=6G-B\-]C3^TL,W_\8)6
M.!L*'QR<TD&=TD7; +@.C399^S<*!)G*4.TC?B,B4&TSU#N(.)7X4.!;-@NS
M;,+F83K/V RU;AHFB%0:Q?/!'N1M[^"[MP\YWEZ[BE?<2J/T+NC:&D8GL,(?
MO;Q3"Q#U;Q&[P<9K';+7+]FE <W_KFK"TH/!VP]G!?47V_-\9?<EKBGF?K<-
MZY+8PBQ CL[QWUW,8G?/?4SQ"-;.QVP,XR?N)O;X[_:O 1S9?:BHF^N'QN[0
M3>^%0;!_8;!_(_'NYL.9=QP6,ONFWJ:[NJ5C"."KT=@;IE_D^([<;?0=;V#%
M/EJH!;,1.'\R."SZ+9_#!P.9_7=:W0L_*S/XO3O9N''GWV<:AY>4YOONX4M$
M/DM!SUE*S)9%TVE'W!E8))[%MAA2GX -N]7J<A3'X1ST\H"F)-%XMN=N=CF?
MA_/IU#T#X8^^2-IL,IZ#L8@=YQ&2XM_EI<VR#/R7LG$XA=11F"#CDF@T&D#+
M9L9K=RC>91C[Z#=#O9>#V3 ]?#\1)-,1ZED<)"QC"?AUEF5!.@LGDVDPCL"U
M:9($9U]+OO+*_CL3?3^[QVG[($>\5]B3N%V(.VRIC"IEP=VF!A_N.-QRO3^0
M;\_V-NBQU_2+!;3SI3)F"-.;'L1/V=)K)+_<:KY0QN[VM;@5%64U.H<Q 6R,
M^@\N@  ZYJ#S XPHU=:B/PE3-!D)7)T&-Z(L87K89K3;^N\/O<F(.8UD21I.
MXG%P\R6O$H2I=-(74!=JZJEWWU>]7RO88TSZ30;YN:EJ]\.%[F[WLX]K]VN'
M_7#WFQ& #WMLE"RQQ-0XFHXOW/O2]J)66_O;AX6J:[6Q7]>"@TYH )XO%0C<
M7] "W8]AGOT?4$L#!!0    ( )*+J%JA("N#2 0  *L)   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;(U6VV[C-A!]UU<,U*)( #6V9-E.LK:!V.FB
M6V2+(-FV*(H^4-)8(I8BO21EQW_?(64YVJWC]L7F9>;PS.',4+.=TI]-A6CA
MI1;2S,/*VLWM8&#R"FMFKM0&)>VLE:Z9I:DN!V:CD17>J1:#9#B<#&K&9;B8
M^;5'O9BIQ@HN\5&#:>J:Z?T2A=K-PSCL%IYX65FW,%C,-JS$9[2_;1XUS09'
ME(+7* U7$C2NY^%=?+M,G;TW^)WCSO3&X"+)E/KL)A^*>3ATA%!@;AT"H[\M
MKE (!T0TOAPPP^.1SK$_[M#?^]@IEHP97"GQ!R]L-0^O0RAPS1IAG]3N9SS$
M,W9XN1+&_\*NM4VG(>2-L:H^.!.#FLOVG[T<=.@Y7 _?<$@.#HGGW1[D6=XS
MRQ8SK7:@G36AN8$/U7L3.2[=I3Q;3;N<_.SB";<H&X0GS%4IN5-J-K $[+8'
M^0%DV8(D;X#$"7Q4TE8&?I(%%E\##(C1D5;2T5HF9Q'O,;^"41Q!,DS2,WBC
M8Y@CCS?YCS#76M6P(JZ:TH&DMA6LO,BHX:^[S/CUOT\IT.*/3N.[TKDU&Y;C
M/*3:,*BW&"Y^^"Z>#-^=89\>V:?GT/_O)9T%.4TQ'E_!"73X5)%62E#)<EF"
M99E V&BUY04:X+)M!F08L(PJ'0IN6%EJ+)G%@FJU!<SVSJ=H2&DF"W!'\AS-
M+3Q3:RD:@8%:P_U7KD^OKH\]U^>#:^#2P>7$*/@3F6[3#2A9L,[H!BEA>A8=
M@&$"3022.MSW,!I'H]&$!O$HBM.;H$.&,4V'])NF<?! *])@!%KMF;![ST'9
MBHX@MVF:0AK%UW'P25DFNG -@8[3*$F&-$B2:#J-X5<Z\[C-92Z: F_A@E^V
MI%S\&5<D)6I.2 >UB&QKZ[1?<K5E,B<RW0A&#Q$)1<++(H(/DIS7>Q%YDBN4
MEKT7^!(!8>\JGE>@&DT7I+&3 IC&CDQ!@Z-0SWZ7G.BR6TM;:=64+03IYQJL
MPZ7KMIIGC4^5#=-6HOX7++RMXCL_O."D TV!>MBA24<!24"W85SD/F>LTO0V
MN$.;.N."YR13KG3A=S>"TEFZ.\B$4NV:Y<90 K$UR0+K1H@?:5"3M%A*4H^[
M5.@.W*+81\?DNCJ?]7G%9$EW1I%1UT>M>YGNVTK>M17!F:-J>3_770BK%L*)
M<]]!G.Y,#Z\0O8Q>,N$3@%GXA<F&'E&(*=DFT= G71JE-TFPQ))+Z5/G8/ZM
M17LVJ4:4N@@NXDM*_NDH)MMD,@GZS<")+ZG<9"_BB^02+JA:;B9 @Y0\K^&R
M3[!7E)Y ,AYW1 (JVV_Y];<=EXYCT.-X2"Y?:-%P$@>.1(]H<(IHSRF)QI,8
M3O7C0>\!I:>@])\)=.548K9]2X^KQR^1N_8!?C5O/V,^,DWZ&Q"X)M?AU70<
M@FX_#=J)51O_'&?*TKOCAQ5]3:%V!K2_5LIV$W? \?ML\0]02P,$%     @
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MU6U83/']B 2UX ^GH=<A$2KI6^42Y*3$5GJN3=E*1C6V]6/QYD F#VAFVE_
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M\49\5"M)8%)YG4OD'3JP@UMB;\C.NB;M%8[#G21Q)[$!.'REF2KB)"V:27K
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M$TV=$_,Z9\6CY./'*W&I"S;VEJKI#7\/?]4TK$D# %S8G>\R>4!0>".<TM:
MG>SE=$3$)T8DU2NJWW>4@'Q<PR^A,4A!J+[2?39X-CW%#(2BTV=J=0]=U)Y)
ML0BV<N7WOQEP5'E6Z"M(.*.*&N+8#G>.6%KK$-N8;S3UT'$2'=&BP,@EIE0=
MINC&38+<U&6F1JJQ3=>9S/<JUJ&M_6UQVK$K6VFP^&=Q.II,)F+J_YZ_')V]
MG(5[@6B[Y9["<ZD-_:H F;ETX6SP2Y$T16 Z'?ARCETUL#!23?=10SI[L\8
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MU1 Z(Q3<XAI-BW!I*QQR.MF#2[M&YT$H-4#=*+M%]+"I+>C0?/AM2]UJX$X
MPE00Y,L2N?#_M/T-^KC >+MA2N%(EI)M<)QL$,_2!#3617&=*LDA8UI65;)E
M[B6B6^1V,. S>D?B(12U]$.X%E36;/61_4@=W$4'6FRA0/Y4K)%BO)*^='B0
M$?JS??7B+,]./WHHK'!56*S81DG6<:ZKUG&F0=B^1<&'@J%\@!\_ZH)M[ H@
M&N;!^.TA=2?@L4SF?YF-/T#VX0R>>HCI08O0Z%:Q$7HF:0UUW6(?W??:BZ[%
M_-O>->IKX5:24RI<,G0T/'V?@.N:7S<AV\2&4UCB]A6'-?]?H L;>'UI+>TF
M(<'^'VC^%U!+ P04    " "2BZA:3Z#9#*<(  "!%@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6RU6&MOVS@6_:Y?07BF@Q90;$E^ITF ))UBN]B9
M+9)V%HO%?J EVF8CB1J2BIO]]7LN*<ER8Z?H OO%UH/W><Z]E]3%3ND'LQ7"
MLJ]%7IK+P=;:ZGPT,NE6%-P,525*O%DK77"+6[T9F4H+GCFA(A\E430;%5R6
M@ZL+]^RCOKI0M<UE*3YJ9NJBX/KI1N1J=SF(!^V#.[G96GHPNKJH^$;<"_NY
M^JAQ-^JT9+(0I9&J9%JL+P?7\?G-A-:[!7](L3.]:T:1K)1ZH)L/V>4@(H=$
M+E)+&CC^'L6MR'-2!#?^;'0..I,DV+]NM;]WL2.6%3?B5N7_D)G=7@X6 Y:)
M-:]S>Z=V?Q%-/%/2EZK<N%^V\VO'XP%+:V-5T0C#@T*6_I]_;?+0$UA$)P22
M1B!Q?GM#SLMWW/*K"ZUV3--J:*,+%ZJ3AG.R)%#NK<9;"3E[]:%,52'8)_Y5
MF(N1A49Z/DH;Z1LOG9R0CA/VFRKMUK!?RTQDAPI&<*7S)VG]N4E>U/A.I$,V
MCD.61,GD!7WC+KZQTS?[;GSLG31IKDRM!?O7]<I8#4;\^UC,7N/XN$:JDG-3
M\51<#E &1NA',;CZY:=X%KU]P=])Y^_D)>W?Q>-%Z>.^Q8MAT%?+KH.F!)E:
M,[L5[%85%2^??OEID<3SMP:\TUJ4EO$R(X8+W&7,(H655H_2U:,TC!NV5CFJ
MVIRS>S2+K,Y% (VW/>EWK30!\+&5#@A<0G@<_%-P[<F#M:DH5D(3_+T5K3KI
M0R WQ%?T)"/.@_<B$YKG[&?F?$_>[J^">\NMZ)['4?!)69X'Z4EU_;6=W\^7
M!:]7HA1K:=_L[<<L;NR]CMD;]].8.TC?MX9:5_W2(Q[UXXHC *=%JLI4YI*[
MGM;@]WEX/V3KQA<#/VJK@&Y/H2;?K#J*MEBOA>N-SP1> /GNE",O^O%#P+__
M;D!)/(S8J^:O 6"_1IB0E1AK\*WUJ4'. *'AF+UYQ>+A!)(?2BM0+J!LFFKA
M FH1B(8Q+,3>PNV6EQLRP1YY7OO(.26'ERF@3V@QE-)%A(O@-ZX?*.NHM0<X
MLN-:<U"OQ?05M$^AMB.;U;4XJROVNE,$]Z#G P"3NA 'LJ_CQ%OY.S*O624P
MHTK';"L* ]63SL"O)Q'>J]M?_2[LGK8] 6"] N!6"D<+I+4/G&O8KN8)/ 9V
M&&DL-#34\"R2Y>:01^_Z]<&-$0"'E/2,_1!ICN@[#WXG%B!!0*S<,,P M#A@
M\80]#3#)#%57$H>+:.+J;!E.)Y/@#OV3ZW3;=,%'[%\J!P%I!DTR:;_1,@UG
M\XG_!1E5^G!&^X4,N2B(3/R 6/$\G,=S%L_"Z7A)W-46R*?*( &3<<PFRP7Q
M$H23JURTJ1F'4;+ [V22[$/5<*ZLH3*<S);T.XF#SZ5,><6F;$KLJ:V#LF$Y
MO  \E L*I^)/%)9A2WB#UO<WL4&EK(5 =)5$8Y+_:9B.//!":=L^B,-H.L9O
M/(^#VW:M\^=$YI(D7$9CELS"63P./MS=LOMF<Q;/QE_V#B*$>=QU1\_O:3B?
M3MD$O['OEX>3J<E/O(!L1&E=AO/%(OCC6)VZ1?',-6I:A\#?.(X<:.S3_6?V
M>HGES=^I-KP2&UF61#$*7)29NRQ43=G%FKHDN4WIDD0FNG;T0J/]W!>B*7K3
M" 6GW]SPW$7*+?LK+VN:]+Y Q\1OHA#( PJ#G0 KY\0.M*EV-#Y1E1V.^Q:+
MGN9OBW_\?],\:;UFUR9XL>V$_0''MCP['(VTS+@I47ZO(\#,OBDT+0$F)E%3
MY4DT3MAG*]OJ"(Z-XA^P1TM/ULW)CE/P)Y ()ZK5%Q02,AUPJE- GH._!2K2
M\;-&Q]1MK:&)+!)G8KP8M]1U$["$U%W32VY5)NAEO%S,0K<Z5<#05,K3N@/0
MI<H'F?-=R+):!$!<[4JAS5:BI;FA:6 &T&XYAI!*'1\R*!&/4M4FQTY4^P6I
MJO/,KZ YZR9';;%G'[)/6^3GB&)*@@O6K?;U!J>"PU1Y[4@/\E4[W." 3Q7,
MD\?K-5I(8XU2SJGO-O-/Z6][PA Y8VB@!#0EZ)EC(94T.@JVZ%FP>NI:';(?
M$M0X-J+DM2HP]CFF0P,.#%+Y4(XIG+U6I#D5VN*<C71CN&Q5#E1-FR7WC!9Q
M0JI2VD,/PVC9@L(O@VGTBJE'4('C7@MQYNH1M)0J&[+K T&7+QI66@K4I3D6
M(O6M/??8][GG@@]V6PF22\H.6%=0@LC/M=3H_07R(JO\J4T [;3$J8.*#YI[
MY*TLNH7//(5^QXZJRC$8@6R0JW)S1O8)V3/Q5125]9NB?D@9B@Z.4S%G7W <
M=Z/20:O%G[4$BQTQNYZSSUAV-&/(P76]J6G(3:EYQ?-A0/+/$^>I<2P69*Y4
M'IRT:;">3RT7\$;J;C0][SU $X0^U6X"WVH,*F5-U*GW7<[%BNFWWQ1 _[$Y
M[,#%1B>C]E57JCP*GR\F5WV^DNRSPD-$34425U%UU_>W;#Z)SN(H/#C5ANS:
M!L\F0\C\%JQS8><^T[@Z>>0R=Z;0A#)"['!ZT(3/:]IJNE) >VGR[NHIEP^"
M^@80<0_=&H@'W4QO][W/9L&Q?.UD3J<3YE-+I+I.48W4:O.G;Z<:<8]>$L6.
MG40"OD&7,.2S.6)_HVG\'/'",_G8T:9I2KY.,1=C;."6;+P,DWGB*"'A6^K3
M2B7?-JK>Z:%2QE429;&W;VEJ-^=ZXPY@OGO[C!NW.4BBM\<R[E[%;XD[;@(:
M,HA.ZY#F-<W*IN:Q#Q&/W(]1MR.K[59I\ Y)[CM[X*4#A(!UH'3NRC41@2#(
MA3'>&<ZHKSKWY%8I.O& !62I\VKX/^Q</$RG]XQ^A^*V1:5BQSX]C7J?!0N!
M!-/'3T,CMK3^"V'WM/N^>NT_*^Z7^X^S.,EB;TM1KR$:#>?3 =/^@Z>_L:IR
M'QE7REI5N,NMX* >+<#[M5*VO2$#W5?GJ_\"4$L#!!0    ( )*+J%KTZ4+B
M0P8  $D/   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;+U7;6_;-A#^
MKE]!N$7A )JM%UN6TB1 TJQ;@'4+DF[#,.P#+9TM(I*HDI2=[-?OCI15IW72
M8NCVQ;9$WG//W3UW-$^V4MWI$L"P^[IJ].FH-*8]GDYU7D+-]42VT.#*2JJ:
M&WQ4ZZEN%?#"&M75- J"9%IST8S.3NR[:W5V(CM3B0:N%=-=77/U< &5W)Z.
MPM'NQ8U8EX9>3,].6KZ&6S"_MM<*GZ8#2B%J:+20#5.P.AV=A\<7,]IO-_PF
M8*OW?C.*9"GE'3U<%:>C@ A!!;DA!(Y?&W@#545 2.-#CSD:7)+A_N\=^EL;
M.\:RY!K>R.IW49CR=)2.6 $KWE7F1FY_A#Z>.>'ELM+VDVW=WB@;L;S31M:]
M,3*H1>.^^7V?ASV#-'C"(.H-(LO;.;(L+[GA9R=*;IFBW8A&/VRHUAK)B8:*
M<FL4K@JT,V>WL,84&W;5N )CIDZF!H%I>9KW(!<.)'H")(S8.]F84K/OFP**
MQP!39#30BG:T+J)G$2\AG[ X]%D41+-G\.(AS-CB)5\(\P9:J8QHUNS/\Z4V
M"D7QUZ%X'5I\&(T:Y5BW/(?3$7:"!K6!T=FK%V$2O'Z&ZVS@.GL._6M+\BS(
M88IA-O$.H+/W)7AO9-WRY@$;;=U57%7T:T,]P(313#LKS7A3,%,"XVVK),]+
MUFDHV/(!-=E@$UMH(QEL>-5Q ZP%9?TT.5A;7E4RIP4D)3N5@YX\<N]@G%.<
M/,H2U.A2R6Y=(L0.FGC+%2T 6 1E2\N7%0QL?;8M!7+D"BQIS6MDH>WO'AR5
ML+<;<&,!!A1V&H7%*3AT1 :%T+@]-ZSAIL-]UCFXL2*,0,Y]K"X?0,GIH2>,
MQ@ZQ5+Q]8$O,7&$3O *E/4R7L2N$09"[7 A-60*N\I)X4OH*V. <;?%QTL.1
MT1)H?;<7_5/ 78,5VD!C[43#-EP)V2'+$J/21+\'LPR]2UA#8U.R 78I$$IC
M]90L.JR1CY%4E:M^)7*<R12N7<0Z60F@!]VIM<AY9;=M98>?.3'!:7\'>'2P
M"R$O>'-'9'%NT6!&91FH66[15TK67E<O1651<JD*Y[*M4,B-X?T3AB4*(%.I
M4"P4BNXPVPX%R[6$DE<K>B^: JM3=)S@I6*KSM8.&3\M.ZXU&(O#4<K&,G&[
M4 \"<]%(0Q7^3$&N)(!^P+>%Q+K!:F]? ;FPIUG-[T"Q0J)'!/,^[3E&SBP-
M#.!CFR)_!14V#V4;.:&@#3[9GH/5RJ;S$"_*FH]"I83BZ^K!/P NM$=QN2YR
M$OZ\HR8X0%&SS$D6A=IH68G"4KK@E>WR6_M?@I*]#\^7^(^@3Z=+\(2]%0U:
M"%YY^SO1\8ZWH&(@%,Z,K3YFMZ3MK@(/"SO8/AID:-O/-^]1Q^T)[Z#.WQ,O
M[P]L'W>"X:X<ZB5&NCN#_@W>ST#YQ!;LL,XO69*F^#GWPUF W[/4C[.(7LS\
M* I0B=J08@>#,=SG55?8SJ_IT/I[&'H\_] )965@>+,65"&7U"/VZD4:A=%K
M%OKA(F)A[*?A@H4S/TLS[Q*-<(#!?>LZ.)S[:8"K?K*(,4H_G24L1EY1,AP3
M.9[K2BP[ZWJ,!F&8L2,6^5$V)_1%E+$LF'N_T AC+A5N / "AZB@,]:F9G :
M+_Q%$'M7V)F?L/'G2<#&_,C[26HW#?:/@)=L3-SF*3OJO0V6XS#SY_&,]99+
MVX*['C'\WJ9_/%_X*6;\R$,7=L;*QAYI_9AX1,9[4V)B"8.MN%",SAP[:"@?
M6)(^-1KGD..'8Y'3X#(/Y"K,8O3S@Y3%5J!L!(X/H:PLO_/.]XL9^HMY[%FY
M,&F#>NGR\(WU&W\#_>Z411J>S4)BNO#CF,0<1?YB$?X'&D[F 8DW3A(6)GX0
M)I]I.$K]))O91$8L0ST&;!;X8?*4A/O]).$@SM@X0<,$'\=Q[,_"<!#7UT@9
M':6+Y)"4P]0/@O!9,8<9-E&Z.*#FV,^R] MB#K,$K>?_CYH#K #FZJ"B,=;(
MCV<+[^KZYA6OV]>7CQ8#;+H@>"SZR,?^^%3T?<8._7^>[EUO:E!K>XG3R+AK
MC+OI#&^'>^*YNQY]W.XNF>\X_D7!_%>P0M-@LIB/F'(7-_=@9&LO2TMI\.IE
M?Y9XUP5%&W!]):79/9"#X?9\]@]02P,$%     @ DHNH6E_$X>"L"   -14
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MZS'0=9/5 :G2'^R5(MLF?IC9>PFU2[#K:Z7H%+@-FILN_@-02P,$%     @
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ME$7J,&2$-AQ[:+^!\!.][#OB3U7=::1I_**KD\$,)8ZDX)2Z?0:H;^HZORN
M,'%EP G2ZJ98EH8AJPMXN6@V%M1M*Z#*#;",F(=D#:T.5KJL&R /A$6#>W:
M5;=IV0OUT2< TJYN=HF^:>JVG77UK((YVQ09:)K_ U0'F2XX<81.D0L5)[I=
M ]AGN!A8TQ)X"*@;V1>@<T_D]$3=I0TPLT[8F$"!M"'8-L#4'Q%L:%W 1PV<
M74F'#;P3J"#17RK@J;IK3)7ST#7LJ@'D;[Z8;M9N388'KH&3\ \ >G.+NL@*
M>&C=M KI &;32^# @% MDLX2D2=MZRI%L/>@6S CRHHFZS=PZC UK/I7($B
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M6U&%8&187\=35[4=F[:(1.T_"=0>($"K*%@]*<!/P=@#(&8=1ZRJ#/^[J7-
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M!UUJ8>3D=TFDNO\KRI>@J=%#YK-@V)+U61Y=K=)8ZQ-D]::PR3VC'[7JCD9
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M&:D>(R/'L<U7^_05C_ @R6FWKKY1<HKLTX'LP]$.2;^?OJ8;*D*$U5(:Q"&
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M:5D62IB>Q^W/\&@\0R"[JI:086>J('K3#2?W)7^W((RDT#YJ/A>J6%[E"V(
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MF<V/9V=GLQ<GB:M8Q4(%2C<DIX]36X<:L)?-W@4FWW$3.K+T4?&SO5C;FMH
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M>]YN!T1-CN2TE&OHS&9;UCOC(H(M-=NW?LBZX>N(B$W-[*KMP!AHG^@;*3=
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M^KES:<+92\?]+AR[VO"@9@O4.]^9##&HI&W*M[-VS6_1U/P?]Z9S7C&]X]*
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MTC&>F#[&\/H=YX5L%6BU,7^5I3'C,&[?*S"R3>Q::Z7[<R-3PB(4G7<A(YI
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MS8*N62B- [U?":%W Y-@?W&;_0502P,$%     @ DHNH6G2?ZB ' P  [08
M !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULG57;;MLP#'W/5Q#N4&Q
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MPS6U7#0^@/9+37=XF/@#VB8^_0]02P,$%     @ DHNH6JVWEPNW P  O@D
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M(00<<FT0* Z/< 6<&R"D\=\>TQU,&L6Q?$#_9'U'7S94P97@7UFAJY6;NJ2
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M-[JZ^%4O5A7NLC53%J]N;KC$NS)H,L#_YTK9YH4<M+?OZ;]02P,$%     @
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M-^&'N#9$''2MCXLA#+_[FX%K!\1AD[J0HB@-*/1.5031]BUL;8.XTZ0JFC!
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M(OU^#K8<^6$JCTFA?@V[$V$JTES+<C5<VCRSTNQK(@&6C=7RI]8%@E2 5\[
M1 NQT)K.J-6!WT<7EKY3<>Q,)R9:B(76I+,6'+Y;<337K-T;WQ)37MMG;-J>
M\4M N\'7==)!;[!>3B!IA8JEEU >?BT]?+?V0,H =^*Y\8\I2":H:"$66M,5
MM<#Q1_CQCZ1+*CHQT4(LM":=M6CRW:IIC_A'$D$5F8>MV<1?+_A>0GG16GE1
MM_*ZA 7D<R"GD$>)U=1[1/^RV9<<G,'OGLNN!*.BA5AH33_4LH[ZZ,%/404=
M*EJ(A=:DLY9]U"W[=@_^"G M7/WAVN;_1+/>6E2[I[>O^;6,HVZ=A1K5=G-W
M1C7JZ08J6HB%UO1#K:]H#S^J4142*EJ(A=:DLU9(U'V LD=4]UO#=;VD?Z)9
ML![5+Z%H:*UHJ%O1G/.<9_/,'8R8XF2"BA9BH37IJZ4.'>('(ZI<044+L=":
M=-9RA;H/9$PPFD@L3F_-1B%- -I8Y")N_4O]%C!_1!Z R;:N$W?7G5E["55"
M:U5"W:KDR\+^L9)GY?DNJRAK9<P-Y-L#(=UV:#YQ]]R9L)<0*$$M4 *W0#EG
M]UN3GAMBY_L5J+H""ZU)7ZTK GQ=$:#J"E2T$ NM26>M*X*MNF*'I+<%C/:?
M3GKNKCNS]A)R)%BY,>66(\]/>EN :*_,>NV4X5Z,>@GE$-3*(7"?S-A[F.1K
M I+-'MRY#U4NH**%6&A-#FNY$. ?J 2H!RJH:"$66I/.6GX$;OGQ48CXCIME
MR;,9X_*I(^ *9?6D>_U"1DL3WZ=!;_/>6NB>T[XVUYHA<!^/? *MRZM9D_*.
MA3,44<4"*EJ(A=;DL18+ ?[91H!ZMH&*%F*A->FL543@+OZ?<7.V0GC&U=F6
MENUW9]V3VM7H[LJ5^0SDM'CU0)'B.+*\>[Y\6K[><.H?38JW -:>?_"//A27
M_;LU3/G.Q#F34YXKDL*-@?0.AB:!RO(UA/*+%K/B8OZUT%IDQ<<$6 S2-C"_
MWPBA'[_8 98O@XS_ U!+ P04    " "2BZA:J4'3]&0#  #I#@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U,2YX;6RMEVU/VS 0Q[^*E:&)25OST"?*VDBE
MV30DT"H*VPNT%R:Y-A:)76RGA6\_VPFAA32T6]XTMN/[W]TOMNL;KAF_%S&
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M'@P3E:<@CH$FC@%>D#HD]8?-8O ?;Z@-7=/( "]I': B!!8%RU 1+(TZ581
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MBG&W)>...%R#W?%E;*3)8(24Z+J%$=@2&K)CPA=IPA?!A.\(820 A1%X7'2
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M6V&KB"3.@:'VWU%J6A##M ";MS;F=O_RF)UX^YM=;*$%E(4=\Q1K9A##=W)
MRAD[O8YS9:V-4Y.*&"85R)03MH;&CBE_CS5YB)$*27<^"5M"XPF,5]:"9[CS
MA0_5MVU<)\6]R$J2\CO5S7L=JW@4FR^PV'R0^;+^#HA)+F6^J!_G/%&$NFJ@
M?G^7JXEK/E1?*[']&I'Q_U!+ P04    " "2BZA:%_^&8=D"  !?!P  &0
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MNC5=C?-*L&KG1^A:61K(?IG1"XC:*=#Y1M%PK 7GH'E3XS]02P,$%     @
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M8>"9S#'?)P@ICDTPXX=@3N-.QFO,SB#IG4 <Q?T6AV:_#T\ZW$F:O4T\W_
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M+?0]B2_(&]Y;S,WW.C7+Q3KUB[G2<F*6+,%10+7#H%YA$+]\T>ZUWM0I\9_
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M+W-H965T-3@N>&ULK5=M;]LV$/XKA%8,+=!$KY;MS#90VPL68,&">-TP%/U
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M7N:VBMS&GMRZ0:ZB,%TF9!8N^$(&#$1'-KTQGGMS;BB)%WS>)YKYL>C!KV1
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MANAJ"^)-:VSRW\M%ST<R>UKQ><H7Y,)[\!9<@#ZY*5<OS*&F"Y1F06DVE.9
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M+A1-Y#]M"BJ3]MN3YH_F<YF1B,XL_>R55&RI-?_E)SQR?FL3$23,@X3YD+
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MWN-SKJ_O':RY>)8%@$(O)65RZ!1*+:]=5Z8%E%A>\"4PO9-S46*EIV+ARJ4
MG%FGDKJ!YT5NB0ESDH%=FXIDP"M%"8.I0+(J2RQ>1T#Y>NCXSF;A@2P*91;<
M9+#$"YB!>EQ.A9ZY+4I&2F"2<(8$Y$/GQK\>Q\;>&GPGL)9;8V24S#E_-I.[
M;.AXAA!02)5!P/JW@C%0:H TC5\-IM,>:1RWQQOT6ZM=:YEC"6-.GTBFBJ%S
MZ: ,<EQ1]<#77Z'1TS=X*:?2?M&ZMHTB!Z655+QLG#6#DK#ZCU^:.&PY^(<<
M@L8AV'7H'7 (&X?0"JV965D3K' R$'R-A+'6:&9@8V.]M1K"S"W.E-"[1/NI
M9*;3(JLH()ZC.[8"IKAX10\@0:Q HM,)*$RH/$/GZ'$V0:<G9^@$$8:^%;R2
MF&5RX"I-PX"Y:7/DJ#XR.'"D'Z![SE0AT1>60?8>P-7\6Q'!1L0H.(HX@?0"
MA?XG%'A!KX/0^._=PR-TPC:FH<6+#N"]Q7%"9$JYK 2@'S=SJ83.VI]=$:L!
MPVY \Y*OY1*G,'3T4[57XR0?/_B1][E+[7\">Z>]UVKO'4-/1K @C!&VT(^+
M8I9"E]H:(K80ILRLDB"XO!JXJVT5^T:^=_5F](Y=OV77/\IN*OB*V *DZQ_B
M<\DI*-#YW%Q8%]D:L;_%X]R_C';([AO%41!WDXU:LM%1LD^"*#CG>=[YQH[Z
M_FO&1/L:HUYX@'_<\H^/\M>O^P]Y$._G@>^%.Z'M,-I.EIJ:NU4!2Q +VQ@D
M2GG%5%U'VM6Z]XQT[[$U>F==]Z0;6XK=-YBZH=UCH5-;(@JYAO0N8ATN43>)
M>J+XTM;9.5>Z:MMAH?LJ"&.@]W/.U69B#F@[=?(;4$L#!!0    ( )*+J%H+
MVDU;Y@(  "L+   9    >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;*V674_;
M,!2&_XJ5H0FDC7PU:<O:2+0=#&E,%8QQ@7;A)J>-16)GMMO"OY^=I"%E(:-2
M;EI_G<?OZQPG9[1E_%'$ !(]I0D58R.6,CLS31'&D&)QRC*@:F;)>(JEZO*5
M*3(..,J#TL1T+,LW4TRH$8SRL3D/1FPM$T)ASI%8IRGFSQ-(V'9LV,9NX(:L
M8JD'S&"4X17<@KS+YESUS(H2D12H((PB#LNQ<6Z?36U+!^0K?A'8BEH;:2L+
MQAYUYRH:&Y96! F$4B.P^MO %))$DY2./R74J/;4@?7VCGZ1FU=F%EC E"7W
M))+QV!@8*((E7B?RAFV_06G(T[R0)2+_1=MBK><9*%P+R=(R6"E("2W^\5-Y
M$+4 VW\CP"D#G-<!O3<"W#+ S8T6RG);,RQQ,.)LB[A>K6BZD9]-'JW<$*H?
MXZWD:I:H.!E<T0U0R?@S.IZ!Q"01Z ?F'.O#/4&?T=WM#!T?G: C1"CZ&;.U
MP#02(U.JO37!#,M])L4^SAO[V ZZ9E3& GVE$43[ %.)KI0[.^43IY4X@_ 4
MN?8GY%A.KT'0]/WA;HL<MSI(-^?Y_SW(A^]J"EU)2,7OIH,J.&XS1U_;,Y'A
M$,:&NI<"^ :,X.,'V[>^-)GL"+9GN5=9[K71:Y9)FF'"U>V6*(PQ7T&3[P+6
MSV'Z[;()>KX_,C=U._^N\=Q!KUJT)].K9'KOE'E!*%%7)4*7C$4"/5Q#N@#>
M^)!:D8<^I(Y@>^[]RKW?45[Z75KN"+9GN5]9[G>9EZVP0WT7,*^6P([M#)L3
M>%#Y&;S3S[WZ).H7\9RSE1+3GL*MT$-]=03;\S^L_ \[2N%AEY8[@NU9MJV7
M[[+591*WTPZU7M+J[V'7\;Q7:6S6RHX4E#!=C0D4LC65Q7>\&BTJOHFN^'39
M\FI<58+G>?UCOF"*,O):^254H 26"FF=]M7-XD5E5G0DR_+B9L&D*I7R9JRJ
M6>!Z@9I?,B9W';U!51\'?P%02P,$%     @ DHNH6F+_;.B' @  & <  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S$N>&ULK55=;YLP%/TK%JNF5MK*5R!I
M1Y#:9-/V,"UJUNW9A9M@U=C,-DGW[V<;@F@@51[V OZXY_C<8_LZV7/Q+ L
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M _#YBG.UO]$G\?J?%_]_4$L#!!0    ( )*+J%IK]@Q':P(  , %   9
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M;:-J0GNGB^H3S#?,<U()1&&I=,Y%I,K%ZU-!/9%L91KK@DG5ILVP4 <IX#I
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M91@%V=\U^HD6K6W7*Z&Q^=OA#N]G((T KF^$T(\3<P,8;WSEOU!+ P04
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M-C#7%]+4<GZ2;G;<[X:=_ ]02P,$%     @ DHNH6I2;BZ"76P  CYL' !D
M  !X;"]W;W)K<VAE971S+W-H965T-SDN>&ULM-UK3^-8PN[]KV+UOK75(W57
MDT XS#/3DKM\/I]/H_N%*[@@&DAH)U1W;\V'?Q)(*DX(-L[\TQI-I0K\6X$
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M$;1J%=4D5)-134$U%=6TM;;3N[!_1SP='=) -1/5+%2S4<U!-1?5/%3S42U
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M-175-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42U!M135,E3+4:U
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MD!R6=,WUO=A^A=9/9/@RP97])=NF-@P=DJV5%F4+1@4EJYHG?6[[L ?PXB,
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MFS$2\_BIO^'1;!VJA:@645JWX=MLG:[,ZTSO#N&9[5S^5YG*^.2#<FK[[!$
M3=FAFH5J-JHYJ.:BFH=J/JH%J!:B6D1IW5&A3=GI!GU03B<S2+>H9J*:A6HV
MJCFHYJ*:AVH^J@6H%J):1&G=L:#-X^EOY/':&<)Z%[[M;7\T?H=J)JI9J&:C
MFH-J+JIYJ.:C6J#WGU1N-'J57 S1Q4:4UNWL-H&GJQ-X)\_]Q9^B.9-VGHG;
M-*YG!C?JK0(TJH=J)JI9J&:CFH-J+JIYJ.:C6H!J(:I%E-8=+]JHGHY']70T
MJH=J)JI9J&:CFH-J+JIYJ.:C6H!J(:I%E-8="]JHGJZ.ZMTMXYH525DVI\1N
M/HRW3A:+IZ_-*70+N4C*JOE&C>;K;YKOENF- ZB7</;8@,;Y4,U"-1O5'%1S
M4<U#-1_5@KWV,I!T,9J\'[_>8$ #?936;?HVT*>K WV?XS2NW_T+\9N<+;,\
MS1?-',#+9NKM 33<AVHFJEFH9J.:@VHNJGFHYJ-:@&HAJD64UAT.VA2@CI]X
M3T<C@*AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEI$:=TOQFJC@@9]$CXU>.Y0@&HF
MJEE&[^D&7^U:MD^ZEX.NF8MJ'JKYJ!:@6HAJ$:5U6[?-_!GJ&-;;LWKQI[C;
M?[>5N-T>(_A2_[MM3I6OG/FK%WQVBZ,)052S4,U&-0?57%3S4,U'M0#50E2+
M**T[9+2I00,_(Y^!9@51S40U"]5L5'-0S44U#]5\5 M0+42UB-*Z8\&+[\15
MYH^FUO>D$O6D?YZ4Z[RLY_U'OT)'#9T]!)":B6H6JMFHYJ":BVH>JOE[K7,R
MLO%XI'<WJ0)TH2&J1936[>TV^V>HLW\G;1I$<5G)0C1?OS,KDO7VJ-]IGQ]0
M+_WL 0$-#:*:A6HVJCFHYJ*:AVH^J@6H%J):1&G=<:--%AH3?/L 30VBFHEJ
M%JK9J.:@FHMJ'JKYJ!:@6HAJ$:5UQX(V-6@HDTC=(P.KW5RA?#E7.'S6N'=8
M0 .$J&:BFH5J-JHYJ.;NM9?S\O&/67L/7:B/:@&JA:@645JWW]MDH*%.!N[[
MO=OCQ\\BH-;.;G T!8AJ%JK9J.:@FOO&*V1R]$0?'KH>/JH%J!:B6D1IW9YO
M@X&&.ACHAIZXE6FZ2>-"_+:41;R6FRJ9E2(,;[<?+KK)JF61UQL#LDS*EWL/
M0KF(9T]-=5.<5$]O'%)$PX2H9J*:A6HVJCFHYJ*:AVH^J@6H%J):1&G=(:0-
M$QIXF-! PX2H9J*:A6HVJCFHYJ*:AVH^J@6H%J):1&F=L6#<A@G'ZC#A81BH
MQ"S/RF0N=Q\FZAL$U-2Y@P"JF:AFH9J-:@ZJN:CFH9J/:@&JA>,?(Z3:^/59
MDJ.^>UV,VK.D[YIV6"ZEK,RXBJ?7*UDL9#._+^M^W&1U61,N/-PJ"GG?G#/X
MPXT^&-:5[=VGU^MX(:.X6"19*5)Y7Y>.WEU.!KN/!3Y?J?)U0XJO>57EJ^W%
MI8SKKF_N4/_^/L^KYRO- A[SXMMV]:;_!U!+ P04    " "2BZA:_U'H^[82
M  #]*@$ &0   'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6R]W6MOVT:BQO&O
M0G@/%KN 5Q8I4J*RB8'&YEP631LTYYR^"/J"D1E;J"XN)3D)L!]^25GQ:"AI
M2"[_55'$U_D-;3\0.7HTTNLOR_SWU4.6K;VO\]EB]>;B8;U^?'5UM9H\9/-T
MU5L^9HOB*Y^7^3Q=%Q_F]U>KQSQ+[[:#YK.KH-\?7LW3Z>+B^O7V<^_SZ]?+
MS7HV763O<V^UF<_3_-O;;+;\\N;"O_C^B5^F]P_K\A-7UZ\?T_OL0[;^O\?W
M>?'1U8MR-YUGB]5TN?#R[/.;BQ_\5]H/^N6([;?\_S3[LMI[WRM_ED_+Y>_E
M!_KNS46_/*1LEDW6I9$6;YZRFVPV*ZGB0/[8J1<ODY8#]]__KHOM3U_\-)_2
M57:SG/TZO5L_O+F(+[R[['.ZF:U_67Y1V>XGBDIOLIRMMO]Z7W;?V[_P)IO5
M>CG?#2Z.8#Y=/+]-O^Y^$WL#_,&) <%N0% =$)X8,-@-&%0'#$\,"'<#PJ8S
M1+L!4=,!P]V 8=,!H]V 4=,!\6Y W'3 >#=@O(W#\]]O^\>_3=?I]>M\^<7+
MR^\NM/*=;8*VHXN_^711IOW#.B^^.BW&K:\_/*?<6W[VU@^9]VN:Y^EBO?+^
M=INMT^EL]7?O'][_>%?>ZB'-L]7KJW4Q9SGR:K+S;Y[]X(3_KW31\X+PT@OZ
M071D^*U[^&TVZ7D#?SL\/#(\<0__:?E4S!Z='"[<P]^E><_S!R>'RYJ??3-[
M.?C!D>&J;O9OGA^?'*W=HW]X+(^]?VSX59&1EZ $+T$)MM[PE#>9;.:;6;K.
M[KR?BZCDWLUR7MS /I2W?$^9IQ>3Y3SS_O;C<E6$YN./Q7!/K[/YZK=CH7F>
M:W!\KO(6_M7J,9UD;RZ*&599_I1=7/_U+_ZP_\]C$2*QA,0$B4D24R2F(<S*
MY> EEP.7?OW39OZI"&-Q^W7Z)LHIM$W;,Q9ML?):XNG:]X/ CZ+1ZZNG_221
MLPH2DR2F2$Q#F)6D\"5)H3-)R=<LGTQ7F?>83R?9L1PYQ[?-$8DES]AX+Y1!
M+X[L0(K#;XI[OOT]\O![1KV*H\@CU^X)K3]D]/*'C)Q_R'?3Q72^F7L?WV7E
M;</1$Y!3:/NG)+&$Q 2)21)3)*8AS$K;\"5MPS->& W)7))80F*"Q"2)*1+3
M$&;E<O22RU''TYES?-NLD5A"8H+$Y.C@=#4X.#^2$VH(LR(4OT0H;G4B]?[M
M%>OY37E_0;DB]M[K]\GWNPSVO^G#YM,J^V.3%9]-GK*]KQU+H?,0VJ:0Q!(2
M$R0F24R1F(8P*Z[CE[B.SW@F'I.Y)+&$Q 2)21)3)*8AS,JEWS=WLO8[GHMW
M@+V""\?VF>76/4W;'*&:0#6):@K5-*798=J[Q]YWGY73KW_^6=E]#&UO_E M
M036!:A+5%*II2K-S:PH$_YP-@H]6"*B6H)I -8EJ"M4TI=D!-4V"[ZX2&IRE
M!T?.TOU1]2Q-WB6>H)I -8EJ"M4TI=EA,F6"[VX3;O/T/EVEDX,S\=%<H<T"
MJB6H)E!-HII"-4UI=OY,!^)'YSS;HGT)JB6H)E!-HII"-4UI=D!-;>([[_UN
M4MR_K2$^^K]=?@R.!Q8M4G;:?ND_C()Q7&E/$W16@6H2U12J:4JSHVB:$K]C
M5?*V!G %$6U9=EILWTT4C^-J$-$&!=4DJBE4TY1F!]'T+;Z[<$F^/D[S=/LH
MX+OBS'TTB6[!E42T::DYCN>'3@XOO5,/_$S0PQ&H)E%-H9JF-#NBIF/QG7>5
M7[_??)I-)^:!PLYE#=JAH%J":@+5)*HI5-.49C\(V30I0?^,RYJ [ 5N42U!
M-8%J$M44JFE*LP-JVIG W<XT6=;4$!\'Q\.*5C([S7H<<S@8A6'U8<SHM +5
M)*HI5-.49N?0M"V!\\[R!FN:&N!4"MFM&\_::#^%?E1-(+LG@]V4P>[*8+=E
M_!EU2F#JE*"N3JE=S-0(IR)(]@2W-<>PW<3U?2$S/'JB1@L:5).HIE!-4YH=
M3U/0!.Z"YL/C<K%:YLU6,FZK=>30@@;5!*I)5%.HIBG-SI\I:()S%C0!6M"@
M6H)J M4DJBE4TY1F!]04-$'W@J:&.'4"1\N9X+"<B<-Q\5_U,A(M9U!-HII"
M-4UI=@Q-.1-T+6=J@%,A1(N9G5:SD$%;&523J*9035.:G4#3R@2=6YD:X50$
MT4:FYA@:+&301@;5)*HI5-.49L?3-#*!NY$IGR>D^),&WOM\^E3DL[AR?,I6
MZWGY$._IPML5-LD?F^GZ6\/5#MK;H%J":@+5)*HI5-.49C])A^EM!N?L;09H
M;X-J":H)5).HIE!-4YH=4-/;##KW-C=NHG7L#AN8L!\5_U>?1P8M8%!-HII"
M-4UI=J!, 3/H6,#<N('6<7K6G%O3$W1*@6H2U12J:4JSL[3W'%==JY0;M] Z
M3.[C^7FR?GYRN?+",SYZ%D1+$523J*9035.:'313B@S<I<B[-)\\;)\RD%M-
MN*=LG4RT.T$U@6H2U12J:4JS8VJZD\$YNY,!VIV@6H)J M4DJBE4TY1F!]1T
M)X/.W<F-FV@=N\,6).C'8?5) !-T5H%J$M44JFE*LP-E6I!!UV?S<@.MXW38
M9PSZU2BA=0:J2513J*8IS8Z2J3,&7>N,&[?0.DL-MHH$(]=B BTF4$VBFD(U
M36EVT$PQ,:@K)OZKQ<2E]VYY-_T\+:[MG,L*M*1 M035!*I)5%.HIBG-?OYG
M4U*$YRPI0K2D0+4$U02J2513J*8IS0ZH*2G"[B6%FV@=N\.28A2,AP<;CM%9
M!:I)5%.HIBG-#I0I*<*N)84;:!VG(_L]JLL*=$:!:A+5%*II2K.C9#J*L'-'
MX19:9\E]//7+"O1P!*I)5%.HIBG-#MK>RW0T[BA^7*:+9B6$VVP=/?;%.] 2
M M4DJBE4TY1FY]"4$.$Y2X@0+2%0+4$U@6H2U12J:4JS VI*B+#[!HX:XF-X
M/*QH=1$>5A>CJ-\_N"Y$FPM4DZBF4$U3FIU"TUR$7?=OU "G,HCV'>'A$VM%
MO7A<;<_0206J2513J*8IS<Z@J3S"SCLX:H13(42+DIIC>'Y.+>>*!BU*4$VB
MFD(U36EV/$U1$KJ+DA^*F\;9\XKFE^Q^NEIG>7%->3O-L\FZX?(&+4-0+4$U
M@6H2U12J:4JS7T/1E"'1.<N0""U#4"U!-8%J$M44JFE*LP-JRI"H>QGB)EK'
M[LB.C4$T#*I7B>BL M4DJBE4TY1F!\J4(5'7,L0-M([3X8Z-@Q?;3= I!:I)
M5%.HIBG-SI)I0Z+.;8A;:!TF]_'4[]A #T>@FD0UA6J:TNR@F38D<K<AS=8.
MC1Y1Y9ZI=2#1C@35!*I)5%.HIBG-3N?>*[&?LR.)V%=M9U^VG7W==O:%V]E7
M;F=?NOW/Z$@BTY%$W3=JN(G6L3ML.\)X%$;5UQ)!9Q6H)E%-H9JF-#M0INZ(
MNF[4< .MX]3@%<D3=$J!:A+5%*II2K.S9&J+J/-.#;?0.DSNXVFPB$ +"%23
MJ*9035.:'3130$2-GD(*W/3MGK!U+M%" M4$JDE44ZBF*<T*Z= 4$L-S%A)#
MM)! M035!*I)5%.HIBG-#J@I)(;="PDWT3IVAX5$%/N#<5BY_D-G%:@F44VA
MFJ8T.U"FD!AV+23<0.LX-=B=@<XH4$VBFFKPV]#4C'9 3,LP[-PRN(76"7$?
M3WD=Z7R $GHT M4DJJF.ORE-'8V=+%,K#-VUPK\VQ=73=DG0Z'+?K;5.&5H=
MH)I -8EJ"M4TI=D)--7!\)S5P1"M#E M036!:A+5%*II2K,#:JJ#8??M%37$
MB4<5NT>U#NMAX5#NKCBXL$/[!E23J*9035.:G4+3-PR[;J^H 4YE$&TIALVV
M5Z"3"E23J*9035.:G4'34PP[]Q1NH76<ZE[J8M$K+EY=ZQ"TIT UB6H*U32E
MV4$S/<70W5.854GSG=]NLG7RT"8"U02J2513J*8IS8KAR#01HW,V$2.TB4"U
M!-4$JDE44ZBF*<T.J&DB1MV;"#?1.G:'3<2@?V25@<XJ4$VBFD(U36EVH$P3
M,>K:1+B!UG$ZW!H1]ZJ/D$.G%*@F44VAFJ8T.TNFM!AU+BW<0NLPN8^G?K6
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M' (]CA#5(E23J!:C6H)J*:HI5,M035-:.U;K*M3 W(5RBE^VUF*UV9:[_52
M]9!_??KO:R>E: L*U1Q4<U'-.VC-$T1[.CHY*44K3F?&'(\O3VX)0,M+J!:A
MFD2U&-425$M13:%:AFJ:TMJ+]M=M*-O<AFI/L>Y_PS_\5F\M%_DOB^5^5X)7
MDM0L]TU25'-0S44USSZMQMB34?>B%CIF<&;,D3WK_GJ/CAFB6H1J$M5B5$M0
M+44UA6H9JFE*:R=IW8NRS;VHS]?7B_T>4/FR1X2BY2A4<U#-134/U7Q4"PY:
MZZ[RX6S>C5JT&H5J$:I)5(M1+4&U%-44JF6HIBFM';5V';7F:M0_._FZ*%Z]
M!F66>B<LVHI"-1?5//NT&S,>#+KGJ&C9"=4$JH6H%J&://-6#:M?*#IEI\.S
M6K\!#,>='TL)>F0IJBE4RU!-4UH[$.NN4_70. >:+Y9?K<5J6U3ZULJOKLK=
MTPI]^?;<XF$_F;G>J4AJ#JJY!VV_9L*V7OI\,&M_W7OHH#ZJ!:@F4"U$M0C5
M)*K%J):@6HIJ"M4R5-.4UL[9NFAEFQL8_SS>\;1=UZW\_*6H__K]_V:W=^"B
M#2Q4<U'-0S4?U0)4$Z@6HEJ$:M(^W<=I,+#MP7@\[9ZSHNTJ5$M13:%:AFJ:
MTMJ96S>N[#?VAKKXCPOKYVV5O-:7M2565];_CHO[7XKR[':F9JQWT*)%*U1S
M4<U#-1_5 E03J!:B6H1J$M5B5$M0+44UA6H9JFE*:X=QW<BRGPL'T.;2-MJZ
M0C4'U5Q4\U#-1[4 U02JA:@6H9I$M1C5$E1+44VA6H9JFM+::5S7LVQS/:OG
M$E=FK7<:/VO[]1CJ2T07LWGG1B8''=5%-0_5?%0+4$V@6HAJ$:I)5(M1+4&U
M%-44JF6HIBFMG;-U<\LV5W>2W7Z^H55Y+8NGS#V[SXI9ZYVSLY/ILO'I1A0.
M.JB+:AZJ^:@6H)I M1#5(E23J!:C6H)J*:HI5,M035-:.V;K)I=M;G*%^6J7
MEU\M^](>64HHUWJYWF:<\D4;7:CFH)J+:AZJ^:@6H)I M1#5(E23J!:C6H)J
M*:HI5,M035-:*Y6'=4-L>$E.^0[15ABJ.:CFHIJ':CZJ!:@F4"U$M0C5)*K%
MJ):@6HIJ"M4R5-.4UD[CNF4V-+?,>D[YFK7>:8P6S%#-/6C-E6(GTXO.'44>
M.J:/:@&J"50+42U"-8EJ,:HEJ):BFD*U#-4TI;53UJY3UEPP:Z][6$7MX],^
M7,MJQ/W:,J^VS<QL[[A%VV:HY@Y/2T?SRWDW;=&MM5 M0#6!:B&J1:@F42U&
MM0354E13J):AFJ:T=MK6[;7J(7AYS:SU#EE2<U#-/6C-2W^3L3V?#;HY2X[J
MHUJ :@+50E2+4$VB6HQJ":JEJ*90+4,U36GMG*W;:T-S>ZV]UM=QD9KG;16N
M\OW:-:^>UZ+U-51S4,T]:*UU#^Q1-V_15AJJ!:@F4"U$M0C5)*K%J):@6HIJ
M"M4R5-.4UL[;NKDV-#?7GNYC.*Y5HY_.:/>+,ICN93"+O8,6K:^AFHMJ'JKY
MJ!:@FD"U$-4B5).H%J-:@FHIJBE4RU!-4UH[D>OZVA"MKPW1^AJJ.:CFHIJ'
M:CZJ!:@F4"U$M0C5)*K%J):@6HIJ"M4R5-.4UD[CNKXV1.MK9JUW&J/;B:&:
M>]!FC4D(^V(TFW=7+4-']5$M0#6!:B&J1:@F42U&M0354E13J):AFJ:T=L[6
M];4A6E\S:[US%MV'#-7<X6FU[OSU-;2_AFH!J@E4"U$M0C6):C&J):B6HII"
MM0S5-*6U<[;NKPW-_;7C5&_QQ\.B?+Z>=OW* KQFJ7?&HITU5'/?^)S%>7EA
M#28_6/O6W_CL9 ):4T.U -4$JH6H%J&:1+48U1)42U%-H5J&:IK26N$[JFMJ
M(_-&9E_N%L6-]?GZ?K%:;+;[^'TLK/3FICK++5\NN5G_LC[?%ZOKXMIR[Q^6
MZ^>=(C_?EL73?;W&2W/F\?M&-JHYJ.:BFH=J/JH%J"90+42U"-4DJL6HEJ!:
MBFH*U3)4TY36SN^ZV#8:D)?F1FBQ#=4<5'-1S4,U']4"5!.H%J):A&H2U6)4
M2U M136%:AFJ:4IKI[%=I[&Y /?3?F.+3;[<+\?SRCW!9J%W J-=M]&9W<NZ
M*Z:YZ) >JOFH%J":0+40U2)4DZ@6HUJ":BFJ*53+4$U36CM8ZZY;]= 4K.K0
M)5;'+G%S;N(;%T S#]D[B4G-0347U3Q4\U$M0#6!:B&J1:@F42U&M0354E13
MJ):AFJ:T=F37M;G1")V90+MRJ.:@FHMJ'JKYJ!:@FD"U$-4B5).H%J-:@FHI
MJBE4RU!-4UH[C>M2W<A<JE/';3>?;QJN8OFA*)_O&G[S#F(SW3N:T78=JKD'
MK;D:VN#"[FS-X:%C^J@6H)I M1#5(E23J!:C6H)J*:HI5,M035-:.W+KUMS(
MV /Y]/EE@^.'=OB^-C.,UN90S4$U]Z UYYDG)UMS>.B8/JH%J"90+42U"-4D
MJL6HEJ!:BFH*U3)4TY36CMFZ#C<RU^'BQ6IQO[LW3_6B'3A4<U#-134/U7Q4
M"U!-H%J(:A&J252+42U!M135%*IEJ*8IK1W!=5-N-$.G>M&F'*HYJ.:BFH=J
M/JH%J"90+42U"-4DJL6HEJ!:BFH*U3)4TY363N.Z3S<R=\-ZK@]AUGJG,=JI
M0S47U;R#UIPK'EYTIHI]=,@ U02JA:@6H9I$M1C5$E1+44VA6H9JFM):(3NN
M>W-C<V^N.^M0Q:Q8/1:;[;JT].+V;KLYTX^KGN24^6V^R:\LN;A?;(MKX[2%
M^1CZ1C.J.:CFHIJ':CZJ!:@F4"U$M0C5)*K%J):@6HIJ"M4R5-.4UL[PNCLW
M1KMS8[0[AVH.JKFHYJ&:CVH!J@E4"U$M0C6):C&J):B6HII"M0S5-*6UT]BN
MT_B-S>.*\JHZ6<YOG^].R\OM(E]:R\5ON\5UOMVO '^=WU?_>G82PVSWSF:T
M58=J[D$;7#;F'2XO+KMKKZ&#^J@6H)I M1#5(E23J!:C6H)J*:HI5,M035-:
M.W3K7EWUL.<TQAO;;U3/^'GWRZ;X;;>?V7 ?WUK_QWP O9.9U!Q4<U'-0S4?
MU0)4$Z@6HEJ$:A+58E1+4"U%-85J&:II2FL'>-VR&Z,MNS':LD,U!]5<5/-0
MS4>U -4$JH6H%J&:1+48U1)42U%-H5J&:IK2VFE<M^S&YI9=SULOQJ=U,_OB
M<MK^5?Z+><S>*8L6YE#-0S4?U0)4$Z@6HEJ$:A+58E1+4"U%-85J&:II2FNG
M;%VL&YN+=6<F+;[[,L;F0^I]XHR6\U#-134/U7Q4"U!-H%J(:A&J252+42U!
MM135%*IEJ*8IK1WI=8EO/$6G,= ^'ZHYJ.:BFH=J/JH%J"90+42U"-4DJL6H
MEJ!:BFH*U3)4TY363N.ZSS<V[WSWCF6,S4+O!$8[? >MN;S$J+N(CXL.Z:&:
MCVH!J@E4"U$M0C6):C&J):B6HII"M0S5-*6U@[6NYHW?VK;MCS?7JC 3O9,5
M[>.AFHMJ'JKYJ!:@FD"U$-4B5).H%J-:@FHIJBE4RU!-4UHK@B=U<6]R2<XT
M3- *'JHYJ.:BFH=J/JH%J"90+42U"-4DJL6HEJ!:BFH*U3)4TY363N.Z@C<Q
MEDH^O6S4L5W7JV3F+PMGOG[KA-GMG<MH&0_57%3S#MJX,3<RF]NS\:2S< 4Z
M:H!J M5"5(M03:):C&H)JJ6HIE M0S5-:>W$M>O$?:-F]R<6@C?3O4,7;=FA
MFHMJ'JKYJ!:@FCAHS3L:9Q?#4?N'2XB.&:&:1+48U1)42U%-H5J&:IK2VI%;
ME^RJAWUF?;_+6D'F8^B=S:3FH)J+:AZJ^:@6H)I M1#5(E23J!:C6H)J*:HI
M5,M035-:.\/KGMT$[=E-T)X=JCFHYJ*:AVH^J@6H)E M1+4(U22JQ:B6H%J*
M:@K5,E33E-9.X[IG-WEC-[L_LU:0V>Z=S6@[#]7<@]9=*Z@SU^NA@_JH%J":
M0+40U2)4DZ@6HUJ":BFJ*53+4$U36CMTZ]K=Y(W:W>DT!KQ6D/D >B<S6K)#
M-1?5/%3S42U -8%J(:I%J"91+4:U!-525%.HEJ&:IK1V@-<ENPE:LIN@)3M4
M<U#-134/U7Q4"U!-H%J(:A&J252+42U!M135%*IEJ*8IK9W&=<EN8B[9]5PK
MZ*#-&K_*VQ>CV7S662W(/&KOG$6WPT,U#]5\5 M03:!:B&H1JDE4BU$M0;44
MU12J9:BF*:V=LW7G;F+NW*FRN"G*LK@^GO;6DQ-G%A*2Q6U^]=7Z4BQWR[Q<
M;+^:)RS0KAZJ.:CFHIJ':CZJ!:@F4"U$M0C5)*K%J):@6HIJ"M4R5-.4UHKN
M:=W5FZ)=O2G:U4,U!]5<5/-0S4>U -4$JH6H%J&:1+48U1)42U%-H5J&:IK2
MVFE<=_6FYJY>^Z:+YYD*JRQ^VRWV)]<WZ])Z7._OO3@;S6A=#]4<5'-1S4,U
M']4"5!.H%J):A&KRH'7NRNFL3Q6C8R:HEJ*:0K4,U32EM2/7KB/77-;[O+6V
M=X45Y^6OQ=;Z.5\6YZHB9P,7K>JAFH-J+JIYJ.:C6H!J M5"5(M03:):C&H)
MJJ6HIE M0S5-:>U@KBM]U4-R9F*(IC&I.:CFHIJ':CZJ!:@F4"U$M0C5)*K%
MJ):@6HIJ"M4R5-.4UD[CNIPW-=9-/CV?&.>WQ7XEH:OU_?UBLUFL5U:9;XNS
M<8RV\U#-0347U3Q4\U$M0#6!:B&J1:@F#UJW(S3L3D>@M3M42U%-H5J&:IK2
MVCE;U^ZFYMJ=7ZZKL]Z'<GU5%-<;ZZ9<WUM5U.[RU?-*0OOHK6)W\W1._,K"
M\>8A>F<OVKY#-1?5/%3S42U -8%J(:I%J"91+3YHS:7]!J-!.\<3=,@4U12J
M9:BF*:V=O'7W;FKNWB7%MI.[F^J<]]V9B_;J4,U!-1?5/%3S42U -8%J(:I%
MJ"91+3YHS:UF!L-)-W/1NARJ*53+4$U36CMSZ[K<U%@ ^13GY=7=ON(\M%2Y
M>-RO1_R\;-O3Q;?%RE*[7Y:+*\O];;>_3_AE*6/C93FT4X=J#JJYJ.:AFH]J
M :H)5 M1+4(UB6HQJB6HEJ*:0K4,U32EM2.[[M1-9^AE.703.U1S4,U%-0_5
M?%0+4$V@6HAJ$:I)5(M1+4&U%-44JF6HIBFMG<9U\VYJ;MY]?MG'XZ&]Z/QK
MTQ1HFP[5'%1S4<U#-1_5 E03!ZWYZ_;\\O*RL[P\.F:$:A+58E1+4"U%-85J
M&:II2FO%[*QNR<V,O8^^"TF8M;XIBVH.JKFHYJ&:CVH!J@E4"U$M0C5YT)H_
M3X:=GR8Q.F*":BFJ*53+4$U36CMCZ^[;[)W[U.6K:ZM\WK-CO=MNMM6?%ZO;
M'ZSBCX=%65C7K]QQ9N9[AR[:?T,U%]4\5/-1+4 U@6HAJD6H)M_X5HOS\L*R
MIS]8^TLOLW-GO>CA)*B6HII"M0S5-*6U$]FN$]E<C?M'4=Y;?_E:Y.7FKV<3
M%RW H9J#:BZJ>:CFHUJ :@+50E2+4$V^\:TTMIZ^C<Y&+5IV0[44U12J9:BF
M*:T=M779K7IHG,>]_K^[S7[_N?SZ\>E6W]5ZNY]I>"C*Q?KZ;/@:P=[A2VH.
MJKFHYJ&:CVH!JHDWON0F@^I7J:_G(BE$CR-"-8EJ,:HEJ):BFD*U#-4TI;7#
MM^ZVS<S=-E46]XO=O?60+YX7V7DXW(OVL*P&?;H5[>7JVBO7U<PC]$YCM.Z&
M:BZJ>:CFHUJ :N*@M6YCG8R[U]70,2-4DZ@6HUJ":BFJ*53+4$U36CMYZ[;;
MS-QVT\7U[JHZZRUZ7E]#"VZHYJ":BVH>JOFH%J":0+7PH+6RNY/<$3JB1+48
MU1)42U%-H5J&:IK2VEE;]]MFYG[;R_6U[;H^G<U?[A\SI"U:;4,U!]5<5/-0
MS4>U -4$JH6H%J&:/&C- K!].1O-NDM+HJ,FJ):BFD*U#-4TI;43MVZWS;YO
MNZTZ#SZ^3KW,1#3^\<M=OBCO\]73'1-?[A;%C>7^45SMMHO'PDIO;JI3Z=)8
ME3,??^]D1ZMRJ.:BFH=J/JH%J"90+42U"-4DJL6HEJ!:BFH*U3)4TY36SO^Z
M*C=#JW(SM"J':@ZJN:CFH9J/:@&J"50+42U"-8EJ,:HEJ):BFD*U#-4TI;73
MN*[*S=BJG)GK'<=H50[57%3S4,U'M0#5Q.RT*F>?5N70,2-4DZ@6HUJ":BFJ
M*53+4$U36BMFYW55;FZNRL7YU_V4A\TMZ&,>L&\0HYJ#:BZJ>:CFHUJ :@+5
M0E2+4$VB6HQJ":JEJ*90+4,U36GMP*Y[=_,!.4LQ1VMVJ.:@FHMJ'JKYJ!:@
MFD"U$-4B5).H%J-:@FHIJBE4RU!-4UH[C>TZC<U%H9XK39BUWFF,5O!0S44U
M#]5\5 M03:!:B&H1JLF#-F],QPQ/]OQ$ATQ0+44UA6H9JFE*:X=LW;:K'K[K
M5KAO7&K"S/=.75)S4,U%-0_5?%0+4$V@6HAJ$:K)-[[5TJOMA36X-"PU@1Y.
M@FHIJBE4RU!-4UH[D>L*WMQ<P?OFFY/-;N\H1HMWJ.:BFH=J/JH%J"90+42U
M"-7D06O>G#RZ'%?_UST'1JMWJ):BFD*U#-4TI;43MZ[>S<W5NV^Y3F>^3(>6
M\E#-0347U3Q4\U$M0#6!:B&J1:@F42U&M0354E13J):AFJ:T=E[7];WY!+U,
MAY;V4,U!-1?5/%3S42U -8%J(:I%J"91+4:U!-525%.HEJ&:IK1V&M?5OKFY
MVO>Y.D^^+JZM;5'>+U;Y=K%>/<T66]?%YJI</.S_XFPLHXT[5'-0S44U#]5\
M5 O>^%)Y^K+8KJV;?2MS?\%AO2K^YUV^O'E>$M*Z62^7Z]\7JUMK>U=85\OU
M9O^X^D&__^/ZYJ8HJS^?#7"TFX=J$:I)5(M1+4&U%-44JF6HIBFM'>!U-V]N
M;)L<IS_ ?4?- _:.=K2^AVHNJGFHYJ-:@&H"U4)4BU!-HEJ,:@FJI:BF4"U#
M-4UI[<"NZWOS.3K_@;;W4,U!-1?5/%3S42U -8%J(:I%J"91+4:U!-525%.H
MEJ&:IK16&@\NZYK?_K%Q!J1GG?H-KV\BLYS#<B[+>2SG'[G6GFS3[EK$ 3NJ
M8+F0Y2*6DRP7LUS"<BG+*9;+6$YC7"=Y!XWD->_>U;,B\@;7/WC1RA[+N2SG
ML9Q_Y$P+"0?LF(+E0I:+6$Z^YQ,<LV,F+)>RG&*YC.4TQG7"U&Z$J;EO]V>K
M(&_X_=,5K>"QG,MR'LOY;[W5^RG_@6'3RX ]'L%R(<M%+"?_["<_9H\G8;F4
MY13+92RG,:Z3RL-&*@_-DPN]M\-[0^R?PR3GL)S+<A[+^6^]N:]O/!>P1R)8
M+F2YB.4DR\4LE[!<RG**Y3*6TQC7R>-1(X^_4SWO#;A_+*,%/99S6<YC.9_E
M I83+!>R7,1R\L@UFWKCV6 X'YU,5:!5/99+64ZQ7,9R&N,Z(3QNA+"YL?=E
M?7^_7AWO?S#<B?8&U#]TT2X>R[DLY[&<SW(!RPF6"UDN8CG)<C'+)2R7LIQB
MN8SE-,9UHGG2B&:TG'?DL(!&ZWDLY[*<QW(^RP4L)U@N9+F(Y23+Q2R7L%S*
M<HKE,I;3&-<)Z&DCH,TE+/4R:;&ZMC;Y<M^L,DY;H#T]EG-8SF4YC^5\E@M8
M3K!<R'(1R\DCU]K]=# :7,YG)_,6:,>.Y5*64RR7L9S&N$[VSAK9:Z[:G9VW
ML/YULJA0]5?ZG\+RUN4O15X^7?;[?%L6[6U/SZ<U6KUC.8?E7);S6,YGN8#E
M!,N%+!>QG&2YF.42EDM93K%<QG(:XSJ1/F]$.EK&.W)80*-U/)9S6<YC.9_E
M I83+!>R7,1RDN5BEDM8+F4YQ7(9RVF,:P?TH-'.&YC;>7T[(F:N=T ?N,&H
M>8'[8C;OK$3KL..Z+.>QG,]R <L)E@M9+F(YR7(QRR4LE[*<8KF,Y33&=:*W
M4<\;F.MY?[I18O;[9['Y<,/=ZL*R#1LT..P!N2SGL9S/<@'+"98+62YB.<ER
M,<LE+)>RG&*YC.4TQG5"VFZ$M+F.U&-..L[+J[OGM>+D.E^=+@97/>?I'TXG
MJZM_^7+Q'Q?5,-5KK"]K2ZRNS#/9YL/NG_ULFQ#E7);S6,YGN8#E!,N%+!>Q
MG&2YF.42EDM93K%<QG(:XSH_"!I-P^HQ.9-]X+" )CF'Y5R6\UC.9[F Y03+
MA2P7L9QDN9CE$I9+64ZQ7,9R&N,Z =VH'@[,U</>,]ELX?# -3<5GET,3J:Q
MV1XARGDLY[-<P'*"Y4*6BUA.LES,<@G+I2RG6"YC.8UQG=QMM T'W] V_/89
M$O-=?>@4"EM^1#F'Y5R6\UC.9[F Y03+A2P7L9QDN9CE$I9+64ZQ7,9R&N,Z
M/RD:Y<<!6WX<L.5'E'-8SF4YC^5\E@M83K!<R'(1RTF6BUDN8;F4Y13+92RG
M,:X3T(WRX\!<?NP]A<*6'P_<.VX&9&N-*.>QG,]R <L)E@M9+F(YR7(QRR4L
MEQZYYH3FM#NAJ=A!,Y;3&-=)U$:E<6"N-!XG09YNY:MW?SV?IFPY\8TCB_/R
MPKC0KL,>D,MR'LOY+!>PG&"YD.4BEI,L%[-<PG(IRRF6RUA.8UPGCQM]Q(&Q
M4/,GUB<UP_W3^9EKKI P'5]>7IZ<ZK*50Y3S6,YGN8#E!,N%+!>QG&2YF.42
MEDM93K%<QG(:X]H9;#<JA[:Y<MCC@F&X6Q7_WUPO-']8O7\"H)S#<B[+>2SG
MLUS <H+E0I:+6$ZR7,QR"<NE+*=8+F,YC7&='Q2-@J0]0*\7VFP?$N4<EG-9
MSF,YG^4"EA,L%[)<Q'*2Y6*62U@N93G%<AG+:8SK!+3="&AS.;+O]4(SUS^@
M[7=>+T3'=5G.8SF?Y0*6$RP7LES$<I+E8I9+6"YE.<5R&<MIC.M$;Z..6#VF
M+BR:J?ZQ:SZR=ZP3@AZ0RW(>R_DL%["<8+F0Y2*6DRP7LUS"<BG+*9;+6$YC
M7">/&^U#^WMM?&B&^Z?SF1WC+L]<6$2'=5G.8SF?Y0*6$RP7LES$<I+E8I9+
M6"YE.<5R&<MIC.MD<*.):'];$S'._UC<[^Z_SY8"YF/J']]LBQ#E7);S6,YG
MN8#E!,N%+!>QG&2YF.42EDM93K%<QG(:XSHIWV@1VFR+T&9;A"CGL)S+<A[+
M^2P7L)Q@N9#E(I:3+!>S7,)R*<LIELM83F-<)Z ;+4+;W"),=ONSY7U"_WZ<
M%"F+IRN$U^<#FFT1VJ=[SPTOS\Z L"U"E/-8SF>Y@.4$RX4L%[&<9+F8Y1*6
M2UE.L5S&<AKC.M';J!O:YE*?^]MNL?UJO6QB>_:VY_]<E[\^+I;+XHV)#;:.
MB'(.R[DLY[&<SW(!RPF6"UDN8CG)<C'+)2R7LIQBN8SE-,9UPKO13;39O1)M
MMI&(<@[+N2SGL9S/<@'+"98+62YB.<ER,<LE+)>RG&*YC.4TQK4#>M@H+@[-
MQ<6?\^J<N<KGS3Z??[#N#Y<5\\>BS&_W^W0MEE^M;9E?%]=6?K_>5:?=?UFL
MK(>BO*I.P?]Z-L3-0_8.\0.WW]OL9?;C9!%J=$R7Y3R6\UDN8#G!<B'+12PG
M62YFN83E4I93+)>QG,:X3C0WJH)#\^:$_:/Y!VM[5QW+W7IY;5VM5YOB:K==
M/!9/3UJL;JN7?-U8_[*<Y_^(U;:X+<KS$<[6#@]<ZP:^DP1GNX0HY[&<SW(!
MRPF6"UDN8CG)<C'+)2R7LIQBN8SE-,9U$MQN)+BY2]A)\,-)\SZ\?\DW56JO
M5];C>KF[+ZS?B_U>N?L@/Z3[T[7%\]',%@X/7.OL^O)B/CV)9[9OB'(>R_DL
M%["<8+F0Y2*6DRP7LUS"<BG+*9;+6$YC7">>&WW#ZK$IGK_DFSOK>E>=2B^6
MB]MB?X/T3?%*Z!JE_J$[/#D?ML^ME(<.Z[*<QW(^RP4L)U@N9+F(Y23+Q2R7
ML%S*<HKE,I;3&-<)W4:I<&@N%>X++8OMT_T;5=A:BY6I1VBV^L?N:8]P,)E/
M1B>QR_8(4<YC.9_E I83+!>R7,1RDN5BEDM8+F4YQ7(9RVF,Z\1NHT<X-/<(
M5?YUG[F;E^D(:['9[)Y*@5?KS78_'_QOYR.8[0(>N&DS@NW3N6"VXH=R'LOY
M+!>PG&"YD.4BEI,L%[-<PG(IRRF6RUA.8UPG@!L5OZ&QH_*MMS'OEW1>KQZ+
M<KOXI?IK5:[OJ^!>EU^M9+TM-N;;G<V'U#^[V9H@RKDLY[&<SW(!RPF6"UDN
M8CG)<C'+)2R7LIQBN8SE-,9U0KY1$QP^MV&HVYV';$T0Y1R6<UG.8SF?Y0*6
M$RP7LES$<I+E8I9+6"YE.<5R&<MIC.L$=*-,.#27"9\"N<KGJ[*X7FP;=V2<
MCV>V+GC@.K=:#&8GLQ]L#Q#E/);S62Y@.<%R(<M%+"=9+F:YA.52EE,LE[&<
MQKA.[C9Z@$/S'H6'9>R>SX\_OS%KP78 4<YA.9?E/);S62Y@.<%R(<M%+"=9
M+F:YA.52EE,LE[&<QKAV.(\:'<#1)3IK,6+[?2CGL)S+<A[+^2P7L)Q@N9#E
M(I:3+!>S7,)R*<LIELM83F-<)Z ;3<"1N0EX.'L^U$B>[Y>S\MWV;ETN_NN5
M%>C,9/^09C<.1#F7Y3R6\UDN8#G!<B'+12PGCUQKB_KGE12[-]_'/9Z;L(>9
MLIQBN8SE-,9UXM5NQ*NYIM>.UX>\M![SY>X=>_^9W?X92W(.R[DLY[&<SW(!
MRPF6"UDN8CEYY&:MJQQ59@Y. O9]3TS8 TQ93KWWP\C8<37&=7*ST9^K'K\W
M-X]GI?N[BE\[(S5J_=.2Y!R6<UG.8SF?Y0*6$RP7LES$<O+(M:J@]G@TF4Q/
M\_+TJ8/Y<#H;S.V3Q"0/,F4YQ7(9RVF,Z^1JHR(W>KLBU\W5]6Z[V>:K_3(^
MY\.5;<JAG,-R+LMY+.>S7,!R@N5"EHM83AZY=X7KF6[H:^'*%N%03K%<QG(:
MXSKAVBC"C=XHPKUL9+JZMC;'!7H,O^.S_3>4<UC.93F/Y7R6"XY<\SM^;@\O
MIY/V][M@QPU9+F(YR7(QRR4LE[*<8KF,Y33&=:*W48$;F2MPW[Z?M!GN'\)L
MD0WE7);SCEPSYF;CZ6#4.:WQV7&#<^.^$J]L^0SE(I:3YSXK@X%M#\;CZ<D9
M*5LL0[F4Y13+92RG,:X3G8UBV<B\_]S+6>O3NI#[4]:'HGQ.S'=<IF);9BCG
ML)S+<MZ1FS>^7X<7XY/H9,MC9P:== <5[* ART4L)UDN9KF$Y5*64RR7L9S&
MN$ZV-CIA(W,G[)5N0I6K]J4]L@YGK99^VN]SOXRZL;U@'JQ_V+);S*&<RW(>
MR_DL%["<8+F0Y2*6DRP7LUS"<BG+*9;+6$YC7">^&]6R$;O%W(BMEZ&<PW(N
MRWDLY[-<P'*"Y4*6BUA.LES,<@G+I2RG6"YC.8UQ[8 >-^IE8_,6<^X?17FU
M>)F[>'.ZPLSU#FB4<UC./7*M7_6G%YVY0(\=U6>Y@.4$RX4L%[&<9+F8Y1*6
M2UE.L5S&<AKC.L';J(V-WU4;ZS^Q43WCY]TOF^*WW7Y]2O>QN4KE^<AFRV8H
MY["<RW(>R_DL%["<8+F0Y2*6DRP7LUS"<BG+*9;+6$YC7"?:[4:TV^BDQYAM
MJJ&<PW(NRWDLY[-<P'*"Y4*6BUA.LES,<@G+I2RG6"YC.8UQG8!N=..JQ]_G
M7K<#W+Y#:#:SQYT; +Z\<0C]4YCD7);S6,YGN8#E!,N%+!>QG&2YF.42EDM9
M3K%<QG(:XSHIW&C2C<U-.E6NKXKB>F/=E.M[:WM76,5Q,KHZ=_[]F-&O[7UT
MT)N;%>VWZ3S)8;8LAW(NRWDLY[-<P'*"Y4*6BUA.LES,<@G+I2RG6"YC.8UQ
MG1QNE.[&YM+=ZS/1JEP\[D^(U;(:O[L=4IBO=GGY]7FZ6@GE6B^GU>;I:+:S
MAW(.R[DLY[&<SW(!RPF6"UDN8CG)<C'+)2R7LIQBN8SE-,9U\KW1[!M/V.EH
MML^'<@[+N2SGL9S/<@'+"98+62YB.<ER,<LE+)>RG&*YC.4TQG4"NM$?')O[
M@]^\Q*79[9_4;'<0Y=PC]]9*?AX[KL]R <L)E@M9+F(YR7(QRR4LE[*<8KF,
MY33&=3*XT3,<FWN&?5<>,G/]HY=M$J*<>^1:*W4-1H/+^>PD>]F2(,H%+"=8
M+F2YB.4DR\4LE[!<RG**Y3*6TQC7R=Y&27!LWG^N=P>%+0FBG,-R[I%KGO;:
M%Z/9F>AEZW\H%["<8+F0Y2*6DRP7LUS"<BG+*9;+6$YC7#MZ)XWZW\1<_WNY
M9+<_[2T7MW?;UFK&/UC%'P^+LK"N\^WY79C-?N\L1CF'Y=RW/IEAOKJP!I,?
MK/TUT?G9^6'T@'R6"UA.L%S(<A'+29:+62YAN93E%,ME+*<QKA/2C:K@Q%P5
M_$=1WEM_^5KDY>:OYT.8;?BAG,-R[EN?K+'U](DZG[YLFP_E I83+!>R7,1R
MDN5BEDM8+F4YQ7(9RVF,ZZ2OW4A?\P9TYTZ1GS=2LJZ6Z\V^FOWZV3';[$,Y
MA^7<MSZ/K;/CT?E\9LM\*!>PG&"YD.4BEI,L%[-<PG(IRRF6RUA.8UPGGQME
MONKQ.^Z>.'/[<IS_L;C?W7_W.YK-!]@_Y4G.83F7Y3R6\UDN8#G!<B'+12PG
M62YFN83E4I93+)>QG,:X3N0WFH.3YTX,=4?SA-U_#^4<EG-9SF,YG^4"EA,L
M%[)<Q'*2Y6*62U@N93G%<AG+:8SK!'2C4C@Q5PJ_?8$-,]P_JMEV(,JY1ZYY
M7]UX.+:GH^Z]'>BX/LL%+"=8+F2YB.4DR\4LE[!<RG**Y3*6TQC7">%&[V]B
MWM'/-#%21?)^FF/X,B$B5H_%9OLT([)866KWRW)Q9;F_[1;;K^^=!6%K@RCG
ML)S+<A[+^2P7L)Q@N9#E(I:3+!>S7,)R*<LIELM83F-<)]\;M<')E)T%8=N"
M*.>PG,MR'LOY+!>PG&"YD.4BEI,L%[-<PG(IRRF6RUA.8UPGH!N=P@G;*31S
M_0.:[12BG,MR'LOY+!>PG#ARK=V[A[/!;-B>-PK9<2.6DRP7LUS"<BG+*9;+
M6$YC7"=Z&Y7"B;E2^"<FH-ER(<HY+.>RG,=R/LL%+"=8+F2YB.4DR\4LE[!<
MRG**Y;(CU_SA/[7GDVXA6&/CMD-XVB@73LU]N)?SW^=>=W7R^U"4S]G[=LG;
M;/?.891S6,YE.8_E?)8+6$ZP7,AR$<M)EHM9+F&YE.44RV5'KKG^_/"RF\'4
MF)T,;G0'I]^ZS>"?O0AHO)OZ?*2S-464<UC.93F/Y7R6"UA.L%S(<A'+29:+
M62YAN93E%,ME+*<QKA/^=B/\V8T(IVQ=$>4<EG-9SF,YG^4"EA,L%[)<Q'*2
MY6*62U@N93G%<AG+:8SK!'2CNU@]_GXS)$:[?UJ3G,-R+LMY+.>S7,!RXLC-
M&[^I#B[L<?=B(3IJQ'*2Y6*62U@N93G%<AG+:8SKI'"C3C@U;T3X7>=(>I70
MS^<\VUY$.8?E7);S6,YGN8#E!,N%+!>QG&2YF.42EDM93K%<QG(:XSH_#QKM
MQ>F8G39A.XLHY["<RW(>R_DL%["<8+F0Y2*6DRP7LUS"<BG+*9;+6$YC7">@
M&\W&J;G9^.UW]YGA_E'-EA11SF4YC^5\E@M83ARYMV^Q1L>-6$ZR7,QR"<NE
M+*=8+F,YC7&=$&[4#Z?OVK7P[*S)TQIZ]K?/F2Q6K3F3\U'.UAE1SF$YE^4\
MEO-9+F YP7(ART4L)UDN9KF$Y5*64RR7L9S&N$[@-^J,TQD[+<+6&5'.83F7
MY3R6\UDN8#G!<B'+12PG62YFN83E4I93+)>QG,:X3D W2H]3<^GQS]U-PO8>
M4<YA.9?E/);S62Y@.<%R(<M%+"=9+F:YA.52EE,LE[&</G+-FZ*F%_4]4>T0
MGC5*CS-SZ?%[3HMT;B4YF^/FP^N=XRCGL)S+<A[+^2P7L)Q@N9#E(I:3+!>S
M7,)R*<LIELM83F-<)_ ;#<O9 )T6F;$M2)1S6,YE.8_E?)8+6$ZP7,AR$<M)
MEHM9+F&YE.44RV4LIS&N$]!V(Z#-&P_^J6D1L]T_K=E*),JY+.>QG,]R <L)
ME@M9+F(YR7(QRR4LE[*<8KF,Y?21:TZ+S.S7YT4:5<?J\9^:%R'W(C ?2__4
M)CF'Y5R6\UC.9[F Y03+A2P7L9QDN9CE$I9+64ZQ7,9R&N,ZZ=ZH4,[8'1EG
M;*<1Y1R6<UG.8SF?Y0*6$RP7LES$<I+E8I9+6"YE.<5R&<MIC.L$=*/3.#/O
MR-AW+P(SUS^@V4XCRKDLY[&<?^1:NT3.!L-Y9Y?(@!U7L%S(<A'+29:+62YA
MN93E%,ME+*<QKA.]C;;B['NU%<UP_Q!FVXHHY[*<QW+^D7M'"+,]1)0+62YB
M.<ER,<LE+)>RG&*YC.4TQG5"N-%6G)G;BG_N(B!;-40YA^5<EO-8SC]RS>L3
MXPO[)(39!B'*A2P7L9QDN9CE$I9+64ZQ7,9R&N,Z(=QH$,[,&R)^KVN _=?4
M,Q]H_T1GNXDHY[*<QW(^RP4L)U@N9+F(Y23+Q2R7L%S*<HKE,I;3&->)_D8W
M<39G+Q"R=424<UC.93F/Y7R6"UA.L%S(<A'+29:+62YAN93E%,ME+*<QKAW0
M\T9O<?X=-VLTV[W3&N4<EG-9SF,Y_\B9%_L/V%$%RX4L%[&<9+F8Y1*62UE.
ML5S&<AKC.BG<*!/.OW6[QL/<QTM,?[XMB_9$1_6D_UR7OSXNELO"//MA/HC^
M<<U6$%'.93F/Y7R6"UA.L%S(<A'+29:+62YAN93E%,ME+*<QKA/K=B/6V8T8
MYVSK$.4<EG-9SF,YG^4"EA,L%[)<Q'*2Y6*62U@N93G%<AG+:8SK!'2CG5@]
M?L=Y]V8?SS\<9CJL?+>]6Y>+_RJNSX>TD>P?TL.3.\P&E]7_VK^Y.^RP+LMY
M+.>S7,!R@N5"EHM83K)<S'()RZ4LIU@N8SF-<9WT;;0'Y^_:@/&0O@]Y:3WF
MR]U[YIW9&N&!FS4B^/*BBN#!20:S!4&4\UC.9[F Y03+A2P7L9QDN9CE$I9+
M64ZQ7,9R&N,Z&=PH",[-!<$OZ]5F<5V4^7:QC^+G,^#UC775R.9]()_/8;8M
M>."F;YX*LS5 E/-8SF>Y@.4$RX4L%[&<9+F8Y1*62UE.L5S&<AKC.C'<* O.
MS67!PZGP89ZXOK+W>6MM[XK]AN2_%EOKYWQ9I?/I)<#SX<RV"%'.83F7Y3R6
M\UDN8#G!<B'+12PG62YFN83E4I93+)>QG,:X3H8WNH;S*7NUCZT7HIS#<B[+
M>2SGLUS <H+E0I:+6$ZR7,QR"<NE+*=8+F,YC7&=@&[T$.?F'N+GE\4WUC<W
M1;E8W1[N>GYU?H.M"Z*<PW(NRWDLY[-<P'*"Y4*6BXY<:UYM?#JQ)MEQ8Y9+
M6"YE.<5R&<MIC.MD;Z,(.'_G)H7O7(C.S/6/7K8(B'(NRWDLY[-<P'*"Y4*6
MBUA.LEQ\Y%KW'@WM^:3]<R%AATU93K%<QG(:XUK):U_6#;_]8^-9[V-1YK?'
M@M_[VWUON'TCF.4<EG-9SF,YG^4"EA,L%[)<Q'*2Y>(CU^IM7EYT$Y@=-64Y
MQ7(9RVF,>T[@CYN[HM@Z^3;_].-]4=X67XKE<F-=K7>KBK<_-/[6*HN;_4_M
MO\6##Q]/_O[SX&^?[?W??ZR93S\^5%$=Y^7M8K6QEL5-15Y>3*L?T.7B]N[E
M#]OU0W7V_<'Z9;W=KN^?'MX5^751[I]0_?O->KT]_F$_P._K\M>GP_[T_P!0
M2P,$%     @ DHNH6GE[S8(! P  ;@@  !D   !X;"]W;W)K<VAE971S+W-H
M965T.#@N>&ULK5;;CMHP$/T5*Y6JK53(!0C;+42"W>WE856TJ+L/51],,A +
M)TYM!Y:_[]@)*6P#0FI?$E]FCL^9F7@RV@JY5BF )B\9S]782;4N;EQ7Q2ED
M5'5% 3GN+(7,J,:I7+FJD$ 3ZY1Q-_"\T,THRYUH9-=F,AJ)4G.6PTP25689
ME;LI<+$=.[ZS7WADJU2;!3<:%70%<]#?BYG$F=N@)"R#7#&1$PG+L3/Q;VZ'
MQMX:/#'8JH,Q,4H60JS-Y&LR=CQ#"#C$VB!0?&W@%C@W0$CC5XWI-$<:Q\/Q
M'OV3U8Y:%E3!K>#/+-'IV+EV2 )+6G+]*+9?H-8S,'BQX,H^R;:V]1P2ETJ+
MK'9&!AG+JS=]J>-PX! ,3C@$M4/PVJ%_PJ%7._2LT(J9E75'-8U&4FR)--:(
M9@8V-M8;U;#<9'&N)>XR]-/1',LB*3D0L23/5C,D9+(!B2DDGR7--?E$F21/
ME)?6:*Y%O";?"I,$14K%\A69<AJO.P@E.*AZKU-(%IO-!Y$ )U=WH"GCZMW(
MU4C;'.[&-<5I13$X0=$/$"/7J2+W>0+),8"+>AO1P5[T-#B+> =QE_3\]R3P
M@GX+H=O+W7MGZ/2:'/0L7G@J!RF5T)EB,29D1G?XC6@RD1C[%=CQC\E":8D%
M_[,M>!5VKQW;7 (WJJ QC!W\RA7(#3C1VS=^Z'UL$_Z?P(["T&_"T#^''CTR
MM>XL)0!AN0;$UT12#6V:*R"_*FIS46TBK^OU,9>;0S4GS/S&[(CGH.$Y.,OS
M_J7 .PASA20S<L5RL@,JVRO[/-*@\B37)*L*'$L]H3O5EIG+D(9[I+ %Z$AM
MV*@-+U.[$9QJQIG>M0D-_PZUCZ'^\"HC+69>]SH<M&=DV' <7L8Q81N60)Z0
M'0.>M/$\"]1>X*0M'?^.4REU#Z[N#.3*=C1%8E'FNKK0FM6J:4ZQ:=KF\FH=
MF^G$]A#W#TS5B1^H7#&\JSDL$=+K#K&49-7=JHD6A6T0"Z&QW=AABC\$((T!
M[B^%T/N).:#YQ8A^ U!+ P04    " "2BZA:Z)G>@W(%   B&@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970X.2YX;6RU65USVC@4_2L:MK/3SE!LR5^0)<PD
M.+N;F>ULIFG2ATX?A"W 4]NBDH#DWZ]D&QN,$<;9OB2V['ON/??J2@=YO*7L
M!U\2(L!+$J?\NK<48G5E&#Q8D@3S 5V15#Z94Y9@(6_9PN K1G"8&26Q@4S3
M-1(<I;W).!M[8),Q78LX2LD# WR=))B]WI*8;J][L+<;^!PMED(-&)/Q"B_(
M(Q%/JP<F[XP2)8P2DO*(IH"1^77O!E[YR%4&V1O/$=GRO6N@J,PH_:%N[L/K
MGJDB(C$)A(+ \M^&3$D<*R09Q\\"M%?Z5(;[USOT/S/RDLP,<S*E\=<H%,OK
MWK '0C+'ZUA\IMN_24'(47@!C7GV%VR+=\T>"-9<T*0PEA$D49K_QR]%(O8,
M)-%F U08H)H!M$X86(6!5?=@GS"P"P,[RTQ.)<N#CP6>C!G= J;>EFCJ(DMF
M9BWI1ZFJ^Z-@\FDD[<3D44ZD<!T30.?@4=#@!_AWE17D1A4D$J_@O4\$CF+^
M 7P$R$00X#24%] #=S_7ZH7[-""IJAYXB'$*OGTBR8RP[_+UIT<?O'_W ;P#
M!N!+S @'40J>TDCPOAR4UU^6=,TE(!\;0K)1,1E!$?EM'CDZ$3E$X!--Q9*#
MNS0DX2& (=-0Y@+M<G&+M(@^"0; @GU%TVX(R&]O;FG"L<K26!F>>ZHT*F,?
M;^6D#L&4)K+3.<Y+PQA.%T1VGP"S5[#_W@-^S89OMIB%X-L_$A+<"Y+P[TT)
MSOU;S?[5BG/%5S@@USVYI'#"-J0W^?TWZ)I_-"7G?P([2)5=ILK6H4_R.<O!
MC"RB-(W2A5P+Y%P,2!/K',K)H-2RN)F@H9S/0V]L;/8):5UV).24A!PMH:_9
M>B4+>K,A3*Z_X.Z%L"#BLL=8%)!^.Z:YC]$>4]L<0+?&4QM)1YYNR=.]C.=4
MMC23FP'X0EC2Q$F/YX)7@AD'-DCRM0'9(,2O3<O+5(_T#3:UC*\W<@KWWLZ]
MV^#](%%>F2A/BWRS6#"RP$*VLTQ0)/?= #SC>-U8=RU4<T5!$]D..&=GQK D
M/&S5TG_)M4[4E_><YO"HD:%C6M;(KDUPK:..-$8EC=';&EG#;W34OM8 U;M7
MZ[XC.6A6ZL%L5:4=JT8>!<9^H3XBT[/K==+[ZLIE3PG!MY5*3Q(>50L-AG6&
MV@BZ,D050]2J6E(QSTDDJ1IW+ZN(G2"$CJMFV=""J$Y*Z[0KJ4HE0:VR.%^V
M=FRMX_*-!@ZL<_T5*@=6,@>VTSDD#<]L_?!8Y5@C%SK(.60T/>/QQ#;8 %\7
M48<4*^$#WZA\6G _UCW(&R"OSEP?R"GFYT35(>]*"$&]=+AH@R^PO/VMSZW3
MZZ1O]%:MM,-A BJ! _4*9S>WGPE7Y5>_,LG+B@3J1E"PD<.-J?#:371?[[YK
MZU9R!NKUS-EY?2GO89M)[NNCZLJZ4C_P0OESH.\O)ZWW=H'Z]_50'1.#*N&$
M],+I9+M?FI+"CVXI\/6Q=.5:"2ND%U8UD8AG<>.B5J <["G.T'7<^B:L=]>5
M3J6BD%Y%M=6))WFB8UWO#>Q1G>6OD%6HDE7H0EEUT+EG.>K![:)1H=FB4_58
M71-1:2ZD5T"G._5<#CH<(#7^#.\"=#X!2I$=CE1:!9W5#KN>IFO!!<XE&1;
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M#F[IH)DSB\AT6DLL<#!A=(^8LI9H:J&YT=XR&Y*I,JX$DT^)]!/!2NHBVB:
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M="Z'KYD>.<P'F&)RN\1L0S*.$EA+2.M\*-]$5@Q#Q4;07,\3MU3(Z40O8SE
M E,&\OF:4G'8J NJD33X"U!+ P04    " "2BZA:\XY.?N40  "B\P  &0
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M(\-;5Z(ELEJQ_;+8_@>9L=^F!"V1U23 UO9C;+W3C@5!U6D=[.[NC?NB7/?
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M[VJDUU<T=W S4'QK;Z455[K=V<=2?[: , GZ_9IS=1B8";H/H?0W4$L#!!0
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M=8M-.RB[ +_G4IKCP&[0_0U(_@502P,$%     @ DHNH6K#-,X$S!   A0X
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M_<PND4G:VL@1LY%[Q0E8\YX'MPJH _P9FK84!  U6ZXVD<1L(H^8RC43!K<
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MLOLBTTWY0L4LE3*-RX]KP1<B*P+4[\LTE<]?BAWLW_J9_ ]02P,$%     @
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MH)J+:AZJ^:@6H%J(:A&JQ:@F*4T-M*ZC,==W-.*'HMDRJ6[%IR+?]F<86K1
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MORZ*^N&+=@-?BO+WW6Z_^S]02P,$%     @ DHNH6OA8NU=@ @  6 4  !H
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M2$GLS([@,UPC1T457+Y45&_@6HJJA*N*9Y0OX?9V H]3+.8HGTSN6\P_9P=
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M4)&@,G]0E: Z?Y U*J,!)#58 [2VRK4%>&T5; L0VRK9%F"V5;0M0&VK;%N
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M.^V>+O<.U]__7'Y=;!'ZY+J_S1@?_P)02P,$%     @ DHNH6O)^ ^]Q @
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M*>SW<=S_X_CE&?=5.[SFB^4?R#<_ 5!+ 0(4 Q0    ( )*+J%I&QTU(E0
M ,T    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ DHNH6IJ][\;R    *P(  !$              ( !PP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ DHNH6IE<G",0!@  G"<  !,
M         ( !Y $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "2
MBZA:GEQ<-H,*  "P2@  &               @($E"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ DHNH6I;=&X[:!P  "28  !@
M         ("!WA(  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( )*+J%I/?BOM3@,  $P+   8              " @>X:  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "2BZA:J67E[8('  #_)@
M&               @(%R'@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ DHNH6LOK%7$H"P  $%T  !@              ("!*B8  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( )*+J%IU2RA,<PP
M %T_   8              " @8@Q  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " "2BZA:GKEIO%@"  "M!0  &               @($Q
M/@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ DHNH6DC"
MH!E# @  D 8  !@              ("!OT   'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( )*+J%HM<:4ZYP4  , 7   8
M  " @3A#  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "2
MBZA:?73='2$-   C(@  &0              @(%520  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( )*+J%K4_4J/'2H  "B&   9
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M970Q-2YX;6Q02P$"% ,4    " "2BZA:'F[#]@(#  #-!@  &0
M    @(&<H0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M )*+J%HTGWY+IPH  ,L<   9              " @=6D  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ DHNH6NF:\IG_ @  "@<  !D
M             ("!LZ\  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " "2BZA:.VLM=VP1   M.   &0              @('IL@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( )*+J%HV9.&.3@8
M /,.   9              " @8S$  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ DHNH6A#5,6X\"P  \AH  !D              ("!
M$<L  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "2BZA:
M[K*5L402  !:-   &0              @(&$U@  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( )*+J%HO3B#:ZPP  !@C   9
M      " @?_H  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ DHNH6J$@*X-(!   JPD  !D              ("!(?8  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "2BZA:3]NSHTP-  !_(P
M&0              @(&@^@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( )*+J%I7LU$D"@,  (T&   9              " @2,( 0!X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ DHNH6D^@V0RG
M"   @18  !D              ("!9 L! 'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " "2BZA:].E"XD,&  !)#P  &0
M@(%"% $ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( )*+
MJ%I?Q.'@K @  #45   9              " @;P: 0!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ DHNH6EB_-T@U @  ]00  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( )*+J%H-:6E:@P,  &P(   9
M  " @?YL 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
MDHNH6F[?HB"& @  'P8  !D              ("!N' ! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " "2BZA:GR@.=_<"  "<!@  &0
M            @(%U<P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( )*+J%K[4D-_"00  ,0)   9              " @:-V 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ DHNH6G2?ZB ' P
M[08  !D              ("!XWH! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " "2BZA:7PKXEF8#  #0!P  &0              @($A
M?@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( )*+J%JM
MMY<+MP,  +X)   9              " @;Z! 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ DHNH6M<_+WKN!   80P  !D
M     ("!K(4! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )*+J%K/_G7J,00  ",4   9              "
M@?:> 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ DHNH
M6E/B@ B. P  !!(  !D              ("!7J,! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " "2BZA:VKH>)\@#  !W$0  &0
M        @($CIP$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( )*+J%HWNE*.:0<  !@R   9              " @2*K 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ DHNH6JE!T_1D P  Z0X
M !D              ("!PK(! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " "2BZA:!Z>9ZC\#  "Y"@  &0              @(%=M@$
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( )*+J%J$75)V
M8 @  %)$   9              " @=.Y 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ DHNH6A?_AF'9 @  7P<  !D
M ("!:L(! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "2
MBZA:M3!!3TL#   4#   &0              @(%ZQ0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( )*+J%I\HW_R1@,  ($)   9
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M970V,"YX;6Q02P$"% ,4    " "2BZA:T.,PX D$  !Q#@  &0
M    @($+X $ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M )*+J%K(=5%6N@8  +9'   9              " @4OD 0!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ DHNH6BV572^L!0  +"(  !D
M             ("!/.L! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    " "2BZA::$L236()  !&:@  &0              @($?\0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( )*+J%I^\6-+V ,
M .\8   9              " @;CZ 0!X;"]W;W)K<VAE971S+W-H965T-C4N
M>&UL4$L! A0#%     @ DHNH6KW[1VH>!0  6RL  !D              ("!
MQ_X! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " "2BZA:
MTH/R@W $  !>'@  &0              @($<! ( >&PO=V]R:W-H965T<R]S
M:&5E=#8W+GAM;%!+ 0(4 Q0    ( )*+J%IXZBOQ3P,  '0,   9
M      " @<,( @!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%
M  @ DHNH6AT*E5G) @  M0<  !D              ("!20P" 'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " "2BZA:"]I-6^8"   K"P
M&0              @(%)#P( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+
M 0(4 Q0    ( )*+J%IB_VSHAP(  !@'   9              " @682 @!X
M;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ DHNH6I$O)7JW
M P  A1$  !D              ("!)!4" 'AL+W=O<FMS:&5E=',O<VAE970W
M,BYX;6Q02P$"% ,4    " "2BZA::_8,1VL"  # !0  &0
M@($2&0( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( )*+
MJ%HQ?8.OL 4  &PD   9              " @;0; @!X;"]W;W)K<VAE971S
M+W-H965T-S0N>&UL4$L! A0#%     @ DHNH6M0^3#?8 @  I@D  !D
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M=#<Y+GAM;%!+ 0(4 Q0    ( )*+J%I$K9QA@@(  ,@&   9
M  " @3*. @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @
MDHNH6BH9K3UF @  N@4  !D              ("!ZY " 'AL+W=O<FMS:&5E
M=',O<VAE970X,2YX;6Q02P$"% ,4    " "2BZA:#WGTSZ("  "?!P  &0
M            @(&(DP( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4
M Q0    ( )*+J%IBC\?@\ 4  +HD   9              " @6&6 @!X;"]W
M;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ DHNH6F/'3GI&"P
M!*   !D              ("!B)P" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX
M;6Q02P$"% ,4    " "2BZA:_U'H^[82  #]*@$ &0              @($%
MJ ( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( )*+J%IR
M:/#E; D  ,9M   9              " @?*Z @!X;"]W;W)K<VAE971S+W-H
M965T.#8N>&UL4$L! A0#%     @ DHNH6L\C:]UQ-@  8%8$ !D
M     ("!E<0" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )*+J%KE7^_&?0,  )X.   9              "
M@<,* P!X;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ DHNH
M6O..3G[E$   HO,  !D              ("!=PX# 'AL+W=O<FMS:&5E=',O
M<VAE970Y,RYX;6Q02P$"% ,4    " "2BZA:0@/A$TP#  "5#0  &0
M        @(&3'P, >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0
M   ( )*+J%IQNCW#*0,  !0)   9              " @18C P!X;"]W;W)K
M<VAE971S+W-H965T.34N>&UL4$L! A0#%     @ DHNH6D519'1% @  _00
M !D              ("!=B8# 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q0
M2P$"% ,4    " "2BZA:UL^Z(9$'  #C20  &0              @('R* ,
M>&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( )*+J%I:FJ-S
M9@(  *\%   9              " @;HP P!X;"]W;W)K<VAE971S+W-H965T
M.3@N>&UL4$L! A0#%     @ DHNH6@Y)Z&WP @  3PH  !D
M ("!5S,# 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4    " "2
MBZA:Y@K77(H#   2#   &@              @(%^-@, >&PO=V]R:W-H965T
M<R]S:&5E=#$P,"YX;6Q02P$"% ,4    " "2BZA:L,TS@3,$  "%#@  &@
M            @(% .@, >&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"
M% ,4    " "2BZA:O*401,<"  !4"   &@              @(&K/@, >&PO
M=V]R:W-H965T<R]S:&5E=#$P,BYX;6Q02P$"% ,4    " "2BZA:%>,N-+P#
M  # #P  &@              @(&J00, >&PO=V]R:W-H965T<R]S:&5E=#$P
M,RYX;6Q02P$"% ,4    " "2BZA:3@W9]D@'   !-   &@
M@(&>10, >&PO=V]R:W-H965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " "2
MBZA:O9+RKB,"  "F!   &@              @($>30, >&PO=V]R:W-H965T
M<R]S:&5E=#$P-2YX;6Q02P$"% ,4    " "2BZA:K8LXG1 ;  #E[ $ &@
M            @(%Y3P, >&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"
M% ,4    " "2BZA:^%B[5V "  !8!0  &@              @('!:@, >&PO
M=V]R:W-H965T<R]S:&5E=#$P-RYX;6Q02P$"% ,4    " "2BZA:<//]@E<#
M  #.%0  #0              @ %9;0, >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( )*+J%J7BKL<P    !,"   +              "  =MP P!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( )*+J%JE %-'X0<  /=%   /              "
M <1Q P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "2BZA:F-"7[@4#  #:
M/@  &@              @ '2>0, >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " "2BZA:\GX#[W$"  ")/   $P              @ $/
L?0, 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     <P!S *0?  "Q?P,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>523</ContextCount>
  <ElementCount>692</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>181</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/NatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Asset Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/AssetAcquisition</Role>
      <ShortName>Asset Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/GoodwillAndIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999024 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999029 - Disclosure - License and Distribution Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/LicenseAndDistributionAgreements</Role>
      <ShortName>License and Distribution Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/BenefitPlan</Role>
      <ShortName>Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://celularity.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Asset Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/AssetAcquisitionTables</Role>
      <ShortName>Asset Acquisition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/AssetAcquisition</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/Inventory</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/GoodwillAndIntangibleAssetsNet</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/Debt</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/Equity</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/Stock-basedCompensation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/RevenueRecognition</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/IncomeTaxes</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celularity.com/role/SegmentInformation</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Nature of Business (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/NatureOfBusinessDetailsNarrative</Role>
      <ShortName>Nature of Business (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/NatureOfBusiness</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Schedule of Property and Equipment Estimated Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails</Role>
      <ShortName>Schedule of Property and Equipment Estimated Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Schedule of Potentially Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails</Role>
      <ShortName>Schedule of Potentially Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Schedule of Purchase Price Allocated to Acquired Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails</Role>
      <ShortName>Schedule of Purchase Price Allocated to Acquired Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Asset Acquisition (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/AssetAcquisitionDetailsNarrative</Role>
      <ShortName>Asset Acquisition (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/AssetAcquisitionTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Schedule of Financial Assets and Liabilities Measures at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails</Role>
      <ShortName>Schedule of Financial Assets and Liabilities Measures at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Schedule of Convertible Note Valuation Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails</Role>
      <ShortName>Schedule of Convertible Note Valuation Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails</Role>
      <ShortName>Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Schedule of Convertible Notes Valuation Model (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails</Role>
      <ShortName>Schedule of Convertible Notes Valuation Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails</Role>
      <ShortName>Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999067 - Disclosure - Schedule of January 20224 Bridge Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails</Role>
      <ShortName>Schedule of January 20224 Bridge Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999068 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails</Role>
      <ShortName>Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999069 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical</Role>
      <ShortName>Schedule of November 2024 Purchaser and Placement Agent Warrants (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999070 - Disclosure - Schedule of Significant Inputs for Sponsor Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails</Role>
      <ShortName>Schedule of Significant Inputs for Sponsor Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>999071 - Disclosure - Fair Value of Financial Assets and Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>999072 - Disclosure - Schedule of Major Classes of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails</Role>
      <ShortName>Schedule of Major Classes of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>999073 - Disclosure - Schedule of Inventory Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfInventoryReservesDetails</Role>
      <ShortName>Schedule of Inventory Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>999074 - Disclosure - Inventory (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/InventoryDetailsNarrative</Role>
      <ShortName>Inventory (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/InventoryTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>999075 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>999076 - Disclosure - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>999077 - Disclosure - Property and Equipment, Net (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/PropertyAndEquipmentNetDetailsNarrative</Role>
      <ShortName>Property and Equipment, Net (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>999078 - Disclosure - Schedule of Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails</Role>
      <ShortName>Schedule of Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>999079 - Disclosure - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails</Role>
      <ShortName>Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>999080 - Disclosure - Goodwill and Intangible Assets, Net (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>999081 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Schedule of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>999082 - Disclosure - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfDebtDetails</Role>
      <ShortName>Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>999083 - Disclosure - Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/DebtDetailsNarrative</Role>
      <ShortName>Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/DebtTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>999084 - Disclosure - Schedule of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfLeaseCostsDetails</Role>
      <ShortName>Schedule of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>999085 - Disclosure - Schedule of Cash Activity Related to the lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails</Role>
      <ShortName>Schedule of Cash Activity Related to the lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>999086 - Disclosure - Schedule of Future Minimum Payments under Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails</Role>
      <ShortName>Schedule of Future Minimum Payments under Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>999087 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/LeasesTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>999088 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>999089 - Disclosure - Summary of the Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/SummaryOfWarrantsDetails</Role>
      <ShortName>Summary of the Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>999090 - Disclosure - Summary of the Warrants (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical</Role>
      <ShortName>Summary of the Warrants (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>999091 - Disclosure - Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/EquityDetailsNarrative</Role>
      <ShortName>Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/EquityTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>999092 - Disclosure - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails</Role>
      <ShortName>Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>999093 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>999094 - Disclosure - Schedule of Stock Option Activity (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical</Role>
      <ShortName>Schedule of Stock Option Activity (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>999095 - Disclosure - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails</Role>
      <ShortName>Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>999096 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>999097 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>999098 - Disclosure - Schedule of Disaggregated Revenue by Product and Services (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails</Role>
      <ShortName>Schedule of Disaggregated Revenue by Product and Services (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>999099 - Disclosure - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails</Role>
      <ShortName>Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>999100 - Disclosure -  Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical</Role>
      <ShortName> Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) (Parenthetical)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>999101 - Disclosure - License and Distribution Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative</Role>
      <ShortName>License and Distribution Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/LicenseAndDistributionAgreements</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>999102 - Disclosure - Benefit Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/BenefitPlanDetailsNarrative</Role>
      <ShortName>Benefit Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/BenefitPlan</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>999103 - Disclosure - Schedule of Current and Deferred Tax Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails</Role>
      <ShortName>Schedule of Current and Deferred Tax Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>999104 - Disclosure - Schedule of Reconciliation of the U.S federal statutory income tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails</Role>
      <ShortName>Schedule of Reconciliation of the U.S federal statutory income tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>999105 - Disclosure - Schedule of Deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>999106 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>999107 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/IncomeTaxesTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>999108 - Disclosure - Schedule of Financial Information by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails</Role>
      <ShortName>Schedule of Financial Information by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>999109 - Disclosure - Segment Information (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/SegmentInformationDetailsNarrative</Role>
      <ShortName>Segment Information (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/SegmentInformationTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>999110 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/RelatedPartyTransactions</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>999111 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celularity.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celularity.com/role/SubsequentEvents</ParentRole>
      <Position>107</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>celu-20241231.xsd</File>
    <File>celu-20241231_cal.xml</File>
    <File>celu-20241231_def.xml</File>
    <File>celu-20241231_lab.xml</File>
    <File>celu-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1263">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>130
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "CELU",
   "nsuri": "http://celularity.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "celu-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "celu-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "celu-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "celu-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "celu-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    }
   },
   "keyStandard": 439,
   "keyCustom": 253,
   "axisStandard": 40,
   "axisCustom": 0,
   "memberStandard": 47,
   "memberCustom": 114,
   "hidden": {
    "total": 222,
    "http://fasb.org/us-gaap/2024": 130,
    "http://celularity.com/20241231": 89,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 523,
   "entityCount": 1,
   "segmentCount": 181,
   "elementCount": 1139,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1263,
    "http://xbrl.sec.gov/dei/2024": 46,
    "http://xbrl.sec.gov/cyd/2024": 12,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://celularity.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://celularity.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://celularity.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://celularity.com/role/StatementsOfStockholdersEquity",
     "longName": "00000005 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://celularity.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-012024-12-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://celularity.com/role/NatureOfBusiness",
     "longName": "999014 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://celularity.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999015 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://celularity.com/role/AssetAcquisition",
     "longName": "999016 - Disclosure - Asset Acquisition",
     "shortName": "Asset Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilities",
     "longName": "999017 - Disclosure - Fair Value of Financial Assets and Liabilities",
     "shortName": "Fair Value of Financial Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://celularity.com/role/Inventory",
     "longName": "999018 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "999019 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://celularity.com/role/PropertyAndEquipmentNet",
     "longName": "999020 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://celularity.com/role/GoodwillAndIntangibleAssetsNet",
     "longName": "999021 - Disclosure - Goodwill and Intangible Assets, Net",
     "shortName": "Goodwill and Intangible Assets, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "longName": "999022 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://celularity.com/role/Debt",
     "longName": "999023 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://celularity.com/role/Leases",
     "longName": "999024 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://celularity.com/role/CommitmentsAndContingencies",
     "longName": "999025 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://celularity.com/role/Equity",
     "longName": "999026 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://celularity.com/role/Stock-basedCompensation",
     "longName": "999027 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://celularity.com/role/RevenueRecognition",
     "longName": "999028 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://celularity.com/role/LicenseAndDistributionAgreements",
     "longName": "999029 - Disclosure - License and Distribution Agreements",
     "shortName": "License and Distribution Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:LicenseAndDistributionAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:LicenseAndDistributionAgreementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://celularity.com/role/BenefitPlan",
     "longName": "999030 - Disclosure - Benefit Plan",
     "shortName": "Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DefinedBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://celularity.com/role/IncomeTaxes",
     "longName": "999031 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://celularity.com/role/SegmentInformation",
     "longName": "999032 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://celularity.com/role/RelatedPartyTransactions",
     "longName": "999033 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://celularity.com/role/SubsequentEvents",
     "longName": "999034 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999035 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999036 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:ScheduleOfEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:ScheduleOfEstimatedUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://celularity.com/role/AssetAcquisitionTables",
     "longName": "999037 - Disclosure - Asset Acquisition (Tables)",
     "shortName": "Asset Acquisition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
     "longName": "999038 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)",
     "shortName": "Fair Value of Financial Assets and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://celularity.com/role/InventoryTables",
     "longName": "999039 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "999040 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "CELU:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "CELU:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://celularity.com/role/PropertyAndEquipmentNetTables",
     "longName": "999041 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables",
     "longName": "999042 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:ScheduleOfIntangibleAssetsNetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:ScheduleOfIntangibleAssetsNetTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "999043 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://celularity.com/role/DebtTables",
     "longName": "999044 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://celularity.com/role/LeasesTables",
     "longName": "999045 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://celularity.com/role/EquityTables",
     "longName": "999046 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://celularity.com/role/Stock-basedCompensationTables",
     "longName": "999047 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://celularity.com/role/RevenueRecognitionTables",
     "longName": "999048 - Disclosure - Revenue Recognition (Tables)",
     "shortName": "Revenue Recognition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://celularity.com/role/IncomeTaxesTables",
     "longName": "999049 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://celularity.com/role/SegmentInformationTables",
     "longName": "999050 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://celularity.com/role/NatureOfBusinessDetailsNarrative",
     "longName": "999051 - Disclosure - Nature of Business (Details Narrative)",
     "shortName": "Nature of Business (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
     "longName": "999052 - Disclosure - Schedule of Property and Equipment Estimated Useful Life (Details)",
     "shortName": "Schedule of Property and Equipment Estimated Useful Life (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_BuildingMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_BuildingMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
     "longName": "999053 - Disclosure - Schedule of Potentially Dilutive Securities (Details)",
     "shortName": "Schedule of Potentially Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999054 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails",
     "longName": "999055 - Disclosure - Schedule of Purchase Price Allocated to Acquired Assets (Details)",
     "shortName": "Schedule of Purchase Price Allocated to Acquired Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:PaymentsToAcquireOtherProductiveAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember",
      "name": "us-gaap:PaymentsToAcquireOtherProductiveAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://celularity.com/role/AssetAcquisitionDetailsNarrative",
     "longName": "999056 - Disclosure - Asset Acquisition (Details Narrative)",
     "shortName": "Asset Acquisition (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember",
      "name": "us-gaap:AssetAcquisitionPriceOfAcquisitionExpected",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember",
      "name": "us-gaap:AssetAcquisitionPriceOfAcquisitionExpected",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails",
     "longName": "999057 - Disclosure - Schedule of Financial Assets and Liabilities Measures at Fair Value (Details)",
     "shortName": "Schedule of Financial Assets and Liabilities Measures at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ShorttermDebtFairValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails",
     "longName": "999058 - Disclosure - Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis (Details)",
     "shortName": "Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ReceivablesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails",
     "longName": "999059 - Disclosure - Schedule of Convertible Note Valuation Model (Details)",
     "shortName": "Schedule of Convertible Note Valuation Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "CELU:FaceValueOfNotesReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "CELU:FaceValueOfNotesReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails",
     "longName": "999060 - Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)",
     "shortName": "Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails",
     "longName": "999061 - Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)",
     "shortName": "Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_ContingentStockConsiderationMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31_custom_ContingentStockConsiderationMember",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails",
     "longName": "999062 - Disclosure - Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis (Details)",
     "shortName": "Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_YorkvilleMember",
      "name": "us-gaap:ShortTermBorrowings",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_YorkvilleMember",
      "name": "CELU:FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails",
     "longName": "999063 - Disclosure - Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)",
     "shortName": "Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-12-312024-12-31_custom_ConvertiblePromissoryNotesMember",
      "name": "us-gaap:DebtInstrumentTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
     "longName": "999064 - Disclosure - Schedule of Convertible Notes Valuation Model (Details)",
     "shortName": "Schedule of Convertible Notes Valuation Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails",
     "longName": "999065 - Disclosure - Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis (Details)",
     "shortName": "Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
     "longName": "999066 - Disclosure - Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)",
     "shortName": "Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
     "longName": "999067 - Disclosure - Schedule of January 20224 Bridge Loan (Details)",
     "shortName": "Schedule of January 20224 Bridge Loan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
     "longName": "999068 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)",
     "shortName": "Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical",
     "longName": "999069 - Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details) (Parenthetical)",
     "shortName": "Schedule of November 2024 Purchaser and Placement Agent Warrants (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2024-11-25",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
     "longName": "999070 - Disclosure - Schedule of Significant Inputs for Sponsor Warrants (Details)",
     "shortName": "Schedule of Significant Inputs for Sponsor Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_SponsorsWarrantsMember",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
     "longName": "999071 - Disclosure - Fair Value of Financial Assets and Liabilities (Details Narrative)",
     "shortName": "Fair Value of Financial Assets and Liabilities (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember",
      "name": "us-gaap:ConvertibleDebtFairValueDisclosures",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember",
      "name": "us-gaap:ConvertibleDebtFairValueDisclosures",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails",
     "longName": "999072 - Disclosure - Schedule of Major Classes of Inventories (Details)",
     "shortName": "Schedule of Major Classes of Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELU:InventoryRawMaterialsCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELU:InventoryRawMaterialsCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://celularity.com/role/ScheduleOfInventoryReservesDetails",
     "longName": "999073 - Disclosure - Schedule of Inventory Reserves (Details)",
     "shortName": "Schedule of Inventory Reserves (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "CELU:InventoryReserveCurrentAndNoncurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:ProvisionForObsoleteInventory",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfActivityInInventoryReservesTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://celularity.com/role/InventoryDetailsNarrative",
     "longName": "999074 - Disclosure - Inventory (Details Narrative)",
     "shortName": "Inventory (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:InventoryImpairmentCharge",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_InventoryFinishedGoodsMember",
      "name": "CELU:InventoryImpairmentCharge",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "999075 - Disclosure - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELU:PrepaidClinicalExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "CELU:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELU:PrepaidClinicalExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "CELU:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "999076 - Disclosure - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://celularity.com/role/PropertyAndEquipmentNetDetailsNarrative",
     "longName": "999077 - Disclosure - Property and Equipment, Net (Details Narrative)",
     "shortName": "Property and Equipment, Net (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails",
     "longName": "999078 - Disclosure - Schedule of Intangible Assets, Net (Details)",
     "shortName": "Schedule of Intangible Assets, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfIntangibleAssetsNetTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfIntangibleAssetsNetTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails",
     "longName": "999079 - Disclosure - Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)",
     "shortName": "Schedule of Aggregate Amortization Expense Related to Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative",
     "longName": "999080 - Disclosure - Goodwill and Intangible Assets, Net (Details Narrative)",
     "shortName": "Goodwill and Intangible Assets, Net (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "999081 - Disclosure - Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Schedule of Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELU:AccruedClinicalTrialExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELU:AccruedClinicalTrialExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://celularity.com/role/ScheduleOfDebtDetails",
     "longName": "999082 - Disclosure - Schedule of Debt (Details)",
     "shortName": "Schedule of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELU:ShortTermDebtUnaffiliated",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELU:ShortTermDebtUnaffiliated",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://celularity.com/role/DebtDetailsNarrative",
     "longName": "999083 - Disclosure - Debt (Details Narrative)",
     "shortName": "Debt (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-11-252024-11-25",
      "name": "CELU:PercentageOfCashFeeEqualToAggregateProceeds",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://celularity.com/role/ScheduleOfLeaseCostsDetails",
     "longName": "999084 - Disclosure - Schedule of Lease Costs (Details)",
     "shortName": "Schedule of Lease Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://celularity.com/role/ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails",
     "longName": "999085 - Disclosure - Schedule of Cash Activity Related to the lease Liabilities (Details)",
     "shortName": "Schedule of Cash Activity Related to the lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "CELU:CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails",
     "longName": "999086 - Disclosure - Schedule of Future Minimum Payments under Operating Leases (Details)",
     "shortName": "Schedule of Future Minimum Payments under Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://celularity.com/role/LeasesDetailsNarrative",
     "longName": "999087 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:OperatingLeasesRentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "CELU:OperatingLeasesRentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999088 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "CELU:AccruedResearchAndDevelopmentSoftware",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-03-272025-03-27_custom_HackensackMeridianHealthMember",
      "name": "us-gaap:AffiliateCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://celularity.com/role/SummaryOfWarrantsDetails",
     "longName": "999089 - Disclosure - Summary of the Warrants (Details)",
     "shortName": "Summary of the Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-01-24_custom_JanuaryTwoThousandTwentyFourPIPEWarrantMember_us-gaap_SubsequentEventMember_srt_MinimumMember",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical",
     "longName": "999090 - Disclosure - Summary of the Warrants (Details) (Parenthetical)",
     "shortName": "Summary of the Warrants (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "AsOf2023-07-31",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-13_custom_StarrForbearanceAgreementMember",
      "name": "CELU:NumberOfWarrantsRepriced",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://celularity.com/role/EquityDetailsNarrative",
     "longName": "999091 - Disclosure - Equity (Details Narrative)",
     "shortName": "Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:CommonStockVotingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails",
     "longName": "999092 - Disclosure - Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)",
     "shortName": "Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R89": {
     "role": "http://celularity.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "999093 - Disclosure - Schedule of Stock Option Activity (Details)",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical",
     "longName": "999094 - Disclosure - Schedule of Stock Option Activity (Details) (Parenthetical)",
     "shortName": "Schedule of Stock Option Activity (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TwoThousandTwentyOnePlanMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31_custom_TwoThousandTwentyOnePlanMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails",
     "longName": "999095 - Disclosure - Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)",
     "shortName": "Schedule of Activity Related to RSU Stock-Based Payment Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "longName": "999096 - Disclosure - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_us-gaap_CostOfSalesMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999097 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
     "longName": "999098 - Disclosure - Schedule of Disaggregated Revenue by Product and Services (Details)",
     "shortName": "Schedule of Disaggregated Revenue by Product and Services (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R95": {
     "role": "http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails",
     "longName": "999099 - Disclosure - Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)",
     "shortName": "Schedule of Changes in Deferred Revenue from Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical",
     "longName": "999100 - Disclosure -  Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) (Parenthetical)",
     "shortName": " Schedule of Changes in Deferred Revenue from Contract Liabilities (Details) (Parenthetical)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "CELU:UnearnedRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R97": {
     "role": "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
     "longName": "999101 - Disclosure - License and Distribution Agreements (Details Narrative)",
     "shortName": "License and Distribution Agreements (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredRevenue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "link:footnote",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredRevenueByArrangementDisclosureTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-08-252023-08-25_custom_RegeneronResearchCollaborationServicesAgreementMember",
      "name": "CELU:NonrefundableUpfrontPayment",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "CELU:LicenseAndDistributionAgreementsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://celularity.com/role/BenefitPlanDetailsNarrative",
     "longName": "999102 - Disclosure - Benefit Plan (Details Narrative)",
     "shortName": "Benefit Plan (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DefinedBenefitPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails",
     "longName": "999103 - Disclosure - Schedule of Current and Deferred Tax Provision (Details)",
     "shortName": "Schedule of Current and Deferred Tax Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails",
     "longName": "999104 - Disclosure - Schedule of Reconciliation of the U.S federal statutory income tax (Details)",
     "shortName": "Schedule of Reconciliation of the U.S federal statutory income tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R101": {
     "role": "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "longName": "999105 - Disclosure - Schedule of Deferred tax assets and liabilities (Details)",
     "shortName": "Schedule of Deferred tax assets and liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://celularity.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails",
     "longName": "999106 - Disclosure - Schedule of Unrecognized Tax Benefits (Details)",
     "shortName": "Schedule of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R103": {
     "role": "http://celularity.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999107 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails",
     "longName": "999108 - Disclosure - Schedule of Financial Information by Segment (Details)",
     "shortName": "Schedule of Financial Information by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:DirectOperatingCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://celularity.com/role/SegmentInformationDetailsNarrative",
     "longName": "999109 - Disclosure - Segment Information (Details Narrative)",
     "shortName": "Segment Information (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "From2024-01-01to2024-12-31",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R106": {
     "role": "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "999110 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-31",
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-01-012024-12-31_custom_COTAIncMember",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R107": {
     "role": "http://celularity.com/role/SubsequentEventsDetailsNarrative",
     "longName": "999111 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "AsOf2025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net of allowance of $6,294 and $5,837 as of December 31, 2024 and 2023, respectively",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r886"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r746",
      "r806",
      "r908",
      "r1191",
      "r1192"
     ]
    },
    "CELU_AccrualsForConstructionInProgress": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AccrualsForConstructionInProgress",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals for construction in progress",
        "documentation": "Accruals for construction in progress."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AccruedClinicalTrialExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AccruedClinicalTrialExpense",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued clinical trial expense",
        "documentation": "Accrued clinical trial expense."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AccruedComplianceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AccruedComplianceFee",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compliance fee",
        "documentation": "Accrued compliance fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other current liabilities",
        "verboseLabel": "Accrued expenses",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued professional fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "CELU_AccruedResearchAndDevelopmentSoftware": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AccruedResearchAndDevelopmentSoftware",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued R&amp;D software",
        "verboseLabel": "Accrued research and development software",
        "documentation": "Accrued research and development software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r168",
      "r663"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r88",
      "r178",
      "r658",
      "r698",
      "r699"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r11",
      "r18",
      "r532",
      "r535",
      "r589",
      "r694",
      "r695",
      "r1045",
      "r1046",
      "r1047",
      "r1061",
      "r1062",
      "r1063",
      "r1064"
     ]
    },
    "CELU_AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "documentation": "Accumulated other comprehensive income to other expense upon short term debt conversion."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired in-process research and development",
        "documentation": "Acquired In-process Research And Development."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AcquisitionRelatedContingentConsiderationObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AcquisitionRelatedContingentConsiderationObligationsMember",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition - Related Contingent Consideration Obligations [Member]",
        "documentation": "Acquisition - Related Contingent Consideration Obligations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "CELU_AdditionalLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AdditionalLicenseFee",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional license fee",
        "documentation": "Additional license fee."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AdditionalLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AdditionalLoanMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Loan [Member]",
        "documentation": "Additional Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r886",
      "r1224"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1156",
      "r1226"
     ]
    },
    "CELU_AdditionalWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AdditionalWarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional warrant liability",
        "documentation": "Additional warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "CELU_AdjustedAdvanceNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AdjustedAdvanceNoticePeriod",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjusted advance notice period",
        "documentation": "Adjusted advance notice period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax withholding on vesting of restricted stock units",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance and modification of warrants to RWI and C.V. Starr",
        "documentation": "Adjustments to additional paid in capital issuance and modification of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of warrants from liability classified to equity classified",
        "documentation": "Adjustments to additional paid in capital reclassification of warrants from liability classified to equity classified."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants to RWI and C.V. Starr",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r41",
      "r117"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising and Marketing Costs",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "CELU_AdvisoryAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AdvisoryAgreementMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advisory Agreement [Member]",
        "documentation": "Advisory Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AffiliateCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AffiliateCosts",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliate costs",
        "documentation": "Costs associated with revenues arising from an entity that is an affiliate of the reporting entity by means of direct or indirect ownership."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "CELU_AggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate offering price",
        "documentation": "Aggregate offering price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r956",
      "r970",
      "r996"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r948",
      "r959",
      "r973",
      "r999"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r991"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r949",
      "r960",
      "r974",
      "r991",
      "r1000",
      "r1004",
      "r1012"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r471"
     ]
    },
    "CELU_AllowanceForCreditLossesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AllowanceForCreditLossesPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for Credit Losses",
        "documentation": "Disclosure of accounting policy related to allowance for credit losses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable balance, net of allowance for credit losses",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r287",
      "r291",
      "r292",
      "r294",
      "r1192"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, allowance",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r287",
      "r291"
     ]
    },
    "CELU_AmendedAndRestatedEmploymentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AmendedAndRestatedEmploymentAgreementMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended and Restated Employment Agreement [Member]",
        "documentation": "Amended and Restated Employment Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AmendedEmploymentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AmendedEmploymentAgreementMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended Employment Agreement [Member]",
        "documentation": "Amended Employment Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AmendedTerminationDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AmendedTerminationDateDescription",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended termination date description",
        "documentation": "Amended termination date description."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r96",
      "r380",
      "r1172"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "CELU_OperatingIncomeCostsAndExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative",
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of acquired intangible assets",
        "verboseLabel": "Amortization expense for intangible assets",
        "terseLabel": "Amortization",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r313",
      "r320",
      "r848"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "CELU_AnnualMaintenanceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AnnualMaintenanceFee",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual maintenance fee",
        "documentation": "Annual maintenance fee."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AnnualRateOfBaseSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AnnualRateOfBaseSalary",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual rate of base salary",
        "documentation": "Annual Rate Of Base Salary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive securities",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "CELU_ApplicableFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ApplicableFees",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Applicable fees",
        "documentation": "Applicable fees"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 2023 Registered Direct Warrants [Member]",
        "documentation": "April 2023 Registered Direct Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 2023 Registered Direct Warrants Modified [Member]",
        "documentation": "April 2023 Registered Direct Warrants Modified [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AreaOfBuilding": {
     "xbrltype": "areaItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AreaOfBuilding",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of building",
        "documentation": "Area of building."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative",
      "http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r1152"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total consideration",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r1153",
      "r1154",
      "r1155"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1153",
      "r1154",
      "r1155"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition-related contingent consideration, net of current portion",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition-related contingent consideration",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionContingentConsiderationTableTextBlock",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Purchase Price Allocated to Acquired Assets",
        "documentation": "Tabular disclosure of contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative",
      "http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r1152"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative",
      "http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "us-gaap_AssetAcquisitionPriceOfAcquisitionExpected": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionPriceOfAcquisitionExpected",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration for assets",
        "documentation": "Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Total assets acquired",
        "documentation": "Asset acquisition recognized identifiable assets acquired and liabilities assumed inventory assets.",
        "label": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Inventory",
        "documentation": "Asset acquisition recognized identifiable assets acquired and liabilities assumed inventory.",
        "label": "AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative",
      "http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://celularity.com/role/AssetAcquisition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "CELU_AssetAcquisitionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AssetAcquisitionsPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisitions",
        "documentation": "Asset Acquisitions [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets [Default Label]",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r141",
      "r172",
      "r208",
      "r240",
      "r248",
      "r273",
      "r277",
      "r288",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r526",
      "r529",
      "r563",
      "r652",
      "r751",
      "r839",
      "r840",
      "r886",
      "r915",
      "r1108",
      "r1109",
      "r1179"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r182",
      "r208",
      "r288",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r526",
      "r529",
      "r563",
      "r886",
      "r1108",
      "r1109",
      "r1179"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total fair value assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r876"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AssumptionOfShorttermDebtUnaffiliatedByRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AssumptionOfShorttermDebtUnaffiliatedByRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assumption of short-term debt - unaffiliated by related party",
        "documentation": "Assumption of short-term debt - unaffiliated by related party."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_AtTheMarketSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AtTheMarketSalesAgreementMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At the Market Sales Agreement [Member]",
        "documentation": "At the Market Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r927",
      "r929",
      "r952"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r927",
      "r929",
      "r952"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r927",
      "r929",
      "r952"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "CELU_AwardsWithPerformanceConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "AwardsWithPerformanceConditionsMember",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards With Performance Conditions [Member]",
        "documentation": "Awards With Performance Conditions [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_BaseRentalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "BaseRentalPayments",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base rental payments",
        "documentation": "Base rental payments."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_BaseSalaryEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "BaseSalaryEffectiveDate",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Bonus program effective date",
        "documentation": "Base salary effective date.",
        "label": "BaseSalaryEffectiveDate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "CELU_BiobankingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "BiobankingMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Biobanking [Member]",
        "documentation": "Biobanking [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_BonusProgramEffectiveDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "BonusProgramEffectiveDate",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bonus program effective date",
        "documentation": "Bonus program effective date."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_BridgeLoanAndWarrantIssuanceTrancheTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "BridgeLoanAndWarrantIssuanceTrancheTwo",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2024 Bridge Loan - Tranche #2 warrant issuance",
        "documentation": "Bridge loan and warrant issuance tranche two."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BridgeLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BridgeLoanMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bridge Loan [Member]",
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r519",
      "r867",
      "r868"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r519",
      "r867",
      "r868"
     ]
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "CELU_OperatingIncomeCostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/role/StatementsOfCashFlows",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of contingent consideration liability",
        "verboseLabel": "Change in fair value of contingent consideration",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r1051"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquisition-related contingent consideration obligations",
        "verboseLabel": "Contingent consideration",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r125",
      "r520",
      "r544",
      "r545",
      "r546"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://celularity.com/role/NatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r103",
      "r104"
     ]
    },
    "us-gaap_BusinessExitCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessExitCosts1",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exit or disposal costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "CELU_CEOPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "CEOPromissoryNoteMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CEO Promissory Note [Member]",
        "documentation": "CEO Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_COTAIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "COTAIncMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "COTA Inc [Member]",
        "documentation": "COTA Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_CVStarLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "CVStarLoanMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CV Star Loan [Member]",
        "documentation": "CV Star Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_CVStarrBridgeLoanNetOfDiscountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "CVStarrBridgeLoanNetOfDiscountMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CV Starr Bridge Loan Net of Discount [Member]",
        "documentation": "CV Starr Bridge Loan Net of Discount [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_CVStarrCoIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "CVStarrCoIncMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "C.V. Starr Co Inc [Member]",
        "documentation": "C.V. Starr Co Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property and equipment included in accounts payable and accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r166",
      "r824"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r128"
     ]
    },
    "CELU_CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock",
     "presentation": [
      "http://celularity.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Activity Related to the lease Liabilities",
        "documentation": "Cash And Non Cash Activity Related To Lease Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r100",
      "r204"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r100"
     ]
    },
    "CELU_CellTherapyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "CellTherapyMember",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative",
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cell Therapy [Member]",
        "documentation": "Cell Therapy [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ChairmanAndChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ChairmanAndChiefExecutiveOfficerMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chairman and Chief Executive Officer [Member]",
        "documentation": "Chairman and Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ChangeInFairValueOfContingentStockConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ChangeInFairValueOfContingentStockConsideration",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of contingent stock consideration",
        "documentation": "Change in fair value of contingent stock consideration."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ChangeInFairValueOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ChangeInFairValueOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      },
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of debt",
        "label": "Change in fair value of debt",
        "documentation": "Change in fair value of debt."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "CELU_ChiefAdministrativeOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ChiefAdministrativeOfficerMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Administrative Officer [Member]",
        "documentation": "Chief Administrative Officer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ClassCommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ClassCommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A common stock, par value $0.0001 per share",
        "documentation": "Class A common stock, par value $0.0001 per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/Cover",
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r175",
      "r176",
      "r177",
      "r208",
      "r231",
      "r232",
      "r234",
      "r236",
      "r242",
      "r243",
      "r288",
      "r349",
      "r351",
      "r352",
      "r353",
      "r356",
      "r357",
      "r386",
      "r387",
      "r390",
      "r393",
      "r400",
      "r563",
      "r704",
      "r705",
      "r706",
      "r707",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r738",
      "r760",
      "r782",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r1032",
      "r1054",
      "r1065"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r242",
      "r386",
      "r387",
      "r388",
      "r390",
      "r393",
      "r398",
      "r400",
      "r704",
      "r705",
      "r706",
      "r707",
      "r855",
      "r1032",
      "r1054"
     ]
    },
    "CELU_ClassOfWarrantOrRighstExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ClassOfWarrantOrRighstExpirationDate",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant expiration date",
        "documentation": "Class of warrant or righst expiration date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Exercise per share price (in Dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants to purchase aggregate shares",
        "verboseLabel": "Aggregate shares",
        "terseLabel": "Warrants",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares",
        "verboseLabel": "Warrants to purchase aggregate shares",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "CELU_ClinicalAndRegulatoryMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ClinicalAndRegulatoryMilestones",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical and regulatory milestones",
        "documentation": "Clinical and regulatory milestones."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "CELU_CommercialLicenseToDentalProductsAgreementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "CommercialLicenseToDentalProductsAgreementPeriod",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial license",
        "documentation": "Commercial license to dental products agreement period."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_CommercialLicenseToDentalProductsAgreementRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "CommercialLicenseToDentalProductsAgreementRenewalTerm",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial license to dental products agreement renewal term",
        "documentation": "Commercial license to dental products agreement renewal term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Note 12)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r132",
      "r655",
      "r737"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r339",
      "r340",
      "r808",
      "r1096",
      "r1101"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r906",
      "r907",
      "r909",
      "r910",
      "r911",
      "r912",
      "r1061",
      "r1062",
      "r1064",
      "r1156",
      "r1223",
      "r1226"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://celularity.com/role/BalanceSheetsParenthetical",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://celularity.com/role/BalanceSheetsParenthetical",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r738"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://celularity.com/role/BalanceSheetsParenthetical",
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Issue of common stock",
        "terseLabel": "Common stock shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://celularity.com/role/BalanceSheetsParenthetical",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common stock shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r82",
      "r738",
      "r757",
      "r1226",
      "r1227"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value, 730,000,000 shares authorized, 22,546,671 and 19,378,192 issued and outstanding as of December 31, 2024 and 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r657",
      "r886"
     ]
    },
    "us-gaap_CommonStockVotingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockVotingRights",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, voting rights",
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r987"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r186",
      "r188",
      "r194",
      "r647",
      "r668",
      "r669"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss)",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r64",
      "r65",
      "r285",
      "r807"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r64",
      "r65",
      "r285",
      "r701",
      "r807"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r64",
      "r65",
      "r285",
      "r807",
      "r1035"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations of Credit Risk and Significant Customers",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r151"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r64",
      "r65",
      "r285"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r64",
      "r65",
      "r285",
      "r807"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ConsultingAgreementMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement [Member]",
        "documentation": "Consulting Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent consideration accrued in connection with Rebound asset acquisition",
        "documentation": "Contingent consideration accrued in connection with Rebound asset acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Consideration by Type [Axis]",
        "documentation": "Information by type of contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ContingentStockConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ContingentStockConsideration",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent stock consideration",
        "documentation": "Contingent stock consideration."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ContingentStockConsiderationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ContingentStockConsiderationMember",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Stock Consideration [Member]",
        "documentation": "Contingent Stock Consideration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r423"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recognition of unearned revenue",
        "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied."
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r423"
     ]
    },
    "CELU_ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferral of revenue",
        "documentation": "Contract with customer liability increase decrease for contract from business combination and deferred revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue, net of current portion",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r423"
     ]
    },
    "CELU_ContractedStoragePeriods": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ContractedStoragePeriods",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contracted storage periods",
        "documentation": "Contracted storage periods."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued for short-term debt conversion",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of notes",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1165"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "CELU_ConvertiblePromissoryNoteDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ConvertiblePromissoryNoteDiscountPercentage",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original issue discount",
        "documentation": "Convertible Promissory Note Discount Percentage."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ConvertiblePromissoryNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ConvertiblePromissoryNotesMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfDebtDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes [Member]",
        "documentation": "Convertible Promissory Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "CELU_OperatingIncomeCostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenues",
        "verboseLabel": "Cost of revenues (excluding amortization of acquired intangible assets)",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r208",
      "r288",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r563",
      "r839",
      "r1108"
     ]
    },
    "us-gaap_CostOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenueAbstract",
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenues (excluding amortization of acquired intangible assets)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenues",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r213",
      "r362",
      "r388",
      "r596",
      "r607",
      "r651",
      "r827",
      "r829"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r1106"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r1106",
      "r1107"
     ]
    },
    "CELU_CryoportSystemsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "CryoportSystemsIncMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cryoport Systems Inc [Member]",
        "documentation": "Cryoport Systems Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1057",
      "r1151"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income tax expense",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r1057"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1037",
      "r1057",
      "r1151"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r285"
     ]
    },
    "CELU_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer One [Member]",
        "documentation": "Customer One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1087",
      "r1088",
      "r1091",
      "r1092"
     ]
    },
    "CELU_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Two [Member]",
        "documentation": "Customer Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1022"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1022"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1024"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1024"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r1026"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r1024"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r1017"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1018"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1018"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1016"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r934",
      "r1019"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r1021"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r1021"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r1022"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1025"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1023"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r1020"
     ]
    },
    "CELU_DailyInterestAccruingRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DailyInterestAccruingRate",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Daily interest accruing rate",
        "documentation": "Daily Interest Accruing Rate."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_Debt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "Debt",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total debt",
        "documentation": "Debt.",
        "label": "Debt [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r28"
     ]
    },
    "CELU_DebtConversionOriginalDebtAccruedInterestAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DebtConversionOriginalDebtAccruedInterestAmount",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DebtConversionOriginalDebtAccruedInterestAmount]",
        "documentation": "Debt conversion original debt accrued interest amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtConversionOriginalDebtAmount1",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Original Debt, Amount",
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r28"
     ]
    },
    "us-gaap_DebtDefaultShorttermDebtAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDefaultShorttermDebtAmount",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term debt, unpaid principal balance",
        "documentation": "Amount of outstanding short-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://celularity.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r206",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r347",
      "r348",
      "r358",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r374",
      "r381",
      "r382",
      "r383",
      "r571"
     ]
    },
    "CELU_DebtInstrumentAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DebtInstrumentAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DebtInstrumentAccruedInterest]",
        "documentation": "Debt instrument accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r72",
      "r73",
      "r130",
      "r131",
      "r214",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r884",
      "r1055",
      "r1097",
      "r1098",
      "r1099",
      "r1171",
      "r1173"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable interest rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DebtInstrumentContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DebtInstrumentContributionAmount",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument contribution amount",
        "documentation": "Debt Instrument, Contribution Amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price per share",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r361"
     ]
    },
    "CELU_DebtInstrumentDefaultInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DebtInstrumentDefaultInterestRate",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument default interest rate",
        "documentation": "Debt instrument default interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DebtInstrumentDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DebtInstrumentDiscount",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount",
        "documentation": "Debt instrument discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amont",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r571",
      "r572",
      "r851",
      "r852",
      "r884"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r562",
      "r851",
      "r852",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1165"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r377",
      "r1171"
     ]
    },
    "CELU_DebtInstrumentInterestRateDuringPeriodInEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DebtInstrumentInterestRateDuringPeriodInEventOfDefault",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate during period in event of default",
        "documentation": "Debt instrument interest rate during period in event of default."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Default rate",
        "verboseLabel": "Loan interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r384",
      "r571",
      "r572",
      "r884"
     ]
    },
    "CELU_DebtInstrumentInterestRateEffectivePercentageInEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DebtInstrumentInterestRateEffectivePercentageInEventOfDefault",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective percentage in event of default",
        "documentation": "Debt Instrument, Interest Rate, Effective Percentage in Event of Default."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal debt outstanding",
        "verboseLabel": "Debt issued",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r850",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMeasurementInput",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible promissory note valuation measurement",
        "verboseLabel": "Unsecured senior convertible notes valuation measurement",
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r214",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r365",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r884",
      "r1055",
      "r1097",
      "r1098",
      "r1099",
      "r1171",
      "r1173"
     ]
    },
    "CELU_DebtInstrumentOriginalIssueDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DebtInstrumentOriginalIssueDiscount",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Original issue discount",
        "documentation": "Debt Instrument Original Issue Discount.",
        "label": "DebtInstrumentOriginalIssueDiscount"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DebtInstrumentPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DebtInstrumentPayment",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DebtInstrumentPayment]",
        "verboseLabel": "Debt instrument payment",
        "documentation": "Debt instrument payment."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DebtInstrumentPerDiemInterestAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DebtInstrumentPerDiemInterestAmount",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diem interest payment for each day",
        "documentation": "Debt Instrument Per Diem Interest Amount."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DebtInstrumentRedemptionPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DebtInstrumentRedemptionPremium",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:DebtInstrumentRedemptionPremium]",
        "documentation": "Debt instrument redemption premium."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Term (years)",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, unamortized discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1111",
      "r1170",
      "r1171",
      "r1173"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1150",
      "r1151"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax expense",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred income tax liabilities",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r481",
      "r653"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_DeferredRevenueByArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueByArrangementDisclosureTextBlock",
     "presentation": [
      "http://celularity.com/role/RevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Deferred Revenue from Contract Liabilities",
        "documentation": "Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueRevenueRecognized1",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Received payments",
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1150",
      "r1151"
     ]
    },
    "CELU_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized research and development",
        "documentation": "Deferred tax assets capitalized research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r498"
     ]
    },
    "CELU_DeferredTaxAssetsImputedInterestOnContingentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DeferredTaxAssetsImputedInterestOnContingentPayments",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Imputed interest on contingent payments",
        "documentation": "Deferred tax assets imputed interest on contingent payments."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DeferredTaxAssetsIrcSectionInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DeferredTaxAssetsIrcSectionInterest",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRC Section 163j interest",
        "documentation": "Deferred tax assets irc section interest."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DeferredTaxAssetsLegalFeeCapitalizationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DeferredTaxAssetsLegalFeeCapitalizationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal fee capitalization and amortization",
        "documentation": "Deferred tax assets legal fee capitalization and amortization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "CELU_DeferredTaxAssetsStartupCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DeferredTaxAssetsStartupCosts",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Startup costs",
        "documentation": "Deferred tax assets startup costs."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credit carryforwards",
        "documentation": "Deferred tax assets tax credit carryforwards research and development."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "CELU_DeferredTaxAssetsUnicap": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DeferredTaxAssetsUnicap",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unicap",
        "documentation": "Deferred tax assets unicap."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanTextBlock",
     "presentation": [
      "http://celularity.com/role/BenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Benefit Plan",
        "documentation": "The entire disclosure for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r425",
      "r611",
      "r866"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/BenefitPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contributions made to the plan",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DegenerativeDiseaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DegenerativeDiseaseMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Degenerative Disease [Member]",
        "documentation": "Degenerative Disease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r39"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r240",
      "r253",
      "r277",
      "r839",
      "r840"
     ]
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1087",
      "r1088",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_DirectOperatingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DirectOperatingCosts",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct expenses",
        "documentation": "The aggregate direct operating costs incurred during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://celularity.com/role/RevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Disaggregated Revenue by Product and Services",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1112"
     ]
    },
    "CELU_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Lease Costs",
        "terseLabel": "Schedule Of Cash Activity Related To Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DisclosureLicenseAndDistributionAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DisclosureLicenseAndDistributionAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License And Distribution Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r438",
      "r466",
      "r467",
      "r470",
      "r870"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Current Assets",
        "verboseLabel": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DiscountOnWarrantAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DiscountOnWarrantAmount",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discount on warrant amount",
        "documentation": "Discount on warrant amount."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DiscountsArisingFromLoanArrangementRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DiscountsArisingFromLoanArrangementRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discounts arising from RWI loan arrangement - related party",
        "documentation": "Discounts arising from loan arrangement related party."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r929",
      "r952"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r929",
      "r952",
      "r992"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "CELU_DrAndrewPecoraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DrAndrewPecoraMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr Andrew Pecora [Member]",
        "documentation": "Dr Andrew Pecora [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DrHaririMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DrHaririMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr Hariri [Member]",
        "documentation": "Dr Hariri [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DrRobertHaririMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DrRobertHaririMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr Robert Hariri [Member]",
        "documentation": "Dr Robert Hariri [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DragasacLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DragasacLimitedMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dragasac Limited [Member]",
        "documentation": "Dragasac Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_DragasacWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "DragasacWarrantMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dragasac Warrant [Member]",
        "documentation": "Dragasac Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share - basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r229",
      "r231",
      "r234",
      "r235",
      "r236",
      "r239",
      "r517",
      "r523",
      "r539",
      "r540",
      "r648",
      "r670",
      "r831"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share - diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r231",
      "r234",
      "r235",
      "r236",
      "r239",
      "r517",
      "r523",
      "r539",
      "r540",
      "r648",
      "r670",
      "r831"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r238"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r873"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r483",
      "r508",
      "r873"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r873",
      "r1058",
      "r1142"
     ]
    },
    "CELU_EffectiveIncomeTaxRateReconciliationDeferredTrueUp": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationDeferredTrueUp",
     "calculation": {
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred true-up",
        "documentation": "Effective income tax rate reconciliation deferred true up."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_EffectiveIncomeTaxRateReconciliationInterestAccretionExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationInterestAccretionExpense",
     "calculation": {
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest accretion expense",
        "documentation": "Effective income tax rate reconciliation interest accretion expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r873"
     ]
    },
    "CELU_EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant",
     "calculation": {
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mark to market warrant",
        "documentation": "Effective income tax rate reconciliation mark to market warrant."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "calculation": {
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss."
       }
      }
     },
     "auth_ref": [
      "r873",
      "r1058",
      "r1142",
      "r1144"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other permanent items",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1143"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfU.sFederalStatutoryIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State income taxes, net of federal benefits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r873",
      "r1058",
      "r1142"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r484",
      "r873"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Stock based compensation expense",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued wages, bonuses, commissions and vacation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated weighted-average amortization period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1140"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_EmploymentOfImmediateFamilyMemberMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "EmploymentOfImmediateFamilyMemberMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employment of Immediate Family Member [Member]",
        "documentation": "Employment of Immediate Family Member [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationDateOfIncorporation",
     "presentation": [
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Date of incorporation",
        "documentation": "Date when an entity was incorporated"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/StatementsOfStockholdersEquity",
      "http://celularity.com/role/SummaryOfWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r160",
      "r190",
      "r191",
      "r192",
      "r215",
      "r216",
      "r217",
      "r219",
      "r224",
      "r226",
      "r228",
      "r241",
      "r289",
      "r290",
      "r327",
      "r402",
      "r506",
      "r507",
      "r514",
      "r515",
      "r516",
      "r518",
      "r522",
      "r523",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r573",
      "r575",
      "r589",
      "r667",
      "r694",
      "r695",
      "r696",
      "r713",
      "r782"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r945",
      "r956",
      "r970",
      "r996"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r953",
      "r967",
      "r993"
     ]
    },
    "CELU_EvolutionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "EvolutionMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Evolution [Member]",
        "documentation": "Evolution [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r991"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_FaceValueOfNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FaceValueOfNotesReceivable",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Face value",
        "documentation": "Face Value Of Notes Receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liabilities",
        "label": "Change in fair value of warrant liabilities",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "CELU_FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment through accumulated other comprehensive income",
        "documentation": "Fair value adjustment through accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_FairValueAdjustmentThroughEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FairValueAdjustmentThroughEarnings",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment through earnings",
        "documentation": "Fair value adjustment through earnings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r555",
      "r876"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r555",
      "r876"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r880"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r880"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Convertible Notes Valuation Model",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r880"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r551",
      "r556",
      "r878"
     ]
    },
    "CELU_FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Short-term Debt Obligation Measured on Recurring Basis",
        "documentation": "Fair Value Assets Of Yorkville Debt Measured On Recurring Basis Unobservable Input Reconciliation [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r554",
      "r555",
      "r557",
      "r601",
      "r602",
      "r603",
      "r851",
      "r852",
      "r864",
      "r865",
      "r866",
      "r876",
      "r880"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r546",
      "r876",
      "r1160",
      "r1167"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Assets and Liabilities",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r552",
      "r553",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r645",
      "r876",
      "r881"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r427",
      "r432",
      "r543",
      "r555",
      "r601",
      "r864",
      "r865",
      "r866",
      "r876"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r427",
      "r432",
      "r543",
      "r544",
      "r555",
      "r602",
      "r851",
      "r852",
      "r864",
      "r865",
      "r866",
      "r876"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r543",
      "r544",
      "r545",
      "r546",
      "r555",
      "r603",
      "r851",
      "r852",
      "r864",
      "r865",
      "r866",
      "r876",
      "r880"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Warrant Liabilities Measured on Recurring Basis",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r1157",
      "r1158"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Contingent Consideration Obligation Measured on a Recurring Basis",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r551",
      "r556"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r546",
      "r876",
      "r1160",
      "r1167"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of debt into common shares",
        "documentation": "Fair value measurement with unobservable inputs reconciliation conversion of debt into common shares."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of convertible promissory note",
        "documentation": "Fair value measurement with unobservable inputs reconciliation convertible promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustment through interest accrual",
        "documentation": "Fair value measurement with unobservable inputs reconciliation fair value adjustment through interest accrual."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value adjustments",
        "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1162",
      "r1166"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchases, settlements and other net",
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1166"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net transfers into (out of) Level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r1164",
      "r1166"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value adjustments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1162",
      "r1166"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchases, settlements and other net",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)",
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r1163",
      "r1166"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal repayments",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r556"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net transfers into (out of) Level 3",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net",
        "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r1164",
      "r1166"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r556"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r541",
      "r543",
      "r544",
      "r545",
      "r546",
      "r554",
      "r555",
      "r557",
      "r601",
      "r602",
      "r603",
      "r851",
      "r852",
      "r864",
      "r865",
      "r866",
      "r876",
      "r880"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r876",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1167"
     ]
    },
    "CELU_FairValueNetAssetLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FairValueNetAssetLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value, Beginning Balance",
        "periodEndLabel": "Fair Value, Ending Balance",
        "documentation": "Fair value net asset liabilities",
        "label": "Fair value net asset liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value, Beginning Balance",
        "periodEndLabel": "Fair Value, Ending Balance",
        "label": "Fair Value, Net Asset (Liability)",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": [
      "r1157",
      "r1158"
     ]
    },
    "CELU_FairValueNetAssetsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FairValueNetAssetsLiability",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the warrant liability",
        "documentation": "Fair value net assets liability."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_FairValueOfWarrantModificationForProfessionalService": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FairValueOfWarrantModificationForProfessionalService",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant modification for professional services",
        "documentation": "Fair Value Of Warrant Modification For Professional Services."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_FairValueOfWarrantModificationForProfessionalServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FairValueOfWarrantModificationForProfessionalServices",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of warrant modification for professional services",
        "documentation": "Fair Value Of Warrant Modification For Professional Services.",
        "label": "FairValueOfWarrantModificationForProfessionalServices"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_FairValueOfWarrantModificationIncrementalForEquityIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FairValueOfWarrantModificationIncrementalForEquityIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant modification",
        "documentation": "Fair Value Of Warrant Modification Incremental For Equity Issuance Cost."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_FallInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FallInCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fall in cash and cash equivalents",
        "documentation": "Fall In Cash And Cash Equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated useful lives",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r299",
      "r319",
      "r848"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1228"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r820",
      "r848"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r820",
      "r848"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r820",
      "r848"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r820",
      "r848"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r820",
      "r848"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r323",
      "r324",
      "r613",
      "r614",
      "r820"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortizable intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r319",
      "r614",
      "r848"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r319",
      "r323",
      "r324",
      "r326",
      "r613",
      "r820",
      "r848"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r323",
      "r324",
      "r820"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAggregateAmortizationExpenseRelatedToIntangibleAssetsDetails",
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortizable intangible assets, net",
        "totalLabel": "Amortization expense",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r1088"
     ]
    },
    "CELU_FloorPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FloorPrice",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Floor price",
        "documentation": "Floor price."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_FlorhamParkNewJerseyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "FlorhamParkNewJerseyMember",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Florham Park New Jersey [Member]",
        "documentation": "Florham Park New Jersey [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ForbearanceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ForbearanceAgreementMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forbearance Agreement [Member]",
        "documentation": "Forbearance Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ForbearanceExtendMaturityPeriod": {
     "xbrltype": "dateItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ForbearanceExtendMaturityPeriod",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forbearance extend period",
        "documentation": "Forbearance extend maturity period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r974",
      "r1000"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r974",
      "r1000"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r974",
      "r1000"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r974",
      "r1000"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r974",
      "r1000"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_GXSponsorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "GXSponsorWarrantsMember",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "GX Sponsor Warrants [Member]",
        "documentation": "GX Sponsor Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_GainLossRecognizedInEarningsFromChangeInFairValues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "GainLossRecognizedInEarningsFromChangeInFairValues",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain recognized in earnings from change in fair value",
        "documentation": "Gain loss recognized in earnings from change in fair values."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      },
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss on debt extinguishment",
        "negatedLabel": "Loss on debt extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42",
      "r43"
     ]
    },
    "CELU_GenesisEquityGroupFundingLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "GenesisEquityGroupFundingLlcMember",
     "presentation": [
      "http://celularity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Genesis Equity Group Funding LLC [Member]",
        "documentation": "Genesis Equity Group Funding LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r300",
      "r646",
      "r840",
      "r847",
      "r877",
      "r886",
      "r1079",
      "r1080"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Net",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1081"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1081"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "CELU_OperatingIncomeCostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      },
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative",
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/role/StatementsOfCashFlows",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill impairment",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r301",
      "r307",
      "r311",
      "r847",
      "r877"
     ]
    },
    "us-gaap_GoodwillImpairmentLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLossNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill impairment",
        "label": "Goodwill, Impairment Loss, Net of Tax",
        "documentation": "Amount, after tax, of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_GovernmentGrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "GovernmentGrantsPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Government Grants",
        "documentation": "Government Grants [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from issuance of common stock",
        "documentation": "Gross proceeds from issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_HLICellularTherapeuticsLLCAndAnthrogenesisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "HLICellularTherapeuticsLLCAndAnthrogenesisMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "HLI Cellular Therapeutics LLC and Anthrogenesis [Member]",
        "documentation": "HLI Cellular Therapeutics LLC and Anthrogenesis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_HackensackMeridianHealthMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "HackensackMeridianHealthMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hackensack Meridian Health [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r927",
      "r929",
      "r952"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "CELU_OperatingIncomeCostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      },
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPR&amp;D impairment",
        "verboseLabel": "Indefinite-lived IPR&amp;D",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r313",
      "r325"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of intangible assets",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r1052",
      "r1093"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r109"
     ]
    },
    "CELU_InProcessResearchAndDevelopmentImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InProcessResearchAndDevelopmentImpairment",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "IPR&amp;D impairment",
        "documentation": "In process research and development impairment.",
        "label": "InProcessResearchAndDevelopmentImpairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In-Process Research and Development",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss from operations",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r90",
      "r102",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r233",
      "r236",
      "r523"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Loss before income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r135",
      "r140",
      "r649",
      "r665",
      "r833",
      "r839",
      "r1066",
      "r1068",
      "r1069",
      "r1070",
      "r1071"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r335",
      "r336",
      "r548",
      "r551",
      "r556",
      "r691",
      "r693",
      "r767",
      "r820",
      "r879",
      "r1194"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r548",
      "r551",
      "r556",
      "r691",
      "r693",
      "r767",
      "r820",
      "r879",
      "r1194"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r483",
      "r484",
      "r492",
      "r502",
      "r873",
      "r1147"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r483",
      "r484",
      "r492",
      "r502",
      "r873",
      "r1147"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://celularity.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r476",
      "r483",
      "r488",
      "r489",
      "r490",
      "r495",
      "r501",
      "r509",
      "r511",
      "r512",
      "r513",
      "r709",
      "r873"
     ]
    },
    "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax examination likelihood settlement",
        "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority."
       }
      }
     },
     "auth_ref": [
      "r1145"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfCurrentAndDeferredTaxProvisionDetails",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expense",
        "totalLabel": "Total income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r157",
      "r227",
      "r228",
      "r240",
      "r256",
      "r277",
      "r482",
      "r483",
      "r510",
      "r671",
      "r873"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r478",
      "r479",
      "r495",
      "r496",
      "r500",
      "r504",
      "r703"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 27.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "CELU_IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued R&amp;D software",
        "documentation": "Increase decrease in accrued research development software expense.",
        "label": "IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 31.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r1051"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 30.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liabilities - operating",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1036",
      "r1051"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other, net",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 26.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "CELU_IncreasedNotePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IncreasedNotePayments",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increased total note payments",
        "documentation": "Increased total note payments."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_IndefiniteLivedIntangibleAssetsAmortizationMethod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IndefiniteLivedIntangibleAssetsAmortizationMethod",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated useful lives",
        "documentation": "Indefinite lived intangible assets amortization method.",
        "label": "IndefiniteLivedIntangibleAssetsAmortizationMethod"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r317",
      "r322",
      "r848"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r322",
      "r326",
      "r848"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired IPR&amp;D product rights",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r322",
      "r848"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r317",
      "r322",
      "r848"
     ]
    },
    "CELU_IndirectExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IndirectExpenses",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indirect expenses",
        "documentation": "Indirect expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r949",
      "r960",
      "r974",
      "r991",
      "r1000",
      "r1004",
      "r1012"
     ]
    },
    "CELU_InitialAndSecondTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InitialAndSecondTrancheMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial and Second Tranche [Member]",
        "documentation": "Initial and Second Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_InitialLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InitialLoanMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Loan [Member]",
        "documentation": "Initial Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_InitialMonthlyBaseRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InitialMonthlyBaseRent",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial monthly base rent",
        "documentation": "Initial monthly base rent."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_InitialTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InitialTrancheMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Tranche [Member]",
        "documentation": "Initial Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r1015"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r1015"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r1015"
     ]
    },
    "CELU_InstrumentSpecificCreditRiskIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InstrumentSpecificCreditRiskIncome",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Instrument-specific credit risk income",
        "documentation": "Instrument specific credit risk income."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_InstrumentSpecificCreditRiskLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InstrumentSpecificCreditRiskLoss",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Instrument-specific credit risk loss",
        "documentation": "Instrument specific credit risk loss."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r1088",
      "r1090"
     ]
    },
    "CELU_InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest accrued on senior secured loans within long-term debt - related parties",
        "documentation": "Interest accrued on senior secured loans within long term debt related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomePurchasedReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomePurchasedReceivables",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables purchased",
        "documentation": "Interest earned from receivables purchased; for instance, receivables purchased through a factoring arrangement."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r201",
      "r202"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "CELU_InventoryAcquiredInConnectionWithReboundAssetAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InventoryAcquiredInConnectionWithReboundAssetAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory acquired in connection with Rebound asset acquisition",
        "documentation": "Inventory acquired in connection with Rebound asset acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://celularity.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://celularity.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r295"
     ]
    },
    "CELU_InventoryFinishedGoodsCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InventoryFinishedGoodsCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails": {
       "parentTag": "CELU_InventoryGrossCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Inventory finished goods current and noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_InventoryFinishedGoodsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InventoryFinishedGoodsMember",
     "presentation": [
      "http://celularity.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Finished Goods [Member]",
        "documentation": "Inventory Finished Goods [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_InventoryGrossCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InventoryGrossCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails": {
       "parentTag": "CELU_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory, gross",
        "documentation": "Inventory gross current and noncurrent.",
        "label": "InventoryGrossCurrentAndNoncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_InventoryImpairmentCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InventoryImpairmentCharge",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celularity.com/role/InventoryDetailsNarrative",
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory impairment",
        "verboseLabel": "Inventory impairment charge",
        "documentation": "Inventory Impairment Charge."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://celularity.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r825",
      "r886"
     ]
    },
    "CELU_InventoryNetCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InventoryNetCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory, net",
        "documentation": "Inventory net current and noncurrent.",
        "label": "InventoryNetCurrentAndNoncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, net of current portion",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r165",
      "r180",
      "r295",
      "r296",
      "r298",
      "r610",
      "r830"
     ]
    },
    "CELU_InventoryRawMaterialsCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InventoryRawMaterialsCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails": {
       "parentTag": "CELU_InventoryGrossCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials",
        "documentation": "Inventory raw materials current and noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_InventoryReserveCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InventoryReserveCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails": {
       "parentTag": "CELU_InventoryNetCurrentAndNoncurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfInventoryReservesDetails",
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: inventory reserves",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Inventory reserve current and noncurrent.",
        "label": "InventoryReserveCurrentAndNoncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_InventoryWorkInProgressCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InventoryWorkInProgressCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails": {
       "parentTag": "CELU_InventoryGrossCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfMajorClassesOfInventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work in progress",
        "documentation": "Inventory work in progress current and noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_InventoryWorkInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InventoryWorkInProgressMember",
     "presentation": [
      "http://celularity.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Work in Progress [Member]",
        "documentation": "Inventory Work in Progress [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfInventoryReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Write-offs",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "CELU_InvestorRightsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "InvestorRightsAgreementMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Rights Agreement [Member]",
        "documentation": "Investor Rights Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_IssuanceOfCommonStockAsCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IssuanceOfCommonStockAsCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock as compensation expense",
        "documentation": "Issuance of common stock as compensation expense.",
        "label": "IssuanceOfCommonStockAsCompensationExpense"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_IssuanceOfCommonStockAsConsiderationForSettlementAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IssuanceOfCommonStockAsConsiderationForSettlementAgreement",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock to Palantir as consideration for settlement agreement",
        "documentation": "Issuance of common stock as consideration for settlement agreement.",
        "label": "IssuanceOfCommonStockAsConsiderationForSettlementAgreement"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_IssuanceOfCommonStockMinimumOptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IssuanceOfCommonStockMinimumOptionPricePerShare",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock minimum option price per share",
        "documentation": "Issuance of common stock minimum option price per share."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock to Yorkville for debt extension and SEPA commitment fee",
        "documentation": "Issuance of common stock relating to debt extension and commitment fee.",
        "label": "IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_IssuanceOfCommonStockUsedInResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IssuanceOfCommonStockUsedInResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock for stem-cells to be used in research and development",
        "documentation": "Issuance of common stock used in research and development.",
        "label": "IssuanceOfCommonStockUsedInResearchAndDevelopment"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_IssuanceOfRwiWarrantsInConnectionWithForbearance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IssuanceOfRwiWarrantsInConnectionWithForbearance",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of RWI warrants in connection with forbearance",
        "documentation": "Issuance of rwi warrants in connection with for bearance."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of unsecured senior convertible notes, net of fair value adjustment",
        "documentation": "Issuance of unsecured senior convertible notes, net of fair value adjustment."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_IssuanceOfWarrantsOnSeniorSecuredBridgeLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IssuanceOfWarrantsOnSeniorSecuredBridgeLoan",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of warrants on senior secured bridge loan",
        "documentation": "Issuance of warrants on senior secured bridge loan."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_IssuancePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "IssuancePricePercentage",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance price percentage",
        "documentation": "Issuance Price Percentage."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2024 Bridge Loan Tranche One Warrants [Member]",
        "documentation": "January 2024 Bridge Loan Tranche One Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2024 Bridge Loan - Tranche #2 Warrants [Member]",
        "documentation": "January 2024 Bridge Loan - Tranche #2 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_JanuaryTwoThousandTwentyFourPIPEWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "JanuaryTwoThousandTwentyFourPIPEWarrantMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2024 PIPE Warrant [Member]",
        "documentation": "January 2024 PIPE Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_JanuaryTwoThousandTwentyFourPipeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "JanuaryTwoThousandTwentyFourPipeWarrantsMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "January 2024 PIPE Warrants [Member]",
        "documentation": "January 2024 PIPE Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2023 Registered Direct Warrants [Member]",
        "documentation": "July 2023 Registered Direct Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_JuneTwoThousandTwentyThreeLoanWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "JuneTwoThousandTwentyThreeLoanWarrantsMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 2023 Loan Warrants [Member]",
        "documentation": "June 2023 Loan Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_JuneTwoThousandTwentyThreeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "JuneTwoThousandTwentyThreeWarrantsMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "June 2023 Warrants [Member]",
        "documentation": "June 2023 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LaboratoryAndProductionEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LaboratoryAndProductionEquipmentMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Laboratory and Production Equipment [Member]",
        "documentation": "Laboratory and Production Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfLeaseCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r885"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://celularity.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Costs",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1174"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r588"
     ]
    },
    "CELU_LegacyCelularityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LegacyCelularityMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Celularity [Member]",
        "documentation": "Legacy Celularity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LegacyCelularitysMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LegacyCelularitysMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legacy Celularitys [Member]",
        "documentation": "Legacy Celularitys [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://celularity.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Payments under Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1175"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option to renew lease term period.",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://celularity.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "CELU_LetterAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LetterAgreementMember",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter Agreement [Member]",
        "documentation": "Letter Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r72",
      "r73",
      "r74",
      "r77",
      "r78",
      "r79",
      "r80",
      "r208",
      "r288",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r527",
      "r529",
      "r530",
      "r563",
      "r736",
      "r832",
      "r915",
      "r1108",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r133",
      "r660",
      "r886",
      "r1056",
      "r1076",
      "r1169"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r164",
      "r208",
      "r288",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r527",
      "r529",
      "r530",
      "r563",
      "r886",
      "r1108",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total fair value liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r1157"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LicenseAgreementMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement [Member]",
        "documentation": "License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LicenseAgreementNoticePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LicenseAgreementNoticePeriod",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "License agreement period",
        "label": "License agreement notice period",
        "documentation": "License agreement notice period."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LicenseAgreementWithBiocellgraftIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LicenseAgreementWithBiocellgraftIncMember",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement With Biocellgraft Inc [Member]",
        "documentation": "License Agreement With Biocellgraft Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LicenseAndDistributionAgreementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LicenseAndDistributionAgreementsTextBlock",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Distribution Agreements",
        "documentation": "License And Distribution Agreements [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LicenseFeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LicenseFeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License fee expense",
        "documentation": "License fee expense."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LicenseFeePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LicenseFeePayment",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License fee payment",
        "documentation": "License fee payment."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LicenseFeesPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LicenseFeesPaymentPeriod",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License fees payment period",
        "documentation": "License fees payment period."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LicenseRoyaltyAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LicenseRoyaltyAndOtherMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Royalty and Other [Member]",
        "documentation": "License Royalty and Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76",
      "r1055",
      "r1106",
      "r1107"
     ]
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-paid advance maturity period",
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bearing interest",
        "documentation": "The effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76",
      "r1055",
      "r1106"
     ]
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r1055",
      "r1106"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum advance amount",
        "documentation": "Maximum amount borrowed under the credit facility at any time during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of credit aggregate limitation amount",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76",
      "r348",
      "r1055",
      "r1106"
     ]
    },
    "CELU_LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in bearing interest",
        "verboseLabel": "Line of credit percentage",
        "documentation": "Line of credit increase in interest rate during period in event of default."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for legal settlements",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LoanAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LoanAgreement",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan agreement",
        "documentation": "Loan agreement."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_LoanAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "LoanAgreementMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Agreement [Member]",
        "documentation": "Loan Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term debt - related parties",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermPurchaseCommitmentPeriod",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License agreement period",
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r346",
      "r472",
      "r849",
      "r1102",
      "r1103"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r346",
      "r472",
      "r849",
      "r1102",
      "r1103"
     ]
    },
    "CELU_MachineryEquipmentAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MachineryEquipmentAndFixturesMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery, Equipment and Fixtures [Member]",
        "documentation": "Machinery, Equipment and Fixtures [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r285",
      "r859",
      "r897",
      "r902",
      "r1112",
      "r1193",
      "r1195",
      "r1196",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "CELU_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2024 RWI Forbearance Warrants [Member]",
        "documentation": "March 2024 RWI Forbearance Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MarchTwoThousandTwentyThreeLoanWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MarchTwoThousandTwentyThreeLoanWarrantsMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2023 Loan Warrants [Member]",
        "documentation": "March 2023 Loan Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2023 Private Investment in Public Equity Warrants [Member]",
        "documentation": "March 2023 Private Investment in Public Equity Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March 2023 Private Investment in Public Equity Warrants, Modified [Member]",
        "documentation": "March 2023 Private Investment in Public Equity Warrants, Modified [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MarketConditionStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MarketConditionStockUnitMember",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Market Condition Stock Unit [Member]",
        "documentation": "Market Condition Stock Unit [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketingAndAdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising and marketing costs",
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "CELU_MasterSubscriptionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MasterSubscriptionAgreementMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Master Subscription Agreement [Member]",
        "documentation": "Master Subscription Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_MaterialCybersecurityIncidentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r964"
     ]
    },
    "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r965"
     ]
    },
    "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r966"
     ]
    },
    "cyd_MaterialCybersecurityIncidentNatureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentNatureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Nature [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r966"
     ]
    },
    "cyd_MaterialCybersecurityIncidentScopeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentScopeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Scope [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r966"
     ]
    },
    "cyd_MaterialCybersecurityIncidentTimingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "MaterialCybersecurityIncidentTimingTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Cybersecurity Incident Timing [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r963",
      "r966"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r434",
      "r472",
      "r546",
      "r608",
      "r690",
      "r692",
      "r700",
      "r728",
      "r729",
      "r790",
      "r792",
      "r794",
      "r795",
      "r797",
      "r818",
      "r819",
      "r845",
      "r855",
      "r869",
      "r880",
      "r881",
      "r882",
      "r883",
      "r898",
      "r1110",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186"
     ]
    },
    "CELU_MaximumPercentageOfCommonStockIssued": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MaximumPercentageOfCommonStockIssued",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum percentage of common stock issued",
        "documentation": "Maximum percentage of common stock issued."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MaximumPercentageOfSalesCommissionFromGrossSalesProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MaximumPercentageOfSalesCommissionFromGrossSalesProceeds",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales agents commission rate",
        "documentation": "Maximum percentage of sales commission from gross sales proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2023 Private Investment in Public Equity Warrants [Member]",
        "documentation": "May 2023 Private Investment in Public Equity Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2022 Private Investment in Public Equity Warrant [Member]",
        "documentation": "May 2022 Private Investment in Public Equity Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2022 Private Investment in Public Equity Warrants [Member]",
        "documentation": "May 2022 Private Investment in Public Equity Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member]",
        "documentation": "May 2022 PIPE Warrants and April 2023 Registered Direct Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_MeasurementInputCreditSpreadMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputCreditSpreadMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Credit Spread [Member]",
        "documentation": "Measurement input using amount above (below) yield between two debt instruments similar in maturity, but different in credit quality."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r880",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r880"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r880"
     ]
    },
    "CELU_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Milestone payments",
        "documentation": "Milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MinimumGrossProceeds": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MinimumGrossProceeds",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds",
        "documentation": "Minimum gross proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r434",
      "r472",
      "r546",
      "r608",
      "r690",
      "r692",
      "r700",
      "r728",
      "r729",
      "r790",
      "r792",
      "r794",
      "r795",
      "r797",
      "r818",
      "r819",
      "r845",
      "r855",
      "r869",
      "r880",
      "r881",
      "r882",
      "r898",
      "r1110",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186"
     ]
    },
    "CELU_MinimumNumberOfSharesOfCommonStockPurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MinimumNumberOfSharesOfCommonStockPurchase",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum number of shares of common stock purchase",
        "documentation": "Minimum number of shares of common stock purchase."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MinimumRequiredDailyVolumeWeightedAveragePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MinimumRequiredDailyVolumeWeightedAveragePrice",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum required daily volume weighted average price",
        "documentation": "Minimum required daily volume weighted average price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "CELU_ModificationOfCVStarrWarrantsInConnectionWithForbearance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ModificationOfCVStarrWarrantsInConnectionWithForbearance",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Modification of C.V. Starr warrants in connection with forbearance",
        "documentation": "Modification of CV starr warrants in connection with forbearance."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MonthlyMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MonthlyMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Monthly milestone payments",
        "documentation": "Monthly milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_MsHaririMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "MsHaririMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ms Hariri [Member]",
        "documentation": "Ms Hariri [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r285",
      "r859",
      "r897",
      "r902",
      "r1112",
      "r1193",
      "r1195",
      "r1196",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative",
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flow from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://celularity.com/role/StatementsOfStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r102",
      "r136",
      "r162",
      "r184",
      "r187",
      "r192",
      "r208",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r227",
      "r228",
      "r233",
      "r288",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r517",
      "r523",
      "r540",
      "r563",
      "r666",
      "r759",
      "r780",
      "r781",
      "r913",
      "r1108"
     ]
    },
    "CELU_NetSalesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NetSalesPercentage",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net sales percentage",
        "documentation": "Net sales percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_NewLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NewLineOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New line of credit",
        "documentation": "New line of credit."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_NonCashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NonCashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non cash interest expense",
        "documentation": "Non cash interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non cash lease expense",
        "documentation": "Non cash lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense",
        "verboseLabel": "Other expenses",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "CELU_NonrefundableUpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NonrefundableUpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrefundable up-front payment",
        "documentation": "Nonrefundable up-front payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060"
     ]
    },
    "CELU_NotesAndPurchaserWarrantsPrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NotesAndPurchaserWarrantsPrincipalAmount",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes and purchaser warrants principal amount",
        "documentation": "Notes and purchaser warrants principal amount."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 2024 Placement Agent Warrants [Member]",
        "documentation": "November 2024 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_NovemberTwoThousandTwentyFourPurchaseWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NovemberTwoThousandTwentyFourPurchaseWarrantsMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "November 2024 Purchaser Warrants [Member]",
        "documentation": "November 2024 Purchaser Warrants [Member]",
        "label": "November 2024 Purchaser Warrants [Member] [Default Label]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 2024 Purchaser and Placement Agent Warrants [Member]",
        "documentation": "November 2024 Purchaser and Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_NovemberTwoThousandTwentyFourPurchaserWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NovemberTwoThousandTwentyFourPurchaserWarrantsMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 2024 Purchaser Warrants [Member]",
        "documentation": "November 2024 Purchaser Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative",
      "http://celularity.com/role/SegmentInformationDetailsNarrative",
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r840",
      "r1067"
     ]
    },
    "CELU_NumberOfSharesIssuedForPiggybackRegistrationRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NumberOfSharesIssuedForPiggybackRegistrationRights",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued for piggyback registration rights",
        "documentation": "Number of shares issued for piggy back registration rights."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_NumberOfWarrantsRepriced": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "NumberOfWarrantsRepriced",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants repriced",
        "documentation": "Number Of Warrants Repriced."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_OfferingPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "OfferingPricePercentage",
     "presentation": [
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering price",
        "documentation": "Offering price percentage."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_OfficeManufacturingAndLaboratorySpaceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "OfficeManufacturingAndLaboratorySpaceMember",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Manufacturing and Laboratory Space [Member]",
        "documentation": "Office Manufacturing and Laboratory Space [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_OperatingIncomeCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "OperatingIncomeCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "documentation": "Operating income costs and expenses.",
        "label": "OperatingIncomeCostsAndExpenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "negatedLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r833",
      "r1066",
      "r1068",
      "r1069",
      "r1070",
      "r1071"
     ]
    },
    "CELU_OperatingLeaseCommencementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "OperatingLeaseCommencementDate",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease commencement date",
        "documentation": "Operating lease commencement date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r885"
     ]
    },
    "CELU_OperatingLeaseExpiryYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "OperatingLeaseExpiryYear",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expiry year",
        "documentation": "Operating lease expiry year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfFutureMinimumPaymentsUnderOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "verboseLabel": "Operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfCashActivityRelatedToLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating cash flows from operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r578",
      "r584"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets - operating leases",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r586",
      "r885"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r585",
      "r885"
     ]
    },
    "CELU_OperatingLeasesRentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "OperatingLeasesRentExpense",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expense",
        "documentation": "Operating leases rent expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "CELU_OperatingLossCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating loss carryforwards expiration year",
        "documentation": "Operating loss carryforwards expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_OptionFeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "OptionFeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option fee expense",
        "documentation": "Option fee expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of intangible assets",
        "label": "Other Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1095"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other long-term assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of debt due to change in credit risk, net of tax",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r528"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of debt due to change in credit risk, net of tax",
        "label": "Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, before Tax, after Reclassification Adjustment, Attributable to Parent",
        "documentation": "Amount, before tax, after reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r525",
      "r528"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r11",
      "r127",
      "r185",
      "r188",
      "r224"
     ]
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94"
     ]
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other general and administrative expenses",
        "documentation": "Amount of general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r1225"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental non-cash investing and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total other",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_OtherNonoperatingIncomeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "OtherNonoperatingIncomeExpenses",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expense, net",
        "documentation": "Other nonoperating income expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1043",
      "r1077"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "CELU_OtherShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "OtherShortTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term debt - other",
        "documentation": "Other short term debt."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_OtherShortTermDebtDueToRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "OtherShortTermDebtDueToRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other short term debt due to related party",
        "documentation": "Other short term debt due to related party."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r947",
      "r958",
      "r972",
      "r998"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r961",
      "r975",
      "r1001"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r950",
      "r961",
      "r975",
      "r1001"
     ]
    },
    "CELU_PIPERelatedCostsIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PIPERelatedCostsIncludedInAccruedExpenses",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PIPE related costs included in accrued expenses",
        "documentation": "PIPE related costs included in accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PalantirTechnologiesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PalantirTechnologiesIncMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Palantir Technologies Inc [Member]",
        "documentation": "Palantir Technologies Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Costs",
        "documentation": "Patent Costs [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForManagementFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentForManagementFee",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for fee",
        "documentation": "Amount paid to managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP)."
       }
      }
     },
     "auth_ref": [
      "r1050",
      "r1176"
     ]
    },
    "CELU_PaymentOfOptionFeeInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PaymentOfOptionFeeInCash",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of option fee in cash",
        "documentation": "Payment Of Option Fee In Cash."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PaymentOfSepaCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PaymentOfSepaCommitmentFee",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of SEPA commitment fee",
        "documentation": "Payment of sepa commitment fee.",
        "label": "PaymentOfSepaCommitmentFee"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PaymentPlansForCustomerToPayOverTimePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PaymentPlansForCustomerToPayOverTimePeriod",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over time for a period",
        "documentation": "Payment plans for customer to pay over time period."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PaymentSubscriptionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PaymentSubscriptionPeriod",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment subscription period",
        "documentation": "Payment subscription period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement payment",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "CELU_PaymentsForMasterSubscriptionAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PaymentsForMasterSubscriptionAgreement",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for master subscription agreement",
        "documentation": "Payments for master subscription agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of PIPE and other issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax withholding on vesting of restricted stock units",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of acquired in-process research and development",
        "label": "Payments to Acquire in Process Research and Development",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails",
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Rebound asset acquisition",
        "label": "Cash payment",
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capital expenditures",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "CELU_PaymentsToRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PaymentsToRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount paid",
        "documentation": "Payments To Related Party."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "CELU_PercentageOfBaseSalary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PercentageOfBaseSalary",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of base salary",
        "documentation": "Percentage Of Base Salary."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PercentageOfBeneficialOwnershipLimitation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PercentageOfBeneficialOwnershipLimitation",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of beneficial ownership limitation",
        "documentation": "Percentage of beneficial ownership limitation."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PercentageOfCashFeeEqualToAggregateProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PercentageOfCashFeeEqualToAggregateProceeds",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of cash fee equal to aggregate proceeds",
        "documentation": "Percentage of cash fee equal to aggregate proceeds."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PercentageOfChangesInCashFlow": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PercentageOfChangesInCashFlow",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of changes in cash flow",
        "documentation": "Percentage of changes in cash flow."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PercentageOfConversionOnOutstandingCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PercentageOfConversionOnOutstandingCommonStock",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of conversion on outstanding common stock",
        "documentation": "Percentage of conversion on outstanding common stock."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PercentageOfCouponRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PercentageOfCouponRate",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Coupon rate",
        "documentation": "Percentage of coupon rate."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PercentageOfExercisePriceEqualToOfferingPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PercentageOfExercisePriceEqualToOfferingPrice",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of exercise price equal to offering price",
        "documentation": "Percentage of exercise price equal to pffering price."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PercentageOfPartialLiquidatingDamagesOnPurchasePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PercentageOfPartialLiquidatingDamagesOnPurchasePrice",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of partial liquidating damages on purchase price",
        "documentation": "Percentage Of Partial Liquidating Damages On Purchase Price."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of partial liquidating damages on subscription amount",
        "verboseLabel": "Percentage of partial liquidating damages",
        "documentation": "Percentage of partial liquidating damages on subscription amount."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PercentageOfSharesRequiredForVoting": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PercentageOfSharesRequiredForVoting",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of shares required for voting",
        "documentation": "Percentage of shares required for voting."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PercentageOfUnpaidBaseSalary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PercentageOfUnpaidBaseSalary",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of unpaid base salary",
        "documentation": "Percentage of unpaid base salary."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PlacementAgentWarrantIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PlacementAgentWarrantIssuance",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 2024 Placement Agent warrant issuance",
        "documentation": "November 2024 Placement Agent warrant issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails",
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails",
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_PledgingPurposeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PledgingPurposeAxis",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pledging Purpose [Axis]",
        "documentation": "Information by pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r875",
      "r887",
      "r1033"
     ]
    },
    "us-gaap_PledgingPurposeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PledgingPurposeDomain",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r875",
      "r887",
      "r1033"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "CELU_PrePaidAdvanceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PrePaidAdvanceAgreementMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Paid Advance Agreement [Member]",
        "documentation": "Pre Paid Advance Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PrePaidAdvanceIssuedDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PrePaidAdvanceIssuedDiscountPercentage",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-paid advance issued discount percentage",
        "documentation": "Pre paid advance issued discount percentage."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PrePaidAdvancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PrePaidAdvancePeriod",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-paid advance period",
        "documentation": "Pre paid advance period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r906",
      "r909",
      "r910",
      "r911",
      "r912",
      "r1223",
      "r1226"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://celularity.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r386"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://celularity.com/role/BalanceSheetsParenthetical",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r738"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://celularity.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r386"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://celularity.com/role/BalanceSheetsParenthetical",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r738",
      "r757",
      "r1226",
      "r1227"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized, none issued and outstanding as of December 31, 2024 and 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r656",
      "r886"
     ]
    },
    "CELU_PremiumPaidForPrivatePlacementPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PremiumPaidForPrivatePlacementPurchase",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Premium paid for private placement purchase",
        "documentation": "Premium Paid For Private Placement Purchase."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PrepaidClinicalExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PrepaidClinicalExpense",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid clinical expenses",
        "documentation": "Prepaid clinical expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "CELU_PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock",
     "presentation": [
      "http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets",
        "documentation": "Prepaid Expenses And Other Current Assets Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance expense",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r846",
      "r1077"
     ]
    },
    "CELU_PriorPaymentToRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PriorPaymentToRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior payment to related party",
        "documentation": "Prior payment to related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassifications",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ProceedsFromConvertibleNote": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ProceedsFromConvertibleNote",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from Sanuwave convertible note",
        "documentation": "Proceeds from convertible note.",
        "label": "ProceedsFromConvertibleNote"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from registered direct offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from sale of common stock",
        "verboseLabel": "Net proceeds from offerings of equity securities",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from PIPE financing",
        "verboseLabel": "Aggregate purchase price",
        "terseLabel": "Proceeds from PIPE financings",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from pre-paid advance",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r1055"
     ]
    },
    "CELU_ProceedsFromLinesOfCreditGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ProceedsFromLinesOfCreditGross",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from pre-paid advance gross",
        "documentation": "Proceeds from lines of credit gross."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ProceedsFromNotesAndPurchaserWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ProceedsFromNotesAndPurchaserWarrants",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from notes and purchaser warrants",
        "documentation": "Proceeds from notes and purchaser warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromOtherShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromOtherShortTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds",
        "label": "Proceeds from Other Short-Term Debt",
        "documentation": "Amount of cash inflow from short-term debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "CELU_ProceedsFromPrivatePlacements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ProceedsFromPrivatePlacements",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from private placements",
        "documentation": "Proceeds from private placements."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ProceedsFromShortTermDebtUnaffiliated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ProceedsFromShortTermDebtUnaffiliated",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of short-term debt - unaffiliated",
        "documentation": "Proceeds from short term debt unaffiliated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r15"
     ]
    },
    "CELU_ProceedsFromTheSaleOfCommonStockInAtmOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ProceedsFromTheSaleOfCommonStockInAtmOffering",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock in ATM offering",
        "documentation": "Proceeds from the sale of common stock in Atm offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "CELU_ProceedsFromWarrantsAndShortTermDebtRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ProceedsFromWarrantsAndShortTermDebtRelatedParties",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from warrants and short-term debt - related parties",
        "documentation": "Proceeds from warrants and short term debt related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r281",
      "r612",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r822",
      "r857",
      "r896",
      "r898",
      "r899",
      "r903",
      "r904",
      "r1104",
      "r1105",
      "r1112",
      "r1193",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "auth_ref": [
      "r281",
      "r612",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r822",
      "r857",
      "r896",
      "r898",
      "r899",
      "r903",
      "r904",
      "r1104",
      "r1105",
      "r1112",
      "r1193",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "CELU_PromissoryNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PromissoryNotesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes receivable",
        "documentation": "Promissory notes receivable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r588"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://celularity.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r152",
      "r155",
      "r156"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r167",
      "r664"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r588",
      "r650",
      "r664",
      "r886"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r152",
      "r155",
      "r662"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://celularity.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r588"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment expected useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for credit losses",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r293"
     ]
    },
    "CELU_ProvisionForInventoryObsolescence": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ProvisionForInventoryObsolescence",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for inventory obsolescence",
        "documentation": "Provision for Inventory Obsolescence."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ProvisionForObsoleteInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ProvisionForObsoleteInventory",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfInventoryReservesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for obsolete inventory",
        "documentation": "Provision for obsolete inventory."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PublicUtilitiesInventoryAxis",
     "presentation": [
      "http://celularity.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Axis]",
        "documentation": "Information by type of inventory held."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "presentation": [
      "http://celularity.com/role/InventoryDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "CELU_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Warrants [Member]",
        "documentation": "Public Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PultheraLLCBindingTermSheetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PultheraLLCBindingTermSheetMember",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pulthera LLC Binding Term Sheet [Member]",
        "documentation": "Pulthera LLC Binding Term Sheet [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PurchasePriceContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PurchasePriceContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price contingent consideration",
        "documentation": "Purchase price contingent consideration."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_PurchaserWarrantIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "PurchaserWarrantIssuance",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "November 2024 Purchaser warrant issuance",
        "documentation": "November 2024 Purchaser warrant issuance."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "CELU_RWIBridgeLoanNetOfDiscountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RWIBridgeLoanNetOfDiscountMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RWI Bridge Loan Net of Discount [Member]",
        "documentation": "RWI Bridge Loan Net of Discount [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r426",
      "r434",
      "r461",
      "r462",
      "r463",
      "r472",
      "r546",
      "r604",
      "r606",
      "r608",
      "r690",
      "r692",
      "r700",
      "r728",
      "r729",
      "r790",
      "r792",
      "r794",
      "r795",
      "r797",
      "r818",
      "r819",
      "r845",
      "r855",
      "r869",
      "r880",
      "r881",
      "r882",
      "r883",
      "r898",
      "r907",
      "r1100",
      "r1110",
      "r1160",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r426",
      "r434",
      "r461",
      "r462",
      "r463",
      "r472",
      "r546",
      "r604",
      "r606",
      "r608",
      "r690",
      "r692",
      "r700",
      "r728",
      "r729",
      "r790",
      "r792",
      "r794",
      "r795",
      "r797",
      "r818",
      "r819",
      "r845",
      "r855",
      "r869",
      "r880",
      "r881",
      "r882",
      "r883",
      "r898",
      "r907",
      "r1100",
      "r1110",
      "r1160",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186"
     ]
    },
    "CELU_ReacquiredRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ReacquiredRightsMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reacquired Rights [Member]",
        "documentation": "Reacquired Rights [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfConvertibleNoteReceivableMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible note receivable",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "documentation": "Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r1157",
      "r1158",
      "r1165",
      "r1168"
     ]
    },
    "CELU_ReceiveForMonth": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ReceiveForMonth",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receive for month",
        "documentation": "Receive For Month."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Recently Adopted Accounting Pronouncements [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reclassification of warrants from liability classified to equity classified",
        "negatedLabel": "Reclassification of warrants from liability classified to equity classified",
        "documentation": "Reclassification of warrants from liability classified to equity classified.",
        "label": "ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r942",
      "r953",
      "r967",
      "r993"
     ]
    },
    "CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption premium percentage if volume weighted average price is less than $0.75",
        "documentation": "Redemption premium percentage if volume weighted average price is less than stated price."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redemption premium percentage if volume weighted average price more than $0.75",
        "documentation": "Redemption premium percentage if volume weighted average price more than stated price."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ReducedExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ReducedExercisePrice",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduced exercise price",
        "documentation": "Reduced exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ReductionInLineOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ReductionInLineOfCredit",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction in line of credit",
        "documentation": "Reduction in line of credit."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ReductionOfResearchAndDevelopmentExpenseResultingFromGrant": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ReductionOfResearchAndDevelopmentExpenseResultingFromGrant",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant monies",
        "documentation": "Reduction of research and development expense resulting from grant."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification",
        "documentation": "Reduction of right of use assets and associated lease liability due to lease modification."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_RegeneronResearchCollaborationServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RegeneronResearchCollaborationServicesAgreementMember",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regeneron Research Collaboration Services Agreement [Member]",
        "documentation": "Regeneron Research Collaboration Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_RegeneronServicesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RegeneronServicesAgreementMember",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regeneron Services Agreement [Member]",
        "documentation": "Regeneron Services Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_RegisteredDirectWarrantIssuanceDuringJuly": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RegisteredDirectWarrantIssuanceDuringJuly",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2023 Registered Direct warrant issuance",
        "documentation": "Registered Direct Warrant Issuance During July."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_RegisteredDirectWarrantsIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RegisteredDirectWarrantsIssuance",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfReconciliationOfWarrantLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "April 2023 Registered Direct warrant issuance",
        "documentation": "Registered direct warrants issuance."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_RelatedPartyBaseSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RelatedPartyBaseSalary",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base salary",
        "documentation": "Related Party Base Salary."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_RelatedPartyCashBonus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RelatedPartyCashBonus",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One-time cash bonus",
        "documentation": "Related party cash bonus."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r433",
      "r593",
      "r594",
      "r654",
      "r661",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r756",
      "r758",
      "r789"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r593",
      "r594",
      "r595",
      "r596",
      "r654",
      "r661",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r756",
      "r758",
      "r789"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contribution made",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r593"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r593",
      "r594",
      "r1178"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r763",
      "r764",
      "r767"
     ]
    },
    "us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionTermsAndMannerOfSettlement",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party description",
        "documentation": "Description of the terms and manner of settlement of the related party transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r433",
      "r593",
      "r594",
      "r654",
      "r661",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r756",
      "r758",
      "r789",
      "r1178"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r590",
      "r591",
      "r592",
      "r594",
      "r597",
      "r710",
      "r711",
      "r712",
      "r765",
      "r766",
      "r767",
      "r786",
      "r788"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash payment",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payment",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_RepaymentsOfOtherDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfOtherDebt",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for debt",
        "documentation": "Amount of cash outflow for the payment of debt classified as other."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "CELU_RepaymentsOfShortTermDebtRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RepaymentsOfShortTermDebtRelatedParty",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of short-term debt - related parties",
        "documentation": "Repayments of short term debt related party.",
        "label": "RepaymentsOfShortTermDebtRelatedParty"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_RepaymentsOfShortTermDebtUnaffiliated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RepaymentsOfShortTermDebtUnaffiliated",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayments of short-term debt - unaffiliated",
        "documentation": "Repayments of short term debt unaffiliated.",
        "label": "RepaymentsOfShortTermDebtUnaffiliated"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "auth_ref": [
      "r212",
      "r213",
      "r362",
      "r388",
      "r596",
      "r607",
      "r651",
      "r828",
      "r829"
     ]
    },
    "CELU_RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Required monthly payment if daily volume weighted average price is below $0.75 for any five of seven trading days",
        "documentation": "Required monthly payment if daily volume weighted average price is below stated price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "CELU_OperatingIncomeCostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r820",
      "r839",
      "r1187"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Costs",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "CELU_ResortsWorldIncPteLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ResortsWorldIncPteLtdMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Resorts World Inc Pte Ltd [Member]",
        "documentation": "Resorts World Inc Pte Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r954",
      "r968",
      "r994"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r944",
      "r955",
      "r969",
      "r995"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r951",
      "r962",
      "r976",
      "r1002"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/LeasesDetailsNarrative",
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash",
        "verboseLabel": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r1040",
      "r1053"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails",
      "http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r117",
      "r659",
      "r697",
      "r699",
      "r708",
      "r739",
      "r886"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r215",
      "r216",
      "r217",
      "r219",
      "r224",
      "r226",
      "r228",
      "r289",
      "r290",
      "r327",
      "r506",
      "r507",
      "r514",
      "r515",
      "r516",
      "r518",
      "r522",
      "r523",
      "r531",
      "r533",
      "r534",
      "r536",
      "r538",
      "r573",
      "r575",
      "r694",
      "r696",
      "r713",
      "r1226"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total net revenues",
        "verboseLabel": "Total revenues",
        "terseLabel": "Net revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r240",
      "r249",
      "r250",
      "r271",
      "r277",
      "r281",
      "r283",
      "r285",
      "r421",
      "r422",
      "r612"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r821"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://celularity.com/role/RevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r424"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues",
        "label": "Revenues [Default Label]",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r193",
      "r208",
      "r240",
      "r249",
      "r250",
      "r271",
      "r277",
      "r281",
      "r283",
      "r285",
      "r288",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r563",
      "r649",
      "r839",
      "r1108"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_RobinLSmithMdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RobinLSmithMdMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Robin L Smith Md [Member]",
        "documentation": "Robin L Smith Md [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "CELU_RwiForbearanceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "RwiForbearanceAgreementMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RWI Forbearance Agreement [Member]",
        "documentation": "RWI Forbearance Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SaleOfBiomaterialProductsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SaleOfBiomaterialProductsAmount",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of biomaterial products amount",
        "documentation": "Sale of biomaterial products amount."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SaleOfStockConsiderationCashDueDiligenceFee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SaleOfStockConsiderationCashDueDiligenceFee",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash due diligence fee",
        "documentation": "Sale of stock consideration cash due diligence fee."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SaleOfStockConsiderationCommitmentFeeInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SaleOfStockConsiderationCommitmentFeeInShares",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitment fee in shares",
        "documentation": "Sale of stock consideration commitment fee in shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consideration shares of common stock",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SaleOfStockMaximumAverageDailyTradedAmountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SaleOfStockMaximumAverageDailyTradedAmountPercentage",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, maximum average daily traded amount (in percent)",
        "documentation": "Sale of stock maximum average daily traded amount percentage."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days",
        "documentation": "Sale of stock maximum average dailyTradedAmountThresholdConsecutiveTradingDays"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of stock, percentage based on volume weighted average price",
        "documentation": "Sale of stock percentage based on volume weighted average price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Average price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r1034"
     ]
    },
    "CELU_SanuwaveForbearanceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SanuwaveForbearanceAgreementMember",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sanuwave Forbearance Agreement [Member]",
        "documentation": "Sanuwave Forbearance Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://celularity.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses and Other Current Liabilities",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ScheduleOfActivityInInventoryReservesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ScheduleOfActivityInInventoryReservesTableTextBlock",
     "presentation": [
      "http://celularity.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory Reserves",
        "documentation": "Schedule Of Activity In Inventory Reserves [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Potentially Dilutive Securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentConsiderationObligationsMeasuredOnRecurringBasisDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfContingentStockConsiderationObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "documentation": "Disclosure of information about contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Current and Deferred Tax Provision",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "CELU_ScheduleOfConvertibleNoteValuationModelTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ScheduleOfConvertibleNoteValuationModelTableTextBlock",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Convertible Note Valuation Model",
        "documentation": "Schedule Of Convertible Note Valuation Model Table [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://celularity.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Debt",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred tax assets and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1146"
     ]
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan [Table]",
        "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r50",
      "r51",
      "r52",
      "r53"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of the U.S federal statutory income tax",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r873",
      "r1142"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "CELU_ScheduleOfEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ScheduleOfEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment Estimated Useful Life",
        "documentation": "Schedule of Estimated Useful Lives [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Assets and Liabilities Measures at Fair Value",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1157",
      "r1158"
     ]
    },
    "CELU_ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock",
     "presentation": [
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Significant Inputs for Warrants",
        "documentation": "Schedule Of Fair Value Significant Inputs For Warrants Issued [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r319",
      "r323",
      "r324",
      "r326",
      "r613",
      "r820",
      "r848"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r322",
      "r326",
      "r848"
     ]
    },
    "CELU_ScheduleOfIntangibleAssetsNetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ScheduleOfIntangibleAssetsNetTableTextBlock",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets, Net",
        "documentation": "Schedule Of Intangible Assets Net [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock",
     "presentation": [
      "http://celularity.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Major Classes of Inventories",
        "documentation": "Schedule Of Inventory Current And Noncurrent [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://celularity.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Prepaid Expenses and Other Current Assets",
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r588"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r763",
      "r764",
      "r767"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://celularity.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Financial Information by Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r38"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails",
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails",
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Activity Related to RSU Stock-Based Payment Awards",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14",
      "r120"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r113",
      "r115",
      "r116",
      "r117",
      "r175",
      "r176",
      "r177",
      "r242",
      "r386",
      "r387",
      "r388",
      "r390",
      "r393",
      "r398",
      "r400",
      "r704",
      "r705",
      "r706",
      "r707",
      "r855",
      "r1032",
      "r1054"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://celularity.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of the Warrants",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r872"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Aggregate Amortization Expense Related to Intangible Assets",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r1089"
     ]
    },
    "CELU_ScientificAndClinicalAdvisorAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ScientificAndClinicalAdvisorAgreementMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scientific and Clinical Advisor Agreement [Member]",
        "documentation": "Scientific and Clinical Advisor Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SecondLoanAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SecondLoanAgreement",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second loan agreement",
        "documentation": "Second loan agreement"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SecondTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SecondTrancheMember",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Tranche [Member]",
        "documentation": "Second Tranche [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SecuritiesPurchaseAgreementDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SecuritiesPurchaseAgreementDate",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities purchase agreement date",
        "documentation": "Securities Purchase Agreement Date."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Purchase Agreement [Member]",
        "documentation": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "CELU_SegmentContribution": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SegmentContribution",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment contribution",
        "documentation": "Segment contribution."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative",
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r240",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r285",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r326",
      "r337",
      "r338",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r836",
      "r839",
      "r840",
      "r847",
      "r901",
      "r1193",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "auth_ref": [
      "r283",
      "r284",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r725",
      "r726",
      "r727",
      "r791",
      "r793",
      "r796",
      "r798",
      "r805",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r823",
      "r858",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r900",
      "r907",
      "r1112",
      "r1193",
      "r1195",
      "r1196",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://celularity.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r240",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r260",
      "r262",
      "r263",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r285",
      "r834",
      "r837",
      "r838",
      "r839",
      "r841",
      "r843",
      "r844"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r280",
      "r283",
      "r835",
      "r836",
      "r842"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "CELU_OperatingIncomeCostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SequenceLifeScienceIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SequenceLifeScienceIncMember",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative",
      "http://celularity.com/role/ScheduleOfPurchasePriceAllocatedToAcquiredAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sequence LifeScience Inc [Member]",
        "documentation": "Sequence LifeScience Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ServiceAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ServiceAgreementTerm",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service agreement term",
        "documentation": "Service agreement term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServiceMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDisaggregatedRevenueByProductAndServicesDetails",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "CELU_SettlementAndReleaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SettlementAndReleaseAgreementMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement and Release Agreement [Member]",
        "documentation": "Settlement and Release Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Shares, Granted",
        "verboseLabel": "Number of shares granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Granted",
        "verboseLabel": "Grant date fair value of units granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Shares, Outstanding beginning balance",
        "periodEndLabel": "Number of Shares, Outstanding ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Grant Date Fair Value,Outstanding beginning balance",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Outstanding ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r451"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of Shares, Released",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value, Released",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails",
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails",
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares remaining available for future grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "CELU_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod]",
        "documentation": "Share based compensation arrangement by share based payment award number of shares issued for future issuance automatic increase period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, stock option exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options Forfeited/Expired",
        "label": "Remaining stock options forfeited upon termination of the advisory agreement",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails",
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Granted",
        "verboseLabel": "Options outstanding including awards",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant-date fair value of stock options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options beginning balance",
        "periodEndLabel": "Options ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, beginning balance",
        "periodEndLabel": "Weighted Average Exercise Price, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option vesting",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of modified warrant, incremental expense",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfActivityRelatedToRsuStock-basedPaymentAwardsDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Forfeited/Expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ShareIssuedPurchasedPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ShareIssuedPurchasedPrice",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share issued purchase price",
        "documentation": "Share Issued Purchased Price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price",
        "verboseLabel": "Common share price",
        "terseLabel": "Share price per share",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1114"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSUs one-time grant value",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option, expiration period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://celularity.com/role/ScheduleOfWeightedAverageGrantFairValueOfStockOptionsUsingBlack-scholesOption-pricingModelDetails",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Contract Term Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding",
        "documentation": "Number of non-vested options outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Contract Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Contract Term, Vested and expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested options to acquire shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested options to acquire per share",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of fair market value",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued pursuant to short-term debt maturity extension, shares",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase price of per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balances, shares",
        "periodEndLabel": "Balances, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax withholding on vesting of restricted stock units, shares",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term debt",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "verboseLabel": "Short-term debt - related parties",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r130",
      "r886",
      "r1190"
     ]
    },
    "CELU_ShortTermDebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ShortTermDebtPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt - Yorkville and Unsecured Senior Convertible Notes",
        "documentation": "Short Term Debt [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ShortTermDebtRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ShortTermDebtRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term debt - related parties",
        "documentation": "Short term debt related parties."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ShortTermDebtRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ShortTermDebtRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total debt - related parties",
        "documentation": "Short-term debt - related parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfDebtDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r1097",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails",
      "http://celularity.com/role/ScheduleOfDebtDetails",
      "http://celularity.com/role/ScheduleOfYorkvilleConvertiblePromissoryNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r1097",
      "r1098",
      "r1099"
     ]
    },
    "CELU_ShortTermDebtUnaffiliated": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ShortTermDebtUnaffiliated",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total debt - unaffiliated",
        "documentation": "Short term debt unaffiliated."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShorttermDebtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShorttermDebtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/BalanceSheetsParenthetical",
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term debt, fair value",
        "verboseLabel": "Short-term debt - Yorkville",
        "documentation": "This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r1157"
     ]
    },
    "CELU_ShorttermDebtUnsecuredSeniorConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ShorttermDebtUnsecuredSeniorConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term debt - unsecured senior convertible notes",
        "verboseLabel": "Fair value of debt",
        "documentation": "Short-term debt unsecured senior convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r205"
     ]
    },
    "CELU_SoftwareCeaseUseCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SoftwareCeaseUseCostsMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Cease Use Costs [Member]",
        "documentation": "Software Cease Use Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "CELU_SponsorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SponsorWarrantsMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor Warrants [Member]",
        "documentation": "Sponsor Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_SponsorsWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "SponsorsWarrantsMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsors Warrants [Member]",
        "documentation": "Sponsors Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_StandbyEquityPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StandbyEquityPurchaseAgreementMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Purchase Agreement [Member]",
        "documentation": "Equity Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_StarrForbearanceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StarrForbearanceAgreementMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Starr Forbearance Agreement [Member]",
        "documentation": "Starr Forbearance Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://celularity.com/role/GoodwillAndIntangibleAssetsNetDetailsNarrative",
      "http://celularity.com/role/ScheduleOfFinancialInformationBySegmentDetails",
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r161",
      "r240",
      "r245",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r261",
      "r262",
      "r263",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r285",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r326",
      "r329",
      "r337",
      "r338",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r836",
      "r839",
      "r840",
      "r847",
      "r901",
      "r1193",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/Cover",
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r175",
      "r176",
      "r177",
      "r208",
      "r231",
      "r232",
      "r234",
      "r236",
      "r242",
      "r243",
      "r288",
      "r349",
      "r351",
      "r352",
      "r353",
      "r356",
      "r357",
      "r386",
      "r387",
      "r390",
      "r393",
      "r400",
      "r563",
      "r704",
      "r705",
      "r706",
      "r707",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r738",
      "r760",
      "r782",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r1032",
      "r1054",
      "r1065"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/StatementsOfStockholdersEquity",
      "http://celularity.com/role/SummaryOfWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r82",
      "r85",
      "r86",
      "r160",
      "r190",
      "r191",
      "r192",
      "r215",
      "r216",
      "r217",
      "r219",
      "r224",
      "r226",
      "r228",
      "r241",
      "r289",
      "r290",
      "r327",
      "r402",
      "r506",
      "r507",
      "r514",
      "r515",
      "r516",
      "r518",
      "r522",
      "r523",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r538",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r573",
      "r575",
      "r589",
      "r667",
      "r694",
      "r695",
      "r696",
      "r713",
      "r782"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r725",
      "r726",
      "r727",
      "r791",
      "r793",
      "r796",
      "r798",
      "r805",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r823",
      "r858",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r900",
      "r907",
      "r1112",
      "r1193",
      "r1195",
      "r1196",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://celularity.com/role/Cover",
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r241",
      "r575",
      "r612",
      "r702",
      "r724",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r738",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r747",
      "r748",
      "r749",
      "r750",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r758",
      "r761",
      "r762",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r782",
      "r908"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://celularity.com/role/Cover",
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative",
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss",
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r241",
      "r286",
      "r575",
      "r612",
      "r702",
      "r724",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r738",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r747",
      "r748",
      "r749",
      "r750",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r758",
      "r761",
      "r762",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r782",
      "r908"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r946",
      "r957",
      "r971",
      "r997"
     ]
    },
    "CELU_StockIssuedDuringPeriodSharesATMAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesATMAgreement",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under ATM Agreement, shares",
        "documentation": "Stock issued during period shares for ATM agreement."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock to Palantir as consideration for settlement agreement, shares",
        "documentation": "Stock issued during period shares for consideration for settlement agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued pursuant to short-term debt conversion, shares",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r46",
      "r82",
      "r85",
      "r117",
      "r375"
     ]
    },
    "CELU_StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock to Yorkville for debt extension and SEPA commitment fee, shares",
        "documentation": "Stock issued during period shares for debt extension and commitment fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants in PIPE Offering, net of offering expenses, shares",
        "verboseLabel": "Purchase and sale of shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r81",
      "r82",
      "r117",
      "r704",
      "r782",
      "r800"
     ]
    },
    "CELU_StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in Registered Direct Offering, net of offering expenses, shares",
        "documentation": "Stock issued during period shares of common stock in registered direct offering net of offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_StockIssuedDuringPeriodSharesOfResearchAndDevelopment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesOfResearchAndDevelopment",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for stem-cells to be used in research and development, shares",
        "documentation": "Stock issued during period shares of research and development."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in PIPE Offering, net of offering expenses, shares",
        "documentation": "Stock issued during period shares PIPE offering net of offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting of restricted stock units, shares",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r81",
      "r82",
      "r117"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock as compensation expense, shares",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r81",
      "r82",
      "r117"
     ]
    },
    "CELU_StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued pursuant to short-term debt maturity extension, shares",
        "documentation": "Stock issued during period shares short term debt maturity extension."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails",
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options, shares",
        "negatedLabel": "Options Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r81",
      "r82",
      "r117",
      "r447"
     ]
    },
    "CELU_StockIssuedDuringPeriodValueATMAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodValueATMAgreement",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under ATM Agreement",
        "documentation": "Stock issued during period value for ATM agreement."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_StockIssuedDuringPeriodValueConsiderationForSettlementAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodValueConsiderationForSettlementAgreement",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock to Palantir as consideration for settlement agreement",
        "documentation": "Stock issued during period value for consideration for settlement agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued pursuant to short-term debt conversion",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r82",
      "r85",
      "r86",
      "r117"
     ]
    },
    "CELU_StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock to Yorkville for debt extension and SEPA commitment fee",
        "documentation": "Stock issued during period value for debt extension and commitment fee."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock and warrants in PIPE Offering, net of offering expenses",
        "verboseLabel": "Issuance of common stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r81",
      "r82",
      "r117",
      "r713",
      "r782",
      "r800",
      "r914"
     ]
    },
    "CELU_StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in Registered Direct Offering, net of offering expenses",
        "documentation": "Stock issued during period value of common stock in registered direct offering net of offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_StockIssuedDuringPeriodValueOfResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodValueOfResearchAndDevelopment",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for stem-cells to be used in research and development",
        "documentation": "Stock issued during period value of research and development."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock in PIPE Offering, net of offering expenses",
        "documentation": "Stock issued during period value PIPE offering net of offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting of restricted stock units",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r117"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock as compensation expense",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r81",
      "r82",
      "r117"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r82",
      "r85",
      "r86",
      "r117"
     ]
    },
    "CELU_StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued pursuant to short-term debt maturity extension",
        "documentation": "Stock issued during period value short term debt maturity extension."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Retirement of shares in connection with reverse stock split, shares",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r81",
      "r82",
      "r117"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Retirement of shares in connection with reverse stock split",
        "label": "Stock Repurchased and Retired During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r81",
      "r82",
      "r117"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/StatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balances",
        "periodEndLabel": "Balances",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r85",
      "r86",
      "r106",
      "r740",
      "r757",
      "r783",
      "r784",
      "r886",
      "r915",
      "r1056",
      "r1076",
      "r1169",
      "r1226"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://celularity.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://celularity.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r207",
      "r385",
      "r387",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r399",
      "r402",
      "r537",
      "r785",
      "r787",
      "r804"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split ratio",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://celularity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r599"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celularity.com/role/SubsequentEventsDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r599"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://celularity.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r599"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celularity.com/role/SubsequentEventsDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r599"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/NatureOfBusinessDetailsNarrative",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative",
      "http://celularity.com/role/SubsequentEventsDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r599"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://celularity.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r600"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://celularity.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r990"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "CELU_TaxCreditCarryforwardsExpirationYear": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "TaxCreditCarryforwardsExpirationYear",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforwards expiration year",
        "documentation": "Tax credit carryforwards expiration year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tenant Improvements",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1189"
     ]
    },
    "CELU_ThreeCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ThreeCustomersMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Customers [Member]",
        "documentation": "Three Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1177"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r989"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r1073",
      "r1074",
      "r1075"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfIntangibleAssetsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_TrancheOneWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "TrancheOneWarrantMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche One Warrant [Member]",
        "documentation": "Tranche One Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_TrancheTwoWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "TrancheTwoWarrantMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tranche Two Warrant [Member]",
        "documentation": "Tranche Two Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "CELU_TwoCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "TwoCustomersMember",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Customers [Member]",
        "documentation": "Two Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_TwoThousandAndSeventeenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "TwoThousandAndSeventeenEquityIncentivePlanMember",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 Equity Incentive Plan [Member]",
        "documentation": "2017 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 and 2017 Equity Incentive Plan [Member]",
        "documentation": "2021 and 2017 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_TwoThousandAndTwentyOneEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "TwoThousandAndTwentyOneEquityIncentivePlanMember",
     "presentation": [
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Equity Incentive Plan [Member]",
        "documentation": "2021 Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_TwoThousandSeventeenPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "TwoThousandSeventeenPlanMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 Plan [Member]",
        "documentation": "2017 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_TwoThousandTwentyFourWarrantRepricingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "TwoThousandTwentyFourWarrantRepricingMember",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024 Warrant Repricing [Member]",
        "documentation": "2024 Warrant Repricing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_TwoThousandTwentyOnePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "TwoThousandTwentyOnePlanMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfStockOptionActivityDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Plan [Member]",
        "documentation": "2021 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/LicenseAndDistributionAgreementsDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "CELU_UnearnedRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "UnearnedRevenue",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfChangesInDeferredRevenueFromContractLiabilitiesDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:UnearnedRevenue-0]",
        "documentation": "Unearned revenue."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_UnitedStatesFederalAndStateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "UnitedStatesFederalAndStateMember",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States Federal and State [Member]",
        "documentation": "United States Federal and State [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_UnpaidBaseSalary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "UnpaidBaseSalary",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unpaid base salary",
        "documentation": "Unpaid base salary."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance beginning",
        "periodEndLabel": "Balance ending",
        "label": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r493",
      "r872"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease related to current year tax provisions",
        "label": "Decrease related to current year tax provisions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r872"
     ]
    },
    "CELU_UnsecuredSeniorConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "UnsecuredSeniorConvertibleNoteMember",
     "presentation": [
      "http://celularity.com/role/ScheduleOfDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Senior Convertible Note [Member]",
        "documentation": "Unsecured Senior Convertible Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_UnsecuredSeniorConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "UnsecuredSeniorConvertibleNotesMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables",
      "http://celularity.com/role/ScheduleOfConvertibleNotesValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unsecured Senior Convertible Notes [Member]",
        "documentation": "Unsecured Senior Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_UpfrontFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "UpfrontFee",
     "crdr": "debit",
     "presentation": [
      "http://celularity.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront fee",
        "documentation": "Upfront fee."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_UpfrontPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "UpfrontPayment",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/AssetAcquisitionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront payment",
        "documentation": "Upfront payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r149",
      "r150",
      "r153",
      "r154"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance increased amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r497"
     ]
    },
    "CELU_ValuationInputForConvertiblePromissoryNote": {
     "xbrltype": "percentItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ValuationInputForConvertiblePromissoryNote",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "Valuation input for a convertible promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_ValuationInputForConvertiblePromissoryNoteTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "ValuationInputForConvertiblePromissoryNoteTerm",
     "presentation": [
      "http://celularity.com/role/ScheduleOfConvertibleNoteValuationModelDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term (years)",
        "documentation": "Valuation input for a convertible promissory note term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://celularity.com/role/ScheduleOfLeaseCostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://celularity.com/role/ScheduleOfLeaseCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable lease cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r885"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://celularity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139"
     ]
    },
    "CELU_WarrantExpirationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantExpirationTerm",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant term",
        "documentation": "Warrant expiration term"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://celularity.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://celularity.com/role/BalanceSheets",
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities",
        "documentation": "Warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantLiabilityPlacementAgentWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantLiabilityPlacementAgentWarrants",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability - November 2024 Placement Agent Warrants",
        "documentation": "Warrant liability placement agent warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantLiabilityPrivateInvestmentInPublicEquityWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantLiabilityPrivateInvestmentInPublicEquityWarrants",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability - May 2022 PIPE Warrants",
        "documentation": "Warrant liability private investment in public equity warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantLiabilityPublicWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantLiabilityPublicWarrants",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability - Public Warrants",
        "documentation": "Warrant liability public warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantLiabilityPurchaserWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantLiabilityPurchaserWarrants",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability - November 2024 Purchaser Warrants",
        "documentation": "Warrant liability purchaser warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantLiabilityRegisteredDirectWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantLiabilityRegisteredDirectWarrants",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability - April 2023 Registered Direct Warrants",
        "documentation": "Warrant liability registered direct warrants."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantLiabilityRegisteredDirectWarrantsTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantLiabilityRegisteredDirectWarrantsTwo",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability - July 2023 Registered Direct Warrants",
        "documentation": "Warrant liability registered direct warrants two."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantLiabilitySponsorWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantLiabilitySponsorWarrants",
     "crdr": "credit",
     "presentation": [
      "http://celularity.com/role/ScheduleOfFinancialAssetsAndLiabilitiesMeasuresAtFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability - Sponsor Warrants",
        "documentation": "Warrant liability sponsor warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/ScheduleOfPotentiallyDilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r906",
      "r909",
      "r910",
      "r911",
      "r912"
     ]
    },
    "CELU_WarrantsAndRightsIssuedClosingDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantsAndRightsIssuedClosingDate",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights issued closing date",
        "documentation": "Warrants and rights issued closing date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/SummaryOfWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration date",
        "verboseLabel": "Warrants and rights outstanding, expire date",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant and right outstanding measurement input",
        "verboseLabel": "Warrants measurement input",
        "terseLabel": "Warrant measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails",
      "http://celularity.com/role/ScheduleOfMay2022PipeWarrantsAnd2023RegisteredDirectWarrantsDetails",
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails",
      "http://celularity.com/role/ScheduleOfSignificantInputsForSponsorWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Term (years)",
        "label": "Warrant term (years)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "CELU_WarrantsAndRightsOutstandingTermToInitialExerciseDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantsAndRightsOutstandingTermToInitialExerciseDate",
     "presentation": [
      "http://celularity.com/role/ScheduleOfJanuary20224BridgeLoanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term to initial exercise date (years)",
        "documentation": "Warrants and rights outstanding term to initial exercise date."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantsAndRightsOutstandingTermToSubsequentFinancing": {
     "xbrltype": "durationItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantsAndRightsOutstandingTermToSubsequentFinancing",
     "presentation": [
      "http://celularity.com/role/ScheduleOfNovember2024PurchaserAndPlacementAgentWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term to Subsequent Financing (years)",
        "documentation": "Warrants and rights outstanding term to subsequent financing."
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants, each exercisable for one share of Class A common stock at an exercise price of $115 per share",
        "documentation": "Warrants, each exercisable for one share of Class A common stock at an exercise price of $115 per share"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantsLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantsLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://celularity.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liabilities",
        "documentation": "Warrants Liabilities [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "CELU_WarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "WarrantsOutstanding",
     "presentation": [
      "http://celularity.com/role/SummaryOfWarrantsDetailsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding",
        "documentation": "Warrants Outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r236"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://celularity.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r236"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://celularity.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "CELU_YorkvilleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://celularity.com/20241231",
     "localname": "YorkvilleMember",
     "presentation": [
      "http://celularity.com/role/DebtDetailsNarrative",
      "http://celularity.com/role/EquityDetailsNarrative",
      "http://celularity.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetailsNarrative",
      "http://celularity.com/role/ScheduleOfDebtDetails",
      "http://celularity.com/role/ScheduleOfReconciliationOfShort-termDebtObligationMeasuredOnRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Yorkville [Member]",
        "documentation": "Yorkville [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715-20/tableOfContent"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "715",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477317/912-715-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 6-K",
   "Section": "General Instruction",
   "Subsection": "B"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "Instruction",
   "Paragraph": "2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 8-K",
   "Section": "1.05",
   "Subsection": "a"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>131
<FILENAME>0001641172-25-009319-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-009319-xbrl.zip
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M!RG+IP=\M^B^T\0;6,:&#*(]-$BD*LTV$ L!-IP>+0$C@\B.C!PI2\X*TD*
M#8>)113)(,C3A9-4[,Z>E2S$V_"[] LM&21M%6-2%F+I;POY-!PQ4'WH=<O
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M'Y[1FN&(4%9_ J[*DRVP"XS=H[V8U^9KFG 4!?-G40@?A/FT$P,)4E)SF:V
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MQHTXPSX57& 0UC <P'M%.'N\"*9S^+O*F V@"PR)SEZ@Z&OCM%GSW05RK]7
MEB>4UX1#V%WM=*(%P D&V",5U,1_18PP4C]9T9:Y0/8,+N?*UY*Z;B-: +K
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M3KBE\D-<[:&HL=35X:"Y#"'?R(!=&.'RTK-\[(MRKM[.J)_>'U[?"7%6P@Z
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M(3%?JIUO,Y3^P+HN'/S9DSY?BSW;FH8!Y&K!?@+A9% NYZ(][]\7W0@/G-S
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M?"M<^73$LA[0#2+]CLE^/N?^&F^0^/E?4$L#!!0    ( )*+J%HCA\TIH20
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MBO7<6!8^ EUY%]0FQ'^J(E[X>D2<TELBV8N+V?60\YCRUSTJ13D%=,^JZ*:
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M6\BG<P[S.<F$AV^F9LI?W"!FD1C']LM7BA<KQ-]R4A"N](13:(+X+TX"S^$
M)Z?KCNS0Y@51?MDE"[4H$W=^3W;&]T* H)6.;38+)_A+'M)1(>E\)D=,94[$
MG5@Q=WD2?XTB%IG[37Q1>KC]^.)\5YI]*CX5,A'7P3:.0G[M<LO<)$+;]>1'
MI7M;3'(DL)TEH4X*?6K5@)X& Q( /]9<4=US86/9@5OW'X2>^ZYX!&M9>(=
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MR1%I 4UEU-K8]-]@6"H:&8J'[Q1,5EZU%Q < <)T4)D3(U_<A4\,6:7LV38
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MY25)3&NP9WR7KX84^\,Y^SN.2@CQ]RD9&FM17;-#/I$]BL.!]H1I.DL$$^H
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M(KE%*>S+7@M*I7M/4%3G!53A&J((O (ZI@R%28+)ZA:G*-G2P\&#=0#;NPZ
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M9V4C%A!15EO8_.8 Y<O U]V>+UT* 9Q63EJYM$-/M,=R=V8<QA*(LYO&,$-
MBP;K*])2GD"H*S8S>X55S[QD?AGAYRW7._54OZC74V4C#<JAWANA/4<V0?[/
M,_STWE\%!?5G*PIG4D1WK^["Y,>-%WNSXHB.@_N4'MUHMCH/$U9^,R.(R]C)
M!\K,M@WCK#KL@(T[V X\\&+&;C'TH#IVFYS>T,^1T(MV2+N*?:J?Q*F,P8_[
M#*Y'V^-T/5X+7/'FWBW+3D>CZ6F6T/66[$^[;]^^_7+R:9_THA.;9-MN[9%X
MGRT6'EF-IO?A+,Y/=#JS?!]G["&GV9A.?[^2C%$E_/,^X>50>;GA[6"#[6B#
M[7#M,92_E#[TBSBTRKY=)?W+/NEYI\%.K_8HK*33;ERXQ?ON=$FOM2= Z%_W
M*6>##?+1F-PWXQ4<)?E2WAFR/;:NXB>ZLC#9+U:=T_WK/MV5UNV1-"9H2177
MS9OO<5E!+2/,Q5V(B$?MMWUJRX$&ZY%RN>9C#<K!!NO1VN2&/<67KM@[]'2B
MYHF>MRCE,/#AESH#1=^<\$WO_S'(^[='\F\8!\]A%%&2K^+4BV<L6:F0%$#Y
MR3[EZR%RRK>#E/)NG0.Z>Q&J! %32+Q:/]3.W7(TT3SJ:+567XBMDEP[28N&
M[1%RC;R$+[W:R;ANVAXQ6Z]2DON8\F,+Q< 1^*%V!%;ZY]#NC= >X=QG G(:
M:V?=NFF+.@6[/+Q[A&Y05>IJYUG1-[]<#'8[MT?O':)G$4NFJ^4+5$FM'6%E
MM\%.OQ872NCG;[;& :6B"-AB5\6UH8X[06L'63E(/CFKPPRJX[3'0_F$Y#CR
M>"+^6#NVRO:#HD.;NLOF=5(>7;5#J6@_*#NTN)**FN97\123!;2(/M:.F;+;
M8*=?F^LGSSP;>U3!>" >7;%^G@W"H[5VOI2=!WGOP6[W-J\]CPGZ,V/5X)^
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M.%%Z2U1N,]NA3 BCO*.M-XT:P:7(#KB[6GR1I5+(7*[[ ,U?J;XC% X'16=
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MV](V>=GK8M!E;6N)7T;2K7?GCY(8'"IC4Y(GK9JWV\QRO5RA;+&(</?.GB8
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M"PA7Q31B*Y&&U0V*?;H%Y7;NT73/)K>=C)SM*=^/!)DUOXHR:W8_S'Y3^?2
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M<Q1D$>7RFCTV>H:3-#E'*65CRU^8LD&^??OVRZ^?!N\&[ "(<)(11/^Q[C_
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MPZ\LNO> 4U\OO-<:8,?P7D?5@&-XKR)XCNH$8SH,(@0%2B<2K[73090RND%
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M\'2U;3+VBIH+SQX)Z"2*;W 03D,_[W(5^R3OX$75D<YP(E#[N_BZV_.E<T&
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MFAH*LE&;.41.NW4KX@Q'F!*R'@7N+7[%/MDR!O-CMT(\E*SS@K=Z6"HQ57;
MA=+<]3CVZ7"KKSB@9J5/Z1^Y&XHPM4@1*TZ:LR"=;K6&,>4 :"+9^HR!=P[&
M9)P?T[#+/\7E/ C"Y97Z+[Z8D6HW)DX-#!3BP3KVP? ]+[ECY F%F2[S?"^?
M3GPOE3=9!_Z6PL\R*,>[OLVZOLVZOLVZOLW*-?":^09DT[JS_37S34\@M]DG
MT9O,-Z-*0ICB2LZA/],S3)VT+$K#]"$[CC(CNM<M)5&5663.$Y5\&%.I0NO*
M2I$3,-['G.^AL,3'/HJB_(98?#P0=+G8LX(4)HN"UJLDRG8R7ELS!P@YPD1*
MN7TGBO-D8?/)XGQY67O!L=F0("5W)+_A.&YKZ&PAF W']QH\BJU;PYZ3EPC_
MG3 '/MM8Y>E$P Z7NR6)(;+II<@II=(,#W 70]N3!&VI;.S=HW2*Q^H=2X\(
M+=VVCNB57A;RFAN+"I9.%Z%L5"[^]"Y^41A79$)_VLN#_K"8L84=V*_HWRM_
MOKS=Z9 _4!Z=BP.<$ 7!18..]Q<N7H1/6D=[AT8XK=P/U"'O<JV7H/X-O7F;
M9"/"_:#)XE/':SF@K$1 'H3L)[UVAPQ9"HD,V6J3Q6?KD#TA#T+VLS&+[IH6
M4L0GZ!BV]AF=]0G]KFDA+3 M>Z]%5AY@#&N:I19P&82XKSDGLX+!+HNAH<CG
M#A-"2I@'+Y8;!TH#5\M9.OF_O'@]Q>&2A!L4.'A, C=%&@Y[9IV5^BZ&MA:<
MU"#,FBB 4C5W!=U*.M?WES]_%0  3P2ZY_ W%/[ <:ER)4'"R2ONM'C_\7)%
MJ,H^*,"/QJ8KRW/C!2NQ&7?0Z&*-. X4%F5"R:F3G9J/FIDQFGA(<K&VU]9I
M K?-UD5-D70:./K \$'^G$Y?.L6%FPROZ6)H:&OA*S%1H18\N'ULZM(#L'W&
M5%-<%6@Y+1?#KIVCJLB"Q(+ FO.5 KM5NAUE#$P"Z?/>&H,LWO,FJ&FI->4#
MW!I^MTV@\B=,AR421Z_(\]EYY)Z$:?*I,WQA#;^X^-U6PZKSS&%*2$'*J'E#
MU,3$0Q0EV*4<W"<LX1G[D;D21DE,911[SD/@A)@. 69P3%=:$[1<D%X:QA#<
M#WNW>%*NV#,,M*(&X"2)HQA14SM8I89V?AG=P@*J\-4+4M;.T )W]=[5IYXF
MH;-FDR[T',IU%I&=,IR#(5'*5KYYH2K9(E:@K=L[A;Q[VWIAVE@I,[..3US5
M30(-I%W]RYJ?_BLW]#(.ARWLNIRO7*B.:46G?W%'$(ME#N81/>1NLM3-+",0
MNQ^[]5X]%P?N#,5M9.96_?15(1M"9MW52F.^K:G^U+ 2T56#=0 (Z?,G4_K<
M47:ZB].>.GQ#0O_<UT7L[HV:0UZ$2^V?DQCY#T$<>D'D.2VO7"I?OSR%ZPXU
M2%V_& _O%.68+"NE9B%Q*7?5O[,\DT\D_A>.]QDH*_&/Y]9V./?SEZ>P'<(&
M.J[-1R3K9CZ;N_<DS'_%V@FLZF[IN"JQ#OQ ;39[#]/$PW50(._P@JH%5Z/@
M:Y>GF>VA!.I?_RY<#G@]U]ANGX"KEIX%'*BX_:N4?,#^*' +#]F<L%]5KDNS
M"=R>L:5*P86J;F?(@;K;OVL?D8?W3^+387POWAGPR!]^_*JQC4$#E?4R+H]F
M7O3C/L3X(8@Q/17%':HJ[]-716T(&:BF9F^/FAR'1#-TCL.-[&*]E6]>J&*V
MB!6HD<;N?\X]Y51J)+=8WAW^V(7J8!L@@<IGV3U47?WY3U$!B12-7<\T7C2K
ML4DS9N%'^YC@%O8ST><N5(?:@0D,R+8WVQ"$8E&T(8K#A/TRFL1K',[7*.!&
M>;2PM=6DX$(5M3/D0-WMWR.7FOR;B#733>)5^UN&%IP>QNY^BAO8&QQ0,<<1
M*[E3\]BH/,3EJ5=-UD'Q5VY0.JZ>6B9RN?4BM%J%>,6B[F:LZE*";W;3D+B)
M$Z>%F-(K^BBOA%HR4ZFG^OFDGFH^^H L!P?C#_(/#%YV@_P3 Q2X@^(C9<%5
M0V56*\1Z657=E-P3=3B=#/*>9N8Y0)>DZJFXES6%3%7%=31[53#A1SVU77E4
MDE@YGS*3,)\O<$9\?DMC>:.4$"<2ZD'!&!!!5%T9H01%>TYXS;M/BR^$]01]
MF$73^?)UR<#*9%$:Y&1I.MF<7EF:G8-F75?_4E)_(J:WFW6JCBF<L2'-;U1M
MMNCZR-X ^5."M;LA@.PPC_2S081G9(?\>$?I3:U$86XO49?.RP35 5N)> CX
M#P:3X*9'C'O*\YBNO2%R8I;/=YQ$,=G@\.[-\1,6+32*(DS_<>?H#9X:#09;
M?#%C\S8\$S?E$!+\._.6[7C-S/SH(;C%2QR&I75;Y?'10R\L"L<3&KA?1 9N
M_IF!%PR*#Y5F+I/.H/C6H/*QBJ&[Q\DZ+*8HI&>4-8X]!_FGP S?O3L&1B<R
M@W\<?+]5I/(%CJYLE)TX]%Z2=)+2>90EL\UI>D(ARRSQBGE@#(_!R =-/1S5
M80?[<4MN!^70AEP?9?E9!6<'KZWA:ML2A\9Q.VM<&##L4,%L"]P4-03$DG=/
MEA67JSC--=#<7,)K/NI$A6CK[(!J=FZZTCV1 .U_PU)_1G0M]D05(O*1:@]D
M)@>V6"[D/);LNZTW)5XKW2CMJT"G^;EG>(4#'))@AB-,/[0>$Y\*CF1YK@H#
MKCQ7""W11F,9*L/>=%H2#>SJ7K]EHFTH18@#_;.R<XF)6 .EHUD\4[K\K'&(
M'A_'-U[ZOH@%'C^O,1;+1]K/5&UH#0)2XTV[3TCLC"N5A/DM;CQ"6_NK$"WC
MA\!1\<S)^W=>IU2?Q.KQ"$GNLSD7=G$.S^)S6(@%"5(\A.:$I)O=9H42SQ;E
M[STB4U:W!6ANQE10PYJH,&"?8:!#,#8?\K4)S]*+TTK"9)GI=M)T8:A2HWAR
M$ 6B(3G\86R!HYLDV>"]QXY]A&$HW(*$G>S>@!3XM2A;-T"M;+63=#.S':D@
MKR0K>S>E-L1E\R:E6:26;E6%CX5=I.%7[)-MNB]G:3L5"M#*.B\^F=G.U*;7
M23E9)78@*7[27(>.VHWTSTG@LB7_^Y;R&,1YT#M@&0MZ4/TS%-,OO3!3HAP"
M77<9J3R"K["[F9\$ )O7U'*489([\IT>NS6>2$Q_(RRF)>IB.=QRTJWS"1R%
MFY3_*?(U"A)L2+M:+*UZ+%AWE,X)%5@U10O[97!(*>B3MF2"*$\'^X'G$@P:
M]9HO;;*M?K+,'FW>LS1&8Q2MH;L:H+G%(,O)AJ VEZ6).7BR HJW25@6SDF?
MR3[AG^E?A+Y\A>X62ZP^&Z!A8)D$LRRWS45XU+^W,N3R =ZEZ5WQRB4 +BW"
MVATWLQAKF%P(TJ:I>@!(F5N:%7= ?G[PGI-;2C#RRZ<3Q4%<:'#4'<9RD31C
M![0'-=O;ZM3-<(!_(E]@D#<:ZV*D=\(3*,)V;'KI4G;2SG+H 7I!6#5[__:?
MC_)SHXJ;Y*1Y;T#FD0UBW=32EF(M]J^>M.L-NDJ^U,9)M@%81ZZ;HE N7I00
M %E>4\O!A4D&\:U8S=T^LLOSWDQ]%*B\C'I__#(J[S]@ W"?0'7S*"X)V?NR
M]'XF\U7,T1O="%\]=N,'O@<<OOM=^!XP&S5[]54\>Z,##\J1NW[\QQR.@>/Y
M7OXD]/NOT3VF&H1\IID)G7Z[['Z+4BG@^H.(Z\-OL-_$:SSX_NOS8)E]:A 5
MWQIXZ<<&,<6D8R0J<F8/6=-P2I4GH,-W?PAS'!5B9BRA=.!4_+ZY!Y_?@[!T
M,U-NBT15 @X_BCBL#I<J<S%@-WR5ZEG*2+C>?#IF)>L_2 >PY\GEW7*)'?;]
MDCV69/UP)IUL&9QXO7K#&(I!5"!2\H:SQA#6/.]L).+C4,6ZT%G_*+1D9)3$
M:\*FNDH,W6E[8^%S]47""^V! +#HR>@IH6H!6KP>)D/I0*AE<K$]@$Z':.P/
MFSM3?)T^U?Q.46/55.F"4!RS68X=]K/P&9*TGZ$GF-(Y06KR8-TB-Z$+/V)Y
MV1])%(WIH7"W)&%:<Q2>2W ?4Z_$=!PU)%Q!DM,\@V J[MZV7O9N]U\801-)
MM7LO!56;0>MF&^5W3&UE+ZY2/MJ0A.LFS7L).O52C(IL@:<.O1..2X;:9%/I
MVDL)U6(./%N8FF0LG"1[7^#[Y"<*''SL^LJ2<ST$LIE7=Z1>"OL<7B'9&PLI
M!%Q_L(B!#GV6I(@E2&#&JFP"Q);L3W& ?.9$IF?IHASCR''"! LJYYPQZ 4*
M7IEM2#D^FKIJV[OT[[V +DD>\A\"NA5M4CAN=L^9 2UP[ O+,Y2##BJCLO(,
M^;BF*S+D9,SPEH3LR%NA\D05>"F-57H;"J8L!2N@LI2O++]AD\&L\9+7$?)Q
M*&9S%*UWDY=Q S=)1&&(HIP+U:0G_&[FWIR?(2H@,XH(&(M,WF*-EOAGCYH9
MSH0BQ/8X$3N'/YM\Y4T$8+-7_&PA=>H1'V/?G[-\8=N=T -^TLZ0QYNOSD1"
MJ.Y5!P#SQB,O*/A!5TTAEL?-3*4#E&+))13$4C.8MUFFP30(A!Z1,1(D*6 =
MP/:=E\M0A5=,,;A27\LVF!%DDR-PBZ4;NLYS%<5EP0I8J@?->BBO4_JM.[#>
M>B%VXO*>B5$LK'UXVKJ'<@'9Z.@6)B<]G<-YI0A@&^*T[!/>(A:LNTE)*QU]
M3?=0%LLP<C<4TBC.=E3XA5)QH:[0NT^BJ\N6[LL18.H\!&XZ>?-/\]8JUNZX
M69^0!^FW[CHC\[6SV(3B2.(%">4R7UE)((WT%/7MD\SJ,:5P]="M()](0(K=
M,.-!NMZ!77HH-C$OD+2,)6>0:]D-IKSO+]=P=/=&EVQ*MQ>@<)="07EFOB@*
ML)]RG5V0G3-?&W^TAQK3-AJ0SC7-)7&VSA7NQS'9O% .&(L9UZOL;!=Y;LYY
M-8?]81#%9 ET*1YF[01)PCHBH(>ZV"4RD%XV3<AQMEY^)<3]Z?G^PV:+O##+
MV!D)CAW\]CV4NH 1T:6GWK/X-"0.U3Q^_M,]9> A7;%_G\13GS'M+O#SZXMM
M&+__SA\1TXV)+A7>BX^SE[3PY!+WZY,4U1D"I6<L$V=JLC<XT8O[]5!Z"@R!
MTJMXH3J. LOXK;"I\@[ZM&YQ'M15C?7J./W"#/LHQNX4A?&N6KM(@9_A2;GA
M?+!!.MJ@.IP]K[P!AD_4E'=])>MI.G(-$N;-[N OJK%KM8:S)GI-5<!@Y%H#
M%*V/70-X$D>N"3M9$+?61%#'=[526"RZ!@2HE8512;J9B6M305Y)5O9&N;4A
M+INCX#2+M-.8N-MP1N@!-_Y?>CP*/7'0$:>IH<@XM2E!Y+3K7NJ@C'&;]'!*
M#6UJ<[.82?=NL_5)FKM.K<QNC1$6/!VQ42AU>0+GA&9I[:F@5O5F@UV/TG:/
M-IZ?AUD*):78FW+4$S'58@A>MXQY'.8[0>UUSA-O?O.+./8)H;"H7$O#2L,<
MGU_=@<P<"L5R(>>Q9-\!T91X;3Y$MJ@"G1XHG[&3A&FJR6D2.FM4J1,EW#:E
M_4R%MFNH>J[&&SA/=6?@)BA0DPFGY>)C;Z4 <0/A_E'SL9+=7-,5@D7 *Z$/
MMC=UV:%!!F*>P/M[S9)X=CSZ86_I.92-,6WO.<@?N:]>1$+%U4I]A,70T),G
M'0M773;AVV+=%G5&Q$[1>N:W7@P_]%8T0I9 ,7PP=J17,UX:^>6Y8UR$O58?
M-(M>+%1)K./[M=(_+X(<EED_?/3UA6.S(=6" 'OED;? ^UO3#R_T[6HV?FY#
MNM^&^.<4.R1$$G1/FYHZ>JNB"U ,'JPUHTN%ZP6/SQLO7G]SA>!R6AH[C:F!
M"U(,'[9T&Y"3^>@A<,1&8[7-8FBUNG)H!;'4;0*.PQUA,7O/NXC%QDAA!9HO
MWALR[A01%I(-GDIT&VOC/Y]C%#+_BQCDHV:+]U;O97QR05!UWU+.,#7_XN@O
M0D])5+#3&#_&DC47[K%X;\BOI[CVRB@'46_LQ-.7->WN[\2+=V.RV9*@1M8T
M?K>+,&N5H+$HD^T1F3)["6AN.(^:$&NBPH!]5JP.P=ALRVH37J<6[#?VJ&C^
MD\S7)(E0X,Y_4CIV<]H'3T/OE;+T$+SB*,Y>$DR3%]]S,JK_2MV@,7SOR\;7
M-?S"D+DAGEVD)4;!157SL41 -#LJG2OATS$6[WLL1X@=<*G]H->=&X5Q99VE
M/^W76/K#8LX>O;"G9:[WZKD)\H&S"VT+-.WW>07F"Q*0WFPG=<7#\JVE3#'^
MUMYV3NZ"6%21B\>@;)".SS%2&0ADI89'ZR<:"\5HY:FG/5'WRH/?]7YVQLR1
MN?:%)P_-U>YO0R7 #^C[HZ=0GS ![D>:/?SC-4L.@ (6#[+V\/+N#3L)>]4Z
M62X]1Q(:K]:Y\Q S/4*IP1PDK(_&HC.>UX2"@,/-+7Z)62BJQ$G%;][OPYZ8
M-U!FUHA,FE4>ZF#(,27$62(3>UU2NL1BY0%-G^BZ3?Q_-YE2'KR(!<P]$4D!
M7*"UJ6I4,MTG:I1#6'\V]\B'53&4[S5'S2YBC^&R;E$.Q^<U"O$-BK#+W%L4
MF),$;3>[?9LIRIYLID5#2\X"=^JCX EM%%; -KYF9E?C2_9X26P/7;NVPKYK
MD<V;L"E-:V?GUA#0&L6AYZ1EWXGS@U6 CV;/WV4O"(7=%D-3Y53:7"&.HUVE
M $#"'C9^F79^76%*-7M$)#PY'#2ZB',#AVW.B<ZP4&0+]5$S,_LT#TDNUO9N
MKTW@MGE#JRF23BW(!X8/\MFLI=-9:#[RFBZ&73N:A4I,5*@%5_T_C+TH K;%
M=,O+&)C_)+(=O\8@BZ&AJ$BAV)KR 0KTHSF!%O%-8Q]%T629'D$4XR-/NUS$
M%B^%A/.*PUBAM J)LFV(U]9P1"2(,)%2;M]IX#Q9V'PN.%]>EIJL=-W>D" E
M=R3;M4[;&HM[$\R'XP*#?)K!R:/Y=;HD[&;,2DO@<,M69&8FP[%M_);]WFY
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ME03DC$!":/J>2D$(M>"_ .!5(6\:T0QE:@R"!/DS2KH"Y/S&O8)<Q ($>=-
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MR_S8LMJEPDX7+#TUO,1OQ+K>DN8A8OZF*AC[)3LGAOV+!;?1W_P_4$L#!!0
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M_?KCR%:C]*-OL&M,TB*YS.>AGFH'@D_;#JF.<&"H[]V%AZ**LEG@AYK>87_
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M,9FX-T/?!XEFN\5(Y:P<G&1S$<M)MT(QMT(G#-3,*[2+"'IAEM _UK;0CDX
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M].>,= H^B6(&/B2-6AH,@8P0IV3J%/B![58%#K6ZL*GEDR#EDT0*B$/F3$3
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M1D'XHM ])B]I;'41X$Q#_NJ4'>-H7[]LCI7@Y#T:NAB%&UNHB\<C:Z@UY[&
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MO_G^\7>HU?+\^3\4#R1BA1'O#]O'(E-4GY)*^2*!!F++ XD(""JH<4W9\*%
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MG'8#3'R!A=T!3/ SSDL:7>NUOYNB9"M^MYN'Z*NJ%;I:\7PV88Z+DU,*+B;
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M8ZDS;MDUU[**5Z/2=%!9RU;[RB4J+FH- 6"QA:,6;-98 3-RF W=4'$Q;0V
MJKA(9Z3M]07UJ4[J-VU_U6'-#@C1B2JK>BP[03G'@-=22\Z.C0HO66M#6_1U
M1B[2EF_VU@L.25KM(116%KSBRRK4M63/&A/6[EW8*@>EI]8A+36EFN!IJ4,M
M7G3R6.Q9!4(F1,,G-5"F2Z3I+<]+MQH(\\T$Y:I#;82Y-L#S=U[IA'5SOR/+
M0(W"EU'@+N"$WT1$)Y=T4EJECQG^4%2J>GAJ<9^5\$R@AS7P5+)0&&:)4U+^
MCFO4@\O[*-]_B5XPRV)NE5%.M8-'2/OA]-'C<:@3I>,F2-_$=%^-6SG=WS4F
MT.,!?=_,_7\GG25!Y?!5FD=YO,#D7VL( *<M'+7@ML8*],F_&;IA\K]I#2PY
M^;?HU-O:G+S(74&J!TRV[.36X+2O&'EG6PDR!'!S43HRL#,1G*3'X=8/(+I[
M(]G LV3&SBIJK3Y'.3[,?;IT@SN\:X;9MYN10Q_S:+-)LY1AD+T42T5O_'1R
MI*.DE1:H8:L+8G%2W^K6U]5/*;<?F/ 0*1^>\7V4C6MW7.>K:GN[V6 RN$]-
MU1@M# 2)C]:.24.C41M>5+2%K ^(U3-&)34CU&))<[1Z>$__N3;F@9I.H=!2
M,0@5[4.AE18\ZKG&P#'ETD'YGS#QL [(-);3V&PLM::3]D<O(^2>4TI14'VJ
M$:9 HEJ!L<9?P3)ESV^J#&6I&'ZHIJT"9:4%BE8NB%V':@O/#I:X(Z@+R7U1
MMC5)7RC,=1;%LMJIKLJ>[PUR<&AR@Y"%9O">=!9<?6^ZOEY?]NLNH#C)AZ2W
M.WZKW^573.*T% 9S#GJAF*AU0T5"J1)(_NF0FN<.N-'@$9-/'(K:5'@F-K&\
M"?P/Q4/TE664LFO.66W @CA=;C+?7(@][+E.R_:R76U!&0\LY,>T#5!M]*57
M9U78VKT<V@9821V2QFR84#>'?9X".#0JZW"N*;(TRM;[QRR-%<L_,_1##QBT
M;IG&#%)ED&';!K$^?!/\E):L"%2"DI3@N%ILL6>QV%W7WVM=/2]*8_*;5"-$
M!-9 EP59B3C4.*J&JIBR\^D4'Z?VASJ[1:"8Z0<GG/V&Z-$[JE"WNH_;XOXF
MTC?4N*W2-V2[V\&9R_QD_Y_E.[]$63W0:<<@[(=5GHS_82"YIN&^2,036'&V
M9V.;RZ\Q+W9U1T/#)>T;E D?OD'X;$%A7O"P%?I% &:T$\1M62!(&ROH^Z2Q
MPQ*X>'QX54<)W#^8]W&#60#[_=L.$J?X/-]0$UZ\17IM8#O>#NZKB%2Z#G,)
MAV2Y87;M T45>J2SD3QO9M$'')% M>>!<<5O9?2:+9>Y=AZPC$/'L06SB829
M)UZ"Z_U^MZNO$8LRYL555GRYSC<%V=9WHNIS9:VU?09,1Y>&=+=4!3/*<,,K
MW)(\T$9)6L994>Y)G4W3I<:FO;GP)V';,N'K*$UTM;0G4GYK8D@ACFM>C$3
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MA'OE^,1*U^\PT,&=\9C00C$X^>:@%8>)9XTR:K7K<T>]?G!6:DK3VW7/+@:
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MM?-Z%22*H68[L ZCR-GJ.,L];*Z;;#J.=SC'F]0U&6*&Q3 #G]FNRX<VSN;
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M&([7^#A$LB\XLDE<NX?YQ*\YU.9NE/X@FTLVFN$ULT$^ POJ\[0C2X;VMY^
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M9+'NQG%)Y,>Z:I6T$<8<9+OVX$.#S!'*ZL*H6P0. 5K.FB-C26#:]JUN-B2
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MH25%>JDPU$_K'Y?*7W>@27G/?*],F:Z[;K-1KY>MSJEREZ3.2!H<"G[Z#:$
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MK+<%7]S>UE5919DF.XX_VYH8]C6BCUD7#QJ,>BJJO&[C.QI8/)9\2Q(<:=*
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M4;Z/01L]&M!Y*#E$V2$+N O)A"9MDL&H&T<>)#<; K@I1GA [@9=ZB%/14=
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M\ :_!^]ABU*FW'<#ZL__=/0AG*&CO^49^[G.-G#2]WW/6CFKY-V%S@HK^6H
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M;4#^2J0XTLF#=[]"(A$BL:3):FJ BG-> Q[T9+AZUZJCFL:JK7TJJ,-&#+S
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M\#Q:IU64W7#KP8,_-Z%U^QY*.U-L_E +^1'ROZ@=?WO+JGW18$7?\XV2HLG
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MIY1.RWR3\7-$YT7FB4N@A_GT(;4D-\@*?@^@J0$^[UY;CXN$9=]FA"W%J>\
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MEBRW,[EYX,&HH8@Y<VI8(V:C%70(V]+9;/?A\#CS=5C#HY;XB,_E6IN#N++
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M_@\)2Z]C@]4#R, X#)^08M1Q8B,("BX30MBO+,E7,HL)@(B6 (S%\)DD%E@
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MU%AOXTTX[D 0=JC Z3C;\";GZ>N=^W\3K@R:I@E;B['_1-A2,?YL._$FN'7
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M_4#2UG9;D[594 ]\R2HNS]?F0@,@XO<-9EU2?)^S4C2(TQE"[ >8%D8+Q7%
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M1&%W&D(/G(<]<1KTJY;85:R5I/RDE/Z>L&C*OSG)R&TVU8=9=130VTY>&35
M!^@.\%/B["EQ]I0X>TJ<=><TSX)X^KR^^C/G+$YR%BZ"%*A]&"EV#A04!!M%
M.,+B.F'/)&!P^]<1@-VWV(HW2XV^"F_JPLL28^/98Y:$7X /$K1)_%@$;-=D
MC4#H.;-UEHP+<T=;/Q Q6EES=>Z0!#M]YB)9+I.XJ EN2MCH:HL==%);4E/Y
M2D'19ZO?11C!7*2\T0Q:D^1G=-5WRH>N]=-="M5="KP\R]-=BL/=I4"^@.?%
M'0K<.WB'S=W_Z&PA>$>Y^]NK'*;5N-T2NA7"MGRE )Y@\)@_I^3/G,M[]<+_
M![ TJPC\6 2L%V>5.+5D'V^0,2[0:A(_T#%8FQD;7TYR#=9,\Y>B.=0%ZZS4
MH='&](@<8BY+658#A/]K"P;_QQ\/03Q7S5C\[[4_^S$"P//3+O.UFI<'UJW2
MM"L&H<;L6+^[^NK69<6JD]G#H,R[X(TN\Z5.G8TFT-EA^"U.4U\M;78*@[Z7
M$3NQ&UDN6O@)]=N8KK9'-D-H)*G53_4!"LA3D&H*/V!1&Y<6CP'?;>Q57$;O
M8 #2XLU$1IVV3[U6^G#D;! '/5B0LK,EU,G@;%]HHV^-K(ZT>Q/3C :1UG$@
M&G:T0W<;V&A6*:<CO9Y-^9(CGRLQJK:[*?0"C;.<$AOMZJ1%.<H\B;LP\C5I
M^D*G>1"ICS6*IGZLE#9''(4@I:'\?- =>HN7WVFVD+=%1=V&!5T])5=QILMN
MZQ+(U G^L4EK=SJL3*(YBJ4LQ,-T?,V)IQ<+2F97;WRY%_?"QK,9#0G3^_6!
MQ'@K<!]%=[C^K92$?G+;)'<4"6;BO9,DYO],@6E$W61'-AW"A*I%]'"P:K!E
M.M<IFON!#<CNFL^$=0N$[9'ND]?RQT?XC1!GMYZU]J1+;A'<>S)__492\2*\
M?K;::>2'_=O.33LBX%^;+=DQ34&-9GZHOL-DNI7M=C<E2I.%"_+TFI@F$-%<
MV1IZKG96$Z;3%.H[(H.@CH[4Y5?',;%0;[LU]&#M+.L$JEZ5H&X]07R7^TC"
M))Z67$"\0BH::*8GGB6#A$9?$KN6EC)L=+84%5O'>9:*6R5"UISQ_YT01I.N
M FN:Q0K6XS&58-M;6*<#;O<REA*Q]KTM2RC\*=2FD]CG0;:I\701K/A?.NN\
MF6VMHY>CJO[62\(#CJ";-,W)M"IBS:TK%*J<JQZUA1(?75TY.ZUX.>ZJ!Y$?
M@HST7]#4O6!?_AEJW)GTY"HD6V/E)@X9"5)R$ZN8N8EE@IMX#746Y)&JBN.^
MG1Y5Q;DA!'9[&N#3AI@^.(/R_IF\+'5'8S'-CU="IQ-&Y1K^N.#:49T/;'N!
MGAB\ ;&GGARA5J[#VUE^AZUB*5! !2.%EE_Q!A\;C;C:I=2^?4YB,J,A/W*.
M7V/"1 #JEBYIH4#51@5.#X3'F6O#?J]BJQM7 Z<8L?>Y./>/9W*LICNF4A5J
M4 T?BPZP+YK9#R)K[;B%Z8'\F5/._F5 H_5O290OR>^$SA<9F9Z]$,:M24ZZ
M>JC G8"/V;[A9:DF9P7 "B[NDCA;1.M)L!9!PIN9@:N;])Q$R:N,*DYU< [8
M/Q1I?SPJ@RO7F1%,R;+<#I$EK2_(-S,=G[<D39\600RQ@R$_ 34%/UPSP\OO
MHS7<)8PXM87.#T MP1\'T/#J17<2R2V'"O'-+>)M&RAH7GEXVD+6]&[Y+ 3?
M/^_UD(#!+5 =:O4N5F5K*#S^.&L,@CMS<"<A(=/TFO,OV$LKGG]E2=J5'E/X
M?_5$Z#=E[4^)(#6@3U)*-M5SEH8$"I,?OA:S/)Z U"75U=N*,JG8/F&&-C44
M.C_\,%:B>8*BN)Q2W$9+.7-C1N<T#B+QVR*B_T$-(8 4_8Y>'_S *G&T5FF^
M'X8L)],JLE&PHUB\K'L!A]"]P*J7B%Z.N?(NJ."VNB-6^ 4+GSIX )K[@2+L
MAU>FIY#.A^;VRZ632#, .]I"0?#''Z(5&GTP/9!5P9$H1&EXJ+.DT9! T?'#
M1V&6YX"CH3'G@D9%BP:J?S_<#0"!#@A RUL%@J"#"@J"/TX%H"+0)ZM=/J\#
MRGX+HESCBE,2H%=CZ+N6:\3W IXR*TC.HUDYCRHWVC6Y='10L+SR0,"4@8Y9
M??&#+_MVJ[U7[@65P+U=W .\E@O;+A-V2<D2?'HU4D+A\\.[ !;+DX%52TJI
M'['4XTM) $[\]@(GDS3XHVW@;4@AV(31.*2K(()N1EID4)B]<R\85>'AU*HL
M7 Z^MF'5 Q1;?[P6/12$/N7N&N-=D.7BT?++( .?$'9IH*AYY<TP*\$SG&J6
MMG54RO"VP7<+[ **HA\^$7OYG+I(=O/5-[&"N'93M;;2JQ(!+#M!+U]B/5OV
M4]-!W%KE&;1^G0=T:.BD@R+CA]L$*)0GLR(_O_ A_B^IR^)HNEEJE?[(DA9
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MR7K,056!OBPU<E1JL9\KOHR&X@45;;9'=ZJ+J1LHH%[Y'WJI"AW@NM=4+LS
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M#XLYKXVP% 3J[2U%\REI,3TEK1 G'$!:,^*^J?LT"7:_:1_+E(NJ'LEZ(#]
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M-=EO@<Q>&<<.>+H_8T<!B$'XA7#G[I=/)*,1#9)_DB N5OIP0T,GJ+H8/P_
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MW\ _"L:M2,%S-&UGO'L0__$GZP?QLS_M#7I^(-]7(QN>P^OZ^&&0@AZ_Z\C
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M1PI+<GWDG7184C4U00(,@KVFV-<0E@A(R$0'X)3CP@9L'-K ,+R8UG-@F(O
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M"-&>A@(R 5U?M9(@/:\8$_)Y63 RZ7^E1;Z:D#9=)R!,QTC.?&<J3&,FWB>
M'H/L(1/Y<Z/?@K@DCR03TP8!I>[L4T)S"\1,W/ )N4JZ;O.\M%I630=H D3/
M$))1W4+%KHA303+D$DX'E.EKM:GXT:=NF^MZ7OV0U9=NFUZ-KA:!OZ4%H\I8
MSDW5 3O92D]8950["LM@VCKD'%GRTX60IB<BLL%$-VE6S4-A*()Z@N\Y,0$
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MW/Z[1(S<@_D<Q$&F,HI5C:%LQC]LZ\EUQ&-9I$/><GUI3&185RC_\4_;-JQ
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M(9OX)6M/PR">1^\T3S.@BK(9 ?WR<@QM9<\R5V>EZJ,;X+E(U1H*BK/(X1%
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MBT?!8V"]75 793@Y,?[^DC$I@9!KUJZ&=Y71?1LB9A27U3 !'YQ,3%EJBE/
MVL/#*;8<91;L\L*'H(?1F[I &E!I93IP8F T7+8F%"445H<#Q0E8<CIC(!DT
M4V,3.#Y*"JC49>FB<(?D]<E7+-5&!O.*^#HNV[!:ZZALV.2VQ/_?WLLW'0;\
MKAGROXZ.HC=&9\GSZ!RVZ@NX[R\R7&#XZ.C(2;>SM_]VS^81CT ZTZCN$3XD
M\0R_ZX0I7K;#%/#\YB0*3Y[NR=0.>J"UJV8ED.;^:AT]JR(3S3FTXG1I"^!,
MIW2'E^/ACS$<T[KHG'3N)3DV<BQT_ "6:\7*C0JM/AZ--)IVSZ,9+7>XFL]6
MK"9/X[R]^/*U>_YY^XG!*WV [Y1?X]?,U]^ 6G(UPV\?E_-4/]RYW@(&_P_7
M#C#^[8GLF/+WSO5 P?X^TKCGV^7+:_$_[$ND\33+7'S/>71!EP$=35<37&BR
MR3,]AK\LZ']C)7$:S+XR>:5$X0+=/S7(J*#ZH66/;H,P[:J;+\B)6)8T-U;C
M72#MN@;#?&*RK?._>MN\W]6?M:OW)"ATYB,Z8J&+L_P@T2F8R,Z,$K?[7[41
M=[X=T8Z>%?HH!FE0D*<L+>QTY2[\I\YU 5OME:WS4E-2[,24#]"*XI"2UIS=
MN@BBTY(.MW%C#]A.=^9A'MF9SKWY-8?]8^>#,'>.PN8<%:>\ Y5Y<Y!NY6"Z
M1&(RJ_+&=>G"YDCM"":5FAA%B)W#_-!4[\5&+S8^2VSL23#A-:SHHJ,.H'MG
M8V1NPEMNHL7#KLNE@-Q <J\QOP/._U94=]"$;=TWWD\COC\28#X2NU@5AUV?
M,3[@\/*Z4"%H"!0JCSFA!B5&T3(()*!A4:YQCFY8&*#R(%J,R[5M,GI!81@A
MAP(S;I0F&BWBDNHX1$>:J:+J!MBQ^@(]B!+LQ\\NVM^]%(1D6:M\*;1[$.9*
M'S9Q))/3T'-%'E[@N:JNA!+6"S%W/Z9'&DP>P)A]>TGH &E2J>L\:?O9.J&7
M7MKVTG9W2_MY M<1N?L385\,Q..7)W_8FNF+;9TEG6J)$M0TD'8L"GQAA$LT
MW&T9Q* 1Q"B20!PE-5 Q*RQ5$+N,U4:FV0URYM;\/ ^'/VXO:VYV0WP[LF8_
MO*)/;L\K>AO"P-46]B[2O=X[7_Z<?K)')Z!X.EKI#A\JT'0I-Q-/KS-TK!AW
M9&TJI[[%<Z?7<;_!O;,/.B[L[SW:X7XW^_QUV>;GHERB8MJMP,>-?V%F,RHB
M>GDRC$Y!*VT\)YA2?2UW0*M&JE5VY=)<7,)WMF![VWUZWNNQ=TF>_+@/\F3G
M0N^_?WKVXT^[HO*&14HGJ$D)S-<*; ZPP%+#/%090!A@.C)G1[,7#<>8:)9&
M4GGQFFYS4=JJDZ7I:API /3BEJ3&3T^V5N%W;X+U8J,7&WLC-@J$LP$U1.*V
MY!IK14 :@!P"(Z)*-XJ]8''WAE0)";U40,(+N*??_/WF[S?_5[3YT5^>V5*T
MA@W6 HB&L!*VK4](>/1/.RJCA+.L),T#KYKBS1-.Q&_#HC%L0%VAF;.RD!=S
M1 )Q5#9P$#SI0906ANL8?#6&*DL;"[8=._JQ4(S*D.L\HWH->(),'D/*8#--
M)9E?$18$IJ$P.=V:"2_F9JC=H) K]%@5349(82LM(=0B4G4UL06L> +*%:PN
M8CD%S^TDK;5'D@>^\(%IF)8I2:(BTEQ3BT)7JY&%Y45E[U( $B@"_3''JK5N
ME6SE3,AV)?5MQ4%[ =T+Z"_J)-H7-]&%S\!P/B%,;1TKDY?54BDJ.GY&I<WJ
M2@^CMY7'-J"L-L-2%3$F2Q'F4K_$.1<CA;5.B J#TG6+&C-^1 =#81E91<#N
M<AV#V,6H+,@Q7BBC7'(/;G9!10 1J#AOT$EYI#K7G"Q8*./.JBF(P(7$92,]
MU<58Y_$"@5M@((-UPH<NXQ=3C*)RBODV(7VW)>P>/7[42[M>VGU):;<G.<1O
MI:I6)8EAW3"W;>?V(/+9_PXK8&X+2@U,I<+2YWE@-C'#37'%:./2VM(]+L10
M(<$&O-QU$,.4TN;4TC!W6(&<);%9#"B[+L=4X(+K $>V4$T670<+#>5I4'@*
M$C9>;WXW1:2AELD MJ6K;EY;3WN'Y>/M%J8^[@M3^\+4OGU$'QN_845@3]2
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M&"S>PRQ8W_WCS#WK++VT"R\_<[\>E&;)L6ID/*:&LG/5[)GQ?Z$0":ZP#;0
MO:?U&N.1D+F01#/!87L$21,J*8\H, YKNF-*5P\WFFB:(1B%"=6$;K=K=WHW
M?<<!PN,R[/?:;]N G6="9K"QV]93CD=@OW]]TS? >JV(KSOMMS=GR&Y!^GT!
M.'RG=R8 :;MG-$B9@#A(S NSU! C10P?#ND1NHX%':=S!:_OR+%>NRFBG@5$
M5>X 31(:X6A(84(2B[P0@O%X<X\BF@;2M9UK"]Q@M*$[HPY%FZ$8W\'K4.0L
M@LZ-\V8 099+\;E* $<HNY%M2J%"UFL>4U$JU$%2Y;:"D04Q59%D6]3,C'N:
M0N>-A<FDI!B@$IHP3GC$2 KJT2-4.:7I(262Z:,% 8^:0/*<8HQ(I--[IF#,
M^0%QI1@TKEXKG&L[]D]/&0H""XM:%D,>D0<H%E@,'HUHMJ42NNW2T699VR]1
MV1?Y.CZGZ)9J89GX\V40ACZ\(ED^A'!Y/[WU83Y?75@R%SD#=T)*7)3$ [?J
M-0/[0*6BQTO+@ARA7/*N+DSYMXOF!]N&&:-I/( 5V=$APC\=S'<,84-8%@NW
M&L"<* VV7>WQ72_X^:3I20I;(6,JO^X-)BF)?H,V^J!$RF+,)AQ/YCY,?7SG
MQIZ'6Y5W#:=1Q)O5>'J**^J*+1)I2G*%BD[_AO# 8KTWF3D_?FO;%*Y/')\I
M?E(BDIZ,Q7W,4Z=3FA0([X0XHWXT+?3,@69M+B8#O*,%)S?./&P9$TNC+K4B
M6N:45A[;S.GN#U!+ P04    " "2BZA:_7Z,_XT#  "2#P  "@   &5X,C,M
M,BYH=&W55VV/VD80_H[$?Y@B]>4DS&N.$'"0 )O$+0?(.*WR<6TOL*V]ZZS7
MO7-^?6;]<L=559-*7"3X@+WK9V:>><:SWC7?>W?K6;-AOK?G%EY!_TS/\=;V
MS.R65WS:K1Z;BZWU$?;>Q[7]MG407$V@WTL4>"RF*6SH/;@B)KQ=3K1A3R4[
MM- 037>UG:(/RB 1._()!)0K*J?PK;ZF$!-Y9-Q0(ID PA\G?*&4B(NYULQ<
M;3?>.4_C0&(6Y9.O>2^P*?M,2S*MV4_<3Y.IV=4.49'=/W+YO[PKSN<22'8\
M792RN9C9#R?F,]5L#(:=@=E=S%XR@;*&%\Z@UOT*J2^WF[V]\9J-[0J<C67O
M;/Q#]Z[]SME[MFM;L/NP6#M+F"^7VP\;S]F\@Y7CWETTV__LD)=6X>6[YL\L
M5>R05Y.,AU2['+SJW%ZV__^@S48@>(KN00E0)PJ,!T(F0A+%! <_!TD/5%(>
MZ$<%PJ5'EJH*L%=$T1CM4Q '6-(HBXAD*F^#PX,.(&(E9 Q[HP^_;$3:@>%P
M: QNQZ->#P@/R^'HMO^F?]-N-BKL\!P[&KT>CYZPKP?]-^.;8ERAQ\_0O=[@
M]LPS&@]O-#6124P%$U,0(N40[D@.XS8,$-_6/#6 9*%>5Q"N$STP3GC 2 3I
M4Y:D2-2B 8U]*F'8+UR\*D(>A"P,<TJ*&PX42Q>VX?[$@E,=GJ5:Y"C#)Z6D
M.#'G/,,X;HFH5&LV^CWC-UT87Y.)$*]Y(DU?9.H\@0YLG]*KG"-5C/^01(03
M)60."9'D*$ERJNPU4_J I2R*BTFEF8^)<J4S#D7F*\!W(Z"2,WYL-C1\*>*$
M\/QG].VS",NLR2%(,9Y1+0V!HT!T;=AYUB17V2+?H<VO<FVZ).ENVFTV;)9R
M*N=Q@EVU7N^N+(52]Z^H_TCHV[>$K9GM[#>V.[_;V6ZIRTNUTB7E<%(:,8XK
MNC;YE<J4YE=6T+/5]<J8?\\EH/;^@V' BM$HG,".'.D477S*]'<%(TUAF^B]
M0CJ!-4D5&$9U%#,MY_?GK?&XBQOID+Z0(96/<XN(!']!'WFG(F(A1O?FB[4-
M2QO;8FY9N-%\V^JUBO%^-U_6XRI"Y2T04422%(G5=U.X9Z$Z:4UZ/_[;%\!S
M:Q]_4ZE80*):"-R%/E<FHH?"PJHMSEP_5<:S]/'3U7\Z [RB$K4H9U)VM9:E
M7M?ZVG7UF;H\9.NS^!=02P,$%     @ DHNH6H*]7R7&"   <4,   H   !E
M>#,Q+3$N:'1M[5SM4R(]$O]NE?]#SJI]2JMX$=1[0=8JA/&1.U8L'*^>_1AF
M,I S)&PRHW)__74G XR(NPXK^U <?A"9R4MWI_N77W=FK%_[7SH7^WOU:Z_1
M@D^"/W6_[7>\BWK9?<+=<GJ[?MEM?25W_M>.]_D@4C*ND<KQ."8^'S%#;M@3
MZ:D1E05WH4#NF.;1 72$KK=Y^YV3$=4#+HNQ&M<(-)]=Z*LX5J.7UP2+8-3C
M<Q*SY[A(!1_(&@F8C)D^N*A?=6_\[/S%B(ZXF-1^)(%M:_A_F1,81KJ\^$WV
MS?B\7KX$"^&X\''[YZFH^6 8?["&WO.0]WF\OW=2*54V1='96FZ$$-OK4&M1
ML>GU_/95N]GPV]V;_;W;^][=?0.&][M;K7;OON/=[>]53FBQ<GI(CPB5(:F<
MA>FW^YN6UR/^M4?NO.9]K^VWO3OB_=&\;MS\[I%&TR?=*U+YQ\EI8:NMU  3
M-5K=6]]KD8QGH%'07<C)<14-8>W4Z%TV;KR[8O>/CO=U:J+J\7%UJRVT60CQ
MG\3$/)I\I([MPOY>3_69CLD_2^2::JYY 6RI<2(2#VE<6]3<;UQV/-+T.IW;
M1JO5OOG]\\'Q@?U^=]MH3K^GPCWQ,![B9,>?W.SY356I+K,5&,'OY5^#1]0L
MH&)J4I@!:5+=;^4?*]7MN%0]X_(C%Z52FMG<;UVL)-NZW29EK._\&=)'1C1[
MY.R)A>!5W)"&E D5I,?&"GQ/27*E] A&+_Z+J(@TF4@$.&,\(6T9E,Y?V*/L
M]_ 7NN'.(W^-1U8WWB,OJ6%A/J\$IQM-R(-43X*% U9PCJF=1X8*II<J)@',
M1+D$!C$AB8QUPHB):<Q&L-^@JU)P!-AX.#AS1 .XI'-*,>(Q++H;]-5HD@7,
M&*HGV&1$'Q@(F1' P+40) ?Y!.8C*! V"+@.DA$TD] ]GSR)#)DF3T,>#(E)
M\-=\LB>F63HCFF;$C6 TY'( GA</P71FS *K#0HQ!CU4" 8$%\^[-OU)=C5V
M\?\GQ__)_TG\,Q)Q"4&#\3?W^X)-'Q3<UIG[7$:P9=&8PSA<!B()86^#0$2_
MS2>(<_("1#S78D+&$$<(+@@Z0LP!(0TOLR G %3(48H"MD@$-  44!!]5K:<
MLJ"F 35#$@GU9*9XHMF FUA3D(KB16<1T+^0B70SE7QNAUW\;D;\GFY\_/I#
MEC=HIB[YFS;?$G5NT@A-DQ?<E504<?AZ:%P!H$VH9C:,("QX7S#T8,(@T/N"
MFR'V@&;YQ!@!-T!^@)U#;@*A3 *3(&O02A@[[UBK@(5PV9!#")^00?"Z&/&>
M@R&5 T8:L&WV$@$M;,WB[) =Y8];6^# KDY=C@FQ= B!PA#<B#/ X6(3!?^.
M5/FD>*%"=)25*@*IT-R+< (M,#VH[2!B)8A8.9[7AC6']&C3P:;%# R=ER]8
M-OSC&"] "@!;: )\Y+U=\LD!]+K/(%Z=#BEA5XF&V6 C?N3&<@%HQ:2=%*LX
M<Q:1I2V:"6H!P#'V50&XD/(?'(D#_0 MC1(\I+$U0=_PD$,RCZ;A+F.QK$OB
MM(E!KF^1V]@L@LN<UA@JPT#5&#@0SC"F&&Q8/0 J!=:UZLVS$8 WE]MDDSWX
MJ\^P(1 8Z,_"'6'9&C3J;S,:O7N+?P5*/^BY2@*3 LG[L G [Y&'2 6H49(B
M&:,&X HK%@@M5".<Y(4"["HX[7.!I4-(7I:Q'<1>BP@VV!T2OFB:J7A8@OCL
M3)5/F'&BQX!,QJ9Q0:!T:%6SA9(!DY"="0 HN,/&")/8))&Q R& 4SX&)K6#
MH:V!H6#C8<A[I"+!+3M_T+$H8D','\&MS9*:P2Q!>T>"Y+ZF981\DKRL.5C4
M@5F F"#HP,A]E<1OB_L.8I<S(YL-S;!Z%"VIB2Z4.4D?BUA8E[(0S=R"@/#G
M*,D."[8%"\*-QX*6"X:?C$ \,DDK"?;.4DQX-X7)"TN0]*@@2#3&628/6"+"
M2)D8KN,3!#"Q 4<DWQ)((T".P^5=\LD2 13!KK\P=&J2 &+>GB/A$9,]$W4:
M'SD5AM3,<C?D"Q:Z6&CY7/XZ<\JU)D3P!R;20Z6%P0LKKM2*E'&';1L 26>[
M^K"M#]L'%<(I^!7F&S*2B0Q,Y!-EOI%CH.?(V=*#U"6JT"3DL=(K'.[@@+8W
MS#\:\3AF[#N,K:\@$</[(0?-<49R",@#-,8@IX)/K":ME*FQ;PD'PUC0361@
MSZJ.=F7@K6$YFU\&;HB<FQ96-3A !AY<X'E)P!G$;)JUS"JL3XP^8&;A<G^;
M6]AZ"&[9LV/994B0\_CZK=,<5]]T1UU+-GP:0D?#9OO]&Z&?$UG2D@N,#SBA
M-&"G39P,F-\D(X@@L+LU4\H-EYZC[[C 5B' YI=>&W*2D\IKV#L+$&+,<@F(
M:/L@5!KZ!<?9N7Q4XI$A<9=TD#XIIE/ZP49CH28,[CX-E2,<- LL.5F.$A^2
M7)6^'W6_Y&GGZFGI#"_:-><R9#A5T5W]R$6?/M3]UF/-62!9!)I5H\M!4!^
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M@@N68B5[S%7J"U:A[?VKT.>K,+ODAIG0*4*;4N&G6U^^)=OCA_4,NWL88A'
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M#.K9GF0%@C/?7DMX2C]>8!CYRA#+@L##*\H2ZLL[]=&STNV%WL7+K>W\J5#
MO$H=LPXCC)$&2D6?8.C7H=: H1=V:NHP(+Z$0B'9*;K]W^^^5[C2]CXD^4YM
MT,<*[ =;%ENMC>]SS;KLN/=0>S/5*<_D-IN &Z+7J[3=F6J6T!.)4S9<65*^
MC/SU>K8@]4:J>A,U>C55O<'Z#U!+ P04    " "2BZA:U9C J&V<!0!(IC(
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M>V*)4*0AL 7V$ @H*P(*EP$Q^30[MOSS%-@5[A=K7YJUSX_OEYYE[IY#6ET
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MPR<+5I4GFC[T=6W(/M7 !$J88W![D0%L?>H(^*4K O/)R0)_(9KN#LR64T'
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MSG*^'75Z.@ADQ6T!B;X$M>E+4.0.HFAK46?XY)[_UA+PJ3%\6GEO4R<>]2F
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ME.T!A35/*LI43![E'"F-FK(NN8CZ3)218>KF<,HVUVI@Q-RL ZDE]-@5PU;
MH@JP*,SQG6L/5V>@;-S[;$?16)B0$F@4:"R9; SV?MHU-*[4]VI'T5BL;!1H
M%&@LA6STX^0LYD7H$\%L2-.P1MJDPKC;"!(+:%%WX23@4 4X%"X=GJFLDK%,
M7ZR.H;(_[N5Q'3;7UP+$0FKLBH00D"@[)$H0>ZH=2,KOZY<1B26(.PDD"B26
M(^:T$T@LEX]?1B26(-XDD"B0N(44_B<B*S\<C1*UZM'-M:# 4JWB:5!W420
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MA2>G'M<2DB4&1E@VX0KDNO/7#(8XQ1+7)^$\OM1!*)U=5CH%5SHT^<ZI@*"
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M(QZ6T%#[4\Y<CPZ05+:BJK^*XF-)Q6F$4!5(,\]09C(*I%GX'>4:P1JYLX8
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MB=^Y$J#9/F@*KO^)3P1[='1[!$;CW5WW4C-4,"*?"1WW1H34' E+)R[,Y&P
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M5>!6R)?M><>EC'_&PT3(E]+(EW(!)]X+OJ)/)A##_H=,-:I5'RE/1 =ZJ8]
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MGCNU:"2S,F9#,Q=B,%V&@T"+D"WI90N=FA.3VKVI99.QM:/ 22""D#CI)([
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MX@-F2\#>B=J*CXT9<@PRS,3W?O QCJB+4HSA'F[9(QHS>O&:"1 $G@YX>S'
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M)A18Z877I)+7,F/R]?H9(A'N1N[ D!KV%W1?(/A"\$5)^8(5*"(ON-K13Z,
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MY(#K6,:4)Z S%&95,QZ=]7KV:B]\IG"9A.59O&I,_2S4P+ZVWD,?5C,">]5
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M:0+LK.DL/Y]$"_%VHKA<;^R13!!/_(DH,__6Q=C?NN_WRG/[:(;(0Y$XSP6
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MWFB<HA'6F_O#]?YP_0@.UR#1)(9?$17>]$_S#LP$./LBX*"1I>TX)<?/$8X
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MUXS*M09_'Q-;38Z_^?NSS(ZPZX10Q_3#N;KR]J>MP6UG8[S>GR51!L"WY$.
M;\K<Z.EUC#Y.D-\_,Q'0X!MXAPV-%>GD.<"9.$,2%EPT6 5]^L&*WNXRGVW!
M+1YR&[\$1=)3(E")G=-$<SV8IY@#;Y7+:F$,'4Y.(=U/&+FGH#U-]-,FN(!
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M+VEKDA@5L<%#UI> O$-/FH7T]SM'XFOE(9 /38Y.7KI'"G*'JZ*>5+0Y*C8
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MHR]K*OR-7D\P1GDY?4:O&S1K&E"*RC[E]"YVA0,C>PQ19Z6%&&]\J_?'CB)
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M*FN"4FQQ-VDD?QIXYURNTF3EG+?4,9>=-Q/LCOEX&IMS\G1^X_U ;<6A-^S
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M7Q,V.I-CUXE(J8P""M_RE9!3\F?"Z]#WV^8]USQHA@^_O"I*N^'UOTZ/H$5
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MF9=H2FGY MDJ5FJ]$MDWFBY>$H$?^!UH^R8_Y>]IER1',Z_P&=G/N,4)@E=
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M\X-+O(A*H"/'WRX&"MC)JUA*.G<D0,.82N:+]16U>Q-P;P(^9A.PVU=D;-L
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MR':&13S+M4 19N_'FGU9(;CSI;RDJ8=8.7Y/I>*_'^U/:*""-%R146E$7DU
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M80=ZXKJJ8G:B7-'X.##!(^TSU .947J>4Y)8GW/YC&N<!&"O=&G+<D??3@2
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M<DY^(DVO"PQ%HD;P8%SX/3'0"*K0</DT:--#^$<4*6PTX,LF4QM6FF97T&"
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MF<HB,B,K@I>?/P.YE@2Y3:+HD)F;:FFM=&*W1)'>&\&_4J>3]DZX:)H:8HE
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M)K;OR.G=1BBTY,/33*[&F/M6\,\T) /"T15O ^!"B6"C3,N85 M)<F:A\K/
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M/VD#K[0%V/ULQRU00IOV\/FS(FK/P53%/:E$5\9J>') &;<[0N)CT+;[E6.
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MPS,R";0/:/O$V$USY6$*#\WAJ&UF[-;16$;*B1=HI(31L]TGN<9\BDLR4P8
M(9!*$Y9SJ/).DI,OY3+)IGF@ X9HS!4IO+ *S%V79+.Z'E692W"*>(F=NU[D
M6I$$MFOPD 305,YGLNEQ!FJ^3W=%4 7912AM5/1V*6?6OK)]<LD)02AZ9!KZ
M9-\)8)*K@/WV%. W,#(1P@*><MODRIF./338^>%"O 14;E3&PW:Z*H5LM)&-
MS&O)E.LJ2A$O_>O%\^$8*-)-<3:<] '6!J7^$UW*R5T5B;6U[+, $%ZR3,SW
M6&N<3L&],$KCB3#4F?<0UH*[BRFP$%0KL,B01R$YZJ?00(V8@*+=C?$TNIX7
M\GYZ+2IZ6PNO ^Y]=@':JXXYG"?)ZM7? (\^(T0ZVO1F(G2,\XWR?D!_9 HX
M17DZ\)KM )JBG^3*/OT!672<7]XG?=\*R72H'RL;^ED ?V<R AXS/=@@@FT>
MUV4AM@+.\4ZXP3EU-MB]_I;CS+D&+EW%[M/4-6>)7?K,@45HML6=(HQOF5(=
M"3Z,,CMWC$859GN+FT5]W"]IN#S. /U1'VY9-0-D7>#XEK0_&ES*I"Q,D6&_
M+%:ONXS/C?"%CRVAYNF0RV$/6M^4CQT_E)Q0OJ11F8YN=KCUAT6H5/2(CCZ7
MXX'59?;(6&>WLP\;VNZJL@WS\ UW=)S9#5H5I2N%(]\I;%_-T7"LH!2=?]1L
M)-Y7?B/$3A8RIUHCH4Z"[@^Y I4=5_CW;X\%J S+>'-K$N -D3]Z% *Q8>;O
M'06=-^Z&D?&%5+F@B:XH:-N=D*S>6!8: ;WUNRGJ)H]Z/TE-<5D:$&BM @-<
M,: (U<KRE[(+H3?I^R8A77,!O1.P24X"\Z853/,!5/S)@('IO&5GYHU_7'%A
MDGZ/>J4TIET5U+0"(.IBID37-D7]P^V73O L-F6'N>JET:-.C9K3+0I"$;YE
MPZ+P0+4-1<-<G"L@.A/I(YDO1C[(RW+&)R8$WN[M9JOR3H+9%W)S<@**:^E[
M*\)S;;7FGA(<2O@6"#&F7'[F[R:#<D31OA5D<;=5AX3]93XD_+_ [D"BCNT$
M#K7E3_ S0AZ>Q6V&"EF;P' +LBG2I<:H@4!^#I=F#?45A_*)^:C S6T2>=9U
M5=4*2)L#X/=YGWW)G6!^LX3ZK6TG]?'RA>U4-'E-;=0$B6*1S.*%?BU^[LQF
M%N"LY3<'VZ\W@4%\F,NC*"D'=WL"6LB/<P*M\0#8WI<$JT@D64]B%JZ]B1,2
M#?'UXN5P"I#@I5"A@/W]J><FJ4YDZ0G1E+9[ERBJ%J*/T9(XO*HN)6-5;[J%
M%=?S\=(.C) BJK=V\W.3A*%25P6 ^XI3&0PXT8=@73@IY]BP.?5JM.]^W-J,
M'W:+Z?HHM'LUQHJ.L[<SR_^[%_GQKDK@H(%'^.+O7U@J:#K,:>K0 B^]':&3
M0#S0,@*<L:GD\:D*I(+%Z?<R42%3LQ)T^^8KYCTWPW,=>+@KWJ"&EW1G7U O
MDV>*4B/R=_QTM'#1_Q2TZ=9[D1+;[;+HEMCVX5+RO:BO7,BO-M)A%EJ]Z3\$
M7W-[I+\,4L7:0"Z%8QW;N @J>W0J[S-NH)^N=$L=C2^:#ADJ5@&TL0.OA?(:
M R/(]%J_)W>7Q"Z=U;:D2>O;$[>K^!^U!GT6(8UE]T.U2G*75F,QI5"-GX**
M'"WNZH@XCE=!^P1]8"-%$KFWRP(PP4P^W7D941ZT60!;,CGI B24"\Q87\9Y
MX8[31KS3H"/G-L<@?>RCP.R-@7JD"A"70L#JKCTXW;L?(^CJTR<SZ.IG@ZY^
M-X.N/@S0U:_3J//U\^__\V4DAQH$3*&??7'+'7>U,G[?>K0$=)*U:F'UNI.X
M]\9%X*R:1YI[CSO#Q:Z<5+.;]2Z&3"Y5Q_X V@+(>68/)$"(7:,L[ML"[2H*
M:V)?)K:>4#",7427[G/UJ>3/^B7LE@CQX:^P1O%.&R"R[[3Q\Y/?/[4+^*7T
MMPN/ ;_ 744VZV;5AZ22'PL-@%ORGSWYS#]*QI#C7YY^QJ^QLZXR-SS=[+S]
M:&"AL]_E@)/MJW>\*=$J2FA=\O@ EEM6(DA+DS$>C'4<6Q?L[YX^^<WKWT;O
M)<]>?G/C^M3"PR+;G,\TT\]]_K>;//;^'-BA [6&)JZ5$AOQ/<^[JOF&S#5<
M8NOKX.,HX\S2A?.KM9A:K:^_N\FM#[K%3^2!W11)=Z[_ =<B& EZYNC5%^FK
M-\9@*CTT4N<L^'VM(\7\=^,E45P^[3)^4_SV4G(#S5VU%G%XU7Q#-FES$C#-
MYU5S)R.PW2DVBO6B64<%8HG*/>Y^27-(F'?-A?N#E)K4B:T0VVX\,XLXB-W@
MZV$?9+)S!,I(<X'\U6 3QH\,YY@_G<ZR[TV3+6DY84&#QA('X@T;%.>W_A.(
MP54A <5^P2&*UD("FY1;7=\F;ILYI)UHTN<\R[O,LP1,9*)>'IG#+L"N?9N9
M2]58)<E#D\]F9>8K_CUF4IX'\/0$$BN76@_W-Q_W%LH[AS"@K%C]]8=S,6Y2
M;#*HA^,R%!899-$5CJG8=52Y>>-TJVVY/J(Y*Q*_&4^!VV-*VA,>%!(I@)#'
M',I49^^NO"NB.TM7?39H\9U$GT\G7FX\<,<7%D;3$$!I!EL7C!=?I;(>TI$)
MK_H,H9X[?I'60J:G=Y4 @Y/&S^!-*N"0C+=/DAY3??2*:B]G0=.?]+*SH.DO
M+]?Q:PF:!LV)1Z I0M9'X&888=]H$T,O2#<%I3F(72X-$R*D$R($<@'(7MY5
M=PU?P5(KHS_V;:, GB9@7,:IT:$A^DPF:Y8Y>>2CFO5P'MR2?*RRS1*"8'A
M0)AEBQHDP"1&_A"A$VZMW+23T'B:[=CH@H7E.'7A9N7"QS^JV8X]N"7Y:.V8
MR32(NQ98[HT=,O)""D]D8(<$<5)TZ/YU+ +)9&(0^5_JWH2?RK(?J2,R=<IL
MUCZ 4<UF[<$MR4=KUA+W+'IDT;4JNHYSR&B6"-2V@5H!O20TNDH[I] 3*YF\
MH193A&=-(;MFN_;X1S7;M0>W)+-=$\WI8K650!)$KW5W#/9I3&O-U0J(>PB'
MW&R9'O^H9LOTX)9DMDRI96)DBA")C05]Q599"XOR5?><,(ML5TU[6]2*#^H
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M0G#0!_.OI3N+UH3#M)I<.(% BA(R1]NG@*J+?N M@[AJ140%N3SVY&K>$9F
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MJTC8X*PA2/+P4K+)A_6:A!ABLAYUV]#QG/?\NZSSLLF6CH7R]2(BG(J=J/D
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M8%] ?T].=R;S:ZL:IAB'RJX&SB1 !Y<+F$P$:]L8>745]JL"HAH:Y+QH,%R
M3)=%[)WK7E=*3^XL5B;$66?'$GY_G0S+:'5P^YA-!/<'4 TI-1>3VAKF#Y>M
M+E'9MDUK)__2A, NKB$!..3\4EW()/4]JB]IUM;1$XVO89.IRY217SJYQ!Q(
MVZ6NKSRP04?1F8. 11K:9+:V73 @;YQRJX>PWQ!@A=I=9I.AI]Q:G%VB'OYY
MN$[L@)?U+3(C?*D9U="FHO?#R:4+/2;#%^MF=0R-EGDV90X*7\,=G6I'+#-T
MU5,J*CO P>=)786!DY9G#)%A,KB=%8/YR:@X03YT #,Q3]#"@MRO8W /S2G4
M[9$V"$0HBL8.H8N6]P4&=%\Z.^2%%,;V")QVMH59)_:7<)'L C8@1 S6>'(F
MHC4XAI@2[=@TQ4_C;)SR4>)IF@CH%@CHLC2@,T" P]::%%<"'@B<ATYUS<CB
MM:,%!<>SA(1LM?]>=.OB7\AV9M_]Y;G+_UTB&!@_>5?98Z6U*DZF,!=%V--0
MD5/3AUQ[LH-SIGJF_#IO[D21(21=LH\HVGN$ :KE2WXHA9[ ]R\Q2'=)>[=.
M!:91U5, ]&YGYX&-/]N*EZ(*'HP+6]Z^$!P@/TZY*Y<P%EH=3'QGI(-WU;^.
M%>T?J(C[-N=]LV9+,I##XW\HH>ISBK+DRUTX+G+DH<7 #%SZK*XL7_O>,*GC
M*R>X A:- !9E=Y;AX2YM,B(,=9QS*.]HR#=8AG-H08[@AIM,;3Y9[)I!=SO%
MNO-F_5^?_/[Z4\,2:L;A;3=U]N]NZL4OOZFS?W]3+RYOZE]N9SSL??L+6]%7
M''EGKV)@R]TRKTKE.*&E^)ZU(ECQ$MMC-ASO\&YKS0<V9MQ0O,:_P!#PXAQT
M<00P@^KE1'\0$O=2XTR_II*72;444$^V&)F@;HR]FK.4ZZ,U!^.D2^,2EY'+
M@MF:RNY<VE\;FZ:TP)H-7,&DT3Z_(#@[WV+OEZ=!>,VG-Z?^V_$ 2J+(@!ZC
M@:@8G33X&1?5L6;/N], 0*67 X6R].:Q%G4FOCZ'C+?5*I*G#\X!ISSL*.!7
MA^?BAS)VPI$+O[XM^Z!HC5VO>>:@?]WUQ_4)VKY=GL4 -S:3*ZY(N7.\0 TB
MVT %9/B"M1%H_Z *0SC@V[*XJ^R@C\\M DU!8'#COS&;C-H"M?<NQ*<UGV_+
M>0L+3B32BBF2:]H1' !MRYT7%@PIK9UT(I9&HBH=@\5J:P/A6>)Q5H$X7OL,
M(7$:J<P3PJ6&0K=FEPO,+T]L!4]\9/"'*Q.;*%3G*EQ;F*HLFKA2^.E;%54\
MA@#:_<(P6Z<M$.O)V1]*C7H*JZ^>OPRQ!Z-$$VHE>MXM>52Z"Y1>-^!I(<6I
ML7[1%CK+%RCXK-EBB@?$=Y&Z37B=O9I^E Y&WY??@KN$D$63W@:& ]78,L$C
M0UH$\X8S')W7\7'7SU:@A!"Y91-AG+Z9.-,PG%NW6VB *0MJP@$#?BN32EQ;
MNF9P.OC<L@;EFMM'F8@CI)LLC<(+(C?36ZZ'6 +O*5N*TN6IA\,0X$8F]Z$E
M"Q/EKX!GQ:Y4%I "6++%J3DN1"94C:XMD=K4,R.%I8$B [)R4JBL3V<,R8BD
M;3#]@VZ9R<EFELAEZ<P!'F;BNJ[=7/ZW7$MOW6+UU3<OXV5CLULH^BT2=S#Q
MC DG=:DTI^XT^Z,<M]&.&W/1=0ES*3?IP/]:M4>H4KE"51R&C6!B+[1T'7+=
M;=2[+4WCB(R$2TUX\,:NDJ:,K[.H<I]DTS6=9Q!H(0NZ<,A47J0+K7V-4=%,
MR"!L:+"E$:@PC#H;LN(U;4KP/:%T-1/6OR?'[88.=[KX>A+-X@P/K"%ZPM%3
MCS[1N>%_S54R"+>1I-E+IP\D;6:FH\/=?X.&?052N*%Y86%S7:Q@R=0%#6!+
MW$5[US"(-YY#=K&T=& )6G7$FOJVD6)5\ CS+/$-67G&_FSZ?R98E\Y<2A\Q
M(;%IW)!!W >, PHR,79EH59@P$,ERD!"("%D8:=$;<XM51BBN5@AB[YNC[>)
MO^GEEI*^O(#\JEI?4L?%_).CQ,6E*-'G-"\%C=5&7KHNX5&)-#3X+H%QD7\.
MU721[9;BR)#^#5<_GJ4A9R6W5]OLJRX"GOM4F;Q8HYE3]XH]+#.?U"OMB+?H
M.4I%9MI*&8P"ZL[<@6*>T8.*-G18>WE%N8EALU/"C,Q%T58%2I89\?.E\%HT
MS?W:)9QVE\B[? -I-@W4,V?)2UD9PV;@*SGCI-ZG<&F=M0CYCEA[\_.-<F5"
M"CN"KW5:'_T]<QE]_71&7_]L]/7O9_3UPW6)_N/_O$@[2<87+0QK)MD8<_.?
MO_I6XAFUH4)JZ?HQ\VALS^8KL<.XP-],2!2ZCD<?V'* @#P1%Y ;.G +-+"8
M603X2#&B)8; @MGTP-56L61R]GY29M=Z=CM?",U"7XY>5)V3!G%5[. M;9K5
M<4)9JP6;>+&HN4:$GRQJ50>3G ![9:!/I"6.H]8+A@Y2E]TW[>L!#X$UWO$-
M'AR3HO:LBJX&Y; B\!XDJ=8A]3*5X(A9MNM':_<?^I#3*@7MAG53-])F+?'?
M:;$]TH,6[&Y<\4X7[O*Z+[JI!KYI[T"2>X+>40]4W1S(J1G/UO' K.<&4(F_
M V!&Q W+$/.!YR1)8OW.[HKN-9#ATB9LV+W@\? E:)Y;[)Z0'?HNZ9_> Z/G
M8WP-VI62GN5\, "%RZH)#8:V/;$;_OU-24_=DHL+@KH$:ZH;E"%.L>]!?HS[
MV4%[\/69,=SQ9_G+)U65TW#'F((J?*0JE'_N==EIJ@S(/$V) PHZ73<3F.2Z
MXF"9:Q4":7I=BG1]$CC64SJ*AZ+?WA=O$E+$CP2IN]""D.GS(2YK7!)>7+ZL
MM\C?^SA/ZS",?.1^CH "'YU7.:3H#]:;/EE-&W!;@D;:'VW,=K?XS?.;5U??
MRW/RQ=__2Y^(*6+D\VI[VM/O,>4#5YUH)^[D([\5%5QM0UY9$LZRUP%)&/FR
M88>RT+@!](;TV294B="V!YQ0(7<Q^1I9(C9]&=J?(7OC5>J-"_)X6!OL$5*!
MQF'8(>' 5[<V&+#/!#XM6GANG+":'(,T* PK15B9OW!7M<=N)DEX7P9.@&]"
M09XN*59(#(OMD@"$4W'=P1="'6MY.E<K4"@N;GII9+#[- M&;:H'.T&"JV5,
MQR9[CE6[.SXCR<AR8?8T.:#)D35)]T\V? "],H_@CK,<T_:Z W2[-^.,$G9C
MO6)PR-&L KL;*'6'ECNE F-BL6"SJC+TRI]+@5C;N;#@3G!TD8\KY6FY1*36
M;NG,83C0Z(^9$\R%-DFX(3[J5JQ!<#QHC<GS89CYVD";FM;GJ@,%X>@7VO'=
M\$:@;9;VGCK_/ND$F*59WC$I&%UA5TL&(62R/;73R7 '(UX'U9IEQ<B4UB$B
M(4:LN)+_;Q+R:42_.&&X &?ME??-+'[&.ED!4\BQSBU^K&F08T"6XHZ.,#K1
MV;HSVL'0*N1E+3I+LD42P?1Q6<> _R"Y4+2)-X>+JML7.]&M%VEAW!%&:1)+
M/VDOE6N\TZ9435>[=Q=FV,8&G24CL_) >LW Z7+,KDU@N::GK+4,*U'J$%2T
M=\DM?*)"T\* ,)NNE)C_E^\'7W _=:YR?["^T\E,?F,JXX6KX8JN!F@:DQ\O
MWJ.["K*WN0JN(9$(.BZFMKD?4;1J^J<2_K7JSJA@S&468#,J9FR)<K  )>N0
MN84,0TK&DEYMUXOGIC"8+">\9-OA2%]=2?HJ:-B@=*T3B&M5M84ZX;C+X@[T
M[.;,75ZLM%"55&\DC>>?9(E*'@;]U7SO_<I#YO0 +SMDGZSZBE:B)IP/:^J1
M(BZ"1%B(4[0X=*[ %.@>P#N P^D%N9,QR(Z<![JOTYVL9+E.LPI!5]RC;\H@
M"V_ B"KA4:W)(]Q&;%6SL[<@DA1,9,WFY+C79*C%"U'[P0!V(:C2,"07PD[I
M460<>/"EL#$+O?\$="2I3S7L'B"&3LY6L5U2UH\7@(*I]M(#'[UPDW5 !3WA
MG%"Z1MR_T.S8#!$,&0HP ?O NO2A786?@G9)VNF2I=%01L5O+0:2<<;];P7D
MH$E.XV!QW7&Q8K$KBS6.0<8H LTJ=7PO5MT6]8=8/M(Z#I(9-BF!&JVL;_OM
M*;F')^\OKD=(0\U> +W",'VG!-- O'6H[XAPB/\Q $MB :;<;/@VHX])QOHT
M^'BRNUR;S3E,@EBSU3;3!/A*P[25BFX%Y2L'2^2R>RZ=CR8T'%TIX!\ RQN$
MC2<N5'8#F2RIZ\>NTLP%?.?;=:<IJGTE;BCUD:[?FVREX;4O4ZZFG>@?3%?G
M92S!LQE+\+.Q!'^8L00?Q^4?9&T%Q.X+W_&"+119J6:DW!:[#: (V^)_BG;=
ML,9MW=17[H\."QWP9/$FA)<G[IWR]S#W&[/FFEYG0/,ZG#Q42^Z=&H+!V!?K
M8E_<SK*W[S_UPM0Z1<N9#O3DIF6X]+)U)":*^U#H'3"R3 VD<A.>T"7L,(.(
MK%(<ZFI;[H%V!-U"W(-AZTDO3)N0,*3<\XYZ'OS:0V"XND:JN_Z=J+&+2KWY
MRS1PKQD+C=6&5<=R>H%ZO3,NEG75D?\GN$9K#^._CV_IQGVSZ[?PL.^9R%W:
M?T*I;BU$%DAWD)];=-9T;/PMRH0X?;XEL$.6P,;'DZ%D,V&@&M4-W5K?:(!V
MIYW0 Z_::LGIHMC@5)<5&P*V-74 4TX-B+U7PX?2TTI.A]7&NV12RKQ3BGT5
M*QQJ/<05 [T-1Q@VL0SHGYC7;$ -$IGSIQ\_D)Q-5'.Q:\@Q1:%;-A,G@[0?
M8=A<0U_OD2?:EIEN]>'4BBL>Y.E]B<$3X;_PWCK>@?-H*%DY<A.&IM+E.6$W
M186E%O*E# NY$2RS 6*=;**J^01%/2=D^T.9I QY*E.YOT3OG-;QXB)E;O,_
MY\U03?;:.?*?LT>V0] #S)A*9"EG3A-$7-+'^%89+#8YTE5K[PL3EX_L6RQ>
M:PQTCK0E:A^$(E$^I4SBM ^R7T]S]V%?9;\V3\!7L-Q8PU=AT6<7XEUYGDR:
MSZV)%SK$^/AJ'D/L$3WW2N3%0V)[G-I(J5$MS9&V5Z3G-SO7<1"5GLZU%LQN
MY_MS.Z$J%&QR*'<DSB94-4KQ:VQIZ88N=_)79-W)6H-=%?\;&E9S\WY$%$PS
M26A.,J$&YWUFYG!V^=#%C)!EIZDP:)6^Q!\VZ74&7Y9O7%91J_I>.&N5,XTO
M8.<$^W%/N[%,.;F3$@Z7L\KD'!3A670>JQ6$[UU#+PI?G__M)L>-GNF;1=Y>
M#)+Y).EJW[&/M93QTG/I6];'1%\1< =Y?+NBC0/85+Q6H;-UT,/LIHJIE?F!
MG++,#"@4Y_\LBP*:K82J]Q"I[A*JTYB!/0N"B128Q:84V%\6>,1KPZ0PO4!
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MW&)R_3L9HLB?VF-]R!(TZ(SB*S"'AO6N.,@SFRZ1E\X&Q4ZX'=H^\A-?T['
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MV^\6WBYB$.(DZW-HAK1<M%=.2J2A"\MH7*:ZS?X\=6>[L$][\)IW9Q02EXS
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M07[381E5^C<@!&R4!VF=P8^PPIH0Y<[&Z06,:C9.%S<E5V*<)+JA\76^_)\
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MB(4WI@.M(#:HZ9O0LS035KV,4<WVY^*FY$KLCSI' 7.K[A&UH^>5[Z3S3-E
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M!1;2J2UC]K?>=2Y^7,QA]EWM8OBIEK]CPQ]/HB.KX+$%7OP?#)%A2P7BTO3
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MOFV(2H:'$Z5J=TU7JA^*:5'9IS@1A)!:EQ4"6P/,0^8 *[(T$D93XWO'C$=
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M8%L,(89.\*7_-<#K@'#,$7A)A#(HU3>"O])U3H.BU7LD6L)]K4C&)%U%T*(
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M"AZU"*R6[=D%D8T7A)M:$%-3+C/."<[NY&1G[S'9#BR1+[EVF^-;Y; ]LSU
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MQI1=F>W%]8]JMA<7-R578B]&J=!\M6J&FH#2NS9?]3,IULL8U6P@+FY*KL1
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MSP5]@IHDRN#&OPYE0=P=:W.!TU4,.2AAK'1Y!Y<OP2<H6[EHV9.W!!]O8:O
M!EJOT07L0W$C 8["=6%<%0ZE;*TW,9OTIQGRJZK?-,/=QIVV0>>6]4*I7M"<
MXDJ3A8WA75D/(TX96:G!>]R6=;D=MF'U6UU?1^=]TY&]HTB2*G8UF7DX.O1B
MZ'?Z[*]RA1\'<+#Q%[)3Y(KA#F77#;+NT)6%)T+JAVSE6UK<Z(<6X*63N2?N
M-4?GT%;W*#\[.N_Q_M^M%T'^#RTQNKSP5KH-;3\DUTFV.MVWI*.+[LWAB XP
MCL"$6GPI5WC\%F^B& ^LVV8;3HC1X/2\2ZV.[.1@<_"(';U=<_UH7_!"@>K2
M460V&LM>+,X=GI9Q2'1$@PFZ@7_<$+[+MQ)<W&;?>!T(/8F)+A]W!<=F;FSC
M3E@W$Z^\CN/&._'4GKF11L%P"_)X@CXU#],)TI4]D$VY!$N8(_4<7  B5)_C
MB^GW&)OA399E\<]Y]R;[=6AZB9/RCN.KE@56S'N-2R\_.T>W[FL(FHD $G8K
M.2-3NY-?"\;*$\X([=1[JBCAQLM@.[;PY"MB=])USLN%5_M3^!V18_)CW>'[
M.GL%QV:5??'%(OOBLR^^I/6^][!SX.V5ZY(U*WAY.F6YVL"LXLME7U>LR-K[
M3BT/_<A:I^S++[[\[)/UIS /X 'CI__KCY\M/OOL,W9.<^M+X@!*.!UAZGCO
MP^6&FE((>^_RW<ZC)#J&W86'=0KFE-8&.=0T(IQ+,.GP _@E#:L)C_E[?DQK
M9\H:TP]X$_/%WWTF7]1GIG=2UFYLR":?4OT,AD?@85(W^VQ5@6$OP'.6K!-N
MJD6\Y>=_T"F0@0E]6)%1>J2B&4'7OW&#I(C,>].];FC->E@,*-):XOK']Y77
M]1# 87CC;^'"L))N_I/>>@U[I(']U(JUACNKK0Y'6Z$&U"5R]$.-&YZ\]G!3
M\I9@J\):S&%H/7S@,<NDCW?\YE:??O+YI[?9#T/;#2A^ ,^0?NE?/O_LD^+3
M3[[X=$$/1&=#3<2O!]):@:G&5X)"M?J*:2XZ%(?#G;_,NY*CZD(-<%B!6.A9
MJ#9"] 1T+79#MX.8"*?#G#T.OO<WL#6?Z]R%E9K)2N6G#:=_LF8SYIZ%2?P/
M"/+P.7_(:U_=9G%?_LGL2YS)@AZ/+DU3X/G]Y'ARP]TV<AV:N%Q?]>CJX#O
M35<YWA]G'3;+T$I8F?,9(H./#[]:P6.MA\JRW>%?W;DC7N\_Y>I0;-#"+/@U
M;Q X:F 0/1L/\^-D\,1;-3K:'289DP$LCH[HL4'A.0PWN7U?(WM=_--_FOFG
MWYM_^O<S__0S\$]?8:[PN[432\;6IWNG6&;=M)-4I4>ADT0JQ7&Z824AV<H[
M*RT4J %7ZCVO.+'&4(A_?>H7?_/%[V^_G!G,GZ+\/S.8[ZZ%P5SB;1I??@^&
M0).35!ZD"#T$TUU,-P;K,N,@KW]4,U3IXJ;D2J!*.8TLC3E#C'<J\9UG&*U^
M\=E7$._6!_Z</OG\*T498#BE6>9EV[RA[+)X,))-2Z].X^ [@!>3%Q2!HC^#
MX6_78X"'R;<6,]FSR;K^4<TFZ^*FY$I,UJ[ING)9'6B G-L4JX*ISF) %%V%
M'6R$:A.;@\"P>X/AZA#F76 ?FWY#?"5TD 1"(/R!,SG';(%F"S1;H+'3I(7.
M?(OU4"X+DOI!$$>8.T%>QJAF2W%Q4W)5EJ+PC$4L+'",,#>V#FD2OIBD832*
M^7N$F"6\@G.OR/, 'K^EM^^('Y(A?AT6I5>^.P]7;(4Y@0#=0[O:Y-QV87HB
M3!.SJ73C)87+>E?EV)5H6P9<NEB*LAIZP?I2OX1OL4B#%9]F7T,TOBEW";91
M:P'X)'S=53X@S&R$GD2(<5Y5,[K\F='E"M+&7(TMVI@UH'!R 9[6WA>,KXC&
M(P$EXE3CRD(41H".V^;7!:U36$DE/.[_T)^=7Z]1DVK!\'*\0="(PJ5DJ$0T
M!BL]+=T:(C4*W%9565.35-_"=74%4L-+US5PKUYQ)K%%A7 M+)6ES3>W[J<F
M:W.4U9,'#RA,PM+&H.YT,Q*,BLY.+ "-S#$ANV3[F3\A(+(F@#PEJB"8K#MN
M0L).'-XS8AXP/MWBVR6 @J;<O%3W8,(5DD- )1PWO T! I\T)_ BL)T,'XMJ
ML'P\($RN1SS+7;ERL%L)\X!O'8XA>G^_-/"E#.%L0\L/2 6H92.3CI^DUS/K
M"EZZKSN:AK;%&B1#? 334;8%=[CY+N! EHCBN/>.TH*$PJ#?$&)[N.-_#FVZ
M6&@5C%9;)JM-8>/_R,2Z1TWL0N!_VN:V)*P6(I40Z$C6E7$HV*;%R,*,CH+;
M[#7V@_.Q$"8QMG7I55RPT/!R_=M0K(VFF'%'-1B%.!2VS 1F4?Z=7>O7ON7:
M+(M2PB:K_)W'-K2Z1#0.=_ZIA;<ORJ4O:NZ5>!+7X148W)L^?^,Q3G2$XNMH
MUS%*CA!FL*@1&5@TJX&W%\[M-[[*]PAM@O^1M5# 1X1!A75 \-0\$V  S+.T
M$VOO'_^"XM:C1D9WSFG!>^-:UGL@Y* =V,1D"&'<[F"$L!NF.AE:#X?*BFQD
MZ[?-/1\T IXW'8RS2_&<+@7V[W!2-,NW#&.4_M&>#F!$\9*/T=/* I^@:7=R
M7!!&6W_UB=2&SOU BD6?+F)'3;RG"_=<'I#8)UR1_U-_2XL;#:'9/W3>/'Y?
M!%/('@0=@\R[BD!>:I%K<CC.X&M%V7IN>HX ?[O.MVB-"2A#R/9U?@^/"J<-
M' ?-UO17F\&R6^6?'$;SP9?.#**90317#J+A/,W$;N=.UX)]X'[3>L], ^1=
MM?<"L+N[\]2=@G^_.7@4WP7GOA-N(+(8"%\&WS';^NW2>&''MZ21*!S95]*7
MV%.8@='!7'JZ_E'-">6+FY*K2BB#%T&==)3@JZTGH@PH8(JP?S7;0SB+Y"<$
MX:U[C00$FJ-=0E4U<8T.#1!&*36:GYR0Q;$9.^)UQ 6:[=+UCVJV2Q<W)5=E
METS[EF2F=Y[8@\1VL'JOC9N6F*VM*NKBK0[:V 516(F$3Z>]I(5\#YO#_%N_
M&JA1H4%6!=\NE,X:+H<YUU^:5@#1U("(':99/: ?1E7[H=_ %_X'QA N/QNS
MZQ_5;,PN;DJNQ9@5]U@PH?%)3W72S+P>D4H3T5ZGM2MDCZWSV&Y!,9PD^J>-
MV6QMKG]4L[6YN"FY%FLS[3K5C>2*3CM!6IGDLHKTK+,/-%F,\6]7?L<09P9W
M@+E:9 8X0B/!8F_@,KEO>I^0=E3Y?I$-.^&$R7>8T,XIDXX9+J(V@.'#7_?-
M#16#R>?+J8;=4R\JY<R2FBW<)!0_\;(\#F2Q["LF?:%A* N+VM/9A+ZL4<TF
M].*FY&I-*-J<CV";&BY4DH&4ZN3R8(TLM^&*?6KC#R@0!L-L"X!RAW.%TAE!
M_C)&-9NVBYN2*S%MJO,H6:K(V3<%35!4.6/"T&,+'*E4D(RHP\"A%'^-^#VP
M@VDE0&THXC*H,$GE@_'UT0\5.(.BF[N!.-0#^DP^EAR<P:(E^+,9RWX!>(Y$
M]T"XM.X0JF:637J,O1:/_(O/?J<S'*!J_\[TD-G7\53+_HI!!*R-;_[]Z[]J
M28KQ95S74LY IQ35N$J6(:M"2-,DLFGV2("=??[E_PY07-DF]F2W9SF1G'5,
MW1FP>/:Q")E$0AX)9B=!YY'8 [L!C#K:PH6(Z_>8Y#<=+]RJ(9Y^W%LK]%MD
M TO?QPBA1)O=)9N]089*F"2"X*V,+ 01=N]V2"6HLX4QU8TB[B8,1P3]$UHU
M8*?*[<X7GFI_[9UO%QERD,,;@1@3XU)Z7V\/-%C?(;SUOJD($V%05?JBS5NT
MMRH[^"]LEDNOU0GF\.3K1$+Q,$5'F$.*$>W+$G+PU:9I"+D<0N"!OH\+0"ZE
MWE=\JT@76OBN)%)S</S&T#(,G-&/G "8&3QXBBX[9<)MZ\6["&DH6SOLE@\%
MXKTJQKH_?C8SUKTW8]V7,V/=RV"L^SCT_N<"5>6B[0Q[#-@J"L2_WF UI0T%
MV->]7"'X"$J'NX;3IJ7N-61\61&6MXU>X]]K8KJBW].'K^!<@O$$N)S0J5?@
M-=P3,]ZPE6I-%--!*NR*;D'*QX%]>N@FR?&FL/,(?['?$>[6"5F /"*!86Z*
MDHKA-"[FF-5!D$<S<$,*-L+$,K>4M#ORE_QV5S4'CUTF,U;^>;'R'V\S?-*T
M) Y%JQ%!$2)W,G4)-WT)/.8P!%O^@FZ0D$S_,K1E!TM0$/M$W(0_I#V65<TJ
M--I)HOWXNA,C@[WD".5J+M;1 ,[?__1V#YI&W^C'9@B?GMOK+JHAJ9 7"F]Q
MEF\5&MM@=E;>%X1'X8Z;\(#X$ -L/.X%8/\*_C137<XH_1FE_^RY,%3W83Z%
MMKS/F9JVRLMMC.;"1D?2N0%;<D1::^DW>;6>JX37/ZHYE7YQ4W(EJ70U'R=M
M!KH/&,""-T/YG'59#."Q@S=0#)AXWW-&301\;1<K:\!L_:3K;MK,U7]7H$5T
M^6<H_<L:U6RF+FY*7HJ94N%B-AX?P!I!- BA&>?M62>H#<Q#%A(64OBAR$/U
M&UL1D0",BR*S';O^4<UV[.*FY*78L<[[-Y2C:4C=N-VUOE\@Y !5SSR*KC%K
M2*1*0M-R#R.VVH7&\LQ6YZ6,:K8Z%S<E+\7JY%3PYZ*.^C!8KU^C;V1SU(I<
M>GSJ?D9KOHQ1S=;GXJ;DQ5B?4[';XR*U(QP>.4ZD8KI>YR42UC0K%$OQW .-
M)>@*F4"1L$;LV7JH*D1KP9O 8'&'OE7?A^X>UD.5TIW\A.IR0:%TDQ/&"W[8
M$1]D8C0)1L<CP^JVKSNL,3%KA;!"UCF*Z>:(1EW[NLA)ZW,&?CY_7?LGE,R-
M03[+EA-Q$?KD)+X]H/:@UE80:"=N>BXITC:K2H5!$-MH7*I_4<7"5ZL^+'Z&
MW-%NP>QK.);=WV]?WX8"L52525\\UGSMNIN9*Y]AO7P+LP+SA^C,A0L8X"^"
M?Q2)5G'*>3D@Q+'61%5B.4C(4B:<;) %%)!905-&6(/1E:6V?PO_L6I:K%M#
M!.F63:^H!+S<U%H:NWL$"B/@#MV&UB5<]J<FL B*[2.U^+Z\HQ'2MXC;%:5H
M=E5ZW<XIN@GIP?)>T2)UAT+#G*TCN"C6&=JA(EC"\D!P5T]OB4>\0*$)3-$)
M2I69!G/A:+:1\#'Z1)[=G<5598*K.@.PH#EJ?2<H7]S!Q.:+"L^DJ-XR._/Q
ML2?Y18);N./%<9O]O&$5<H,<MS-E&A>86(3F9],(+)9'9]';\/MUOF*\%Z4,
MX/W9(HM#O'GMT77:>&H-PW0$3NRRE6<@JT0@+ICZ0?'!W$&V:3I/H."[FFR<
M]J:.WE<<T6WVG:PJ//]9@WKO'=M8)?-NLOORK@'KVB%*C=YGFO/ I20FU\@\
MGK_S*%&">.R26X>E8<Z=X@^?).&.TT]/(Q.,B&9Z/<G25V#?0V+B<; N,-_Q
M4W+!38!!I;[XB5O-!\"S. R^0RKZDTL/5QEC)I/-%UQ)@YB<V'8CQ"0M%[C4
M&IZG,\!*BZ1T3!2?DKJ>@U0>E4)B-XKI3<"\(KD^QG]7M.C$E4UG@H%L?K<.
M*WDOZH;X*)DO^9OZ&F]&KW'<=8(O"_UK],I@T^(K@ <9ZF 8*NJ5SVN7KT(3
MC[1H(=7NXW<X-XC1FSVQPU-X;(<M7V2\8*A;!MY(!\_'WY_/07-[X6:&L=NO
MD8N>.U0,#MHP8!'^('0]3ZM^\ODFD@O2E?(8G9 9I_PT0_[9DT<CJD+H/J,V
M@I47>O<)1C$#TC$XLW8FU!?<8RZME6(2IME%W=DNJB?P\FI6:+24U!O\<.KB
MG^Z,6HU%92-]?0FG0<E'@3ET$KV00)I) I%YQ0YL?(-'(A&SS_$D]@N\#/ Q
M4 BDFVSK;';1V=R3)$D?/,\,E3,":VG\#7+,8R046IB'NNPE]F%UCP21%3LD
MG8IYC2W>;.F>:,A/N!Q(OZ6 &!&,Z0%3K!BEA7EW;'N*@4Z[+EK*"MZ&G["1
M[V+QM&T6@EANT<5NV7--QBZ8L_6 _K$:,Q%ZHI9=I>"D1X@!N&G_#0^+]G+%
MT1E3!W"GA,A[>QWJ6*7.B9$4DWJ;_269J0=F2;*",F055!N9X0<.,O7IW:2F
M3U"R6@[,R:XJGGVST#$MPH 6IQ9&"!P,%-V\4"LW1,SQIY6). Y7=2 ;B5N!
MH$F9-HI13ENC]]S2E]DM>;X)^/.Y"?B]FX#_,#<!7T<3\'AM)*?P!_;"A,3#
M_5AV;[)OY4B:G9VG\H#_CBEC/$PDZ*$T,!PRS9;T#VL^&]E?H72Y)&+T/&?Z
M?][)76B)DLS,0I5E*2$DUY(*3#Q/YH;CY\VSNKNJ6>(,M;XH>07$:=.86@JD
MR+R$4XV%A1X)\;+[I@(GI=(20E%V[2 .F$;G>==GR8B7<$S>@0]9%WBP->V_
MHO/7^W_ZM^!%N0[K)YX$$;=E778;CRWRX'>%8H4.]SXO*XF[%TI40O?&E3EL
MN:*U+@M/A1'[A;#.82S[?H-.W+JBLA<6S"@?@#J\++$)YARA#43?(F0KY/61
MCT27&VK.R!)+8$L%+_SI4 OE$(Y[B3#X<%_<>C1P64:WCWQ-.&G'4Z2!B$PG
MW^40E2*7_BCBB"5T _#'1,RJW''QB7UU\(BW.%!\+_@V*_!;C<_K&,G!GP?:
M@Q^'KBMS&M;?WT#\4'MD^6G;IBV[;?1S[WRS:[#DB4*M5 JEY% M=1X8@>4;
M2@N*,1D.04,-[K3O4*T89FJ'9HEQ!91#YK%91YTNA])'\(,POO"R)L.5Q[[S
M!:T9C#>,*1UP"6UAM9 NJCQ.F(8P_O!B-&;S;W-80$M<=U,VFFI^O(IN,ULV
M)ZS#JFKX?DBE!5^"7V7_G5>5/V1_SFO.7[VF2B.&1>$C^&E)BKTKYKRD2*/U
M*U_>B\"S2++Z[%LI?G_C89Y@/WY7:PW.T'(Y%=K[]IOOOHXR>XKB@-O>!!I+
M8KYJFYS$[L(+Q\<L>XY:HAUHT6G@&!-W&17J*^2:DU0;#"IO>Z'MI%7Z4TLS
M<%@D@_\1XN'VWB_"?.(X6<JVXA5?MELM$!?\I!0Z]]GK__[SU%ODZFL00(;7
M1Q8T7\$QV3D&/\$KIH!Z0<M>"I!HE][BE[3\2G$MLCG1F,KP>BF\A-]R])QG
MW:'K/:X(>BE,R$PE&HEY]< V4KA2T\+M(D7B, N3;SXD&H[G!]\?"1+#287R
MG6QW*I\3R3(OW!L((;R9O6[3M*@;WBV<Y%!I2\3J,^LOEPPPXU>7U3YO;W G
MP2MN">2O.594H>X6>C80.".&]E-;QUAFRHF K3]92Y:7>.:,M#N1OI SM*!4
MZ@X^DN0D2LX?XV=AFM!A]D!2-=\/:"&9YRY0UHD"\T%9NJ?-.O%PH/4+]RF:
M/<HRPYJ8F@0]RGVXD?/U?=DV]=: 27 YXZ&VPS>QXEB6CSEV)&,%1Y])$P98
MI;1'C611S%FN5C6^-]B2CSL2F]8A9<C$&B? AO5<X-5,KVX9YV-O20,^2)&*
M7B.M2S=AGNA(@2_KFZ \&\Y/[7%14Q^P7]([EK<B(X3EG>;B%OS?6%ZM^-W)
MWRO2J8$C -PA]%IP,V/::'R?>&$JA/?@'E8'50]G^A53 .<$'1]$;,""S'1X
MV5Z2E^S[6WEW]JN<+E<;#L"WL)&0-M@H(#!)0X&18$JR-^2!.9P8!=POZ+M;
M>6_4F6=,3*2:)*"(*U':G>:$E5:-NOJHS5&LF>*=A \?MR48A7M,R>7UU+:R
M%6LNWJ?)73$/.#EY3_E-\\I@2NX:E/K %-X*'-Y!MA9R3@S%G>_GJM"3Q,3?
MK4=*[N%,R^$H.2"PH6AH-5#AL:,3%(XE;.Y'$-NN(5 =M;KRWX<Z;JF)[TI<
MD(;.@0K,[ K82$(W6D%DHVE:H6:<@^BGJA'I-,A1MQ8@T&31 (+8DN-#=$4S
M4;<(BX"5L'D5, I)UUICW:NP\'1%T8IQ@^ SDU63!"=DU<"-\CUYK+?9SUX7
M;V 2%;9:O@.!B9(*3KKD5X27-8_KTJH#/AVEP<&DAJ>D'V%R=;+L]2YLI*,8
M!\Y\-N-.S3BYD#KF_:;!<?.8AXXL]1U,GBUJX/Y>B_,=?LA@!PXM[>;%H< !
M@0<I[]E(LQ'FP(T!*WLA^'M#^0S9K_B:1R=0.A'9BJHOX=7!%_AF:SCAR2-N
M_=U0Y2U<--HA7DD0<>'2",6T"A\.(5_BGDIFQCC%(<$A9Q*/7[$1G.70\PU_
M#<?=69 .!@J\2YP8JT@C&TI,Y!9-PR?0=7ABE-=OW+#QV?<SQ$ TK1!6F%8=
M6X&D72G@7(&J<YO$?  ]Q9"_JYUF51>/F!=PVS&5@$J]2\S*:8>-PDUSB;(/
MAMHP#SLU-13!.I=]9UPDP7V39PW_ZT6:L\+R<^7OL>*,1^2 C*AL+99ET_O5
MIH9XZHZCF!W".O.5'S@/&"/_H\2S+61;L(1)1%,*$$MP&2JF\Y&V)\"#YX@X
MOIX%QA8:;(1:N<&C"9"5XWE*?PE+"<P5F&4\#11S[)"-L@XU#@2[#NTJ(G\U
MC'IR_.IO?,>P9?M6G2G'IR1!1>#8Y'5 Z;:EY]4O>$+=&+()J&],DPEUQU%@
M01'T#=<:"/ZA7E=<'Z'O):B=]8V#D!65Q^Q2PRNAL:7&EY)"8R8X[6;C^D1#
M?@6;6*8?VQ+152S".MA[P;F?Z&JI_%U>+3!1B<E\;F,*8'U:,VPK_>/6G;/K
M3C,A_S][;][<MI'M@?[?GP(OY=R2JR!&I$0MR4RJ9-E.G.MM+">>N:]>I4"R
M*2(& 0X6R<RG?V?K!2 HR1(E61)OW:IQ**#1??KTZ;/^CO]I&A.^3@Y^$J()
M23@_TT?#JD<V,.OQI)L:5]NF.O&#(RSV6"2B$D<- !OGHOT<L3]ZH2S3>-;S
M*I'9LOK*+\&_HUP^;)HD<$$R'8-9CO?:D#S%7OP&M5KWN>,H'T0@4#???<'X
MQB&&J"@(D(U&FR]S],I_PCJ_XS+7<)E]P"22*<WDR$0*W^=X+Y$$I]?QC[A?
M;Z-B%/TW.!)/\QNZ#CN*\^AX16:#J&**7*&@D%M*3]'+K%.3<\8N,Y0@6 G"
M,9J&4UFL,]E8Q!4>X3Z'KBY;GE!DW+@7W:Z0'\WUA;B LE($./6*9U$.Z2^R
M0-<!A)0)US.C)!T^(;8*P0Y+T=)TJ^:>(U:B8<2A$[P!DP<G@0'9 HBJS86=
MTZZ@OPV,M%E6%)CI9J)EO[U[=NSVU2W4;Z$;\G0Y!.>S& EA<KP6V91;<)RR
MYD3V5UV,BP\2G:PA5Y</Q=2*QE@H([UKT@Q,*Z OQE\DPE5,,;R6N]DI.2X=
MB7N12__\@\ASQ7@&6TUT4]33Y&&S*FY&9VX-G1(7T3:1X3?%RFH*\,",E+4O
M:_V&Z51FP6>M9[!,V1[X\IE/NI#G=X:YEE+O@P48!M+-VURB.:J!H.AE4Z[D
MLS:$4[H4(BJ1S!OI!&M51_425-? !A@?]G^Z,AWI?G4>Z:V3#J^==+BW3CJ\
M'TF'=^+K(.O21K3.8)_1(M.VCU+SL@V67;9U&Z\UL__<K#BNZ[2!(%:\ULTX
M[C0W#O@#P1FD[E0T-3U:";]T@F-)M4!'";EJB1<QOP,5JYB5(?$@*)MN0VT3
M9SGU9ON<9F>)'IWPO4L^DC(NQ-.*5D#H*6:!8S#MZ9_-"0L>!JZE9=:*%-%"
ME$%Z)1Y47.0@=W<;<:3S!_F(*4N%D2HN2:I 2OG-<Z*YS56"45_CW$%UK$HY
M:(VN\:D>U3/;6B9&,3H.:_N9(HL+(*A(WI5AO+C;ZL(EB"G'622"J0&:%5[8
ME +E)=)@9ALK9U-L;$G+1AW:SFL:%]Y#5.4B?GY5]S%0B0D!R35V4V2+4\+'
MG#1 "UOD".NJ]_O:X2N4VH.V5*LE&*I4GU !BY.#<8IE4IF?DVF(V5")B=DQ
M!R8:6B2K5BI)UJG)= LYKFI<>2*)%9NN-M]$TL6XK[V95!$:V*RZOX[2'LQ:
MO'0'QI?PBT1KD3"C^E9>L 8;P"C^GC68R< #VS QX6:_3:KOJ20G9#,OL7ZS
MR-[2A&PBQJ)ER<S^V!V/J]8H:+!X],_OWA[^N;75M1U07@&KJNZS3O![R@ (
MG, Z'B.2Q%0+2-DMW/&-"_-V.@'=QW6\S5;7[/*^GHY;4<+K1Z;7.#)'G>!H
M/D!Y1Z&F^0-1A'&]7T9?_CS8[_ZIA_/1YF9ME5@)]<9>AN]9X]+%RRP_Q/]%
MM*M7R/@P5_CG83JBA^&?'PD%K/@(:WJ6P!7R9_SLSV%OJ[>SU=WJ_ODG_JO;
MV^[^>?+LY=&'-^]?'KXZ?/-Q\\.??Y\-_C4=35Y//B;Z.XXC\@1GD[3\\\,O
MR=__Z7TY'6[_,?^_X\/RU8NW_?],_Y@/>W_\-?KW;[/1KY]/?I\F?T?S9V__
M\ZD_^;_>'^7_?>IOO?KE9?5_1\\^CG[];3+ZY8]4'S][$?W[[5^#7P[^AO>2
MP\,__[Q"![ K&@7QEQ_3+'U;45M';@7\I?R@Q__\[B6H $B:S:TN_'^9T;^[
MO<WM[G<NX?6P_.=W1UGZ^Q;\7[\'SWT7Z&(8S=!MD5= -=Q3K%[C![XC),I_
M?@>;^^/-[.V*[1S79!!427_"@2TR?L% ZFA@4*V>6P9ZZ4[R:&K*5RQ_;[W\
M"OY^!>.?X 1&CH';N/?O_NR7?O_HEW?O/M\RLUZ5B\[AE.VOY906*E'7R,:N
MR8XL;,C>E3;D91*=_#D:?&S?CW_]Z^^W;W\M!\__%=^3#:',8SC1\9?RQT&6
M)3I*6_9FY^I[@P2C:C9SJ(I__%";JKG&%K>-APJ5S8\@> $Q6M@>8^.>3;Q8
MI(7$6U)J=V[=Y]9FI,^0:[ZX&*I [ :,E,,+''%*L.UYQ1YY]#.0;3TNP73,
MHVH4<E8#1B$<W-D,1N&(#%6-Q/G(X/3R>D[CC ,,:*W,$.Q@2%F/AAJ;N4Z0
MF HATMBJLR&)SC)Z+C\*<9UP6#:1\']QC,1!GMD43%-Z@PB.I0E"'9&7E3):
M7I&IK$LED)/SSCG?9\I0"KKIY5YF)L!GRF?\$*RD]X'E66*IBR TCF98E11(
MF(UVD;<=\6-,\%+23Z@(+C0^%]B/X<1_P5+:^SS50>7U;YED=*S4&GZN9KA_
M"*-)M2@E5LZ9B%G)&"BAPG2=; 1'\K1*L'C%E,70)6=M?+!Z=2G5,>95ZETV
M0Z_(@O#:7R:\/B)SO0?>FK^C!)V320E7IURDV$@7/N#NVG.%V<Z+:BM^\7SG
M\X>_'I0PZY\KS+Z:@-_]3(4+Z4E&G$J97[6G61ZY+#0]'G.F.^::%L((P+.&
M42A=;(#JQDAC5@.RR*7WW\EBMY 7Z0GR^/F[?3!X/OW/[A_3O_/Q@]KMW4M>
M7:WD^N[GFK!>(FF726#[/\V_WK2]9OCD:.MPT<(9'R?EZ_^<[L^>[S/I1;-G
MYERJYO>8KG7-_^;LP\:\&K8N1B3=(EO,N-XO;P[?ZC?_.OP2M2RRN9">'[.\
M/T&9IE X7"84/L#A>#?V>/U\JV(V?7_RHDC?O$T/[HDH.,>LV#OW_"^EC/2?
M7Z8^&;6!<).E/DX7)/=1FY$:>/LFZ:RUL; <PQ:["'35)-9CA/(:4OUB\(YQ
M;D-,$3EZ\2Z4$CRZ93)X)-7!PM1872BD<AS&0S"R96+K*C;J"Q-:\ZGV@?4K
MS$^Z@+62-[_F?P%#_/5E>/]9:_^25\NE:48E539*=Q6VFD0%E_\0@'JOSUG?
ME&=G\\8I <Y_*[2P_=B91 ".7:24#:9ZI(9B_ FGI;&O1O+0).(F 1_%2;LN
M( M:]><X2;#.W\XGE*H;L32P$-WJ3H6@ML.0B$^74L,3. 1H?@'S6!.&\[E&
MU7FW] *[[U[" X#P!CB/=SD&*+"%BRXNS^X[;^:_O>KN[@V/1_>?W0\NZP2X
M+,W86Q.GK,AAYH?EXU)'4U=CA6:@9D#:*QR*$+O@G!%0;^%'MT%FCI%W\3_0
MVBR,G4B(@FC4(F8#LK:V_C[&;:B?.5?3C> M0_A?:RR'+F45S\E2SORXN#+;
M7\+8OD:TEQE5U<&-X.5+3C7"8!;U8HQ%CE_J9'^6P73?C9\;E'5K^US X/_^
M\OIH;_LPW_UR<N\9?'?K7 :_F$3,SP-\#C?"0M93W1$FCT\I \&\1PFC-4YB
M'Y-P?2D[B18B&2!*0NL7>Y^O?^&+A?LRRU_1\813X#YS-5GX;C0^_F_WX];I
MV_OB&SV'5;KGLLJUJ/?=ST=UK=-W"UBIX*1!,V,D2VLN3DX@H8A)J 1$IZP*
M=C1F>$G3("#$='H"?S?I/%8H>ZXQ<IZA4+.^*PO-T_J"L*/#$H(9HLF$*%G4
MI2?!B@PD\J4Y]C)AP@ONGP^D=G_,Z$"?[Q3Y?#0X>'?\\?-O7^X)RU[*)[)[
MZ:#<UU+RNY_=R\O<TLPI?)M'U8AJ#F5LBZFT*$*QA)[XF=*4ZF)3V!OEI -W
MR7(5C4YC:HRWSE]XN)T\;KS]6L:MM-"0PC@ V!O/@<D(=7R[&P9X^D*3==F4
M5L^72RN.1B7S0X&I>I=_T!&V>APD\]>$C_ Q:S[U09]@;S$XTR*V7K:+K;UW
M[W?_3K=.WGR,[J_<&H-6WA1<%\6(KT_4[WY.LZ6BBSNFD2$Z;P04O22!(2GP
MA>FV9M*985RR1.3"'$E;XQ+;049I6MDD6;S!7V(]7G=K\W_#6L%WU"KY&)>'
M/^OJ%!G4:@&BRF X9K5T2127/EP5V]-6L.8,;HL55Z"$Z%/N7"1@4A2J(%@,
MU\U("N(H@[2H"*X..Z+.I1LI!<FDZAY>( A,FY^-^D$TTO^MD$+2$I#S30UD
MI$#4>>W.3JH(=U"[HB^N&\M*W_'!O=121ZQ:+C(!PK@Z/9_0RF$-6A 2^I#5
MQV:N7-(L+"'?B.W*QQ>7=#Y<RC,UK*XS;?OE<4!3 %B-)X;2O*MRDN4@L$:(
MHZ6G,U.B7Y;1\+/KI86[+>%3\B2.*L( K4=<I0;.]&%D8$:"W\NU+6K3YC_5
M&>V"U$UROKGT0S"UEEG>U%1M3K6UBN6K)OZ[_%4SZ]JD?U*3[$Q3ZO89.J!P
M UW8'_L22MB5L^&Q4"#E3E[\3^'QAUM5UQ)*P>JK<ZOMMM?5=M>NMMM_V-5V
MWP"[_V-@5WF3R;#"+S>8[+M=3_;M=;#ZGCSF^L[RX>L\=(L?76DR)]Y=LSF7
MBGTA_QO<"-W^5@C:9%" BH$=;+%L!WUK%&\+@R0:8*):EMM,L@K[ U74.K.@
MTG"X8EXF63Z)IG#B\4+%2?V&-_K<@A GA%D&VD>,+R*"16]K>S=TS7VP@ CU
M0;K94 68X:U(N!4(A&$@<5 K&2!RWJGH'/B"_A)SBR5LOYMP[;Z!5O&JY@P<
M'^$!XW^1*8/B!/0*;NO)JL_=\-?],39O7@;LU&7 =B=XC1@J ?D2-5Z<J*,\
MB*3_^^<# -5=&7 )_%_;[)7 '5 >G'(M4US#&[/ _@2'PQJO;"6>:H;-*$W
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M*\RUO3+$VLF&,:M9)>CFJ9[;V8^I#MI+Q.9$@$71:4]/7;U;7W\WK)3 ?92
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M"J<U[]T-[SF>VE_DJ?Y!V-W;O:0LBPB-%+M62 ._\X3:<2U)3'V0++;SY9>
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MQMYB!#(E*.R(OD3IW&,RLDW;06ZX%TDC $&V])H)N1+06+? +G*F^#"KDE'
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MO88Z"O/E38;O4^Y^)S!0K<\'G^2OYI4.G#C#_[4$VUI><&B3OZ2@F X/YK:
MV-[K*^]2</>&5S9N*\7M/&C>IB<R"<&%*;*\:;PQT%'NE:!3(-),%6]5^,;^
M]W"]I+#E42$&=A?$JIQ42C/&F4A7#6G%1WT-7:QU.5,]E8:/Y*^88BH1!E0,
MY7!OT9FI;(3%_"46/*A.\/N,TG069L*719- N:YQ BP8GV),,*M'9=S_G0Y%
MK<9;+<4#%!1 "_WG>L"CLO"DU]GO!QLU*$ /_H^R"19  >%7_B]*_P3YQFJ
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M]9#*9*<8"345Y)L$=*(&<>;EKDDT*C17OQ?L-7P0IX*ZM115TU60ML*ED#.
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M"(61Y=C>;C %)8P'+:@TB9@&T[H<K)G/?S*.X3H33I:4,^JIIX3-EFY\#92
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M8X7SS.?WV5=G/7-$&\+?B^(<-8&*4_ I'YI:6)I #6^@C:<^*F'[3 ^CJC#
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M%Z>MVK[4Z&E:I0D&F7#J8/G$"?5GKH9P8 KTR\^-\J=K\4GNYTH')]<G&#[
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M^'IQWX4XPS5$[.U]#YSS,CC0B_#8:@&==@)\#Z\@RIJMK!$X7<29A <)5=<
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M^0/57JQ_0L#!09G-AE'9_F<#+CHBAP3^ZCZKSOTL)Q;QCC)N#K.QN5>7+H!
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MA (^W*93=N'4;%<>0?<_"=<NQR/YK)&0$TBYB5>0G7O7'[Y-X06HEMG]CII
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M((BYA2@Q!$Z8X>A,AN0%<\HV4U3'[R_@+(GC3]&I=#:VXW=#*3.5(MT!XMB
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M0"B)+ 4F3_/I^/I')<<?YOC]895,Y4B&WW'Z7G[6U="F4!,80-!%U%ZZ!-Z
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M%2\Q5AG63/UV LK/$G@6CDIG7#]OY?.XF60);AZ*X<M_6^ PB:P7EFAZ4Y*
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M9S/QY6?X(FDI-)(&BJ;/X:IY?7=_F7MMCN5HFU;%K\.2#Z*?D@ 2B&3G2*3
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MFLV3;* ;D E#]RDX>?X+C"S9!%D.ZV3)(\L"= 3-L3\(Z/ SE[@BS@%*NSE
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MXRA;V.6"C@:=G7FD5MH;F#Y^O/[)E)D '0Q"GL[>C MU:>H;)4^[4?+T=I9
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MW,1>UNI8H8Z3J]@)K [$EH5QW/1>USMT2P$. WLYLG4IF=W5I"P/@:B@X:C
M,%?&:Y]3/\L?/>.&'T8;SXA)/W2'/\CVQI/ K'<6P ([A-,-<R3R'=(TDXZO
MT=61GWO ^RH76^N3S=U[5%%'<RE*P/IO1:V; Z"[X_Z*PD@V!:4&5GCFM#_W
MZLLX]7AYN1]CE,DA&*8#C>;ZG03KKN\B$YA+0B(9T4:G7(SU"@E7A.:*3=H@
MT7$W\)J+<7"'+^RFUL/N M4\TU79R\Y4U#60R]Q6>OQ1U*I8UH3AF9.*QM7C
MKE0XT=K373R9GIJ U YIMRI'=XTH.V-JFD $\IO059"YQRWK3N/>R\BLL,5*
MY5"CFND5XNU0 ,U*MDEP"IRXH25($$X)IS_Q1&HBZ'PV&1*PMTRP05WB23@#
MLC3/1JLEK?.:K;=+G1[A,DZ&\X'3-\"K_ /?+/Z.=K85814)8:AG&L IB,BV
M$N(Y^I#X2'262I9F8^P-?]RLL#5:;N*%33!)8FPNGXVVSGH=2);6@F1#!R-!
MEDJ@!W0=2+9[N:!*V#*WVO[ZHV<J_<IW];M+_B/:=.+XE5&;)DX PC(P-40/
MV^(\!3G;5LR",%)(+ Z7W+ "B_.II.7!@7'()H0.5_&Q@C\R=#85WP"?C7W%
M5VO_#6'B> H6>A/FA^W'Z=6T8D:;^!*!6KO6-3"R-IR(UD:>"(>S^7#9% OP
M"N_II&WX_G+!!BS-D_ +\70ZO^/0";\Y8KU +7@/P=_H8R!59Z&$97!5[^]^
MUZI]]G;:/3*MU]Z]G]9[8J-;0P4Q@[!32%PFT::48>DLE_@@=N2#^!R';,)L
MHKXJAF8BGJF]SEF1]PY]];G?$+F<=I>>7I<MK6>^"SJ8)4LNP/8 I%ORGW'7
M_#BH:/@FK'8&AAGV_D]8^.RQH*%Y)B0V$\TYX>A,Q)E(IQQ0BX1#-F$S4=\5
M1_,1W^'KL'E]#H.;CE1%_W;G32Q#\5/FO7O=%E*@QAV9!HUW[E66J8M9LM(I
M"-[6:I$_SX2$XG 3;Q8D+!=?VY>$%\+RPGK0S:5(.++8&%LC;QQXMDPN5$J%
MEO4HFX,BUIB!O@9TU:?K>[8'QOFN< SZKQ-#H'1X6ZOC:/3>KJ9+0+^P-ON-
MNE3@;BD&/M+0%%GZ3I$7N&C>&%(@UW)8*(C.I4BD'+'<P0;P$H[:DJ,V 3T1
MSQB=B=CAL1'JKSQ07P,FJO=KZ-J;+ 'I<F+-^'"OQP)<WYOCG&;:G:$Y@_FA
M4"R6F\5IM_'<F3;D;*E<'%Y)X\/)S_ I"P6F51;JC./Q9/^[E$B$]=,^R^!L
M%Q+ZB19L9>ET*EI%/1I'2<)36_#4)O GZWKCZ2R_NR0]?O,-@/(8C7FRS4J^
M+CO37P]*\Z:1-[N/.^S?WM44*21YT)ZIGJ*]6]V+96>['IQ/*KOV3:,]*=IM
M--,;P@0/Y6UK]M1**,,0[,Q) PW3*JA2&?[6&;O(S*74JH7KSK3W],Z.&ZRJ
M\=%.E8W.-<JN*M^T:E2MY ))-L?Z::02;+@A@S-,.*V+(9'.PV0/4=4Z*4;8
MH"HQ)/PN#)U*[RXQH+P.9G%Z!:28-$:J G"K%GP@-E-3W]7LPY]:3SDD1^@J
M7&V"+GJK59< -25(#D,^E6YOV\J4+YN$!%8BXVR2<#^12%.P)DHY9K>S;+AU
M"+9ANKD_EO6[F11WG6(E]E#; :R"M<88D@ %T[6>!6HZ=OY=C"PB)3.Y@[![
M,LYF)[?,!E$.I;^1F&G#13Z6>YW^YAD\B\D#) /MO:BI&(>Z"JAI)O#'N;?&
M!VC<OYF58;0Y]S'I;,[^+3]72U#'[\(;0&SAD()2(2T2!W38""1.]%O#9>%4
M/I9HLUF6/N#9V\?&10%O5);9FRZ<P6,$\U%BA*?S46(AR^;OE&GV^5"[I%\P
M*W#6#1V/;"I1W0GUQ8XC_^T;8$BD)2SF;HCY^3!F2!0FD?*180ZV$NK(F"E<
M!#DH-VU0JUFBA5/IG?I' Z007<FJH(JK \C9I\PED]68]/4!Q(\#W@$+0>6>
M0X(DJ+S'&'=2M%N5#N)G+=O#(XV"*K4&FFZV@3Y$(X,\,W-MC<_-_C;JP\ZT
M6DSQ-X^MMZO7:(,>.W 4SMG2]A!8JW3=0!2Z,"&)K%F)\Y.O3[J4?<E #L98
M(34V$G4Y3"9R[]7I %KT3+%!\>)(%.@P/,UEXVLUXXO3ES.<;H*1[0FN]^;(
M=:\*O9ZLR(AF2_Y-#,^B,!Q]5-/-*_'Y&/R;,TJ@\,TR#(\]!#D%<5M7CAR(
M:\+A+D<DZ2-'<[E82HX3'MB>!S;!+)'RF"S-,[$D@&T:C.:]F]H#T(+K12/E
MAD--Q>/D*FK!'-9[/?@:M;^L!%?8VB^!D_[TE&-+KIQ7@LT!H Q(&VLB)*(.
M94V#E%6JT+Z#O[8H= IB%]2SS\66&G+D] ZF66Z4WE!H1V+P,</MN/?GBCCY
M6HUR'N>:X^N'=$Y2P7VT64$[B9;+AC$65!$DFN46XD9:L223C9)EDQGC>\P&
MF]"6A%>'C=6ILVK&FHNWEA8.E7"HD*.;23;1OZ_ <EH2!MIAOEYAVP4FWX^V
MI]P.%$J+$@AD6^5& :N1%C&H'CCY)G.K^20<GJ9)%.FPL=2N'O>A![46TNQ.
M\X * 9R.'A_MQ!^]!.:.O[V^_C.0#JHC9EBGXPG&?D+YG+R,$Q+.B)3&I*.U
MPQ(\\^+9;@MCO*DK7GVU8MMZ]5Y#E]\@5S84001..<R\T?OQW.R7VO?%A[MH
M^YOMVKG7J#3*LRR6DV#B]=47@?@E))"%Z]VZV*DFB5OO/2MLL'73)!P>#$OG
M,CLV=DLKD!8[8.LCM""C_ %T43;\/(M/)5:\E=_Y^TKO&%3&Y; )L/>.54@<
M,]$LHB32M9%=PF%LAD0F2":^]GT)"VS+ ANP-4-D$'4JOGS^57E 2[7=MB75
MUMK"!^IX.= 4!$I7FMX:"#JX%"#%BMH0M987T(K]S?2[W_E^3GZZ?5'X(U-L
M(5FH]QE=*,AO3D$.A%\=_JC+(C+9+21&)WX2.!RPWGA;]@J)SR122-+Q#"U(
MV((46VS";"(>GG@:>/K"=6Z#QZ$"5RH+2F/<561Q=491E6_FN^W<W>/O'79<
MC$H?UD%?-DR &F](L@Y$,TD<\G&=9;))XM!N3'M?&0V%9B3<//G=1[)+/CIH
MO8=\^@[)BIKATQ8-0UEI_&JDN*R>.3[_J2<LA+VGL[&6;C*1B B3E.L2A,7\
M@<+BD9U70*71!R;"(&F62%D/G<EP>]%F,G@9]7R/#02H<STV'KH<$+56)7-[
M4/4]*P#5MZV&7V%U(J"?U7N"<V XZSY+HD0H2^<B-N42O-\+=MJ$_B1<16R:
M3N5W[,S->^X 1"_T?ZC]\AM<,O:P.)Y)](>"*LW_PO/)!ER")BW/01*5,8+9
M\H<X$-0^: HF*$,#1C3A%>*Y-AX'CXV,7.T7K@]G@$\PG1Q=(;)-%NJ+9!,&
MM63"-PMMW2]@1DFLM'M<PNCOB5D<+W.&O&+"S?V91P7^</LU[1E#;3 (]H"C
M-MTR1*?^,#R=Y:+M(;#.VF!)W30=N=69*O>%0>VE.6:+T1:XQF-F% -?!)1@
M4EW0EU75CAU.@* GVN).;Y=YT2X8]=Y*@2:27)6BF6RT7H/$"-E7MF)]V8I(
M?1I/\ZGXJA0WC@WXY!U1[DRK]Q7P)IK*>_Y0_?Q$K@N 8@!Q7Q3LUPQ\J*2-
MNPKXG%#_;R!Y)O&^'8FTKRF1(S+,*D7G<[FCNBD2OOJ<!I(CTB@I7@UDH^.J
M-1Z-%)SQ+BB(,E>*]EY1K6W"A<TU?JTU,A.V:W:;V6AS#*.:'.K=*R7)AJAH
MQEBW&N"X_5_EV>:3CJ_[AFLG1;N-@<>*BO*N#+,AR%(-6-5NTT>IH+V.Z_=_
M\OT#U=Q6SP9%P42X5X3"4$ZMS>\=GRU=CA'>? L<$,[UFB.1V,2D3]+UNF^'
MO<$KFB/B1*%3N1UK,"D/"N)IC35-15?XK.&_*KGARHH)AO,=[$M99OKXYSES
M_;C# C52B@P\A NLOG@&E4"S-6EA?^S8<W"T\Q7EXIS?"D__+GN&?U=4<:SK
M0+H<FS7-? (8_=S<U"F?,ZZDMO9^5XIVY-M.ZOGQ8&<LS,"9ZHS"X<I8PJ.)
MH&"+<(VF 9\X$= X./11^$M]#/^.)Z@;>]C!A.R5N3%0&8RCPFE./(E4%CY:
M+]/^%3T=#@-LT*9X$O5-++N[+-8Y[,6S#PWX^GH/5^T6A@A<4+(OD!C+MGS+
MWLCWTW'_X4H^I,CQ2H-RKNLQWB@V+1>[0HDN:8Y<EC:(TEH."8F@1)KQTKG3
M[)VRYZ>_"3Y)^!W2=":_X^$>F5F?O3M-DGL0XTQ,IN)#RQ1TW9F/4E$A#56
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MU*+](31N W4>\/[& K_F3>LNW>[FW[1CR_Q;)-%<X!@/D'!")A-*=*F"8B4
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M(%!TN #.:*XP^>1(\<P-++IRZ4%4@5N"?1RX_EE2=4V6Y;:DTHR*+2':MJG
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M2[9$ZI6G=E=H![E/P<H,('82:.3Q5R):/RIP857FDW+VR5U"F&5R ]+1:"6
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M:%%]/0]:M TJY'&'BIXG Q2M& !%U2]=C)LKG[YUQLG>X'#]'F!$1>?,5)!
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M")?ZSF$3206/\;2 #305I@*.>>"LJI+((3>/HV4Q!X\U1C-C!74H!C\ +&!
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MT8R36":9?F-01?S"JC+=YYG?6 =(F$[*C@2IA^>+SL?^,9^#W]DL9/+/O_\
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MH#B7]N]^=AE>8*,W$U]JS[,7^:K$K@^J& 5>'0+!X;X906.Y/__^)Y?#6A"
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MCGVWC-XYDVFH.5@0"6YZ"[RB;6RY*]0\JSX_E=K3C\]BDH-(>^-#^P61_/?
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MLCYUMZD9GZ_[,[GUWOP>LHFD[G:"5,&51"$ID:K@2]K<N0T5K@H0K3)S=A9
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MO +OC_6:7TU61]B'1LLJ4"/2 .-H9H1T#%(X-. J\"$<7.8F\ @M#I'6 @L
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M)/\-3894,43:(>I(&2#_"HDOH"L@(2]!3%'L:\0#V58=-.?AH/R 1R!(KF'
MJ6G(R5GGKU$*1.FW@HTY=22QDB -P0@B:MX$%0K8/A'HBREFL ''9A1N0L._
M,(961MA D+Y@ULH;Q]BMSY&^<>L6J*)@WQ==1=DLR,J LV1%9P\:?,JH7H^[
MV8J!_PLX)H/4'5@?!C4'F+"IZ[S5&Z9*\.W@Y[8C!58ARU-$][&D 68\P=HZ
M=(+U!1H;#DG/KXG[9CB.!7H0C WV" @EY&![0EGPB*F_G3O!C "#<!@/9\C
M,S)K>8(F91CP\!>OZEOK>!3X*@HF\&,>R0I:#_@?%3",/G\(_&"]$NR<Q-#6
M+P&%O:CJ0T O+IDGZ!>8*A!RN(<LIBGP"S1?$>P0EZ$G@#' :%D,4ANP)(-8
M25^FPL#I@L=L-M)Y4)^4IA@D]_PE,"7"5$'T X=ZL)NH*R=Z Z#1F\8.=8Z7
MK&W1646#F7KV.#I,&/S&$"BX;"#)F 1XTA(M27$]@BC;ATH*"/6,8\$F0T)
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M 6RTC)0+K_N'SF.S(]CB#E?H01?X<\@G"N13L(>,H:086>-5M"7&F*>U*_A
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M,WXXWL;&<%T9Z/FQ0V:[2-6"B!1LJ8 GDL&4=MF8"IA_D:^K&8XIRF+'4O<
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M<A_:0L(&BU<728@):F<D*Z3<$?[A-5(@983!6;C:1YD&H&/*89J</N+P /B
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M"20K$YQ&]J[Q,>&_3$[K>MDQIH@>^ZX\HY80KX9=UBQ'!W6V2="S^$OL*/X
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M%.?!;QS//,@,S#UN<!EIKN='EA7$]-%D GD$\\&"0\]RG&HFS)MJ!M\"2R;
MRICCX =@*B2(F'=UTA^,GDR_J=%S4#Z-_N?(?[KEL(+_GR#7X9!\\&[>=)*]
MH?\HRL^G%_I4YOH3$N@P]Q+,LO_42V_U:H_2^O''^AXL!7!$GT@0AC;%TM0%
M30P,H\A3>U\DG:8X9(&M01*U"%>I!PMJ/4V8S))]5==)F ,_&.'+"C=*"_FQ
M)T;\X<1V3FR-&Q]_GUNV<=#I?ZMS0,5HH^ U+LJ59-I7RMZS=$6LPHEY5#NF
M<^*(S%X5=0WM2@&=R%1Y@324XU*WR%T1JL^FXQ!B9CP'ID>$ 'W\6]E_)1XY
MX%H6O(5A]L.'^V2\A "&&=SA\V Q6 54 *2<@3#;0Q7I\W=RV_OP( S%HI)6
M>A\$A,$P3-@^)( D@"!".2:B+^K+Z(M*48(.[*WIB_.*6_Q5'ERTW,:V] 6>
M$."W8Z^@+\IYS 5(UQ=1/<';^X'2,X8?%F,D:H80Z_H4$CPB.D;'3AOY&H%-
MB8O6LT$ S (4 A8@.G8:I&06'](F&OJ/;;O$)814031+\'K0NDO%#[3NU=&Z
MJQ]HW=M'ZY[79E:.N^LP K6O#T+UL.@PH.N##/OQF\\"V81C[C.>F@ZVH-&&
M4J;_(NIL7_ ]\)27%L3/VI> ]B(>..#486>6AA]!7UDX'(A5(&AB!2P@#T/%
M[!&+BD2*R30SK#(%-[0.7N>ZAJ/IL2Z%V44'0<>[:(:W76H:/IC6XT33=34P
M;27<B(\3+7B&$1Q@7Y5M]+&IP(K8 ;T-]A\D /:1#(J,%@NV9? [#<0)_*UF
M6F!!0%^>\NUDA!+!D;/#8]1&LL)/3+XYZK2\VRG;MZ.M3[[ YX68Z:I&S\)H
M@@Z>-\:!&7EE_W!^//Y.VCEWIPLT,AW -+6;,?I^Y<KXB2Y'T''0I"'%3(Y$
M]DB9C&XB/^5@Y*69=YP0Y6TE3NY^CMN7?7DTJ7(P4O08(D<0(3\B,1E#-S:U
M#$&0K"1/FC>%'-"R_U,&NS*%<EDMSZP (?,Z9%),3YZ$6)P^$Q'QE;L/;0DN
M3-R$-Z05/K]\(9'D'A(^&<!F96\,+RO;2)M4EF.-QJN7BUY%/KIO3IZ.U?[K
MJ+'8J$PLEPN;T\@0+*I(B%@'BROZ<;7?E45;%%X]LS8OCXV#1ZUY5>(&%T=Z
M.;P,8[YM"!MEO(6&76<O)F33S3P2%6 DH(;'K*:TP\?)L>WX$&]\[^ ;LAGD
MYG3XZ^#'WY/;Q\BT>M7;?&;,^<W=ZXNT+Y:;G_C85Y:CIEV,# >DD5#X0II4
M/T\7OZS;'Y=U>E'W3V2L(ID-/G$+WSE4;Y_-8+G(K/)W9%_JM]]?VL./.][_
M2P*]@N)1V4!=)8&SG'?=U][;=;\LN_?JWTXJ!U?#^V[_K5D)B['N0A[="I5<
MG@T1&3A3?^\VQ+(\?&[<:#?%]M^SN[^OR?28RY^+6":5ZA*6">T9F6.88"0-
M;PH'L/!0U16(\OC1PH)HNWB$#9VI'HU#X+?@#S&;!IDW$)Q@=H\6/Q\ZOZK>
MURX>,_FJ]J*W?@Z^%VL;,DV6JL?=I.]76=WWJ^XWFLE3!OP*7"$",Q**A";5
MMP+R# MB*W% 6O4<@+3>!(,?W=QU;V_&VO'-XU8'YVV4@_,:95">-\I -M"[
M^5+FV#0<G>6#LX2"#/7/6E_KD1LTB<61]M?@);@"B8#.LWJ2OFX^VU@$N,IK
MDC;R:T13@!K\DT+LA%]MDVJ38_3B&.9_"V+0:2C]'V.S='[#C43PH<;  2*4
M"% YM4HGE8P[E%BIYC54,ED6]L46[HA ]J4^+< D@(&,IQR)NFG; IU<1?L-
MV#0 CZF3V@V\>SBN.2EY\,P=.B/3<K29JL1C9>;'S$NF/+X/7/NL*8^*<M((
MW0),\6*[\%!#%]/2,71843//Y;0\,/ZK4O)XH@ ?V;@K!,#*&:@JQJ33<$FR
MZ%.OBVT$D]2+&>JSJ'I@@R%K8\+5J28J9BBF5I.J!Q KZRZ9%3B2'U4OYNA]
M$<OW"\]#U0"8]6!):U<=R :9*H"['SCH4#R8A-:I)4UC.LC-ZJE(U=>L[JN#
M^]E)__'R^J'!B9A/O(W8.Y4]1,2-:/B%TH0I&KZ69N_(6!&WD/>IBU52&?5^
MZI^/U:[%%T!74[''NQJIVL"*!)>*AY'%"^!9>C-R21@@6J?EF 4\J&[@]0W!
MF(T"Z=]U5,,.6Y!"O/W)QG*NLQ(L7"$DA/L1^=F@L3,DHVX>0#CA"B]N:&AJ
MLF8^M&BU6**3N^A/VP:JR0]HQYO=BI%M_;D@29_P.NR?ZL^GA^KW:EM-LD>"
M!Y8EXE?=*Y;(K##ZT\+P-AF0<F(WM%B0KUI?!#W55P-$ ]82 53#([!YE2!@
ME9#4&PDEFRY,^A7'8,+X$AZ<A V2:B"B(QD=:#91/V.WJZ/C,*%;$7^9B;LC
M>;'W9XGHT^CD3[Y*Z9H-N46\C!N70^.N/R0I(DE6^?%(5<JW31^JHN,/"LXR
M52F6Z+'.Y#8%+"! >728-9)SE 5H^D76%_IZ,OK6'OIVL3.T3'<P]-J3V'AA
M$@&'ZELR=P$)0J"' ]R .&3 95%:/B2 28!V>%:I*]^EIPA:"U9]R\,&;O4:
M249JJ46F4:Z*U,+5IWC9!P("EE9DG6.9R@<S4V:^/1[?#1X?C,;!G-I4'YK-
MIAF0S=>L;/<6J"V7Z_= BHNI=2J"7Z>2A/\5 UD?-:W@)H'<*0O+\!7V/H!7
M)!/[3MS<A!FO_N@Z(7Z.9DSN(GU()KR0CDABL;M"_.3,.@\OS0T7Y.8*(CF)
M'>ZZM?!N_UOOK]HL/IU>5#B YSG-YG-0GA.WGF6:ZPH1W5H>DS>KA5JUE!C4
MC9V\65GBW+>-&U%SOQ>OKMKW%]=_MW3N^<%&U/( ,*D6JJ5RFEG/#\V\Y52+
M$)J*&9/_?U\3,KTID->JC5C"%N]-"UU2Z/#$#MKRN:.\LRF04U&J,<@:'%E]
MM@!'R1!HAR7$2@ 1"E_D7K]DT"P(Q6SYMG[TV_#X2-K!"]W[B8,C Z<C<*=3
MX)_WGB%KA*N4#H?4D/AHLDZ^F\YR6G!@Y/$2 R.K4HVWA>.'"WM_)[N'S4?T
M9IK&/2%[XYZ;W0Y^'%R;TLU4\9,T'7Z3BV8\YX^0K.ZAO3*S-K(3JAPC2PWI
MQCP"'K74LNRY\R.%A)0XHW:0+DDC([=U\%/Y^N6W>2!_U_T@P>&<''?,A+=Y
M R/S..QZ'G@H4BDEND5R/XFC(F.RO,E#8?E$)8'\ZB!5:RIQ0P#QX6^5#:[-
M@_J/XNUEMUOC6J)SJ4KC-Q\;/:7LD2.CY-6^7-I/K)PD-6=)0R,;689&\H2)
M3(O<22XY:I^=22?:Y<ES I>("MX3T 9M*L>ID6FTVA!3Y978KZ8Q50Y3(X4%
MID:2(9'XHVFUZ5FF1&Z?.^_.?KN3RO>#RD__*KM8-%>:"]\LDO2L+Y3TQ"T-
M4H78VTD)SW?C?) &CSC 3*&GFZ34S,/ H_6.("W8Z\_F9(2GBOC3 SU@"NZM
M-#>L3C33M>DW"/'?@.>80 05DFF6ZE"_.S+%Q/.>V-1Z'_AYP[Y)K90UI..#
M4\?*]<(J8:;\^GU@C4IZZWINH\>B;DAMK^1%:6+7G23_(3'.8Y)]JB<B+#?)
M_GA13R1XS)M3W^U?+[_OG=K1S*KEZ'C@XUWUZL_%RZPW$AT/87''HYF+XX'/
M>MO"?7=B'UU9/Q3I9.ZPT-6\#."%7(6^D=]T^F2;,'4Z?6L=CL9.<(7R4S\;
M_SYU]9*^09\A?Q;)J^,CS6W8YK#Y]%GSR79&R(L8[Q+OR<]C2;IZZL@WE8P^
M0RY\LXC; !.8<I\T'VN ^O6^2<7"@5@Y8H< (DPUIAJ ^PXA:N3B5]I0L4D*
MFY><Q+>&<?9;MX.GG8IMZ7_/3_N5;=2UY*@65ZM1*6>N48GK#$J=60=\O_2D
M^.+BD^*WR$WW1<NRJ_W!Z7$U]RGM>?%)93U#UWGPLY2AZQPSB)^I_^T[VO/Y
MX7")D>Q;9(AVW7A^*!^_?-<;Z?/0US$./2^.J>6!FE]/9)DO9+XYSQEDNCDY
M^[B26HJ#WI='FHY^-2<:QF&F-S%L./G>N!+I^O*#++?'9-;]D77V[<?C;5>+
M+4L6/X.]8W]9::IY/E98<JEQ(^\AY?Y02&X@I)"L6:2<!T)NCQ\TY?+&NFOW
M+\W^*QG&F(N>:BX4.UAEMN+[2 >$F[P" XZHPR$PIR98?41ZV7W,=Y@_.:7#
M3OP)C]Z++6TP0,3UX.(5TM3B0\&/0TOI=%I!)TC8]B0^\HBPR4E\_!R6P+N%
MA2;OH3>E#-^KK#I\KRE55K.@?CZJQ\?-@]KYEJ?G-??03C)JHM).3<@KT+'@
MX1E!0F1&4'!J+!L0!#(>F0P4Y,CYDX&X#K60- LQ*!2!X;4&68*-5!:D'!/&
MD*#3OE''#BGO9PG=@M>8C3?A*088*P/OP+)$1]_Z+=YQFLX/W^"1'KK,CW!*
MG/E56FI&X,I"4S.NW='9Z.I%4[<WY6\AB<GJE>8ZF8M J@0GT@!#C$T'<LBR
M[@V"B3GSR-07KMT&E\.;SX37_&N,C(R)#*8,LGORX#\A9?"?F.?@OTA_MS_R
M#LE)=%J>K:IDTE=A Q/P%I>&\E^G;[P<O'R[*F][AEU&:<C%XUYA3ATVX/RY
MAN_$X U<.CV<!/<#Z$+</;"=4>E">%1ZXE7%KLX,P]%9K2Z'YH>N6L=T0 NF
ME4/PE9GT<U<&_<*XLI?5Y?F@>_"M?7GN2,5>I,(:U!OK,2;5.NFYSO@5YR'#
M>92OE I2"F(8QOX2J#Y7-/ =,'1-5W6> 5<F *L!K,!AT9'##O$#!-T TXY=
M)LR)Z9DC5?RLOHQ59&%^B;M!!)NU06-F-)$'0@>@8=V*A,I2AP#I,U'Q-Y K
M+XJ-%V#6( 8D6+0#M$ \?''OI@<Q9O1E6(9P+ -ZJT:FHNKDY?RK1BJ!&.-4
MG$W*O] W,$%#IX#6C5ROGDI>2@Q"*I5[4G$/_;=>^2Q_P8_Z^#$V@3&&F$H7
MD0Q[?2^()B2?!I:$PYD)SRP_@BGC7_6:$? HZ0/X2G*FKVB"IO0Q07/U"9JU
MCPF:.SQ!<Y%YT> PFQ"$7KYB%C39#7D+N^%CNO2"];-"7/VL#LZT@2ZXWMSO
M]J;Y$@>!P.,%6Q/ANJ#+,5GE<)']D93B"L%2W/2-K*DPM[1P8>XB,[=S#][/
MCG3=,@>5$VTS?8.AZ=K+Q]^1NLNCFRQ]JENT8E?(4+%[F%33=T5?@K.J27BZ
M6V0&9>J<'A^<3RY:_ES-J_A2Y05*^F)WO6[FR"<D6J_FVFR8/,@U>\TO99!M
ML\KTT1XHY[I:&6^\W9!R2;[\LE"9RJH=ARN4=0KSN\'LN&ZPUD+=8#O"9(/S
M;ZY;=R_+S14:PO)BEP6*.R48@+)(3YCN&3K)M9V1(LQLYHT=6Y(IIS+((J4H
M6V60D]YWI=S5;NH]O_3@EB]!R5!LDAM7)!:;2,6\BTT$;018PAAXE!6;8.<U
M9AYC/-Q=;5U3&8/<D#8HZ\I0UX9RMZ:NIUCFF)W+/^^.U1^7Y=FFYAZM/I*1
M9_FD\V!<'T/I>0U9<80*RH2T7/F,5Q1:J&4>QYA:+DPW+_Y_4DS5,#BW3*:$
MN3)5^9"IH'HVC%^GCY-2ZZXNOW?!"#%_5O<DB?G+*S$_\UV>35<'PU*'81F!
M>\2#J(=D+C9-810>%S F,&$3Y!"#>7$IVXK\!.<Y-FT?6S(X9:^ Q^BUCT_N
M;L2>[E54 +CP#+U;>R&F+(/D9M8*;E2)2&LI+*V"-[ $CU2,MI,4<S)P7H_X
M?;N_'M]?OTSJ3WD91[D*1";32:KD9SIA-\L6Y3ZPM 9.%F2:;)[Q2> P>B=@
M-HTR'\EH83>,%MB;7+B66/05J.9 I/WK&D2->;X?ACC@4U')UGSBNG#INA$S
MSS*N&B*_@F,0BMJK%(JS?G^B7KK/M5EI]ZN5B?C5UG\?9:T 2:YE+NU7&LW$
M#GE^3F6 DWU10M*(J!BXA7"<7_<&1!#TW.P<7\Z7X^N!,4ZOA^-/SL_K#YW9
MV=_9*ZC/1QQ?YT8]K8_CL]9+I'%\LY&%X=]'-5-J^3[T"2=?;EF+^</U1^&$
M'0Q[H=].:_OQ1$275 OCHF'?5/!Q<6/J)EEE;J?3*I#1%Z'WXECMQ$2,C5?#
M,-![X'/TT'HF:),FU.FCA_VG2;#75ATD@_@U]'4"6T,'"B,=S1(_0XWCI8DL
M7ZE$'='/VH14@CRCA9+I'6,-RJ7@CZ1TQK._QY:Z1PQT@MJ*Z!^MLESZA%9O
M>$AO;A!(/\12S0WHH27[&V**;(78?@?_ZS+AY!/^A4RB!07PKHKG+JK:!-?;
MDI$K\*0MZRISG-#)*6[/L?^#@[A0QP<@I;9J33#'$8/24#E[$FV75=ZB[X1W
M*!J0O^LZK H0B;K;1UJ*(/R%<N_?5#(2YL0PS DI/*9XNY[O13\B^!_A(B6!
MNM\IR=8#&S*!<<QGV8*SIA7&[T0KII8A$.B$0 4D1FM 1'8U>\@435RIY=R)
MQE!6IL(34A$FRMKXA&P,*<*S*2G&$V@=GAGY>J2'D8:A"B.FY@^KW$!IG:=1
M8"R0SJI".<\EWI/"E7L"4;4\!)LW(<$ON8BG!Q* B '8#G3S4[OIP+0L\QEF
M_^5=*#K16\CFN;3<X2 )M'Y^FWYDE:L7ATJE/$HERH5F,='<"?84@(D.PQ!5
MVBP -P6<8[JC2\0A5"7,J]M@A>2\NF6_QKE$/GL,K\4]5[04&M^FQQJZK7K0
M?.$'_6V_[CG!Y<:#%+-64S)AU=!U$X@VL)JMOO8"XR-Q[#+I*L*%G"2JAVL,
M'@WX33C"1@="6[@,#[X-CH&WIKHJOVQ2@NNU=_CTK31H2;EF,WT 0GA./ZJI
MMH"C=&2*$297,$)1"M354H 9= \F?CFOT4*^W6=M7]TOB!>TSP/[$U_P>]'N
M!*YF5W;\L"&Y\8 7H3\-CLOV)N] 89H">ANN<#*I)>!G$AV9S4?%\U=,03<-
MZ"D%446&H$W?/_+@\VU<G4P5:6A_7CDO'!:MYDUL^WGV8KA$GY/1QK3<F%&W
MAZ]G<D3^\8(AE$]Y[^NY?,-=?4C-F6Q:@4#$#RK]D/YPP(2BTUH]VX@O1PR7
M81*.3W[62\##]_K#JXDB9D:9["+K42#/8FWWK"(_!;M ,(F2E+6S=X>;Q[#9
M2'1""/<D<P23CA?"'A&N)H>G\<L<^9&.O>QKP.?!%7D%^*QXOU+%S9] */1Y
M>)(J,BC0%(_1IM%)[YT51&I-CK7!8-J5>X_4B R\/HX@F,/AUZ1C&@DR,M])
M(@Z9T2J,,!GA:E="*]#M>!]TFH4WR-/VRG"^8GQK"-[V( F%],-?2EB_9Y6N
MUGL3R+CK\.M&'MO A?)D;JW8I<!OPV)OR9I-'#$\@<7+3>$S.7JA!AS$,I#Z
MHCU_=.H3GE@JV-XCR.4(8G8EG0J]@N'L<%0:D0-I&],B^%YA73>7BW&5K(";
M^L#=QNU<,E8^BCQ"N[=]4S$%P-2?\WW5[Y!WG?NO.B1ONC(8WHP/KY-0!9<>
MC:.HH"U#(?8&Y7YFKKU(QIVFGDJ_?@S]TE=O@<"^:=N%+I#L8#K+;#Q+AC)U
MBR$C<*&<8TJ)6]I<<S9=-X*L%%)*B4X L?+YPC:*%(?N@!>X_H7XNLH%.0RF
M\/4L#9N!7$WV&MCLCXWL_[UKD'#R&/[W!=D,8\76X>3NYGO5&#XTEF-%F]M/
MED:TI<FT,E/"_O\$MA]BTYPJ,6LI;%H0QTBW\I-OT?^:!AFN1RBK@8V85LO+
M]R'"IUD):XN^ TI9UZ:ZCMR7I_K9]=/T2O%;$O&:_4)DMI>T:EQ2K9VT_+P5
MT$))IA0%U$C30'"YRP9Z]SLQ<O$(+PS768[K#F)V;WR74#RT!=\(5$*?.N8^
MY<W 8[&_??'."Y>G/E 0(%C$X6* >8)CL]09@J E,S]PUQ*4.()IRVI1S!Y!
M)* EK,C&HG@)7,1^3E$LAD008AVK+B(V;2+%\ O$RJ97EY\<Z.'6:D<#WP_9
M1F"QF1#_AEB][VO"(?55V48?FWIEW"038?GG)4#!+RW&42?@^\,.;9(GH(D'
M[#R006S)7B&.DWN4"43*?=+,VX, >V 9B\C7XMBB!YD4"BF,9(5/F]P<=5HL
M%)&-= 62WH "]V@$'>W.4L&:()8J/ZZ&52G!V?*(&$&&P$?O,2+8X6F1PF !
MZ $Z1/MFC!:@7!D_94L#KQ^THQ2GVLM2F9;-XY_\E&[*_$M.6I+':"X>C:S<
M50_&3[^NY+;*M6A02D:H&*$@(E(7MBZ.32T#UE%6HB5U=)3WI++_$[M=4DB3
M,?*Y4)HWY<Y)J;7CR83CT#CLDGT<SVOEL)BBAH6&FL\.U</COMILV2W=XU"V
M_R"'OAKN\_X0V&J0)\N;&#J ]*:0?=9=/BRX<0[*Y%O9G5)K6+X;WIGUW>*R
MQ7AHGM]4SLN]+\_K8,/6-:U)('=V3-:;=(L2*+?M-Z5L6U7.G/KH>#"NG_1/
M!J^F$C[7B[B\' YX1KQXKMX]$1,>_*YPAP>=VT,JQNT J$!CP6+#7/%\M\^Q
MBU4LAB[V;J\Y*UJ-JT,.5&"7*PXW<>FO7F%;W6\T$U4S5V_H85\DNN(AU*V1
MJ?@YPTSEZ'/+3R#]X,.\QC1*Q<5KV_A--D&Z.T;O>?W&QT5+.;L?%Q^;S_V$
MP"XAGQV@7^;0;81BVS$]<G.R$@V/?;&%L>^09ZI/"Z)AB@/(IB)GBP"(X80I
MP17#EHD0+$KBFRRX>R!6D2</9KM#IX"83)NI2A)XQPZJ[<5\LJ=?SO6E>3LJ
M2SX$",85]/''"NC</$+,!02)-YYC2+E1Y2Q5J]5F&2#<>4:NY (I4Y!JI40U
MS7.JB!'G$&T]-!FOAZT+(*B,Q!AXCX6ZH*Q.[?<AM3SQ_1>!Q'$F'*)PUL:B
M0X)^'A=61 *DNQ:=$/:H<D4,U&ORXH'/0]4 '/4@,GI7'<A<5L5[C&XE@A_)
M<&$AN@O5RTCCD!;W52O[&L7JZQ;+ZU]/WZX?GH\>?F^@LK"Q5ZRNV1RJY('/
M(Y4+]12?0"8@C"Q'D)3(:R?.5R4/\M@T"0F]('MMWA)9E;-GEQ7-41YEJSM5
MDK2^1\=,(9.X0:]1<FZ3 ?,"_*FEA4M(X5C+':"]"+3@YA5A:Y8^L#57Q]:L
M?V!K[C"VYK':M?BJSFHJN&97(\DQ?.MB]'H/N;(0F#-!XDJ!(1 %C*8X\'J)
MX 8NB&P^)ZWT2TJC"[[OSD^8P.&I-673F;$'F4&O2PX/X,%6*ET%!N"/FRD*
MO#HP@5CD!;CRG0TB3<=.F8]/5H74'@X#T)]RNT'/-0/\ZI1[]%JUT?UNWYN6
MKIP8O8ZCGCM*]";WBLWQW.(8,R#T"2]M^_ME='S^K31Z>$R\BD>+8J!5]XHE
M@H%&?TIP].F=F[9%]F#L\A=#2:LLA)+F2RJY2&N)2&GA1D?@V:CD%A*J#:!*
MQ;6AX'D,#I@OEE[[*<$G08)E(#+3 ERL)<9N5T<'P"J-6:<CEIET?^:08_]K
MUC2'["&,W ]4X=R9-\S\O<M!^?>9Y#Q<^<S?H1V$4-"=Q=&))5]L7&QS4A'@
M^CR0^J5".=GSP=/!D(U-^S5Q6)&K=20MIZR;@4Z%J=(>8\3\)'6'>!??:@R#
MH51A]Z.,8Q!QXRRK2T+LO#D^-JXO[Q[OCIO/X\<UC<C<H!Y/!N>I%O,>HLFE
MBKV4:'RN>$W3P=\<*SX>R/7RP\OH%NH2TC+//LZY31-.F\\Z;U(/5U?#8*MF
MRD@+M*$_+JV?"3T -#ED29DUSI?H/;-C'")'CL$\O(^J9]*T&1YM1@""\$0
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M$(/O*\?/>VCR.NG(8$/OR3]U'Q\B_7NX=ALONTQ>P9QW0;8T/((-1UN\;PP
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M#-O1!S:QT,&UZT_L14Q\0#X.9L:TIZ%-;>^1ZUFMKMT9(O!AZP"; VX1@G
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M_(<Z]=*-UGAC:B&><>R,X>_L1Q;A@3^2?QLF'92)O@*[\X_\W?A!;-V!07T
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M<W.7KZ#Z0UPG&-+/%/<(PNLG 7 -P5U=/"=2#841L#(N4$VMZ1T=OA.^-KW
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M^T7GSJI)7D%2@"XDEMFB<$I2_DDXSR1L5 F=SU@E6OQGF:>(MV$2_$02_I<
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M[+30>W@5)^!\!YO=1U/93 AW!4MG A4'GJE!34PLX(5)5&!Q=(--8* [$G2
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M-5<J+[-YUSNXB>+1VTQ/\1M%;R%YV2;;;)2>VXU>_0O%S1:AKR*&I:&YTOM
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MB\*36QR.4U@$JZ'E&[$8$LBDE,N5<@F&Z 5T1<86=85<>:E>V@C)6#Y6FE\
ME[Z!MSHH(H,4[EYU_Q8ZE]O]0W-Y-LA,<KYEPV1^:<P>I2]N+M6<?_?R.,4K
M,2][ W7+B\M>*ENG_DLY;._L/#A/RMKP;=*B,UH\2H9T@ P63_$#\$70[JG\
MKOYU;Z^W)]8RB]XS\L7BUH^2P1)^@]9/YDS?L+8K;)8'*]#8TX]-9<3@UV3-
M'K5,?45V3".3'3/I_WUJ6A='M>V]UH+&Q3+VN'+[(B1$V>K8%257*"BY<KFZ
M0BB"9%T'&)G-VN]E$Y$\M88WO=-S"2Z9Z_O_&:I$D']*TG\'\[^GKSI=@U D
M'R;1 [DVC<X81-Q[JT%>.H 7X1OEMFZ:Y/YIDW7^WV_Y;_AOMF[\]]R+>3:T
M80\^FO\/N7JHZB+7CJD.7/T?F?_T;6FWW- >9+G)V'+SFX6R846?.]?ZNWFB
MN=6K&^=OZ>Z@4ZPL3AS^-HH#A:=LN,9$IX_Z]O.[\D/$!LLQ5WR6"&#0725_
M/[FJCCIGM;O"R\CX%KLJN"TZMCVT[*%.U3O[!ZIX0I27OOF/J0+[Z-;&U<6W
MG_L67!&63F^79V/8DX<]7=9?]/8(?T6N//C%=',=37?;CM'2-5EM$>B7PX\!
MHE6ML:QV'9W\96C+CHZ>@"E87;_7/;B+EZMOD)_3KVB!NSFO* 4!24?>?$$4
M'0E$V1?H*P .,DR<;[[\'E=ZW>.#7L2E_\P;";'=:$0680%T,X.>-;P_WS,G
MMX67IW;Q>GQWT1CN[YXHK1NEU[8>NZW";5?;ZYG[NQKY]T&O99U/]IN]G;L_
MYSWUYF5R>-&PK_9VQW<WY;RZ=YU7;TYZK>9C(^[Z;^X<7?T31[68.S^OD&N?
M8_4Y2!."";5,,*%2+N3JM:A!L=3Z,O6NVA[[Y.[IIB:WQO*VHW955VU3!E7E
M@:,_&63]P*>"NPF.ZG\G55^NSLG&GGPQM-N/E W]E]I]8K[@!QK<3)O7(N0$
M8(OS!HE7NQ>5GGK>VFK'>.#D >%@Q*RR[> _X% "/$U^C\" _!1 CJ_(X*MS
MX[$GWT<<"I.-2%('I:"0S^RUJU0WJU%N="H'1&^JLD6NC!3\/;-AQ5S\O6(U
M>WL]>=DJG77VU5ZLR_BC,=YR-&^AL+J2?&2Z3?F27.!#W>GS.]_3$,^J2Y[8
M[H%;2=O$!W"4L3H/22;LN!0C804.:0_A1=D9'X5J(?2:+]Q/!H_]T</!U855
MJ,>CU^^%=6+J[?N)^^>R77'V3AX&O04Q=:$8@:E!CBP/.]*9?EX.@40D7[X@
ME[QK^_G"XLV+TD:>+ZL:K)V@:"+V*(\$].@.T9,N@ S9'9C&$(66W.UPOT<X
MKKF.]E354@/X=&?AJ."O"^>Y;E8Z6\>>AH_:YAM T!%421,"C-IV2%=G=*:5
M<L5J*5>JQNKJ,%/)P%3A\]]:]?DS+@XS0*]5,P>=ZM,?I?U!.2!RXR$6R)9F
M4<N5ZO5<O5Z/Y0"V!BF*LIMRHT,N\CBE04UU:]JZ%;60H_=5PW+QHRZAV*;\
MRWZ&9^5D76WW0AH+'R 9H+@\T(HN+-!=A'<VAH1]>O RE5LC'1E!EMP@! <L
M3E>80U9F+HAH.P;THZ<;"5)>,2)>IFQD-APG'6V@;;D' QL,_2D [=&(TNR[
M8<G;X-1S7/]O/SX>PIXMG EV7TANLR=D*$HY>A@T%5S@7B)=[L@<2@QHTZO\
M"U=_X>JY<'452FV/3T>[@\O'(R4!5Q?7B:M+]Y/^SKA9>CPPSC1U05Q=S"_@
MJ^;B1'2KXP2:(#3 '8T)O>2+M%F"0B/^I5S8D4V$6O-+^>1C6S,ZA!/PG7 W
M=48.>8DC$]UZ DM7\@'7MS3;]5V<U_5=5(K"M7!D6$0W-AU=,X9$;1E$=XQ#
MEP\00-B_MWU^BYP<6G]*QN^M8MW\H-[NX@:A&;\1DLD1O "*B_E9N/*OEF.Z
M&%#E[[M4YG=D+W<.S?*9:JO4U)SVHVXHG\BWMSB?E3(#C6KTS#\&,R(LPM*J
M%4_S&FG0M/>M-F>+O?W>Y+%T^.M/^3/HFFD*A(Z]LIH)\=G5RY+C", ZDZ%V
M?+$WJC:;6_$3/S^D2@@=^F)1TQ3S/?'8)1XF;6Y>;S+T,T\$:>:DO]5>+%%*
MX_:PX_PI:\W+0OUS,4Y:/5+*'H+$#C)?T: OJW6]5BNQ#[?/:W_&U;/F2RDA
M[H(SN]9FM>[<3VZT>K_KFB7]M[F@U5I2(JS64\M/GBJAS5E&@U&*RI721D1'
M1W@_F0SZ>3"BXS\Z/\O[2,>Q^]-*?ZFU9^6\4BC-ES:0.,B%K#^8Z2(X3D<M
M5_\[ @?L$_F?R_% #[E-0Y^8IV)F^_3N[VWIR>SMEN.NG;5="&5('"!433/X
M9HI>W-T938N(0IS W;*4[O_QH0O?31WEO?]BS(B2G<YS;5(^V6X:?V-MZP_#
MF,%*H !C9F^;5]C,1Y4H4!SM,>:FW/"]]%SY4DV,.AJ^1;U^/=L$;Z&OPXU^
MGT!==:B;8U^)!_"38<F=D6E2U6W+ ]82@OR;/(8\ITN^+,TM%=QHO2 FOF,,
M#=UMJJ:I:UOC\*EFE(]Y\KV6(!V9(V9N_G'PU"LJ.V6_G*?!Z>R5\[Q98R+]
MN:81UGD.+UE4TP;42EG;^"LU[ (2>YO0$^1"RD#5__E?M8)2_=>-C#%C4+KK
MV.0/ \=N$\%U01#%_'4(5 _('XDJHJ(\=4V)169G["F[!&DQ8G+-ZMX/K+)5
M$87M<XC=P>&#O=\ESWOPF^MP.E%(&H"Y@BOP;0ACTID&)0T^X4O:FY"YM$'L
M#7*ANL1>)/NN!"],N"GC9:YOF";Y]W^-GYNT:&FF#X#74*VHA*KEV:HM7D(U
M5<D;^G=\?3,[4,S<S2M#6ZR9U FY!F3U0V>D!XE>GBI/WS;<MFF[(P<<8$2Q
MZ):+8<1SW20RI35M=^BBGMLBU[]VIHY!S-Q+LHPMDP@9V=; 4SBUO-B=)^.3
M[R?YD[T_VT]:\>J\O4"E5*H#44J;H0!$K5 @5O;E^8'9.'<&6^UO/U&9;. B
M97$?'@MYI[DJM@D5WZWC?82=%)EF#\G[5IN<C/&D0\\I:_5K8+\T+$V'1Q9*
M8LWCFEZ:W\3ZNGU+QB$-0(Y<U-TMM6S5T>!FT Q';P]M!_*^[ %A<#]++'S?
MXP5/0;E+K_ GG7XRGNSR=_@[/**0_Q<_!K_%?RO__MB4+OFW\</P2$,C].!I
MN5W,$R#+-+RG4IA!EDIXV96_LT?O7YRZ_*D ./3^P+3'NDZ].%./(]K))9?O
MB&Q\3)\HA9]X(CPQQ]X*FR8*GB8LT,*>'%@R0Z+F(&..?8K<MEK4'[ \B/^5
M&$1XCT .!?T=+%6R,0$"_H*X2WQB8%\Y\>3(%HF2!8,*+OG-=;.;R.02*'_]
MI6V.-')=_7\;&_*NH9O:/_*9VM7_)>^!F[<-/K^B(F]L,-^C9CRE;2E&E^C]
MO8*>0[^F5ZSA#=?X!M\P79P;*N*==E#Z?N,(;W!4E;;@5!7_"+RL.X'7?0L0
MBY/I7QE@Y3]RPU%;1OM?^81<@I24)S903RE4Q*_]#_\>_,T'"1PA_/=_")TC
M*.[HZN-&2R=,1QX^P'-B5";;XB3VN$G@$?'HQ8>+2X+%TN4(C)&9.U]+LP;K
M#WS[" &CU) I?)3Q\B5*BQB5Q*(<@RK0G2=6;V"X[@C%GF9##0,JT'"G4@M$
M<\A''N*=W@# VT538FL\!4X:H#T\6Q>7W'A2#1-X8M=V]D IBHX+)5\-I.7"
MNH#Q8HVF!D??IY9.;P'O$H#O+LWN^3TT&WO=8>'ZL#3+Q%@5G2(= 03*5H4L
MV;DID];V*&?+GRKD\G4E5R[$EZE)#61FOW./PA/YDN9"K(,GPZGB;X8GV\5!
M\^RF5SW^VWM3/!G*W%X=3V8<353,YXKUZ:IUB;$DT[#/4(@5K40I6K5=[F]D
MU16RRLF$'^^,AL2B8P P0N_2F'Q8LTO1KWPVP,5,P"/9-8  HN )/B6W*#A;
M_)"D @_"@@YHK97#9ZB ^PP;H7="[NJ26&6?K%C7")_LXO;WV08:?.G[;-5G
MN*9[;7C+*Y7S"CK3WJS8]1N%UM[H9&];;R7V4POZ&U8L%X(<;+AZ^Q]MY,#)
MAP2F]$U,B'N5D_[VT\]XXDX;+G&P8H*2T(WH<3)> P4B,HX]ZO:"OX=+HC6>
MXN;*,FX(LEPX @(A3SM"(1ER"0MFX16A#>Y'9V3?ZV'?R<-NN;-]?6B=:YV5
M*?T46X_TE2Z-U4-L.U=\D#D^-PJ"RH?S^?:SM!F;:_<?7F0PM(>J&0VS=7-D
MJM!C,!AU$"OFR"\% .-'&,GO\.^P-$M3G?^?O2_M:EM;VOSN7Z%.O[=7TLMP
M/0\YI[.6,4,@! @S^<*2)=D6R)*C ;!_?5?M0;-LV9:,(;RK^UP"MK1W[=HU
M/E7%I#(1RIIBX8PA^LJ"]TK1 C]A(O04V" "ME1=(6C N/!(-*2R+?@ *F4?
M/B6ZMUA%4^!:A20SPQ=L=\TF6)U>JXW3!:MG9*:3W]\KP!&-X_.'Q+:$\4>T
M439?G5[]''3;[.1)2%*LFI6L5-K%5GLV_#XKBX_?<UFFERSHC!MZ(7)]V<LL
MI_< MYR @75!Z?>Q=.H)C=2!:MFLW:O%.1J%$AS=2+C8:FT+=*O^1P3"?&3)
ML!QWT05O1?90M 4%&\J2ID-4)F&R'5'I( 5!5*&,X[D_F2,BB)PC7R8EK*(J
MH\S$OTJB-11@O4/R+I0P.J-*D1JZV"^!HN<*L:(K2/99P8UMH2/+*E(&;>8B
M?X!*;!<$:^!7H_0(/JG@T4$D3@$'><BX15A"7U%I&!O=!C34+?XBWY=$"6Z!
MB75I%@F=JO *>F8\5NRE3TT/1\(1@P71OT1"6U@T/,#J@W(07\AQ8*B<**2>
MI@Y$&ETV:1:)8LA]CV"T[BF@UI3TG$R(\:KQWO6&W@)Q,E$&WH?+!KZA7%A
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MV9W'AMSPY6)E?C>YNEW)TDM^JQ<\"^;,\I$?M/N[JT3CC%@N@-Z0&1MH*H+
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M ^Q9:DAX!G438;0LP=21QJ27ABUJH8!HL@":5OYHO\]/SD[V1ZV8&&5H.\6
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MVE/@ZNBK36?GU&^$R)]OU_!%"1\+Z VWM)A)WY!/LMQ0,1?)6ZD6J]5*AIW
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MHYP2YJ&PA' H#9S;D6Q*=G@&]&,A81<0<JW2<B%>MSZ[WB[6JED.@8^]C'G
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M7G5<N-?AR2ZNRPVW(4#)&".-,-(I@DR"QZ&-X8H88GN(HQ  1:,&E.W/CLE
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M#!7E0WV\LOKHNJ',@BN X!_FA,8?2=!?@4\P9&^T\)A+I)]$(J)KB$&/)U0
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M;+0JS><-H455F!5:9!N,M_[7P%B[_599W+TX/%<?(SV#TIKLD3TDV.RK\U.
M9S(:]I%LCQ>H9HE(C7;<\5DLKLJ4QKK.K_UPOGOS\M*1?\:>G^4V]%NDW],:
M+WXMKL]3A)S>W4ZZVG1[1<$K*]H6KM")IUD,7ZF(#[;FO[IN4X:85$ E[L!C
MVAVNX;P/FSWGX/CXY;3>C[VO:?H:1O:PGON:B?\\X[9R3N?Q*:\@BY@,[,_;
MPJ5!BK""Q^^#P3$V0'O;LQR"8;>>,C%8YY4(L_B:%';<[WLD7S._B$_36ZVR
MMR=5O)YPWK+\JFHFR\3M9#U<DT4M_PRN<2G N2<&WYII2.)57,L8#WD!I&7K
M'X%&Y:RO^,X+A5#P'X'D@/ #U0\HYNI0S.K?"<4D :_US_!HEUV7P]>7!.V&
M'=J/#$M(DP9W=(+]5Y*^=3^]O:B.7WY8PS.UO\2LCO4&"LO-[4+,W(\3$,V_
MOLN6TVU^^L9V2>IK P,^WCSTYMU@B/P05'^)A.B6VY,N+[QVP1*?0*A:M*2"
MZCXFWX5:J?SY\8M;7ZR3:+W&N_R0(F],;JD6+]+&FG>$7A:P5MN8H/?Q/#2$
M$<*%P)%61\Y(0!GBZW?'LWXT^T"PFCCY@4)G54D=BSI/]?6)+X;%@)XQKV*
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ME5(*?9&R"B"2#/LXXEE'/$^RU==GW"]VP$D6_QP9A\W25=V!]YRZ4Y9)T4=
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MTAR.QHZ-4H*6J9_J%$XZ )X^$R<8]4HP+Z^UB[:^8Y9L77W%!@QT]8+*&S'
MF4KN!H0QV\$&<54*>B]P6;-(-;3?6.0F6[K&7^5,9F&F:.6]Q&4NS;C,Q\I
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M%$F*#,9D)P"C?9T)0/1<^F6/[<J>YE0<_9(OGW_MY>6YIQ4XK-<'UD@%3(%
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MP/]P_Y)PL70Y/B99CEGC2)B"@=^#KWYEJ[S8N\"@+<LZX_C1Q8TVID4LI_<
M[@/P.V@)^+;NP,LU=:3:5)0Z0 "3UTI:0K55(:^HMJH<D4/*"W7XUCEML06&
MIJS@'\OM5J-(/BT9)KHI!D7K>,%7_!3=I"8^%P7940JHRYYUQ;2&ZEB0AJ(^
M ++:0]$6AN(3/%8BL5P9'J(\J89C:1/!,.D'),/19/H)U&YD:A31A]O"Y1#H
M$_-@) +9+/DTA1'!H@I!4M&G WF 7@XY-U@ )16\?IYO99AA?;P--!,&BHX'
MC02*+*R(2"59Z:NZ(A=Z$[=4%:A/'#Y'LRVA#SI,L$U1MT1V./!"#'TCC7$[
MWE.!S!+(-U%%WC6DQZ&AP:E:G$KD=_@A$4]J;# M"B\>&;@?6%.A7OJ/8("0
MA,_80U-1MD@L?4S"]>"!!+Y(Z(7MADT599<5MT6$8WF\)\SG/;)YYM^J2!W@
MNA$2"-?95TW+%D:83AAK$TZ )U1,G$V9^T/B\,U_++9ID9Z\K8[<#T96"L\G
MW#$>:Z AX&0+FJ$/MO#]>+);RHLR CF" QT#6P*]A0O'RRRC5"%]6<C1FB#5
MP0:3"6.ZCIE',3F68D"#CC. !PGE.GIXY>9V ;\?)1QEC;B] .5T@QZ.Q)(C
ME)\X+_BL**!'5/; :0)#)XF; A4UED"5#[LMY'';KX:X>_O* DZY #?;;18#
M)Q-3]T:OQ5@AJQ"<L:'',CX50T1N41ED1T06\ *397C+05YU+KI"LU;:*I>*
M8!M^HZ8]8O9@U6 '?.,<#4\GMRY4_8/OZK$;A,P] $EDV;%[>!XJX)+8N!<R
M Q D 'P %U\I_4/$D:8^*MJD@%()>9G\J?P/%3H6$[CP9GZ=!U@]%O\J%3Z%
MMZ&'00_:M2%X(_D*+/) S^$:D^3DDT(<*UT9B&2X*R@D&6]O$<D(5A%>&8OA
M'6D#2M,"SS!R>C[-4$3E^$"O9JPV*=+TI292#*QEX_$-\)L%:@:@&07B4 >R
MJR 4X.X29Q66]7$!5\BLV(5(>*THT";[[D6C2$^B1UU.\7C"#O(5,9MERK64
MW9$3?0PN< :GGX&O%UPH,Y^)&;$5$]D\P.(=";0ULJ<V":>$4#?A'_&6QMWD
M K^[N(SH^Q,O&[U7<:*!&2U4CT?"B/Z)T-'BK'#]5I<HN4.=1>5FY'?[P^/*
M\Z,Z+(^]+%%,V:)O==0XG!>+6G2-R\QMKY9JF606RL5&.:X6A$B)PMS4T K'
M$4&IW8J*L]_IWS7V-N\T9HY8A[/( L!4;1<KS;@VSC1-)SLFMVF)0D8(0FAB
M8CCB[T\+O9[D?_O%#KG8<BJ(6XEJ"O1RN&_F&Y8\9O G5 R^*@GFKFBP"VP
MRAQ6JD2L&"M)B%A)!G7Z+7PA.)=$>8D.A@>8FV,JFO(DTL@!J:WAT5O0&_[%
M!E89-*7<Y:I]U&VH533%LNAB1 %=2;(\=6@8.. 9%!LQ9OBJ/BR5=6) J,Y.
MKIN*R^ZUT@"LHIF]:?^B?GGYT_[Y,'+E_%72BZ/9N-U%W\JTRU'-^*X?M)K=
M@T:JU^8+S:KEGQ%;&95;RQ,^-C/)%73 9$/Q!RQ<4Q@$'(J< CJ5@@7W2^VK
M$@HM'N:@%OD,IL90%GY$!W((Y0I8WKH]M )O=SWFL:&IT@0E+ F7H'WL-6&&
MBU4 GUO4R&!['^C4D^9TX/U8-(G()[6(/DG/HZ&+YO'Q[L[*5R<P@9N6.^.+
MID,LR&[ ,S =1<9;)!O^BSLVO]_U>C_M\T,O 7WHDH!^*WIA:YDOA]WHGJR.
M;O33TJ"GS5K.,I<DS8(6N.Q!,!>"A/$R/0,+68KNOTFE3*[XTJN/%0/U\M*K
MUXU%;SX_-_=J%0P,,,?<K'@CA"9"=,.M!L8+TE,4/6"1Q,?$,-"#V4CR!N+*
MDF MVB8L_,F?CR/U3&6HZ!:&?# B&I18?15,'?_]-A7;,74WUDZ2/&2AF/(U
M'(N^CL:%X<F69*H]Z@R3P#3&A\1GB^>('L 3L&35#?@S2(#*P[0LN4 D&QZ<
MAED1TR+![9YC@75E64$Q$HS#*R]@=^AN_#_BX1<""T!$ LIB+S1.B(&_@?_/
M4/=@A<*AC%FI-F[(]Y(0]6 QL \"4_!!&?R+(CF! J[%L14:Z*Z4RFW\!NX*
M*0CO_$<8&L\8<"L&LEY@/]M 7O@F2^H\D[5*-!I/LD%@I-%P"8W9\_A./%V*
M!1KV $;5#-""-.#!#&9D6I6<VD105%1:-(5%6!*^P>,RCD7Y4N1;9DF5-1C!
M&9>W<NLY4-@: ^W.NAU#O1IIQZ ,\ *?*V-LHJT/=E5+@KL*U$WHNQ"(;*3X
M]OUT],L^E"]?NC<])5M .@,:9'DPY?9V(52O7\'RF59+^O%TIN]JE4_?V*9!
M>E")3^J*V"F&#W1]70;>OD.&_CX7;Z8R<,!WU_"G)U5YMH@Q:%'*4_W",HVF
M(8)8=UA8%-XC#A2:SP<93<.HBC^X3^<':"B%*(03I+ZD4.GJOIX^AK[4I];L
M(>BA >;R^*-9CFF6.0>W%VS4T[X+867\8]V/5?E>ENX=]HOX^*O6_:E<[!P]
M]QJJ!^XFC\07>RE'3IMYYE#B<I8+L-;K:0V?PY-]G^G#WOKI&\F1)\969158
M3Y?LF(U^%;H*Z 74HN)X4@1O@"7IT-P 083A3PJJV%&-'5%_A"]3'2H-5<5/
M.EPC^A5P[(^H")^'!G%A/(;PS!_R5>5%D1SR'J,/[A1^Q[&(ID0=:6..F:V2
MT)0H4GP^!R2@:22:U$3K.?) (=EN<*P&@D'47Q^>8ICP2R!MP<^\/K9C8!;"
MOIRAR>_)<VR"X^"THON.71.F#T5-<JC-"*859K+9##@W&J600:EHY+E_^4P!
M3:RIC#N @83JN)F@AB<^?J%I</BC9/,QR["XW> O7-O3=[Y1!BB0G"-953*H
MA\QW+<:]E;\DCFTXU_0HU\0PG\!>7AB!<8W(FC[\2=/@(T4_7@4(*H,UI)+L
M([Z K(=9<J>[/PE9"%2 L0WG$)X\8MQ!'H4X 4ET]\,X3L6=N(H(44'(Q2Y/
M8Q;;<&PW_RG!IY\4"K' \S%BK7Q/YGU$Q#=H(Q3=@+8629ER9N1P9Y% D.#W
M(A:JT'L;9=TBM>7]L""2*&*Y65?B@@V/-C9SIU N/U%3G<DCJG 5U+[LT=O!
M&]L#U2P3#=Y73*M 60W^HC))Z7-E^/WEW:K8%>82FWV)!K_Y9U%:(7!&Q[B0
M0N4AW.DGT42TFS >B@2"T_?+@^U"['6')\B.A)3'2TQO&[AI5$[0/\(=Y.X'
MF+<#!,"2CSUCM3"Z3@KRQR-)X'KZAN!K%?PR.$@CBLHEKE@!M+"JD:=@D(R^
M<JR)"$H0V;\PW"4K!']E(I(498P#U*9/0?=*&8I:GT3*P&6$#SL(FH"SX?X1
MK/CC_F[01I),3(8_0.4-)H%-F()^"JZF"@\D":,8'<B""*@9:*QBMFGC1HD+
M8?M:(/5.N R_-J$ -FH9L$"-&_(1E'Z?<';<NI"!BQBF\M 3T8>K5@'W104:
ME291X;8MG*/X$%Q%Y0L_\3+SBZ&"F%+###R>ZCU*3@:MV(ALV0(E ^6/DH%L
M2P8:?U')0(!7<V[S69_1YC,<(_*%378F[(])/3Z;L3T^%WKB_;3YTWK:G[:^
M3[IOL\'G/L<H%OSB#:0E%[8?_3KSV$B@86=-UIT]8WPN3A[2-.QTC\P?)!1(
M?<* CKC;V):=@5W](VQN!T^W/WM[[WYF>>4%-UEV6%J'1[R"59;HNS#7A5=5
MBD?*0>.7<Z@^BN^^8RAN_TUV"J5'MFJ3T)F<O")_5C/A3R\>Q=GS7%:?I4KS
MT$2T3DKV3'E//1<V50.NR%/71]Q:)L3UAP585(!3>733L0Z>*_O'EUK65(X+
M1F1 [Q2R>46BM^.(/I5/KF^T\6CWU^]FUI0B(ZRR8$723FO=':HS.0"</Y$M
M4;&Z7MB+!TAG1NN/?N";H"4_M'O&LO#O4K=_M=K;9$T6,VS:-7U8EP'2,Q8S
MOJ)DWZCVL$M,'L7<X_G;#LU!(CB2(<*G^]K+X7/_M/S[.)]9\<S_K)5B^ZF?
M^#+0N3;.#WTZ_/%4#4B7H/(LI$6TPT[$+PV%WK)H@MA(,< Q=0O\O_FPPDY:
M\*P:64RJKQ?+7H>[C]-:Y;02O;[0L6511%IK%:OMN,+%Y<XMX5C>[>$E(] :
M64R3K(.VJF1XJV*5<]6GG+N&99_V&9&XVFT8NZ731N-L7*TLH79G]=8/++1K
M<-342EBNO&<?I^P9WZC-ZQD_;Q&O,KPYP "9*IDLJN;*Q7)LE?7[)FQ:?9#%
M_/IRM=@JKSAXW!VTLM%TGB&Z,RF>K!7;K?F3.I>0U_O^N;\$/>J"IG'S?.#&
MU-+K_=IQ];C_IYS??/$4HU"" -=7GW6RQ'/2C;V/.8I,7:I&)GWEZ\56*;/Q
MU"M&.M__D<[6B<TL'*]RL=&L?ASHF@XTI2YN9N&;54K%5JV1P]'.&Q;TUYQO
ML@W0S,)] ]59K>1Q@/&&0<=K_\W2R5U?20TW"WZ,JQ>W.R>_'RZ7":*F].:B
MM@";'G414^SS2H.G%N#)9<?&DV[B,6>1J5W0K"W%JMAU WX78R"48[N*K39A
M_DV?;IZ'.\="R,)KKA0K[7H^8\ ^CG5%.R$CG[U9R?#*+F I_%6G/,-:R")B
MT"YE=TG_FR+6>XIU;P>T*K2CRYU 2>@>==>YT?!D/#[]?FX]_#@;KB66\.D;
M61TO6HVK60T'%'**-LW_X!I#C&]],7E'!E>!#LT=/9?BNBPG/5J9^!K-8K,4
M%P>(XI*6BSERU^)0IR7K;,MNN+%]-_JAE7Z/:I-VGEDB_OJ/^_\&%Y/F_F]<
M<(&8"F&N7_*F9].6L=Z8GQ..DNFS^&7&#:_X+ /:A YG&O(\N:H[8':<NOT7
M^*6?M _-VM6OV_/!0RYV06J;%1=+NXEY32)6=U'R\(EB.6_I[V?KDGWL=^/W
MN[I'EOJM$>1-^OTFQ,.X+35?P"PG7]O+65()H3 ,W]8SG)\^2_S6_:VY#-UM
M74 I%?+&_G][;[J=-K.MC?[G*G2RSEXG^18F2*)]LW:^@;O$B;L8)T[R)T.@
M A0+B4C"-KGZ,V=5J4$($%A@9-<8>Z\WMD&J]IG],\\:M?;WR8^K_G4U.U4K
MI1>:V65917.S#DL]XO)M-"(FYKF#\\QS&.QQENX2>)X+0&NB\GI:[[P 1;-8
M59-Z[Z8JP%D5EULKJ<7[E'\CX' F[M&#YVB4;49S)B<>&;JPMC3V95-:-I_9
MV4?VSH^K_:LO9Z?JN+,#^C1O A<E0G^1.I>8[_.>[Q-%.6;TZS4#'!N5!1L$
MO;6DB5S.5,>OUHN-Q/J'Y=)D!3T_*QV=U:+BO_^1# ^>TDUZ_VOM#64QM"W.
M@4^)^(33-*>#V7#09)WE6:HJ^;06< P[G':?04>?Q5MI5T[ZZY;C8,<72GXQ
MW<SMHC?G*Z>\W^9$]M6FK]4_9[9[?SJXKVTI/'D0]*GI:883=BKN!D,.FH^R
MHA6_2>AD]PZ8&$RV5V]&KF]=:&_I^JTIP#,V!]<->J:-AGRP;1U[?9P,1W#5
M<:50&_*A1[N\J9R>&_I7+VPCD8JL[%%14'],DA$,:O=NCQA,WD7Z433L?^G8
M7<"4*TYTW;+TPY#".KP<0<J0^^VJ.SK\/B:WC[\8ZXCHO=W;=S&8O-^(: )=
M*U*4?-$["2J1:6/B0$",]T?-1G/0^-DU-QJL>?4^.IX7Y<@7\WQ>\\Q+8&;>
M-<Y>W^?C6ZCT+X:C]71U)8O41+E8KZ93TK.JA)I)<UX:4O]X]T/^\&,@?^NO
MPW&18>"%$G&Q?DLOTA<OYON\YYNC6,OVX#U%YGFV,7E9V60FZB-B)TG0SCM?
M;*Z)JO]207N_DK:53,(L(_6R&I PJYG1WM_>'FM._5OY>B)X<7=TW#O+BQL>
MS\-,CN<LZ_WGQH<[[>1&.W'3-V5X)C2\X>(V,EG<!:SWQY\__K4.]G^<GMQF
MO<HYH_\-%_TX:='__CVIM3[9Y/)/I9/U2@G6^U=;9;U7,UMKP7J_"U)22/>,
ML?!EB=L7+?9V69)MB/6^9VK7'ZKUNG>N"];[E/2[LM+$,2VBWQ54Y*&[2 UH
M;-05V(ED-1OB^$I%%L3Q6>Q6.M(A6<V"G%"N%U4U.VKR%T,</[-YL;W)(N"F
M*,5Z/<,[M1YM_.5!P_[V5W,^?58%;7Q:N:56ELFM)\KI>2SK]KHB)AO:^%IU
M'<:,?"]L6FF0"05=I:C6EC.=/F4*6.;K'%O&3 )JM6)9?N0R)J-U6M+X#Y6#
MW]7C;Q>?]-NM5%((TOATA,5S;_EB<EA9S8(T7FD4:\VDDNLG3&A[QENZ6")6
MLB&-KU>7-U(1&YK-AJ:4Q)4L[+)FL9ZB8]3SS<G<XO;&=B\+RZU2+LHI]*CM
M,L9_O.U>UGJV5?W4$(SQ*4_D5ACCUU4**IDRQJ^I'0C&^#4W=XEZD UC?%G=
M#*%XOK=UHY<VK9:PGKT^Y_+60!%<7=XLN;O/@#5^(SL=V\A,ZZ!5M5B1E_M\
M,R$K/%J317XD?[Y7OGFUSO?-L,7.SD*PR#_#P;Q(%ODE8%+-R/IHU).DP;8X
MY*_WE<I'Z[#9.LN0V'1VJ()#/L>#>>8<\LON>29A!KE1+)>7*PNSR[0)#OFJ
M?N =G%WWOCMD2UK!(K+XW3GH8C#9*@!I:)DVPUN^Y$[7,F4TE)M*46FLT\([
MK<J_G)]\<#/^^>?!OF]GF/DA^,D%/<3+FF>>0RX[Q$^^#'VS=<,4F\VDEA$;
M(2=7MTM.?C/XT>H=:N3W9)TXD" G7QTC!(&$F&^."#.V+@BV34Z^1)2LV31^
MKB)? T4^J2>LX"9_P<;O3@TF+[2-3\A-[MI_S+_]KW\>G&VU3A;<Y"]A,(*;
M?.'U6TM^9\M,#M=634RC>2P[N9R:G?RC?%6_N- N#_L;K<$2=.2Y'DR> ^K)
MYW^=VY])&W995HIJ)<G[GDD,??\1A.R_>\V&\4/='W_:5ISMY/+JW]IP].Y0
MX$(N!Y-'7."1]I1W8RV<R"0$7ZX7&^5TY)EKX$1S99KZ[Y7!GP^W'PWSPSIF
MBJ"I%W&K%S?/EQN?RYR(?@GDKMG7/5[4D+975%;E58<KT] ?#$<CS;G3Q\9F
MRJ\%#;V(,HGYOO2H6N9T\\O@>[-)JQNCF^>O.A\/80F[N.H^MC=:U5]_Y<:5
M;M[\[LHWH7-M@\3T\=%,_9BZ"0"!]1VA4>$@S\G4+C5?S7!>F9I']$O-\2;7
MCF:Y;,G=0\/MFK8[=L@UO'+?M+NWKZ969\K^6.$IO_Z.AX<-QQD9WYQ'KRG]
M7T4MU6?VGJ\O_Z5AZ01?L,<_2[E.E7))8IQ-P:24^J^_C=^6._IZ]J"/>J_>
M\XD5Z,RDZ-0"ZJ;.>[YYV^A<L*%WP&K\UP"KC5!R8JRA JL:F;QUZ6@X,NT)
M+<]N]1U"7?72O>$-"H=."=[8 =5%^J@YAF/ \=WX>L0VM%RJ&M8VUBCYO=EQ
M[UY8A4^:-=:<B:14&25T$<-[5'9(GBT!W#G$=25 ;AI=UZP))1&KOW.E[MAQ
MZ+;8#M8,2W#],3PO.81RH='H2G%ZKXK26>FP5)0N!_0_"4\M' S0@P+SP_-P
M,#!(3SIZ(-TQ+:J[Z/6,+G&*DH:'0L<1>F0XLAUXNCF!-^OC+I%&&CLY=D\:
M&*[D:B9.<#1VW+$&OX8OX:])>,2TX(C!W[!N:C@>%NZU/@$POR,F/7ATL# K
M#?X,D^4/U4F/.,C[-K8\PYPEV"Y)+9J+$/]#I2C]O],HT"P?1%TKW2[ J.Y'
MG0SBMBR=RL_(KWX9)[^Z^+ 8&_X<7(QQX3ML9]C&^#3X!U_([\9!N=.Z,EY)
MGN'A">-C"=(HEEII:<8^+>U;[D4OE"5!W7+"$*<DBU).2VQ2GN6I4>I)U (4
M7J5[S86][N(UH(=,BRU! 2:-YP&CW6@*4\SJP)&PX/BY P+6:"G"9)U7>/ !
M+O<3.;$* :2!RCD"K CN=!O Q:%G4KH<.]V!YI*(S&%;&[^J1U%Z$__K_K>#
M+Q_"=W_I.KVC*BBQU5^_PG]E<5N_?!S7?K@W\EV[&MS6R'1&_G2TJ>F\2J'A
M4;U;J8;_6GPGHW<07S&$)PYT;3(A&HB(V)U57TW7O"]<OU?O?0$E*PPY9]15
M_\[BAAXZ6E^#%91.C:$!JUJ44%]@@Y4 ]"V;8GP'A82AX_X79G!8#C?WJX4?
MVX=!M2G><V_*IC8T?,;U9$0N>I$\A>EO+U@T_VS<C.V[WL6'T[^_0R1GTP&@
M@C/!!-C"8$=\]O,MM+0GQ?_;TO''CDPV7)WE1E("/3L]H/1$E@4.AN91*4 =
M5?<&_$4?$Z8Z#'$L%#IPTA*^SM(U1\+##N\T8_J2Y&CP=1=5*0-?"1I25W,1
M>QQ[W!^ =@ J!*@4(%1Z$JI.H/*[X26FQUKKP_+TX51)%O&D$8:@B.[BI]&7
MYDCP5_@CA;>9XQRUF"[Y-W'O3EQ4A[H$4UZ&<&';'MI)^3G@K<ZE43\Z.[LY
MK <'_#RZ.JP.TU]=*6EUEZDR2]?KZ:Y$%IX/!>Y$8JB0W0FX AI-\F/)?/"C
M2337X\<.=6\XY<'?B[ 4\,<1<0I\@2=X-,D#<;IP =["0MT1Q\4GC0"W"2CQ
M<"E&(]/HHENDB!M$KXVIP05JH9R&50;Q#\M,C8' 4@$A(%V>7!Y)-QJ>'R\0
M= !MDT $%+@(P*L=_6I).K&8$F!0=2VBW(=V"PZ&)FSC=>7DK7"A=:HNT-6H
ME)NM(E<"AZ@5LD7"41N>1PB?3B%N-75LS='QCRPYV7;H(CCV'9K #!DZMC5V
M\1SW'6U8Q$6,_8; H>Y2@RA^V2.\:_OXG4OVE2/_"QFJ)-QN!]W>M]I#HSU^
M69<^VMV?1/^21OD93P[KWUO?SGY.].#^[T?7*;),CU9[5IEL=II2<TI3FKNA
MK]X?DX[#E*3:0B6I.&4%WP^,+JI,I0)7D&BFG:\;Q8]6)$/H$JXTS!<,Y(O>
MK(IDZ+_TT:\QP!C)A2#11["A/S]^//U>"PY2.$.\JN/5]*9%R_-D D-.:RJ?
MG!\'$F-/B8@,W%!0HY2DPA%ZNO['][C,KI<T'G&3&7'2[?%%XY"/E31]&]TJ
M(#WH(!&88:&8QN26I%:W2TMK^N9DRFU4H/UV&.\^F.DHVFWD8L+KZCMT0@L@
M .%$WX\!OZ3_PH'@.^(W0$V^ 7D^^S_NM8>#RX>'X:@SY^RO<^AWX;BKV1SW
MQ#(I?MJCYYNZ'NF:A%('S8=>(7Z*CK<GHC=^?+J7[1ME>&V??58V+X,?>3I6
MD;QR-6O)2S58W>Z.HP SI=915[$&!\D=FYZ/C,&Q*B;!F&99J(D[:!A.7U6<
M;8&;J!5FF?K"/<GO'.AT](%7\+QI6,N-45BI?#BKJV=GWS^%'K'6W%5:"&C)
M:_%T@)9)J+LQU]HK29=AV"3AK$4/%UB"]'#BBAH^XJ%59SN^61CB(3UW>*J'
ML/S6C% ]C,!AL,JY!,-A_;#^\<^'T\%D\+S ,&:&).]2X*@ML A7=0X0/EU<
M)!JN+>#2LW9.Y/U__Y^]/>G8(*;^#UR"/GD';_HS)J"#PH JRCOI&Q8ZPK]5
M5=K;X_DZNG&7-DV2#3CX>XUF M!<$*E+3)/GE- @%?X,R]/U?YY^0]<V36WD
MPE#\?[V3_%Y;9>RR.-M<=7X=MF>/DA)7YJ2'L\:64Z][-;5P_I*]D_ F_2.U
M'*V#E=KG<'+8LI[;N'JR6H]^[:W_/?Q;F"[CY\K\]RVL<\**.T2[W6-$'?^
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MBED&)&U),X@!3MI@T2*KJMF<&RRBSL#9U<&#P2<BL9E(="H2G\N4/O3AZ$/
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M'9Q!$2Q8T4DG-U59J2J*7*W)2NVMKE::2E/1&ZG\= N!HRBQDI8S;2+)+,D
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M<JWI@PV%&KD<H6/!EAFIJOVF/4&).8I@C=2E(W@N^Q0V&L9..,C;DAJ1Y+*
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M260RBK"OT,!51-B%0!$"93<$BB &R(% >;01TAZ/1B85&9HIG1+/(TXDOQ>
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MI23_^U\-1:F\F_Z/@*85H4E92T%"^$D+77)#^EIJEPY* <C(:K6\%(F:Y9I
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M+Q<G+J^.Q%GPS\*E0S#!<?NB8S>1XKF374=G>X!>4=J*;8YA\CJM#?)F>_Z
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M.Z^!/..I">5J1>7J [%[/8=,D&"W3Y-:A&](^(9V -VWH!GY9Y\.$<]_D5\
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M\I6$H&INSP1:TVPZUZ) C]LP_-H/LVX5(HX)SX7?+[K';<!80!VE</I&%:\
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M-U=?6YM0-Y KL]>RI[;:6PVHA+KL$.&23J.1JM CO>-75CZJQ)AH^6I6"%/
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MN.V^U,)^COZG"<_>/ AM265)XAC)?()4. /2KIMO*Y7.*W<5UQYI GR%AJ[
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MZ%!Q))/ZA#BF"'SKE!==:6X=&?\&JQ;2]5 +*(]"&"@N^0$REB1US)VVQU-
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M)BVEZ;<O?@/(R4.'RV:81^(_]XQ=+GTH!TU#SHL3L)-6XEK3LIXJ32-*;[^
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M?P783)2$>9A> >JQ/%D=FM$#N%>?ME;;*DJM^9G>GFCOF1T7 $//%*X 'J3
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MB2(#,R[/G[Q@Z9*>>M#!;?/_M?>5875E2Z(')VB"!7>W0'"'$-S=W2$'=Y=
MPL$A0'!W=Y= </?@[NX.#]*W^W9/S[U]9][,L^_]6&N?DJ5[[[-6U:Y:)3_A
M (2[5"F3$EY9EH=W@3Q=^BH9K/2Y=<GF9LKVAC6.5.'[!49_5&JH$J,O'G\K
MS#A<]-DM%7F\2I5_9CPC6J@LRA8G%4\7!8@6@YU'4&W\S/2\B1?OG45N&D:6
M%1E1/#*G5%@D-#N$]5EAD5CV&+=(+BEG8HW,P^=L-?$&[_ZW+[K6.UR-BD.R
M57](&)CES J8T3NUXPK(E3/8PL 0I_FUNY(5>FIB"P6+A3MFPD$+=._O#F#
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M/]^W[+CX5/5AGRJ+5-^_ 6+(4#G28Q:_OFU\%;'G7"0I!P(4N.3,F&/X3NY
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M/]\J-#>6NVX.%;L1TQ+.1\!'IY77]PB.BW'/X2_^#7AA<1UN6[R9/J+M\ B
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MHZ%NA;SV/N*@DPT(,"'P5^,QA0"_;(_DS>)YB,N7RI&R33,Y65518V! PLD
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M$TEO.E<\8,3JZL<.UEH:*UZ_U9@EOBL(U8F]S8GD&.22AQ!_@PA+:[6_?WA
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MCZDQ'_L4&N7FQ?;A*1'[=$_F^TS.-5T]+(!/'LO<A+A7W7KUW@'2*+KSLFY
M6RA2Q)KOB%440T1[5"3JFU6K\=)K%>Q;!?@IRG3 P_J&7U]$UK&YL=:)0748
MI<8Z+I']1&M#YQ#0*U*R"^_7"-*JUL^0<E%:ROU"85P3>R3KBB,:D2F2PH^:
MC>Z8G[Y#E#FJ.ZTO;T_$Q8,U #"LN6&6+K<HPTDXU=ARLE7<&)J7-($R5/?P
ML!!64[L5PD0IW0.SY@PS>VT]UP@8<&J#S1V$-SY_;17Y5M.OHLN]%7?A.,<>
MDMS?*OGX12]Y]]JJ> #<(CLH;S&C(2ND_7M("?RQH+WDH=*,3#6Q=1ZC+T1G
M 7O5>EW27X;LT9@S> ZY_,]&>JSZL&R%\^Q<XFR3]@<H1$_\R1W "*G:#*%W
M %[M<6+$0S]B%5V BJI>Y],:^!,'ZM9($?-)(X&/3HO[/YV8.#F\%^CF'T:0
MFE4*V*ZF)-SDDT\$4\?KKS(5UH6@%26;,=0:]+HZ,H?UGBB.R%PH.:I;#9^Q
M0N(+<TI2A-;)0_F#?>>KB5<U.2W165C..L/R=.<D[<5"VAU?0REX'NB?KGR^
M(BFD_JXGGOSVJ3-;1/R -GZFVGG$ 887$.PTN_GQ=64465_C,^, &JL+[\9Q
MOD22?."8Y@CX@E5T^F25^W.C&+HX[ )5'#Y4,U2A)U@_FRR^P72!-G<<SN-^
MO]#9RM%,R'\'^W$T0$YX:6DH.Z6/X[D4L<8[C5M2A*2+S]F8QOVF]#M M\T@
MHA:><,.&52'Q\_Z"SZ05PO+K>*$2XD55ZMGT'2#A:_EJ*2 =SOQ.18H8\'O1
M'RF85!G?VTO^SM[>\]"8YYE9\%B-CL%[1?CN'6 9.'I@5P$1$<DO+M^^+K70
MN'\MBYDS4K.XYR6S)V%WC7L'L.@\%#&9#5X5NCK6Z2RW6".58F&5HR78)7W
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M"+E9O-U\-:ZQ\8>1;_NB.%XY/UU=WNH$S2K(0>JL RT",R)>1)N2LD ' :?
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MQ#+"I2@QZXD9K?'89\2DM8*5DQ.EE[ZZXU7&UCE3\[K;68NRP4M?_64:7I#
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M4BX$_7B?E"]=!CDZ&PW96YH[NM0': 7"CUB1NTMHSO;</#)>^TQSA0?JRM3
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MTOF)D!)Q@0# :WTRQ\N+(B+#3ETF$#M%2V6M;JVJL1HLJN38D3[N>;XGV,.
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MHQ]RVW=%*FT(\I)2B[L8J?M11*YDU]=%0F=T/RI0?40I)PL$.V#(%K\!+O]
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MA6$0$PZ<[RA4H0+U/%#K F9:R6P/"H"YFUB<G*=8*RGUIOC[[C+!D=CPI\E
M=)<934[JD+L;QUA@_2PT)LQ0'@6A8Y8=]*LG9I5=7_:5KY6Y[#4\$^1&^B/W
M99$D)A5)X+ZPB4OFN?"K#>5!ZD;V=L KDY+&-G2S/^G?$-KP7I'(FZ#8$WO1
MC>5"#@3/BO*DAF6JEJ128N)Z2)4"=4I<*]?;R9])+B#W:N].*"]&JPE4#,87
MU5?-Z!,@5;HY0;*US<FP:T;FEJA<!?B)%'(^.A/R$#:7LGG[3[!IS7^ Q"\/
MC@)_/,RNOI6.K$=\$U:O_0!6_IJ;,S1;==A?DAMGQ+)<5UNC05_*,H<,#?*E
MOTR*.EW*;;SPS9X"V1*UN#LP[XZO24+"98*FLPR^%_.G!7)[N?6CF1[7Q\M-
MOV>1W9401ZL1.T7 #,2U\H;3X@!W10D6BKOGT23+P /"&J1) ]?E3;17M<4W
M!:S-W4V=<9.=E2?$^DLMYTR@*/@DN"MWF44N'SLWG7-,WVP5.;RV*OD5;$LM
M4V#3*V19+>@-!_1&T.%<K9@W@TSC?1M_+V013T6X.9(YZO&B*.^,1#U\-DDT
MJW4;V]=IDS2 K?FSSZN2#^-T\S5EELNAQ ULEF*,&%+3$G.JWC1>3K,0>(S]
MY&1TYWSO13V3^<ESHBC9,I:Y1<OLL%<_ ZU2"+X(!?Q,:H9]/3 @$G"NNO-0
MR5S]H2KYRJI'@L(8P5V)^\*UL#]ORZ:A,XUX;K[#"8]Y^AG#JIN78JSI^:LC
M/I,;ZQP"3FDZV2+C435EE]PPI#ZL!!,$W]29L7[R=B=P1_M9#T9')?15\8%F
MO@JJ&S="F!?G@)G7DVKH?CV(?5:LH- SL:2+.NL=UMP9W4C%#>-B8H5&4FC2
M-PNJ^'>JS95S7?!C23&#%HK28K G=C6?EW5PM_F\@\9)*>6JP ZF7.DY.'O*
M@FRB5&%DK.K@NR9WI) ;=FM]QZK>.[1$:JWT_6D" UXJ*L)=N3(?FKH$S6JH
M(Z'?56RQ$ZQ7#/G03[E[G>2C93U^8; '*\W8;D5D]EM;]&)NKP.^74W;:7C.
M3)NA-'=Y =9E"6LL5=)W,SI;SB#:[I)EK9U"M^55 .J$-8FI\-39.2MS^PB(
M%R*K*+KN&GH>^\4V:A[</E*/5K"1];ZNHN9G]-TO66(F?S^K"'LHNN^%LE=1
MNN2BN1;WQUIHR1(4,8]Y6OH5#X1-]CSV.Y+)"5TIO1G&!DH/*96'V,@+8$VC
MRVLEYE+E\7>L&(N3"^A&V=!Z>_WL]A_:FU=^:B#6-@G?3X-V&@C73X"VX->!
MUAZ@=+, A@4RK^($-&XAS1"_%Q7+49-$<X?<7QR!QA\;P&A)7)#:2@T;",U/
MN$XT"D 8F%?7G8MDI!RQ:!GM[+"D)"=Z_AY@5)IXMEO5@V?%2T#=:/-M.8QD
M0G81ZQEP20M54,R<N\J(&F#[A7TZYFKIQTX]L2LFQ-"=LQV1GH,UI[;43D?8
MQ784MVB1E.Q<=&@46&?N?*1Z:8W&VAN3:H>(\?Z2V4!1L:R@01Q'^9]#(?P;
M>0(UC0I*S-S<+P*&6= T2SM'SU\=UL-%)-],;8-WME/&;KAILY:T^!6DY74A
M7<GAR8VC-;878$!OU<0IBOZ094X=]D"T)JD$,/18$E$IF*"YQ\"*7SD%$NZP
M'?AJ_/PKHO^Z_VJXV$ H-)?@KCJW8Y'UMKQDIO]5DJ<8%8E,S2S>"AK=>B5H
M49%9X&5^[YFMF0K7O/'WJF@T>SB]P0:9O4\B\(!41-=TC(_+I&]$]5GZPB%5
MEN[XW3QA]/JI;@M0/N\(CKY-7(,O1_UDPV54T9NX2DN:5KH!=.%M);K3+HQ:
M)B<792P.]X!7;<#H5F'ZFM<U(NAV6:2\N$[6\/U.M9K<^*S(EA7!%9M5QK;&
MV.%].UQD%0#UBRK/CYU$2MEXY_'Q]BW4_BQZ2L??A901GGO+GY1@:._+-1TR
M$6'X;T]23H?6A7Z+4E= 8RLL75"T*Y:F..M0'*GG+Y4L-4VHC>L(#@1]7E#R
M*3>%(YBQ0\2J--DF$KPV=X*-1YPM'?$T#C*IT/C9=41+OD)!>.[NG/X$+452
M;-0*LX2Z-BA"2=8YX(WQ-U8 HA+<6X/3!?U25J7(B(K5'ZYS(Y=&LADF9W/J
MB<H?ASYQ":N7%%Q8:XUQ\"Y50RG,:THSOTT'.D*0(U B;8B_B_#R%&]CP>E,
M&[.K2807='BNMFOZ*<&_0B$4:C]-Q]B.))J$S4BCQSNO=ZO"=L<Y&<V;TK_N
M;0^EU&PQ9DJJ4:F\C=.-HZHNQ5([0( T4D"M%T-!J8+O.D<\2[(1GZ<SP(K:
MGA3R1?4[VW2^_,(3\"8$Y],G&WJXDS^FG&GW>'\8WN5[(Y" 9Q+N:'.G:;'\
MJMX@V;ET]F&FKDP7XL&HN]1/4W$KPO5K3U*G/GSK5?I2=DT5K71EQC+9BXOI
M O4Y-I>X\-DL!DHI/7E*B-4W!!4S(7X7$/F6H_#U0=.-EM9!62L0OPV_Q.6H
MX68%]R,?1J%0\O&^5OKPR8QW-]_HW4W9A?*IH7COX3L)=EEEU_V;U]8H]X!!
M4M#=S>O?,<C^S&L'WD;FW@.&_M)2_H^,LDK>U.URQ76JZST ;;K5^[CKXSV@
M">TO(<3^7#&1\3 EW6PZP:QXJ&"\P_'^(Z.=9GSNGS=S/'BA/??B'I#*EW9[
MH?,84NU/; /6-3GP'I#NF'=[J7.0]4<F\^1:N)Y9:#W5N_7L(.WF\#&51^L]
MX#$@X9]XQPWOR2OK6_@2X?W>>X _^1\9_(?OLFAZ+G!\AP_QNP>L1^3= [SP
M?\=3^[N*LK=W7:/>&Z0/"QDOE1OZ/S$-0H/[:*":];2#AGJZ>X# 7Q\*^9]9
M-_(SH:1[@,@VZ/JH:5'RCXSXYIFWB[KGH,"#2KN+PI?+!?> >?][P-*F\*+;
MQ7O?ZY2_/9?@/SX*!5)R8,L](/CO['$/:#T]^ 9__F]8%-GDR@KI1O:O%GC]
M#^FQ\?<5VT/W@/*3^2LD=>_YN'L JO ?F=>@G]>MHWNNZ_]Y+Y-W\TR;PTNS
M'Q1>='<!W;EL>9\O>C\&S?PC=R*\X\E]]WD\[7S5NS7R#^70T9V[@__9+GKZ
MP!^,"?^C'LH#%%X&!7 RRXRW(CO"<?[J0<7W%YEIATM+R@4Z@\-4/FX>/\R"
MJR;0JZ5#K"<];:/ )B,.)XXN.Y91T)4W_J)($SG\\J,9T!W#G\G=5%\_?9LL
MPLK8E9NQSI 6RDOL6TJQ&J'*D76WY9S>HIWWL.FT6@Z3(/"HQMZCBX):GA<1
M188X;M3S9PWFS18?2MN3.*N,M!>\_/79R6(%<3V:YZ0TWX5*]MF/1!;P8AX^
MXD[?]<*BDV\=6;)B_\(M\XDJ1^:/4!-#M=C R]" V6CW8_7CUNL7?91Y$97N
ML_@B 7LMLT;<\E0(2GJ]( K$9? :RXUE,6U&:6=YOW5Y"455R!K'+T1E0V-^
MZ<$E=Y5T<R+F4H@I:>7</8"%5UEI<I(_(>=CS4%NHJ-M?C^'U6X^M>D;YJZ>
ME!Q/9#I.UECE#3L%]V=MV>:L'6S"P=;4$>^>:K8@QW.1VCA9MIR\ C78>Y&/
M53H=6 Z4.19K:6D)'&FT1DL^4Z)4\/')YVW><U?1RKUPPN!RI</G3F#G<W7?
M,YI3\D0"?+2X8<Y3W3Q0;:4Y>EECGH-^V1?=O@XUC,2IB?ORZWC^0NI&S+HL
M$S*V;_5Z=W_I"R--Q5OT()F]F5:!"#3R>L911RUU4GSQ&N@^[DV225@T<J<&
M?.E3;N P,T=!&4W5?.V>#I]6?UH2P?)(60^J+#%582WDJ:H!$1WUW&><$8'!
M._PROZ8_C5A_XLO$B(22(B^18'_IDSI_Z!XI_W7=O.-_\.#YWSEH/8S:7SW"
M_]I$#3;?L<NH.6+%Y*#8&+$[D1#-*5<P_[4+UB"U262T(/SSKWU=N>E@+\%;
MGS-+323TU2XSB:[4C4AAV"8#7=]%.(..LETJVH%1('?@IX9:B&Q=J#_3WLX'
MP4!.YC3?P  /"5A*?&85V&BF!^TXS:PKLO6.\V";LS'4*6;JIT=ZM5;6AJV6
M5U2VF8H0J3LYMDQ,[\I-KYW(N5!EB70=I-^A+RDN2=PW8P/L6WD^1?EM@$TC
MF;N17X6.M/;"OLM&0[7.]<57(J9U '19]% B9! QP>8'K)S?^0VQ-Q_TX-R?
MMJ+)$J28-E@OR#L BX5^K*L5,"94BE4(9(JI,SJ#%+[-W#CG\V]I%?-OS/M>
M%E.IL5UBK5K=D&3?;\M H4^7ZN,5=[HS)&Z+':$Z\DY0J5.T<%ER- :]BJLE
MD"(HH6Q5<W/RB@@WCG&S8-G.1.<@U(1//%:((%1YC*7)E7\0Y9///0!3=.'6
MK*D=PPV(Y\D..KC=B;>_I-K%&_^QQJ%_0S7/>\LXY.!)U;ZN!5T9-PROV*XT
MC.!9Z8D<Q>TQ(4<N8ZHW@$S\H 9[L+%W)?0U8O55?ZPI-B:>>S_:..:H@WZ!
M.CZW=:5V&GJ$]6V=5F"9YX;G"ERWV,=01BL;M90T[0]IZR>6D <MF5YU!7J(
M.R^5%[609G4]V8%(:U"@.W:56,Q/FB<(X47#.*LBY;]9.D6N*N'@K#Y%B%'?
MLX%%!J^/<89+V)=HJJJ]/=) _AK%0+@_FG]K[@X\Q"M*OP">8GC>#5-'/*WP
M0/(XZ<%5GV_1IDB2 !(M%I?L?.[K]K6'\)9$8E\(+5U+C>XZ7$9IM_A2)/!8
MH+H1?5#4RL@)X5;W#F;A<*WT?*OISH"+7F3]!%!^_=P-6FL<8F792)JB(_^U
MH1-50@I0L\%ZYZYXKDX>5"]*X@0N/CNKHHADXT%AIA6\99AC.(@;S\@U':_]
MV$'B](% Y(;Q'I"V+9K R6TR,'V'H.R6LA]X@T&;5_CA6/L]=R:_'<I&I1*G
MH.3; SZ0JSTUK#1]OD9%V 8B@O2]J*M-/1?B;G6U\[7#W$Q4U@2%/V@/J%ES
M<#N>M73MOAV=!:H S4A@VLUE*PQI0J^N[@'1O/.H%Q'W@/>CE143+-S]N@'$
M2=316.2IPGP0ZQ*=C3OT-%5HGG-]/7]&<%.@L .<_-8<0CU40(<&)A6<^Z%[
M JTN87J ]0*U<FD0TUR],<=@G %I<O=-'TE9&[FM1$#X2&S,J);.)0%WWQ(0
MJ6W\"@I>*;%9E=7HSHA=3U;QS-V,YV95W[)3U2C9IO]:'?E4-6(LJ!$'>AJZ
M;9[V;$Z<6GG=P6E\P7^PP<DLDQ.5!SX'?;V,DSI!AU*&/C-[%2^$/MWP\5#J
M#VF3I$0$17(R?3"A_Y%3 C]XJ,*P" " _J]F-WI8Z9)N_(N,H_^K%W/>#+G,
M?RB*W&]@$>5CY*K_NF14LE)>%WER3_3"B-09 #-$\K+B;QZ5>_&(1 .\)V*5
M%0?08A \&.P%8MB#"5!"?M<PL'[(]'FF,/S/)E*VJQM$3(J]V[S9B-FOY/(A
M_5WL]7:X<X#1PTV!]M(&PO+.0>O S/]_7<K('>(;@I\V<>H6-&5+FQ5.P7IT
MDW0D0^%:;[[?%8_0IH_7><=9#+>CEX_PIO]MESA@]$]@GBTA_XVA"_/V0QS_
MBFK[ITQ?O_.&&?U=_^A^?,NB_-</_C3O 9&<YOTO6B&0L^=!>U0&J*MOX>+A
M,Y8;[-O:U1LB:LR-.-]!,VN^QSM;,\!]CG/&JN5[T<5IFPNKI>EA'A3-K ['
M[Y+O6!1DN59E![K:HT3=!-G[\,5$ $I<ZPVSL[GLQ$9G.:&T+LN0H+H=4M6(
M9H>,5BF<J"%YS=W!<(=0 _] &"U;N]$4.DWB,T<CT@*6>LNL:2#"J]$9P8Z\
M:?UK <-C_%)3NS=KDI+BMN?:0E4:MZC$Q-)[Z6/.;+WY'W#@A]Q6[#?851(Z
M86^W@O.L4@SC)0*X78(D;2>)O 9$?T6$A*P)8)=H;ZM;90G>A/0C9@@@*XDM
MXH1AOHJ(<5_"PH%IF2GS@57%:$U*%MXP%CWEZ8MF'ZPD"4=BA0VKJLS158SD
M1@QLR INA/Z*8Z9\7>Y>3NHO;KNL188W.D9F'@"E=+5LQ]YG>;&/I;^[*QO]
M=DV%[Q5CDC7)1MN'T3*E/)?]M3<B!=A,.M?93ASE%_,2";+FJZ[?(;305CU*
M'0X2G.EM4+26_Z^(B)#UKK 3[YW]*M<8^/50ZY_?[@%NA@((4]MJL*[(W1TF
MW518YYX:V?;.X(MVI2R+<_+>:+]O]HRDX;@=;<OTEAZBA6W>KE0:V>-#'4A3
M54E.<6SPW!YW*8S*ZYU\@D7SU-'=Z@/B(<#@Y#K/,9V/NZ!HD>SP*T9NJ0FF
MTYQD#==@YKIO:P&&DQMS?@K;\G-":513\X+)405VVT2-._"=!$2I*NZ85YK#
MF?7+H G'W /T1HKZB1 I47BNH#Y"),)F0LZAIO"3(HV.[XE[--7OPGX=BLED
MV*#N=;W_(LR7!\RPS\K-K.E+(S8YJ\W:W)G /*PP9>S"6PFK:=U[6+O9+V/0
M#E=RQJT.@$/."<*2X4?)*FI4+Z,:Q.T3O+B'=V;?$JX\P4F5"*%LQ?&N'? .
M2.CD^W6E\Z7,48M+\06UZ-+7?-W!M[YBO@V^B:2XN,NU">V>=ECPL'[T\M(?
M/WMP^UQE;)X=.2W#\^).]RVG<+__4<D7\\& :Q@H$-41"URP UF9K4K(TP#9
MBS)K7E]\^*3S0L>TS-"&N7A7O&T&@8YW7?B]ER/&?)C"F2#9.BC57=:\IM57
M,(/2D8KGX_3VQYT5(0,G!Q5>RV5/LOV/@4#_//,I6A>/2/H A2SJ[SO5^UJD
MLJ$:$9L[#UWUI?\?$:_P)3B8%7] V/XM9: *>8$Y+,[7)6#^EW*-'Y7J$U]R
M'@*R>P"7) ?<I+RF%B2H$B5KZ)/K,(NV6F=Z!R*J:)P=DD7YVQ/. O-E0=HM
M"?FSH'N P['$2+OB^U!HQMTKP 9],>VA52SES]CZ.FMFC!6=EVMOX*BO2,CB
M\%*6M:CDHQ0],V<$?VIES;3KJP3;UL2F5L_0PV=F5D_K$' 5+.VR=?:SZ%:D
MHE#KVB*VT2*A9Y_B>BLW0JWJQ1']<S5#N?#N 6;5-4=M/PKT"@NQ2.(L8C;H
MX;,RO^LU-0X[; =.D,Q<VA6*,F'[4B\& 2RTX0V60_PNYJ4U:&L,ZL0@E-#F
MH;0W4FY/*N!&Y#5W[CA&=DO1V22=B#@EJG7A.AKO ;74PJWF&<HJ(MUVV0;8
M0R$ ];]- .@>)@!%^6;*;DJQ"0GGV-/3G6PC4C9/_Y(R^QY R*$%4CTH?@L,
M7SNBF6>28E.SW=Q50BZ0IGV?$C<\9N+%.N0A,P#^D$7:'L0VO%#T>;MB87D.
MTB5S:=R<BGXH5%24R#%EY5#&C&S>2LAZ-TC N:F_.!AY> ^@>;)^=QUS8^Y6
MH4NH)C7 23W>5;(6-A'MW5I[\?D>(/YD^>XZX3$AB[_](?Q="$;7[3G=Q;CV
M@/"OIN<U:?KCQQ+F/<*+FC<B]X!,7]M[@&?/8^:5FM]M$9<?/]KDS/;.\"*0
M?<=MSJ3?E>Z&,2V(_$3.2GB_1K@S\D)%^)GP1OJ,][R==SC9XZ<^6_.,U.@G
M+*/^\RT?02#K2TBW.,21UWN@PZRIKLN$)9+!\FW7+,Z5M(-2+PKO8='J>T#C
MRN^\$W]6R)WG'L!V\S;Q3-":PZ@^Y@YWL!WKBIZ;_'PF;5GRSPH9DZ_I!-D+
M/1CA:RJ&*_=?+[+\O@CV(KFX!Y ?"<\\K&CM[@%_4!AI%:>FC)H<T\,[\I(>
M7_A\IFE9]F\:H_V=QFK_NS3^_=C^9/J_L^'.\DW?(:;QY&G],/@(]"?;D_^=
M0H+)WHE>+W]=DT' [-K2?V?\/ZOS,_+X=3MOFOX$3U;(D?"%BK;PPQ?Y_$^^
M4/O@90]&2+O>TSG,BA;^Y?OPI2SLE?;+*$9W5NMJOTHBR*C-1'RI'P4>X(?O
M<FKP)Y61S&AJ=/!),]&LM(<0/*]/7<#6CLP?9*[T&WUK-J'P:D4L#,Y;%YR
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M=ZPE4B0B;T.J[R0/<B_5PR0N=9B N];M7'S/JO MKO>HL3OSZX*%958]A";
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MZG]A:?%_DO?Z(/W>\)ID68Y?%_IOU%Q!5[CA2NYI[&-RK]PG8F'H88XY??<
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M?)I\KIZL(KR1:=]HLGC,QOUBWHK-3$M'=(QZG)-8=2?'I9(XB2%Z47)O675
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MV\M+S()KE+=\=O(K.)Q=A_+=ZC9'-NN=VP) W1PC\XN4[]IO.*99IW&LJXZ
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M\[ .[N-4W;^U.Y=H6"UXC_.U;<V90;)A;7-5DPIQ\P!Y,5DES>H=BMCLKWD
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M.1<]-UO2Q[G(6*4^FHSO&W]\]QY/+'.H6A'PX<;XCE^I3WCA!Q.O7S!W_A,
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M1SN1UX$E\6VP.<K$BH&QB*91P01"['M[^K5@TO.+W'@D</S8LWM,>09;-/F
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MK/L?K_$=6L&V[]0@$]*FB_(NME_D$[M'2(V"2HT)WT>YEW"IP /-;2)^_&1
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M)1P7H(]1ACJA%&DL$>DN[_:]>Q9LA%JI0/?:.#6("MYO64N(@UT4 ==]7[K
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MET#[H2.;-8_ .I"\"/:N)OXJLOE\\"$BT<QY>7JG$D=F@_<%\V VU/I$\@F
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M\4)E#@1V-.8SG%.X,)[2$RV4B_*F7+,U,2,*&M_QM#RPC(]4C>Y5&D=;F)\
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MO(-9_&#K+&UF<&7T]4""IZDH8DBV[K5_ESWH"Q'[72_[!+20<"V?//0_&Z%
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M?=JCJB:4#! YH\KA)X#@W&FY$B83CT#.V%N]I>KH\WFKWNZ% :UQ;M:9PB=
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MU+_CLD7\]2L9F1<(D*L%DW[&\TD#DCT&@W1_A3O^+^[>.BH.)VD4'2 )2;!
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M3#D]^(I".TTWB7@+?HAE7N<+92\M:@YQ8RR@=OM-X>[UAS-D-27L,>0E2&0
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M>S^EW3LPK/N_-4_YYT.9US$6=\:4)?<=!#[.[=81F43 'C%ZC3V>[5*G)FO
M!!#&.]/V_$R5%)=7H3B]O) ,VC38 7R" )\!7<(%M"6]^+T;7XH^X(.6LT-[
MG JAXY:Q0U])(FUEW;K3#9E'? IOVS1Z6YX!KFZ*D4&.3.3!FVB&@,J[&6']
M=0AW%XD-/LM ",HO44W^_(*FLU;_!%U3<7)52RSK'0S&O"\R>C= 9;0:T17$
MHFTB?7G*8#!#?U34TSE.KQ-'&U]%\KA'J+F*9Y;ZP'V'4^E-BZR^C;UU#->O
M$:$M-\.*@B-:-42B&[%+ <ZN,0S;6>)IJ2$:>EVCB-+ET/EFT;/AL$/R9"R)
M4V=\YT-@Y-2Q85,S<]]6("AY(G6+JDB$FSJ[Z16ZO%CM9P(TU^K^#_N'Z*KZ
MSX"W<"T6I,T,3/IQ%_"M]A]^ZB51R,<$D3:]?3 OSO7OKV'ULR$ IA>GW*AA
M+71H9C68,<Z+!G?!'.Q;Y!>L81\BO#W^%43\J;%H#?H@E1_8F]6SP]]8O&(-
M#>@, 3*1-]?3[ASC=B<[+R) 5N&NS I"#BL,@XB6BL&GP3U40&&'OE.] (+/
M[I,;TQX2>.*8'\2U.)<Z"F?D9A0X-S%=XQO.FT[@4N5'^5=5P,@!TUO5]T*_
M,Z4G!:XM!D]K!$PY0AV&#0"W[=]C)1B6\^L%@.PPB!O ,M>8!&EAS3JJ(TS3
MPU]?2LDRR3+SMTABA%;7>#_*4,90;^!U1-FK-A9CXE+D%Q6)V1B#2/QA3:*#
ME@BG"^Q*72+<9X^,:GJR/I/N2J9/(^@<U"7\KN%VZ_QP_PM^":Z0E4:J!#8_
M9VUZTNIX.P;TG?QM^Y%I'H_X:?>^F\A(#CT$W3;,)[)5I:!UNI;G#0>N6<R[
MSPN#?>(GRI8>LN \C=JH<'5!,OA\VNQMJ+?>-=G8N.11XY!AT3#Q>E//R_KZ
M^3UU+J_O:T23,&["+#O3JX8L!F0.(S?%/A_P%F\,=3"6KR:T28H(9TY-K=<<
M_]M@1Y036:L2U$,5:5.*H-0ZFB4P[O-&I.0&J,@=)I@RV!F-CAU!8$F0B[5]
MUMG+7J2)[]CVC1N1Y$+C&5]J<@M6)7DXHC"01 <K3!F[_&+(2H:G$+HNWLEX
MN)R?G-I1_$0PI1Q2#-_9J3^&&ZB->T7:&TN=2;"1!;D'8ZB7I5XIT!=3.KF2
MZ[:.YG$\H1'P:V)-IM/Y ! J.VXCN+=C4L>PVV=QO4-_N5Q1LC1$(+NI@&A4
MJ%V,#[3C^!EJP@O0@G'APT@[Q. (D.PF/IL3>'>8D*-80%-S5UI(:N1%K&'$
MA$7>1!'VGCID'-*UN7S$O?AY+NN7\1ON90J6];4RMCFC/H@*OZ?.KOP@+_(?
MHV7\2:K_\HN=:OL_H/Z'WR'>?'<A/.-__ZU/X:,@@@CEL9M\JB,ZH$;!-%4^
MPP*@0<.!'&?BC1DBO;@>-@8[+M% &&<Z]N?A#:6HW1_ZM;"K7.2W?X*?6J])
MQ>Z]H(@MQY#-8,QR1SE[7ZV_< IVC*DAU[Q(-(FU_4,G.+<GE0R@SET2^DN\
MPC^#LTK\M1PF]LG>OIH#STA>S)]_"LOX_;[Z1?'X-J*;[T!0_VYVR-U'4?0@
M;-8:!:.TM,@8AR7N99-0CS"MC"MW. TWMO0TI/G'1F(DUO X<H*<6E?H]HAS
M?3T?]0JEO9']<NX,;V$=R\1)S2/AL%=/]CM*$W-#6U$$)XT"&QN#%Z?!HAV5
M8DP4\4,$BL4J!X<K_GGJMN^(!*48^35EP?X)\/OAMF^7E7$,6WA>(-)X)1D:
M4X'9E5RXM$UM7_W7[X9ZG8O D,4.7X)ZE/515DRG^Y'A2S:=WCS]V0MW!CJQ
M>^5?SI0$]0I8 7XH\9YTC$_3*A16C#SV 5>_?G7[:)GL;%Q']LNXR1%T=#@!
M+G'R#K6O<9:69A?R>L/#-#&8FE15\#3RDFKJF7AM*7YYZ2LT>]-<E NL4 I
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M$5-:X^55&58W$?+E(QOTR!'5[)!+Y. &FO&]!:4<:!O@:3J,,([GDWQ.]?,
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ME-";=) F+2A5>I/>0DMNL*QU_[__?>]Z[[KOM_?#?,C,[)D]SYYSYIG)GGT
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MC&(N_^K ?NFVIN#,I\ '#[X$1?1VT[PR)7E=TTO&!P=/2E\ J3Z1A&%IN7
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MD7'_/D-^MQ:0A?C?*T<X_<L*U_ =G>F60FBS.=CB3!5HKB:PWC-:1]UD0%[
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M,#(T,3(S,2YX<V102P$"% ,4    " "2BZA:(X?-*:$D  #)X $ %0
M        @ %6*P  8V5L=2TR,#(T,3(S,5]C86PN>&UL4$L! A0#%     @
MDHNH6ANQ, 0DD0  NM4) !4              ( !*E   &-E;'4M,C R-#$R
M,S%?9&5F+GAM;%!+ 0(4 Q0    ( )*+J%JPV9OG+@L! ,8)#P 5
M      "  8'A  !C96QU+3(P,C0Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "2
MBZA: *S?M9^T  !U/ P %0              @ 'B[ $ 8V5L=2TR,#(T,3(S
M,5]P<F4N>&UL4$L! A0#%     @ DHNH6BK^!)%_+P  >Z0!  H
M     ( !M*$" &5X,3DM,2YH=&U02P$"% ,4    " "2BZA:5O2BWW,#  #D
M#0  "@              @ %;T0( 97@R,RTQ+FAT;5!+ 0(4 Q0    ( )*+
MJ%K]?HS_C0,  )(/   *              "  ?;4 @!E>#(S+3(N:'1M4$L!
M A0#%     @ DHNH6H*]7R7&"   <4,   H              ( !J]@" &5X
M,S$M,2YH=&U02P$"% ,4    " "2BZA:10*"';T(  #L0@  "@
M    @ &9X0( 97@S,2TR+FAT;5!+ 0(4 Q0    ( )*+J%KN$A/H'P8  ,@J
M   *              "  7[J @!E>#,R+3$N:'1M4$L! A0#%     @ DHNH
M6M68P*AMG 4 2*8R  P              ( !Q? " &9O<FTQ,"UK+FAT;5!+
M 0(4 Q0    ( )*+J%I_:M%KE(0  %^O   0              "  5R-" !F
M;W)M,3 M:U\P,#$N:G!G4$L! A0#%     @ DHNH6JBJZ&(9Z@  Y"P! !
M             ( !'A() &9O<FTQ,"UK7S P,BYJ<&=02P$"% ,4    " "2
MBZA:;-)8=#6B  !!M0  $               @ %E_ D 9F]R;3$P+6M?,# S
:+FIP9U!+!08     #P / (\#  #(G@H    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CELU="http://celularity.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="celu-20241231.xsd" xlink:type="simple"/>
    <context id="From2024-01-01to2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ClassCommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CELU:ClassCommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">CELU:WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-04-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2025-04-06</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_LicenseRoyaltyAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CELU:LicenseRoyaltyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_LicenseRoyaltyAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CELU:LicenseRoyaltyAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-22_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-22</instant>
        </period>
    </context>
    <context id="From2024-02-222024-02-22_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-22</startDate>
            <endDate>2024-02-22</endDate>
        </period>
    </context>
    <context id="From2025-04-222025-04-22_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-22</startDate>
            <endDate>2025-04-22</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LetterOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LetterOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CellTherapyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:CellTherapyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CellTherapyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:CellTherapyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">CELU:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">CELU:SequenceLifeScienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-09</startDate>
            <endDate>2024-10-09</endDate>
        </period>
    </context>
    <context id="AsOf2024-10-09_custom_SequenceLifeScienceIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">CELU:SequenceLifeScienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-09</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_SequenceLifeScienceIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">CELU:SequenceLifeScienceIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:AcquisitionRelatedContingentConsiderationObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ContingentStockConsiderationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:ContingentStockConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_UnsecuredSeniorConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_GXSponsorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:GXSponsorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_srt_MinimumMember_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:LetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SanuwaveForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_srt_MaximumMember_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:LetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SanuwaveForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:LetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SanuwaveForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-10</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="From2024-06-032024-06-03_custom_SanuwaveForbearanceAgreementMember_custom_LetterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:LetterAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SanuwaveForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-03</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_YorkvilleMember_custom_UnsecuredSeniorConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="From2023-12-312023-12-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-12-312023-12-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-12-312023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:AcquisitionRelatedContingentConsiderationObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:AcquisitionRelatedContingentConsiderationObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:AcquisitionRelatedContingentConsiderationObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:AcquisitionRelatedContingentConsiderationObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ContingentStockConsiderationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:ContingentStockConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ContingentStockConsiderationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:ContingentStockConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ContingentStockConsiderationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:ContingentStockConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ContingentStockConsiderationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">CELU:ContingentStockConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_YorkvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_YorkvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_YorkvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_YorkvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_YorkvilleMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputCreditSpreadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputCreditSpreadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="From2024-12-312024-12-31_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_us-gaap_MeasurementInputPriceVolatilityMember_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputCreditSpreadMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="From2024-12-312024-12-31_custom_UnsecuredSeniorConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="From2024-12-032024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="From2024-12-032024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_UnsecuredSeniorConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_us-gaap_MeasurementInputPriceVolatilityMember_custom_UnsecuredSeniorConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-16</instant>
        </period>
    </context>
    <context id="From2024-01-162024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-16</startDate>
            <endDate>2024-01-16</endDate>
        </period>
    </context>
    <context id="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-16</instant>
        </period>
    </context>
    <context id="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-16</instant>
        </period>
    </context>
    <context id="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-16</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="From2024-11-252024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="From2024-12-032024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="From2024-11-252024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="From2024-12-032024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-03</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPurchaserWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorsWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SponsorsWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:SponsorsWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InventoryFinishedGoodsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">CELU:InventoryFinishedGoodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InventoryWorkInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">CELU:InventoryWorkInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LaboratoryAndProductionEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:LaboratoryAndProductionEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LaboratoryAndProductionEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:LaboratoryAndProductionEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MachineryEquipmentAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:MachineryEquipmentAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MachineryEquipmentAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:MachineryEquipmentAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_CellTherapyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:CellTherapyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_custom_CellTherapyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:CellTherapyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MinimumMember_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MinimumMember_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_MaximumMember_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_srt_MaximumMember_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ReacquiredRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">CELU:ReacquiredRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ReacquiredRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">CELU:ReacquiredRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:UnsecuredSeniorConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_UnsecuredSeniorConvertibleNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:UnsecuredSeniorConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CVStarrBridgeLoanNetOfDiscountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CVStarrBridgeLoanNetOfDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CVStarrBridgeLoanNetOfDiscountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CVStarrBridgeLoanNetOfDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RWIBridgeLoanNetOfDiscountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:RWIBridgeLoanNetOfDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_RWIBridgeLoanNetOfDiscountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:RWIBridgeLoanNetOfDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CEOPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_CEOPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-15</startDate>
            <endDate>2022-09-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-122024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-12</startDate>
            <endDate>2024-01-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:PrePaidAdvanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-09-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-13</instant>
        </period>
    </context>
    <context id="AsOf2024-05-01_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-11-012024-11-30_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-03-162025-03-16_custom_YorkvilleMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-16</startDate>
            <endDate>2025-03-16</endDate>
        </period>
    </context>
    <context id="From2025-03-172025-03-17_custom_YorkvilleMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-17</startDate>
            <endDate>2025-03-17</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-17_custom_YorkvilleMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-17</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25_srt_MaximumMember_custom_UnsecuredSeniorConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="AsOf2024-11-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2024-11-25</instant>
        </period>
    </context>
    <context id="From2024-11-252024-11-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2024-11-25</startDate>
            <endDate>2024-11-25</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_UnsecuredSeniorConvertibleNotesMember15557562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember15557609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:UnsecuredSeniorConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-21</instant>
        </period>
    </context>
    <context id="From2023-08-212023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-21</startDate>
            <endDate>2023-08-21</endDate>
        </period>
    </context>
    <context id="AsOf2023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-12</instant>
        </period>
    </context>
    <context id="From2023-10-122023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ChairmanAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:CEOPromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-17</instant>
        </period>
    </context>
    <context id="From2023-03-172023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-17</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-17</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_WarrantMember_custom_LoanAgreementMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember_custom_TrancheTwoWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheTwoWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember_custom_TrancheTwoWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheTwoWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-04-15_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-15</instant>
        </period>
    </context>
    <context id="From2025-02-122025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-12</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_LoanAgreementMember_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:InitialLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-16</instant>
        </period>
    </context>
    <context id="From2023-05-162023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:InitialLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-16</startDate>
            <endDate>2023-05-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:AdditionalLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="AsOf2023-06-21_us-gaap_BridgeLoanMember_custom_InitialLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:InitialLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="From2023-06-212023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:AdditionalLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-21</startDate>
            <endDate>2023-06-21</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-14_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-14</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:AdditionalLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="From2024-01-122024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:AdditionalLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-12</startDate>
            <endDate>2024-01-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember_custom_AdditionalLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:AdditionalLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheOneWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheOneWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2024-01-16_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheOneWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-16</instant>
        </period>
    </context>
    <context id="AsOf2024-07-15_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:TrancheOneWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_InitialAndSecondTrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:InitialAndSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_InitialAndSecondTrancheMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:InitialAndSecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_us-gaap_BridgeLoanMember_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember15559390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-08-05_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-05</instant>
        </period>
    </context>
    <context id="From2025-02-122025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-12</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_BridgeLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CELU:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-13</startDate>
            <endDate>2019-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CELU:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CELU:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CELU:OfficeManufacturingAndLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-13</instant>
        </period>
    </context>
    <context id="AsOf2023-09-14_custom_FlorhamParkNewJerseyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CELU:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-14</instant>
        </period>
    </context>
    <context id="From2023-09-142023-09-14_custom_FlorhamParkNewJerseyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">CELU:FlorhamParkNewJerseyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-14</startDate>
            <endDate>2023-09-14</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_HLICellularTherapeuticsLLCAndAnthrogenesisMember_custom_LegacyCelularitysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:HLICellularTherapeuticsLLCAndAnthrogenesisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_HLICellularTherapeuticsLLCAndAnthrogenesisMember_custom_LegacyCelularitysMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularitysMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:HLICellularTherapeuticsLLCAndAnthrogenesisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2021-05-052021-05-05_custom_PalantirTechnologiesIncMember_custom_MasterSubscriptionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:PalantirTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:MasterSubscriptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-05-05</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-03-31_custom_PalantirTechnologiesIncMember_custom_SoftwareCeaseUseCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:PalantirTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">CELU:SoftwareCeaseUseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="From2024-01-102024-01-10_custom_PalantirTechnologiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:PalantirTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-10</startDate>
            <endDate>2024-01-10</endDate>
        </period>
    </context>
    <context id="From2024-05-062024-05-06_custom_PalantirTechnologiesIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:PalantirTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-06</startDate>
            <endDate>2024-05-06</endDate>
        </period>
    </context>
    <context id="From2021-12-012021-12-31_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="From2023-12-212024-06-03_custom_SettlementAndReleaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SettlementAndReleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="From2023-12-212024-06-03_us-gaap_CommonClassAMember_custom_SettlementAndReleaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SettlementAndReleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-21</startDate>
            <endDate>2024-06-03</endDate>
        </period>
    </context>
    <context id="From2023-04-172023-04-17_custom_EvolutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">CELU:EvolutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="From2024-05-072024-05-07_custom_EvolutionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">CELU:EvolutionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-07</startDate>
            <endDate>2024-05-07</endDate>
        </period>
    </context>
    <context id="From2025-04-212025-04-21_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-21</startDate>
            <endDate>2025-04-21</endDate>
        </period>
    </context>
    <context id="From2025-03-272025-03-27_custom_HackensackMeridianHealthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELU:HackensackMeridianHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-27</startDate>
            <endDate>2025-03-27</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_PreferredStockMember_srt_MinimumMember_custom_LegacyCelularityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">CELU:LegacyCelularityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2022-09-082022-09-08_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-08</startDate>
            <endDate>2022-09-08</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AtTheMarketSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AtTheMarketSalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AtTheMarketSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-20_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_srt_MaximumMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="AsOf2023-03-20_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="AsOf2023-03-20_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-20</instant>
        </period>
    </context>
    <context id="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_ChairmanAndChiefExecutiveOfficerMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-09-14_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-14</instant>
        </period>
    </context>
    <context id="From2023-03-142023-03-14_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="From2023-04-102023-04-10_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-10</startDate>
            <endDate>2023-04-10</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-10_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-10</instant>
        </period>
    </context>
    <context id="From2023-04-102023-04-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2023-04-10</startDate>
            <endDate>2023-04-10</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2023-04-10</instant>
        </period>
    </context>
    <context id="AsOf2022-05-18_srt_MaximumMember_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-18</instant>
        </period>
    </context>
    <context id="AsOf2022-05-18_srt_MinimumMember_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-18</instant>
        </period>
    </context>
    <context id="From2023-04-102023-04-10_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-10</startDate>
            <endDate>2023-04-10</endDate>
        </period>
    </context>
    <context id="From2023-07-312023-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2023-07-31</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-31_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="From2023-05-182023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-05-18</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-18</instant>
        </period>
    </context>
    <context id="AsOf2023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-18</instant>
        </period>
    </context>
    <context id="From2023-05-182023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-18</startDate>
            <endDate>2023-05-18</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-18</instant>
        </period>
    </context>
    <context id="From2024-01-122024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-12</startDate>
            <endDate>2024-01-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="From2024-01-122024-01-12_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-12</startDate>
            <endDate>2024-01-12</endDate>
        </period>
    </context>
    <context id="From2024-01-122024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-12</startDate>
            <endDate>2024-01-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_srt_MinimumMember_custom_InvestorRightsAgreementMember_custom_DragasacLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:DragasacLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:InvestorRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_srt_MaximumMember_custom_InvestorRightsAgreementMember_custom_DragasacLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:DragasacLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:InvestorRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="From2024-02-162024-02-16_custom_ChiefAdministrativeOfficerMember_custom_AmendedEmploymentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChiefAdministrativeOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:AmendedEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="From2024-02-162024-02-16_custom_ChiefAdministrativeOfficerMember_custom_AmendedEmploymentAgreementMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChiefAdministrativeOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:AmendedEmploymentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-16</startDate>
            <endDate>2024-02-16</endDate>
        </period>
    </context>
    <context id="From2024-01-122024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-12</startDate>
            <endDate>2024-01-12</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-24</instant>
        </period>
    </context>
    <context id="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-24</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_us-gaap_CommonStockMember_custom_RwiForbearanceAgreementMember_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RwiForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_RwiForbearanceAgreementMember_us-gaap_WarrantMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RwiForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-12_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-12</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JuneTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JuneTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-13_us-gaap_CommonStockMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_YorkvilleMember_us-gaap_CommonClassAMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_custom_YorkvilleMember_us-gaap_CommonClassAMember_custom_StandbyEquityPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember15564515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:YorkvilleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">CELU:ConvertiblePromissoryNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:StandbyEquityPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-13</startDate>
            <endDate>2024-03-13</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DragasacWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_PublicWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:SponsorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JuneTwoThousandTwentyThreeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JuneTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JanuaryTwoThousandTwentyFourPipeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember15565437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-01-24_custom_JanuaryTwoThousandTwentyFourPIPEWarrantMember_us-gaap_SubsequentEventMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPIPEWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-24</instant>
        </period>
    </context>
    <context id="AsOf2025-01-24_custom_JanuaryTwoThousandTwentyFourPIPEWarrantMember_us-gaap_SubsequentEventMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:JanuaryTwoThousandTwentyFourPIPEWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-24</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonClassAMember_custom_DragasacWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:DragasacWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SponsorWarrantsMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:SponsorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_StarrForbearanceAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:StarrForbearanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13_custom_CVStarrCoIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">CELU:CVStarrCoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2024-03-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <instant>2024-03-13</instant>
        </period>
    </context>
    <context id="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-24</instant>
        </period>
    </context>
    <context id="From2025-01-242025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">CELU:TwoThousandTwentyFourWarrantRepricingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-24</startDate>
            <endDate>2025-01-24</endDate>
        </period>
    </context>
    <context id="AsOf2021-07-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-01_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember15566546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember15566546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2022-08-162022-08-16_custom_AwardsWithPerformanceConditionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-16</startDate>
            <endDate>2022-08-16</endDate>
        </period>
    </context>
    <context id="From2022-08-162022-08-16_custom_AwardsWithPerformanceConditionsMember_custom_InitialTrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:InitialTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-16</startDate>
            <endDate>2022-08-16</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-16_custom_AwardsWithPerformanceConditionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-16</instant>
        </period>
    </context>
    <context id="From2022-11-012022-11-01_custom_AwardsWithPerformanceConditionsMember_custom_SecondTrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-01_custom_AwardsWithPerformanceConditionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_AwardsWithPerformanceConditionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-08-162023-08-16_custom_AwardsWithPerformanceConditionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:AwardsWithPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-16</startDate>
            <endDate>2023-08-16</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember15566875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:MarketConditionStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:MarketConditionStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:MarketConditionStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_MarketConditionStockUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:MarketConditionStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MarketConditionStockUnitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELU:MarketConditionStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandTwentyOnePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandTwentyOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_TwoThousandTwentyOnePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELU:TwoThousandTwentyOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-08-252023-08-25_custom_RegeneronResearchCollaborationServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RegeneronResearchCollaborationServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-25</startDate>
            <endDate>2023-08-25</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RegeneronServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RegeneronServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-12-31_custom_RegeneronServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RegeneronServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_RegeneronServicesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:RegeneronServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PultheraLLCBindingTermSheetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:PultheraLLCBindingTermSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_PultheraLLCBindingTermSheetMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:PultheraLLCBindingTermSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-03-172023-03-17_custom_PultheraLLCBindingTermSheetMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:PultheraLLCBindingTermSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-17</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="From2023-03-172023-03-17_custom_PultheraLLCBindingTermSheetMember_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:PultheraLLCBindingTermSheetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-17</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:LicenseAgreementWithBiocellgraftIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_UnitedStatesFederalAndStateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CELU:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_UnitedStatesFederalAndStateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CELU:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_UnitedStatesFederalAndStateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CELU:UnitedStatesFederalAndStateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_BiobankingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:BiobankingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_DegenerativeDiseaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:DegenerativeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_BiobankingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:BiobankingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_DegenerativeDiseaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">CELU:DegenerativeDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_DrRobertHaririMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:DrRobertHaririMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-252023-01-25_custom_DrRobertHaririMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:DrRobertHaririMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-25</startDate>
            <endDate>2023-01-25</endDate>
        </period>
    </context>
    <context id="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:DrRobertHaririMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-25</startDate>
            <endDate>2023-01-25</endDate>
        </period>
    </context>
    <context id="From2023-01-252023-01-25_custom_AmendedAndRestatedEmploymentAgreementMember_custom_DrRobertHaririMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:AmendedAndRestatedEmploymentAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:DrRobertHaririMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-25</startDate>
            <endDate>2023-01-25</endDate>
        </period>
    </context>
    <context id="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_SecuritiesPurchaseAgreementMember_custom_DrRobertHaririMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:DrRobertHaririMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_DrHaririMember_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:DrHaririMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-20</startDate>
            <endDate>2023-03-20</endDate>
        </period>
    </context>
    <context id="AsOf2003-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2003-08-21</instant>
        </period>
    </context>
    <context id="AsOf2023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELU:ChairmanAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-12</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConsultingAgreementMember_custom_DrAndrewPecoraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:DrAndrewPecoraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-21_custom_ConsultingAgreementMember_custom_DrAndrewPecoraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:DrAndrewPecoraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-21</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-01_custom_ScientificAndClinicalAdvisorAgreementMember_custom_DrAndrewPecoraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:DrAndrewPecoraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ScientificAndClinicalAdvisorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-01_custom_ScientificAndClinicalAdvisorAgreementMember_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ScientificAndClinicalAdvisorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-01</instant>
        </period>
    </context>
    <context id="From2022-09-012022-09-01_us-gaap_RestrictedStockUnitsRSUMember_custom_ScientificAndClinicalAdvisorAgreementMember_custom_DrAndrewPecoraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:DrAndrewPecoraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:ScientificAndClinicalAdvisorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-01</endDate>
        </period>
    </context>
    <context id="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:RobinLSmithMdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-16</startDate>
            <endDate>2022-08-16</endDate>
        </period>
    </context>
    <context id="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember_custom_InitialTrancheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:RobinLSmithMdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:AdvisoryAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">CELU:InitialTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-16</startDate>
            <endDate>2022-08-16</endDate>
        </period>
    </context>
    <context id="From2022-09-012022-09-01_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:RobinLSmithMdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:AdvisoryAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-01</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:RobinLSmithMdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:RobinLSmithMdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELU:AdvisoryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_COTAIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:COTAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_COTAIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:COTAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_CryoportSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:CryoportSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CryoportSystemsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:CryoportSystemsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-17_custom_CVStarLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:CVStarLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-17</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CVStarLoanMember_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:CVStarLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CELU:MarchTwoThousandTwentyThreeLoanWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_CVStarLoanMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:CVStarLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-16_custom_ResortsWorldIncPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="AsOf2024-01-12_custom_ResortsWorldIncPteLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-12</instant>
        </period>
    </context>
    <context id="AsOf2023-03-16_custom_ResortsWorldIncPteLtdMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ResortsWorldIncPteLtdMember_us-gaap_CommonClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELU:ResortsWorldIncPteLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_custom_MsHaririMember_custom_EmploymentOfImmediateFamilyMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:MsHaririMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MsHaririMember_custom_EmploymentOfImmediateFamilyMemberMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">CELU:MsHaririMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELU:EmploymentOfImmediateFamilyMemberMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELU:GenesisEquityGroupFundingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-01</instant>
        </period>
    </context>
    <context id="From2025-05-012025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELU:GenesisEquityGroupFundingLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-01</endDate>
        </period>
    </context>
    <context id="From2024-10-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001752828</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>CELU:Integer</measure>
    </unit>
    <unit id="Segment">
        <measure>CELU:Segment</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-01-01to2024-12-31" id="Fact000004">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-01-01to2024-12-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-01-01to2024-12-31" id="Fact000006">0001752828</dei:EntityCentralIndexKey>
    <CELU:PromissoryNotesReceivable
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0088"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:AccruedResearchAndDevelopmentSoftware
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0136"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0140"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0168"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0185"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0191"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0192"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0286"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0385"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:FairValueOfWarrantModificationForProfessionalService
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0391"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:FairValueOfWarrantModificationForProfessionalService
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:FairValueOfWarrantModificationForProfessionalService
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueATMAgreement
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueATMAgreement
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0451"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueATMAgreement
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0463"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0525"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0526"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0540"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0581"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0584"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0630"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0633"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:AcquiredInProcessResearchAndDevelopment
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:IssuanceOfCommonStockUsedInResearchAndDevelopment
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0645"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:IssuanceOfCommonStockAsConsiderationForSettlementAgreement
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0649"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:IssuanceOfCommonStockAsCompensationExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0655"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:DiscountsArisingFromLoanArrangementRelatedParty
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0657"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0664"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ChangeInFairValueOfContingentStockConsideration
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0669"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:NonCashInterestExpense
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0673"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0715"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0717"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ProceedsFromConvertibleNote
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0721"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ProceedsFromTheSaleOfCommonStockInAtmOffering
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0735"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:PaymentOfSepaCommitmentFee
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0742"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:RepaymentsOfShortTermDebtRelatedParty
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0756"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0759"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ModificationOfCVStarrWarrantsInConnectionWithForbearance
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0790"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:IssuanceOfRwiWarrantsInConnectionWithForbearance
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0793"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:IssuanceOfWarrantsOnSeniorSecuredBridgeLoan
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0795"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0798"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:PIPERelatedCostsIncludedInAccruedExpenses
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0801"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0804"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0808"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:InventoryAcquiredInConnectionWithReboundAssetAcquisition
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0811"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0814"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:AssumptionOfShorttermDebtUnaffiliatedByRelatedParty
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl0817"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      id="xdx2ixbrl0878">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl0886"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1032"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1033"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ContingentStockConsideration
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1037"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ContingentStockConsideration
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1038"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShorttermDebtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1042"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShorttermDebtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1043"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1047"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1048"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityRegisteredDirectWarrantsTwo
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1052"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityRegisteredDirectWarrantsTwo
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1053"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityRegisteredDirectWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1057"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityRegisteredDirectWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1058"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1062"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1063"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPurchaserWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1067"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPurchaserWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1068"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPlacementAgentWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1072"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPlacementAgentWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1073"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilitySponsorWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1077"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilitySponsorWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1078"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPublicWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1083"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPublicWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1084"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1088"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ReceivablesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1097"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ReceivablesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1102"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1103"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1113"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ContingentStockConsideration
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1117"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ContingentStockConsideration
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShorttermDebtFairValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShorttermDebtFairValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1123"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityRegisteredDirectWarrantsTwo
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1127"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityRegisteredDirectWarrantsTwo
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1128"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityRegisteredDirectWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1132"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityRegisteredDirectWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1133"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1137"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1138"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilitySponsorWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1142"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilitySponsorWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1143"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPublicWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1148"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:WarrantLiabilityPublicWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1149"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1153"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1171"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ReceivablesFairValueDisclosure
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1177"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="From2024-01-012024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember"
      id="xdx2ixbrl1199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="From2024-01-012024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember"
      id="xdx2ixbrl1201"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="From2023-01-012023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember"
      id="xdx2ixbrl1209"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="From2023-01-012023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember"
      id="xdx2ixbrl1211"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="From2024-01-012024-12-31_custom_ContingentStockConsiderationMember"
      id="xdx2ixbrl1221"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="From2024-01-012024-12-31_custom_ContingentStockConsiderationMember"
      id="xdx2ixbrl1223"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2024-01-012024-12-31_custom_ContingentStockConsiderationMember"
      id="xdx2ixbrl1225"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
      contextRef="From2023-01-012023-12-31_custom_ContingentStockConsiderationMember"
      id="xdx2ixbrl1231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="From2023-01-012023-12-31_custom_ContingentStockConsiderationMember"
      id="xdx2ixbrl1233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember"
      id="xdx2ixbrl1477"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember"
      id="xdx2ixbrl1479"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember"
      id="xdx2ixbrl1481"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_ConstructionInProgressMember"
      id="xdx2ixbrl1646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl1670"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1803"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ShortTermDebtUnaffiliated
      contextRef="AsOf2024-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      id="xdx2ixbrl1818"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ShortTermDebtUnaffiliated
      contextRef="AsOf2023-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember"
      id="xdx2ixbrl1822"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:ShortTermDebtUnaffiliated
      contextRef="AsOf2023-12-31_custom_UnsecuredSeniorConvertibleNoteMember"
      id="xdx2ixbrl1825"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:OtherShortTermDebt
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1827"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl1855"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:AccruedResearchAndDevelopmentSoftware
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl2240"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2668"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2684"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2686"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      id="xdx2ixbrl2700"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      id="xdx2ixbrl2736"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2920"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2921"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2923"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2926"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2935"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2936"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2938"
      unitRef="USD"
      xsi:nil="true"/>
    <CELU:EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2955"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2961"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl2967"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl2968"
      unitRef="Pure"
      xsi:nil="true"/>
    <CELU:DeferredTaxAssetsIrcSectionInterest
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl3003"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="From2023-01-012023-12-31"
      id="xdx2ixbrl3021"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="From2024-01-01to2024-12-31"
      id="xdx2ixbrl3025"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_CellTherapyMember"
      id="xdx2ixbrl3064"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_CellTherapyMember"
      id="xdx2ixbrl3129"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_custom_CellTherapyMember"
      id="xdx2ixbrl3134"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-01-01to2024-12-31" id="Fact000015">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-01-01to2024-12-31" id="Fact000016">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000017">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-01-01to2024-12-31" id="Fact000018">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2024-01-01to2024-12-31" id="Fact000019">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2024-01-01to2024-12-31" id="Fact000020">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-01-01to2024-12-31" id="Fact000021">001-38914</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-01-01to2024-12-31" id="Fact000022">Celularity Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-01-01to2024-12-31" id="Fact000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-01-01to2024-12-31" id="Fact000024">83-1702591</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-01-01to2024-12-31" id="Fact000025">170 Park Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2024-01-01to2024-12-31" id="Fact000026">Florham Park</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-01-01to2024-12-31" id="Fact000027">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-01-01to2024-12-31" id="Fact000028">07932</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-01-01to2024-12-31" id="Fact000029">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-01-01to2024-12-31" id="Fact000030">768-2170</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_ClassCommonStockParValue0.0001PerShareMember"
      id="Fact000031">Class A common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_ClassCommonStockParValue0.0001PerShareMember"
      id="Fact000032">CELU</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_ClassCommonStockParValue0.0001PerShareMember"
      id="Fact000033">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember"
      id="Fact000034">Warrants, each exercisable     for one share of Class A common stock at an exercise price of $115 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember"
      id="Fact000035">CELUW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2024-01-012024-12-31_custom_WarrantsEachExercisableForOneShareOfClassCommonStockAtExercisePriceOf115PerShareMember"
      id="Fact000036">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-01-01to2024-12-31" id="Fact000037">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-01-01to2024-12-31" id="Fact000038">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-01-01to2024-12-31" id="Fact000039">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-01-01to2024-12-31" id="Fact000040">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-01-01to2024-12-31" id="Fact000041">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-01-01to2024-12-31" id="Fact000042">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-01-01to2024-12-31" id="Fact000043">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-01-01to2024-12-31" id="Fact000044">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-01-01to2024-12-31" id="Fact000045">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-01-01to2024-12-31" id="Fact000046">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-06-30"
      decimals="-5"
      id="Fact000047"
      unitRef="USD">38500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-04-06"
      decimals="INF"
      id="Fact000048"
      unitRef="Shares">23949229</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000049">None</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000052">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
incorporate cybersecurity into our Enterprise Risk Management program. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240101__20241231_z5pG55CGOOk"&gt;Our cybersecurity program &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zQQzNNHtbDQi"&gt;incorporates&lt;/span&gt; cybersecurity processes,
technologies, and controls designed to identify and manage potential material cyber risks including, but not limited to, operational
risk, intellectual property theft, fraud, harm to employees, patients, or third parties, and violation of privacy or security-related
laws or regulations.&lt;/span&gt; Our cybersecurity program is designed to be aligned with applicable industry standards set by the Center for Internet
Security. Our cybersecurity program employs a range of tools and services, including regular network and endpoint monitoring, managed
detection and response, system patching, managed security services, server and endpoint scheduled backups, awareness training and testing,
periodic vulnerability assessment and penetration testing, to update &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_dbT_c20240101__20241231_z4Eu0iED4kRj"&gt;our ongoing risk identification and mitigation efforts and is assessed
periodically by independent &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_908_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240101__20241231_z9bDmY6Vmzrf"&gt;third parties&lt;/span&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90A_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240101__20241231_zpmPgEsnMNn9"&gt;Our
cybersecurity program is managed by a vice president of global security and cybersecurity who reports to our Chief Executive Officer,
or CEO, providing routine security program updates and briefings&lt;/span&gt;. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_c20240101__20241231_zlMHrjVtZjxc"&gt;The current vice president of global security and cybersecurity has
more than 25 years of experience in cybersecurity, federal law enforcement, and cyber investigations, while possessing the required subject
matter expertise, skills, experience, and industry certifications expected of an individual assigned to these duties&lt;/span&gt;. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_c20240101__20241231_z4MyJI167cSd"&gt;Our information
security team, which includes the vice president of global security and cybersecurity, as well as additional professionals, is responsible
for leading enterprise-wide cybersecurity strategy, policy, standards, and processes&lt;/span&gt;. The vice president provides regular updates to
our CEO and other members of management. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240101__20241231_zXxLC73Ar6xg"&gt;Our board of directors has ultimate oversight of cybersecurity risk, which it manages as part
of our Enterprise Risk Management program&lt;/span&gt;. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90F_ecyd--CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_c20240101__20241231_zOdfSq1T0vNi"&gt;Cybersecurity periodically provides updates to our management on cyber risks and threats,
the status of projects to strengthen our information security systems, assessments of the information security program, and the emerging
threat landscape&lt;/span&gt;. &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_901_ecyd--CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_dbT_c20240101__20241231_zkCb9OSTkJx"&gt;Management&lt;/span&gt; informs the audit committee or the board of directors of risks from cybersecurity threats as necessary or
advisable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the year ended December 31, 2024, we are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90D_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240101__20241231_z7OP6zn0gMTa"&gt;not&lt;/span&gt; aware of any material cybersecurity incidents. While we have not, as of the date of this
annual report on Form 10-K, experienced a cybersecurity threat or incident resulting in a material adverse impact to our business or
operations, these threats are constantly evolving, thereby increasing the difficulty of successfully defending against them or implementing
adequate preventative measures. There can be no guarantee that we will not experience such an incident in the future. We maintain cybersecurity
insurance coverage that provides protection against losses arising from certain cybersecurity incidents. In addition, we seek to detect
and investigate unauthorized attempts and attacks against our network, products, and services, and to prevent their occurrence and recurrence
where practicable through changes or updates to our internal processes and tools and changes or updates to our products and services;
however, we remain potentially vulnerable to known or unknown threats.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000053">Our cybersecurity program &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_907_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240101__20241231_zQQzNNHtbDQi"&gt;incorporates&lt;/span&gt; cybersecurity processes,
technologies, and controls designed to identify and manage potential material cyber risks including, but not limited to, operational
risk, intellectual property theft, fraud, harm to employees, patients, or third parties, and violation of privacy or security-related
laws or regulations.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000054">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="From2024-01-01to2024-12-31" id="Fact000055">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-01-01to2024-12-31" id="Fact000056">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000057">Our
cybersecurity program is managed by a vice president of global security and cybersecurity who reports to our Chief Executive Officer,
or CEO, providing routine security program updates and briefings</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000058">The current vice president of global security and cybersecurity has
more than 25 years of experience in cybersecurity, federal law enforcement, and cyber investigations, while possessing the required subject
matter expertise, skills, experience, and industry certifications expected of an individual assigned to these duties</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000059">Our information
security team, which includes the vice president of global security and cybersecurity, as well as additional professionals, is responsible
for leading enterprise-wide cybersecurity strategy, policy, standards, and processes</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000060">Our board of directors has ultimate oversight of cybersecurity risk, which it manages as part
of our Enterprise Risk Management program</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000061">Cybersecurity periodically provides updates to our management on cyber risks and threats,
the status of projects to strengthen our information security systems, assessments of the information security program, and the emerging
threat landscape</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="From2024-01-01to2024-12-31" id="Fact000062">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-01-01to2024-12-31" id="Fact000063">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <dei:AuditorFirmId contextRef="From2024-01-01to2024-12-31" id="Fact000064">274</dei:AuditorFirmId>
    <dei:AuditorFirmId contextRef="From2023-01-012023-12-31" id="Fact000065">34</dei:AuditorFirmId>
    <dei:AuditorOpinionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000066">We
have audited the accompanying consolidated balance sheet of Celularity Inc. (the &#x201c;Company&#x201d;) as of December 31, 2024 and
the related consolidated statements of operations and comprehensive loss, stockholders&#x2019; equity, and cash flows for the year
then ended, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the
financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31,
2024, and the consolidated results of its operations and its cash flows for the year then ended, in conformity
with accounting principles generally accepted in the United States of America. </dei:AuditorOpinionTextBlock>
    <dei:AuditorName contextRef="From2024-01-01to2024-12-31" id="Fact000067">EisnerAmper LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-01-01to2024-12-31" id="Fact000068">Iselin, New Jersey</dei:AuditorLocation>
    <dei:AuditorName contextRef="From2023-01-012023-12-31" id="Fact000069">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-012023-12-31" id="Fact000070">Morristown, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">738000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000079"
      unitRef="USD">227000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">6294000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">5837000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">13557000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">10046000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <CELU:PromissoryNotesReceivable
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000089"
      unitRef="USD">2072000</CELU:PromissoryNotesReceivable>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000091"
      unitRef="USD">5409000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000092"
      unitRef="USD">5753000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000094"
      unitRef="USD">857000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000095"
      unitRef="USD">1695000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000097"
      unitRef="USD">20561000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000098"
      unitRef="USD">19793000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">61600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000101"
      unitRef="USD">67828000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">7347000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000104"
      unitRef="USD">7347000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">9248000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000107"
      unitRef="USD">11001000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000109"
      unitRef="USD">10830000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000110"
      unitRef="USD">10990000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000112"
      unitRef="USD">10239000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000113"
      unitRef="USD">9936000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">12587000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000116"
      unitRef="USD">16657000</us-gaap:InventoryNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000118"
      unitRef="USD">270000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000119"
      unitRef="USD">337000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000121"
      unitRef="USD">132682000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000122"
      unitRef="USD">143889000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000130"
      unitRef="USD">23296000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000131"
      unitRef="USD">14144000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000133"
      unitRef="USD">19842000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">7580000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <CELU:AccruedResearchAndDevelopmentSoftware
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000137"
      unitRef="USD">3500000</CELU:AccruedResearchAndDevelopmentSoftware>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000139"
      unitRef="USD">650000</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <us-gaap:ShorttermDebtFairValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000145"
      unitRef="USD">2485000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000147"
      unitRef="USD">17223000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000142"
      unitRef="USD">2485000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact000143"
      unitRef="USD">19331000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000149"
      unitRef="USD">3876000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000150"
      unitRef="USD">19909000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000152"
      unitRef="USD">3876000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000153"
      unitRef="USD">19909000</us-gaap:ShortTermBorrowings>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000155"
      unitRef="USD">3531000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000156"
      unitRef="USD">2834000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">53680000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">67298000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000161"
      unitRef="USD">2724000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000162"
      unitRef="USD">3186000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000164"
      unitRef="USD">1413000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000165"
      unitRef="USD">1606000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact000167"
      unitRef="USD">35927000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">26548000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">26177000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <CELU:WarrantLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000173"
      unitRef="USD">3264000</CELU:WarrantLiability>
    <CELU:WarrantLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000174"
      unitRef="USD">4359000</CELU:WarrantLiability>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000176"
      unitRef="USD">9000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000177"
      unitRef="USD">9000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000179"
      unitRef="USD">280000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000180"
      unitRef="USD">294000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000182"
      unitRef="USD">123845000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000183"
      unitRef="USD">102929000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000194"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000196"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000198"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000200"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000202"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000204"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000206"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000208"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000213"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000215"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000217"
      unitRef="Shares">730000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000219"
      unitRef="Shares">730000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000221"
      unitRef="Shares">22546671</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000223"
      unitRef="Shares">22546671</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000225"
      unitRef="Shares">19378192</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000227"
      unitRef="Shares">19378192</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000210"
      unitRef="USD">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000211"
      unitRef="USD">19000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000229"
      unitRef="USD">908523000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">882732000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000232"
      unitRef="USD">-899683000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">-841791000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000235"
      unitRef="USD">-5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000238"
      unitRef="USD">8837000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000239"
      unitRef="USD">40960000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000241"
      unitRef="USD">132682000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">143889000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_ProductMember"
      decimals="-3"
      id="Fact000247"
      unitRef="USD">35336000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_ProductMember"
      decimals="-3"
      id="Fact000248"
      unitRef="USD">13149000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_ServiceMember"
      decimals="-3"
      id="Fact000250"
      unitRef="USD">5140000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_ServiceMember"
      decimals="-3"
      id="Fact000251"
      unitRef="USD">5441000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_LicenseRoyaltyAndOtherMember"
      decimals="-3"
      id="Fact000253"
      unitRef="USD">13744000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_LicenseRoyaltyAndOtherMember"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">4181000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000256"
      unitRef="USD">54220000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000257"
      unitRef="USD">22771000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_us-gaap_ProductMember"
      decimals="-3"
      id="Fact000265"
      unitRef="USD">4924000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_us-gaap_ProductMember"
      decimals="-3"
      id="Fact000266"
      unitRef="USD">8628000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_us-gaap_ServiceMember"
      decimals="-3"
      id="Fact000268"
      unitRef="USD">1172000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_us-gaap_ServiceMember"
      decimals="-3"
      id="Fact000269"
      unitRef="USD">1650000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_LicenseRoyaltyAndOtherMember"
      decimals="-3"
      id="Fact000271"
      unitRef="USD">8893000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_custom_LicenseRoyaltyAndOtherMember"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">5738000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_LicenseRoyaltyAndOtherMember"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">8893000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_custom_LicenseRoyaltyAndOtherMember"
      decimals="-3"
      id="Fact000275"
      unitRef="USD">5738000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000277"
      unitRef="USD">17386000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000278"
      unitRef="USD">30465000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">58643000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">50576000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000283"
      unitRef="USD">-193000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000284"
      unitRef="USD">-104339000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000287"
      unitRef="USD">112347000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">107800000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000292"
      unitRef="USD">1753000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000293"
      unitRef="USD">2193000</us-gaap:AmortizationOfIntangibleAssets>
    <CELU:OperatingIncomeCostsAndExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">92578000</CELU:OperatingIncomeCostsAndExpenses>
    <CELU:OperatingIncomeCostsAndExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">215058000</CELU:OperatingIncomeCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">-38358000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">-192287000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">331000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000305"
      unitRef="USD">320000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000307"
      unitRef="USD">6264000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">3015000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000310"
      unitRef="USD">-398000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">-6164000</us-gaap:FairValueAdjustmentOfWarrants>
    <CELU:ChangeInFairValueOfDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000313"
      unitRef="USD">492000</CELU:ChangeInFairValueOfDebt>
    <CELU:ChangeInFairValueOfDebt
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">1177000</CELU:ChangeInFairValueOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000316"
      unitRef="USD">-3908000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <CELU:OtherNonoperatingIncomeExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">-9599000</CELU:OtherNonoperatingIncomeExpenses>
    <CELU:OtherNonoperatingIncomeExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000320"
      unitRef="USD">-6290000</CELU:OtherNonoperatingIncomeExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000322"
      unitRef="USD">-19534000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000323"
      unitRef="USD">-3998000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000325"
      unitRef="USD">-57892000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000326"
      unitRef="USD">-196285000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000329"
      unitRef="USD">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000331"
      unitRef="USD">-57892000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000332"
      unitRef="USD">-196295000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000334"
      unitRef="USD">-5000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000335"
      unitRef="USD">146000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000337"
      unitRef="USD">-5000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000338"
      unitRef="USD">146000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000340"
      unitRef="USD">-57897000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000341"
      unitRef="USD">-196149000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000343"
      unitRef="USDPShares">-2.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000345"
      unitRef="USDPShares">-2.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000347"
      unitRef="USDPShares">-11.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000349"
      unitRef="USDPShares">-11.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000351"
      unitRef="Shares">21890518</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000353"
      unitRef="Shares">21890518</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000355"
      unitRef="Shares">17813044</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000357"
      unitRef="Shares">17813044</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000365"
      unitRef="Shares">14892129</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000359"
      unitRef="USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000360"
      unitRef="USD">844373000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000361"
      unitRef="USD">-645496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000362"
      unitRef="USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000363"
      unitRef="USD">198901000</us-gaap:StockholdersEquity>
    <CELU:StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000373"
      unitRef="Shares">1780220</CELU:StockIssuedDuringPeriodSharesOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses>
    <CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000367"
      unitRef="USD">2000</CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses>
    <CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000368"
      unitRef="USD">1320000</CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses>
    <CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000371"
      unitRef="USD">1322000</CELU:StockIssuedDuringPeriodValueOfCommonStockInRegisteredDirectOfferingNetOfOfferingExpenses>
    <CELU:StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000381"
      unitRef="Shares">270731</CELU:StockIssuedDuringPeriodSharesShortTermDebtMaturityExtension>
    <CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">712000</CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension>
    <CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000379"
      unitRef="USD">712000</CELU:StockIssuedDuringPeriodValuesShortTermDebtMaturityExtension>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000389"
      unitRef="Shares">108637</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">304000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000387"
      unitRef="USD">304000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <CELU:FairValueOfWarrantModificationForProfessionalService
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000392"
      unitRef="USD">403000</CELU:FairValueOfWarrantModificationForProfessionalService>
    <CELU:FairValueOfWarrantModificationForProfessionalService
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000395"
      unitRef="USD">403000</CELU:FairValueOfWarrantModificationForProfessionalService>
    <CELU:StockIssuedDuringPeriodSharesOfResearchAndDevelopment
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000403"
      unitRef="Shares">169492</CELU:StockIssuedDuringPeriodSharesOfResearchAndDevelopment>
    <CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000398"
      unitRef="USD">1000000</CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment>
    <CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000401"
      unitRef="USD">1000000</CELU:StockIssuedDuringPeriodValueOfResearchAndDevelopment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000406"
      unitRef="USD">2290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000409"
      unitRef="USD">2290000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000417"
      unitRef="Shares">559481</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000411"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000412"
      unitRef="USD">4598000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000414"
      unitRef="USD">-155000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000415"
      unitRef="USD">4444000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000425"
      unitRef="Shares">83759</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000423"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000433"
      unitRef="Shares">-19130</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000428"
      unitRef="USD">101000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000431"
      unitRef="USD">101000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000436"
      unitRef="USD">15017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">15017000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <CELU:StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000447"
      unitRef="Shares">1519579</CELU:StockIssuedDuringPeriodSharesPIPEOfferingNetOfOfferingExpenses>
    <CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">1000</CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses>
    <CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000442"
      unitRef="USD">12680000</CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses>
    <CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">12681000</CELU:StockIssuedDuringPeriodValuePIPEOfferingNetOfOfferingExpenses>
    <CELU:StockIssuedDuringPeriodSharesATMAgreement
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000455"
      unitRef="Shares">13296</CELU:StockIssuedDuringPeriodSharesATMAgreement>
    <CELU:StockIssuedDuringPeriodValueATMAgreement
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000450"
      unitRef="USD">136000</CELU:StockIssuedDuringPeriodValueATMAgreement>
    <CELU:StockIssuedDuringPeriodValueATMAgreement
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">136000</CELU:StockIssuedDuringPeriodValueATMAgreement>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
      contextRef="From2023-01-012023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000460"
      unitRef="USD">146000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000461"
      unitRef="USD">146000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">-196295000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000467"
      unitRef="USD">-196295000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000475"
      unitRef="Shares">19378192</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000469"
      unitRef="USD">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000470"
      unitRef="USD">882732000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000471"
      unitRef="USD">-841791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000473"
      unitRef="USD">40960000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000483"
      unitRef="Shares">19378192</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">19000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000478"
      unitRef="USD">882732000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000479"
      unitRef="USD">-841791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000481"
      unitRef="USD">40960000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000491"
      unitRef="Shares">2141098</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000486"
      unitRef="USD">6000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000489"
      unitRef="USD">6000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <CELU:StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000499"
      unitRef="Shares">116964</CELU:StockIssuedDuringPeriodSharesForDebtExtensionAndCommitmentFee>
    <CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000494"
      unitRef="USD">317000</CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee>
    <CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000497"
      unitRef="USD">317000</CELU:StockIssuedDuringPeriodValueForDebtExtensionAndCommitmentFee>
    <CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000502"
      unitRef="USD">3261000</CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants>
    <CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000505"
      unitRef="USD">3261000</CELU:AdjustmentsToAdditionalPaidInCapitalIssuanceAndModificationOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000513"
      unitRef="Shares">20744</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000508"
      unitRef="USD">58000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000511"
      unitRef="USD">58000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000521"
      unitRef="Shares">191</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000515"
      unitRef="USD">17000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000516"
      unitRef="USD">-17000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <CELU:StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000529"
      unitRef="Shares">60584</CELU:StockIssuedDuringPeriodSharesConsiderationForSettlementAgreement>
    <CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000524"
      unitRef="USD">175000</CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement>
    <CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000527"
      unitRef="USD">175000</CELU:StockIssuedDuringPeriodValueConsiderationForSettlementAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000532"
      unitRef="USD">11569000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">11569000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000538"
      unitRef="USD">2970000</CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified>
    <CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000541"
      unitRef="USD">2970000</CELU:AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
      contextRef="From2024-01-012024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000546"
      unitRef="USD">-5000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000547"
      unitRef="USD">-5000</us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionBeforeTaxAfterReclassificationAdjustmentAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000555"
      unitRef="Shares">401013</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000563"
      unitRef="Shares">-109790</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000558"
      unitRef="USD">434000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000561"
      unitRef="USD">434000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000571"
      unitRef="Shares">478881</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000566"
      unitRef="USD">1700000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000569"
      unitRef="USD">1700000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000579"
      unitRef="Shares">59176</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-012024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000574"
      unitRef="USD">158000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000577"
      unitRef="USD">158000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000583"
      unitRef="USD">-57892000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000585"
      unitRef="USD">-57892000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000593"
      unitRef="Shares">22546671</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000587"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000588"
      unitRef="USD">908523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000589"
      unitRef="USD">-899683000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000590"
      unitRef="USD">-5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000591"
      unitRef="USD">8837000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000601"
      unitRef="Shares">22546671</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000595"
      unitRef="USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000596"
      unitRef="USD">908523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000597"
      unitRef="USD">-899683000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000598"
      unitRef="USD">-5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000599"
      unitRef="USD">8837000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000606"
      unitRef="USD">-57892000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000607"
      unitRef="USD">-196295000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000612"
      unitRef="USD">7922000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000613"
      unitRef="USD">9324000</us-gaap:DepreciationDepletionAndAmortization>
    <CELU:NonCashLeaseExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000615"
      unitRef="USD">160000</CELU:NonCashLeaseExpense>
    <CELU:NonCashLeaseExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000616"
      unitRef="USD">-13000</CELU:NonCashLeaseExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000618"
      unitRef="USD">457000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000619"
      unitRef="USD">1233000</us-gaap:ProvisionForDoubtfulAccounts>
    <CELU:ProvisionForInventoryObsolescence
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000621"
      unitRef="USD">-186000</CELU:ProvisionForInventoryObsolescence>
    <CELU:ProvisionForInventoryObsolescence
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000622"
      unitRef="USD">1328000</CELU:ProvisionForInventoryObsolescence>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000624"
      unitRef="USD">-398000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000625"
      unitRef="USD">-6164000</us-gaap:FairValueAdjustmentOfWarrants>
    <CELU:InventoryImpairmentCharge
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000627"
      unitRef="USD">466000</CELU:InventoryImpairmentCharge>
    <CELU:InventoryImpairmentCharge
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000628"
      unitRef="USD">5384000</CELU:InventoryImpairmentCharge>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000631"
      unitRef="USD">112347000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000634"
      unitRef="USD">107800000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000636"
      unitRef="USD">11569000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000637"
      unitRef="USD">15017000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000639"
      unitRef="USD">-193000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000640"
      unitRef="USD">-104339000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <CELU:AcquiredInProcessResearchAndDevelopment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000643"
      unitRef="USD">3000000</CELU:AcquiredInProcessResearchAndDevelopment>
    <CELU:IssuanceOfCommonStockUsedInResearchAndDevelopment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000646"
      unitRef="USD">1000000</CELU:IssuanceOfCommonStockUsedInResearchAndDevelopment>
    <CELU:IssuanceOfCommonStockAsConsiderationForSettlementAgreement
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000648"
      unitRef="USD">175000</CELU:IssuanceOfCommonStockAsConsiderationForSettlementAgreement>
    <CELU:IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000651"
      unitRef="USD">317000</CELU:IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee>
    <CELU:IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000652"
      unitRef="USD">712000</CELU:IssuanceOfCommonStockRelatingToDebtExtensionAndCommitmentFee>
    <CELU:IssuanceOfCommonStockAsCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000654"
      unitRef="USD">158000</CELU:IssuanceOfCommonStockAsCompensationExpense>
    <CELU:DiscountsArisingFromLoanArrangementRelatedParty
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000658"
      unitRef="USD">2151000</CELU:DiscountsArisingFromLoanArrangementRelatedParty>
    <CELU:FairValueOfWarrantModificationForProfessionalServices
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000661"
      unitRef="USD">403000</CELU:FairValueOfWarrantModificationForProfessionalServices>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000663"
      unitRef="USD">-3908000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <CELU:ChangeInFairValueOfDebt
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000666"
      unitRef="USD">492000</CELU:ChangeInFairValueOfDebt>
    <CELU:ChangeInFairValueOfDebt
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000667"
      unitRef="USD">1177000</CELU:ChangeInFairValueOfDebt>
    <CELU:ChangeInFairValueOfContingentStockConsideration
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000670"
      unitRef="USD">-159000</CELU:ChangeInFairValueOfContingentStockConsideration>
    <CELU:NonCashInterestExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000672"
      unitRef="USD">4144000</CELU:NonCashInterestExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000675"
      unitRef="USD">-300000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000676"
      unitRef="USD">-4157000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000681"
      unitRef="USD">3968000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000682"
      unitRef="USD">6827000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000684"
      unitRef="USD">-6284000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000685"
      unitRef="USD">865000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000687"
      unitRef="USD">-905000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000688"
      unitRef="USD">-5606000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000690"
      unitRef="USD">9239000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000691"
      unitRef="USD">8497000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000693"
      unitRef="USD">12634000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000694"
      unitRef="USD">-1128000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <CELU:IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000696"
      unitRef="USD">-3500000</CELU:IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense>
    <CELU:IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000697"
      unitRef="USD">-3834000</CELU:IncreaseDecreaseInAccruedResearchDevelopmentSoftwareExpense>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000699"
      unitRef="USD">371000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000700"
      unitRef="USD">275000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000702"
      unitRef="USD">235000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000703"
      unitRef="USD">1528000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000705"
      unitRef="USD">-6401000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000706"
      unitRef="USD">-38685000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000711"
      unitRef="USD">161000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000712"
      unitRef="USD">1048000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000714"
      unitRef="USD">1500000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000718"
      unitRef="USD">3000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <CELU:ProceedsFromConvertibleNote
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000720"
      unitRef="USD">-2175000</CELU:ProceedsFromConvertibleNote>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000723"
      unitRef="USD">514000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000724"
      unitRef="USD">-4048000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <CELU:ProceedsFromWarrantsAndShortTermDebtRelatedParties
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000729"
      unitRef="USD">15000000</CELU:ProceedsFromWarrantsAndShortTermDebtRelatedParties>
    <CELU:ProceedsFromWarrantsAndShortTermDebtRelatedParties
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000730"
      unitRef="USD">18369000</CELU:ProceedsFromWarrantsAndShortTermDebtRelatedParties>
    <CELU:RepaymentsOfShortTermDebtUnaffiliated
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000732"
      unitRef="USD">17374000</CELU:RepaymentsOfShortTermDebtUnaffiliated>
    <CELU:RepaymentsOfShortTermDebtUnaffiliated
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000733"
      unitRef="USD">16811000</CELU:RepaymentsOfShortTermDebtUnaffiliated>
    <CELU:ProceedsFromTheSaleOfCommonStockInAtmOffering
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000736"
      unitRef="USD">136000</CELU:ProceedsFromTheSaleOfCommonStockInAtmOffering>
    <CELU:ProceedsFromShortTermDebtUnaffiliated
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000738"
      unitRef="USD">3622000</CELU:ProceedsFromShortTermDebtUnaffiliated>
    <CELU:ProceedsFromShortTermDebtUnaffiliated
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000739"
      unitRef="USD">2000000</CELU:ProceedsFromShortTermDebtUnaffiliated>
    <CELU:PaymentOfSepaCommitmentFee
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000741"
      unitRef="USD">25000</CELU:PaymentOfSepaCommitmentFee>
    <CELU:RepaymentsOfShortTermDebtRelatedParty
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000744"
      unitRef="USD">146000</CELU:RepaymentsOfShortTermDebtRelatedParty>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000747"
      unitRef="USD">6000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000748"
      unitRef="USD">12750000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000750"
      unitRef="USD">58000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000751"
      unitRef="USD">304000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000753"
      unitRef="USD">434000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000754"
      unitRef="USD">101000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000757"
      unitRef="USD">9000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000760"
      unitRef="USD">1553000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000762"
      unitRef="USD">6701000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000763"
      unitRef="USD">24094000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000765"
      unitRef="USD">814000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000766"
      unitRef="USD">-18639000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000768"
      unitRef="USD">10163000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000769"
      unitRef="USD">28802000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000771"
      unitRef="USD">10977000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000772"
      unitRef="USD">10163000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000777"
      unitRef="USD">144000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000778"
      unitRef="USD">1073000</us-gaap:InterestPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000783"
      unitRef="USD">87000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000784"
      unitRef="USD">223000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000786"
      unitRef="USD">1700000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000787"
      unitRef="USD">4599000</us-gaap:ConversionOfStockAmountIssued1>
    <CELU:ModificationOfCVStarrWarrantsInConnectionWithForbearance
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000789"
      unitRef="USD">51000</CELU:ModificationOfCVStarrWarrantsInConnectionWithForbearance>
    <CELU:IssuanceOfRwiWarrantsInConnectionWithForbearance
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000792"
      unitRef="USD">1162000</CELU:IssuanceOfRwiWarrantsInConnectionWithForbearance>
    <CELU:IssuanceOfWarrantsOnSeniorSecuredBridgeLoan
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000796"
      unitRef="USD">2002000</CELU:IssuanceOfWarrantsOnSeniorSecuredBridgeLoan>
    <CELU:ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000799"
      unitRef="USD">-2083000</CELU:ReductionOfRightOfUseAssetsAndAssociatedLeaseLiabilityDueToLeaseModification>
    <CELU:PIPERelatedCostsIncludedInAccruedExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000802"
      unitRef="USD">-69000</CELU:PIPERelatedCostsIncludedInAccruedExpenses>
    <CELU:InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000805"
      unitRef="USD">-1770000</CELU:InterestAccruedOnSeniorSecuredLoansWithinLongTermDebtRelatedParties>
    <CELU:ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000807"
      unitRef="USD">650000</CELU:ContingentConsiderationAccruedInConnectionWithReboundAssetAcquisition>
    <CELU:InventoryAcquiredInConnectionWithReboundAssetAcquisition
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000810"
      unitRef="USD">2150000</CELU:InventoryAcquiredInConnectionWithReboundAssetAcquisition>
    <CELU:ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000813"
      unitRef="USD">2970000</CELU:ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified>
    <CELU:AssumptionOfShorttermDebtUnaffiliatedByRelatedParty
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000816"
      unitRef="USD">2333000</CELU:AssumptionOfShorttermDebtUnaffiliatedByRelatedParty>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000819">&lt;p id="xdx_80E_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zYuxJggu6Kn9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;1. &lt;span id="xdx_825_zvCMjvWeGmob"&gt;Nature of Business&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Celularity Inc., (&#x201c;Celularity&#x201d;
or the &#x201c;Company&#x201d;), formerly known as GX Acquisition Corp. (&#x201c;GX&#x201d;), was a blank check company incorporated in Delaware
on &lt;span id="xdx_902_edei--EntityIncorporationDateOfIncorporation_dd_c20240101__20241231_zuNcLjKQvCya" title="Date of incorporation"&gt;August 24, 2018&lt;/span&gt;. The Company was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock
purchase, reorganization or other similar business combination with one or more businesses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On July 16, 2021 (the &#x201c;Closing
Date&#x201d;), the Company consummated the previously announced merger pursuant to the Merger Agreement and Plan of Reorganization, dated
January 8, 2021 (the &#x201c;Merger Agreement&#x201d;), by and among GX, Alpha First Merger Sub, Inc., a Delaware corporation and a direct,
wholly owned subsidiary of GX (&#x201c;First Merger Sub&#x201d;), Celularity LLC (f/k/a Alpha Second Merger Sub LLC), a Delaware limited
liability company and a direct, wholly owned subsidiary of GX (&#x201c;Second Merger Sub&#x201d;), and the entity formerly known as Celularity
Inc., incorporated under the laws of the state of Delaware on August 29, 2016 (&#x201c;Legacy Celularity&#x201d;). Upon completion of the
merger transaction, GX changed its name to Celularity Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;At the special meeting held
on February 22, 2024, the stockholders of Celularity approved an amendment to Celularity&#x2019;s Second Amended and Restated Certificate
of Incorporation, as amended, to effect a reverse stock split of Celularity&#x2019;s Class A common stock, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240222__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zondG55V88O9" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share,
at a ratio of &lt;span id="xdx_904_eus-gaap--StockholdersEquityReverseStockSplit_c20240222__20240222__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zaVQuXSXhhKi" title="Reverse stock split ratio"&gt;1-for-10&lt;/span&gt;. Following the reverse stock split, each 10 shares of Celularity&#x2019;s Class A common stock issued and outstanding
immediately prior thereto were combined into one new share of Class A common stock. Unless specifically provided otherwise herein, all
share and per share information has been adjusted to reflect the reverse stock split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Description of Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Celularity is a cell therapy
and regenerative medicine company focused on addressing aging related diseases including cancer and degenerative diseases. Celularity
is headquartered in Florham Park, NJ. Legacy Celularity acquired Anthrogenesis Corporation (&#x201c;Anthrogenesis&#x201d;) in August 2017
from Celgene Corporation (&#x201c;Celgene&#x201d;), a global biotechnology company that merged with Bristol Myers Squibb Company. Previously,
Anthrogenesis operated as Celgene Cellular Therapeutics, Celgene&#x2019;s cell therapy division.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is subject to
risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors
of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with governmental regulations
and the ability to secure additional capital to fund operations. Drug candidates currently under development will require significant
additional approval prior to commercialization, including extensive preclinical and clinical testing and regulatory approval. These efforts
require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities.
Even if the Company&#x2019;s drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant
revenue from cellular therapy product sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Going Concern &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company has evaluated
whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability
to continue as a going concern within one year after the date that the consolidated financial statements are issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As an emerging clinical-stage
biotechnology company, Celularity is subject to certain inherent risks and uncertainties associated with the development of an enterprise.
In this regard, since the Company&#x2019;s inception, substantially all of management&#x2019;s efforts have been devoted to making investments
in research and development including basic scientific research into placentally-derived allogeneic cells, pre-clinical studies to support
its current and future clinical programs in cellular therapeutics, and clinical development of its cell programs as well as facilities
and selling, general and administrative expenses that support its core business operations (collectively, the &#x201c;investments&#x201d;),
all at the expense of the Company&#x2019;s short-term profitability. The Company has historically funded these investments through limited
revenues generated from its biobanking and degenerative disease businesses and issuances of equity and debt securities to public and private
investors (these issuances are collectively referred to as &#x201c;outside capital&#x201d;). Notwithstanding these efforts, management can
provide no assurance that the Company&#x2019;s research and development and commercialization efforts will be successfully completed, or
that adequate protection of the Company&#x2019;s intellectual property will be adequately maintained. Even if these efforts are successful,
it is uncertain when, if ever, the Company will generate significant sales or operate in a profitable manner to sustain the Company&#x2019;s
operations without needing to continue to rely on outside capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"&gt;As of the date the accompanying
consolidated financial statements were issued, or the issuance date, management evaluated the significance of the following adverse conditions
and events in considering its ability to continue as a going concern:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;


&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Since its inception, the Company has incurred significant operating losses and net cash used in operating
activities. For the year ended December 31, 2024, the Company incurred an operating loss of $&lt;span id="xdx_901_eus-gaap--OperatingIncomeLoss_iN_pn3n3_di_c20240101__20241231_zBI0HyVmlHq9" title="Operating loss"&gt;38,358&lt;/span&gt; and net cash used in operating activities
of $&lt;span id="xdx_905_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20240101__20241231_zjGCeCbYNwal" title="Net cash used in operating activities"&gt;6,401&lt;/span&gt;. As of December 31, 2024, the Company had an accumulated deficit of $&lt;span id="xdx_906_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20241231_zDCUPldZq8el" title="Accumulated deficit"&gt;899,683&lt;/span&gt;. The Company expects to continue to incur significant
operating losses and use net cash for operations for the foreseeable future.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;The Company expects to incur substantial expenditures to fund its investments for the foreseeable future.
In order to fund these investments, the Company will need to secure additional sources of outside capital. While the Company is actively
seeking to secure additional outside capital (and has historically been able to successfully secure such capital), as of the issuance
date, additional outside capital sufficient to fund operations for the next six months has not been secured or was deemed probable of
being secured. In addition, management can provide no assurance that the Company will be able to secure additional outside capital in
the future or on terms that are acceptable to the Company. Absent an ability to secure additional outside capital in the very near term,
the Company will be unable to meet its obligations as they become due over the next 12 months beyond the issuance date.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;As of the issuance date, the Company had approximately $&lt;span id="xdx_906_eus-gaap--DebtInstrumentIssuedPrincipal_pn3n3_c20240101__20241231_zvdnnGv06CPf" title="Principal debt outstanding"&gt;43,288&lt;/span&gt; of principal debt outstanding, all of which
is currently due or due within one year of the issuance date. As disclosed in Note 10, a substantial portion of the Company&#x2019;s outstanding
debt is subject to forbearance agreements. In the event the terms of the forbearance agreements are not met and/or the outstanding borrowings
are not repaid, the lenders may, at their discretion, exercise all of their rights and remedies under the loan agreements which may include,
among other things, seizing the Company&#x2019;s assets and/or forcing the Company into liquidation.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On April 22, 2025, the Company was notified by Nasdaq that it had not
                                                                                                                                                                                                           paid certain fees required by Listing Rule 5250(f) totalling $&lt;span id="xdx_903_eus-gaap--PaymentForManagementFee_pn3n3_c20250422__20250422__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpm1pT0klGGi" title="Payment for fee"&gt;70,000&lt;/span&gt;, and as a result, the Company will be delisted unless it
                                                                                                                                                                                                           appeals this determination. The Company paid the assessed fees on April 24, 2025, and Nasdaq informed the Company on April 30, 2025,
                                                                                                                                                                                                           that it was in compliance with Listing Rule 5250(f) and the matter is now closed. Additionally, on April 16, 2025, Nasdaq provided
                                                                                                                                                                                                           formal notice to the Company that as a result of the Company&#x2019;s failure to timely file this annual report on Form 10-K, it no
                                                                                                                                                                                                           longer complied with the continued listing requirements under the timely filing criteria outlined in Nasdaq Listing Rule 5250(c)(1).
                                                                                                                                                                                                           Pursuant to Listing Rule 5810(d)(2), this delinquency serves as an additional and separate basis for delisting, and as such, the
                                                                                                                                                                                                           Company&#x2019;s common stock will be suspended from trading on May 1, 2025, unless it appeals Nasdaq&#x2019;s determination before a
                                                                                                                                                                                                           Hearing Panel. On April 29, 2025, the Company filed an appeal requesting an oral hearing with a Nasdaq Hearing Panel. There can be
                                                                                                                                                                                                           no assurance that the appeal will be successful or that the Company will maintain compliance with the Nasdaq listing requirements.
                                                                                                                                                                                                           If relief is not granted by the Nasdaq Hearing Panel or the Company is unable to regain compliance, the Company&#x2019;s securities
                                                                                                                                                                                                           will be delisted from the Nasdaq, which such delisting could have a materially adverse effect on the Company&#x2019;s ability to
                                                                                                                                                                                                           continue as a going concern.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;In the event the Company is unable to secure additional outside capital to fund the Company&#x2019;s obligations
when they become due over the next 12 months beyond the issuance date, which includes the funds needed to repay the Company&#x2019;s outstanding
debt, management will be required to seek other strategic alternatives, which may include, among others, a significant curtailment of
the Company&#x2019;s operations, a sale of certain of the Company&#x2019;s assets, a sale of the entire Company to strategic or financial
investors, and/or allowing the Company to become insolvent by filing for bankruptcy protection under the provisions of the U.S. Bankruptcy
Code.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;These uncertainties raise
substantial doubt about the Company&#x2019;s ability to continue as a going concern. The accompanying consolidated financial statements
have been prepared on the basis that the Company will continue to operate as a going concern, which contemplates that the Company will
be able to realize assets and settle liabilities and commitments in the normal course of business for the foreseeable future. Accordingly,
the accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="From2024-01-01to2024-12-31" id="Fact000821">2018-08-24</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-02-22_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact000823"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="From2024-02-222024-02-22_us-gaap_CommonClassAMember"
      id="Fact000825">1-for-10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000827"
      unitRef="USD">-38358000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000829"
      unitRef="USD">-6401000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000831"
      unitRef="USD">-899683000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000833"
      unitRef="USD">43288000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:PaymentForManagementFee
      contextRef="From2025-04-222025-04-22_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact000835"
      unitRef="USD">70000000</us-gaap:PaymentForManagementFee>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000837">&lt;p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zt50ofiaX3L4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;2. &lt;span id="xdx_821_zk911nBMBO35"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zdyDETNzOD07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s
consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;).
The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and
transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management,
is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zs3ze1DxCDi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The preparation of the
Company&#x2019;s consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the
consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant
estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related
to the Company&#x2019;s goodwill and intangible asset impairment assessments, determination of incremental borrowing rates, and the
valuations of inventory, gross-to-net sales adjustments, contingent consideration, short-term debt, stock options and stock
warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors
that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are
changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual
results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrCWIXAoDtD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Certain assets and
liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an
orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to
be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable
and the last is considered unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Level 2 &#x2014; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active
markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities,
or other inputs that are observable or can be corroborated by observable market data.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Level 3 &#x2014; Unobservable inputs that are supported by little or no market activity that are significant
to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zYWQkJNKxIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Cash and cash equivalents
consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having a maturity when
acquired of less than three months. The Company considers all highly liquid investments with maturities of three months or less at
the date of acquisition to be cash equivalents. At December 31, 2024 and 2023, substantially all cash and cash equivalents were held
in either commercial bank accounts or money market funds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_z1PgwfZPO0v2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;As of December 31,
2024 and 2023, the Company maintained a letter of credit of $&lt;span id="xdx_90C_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20241231__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zjoVwFqEBhq3" title="Restricted cash"&gt;10,239&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zczK3zS7p75k" title="Restricted cash"&gt;9,936&lt;/span&gt;, respectively, for the benefit of the landlord of a leased
property, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJI8ZxNTfRj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;Accounts receivable represent amounts due from customers, typically within 30 to 90 days from invoice date, arising from the Company&#x2019;s revenue-generating activities. Accounts receivable are presented net of an allowance for credit losses. The
allowance for credit losses is determined based on a combination of the aging of receivables, and customer-specific information, including
historical loss experience, current economic conditions, forecasts of future economic conditions and other relevant risk factors. The
Company applies judgment in evaluating the collectability of accounts. Receivables are written off when all reasonable collection efforts
have been exhausted and the amounts are deemed uncollectible. Actual credit losses may differ from management&#x2019;s estimates, and such
differences are recognized in the period in which they become known. The Company&#x2019;s accounts receivable balance, net of allowance for credit losses, was $&lt;span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20241231_zeQQoLgBpzc9" title="Accounts receivable balance, net of allowance for credit losses"&gt;13,357&lt;/span&gt;, $&lt;span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20231231_zcx3fNrMjZqd" title="Accounts receivable balance, net of allowance for credit losses"&gt;10,046&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231_zN2uiosrvhKc" title="Accounts receivable balance, net of allowance for credit losses"&gt;4,452&lt;/span&gt;
as of December 31, 2024, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--InventoryPolicyTextBlock_zZCOVQRpq42a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Inventory is stated
at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. Prior to initial approval
from the FDA or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred.
After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product.
The Company continues to expense costs associated with clinical trial supply costs as research and development expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company periodically
analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i)
expected to expire prior to being sold, (ii) has a cost basis in excess of its net realizable value, (iii) is in excess of expected
sales requirements as determined by internal sales forecasts, or (iv) fails to meet commercial sale specifications, the inventory is
written-down through a charge to cost of revenues. The determination of whether inventory costs will be realizable requires
estimates by management of future expected inventory requirements, based on sales forecasts. If actual market conditions are less
favorable than those projected by management, additional inventory write-downs may be required. Inventory, net of current portion on
the Company&#x2019;s consolidated balance sheets includes inventory expected to remain on hand beyond one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zirH0xyvqwPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zNuXmaECBYkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Property and equipment
are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line
method over the estimated useful life of each asset, as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span id="xdx_8BB_zWqIoqbkfaU7" style="display: none"&gt;Schedule of Property and
Equipment Estimated Useful Life&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Estimated Useful Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 69%"&gt;Building&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 29%; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zZlzOQlagac9" title="Property and equipment expected useful lives"&gt;26&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zB89FzWimrl3" title="Property and equipment expected useful lives"&gt;5&lt;/span&gt; - &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zwDyWQvpt0Rd" title="Property and equipment expected useful lives"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zSXMcDK2itY8" title="Property and equipment expected useful lives"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ7S4NKtSWNd" title="Property and equipment expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Software&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zV3KFxImgR3a" title="Property and equipment expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zdaZ6Eefrqd2" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;shorter of the estimated useful life or the lease term&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zGGLuPyKsfA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Estimated useful lives are
periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When
assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are
eliminated from the consolidated balance sheets and any resulting gains or losses are included in the consolidated statements of
operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as
construction-in-progress and depreciated once placed into service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD7ahGB9k1gg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Long-lived assets consist
of property, plant and equipment, operating right-of-use assets, and finite-lived intangible assets. Long-lived assets to be held and
used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets
may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant
underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes
or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability,
the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset
group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows
expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess
of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. Due to the goodwill
impairment recognized during the year ended December 31, 2023 as discussed below and in Note 8, the Company performed a recoverability
test on long-lived assets and concluded no additional impairment to be recognized as result of this test. The Company did not record any
impairment losses on long-lived assets during the years ended December 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--AssetAcquisitionsPolicyTextBlock_zwRrPSrKxFj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Asset Acquisitions&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company measures
and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes
transaction costs. In an asset acquisition, the cost allocated to acquire IPR&amp;amp;D with no alternative future use is charged to research
and development expense at the acquisition date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--InProcessResearchAndDevelopmentPolicy_zO49g7Q62gg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;In-Process Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of IPR&amp;amp;D
acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of
the related research and development activities. When the related research and development is completed, the asset is reclassified to
a finite-lived asset and amortized over its estimated useful life.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of an
IPR&amp;amp;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to
be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#x2019;s stage of completion, the probability
of technical success, the projected costs to complete, expected market competition, and an assessment of the asset&#x2019;s life-cycle.
The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated
with the cash flow streams.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Indefinite-lived IPR&amp;amp;D
is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The
Company tests its indefinite-lived IPR&amp;amp;D annually for impairment during the fourth quarter. In testing indefinite-lived
IPR&amp;amp;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of
events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the
Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived IPR&amp;amp;D without
performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or
economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess
qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived IPR&amp;amp;D
is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived IPR&amp;amp;D. Under either
approach, if the fair value of the indefinite-lived IPR&amp;amp;D is less than its carrying amount, an impairment charge is recognized
in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2024, the Company did &lt;span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_dxL_c20240101__20241231_zBVtE4RSkLYc" title="Indefinite-lived IPR&amp;amp;D::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0886"&gt;no&lt;/span&gt;&lt;/span&gt;t
recognize an impairment charge related to its indefinite-lived IPR&amp;amp;D. During the year ended December 31, 2023, the Company
recognized an impairment charge related to its indefinite-lived IPR&amp;amp;D of $&lt;span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_c20230101__20231231_zRCobO66Fxgg" title="Indefinite-lived IPR&amp;amp;D"&gt;107,800&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zVgnjKMbbyub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Goodwill represents
the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets
acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if
there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company manages
its operations through an evaluation of &lt;span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_z6ccAPGLi27e" title="Operating segments"&gt;three&lt;/span&gt; different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note
19). The Company determined that the operating segments represented the reporting units.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In testing goodwill
for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances
would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, or the Company
can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances
considered in the Company&#x2019;s qualitative assessment include, but are not limited to, a significant adverse change in legal or business
climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess qualitative factors and the
Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, the Company
would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit
to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, no
impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize
an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value, not to exceed the total
amount of goodwill allocated to the reporting unit. During the year ended December 31, 2024, the Company did &lt;span id="xdx_903_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_do_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zrfBEylpfebh" title="Goodwill impairment"&gt;no&lt;/span&gt;t recognize any goodwill
impairment. During the year ended December 31, 2023, the Company recognized goodwill impairment of $&lt;span id="xdx_901_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zO7f9dSxunO7" title="Goodwill impairment"&gt;112,347&lt;/span&gt; relating to the Cell Therapy
reporting unit (see Note 8) in the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--WarrantsLiabilitiesPolicyTextBlock_zPm9aumjiLI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Warrant Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for
the public warrants, private placement warrants, registered direct warrants, May 2022 PIPE warrants, and November 2024 Purchaser
Warrants and Placement Agent Warrants (collectively, &#x201c;Liability Warrants&#x201d;) in accordance with the guidance contained in
Accounting Standards Codification (&#x201c;ASC&#x201d;) 815-40, &lt;i&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own
Equity&lt;/i&gt;, under which the Liability Warrants do not meet the criteria for equity treatment and must be recorded as liabilities.
Accordingly, the Company classifies the Liability Warrants as liabilities at their fair value and adjusts to fair value at each
reporting period. These liabilities are subject to re-measurement at each balance sheet date until exercised or expired, and any change in
fair value is recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The Liability
Warrants, excluding the public warrants, were initially and subsequently valued using either a Black-Scholes or a Monte Carlo option
pricing model, which are considered to be Level 3 fair value measurements. The public warrants are valued based on the quoted market
price as of each relevant reporting date, which is considered to be a Level 1 fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_zB6GsSXh3MT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In accordance with
Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-02, &lt;i&gt;Leases (Topic 842)&lt;/i&gt; (ASU 2016-02 or ASC 842), the Company classifies leases
at the lease commencement date. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease
based on the circumstances present. Leases with a term greater than one year will be recognized on the consolidated balance sheets as
right-of-use (&#x201c;ROU&#x201d;) assets, lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal
options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and
the corresponding ROU assets are recorded based on the present values of lease payments over the terms. The interest rate implicit in
lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which
are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a
similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liabilities and are
recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants.
Certain adjustments to ROU assets may be required for items such as initial direct costs paid, incentives received, or lease prepayments.
If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company
would reassess lease classification, remeasure the lease liabilities using revised inputs as of the reassessment date, and adjust the
ROU assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company has elected
the &#x201c;package of 3&#x201d; practical expedients permitted under the transition guidance, which eliminates the requirements to reassess
prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy
which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of
exercising will not be included within the ROU assets and lease liabilities on its consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Refer to Note 11 for further information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_ecustom--ShortTermDebtPolicyTextBlock_zJawFRlv44Sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Short-Term Debt - Yorkville and
Unsecured Senior Convertible Notes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company elected
the fair value option to account for its pre-paid advance agreement with YA II PN, Ltd (&#x201c;Yorkville&#x201d;) (see Note 10). As of
December 31, 2023, due to the short-term nature of the debt, the fair value approximated the settlement amount which was fully paid on
January 17, 2024. The Company also elected the fair value option to account for the Yorkville convertible promissory note signed on March
13, 2024 (see Note 10) and the unsecured senior convertible notes issued pursuant to the securities purchase agreement signed on November
25, 2024 (see Note 10). As of December 31, 2024, the estimate of the fair value of the Yorkville convertible promissory note and the unsecured
senior convertible notes was determined using a binomial lattice model and a credit default model. The fair value measurement of the debt
is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair value of debt that is accounted for
at fair value, inclusive of related accrued interest expense, are presented as gains or losses in the accompanying consolidated statements
of operations and comprehensive loss under change in fair value of debt. The portion of total changes in fair value of debt attributable
to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption
exclusive of base market changes and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements
of operations and comprehensive loss. The actual settlement of the short-term debt could differ from current estimates based on the timing
of when and if the investors elect to convert amounts into common shares, potential cash repayment by the Company prior to maturity, and
movements in the Company&#x2019;s common share price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zMzJP3CBwZOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company generates
revenue from its degenerative disease commercial operations (i.e., the sale of Biovance&lt;sup&gt;&#xae;&lt;/sup&gt;, Biovance 3L&lt;sup&gt;&#xae;&lt;/sup&gt;,
CentaFlex&lt;sup&gt;&#xae;&lt;/sup&gt;, Interfyl&lt;sup&gt;&#xae;&lt;/sup&gt; and Rebound&lt;sup&gt;TM&lt;/sup&gt;), biobanking services (i.e., the collection, processing and
storage of umbilical cord and placental blood and tissue after full-term pregnancies), and license, royalty and other revenues.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Product sales&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&#160;&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Biovance, Biovance 3L, CentaFlex
and Rebound are decellularized, dehydrated human amniotic membrane products intended for use as a biological membrane covering that provides
the extracellular matrix while supporting the repair of damaged tissue. Interfyl is an allogeneic decellularized particulate human placental
connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use
in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. &lt;span style="background-color: white"&gt;Rebound&#x2122;
is a full thickness extracellular matrix that contains amnion and chorion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes
revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects
to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer,
determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct
performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied. Sales and
other taxes collected on behalf of third parties are excluded from revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;A performance obligation
is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with
other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance
obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use
and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with
customers and to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration
that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances,
to which the Company expects to be entitled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company offers
volume-based discounts, rebates and prompt pay discounts and other various incentives which are accounted for under the variable consideration
model. If sales incentives may be earned by a customer for purchasing a specified amount of product, the Company estimates whether such
incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction
is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company
considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to estimate what
levels of incentives will be earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company provides
for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore
does not record a provision for returns.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Services&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company separately recognizes
revenues for services to expectant parents who contract with the Company to collect, process and store umbilical cord blood and placenta
derived cells and tissue for private use. The Company recognizes revenue from collection and processing fees at the point in time of the
successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period. Contracted
storage periods are generally &lt;span id="xdx_90E_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z58qSIxTyhdb" title="Contracted storage periods"&gt;18&lt;/span&gt; years and &lt;span id="xdx_900_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zfUgtyGy5kj7" title="Contracted storage periods"&gt;25&lt;/span&gt; years. Deferred revenue on the accompanying consolidated balance sheets includes the portion
of the 18- and the 25-year storage fees that are being recognized over the contractual storage period. The Company classifies deferred
revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;When determining the transaction
price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance,
resulting in a significant financing component. For all plans (annual, lifetime, &lt;span id="xdx_90D_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zieb2Fryhruh"&gt;18&lt;/span&gt;
years and &lt;span id="xdx_90A_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z6PRk83KBTyh"&gt;25&lt;/span&gt;
years), the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans
for customers to pay over time for a period of one
&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z6uayugqonI7" title="Over time for a period"&gt;1&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_908_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zEGtPcJ7xRMe" title="Over time for a period"&gt;24&lt;/span&gt;
months (over time plans). The Company concluded that a significant financing component is not present within either the prepaid or overtime
payment plans. The Company has determined that the prepaid plans do not include a significant financing component as the payment terms
were structured primarily for reasons other than the provision of financing and to maximize profitability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;When considered over
a &lt;span id="xdx_908_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zyN5PDwPyEo7" title="Over time for a period"&gt;24&lt;/span&gt;-month period for over time plans, the difference between the cash selling price and the consideration paid is nominal. As such, the
Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when
considered in the context of all contracts entered into nor are they significant at the individual contract level.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company offers
promotional discounts and other various incentives which are accounted for under the variable consideration model. The Company estimates
whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue
transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method,
the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to
estimate what levels of incentives will be earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;As
the Company&#x2019;s processing and storage agreements contain multiple performance obligations, ASC 606, &lt;i&gt;Revenue from Contracts with
Customers,&lt;/i&gt; requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised
services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the standalone
selling prices of the processing services and storage services and concluded that the published list price is the price that a customer
in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged
the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage&lt;/span&gt;&lt;span style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;License, royalty and other&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Under license agreements,
the Company assesses whether the related performance obligation is satisfied at a point in time or over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;At the inception of
each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable
of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial,
and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved
in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period,
the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate
of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings
in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy
a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the
milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. See
Note 16 for further discussion of the Company&#x2019;s license agreements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;While the Company&#x2019;s
direct sales of degenerative disease products are included in product sales, sales through the Company&#x2019;s network of distribution partners
are included in license, royalty and other revenues. For certain distribution agreements as described in Note 16, the Company will utilize
the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to
invoice so long as the consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue
upon invoicing for these agreements (subsequent to receipt of the related purchase order).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CostOfSalesPolicyTextBlock_z35GVfzsFpM8" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Cost of Revenues&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;Cost
of revenues consists of labor, material and overhead costs associated with the Company&#x2019;s two existing commercial business segments,
biobanking and degenerative disease. Biobanking costs, which include the cost of storage and transportation kits for newly banked materials
as well as tank and facility overhead costs for cord blood and other units in storage, are included in services in cost of revenues. Degenerative
disease costs, which include costs associated with procuring placentas, qualifying the placental material and processing the placental
tissue into a marketable product, are included in product sales or license, royalty and other in cost of revenues depending on the class
of customer. Costs in the degenerative disease segment include labor and overhead costs associated with the production of the Biovance,
Biovance 3L, Interfyl and Rebound product lines.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztoNo8vfpm03" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company has entered
into various research and development and other agreements with commercial firms, researchers, universities and others for provisions
of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expense
as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses,
depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside
vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical
trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. Nonrefundable advance
payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses.
Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or
when it is no longer expected that the goods will be delivered, or the services rendered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Upfront payments, milestone
payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zehqyqrWofT4" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Advertising and Marketing Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Advertising and marketing
costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were
$&lt;span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20240101__20241231_zPHclHX0L6aa" title="Advertising and marketing costs"&gt;23&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20230101__20231231_zFZsOBngTiul" title="Advertising and marketing costs"&gt;44&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_ecustom--GovernmentGrantsPolicyTextBlock_zAOMqF8O9Nv1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Government Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;From time to time,
the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction
to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency.
The Company did &lt;span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20240101__20241231_zPvnZyyuNW4" title="Grant monies"&gt;&lt;span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20230101__20231231_z3b1OtFQdtV" title="Grant monies"&gt;no&lt;/span&gt;&lt;/span&gt;t receive grant monies during the years ended December 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zOVE1KisiZFb" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;All patent-related
costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the
recovery of the expenditure. Amounts incurred are classified in selling, general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zO3jvgy1FGPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company measures
all stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation
expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company
typically issues stock-based awards with only service-based vesting conditions and records the expense for these awards using a straight-line
method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s
board of directors may also approve and award performance-based stock options. The performance-based stock options are earned based on
the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based awards over
the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability
of vesting at each reporting period for performance-based awards and adjusts expense accordingly on a cumulative basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of each
service-performance- and market-based stock option grant is estimated on the date of grant using an appropriate option pricing
model using inputs available as of the grant date. For awards with service-based vesting conditions only, the Company determines the
fair value of the award as of the grant date using the Black-Scholes option-pricing model. Prior to the merger, Legacy Celularity
was a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, the
Company estimates its expected stock price volatility using its volatility since the merger and the historical volatility of
publicly traded peer companies. The expected term of the Company&#x2019;s stock options granted to employees is determined utilizing
the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The expected term of stock
options granted to non-employee consultants is equal to the contractual term of the option award or the Company&#x2019;s estimated
term based on the underlying agreement. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in
effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected
dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay
any cash dividends in the foreseeable future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company classifies
stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award
recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified. The Company elects
to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure
to satisfy a service or performance condition is generally reversed in the period of the forfeiture.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zcClrkt8H3S1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Comprehensive income (loss)
refers to revenues, expenses, gains and losses that under GAAP are included in comprehensive income (loss) but are excluded from net income
(loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss). The Company&#x2019;s only
component of other comprehensive income (loss) is comprised of the portion of the total change in fair value of debt accounted for under
the fair value option that is attributable to changes in instrument-specific credit risk. During the year ended December 31, 2024, the
Company recorded instrument-specific credit risk loss of $&lt;span id="xdx_907_ecustom--InstrumentSpecificCreditRiskLoss_pn3n3_c20240101__20241231_zXuxthYZisj4" title="Instrument-specific credit risk loss"&gt;5&lt;/span&gt;. During the year ended December 31, 2023, the Company recorded instrument-specific
credit risk income of $&lt;span id="xdx_905_ecustom--InstrumentSpecificCreditRiskIncome_pn3n3_c20230101__20231231_zTIEM30L2NXa" title="Instrument-specific credit risk income"&gt;146&lt;/span&gt; and reclassified $&lt;span id="xdx_904_ecustom--AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_pn3n3_c20230101__20231231_zaEvSgctPaZ1" title="Accumulated other comprehensive income"&gt;155&lt;/span&gt; from accumulated other comprehensive loss to other expense, net on the consolidated statements
of operations and comprehensive loss upon short-term debt conversion. These amounts have been recorded as a separate component of stockholders&#x2019;
equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zcM4XvGXdhs1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for
income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns.
Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and
liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets
and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will
be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely
than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge
to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and
considering prudent and feasible tax planning strategies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company accounts
for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount
of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based
on the technical merits of the position. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then
assessed to determine the amount of benefit to recognize in the consolidated financial statements. &lt;span id="xdx_906_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zbOsqvgmw2Xf" title="Income tax examination likelihood settlement"&gt;The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority&lt;/span&gt;.
The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note
18).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zDCGXGQdLZZ3" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Basic net loss per share
of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period.
Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such
as redeemable convertible preferred stock, convertible debt, stock options, restricted stock units and warrants, which would result in
the issuance of incremental shares of common stock. However, potential common shares are excluded if their effect is anti-dilutive. For
diluted net loss per share when the Company has a net loss, the weighted-average number of shares of common stock is the same as for basic
net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact
is anti-dilutive. All warrants are participating securities, as they participate on a one-for-one basis with Class A common stock in the
distribution of dividends, if and when declared by the Board of Directors. For the purposes of computing earnings per share, the warrants
are considered to participate with Class A common stock in earnings of the Company. Therefore, the Company computes earnings per share
using the two-class method, an earnings allocation method that determines net income (loss) per share (when there are earnings) for common
stock and participating securities. No income was allocated to the warrants for the years ended December 31, 2024 and 2023, as results
of operations were a loss for both periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgF07KC77J2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following potentially
dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common stock outstanding, prior
to the use of the two-class method, as they would be anti-dilutive:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span id="xdx_8B6_zFS2Zb9yp5z4" style="display: none"&gt;Schedule of Potentially
Dilutive Securities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_zTLtiqSQNdm2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zcfC9dr3F2Ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zO4pWMMkDXGa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;4,006,525&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;2,820,187&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG54qjzKR72f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;688,106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;823,332&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpDgmRzbMwm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,221,557&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,070,627&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zngdWYOZ7SBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Convertible debt&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,126,496&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;549,681&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zc76zzjiS1Tb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,042,684&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,263,827&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zSxqGmWvKgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze7191TVFkX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Operating segments
are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company manages
its operations through an evaluation of &lt;span id="xdx_906_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_ztB8DCNcXN04" title="Number of operating segments"&gt;three&lt;/span&gt; distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments
are presented for the years ended December 31, 2024 and 2023 in Note 19.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_ecustom--AllowanceForCreditLossesPolicyTextBlock_zhEEiQk5NWE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Allowance for Credit Losses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;With the adoption of ASU
2016-13 &lt;i&gt;Financial Instruments &#x2014; Credit Losses, &lt;/i&gt;as noted below, the Company recognizes credit losses based on forward-looking
current expected credit losses. The Company makes estimates of expected credit losses based upon its assessment of various factors, including
historical collection experience, the age of accounts receivable balances, credit quality of its customers, current economic conditions,
reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_z2szKM6kK2K1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk and
Significant Customers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Financial instruments that
potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, and
accounts receivable. The Company generally maintains cash balances in various operating accounts at financial institutions that management
believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses
related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the
normal credit risk associated with commercial banking relationships.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is subject to
credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts
receivables are a result from product sales and services performed in the United States. As of December 31, 2024, three of the Company&#x2019;s
customers, each of which individually comprised at least 10%, represented an aggregate &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_z4PaOevwtynb" title="Concentration risk, percentage"&gt;46&lt;/span&gt;% of the Company&#x2019;s outstanding gross accounts
receivable. As of December 31, 2023, two of the Company&#x2019;s customers, each of which individually comprised at least 10%, represented an
aggregate &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zx2bmIlaY6N" title="Concentration risk, percentage"&gt;41&lt;/span&gt;% of the Company&#x2019;s outstanding gross accounts receivable. During the year ended December 31, 2024, the Company had one
customer provide for &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFlNmPzgrYt7" title="Concentration risk, percentage"&gt;17&lt;/span&gt;% of revenue and another customer provided for &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zanEqKEWCkk7" title="Concentration risk, percentage"&gt;16&lt;/span&gt;% of revenue. During the year ended December 31, 2023, the Company
had one customer provide for &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmQz2erMMjnc" title="Concentration risk, percentage"&gt;14&lt;/span&gt;% of revenue and another customer provided for &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zc4bGqHB5XBa" title="Concentration risk, percentage"&gt;13&lt;/span&gt;% of revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zAzQwpXzibg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Certain prior period amounts
have been reclassified to conform with current year presentation. On the consolidated balance sheets, short-term debt - Yorkville and
other short-term debt were reclassified to short-term debt - unaffiliated, and short-term debt - related party and short-term debt - related
parties - C.V. Starr and RWI were reclassified to short-term debt - related parties. See Note 10 for further information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zL3RHbbgw3o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In June 2016, the Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-13, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;),
which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types
of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale
debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual
periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption
permitted. The Company adopted ASU 2016-13 effective January 1, 2023. The standard did not have a material impact on the consolidated
financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In November 2023, the FASB
issued ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;, which requires disclosure of
incremental segment information on an annual and interim basis. This ASU was effective for fiscal years beginning after December 15, 2023,
and interim periods within fiscal years beginning after December 15, 2024. The Company adopted the guidance in ASU 2023-07 for the year
ended December 31, 2024, and it is being applied retrospectively to its consolidated financial statement disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z20Svbe71ez6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In December 2023, the FASB
issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which expands the disclosures required for
income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should
be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this
pronouncement on its financial statement disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In November 2024, the FASB
issued ASU 2024-03, &lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;, as subsequently amended by ASU 2025-01 to clarify the effective date,
which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee
compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of
operations and comprehensive loss. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within
fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively
to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods
presented in the consolidated financial statements. The Company is currently evaluating the effect of this pronouncement on its
consolidated financial statements and footnote disclosures.&lt;/p&gt;

&lt;p id="xdx_855_zCWYG4UIoI86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000839">&lt;p id="xdx_841_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zdyDETNzOD07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s
consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;).
The consolidated financial statements include the accounts of wholly owned subsidiaries, after elimination of intercompany accounts and
transactions. The consolidated financial information presented herein reflects all financial information that, in the opinion of management,
is necessary for a fair statement of financial position, results of operations and cash flows for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-01-01to2024-12-31" id="Fact000841">&lt;p id="xdx_845_eus-gaap--UseOfEstimates_zs3ze1DxCDi2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The preparation of the
Company&#x2019;s consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the
consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. Significant
estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, assumptions related
to the Company&#x2019;s goodwill and intangible asset impairment assessments, determination of incremental borrowing rates, and the
valuations of inventory, gross-to-net sales adjustments, contingent consideration, short-term debt, stock options and stock
warrants. The Company based its estimates on historical experience, known trends and other market-specific or other relevant factors
that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates when there are
changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual
results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000843">&lt;p id="xdx_841_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zrCWIXAoDtD5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Certain assets and
liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for
an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an
orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize
the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to
be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable
and the last is considered unobservable:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets or liabilities.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Level 2 &#x2014; Observable inputs (other than Level 1 quoted prices), such as quoted prices in active
markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities,
or other inputs that are observable or can be corroborated by observable market data.&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;Level 3 &#x2014; Unobservable inputs that are supported by little or no market activity that are significant
to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000845">&lt;p id="xdx_848_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zYWQkJNKxIp5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Cash and cash equivalents
consist principally of cash held in commercial bank accounts, money market funds and U.S. Treasury securities having a maturity when
acquired of less than three months. The Company considers all highly liquid investments with maturities of three months or less at
the date of acquisition to be cash equivalents. At December 31, 2024 and 2023, substantially all cash and cash equivalents were held
in either commercial bank accounts or money market funds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000847">&lt;p id="xdx_84F_eus-gaap--CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_z1PgwfZPO0v2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;As of December 31,
2024 and 2023, the Company maintained a letter of credit of $&lt;span id="xdx_90C_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20241231__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zjoVwFqEBhq3" title="Restricted cash"&gt;10,239&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231__us-gaap--PledgingPurposeAxis__us-gaap--LetterOfCreditMember_zczK3zS7p75k" title="Restricted cash"&gt;9,936&lt;/span&gt;, respectively, for the benefit of the landlord of a leased
property, which the Company classified as restricted cash (non-current) on its consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_LetterOfCreditMember"
      decimals="-3"
      id="Fact000849"
      unitRef="USD">10239000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="AsOf2023-12-31_us-gaap_LetterOfCreditMember"
      decimals="-3"
      id="Fact000851"
      unitRef="USD">9936000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000853">&lt;p id="xdx_842_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zJI8ZxNTfRj3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;Accounts receivable represent amounts due from customers, typically within 30 to 90 days from invoice date, arising from the Company&#x2019;s revenue-generating activities. Accounts receivable are presented net of an allowance for credit losses. The
allowance for credit losses is determined based on a combination of the aging of receivables, and customer-specific information, including
historical loss experience, current economic conditions, forecasts of future economic conditions and other relevant risk factors. The
Company applies judgment in evaluating the collectability of accounts. Receivables are written off when all reasonable collection efforts
have been exhausted and the amounts are deemed uncollectible. Actual credit losses may differ from management&#x2019;s estimates, and such
differences are recognized in the period in which they become known. The Company&#x2019;s accounts receivable balance, net of allowance for credit losses, was $&lt;span id="xdx_904_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20241231_zeQQoLgBpzc9" title="Accounts receivable balance, net of allowance for credit losses"&gt;13,357&lt;/span&gt;, $&lt;span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20231231_zcx3fNrMjZqd" title="Accounts receivable balance, net of allowance for credit losses"&gt;10,046&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3n3_c20221231_zN2uiosrvhKc" title="Accounts receivable balance, net of allowance for credit losses"&gt;4,452&lt;/span&gt;
as of December 31, 2024, 2023 and 2022, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000855"
      unitRef="USD">13357000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000857"
      unitRef="USD">10046000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact000859"
      unitRef="USD">4452000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000861">&lt;p id="xdx_849_eus-gaap--InventoryPolicyTextBlock_zZCOVQRpq42a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Inventory is stated
at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. Prior to initial approval
from the FDA or other regulatory agencies, the Company expenses costs relating to the production of inventory in the period incurred.
After such time as the product receives initial regulatory approval, the Company capitalizes the inventory costs related to the product.
The Company continues to expense costs associated with clinical trial supply costs as research and development expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company periodically
analyzes the inventory levels to determine whether there is any obsolete, expired, or excess inventory. If any inventory is (i)
expected to expire prior to being sold, (ii) has a cost basis in excess of its net realizable value, (iii) is in excess of expected
sales requirements as determined by internal sales forecasts, or (iv) fails to meet commercial sale specifications, the inventory is
written-down through a charge to cost of revenues. The determination of whether inventory costs will be realizable requires
estimates by management of future expected inventory requirements, based on sales forecasts. If actual market conditions are less
favorable than those projected by management, additional inventory write-downs may be required. Inventory, net of current portion on
the Company&#x2019;s consolidated balance sheets includes inventory expected to remain on hand beyond one year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000863">&lt;p id="xdx_843_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zirH0xyvqwPf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_89C_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zNuXmaECBYkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Property and equipment
are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line
method over the estimated useful life of each asset, as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span id="xdx_8BB_zWqIoqbkfaU7" style="display: none"&gt;Schedule of Property and
Equipment Estimated Useful Life&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Estimated Useful Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 69%"&gt;Building&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 29%; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zZlzOQlagac9" title="Property and equipment expected useful lives"&gt;26&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zB89FzWimrl3" title="Property and equipment expected useful lives"&gt;5&lt;/span&gt; - &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zwDyWQvpt0Rd" title="Property and equipment expected useful lives"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zSXMcDK2itY8" title="Property and equipment expected useful lives"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ7S4NKtSWNd" title="Property and equipment expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Software&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zV3KFxImgR3a" title="Property and equipment expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zdaZ6Eefrqd2" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;shorter of the estimated useful life or the lease term&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zGGLuPyKsfA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Estimated useful lives are
periodically assessed to determine if changes are appropriate. Maintenance and repairs are charged to expense as incurred. When
assets are retired or otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are
eliminated from the consolidated balance sheets and any resulting gains or losses are included in the consolidated statements of
operations and comprehensive loss in the period of disposal. Costs for capital assets not yet placed into service are capitalized as
construction-in-progress and depreciated once placed into service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <CELU:ScheduleOfEstimatedUsefulLivesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000865">&lt;p id="xdx_89C_ecustom--ScheduleOfEstimatedUsefulLivesTableTextBlock_zNuXmaECBYkd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Property and equipment
are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line
method over the estimated useful life of each asset, as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span id="xdx_8BB_zWqIoqbkfaU7" style="display: none"&gt;Schedule of Property and
Equipment Estimated Useful Life&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Estimated Useful Life&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 69%"&gt;Building&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 29%; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zZlzOQlagac9" title="Property and equipment expected useful lives"&gt;26&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zB89FzWimrl3" title="Property and equipment expected useful lives"&gt;5&lt;/span&gt; - &lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zwDyWQvpt0Rd" title="Property and equipment expected useful lives"&gt;7&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zSXMcDK2itY8" title="Property and equipment expected useful lives"&gt;5&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zJ7S4NKtSWNd" title="Property and equipment expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Software&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareDevelopmentMember_zV3KFxImgR3a" title="Property and equipment expected useful lives"&gt;3&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_iI_dxL_c20241231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zdaZ6Eefrqd2" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2024%23UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0878"&gt;shorter of the estimated useful life or the lease term&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CELU:ScheduleOfEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_BuildingMember"
      id="Fact000867">P26Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember"
      id="Fact000869">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember"
      id="Fact000871">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_EquipmentMember"
      id="Fact000873">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_ComputerEquipmentMember"
      id="Fact000875">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_SoftwareDevelopmentMember"
      id="Fact000877">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000880">&lt;p id="xdx_847_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zD7ahGB9k1gg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Long-lived assets consist
of property, plant and equipment, operating right-of-use assets, and finite-lived intangible assets. Long-lived assets to be held and
used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets
may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant
underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes
or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability,
the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset
group to its carrying value. An impairment loss would be recognized in loss from operations when estimated undiscounted future cash flows
expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the excess
of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. Due to the goodwill
impairment recognized during the year ended December 31, 2023 as discussed below and in Note 8, the Company performed a recoverability
test on long-lived assets and concluded no additional impairment to be recognized as result of this test. The Company did not record any
impairment losses on long-lived assets during the years ended December 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <CELU:AssetAcquisitionsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000882">&lt;p id="xdx_848_ecustom--AssetAcquisitionsPolicyTextBlock_zwRrPSrKxFj7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Asset Acquisitions&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company measures
and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes
transaction costs. In an asset acquisition, the cost allocated to acquire IPR&amp;amp;D with no alternative future use is charged to research
and development expense at the acquisition date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</CELU:AssetAcquisitionsPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="From2024-01-01to2024-12-31" id="Fact000884">&lt;p id="xdx_841_eus-gaap--InProcessResearchAndDevelopmentPolicy_zO49g7Q62gg2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;In-Process Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of IPR&amp;amp;D
acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of
the related research and development activities. When the related research and development is completed, the asset is reclassified to
a finite-lived asset and amortized over its estimated useful life.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of an
IPR&amp;amp;D intangible asset is typically determined using an income approach whereby management forecasts the net cash flows expected to
be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#x2019;s stage of completion, the probability
of technical success, the projected costs to complete, expected market competition, and an assessment of the asset&#x2019;s life-cycle.
The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated
with the cash flow streams.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Indefinite-lived IPR&amp;amp;D
is not subject to amortization but is tested annually for impairment or more frequently if there are indicators of impairment. The
Company tests its indefinite-lived IPR&amp;amp;D annually for impairment during the fourth quarter. In testing indefinite-lived
IPR&amp;amp;D for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of
events or circumstances would indicate that it is more likely than not that its fair value is less than its carrying amount, or the
Company can perform a quantitative impairment analysis to determine the fair value of the indefinite-lived IPR&amp;amp;D without
performing a qualitative assessment. Qualitative factors that the Company considers include significant negative industry or
economic trends and significant changes or planned changes in the use of the assets. If the Company chooses to first assess
qualitative factors and the Company determines that it is more likely than not that the fair value of the indefinite-lived IPR&amp;amp;D
is less than its carrying amount, the Company would then determine the fair value of the indefinite-lived IPR&amp;amp;D. Under either
approach, if the fair value of the indefinite-lived IPR&amp;amp;D is less than its carrying amount, an impairment charge is recognized
in the consolidated statements of operations and comprehensive loss. During the year ended December 31, 2024, the Company did &lt;span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_dxL_c20240101__20241231_zBVtE4RSkLYc" title="Indefinite-lived IPR&amp;amp;D::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0886"&gt;no&lt;/span&gt;&lt;/span&gt;t
recognize an impairment charge related to its indefinite-lived IPR&amp;amp;D. During the year ended December 31, 2023, the Company
recognized an impairment charge related to its indefinite-lived IPR&amp;amp;D of $&lt;span id="xdx_909_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn3n3_c20230101__20231231_zRCobO66Fxgg" title="Indefinite-lived IPR&amp;amp;D"&gt;107,800&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000888"
      unitRef="USD">107800000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000890">&lt;p id="xdx_840_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zVgnjKMbbyub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Goodwill represents
the excess of the fair value of the consideration transferred over the fair value of the net tangible and identifiable intangible assets
acquired in a business combination. Goodwill is not subject to amortization but is tested annually for impairment or more frequently if
there are indicators of impairment. The Company typically tests its goodwill annually for impairment in the fourth quarter of each year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company manages
its operations through an evaluation of &lt;span id="xdx_906_eus-gaap--NumberOfOperatingSegments_dc_uSegment_c20240101__20241231_z6ccAPGLi27e" title="Operating segments"&gt;three&lt;/span&gt; different operating segments: Cell Therapy, Degenerative Disease and BioBanking (see Note
19). The Company determined that the operating segments represented the reporting units.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In testing goodwill
for impairment, the Company has the option to first assess qualitative factors to determine whether the existence of events or circumstances
would indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount, or the Company
can perform a quantitative impairment analysis without performing the qualitative assessment. Examples of such events or circumstances
considered in the Company&#x2019;s qualitative assessment include, but are not limited to, a significant adverse change in legal or business
climate, an adverse regulatory action or unanticipated competition. If the Company chooses to first assess qualitative factors and the
Company determines that it is more likely than not that the fair value of its reporting unit is less than its carrying amount, the Company
would then perform the quantitative impairment test. The quantitative test starts with comparing the fair value of the reporting unit
to the carrying amount of a reporting unit, including goodwill. If the fair value of the reporting unit exceeds the carrying amount, no
impairment loss is recognized. However, if the fair value of the reporting unit is less than its carrying value, the Company would recognize
an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value, not to exceed the total
amount of goodwill allocated to the reporting unit. During the year ended December 31, 2024, the Company did &lt;span id="xdx_903_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_do_c20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zrfBEylpfebh" title="Goodwill impairment"&gt;no&lt;/span&gt;t recognize any goodwill
impairment. During the year ended December 31, 2023, the Company recognized goodwill impairment of $&lt;span id="xdx_901_eus-gaap--GoodwillImpairmentLossNetOfTax_pn3n3_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zO7f9dSxunO7" title="Goodwill impairment"&gt;112,347&lt;/span&gt; relating to the Cell Therapy
reporting unit (see Note 8) in the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000892"
      unitRef="Segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:GoodwillImpairmentLossNetOfTax
      contextRef="From2024-01-012024-12-31_custom_CellTherapyMember"
      decimals="-3"
      id="Fact000894"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLossNetOfTax>
    <us-gaap:GoodwillImpairmentLossNetOfTax
      contextRef="From2023-01-012023-12-31_custom_CellTherapyMember"
      decimals="-3"
      id="Fact000896"
      unitRef="USD">112347000</us-gaap:GoodwillImpairmentLossNetOfTax>
    <CELU:WarrantsLiabilitiesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000898">&lt;p id="xdx_844_ecustom--WarrantsLiabilitiesPolicyTextBlock_zPm9aumjiLI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Warrant Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for
the public warrants, private placement warrants, registered direct warrants, May 2022 PIPE warrants, and November 2024 Purchaser
Warrants and Placement Agent Warrants (collectively, &#x201c;Liability Warrants&#x201d;) in accordance with the guidance contained in
Accounting Standards Codification (&#x201c;ASC&#x201d;) 815-40, &lt;i&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own
Equity&lt;/i&gt;, under which the Liability Warrants do not meet the criteria for equity treatment and must be recorded as liabilities.
Accordingly, the Company classifies the Liability Warrants as liabilities at their fair value and adjusts to fair value at each
reporting period. These liabilities are subject to re-measurement at each balance sheet date until exercised or expired, and any change in
fair value is recognized as a component of other income (expense) in the consolidated statements of operations and comprehensive loss. The Liability
Warrants, excluding the public warrants, were initially and subsequently valued using either a Black-Scholes or a Monte Carlo option
pricing model, which are considered to be Level 3 fair value measurements. The public warrants are valued based on the quoted market
price as of each relevant reporting date, which is considered to be a Level 1 fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

</CELU:WarrantsLiabilitiesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000900">&lt;p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_zB6GsSXh3MT1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In accordance with
Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-02, &lt;i&gt;Leases (Topic 842)&lt;/i&gt; (ASU 2016-02 or ASC 842), the Company classifies leases
at the lease commencement date. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease
based on the circumstances present. Leases with a term greater than one year will be recognized on the consolidated balance sheets as
right-of-use (&#x201c;ROU&#x201d;) assets, lease liabilities, and if applicable, long-term lease liabilities. The Company includes renewal
options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and
the corresponding ROU assets are recorded based on the present values of lease payments over the terms. The interest rate implicit in
lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which
are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a
similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liabilities and are
recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants.
Certain adjustments to ROU assets may be required for items such as initial direct costs paid, incentives received, or lease prepayments.
If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company
would reassess lease classification, remeasure the lease liabilities using revised inputs as of the reassessment date, and adjust the
ROU assets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company has elected
the &#x201c;package of 3&#x201d; practical expedients permitted under the transition guidance, which eliminates the requirements to reassess
prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted an accounting policy
which provides that leases with an initial term of 12 months or less and no purchase option that the Company is reasonably certain of
exercising will not be included within the ROU assets and lease liabilities on its consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Refer to Note 11 for further information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <CELU:ShortTermDebtPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000902">&lt;p id="xdx_84A_ecustom--ShortTermDebtPolicyTextBlock_zJawFRlv44Sa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Short-Term Debt - Yorkville and
Unsecured Senior Convertible Notes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company elected
the fair value option to account for its pre-paid advance agreement with YA II PN, Ltd (&#x201c;Yorkville&#x201d;) (see Note 10). As of
December 31, 2023, due to the short-term nature of the debt, the fair value approximated the settlement amount which was fully paid on
January 17, 2024. The Company also elected the fair value option to account for the Yorkville convertible promissory note signed on March
13, 2024 (see Note 10) and the unsecured senior convertible notes issued pursuant to the securities purchase agreement signed on November
25, 2024 (see Note 10). As of December 31, 2024, the estimate of the fair value of the Yorkville convertible promissory note and the unsecured
senior convertible notes was determined using a binomial lattice model and a credit default model. The fair value measurement of the debt
is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair value of debt that is accounted for
at fair value, inclusive of related accrued interest expense, are presented as gains or losses in the accompanying consolidated statements
of operations and comprehensive loss under change in fair value of debt. The portion of total changes in fair value of debt attributable
to changes in instrument-specific credit risk are determined through specific measurement of periodic changes in the discount rate assumption
exclusive of base market changes and are presented as a component of comprehensive income (loss) in the accompanying consolidated statements
of operations and comprehensive loss. The actual settlement of the short-term debt could differ from current estimates based on the timing
of when and if the investors elect to convert amounts into common shares, potential cash repayment by the Company prior to maturity, and
movements in the Company&#x2019;s common share price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</CELU:ShortTermDebtPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000904">&lt;p id="xdx_846_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zMzJP3CBwZOg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company generates
revenue from its degenerative disease commercial operations (i.e., the sale of Biovance&lt;sup&gt;&#xae;&lt;/sup&gt;, Biovance 3L&lt;sup&gt;&#xae;&lt;/sup&gt;,
CentaFlex&lt;sup&gt;&#xae;&lt;/sup&gt;, Interfyl&lt;sup&gt;&#xae;&lt;/sup&gt; and Rebound&lt;sup&gt;TM&lt;/sup&gt;), biobanking services (i.e., the collection, processing and
storage of umbilical cord and placental blood and tissue after full-term pregnancies), and license, royalty and other revenues.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Product sales&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;&#160;&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Biovance, Biovance 3L, CentaFlex
and Rebound are decellularized, dehydrated human amniotic membrane products intended for use as a biological membrane covering that provides
the extracellular matrix while supporting the repair of damaged tissue. Interfyl is an allogeneic decellularized particulate human placental
connective tissue matrix consisting of natural human structural and biochemical extracellular matrix components and is intended for use
in both surgical requirements and wound care as the replacement or supplementation of damaged or inadequate integumental tissue. &lt;span style="background-color: white"&gt;Rebound&#x2122;
is a full thickness extracellular matrix that contains amnion and chorion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company recognizes
revenue when control of the products and services is transferred to its customers in an amount that reflects the consideration it expects
to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer,
determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct
performance obligations in the contract, and recognizing revenue when, or as, the performance obligations have been satisfied. Sales and
other taxes collected on behalf of third parties are excluded from revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;A performance obligation
is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with
other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance
obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use
and obtain the benefit of the good or service. Transaction prices of products or services are typically based on contracted rates with
customers and to the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration
that should be included in the transaction price utilizing the expected value method or the most likely amount, depending on the circumstances,
to which the Company expects to be entitled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company offers
volume-based discounts, rebates and prompt pay discounts and other various incentives which are accounted for under the variable consideration
model. If sales incentives may be earned by a customer for purchasing a specified amount of product, the Company estimates whether such
incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue transaction
is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method, the Company
considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to estimate what
levels of incentives will be earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company provides
for rights of return to customers on its degenerative disease products. To date, the Company has had minimal product returns and therefore
does not record a provision for returns.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Services&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company separately recognizes
revenues for services to expectant parents who contract with the Company to collect, process and store umbilical cord blood and placenta
derived cells and tissue for private use. The Company recognizes revenue from collection and processing fees at the point in time of the
successful completion of processing and recognizes storage fees over time, which is ratably over the contractual storage period. Contracted
storage periods are generally &lt;span id="xdx_90E_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z58qSIxTyhdb" title="Contracted storage periods"&gt;18&lt;/span&gt; years and &lt;span id="xdx_900_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zfUgtyGy5kj7" title="Contracted storage periods"&gt;25&lt;/span&gt; years. Deferred revenue on the accompanying consolidated balance sheets includes the portion
of the 18- and the 25-year storage fees that are being recognized over the contractual storage period. The Company classifies deferred
revenue as current if the Company expects to recognize the related revenue over the next 12 months from the balance sheet date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;When determining the transaction
price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance,
resulting in a significant financing component. For all plans (annual, lifetime, &lt;span id="xdx_90D_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_zieb2Fryhruh"&gt;18&lt;/span&gt;
years and &lt;span id="xdx_90A_ecustom--ContractedStoragePeriods_dtY_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_z6PRk83KBTyh"&gt;25&lt;/span&gt;
years), the storage fee is paid at the beginning of the storage period (prepaid plans). Alternatively, the Company offers payment plans
for customers to pay over time for a period of one
&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MinimumMember_z6uayugqonI7" title="Over time for a period"&gt;1&lt;/span&gt;&lt;/span&gt; to &lt;span id="xdx_908_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zEGtPcJ7xRMe" title="Over time for a period"&gt;24&lt;/span&gt;
months (over time plans). The Company concluded that a significant financing component is not present within either the prepaid or overtime
payment plans. The Company has determined that the prepaid plans do not include a significant financing component as the payment terms
were structured primarily for reasons other than the provision of financing and to maximize profitability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;When considered over
a &lt;span id="xdx_908_ecustom--PaymentPlansForCustomerToPayOverTimePeriod_dtM_c20240101__20241231__srt--RangeAxis__srt--MaximumMember_zyN5PDwPyEo7" title="Over time for a period"&gt;24&lt;/span&gt;-month period for over time plans, the difference between the cash selling price and the consideration paid is nominal. As such, the
Company believes that its payment plans do not include significant financing components as they are not significant in the aggregate when
considered in the context of all contracts entered into nor are they significant at the individual contract level.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company offers
promotional discounts and other various incentives which are accounted for under the variable consideration model. The Company estimates
whether such incentives will be achieved and recognizes these incentives as a reduction in revenue in the same period the underlying revenue
transaction is recognized. The Company primarily uses the expected value method to estimate incentives. Under the expected value method,
the Company considers the historical experience of similar programs as well as reviews sales trends on a customer-by-customer basis to
estimate what levels of incentives will be earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;As
the Company&#x2019;s processing and storage agreements contain multiple performance obligations, ASC 606, &lt;i&gt;Revenue from Contracts with
Customers,&lt;/i&gt; requires an allocation of the transaction price based on the estimated relative standalone selling prices of the promised
services underlying each performance obligation. The Company has selected an adjusted market assessment approach to estimate the standalone
selling prices of the processing services and storage services and concluded that the published list price is the price that a customer
in that market would be willing to pay for those goods or services. The Company also considered the fact that all customers are charged
the list prices current at the time of their enrollment where the Company has separately stated list prices for processing and storage&lt;/span&gt;&lt;span style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt"&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;License, royalty and other&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Under license agreements,
the Company assesses whether the related performance obligation is satisfied at a point in time or over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;At the inception of
each arrangement that includes milestone payments based on certain events, the Company evaluates whether the milestones are considered
probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it
is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.
Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable
of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial,
and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved
in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period,
the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate
of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings
in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy
a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the
milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur. See
Note 16 for further discussion of the Company&#x2019;s license agreements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;While the Company&#x2019;s
direct sales of degenerative disease products are included in product sales, sales through the Company&#x2019;s network of distribution partners
are included in license, royalty and other revenues. For certain distribution agreements as described in Note 16, the Company will utilize
the practical expedient in ASC 606-10-55-83, whereby an entity may recognize revenue in the amount to which the entity has a right to
invoice so long as the consideration from a customer corresponds directly with the value received. Thus, the Company will recognize revenue
upon invoicing for these agreements (subsequent to receipt of the related purchase order).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <CELU:ContractedStoragePeriods
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      id="Fact000906">P18Y</CELU:ContractedStoragePeriods>
    <CELU:ContractedStoragePeriods
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      id="Fact000908">P25Y</CELU:ContractedStoragePeriods>
    <CELU:ContractedStoragePeriods
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      id="Fact000909">P18Y</CELU:ContractedStoragePeriods>
    <CELU:ContractedStoragePeriods
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      id="Fact000910">P25Y</CELU:ContractedStoragePeriods>
    <CELU:PaymentPlansForCustomerToPayOverTimePeriod
      contextRef="From2024-01-012024-12-31_srt_MinimumMember"
      id="Fact000912">P1M</CELU:PaymentPlansForCustomerToPayOverTimePeriod>
    <CELU:PaymentPlansForCustomerToPayOverTimePeriod
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      id="Fact000914">P24M</CELU:PaymentPlansForCustomerToPayOverTimePeriod>
    <CELU:PaymentPlansForCustomerToPayOverTimePeriod
      contextRef="From2024-01-012024-12-31_srt_MaximumMember"
      id="Fact000916">P24M</CELU:PaymentPlansForCustomerToPayOverTimePeriod>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000918">&lt;p id="xdx_845_eus-gaap--CostOfSalesPolicyTextBlock_z35GVfzsFpM8" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Cost of Revenues&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;Cost
of revenues consists of labor, material and overhead costs associated with the Company&#x2019;s two existing commercial business segments,
biobanking and degenerative disease. Biobanking costs, which include the cost of storage and transportation kits for newly banked materials
as well as tank and facility overhead costs for cord blood and other units in storage, are included in services in cost of revenues. Degenerative
disease costs, which include costs associated with procuring placentas, qualifying the placental material and processing the placental
tissue into a marketable product, are included in product sales or license, royalty and other in cost of revenues depending on the class
of customer. Costs in the degenerative disease segment include labor and overhead costs associated with the production of the Biovance,
Biovance 3L, Interfyl and Rebound product lines.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="background-color: white"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span style="background-color: white"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-01-01to2024-12-31" id="Fact000920">&lt;p id="xdx_849_eus-gaap--ResearchAndDevelopmentExpensePolicy_ztoNo8vfpm03" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company has entered
into various research and development and other agreements with commercial firms, researchers, universities and others for provisions
of goods and services. These agreements are generally cancellable, and the related costs are recorded as research and development expense
as incurred. Research and development expenses include costs for salaries, employee benefits, subcontractors, facility-related expenses,
depreciation and amortization, stock-based compensation, third-party license fees, laboratory supplies, and external costs of outside
vendors engaged to conduct discovery, preclinical and clinical development activities and clinical trials as well as to manufacture clinical
trial materials, and other costs. The Company records accruals for estimated ongoing research and development costs. Nonrefundable advance
payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses.
Such prepaid expenses are recognized as an expense when the goods have been delivered or the related services have been performed, or
when it is no longer expected that the goods will be delivered, or the services rendered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Upfront payments, milestone
payments and annual maintenance fees under license agreements are expensed in the period in which they are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000922">&lt;p id="xdx_849_eus-gaap--AdvertisingCostsPolicyTextBlock_zehqyqrWofT4" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Advertising and Marketing Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Advertising and marketing
costs are expensed as incurred. Advertising and marketing costs are included in selling, general and administrative expenses and were
$&lt;span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20240101__20241231_zPHclHX0L6aa" title="Advertising and marketing costs"&gt;23&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--MarketingAndAdvertisingExpense_pn3n3_c20230101__20231231_zFZsOBngTiul" title="Advertising and marketing costs"&gt;44&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000924"
      unitRef="USD">23000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000926"
      unitRef="USD">44000</us-gaap:MarketingAndAdvertisingExpense>
    <CELU:GovernmentGrantsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000928">&lt;p id="xdx_84F_ecustom--GovernmentGrantsPolicyTextBlock_zAOMqF8O9Nv1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Government Grants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;From time to time,
the Company may be awarded a government research grant. Under these arrangements, the Company recognizes awarded grants as a reduction
to research and development expense at the point in time where achievement of related milestones is confirmed by the governmental agency.
The Company did &lt;span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20240101__20241231_zPvnZyyuNW4" title="Grant monies"&gt;&lt;span id="xdx_905_ecustom--ReductionOfResearchAndDevelopmentExpenseResultingFromGrant_do_c20230101__20231231_z3b1OtFQdtV" title="Grant monies"&gt;no&lt;/span&gt;&lt;/span&gt;t receive grant monies during the years ended December 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

</CELU:GovernmentGrantsPolicyTextBlock>
    <CELU:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact000930"
      unitRef="USD">0</CELU:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant>
    <CELU:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact000932"
      unitRef="USD">0</CELU:ReductionOfResearchAndDevelopmentExpenseResultingFromGrant>
    <CELU:PatentCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000934">&lt;p id="xdx_84D_ecustom--PatentCostsPolicyTextBlock_zOVE1KisiZFb" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;All patent-related
costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the
recovery of the expenditure. Amounts incurred are classified in selling, general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</CELU:PatentCostsPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000936">&lt;p id="xdx_84F_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zO3jvgy1FGPj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company measures
all stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation
expense for those awards, over the requisite service period, which is generally the vesting period of the respective award. The Company
typically issues stock-based awards with only service-based vesting conditions and records the expense for these awards using a straight-line
method.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s
board of directors may also approve and award performance-based stock options. The performance-based stock options are earned based on
the attainment of specified goals achieved over the performance period. The Company recognizes expense for performance-based awards over
the related vesting period once it deems the achievement of the performance condition is probable. The Company reassesses the probability
of vesting at each reporting period for performance-based awards and adjusts expense accordingly on a cumulative basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of each
service-performance- and market-based stock option grant is estimated on the date of grant using an appropriate option pricing
model using inputs available as of the grant date. For awards with service-based vesting conditions only, the Company determines the
fair value of the award as of the grant date using the Black-Scholes option-pricing model. Prior to the merger, Legacy Celularity
was a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, the
Company estimates its expected stock price volatility using its volatility since the merger and the historical volatility of
publicly traded peer companies. The expected term of the Company&#x2019;s stock options granted to employees is determined utilizing
the &#x201c;simplified&#x201d; method for awards that qualify as &#x201c;plain-vanilla&#x201d; options. The expected term of stock
options granted to non-employee consultants is equal to the contractual term of the option award or the Company&#x2019;s estimated
term based on the underlying agreement. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in
effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected
dividend yield is zero based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay
any cash dividends in the foreseeable future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company classifies
stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award
recipient&#x2019;s payroll costs are classified or in which the award recipient&#x2019;s service payments are classified. The Company elects
to account for forfeitures as they occur and compensation cost previously recognized for an award that is forfeited because of a failure
to satisfy a service or performance condition is generally reversed in the period of the forfeiture.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000938">&lt;p id="xdx_84B_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zcClrkt8H3S1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Comprehensive income (loss)
refers to revenues, expenses, gains and losses that under GAAP are included in comprehensive income (loss) but are excluded from net income
(loss) as these amounts are recorded directly as an adjustment to accumulated other comprehensive income (loss). The Company&#x2019;s only
component of other comprehensive income (loss) is comprised of the portion of the total change in fair value of debt accounted for under
the fair value option that is attributable to changes in instrument-specific credit risk. During the year ended December 31, 2024, the
Company recorded instrument-specific credit risk loss of $&lt;span id="xdx_907_ecustom--InstrumentSpecificCreditRiskLoss_pn3n3_c20240101__20241231_zXuxthYZisj4" title="Instrument-specific credit risk loss"&gt;5&lt;/span&gt;. During the year ended December 31, 2023, the Company recorded instrument-specific
credit risk income of $&lt;span id="xdx_905_ecustom--InstrumentSpecificCreditRiskIncome_pn3n3_c20230101__20231231_zTIEM30L2NXa" title="Instrument-specific credit risk income"&gt;146&lt;/span&gt; and reclassified $&lt;span id="xdx_904_ecustom--AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion_pn3n3_c20230101__20231231_zaEvSgctPaZ1" title="Accumulated other comprehensive income"&gt;155&lt;/span&gt; from accumulated other comprehensive loss to other expense, net on the consolidated statements
of operations and comprehensive loss upon short-term debt conversion. These amounts have been recorded as a separate component of stockholders&#x2019;
equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <CELU:InstrumentSpecificCreditRiskLoss
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact000940"
      unitRef="USD">5000</CELU:InstrumentSpecificCreditRiskLoss>
    <CELU:InstrumentSpecificCreditRiskIncome
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000942"
      unitRef="USD">146000</CELU:InstrumentSpecificCreditRiskIncome>
    <CELU:AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact000944"
      unitRef="USD">155000</CELU:AccumulatedOtherComprehensiveIncomeToOtherExpenseUponShortTermDebtConversion>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000946">&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zcM4XvGXdhs1" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company accounts for
income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been recognized in the consolidated financial statements or in the Company&#x2019;s tax returns.
Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and
liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets
and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will
be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely
than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge
to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and
considering prudent and feasible tax planning strategies.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company accounts
for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount
of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained based
on the technical merits of the position. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then
assessed to determine the amount of benefit to recognize in the consolidated financial statements. &lt;span id="xdx_906_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20240101__20241231_zbOsqvgmw2Xf" title="Income tax examination likelihood settlement"&gt;The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority&lt;/span&gt;.
The provision for income taxes includes the effects of unrecognized tax benefits, as well as the related interest and penalties (see Note
18).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement contextRef="From2024-01-01to2024-12-31" id="Fact000948">The amount of the benefit that may
be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority</us-gaap:IncomeTaxExaminationLikelihoodOfUnfavorableSettlement>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000950">&lt;p id="xdx_84D_eus-gaap--EarningsPerSharePolicyTextBlock_zDCGXGQdLZZ3" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Basic net loss per share
of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period.
Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such
as redeemable convertible preferred stock, convertible debt, stock options, restricted stock units and warrants, which would result in
the issuance of incremental shares of common stock. However, potential common shares are excluded if their effect is anti-dilutive. For
diluted net loss per share when the Company has a net loss, the weighted-average number of shares of common stock is the same as for basic
net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact
is anti-dilutive. All warrants are participating securities, as they participate on a one-for-one basis with Class A common stock in the
distribution of dividends, if and when declared by the Board of Directors. For the purposes of computing earnings per share, the warrants
are considered to participate with Class A common stock in earnings of the Company. Therefore, the Company computes earnings per share
using the two-class method, an earnings allocation method that determines net income (loss) per share (when there are earnings) for common
stock and participating securities. No income was allocated to the warrants for the years ended December 31, 2024 and 2023, as results
of operations were a loss for both periods.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgF07KC77J2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following potentially
dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common stock outstanding, prior
to the use of the two-class method, as they would be anti-dilutive:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span id="xdx_8B6_zFS2Zb9yp5z4" style="display: none"&gt;Schedule of Potentially
Dilutive Securities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_zTLtiqSQNdm2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zcfC9dr3F2Ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zO4pWMMkDXGa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;4,006,525&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;2,820,187&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG54qjzKR72f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;688,106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;823,332&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpDgmRzbMwm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,221,557&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,070,627&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zngdWYOZ7SBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Convertible debt&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,126,496&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;549,681&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zc76zzjiS1Tb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,042,684&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,263,827&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zSxqGmWvKgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000952">&lt;p id="xdx_89A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgF07KC77J2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following potentially
dilutive securities have been excluded from the computation of diluted weighted-average shares of Class A common stock outstanding, prior
to the use of the two-class method, as they would be anti-dilutive:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span id="xdx_8B6_zFS2Zb9yp5z4" style="display: none"&gt;Schedule of Potentially
Dilutive Securities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_zTLtiqSQNdm2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230101__20231231_zcfC9dr3F2Ie" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zO4pWMMkDXGa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;4,006,525&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;2,820,187&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zG54qjzKR72f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Restricted stock units&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;688,106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;823,332&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpDgmRzbMwm7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,221,557&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,070,627&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zngdWYOZ7SBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Convertible debt&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,126,496&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;549,681&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zc76zzjiS1Tb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Anti-dilutive
    securities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,042,684&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,263,827&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000954"
      unitRef="Shares">4006525</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact000955"
      unitRef="Shares">2820187</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000957"
      unitRef="Shares">688106</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000958"
      unitRef="Shares">823332</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000960"
      unitRef="Shares">11221557</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000961"
      unitRef="Shares">7070627</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact000963"
      unitRef="Shares">1126496</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtSecuritiesMember"
      decimals="INF"
      id="Fact000964"
      unitRef="Shares">549681</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000966"
      unitRef="Shares">17042684</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact000967"
      unitRef="Shares">11263827</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000969">&lt;p id="xdx_84D_eus-gaap--SegmentReportingPolicyPolicyTextBlock_ze7191TVFkX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Operating segments
are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources in assessing performance. The Company manages
its operations through an evaluation of &lt;span id="xdx_906_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_ztB8DCNcXN04" title="Number of operating segments"&gt;three&lt;/span&gt; distinct businesses segments: Cell Therapy, Degenerative Disease and BioBanking. These segments
are presented for the years ended December 31, 2024 and 2023 in Note 19.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact000971"
      unitRef="Segment">3</us-gaap:NumberOfOperatingSegments>
    <CELU:AllowanceForCreditLossesPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000973">&lt;p id="xdx_841_ecustom--AllowanceForCreditLossesPolicyTextBlock_zhEEiQk5NWE2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Allowance for Credit Losses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;With the adoption of ASU
2016-13 &lt;i&gt;Financial Instruments &#x2014; Credit Losses, &lt;/i&gt;as noted below, the Company recognizes credit losses based on forward-looking
current expected credit losses. The Company makes estimates of expected credit losses based upon its assessment of various factors, including
historical collection experience, the age of accounts receivable balances, credit quality of its customers, current economic conditions,
reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from customers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</CELU:AllowanceForCreditLossesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-01-01to2024-12-31" id="Fact000975">&lt;p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_z2szKM6kK2K1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk and
Significant Customers&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Financial instruments that
potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, restricted cash, and
accounts receivable. The Company generally maintains cash balances in various operating accounts at financial institutions that management
believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses
related to its cash and cash equivalents or restricted cash and does not believe that it is subject to unusual credit risk beyond the
normal credit risk associated with commercial banking relationships.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company is subject to
credit risk from trade accounts receivable related to both degenerative disease product sales and biobanking services. All trade accounts
receivables are a result from product sales and services performed in the United States. As of December 31, 2024, three of the Company&#x2019;s
customers, each of which individually comprised at least 10%, represented an aggregate &lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ThreeCustomersMember_z4PaOevwtynb" title="Concentration risk, percentage"&gt;46&lt;/span&gt;% of the Company&#x2019;s outstanding gross accounts
receivable. As of December 31, 2023, two of the Company&#x2019;s customers, each of which individually comprised at least 10%, represented an
aggregate &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zx2bmIlaY6N" title="Concentration risk, percentage"&gt;41&lt;/span&gt;% of the Company&#x2019;s outstanding gross accounts receivable. During the year ended December 31, 2024, the Company had one
customer provide for &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFlNmPzgrYt7" title="Concentration risk, percentage"&gt;17&lt;/span&gt;% of revenue and another customer provided for &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20241231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zanEqKEWCkk7" title="Concentration risk, percentage"&gt;16&lt;/span&gt;% of revenue. During the year ended December 31, 2023, the Company
had one customer provide for &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmQz2erMMjnc" title="Concentration risk, percentage"&gt;14&lt;/span&gt;% of revenue and another customer provided for &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zc4bGqHB5XBa" title="Concentration risk, percentage"&gt;13&lt;/span&gt;% of revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_ThreeCustomersMember"
      decimals="INF"
      id="Fact000977"
      unitRef="Pure">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember_custom_TwoCustomersMember"
      decimals="INF"
      id="Fact000979"
      unitRef="Pure">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000981"
      unitRef="Pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-12-31_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000983"
      unitRef="Pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerOneMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000985"
      unitRef="Pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerTwoMember_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000987"
      unitRef="Pure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2024-01-01to2024-12-31" id="Fact000989">&lt;p id="xdx_84F_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zAzQwpXzibg3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Certain prior period amounts
have been reclassified to conform with current year presentation. On the consolidated balance sheets, short-term debt - Yorkville and
other short-term debt were reclassified to short-term debt - unaffiliated, and short-term debt - related party and short-term debt - related
parties - C.V. Starr and RWI were reclassified to short-term debt - related parties. See Note 10 for further information.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <CELU:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000991">&lt;p id="xdx_845_ecustom--RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_zL3RHbbgw3o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In June 2016, the Financial
Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2016-13, &lt;i&gt;Financial Instruments &#x2014; Credit Losses&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;),
which changes the accounting for recognizing impairments of financial assets. Under the new guidance, credit losses for certain types
of financial instruments will be estimated based on expected losses. ASU 2016-13 also modifies the impairment models for available-for-sale
debt securities and for purchased financial assets with credit deterioration since their origination. ASU 2016-13 is effective for annual
periods beginning after December 15, 2022 (fiscal year 2023 for the Company), and interim periods within those periods, with early adoption
permitted. The Company adopted ASU 2016-13 effective January 1, 2023. The standard did not have a material impact on the consolidated
financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In November 2023, the FASB
issued ASU 2023-07, &lt;i&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt;, which requires disclosure of
incremental segment information on an annual and interim basis. This ASU was effective for fiscal years beginning after December 15, 2023,
and interim periods within fiscal years beginning after December 15, 2024. The Company adopted the guidance in ASU 2023-07 for the year
ended December 31, 2024, and it is being applied retrospectively to its consolidated financial statement disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

</CELU:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000993">&lt;p id="xdx_849_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z20Svbe71ez6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In December 2023, the FASB
issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt;, which expands the disclosures required for
income taxes. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The amendment should
be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the effect of this
pronouncement on its financial statement disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In November 2024, the FASB
issued ASU 2024-03, &lt;i&gt;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;, as subsequently amended by ASU 2025-01 to clarify the effective date,
which is intended to provide more detailed information about specified categories of expenses (purchases of inventory, employee
compensation, depreciation and amortization) included in certain expense captions presented on the consolidated statement of
operations and comprehensive loss. The guidance in this ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within
fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively
to financial statements issued for periods after the effective date of this ASU or (2) retrospectively to all prior periods
presented in the consolidated financial statements. The Company is currently evaluating the effect of this pronouncement on its
consolidated financial statements and footnote disclosures.&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AssetAcquisitionTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact000995">&lt;p id="xdx_800_eus-gaap--AssetAcquisitionTextBlock_zhxAhBhUhWNe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"&gt;&lt;b&gt;3. &lt;span id="xdx_822_zZ01t3MtGYU"&gt;Asset
Acquisition&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;On
October 9, 2024, the Company entered into an asset purchase agreement with Sequence LifeScience, Inc. (&#x201c;Sequence&#x201d;) to acquire
Sequence&#x2019;s Rebound&#x2122; full thickness placental-derived allograft matrix product and certain related intangible assets. Rebound
adds to the Company&#x2019;s portfolio of placental-derived advanced biomaterial products. The Company will pay aggregate consideration for
the assets of up to $&lt;span id="xdx_90C_eus-gaap--AssetAcquisitionPriceOfAcquisitionExpected_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zJgwKjDGGuJg" title="Consideration for assets"&gt;5,500&lt;/span&gt;, which consists of (i) an upfront cash payment of $&lt;span id="xdx_90B_ecustom--UpfrontPayment_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zFhxnxo7W5n5" title="Upfront payment"&gt;1,000&lt;/span&gt; (ii) an aggregate of up to $&lt;span id="xdx_906_ecustom--MonthlyMilestonePayments_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zpFxjdmJsUbe" title="Monthly milestone payments"&gt;4,000&lt;/span&gt; in monthly milestone
payments, and (iii) a credit of $&lt;span id="xdx_90B_ecustom--PriorPaymentToRelatedParty_pn3n3_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zfl9ECv87zc8" title="Prior payment to related party"&gt;500&lt;/span&gt; for the previous payment made by the Company to Sequence pursuant to a letter of intent between the
Company and Sequence dated August 16, 2024. Pursuant to the terms of the asset purchase agreement, the milestones are calculated based
on &lt;span id="xdx_90E_ecustom--NetSalesPercentage_pid_dp_uPure_c20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zD4yQaSflqdk" title="Net sales percentage"&gt;20&lt;/span&gt;% of net sales collected by the Company from its customers during the preceding calendar month, commencing the first full month after
the closing of the transaction. Transaction costs incurred with in connection with the Rebound asset acquisition were de minimis. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;Concurrently
with the execution of the asset purchase agreement, the Company entered into an exclusive supply agreement with Sequence for the manufacture
and supply of Rebound for a minimum period of six months. The Company retains the right to manufacture Rebound internally and intends
to commence a technology transfer as soon as practicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;The
Company determined that this transaction represented an asset acquisition in accordance with ASC 805, &lt;i&gt;Business Combinations&lt;/i&gt;, because
the acquired assets did not meet the definition of a business. As noted above, the purchase price consists of $&lt;span id="xdx_906_ecustom--PurchasePriceContingentConsideration_iI_pn3n3_c20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifescienceIncMember_zCLr3nEPywra" title="Purchase price contingent consideration"&gt;4,000&lt;/span&gt; of contingent consideration
that is based on future collections of net sales of Rebound. The Company&#x2019;s policy is to record contingent consideration when the contingency
is resolved and, therefore, it is generally excluded from the cost of the acquisition. Further, the contingent consideration comprising
monthly milestone payments does not meet the definition of a derivative and, therefore, is not required to be recorded at fair value.
The fair value of the net assets acquired exceeded the initial cash payments for the purchase, resulting in the write-down of the intangible
assets acquired and the recognition of a contingent consideration liability for the excess of the fair value of the inventory acquired
over the initial cash consideration. Future monthly milestone payments will reduce the contingent consideration liability until it has
been satisfied in full, and then will be recognized as a period cost when incurred. The Company incurred $&lt;span id="xdx_906_ecustom--MilestonePayments_pn3n3_c20240101__20241231__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zRiN36SPa5T" title="Milestone payments"&gt;135&lt;/span&gt; of milestone payments based
on collections of net sales of Rebound for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--AssetAcquisitionContingentConsiderationTableTextBlock_zWprWttZeAY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;The
purchase price was allocated to the acquired assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span id="xdx_8B0_zhki8gkWMykj" style="display: none"&gt;Schedule of Purchase Price
Allocated to Acquired Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zhZC3kVIpmUd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pn3n3_zTu4rAjBYes1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 81%; text-align: left"&gt;Cash payment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_pn3n3_zL14qSuNb2r3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;650&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferred_iT_pn3n3_zpdDNHBxCcL8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,150&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Assets acquired:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iE_pn3n3_z30MMVIHKErb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt"&gt;Inventory&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,150&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iE_pn3n3_zbTaf1s3DQO8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets acquired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,150&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zuJTYBOM6t42" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:AssetAcquisitionPriceOfAcquisitionExpected
      contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember"
      decimals="-3"
      id="Fact000997"
      unitRef="USD">5500000</us-gaap:AssetAcquisitionPriceOfAcquisitionExpected>
    <CELU:UpfrontPayment
      contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember"
      decimals="-3"
      id="Fact000999"
      unitRef="USD">1000000</CELU:UpfrontPayment>
    <CELU:MonthlyMilestonePayments
      contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember"
      decimals="-3"
      id="Fact001001"
      unitRef="USD">4000000</CELU:MonthlyMilestonePayments>
    <CELU:PriorPaymentToRelatedParty
      contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember"
      decimals="-3"
      id="Fact001003"
      unitRef="USD">500000</CELU:PriorPaymentToRelatedParty>
    <CELU:NetSalesPercentage
      contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember"
      decimals="INF"
      id="Fact001005"
      unitRef="Pure">0.20</CELU:NetSalesPercentage>
    <CELU:PurchasePriceContingentConsideration
      contextRef="AsOf2024-10-09_custom_SequenceLifeScienceIncMember"
      decimals="-3"
      id="Fact001007"
      unitRef="USD">4000000</CELU:PurchasePriceContingentConsideration>
    <CELU:MilestonePayments
      contextRef="From2024-01-012024-12-31_custom_SequenceLifeScienceIncMember"
      decimals="-3"
      id="Fact001009"
      unitRef="USD">135000</CELU:MilestonePayments>
    <us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001011">&lt;p id="xdx_89C_eus-gaap--AssetAcquisitionContingentConsiderationTableTextBlock_zWprWttZeAY1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="background-color: white"&gt;The
purchase price was allocated to the acquired assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"&gt;&lt;span id="xdx_8B0_zhki8gkWMykj" style="display: none"&gt;Schedule of Purchase Price
Allocated to Acquired Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20241009__20241009__us-gaap--AssetAcquisitionAxis__custom--SequenceLifeScienceIncMember_zhZC3kVIpmUd" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Consideration:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PaymentsToAcquireOtherProductiveAssets_pn3n3_zTu4rAjBYes1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 81%; text-align: left"&gt;Cash payment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;1,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferredContingentConsideration_pn3n3_zL14qSuNb2r3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Contingent consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;650&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AssetAcquisitionConsiderationTransferred_iT_pn3n3_zpdDNHBxCcL8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,150&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Assets acquired:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iE_pn3n3_z30MMVIHKErb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt"&gt;Inventory&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,150&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iE_pn3n3_zbTaf1s3DQO8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Total assets acquired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,150&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:AssetAcquisitionContingentConsiderationTableTextBlock>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember"
      decimals="-3"
      id="Fact001013"
      unitRef="USD">1500000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember"
      decimals="-3"
      id="Fact001015"
      unitRef="USD">650000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="From2024-10-092024-10-09_custom_SequenceLifeScienceIncMember"
      decimals="-3"
      id="Fact001017"
      unitRef="USD">2150000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <CELU:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="AsOf2024-10-09_custom_SequenceLifeScienceIncMember"
      decimals="-3"
      id="Fact001019"
      unitRef="USD">2150000</CELU:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <CELU:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="AsOf2024-10-09_custom_SequenceLifeScienceIncMember"
      decimals="-3"
      id="Fact001021"
      unitRef="USD">2150000</CELU:AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001023">&lt;p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_z6SiLsoMDCHh" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;4. &lt;span id="xdx_827_ztEHcNuV4JL4"&gt;Fair Value of Financial Assets and Liabilities&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmb9PfWUKqwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following tables present information about
the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value
hierarchy used to determine such fair values:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;span id="xdx_8B0_zIQ9WZasChz3" style="display: none"&gt;Schedule of Financial Assets and Liabilities Measures at Fair Value&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzdSkuVcoJR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKzHQVU6Tj2h" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zApwOvikycBa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIXAcRbJ3x5d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value Measurements as of December 31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zdMFe61yvfVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zWYNCb0WUnu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left"&gt;Acquisition-related contingent consideration obligations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1032"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;1,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;1,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zd4svOi91Nf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Contingent stock consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1037"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1038"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zwUGyLIeWUPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Short-term debt - Yorkville&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1042"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1043"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,865&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,865&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ShorttermDebtUnsecuredSeniorConvertibleNotes_i01I_pn3n3_z0t3w7QzYWHl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Short-term debt - unsecured senior convertible notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;620&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;620&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zUynWyqYoAzl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - July 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1053"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,115&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,115&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_zWEc9xjtmMs6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - April 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1057"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1058"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zUq07lyItO7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - May 2022 PIPE Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;505&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;505&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--WarrantLiabilityPurchaserWarrants_i01I_pn3n3_z2PtyNiQlTp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - November 2024 Purchaser Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1067"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1068"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityPlacementAgentWarrants_i01I_pn3n3_zNBg7V0hk4Dh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - November 2024 Placement Agent Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1073"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_za5eSpLRTsAh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - Sponsor Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1077"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1078"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zKkeFd1iCppf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrant liability - Public Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;287&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1083"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1084"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;287&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zGTzThLR8fVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    fair value liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;287&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1088"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,902&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,189&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuoNHfmxmcGg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj5R1lOBqXD3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsIIUtxsRVa2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBOWcqsAuqA1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value Measurements as of December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zT3saKyHg636" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ReceivablesFairValueDisclosure_i01I_pn3n3_zIP15TdqERni" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt; width: 44%; text-align: left"&gt;Convertible note receivable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1098"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_i01TI_pn3n3_zsY9iNcyNuOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    fair value assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zDRifOTUMxqb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zqB1icF8FiQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Acquisition-related contingent consideration obligations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,606&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,606&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zS4112ALhre2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Contingent stock consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1117"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zvY5jqAgnAgk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Short-term debt - Yorkville&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,223&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,223&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zmNieavx7vW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - July 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1127"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1128"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,529&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,529&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_ziPEtsdI1uv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - April 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1132"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1133"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,487&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,487&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zhq8ZtQ6e1K1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - May 2022 PIPE Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1137"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1138"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;708&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;708&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_zkMudQLWnIg6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - Sponsor Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1142"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1143"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zcieF696gda1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt; text-align: left"&gt;Warrant liability - Public Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;575&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1148"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1149"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;575&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zDNkMAT9gqOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    fair value liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;575&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,640&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zf4pa8jSTNo9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;During the years ended December
31, 2024 and 2023, there were no transfers between Level 1, Level 2 and Level 3.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The carrying values of other current
liabilities approximate fair value in the accompanying consolidated financial statements due to the short-term nature of those instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of Convertible Note Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The convertible note receivable
was received in connection with the disposition of the UltraMIST/MIST business in 2020. At any time on or after January 1, 2021, at the
sole discretion of the Company, amounts outstanding under the convertible note receivable (including accrued interest) may be converted
into Sanuwave common stock at a defined rate. The convertible note receivable was to be paid on or before August 6, 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On December 18, 2023, the Company
entered into a forbearance agreement with Sanuwave (&#x201c;Sanuwave Forbearance Agreement&#x201d;). Per the Sanuwave Forbearance Agreement,
from the period from December 18, 2023 to the earliest of (i) February 28, 2024, (ii) the commencement of bankruptcy proceedings for Sanuwave
pursuant to the U.S. Bankruptcy Code, (iii) the occurrence of an event of default other than payment default, or (iv) the failure of Sanuwave
to comply with any term, condition or covenant set forth in the forbearance agreement, the Company agrees that it will not exercise any
remedy available to it under the convertible note receivable, excluding the right to increase the interest rate. As collateral for payments
owed to Palantir Technologies, Inc. (&#x201c;Palantir&#x201d;), the Company assigned to Palantir the Sanuwave convertible note receivable
in the event of default (see Note 12). On May 10, 2024, the Company entered into a letter agreement with Sanuwave to extend the forbearance
period from &lt;span id="xdx_902_ecustom--ForbearanceExtendMaturityPeriod_dd_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MinimumMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zXnAEax64Pjb" title="Forbearance extend period"&gt;February 28, 2024&lt;/span&gt; to &lt;span id="xdx_90C_ecustom--ForbearanceExtendMaturityPeriod_dd_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__srt--RangeAxis__srt--MaximumMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zDmq86VPpjEd" title="Forbearance extend period"&gt;June 3, 2024&lt;/span&gt;. The letter agreement increased the total note payments to $&lt;span id="xdx_90A_ecustom--IncreasedNotePayments_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zlhdWpGFG3v3" title="Increased total note payments"&gt;2,175&lt;/span&gt;. Upon executing the letter
agreement, Sanuwave made an initial note payment of $&lt;span id="xdx_90B_eus-gaap--RepaymentsOfNotesPayable_pn3n3_c20240510__20240510__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zrJiqYunjp3e" title="Initial note payment"&gt;100&lt;/span&gt; and on June 3, 2024, made a second note payment of $&lt;span id="xdx_90F_eus-gaap--RepaymentsOfNotesPayable_pn3n3_c20240603__20240603__us-gaap--TypeOfArrangementAxis__custom--SanuwaveForbearanceAgreementMember__us-gaap--CreditFacilityAxis__custom--LetterAgreementMember_zQAlStmKJ8z6" title="Note payment"&gt;2,075&lt;/span&gt;, fully discharging
all outstanding indebtedness under the note.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z8ZzFNHpUFr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table presents a
reconciliation of the convertible note receivable measured on a recurring basis using Level 3 inputs for the year ended December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;&lt;span id="xdx_8B9_zFErd4Rfj6ak" style="display: none"&gt;Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;transfers&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;in to (out of) &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Purchases,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;settlements&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;and other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;adjustments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"&gt;Convertible note receivable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ReceivablesFairValueDisclosure_iS_pn3n3_c20240101__20241231_zOLLVDccNtha" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance"&gt;2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3n3_c20240101__20241231_zaj2eaLR5NPk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231_z9GFUYXI1Ohb" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"&gt;(2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20240101__20241231_zVAfHEi1grW8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ReceivablesFairValueDisclosure_iE_pn3n3_c20240101__20241231_zqGG7pp5j9Qf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1177"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zFfljS9cMqYh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;At December 31, 2023, the fair
value of this note was based on a bond valuation which employs a credit default model. The Company utilized Level 3 inputs on a probability
weighted model based on outcomes of a default, repayment and conversion of the note. The measurement was based upon unobservable inputs
supported by little or no market activity based on the Company&#x2019;s own assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--ScheduleOfConvertibleNoteValuationModelTableTextBlock_z7EuHh2GNVD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the convertible
note valuation model were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zacK0CQDrUZ7" style="display: none"&gt;Schedule of Convertible
Note Valuation Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Face value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FaceValueOfNotesReceivable_iI_pn3n3_c20231231_zmau9GTs49T6" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Face value"&gt;4,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Coupon rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20231231__20231231__srt--RangeAxis__srt--MinimumMember_zCS9azBSfThe" title="Coupon rate"&gt;12.00&lt;/span&gt;% - &lt;span id="xdx_90E_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20231231__20231231__srt--RangeAxis__srt--MaximumMember_zkO4ImOn8EX3" title="Coupon rate"&gt;17.00&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Stock price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231_zwuj6HzjR2aa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock price"&gt;0.2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20231231__20231231__srt--RangeAxis__srt--MinimumMember_zDUEeNif64j5" title="Term (years)"&gt;0.51&lt;/span&gt;-&lt;span id="xdx_90B_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20231231__20231231__srt--RangeAxis__srt--MaximumMember_z4mH3Z1StVXc" title="Term (years)"&gt;2.45&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ValuationInputForConvertiblePromissoryNote_pid_dp_uPure_c20231231__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZA4dA31wVBa" title="Risk-free interest rate"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zdApwdr2DKp3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of Contingent Consideration&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair value measurement of
the contingent consideration obligations is determined using Level 3 inputs and is based on a probability-weighted income approach. The
measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#x2019;s own assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_hus-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_z6CBmcdOyEgk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table presents a
reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs for the years ended December
31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zHZbPLTYsDQe" style="display: none"&gt;Schedule
of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_302_134_zNw4XXVgHO08" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;January 1,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;transfers&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;in to (out of)&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Purchases,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;settlements&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;and other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;adjustments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"&gt;Acquisition-related contingent consideration obligations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zYJsuLNyjdMk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance"&gt;1,606&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zDRjxdHhzJ88" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zmmUuDNaRxni" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1201"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zVEsLod7WOd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"&gt;(193&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zt8vlGcR6nXk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"&gt;1,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_301_134_zNC3CdBWLkj4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;January 1,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;transfers&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;in to (out of)&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Purchases,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;settlements&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;and other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;adjustments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"&gt;Acquisition-related contingent consideration obligations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zgKVqS6FHds4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance"&gt;105,945&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zh3XTRHRkxY3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1209"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_z2ZvNt2EbTS3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zSMQPI9PFEGc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"&gt;(104,339&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zN0pxvdHgzl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"&gt;1,606&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zWSf8A9lYiW5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of the liability
to make potential future milestone and earn-out payments was estimated by the Company at each reporting date based, in part, on the results
of a third-party valuation using a discounted cash flow analysis based on various assumptions, including the probability of achieving
specified events, discount rates, and the period of time until earn-out payments are payable and the conditions triggering the milestone
payments are met. The actual settlement of contingent consideration could differ from current estimates based on the actual occurrence
of these specified events.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;At each reporting date, the Company
revalues the contingent consideration obligation to estimated fair value and records changes in fair value as income or expense in the
Company&#x2019;s consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent consideration
obligations may result from changes in discount periods and rates, changes in the timing and amount of revenue estimates and changes in
probability assumptions with respect to the likelihood of achieving the various contingent consideration obligations. The Company has
classified the contingent consideration as a long-term liability in the consolidated balance sheets as of December 31, 2024 and 2023.
See Note 12 for more information on contingent consideration.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of Contingent Stock Consideration&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The contingent stock consideration
liability at December 31, 2024 and 2023 is comprised of the fair value of potential future issuance of Class A common stock to CariCord
participating shareholders pursuant to a settlement agreement signed during the year ended December 31, 2021. The fair value measurement
of the contingent stock consideration obligation is determined using Level 3 inputs and is based on a probability-weighted expected return
methodology (&#x201c;PWERM&#x201d;). The measurement is largely based upon unobservable inputs supported by little or no market activity
based on the Company&#x2019;s own assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_hus-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrgIdd6CCJ6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table presents a
reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level 3 inputs for the years ended
December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B4_zyurDf37iSEl" style="display: none"&gt;Schedule
of Reconciliation of  Contingent  Consideration Obligation Measured on a Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30B_134_zW1PSCMU8oc9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;transfers&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;in to (out of) &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Purchases,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;settlements&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;and other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;adjustments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"&gt;Contingent stock consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zREGJY4dLpHc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zDZshqLpWFv5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1221"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_za5rNgaSgQaf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1223"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrSf4Fxc8xB1" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1225"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zM7E2M5RFyVj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_305_134_zeyYDCS4uIO6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;January 1, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;transfers&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;in to (out of) &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Purchases,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;settlements&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;and other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;adjustments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"&gt;Contingent stock consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zeV8B7OeS81" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance"&gt;186&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrmPNoNkTqsk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1231"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_z6uT9Pz8O09c" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zfkuwXI8oiMf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"&gt;(159&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zF6YQa9MfQzk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_z9KCGkZoOW81" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of the liability
to issue future shares of Class A common stock was estimated by the Company at each reporting date using a PWERM based on various inputs
and assumptions, including the Company&#x2019;s common share price, discount rates, and the probability of achieving specified future operational
targets. The actual settlement of contingent stock consideration could differ from current estimates based on the actual achievement of
these specified targets and movements in the Company&#x2019;s common share price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;At each reporting date, the Company
revalues the contingent stock consideration obligation to estimated fair value and records changes in fair value as income or expense
in the Company&#x2019;s consolidated statements of operations and comprehensive loss. Changes in the fair value of the contingent stock
consideration obligation may result from changes in discount rates, changes in the Company&#x2019;s common share price, and changes in
probability assumptions with respect to the likelihood of achieving specified operational targets. The change in the fair value of the
contingent stock consideration obligation during the year ended December 31, 2024 was de minimis. The Company has classified the contingent
stock consideration as a current liability in the consolidated balance sheets as of December 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of Short-Term Debt - Yorkville and
Unsecured Senior Convertible Notes &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company elected the fair value
option to account for the Yorkville PPA signed on September 15, 2022 (see Note 10). As of December 31, 2023, due to the short-term nature
of the debt, the fair value of the Yorkville PPA approximated the settlement amount, which was fully paid on January 17, 2024. The Company
also elected the fair value option to account for the Yorkville convertible promissory note signed on March 13, 2024 (see Note 10) and
the unsecured senior convertible notes issued pursuant to the securities purchase agreement signed on November 25, 2024 (see Note 10).
The fair value measurement of the debt is determined using Level 3 inputs and assumptions unobservable in the market. Changes in the fair
value of debt that is accounted for at fair value, inclusive of related accrued interest expense, are presented as gains or losses in
the accompanying consolidated statements of operations and comprehensive loss under change in fair value of debt. The portion of total
changes in fair value of debt attributable to changes in instrument-specific credit risk are determined through specific measurement of
periodic changes in the discount rate assumption exclusive of base market changes and are presented as a component of comprehensive loss
in the accompanying consolidated statements of operations and comprehensive loss. The actual settlement of the short-term debt could differ
from current estimates based on the timing of when and if the investors elect to convert amounts into common shares, potential cash repayment
by the Company prior to maturity, and movements in the Company&#x2019;s common share price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zf0Q2VjZAwu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table presents a
reconciliation of short-term debt obligations measured on a recurring basis using Level 3 inputs for the years ended December 31, 2023
and 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&lt;span id="xdx_8BE_zNNatWJYUOr5" style="display: none"&gt;Schedule of Reconciliation
of Short-term Debt Obligation Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zVKESrallsn9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"&gt;37,603&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Conversion of debt into common shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zhvrNP5gY3L3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion of debt into common shares"&gt;(4,599&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Principal repayments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zS1dpiGcM6gi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Principal repayments"&gt;(16,811&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Issuance of convertible promissory note&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4ULDL8Mjadd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of convertible promissory note"&gt;3,150&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Issuance of unsecured senior convertible notes, net of fair value adjustment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zeX9B9QAWsp8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of unsecured senior convertible notes, net of fair value adjustment"&gt;689&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Fair value adjustment through earnings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueAdjustmentThroughEarnings_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zFZNR5QOZBYa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through earnings"&gt;354&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Fair value adjustment through accumulated other comprehensive income&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zhNjeaH9OFa5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through accumulated other comprehensive income"&gt;(146&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair value adjustment through interest accrual&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zLErIKWgnKOd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through interest accrual"&gt;822&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zqe7Y2DTYfic" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;17,223&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Balance as of January 1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zGRO4GIysI72" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"&gt;17,223&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Principal repayments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zF9UaBSzflMi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Principal repayments"&gt;(17,374&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Issuance of convertible promissory note&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zFAaasce3Mwe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of convertible promissory note"&gt;3,150&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Issuance of unsecured senior convertible notes, net of fair value adjustment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zxqiZcy4m6dd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of unsecured senior convertible notes, net of fair value adjustment"&gt;689&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Conversion of debt into common shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zz2hQxzRVtKe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion of debt into common shares"&gt;(1,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Fair value adjustment through earnings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FairValueAdjustmentThroughEarnings_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4SqkTJzQf1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through earnings"&gt;492&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair value adjustment through accumulated other comprehensive income&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zvPuDmokQ0b4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through accumulated other comprehensive income"&gt;5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zbWbs4csl4Af" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;2,485&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zmIi29t9N328" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair values of the Yorkville
convertible promissory note and the unsecured senior convertible notes are based on valuations which employ a Monte Carlo model and a
credit default model. The Company utilized Level 3 inputs in a probability weighted model based on outcomes of a default, repayment and
conversion of the notes. The measurements are based upon unobservable inputs supported by little or no market activity based on the Company&#x2019;s
own assumptions. The fair value of the Yorkville convertible promissory note on March 13, 2024, the date of issuance, was $&lt;span id="xdx_906_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn3n3_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_z71AsINP3rd" title="Maximum advance amount"&gt;2,993&lt;/span&gt; and the
aggregate fair value of the unsecured senior convertible notes at the dates of issuance was $&lt;span id="xdx_90B_eus-gaap--ConvertibleDebtFairValueDisclosures_iI_pn3n3_c20241125__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zZOnHRxRc5gl" title="Fair value of notes"&gt;689&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zfo8uakP2dzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the Yorkville
convertible promissory note valuation model were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;&lt;span id="xdx_8B8_zRmKbrmT24b3" style="display: none"&gt;Schedule
of Yorkville Convertible Promissory Note Valuation Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_307_134_zOfiwpenfdxc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 13, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(issuance)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zMqZRp1rMQYk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.08&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zxs1LosLo8fc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;5.79&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Credit spread&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zLvvUhVDsDF6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread"&gt;7.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_z2IzhynUZUB2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread"&gt;8.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVV2H3Upm6yl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_dp_uPure_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z6Ks0qa9vmYi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtY_c20241231__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_ztu2y3fZZrcd" title="Term (years)"&gt;0.20&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtY_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zs1dCz38dpKc" title="Term (years)"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zemIL64A3Sa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;4.30&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zZvfYkcT7fZa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;4.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zdfWGeHfU5fc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility"&gt;50.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_z2aDlnnw0YM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible promissory note valuation measurement"&gt;50.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zlQo6qILlvDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zTvux3YbDZIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the unsecured
senior convertible notes valuation model were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zk68lVch4AYc" style="display: none"&gt;Schedule of Convertible Notes Valuation Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30A_134_zKMHyYVPLnzg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Convertible Notes Valuation Model (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;November
    25, 2024 and December 3, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(issuance) (1)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zZTqX6286Cd2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.08&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zLdyZuROQD85" title="Common share price"&gt;&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zxflIT1IHQzd" title="Common share price"&gt;2.00&lt;/span&gt;&lt;/span&gt; - $&lt;span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zSgBqNNguSpi" title="Common share price"&gt;&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zyuD3A9OV6wd" title="Common share price"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Credit spread&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zVDI4VzbsIQg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread"&gt;7.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z2uQH62zK8ig" title="Credit spread"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zAh06WBCci26" title="Credit spread"&gt;6.9&lt;/span&gt;&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zhhrcNJelGa" title="Credit spread"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zEAsIfUYXqM8" title="Credit spread"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJd7tlAjGaLh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zUGtc8ylboFa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zkkpx6rrEkKj" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentTerm_dtY_c20241231__20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zMbKtC0UigYg" title="Term (years)"&gt;0.90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z7jKIqN6Tg8" title="Term (years)"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_c20241203__20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zALKmgbTgC79" title="Term (years)"&gt;0.98&lt;/span&gt;&lt;/span&gt; - &lt;span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zRqleYV3qTCj" title="Term (years)"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20241203__20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zSRZYbnhzw84" title="Term (years)"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zMy7V7zPVt29" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;4.20&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zjoNobOYO79f" title="Risk-free interest rate"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zmpMbwWuLrza" title="Risk-free interest rate"&gt;4.30&lt;/span&gt;&lt;/span&gt;% - &lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zifSE1MeQCfg" title="Risk-free interest rate"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zMydr8j9YtB2" title="Risk-free interest rate"&gt;4.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zvRQnJF2wXA" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility"&gt;50.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_fKDEp_zSsteMh4V2u4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unsecured senior convertible notes valuation measurement"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zrJk7b2gmGN7" title="Unsecured senior convertible notes valuation measurement"&gt;50.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td id="xdx_F0A_zCJMq6KSn8i4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;(1)&lt;/td&gt;
  &lt;td id="xdx_F1A_z0jldVQDcmsl" style="font: 10pt Times New Roman, Times, Serif"&gt;As discussed
in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_zwmcYL5ZJcT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Valuation of Warrant Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The warrant liability at December
31, 2024 is comprised of the fair value of warrants to purchase shares of Class A common stock. The Public Warrants are recorded at fair
value based on the period-end publicly stated close price, which is a Level 1 input. The January 2024 Bridge Loan - Tranche #2 Warrants
(prior to reclassification to equity classified) and November 2024 Purchaser Warrants and Placement Agent Warrants were recorded at fair
value based on a Monte Carlo simulation model and the Registered Direct, PIPE and Sponsor Warrants are recorded at their respective closing
date fair values based on a Black-Scholes option pricing model that utilizes inputs for: (i) the value of the underlying asset, (ii) the
exercise price, (iii) the risk-free rate, (iv) the volatility of the underlying asset, (v) the dividend yield of the underlying asset
and (vi) maturity, which are Level 3 inputs. The Black-Scholes option pricing model&#x2019;s primary unobservable input utilized in determining
the fair values of the warrant liabilities is the expected volatility of the Class A common stock. Prior to the merger, Legacy Celularity
was a private company and lacked company-specific historical and implied volatility information for its stock. Therefore, the Company
estimates its expected stock price volatility using its volatility since the merger and the historical volatility of publicly traded peer
companies. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal
to the estimated remaining term of the warrants. Inputs to the Monte Carlo and Black-Scholes option pricing models for the warrants are
updated each reporting period to reflect fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zjyFz6XDPKI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;The following table presents
a reconciliation of the warrant liabilities measured on a recurring basis using Level 3 inputs for the years ended December 31, 2024 and
2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;&lt;span id="xdx_8B5_zcldbup38v16" style="display: none"&gt;Schedule
of Reconciliation of Warrant Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueNetAssetLiability_iS_pn3n3_c20230101__20231231_zv83jol6Vrw8" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Fair value, Beginning Balance"&gt;3,598&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;April 2023 Registered Direct warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--RegisteredDirectWarrantsIssuance_pn3n3_c20230101__20231231_zYQSGJmIAR0e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="April 2023 Registered Direct warrant issuance"&gt;4,280&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;July 2023 Registered Direct warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--RegisteredDirectWarrantIssuanceDuringJuly_pn3n3_c20230101__20231231_zNAbj1Ln54fc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="July 2023 Registered Direct warrant issuance"&gt;2,645&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;January 2024 Bridge Loan - Tranche #2 warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20241231_zzrHJqazzILl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="January 2024 Bridge Loan - Tranche #2 warrant issuance"&gt;1,858&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;November 2024 Purchaser warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--PurchaserWarrantIssuance_pn3n3_c20240101__20241231_zRQhynbDgJS7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Purchaser warrant issuance"&gt;354&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;November 2024 Placement Agent warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PlacementAgentWarrantIssuance_pn3n3_c20240101__20241231_zQ8q8BnPHXC9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Placement Agent warrant issuance"&gt;61&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Gain recognized in earnings from change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20230101__20231231_zSfHqRBVumY4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain recognized in earnings from change in fair value"&gt;(6,164&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reclassification of warrants from liability classified to equity classified&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_iN_pn3n3_di_c20240101__20241231_zAYvgaG8wXdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassification of warrants from liability classified to equity classified"&gt;(2,970&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iE_pn3n3_c20230101__20231231_zsJoXuGoalyj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value, Ending Balance"&gt;4,359&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Balance as of January 1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--FairValueNetAssetLiabilities_iS_pn3n3_c20240101__20241231_zupYiVyrn6Fh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Fair value, Beginning Balance"&gt;3,784&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;January 2024 Bridge Loan - Tranche #2 warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20241231_zL4C51rZusf7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="January 2024 Bridge Loan - Tranche #2 warrant issuance"&gt;1,858&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;November 2024 Purchaser warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PurchaserWarrantIssuance_pn3n3_c20240101__20241231_zYqRQrDzXBv6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Purchaser warrant issuance"&gt;354&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;November 2024 Placement Agent warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--PlacementAgentWarrantIssuance_pn3n3_c20240101__20241231_zm7Vjh1Xt2z4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Placement Agent warrant issuance"&gt;61&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Gain recognized in earnings from change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20240101__20241231_zzkmZsqcwQ4j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain recognized in earnings from change in fair value"&gt;(110&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reclassification of warrants from liability classified to equity classified&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_iN_pn3n3_di_c20240101__20241231_zofKHTbfU5sj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassification of warrants from liability classified to equity classified"&gt;(2,970&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueNetAssetLiabilities_iE_pn3n3_c20240101__20241231_zFbzS9y3Xwj9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value, Ending Balance"&gt;2,977&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_znYBXzYrM7dl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z4HlKRmYDho4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the May
2022 PIPE Warrants and the 2023 Registered Direct Warrants were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BC_zoUjs92MHBnc" style="display: none"&gt;Schedule of May 2022 PIPE
Warrants and 2023 Registered Direct Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30D_134_zEHOvFR1Mwhi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z6PG08ySPr5l" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.08&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zCRK8jT4vjC4" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.47&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zmEvPrAz9hM7" title="Exercise price"&gt;3.50&lt;/span&gt;
- $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zfUk6mHWWwNh" title="Exercise price"&gt;7.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zrMGli18XHq9" title="Exercise price"&gt;3.50&lt;/span&gt;
- $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zJWdhbVywlOe" title="Exercise price"&gt;7.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxGV7EC1yBg3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zEmedH3Yxuyi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zqqmdDhqA1F1" title="Term (years)"&gt;3.78&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zAioW97a69J8" title="Term (years)"&gt;4.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zcGSO7wcj1H1" title="Term (years)"&gt;5.03&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zYPkZGeS1hv" title="Term (years)"&gt;5.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxzAXW7Iyqv5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;4.3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBP1NbAdcYS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;4.60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zGKerOI6ie58" title="Warrant and right outstanding measurement input"&gt;98.5&lt;/span&gt;%
- &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zqXn656Hh2Rf" title="Warrant and right outstanding measurement input"&gt;98.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmDWrMaUJ0jg" title="Warrant and right outstanding measurement input"&gt;97.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zOTYWDqRSdrf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zTcYeIkClw3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the January
2024 Bridge Loan - Tranche #2 Warrants were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zZ0un3uuJzJ" style="display: none"&gt;Schedule
of January 2024 Bridge Loan&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_300_134_zfYZtbJYHUCe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of January 20224 Bridge Loan (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;July 15, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;January 16, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(reclassification)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(issuance)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zAbhamf6yZW" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;3.19&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_z64Ma4fo2Mof" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term to initial exercise date (years) (1)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingTermToInitialExerciseDate_dtY_c20240116__20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_fKDEp_zcXnJ9apWTCk" title="Term to initial exercise date (years)"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z7VZpfBBKDAf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zUspIO83bWra" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zTUh2p0IL1h4" title="Term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zmJhZgZn5kze" title="Term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zQtJ5evwm8fl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;4.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zE6CO87NoSzj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;3.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_za4iYSViZnu7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant and right outstanding measurement input"&gt;112.5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxyeuyuk4Ic8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants measurement input"&gt;107.5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td id="xdx_F04_z71VMIls35L4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;(1)&lt;/td&gt;
  &lt;td id="xdx_F13_zKhae20pVIZ5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;As discussed
further in Note 10, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July
15, 2024, the warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the
Company&#x2019;s own stock. As such, the warrants were adjusted to fair value as of the initial exercise date and then reclassified from
liability classified to equity classified.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8AC_zpGW3SKSXqB5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zvnUoeoQ9v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the November
2024 Purchaser and Placement Agent Warrants were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B0_ztlx07gIa4l1" style="display: none"&gt;Schedule of November 2024
Purchaser and Placement Agent Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_303_134_zf71QPEgAjk3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;November
    25, 2024 And December 3, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(issuance) (1)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zfGGfYtsJZbc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.08&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z46kT17Xe09" title="Common share price"&gt;&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zdPSTTIBsnPg" title="Common share price"&gt;2.00&lt;/span&gt;&lt;/span&gt; - $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zUBNXIdNreje" title="Common share price"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zD6q4W4va4Ei" title="Common share price"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term to Subsequent Financing (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDEp_zWcgJBsQJeA1" title="Term to Subsequent Financing (years)"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241125__20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zwMw4iO8pdL4" title="Term to Subsequent Financing (years)"&gt;&lt;span id="xdx_90F_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241203__20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zsMAnpTzZCy9" title="Term to Subsequent Financing (years)"&gt;0.1&lt;/span&gt;&lt;/span&gt; &#x2013; &lt;span id="xdx_90F_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241125__20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zaZtsaHXQC6i" title="Term to Subsequent Financing (years)"&gt;&lt;span id="xdx_90B_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241203__20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_znGABSFOpMX3" title="Term to Subsequent Financing (years)"&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_z2ubyhNq9aP1" title="Exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;(2)
                                            (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_zNuCSAwlQxbb" title="Exercise price"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_zTugOBVBSw2" title="Exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1479"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1481"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;(2)
                                            (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zyra5DSUeNdi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zqTqJDZCG9w8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zlYgUJDN3XN2" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zrf14xqZGeQg" title="Term (years)"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zQM7oWhv7xg2" title="Term (years)"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zwLjgcQrbbj7" title="Term (years)"&gt;4.9&lt;/span&gt;&lt;/span&gt; - &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zJBWbv0TIhd8" title="Term (years)"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zn5pqv4KyjNf" title="Term (years)"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zjXhXlFf6lch" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;4.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z7kdEynBbjV4" title="Risk-free interest rate"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zYCIPq13Jt7l" title="Risk-free interest rate"&gt;4.00&lt;/span&gt;&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zXs8IFU1i6Yc" title="Risk-free interest rate"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zrczjLQgNIc4" title="Risk-free interest rate"&gt;4.10&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z4DuF0GwDnq4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant and right outstanding measurement input"&gt;50.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zHJJnU0FRPxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants measurement input"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zEtlV5c2Xc8d" title="Warrants measurement input"&gt;50.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F08_zwHFDf6Kt7oc" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F14_zaexGBibPay7" style="font-size: 10pt"&gt;As discussed in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0C_zo1gJoXsJVn6" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_z1UxLlq7Ve35" style="font-size: 10pt"&gt;The exercise price of the November 2024 Purchaser Warrants is based on the lesser of (i) $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zqWPryMPDFY" title="Exercise price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zay0CNo8kkFc" title="Exercise price"&gt;2.85&lt;/span&gt;&lt;/span&gt; or (ii) the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zHA1eE5Olt08" title="Floor price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zJ5hleIJxI8l" title="Floor price"&gt;1.00&lt;/span&gt;&lt;/span&gt;. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F04_zTvOtzIYoIMl" style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_zZ0Nol6SrmT5" style="font-size: 10pt"&gt;The exercise price of the November 2024 Placement Agent Warrants is based on the lesser of (i) $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zO2jaDs7pQ78" title="Exercise price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zCedlLw6AzQh" title="Exercise price"&gt;3.56&lt;/span&gt;&lt;/span&gt; or (ii) &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_ecustom--OfferingPricePercentage_iI_pid_dp_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z7jn9S0Q2kz4" title="Offering price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--OfferingPricePercentage_iI_pid_dp_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6z2KSFYOoUa" title="Offering price"&gt;125&lt;/span&gt;&lt;/span&gt;% of the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6RlELFC2O76" title="Floor price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zXObzrFkExgd" title="Floor price"&gt;1.00&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A2_zrBWg2bfEe75" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--GXSponsorWarrantsMember_zGrSlJfF6DBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the Sponsor
Warrants are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zB0hiBDOJ4C7" style="display: none"&gt;Schedule
of Significant Inputs for  Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30D_134_zAdfdWkMttb7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Schedule of Significant Inputs for Sponsor Warrants (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 68%; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-right: 1.5pt; padding-left: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Common share price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$ &lt;span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zdLpurqPp6A9" title="Common share price"&gt;2.08&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$ &lt;span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zHrA3tQ4MLil" title="Common share price"&gt;2.47&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$ &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zIjzfAiMIA33" title="Exercise price"&gt;115.00&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$ &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zDtY0m1KwlSk" title="Exercise price"&gt;115.00&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_znSj9p5G03x7" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zkmoPeuCUJqa" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Term (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 2.65pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zJG9hzzs3Ie9" title="Term (years)"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 2.65pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zzBfFK2s4on2" title="Term (years)"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zlL5PZSicnPh" title="Dividend yield"&gt;4.21&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zLvpUZm4ACi" title="Dividend yield"&gt;4.12&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zFdi7bi7MYG5" title="Warrant and right outstanding measurement input"&gt;111.4&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zU0Uag68bPC4" title="Warrant measurement input"&gt;100.7&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_z4Jr6QIPfAIk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001025">&lt;p id="xdx_899_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zmb9PfWUKqwf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following tables present information about
the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value
hierarchy used to determine such fair values:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"&gt;&lt;span id="xdx_8B0_zIQ9WZasChz3" style="display: none"&gt;Schedule of Financial Assets and Liabilities Measures at Fair Value&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzdSkuVcoJR7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKzHQVU6Tj2h" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zApwOvikycBa" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20241231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zIXAcRbJ3x5d" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value Measurements as of December 31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zdMFe61yvfVe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zWYNCb0WUnu5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 36%; text-align: left"&gt;Acquisition-related contingent consideration obligations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1032"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1033"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;1,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;1,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zd4svOi91Nf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Contingent stock consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1037"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1038"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zwUGyLIeWUPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Short-term debt - Yorkville&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1042"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1043"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,865&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,865&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--ShorttermDebtUnsecuredSeniorConvertibleNotes_i01I_pn3n3_z0t3w7QzYWHl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Short-term debt - unsecured senior convertible notes&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1047"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;620&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;620&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zUynWyqYoAzl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - July 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1052"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1053"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,115&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,115&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_zWEc9xjtmMs6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - April 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1057"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1058"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,022&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zUq07lyItO7i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - May 2022 PIPE Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1062"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1063"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;505&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;505&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--WarrantLiabilityPurchaserWarrants_i01I_pn3n3_z2PtyNiQlTp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - November 2024 Purchaser Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1067"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1068"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--WarrantLiabilityPlacementAgentWarrants_i01I_pn3n3_zNBg7V0hk4Dh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - November 2024 Placement Agent Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1072"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1073"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;48&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_za5eSpLRTsAh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - Sponsor Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1077"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1078"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zKkeFd1iCppf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Warrant liability - Public Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;287&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1083"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1084"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;287&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zGTzThLR8fVf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    fair value liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;287&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1088"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,902&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,189&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zuoNHfmxmcGg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zj5R1lOBqXD3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsIIUtxsRVa2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zBOWcqsAuqA1" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Fair Value Measurements as of December 31, 2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AssetsFairValueDisclosureAbstract_iB_zT3saKyHg636" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ReceivablesFairValueDisclosure_i01I_pn3n3_zIP15TdqERni" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt; width: 44%; text-align: left"&gt;Convertible note receivable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1097"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1098"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AssetsFairValueDisclosure_i01TI_pn3n3_zsY9iNcyNuOb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    fair value assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1102"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1103"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LiabilitiesFairValueDisclosureAbstract_iB_zDRifOTUMxqb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationLiability_i01I_pn3n3_zqB1icF8FiQj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Acquisition-related contingent consideration obligations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1112"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1113"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,606&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,606&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ContingentStockConsideration_i01I_pn3n3_zS4112ALhre2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Contingent stock consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1117"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1118"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--ShorttermDebtFairValue_i01I_pn3n3_zvY5jqAgnAgk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Short-term debt - Yorkville&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,223&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,223&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--WarrantLiabilityRegisteredDirectWarrantsTwo_i01I_pn3n3_zmNieavx7vW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - July 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1127"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1128"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,529&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,529&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--WarrantLiabilityRegisteredDirectWarrants_i01I_pn3n3_ziPEtsdI1uv" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - April 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1132"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1133"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,487&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,487&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--WarrantLiabilityPrivateInvestmentInPublicEquityWarrants_i01I_pn3n3_zhq8ZtQ6e1K1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - May 2022 PIPE Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1137"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1138"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;708&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;708&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--WarrantLiabilitySponsorWarrants_i01I_pn3n3_zkMudQLWnIg6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Warrant liability - Sponsor Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1142"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1143"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--WarrantLiabilityPublicWarrants_i01I_pn3n3_zcieF696gda1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 10pt; text-align: left"&gt;Warrant liability - Public Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;575&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1148"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1149"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;575&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LiabilitiesFairValueDisclosure_i01TI_pn3n3_zDNkMAT9gqOf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    fair value liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;575&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1153"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,640&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;23,215&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001034"
      unitRef="USD">1413000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001035"
      unitRef="USD">1413000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <CELU:ContingentStockConsideration
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001039"
      unitRef="USD">27000</CELU:ContingentStockConsideration>
    <CELU:ContingentStockConsideration
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001040"
      unitRef="USD">27000</CELU:ContingentStockConsideration>
    <us-gaap:ShorttermDebtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001044"
      unitRef="USD">1865000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001045"
      unitRef="USD">1865000</us-gaap:ShorttermDebtFairValue>
    <CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001049"
      unitRef="USD">620000</CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes>
    <CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001050"
      unitRef="USD">620000</CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes>
    <CELU:WarrantLiabilityRegisteredDirectWarrantsTwo
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001054"
      unitRef="USD">1115000</CELU:WarrantLiabilityRegisteredDirectWarrantsTwo>
    <CELU:WarrantLiabilityRegisteredDirectWarrantsTwo
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001055"
      unitRef="USD">1115000</CELU:WarrantLiabilityRegisteredDirectWarrantsTwo>
    <CELU:WarrantLiabilityRegisteredDirectWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001059"
      unitRef="USD">1022000</CELU:WarrantLiabilityRegisteredDirectWarrants>
    <CELU:WarrantLiabilityRegisteredDirectWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001060"
      unitRef="USD">1022000</CELU:WarrantLiabilityRegisteredDirectWarrants>
    <CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001064"
      unitRef="USD">505000</CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants>
    <CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001065"
      unitRef="USD">505000</CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants>
    <CELU:WarrantLiabilityPurchaserWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001069"
      unitRef="USD">278000</CELU:WarrantLiabilityPurchaserWarrants>
    <CELU:WarrantLiabilityPurchaserWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001070"
      unitRef="USD">278000</CELU:WarrantLiabilityPurchaserWarrants>
    <CELU:WarrantLiabilityPlacementAgentWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001074"
      unitRef="USD">48000</CELU:WarrantLiabilityPlacementAgentWarrants>
    <CELU:WarrantLiabilityPlacementAgentWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001075"
      unitRef="USD">48000</CELU:WarrantLiabilityPlacementAgentWarrants>
    <CELU:WarrantLiabilitySponsorWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001079"
      unitRef="USD">9000</CELU:WarrantLiabilitySponsorWarrants>
    <CELU:WarrantLiabilitySponsorWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001080"
      unitRef="USD">9000</CELU:WarrantLiabilitySponsorWarrants>
    <CELU:WarrantLiabilityPublicWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001082"
      unitRef="USD">287000</CELU:WarrantLiabilityPublicWarrants>
    <CELU:WarrantLiabilityPublicWarrants
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001085"
      unitRef="USD">287000</CELU:WarrantLiabilityPublicWarrants>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001087"
      unitRef="USD">287000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001089"
      unitRef="USD">6902000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001090"
      unitRef="USD">7189000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ReceivablesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001099"
      unitRef="USD">2072000</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:ReceivablesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001100"
      unitRef="USD">2072000</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001104"
      unitRef="USD">2072000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001105"
      unitRef="USD">2072000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001114"
      unitRef="USD">1606000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001115"
      unitRef="USD">1606000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <CELU:ContingentStockConsideration
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001119"
      unitRef="USD">27000</CELU:ContingentStockConsideration>
    <CELU:ContingentStockConsideration
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001120"
      unitRef="USD">27000</CELU:ContingentStockConsideration>
    <us-gaap:ShorttermDebtFairValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001124"
      unitRef="USD">17223000</us-gaap:ShorttermDebtFairValue>
    <us-gaap:ShorttermDebtFairValue
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001125"
      unitRef="USD">17223000</us-gaap:ShorttermDebtFairValue>
    <CELU:WarrantLiabilityRegisteredDirectWarrantsTwo
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001129"
      unitRef="USD">1529000</CELU:WarrantLiabilityRegisteredDirectWarrantsTwo>
    <CELU:WarrantLiabilityRegisteredDirectWarrantsTwo
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001130"
      unitRef="USD">1529000</CELU:WarrantLiabilityRegisteredDirectWarrantsTwo>
    <CELU:WarrantLiabilityRegisteredDirectWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001134"
      unitRef="USD">1487000</CELU:WarrantLiabilityRegisteredDirectWarrants>
    <CELU:WarrantLiabilityRegisteredDirectWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001135"
      unitRef="USD">1487000</CELU:WarrantLiabilityRegisteredDirectWarrants>
    <CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001139"
      unitRef="USD">708000</CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants>
    <CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001140"
      unitRef="USD">708000</CELU:WarrantLiabilityPrivateInvestmentInPublicEquityWarrants>
    <CELU:WarrantLiabilitySponsorWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001144"
      unitRef="USD">60000</CELU:WarrantLiabilitySponsorWarrants>
    <CELU:WarrantLiabilitySponsorWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001145"
      unitRef="USD">60000</CELU:WarrantLiabilitySponsorWarrants>
    <CELU:WarrantLiabilityPublicWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001147"
      unitRef="USD">575000</CELU:WarrantLiabilityPublicWarrants>
    <CELU:WarrantLiabilityPublicWarrants
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001150"
      unitRef="USD">575000</CELU:WarrantLiabilityPublicWarrants>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member"
      decimals="-3"
      id="Fact001152"
      unitRef="USD">575000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001154"
      unitRef="USD">22640000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact001155"
      unitRef="USD">23215000</us-gaap:LiabilitiesFairValueDisclosure>
    <CELU:ForbearanceExtendMaturityPeriod
      contextRef="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_srt_MinimumMember_custom_LetterAgreementMember"
      id="Fact001157">2024-02-28</CELU:ForbearanceExtendMaturityPeriod>
    <CELU:ForbearanceExtendMaturityPeriod
      contextRef="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_srt_MaximumMember_custom_LetterAgreementMember"
      id="Fact001159">2024-06-03</CELU:ForbearanceExtendMaturityPeriod>
    <CELU:IncreasedNotePayments
      contextRef="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_custom_LetterAgreementMember"
      decimals="-3"
      id="Fact001161"
      unitRef="USD">2175000</CELU:IncreasedNotePayments>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-05-102024-05-10_custom_SanuwaveForbearanceAgreementMember_custom_LetterAgreementMember"
      decimals="-3"
      id="Fact001163"
      unitRef="USD">100000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-06-032024-06-03_custom_SanuwaveForbearanceAgreementMember_custom_LetterAgreementMember"
      decimals="-3"
      id="Fact001165"
      unitRef="USD">2075000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001167">&lt;p id="xdx_898_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z8ZzFNHpUFr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table presents a
reconciliation of the convertible note receivable measured on a recurring basis using Level 3 inputs for the year ended December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;&lt;span id="xdx_8B9_zFErd4Rfj6ak" style="display: none"&gt;Schedule of Reconciliation of Convertible Note Receivable Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;transfers&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;in to (out of) &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Purchases,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;settlements&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;and other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;adjustments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"&gt;Convertible note receivable&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ReceivablesFairValueDisclosure_iS_pn3n3_c20240101__20241231_zOLLVDccNtha" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance"&gt;2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3n3_c20240101__20241231_zaj2eaLR5NPk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1171"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231_z9GFUYXI1Ohb" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"&gt;(2,072&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_pn3n3_c20240101__20241231_zVAfHEi1grW8" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1175"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ReceivablesFairValueDisclosure_iE_pn3n3_c20240101__20241231_zqGG7pp5j9Qf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1177"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:ReceivablesFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001169"
      unitRef="USD">2072000</us-gaap:ReceivablesFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001173"
      unitRef="USD">-2072000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchasesSalesIssuancesSettlements>
    <CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001179">&lt;p id="xdx_89B_ecustom--ScheduleOfConvertibleNoteValuationModelTableTextBlock_z7EuHh2GNVD6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the convertible
note valuation model were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zacK0CQDrUZ7" style="display: none"&gt;Schedule of Convertible
Note Valuation Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Face value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--FaceValueOfNotesReceivable_iI_pn3n3_c20231231_zmau9GTs49T6" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Face value"&gt;4,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Coupon rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20231231__20231231__srt--RangeAxis__srt--MinimumMember_zCS9azBSfThe" title="Coupon rate"&gt;12.00&lt;/span&gt;% - &lt;span id="xdx_90E_ecustom--PercentageOfCouponRate_pid_dp_uPure_c20231231__20231231__srt--RangeAxis__srt--MaximumMember_zkO4ImOn8EX3" title="Coupon rate"&gt;17.00&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Stock price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharePrice_iI_pid_c20231231_zwuj6HzjR2aa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Stock price"&gt;0.2&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20231231__20231231__srt--RangeAxis__srt--MinimumMember_zDUEeNif64j5" title="Term (years)"&gt;0.51&lt;/span&gt;-&lt;span id="xdx_90B_ecustom--ValuationInputForConvertiblePromissoryNoteTerm_dtY_c20231231__20231231__srt--RangeAxis__srt--MaximumMember_z4mH3Z1StVXc" title="Term (years)"&gt;2.45&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--ValuationInputForConvertiblePromissoryNote_pid_dp_uPure_c20231231__20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zZA4dA31wVBa" title="Risk-free interest rate"&gt;5.47&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CELU:ScheduleOfConvertibleNoteValuationModelTableTextBlock>
    <CELU:FaceValueOfNotesReceivable
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001181"
      unitRef="USD">4000000</CELU:FaceValueOfNotesReceivable>
    <CELU:PercentageOfCouponRate
      contextRef="From2023-12-312023-12-31_srt_MinimumMember"
      decimals="INF"
      id="Fact001183"
      unitRef="Pure">0.1200</CELU:PercentageOfCouponRate>
    <CELU:PercentageOfCouponRate
      contextRef="From2023-12-312023-12-31_srt_MaximumMember"
      decimals="INF"
      id="Fact001185"
      unitRef="Pure">0.1700</CELU:PercentageOfCouponRate>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001187"
      unitRef="USDPShares">0.2</us-gaap:SharePrice>
    <CELU:ValuationInputForConvertiblePromissoryNoteTerm
      contextRef="From2023-12-312023-12-31_srt_MinimumMember"
      id="Fact001189">P0Y6M3D</CELU:ValuationInputForConvertiblePromissoryNoteTerm>
    <CELU:ValuationInputForConvertiblePromissoryNoteTerm
      contextRef="From2023-12-312023-12-31_srt_MaximumMember"
      id="Fact001191">P2Y5M12D</CELU:ValuationInputForConvertiblePromissoryNoteTerm>
    <CELU:ValuationInputForConvertiblePromissoryNote
      contextRef="From2023-12-312023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001193"
      unitRef="Pure">0.0547</CELU:ValuationInputForConvertiblePromissoryNote>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="From2024-01-012024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember"
      id="Fact001195">&lt;p id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_hus-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_z6CBmcdOyEgk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table presents a
reconciliation of contingent consideration obligations measured on a recurring basis using Level 3 inputs for the years ended December
31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zHZbPLTYsDQe" style="display: none"&gt;Schedule
of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_302_134_zNw4XXVgHO08" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;January 1,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;transfers&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;in to (out of)&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Purchases,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;settlements&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;and other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;adjustments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"&gt;Acquisition-related contingent consideration obligations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zYJsuLNyjdMk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance"&gt;1,606&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zDRjxdHhzJ88" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1199"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zmmUuDNaRxni" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1201"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zVEsLod7WOd" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"&gt;(193&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zt8vlGcR6nXk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"&gt;1,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_301_134_zNC3CdBWLkj4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of Contingent Consideration Obligations Measured on a Recurring Basis (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;January 1,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;transfers&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;in to (out of)&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Purchases,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;settlements&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;and other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;adjustments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"&gt;Acquisition-related contingent consideration obligations&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zgKVqS6FHds4" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance"&gt;105,945&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zh3XTRHRkxY3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1209"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_z2ZvNt2EbTS3" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1211"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zSMQPI9PFEGc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"&gt;(104,339&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--AcquisitionRelatedContingentConsiderationObligationsMember_zN0pxvdHgzl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"&gt;1,606&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember"
      decimals="-3"
      id="Fact001197"
      unitRef="USD">1606000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2024-01-012024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember"
      decimals="-3"
      id="Fact001203"
      unitRef="USD">-193000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember"
      decimals="-3"
      id="Fact001205"
      unitRef="USD">1413000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember"
      decimals="-3"
      id="Fact001207"
      unitRef="USD">105945000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember"
      decimals="-3"
      id="Fact001213"
      unitRef="USD">-104339000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_custom_AcquisitionRelatedContingentConsiderationObligationsMember"
      decimals="-3"
      id="Fact001215"
      unitRef="USD">1606000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="From2024-01-012024-12-31_custom_ContingentStockConsiderationMember"
      id="Fact001217">&lt;p id="xdx_896_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_hus-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrgIdd6CCJ6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table presents a
reconciliation of the contingent stock consideration obligation measured on a recurring basis using Level 3 inputs for the years ended
December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B4_zyurDf37iSEl" style="display: none"&gt;Schedule
of Reconciliation of  Contingent  Consideration Obligation Measured on a Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30B_134_zW1PSCMU8oc9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;January 1, 2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;transfers&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;in to (out of) &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Purchases,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;settlements&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;and other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;adjustments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"&gt;Contingent stock consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zREGJY4dLpHc" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zDZshqLpWFv5" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1221"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_za5rNgaSgQaf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1223"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrSf4Fxc8xB1" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"&gt;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1225"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20240101__20241231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zM7E2M5RFyVj" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_305_134_zeyYDCS4uIO6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Reconciliation of the Contingent Stock Consideration Obligation Measured on a Recurring Basis (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;January 1, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;transfers&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;in to (out of) &lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Purchases,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;settlements&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;and other&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;adjustments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Balance as of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: left"&gt;Contingent stock consideration&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zeV8B7OeS81" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Beginning balance"&gt;186&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zrmPNoNkTqsk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Net transfers into (out of) Level 3"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1231"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_z6uT9Pz8O09c" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Purchases, settlements and other net"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1233"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zfkuwXI8oiMf" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Fair value adjustments"&gt;(159&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_pn3n3_c20230101__20231231__us-gaap--ContingentConsiderationByTypeAxis__custom--ContingentStockConsiderationMember_zF6YQa9MfQzk" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Ending balance"&gt;27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_custom_ContingentStockConsiderationMember"
      decimals="-3"
      id="Fact001219"
      unitRef="USD">27000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2024-12-31_custom_ContingentStockConsiderationMember"
      decimals="-3"
      id="Fact001227"
      unitRef="USD">27000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2022-12-31_custom_ContingentStockConsiderationMember"
      decimals="-3"
      id="Fact001229"
      unitRef="USD">186000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="From2023-01-012023-12-31_custom_ContingentStockConsiderationMember"
      decimals="-3"
      id="Fact001235"
      unitRef="USD">-159000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="AsOf2023-12-31_custom_ContingentStockConsiderationMember"
      decimals="-3"
      id="Fact001237"
      unitRef="USD">27000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <CELU:FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001239">&lt;p id="xdx_89A_ecustom--FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zf0Q2VjZAwu5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table presents a
reconciliation of short-term debt obligations measured on a recurring basis using Level 3 inputs for the years ended December 31, 2023
and 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&lt;span id="xdx_8BE_zNNatWJYUOr5" style="display: none"&gt;Schedule of Reconciliation
of Short-term Debt Obligation Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zVKESrallsn9" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"&gt;37,603&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Conversion of debt into common shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zhvrNP5gY3L3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion of debt into common shares"&gt;(4,599&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Principal repayments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zS1dpiGcM6gi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Principal repayments"&gt;(16,811&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Issuance of convertible promissory note&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4ULDL8Mjadd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of convertible promissory note"&gt;3,150&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Issuance of unsecured senior convertible notes, net of fair value adjustment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zeX9B9QAWsp8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of unsecured senior convertible notes, net of fair value adjustment"&gt;689&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Fair value adjustment through earnings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueAdjustmentThroughEarnings_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zFZNR5QOZBYa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through earnings"&gt;354&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Fair value adjustment through accumulated other comprehensive income&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zhNjeaH9OFa5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through accumulated other comprehensive income"&gt;(146&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair value adjustment through interest accrual&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zLErIKWgnKOd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through interest accrual"&gt;822&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zqe7Y2DTYfic" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;17,223&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Balance as of January 1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShortTermBorrowings_iS_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zGRO4GIysI72" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"&gt;17,223&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Principal repayments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zF9UaBSzflMi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Principal repayments"&gt;(17,374&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Issuance of convertible promissory note&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zFAaasce3Mwe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of convertible promissory note"&gt;3,150&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Issuance of unsecured senior convertible notes, net of fair value adjustment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zxqiZcy4m6dd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Issuance of unsecured senior convertible notes, net of fair value adjustment"&gt;689&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Conversion of debt into common shares&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zz2hQxzRVtKe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Conversion of debt into common shares"&gt;(1,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Fair value adjustment through earnings&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--FairValueAdjustmentThroughEarnings_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_z4SqkTJzQf1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through earnings"&gt;492&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair value adjustment through accumulated other comprehensive income&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zvPuDmokQ0b4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair value adjustment through accumulated other comprehensive income"&gt;5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShortTermBorrowings_iE_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember_zbWbs4csl4Af" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;2,485&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CELU:FairValueAssetsOfYorkvilleDebtMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2022-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001241"
      unitRef="USD">37603000</us-gaap:ShortTermBorrowings>
    <CELU:FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001243"
      unitRef="USD">-4599000</CELU:FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001245"
      unitRef="USD">-16811000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <CELU:FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote
      contextRef="From2024-01-012024-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001247"
      unitRef="USD">3150000</CELU:FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote>
    <CELU:IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment
      contextRef="From2024-01-012024-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001249"
      unitRef="USD">689000</CELU:IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment>
    <CELU:FairValueAdjustmentThroughEarnings
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001251"
      unitRef="USD">354000</CELU:FairValueAdjustmentThroughEarnings>
    <CELU:FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001253"
      unitRef="USD">-146000</CELU:FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome>
    <CELU:FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001255"
      unitRef="USD">822000</CELU:FairValueMeasurementWithUnobservableInputsReconciliationFairValueAdjustmentThroughInterestAccrual>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2023-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001257"
      unitRef="USD">17223000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2023-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001259"
      unitRef="USD">17223000</us-gaap:ShortTermBorrowings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="From2024-01-012024-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001261"
      unitRef="USD">-17374000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <CELU:FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote
      contextRef="From2024-01-012024-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001263"
      unitRef="USD">3150000</CELU:FairValueMeasurementWithUnobservableInputsReconciliationConvertiblePromissoryNote>
    <CELU:IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment
      contextRef="From2024-01-012024-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001265"
      unitRef="USD">689000</CELU:IssuanceOfUnsecuredSeniorConvertibleNotesNetOfFairValueAdjustment>
    <CELU:FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares
      contextRef="From2024-01-012024-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001267"
      unitRef="USD">-1700000</CELU:FairValueMeasurementWithUnobservableInputsReconciliationConversionOfDebtIntoCommonShares>
    <CELU:FairValueAdjustmentThroughEarnings
      contextRef="From2024-01-012024-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001269"
      unitRef="USD">492000</CELU:FairValueAdjustmentThroughEarnings>
    <CELU:FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome
      contextRef="From2024-01-012024-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001271"
      unitRef="USD">5000</CELU:FairValueAdjustmentThroughAccumulatedOtherComprehensiveIncome>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-12-31_custom_YorkvilleMember"
      decimals="-3"
      id="Fact001273"
      unitRef="USD">2485000</us-gaap:ShortTermBorrowings>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember"
      decimals="-3"
      id="Fact001275"
      unitRef="USD">2993000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="AsOf2024-11-25_custom_YorkvilleMember_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="-3"
      id="Fact001277"
      unitRef="USD">689000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_ConvertiblePromissoryNotesMember"
      id="Fact001279">&lt;p id="xdx_899_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zfo8uakP2dzd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the Yorkville
convertible promissory note valuation model were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;&lt;span id="xdx_8B8_zRmKbrmT24b3" style="display: none"&gt;Schedule
of Yorkville Convertible Promissory Note Valuation Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_307_134_zOfiwpenfdxc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Yorkville Convertible Promissory Note Valuation Model (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;March 13, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(issuance)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zMqZRp1rMQYk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.08&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharePrice_iI_pid_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zxs1LosLo8fc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;5.79&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Credit spread&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zLvvUhVDsDF6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread"&gt;7.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_z2IzhynUZUB2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread"&gt;8.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_dp_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zVV2H3Upm6yl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_dp_uPure_c20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z6Ks0qa9vmYi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentTerm_dtY_c20241231__20241231__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_ztu2y3fZZrcd" title="Term (years)"&gt;0.20&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtY_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zs1dCz38dpKc" title="Term (years)"&gt;1.00&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zemIL64A3Sa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;4.30&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zZvfYkcT7fZa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;4.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zdfWGeHfU5fc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility"&gt;50.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20240313__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_z2aDlnnw0YM2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible promissory note valuation measurement"&gt;50.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact001281"
      unitRef="USDPShares">2.08</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact001283"
      unitRef="USDPShares">5.79</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputCreditSpreadMember"
      decimals="INF"
      id="Fact001285"
      unitRef="Pure">7.50</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputCreditSpreadMember"
      decimals="INF"
      id="Fact001287"
      unitRef="Pure">8.50</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001289"
      unitRef="Pure">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-03-13_custom_ConvertiblePromissoryNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001291"
      unitRef="Pure">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-12-312024-12-31_custom_ConvertiblePromissoryNotesMember"
      id="Fact001293">P0Y2M12D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-03-132024-03-13_custom_ConvertiblePromissoryNotesMember"
      id="Fact001295">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact001297"
      unitRef="Pure">4.30</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-03-13_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_ConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact001299"
      unitRef="Pure">4.90</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_ConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact001301"
      unitRef="Pure">50.0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-03-13_us-gaap_MeasurementInputPriceVolatilityMember_custom_ConvertiblePromissoryNotesMember"
      decimals="INF"
      id="Fact001303"
      unitRef="Pure">50.0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_UnsecuredSeniorConvertibleNotesMember"
      id="Fact001305">&lt;p id="xdx_89F_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_hus-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zTvux3YbDZIf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the unsecured
senior convertible notes valuation model were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BD_zk68lVch4AYc" style="display: none"&gt;Schedule of Convertible Notes Valuation Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30A_134_zKMHyYVPLnzg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of Convertible Notes Valuation Model (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;November
    25, 2024 and December 3, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(issuance) (1)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zZTqX6286Cd2" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.08&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zLdyZuROQD85" title="Common share price"&gt;&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zxflIT1IHQzd" title="Common share price"&gt;2.00&lt;/span&gt;&lt;/span&gt; - $&lt;span id="xdx_900_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zSgBqNNguSpi" title="Common share price"&gt;&lt;span id="xdx_909_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zyuD3A9OV6wd" title="Common share price"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Credit spread&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember_zVDI4VzbsIQg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Credit spread"&gt;7.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z2uQH62zK8ig" title="Credit spread"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zAh06WBCci26" title="Credit spread"&gt;6.9&lt;/span&gt;&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zhhrcNJelGa" title="Credit spread"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputCreditSpreadMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zEAsIfUYXqM8" title="Credit spread"&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zJd7tlAjGaLh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zUGtc8ylboFa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zkkpx6rrEkKj" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentTerm_dtY_c20241231__20241231__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zMbKtC0UigYg" title="Term (years)"&gt;0.90&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z7jKIqN6Tg8" title="Term (years)"&gt;&lt;span id="xdx_903_eus-gaap--DebtInstrumentTerm_dtY_c20241203__20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zALKmgbTgC79" title="Term (years)"&gt;0.98&lt;/span&gt;&lt;/span&gt; - &lt;span id="xdx_90D_eus-gaap--DebtInstrumentTerm_dtY_c20241125__20241125__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zRqleYV3qTCj" title="Term (years)"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20241203__20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zSRZYbnhzw84" title="Term (years)"&gt;1.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zMy7V7zPVt29" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;4.20&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zjoNobOYO79f" title="Risk-free interest rate"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zmpMbwWuLrza" title="Risk-free interest rate"&gt;4.30&lt;/span&gt;&lt;/span&gt;% - &lt;span id="xdx_906_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zifSE1MeQCfg" title="Risk-free interest rate"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zMydr8j9YtB2" title="Risk-free interest rate"&gt;4.40&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_zvRQnJF2wXA" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Volatility"&gt;50.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241125__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember_fKDEp_zSsteMh4V2u4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Unsecured senior convertible notes valuation measurement"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ShortTermDebtTypeAxis__custom--UnsecuredSeniorConvertibleNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zrJk7b2gmGN7" title="Unsecured senior convertible notes valuation measurement"&gt;50.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td id="xdx_F0A_zCJMq6KSn8i4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;(1)&lt;/td&gt;
  &lt;td id="xdx_F1A_z0jldVQDcmsl" style="font: 10pt Times New Roman, Times, Serif"&gt;As discussed
in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="INF"
      id="Fact001307"
      unitRef="USDPShares">2.08</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001309"
      unitRef="USDPShares">2.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001311"
      unitRef="USDPShares">2.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001313"
      unitRef="USDPShares">3.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001315"
      unitRef="USDPShares">3.00</us-gaap:SharePrice>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember"
      decimals="INF"
      id="Fact001317"
      unitRef="Pure">7.6</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001319"
      unitRef="Pure">6.9</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001321"
      unitRef="Pure">6.9</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001323"
      unitRef="Pure">7.2</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputCreditSpreadMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001325"
      unitRef="Pure">7.2</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001327"
      unitRef="Pure">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001329"
      unitRef="Pure">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001331"
      unitRef="Pure">0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-12-312024-12-31_custom_UnsecuredSeniorConvertibleNotesMember"
      id="Fact001333">P0Y10M24D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember"
      id="Fact001335">P0Y11M23D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-12-032024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember"
      id="Fact001337">P0Y11M23D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember"
      id="Fact001339">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="From2024-12-032024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember"
      id="Fact001341">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="INF"
      id="Fact001343"
      unitRef="Pure">4.20</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001345"
      unitRef="Pure">4.30</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-03_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001347"
      unitRef="Pure">4.30</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001349"
      unitRef="Pure">4.40</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-03_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_UnsecuredSeniorConvertibleNotesMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001351"
      unitRef="Pure">4.40</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-31_us-gaap_MeasurementInputPriceVolatilityMember_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="INF"
      id="Fact001353"
      unitRef="Pure">50.0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-11-25_us-gaap_MeasurementInputPriceVolatilityMember_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="INF"
      id="Fact001355"
      unitRef="Pure">50.0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="AsOf2024-12-03_custom_UnsecuredSeniorConvertibleNotesMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001357"
      unitRef="Pure">50.0</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001360">&lt;p id="xdx_89F_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_zjyFz6XDPKI9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;The following table presents
a reconciliation of the warrant liabilities measured on a recurring basis using Level 3 inputs for the years ended December 31, 2024 and
2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;&lt;span id="xdx_8B5_zcldbup38v16" style="display: none"&gt;Schedule
of Reconciliation of Warrant Liabilities Measured on Recurring Basis&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Balance as of January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueNetAssetLiability_iS_pn3n3_c20230101__20231231_zv83jol6Vrw8" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Fair value, Beginning Balance"&gt;3,598&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;April 2023 Registered Direct warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--RegisteredDirectWarrantsIssuance_pn3n3_c20230101__20231231_zYQSGJmIAR0e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="April 2023 Registered Direct warrant issuance"&gt;4,280&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;July 2023 Registered Direct warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--RegisteredDirectWarrantIssuanceDuringJuly_pn3n3_c20230101__20231231_zNAbj1Ln54fc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="July 2023 Registered Direct warrant issuance"&gt;2,645&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;January 2024 Bridge Loan - Tranche #2 warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20241231_zzrHJqazzILl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="January 2024 Bridge Loan - Tranche #2 warrant issuance"&gt;1,858&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;November 2024 Purchaser warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--PurchaserWarrantIssuance_pn3n3_c20240101__20241231_zRQhynbDgJS7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Purchaser warrant issuance"&gt;354&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;November 2024 Placement Agent warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--PlacementAgentWarrantIssuance_pn3n3_c20240101__20241231_zQ8q8BnPHXC9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Placement Agent warrant issuance"&gt;61&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Gain recognized in earnings from change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20230101__20231231_zSfHqRBVumY4" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain recognized in earnings from change in fair value"&gt;(6,164&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reclassification of warrants from liability classified to equity classified&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_iN_pn3n3_di_c20240101__20241231_zAYvgaG8wXdd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassification of warrants from liability classified to equity classified"&gt;(2,970&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance as of December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueNetAssetLiability_iE_pn3n3_c20230101__20231231_zsJoXuGoalyj" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value, Ending Balance"&gt;4,359&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Balance as of January 1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--FairValueNetAssetLiabilities_iS_pn3n3_c20240101__20241231_zupYiVyrn6Fh" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Fair value, Beginning Balance"&gt;3,784&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;January 2024 Bridge Loan - Tranche #2 warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--BridgeLoanAndWarrantIssuanceTrancheTwo_pn3n3_c20240101__20241231_zL4C51rZusf7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="January 2024 Bridge Loan - Tranche #2 warrant issuance"&gt;1,858&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;November 2024 Purchaser warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--PurchaserWarrantIssuance_pn3n3_c20240101__20241231_zYqRQrDzXBv6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Purchaser warrant issuance"&gt;354&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;November 2024 Placement Agent warrant issuance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--PlacementAgentWarrantIssuance_pn3n3_c20240101__20241231_zm7Vjh1Xt2z4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="November 2024 Placement Agent warrant issuance"&gt;61&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Gain recognized in earnings from change in fair value&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--GainLossRecognizedInEarningsFromChangeInFairValues_pn3n3_c20240101__20241231_zzkmZsqcwQ4j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain recognized in earnings from change in fair value"&gt;(110&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reclassification of warrants from liability classified to equity classified&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified_iN_pn3n3_di_c20240101__20241231_zofKHTbfU5sj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Reclassification of warrants from liability classified to equity classified"&gt;(2,970&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueNetAssetLiabilities_iE_pn3n3_c20240101__20241231_zFbzS9y3Xwj9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value, Ending Balance"&gt;2,977&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001362"
      unitRef="USD">3598000</us-gaap:FairValueNetAssetLiability>
    <CELU:RegisteredDirectWarrantsIssuance
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001364"
      unitRef="USD">4280000</CELU:RegisteredDirectWarrantsIssuance>
    <CELU:RegisteredDirectWarrantIssuanceDuringJuly
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001366"
      unitRef="USD">2645000</CELU:RegisteredDirectWarrantIssuanceDuringJuly>
    <CELU:BridgeLoanAndWarrantIssuanceTrancheTwo
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001368"
      unitRef="USD">1858000</CELU:BridgeLoanAndWarrantIssuanceTrancheTwo>
    <CELU:PurchaserWarrantIssuance
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001370"
      unitRef="USD">354000</CELU:PurchaserWarrantIssuance>
    <CELU:PlacementAgentWarrantIssuance
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001372"
      unitRef="USD">61000</CELU:PlacementAgentWarrantIssuance>
    <CELU:GainLossRecognizedInEarningsFromChangeInFairValues
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001374"
      unitRef="USD">-6164000</CELU:GainLossRecognizedInEarningsFromChangeInFairValues>
    <CELU:ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001376"
      unitRef="USD">2970000</CELU:ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified>
    <us-gaap:FairValueNetAssetLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001378"
      unitRef="USD">4359000</us-gaap:FairValueNetAssetLiability>
    <CELU:FairValueNetAssetLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001380"
      unitRef="USD">3784000</CELU:FairValueNetAssetLiabilities>
    <CELU:BridgeLoanAndWarrantIssuanceTrancheTwo
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001382"
      unitRef="USD">1858000</CELU:BridgeLoanAndWarrantIssuanceTrancheTwo>
    <CELU:PurchaserWarrantIssuance
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001384"
      unitRef="USD">354000</CELU:PurchaserWarrantIssuance>
    <CELU:PlacementAgentWarrantIssuance
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001386"
      unitRef="USD">61000</CELU:PlacementAgentWarrantIssuance>
    <CELU:GainLossRecognizedInEarningsFromChangeInFairValues
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001388"
      unitRef="USD">-110000</CELU:GainLossRecognizedInEarningsFromChangeInFairValues>
    <CELU:ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001390"
      unitRef="USD">2970000</CELU:ReclassificationOfWarrantsFromLiabilityClassifiedToEquityClassified>
    <CELU:FairValueNetAssetLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001392"
      unitRef="USD">2977000</CELU:FairValueNetAssetLiabilities>
    <CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember"
      id="Fact001394">&lt;p id="xdx_894_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z4HlKRmYDho4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the May
2022 PIPE Warrants and the 2023 Registered Direct Warrants were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BC_zoUjs92MHBnc" style="display: none"&gt;Schedule of May 2022 PIPE
Warrants and 2023 Registered Direct Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30D_134_zEHOvFR1Mwhi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of May 2022 PIPE Warrants and 2023 Registered Direct Warrants (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_z6PG08ySPr5l" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.08&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_zCRK8jT4vjC4" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.47&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zmEvPrAz9hM7" title="Exercise price"&gt;3.50&lt;/span&gt;
- $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zfUk6mHWWwNh" title="Exercise price"&gt;7.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zrMGli18XHq9" title="Exercise price"&gt;3.50&lt;/span&gt;
- $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zJWdhbVywlOe" title="Exercise price"&gt;7.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxGV7EC1yBg3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zEmedH3Yxuyi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zqqmdDhqA1F1" title="Term (years)"&gt;3.78&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zAioW97a69J8" title="Term (years)"&gt;4.09&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember_zcGSO7wcj1H1" title="Term (years)"&gt;5.03&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember_zYPkZGeS1hv" title="Term (years)"&gt;5.34&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zxzAXW7Iyqv5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;4.3&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zBP1NbAdcYS3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;4.60&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zGKerOI6ie58" title="Warrant and right outstanding measurement input"&gt;98.5&lt;/span&gt;%
- &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zqXn656Hh2Rf" title="Warrant and right outstanding measurement input"&gt;98.8&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zmDWrMaUJ0jg" title="Warrant and right outstanding measurement input"&gt;97.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember"
      decimals="INF"
      id="Fact001396"
      unitRef="USDPShares">2.08</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember"
      decimals="INF"
      id="Fact001398"
      unitRef="USDPShares">2.47</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001400"
      unitRef="USDPShares">3.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001402"
      unitRef="USDPShares">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001404"
      unitRef="USDPShares">3.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001406"
      unitRef="USDPShares">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001408"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001410"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember"
      id="Fact001412">P3Y9M10D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember"
      id="Fact001414">P4Y1M2D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember"
      id="Fact001416">P5Y10D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember"
      id="Fact001418">P5Y4M2D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001420"
      unitRef="Pure">4.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001422"
      unitRef="Pure">4.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001424"
      unitRef="Pure">98.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MaximumMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001426"
      unitRef="Pure">98.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentinPublicEquityWarrantsAndAprilTwoThousandTwentyThreeRegisteredDirectWarrantMember_srt_MinimumMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001428"
      unitRef="Pure">97.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember"
      id="Fact001430">&lt;p id="xdx_899_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zTcYeIkClw3f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the January
2024 Bridge Loan - Tranche #2 Warrants were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BA_zZ0un3uuJzJ" style="display: none"&gt;Schedule
of January 2024 Bridge Loan&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_300_134_zfYZtbJYHUCe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of January 20224 Bridge Loan (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;July 15, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;January 16, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(reclassification)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(issuance)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zAbhamf6yZW" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;3.19&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--SharePrice_iI_pid_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_z64Ma4fo2Mof" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term to initial exercise date (years) (1)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--WarrantsAndRightsOutstandingTermToInitialExerciseDate_dtY_c20240116__20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_fKDEp_zcXnJ9apWTCk" title="Term to initial exercise date (years)"&gt;0.50&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z7VZpfBBKDAf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zUspIO83bWra" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zTUh2p0IL1h4" title="Term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zmJhZgZn5kze" title="Term (years)"&gt;5.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zQtJ5evwm8fl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;4.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zE6CO87NoSzj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;3.90&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240715__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_za4iYSViZnu7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant and right outstanding measurement input"&gt;112.5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20240116__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxyeuyuk4Ic8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants measurement input"&gt;107.5&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"&gt;
  &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
  &lt;td id="xdx_F04_z71VMIls35L4" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;(1)&lt;/td&gt;
  &lt;td id="xdx_F13_zKhae20pVIZ5" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;As discussed
further in Note 10, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July
15, 2024, the warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the
Company&#x2019;s own stock. As such, the warrants were adjusted to fair value as of the initial exercise date and then reclassified from
liability classified to equity classified.&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember"
      decimals="INF"
      id="Fact001432"
      unitRef="USDPShares">3.19</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember"
      decimals="INF"
      id="Fact001434"
      unitRef="USDPShares">2.00</us-gaap:SharePrice>
    <CELU:WarrantsAndRightsOutstandingTermToInitialExerciseDate
      contextRef="From2024-01-162024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember"
      id="Fact001436">P0Y6M</CELU:WarrantsAndRightsOutstandingTermToInitialExerciseDate>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001438"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001440"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember"
      id="Fact001442">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember"
      id="Fact001444">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001446"
      unitRef="Pure">4.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001448"
      unitRef="Pure">3.90</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-07-15_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001450"
      unitRef="Pure">112.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-01-16_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001452"
      unitRef="Pure">107.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember"
      id="Fact001455">&lt;p id="xdx_892_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zvnUoeoQ9v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the November
2024 Purchaser and Placement Agent Warrants were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B0_ztlx07gIa4l1" style="display: none"&gt;Schedule of November 2024
Purchaser and Placement Agent Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_303_134_zf71QPEgAjk3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Schedule of November 2024 Purchaser and Placement Agent Warrants (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;November
    25, 2024 And December 3, 2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;(issuance) (1)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Common share price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zfGGfYtsJZbc" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Common share price"&gt;2.08&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z46kT17Xe09" title="Common share price"&gt;&lt;span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zdPSTTIBsnPg" title="Common share price"&gt;2.00&lt;/span&gt;&lt;/span&gt; - $&lt;span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zUBNXIdNreje" title="Common share price"&gt;&lt;span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zD6q4W4va4Ei" title="Common share price"&gt;3.00&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term to Subsequent Financing (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_902_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20240101__20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDEp_zWcgJBsQJeA1" title="Term to Subsequent Financing (years)"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90D_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241125__20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zwMw4iO8pdL4" title="Term to Subsequent Financing (years)"&gt;&lt;span id="xdx_90F_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241203__20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zsMAnpTzZCy9" title="Term to Subsequent Financing (years)"&gt;0.1&lt;/span&gt;&lt;/span&gt; &#x2013; &lt;span id="xdx_90F_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241125__20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zaZtsaHXQC6i" title="Term to Subsequent Financing (years)"&gt;&lt;span id="xdx_90B_ecustom--WarrantsAndRightsOutstandingTermToSubsequentFinancing_dtY_c20241203__20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_znGABSFOpMX3" title="Term to Subsequent Financing (years)"&gt;0.6&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise price&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_z2ubyhNq9aP1" title="Exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1477"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;(2)
                                            (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_zNuCSAwlQxbb" title="Exercise price"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_fKDIpKDMp_zTugOBVBSw2" title="Exercise price"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1479"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1481"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt"&gt;(2)
                                            (3)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zyra5DSUeNdi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zqTqJDZCG9w8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Dividend yield"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_fKDEp_zlYgUJDN3XN2" title="Dividend yield"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Term (years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_zrf14xqZGeQg" title="Term (years)"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zQM7oWhv7xg2" title="Term (years)"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zwLjgcQrbbj7" title="Term (years)"&gt;4.9&lt;/span&gt;&lt;/span&gt; - &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zJBWbv0TIhd8" title="Term (years)"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zn5pqv4KyjNf" title="Term (years)"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zjXhXlFf6lch" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Risk-free interest rate"&gt;4.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_fKDEp_z7kdEynBbjV4" title="Risk-free interest rate"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_fKDEp_zYCIPq13Jt7l" title="Risk-free interest rate"&gt;4.00&lt;/span&gt;&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zXs8IFU1i6Yc" title="Risk-free interest rate"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_fKDEp_zrczjLQgNIc4" title="Risk-free interest rate"&gt;4.10&lt;/span&gt;&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_z4DuF0GwDnq4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrant and right outstanding measurement input"&gt;50.0&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zHJJnU0FRPxd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Warrants measurement input"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241203__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_fKDEp_zEtlV5c2Xc8d" title="Warrants measurement input"&gt;50.0&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F08_zwHFDf6Kt7oc" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F14_zaexGBibPay7" style="font-size: 10pt"&gt;As discussed in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F0C_zo1gJoXsJVn6" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F15_z1UxLlq7Ve35" style="font-size: 10pt"&gt;The exercise price of the November 2024 Purchaser Warrants is based on the lesser of (i) $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zqWPryMPDFY" title="Exercise price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zay0CNo8kkFc" title="Exercise price"&gt;2.85&lt;/span&gt;&lt;/span&gt; or (ii) the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zHA1eE5Olt08" title="Floor price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zJ5hleIJxI8l" title="Floor price"&gt;1.00&lt;/span&gt;&lt;/span&gt;. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F04_zTvOtzIYoIMl" style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_zZ0Nol6SrmT5" style="font-size: 10pt"&gt;The exercise price of the November 2024 Placement Agent Warrants is based on the lesser of (i) $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zO2jaDs7pQ78" title="Exercise price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zCedlLw6AzQh" title="Exercise price"&gt;3.56&lt;/span&gt;&lt;/span&gt; or (ii) &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_900_ecustom--OfferingPricePercentage_iI_pid_dp_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z7jn9S0Q2kz4" title="Offering price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_ecustom--OfferingPricePercentage_iI_pid_dp_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6z2KSFYOoUa" title="Offering price"&gt;125&lt;/span&gt;&lt;/span&gt;% of the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6RlELFC2O76" title="Floor price"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_909_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zXObzrFkExgd" title="Floor price"&gt;1.00&lt;/span&gt;&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001457"
      unitRef="USDPShares">2.08</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001459"
      unitRef="USDPShares">2.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001461"
      unitRef="USDPShares">2.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001463"
      unitRef="USDPShares">3.00</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001465"
      unitRef="USDPShares">3.00</us-gaap:SharePrice>
    <CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing
      contextRef="From2024-01-012024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember"
      id="Fact001467">P0Y1M6D</CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing>
    <CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing
      contextRef="From2024-11-252024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember"
      id="Fact001469">P0Y1M6D</CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing>
    <CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing
      contextRef="From2024-12-032024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember"
      id="Fact001471">P0Y1M6D</CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing>
    <CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing
      contextRef="From2024-11-252024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember"
      id="Fact001473">P0Y7M6D</CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing>
    <CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing
      contextRef="From2024-12-032024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember"
      id="Fact001475">P0Y7M6D</CELU:WarrantsAndRightsOutstandingTermToSubsequentFinancing>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001483"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001485"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001487"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember"
      id="Fact001489">P4Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember"
      id="Fact001491">P4Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MinimumMember"
      id="Fact001493">P4Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember"
      id="Fact001495">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_srt_MaximumMember"
      id="Fact001497">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001499"
      unitRef="Pure">4.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001501"
      unitRef="Pure">4.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001503"
      unitRef="Pure">4.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001505"
      unitRef="Pure">4.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001507"
      unitRef="Pure">4.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001509"
      unitRef="Pure">50.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001511"
      unitRef="Pure">50.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-03_custom_NovemberTwoThousandTwentyFourPurchaserAndPlacementAgentWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001513"
      unitRef="Pure">50.0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember"
      decimals="INF"
      id="Fact001517"
      unitRef="USDPShares">2.85</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember"
      decimals="INF"
      id="Fact001519"
      unitRef="USDPShares">2.85</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:FloorPrice
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember"
      decimals="INF"
      id="Fact001521"
      unitRef="USDPShares">1.00</CELU:FloorPrice>
    <CELU:FloorPrice
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPurchaserWarrantsMember"
      decimals="INF"
      id="Fact001523"
      unitRef="USDPShares">1.00</CELU:FloorPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001526"
      unitRef="USDPShares">3.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001528"
      unitRef="USDPShares">3.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:OfferingPricePercentage
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001530"
      unitRef="Pure">1.25</CELU:OfferingPricePercentage>
    <CELU:OfferingPricePercentage
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001532"
      unitRef="Pure">1.25</CELU:OfferingPricePercentage>
    <CELU:FloorPrice
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001534"
      unitRef="USDPShares">1.00</CELU:FloorPrice>
    <CELU:FloorPrice
      contextRef="AsOf2024-11-25_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember"
      decimals="INF"
      id="Fact001536"
      unitRef="USDPShares">1.00</CELU:FloorPrice>
    <CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock
      contextRef="From2024-01-012024-12-31_custom_GXSponsorWarrantsMember"
      id="Fact001538">&lt;p id="xdx_892_ecustom--ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock_hus-gaap--ClassOfWarrantOrRightAxis__custom--GXSponsorWarrantsMember_zGrSlJfF6DBk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Significant inputs for the Sponsor
Warrants are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BB_zB0hiBDOJ4C7" style="display: none"&gt;Schedule
of Significant Inputs for  Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_30D_134_zAdfdWkMttb7" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Schedule of Significant Inputs for Sponsor Warrants (Details)"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 68%; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2024&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-right: 1.5pt; padding-left: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-top: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 15%; padding-right: 2.65pt; padding-left: 2.65pt; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Common share price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$ &lt;span id="xdx_908_eus-gaap--SharePrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zdLpurqPp6A9" title="Common share price"&gt;2.08&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$ &lt;span id="xdx_902_eus-gaap--SharePrice_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zHrA3tQ4MLil" title="Common share price"&gt;2.47&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$ &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zIjzfAiMIA33" title="Exercise price"&gt;115.00&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$ &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zDtY0m1KwlSk" title="Exercise price"&gt;115.00&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_znSj9p5G03x7" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zkmoPeuCUJqa" title="Dividend yield"&gt;0&lt;/span&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Term (years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 2.65pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zJG9hzzs3Ie9" title="Term (years)"&gt;1.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 2.65pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember_zzBfFK2s4on2" title="Term (years)"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zlL5PZSicnPh" title="Dividend yield"&gt;4.21&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zLvpUZm4ACi" title="Dividend yield"&gt;4.12&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-right: 2.65pt; padding-left: 2.65pt"&gt;&lt;span style="font-size: 10pt"&gt;Volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 1.5pt; padding-left: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zFdi7bi7MYG5" title="Warrant and right outstanding measurement input"&gt;111.4&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 0.75pt; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--SponsorsWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zU0Uag68bPC4" title="Warrant measurement input"&gt;100.7&lt;/span&gt; %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</CELU:ScheduleOfFairValueSignificantInputsForWarrantsIssuedTableTextBlock>
    <us-gaap:SharePrice
      contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember"
      decimals="INF"
      id="Fact001540"
      unitRef="USDPShares">2.08</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember"
      decimals="INF"
      id="Fact001542"
      unitRef="USDPShares">2.47</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember"
      decimals="INF"
      id="Fact001544"
      unitRef="USDPShares">115.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember"
      decimals="INF"
      id="Fact001546"
      unitRef="USDPShares">115.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001548"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001550"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember"
      id="Fact001552">P1Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember"
      id="Fact001554">P2Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001556"
      unitRef="Pure">4.21</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputRiskFreeInterestRateMember"
      decimals="INF"
      id="Fact001558"
      unitRef="Pure">4.12</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2024-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001560"
      unitRef="Pure">111.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_custom_SponsorsWarrantsMember_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001562"
      unitRef="Pure">100.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001564">&lt;p id="xdx_802_eus-gaap--InventoryDisclosureTextBlock_zUj32syHQ38i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 9pt"&gt;&lt;b&gt;5. &lt;span id="xdx_82C_zDfNpZ71Gtsl"&gt;Inventory&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_zbJGEZG537Ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s major classes
of inventories were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B2_zNXMLq17be14" style="display: none"&gt;Schedule of Major Classes of Inventories&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_z0oxNuQH6BM9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_z1Sy0CV749j8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--InventoryRawMaterialsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zhgsDZuCwOoa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;42&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,081&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InventoryWorkInProgressCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zVB3cP12G5M3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Work in progress&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,093&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,696&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InventoryFinishedGoodsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zIJhOEWkJYhc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,964&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,922&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--InventoryGrossCurrentAndNoncurrent_iTI_pn3n3_mtIGCANzRGk_maINCANzn4U_zR9JoHVr99Fh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Inventory, gross&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,099&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;24,699&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--InventoryReserveCurrentAndNoncurrent_iNI_pn3n3_di_msINCANzn4U_zQKbRCaEbD27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less: inventory reserves&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,103&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,289&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzn4U_zjOUTiYxcyBj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Inventory, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,996&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,410&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Balance sheet classification:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InventoryNet_iI_pn3n3_maINCANzRqB_zkUsypJ2wO8b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Inventory&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,409&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,753&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryNoncurrent_iI_pn3n3_maINCANzRqB_zYrOm4DbQWJl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Inventory, net of current portion&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,587&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;16,657&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzRqB_zUrrpmwh493i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,996&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,410&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zGCq0q5VkL9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Inventory, net of current portion
includes inventory expected to remain on-hand beyond one year from each balance sheet date presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company recognized a $&lt;span id="xdx_905_ecustom--InventoryImpairmentCharge_pn3n3_c20240101__20241231_zVK6lO0lri2f" title="Inventory impairment charge"&gt;466&lt;/span&gt;
inventory impairment charge during the year ended December 31, 2024 in the consolidated statements of operations and comprehensive loss
due to lower of cost or net realizable value adjustments for finished goods. The Company recognized a $&lt;span id="xdx_903_ecustom--InventoryImpairmentCharge_pn3n3_c20230101__20231231_zSGpucAq6sT2" title="Inventory impairment charge"&gt;5,384&lt;/span&gt; inventory impairment charge during the
year ended December 31, 2023 in the consolidated statements of operations and comprehensive loss due to lower of cost or net realizable value adjustments
of $&lt;span id="xdx_90D_ecustom--InventoryImpairmentCharge_pn3n3_c20230101__20231231__us-gaap--PublicUtilitiesInventoryAxis__custom--InventoryFinishedGoodsMember_znxgQfGZKCec" title="Inventory impairment charge"&gt;2,129&lt;/span&gt; for finished goods and $&lt;span id="xdx_900_ecustom--InventoryImpairmentCharge_pn3n3_c20230101__20231231__us-gaap--PublicUtilitiesInventoryAxis__custom--InventoryWorkInProgressMember_zTbcT7fYNyu6" title="Inventory impairment charge"&gt;3,255&lt;/span&gt; for work in progress.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfActivityInInventoryReservesTableTextBlock_zoEC85ifNptj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;A schedule of the activity in
the inventory reserves is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zt5KLN76Jir9" style="display: none"&gt;Schedule of Inventory Reserves&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20230101__20231231_zz06ao9xkpqk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"&gt;1,099&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Provision for obsolete inventory&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ProvisionForObsoleteInventory_pn3n3_c20230101__20231231_zPXHSsX6uZx8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions for obsolete inventory"&gt;7,627&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Write-offs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231_zJHTXS7zIXDd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-offs"&gt;(6,437&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20240101__20241231_zid77wqlTBR5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"&gt;2,289&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Provision for obsolete inventory&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ProvisionForObsoleteInventory_pn3n3_c20240101__20241231_zNYqVjdhWtic" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Provision for obsolete inventory"&gt;(186&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InventoryReserveCurrentAndNoncurrent_iE_pn3n3_c20240101__20241231_z4Cf0d7yZPK9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;2,103&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zQ9i1U1FuV17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <CELU:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001566">&lt;p id="xdx_899_ecustom--ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock_zbJGEZG537Ij" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s major classes
of inventories were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B2_zNXMLq17be14" style="display: none"&gt;Schedule of Major Classes of Inventories&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20241231_z0oxNuQH6BM9" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_z1Sy0CV749j8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--InventoryRawMaterialsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zhgsDZuCwOoa" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;42&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,081&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InventoryWorkInProgressCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zVB3cP12G5M3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Work in progress&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,093&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,696&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--InventoryFinishedGoodsCurrentAndNoncurrent_iI_pn3n3_maIGCANzRGk_zIJhOEWkJYhc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,964&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,922&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--InventoryGrossCurrentAndNoncurrent_iTI_pn3n3_mtIGCANzRGk_maINCANzn4U_zR9JoHVr99Fh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Inventory, gross&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,099&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;24,699&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--InventoryReserveCurrentAndNoncurrent_iNI_pn3n3_di_msINCANzn4U_zQKbRCaEbD27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less: inventory reserves&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,103&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(2,289&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzn4U_zjOUTiYxcyBj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Inventory, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,996&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,410&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Balance sheet classification:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InventoryNet_iI_pn3n3_maINCANzRqB_zkUsypJ2wO8b" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Inventory&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,409&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,753&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryNoncurrent_iI_pn3n3_maINCANzRqB_zYrOm4DbQWJl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Inventory, net of current portion&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,587&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;16,657&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--InventoryNetCurrentAndNoncurrent_iTI_pn3n3_mtINCANzRqB_zUrrpmwh493i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory,
    net&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;17,996&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,410&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CELU:ScheduleOfInventoryCurrentAndNoncurrentTableTextBlock>
    <CELU:InventoryRawMaterialsCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001568"
      unitRef="USD">42000</CELU:InventoryRawMaterialsCurrentAndNoncurrent>
    <CELU:InventoryRawMaterialsCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001569"
      unitRef="USD">3081000</CELU:InventoryRawMaterialsCurrentAndNoncurrent>
    <CELU:InventoryWorkInProgressCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001571"
      unitRef="USD">8093000</CELU:InventoryWorkInProgressCurrentAndNoncurrent>
    <CELU:InventoryWorkInProgressCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001572"
      unitRef="USD">10696000</CELU:InventoryWorkInProgressCurrentAndNoncurrent>
    <CELU:InventoryFinishedGoodsCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001574"
      unitRef="USD">11964000</CELU:InventoryFinishedGoodsCurrentAndNoncurrent>
    <CELU:InventoryFinishedGoodsCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001575"
      unitRef="USD">10922000</CELU:InventoryFinishedGoodsCurrentAndNoncurrent>
    <CELU:InventoryGrossCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001577"
      unitRef="USD">20099000</CELU:InventoryGrossCurrentAndNoncurrent>
    <CELU:InventoryGrossCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001578"
      unitRef="USD">24699000</CELU:InventoryGrossCurrentAndNoncurrent>
    <CELU:InventoryReserveCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001580"
      unitRef="USD">2103000</CELU:InventoryReserveCurrentAndNoncurrent>
    <CELU:InventoryReserveCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001581"
      unitRef="USD">2289000</CELU:InventoryReserveCurrentAndNoncurrent>
    <CELU:InventoryNetCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001583"
      unitRef="USD">17996000</CELU:InventoryNetCurrentAndNoncurrent>
    <CELU:InventoryNetCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001584"
      unitRef="USD">22410000</CELU:InventoryNetCurrentAndNoncurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001586"
      unitRef="USD">5409000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001587"
      unitRef="USD">5753000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001589"
      unitRef="USD">12587000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001590"
      unitRef="USD">16657000</us-gaap:InventoryNoncurrent>
    <CELU:InventoryNetCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001592"
      unitRef="USD">17996000</CELU:InventoryNetCurrentAndNoncurrent>
    <CELU:InventoryNetCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001593"
      unitRef="USD">22410000</CELU:InventoryNetCurrentAndNoncurrent>
    <CELU:InventoryImpairmentCharge
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001595"
      unitRef="USD">466000</CELU:InventoryImpairmentCharge>
    <CELU:InventoryImpairmentCharge
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001597"
      unitRef="USD">5384000</CELU:InventoryImpairmentCharge>
    <CELU:InventoryImpairmentCharge
      contextRef="From2023-01-012023-12-31_custom_InventoryFinishedGoodsMember"
      decimals="-3"
      id="Fact001599"
      unitRef="USD">2129000</CELU:InventoryImpairmentCharge>
    <CELU:InventoryImpairmentCharge
      contextRef="From2023-01-012023-12-31_custom_InventoryWorkInProgressMember"
      decimals="-3"
      id="Fact001601"
      unitRef="USD">3255000</CELU:InventoryImpairmentCharge>
    <CELU:ScheduleOfActivityInInventoryReservesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001603">&lt;p id="xdx_891_ecustom--ScheduleOfActivityInInventoryReservesTableTextBlock_zoEC85ifNptj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;A schedule of the activity in
the inventory reserves is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B6_zt5KLN76Jir9" style="display: none"&gt;Schedule of Inventory Reserves&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 80%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20230101__20231231_zz06ao9xkpqk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Beginning balance"&gt;1,099&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Provision for obsolete inventory&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ProvisionForObsoleteInventory_pn3n3_c20230101__20231231_zPXHSsX6uZx8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Additions for obsolete inventory"&gt;7,627&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Write-offs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--InventoryWriteDown_pn3n3_c20230101__20231231_zJHTXS7zIXDd" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Write-offs"&gt;(6,437&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--InventoryReserveCurrentAndNoncurrent_iS_pn3n3_c20240101__20241231_zid77wqlTBR5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Beginning balance"&gt;2,289&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Provision for obsolete inventory&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--ProvisionForObsoleteInventory_pn3n3_c20240101__20241231_zNYqVjdhWtic" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Provision for obsolete inventory"&gt;(186&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InventoryReserveCurrentAndNoncurrent_iE_pn3n3_c20240101__20241231_z4Cf0d7yZPK9" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Ending balance"&gt;2,103&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CELU:ScheduleOfActivityInInventoryReservesTableTextBlock>
    <CELU:InventoryReserveCurrentAndNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact001605"
      unitRef="USD">1099000</CELU:InventoryReserveCurrentAndNoncurrent>
    <CELU:ProvisionForObsoleteInventory
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001607"
      unitRef="USD">7627000</CELU:ProvisionForObsoleteInventory>
    <us-gaap:InventoryWriteDown
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001609"
      unitRef="USD">-6437000</us-gaap:InventoryWriteDown>
    <CELU:InventoryReserveCurrentAndNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001611"
      unitRef="USD">2289000</CELU:InventoryReserveCurrentAndNoncurrent>
    <CELU:ProvisionForObsoleteInventory
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001613"
      unitRef="USD">-186000</CELU:ProvisionForObsoleteInventory>
    <CELU:InventoryReserveCurrentAndNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001615"
      unitRef="USD">2103000</CELU:InventoryReserveCurrentAndNoncurrent>
    <CELU:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001617">&lt;p id="xdx_80C_ecustom--PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock_ztg47MUKmRcf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;6. &lt;span id="xdx_82F_zjXVz5q2zpEa"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqYfYW8Dbhuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Prepaid expenses and other current
assets consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_z4EEgadYQn07" style="display: none"&gt;Schedule of Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zi4ei7GVBExl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zsxUhxK2I4t8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidClinicalExpense_iI_pn3n3_maPEAOAzmHw_zomryCENgGJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Prepaid clinical expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;221&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;688&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzmHw_zs27gXEcEKtc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Prepaid insurance expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;375&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;678&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzmHw_zXnzH76PbSYf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;261&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;329&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzmHw_zVQJCjGAr3fb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;857&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,695&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zEBOwtpqP2yj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</CELU:PrepaidExpensesAndOtherCurrentAssetsDisclosureTextBlock>
    <CELU:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001619">&lt;p id="xdx_898_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zqYfYW8Dbhuc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Prepaid expenses and other current
assets consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_z4EEgadYQn07" style="display: none"&gt;Schedule of Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20241231_zi4ei7GVBExl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zsxUhxK2I4t8" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidClinicalExpense_iI_pn3n3_maPEAOAzmHw_zomryCENgGJ2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Prepaid clinical expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;221&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;688&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PrepaidInsurance_iI_pn3n3_maPEAOAzmHw_zs27gXEcEKtc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Prepaid insurance expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;375&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;678&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3n3_maPEAOAzmHw_zXnzH76PbSYf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;261&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;329&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3n3_mtPEAOAzmHw_zVQJCjGAr3fb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid
    expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;857&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,695&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CELU:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <CELU:PrepaidClinicalExpense
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001621"
      unitRef="USD">221000</CELU:PrepaidClinicalExpense>
    <CELU:PrepaidClinicalExpense
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001622"
      unitRef="USD">688000</CELU:PrepaidClinicalExpense>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001624"
      unitRef="USD">375000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001625"
      unitRef="USD">678000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001627"
      unitRef="USD">261000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001628"
      unitRef="USD">329000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001630"
      unitRef="USD">857000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001631"
      unitRef="USD">1695000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001633">&lt;p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_znGHWKsYKE52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;7. &lt;span id="xdx_82F_zBclf8ZH9sA"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zrEB20Nhmw9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Property and equipment, net consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B0_zV1V4CvDzjj6" style="display: none"&gt;Schedule of Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zu1AF8La1y4c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zohzI8AJFkeg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zon6DKNLfu6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;73,211&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;73,211&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryAndProductionEquipmentMember_zVnagmLc6SSd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Laboratory and production equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,093&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,093&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryEquipmentAndFixturesMember_zoDb4Y1Ecrp8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Machinery, equipment and fixtures&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,163&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,781&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zgtMKGpgvAm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Construction in progress&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1646"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzl3Y_zaEDlb83rPW7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;94,467&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;95,106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzl3Y_zsJCGdbHmB4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation and amortization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(32,867&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(27,278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzl3Y_znmECYxPwsa1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;61,600&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;67,828&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zgb55HJm93u9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Depreciation expense was $&lt;span id="xdx_904_eus-gaap--Depreciation_pn3n3_c20240101__20241231_zrdyFlI62lVf" title="Depreciation"&gt;6,169&lt;/span&gt;
and $&lt;span id="xdx_90C_eus-gaap--Depreciation_pn3n3_c20230101__20231231_zrQCErHj6fHk" title="Depreciation expense"&gt;7,131&lt;/span&gt; for the years ended December 31, 2024 and 2023 respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001635">&lt;p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zrEB20Nhmw9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Property and equipment, net consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B0_zV1V4CvDzjj6" style="display: none"&gt;Schedule of Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zu1AF8La1y4c" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zohzI8AJFkeg" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zon6DKNLfu6f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;73,211&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;73,211&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--LaboratoryAndProductionEquipmentMember_zVnagmLc6SSd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Laboratory and production equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,093&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,093&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--MachineryEquipmentAndFixturesMember_zoDb4Y1Ecrp8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Machinery, equipment and fixtures&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,163&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,781&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zgtMKGpgvAm" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Construction in progress&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1646"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;21&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzl3Y_zaEDlb83rPW7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;94,467&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;95,106&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3n3_di_msPPAENzl3Y_zsJCGdbHmB4i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less: Accumulated depreciation and amortization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(32,867&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(27,278&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3n3_mtPPAENzl3Y_znmECYxPwsa1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;61,600&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;67,828&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact001637"
      unitRef="USD">73211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact001638"
      unitRef="USD">73211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_LaboratoryAndProductionEquipmentMember"
      decimals="-3"
      id="Fact001640"
      unitRef="USD">14093000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_LaboratoryAndProductionEquipmentMember"
      decimals="-3"
      id="Fact001641"
      unitRef="USD">14093000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31_custom_MachineryEquipmentAndFixturesMember"
      decimals="-3"
      id="Fact001643"
      unitRef="USD">7163000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_custom_MachineryEquipmentAndFixturesMember"
      decimals="-3"
      id="Fact001644"
      unitRef="USD">7781000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="Fact001647"
      unitRef="USD">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001649"
      unitRef="USD">94467000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001650"
      unitRef="USD">95106000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001652"
      unitRef="USD">32867000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001653"
      unitRef="USD">27278000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001655"
      unitRef="USD">61600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001656"
      unitRef="USD">67828000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001658"
      unitRef="USD">6169000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001660"
      unitRef="USD">7131000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001662">&lt;p id="xdx_80B_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zB3CJnqs7h1c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;8. &lt;span id="xdx_82D_zil7g7Usjdz1"&gt;Goodwill and Intangible Assets, Net&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company tests its goodwill
for impairment on an annual basis in the fourth quarter of each year for all of its reporting units, or more frequently if events or circumstances
indicate a potential impairment. The Company manages its operations through an evaluation of &lt;span id="xdx_906_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zDWYYDbxvuej" title="Number of operating segments"&gt;three&lt;/span&gt; different operating segments: Cell
Therapy, Degenerative Disease and BioBanking (see Note 19). The Company determined that the operating segments represented the reporting
units.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;During annual impairment tests
and for any period in which the Company identifies an impairment trigger, the Company&#x2019;s methodology includes internally generated
separate cash flow projections for each reporting unit based on the different drivers that affect each reporting unit. The Company compares
the fair values of each of its reporting units to their respective carrying amounts. If the carrying value of a reporting unit exceeds
its estimated fair value, a goodwill impairment charge is recorded for the difference, with the impairment loss limited to the total amount
of goodwill allocated to that reporting unit. The fair values of each of the Company&#x2019;s reporting units were derived using the income
approach, specifically the discounted cash flow method. The use of a discounted cash flow analysis requires significant judgment to estimate
the future cash flows and the period of time over which those cash flows will be realized, as well as to determine the appropriate discount
rate. The discounted cash flow model reflects management&#x2019;s assumptions regarding revenue growth rates, risk-adjusted discount rates,
terminal period growth rates, economic and market trends, and other expectations about the anticipated operating results of the Company&#x2019;s
reporting units. As part of the goodwill impairment test, the Company also considers its market capitalization in assessing the reasonableness
of the combined fair values estimated for its reporting units. Substantial changes in the cash flows assumptions of the different reporting
units may lead to a future impairment or may alter the implied distribution of value between the different reporting units. A material
decline in the Company&#x2019;s stock price may affect the imputed discount rate and the distribution of value between the reporting units,
which may also lead to a future impairment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The carrying value of
goodwill, all of which was assigned to the Company&#x2019;s BioBanking reporting unit, was $&lt;span id="xdx_900_eus-gaap--Goodwill_iI_pn3n3_c20241231_zj9GkYnWr9f1" title="Goodwill"&gt;&lt;span id="xdx_90E_eus-gaap--Goodwill_iI_pn3n3_c20231231_z5kOs5kI5W11" title="Goodwill"&gt;7,347&lt;/span&gt;&lt;/span&gt;
at both December 31, 2024 and 2023. At December 31, 2024, the Company performed a qualitative assessment to determine whether the
existence of events or circumstances would indicate that it was more likely than not that the that the fair value of the reporting
unit is less than its carrying amount. Based on the assessment, there was &lt;span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_dxL_c20240101__20241231_zFlxrRjfSlGj" title="Goodwill, impairment loss::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1670"&gt;no&lt;/span&gt;&lt;/span&gt;
goodwill impairment recognized during the year ended December 31, 2024. At December 31, 2023, the estimated fair value of the
BioBanking reporting unit was substantially in excess of its book value. The relative stability of the expected cash flows of the
BioBanking reporting unit makes an impairment of goodwill in the future less likely.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Degenerative Disease reporting unit goodwill was fully impaired as
of December 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;For the year ended December 31,
2023, the Company recognized $&lt;span id="xdx_908_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20231231_zEJ2KmV5UfQg" title="Goodwill, impairment loss"&gt;112,347&lt;/span&gt; of goodwill impairment charges related to its Cell Therapy reporting unit, which resulted in full
impairment of the reporting unit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;During the first quarter 2023,
as a result of a sustained decrease in its stock price and market capitalization, and its decision to cease recruitment in its GBM and
HER2+ gastric trials, the Company tested for impairment due to these triggering events. Based on the results of the impairment analysis,
the carrying value exceeded the fair value on the Cell Therapy reporting unit. The Company recognized a $&lt;span id="xdx_906_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230101__20230331__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zIZ52k3ea8cb" title="Goodwill impairment"&gt;29,633&lt;/span&gt; goodwill impairment charge
during the first quarter of 2023 in its consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;During the second quarter of 2023,
the Company&#x2019;s stock price and market capitalization continued to decline, and the Company also determined to cease active recruitment
in its AML trial and halted all NK programs. The AML trial was the Company&#x2019;s most advanced clinical program with a relatively large
addressable patient population given the high unmet medical need in relapsed and refractory AML. After the Company ceased recruitment,
it removed all associated cash flows relating to that program including all other NK related programs as well. As a result of these triggering
events, the Company fully impaired the IPR&amp;amp;D assets associated with these product candidates, and performed a goodwill impairment
test on its Cell Therapy reporting unit. At June 30, 2023, the estimated fair value of the Cell Therapy reporting unit was determined
to be at breakeven compared to the carrying value using a discount rate commensurate with the risks associated with the cash flows for
preclinical product candidates. The Company also performed a reconciliation of the aggregate fair value of each reporting unit to the
market capitalization of the Company. The analysis showed the fair value of the reporting units approximated the Company&#x2019;s market
capitalization, indicating an insignificant control premium. Based on the results of the impairment analysis, the Company did not recognize
a goodwill impairment charge during the second quarter of 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;During the third quarter of 2023,
the Company&#x2019;s stock price and market capitalization continued to further decline. The Company also elected to terminate development
of CYCART-19 for B-cell malignancies during the quarter, as well as paused development in exosomes. Therefore, the Company tested for
impairment due to these triggering events. Based on the results of the impairment analysis, the carrying value exceeded the fair value
on the Cell Therapy reporting unit. The Company recognized a goodwill impairment charge for the remaining goodwill balance on the Cell
Therapy reporting unit of $&lt;span id="xdx_90A_eus-gaap--GoodwillImpairmentLoss_pn3n3_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_z2e9ZkJw5FF3" title="Goodwill impairment"&gt;82,714&lt;/span&gt; during the third quarter of 2023 in its consolidated statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Intangible Assets, Net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--ScheduleOfIntangibleAssetsNetTableTextBlock_zp9R0cz9cBoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Intangible assets, net consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;span id="xdx_8BD_zEI0baKYzh72" style="display: none"&gt;Schedule of Intangible Assets, Net&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;Estimated Useful&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lives&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"&gt;Developed technology&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zk4Hg6LIWdI" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Amortizable intangible assets"&gt;16,810&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z8DV7ILVQOCl" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Amortizable intangible assets"&gt;16,810&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zKomfhsDWbX8" title="Estimated useful lives"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zKeqrOcyApE7" title="Estimated useful lives"&gt;11&lt;/span&gt;&lt;/span&gt; &#x2013; &lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zE7O61tLP2jg" title="Estimated useful lives"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zGZ8JDgOKlt8" title="Estimated useful lives"&gt;16&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpey0st8Psof" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;2,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zt79MvYyhrrd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;2,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZNRm9GWyzOe" title="Estimated useful lives"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_znA3YFipl42k" title="Estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Trade names &amp;amp; trademarks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zQtE0ZjLJ3Td" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;570&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z1K0sSPuLrpk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;570&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zypKiA9HYaJ3" title="Estimated useful lives"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zLJ6nI2dRzFj" title="Estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt; &#x2013; &lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zmxkha5Nynoh" title="Estimated useful lives"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zT5gbhQv4yma" title="Estimated useful lives"&gt;13&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reacquired rights&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zCOBGXONR1Xe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;4,200&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z0Q6d4BviyFj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;4,200&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zRVXc399vNK2" title="Estimated useful lives"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zuPFnsfYBbJk" title="Estimated useful lives"&gt;6&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231_zMysKLxwjrM3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;23,993&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zKntFN5eObw7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;23,993&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Developed technology&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zuIiJvpDIE76" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(8,895&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zYggwKni2n4c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(7,722&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMJutBLF2Gzc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(1,965&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zm0AIZpePhp1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(1,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Trade names &amp;amp; trademarks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zRf3C91RYWL4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(385&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zq7vyMKCivQe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(330&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reacquired rights&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zYQCEH6iTGwe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(4,200&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z6rGmCBUzS85" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(3,940&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231_zCO8uBdZSHg1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(15,445&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zsoXmgHUdaga" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(13,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Amortizable intangible assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20241231_zeAQLZlamwXb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets, net"&gt;8,548&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zH0T6eOSvxK1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets, net"&gt;10,301&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Non-amortized intangible assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Acquired IPR&amp;amp;D product rights&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pn3n3_c20241231_zCwQlrHnCual" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Acquired IPR&amp;amp;D product rights"&gt;700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pn3n3_c20231231_zD6WkEBB7u58" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Acquired IPR&amp;amp;D product rights"&gt;700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90D_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20240101__20241231_zJ8NLo7eOplc" title="Estimated useful lives"&gt;&lt;span id="xdx_903_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231_zJRToTbP3Oi3" title="Estimated useful lives"&gt;indefinite&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zN9HH3HOXyC4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Intangible assets, net"&gt;9,248&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231_zw7IsKKgInCa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Intangible assets, net"&gt;11,001&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zwoZkJnhaoif" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Amortization expense for intangible
assets was $&lt;span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240101__20241231_zI6DDFjYdW57" title="Amortization expense for intangible assets"&gt;1,753&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20230101__20231231_zQFQQ2n3b448" title="Amortization expense for intangible assets"&gt;2,193&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20240101__20241231_zeYPlweYr5cl" title="Impairment of intangible assets"&gt;&lt;span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsFinitelived_do_c20230101__20231231_zJXdRaeuQqsd" title="Impairment of intangible assets"&gt;No&lt;/span&gt;&lt;/span&gt; impairment charges were recorded
on intangible assets for the year ended December 31, 2024. During the year ended December 31, 2023, the Company discontinued its unmodified
NK cell and AML Cell Therapy clinical trials and as a result recorded an IPR&amp;amp;D impairment of $&lt;span id="xdx_903_eus-gaap--OtherAssetImpairmentCharges_pn3n3_c20230101__20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InProcessResearchAndDevelopmentMember_zS5kM6D0Kj4a" title="Impairment of intangible assets"&gt;107,800&lt;/span&gt; on its CYNK-001 and GMNK intangible
assets acquired from the Anthrogenesis acquisition.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zsnhUmgIjgEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Aggregate amortization expense
for each of the five succeeding years and thereafter related to intangible assets held as of December 31, 2024 is estimated as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zIfmSuNTef3g" style="display: none"&gt;Schedule of Aggregate Amortization Expense Related to Intangible Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20241231_z5US2EjNLEja" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANziI0_z0mTudr8y395" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;1,493&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANziI0_z1YnuRaZCey1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,356&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANziI0_zYCmO88Xjf94" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,258&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANziI0_zOZP3u3m1stl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,208&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANziI0_zvMflM025v27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2029&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,155&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANziI0_zpwNfqesTSr3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,078&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANziI0_zM1f7lQIOgtf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,548&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z9KRpM8JBAV8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact001664"
      unitRef="Segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Goodwill
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001666"
      unitRef="USD">7347000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001668"
      unitRef="USD">7347000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001672"
      unitRef="USD">112347000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-01-012023-03-31_custom_CellTherapyMember"
      decimals="-3"
      id="Fact001674"
      unitRef="USD">29633000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-07-012023-09-30_custom_CellTherapyMember"
      decimals="-3"
      id="Fact001676"
      unitRef="USD">82714000</us-gaap:GoodwillImpairmentLoss>
    <CELU:ScheduleOfIntangibleAssetsNetTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001678">&lt;p id="xdx_89A_ecustom--ScheduleOfIntangibleAssetsNetTableTextBlock_zp9R0cz9cBoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Intangible assets, net consisted
of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;span id="xdx_8BD_zEI0baKYzh72" style="display: none"&gt;Schedule of Intangible Assets, Net&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1pt; text-align: center"&gt;Estimated Useful&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Lives&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Amortizable intangible assets:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"&gt;Developed technology&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zk4Hg6LIWdI" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Amortizable intangible assets"&gt;16,810&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_z8DV7ILVQOCl" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Amortizable intangible assets"&gt;16,810&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zKomfhsDWbX8" title="Estimated useful lives"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zKeqrOcyApE7" title="Estimated useful lives"&gt;11&lt;/span&gt;&lt;/span&gt; &#x2013; &lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zE7O61tLP2jg" title="Estimated useful lives"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zGZ8JDgOKlt8" title="Estimated useful lives"&gt;16&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpey0st8Psof" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;2,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zt79MvYyhrrd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;2,413&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zZNRm9GWyzOe" title="Estimated useful lives"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_znA3YFipl42k" title="Estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Trade names &amp;amp; trademarks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zQtE0ZjLJ3Td" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;570&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z1K0sSPuLrpk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;570&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zypKiA9HYaJ3" title="Estimated useful lives"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zLJ6nI2dRzFj" title="Estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt; &#x2013; &lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zmxkha5Nynoh" title="Estimated useful lives"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zT5gbhQv4yma" title="Estimated useful lives"&gt;13&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reacquired rights&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zCOBGXONR1Xe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;4,200&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z0Q6d4BviyFj" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;4,200&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zRVXc399vNK2" title="Estimated useful lives"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zuPFnsfYBbJk" title="Estimated useful lives"&gt;6&lt;/span&gt;&lt;/span&gt; years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20241231_zMysKLxwjrM3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;23,993&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231_zKntFN5eObw7" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets"&gt;23,993&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Developed technology&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zuIiJvpDIE76" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(8,895&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--DevelopedTechnologyRightsMember_zYggwKni2n4c" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(7,722&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Customer relationships&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zMJutBLF2Gzc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(1,965&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zm0AIZpePhp1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(1,700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Trade names &amp;amp; trademarks&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zRf3C91RYWL4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(385&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zq7vyMKCivQe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(330&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Reacquired rights&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_zYQCEH6iTGwe" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(4,200&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ReacquiredRightsMember_z6rGmCBUzS85" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(3,940&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20241231_zCO8uBdZSHg1" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(15,445&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231_zsoXmgHUdaga" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Accumulated amortization"&gt;(13,692&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Amortizable intangible assets, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20241231_zeAQLZlamwXb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets, net"&gt;8,548&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20231231_zH0T6eOSvxK1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Amortizable intangible assets, net"&gt;10,301&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Non-amortized intangible assets&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Acquired IPR&amp;amp;D product rights&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pn3n3_c20241231_zCwQlrHnCual" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Acquired IPR&amp;amp;D product rights"&gt;700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_pn3n3_c20231231_zD6WkEBB7u58" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Acquired IPR&amp;amp;D product rights"&gt;700&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 1pt"&gt;&lt;span id="xdx_90D_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20240101__20241231_zJ8NLo7eOplc" title="Estimated useful lives"&gt;&lt;span id="xdx_903_ecustom--IndefiniteLivedIntangibleAssetsAmortizationMethod_c20230101__20231231_zJRToTbP3Oi3" title="Estimated useful lives"&gt;indefinite&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20241231_zN9HH3HOXyC4" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Intangible assets, net"&gt;9,248&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231_zw7IsKKgInCa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Intangible assets, net"&gt;11,001&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CELU:ScheduleOfIntangibleAssetsNetTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-3"
      id="Fact001680"
      unitRef="USD">16810000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-3"
      id="Fact001682"
      unitRef="USD">16810000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact001684">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_srt_MinimumMember_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact001686">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact001688">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_srt_MaximumMember_us-gaap_DevelopedTechnologyRightsMember"
      id="Fact001690">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001692"
      unitRef="USD">2413000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001694"
      unitRef="USD">2413000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_us-gaap_CustomerRelationshipsMember"
      id="Fact001696">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember"
      id="Fact001698">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-3"
      id="Fact001700"
      unitRef="USD">570000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-3"
      id="Fact001702"
      unitRef="USD">570000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_srt_MinimumMember_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact001704">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_srt_MinimumMember_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact001706">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_srt_MaximumMember_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact001708">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_srt_MaximumMember_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact001710">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31_custom_ReacquiredRightsMember"
      decimals="-3"
      id="Fact001712"
      unitRef="USD">4200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_ReacquiredRightsMember"
      decimals="-3"
      id="Fact001714"
      unitRef="USD">4200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2024-12-31_custom_ReacquiredRightsMember"
      id="Fact001716">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2023-12-31_custom_ReacquiredRightsMember"
      id="Fact001718">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001720"
      unitRef="USD">23993000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001722"
      unitRef="USD">23993000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-3"
      id="Fact001724"
      unitRef="USD">-8895000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-3"
      id="Fact001726"
      unitRef="USD">-7722000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001728"
      unitRef="USD">-1965000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001730"
      unitRef="USD">-1700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-3"
      id="Fact001732"
      unitRef="USD">-385000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-3"
      id="Fact001734"
      unitRef="USD">-330000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31_custom_ReacquiredRightsMember"
      decimals="-3"
      id="Fact001736"
      unitRef="USD">-4200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31_custom_ReacquiredRightsMember"
      decimals="-3"
      id="Fact001738"
      unitRef="USD">-3940000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001740"
      unitRef="USD">-15445000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001742"
      unitRef="USD">-13692000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001744"
      unitRef="USD">8548000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001746"
      unitRef="USD">10301000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001748"
      unitRef="USD">700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001750"
      unitRef="USD">700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <CELU:IndefiniteLivedIntangibleAssetsAmortizationMethod contextRef="From2024-01-01to2024-12-31" id="Fact001752">indefinite</CELU:IndefiniteLivedIntangibleAssetsAmortizationMethod>
    <CELU:IndefiniteLivedIntangibleAssetsAmortizationMethod contextRef="From2023-01-012023-12-31" id="Fact001754">indefinite</CELU:IndefiniteLivedIntangibleAssetsAmortizationMethod>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001756"
      unitRef="USD">9248000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001758"
      unitRef="USD">11001000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact001760"
      unitRef="USD">1753000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact001762"
      unitRef="USD">2193000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact001764"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact001766"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="From2023-01-012023-12-31_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-3"
      id="Fact001768"
      unitRef="USD">107800000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001770">&lt;p id="xdx_899_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zsnhUmgIjgEg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Aggregate amortization expense
for each of the five succeeding years and thereafter related to intangible assets held as of December 31, 2024 is estimated as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zIfmSuNTef3g" style="display: none"&gt;Schedule of Aggregate Amortization Expense Related to Intangible Assets&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_499_20241231_z5US2EjNLEja" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pn3n3_maFLIANziI0_z0mTudr8y395" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;1,493&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pn3n3_maFLIANziI0_z1YnuRaZCey1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,356&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pn3n3_maFLIANziI0_zYCmO88Xjf94" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,258&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pn3n3_maFLIANziI0_zOZP3u3m1stl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,208&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pn3n3_maFLIANziI0_zvMflM025v27" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2029&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,155&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pn3n3_maFLIANziI0_zpwNfqesTSr3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,078&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pn3n3_mtFLIANziI0_zM1f7lQIOgtf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
    expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;8,548&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001772"
      unitRef="USD">1493000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001774"
      unitRef="USD">1356000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001776"
      unitRef="USD">1258000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001778"
      unitRef="USD">1208000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001780"
      unitRef="USD">1155000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001782"
      unitRef="USD">2078000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001784"
      unitRef="USD">8548000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001786">&lt;p id="xdx_803_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zTmJ9voyBuPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;9. &lt;span id="xdx_822_z6IxIn0Sz2r8"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zoX30kvD2mj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Accrued expenses and other current
liabilities consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B4_zIUy5zgunx62" style="display: none"&gt;Schedule of Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zUAi0bF2i42i" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zuwPaF1q9IUd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedClinicalTrialExpense_iI_pn3n3_maALCzZ4Y_zzAhWduSOoRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Accrued clinical trial expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;189&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;189&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZ4Y_zJ6XaJr5vRmc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;691&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;573&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_zrvXYFNqhztb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued wages, bonuses, commissions and vacation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,797&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,011&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AccrualsForConstructionInProgress_iI_pn3n3_maALCzZ4Y_zn9pm8Seomub" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accruals for construction in progress&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;135&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;214&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzZ4Y_zppufrkn0l51" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,798&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1803"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AccruedComplianceFee_iI_pn3n3_maALCzZ4Y_zTcBA7RcvQ1f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued compliance fee&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,277&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,145&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_z2OK4PmAx5Bc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;955&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,448&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZ4Y_zaLHpancMSKc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19,842&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,580&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zgkgdF1r8Jhh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001788">&lt;p id="xdx_89E_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zoX30kvD2mj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Accrued expenses and other current
liabilities consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B4_zIUy5zgunx62" style="display: none"&gt;Schedule of Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20241231_zUAi0bF2i42i" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20231231_zuwPaF1q9IUd" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedClinicalTrialExpense_iI_pn3n3_maALCzZ4Y_zzAhWduSOoRe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Accrued clinical trial expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;189&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;189&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzZ4Y_zJ6XaJr5vRmc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;691&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;573&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_zrvXYFNqhztb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued wages, bonuses, commissions and vacation&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,797&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,011&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AccrualsForConstructionInProgress_iI_pn3n3_maALCzZ4Y_zn9pm8Seomub" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accruals for construction in progress&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;135&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;214&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALCzZ4Y_zppufrkn0l51" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,798&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1803"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AccruedComplianceFee_iI_pn3n3_maALCzZ4Y_zTcBA7RcvQ1f" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Accrued compliance fee&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;10,277&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,145&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzZ4Y_z2OK4PmAx5Bc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;955&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,448&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzZ4Y_zaLHpancMSKc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19,842&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,580&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <CELU:AccruedClinicalTrialExpense
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001790"
      unitRef="USD">189000</CELU:AccruedClinicalTrialExpense>
    <CELU:AccruedClinicalTrialExpense
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001791"
      unitRef="USD">189000</CELU:AccruedClinicalTrialExpense>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001793"
      unitRef="USD">691000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001794"
      unitRef="USD">573000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001796"
      unitRef="USD">5797000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001797"
      unitRef="USD">3011000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <CELU:AccrualsForConstructionInProgress
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001799"
      unitRef="USD">135000</CELU:AccrualsForConstructionInProgress>
    <CELU:AccrualsForConstructionInProgress
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001800"
      unitRef="USD">214000</CELU:AccrualsForConstructionInProgress>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001802"
      unitRef="USD">1798000</us-gaap:InterestPayableCurrent>
    <CELU:AccruedComplianceFee
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001805"
      unitRef="USD">10277000</CELU:AccruedComplianceFee>
    <CELU:AccruedComplianceFee
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001806"
      unitRef="USD">1145000</CELU:AccruedComplianceFee>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001808"
      unitRef="USD">955000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001809"
      unitRef="USD">2448000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001811"
      unitRef="USD">19842000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001812"
      unitRef="USD">7580000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001814">&lt;p id="xdx_80D_eus-gaap--DebtDisclosureTextBlock_zW9jjYQNoCx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;10. &lt;span id="xdx_820_zR5uKsA7BlNe"&gt;Debt&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zK6Q9XSMaC9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Debt consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B4_zvoiRhCYEAuh" style="display: none"&gt;Schedule
of Debt&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zHu7pAPGbOW" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zZqnJOOrQPv2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Debt - unaffiliated:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zyA9YHtaLfJi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"&gt;Yorkville - PPA (measured at fair value)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1818"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;17,223&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--ConvertiblePromissoryNotesMember_zqsGDZKzQrz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Yorkville - convertible promissory note (measured at fair value)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,865&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1822"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--CreditFacilityAxis__custom--UnsecuredSeniorConvertibleNoteMember_zHs57v3UQFL3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Unsecured senior convertible notes (measured at fair value)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;620&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1825"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--OtherShortTermDebt_iI_pn3n3_zVEapbxVD6wh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Short-term debt - other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,108&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_zvnBk4RyqYTb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total debt - unaffiliated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,485&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19,331&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Debt - related parties:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CVStarrBridgeLoanNetOfDiscountMember_zB6V0cUxTM8i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;C.V. Starr Bridge Loan, net of discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,652&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,523&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--RWIBridgeLoanNetOfDiscountMember_zqMwMDQu5Axb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;RWI Bridge Loan, net of discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,967&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zy480WSqLQo9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;CEO promissory note&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,876&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,419&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_zH425rxDLV0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total debt - related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;39,803&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--Debt_iTI_pn3n3_zyvhxlDi9rCl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Total debt&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;42,288&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;39,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Balance sheet classification:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShortTermBorrowings_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z8IP16kNtQU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Short-term debt - unaffiliated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,485&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19,331&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2FkvjdwenYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Short-term debt - related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,876&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4DEWC6mnYVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Long-term debt - related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;35,927&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1855"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--Debt_iTI_pn3n3_znK7NZGmPrz7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;42,288&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;39,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zovKF4TJKJr" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Yorkville PPA&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On September 15, 2022, the Company
entered into a Pre-Paid Advance Agreement (&#x201c;PPA&#x201d;) with Yorkville, pursuant to which the Company could request advances of
up to $&lt;span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zEu36Cn8rZZ4" title="Maximum advance amount"&gt;40,000&lt;/span&gt; in cash from Yorkville (or such greater amount that the parties may mutually agree) (each, a &#x201c;Pre-Paid Advance&#x201d;)
over an &lt;span id="xdx_90F_ecustom--PrePaidAdvancePeriod_dtM_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zjdBAdOMizHh" title="Pre-paid advance period"&gt;18&lt;/span&gt;-month period, with an aggregate limitation of $&lt;span id="xdx_90C_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn3n3_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zNU7m9JN3l48" title="Line of credit aggregate limitation amount"&gt;150,000&lt;/span&gt;. Pre-Paid Advances were issued at a &lt;span id="xdx_906_ecustom--PrePaidAdvanceIssuedDiscountPercentage_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zuAVveHPnX2l" title="Pre-paid advance issued discount percentage"&gt;2.0&lt;/span&gt;% discount, bore interest at
an annual rate equal to &lt;span id="xdx_90B_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zXEYolPefsEf" title="Annual interest rate"&gt;6.0&lt;/span&gt;% (increased to &lt;span id="xdx_902_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zOPAPeOsIVR3" title="Line of credit increase in interest rate during period in event of default"&gt;15.0&lt;/span&gt;% in the event of default as described in the PPA) and could have been offset by the issuance
of shares of common stock, at Yorkville&#x2019;s option, at a price per share calculated pursuant to the PPA, which in no event would be
less than $&lt;span id="xdx_909_ecustom--IssuanceOfCommonStockMinimumOptionPricePerShare_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zdxBo79pJM2g" title="Issuance of common stock minimum option price per share"&gt;7.50&lt;/span&gt; per share. The issuance of the shares under the PPA was subject to certain limitations, including that the aggregate number
of shares of common stock issued pursuant to the PPA could not exceed &lt;span id="xdx_908_ecustom--MaximumPercentageOfCommonStockIssued_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zxeqPc6HgnM9" title="Maximum percentage of common stock issued"&gt;19.9&lt;/span&gt;% of the Company&#x2019;s outstanding stock as of September 15,
2022, as well as a beneficial ownership limitation of &lt;span id="xdx_90B_ecustom--PercentageOfBeneficialOwnershipLimitation_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z4JSxLC1JxJd" title="Percentage of beneficial ownership limitation"&gt;4.99&lt;/span&gt;%. Further, Yorkville agreed not to purchase any shares of common stock for
60 days following entry into the PPA, nor could Yorkville purchase more than $&lt;span id="xdx_905_ecustom--MinimumNumberOfSharesOfCommonStockPurchase_pid_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zqBfNCeMMWh5" title="Minimum number of shares of common stock purchase"&gt;6,000&lt;/span&gt; of shares of common stock during a 30-day period,
in each case at a price per share less than the Fixed Price, as defined in the PPA. In the event the daily volume weighted average price
(&#x201c;VWAP&#x201d;) of the Class A common stock was below $&lt;span id="xdx_907_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z5868LZc4olf" title="Minimum required daily volume weighted average price"&gt;7.50&lt;/span&gt; (the &#x201c;floor price&#x201d;) for any five of seven consecutive trading
days, the Company would pay Yorkville a monthly cash payment of $&lt;span id="xdx_908_ecustom--RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_ztiTq3RYLZMk" title="Required monthly payment if daily volume weighted average price is below $0.75 for any five of seven trading days"&gt;6,000&lt;/span&gt;, plus any accrued and unpaid interest along with a &lt;span id="xdx_90A_ecustom--RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zrY1S51BJFB7" title="Redemption premium percentage if volume weighted average price is less than $0.75"&gt;5.0&lt;/span&gt;% redemption
premium until such time as the daily VWAP for five consecutive trading days immediately prior to the due date of the next monthly payment
was at least &lt;span id="xdx_908_ecustom--RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice_pid_dp_uPure_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z4KPhPfgJXPb" title="Redemption premium percentage if volume weighted average price more than $0.75"&gt;10.0&lt;/span&gt;% greater than $&lt;span id="xdx_908_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zDOoDdpW6Etg" title="Minimum required daily volume weighted average price"&gt;7.50&lt;/span&gt;. In connection with the Company&#x2019;s 2023 annual stockholder meeting held in June 2023, the Company
and Yorkville agreed to lower the floor price to $&lt;span id="xdx_90E_eus-gaap--SharePrice_iI_pid_c20230630__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zAkvFJXVaxKe" title="Share price per share"&gt;0.50&lt;/span&gt; (the &#x201c;amended floor price&#x201d;). The Company also received stockholder
approval of the proposal for the issuance of more than &lt;span id="xdx_901_ecustom--IssuancePricePercentage_iI_pid_dp_uPure_c20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zn3DIIExglQ2" title="Issuance price percentage"&gt;20.0&lt;/span&gt;% of its pre-transaction Class A common stock outstanding at a price below
the minimum price pursuant to the PPA. Further, absent prior written consent from Yorkville, the Company agreed it would not increase
the size or amount borrowed under the C.V. Starr loan facility nor would it incur other borrowings or liens of any kind as long as any
amounts were due and remained outstanding to Yorkville until paid in full. The Company agreed that all obligations due and owing to Yorkville
would become secured obligations upon any violation under the PPA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In connection with the entry into
the PPA, the Company received the initial Pre-Paid Advance of $&lt;span id="xdx_902_ecustom--ProceedsFromLinesOfCreditGross_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zyXhcZG3pGNg" title="Proceeds from pre-paid advance gross"&gt;40,000&lt;/span&gt; gross or $&lt;span id="xdx_901_eus-gaap--ProceedsFromLinesOfCredit_pn3n3_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zV57Yp2XMaW6" title="Proceeds from pre-paid advance"&gt;39,200&lt;/span&gt; net of discount. Each Pre-Paid Advance had a maturity
of &lt;span id="xdx_90B_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20220915__20220915__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zAMXcGH2nLZ5" title="Pre-paid advance maturity period"&gt;12&lt;/span&gt; months. Further Pre-Paid Advances would be based upon the mutual agreement of the parties. Direct costs and fees related to the
PPA were recognized in earnings. At issuance, the Company concluded that certain features of the PPA would be considered a derivative
that would require bifurcation. In lieu of bifurcation, the Company elected the fair value option for this financial instrument and records
changes in fair value within the consolidated statements of operations and comprehensive loss at the end of each reporting period. Under
the fair value option, upon derecognition the Company will include in net loss the cumulative amount of the gain or loss on the debt that
resulted from changes in instrument-specific credit risk.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2023, Yorkville elected to convert $&lt;span id="xdx_90B_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zdbfoAHDf6ta"&gt;3,889
&lt;/span&gt;of principal and $&lt;span id="xdx_90A_ecustom--DebtConversionOriginalDebtAccruedInterestAmount_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z40lQakk2ia4"&gt;400
&lt;/span&gt;of accrued interest into &lt;span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z2DWO6oszANe"&gt;559,481
&lt;/span&gt;shares of common stock. Further, during the year December 31, 2023, total repayments to Yorkville were $&lt;span id="xdx_907_ecustom--DebtInstrumentPayment_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zAcYv2w8Pqgb"&gt;18,724
&lt;/span&gt;which consisted of (i) $&lt;span id="xdx_901_eus-gaap--RepaymentsOfShortTermDebt_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zlvW8W8khUld"&gt;16,811
&lt;/span&gt;applied to the principal amount; (ii) $&lt;span id="xdx_902_ecustom--DebtInstrumentAccruedInterest_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zx86s29SeOO"&gt;1,073
&lt;/span&gt;towards accrued interest; and (iii) $&lt;span id="xdx_903_ecustom--DebtInstrumentRedemptionPremium_pn3n3_c20230101__20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zlkSuENUM6y8"&gt;840
&lt;/span&gt;of redemption premium. As of December 31, 2023, the fair value of the debt was $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zb3wzGbR7Hc6"&gt;17,223
&lt;/span&gt;and the principal balance was $&lt;span id="xdx_90E_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20231231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zjBE2fAXjuR8"&gt;16,623&lt;/span&gt;.
Refer to Note 4 for additional details regarding the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On January 12, 2024, the Company
and Yorkville entered into a forbearance agreement (&#x201c;Forbearance Agreement&#x201d;), pursuant to which Yorkville agreed to restrain
from enforcing its rights and remedies as a result of the event of default during the forbearance period. The forbearance period was to
continue until the earlier of January 19, 2024 or the date the Company fully repaid all amounts outstanding under the PPA (&#x201c;Forbearance
Period&#x201d;). During the Forbearance Period, interest accrued at &lt;span id="xdx_907_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zKCOjTBLX1Mf" title="Annual interest rate"&gt;15.0&lt;/span&gt;% per annum. In addition, the Company was to make a cash payment
of $&lt;span id="xdx_90D_eus-gaap--RepaymentsOfDebt_pn3n3_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_z0irwK5bUMnk" title="Cash payment"&gt;17,348&lt;/span&gt; plus per diem interest of $&lt;span id="xdx_909_ecustom--DebtInstrumentPerDiemInterestAmount_pn3n3_c20240112__20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zq6ivEPVgGpf" title="Diem interest payment for each day"&gt;7&lt;/span&gt; for each day after January 12, 2024 until payment was made and was required to issue Yorkville
a total of &lt;span id="xdx_909_eus-gaap--CommonStockSharesIssued_iI_pid_c20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zUz68o3Bi3T" title="Issue of common stock"&gt;100,000&lt;/span&gt; shares of its common stock. On January 12, 2024, the Company issued Yorkville &lt;span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_pid_c20240112__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zRjl56beh1zi" title="Issue of common stock"&gt;100,000&lt;/span&gt; of its common stock in connection
with the extension of the maturity date of the PPA. The PPA was repaid in full on January 17, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 13, 2024, the Company
entered into a Standby Equity Purchase Agreement (&#x201c;SEPA&#x201d;) with Yorkville (see Note 13).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Yorkville Convertible Promissory Note&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Upon entry into the SEPA, the
Company issued Yorkville a $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentIssuedPrincipal_pn3n3_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zqRuDAcD9oRd" title="Debt issued"&gt;3,150&lt;/span&gt; convertible promissory note for $&lt;span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_pn3n3_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zumzYzeIuaSe" title="Maximum advance amount"&gt;2,993&lt;/span&gt; in cash (after a &lt;span id="xdx_90E_ecustom--ConvertiblePromissoryNoteDiscountPercentage_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zNNe1uAB2fuk" title="Original issue discount"&gt;5.0&lt;/span&gt;% original issue discount). The note bears
interest at an annual rate equal to &lt;span id="xdx_902_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_z9uR9tgy4oue" title="Annual interest rate"&gt;8.0&lt;/span&gt;% (increased to &lt;span id="xdx_907_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zJoqJA3cJsO1" title="Line of credit increase in interest rate during period in event of default"&gt;18.0&lt;/span&gt;% in the event of default as provided in the note) and was scheduled to mature
on &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDate_ddp_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zPX3slQ313a5" title="Maturity date"&gt;March 13, 2025&lt;/span&gt;. The note was initially convertible into common stock at a price per share equal to $&lt;span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zwwcRG4MXMc1" title="Conversion price per share"&gt;6.3171&lt;/span&gt;, provided however, the conversion
price was subject to reset on the earlier of (a) the fifth trading day following the effective date of the resale shelf, or (b) the six-month
anniversary of the issuance date of the convertible note (i.e., September 13, 2024). The conversion price was reset to $&lt;span id="xdx_90E_ecustom--MinimumRequiredDailyVolumeWeightedAveragePrice_iI_pid_c20240913__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zrCDfmFiJEAf" title="Minimum required daily volume weighted average price"&gt;2.7546&lt;/span&gt; on September
13, 2024. Upon the occurrence and during the continuation of an event of default (as defined in the note), the note (including accrued
interest) may become immediately due and payable. The issuance of the common stock upon conversion of the note and otherwise under the
SEPA is capped at &lt;span id="xdx_90F_ecustom--PercentageOfConversionOnOutstandingCommonStock_iI_pid_dp_uPure_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zYJvwSu2mJxg" title="Percentage of conversion on outstanding common stock"&gt;19.9&lt;/span&gt;% of the outstanding common stock as of March 13, 2024. Further, the note and SEPA include a beneficial ownership
blocker for Yorkville such that Yorkville may not be deemed the beneficial owner of more than &lt;span id="xdx_909_ecustom--PercentageOfBeneficialOwnershipLimitation_pid_dp_uPure_c20240313__20240313__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zJB78gIBqVle" title="Percentage of beneficial ownership limitation"&gt;4.99&lt;/span&gt;% of the Company&#x2019;s common stock.
As a result of the Company&#x2019;s failure to file its 2023 Form 10-K by April 30, 2024 (i.e., a deemed Event of Default under the convertible
promissory note), the Company began accruing interest at the default rate of &lt;span id="xdx_901_ecustom--DebtInstrumentDefaultInterestRate_iI_pid_dp_uPure_c20240501__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zvYpcemlyPJ6" title="Debt instrument default interest rate"&gt;18.0&lt;/span&gt;% as of May 1, 2024. A further event of default occurred
as a result of the Company&#x2019;s failure to file a registration statement with the SEC for the resale by Yorkville of the shares of
common stock issuable under the SEPA by May 3, 2024 (see Note 13).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company determined that
the convertible promissory note included embedded derivatives that would otherwise require bifurcation as derivative liabilities, and
neither the debt instrument nor the embedded features are required to be classified as equity. Therefore, at inception, the Company elected
to carry the convertible promissory note comprised of the debt host and the embedded derivative liabilities at fair value on a recurring
basis as permitted under ASC 825, &lt;i&gt;Financial Instruments&lt;/i&gt;. Changes in fair value caused by changes in the instrument-specific credit
risk are reported in other comprehensive income, and the remaining change in fair value is reported in earnings (i.e., as a component
of other income/expense). Interest expense is a component of the change in fair value of the convertible promissory note and, therefore,
is not separately recorded. As a result of the fair value election, the original issue discount of $&lt;span id="xdx_907_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20240101__20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zF8BAQKqJNSg"&gt;157
&lt;/span&gt;was recorded to other expense in the consolidated statements of operations and comprehensive loss. In November 2024, Yorkville
elected to convert $&lt;span id="xdx_908_eus-gaap--DebtConversionOriginalDebtAmount1_pn3n3_c20241101__20241130__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zbLAEPypdqoi"&gt;1,150
&lt;/span&gt;of principal and $&lt;span id="xdx_900_ecustom--DebtConversionOriginalDebtAccruedInterestAmount_pn3n3_c20241101__20241130__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_z2kKqmPSaKnb"&gt;169
&lt;/span&gt;of accrued interest into &lt;span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20241101__20241130__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zOArtWavtwlb"&gt;478,881
&lt;/span&gt;shares of common stock. As of December 31, 2024, the fair value of the debt was $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFairValue_iI_pn3n3_c20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_zIaMp8qW1hde"&gt;1,865
&lt;/span&gt;and the principal balance was $&lt;span id="xdx_903_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20241231__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--CreditFacilityAxis__custom--StandbyEquityPurchaseAgreementMember_znp6F7xHbnKe"&gt;2,000&lt;/span&gt;.
Refer to Note 4 for additional details regarding the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 17, 2025, the Company
entered into a letter agreement with Yorkville to extend the maturity date of the convertible promissory note from &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_ddp_c20250316__20250316__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zwfaYR1XLZz3" title="Maturity date"&gt;March 13, 2025&lt;/span&gt; to &lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDate_ddp_c20250317__20250317__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zu81ZUjT0toh" title="Maturity date"&gt;May
12, 2025&lt;/span&gt;. In addition, Yorkville agreed not to declare an event of default until May 12, 2025 (the &#x201c;Forbearance&#x201d;). In connection
with the maturity date extension and Forbearance, the Company agreed to issue Yorkville &lt;span id="xdx_90E_eus-gaap--SharesIssued_iI_pid_c20250317__us-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zx6GQLqCx0vc" title="Common stock issued pursuant to short-term debt maturity extension, shares"&gt;100,000&lt;/span&gt; shares of its Class A common stock. The
shares of Class A common stock were issued with piggyback registration rights such that the resale of such shares by Yorkville are to
be included on any such registration statement filed by the Company following the issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Unsecured Senior Convertible Notes &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On November 25, 2024, the Company
entered into a securities purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with an accredited investor, pursuant to which the
Company agreed to sell and issue, in one or more closings, to the investor and other purchasers in a private placement transaction, unsecured
senior convertible notes and warrants for an aggregate original principal amount of up to $&lt;span id="xdx_905_ecustom--NotesAndPurchaserWarrantsPrincipalAmount_iI_pn3n3_c20241125__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zqaokJSO2pog" title="Notes and purchaser warrants principal amount"&gt;1,000&lt;/span&gt;. The Company issued and sold $&lt;span id="xdx_90C_ecustom--ProceedsFromNotesAndPurchaserWarrants_pn3n3_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_z0IQx2QS1rh7" title="Proceeds from notes and purchaser warrants"&gt;750&lt;/span&gt; unsecured
senior convertible notes and warrants to acquire up to an aggregate of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zzUAAFz4iTCk" title="Notes and purchaser warrant share"&gt;263,156&lt;/span&gt; shares of Class A common stock (the &#x201c;November 2024
Purchaser Warrants&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The unsecured senior convertible
notes bear interest at an annual rate of &lt;span id="xdx_909_eus-gaap--LineOfCreditFacilityInterestRateDuringPeriod_pid_dp_uPure_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zYxt2iPbeio8" title="Bearing interest"&gt;8.0&lt;/span&gt;% (increasing to &lt;span id="xdx_905_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zBdu5baJ7N6h" title="Increase in bearing interest"&gt;10.0&lt;/span&gt;% in the event of default as defined in the Purchase Agreement) and have
a maturity date of one year from the date of issuance. Upon an event of default, the notes are convertible at the purchasers&#x2019; option
into shares of the Company&#x2019;s Class A common stock at a price per share equal to (i) $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zi0JEwZs3O88" title="Stock price per share"&gt;2.85&lt;/span&gt; (adjusted for stock splits, reverse stock
splits, stock dividends, or similar transactions); or (ii) the offering price of a subsequent financing transaction with gross proceeds
of $&lt;span id="xdx_90F_ecustom--MinimumGrossProceeds_pn3n3_c20241125__20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zhhbz5TvXbD8" title="Gross proceeds"&gt;2,500&lt;/span&gt; or more (a &#x201c;Subsequent Financing&#x201d;), subject to a floor price of $&lt;span id="xdx_90A_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zZgHf43ynl4b" title="Floor price"&gt;1.00&lt;/span&gt; per share. The unsecured senior convertible
notes include customary negative covenants restricting the Company&#x2019;s ability to incur other indebtedness other than as permitted,
pay dividends to stockholders, grant or suffer to exist a security interest in any of the Company&#x2019;s assets, other than as permitted,
amongst others. In addition, the unsecured senior convertible notes include customary events of default.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The November 2024 Purchaser Warrants
entitle the investors to purchase shares of common stock equal to each purchaser&#x2019;s subscription amount divided by the exercise price
of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125_zWFBf91CgRbl" title="Exercise price"&gt;2.85&lt;/span&gt; per share. The exercise price, and the number of shares of common stock issuable under the November 2024 Purchaser Warrants,
are subject to a one-time reset upon the completion of a Subsequent Financing, subject to a floor price of $&lt;span id="xdx_906_ecustom--FloorPrice_iI_pid_c20241125_zjCfAPiEvHRg" title="Floor price"&gt;1.00&lt;/span&gt; per share. The Purchaser
Warrants are immediately exercisable and have a &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125_zGMYRS7Phzpg" title="Warrant outstanding term"&gt;5&lt;/span&gt;-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In connection with the transaction,
the Company agreed to issue a &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20241125_zuS67AQUxVBl" title="Warrant outstanding term"&gt;5&lt;/span&gt;-year warrant to purchase a number of shares of common stock equal to &lt;span id="xdx_90F_ecustom--PercentageOfCashFeeEqualToAggregateProceeds_pid_dp_uPure_c20241125__20241125_zrDzroq94yb4" title="Percentage of cash fee equal to aggregate proceeds"&gt;7&lt;/span&gt;% of the proceeds of the transaction
(the &#x201c;November 2024 Placement Agent Warrants&#x201d;), at an exercise price equal to &lt;span id="xdx_905_ecustom--PercentageOfExercisePriceEqualToOfferingPrice_pid_dp_uPure_c20241125__20241125_z8GFkK9M0PJi" title="Percentage of exercise price equal to offering price"&gt;125&lt;/span&gt;% of the offering price. The November 2024
Placement Agent Warrants are subject to the same one-time exercise price adjustment provision as the November 2024 Purchaser Warrants
in connection with a Subsequent Financing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company determined
that the unsecured senior convertible notes included embedded derivatives that would otherwise require bifurcation as derivative
liabilities, and neither the debt instrument nor the embedded features are required to be classified as equity. Therefore, at
inception, the Company elected to carry the unsecured senior convertibles note comprised of the debt host and the embedded
derivative liabilities at fair value on a recurring basis as permitted under ASC 825, &lt;i&gt;Financial Instruments&lt;/i&gt;. Changes in fair
value caused by changes in the instrument-specific credit risk are reported in other comprehensive income, and the remaining change
in fair value is reported in earnings (i.e., as a component of other income/expense). Interest expense is a component of the change
in fair value of the unsecured senior convertible notes and, therefore, is not separately recorded. The November 2024 Purchaser and
Placement Agent Warrants are classified as liabilities since the exercise price was not determined at issuance and may be
subsequently adjusted in connection with a Subsequent Financing. The fair value of the November 2024 Placement Agent Warrants has
been treated as a transaction cost and was reduced from the cash proceeds to arrive at the net proceeds from the transaction. As a
result of the fair value election, a charge of $&lt;span id="xdx_90A_eus-gaap--OtherExpenses_pn3n3_c20240101__20241231__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zczTZ41mF9m9" title="Other expenses"&gt;478&lt;/span&gt;
was recorded to other expense in the consolidated statements of operations and comprehensive loss for the difference between the net
proceeds from the transaction and the aggregate fair value of the unsecured senior convertible notes and November 2024 Purchaser and
Placement Agent Warrants at issuance. As of December 31, 2024, the fair value of the debt was $&lt;span id="xdx_908_ecustom--ShorttermDebtUnsecuredSeniorConvertibleNotes_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_z3vKcOwv2cOk" title="Fair value of debt"&gt;620&lt;/span&gt;
and the principal balance was $&lt;span id="xdx_900_eus-gaap--DebtDefaultShorttermDebtAmount_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--UnsecuredSeniorConvertibleNotesMember_zXsdSvxB7f36" title="Short-term debt, unpaid principal balance"&gt;750&lt;/span&gt;.
Refer to Note 4 for additional details regarding the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Short-Term Debt - Other and CEO Promissory Note&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On August 21, 2023, the Company
entered into a loan agreement with its Chairman and Chief Executive Officer, Dr. Robert Hariri, and two unaffiliated lenders, providing
for a loan in the aggregate principal amount of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zbdjUEhRr5h3" title="Principal amont"&gt;3,000&lt;/span&gt; (of which Dr. Hariri contributed $&lt;span id="xdx_901_ecustom--DebtInstrumentContributionAmount_iI_pn3n3_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zqW02L1sOXX3" title="Debt instrument contribution amount"&gt;1,000&lt;/span&gt;), or the &#x201c;Loan.&#x201d; The Loan bears
interest at a rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_z69gi4gmear2" title="Loan interest rate"&gt;15.0&lt;/span&gt;% per year, with the first year of interest being paid in kind on the last day of each month and matured on
&lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20230821__20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zotw7jUCBqid" title="Maturity date"&gt;August 21, 2024&lt;/span&gt;. Pursuant to the terms of the Loan, the Company is required to apply the net proceeds from a subsequent transaction (as
defined) in which the Company receives gross proceeds of $&lt;span id="xdx_90B_eus-gaap--ProceedsFromOtherShortTermDebt_pn3n3_c20230821__20230821__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zjuKWyn9npXe" title="Gross proceeds"&gt;4,500&lt;/span&gt; or more to repay the Loan. The Company did not repay the Loan upon receipt
of the letter of credit funds in connection with signing the lease amendment (see Note 11) or the January 2024 PIPE (see Note 13), both
of which were defined as subsequent transactions. The lenders agreed to a loan amendment whereby the loan maturity date was extended to
December 31, 2024, and on September 30, 2024, Dr. Hariri and the two unaffiliated lenders entered into an assignment agreement whereby
Dr. Hariri assumed the full loan in exchange for repayment of the other lenders&#x2019; respective principal loan amount, plus accrued
interest. As a result, the loan was reclassified from short-term debt - unaffiliated to short-term debt - related parties. On January
29, 2025, Dr. Hariri extended the maturity date of the Loan from December 31, 2024 to December 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On October 12, 2023, in order
to further address the Company&#x2019;s immediate working capital requirements, Dr. Hariri and the Company signed a promissory note for
$&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zcMYknctZn67" title="Principal amont"&gt;285&lt;/span&gt; which bears interest at a rate of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20231012__20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zoBuhnrs4wAd" title="Interest rate"&gt;15.0&lt;/span&gt;% per year. The note matures together with the outstanding principal amount and accrued and
unpaid interest upon the earlier of &lt;span id="xdx_90B_eus-gaap--LineOfCreditFacilityExpirationPeriod_dtM_c20231012__20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_z4REyKsAH5M7" title="Pre-paid advance maturity period"&gt;12&lt;/span&gt; months from the date of the note or upon a change of control.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2024, there
was no other short-term debt and the carrying value of the CEO promissory note inclusive of accrued interest was $&lt;span id="xdx_901_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20241231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zXsNFuI8eAF8" title="Carrying value of short-term debt"&gt;3,876&lt;/span&gt;. As of December
31, 2023, the carrying value of the other short-term debt and the CEO promissory note inclusive of accrued interest was $&lt;span id="xdx_902_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20231231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zIqfjHOFdT37" title="Carrying value of short-term debt"&gt;2,108&lt;/span&gt; and $&lt;span id="xdx_90F_ecustom--OtherShortTermDebtDueToRelatedParty_iI_pn3n3_c20231231__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember_zIoN2C7pvr7b" title="Other short term debt due to related party"&gt;1,419&lt;/span&gt;,
respectively. At December 31, 2024 and 2023, the carrying amounts of the loans were deemed to approximate fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Short-Term Debt &#x2013; Related Parties - C.V.
Starr and RWI&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;i&gt;C.V. Starr &amp;amp; Co., Inc&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 17, 2023, the Company
entered into a loan agreement (the &#x201c;Starr Bridge Loan&#x201d;) with C.V. Starr &amp;amp; Co., Inc. (&#x201c;C.V. Starr&#x201d;), a stockholder
of the Company, for an aggregate principal amount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zoyjRRhSaYB5"&gt;5,000
&lt;/span&gt;net of an original issue discount of $&lt;span id="xdx_90A_ecustom--DebtInstrumentOriginalIssueDiscount_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z9whcFx8iuN4"&gt;100&lt;/span&gt;.
The loan bears interest at a rate equal to &lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z03A3essdUH5"&gt;12.0&lt;/span&gt;%
per year or &lt;span id="xdx_900_ecustom--DebtInstrumentInterestRateEffectivePercentageInEventOfDefault_iI_pid_dp_uPure_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zRCD2cA2zgL2" title="Effective percentage in event of default"&gt;15.0&lt;/span&gt;%
in the event of default, with the first year of interest being paid in kind on the last day of each month, and was scheduled to mature
on &lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDate_dd_c20230317__20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zEwur4td2ZOd"&gt;March
17, 2025&lt;/span&gt;. In addition, the parties entered into a warrant agreement to acquire up to an aggregate &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_dd_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zzCLqSRPRt65"&gt;75,000
&lt;/span&gt;shares of Class A common stock (&#x201c;Starr Warrant&#x201d;), at a purchase price of $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zqTtew2C4tK7"&gt;1.25
&lt;/span&gt;per whole share underlying the Starr Warrant or $&lt;span id="xdx_90E_ecustom--ShareIssuedPurchasedPrice_iI_pn3n3_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zqiFSRFEmZb" title="Share issued purchased price"&gt;94&lt;/span&gt;.
The Starr Warrant has a five&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zSjWof9RusY4" style="display: none"&gt;5&lt;/span&gt;-year
term and had an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230317__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zEBymEqYunn3"&gt;7.10
&lt;/span&gt;per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In June 2023, in connection with
the Amended RWI Loan (as defined below), the Company granted C.V. Starr additional warrants to acquire up to an aggregate &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zhYRS7YIp159" title="Warrants to purchase Class A common stock"&gt;50,000&lt;/span&gt; shares
of its Class A common stock (&#x201c;Starr Additional Warrant&#x201d; and in combination with Starr Warrant, &#x201c;Starr Warrants&#x201d;),
which additional warrants have a &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_znZKBAhBmZ82" title="Warrants to purchase Class A common stock"&gt;5&lt;/span&gt;-year term and had an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zsBKavssXCXd" title="Exercise per share price (in Dollars per share)"&gt;8.10&lt;/span&gt; per share. The Company applied the guidance for this transaction
in accordance with ASC 470-20, &lt;i&gt;Debt with Conversion and Other Options&lt;/i&gt; and ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;. The net proceeds
of the Starr Bridge Loan and Starr Additional Warrant were recorded at fair value. The fair value of the Starr Additional Warrant was
determined using a Black-Scholes option pricing model. The Starr Warrants met the requirements for a derivative scope exception under
ASC 815-10-15--74(a) for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Under the terms of the Starr Bridge
Loan, the Company agreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends to stockholders,
repay or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of the Company&#x2019;s
assets, other than as permitted, or hold cash and cash equivalents less than $&lt;span id="xdx_90D_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230630__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z8lQ0awJMlya" title="Cash and cash equivalents"&gt;3,000&lt;/span&gt; for more than five consecutive business days. During
the year ended December 31, 2023, the Company&#x2019;s cash and cash equivalents fell below the $&lt;span id="xdx_904_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zkZLrsnBPfG7" title="Fall in cash and cash equivalents"&gt;3,000&lt;/span&gt; minimum liquidity covenant, which
per the terms of the loan agreement caused an event of default. Therefore, the Company reclassified the loan as a current liability reflected
within short-term debt - related parties on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On January 12, 2024, the Company
entered into an amendment which terminated the minimum $&lt;span id="xdx_907_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zL4u0X3gMAu8" title="Fall in cash and cash equivalents"&gt;3,000&lt;/span&gt; liquidity covenant requirement. In addition to the negative covenants in
the Starr Bridge Loan, the Starr Bridge Loan includes customary events of default and the Company granted C.V. Starr a senior security
interest in all of its assets, pari passu with RWI (as defined below).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 13, 2024, the Company
and C.V. Starr entered into a forbearance agreement (&#x201c;Starr Forbearance Agreement&#x201d;) with respect to the Starr Bridge Loan.
Under the Starr Forbearance Agreement, (i) C.V. Starr agreed not to exercise its rights and remedies upon the occurrence of any default
under the Starr Bridge Loan until the Company&#x2019;s obligations in respect of the Yorkville convertible promissory note have been indefeasibly
paid in full, (ii) C.V. Starr consented to the Company&#x2019;s incurrence of indebtedness under the Yorkville convertible promissory note,
(iii) C.V. Starr consented to cash payments required to be made under the SEPA and the Yorkville convertible promissory note, (iv) the
Company agreed to increase the interest rate on the loan outstanding under the Starr Bridge Loan by &lt;span id="xdx_905_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zvUVpCNfamv5" title="Increase interest rate on loan outstanding by basis points"&gt;100&lt;/span&gt; basis points and (v) the Company
agreed to amend the exercise price of (x) that certain warrant to acquire &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zc4aEW9vqFef" title="Warrants to purchase Class A common stock"&gt;75,000&lt;/span&gt; shares of the Company&#x2019;s common stock for $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z9NFnBki9O2i" title="Purchase price of per share"&gt;7.10&lt;/span&gt;
per share, expiring &lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_za9yhXBQjITk" title="Warrant expiration date"&gt;March 17, 2028&lt;/span&gt;, and (y) that certain warrant to acquire &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_z4jmsNlTHxCh" title="Warrants to purchase Class A common stock"&gt;50,000&lt;/span&gt; shares of common stock for $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_zc7GI4BOhWbf" title="Purchase price of per share"&gt;8.10&lt;/span&gt; per share expiring
&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--VestingAxis__custom--TrancheTwoWarrantMember_zLnSiS0CjKUj" title="Warrant expiration date"&gt;June 20, 2028&lt;/span&gt;, each of which are held by C.V. Starr, such that the exercise price of each such warrant in (x) and (y) is $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zaO6xlAVgH06" title="Warrants to purchase Class A common stock"&gt;5.895&lt;/span&gt; per share.
In addition, the interest rate of the Starr Bridge Loan was increased to &lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zESUbTSpiFSk" title="Loan interest rate"&gt;13.0&lt;/span&gt;% per annum. The Starr Forbearance Agreement resulted in
a modification of the Starr Bridge Loan, since the change in cash flows was determined to be less than &lt;span id="xdx_90E_ecustom--PercentageOfChangesInCashFlow_pid_dp_c20240313__20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zP8dfQpo2LS7" title="Percentage of changes in cash flow"&gt;10&lt;/span&gt;%. Accordingly, no gain or loss
was recorded and the change in fair value of the Starr Warrants of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20240313__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zcHgusK9am0a" title="Debt instrument, unamortized discount"&gt;51&lt;/span&gt; was recorded as a debt discount and will be amortized based on
the new effective interest rate over the term of the Starr Bridge Loan. Due to the Company&#x2019;s failure to make certain interest payments
when due, the Company began accruing interest at the default rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_c20240415__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z5gWzIfkNRY8" title="Default rate"&gt;16.0&lt;/span&gt;% as of April 5, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On February 12, 2025, the Company
entered into a binding term sheet with C.V. Starr, pursuant to which C.V. Starr agreed to, among other things, an extension of the Starr
Forbearance Agreement whereby C.V. Starr agreed not to exercise its rights and remedies upon the occurrence of any default under the Starr
Bridge Loan and whereby the maturity date of the Starr Bridge Loan has been extended to &lt;span id="xdx_90C_eus-gaap--DebtInstrumentMaturityDate_dd_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znq7wJDeH5Ce" title="Debt instrument maturity date"&gt;February 15, 2026&lt;/span&gt;. Pursuant to the binding term
sheet, the Company agreed to (i) use a portion of the proceeds from its next registered public offering to pay C.V. Starr approximately
$&lt;span id="xdx_90A_eus-gaap--RepaymentsOfOtherDebt_pn3n3_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zr3kEed3T92" title="Payment of debt"&gt;800&lt;/span&gt;, representing cash interest through January 31, 2025 and (ii) issue to C.V. Starr a new five&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zriDK47dH1q2" style="display: none" title="Warrant term"&gt;5&lt;/span&gt;-year warrant to purchase up to &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTFpUgkYn8Bf" title="Warrants to purchase aggregate shares"&gt;100,000&lt;/span&gt;
shares of its Class A common stock. In addition, the Company agreed to reprice certain outstanding warrants held by C.V. Starr.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2024 and 2023,
the carrying value of Starr Bridge Loan, inclusive of accrued interest and net of discount, was $&lt;span id="xdx_907_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20241231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zfGcje90qJM4" title="Short-term debt - related parties"&gt;5,652&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20231231__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_z6uH0OOCWMRj" title="Short-term debt - related parties"&gt;5,523&lt;/span&gt;, respectively. The carrying
amounts of the Starr Bridge Loan were deemed to approximate fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;i&gt;Resorts World Inc Pte Ltd&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On May 16, 2023, with written
consent provided by Yorkville, the Company entered into a senior secured loan agreement (&#x201c;RWI Bridge Loan&#x201d;) with Resorts World
Inc Pte Ltd, (&#x201c;RWI&#x201d;) providing for an initial loan in the aggregate principal amount of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zTgQBRo1Syd8" title="Principal amont"&gt;6,000&lt;/span&gt; net of an original issue discount
of $&lt;span id="xdx_90E_ecustom--DebtInstrumentDiscount_iI_pn3n3_c20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zyaRxZoBaHl2" title="Discount"&gt;120&lt;/span&gt;, which bears interest at a rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zRoB7Q0TNbb6" title="Interest rate"&gt;12.5&lt;/span&gt;% per year or &lt;span id="xdx_908_ecustom--DebtInstrumentInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zECKK1IiNIw6" title="Interest rate during period in event of default"&gt;15.5&lt;/span&gt;% in the event of default, with the first year of interest being paid
in kind on the last day of each month, and matured on &lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20230516__20230516__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zUKZuv4HB4V2" title="Maturity date"&gt;June 14, 2023&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On June 21, 2023, the Company
closed on an amended and restated senior secured loan agreement (&#x201c;Amended RWI Loan&#x201d;), to amend and restate the previous senior
secured loan agreement, in its entirety. The Amended RWI Loan provided for an additional loan in the aggregate principal amount of $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdXZBrm2lARk"&gt;6,000&lt;/span&gt;
net of an original issue discount of $&lt;span id="xdx_90F_ecustom--DebtInstrumentDiscount_iI_pn3n3_c20230621__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--InitialLoanMember_zCXxZWt6Ezr6"&gt;678&lt;/span&gt;,
which bears interest at a rate of &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zUIsEOrQd1I7"&gt;12.5&lt;/span&gt;%
per year or &lt;span id="xdx_90A_ecustom--DebtInstrumentInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdVlKpZJul2l"&gt;15.5&lt;/span&gt;%
in the event of default, with the first year of interest being paid in kind on the last day of each month, and was schedule to mature
on &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDate_ddp_c20230621__20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zawp11OqPaS4"&gt;March
17, 2025&lt;/span&gt;. The Amended RWI Loan extended the maturity date of the initial loan to March 17, 2025. In addition, the Amended RWI
Loan provided for the issuance of warrants to acquire up to an aggregate &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zyP4srljLJf4"&gt;300,000&lt;/span&gt;
shares of the Company&#x2019;s Class A common stock (&#x201c;RWI Warrant&#x201d;), at a purchase price of $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zW0rrs5fgJF5"&gt;1.25&lt;/span&gt;
per whole share underlying the RWI Warrant (or an aggregate purchase price of $&lt;span id="xdx_90D_ecustom--ShareIssuedPurchasedPrice_iI_pn3n3_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zC7nwY3FxHl8" title="Share issued purchase price"&gt;375&lt;/span&gt;).
The RWI Warrant has a &lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 9pt"&gt;&lt;/span&gt;five&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zrWErKGQkTbi" style="display: none" title="Warrant term (years)"&gt;5&lt;/span&gt;-year term and an exercise
price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230621__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zidNSrUCfNof" title="Exercise per share price (in Dollars per share)"&gt;8.10&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the terms of the Amended
RWI Loan, the Company was required to apply the net proceeds to the trigger payments due to Yorkville pursuant to the PPA. In addition,
the Company agreed to customary negative covenants restricting its ability to repay indebtedness, pay dividends to stockholders, repay
or incur other indebtedness other than as permitted, grant or suffer to exist a security interest in any of its assets, other than as
permitted, or hold cash and cash equivalents of less than $&lt;span id="xdx_904_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn3n3_c20230914__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zCVkeFF9B6L" title="Cash and cash equivalents"&gt;3,000&lt;/span&gt; for more than five consecutive business days, and includes customary
events of default. The Company granted RWI a senior security interest in all of its assets, pari passu with C.V. Starr pursuant to the
Starr Bridge Loan. The Company and RWI signed a forbearance agreement on September 14, 2023, whereby RWI agreed to forebear any action
under the terms of the Amended RWI Loan in relation to the minimum $&lt;span id="xdx_902_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20230914__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z6nRumKmOxie" title="Fall in cash and cash equivalents"&gt;3,000&lt;/span&gt; liquidity covenant and with respect to any potential default
in relation to the Company&#x2019;s outstanding debt owed to Yorkville until December 31, 2023. The Company reclassified the loan as a
current liability reflected within short-term debt - related parties on the consolidated balance sheets. Pursuant to the amendment on
January 12, 2024, see below, the minimum $&lt;span id="xdx_907_ecustom--FallInCashAndCashEquivalents_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z3jtfnxBxGO3" title="Fall in cash and cash equivalents"&gt;3,000&lt;/span&gt; liquidity covenant requirement was terminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company accounted for the
Amended RWI Loan in accordance with ASC 470-20, &lt;i&gt;Debt with Conversion and Other Options&lt;/i&gt; and ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;.
The net proceeds of the Amended RWI Loan and RWI Warrant were recorded at fair value, which resulted in a total discount of $&lt;span id="xdx_908_ecustom--DiscountOnWarrantAmount_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zBbBGCNLt10c" title="Discount on warrant amount"&gt;2,151&lt;/span&gt; based
on the difference between the proceeds and fair value which were recorded as a loss within other income (expense) on the consolidated
statements of operations and comprehensive loss. The fair value of the RWI Warrant was determined using a Black-Scholes option pricing
model. The RWI Warrant met the requirements for a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed
to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On January 12, 2024, the Company
entered into a second amended and restated senior secured loan agreement (&#x201c;RWI Second Amended Bridge Loan&#x201d;), to amend and
restate the previously announced senior secured loan agreement with RWI dated as of May 16, 2023, as amended on June 20, 2023, in its
entirety. The RWI Second Amended Bridge Loan provided for an additional loan in the aggregate principal amount of $&lt;span id="xdx_902_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zzEllrog4Ii8" title="Principal amont"&gt;15,000&lt;/span&gt; net of an original
issue discount of $&lt;span id="xdx_90D_ecustom--DebtInstrumentOriginalIssueDiscount_iI_pn3n3_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zdytJFBLvMA5" title="Original issue discount"&gt;3,750&lt;/span&gt;, which bears interest at a rate of &lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20240112__20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zyksgdLle4p" title="Interest rate"&gt;12.5&lt;/span&gt;% per year, with the first year of interest being paid in kind on the
last day of each month, and matures on &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20240112__20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zgLGuu7uN392" title="Maturity date"&gt;July 16, 2025&lt;/span&gt;. In addition, the RWI Second Amended Bridge Loan provides for the issuance of a &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240112__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zIcHd3biS7cf" title="Term (years)"&gt;5&lt;/span&gt;-year
immediately exercisable warrant to acquire up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--DebtInstrumentAxis__custom--AdditionalLoanMember_zLaVUFeQN3z6" title="Warrants to purchase Class A common stock"&gt;1,650,000&lt;/span&gt; shares of Class A common stock (&#x201c;Tranche #1 Warrant&#x201d;), and a warrant
to acquire up to &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_znnXJkv2AU7a" title="Warrants to purchase Class A common stock"&gt;1,350,000&lt;/span&gt; shares of Class A common stock, which would only be exercisable upon the later of (x) stockholder approval
for Nasdaq purposes of its exercise price, (y) CFIUS clearance and (z) six months from issuance date (&#x201c;Tranche #2 Warrant&#x201d;)
and will expire &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240112__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zGWRpWRxv7q" title="Term (years)"&gt;5&lt;/span&gt; years after it becomes exercisable. The Tranche #1 Warrant and Tranche #2 Warrant were each issued on January 16, 2024
in conjunction with the close of the RWI Second Amended Bridge Loan. The Tranche #1 Warrant has an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240116__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zKffveNuw6z2" title="Exercise per share price (in Dollars per share)"&gt;2.4898&lt;/span&gt; per share.
The Tranche #2 Warrant became exercisable on July 15, 2024 and has an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240715__us-gaap--VestingAxis__custom--TrancheOneWarrantMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zILL7YPzKjzf" title="Exercise per share price (in Dollars per share)"&gt;2.988&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Pursuant to the terms of the RWI
Second Amended Bridge Loan, the Company was required to apply the proceeds of the additional loan (i) to the payment in full of all outstanding
amounts owed to Yorkville under the PPA, (ii) to the payment of invoices of certain critical vendors, (iii) to the first settlement payment
owed to Palantir (see Note 12), and (iv) for working capital and other purposes pre-approved by RWI. Pursuant to the terms of the RWI
Second Amended Bridge Loan, the Company agreed to customary negative covenants restricting its ability to pay dividends to stockholders,
repay or incur other indebtedness other than as permitted, or grant or suffer to exist a security interest in any of the Company&#x2019;s
assets, other than as permitted. In addition, the Company agreed to apply net revenues received through the sale of its products/provision
of services in connection with or related to its distribution and manufacturing agreement with Genting Innovation Pte Ltd (&#x201c;Genting
Innovation&#x201d;), a related party, as a prepayment towards the loan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The RWI Second Amended Bridge
Loan resulted in an extinguishment of the Amended RWI Loan, since the change in cash flows exceeded 10%. As a result, the Company record
a loss on extinguishment equal to the difference between (i) the fair values of the new loan and Tranche #1 and Tranche #2 Warrants and
(ii) the previous carrying amount of the Amended RWI Loan, or $&lt;span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20240112__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zvlAExeNruhg" title="Short-term debt"&gt;3,908&lt;/span&gt;. The Company has not elected to carry the RWI Second Amended Bridge
Loan at fair value, as permitted under ASC 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt; and ASC 825, &lt;i&gt;Fair Value Option for Financial Instruments&lt;/i&gt;.
The Tranche #1 Warrant has been classified in stockholders&#x2019; equity, since it is exercisable into a fixed number of the Company&#x2019;s
own shares at a known exercise price, and therefore is not required to be classified as a liability under ASC 480, &lt;i&gt;Distinguishing Liabilities
from Equity&lt;/i&gt;. The Tranche #2 Warrant was initially classified as a liability, since the exercise price (i.e., Minimum Price) was not
determined at issuance and may have been subsequently adjusted. As of July 15, 2024, the Tranche #2 Warrant became exercisable and no
longer contains adjustment provisions to the exercise price that are not indexed to the Company&#x2019;s own stock, resulting in the reclassification
from liability to equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company and RWI also entered
into an investor rights agreement dated as of January 12, 2024. The investor rights agreement provides RWI certain information and audit
rights, as well as registration rights with respect to the shares underlying the Tranche #1 Warrant and Tranche #2 Warrant, including
both the undertaking to file a registration statement within 45 days of filing of the 2023 Form 10-K, &#x201c;piggyback&#x201d; registration
rights, as well as the right to request up to three demand rights for underwritten offerings per year; in each case subject to customary
&#x201c;underwriter cutback&#x201d; language as well as any objections raised by the Securities and Exchange Commission to inclusion of
securities. If the initial registration statement was not filed on or prior to May 15, 2024, the investor rights agreement provided for
partial liquidating damages equal to &lt;span id="xdx_90F_ecustom--PercentageOfPartialLiquidatingDamagesOnPurchasePrice_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember_zx1nUieJ1XQh" title="Percentage of partial liquidating damages on purchase price"&gt;1.0&lt;/span&gt;% of the purchase price of the Tranche #1 and Tranche #2 Warrants amount each month, up to a maximum
of &lt;span id="xdx_905_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember__srt--RangeAxis__srt--MaximumMember_zADvUSH5nhY8" title="Percentage of partial liquidating damages on subscription amount"&gt;6.0&lt;/span&gt;%, plus interest thereon accruing daily at a rate of &lt;span id="xdx_908_ecustom--DailyInterestAccruingRate_iI_pid_dp_uPure_c20240112__us-gaap--VestingAxis__custom--InitialAndSecondTrancheMember_zEuxq7KRqyOd" title="Daily interest accruing rate"&gt;18.0&lt;/span&gt;% per annum.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 13, 2024, the Company
and RWI entered into a second forbearance agreement (&#x201c;RWI 2nd Forbearance Agreement&#x201d;). Under the RWI 2nd Forbearance Agreement,
(i) RWI agreed not to exercise its rights and remedies upon the occurrence of any default under the RWI Second Amended Bridge Loan until
the Company&#x2019;s obligations in respect of the Yorkville convertible promissory note have been indefeasibly paid in full or March 13,
2025, whichever occurs first, (ii) RWI consented to the Company&#x2019;s incurrence of indebtedness under the Yorkville convertible promissory
note, (iii) RWI consented to cash payments required to be made under the SEPA and the Yorkville convertible promissory note, (iv) the
Company agreed to increase the interest rate on the loan outstanding under the RWI Loan Agreement by &lt;span id="xdx_90C_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_z4U5BpqXOaCe" title="Increase interest rate on loan outstanding by basis points"&gt;100&lt;/span&gt; basis points, or from &lt;span id="xdx_908_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDeDFfe9AsAl" title="Variable interest rate"&gt;12.5&lt;/span&gt;% to
&lt;span id="xdx_903_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zsP2Ah3UhUo7" title="Variable interest rate"&gt;13.5&lt;/span&gt;% per annum, and (v) the Company agreed to issue RWI a warrant to acquire up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zt7mFgp7IfIg" title="Warrants to purchase Class A common stock"&gt;300,000&lt;/span&gt; shares of common stock (&#x201c;RWI New Warrant&#x201d;),
which expires June 20, 2028 and has an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--WarrantMember_zbc9z0r8ODi8" title="Exercise per share price (in Dollars per share)"&gt;5.895&lt;/span&gt; per share. The RWI 2nd Forbearance Agreement resulted in a modification
of the RWI Second Amended Bridge Loan, since the change in cash flows was less than &lt;span id="xdx_904_ecustom--PercentageOfChangesInCashFlow_pid_dp_uPure_c20240313__20240313__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zMAdKWp0k9wf" title="Percentage of changes in cash flow"&gt;10&lt;/span&gt;%. Accordingly, no gain or loss was recorded, and
the fair value of the RWI New Warrant of $&lt;span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn3n3_c20240313__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqXtRNoTm315" title="Debt instrument, unamortized discount"&gt;1,162&lt;/span&gt; was recorded as debt discount and will be amortized based on the new effective interest
rate over the term of the RWI Second Amended Bridge Loan. Due to the Company&#x2019;s failure to make certain interest payments when due,
the Company began accruing interest on the Amended RWI Loan balance of approximately $&lt;span id="xdx_90C_eus-gaap--ShortTermBorrowings_iI_pn3n3_c20240805__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRXqGRYwEYZ" title="Short-term debt"&gt;13,700&lt;/span&gt; at the default rate of &lt;span id="xdx_90C_ecustom--DebtInstrumentDefaultInterestRate_iI_pid_dp_uPure_c20240805__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--CreditFacilityAxis__custom--ForbearanceAgreementMember_zN4itdkarbyd" title="Debt instrument default interest rate"&gt;16.5&lt;/span&gt;% as of August
5, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On February 12, 2025, the Company
entered into a binding term sheet with RWI, pursuant to which RWI agreed to, among other things, an extension of the RWI 2nd Forbearance
Agreement whereby RWI has agreed not to exercise its rights and remedies upon the occurrence of any default under certain loans owed to
RWI and whereby the maturity date of the foregoing loans is extended to &lt;span id="xdx_904_eus-gaap--DebtInstrumentMaturityDate_dd_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z4ZxmFLG2mYk" title="Debt instrument maturity date"&gt;February 15, 2026&lt;/span&gt;. Pursuant to the RWI binding term sheet, the
Company agreed to (i) use a portion of the proceeds from its next registered public offering to pay RWI approximately $&lt;span id="xdx_90D_eus-gaap--RepaymentsOfOtherDebt_pn3n3_c20250212__20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcNg3ZK1tYOk" title="Payment for debt"&gt;1,300&lt;/span&gt;, representing
cash interest through January 31, 2025 and (ii) issue to RWI, on July 24, 2025, a new five&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znRNUkUF9wpk" style="display: none" title="Warrant term (years)"&gt;5&lt;/span&gt;-year warrant to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250212__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--LineOfCreditFacilityAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zkBa73YxmTe1" title="Warrants to purchase aggregate shares"&gt;500,000&lt;/span&gt; shares
of its Class A common stock. In addition, the Company agreed to reprice certain outstanding warrants held by RWI.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2024 and 2023,
the carrying values of the RWI Second Amended Bridge Loan and Amended RWI Loan, inclusive of interest and net of discount was $&lt;span id="xdx_909_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20241231__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zOoCz7iI2ha" title="Short-term debt - related parties"&gt;30,275&lt;/span&gt;
and $&lt;span id="xdx_902_ecustom--ShortTermDebtRelatedParties_iI_pn3n3_c20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--BridgeLoanMember_zU8pYDoUxsY4" title="Short-term debt - related parties"&gt;12,967&lt;/span&gt;, respectively. The carrying amounts of the RWI Second Amended Bridge Loan and Amended RWI Loan were deemed to approximate
fair value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40.8pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact001816">&lt;p id="xdx_894_eus-gaap--ScheduleOfDebtTableTextBlock_zK6Q9XSMaC9d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Debt consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B4_zvoiRhCYEAuh" style="display: none"&gt;Schedule
of Debt&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20241231_zHu7pAPGbOW" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20231231_zZqnJOOrQPv2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Debt - unaffiliated:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--PrePaidAdvanceAgreementMember_zyA9YHtaLfJi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"&gt;Yorkville - PPA (measured at fair value)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1818"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;17,223&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--LineOfCreditFacilityAxis__custom--YorkvilleMember__us-gaap--CreditFacilityAxis__custom--ConvertiblePromissoryNotesMember_zqsGDZKzQrz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Yorkville - convertible promissory note (measured at fair value)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,865&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1822"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_hus-gaap--CreditFacilityAxis__custom--UnsecuredSeniorConvertibleNoteMember_zHs57v3UQFL3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Unsecured senior convertible notes (measured at fair value)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;620&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1825"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--OtherShortTermDebt_iI_pn3n3_zVEapbxVD6wh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Short-term debt - other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1827"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,108&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ShortTermDebtUnaffiliated_iI_pn3n3_zvnBk4RyqYTb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total debt - unaffiliated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,485&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19,331&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Debt - related parties:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CVStarrBridgeLoanNetOfDiscountMember_zB6V0cUxTM8i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;C.V. Starr Bridge Loan, net of discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,652&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,523&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--RWIBridgeLoanNetOfDiscountMember_zqMwMDQu5Axb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;RWI Bridge Loan, net of discount&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,275&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,967&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_hus-gaap--ShortTermDebtTypeAxis__custom--CEOPromissoryNoteMember_zy480WSqLQo9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;CEO promissory note&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,876&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,419&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--ShortTermDebtRelatedParty_iI_pn3n3_zH425rxDLV0i" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left; padding-bottom: 1pt"&gt;Total debt - related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;39,803&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--Debt_iTI_pn3n3_zyvhxlDi9rCl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left; padding-bottom: 2.5pt"&gt;Total debt&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;42,288&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;39,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Balance sheet classification:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShortTermBorrowings_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z8IP16kNtQU8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Short-term debt - unaffiliated&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,485&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19,331&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ShortTermBorrowings_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2FkvjdwenYc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Short-term debt - related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,876&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;19,909&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4DEWC6mnYVi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Long-term debt - related parties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;35,927&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1855"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--Debt_iTI_pn3n3_znK7NZGmPrz7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    debt&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;42,288&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;39,240&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <CELU:ShortTermDebtUnaffiliated
      contextRef="AsOf2023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001819"
      unitRef="USD">17223000</CELU:ShortTermDebtUnaffiliated>
    <CELU:ShortTermDebtUnaffiliated
      contextRef="AsOf2024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember"
      decimals="-3"
      id="Fact001821"
      unitRef="USD">1865000</CELU:ShortTermDebtUnaffiliated>
    <CELU:ShortTermDebtUnaffiliated
      contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNoteMember"
      decimals="-3"
      id="Fact001824"
      unitRef="USD">620000</CELU:ShortTermDebtUnaffiliated>
    <CELU:OtherShortTermDebt
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001828"
      unitRef="USD">2108000</CELU:OtherShortTermDebt>
    <CELU:ShortTermDebtUnaffiliated
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001830"
      unitRef="USD">2485000</CELU:ShortTermDebtUnaffiliated>
    <CELU:ShortTermDebtUnaffiliated
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001831"
      unitRef="USD">19331000</CELU:ShortTermDebtUnaffiliated>
    <CELU:ShortTermDebtRelatedParty
      contextRef="AsOf2024-12-31_custom_CVStarrBridgeLoanNetOfDiscountMember"
      decimals="-3"
      id="Fact001833"
      unitRef="USD">5652000</CELU:ShortTermDebtRelatedParty>
    <CELU:ShortTermDebtRelatedParty
      contextRef="AsOf2023-12-31_custom_CVStarrBridgeLoanNetOfDiscountMember"
      decimals="-3"
      id="Fact001834"
      unitRef="USD">5523000</CELU:ShortTermDebtRelatedParty>
    <CELU:ShortTermDebtRelatedParty
      contextRef="AsOf2024-12-31_custom_RWIBridgeLoanNetOfDiscountMember"
      decimals="-3"
      id="Fact001836"
      unitRef="USD">30275000</CELU:ShortTermDebtRelatedParty>
    <CELU:ShortTermDebtRelatedParty
      contextRef="AsOf2023-12-31_custom_RWIBridgeLoanNetOfDiscountMember"
      decimals="-3"
      id="Fact001837"
      unitRef="USD">12967000</CELU:ShortTermDebtRelatedParty>
    <CELU:ShortTermDebtRelatedParty
      contextRef="AsOf2024-12-31_custom_CEOPromissoryNoteMember"
      decimals="-3"
      id="Fact001839"
      unitRef="USD">3876000</CELU:ShortTermDebtRelatedParty>
    <CELU:ShortTermDebtRelatedParty
      contextRef="AsOf2023-12-31_custom_CEOPromissoryNoteMember"
      decimals="-3"
      id="Fact001840"
      unitRef="USD">1419000</CELU:ShortTermDebtRelatedParty>
    <CELU:ShortTermDebtRelatedParty
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001842"
      unitRef="USD">39803000</CELU:ShortTermDebtRelatedParty>
    <CELU:ShortTermDebtRelatedParty
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001843"
      unitRef="USD">19909000</CELU:ShortTermDebtRelatedParty>
    <CELU:Debt
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001845"
      unitRef="USD">42288000</CELU:Debt>
    <CELU:Debt
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001846"
      unitRef="USD">39240000</CELU:Debt>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact001848"
      unitRef="USD">2485000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="-3"
      id="Fact001849"
      unitRef="USD">19331000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001851"
      unitRef="USD">3876000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001852"
      unitRef="USD">19909000</us-gaap:ShortTermBorrowings>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001854"
      unitRef="USD">35927000</us-gaap:LongTermDebtNoncurrent>
    <CELU:Debt
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001857"
      unitRef="USD">42288000</CELU:Debt>
    <CELU:Debt
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact001858"
      unitRef="USD">39240000</CELU:Debt>
    <us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001860"
      unitRef="USD">40000000</us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod>
    <CELU:PrePaidAdvancePeriod
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      id="Fact001862">P18M</CELU:PrePaidAdvancePeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001864"
      unitRef="USD">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <CELU:PrePaidAdvanceIssuedDiscountPercentage
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001866"
      unitRef="Pure">0.020</CELU:PrePaidAdvanceIssuedDiscountPercentage>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001868"
      unitRef="Pure">0.060</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001870"
      unitRef="Pure">0.150</CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault>
    <CELU:IssuanceOfCommonStockMinimumOptionPricePerShare
      contextRef="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001872"
      unitRef="USDPShares">7.50</CELU:IssuanceOfCommonStockMinimumOptionPricePerShare>
    <CELU:MaximumPercentageOfCommonStockIssued
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001874"
      unitRef="Pure">0.199</CELU:MaximumPercentageOfCommonStockIssued>
    <CELU:PercentageOfBeneficialOwnershipLimitation
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001876"
      unitRef="Pure">0.0499</CELU:PercentageOfBeneficialOwnershipLimitation>
    <CELU:MinimumNumberOfSharesOfCommonStockPurchase
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001878"
      unitRef="Shares">6000</CELU:MinimumNumberOfSharesOfCommonStockPurchase>
    <CELU:MinimumRequiredDailyVolumeWeightedAveragePrice
      contextRef="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001880"
      unitRef="USDPShares">7.50</CELU:MinimumRequiredDailyVolumeWeightedAveragePrice>
    <CELU:RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001882"
      unitRef="USD">6000000</CELU:RequiredMonthlyPaymentIfDailyVolumeWeightedAveragePriceIsBelowStatedPrice>
    <CELU:RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001884"
      unitRef="Pure">0.050</CELU:RedemptionPremiumPercentageIfVolumeWeightedAveragePriceIsLessThanStatedPrice>
    <CELU:RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001886"
      unitRef="Pure">0.100</CELU:RedemptionPremiumPercentageIfVolumeWeightedAveragePriceMoreThanStatedPrice>
    <CELU:MinimumRequiredDailyVolumeWeightedAveragePrice
      contextRef="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001888"
      unitRef="USDPShares">7.50</CELU:MinimumRequiredDailyVolumeWeightedAveragePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2023-06-30_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001890"
      unitRef="USDPShares">0.50</us-gaap:SharePrice>
    <CELU:IssuancePricePercentage
      contextRef="AsOf2022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact001892"
      unitRef="Pure">0.200</CELU:IssuancePricePercentage>
    <CELU:ProceedsFromLinesOfCreditGross
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001894"
      unitRef="USD">40000000</CELU:ProceedsFromLinesOfCreditGross>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001896"
      unitRef="USD">39200000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="From2022-09-152022-09-15_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      id="Fact001898">P12M</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001899"
      unitRef="USD">3889000</us-gaap:DebtConversionOriginalDebtAmount1>
    <CELU:DebtConversionOriginalDebtAccruedInterestAmount
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001900"
      unitRef="USD">400000</CELU:DebtConversionOriginalDebtAccruedInterestAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001901"
      unitRef="Shares">559481</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <CELU:DebtInstrumentPayment
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001902"
      unitRef="USD">18724000</CELU:DebtInstrumentPayment>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001903"
      unitRef="USD">16811000</us-gaap:RepaymentsOfShortTermDebt>
    <CELU:DebtInstrumentAccruedInterest
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001904"
      unitRef="USD">1073000</CELU:DebtInstrumentAccruedInterest>
    <CELU:DebtInstrumentRedemptionPremium
      contextRef="From2023-01-012023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001905"
      unitRef="USD">840000</CELU:DebtInstrumentRedemptionPremium>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001906"
      unitRef="USD">17223000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtDefaultShorttermDebtAmount
      contextRef="AsOf2023-12-31_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001907"
      unitRef="USD">16623000</us-gaap:DebtDefaultShorttermDebtAmount>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2024-01-122024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001909"
      unitRef="Pure">0.150</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2024-01-122024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001911"
      unitRef="USD">17348000</us-gaap:RepaymentsOfDebt>
    <CELU:DebtInstrumentPerDiemInterestAmount
      contextRef="From2024-01-122024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="-3"
      id="Fact001913"
      unitRef="USD">7000</CELU:DebtInstrumentPerDiemInterestAmount>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001915"
      unitRef="Shares">100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-01-12_custom_YorkvilleMember_custom_PrePaidAdvanceAgreementMember"
      decimals="INF"
      id="Fact001917"
      unitRef="Shares">100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact001919"
      unitRef="USD">3150000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact001921"
      unitRef="USD">2993000</us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod>
    <CELU:ConvertiblePromissoryNoteDiscountPercentage
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001923"
      unitRef="Pure">0.050</CELU:ConvertiblePromissoryNoteDiscountPercentage>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001925"
      unitRef="Pure">0.080</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001927"
      unitRef="Pure">0.180</CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      id="Fact001929">2025-03-13</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001931"
      unitRef="USDPShares">6.3171</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <CELU:MinimumRequiredDailyVolumeWeightedAveragePrice
      contextRef="AsOf2024-09-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001933"
      unitRef="USDPShares">2.7546</CELU:MinimumRequiredDailyVolumeWeightedAveragePrice>
    <CELU:PercentageOfConversionOnOutstandingCommonStock
      contextRef="AsOf2024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001935"
      unitRef="Pure">0.199</CELU:PercentageOfConversionOnOutstandingCommonStock>
    <CELU:PercentageOfBeneficialOwnershipLimitation
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001937"
      unitRef="Pure">0.0499</CELU:PercentageOfBeneficialOwnershipLimitation>
    <CELU:DebtInstrumentDefaultInterestRate
      contextRef="AsOf2024-05-01_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001939"
      unitRef="Pure">0.180</CELU:DebtInstrumentDefaultInterestRate>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2024-01-012024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact001940"
      unitRef="USD">157000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2024-11-012024-11-30_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact001941"
      unitRef="USD">1150000</us-gaap:DebtConversionOriginalDebtAmount1>
    <CELU:DebtConversionOriginalDebtAccruedInterestAmount
      contextRef="From2024-11-012024-11-30_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact001942"
      unitRef="USD">169000</CELU:DebtConversionOriginalDebtAccruedInterestAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2024-11-012024-11-30_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact001943"
      unitRef="Shares">478881</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentFairValue
      contextRef="AsOf2024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact001944"
      unitRef="USD">1865000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtDefaultShorttermDebtAmount
      contextRef="AsOf2024-12-31_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact001945"
      unitRef="USD">2000000</us-gaap:DebtDefaultShorttermDebtAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2025-03-162025-03-16_custom_YorkvilleMember_us-gaap_SubsequentEventMember"
      id="Fact001947">2025-03-13</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2025-03-172025-03-17_custom_YorkvilleMember_us-gaap_SubsequentEventMember"
      id="Fact001949">2025-05-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:SharesIssued
      contextRef="AsOf2025-03-17_custom_YorkvilleMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact001951"
      unitRef="Shares">100000</us-gaap:SharesIssued>
    <CELU:NotesAndPurchaserWarrantsPrincipalAmount
      contextRef="AsOf2024-11-25_srt_MaximumMember_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="-3"
      id="Fact001953"
      unitRef="USD">1000000</CELU:NotesAndPurchaserWarrantsPrincipalAmount>
    <CELU:ProceedsFromNotesAndPurchaserWarrants
      contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="-3"
      id="Fact001955"
      unitRef="USD">750000</CELU:ProceedsFromNotesAndPurchaserWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="INF"
      id="Fact001957"
      unitRef="Shares">263156</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="INF"
      id="Fact001959"
      unitRef="Pure">0.080</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault
      contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="INF"
      id="Fact001961"
      unitRef="Pure">0.100</CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="INF"
      id="Fact001963"
      unitRef="USDPShares">2.85</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:MinimumGrossProceeds
      contextRef="From2024-11-252024-11-25_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="-3"
      id="Fact001965"
      unitRef="USDPShares">2500000</CELU:MinimumGrossProceeds>
    <CELU:FloorPrice
      contextRef="AsOf2024-11-25_custom_UnsecuredSeniorConvertibleNotesMember"
      decimals="INF"
      id="Fact001967"
      unitRef="USDPShares">1.00</CELU:FloorPrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-11-25"
      decimals="INF"
      id="Fact001969"
      unitRef="USDPShares">2.85</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:FloorPrice
      contextRef="AsOf2024-11-25"
      decimals="INF"
      id="Fact001971"
      unitRef="USDPShares">1.00</CELU:FloorPrice>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2024-11-25" id="Fact001973">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2024-11-25" id="Fact001975">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <CELU:PercentageOfCashFeeEqualToAggregateProceeds
      contextRef="From2024-11-252024-11-25"
      decimals="INF"
      id="Fact001977"
      unitRef="Pure">0.07</CELU:PercentageOfCashFeeEqualToAggregateProceeds>
    <CELU:PercentageOfExercisePriceEqualToOfferingPrice
      contextRef="From2024-11-252024-11-25"
      decimals="INF"
      id="Fact001979"
      unitRef="Pure">1.25</CELU:PercentageOfExercisePriceEqualToOfferingPrice>
    <us-gaap:OtherExpenses
      contextRef="From2024-01-012024-12-31_custom_UnsecuredSeniorConvertibleNotesMember15557562"
      decimals="-3"
      id="Fact001981"
      unitRef="USD">478000</us-gaap:OtherExpenses>
    <CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes
      contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember15557609"
      decimals="-3"
      id="Fact001983"
      unitRef="USD">620000</CELU:ShorttermDebtUnsecuredSeniorConvertibleNotes>
    <us-gaap:DebtDefaultShorttermDebtAmount
      contextRef="AsOf2024-12-31_custom_UnsecuredSeniorConvertibleNotesMember15557609"
      decimals="-3"
      id="Fact001985"
      unitRef="USD">750000</us-gaap:DebtDefaultShorttermDebtAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fact001987"
      unitRef="USD">3000000</us-gaap:DebtInstrumentFaceAmount>
    <CELU:DebtInstrumentContributionAmount
      contextRef="AsOf2023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fact001989"
      unitRef="USD">1000000</CELU:DebtInstrumentContributionAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact001991"
      unitRef="Pure">0.150</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-08-212023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember"
      id="Fact001993">2024-08-21</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ProceedsFromOtherShortTermDebt
      contextRef="From2023-08-212023-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fact001995"
      unitRef="USD">4500000</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember"
      decimals="-3"
      id="Fact001997"
      unitRef="USD">285000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-10-122023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember"
      decimals="INF"
      id="Fact001999"
      unitRef="Pure">0.150</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="From2023-10-122023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember"
      id="Fact002001">P12M</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-12-31_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember"
      decimals="-3"
      id="Fact002003"
      unitRef="USD">3876000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2023-12-31_custom_ChairmanAndChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fact002005"
      unitRef="USD">2108000</us-gaap:ShortTermBorrowings>
    <CELU:OtherShortTermDebtDueToRelatedParty
      contextRef="AsOf2023-12-31_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember"
      decimals="-3"
      id="Fact002007"
      unitRef="USD">1419000</CELU:OtherShortTermDebtDueToRelatedParty>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember"
      decimals="-3"
      id="Fact002008"
      unitRef="USD">5000000</us-gaap:DebtInstrumentFaceAmount>
    <CELU:DebtInstrumentOriginalIssueDiscount
      contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember"
      decimals="-3"
      id="Fact002009"
      unitRef="USD">100000</CELU:DebtInstrumentOriginalIssueDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002010"
      unitRef="Pure">0.120</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <CELU:DebtInstrumentInterestRateEffectivePercentageInEventOfDefault
      contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002012"
      unitRef="Pure">0.150</CELU:DebtInstrumentInterestRateEffectivePercentageInEventOfDefault>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-03-172023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember"
      id="Fact002013">2025-03-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002014"
      unitRef="Shares">75000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002015"
      unitRef="USDPShares">1.25</us-gaap:SharesIssuedPricePerShare>
    <CELU:ShareIssuedPurchasedPrice
      contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember"
      decimals="-3"
      id="Fact002017"
      unitRef="USD">94000</CELU:ShareIssuedPurchasedPrice>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember"
      id="Fact002018">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-03-17_custom_LoanAgreementMember_custom_CVStarrCoIncMember_us-gaap_WarrantMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002019"
      unitRef="USDPShares">7.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-30_us-gaap_WarrantMember_custom_LoanAgreementMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002021"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-06-30_us-gaap_WarrantMember_custom_LoanAgreementMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember"
      id="Fact002023">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-30_us-gaap_WarrantMember_custom_LoanAgreementMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002025"
      unitRef="USDPShares">8.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-06-30_custom_LoanAgreementMember_custom_CVStarrCoIncMember"
      decimals="-3"
      id="Fact002027"
      unitRef="USD">3000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <CELU:FallInCashAndCashEquivalents
      contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_CVStarrCoIncMember"
      decimals="-3"
      id="Fact002029"
      unitRef="USD">3000000</CELU:FallInCashAndCashEquivalents>
    <CELU:FallInCashAndCashEquivalents
      contextRef="AsOf2024-01-12_custom_LoanAgreementMember_custom_CVStarrCoIncMember"
      decimals="-3"
      id="Fact002031"
      unitRef="USD">3000000</CELU:FallInCashAndCashEquivalents>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002033"
      unitRef="Pure">1</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002035"
      unitRef="Shares">75000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002037"
      unitRef="USDPShares">7.10</us-gaap:SharesIssuedPricePerShare>
    <CELU:ClassOfWarrantOrRighstExpirationDate
      contextRef="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember"
      id="Fact002039">2028-03-17</CELU:ClassOfWarrantOrRighstExpirationDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember_custom_TrancheTwoWarrantMember"
      decimals="INF"
      id="Fact002041"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember_custom_TrancheTwoWarrantMember"
      decimals="INF"
      id="Fact002043"
      unitRef="USDPShares">8.10</us-gaap:SharesIssuedPricePerShare>
    <CELU:ClassOfWarrantOrRighstExpirationDate
      contextRef="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember_custom_TrancheTwoWarrantMember"
      id="Fact002045">2028-06-20</CELU:ClassOfWarrantOrRighstExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002047"
      unitRef="USDPShares">5.895</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002049"
      unitRef="Pure">0.130</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <CELU:PercentageOfChangesInCashFlow
      contextRef="From2024-03-132024-03-13_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002051"
      unitRef="Pure">0.10</CELU:PercentageOfChangesInCashFlow>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-03-13_custom_LoanAgreementMember_custom_CVStarrCoIncMember"
      decimals="-3"
      id="Fact002053"
      unitRef="USD">51000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2024-04-15_custom_LoanAgreementMember_custom_ForbearanceAgreementMember_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002055"
      unitRef="Pure">0.160</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2025-02-122025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember"
      id="Fact002057">2026-02-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="From2025-02-122025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact002059"
      unitRef="USD">800000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember"
      id="Fact002061">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-12_us-gaap_WarrantMember_us-gaap_CommonClassAMember_custom_CVStarrCoIncMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002063"
      unitRef="Shares">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CELU:ShortTermDebtRelatedParties
      contextRef="AsOf2024-12-31_custom_LoanAgreementMember_custom_CVStarrCoIncMember"
      decimals="-3"
      id="Fact002065"
      unitRef="USD">5652000</CELU:ShortTermDebtRelatedParties>
    <CELU:ShortTermDebtRelatedParties
      contextRef="AsOf2023-12-31_custom_LoanAgreementMember_custom_CVStarrCoIncMember"
      decimals="-3"
      id="Fact002067"
      unitRef="USD">5523000</CELU:ShortTermDebtRelatedParties>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember"
      decimals="-3"
      id="Fact002069"
      unitRef="USD">6000000</us-gaap:DebtInstrumentFaceAmount>
    <CELU:DebtInstrumentDiscount
      contextRef="AsOf2023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember"
      decimals="-3"
      id="Fact002071"
      unitRef="USD">120000</CELU:DebtInstrumentDiscount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-05-162023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember"
      decimals="INF"
      id="Fact002073"
      unitRef="Pure">0.125</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <CELU:DebtInstrumentInterestRateDuringPeriodInEventOfDefault
      contextRef="From2023-05-162023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember"
      decimals="INF"
      id="Fact002075"
      unitRef="Pure">0.155</CELU:DebtInstrumentInterestRateDuringPeriodInEventOfDefault>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-05-162023-05-16_us-gaap_BridgeLoanMember_custom_InitialLoanMember"
      id="Fact002077">2023-06-14</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      decimals="-3"
      id="Fact002078"
      unitRef="USD">6000000</us-gaap:DebtInstrumentFaceAmount>
    <CELU:DebtInstrumentDiscount
      contextRef="AsOf2023-06-21_us-gaap_BridgeLoanMember_custom_InitialLoanMember"
      decimals="-3"
      id="Fact002079"
      unitRef="USD">678000</CELU:DebtInstrumentDiscount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-06-212023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact002080"
      unitRef="Pure">0.125</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <CELU:DebtInstrumentInterestRateDuringPeriodInEventOfDefault
      contextRef="From2023-06-212023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact002081"
      unitRef="Pure">0.155</CELU:DebtInstrumentInterestRateDuringPeriodInEventOfDefault>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2023-06-212023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      id="Fact002082">2025-03-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact002083"
      unitRef="Shares">300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact002084"
      unitRef="USDPShares">1.25</us-gaap:SharesIssuedPricePerShare>
    <CELU:ShareIssuedPurchasedPrice
      contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      decimals="-3"
      id="Fact002086"
      unitRef="USD">375000</CELU:ShareIssuedPurchasedPrice>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      id="Fact002088">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-06-21_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact002090"
      unitRef="USDPShares">8.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-09-14_us-gaap_BridgeLoanMember"
      decimals="-3"
      id="Fact002092"
      unitRef="USD">3000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <CELU:FallInCashAndCashEquivalents
      contextRef="AsOf2023-09-14_us-gaap_BridgeLoanMember"
      decimals="-3"
      id="Fact002094"
      unitRef="USD">3000000</CELU:FallInCashAndCashEquivalents>
    <CELU:FallInCashAndCashEquivalents
      contextRef="AsOf2024-01-12_us-gaap_BridgeLoanMember"
      decimals="-3"
      id="Fact002096"
      unitRef="USD">3000000</CELU:FallInCashAndCashEquivalents>
    <CELU:DiscountOnWarrantAmount
      contextRef="AsOf2024-01-12_us-gaap_BridgeLoanMember"
      decimals="-3"
      id="Fact002098"
      unitRef="USD">2151000</CELU:DiscountOnWarrantAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      decimals="-3"
      id="Fact002100"
      unitRef="USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <CELU:DebtInstrumentOriginalIssueDiscount
      contextRef="AsOf2024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      decimals="-3"
      id="Fact002102"
      unitRef="USD">3750000</CELU:DebtInstrumentOriginalIssueDiscount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-01-122024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact002104"
      unitRef="Pure">0.125</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2024-01-122024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      id="Fact002106">2025-07-16</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-01-12_custom_AdditionalLoanMember_us-gaap_BridgeLoanMember"
      id="Fact002108">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-01-12_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember_custom_AdditionalLoanMember"
      decimals="INF"
      id="Fact002110"
      unitRef="Shares">1650000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-01-12_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact002112"
      unitRef="Shares">1350000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-01-12_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember"
      id="Fact002114">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-16_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact002116"
      unitRef="USDPShares">2.4898</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-07-15_custom_TrancheOneWarrantMember_us-gaap_CommonClassAMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact002118"
      unitRef="USDPShares">2.988</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-01-12_us-gaap_BridgeLoanMember"
      decimals="-3"
      id="Fact002120"
      unitRef="USD">3908000</us-gaap:ShortTermBorrowings>
    <CELU:PercentageOfPartialLiquidatingDamagesOnPurchasePrice
      contextRef="AsOf2024-01-12_custom_InitialAndSecondTrancheMember"
      decimals="INF"
      id="Fact002122"
      unitRef="Pure">0.010</CELU:PercentageOfPartialLiquidatingDamagesOnPurchasePrice>
    <CELU:PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount
      contextRef="AsOf2024-01-12_custom_InitialAndSecondTrancheMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002124"
      unitRef="Pure">0.060</CELU:PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount>
    <CELU:DailyInterestAccruingRate
      contextRef="AsOf2024-01-12_custom_InitialAndSecondTrancheMember"
      decimals="INF"
      id="Fact002126"
      unitRef="Pure">0.180</CELU:DailyInterestAccruingRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2024-03-132024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact002128"
      unitRef="Pure">1</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2024-03-132024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002130"
      unitRef="Pure">0.125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2024-03-132024-03-13_us-gaap_BridgeLoanMember_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002132"
      unitRef="Pure">0.135</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember"
      decimals="INF"
      id="Fact002134"
      unitRef="Shares">300000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002136"
      unitRef="USDPShares">5.895</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:PercentageOfChangesInCashFlow
      contextRef="From2024-03-132024-03-13_us-gaap_BridgeLoanMember_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002138"
      unitRef="Pure">0.10</CELU:PercentageOfChangesInCashFlow>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2024-03-13_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember15559390"
      decimals="-3"
      id="Fact002140"
      unitRef="USD">1162000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-08-05_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact002142"
      unitRef="USD">13700000</us-gaap:ShortTermBorrowings>
    <CELU:DebtInstrumentDefaultInterestRate
      contextRef="AsOf2024-08-05_custom_ForbearanceAgreementMember_us-gaap_BridgeLoanMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact002144"
      unitRef="Pure">0.165</CELU:DebtInstrumentDefaultInterestRate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2025-02-122025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember"
      id="Fact002146">2026-02-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfOtherDebt
      contextRef="From2025-02-122025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact002148"
      unitRef="USD">1300000</us-gaap:RepaymentsOfOtherDebt>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember"
      id="Fact002150">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-12_us-gaap_WarrantMember_custom_ResortsWorldIncPteLtdMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002152"
      unitRef="Shares">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CELU:ShortTermDebtRelatedParties
      contextRef="AsOf2024-12-31_us-gaap_BridgeLoanMember"
      decimals="-3"
      id="Fact002154"
      unitRef="USD">30275000</CELU:ShortTermDebtRelatedParties>
    <CELU:ShortTermDebtRelatedParties
      contextRef="AsOf2023-12-31_us-gaap_BridgeLoanMember"
      decimals="-3"
      id="Fact002156"
      unitRef="USD">12967000</CELU:ShortTermDebtRelatedParties>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002158">&lt;p id="xdx_805_eus-gaap--LesseeOperatingLeasesTextBlock_zk9BJsnCoqMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;11. &lt;span id="xdx_82C_zapz0rYJQL0g"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;ROU assets represent the Company&#x2019;s
right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments
arising from the lease. The Company&#x2019;s lease ROU assets and liabilities are recognized at the lease commencement date based on the
present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses its incremental
borrowing rate (&#x201c;IBR&#x201d;) based on the information available at the lease commencement date to determine the appropriate discount
rate by multiple asset classes. Variable lease payments that are not based on an index or that result from changes to an index subsequent
to the initial measurement of the corresponding lease liability are not included in the measurement of lease ROU assets or liabilities
and instead are recognized in earnings in the period in which the obligation for those payments is incurred. Lease terms may include options
to extend or terminate the lease when it is reasonably certain that the Company will exercise any such options. Lease expense is recognized
on a straight-line basis over the expected lease term. Rent expense was $&lt;span id="xdx_90F_ecustom--OperatingLeasesRentExpense_pn3n3_c20240101__20241231_zKsdObsX78n2" title="Rent expense"&gt;4,444&lt;/span&gt; and $&lt;span id="xdx_90A_ecustom--OperatingLeasesRentExpense_pn3n3_c20230101__20231231_ze6GsLJzISk7" title="Rent expense"&gt;3,750&lt;/span&gt; for the years ended December 31, 2024 and 2023,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 13, 2019, Legacy Celularity
entered into a lease agreement for a &lt;span id="xdx_90D_ecustom--AreaOfBuilding_usqft_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_z60z2WxQP3Lj" title="Area of building"&gt;147,215
&lt;/span&gt;square foot facility consisting of office, manufacturing and laboratory space in Florham Park, New Jersey, which expires in &lt;span id="xdx_900_ecustom--OperatingLeaseExpiryYear_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zhWbVzqOWcuf" title="Operating lease expiry year"&gt;2036&lt;/span&gt;.
The Company has the &lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseOptionToExtend_dtY_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zmrWpUdFmIZ4" title="Option to renew lease term period."&gt;option to renew the term of the lease for two additional five-year terms&lt;/span&gt; so long as the lease is then in full force
and effect; both option periods have been included in determining the lease term
used in recognizing the ROU assets and lease liability. The lease term commenced on &lt;span id="xdx_900_ecustom--OperatingLeaseCommencementDate_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zCO9QgObL3z5" title="Operating lease commencement date"&gt;March
1, 2020&lt;/span&gt; subject to an abatement of the fixed rent for the first 13 months following the lease commencement date. The initial monthly
base rent was approximately $&lt;span id="xdx_902_ecustom--InitialMonthlyBaseRent_pn3n3_c20190313__20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zfNcRCna5Uvb" title="Initial monthly base rent"&gt;230
&lt;/span&gt;and will increase annually. The Company is obligated to pay real estate taxes and costs related to the premises, including costs
of operations, maintenance, repair, replacement and management of the new leased premises. In connection with entering into this lease
agreement, Legacy Celularity issued a letter of credit of $&lt;span id="xdx_902_eus-gaap--RestrictedCashNoncurrent_iI_pn3n3_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zlXDWUXcZpVe"&gt;14,722&lt;/span&gt;.
The lease agreement allows for a landlord provided tenant improvement allowance of $&lt;span id="xdx_90F_eus-gaap--TenantImprovements_iI_pn3n3_c20190313__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeManufacturingAndLaboratorySpaceMember__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_zQSRmTAtBdok"&gt;14,722
&lt;/span&gt;to be applied to the costs of the construction of the leasehold improvements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On September 14, 2023, the Company
entered into a lease amendment on the Company&#x2019;s Florham Park, New Jersey facility to reduce the letter of credit by approximately
$&lt;span id="xdx_90F_ecustom--ReductionInLineOfCredit_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zhi0VebCiCX6" title="Reduction in line of credit"&gt;4,900&lt;/span&gt; for a new letter of credit in the amount of $&lt;span id="xdx_905_ecustom--NewLineOfCredit_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zZSwrEwEM3n" title="New line of credit"&gt;9,883&lt;/span&gt; in exchange for higher base rental payments of approximately $&lt;span id="xdx_909_ecustom--BaseRentalPayments_pn3n3_c20230914__20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zF8BZUGPiF54" title="Base rental payments"&gt;400&lt;/span&gt; per year,
effective October 1, 2023. The letter of credit, inclusive of interest earned on the account, is classified as restricted cash (non-current)
on the consolidated balance sheets. The Company evaluates changes to the terms and conditions of a lease contract to determine if they
result in a new lease or a modification of an existing lease. The Company accounted for the lease amendment as a modification since the
change in lease payments did not represent additional ROU assets. The Company reassessed the IBR, and remeasured the lease liability and
ROU asset on the modification date of September 14, 2023. As a result, the Company recorded a decrease to the ROU asset and related lease
liability in the amount of $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20230914__srt--StatementGeographicalAxis__custom--FlorhamParkNewJerseyMember_zr2b0RFxZ1w8" title="Operating lease liability"&gt;2,083&lt;/span&gt; on the consolidated balance sheets reflecting a higher IBR due to lower Company credit rating.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zzZwHVMfDS09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The components of the Company&#x2019;s
lease costs are classified on its consolidated statements of operations and comprehensive loss as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BC_zEvjVtPLhjy8" style="display: none"&gt;Schedule of Lease Costs&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_z01c7OEiLum6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zr2OEtetPtNe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzz3O_zQPvpqJHDyz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,911&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,256&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--VariableLeaseCost_maLCzz3O_z2Dke0KHhmwj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Variable lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,348&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,132&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LeaseCost_iT_mtLCzz3O_z3dA7Ic5ESs5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,259&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,388&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zjRS8CHezIHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_zUyVx6kQYK87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The table below shows the cash
activity related to the Company&#x2019;s lease liabilities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B3_zxKbWd3fK01l" style="display: none"&gt;Schedule of Cash Activity
Related to the lease Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_z4ONtJT2joai" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20231231_zFFb7eV4Du76" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Cash paid related to lease liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zIwRZpFFzHBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;2,995&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_z1WuKGegbIji" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zeGRIeMXVnHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2024, the maturities
of the Company&#x2019;s operating lease liabilities were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B0_zKzb7mbioMVc" style="display: none"&gt;Schedule
of Future Minimum Payments under Operating Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20241231_zt7xViQDUVO" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPznn8_zAFNfB3fXeLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,452&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPznn8_zBDPk29rFmHh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,526&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPznn8_zH75YC2c8TZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,599&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPznn8_zkdyi0jYyBp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,673&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPznn8_zRyx60139Kuk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2029&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,746&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPznn8_zkGgZuJvQkG7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;80,821&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznn8_zpq5tiEUlcw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;98,817&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zbxAJ1eTPXng" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(72,269&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_z8mDX89PLs0c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;26,548&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zPgp2hykfyS2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2024, the weighted
average remaining lease term of the Company&#x2019;s operating lease was &lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20241231_zYNNJYgasNvl" title="Weighted average remaining lease term"&gt;21.3&lt;/span&gt; years, and the weighted average discount rate used to determine
the lease liability for the operating lease was &lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20241231_zEA7EkRXyJth" title="Weighted average discount rate"&gt;14.24&lt;/span&gt;%.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <CELU:OperatingLeasesRentExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact002160"
      unitRef="USD">4444000</CELU:OperatingLeasesRentExpense>
    <CELU:OperatingLeasesRentExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002162"
      unitRef="USD">3750000</CELU:OperatingLeasesRentExpense>
    <CELU:AreaOfBuilding
      contextRef="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember"
      decimals="INF"
      id="Fact002164"
      unitRef="sqft">147215</CELU:AreaOfBuilding>
    <CELU:OperatingLeaseExpiryYear
      contextRef="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember"
      id="Fact002166">2036</CELU:OperatingLeaseExpiryYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember"
      id="Fact002168">option to renew the term of the lease for two additional five-year terms</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <CELU:OperatingLeaseCommencementDate
      contextRef="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember"
      id="Fact002170">2020-03-01</CELU:OperatingLeaseCommencementDate>
    <CELU:InitialMonthlyBaseRent
      contextRef="From2019-03-132019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember"
      decimals="-3"
      id="Fact002172"
      unitRef="USD">230000</CELU:InitialMonthlyBaseRent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="AsOf2023-12-31_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember"
      decimals="-3"
      id="Fact002173"
      unitRef="USD">14722000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:TenantImprovements
      contextRef="AsOf2019-03-13_custom_OfficeManufacturingAndLaboratorySpaceMember_custom_FlorhamParkNewJerseyMember_custom_LegacyCelularityMember"
      decimals="-3"
      id="Fact002174"
      unitRef="USD">14722000</us-gaap:TenantImprovements>
    <CELU:ReductionInLineOfCredit
      contextRef="AsOf2023-09-14_custom_FlorhamParkNewJerseyMember"
      decimals="-3"
      id="Fact002176"
      unitRef="USD">4900000</CELU:ReductionInLineOfCredit>
    <CELU:NewLineOfCredit
      contextRef="AsOf2023-09-14_custom_FlorhamParkNewJerseyMember"
      decimals="-3"
      id="Fact002178"
      unitRef="USD">9883000</CELU:NewLineOfCredit>
    <CELU:BaseRentalPayments
      contextRef="From2023-09-142023-09-14_custom_FlorhamParkNewJerseyMember"
      decimals="-3"
      id="Fact002180"
      unitRef="USD">400000</CELU:BaseRentalPayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-09-14_custom_FlorhamParkNewJerseyMember"
      decimals="-3"
      id="Fact002182"
      unitRef="USD">2083000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002184">&lt;p id="xdx_890_eus-gaap--LeaseCostTableTextBlock_zzZwHVMfDS09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The components of the Company&#x2019;s
lease costs are classified on its consolidated statements of operations and comprehensive loss as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8BC_zEvjVtPLhjy8" style="display: none"&gt;Schedule of Lease Costs&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240101__20241231_z01c7OEiLum6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zr2OEtetPtNe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseCost_maLCzz3O_zQPvpqJHDyz1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,911&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,256&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--VariableLeaseCost_maLCzz3O_z2Dke0KHhmwj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Variable lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,348&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,132&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LeaseCost_iT_mtLCzz3O_z3dA7Ic5ESs5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total operating lease cost&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,259&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,388&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002186"
      unitRef="USD">3911</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002187"
      unitRef="USD">3256</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002189"
      unitRef="USD">1348</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002190"
      unitRef="USD">1132</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002192"
      unitRef="USD">5259</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002193"
      unitRef="USD">4388</us-gaap:LeaseCost>
    <CELU:CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002195">&lt;p id="xdx_89B_ecustom--CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock_zUyVx6kQYK87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The table below shows the cash
activity related to the Company&#x2019;s lease liabilities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B3_zxKbWd3fK01l" style="display: none"&gt;Schedule of Cash Activity
Related to the lease Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20240101__20241231_z4ONtJT2joai" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20231231_zFFb7eV4Du76" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left"&gt;Cash paid related to lease liabilities:&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeasePayments_zIwRZpFFzHBl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,378&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;2,995&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</CELU:CashAndNonCashActivityRelatedToLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2024-01-01to2024-12-31"
      decimals="0"
      id="Fact002197"
      unitRef="USD">3378</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002198"
      unitRef="USD">2995</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002200">&lt;p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zeGRIeMXVnHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2024, the maturities
of the Company&#x2019;s operating lease liabilities were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span id="xdx_8B0_zKzb7mbioMVc" style="display: none"&gt;Schedule
of Future Minimum Payments under Operating Leases&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20241231_zt7xViQDUVO" style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPznn8_zAFNfB3fXeLb" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;3,452&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPznn8_zBDPk29rFmHh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,526&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPznn8_zH75YC2c8TZ3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2027&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,599&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPznn8_zkdyi0jYyBp2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2028&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,673&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPznn8_zRyx60139Kuk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;2029&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,746&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPznn8_zkGgZuJvQkG7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Thereafter&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;80,821&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznn8_zpq5tiEUlcw6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;98,817&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zbxAJ1eTPXng" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Less imputed interest&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(72,269&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiability_iI_z8mDX89PLs0c" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;26,548&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002202"
      unitRef="USD">3452</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002204"
      unitRef="USD">3526</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002206"
      unitRef="USD">3599</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002208"
      unitRef="USD">3673</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002210"
      unitRef="USD">3746</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002212"
      unitRef="USD">80821</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002214"
      unitRef="USD">98817</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002216"
      unitRef="USD">72269</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact002218"
      unitRef="USD">26548</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-12-31" id="Fact002220">P21Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002222"
      unitRef="Pure">0.1424</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002224">&lt;p id="xdx_80F_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zHn1dBx817ye" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;12. &lt;span id="xdx_821_za5rrymlh6ie"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Contingent Consideration Related to Business
Combinations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In connection with Legacy Celularity&#x2019;s
acquisition in 2017 of HLI Cellular Therapeutics, LLC and Anthrogenesis, the Company has agreed to pay future consideration to the sellers
upon the achievement of certain regulatory and commercial milestones. As a result, the Company recorded $&lt;span id="xdx_90D_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HLICellularTherapeuticsLLCAndAnthrogenesisMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularitysMember_zO2zVmIlaPbl" title="Contingent consideration"&gt;1,413&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_pn3n3_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HLICellularTherapeuticsLLCAndAnthrogenesisMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularitysMember_zolUcu0OmSI9" title="Contingent consideration"&gt;1,606&lt;/span&gt; as contingent
consideration as of December 31, 2024 and 2023, respectively. During 2023, the Company discontinued its unmodified NK cell and AML Cell
Therapy clinical trials subject to the contingent consideration agreement under the Anthrogenesis acquisition and, as a result, the fair
value of the contingent consideration obligation decreased significantly as of December 31, 2023. Due to the contingent nature of these
milestone and royalty payments, there is a high degree of judgment in the management estimates that determine the fair value of the contingent
consideration. See Note 4 for further discussion.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Indemnification Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In the ordinary course of business,
the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect
to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement
claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors
and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise
by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required
to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs
as a result of such indemnifications. The Company is not currently aware of any indemnification claims and has not accrued any liabilities
related to such obligations in its consolidated financial statements as of December 31, 2024 or 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Agreement with Palantir Technologies Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On May 5, 2021, Legacy Celularity
executed a Master Subscription Agreement (the &#x201c;Palantir MSA&#x201d;) with Palantir under which it agreed to pay $&lt;span id="xdx_90D_ecustom--PaymentsForMasterSubscriptionAgreement_pn3n3_c20210505__20210505__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--TypeOfArrangementAxis__custom--MasterSubscriptionAgreementMember_zx0KAVOYOD46" title="Payments for master subscription agreement"&gt;40,000&lt;/span&gt; over &lt;span id="xdx_90E_ecustom--PaymentSubscriptionPeriod_dc_c20210505__20210505__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--TypeOfArrangementAxis__custom--MasterSubscriptionAgreementMember_zWtaR8iTPIqa" title="Payment subscription period"&gt;five
years&lt;/span&gt; for access to Palantir&#x2019;s Foundry platform along with certain professional services. The Company intended to utilize Palantir&#x2019;s
Foundry platform to secure deeper insights into data obtained from the Company&#x2019;s discovery and process development, as well as manufacturing
and biorepository operations. In January 2023, the Company ceased use of the software and provided a notice of dispute to Palantir on
the basis that the software had not performed as promised and that Palantir had failed to provide the Company with the professional services
necessary to successfully implement, integrate and enable the Foundry platform. As a result, in accordance with ASC 420, &lt;i&gt;Exit or Disposal
Costs&lt;/i&gt;, during the quarter ended March 31, 2023, the Company recognized the remaining related cease-use costs liability estimated based
on the discounted future cash flows of contract payments for $&lt;span id="xdx_900_eus-gaap--BusinessExitCosts1_pn3n3_c20230101__20230331__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember__us-gaap--IncomeStatementLocationAxis__custom--SoftwareCeaseUseCostsMember_z1e8f410E072" title="Exit or disposal costs"&gt;24,402&lt;/span&gt; which was included as software cease-use costs in the consolidated
statements of operations and comprehensive loss. On December 21, 2023, the Company entered into a settlement and release agreement with
Palantir (the &#x201c;Palantir Settlement Agreement&#x201d;), which was subsequently amended on January 10, 2024 and May 6, 2024, whereupon
the parties agreed that if the Company paid Palantir the settlement fees of $&lt;span id="xdx_90E_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240110__20240110__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember_zaRZoMPdxI11" title="Agreed to pay settlement payment"&gt;&lt;span id="xdx_908_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240506__20240506__srt--CounterpartyNameAxis__custom--PalantirTechnologiesIncMember_zR3lwXVXtcUa" title="Agreed to pay settlement payment"&gt;3,500&lt;/span&gt;&lt;/span&gt;, less any amounts previously paid, and issued shares
as discussed in the &lt;i&gt;Arbitration Demand&lt;/i&gt; section below no later than June 3, 2024, the parties would cease the arbitration and deem
the original Palantir MSA terminated. The Company made the required payments prior to June 3, 2024, and on June 4, 2024, the parties dismissed
all claims and counterclaims. Accordingly, at December 31, 2023, the Company reversed previously recognized costs in excess of the final
settlement amount. The Company had &lt;span id="xdx_90F_ecustom--AccruedResearchAndDevelopmentSoftware_iI_dxL_c20241231_z8AyrJbCfvp1" title="Accrued research and development software::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2240"&gt;no&lt;/span&gt;&lt;/span&gt; liability as of December 31, 2024 and a current liability of $&lt;span id="xdx_906_ecustom--AccruedResearchAndDevelopmentSoftware_iI_pn3n3_c20231231_zt6oUP1d7sR8" title="Accrued research and development software"&gt;3,500&lt;/span&gt; as of December 31, 2023, respectively,
for accrued R&amp;amp;D software on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sirion License Agreement &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In December 2021, the Company
entered into a license agreement (&#x201c;Sirion License&#x201d;) with Sirion Biotech GmbH (&#x201c;Sirion&#x201d;). Under the Sirion License,
Sirion granted the Company a license related to patent rights and know-how associated with poloxamers (&#x201c;Licensed Product&#x201d;).
As part of the Sirion License, the Company paid Sirion $&lt;span id="xdx_90A_ecustom--UpfrontFee_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zxjQOZJfa7Oh" title="Upfront fee"&gt;136&lt;/span&gt; as an upfront fee, a $&lt;span id="xdx_900_ecustom--AnnualMaintenanceFee_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zf23AZAPacRg" title="Annual maintenance fee"&gt;113&lt;/span&gt; annual maintenance fee and may owe up to $&lt;span id="xdx_90B_ecustom--ClinicalAndRegulatoryMilestones_pn3n3_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zIEPMjSvUaK3" title="Clinical and regulatory milestones"&gt;5,099&lt;/span&gt;
related to clinical and regulatory milestones for each Licensed Product during the term. The Company also agreed to pay Sirion low-single
digit royalties on net sales on a Licensed Product-by-Licensed Product and country-by-country basis and until the later of: (i) expiration
of the last to expire valid claim of the patents covering such Licensed Product, and (ii) &lt;span id="xdx_900_eus-gaap--LongtermPurchaseCommitmentPeriod_dtY_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zzsBGGpBl9Fa" title="License agreement period"&gt;10&lt;/span&gt; years after first Commercial Sale of a Licensed
Product. In addition, the Sirion License is subject to termination rights including for termination for material breach and by the Company
for convenience upon &lt;span id="xdx_90A_ecustom--LicenseAgreementNoticePeriod_dtD_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zb44zc04qRwi" title="License agreement period"&gt;30&lt;/span&gt; days written notice. During the years ended December 31, 2024 and 2023, no milestones have been achieved and no
royalties have been earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;At each reporting date, the Company
evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions
of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such
legal proceedings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;i&gt;Civil Investigative Demand&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company received a Civil Investigative
Demand (the &#x201c;Demand&#x201d;) under the False Claims Act, 31 U.S.C. &#xa7; 3729, dated August 14, 2022, from the U.S. Attorney&#x2019;s
Office for the Eastern District of Pennsylvania. The Demand requests documents and information relating to claims submitted to Medicare,
Medicaid, or other federal insurers for services or procedures involving injectable human tissue therapy products derived from amniotic
fluid or birth tissue and includes Interfyl, a biomaterials product. The Company is cooperating with the request and is engaged in an
ongoing dialogue with the Assistant U.S. Attorneys handling the Demand. The matter is still in preliminary stages and there is uncertainty
as to whether the Demand will result in any liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;i&gt;Arbitration Demand from Palantir Technologies Inc.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On April 20, 2023, Palantir commenced
an arbitration with JAMS Arbitration asserting claims for declaratory relief and breach of contract relating to the Palantir MSA, seeking
damages in an amount equal to the full value of the contract. The Company responded to the arbitration demand and asserted counterclaims
for breach of contract, breach of warranty, fraudulent inducement, violation of California&#x2019;s Unfair Competition Law, amongst others,
in relation to the Palantir MSA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On December 21, 2023, the Company
and Palantir entered into the Palantir Settlement Agreement to resolve the JAMS Arbitration. The Palantir Settlement Agreement was subsequently
amended on January 10, 2024 and May 6, 2024. Both parties agreed to dismiss the arbitration proceeding and dispute and provide for mutual
releases upon the Company&#x2019;s satisfaction of a settlement payment obligation. Through June 3, 2024, the Company made total settlement
payments of $&lt;span id="xdx_90F_eus-gaap--PaymentsForLegalSettlements_pn5n6_c20231221__20240603__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_zALaKV4zO3D9" title="Settlement payment"&gt;3,500&lt;/span&gt; and issued Palantir an aggregate of &lt;span id="xdx_90C_ecustom--NumberOfSharesIssuedForPiggybackRegistrationRights_pid_c20231221__20240603__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SettlementAndReleaseAgreementMember_zc8MPuma22H3" title="Shares issued for piggyback registration rights"&gt;60,584&lt;/span&gt; shares of the Company&#x2019;s Class A common stock as consideration for
further amendments to the Palantir Settlement Agreement. On June 4, 2024, the parties dismissed all claims and counterclaims. The Palantir
MSA is now fully terminated and neither party has any further rights or obligations thereunder. The shares of the Company&#x2019;s Class
A common stock issued to Palantir were issued with piggyback registration rights. Resale of such shares by Palantir shall be included
on any future registration statement filed by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;i&gt;Celularity Inc. v. Evolution Biologyx, LLC, et
al.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On April 17, 2023, the
Company filed a complaint against Evolution Biologyx, LLC, Saleem S. Saab, individually, and Encyte, LLC (collectively,
&#x201c;Evolution&#x201d;) in the United States District Court for the District of New Jersey to recover unpaid invoice amounts for
the sale of its biomaterial products in the amount of approximately $&lt;span id="xdx_90E_ecustom--SaleOfBiomaterialProductsAmount_pn3n3_c20230417__20230417__srt--LitigationCaseAxis__custom--EvolutionMember_zj67dzFHRaQl" title="Sale of biomaterial products amount"&gt;2,350&lt;/span&gt;,
plus interest. In September 2021, the Company executed a distribution agreement with Evolution, whereupon Evolution purchased
biomaterial products from the Company for sale through Evolution&#x2019;s distribution channels. The Company fulfilled
Evolution&#x2019;s orders and otherwise performed each of its obligations under the distribution agreement. Despite attempts to
recover the outstanding invoices and Evolution&#x2019;s promise to pay, Evolution has refused to pay any of the invoices and has
materially breached its obligations under the distribution agreement. The Company&#x2019;s complaint asserts claims of breach of
contract and fraudulent inducement, amongst others. On April 4, 2024, Evolution filed a counter claim alleging damages in an amount
to be determined resulting from alleged breach of contract, breach of warranty, quasi contract and fraud. The Company believes
Evolution&#x2019;s counter claims are without any merit, and the Company intends to vigorously pursue the matter to recover the outstanding
payments owed by Evolution, including interest and associated attorney&#x2019;s fees, as well as defend against Evolution&#x2019;s
counterclaims.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;i&gt;TargetCW v. Celularity Inc.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 27, 2024, WMBE Payrolling,
Inc., dba TCWGlobal, filed a complaint in the United States District Court for the Southern District of California alleging a breach
of contract and account stated claims relating to a Master Services Agreement dated May 4, 2020, or the TCWGlobal MSA, for the provision
of certain leased workers to perform services on the Company&#x2019;s behalf. The complaint alleges that the Company breached the TCWGlobal
MSA by failing to make payments on certain invoices for the services of the leased workers. On May 7, 2024, the Company entered into
a settlement agreement and mutual release with TCWGlobal whereupon the Company agreed to pay $&lt;span id="xdx_909_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20240507__20240507__srt--LitigationCaseAxis__custom--EvolutionMember_z1PI9jEe0ge3"&gt;516&lt;/span&gt;
in tiered monthly installments, with the last payment due and payable on May 1, 2025, in exchange for a dismissal of the complaint
and full release of all claims. The Company defaulted on the payments in November 2024. On April 21, 2025, the Company was served with a motion by
TCWGlobal to enforce the settlement and enter judgment against the Company in the amount of $&lt;span id="xdx_900_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn3n3_c20250421__20250421__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_znCxXqvPxlu9" title="Payments for legal settlements"&gt;350&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Hackensack Meridian v. Celularity Inc&lt;/i&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 27, 2025,
Hackensack Meridian Health (&#x201c;HUMC&#x201d;) filed a complaint in the Superior Court of New Jersey seeking $&lt;span id="xdx_90C_eus-gaap--AffiliateCosts_pn3n3_c20250327__20250327__dei--LegalEntityAxis__custom--HackensackMeridianHealthMember_zRwEeSLzZ0O6" title="Affiliate costs"&gt;946&lt;/span&gt;
allegedly owed by Celularity for costs associated with clinical trials. The amounts claimed were part of a three-party arrangement
with a contract research organization (CRO), which the Company engaged to make payments on behalf of the Company to HUMC. The
Company has asserted that it believes there are improper charges in the claim. The parties are attempting to agree on the actual
amounts owed by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2024-12-31_custom_HLICellularTherapeuticsLLCAndAnthrogenesisMember_custom_LegacyCelularitysMember"
      decimals="-3"
      id="Fact002226"
      unitRef="USD">1413000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="AsOf2023-12-31_custom_HLICellularTherapeuticsLLCAndAnthrogenesisMember_custom_LegacyCelularitysMember"
      decimals="-3"
      id="Fact002228"
      unitRef="USD">1606000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <CELU:PaymentsForMasterSubscriptionAgreement
      contextRef="From2021-05-052021-05-05_custom_PalantirTechnologiesIncMember_custom_MasterSubscriptionAgreementMember"
      decimals="-3"
      id="Fact002230"
      unitRef="USD">40000000</CELU:PaymentsForMasterSubscriptionAgreement>
    <CELU:PaymentSubscriptionPeriod
      contextRef="From2021-05-052021-05-05_custom_PalantirTechnologiesIncMember_custom_MasterSubscriptionAgreementMember"
      id="Fact002232">P5Y</CELU:PaymentSubscriptionPeriod>
    <us-gaap:BusinessExitCosts1
      contextRef="From2023-01-012023-03-31_custom_PalantirTechnologiesIncMember_custom_SoftwareCeaseUseCostsMember"
      decimals="-3"
      id="Fact002234"
      unitRef="USD">24402000</us-gaap:BusinessExitCosts1>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2024-01-102024-01-10_custom_PalantirTechnologiesIncMember"
      decimals="-3"
      id="Fact002236"
      unitRef="USD">3500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2024-05-062024-05-06_custom_PalantirTechnologiesIncMember"
      decimals="-3"
      id="Fact002238"
      unitRef="USD">3500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <CELU:AccruedResearchAndDevelopmentSoftware
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002242"
      unitRef="USD">3500000</CELU:AccruedResearchAndDevelopmentSoftware>
    <CELU:UpfrontFee
      contextRef="From2021-12-012021-12-31_custom_LicenseAgreementMember"
      decimals="-3"
      id="Fact002244"
      unitRef="USD">136000</CELU:UpfrontFee>
    <CELU:AnnualMaintenanceFee
      contextRef="From2021-12-012021-12-31_custom_LicenseAgreementMember"
      decimals="-3"
      id="Fact002246"
      unitRef="USD">113000</CELU:AnnualMaintenanceFee>
    <CELU:ClinicalAndRegulatoryMilestones
      contextRef="From2021-12-012021-12-31_custom_LicenseAgreementMember"
      decimals="-3"
      id="Fact002248"
      unitRef="USD">5099000</CELU:ClinicalAndRegulatoryMilestones>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="From2021-12-012021-12-31_custom_LicenseAgreementMember"
      id="Fact002250">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <CELU:LicenseAgreementNoticePeriod
      contextRef="From2021-12-012021-12-31_custom_LicenseAgreementMember"
      id="Fact002252">P30D</CELU:LicenseAgreementNoticePeriod>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="From2023-12-212024-06-03_custom_SettlementAndReleaseAgreementMember"
      decimals="-5"
      id="Fact002254"
      unitRef="USD">3500000000</us-gaap:PaymentsForLegalSettlements>
    <CELU:NumberOfSharesIssuedForPiggybackRegistrationRights
      contextRef="From2023-12-212024-06-03_us-gaap_CommonClassAMember_custom_SettlementAndReleaseAgreementMember"
      decimals="INF"
      id="Fact002256"
      unitRef="Shares">60584</CELU:NumberOfSharesIssuedForPiggybackRegistrationRights>
    <CELU:SaleOfBiomaterialProductsAmount
      contextRef="From2023-04-172023-04-17_custom_EvolutionMember"
      decimals="-3"
      id="Fact002258"
      unitRef="USD">2350000</CELU:SaleOfBiomaterialProductsAmount>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2024-05-072024-05-07_custom_EvolutionMember"
      decimals="-3"
      id="Fact002259"
      unitRef="USD">516000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2025-04-212025-04-21_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact002261"
      unitRef="USD">350000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:AffiliateCosts
      contextRef="From2025-03-272025-03-27_custom_HackensackMeridianHealthMember"
      decimals="-3"
      id="Fact002263"
      unitRef="USD">946000</us-gaap:AffiliateCosts>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002265">&lt;p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1AgSkNrKyvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;13. &lt;span id="xdx_82E_zpoHaW1MBjyf"&gt;Equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2024 and 2023,
the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue &lt;span id="xdx_903_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zzP46tktkF21" title="Common stock, shares authorized"&gt;&lt;span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zngpxZf0Dl7h" title="Common stock, shares authorized"&gt;730,000,000&lt;/span&gt;&lt;/span&gt; shares of $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zz2jOAbkxrR" title="Common stock, par value"&gt;&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zcBIpKkDLQUj" title="Common stock, par value"&gt;0.0001&lt;/span&gt;&lt;/span&gt;
par value Class A common stock. As of December 31, 2024 and 2023, shares of Class A common stock issued and outstanding were &lt;span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zffNudoe2Wzc" title="Common stock shares issued"&gt;&lt;span id="xdx_904_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zCc7uYAiYQk8" title="Common stock shares outstanding"&gt;22,546,671&lt;/span&gt;&lt;/span&gt;
and &lt;span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zp3OXOlt9rih" title="Common stock shares issued"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zABHH19CG8Eh" title="Common stock shares outstanding"&gt;19,378,192&lt;/span&gt;&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;Voting Power&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Except as otherwise required by
law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess
all voting power for the election of the Company&#x2019;s directors and all other matters requiring stockholder action. Holders of &lt;span id="xdx_908_eus-gaap--CommonStockVotingRights_c20240101__20241231_zOfJh576ymZ" title="Common stock, voting rights"&gt;common
stock are entitled to one vote per share&lt;/span&gt; on matters to be voted on by stockholders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;Dividends&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Holders of Class A common stock
will be entitled to receive such dividends, if any, as may be declared from time to time by the Company&#x2019;s board of directors in
its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock
be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;Liquidation, Dissolution and Winding Up&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In the event of the Company&#x2019;s
voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, the holders of the common stock will be entitled
to receive an equal amount per share of all of the Company&#x2019;s assets of whatever kind available for distribution to stockholders,
after the rights of the holders of the preferred stock have been satisfied.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;Preemptive or Other Rights&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s stockholders
have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;Election of Directors&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s board of directors
is divided into three classes, Class I, Class II and Class III, with only one class of directors being elected in each year and each class
serving a three-year term, except with respect to the election of directors at the special meeting held in connection with the merger
with GX, Class I directors are elected to an initial one-year term (and three-year terms subsequently), the Class II directors are elected
to an initial two-year term (and three-year terms subsequently) and the Class III directors are elected to an initial three-year term
(and three-year terms subsequently). There is no cumulative voting with respect to the election of directors, with the result that the
holders of more than &lt;span id="xdx_907_ecustom--PercentageOfSharesRequiredForVoting_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__srt--RangeAxis__srt--MinimumMember__us-gaap--BusinessAcquisitionAxis__custom--LegacyCelularityMember_z7BtHAhb1u0g" title="Percentage of shares required for voting"&gt;50&lt;/span&gt;% of the shares voted for the election of directors can elect all of the directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company&#x2019;s Certificate
of Incorporation authorized &lt;span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20241231_zMPMSSRnujr" title="Preferred stock, shares authorized"&gt;10,000,000&lt;/span&gt; shares of preferred stock and provides that shares of preferred stock may be issued from time to
time in one or more series. The Company&#x2019;s board of directors is authorized to fix the voting rights, if any, designations, powers
and preferences, the relative, participating, optional or other special rights, and any qualifications, limitations and restrictions thereof,
applicable to the shares of each series of preferred stock. The Company&#x2019;s board of directors is able to, without stockholder approval,
issue preferred stock with voting and other rights that could adversely affect the voting power and other rights of the holders of common
stock and could have anti-takeover effects. The ability of the Company&#x2019;s board of directors to issue preferred stock without stockholder
approval could have the effect of delaying, deferring or preventing a change of control of Celularity or the removal of existing management.
As of December 31, 2024 and 2023, the Company did &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20241231_zDOurdQhr3Q5" title="Preferred stock, shares outstanding"&gt;&lt;span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_pid_do_c20231231_zup0S26onVL8" title="Preferred stock, shares outstanding"&gt;no&lt;/span&gt;&lt;/span&gt;t have any outstanding preferred stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;ATM Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On September 8, 2022, the Company
entered into an At-the-Market Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with BTIG, LLC, Oppenheimer &amp;amp; Co. Inc. and B. Riley
Securities, Inc., acting as sales agents and/or principals, pursuant to which the Company may offer and sell, from time to time in its
sole discretion, shares of its common stock, having an aggregate offering price of up to $&lt;span id="xdx_909_ecustom--AggregateOfferingPrice_pn3n3_c20220908__20220908__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zD6ESkPAXEbk" title="Aggregate offering price"&gt;150,000&lt;/span&gt;, subject to certain limitations as set
forth in the ATM Agreement. The Company is not obligated to make any sales of shares under the ATM Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Any shares offered and sold in
the at-the-market offering will be issued pursuant to the Company&#x2019;s shelf registration statement on Form S-3 and the related prospectus
supplement. Under the ATM Agreement, the sales agents may sell shares of common stock by any method permitted by law deemed to be an &#x201c;at
the market offering&#x201d; as defined in Rule 415(a)(4) of the Securities Act of 1933. The Company will pay the sales agents a commission
rate of up to &lt;span id="xdx_905_ecustom--MaximumPercentageOfSalesCommissionFromGrossSalesProceeds_pid_dp_uPure_c20240101__20241231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_zdO9IkuS93f9" title="Sales agents commission rate"&gt;3.0&lt;/span&gt;% of the gross sales proceeds of any shares sold and has agreed to provide the sales agents with customary indemnification,
contribution and reimbursement rights. The ATM Agreement contains customary representations and warranties and conditions to the placements
of the shares pursuant thereto.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;During the year ended December
31, 2023, the Company received gross and net proceeds of $&lt;span id="xdx_90C_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_z7Ifc1hiRyL4" title="Gross proceeds from issuance of common stock"&gt;141&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember_z7mqmJ7afdyi" title="Net proceeds from sale of common stock"&gt;136&lt;/span&gt;, respectively, from the sale of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zaR0ZLiUtpta" title="Purchase and sale of shares"&gt;13,296&lt;/span&gt; shares of its common stock
at an average price of $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20231231__us-gaap--StatementEquityComponentsAxis__custom--AtTheMarketSalesAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zIYKuW2yGU4i" title="Average price per share"&gt;10.60&lt;/span&gt; per share under the ATM Agreement. No shares were issued under the ATM Agreement during the year ended December
31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;March 2023 PIPE&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 20, 2023, the Company
entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief Executive Officer, Dr. Robert
Hariri, providing for the private placement of (i) &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zK3ykL2gkUj8" title="Purchase and sale of shares"&gt;938,183&lt;/span&gt; shares of its Class A common stock, and (ii) accompanying warrants to purchase
up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230320__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zoZcbsY43TCa" title="Warrants to purchase aggregate shares"&gt;938,183&lt;/span&gt; shares of Class A common stock (the &#x201c;March 2023 PIPE Warrants&#x201d;), for $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230320__srt--RangeAxis__srt--MaximumMember_z5gfR1FtFkmf" title="Purchase price of per share"&gt;8.34&lt;/span&gt; per share and $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230320__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z8TnFe7dODY7" title="Purchase price of per share"&gt;1.25&lt;/span&gt; per accompanying
March 2023 PIPE Warrant, for an aggregate purchase price of $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zcVg0HpFPsg1" title="Proceeds from PIPE financings"&gt;9,000&lt;/span&gt; (of which Dr. Hariri subscribed for $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zjfYZQdKVF46" title="Proceeds from PIPE financings"&gt;2,000&lt;/span&gt;). The closing of the private
placement occurred on March 27, 2023. Each March 2023 PIPE Warrant had an exercise price of $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zsyIHdhlRZF3" title="Exercise price"&gt;30.00&lt;/span&gt; per share, is immediately exercisable,
will expire on &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zfL3kXj8747e" title="Expiration dateity"&gt;March 27, 2028&lt;/span&gt; (&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zp35YvnYCo76" title="Term (years)"&gt;five years&lt;/span&gt; from the date of issuance), and is subject to customary adjustments for certain transactions
affecting the Company&#x2019;s capitalization. The March 2023 PIPE Warrants may not be exercised if the aggregate number of shares of Class
A common stock beneficially owned by the holder thereof (together with its affiliates) would exceed the specified percentage cap provided
therein (which may be adjusted upon &lt;span id="xdx_900_ecustom--AdjustedAdvanceNoticePeriod_dtD_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zRVFHUCoz1Fh" title="Adjusted advance notice period"&gt;61&lt;/span&gt; days advance notice) immediately after exercise thereof.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company accounted for the
March 2023 PIPE Warrants and common stock as a single non-arm&#x2019;s length transaction. The Company applied the guidance for this transaction
in accordance with ASU 2020-06, &lt;i&gt;(Subtopic 470-20): Debt - Debt with Conversion and Other Options, ASC 815 Derivatives and Hedging,
&lt;/i&gt;and &lt;i&gt;ASC 480 Distinguishing Liabilities from Equity&lt;/i&gt;. Accordingly, the net proceeds were allocated between common stock and the
March 2023 PIPE warrants at their respective fair value, which resulted in a net premium of $&lt;span id="xdx_90E_ecustom--PremiumPaidForPrivatePlacementPurchase_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zeezlJFGJPU3" title="Premium paid for private placement purchase"&gt;1,650&lt;/span&gt; based on the difference between the
proceeds and fair value of the common stock and March 2023 PIPE warrants, which was recorded as additional paid-in capital within stockholders&#x2019;
equity on the consolidated balance sheets. The fair value of the March 2023 PIPE Warrants was determined using a Black-Scholes option
pricing model and the common stock based on closing date share price. The Company evaluated the March 2023 PIPE warrants under ASC 815
and determined that they did not require liability classification and met the requirements for a derivative scope exception under ASC
815-10-15-74(a) for instruments that are both indexed to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity. The
warrants were recorded in additional paid-in capital within stockholders&#x2019; equity on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On September 14, 2023, the Company
entered into a warrant amendment on the March 2023 PIPE Warrants with the unaffiliated investor to reduce the exercise price from $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230914__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zLCkFRXrdeu9" title="Purchase price of per share"&gt;30.00&lt;/span&gt;
per share to $&lt;span id="xdx_907_ecustom--ReducedExercisePrice_pid_c20230314__20230314__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zXSK6B6aw8cb" title="Reduced exercise price"&gt;10.00&lt;/span&gt; per share for warrants to purchase &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230914__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z9RDuUMosfV5" title="Warrants to purchase aggregate shares"&gt;729,698&lt;/span&gt; shares of Class A common stock. The warrant amendment was executed as consideration
for professional services rendered to the Company. As a result, the Company accounted for the transaction in accordance with ASC 718,
&lt;i&gt;Stock-Based Compensation,&lt;/i&gt; and based on the calculated incremental fair value attributable to the modified warrant compared to the
original warrant immediately prior to the modification, recognized an expense of $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pn3n3_c20230101__20231231_zOy4dfKxKBn" title="Fair value of modified warrant, incremental expense"&gt;402&lt;/span&gt; within selling, general and administrative on the
consolidated statements of operations and comprehensive loss for the year ended December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Registered Direct Offerings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On April 10, 2023, the Company
closed on a registered direct offering of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230410__20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zwUmyepiUhzc" title="Purchase and sale of shares"&gt;923,076&lt;/span&gt; shares of its Class A common stock together with warrants (&#x201c;Registered Direct
Warrants&#x201d;) to purchase up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zhkBnS8qbxIi" title="Warrants to purchase aggregate shares"&gt;923,076&lt;/span&gt; shares of its Class A common stock at a combined purchase price of $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230410__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zztqIc7PO2hj" title="Purchase price of per share"&gt;6.50&lt;/span&gt; per share and accompanying
warrant, resulting in total gross proceeds of approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230410__20230410_zGluPZdW76k4" title="Proceeds from the exercise of warrants"&gt;6,000&lt;/span&gt; before deducting placement agent commissions and other estimated offering
expenses. The Registered Direct Warrants had an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230410_z31MTntvPOoi" title="Exercise price"&gt;7.50&lt;/span&gt;, became exercisable beginning six months after the date of issuance
and will expire &lt;span id="xdx_90C_ecustom--WarrantExpirationTerm_pid_c20230410__20230410_zYXkG0vtmhAe" title="Warrant term"&gt;five years&lt;/span&gt; thereafter. The Company used the $&lt;span id="xdx_901_ecustom--DebtInstrumentPayment_pn3n3_c20230410__20230410_zPp8EQfAXuT4" title="Debt instrument payment"&gt;5,505&lt;/span&gt; net proceeds from the offering to repay its obligations to Yorkville
under the PPA. The Company considered the appropriate accounting guidance and concluded that the Registered Direct Warrants qualified
for liability treatment, and therefore, recorded the warrant liability at fair value $&lt;span id="xdx_907_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20230410_ztrGXk6yLaql" title="Fair value of the warrant liability"&gt;4,280&lt;/span&gt; which was based on a Black-Scholes option
pricing model. The remainder of the net proceeds were allocated to the Class A common stock issued and recorded as a component of equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Upon the closing of the registered
direct offering on April 10, 2023, the Company amended the existing May 2022 PIPE Warrants, to reduce the exercise price from $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220518__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zGrnJRVLD608" title="Shares issued price per share"&gt;82.50&lt;/span&gt; to
$&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20220518__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zCELkqsrdzHk" title="Shares issued price per share"&gt;7.50&lt;/span&gt; per share and extended the expiration &lt;span id="xdx_901_ecustom--AmendedTerminationDateDescription_c20230410__20230410__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember_zcTecCUbCKe7" title="Amended termination date description"&gt;date to five and one-half years following the closing of the offering&lt;/span&gt; or October 10, 2028.
The modification resulted in the recognition of additional warrant liability of $&lt;span id="xdx_90C_ecustom--AdditionalWarrantLiability_iI_pn3n3_c20230410_zGMsvzy7DaQ3" title="Additional warrant liability"&gt;1,389&lt;/span&gt; based on the Black-Scholes option pricing model
as of the modification date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On July 31, 2023, the Company
closed on a registered direct offering of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230731__20230731_z97b5JcdWJjf" title="Purchase and sale of shares"&gt;857,142&lt;/span&gt; shares of its Class A common stock together with warrants (&#x201c;July 2023 Registered
Direct Warrants&#x201d;) to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230731__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zWcY2JCiJ0bf" title="Warrants to purchase aggregate shares"&gt;857,142&lt;/span&gt; shares of its Class A common stock at a combined purchase price of $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230731__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zKJNpgRDRJ2c" title="Purchase price of per share"&gt;3.50&lt;/span&gt; per share and
accompanying warrant, resulting in total gross proceeds of approximately $&lt;span id="xdx_900_eus-gaap--ProceedsFromWarrantExercises_pn3n3_c20230731__20230731_zX8t6hhn1Li6" title="Proceeds from the exercise of warrants"&gt;3,000&lt;/span&gt; before deducting placement agent commissions and other
estimated offering expenses. The July 2023 Registered Direct Warrants have an exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230731__srt--RangeAxis__srt--MinimumMember_zmmdIsfhFQxg" title="Exercise price"&gt;3.50&lt;/span&gt;, will be exercisable beginning six
months after the date of issuance and will expire &lt;span id="xdx_903_ecustom--WarrantExpirationTerm_c20230731__20230731_z07eBOkj6o1j" title="Warrant term"&gt;five years&lt;/span&gt; thereafter. The Company used the $&lt;span id="xdx_90F_ecustom--DebtInstrumentPayment_pn3n3_c20230731__20230731_ztBPn20dwIO6" title="Debt instrument payment"&gt;2,740&lt;/span&gt; net proceeds for working capital
and general corporate purposes. The Company considered the appropriate accounting guidance and concluded that the July 2023 Registered
Direct Warrants qualified for liability treatment, and therefore, recorded the warrant liability at fair value $&lt;span id="xdx_90B_ecustom--FairValueNetAssetsLiability_iI_pn3n3_c20230731_zl4YeRxKLODi" title="Fair value of the warrant liability"&gt;2,645&lt;/span&gt; which was based
on a Black-Scholes option pricing model. The remainder of the net proceeds were allocated to the Class A common stock issued and recorded
as a component of equity.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In connection with the July 31,
2023 registered direct offering described above, the Company also entered into an amendment to certain existing warrants to purchase up
to an aggregate of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230731__srt--RangeAxis__srt--MaximumMember_zMsM43C6hZdc" title="Warrants to purchase class A common stock"&gt;892,856&lt;/span&gt; shares at an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230731_zbPoZKRZzIWj" title="Exercise price"&gt;7.50&lt;/span&gt; (consisting of all the May 2022 PIPE Warrants and a portion of the Registered
Direct Warrants issued in April 2023), and such amended warrants have a reduced exercise price of $&lt;span id="xdx_907_ecustom--ReducedExercisePrice_pid_c20230731__20230731_zmFbXSS0NRPb" title="Reduced exercise price"&gt;3.50&lt;/span&gt; per share. As noted above, the
modification resulted in an increase to the warrant liability of $&lt;span id="xdx_90A_ecustom--WarrantLiability_iI_pn3n3_c20230731_z6vCgBkY7lwh" title="Warrant liabilities"&gt;511&lt;/span&gt; based on the Black-Scholes option pricing model as of the July 31,
2023 modification date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;May 2023 PIPE&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On May 18, 2023, the Company closed
on a securities purchase agreement with a group of accredited investors, providing for the private placement of an aggregate (i) &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230518__20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zB97X1Rtinuj" title="Purchase and sale of shares"&gt;581,394&lt;/span&gt;
shares of its Class A common stock and (ii) accompanying warrants to purchase up to &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zKYoNmWrCRG" title="Warrants to purchase aggregate shares"&gt;581,394&lt;/span&gt; shares of Class A common stock (the &#x201c;May
2023 PIPE Warrants&#x201d;), for $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zMwKBz0fhIQi" title="Purchase price of per share"&gt;5.20&lt;/span&gt; per share and $&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230518__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zsZV7NXXM2sf" title="Purchase price of per share"&gt;1.25&lt;/span&gt; per accompanying May 2023 PIPE Warrant, for an aggregate gross purchase price
of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230518__20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zOKEFWvqbl44" title="Proceeds from PIPE financings"&gt;3,750&lt;/span&gt;. Each May 2023 PIPE Warrant has an exercise price of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zJVpUs9ia6ja" title="Exercise price"&gt;10.00&lt;/span&gt; per share, is immediately exercisable, will expire on &lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_pid_c20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_z9oF7VthUw6c" title="Warrants and rights outstanding, expire date"&gt;May 17, 2028&lt;/span&gt;,
and is subject to customary adjustments for certain transactions affecting the Company&#x2019;s capitalization. The May 2023 PIPE Warrants
may not be exercised if the aggregate number of shares of Class A common stock beneficially owned by the holder thereof (together with
its affiliates) would exceed the specified percentage cap provided therein (which may be adjusted upon &lt;span id="xdx_904_ecustom--AdjustedAdvanceNoticePeriod_dtD_c20230518__20230518__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zEwTiSCUUkNj" title="Adjusted advance notice period"&gt;61&lt;/span&gt; days advance notice) immediately
after exercise thereof. The Company evaluated the May 2023 PIPE Warrants under ASC 815 and determined that they did not require liability
classification and met the requirements for a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed
to an entity&#x2019;s own stock and classified in stockholders&#x2019; equity. Accordingly, the proceeds were allocated between common stock
and the May 2023 PIPE Warrants at their respective relative fair value basis to stockholders&#x2019; equity on the consolidated balance
sheets. The fair value of the May 2023 PIPE Warrants was determined using a Black-Scholes option pricing model and the common stock based
on the closing date share price and were recorded in additional paid-in capital within stockholders&#x2019; equity on the consolidated
balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;January 2024 PIPE&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On January 12, 2024, the Company
entered into a securities purchase agreement with an existing investor, Dragasac Limited (&#x201c;Dragasac&#x201d;), providing for the private
placement of (i) &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20240112__20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zVumiEmKFrIh" title="Purchase and sale of shares"&gt;2,141,098&lt;/span&gt; shares of its Class A common stock, par value $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zfYMSMtMZoF" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share, or the Class A common stock, and (ii) accompanying
warrants to purchase up to &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember__srt--RangeAxis__srt--MaximumMember_zv4Clk7iU4yk" title="Warrants to purchase aggregate shares"&gt;535,274&lt;/span&gt; shares of Class A common stock (&#x201c;January 2024 PIPE Warrant&#x201d;), for $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zW64YVJ4iIu9" title="Exercise price"&gt;2.4898&lt;/span&gt; per share and
$&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240112__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zxNERNQXYr16" title="Purchase price of per share"&gt;1.25&lt;/span&gt; per accompanying January 2024 PIPE Warrant, for an aggregate purchase price of approximately $&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20240112__20240112__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zr1UDANRGaKg" title="Aggregate purchase price"&gt;6,000&lt;/span&gt;. The closing of the private
placement occurred on &lt;span id="xdx_903_ecustom--WarrantsAndRightsIssuedClosingDate_c20240112__20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_znP3dpZ8rWg7" title="Warrants and rights issued closing date"&gt;January 16, 2024&lt;/span&gt;. The securities were issued pursuant to an exemption from registration provided under Section 4(a)(2)
of the Securities Act and Regulation D promulgated thereunder. The offer and sale of the shares and January 2024 PIPE Warrant (including
the shares underlying the January 2024 PIPE Warrant) has not been registered under the Act or any state securities laws. The securities
may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Each January
2024 PIPE Warrant had an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zp56Yzz1qWqe" title="Exercise price"&gt;2.4898&lt;/span&gt; per share, is immediately exercisable, and will expire on &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zgcjS8Aqm85d" title="Warrants and rights outstanding, expire date"&gt;January 16, 2029&lt;/span&gt; (five&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240112__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zsflcWEiRANd" style="display: none" title="Term (years)"&gt;5&lt;/span&gt; years
from the date of issuance).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company accounted for the
January 2024 PIPE Warrant and common stock as a single non-arm&#x2019;s length transaction recognized in equity. The Company applied the
guidance for this transaction in accordance with ASU 2020-06, &lt;i&gt;(Subtopic 470-20): Debt - Debt with Conversion and Other Options, ASC
815 Derivatives and Hedging, &lt;/i&gt;and &lt;i&gt;ASC 480 Distinguishing Liabilities from Equity&lt;/i&gt;. Accordingly, the net proceeds were allocated
between common stock and the January 2024 PIPE Warrant at their respective fair values, which resulted in proceeds of $&lt;span id="xdx_90D_ecustom--ProceedsFromPrivatePlacements_pn3n3_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zdQkTf053Oti" title="Proceeds from private placements"&gt;909&lt;/span&gt; allocated to
the January 2024 PIPE Warrant and the balance of the proceeds allocated to the common stock. The fair value of the January 2024 PIPE Warrant
was determined using a Black-Scholes option pricing model and the common stock based on closing date share price. The Company evaluated
the January 2024 PIPE warrant under ASC 815 and determined that it did not require liability classification and met the requirements for
a derivative scope exception under ASC 815-10-15-74(a) for instruments that are both indexed to an entity&#x2019;s own stock and classified
in stockholders&#x2019; equity. The warrants were recorded in additional paid-in capital within stockholders&#x2019; equity on the consolidated
balance sheets. Also in connection with the January 2024 PIPE transaction, the Company repriced legacy warrants held by Dragasac to purchase
&lt;span id="xdx_902_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_z8xcTaqW9Cc5" title="Number Of warrants repriced"&gt;652,981&lt;/span&gt; shares of common stock with a previous exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_z305bCEZgp9i" title="Exercise price"&gt;67.70&lt;/span&gt; per share to a new exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zM2WcHcid9tf" title="Exercise price"&gt;2.4898&lt;/span&gt; per share. The modification
of warrants resulted in incremental fair value of $&lt;span id="xdx_90A_ecustom--FairValueOfWarrantModificationIncrementalForEquityIssuanceCost_pn3n3_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_zDX9Y1DZcBK6" title="Fair value of warrant modification"&gt;524&lt;/span&gt;, which has been recognized as an equity issuance cost and had no net impact on
stockholders&#x2019; equity as the warrants remain equity-classified after the modification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In connection with the execution
of the securities purchase agreement, the Company also entered into an investor rights agreement with Dragasac dated as of January 12,
2024. The investor rights agreement provides Dragasac certain information and audit rights, as well as registration rights with respect
to the shares (and shares underlying the January 2024 PIPE Warrant), including both the undertaking to file a registration statement within
45 days of filing of the 2023 Form 10-K, &#x201c;piggyback&#x201d; registration rights, as well as the right to request up to three demand
rights for underwritten offerings per year; in each case subject to customary &#x201c;underwriter cutback&#x201d; language as well as any
objections raised by the SEC to inclusion of securities. If the initial registration statement was not filed on or prior to May 15, 2024,
the investor rights agreement provides for partial liquidating damages equal to &lt;span id="xdx_908_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--InvestorRightsAgreementMember__srt--CounterpartyNameAxis__custom--DragasacLimitedMember_zZajXYhPwtjc" title="Percentage of partial liquidating damages"&gt;1.0&lt;/span&gt;% of the subscription amount each month, up to a maximum
of &lt;span id="xdx_904_ecustom--PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount_iI_pid_dp_uPure_c20240112__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--InvestorRightsAgreementMember__srt--CounterpartyNameAxis__custom--DragasacLimitedMember_zaMhrDSfYPJe" title="Percentage of partial liquidating damages"&gt;6.0&lt;/span&gt;%, plus interest thereon accruing daily at a rate of &lt;span id="xdx_90C_ecustom--DailyInterestAccruingRate_iI_pid_dp_uPure_c20240112_zbXo20ukgOSi" title="Daily interest accruing rate"&gt;18.0&lt;/span&gt;% per annum. The Company began to accrue partial liquidating damages and
interest as of May 22, 2024. As a condition to closing, the Company entered into an amendment to an amended and restated distribution
and manufacturing agreement with an affiliate of Dragasac to add cell therapy products in clinical development, investigational stage
and/or in near-term commercial use to the list of products under the scope of the exclusive distribution and manufacturing licenses (including
unmodified natural killer cells (such as CYNK-001) for aging and other non-oncology indications, PSC-100, PDA-001, PDA-002, pEXO and APPL-001
for regenerative indications).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Effective February 16, 2024, in
order to comply with Section 4.15(a) of the securities purchase agreement, the Company entered into an amended employment agreement with
its Chief Administrative Officer (&#x201c;CAO&#x201d;), whereby the CAO agreed to decrease his base salary from $&lt;span id="xdx_909_ecustom--RelatedPartyBaseSalary_pn3n3_c20240216__20240216__srt--TitleOfIndividualAxis__custom--ChiefAdministrativeOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--AmendedEmploymentAgreementMember_zbbHV3NbmJe7" title="Base salary"&gt;500&lt;/span&gt; to $&lt;span id="xdx_90E_ecustom--RelatedPartyBaseSalary_pn3n3_c20240216__20240216__srt--TitleOfIndividualAxis__custom--ChiefAdministrativeOfficerMember__us-gaap--RelatedPartyTransactionAxis__custom--AmendedEmploymentAgreementMember__srt--RangeAxis__srt--MinimumMember_zeV1eDFu5Akf" title="Base salary"&gt;425&lt;/span&gt; per year through
December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;Warrant Modifications&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 26.95pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On January 12, 2024, in connection
with the January 2024 PIPE, the Company agreed to amend the exercise price of legacy warrants held by Dragasac to purchase &lt;span id="xdx_90E_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zFCusVhahAEd" title="Number of warrants repriced"&gt;652,981&lt;/span&gt; shares
of common stock, which expired &lt;span id="xdx_90A_ecustom--ClassOfWarrantOrRighstExpirationDate_c20240112__20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zWT8tw3Gisde" title="Warrant expiration date"&gt;March 16, 2025&lt;/span&gt;, from $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zVYwpQnpNtl8" title="Exercise price"&gt;67.70&lt;/span&gt; per share to $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zg8XKimAshxc" title="Exercise price"&gt;2.4898&lt;/span&gt; per share. On January 24, 2025, the Company agreed to
reduce the exercise price of both the January 2024 PIPE Warrant and legacy warrants held by Dragasac from $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_z1poJw3q6s93" title="Exercise price"&gt;2.4898&lt;/span&gt; per share to $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_z92lFZYHPcKl" title="Exercise price"&gt;2.07&lt;/span&gt; per
share. See Warrants section below for additional information. On March 13, 2024, in connection with the RWI Forbearance Agreement (see
Note 10), the Company agreed to issue RWI a warrant to acquire up to &lt;span id="xdx_908_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zSKeJ2LN7H21" title="Number of warrants repriced"&gt;300,000&lt;/span&gt; shares of common stock, which expires &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20240313__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrNMxVQS955" title="Warrants and rights outstanding, expire date"&gt;June 20, 2028&lt;/span&gt; and has
an exercise price of $&lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--RwiForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember_z5Sjbby3oO6k" title="Exercise price"&gt;5.895&lt;/span&gt; per share. Additionally, on March 13, 2024, in connection with the Starr Forbearance Agreement (see Note 10),
the Company agreed to amend the exercise price of the &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zZZJdsMCtTSc" title="Warrants to purchase aggregate shares"&gt;75,000&lt;/span&gt; March 2023 Loan Warrants expiring &lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRighstExpirationDate_c20240313__20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zobszqjG8aF" title="Warrant expiration date"&gt;March 17, 2028&lt;/span&gt; from $&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240312__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zqGvLWEpkxZd" title="Exercise price"&gt;7.10&lt;/span&gt; per share to
$&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zIfevTWfKf7a" title="Exercise price"&gt;5.895&lt;/span&gt; per share (the &#x201c;Minimum Price&#x201d; as determined pursuant to Nasdaq 5635(d) on March 13, 2024) and the &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_z1LcfNkglVZf" title="Warrants to purchase aggregate shares"&gt;50,000&lt;/span&gt; June 2023
Warrants expiring &lt;span id="xdx_90F_ecustom--ClassOfWarrantOrRighstExpirationDate_dd_c20240313__20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zvxc5pNAp7Ef" title="Warrant expiration date"&gt;June 20, 2028&lt;/span&gt; from $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zb7tOaqwWeZ5" title="Exercise price"&gt;8.10&lt;/span&gt; per share to $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--TypeOfArrangementAxis__custom--ForbearanceAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--LoanAgreementMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--WarrantMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zE8mefiFdKR" title="Exercise price"&gt;5.895&lt;/span&gt; per share, each of which are held by C.V. Starr.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Standby Equity Purchase Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 30.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On March 13, 2024, the Company
and Yorkville entered into a SEPA. Under the SEPA, the Company has the right to sell to Yorkville up to $&lt;span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zHm3cP8anGna" title="Common stock, shares authorized"&gt;10,000&lt;/span&gt; of its Class A common
stock, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zIiDz8rMAhFh" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share subject to certain limitations and conditions set forth in the SEPA, from time to time, over a 36-month
period. Sales of the common stock to Yorkville under the SEPA, and the timing of any such sales, are at the Company&#x2019;s option, and
the Company is under no obligation to sell any shares of common stock to Yorkville under the SEPA except in connection with notices that
may be submitted by Yorkville, in certain circumstances as described below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Upon the satisfaction of the conditions
precedent in the SEPA, which include having a resale shelf for shares of common stock issued to Yorkville declared effective, the Company
has the right to direct Yorkville to purchase a specified number of shares of common stock by delivering written notice (&#x201c;Advance&#x201d;).
An Advance may not exceed &lt;span id="xdx_909_ecustom--SaleOfStockMaximumAverageDailyTradedAmountPercentage_iI_dp_uPure_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_z3CINtoAGEK7" title="Sale of stock, maximum average daily traded amount (in percent)"&gt;100&lt;/span&gt;% of the average of the daily trading volume of the common stock on Nasdaq, during the &lt;span id="xdx_907_ecustom--SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays_pid_dc_uInteger_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zAxLxSh7pZVe" title="Sale of stock, maximum average daily traded amount, threshold consecutive trading days | Days"&gt;five&lt;/span&gt; consecutive trading
days immediately preceding the written notice.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Yorkville will generally purchase
shares pursuant to an Advance at a price per share equal to &lt;span id="xdx_905_ecustom--SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice_iI_dp_uPure_c20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zqXzvyuHVZP7" title="Sale of stock, percentage based on volume weighted average price"&gt;97&lt;/span&gt;% of the VWAP, on Nasdaq during the three consecutive trading days commencing
on the date of the delivery of the written notice (unless the Company specifies a minimum acceptable price or there is no VWAP on the
subject trading day).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The SEPA will automatically terminate
on the earliest to occur of (i) the first day of the month next following the 36-month anniversary of the date of the SEPA or (ii) the
date on which Yorkville shall have made payment for shares of common stock equal to $&lt;span id="xdx_905_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zPqKiPWctZOj" title="Consideration shares of common stock"&gt;10,000&lt;/span&gt;. The Company has the right to terminate the
SEPA at no cost or penalty upon five trading days&#x2019; prior written notice to Yorkville, provided that there are no outstanding advances
for which shares of common stock need to be issued and the Yorkville convertible promissory note (the &#x201c;Initial Advance&#x201d;) (see
Note 10) has been paid in full. The Company and Yorkville may also agree to terminate the SEPA by mutual written consent.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As consideration for Yorkville&#x2019;s
commitment to purchase the shares of common stock pursuant to the SEPA, the Company paid Yorkville a $&lt;span id="xdx_908_ecustom--SaleOfStockConsiderationCashDueDiligenceFee_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zIqR9onD240h" title="Cash due diligence fee"&gt;25&lt;/span&gt; cash due diligence fee and a
commitment fee equal to &lt;span id="xdx_90B_ecustom--SaleOfStockConsiderationCommitmentFeeInShares_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zBJBNQUMgIqh" title="Commitment fee in shares"&gt;16,964&lt;/span&gt; shares of common stock. The Company recorded direct issuance costs of $&lt;span id="xdx_901_eus-gaap--PaymentsOfStockIssuanceCosts_pn3n3_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zYf40Wn1Nbkd" title="Payments of stock issuance costs"&gt;125&lt;/span&gt; inclusive of the commitment
shares as other expense in the consolidated statements of operations and other comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In connection with the entry into
the SEPA, on March 13, 2024, the Company entered into a registration rights agreement with Yorkville, pursuant to which the Company agreed
to file with the SEC no later than May 3, 2024, a registration statement for the resale by Yorkville of the shares of common stock issued
under the SEPA (including the commitment fee shares). The Company agreed to use commercially reasonable efforts to have such registration
statement declared effective within 45 days of such filing and to maintain the effectiveness of such registration statement during the
36-month commitment period. The Company will not have the ability to request any Advances under the SEPA (nor may Yorkville convert the
Initial Advance into common stock) until such resale registration statement is declared effective by the SEC. The Company has not yet
filed a registration statement with the SEC for the resale by Yorkville of the shares of common stock issued under the SEPA, which is
deemed an event of default under the SEPA and as a result, the interest rate on the on the Yorkville convertible promissory note (see
Note 10) increased to &lt;span id="xdx_908_ecustom--LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault_pid_dp_uPure_c20240313__20240313__srt--CounterpartyNameAxis__custom--YorkvilleMember__us-gaap--ShortTermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__us-gaap--StatementEquityComponentsAxis__custom--StandbyEquityPurchaseAgreementMember_zENZycd17X28" title="Line of credit percentage"&gt;18.0&lt;/span&gt;%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company determined that the
SEPA should be accounted for as a derivative measured at fair value, with changes in the fair value recognized in earnings. Because the
Company has not yet filed a registration statement and no shares can currently be issued under the SEPA, the SEPA is deemed to have no
value as of the issuance date and as of December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2024, the Company
had outstanding warrants to purchase &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_z5BOd94ACYgc" title="Warrants to purchase aggregate shares"&gt;11,221,557&lt;/span&gt; shares of Class A common stock. A summary of the warrants is as follows:&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zqDAMexY9Ui5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;span id="xdx_8B8_zKad2K7DCD7" style="display: none"&gt;Summary of the Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left"&gt;Dragasac Warrants (1) (4)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____z0ajEyNc7Gri" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of shares"&gt;652,981&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____z8rfYtZnGm0c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise price"&gt;2.4898&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____zinEqo0yyrj2" title="Expiration date"&gt;March 16, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Public Warrants (2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zD7zdoffSM62" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;1,437,447&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zB5PsoNJXGE8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;115.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zbLI7oxrz5Ye" title="Expiration date"&gt;July 16, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Sponsor Warrants (2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zOETGiKL24Af" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;849,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zG7kLfJ7pqBa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;115.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zw7uGCgnGvxd" title="Expiration date"&gt;July 16, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;May 2022 PIPE Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zNBLwgk4u2M6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;405,405&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zYnIQ2JKWm62" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;3.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_z9aJUtHsiila" title="Expiration date"&gt;October 10, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;March 2023 PIPE Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zUxz96duCA9h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;208,485&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zrAr8lT7pT7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;30.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zbMTTbD0VWKc" title="Expiration date"&gt;March 27, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;March 2023 PIPE Warrants (modified)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zP7VnzVPnA1g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;729,698&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zB4FeFTE49ka" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;10.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zTinxyaSs7C4" title="Expiration date"&gt;March 27, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;March 2023 Loan Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_znGDbJamzLb2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;75,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_zuYOPZJcdbu5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;5.8950&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_z8mn0HGHCDu2" title="Expiration date"&gt;March 17, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;April 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKOrvgR95rk7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;435,625&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_z5ana1gABy3f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;7.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zJKCZ8wAHof9" title="Expiration date"&gt;October 10, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;April 2023 Registered Direct Warrants (modified)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zq37NcuNL3a8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;487,451&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zDignA4wcAh9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;3.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_z3dbEpyhwLI5" title="Expiration date"&gt;October 10, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;May 2023 PIPE Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zI4rOAiVvCij" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;581,394&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zvM8PcQRmBAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;10.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zd5RNva34Wxe" title="Expiration date"&gt;May 17, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;June 2023 Warrants (3)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zeCpcQOTjk6f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;50,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zdMvnGprRZpf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;5.8950&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zBVhMP3jdaTi" title="Expiration date"&gt;June 20, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;June 2023 Loan Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zQQc2iOSUeJ9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;300,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_z77BMZWgNc9f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;8.10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_ztf6Zdk7HOP3" title="Expiration date"&gt;June 20, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;July 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zFxWian5umj6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;857,142&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zhUxE7E1J034" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;3.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKAC9gfv4dya" title="Expiration date"&gt;January 31, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;January 2024 PIPE Warrants (4)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_zyfcgBb1FFFj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;535,274&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_z5X4MytO6C6g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.4898&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_zu80bN8I5Ofk" title="Expiration date"&gt;January 16, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;January 2024 Bridge Loan - Tranche #1 Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zE6EeyOX72B" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;1,650,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zXUvDttoFB0b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.4898&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_z7usxMXNNxQg" title="Expiration date"&gt;January 16, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;January 2024 Bridge Loan - Tranche #2 Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zOZ7yCW1h3Tg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;1,350,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zqSWqzySTfn6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.9880&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zgQ38ONYpxVg" title="Expiration date"&gt;July 15, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;March 2024 RWI Forbearance Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_ziSrMKBgY6n6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;300,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zYFg60Zj7Nq" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;5.8958&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zz6eqvfyOVsk" title="Expiration date"&gt;June 20, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;November 2024 Purchaser Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember_zaMPNsvijBw9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;263,156&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember_zlIGAKCCmTri" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.85&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember__srt--RangeAxis__srt--MinimumMember_zemQZleBalsi" title="Expiration date"&gt;November 25, 2029&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember__srt--RangeAxis__srt--MaximumMember_zFdB8Lo57Zge" title="Expiration date"&gt;December 3, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;November 2024 Placement Agent Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_ztFSS2vs3ty9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;52,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zFUgq2fTDmKl" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Exercise price"&gt;3.56&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_z9H1KcEEjrv1" title="Expiration date"&gt;November 25, 2029&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_z6Q7qsYVDzna" title="Expiration date"&gt;December 3, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zmqvCnSL8DGb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;11,221,557&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F01_zaUWrq4ZJf36" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_zU7ufP8Z2xui" style="font-size: 10pt"&gt;In connection with the execution of the January 2024 PIPE described above, the Company agreed to reprice &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_z0CxQy6hgMJh" title="Number of warrants repriced"&gt;652,981&lt;/span&gt; legacy warrants held by Dragasac with a previous exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zJ7gS6haRbBc" title="Exercise price per share or per unit of warrants or rights outstanding"&gt;67.70&lt;/span&gt; to a new exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zYVzxB4PfIah" title="Exercise price"&gt;2.4898&lt;/span&gt;. The term of the warrants was unchanged.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F02_zpkmujJUSn29" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_zsXTc6rGNjph" style="font-size: 10pt"&gt;The number of Public Warrants
and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_zHSrw9l6fBM" title="Warrants outstanding"&gt;14,374,478&lt;/span&gt; Public Warrants and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zhb8lpf7vX1c" title="Warrants outstanding"&gt;8,499,999&lt;/span&gt; Sponsor
Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant
is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfdpdBsJpoed" title="Exercise per share price (in Dollars per share)"&gt;115.00&lt;/span&gt; as a result
of the split.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F07_zYFMOuFpTkL1" style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F14_zmEyC4kJiPda" style="font-size: 10pt"&gt;In connection with the execution
of the Starr Forbearance Agreement on March 13, 2024, described above under Warrant Modification and further in Note 10, the Company
agreed to reprice &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zNKnX4iQB39l" title="Number of warrants repriced"&gt;75,000&lt;/span&gt; warrants with a previous exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zB4Cdrckei1h" title="Exercise price"&gt;7.10&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zGIhzk4KHX5l" title="Number of warrants repriced"&gt;50,000&lt;/span&gt; warrants with a previous exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313_ztdMSGu7CCBf" title="Exercise price"&gt;8.10&lt;/span&gt;
held by C.V. Starr to a new exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zYKfrX5dCT29" title="Exercise price"&gt;5.895&lt;/span&gt;. The term of the warrants was unchanged.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F04_zDR8Xy7PCx4h" style="font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1E_zWd9mgsl4eQl" style="font-size: 10pt"&gt;On January 24, 2025, the
Company agreed to reduce the exercise price of the Dragasac warrants and the January 2024 PIPE warrants from $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zDOZqY4vlhF5" title="Exercise price"&gt;2.49&lt;/span&gt; per share to $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zfw8z5NDCiqh" title="Exercise price"&gt;2.07&lt;/span&gt;
per share. As a result of the price reduction, the holder agreed to immediately exercise the warrants in full and to purchase an aggregate
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zs0kpvh31E5b" title="Aggregate shares"&gt;1,188,255&lt;/span&gt; shares of the Company&#x2019;s Class A common stock for gross proceeds to the Company of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250124__20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJKjoIgtMeje" title="Proceeds from the exercise of warrants"&gt;2.5&lt;/span&gt; million&lt;i&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002267"
      unitRef="Shares">730000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002269"
      unitRef="Shares">730000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002271"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002273"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002275"
      unitRef="Shares">22546671</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002277"
      unitRef="Shares">22546671</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002279"
      unitRef="Shares">19378192</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002281"
      unitRef="Shares">19378192</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockVotingRights contextRef="From2024-01-01to2024-12-31" id="Fact002283">common
stock are entitled to one vote per share</us-gaap:CommonStockVotingRights>
    <CELU:PercentageOfSharesRequiredForVoting
      contextRef="From2024-01-012024-12-31_us-gaap_PreferredStockMember_srt_MinimumMember_custom_LegacyCelularityMember"
      decimals="INF"
      id="Fact002285"
      unitRef="Pure">0.50</CELU:PercentageOfSharesRequiredForVoting>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002287"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002289"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact002291"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <CELU:AggregateOfferingPrice
      contextRef="From2022-09-082022-09-08_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact002293"
      unitRef="USD">150000000</CELU:AggregateOfferingPrice>
    <CELU:MaximumPercentageOfSalesCommissionFromGrossSalesProceeds
      contextRef="From2024-01-012024-12-31_custom_AtTheMarketSalesAgreementMember"
      decimals="INF"
      id="Fact002295"
      unitRef="Pure">0.030</CELU:MaximumPercentageOfSalesCommissionFromGrossSalesProceeds>
    <CELU:GrossProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_custom_AtTheMarketSalesAgreementMember"
      decimals="-3"
      id="Fact002297"
      unitRef="USD">141000</CELU:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-12-31_custom_AtTheMarketSalesAgreementMember"
      decimals="-3"
      id="Fact002299"
      unitRef="USD">136000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002301"
      unitRef="Shares">13296</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2023-12-31_custom_AtTheMarketSalesAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002303"
      unitRef="USDPShares">10.60</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002305"
      unitRef="Shares">938183</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-03-20_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_srt_MaximumMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002307"
      unitRef="Shares">938183</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-03-20_srt_MaximumMember"
      decimals="INF"
      id="Fact002309"
      unitRef="USDPShares">8.34</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-03-20_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002311"
      unitRef="USDPShares">1.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="-3"
      id="Fact002313"
      unitRef="USD">9000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_ChairmanAndChiefExecutiveOfficerMember_us-gaap_PrivatePlacementMember"
      decimals="-3"
      id="Fact002315"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002317"
      unitRef="USDPShares">30.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      id="Fact002319">2028-03-27</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      id="Fact002321">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <CELU:AdjustedAdvanceNoticePeriod
      contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      id="Fact002323">P61D</CELU:AdjustedAdvanceNoticePeriod>
    <CELU:PremiumPaidForPrivatePlacementPurchase
      contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="-3"
      id="Fact002325"
      unitRef="USD">1650000</CELU:PremiumPaidForPrivatePlacementPurchase>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-09-14_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002327"
      unitRef="USDPShares">30.00</us-gaap:SharesIssuedPricePerShare>
    <CELU:ReducedExercisePrice
      contextRef="From2023-03-142023-03-14_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002329"
      unitRef="USDPShares">10.00</CELU:ReducedExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-09-14_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002331"
      unitRef="Shares">729698</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002333"
      unitRef="USD">402000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-102023-04-10_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002335"
      unitRef="Shares">923076</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-04-10_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002337"
      unitRef="Shares">923076</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-04-10_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002339"
      unitRef="USDPShares">6.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-04-102023-04-10"
      decimals="-3"
      id="Fact002341"
      unitRef="USD">6000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-04-10"
      decimals="INF"
      id="Fact002343"
      unitRef="USDPShares">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:WarrantExpirationTerm contextRef="From2023-04-102023-04-10" id="Fact002345">P5Y</CELU:WarrantExpirationTerm>
    <CELU:DebtInstrumentPayment
      contextRef="From2023-04-102023-04-10"
      decimals="-3"
      id="Fact002347"
      unitRef="USD">5505000</CELU:DebtInstrumentPayment>
    <CELU:FairValueNetAssetsLiability
      contextRef="AsOf2023-04-10"
      decimals="-3"
      id="Fact002349"
      unitRef="USD">4280000</CELU:FairValueNetAssetsLiability>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-05-18_srt_MaximumMember_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002351"
      unitRef="USDPShares">82.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-05-18_srt_MinimumMember_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002353"
      unitRef="USDPShares">7.50</us-gaap:SharesIssuedPricePerShare>
    <CELU:AmendedTerminationDateDescription
      contextRef="From2023-04-102023-04-10_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantMember"
      id="Fact002355">date to five and one-half years following the closing of the offering</CELU:AmendedTerminationDateDescription>
    <CELU:AdditionalWarrantLiability
      contextRef="AsOf2023-04-10"
      decimals="-3"
      id="Fact002357"
      unitRef="USD">1389000</CELU:AdditionalWarrantLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-07-312023-07-31"
      decimals="INF"
      id="Fact002359"
      unitRef="Shares">857142</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002361"
      unitRef="Shares">857142</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-07-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002363"
      unitRef="USDPShares">3.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2023-07-312023-07-31"
      decimals="-3"
      id="Fact002365"
      unitRef="USD">3000000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-31_srt_MinimumMember"
      decimals="INF"
      id="Fact002367"
      unitRef="USDPShares">3.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:WarrantExpirationTerm contextRef="From2023-07-312023-07-31" id="Fact002369">P5Y</CELU:WarrantExpirationTerm>
    <CELU:DebtInstrumentPayment
      contextRef="From2023-07-312023-07-31"
      decimals="-3"
      id="Fact002371"
      unitRef="USD">2740000</CELU:DebtInstrumentPayment>
    <CELU:FairValueNetAssetsLiability
      contextRef="AsOf2023-07-31"
      decimals="-3"
      id="Fact002373"
      unitRef="USD">2645000</CELU:FairValueNetAssetsLiability>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-07-31_srt_MaximumMember"
      decimals="INF"
      id="Fact002375"
      unitRef="Shares">892856</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-07-31"
      decimals="INF"
      id="Fact002377"
      unitRef="USDPShares">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:ReducedExercisePrice
      contextRef="From2023-07-312023-07-31"
      decimals="INF"
      id="Fact002379"
      unitRef="USDPShares">3.50</CELU:ReducedExercisePrice>
    <CELU:WarrantLiability
      contextRef="AsOf2023-07-31"
      decimals="-3"
      id="Fact002381"
      unitRef="USD">511000</CELU:WarrantLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-05-182023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002383"
      unitRef="Shares">581394</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002385"
      unitRef="Shares">581394</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002387"
      unitRef="USDPShares">5.20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-05-18_us-gaap_CommonClassAMember_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_us-gaap_PrivatePlacementMember"
      decimals="INF"
      id="Fact002389"
      unitRef="USDPShares">1.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-05-182023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="-3"
      id="Fact002391"
      unitRef="USD">3750000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002393"
      unitRef="USDPShares">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      id="Fact002395">2028-05-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <CELU:AdjustedAdvanceNoticePeriod
      contextRef="From2023-05-182023-05-18_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      id="Fact002397">P61D</CELU:AdjustedAdvanceNoticePeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-122024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="INF"
      id="Fact002399"
      unitRef="Shares">2141098</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="INF"
      id="Fact002401"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002403"
      unitRef="Shares">535274</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="INF"
      id="Fact002405"
      unitRef="USDPShares">2.4898</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2024-01-12_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="INF"
      id="Fact002407"
      unitRef="USDPShares">1.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2024-01-122024-01-12_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="-3"
      id="Fact002409"
      unitRef="USD">6000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <CELU:WarrantsAndRightsIssuedClosingDate
      contextRef="From2024-01-122024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      id="Fact002411">2024-01-16</CELU:WarrantsAndRightsIssuedClosingDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="INF"
      id="Fact002413"
      unitRef="USDPShares">2.4898</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      id="Fact002415">2029-01-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-01-12_us-gaap_CommonClassAMember_us-gaap_PrivatePlacementMember_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      id="Fact002417">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <CELU:ProceedsFromPrivatePlacements
      contextRef="From2024-01-122024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="-3"
      id="Fact002419"
      unitRef="USD">909000</CELU:ProceedsFromPrivatePlacements>
    <CELU:NumberOfWarrantsRepriced
      contextRef="AsOf2024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="INF"
      id="Fact002421"
      unitRef="Shares">652981</CELU:NumberOfWarrantsRepriced>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="INF"
      id="Fact002423"
      unitRef="USDPShares">67.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember"
      decimals="INF"
      id="Fact002425"
      unitRef="USDPShares">2.4898</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:FairValueOfWarrantModificationIncrementalForEquityIssuanceCost
      contextRef="From2024-01-122024-01-12_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="-3"
      id="Fact002427"
      unitRef="USD">524000</CELU:FairValueOfWarrantModificationIncrementalForEquityIssuanceCost>
    <CELU:PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount
      contextRef="AsOf2024-01-12_srt_MinimumMember_custom_InvestorRightsAgreementMember_custom_DragasacLimitedMember"
      decimals="INF"
      id="Fact002429"
      unitRef="Pure">0.010</CELU:PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount>
    <CELU:PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount
      contextRef="AsOf2024-01-12_srt_MaximumMember_custom_InvestorRightsAgreementMember_custom_DragasacLimitedMember"
      decimals="INF"
      id="Fact002431"
      unitRef="Pure">0.060</CELU:PercentageOfPartialLiquidatingDamagesOnSubscriptionAmount>
    <CELU:DailyInterestAccruingRate
      contextRef="AsOf2024-01-12"
      decimals="INF"
      id="Fact002433"
      unitRef="Pure">0.180</CELU:DailyInterestAccruingRate>
    <CELU:RelatedPartyBaseSalary
      contextRef="From2024-02-162024-02-16_custom_ChiefAdministrativeOfficerMember_custom_AmendedEmploymentAgreementMember"
      decimals="-3"
      id="Fact002435"
      unitRef="USD">500000</CELU:RelatedPartyBaseSalary>
    <CELU:RelatedPartyBaseSalary
      contextRef="From2024-02-162024-02-16_custom_ChiefAdministrativeOfficerMember_custom_AmendedEmploymentAgreementMember_srt_MinimumMember"
      decimals="-3"
      id="Fact002437"
      unitRef="USD">425000</CELU:RelatedPartyBaseSalary>
    <CELU:NumberOfWarrantsRepriced
      contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember"
      decimals="INF"
      id="Fact002439"
      unitRef="Shares">652981</CELU:NumberOfWarrantsRepriced>
    <CELU:ClassOfWarrantOrRighstExpirationDate
      contextRef="From2024-01-122024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember"
      id="Fact002441">2025-03-16</CELU:ClassOfWarrantOrRighstExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002443"
      unitRef="USDPShares">67.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember"
      decimals="INF"
      id="Fact002445"
      unitRef="USDPShares">2.4898</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002447"
      unitRef="USDPShares">2.4898</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002449"
      unitRef="USDPShares">2.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:NumberOfWarrantsRepriced
      contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_custom_RwiForbearanceAgreementMember_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002451"
      unitRef="Shares">300000</CELU:NumberOfWarrantsRepriced>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-03-13_custom_RwiForbearanceAgreementMember_us-gaap_WarrantMember_us-gaap_CommonStockMember"
      id="Fact002453">2028-06-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-13_custom_RwiForbearanceAgreementMember_us-gaap_WarrantMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002455"
      unitRef="USDPShares">5.895</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember"
      decimals="INF"
      id="Fact002457"
      unitRef="Shares">75000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <CELU:ClassOfWarrantOrRighstExpirationDate
      contextRef="From2024-03-132024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember"
      id="Fact002459">2028-03-17</CELU:ClassOfWarrantOrRighstExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-12_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember"
      decimals="INF"
      id="Fact002461"
      unitRef="USDPShares">7.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember"
      decimals="INF"
      id="Fact002463"
      unitRef="USDPShares">5.895</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember"
      decimals="INF"
      id="Fact002465"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <CELU:ClassOfWarrantOrRighstExpirationDate
      contextRef="From2024-03-132024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember"
      id="Fact002467">2028-06-20</CELU:ClassOfWarrantOrRighstExpirationDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember"
      decimals="INF"
      id="Fact002469"
      unitRef="USDPShares">8.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-13_us-gaap_CommonStockMember_custom_ForbearanceAgreementMember_us-gaap_WarrantMember_custom_LoanAgreementMember_custom_CVStarrCoIncMember_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember"
      decimals="INF"
      id="Fact002471"
      unitRef="USDPShares">5.895</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-03-13_custom_YorkvilleMember_us-gaap_CommonClassAMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact002473"
      unitRef="Shares">10000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-13_custom_YorkvilleMember_us-gaap_CommonClassAMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact002475"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <CELU:SaleOfStockMaximumAverageDailyTradedAmountPercentage
      contextRef="AsOf2024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact002477"
      unitRef="Pure">1</CELU:SaleOfStockMaximumAverageDailyTradedAmountPercentage>
    <CELU:SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact002479"
      unitRef="Integer">5</CELU:SaleOfStockMaximumAverageDailyTradedAmountThresholdConsecutiveTradingDays>
    <CELU:SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice
      contextRef="AsOf2024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact002481"
      unitRef="Pure">0.97</CELU:SaleOfStockPercentageBasedOnVolumeWeightedAveragePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_us-gaap_CommonClassAMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact002483"
      unitRef="USD">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <CELU:SaleOfStockConsiderationCashDueDiligenceFee
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact002485"
      unitRef="Shares">25000</CELU:SaleOfStockConsiderationCashDueDiligenceFee>
    <CELU:SaleOfStockConsiderationCommitmentFeeInShares
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="INF"
      id="Fact002487"
      unitRef="Shares">16964</CELU:SaleOfStockConsiderationCommitmentFeeInShares>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_StandbyEquityPurchaseAgreementMember"
      decimals="-3"
      id="Fact002489"
      unitRef="USD">125000</us-gaap:PaymentsOfStockIssuanceCosts>
    <CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault
      contextRef="From2024-03-132024-03-13_custom_YorkvilleMember_custom_ConvertiblePromissoryNotesMember_custom_StandbyEquityPurchaseAgreementMember15564515"
      decimals="INF"
      id="Fact002491"
      unitRef="Pure">0.180</CELU:LineOfCreditIncreaseInInterestRateDuringPeriodInEventOfDefault>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002493"
      unitRef="Shares">11221557</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002495">&lt;p id="xdx_893_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zqDAMexY9Ui5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;span id="xdx_8B8_zKad2K7DCD7" style="display: none"&gt;Summary of the Warrants&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Expiration&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: left"&gt;Dragasac Warrants (1) (4)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____z0ajEyNc7Gri" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of shares"&gt;652,981&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____z8rfYtZnGm0c" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Exercise price"&gt;2.4898&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_fKDEpICg0KQ_____zinEqo0yyrj2" title="Expiration date"&gt;March 16, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Public Warrants (2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zD7zdoffSM62" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;1,437,447&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zB5PsoNJXGE8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;115.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_fKDIp_zbLI7oxrz5Ye" title="Expiration date"&gt;July 16, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Sponsor Warrants (2)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zOETGiKL24Af" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;849,999&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zG7kLfJ7pqBa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;115.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_fKDIp_zw7uGCgnGvxd" title="Expiration date"&gt;July 16, 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;May 2022 PIPE Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zNBLwgk4u2M6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;405,405&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_zYnIQ2JKWm62" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;3.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember_z9aJUtHsiila" title="Expiration date"&gt;October 10, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;March 2023 PIPE Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zUxz96duCA9h" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;208,485&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zrAr8lT7pT7b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;30.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zbMTTbD0VWKc" title="Expiration date"&gt;March 27, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;March 2023 PIPE Warrants (modified)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zP7VnzVPnA1g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;729,698&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zB4FeFTE49ka" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;10.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember_zTinxyaSs7C4" title="Expiration date"&gt;March 27, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;March 2023 Loan Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_znGDbJamzLb2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;75,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_zuYOPZJcdbu5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;5.8950&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_fKDMp_z8mn0HGHCDu2" title="Expiration date"&gt;March 17, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;April 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKOrvgR95rk7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;435,625&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_z5ana1gABy3f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;7.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zJKCZ8wAHof9" title="Expiration date"&gt;October 10, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;April 2023 Registered Direct Warrants (modified)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zq37NcuNL3a8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;487,451&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_zDignA4wcAh9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;3.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember_z3dbEpyhwLI5" title="Expiration date"&gt;October 10, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;May 2023 PIPE Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zI4rOAiVvCij" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;581,394&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zvM8PcQRmBAi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;10.00&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_zd5RNva34Wxe" title="Expiration date"&gt;May 17, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;June 2023 Warrants (3)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zeCpcQOTjk6f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;50,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_fKDMp_zdMvnGprRZpf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;5.8950&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeWarrantsMember_zBVhMP3jdaTi" title="Expiration date"&gt;June 20, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;June 2023 Loan Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_zQQc2iOSUeJ9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;300,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_z77BMZWgNc9f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;8.10&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JuneTwoThousandTwentyThreeLoanWarrantsMember_ztf6Zdk7HOP3" title="Expiration date"&gt;June 20, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;July 2023 Registered Direct Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zFxWian5umj6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;857,142&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zhUxE7E1J034" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;3.50&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember_zKAC9gfv4dya" title="Expiration date"&gt;January 31, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;January 2024 PIPE Warrants (4)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_zyfcgBb1FFFj" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;535,274&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_z5X4MytO6C6g" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.4898&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourPipeWarrantsMember_fKDQp_zu80bN8I5Ofk" title="Expiration date"&gt;January 16, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;January 2024 Bridge Loan - Tranche #1 Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zE6EeyOX72B" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;1,650,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_zXUvDttoFB0b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.4898&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember_z7usxMXNNxQg" title="Expiration date"&gt;January 16, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;January 2024 Bridge Loan - Tranche #2 Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zOZ7yCW1h3Tg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;1,350,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zqSWqzySTfn6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.9880&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember_zgQ38ONYpxVg" title="Expiration date"&gt;July 15, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;March 2024 RWI Forbearance Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_ziSrMKBgY6n6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;300,000&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zYFg60Zj7Nq" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;5.8958&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember_zz6eqvfyOVsk" title="Expiration date"&gt;June 20, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;November 2024 Purchaser Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember_zaMPNsvijBw9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;263,156&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember_zlIGAKCCmTri" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Exercise price"&gt;2.85&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember__srt--RangeAxis__srt--MinimumMember_zemQZleBalsi" title="Expiration date"&gt;November 25, 2029&lt;/span&gt; - &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPurchaseWarrantsMember__srt--RangeAxis__srt--MaximumMember_zFdB8Lo57Zge" title="Expiration date"&gt;December 3, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;November 2024 Placement Agent Warrants&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_ztFSS2vs3ty9" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;52,500&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zFUgq2fTDmKl" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Exercise price"&gt;3.56&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right; padding-bottom: 1pt"&gt;&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember__srt--RangeAxis__srt--MinimumMember_z9H1KcEEjrv1" title="Expiration date"&gt;November 25, 2029&lt;/span&gt; - &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20241231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember__srt--RangeAxis__srt--MaximumMember_z6Q7qsYVDzna" title="Expiration date"&gt;December 3, 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20241231_zmqvCnSL8DGb" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares"&gt;11,221,557&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_F01_zaUWrq4ZJf36" style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F10_zU7ufP8Z2xui" style="font-size: 10pt"&gt;In connection with the execution of the January 2024 PIPE described above, the Company agreed to reprice &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_z0CxQy6hgMJh" title="Number of warrants repriced"&gt;652,981&lt;/span&gt; legacy warrants held by Dragasac with a previous exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zJ7gS6haRbBc" title="Exercise price per share or per unit of warrants or rights outstanding"&gt;67.70&lt;/span&gt; to a new exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zYVzxB4PfIah" title="Exercise price"&gt;2.4898&lt;/span&gt;. The term of the warrants was unchanged.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F02_zpkmujJUSn29" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1D_zsXTc6rGNjph" style="font-size: 10pt"&gt;The number of Public Warrants
and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_zHSrw9l6fBM" title="Warrants outstanding"&gt;14,374,478&lt;/span&gt; Public Warrants and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zhb8lpf7vX1c" title="Warrants outstanding"&gt;8,499,999&lt;/span&gt; Sponsor
Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant
is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfdpdBsJpoed" title="Exercise per share price (in Dollars per share)"&gt;115.00&lt;/span&gt; as a result
of the split.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F07_zYFMOuFpTkL1" style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F14_zmEyC4kJiPda" style="font-size: 10pt"&gt;In connection with the execution
of the Starr Forbearance Agreement on March 13, 2024, described above under Warrant Modification and further in Note 10, the Company
agreed to reprice &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_903_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zNKnX4iQB39l" title="Number of warrants repriced"&gt;75,000&lt;/span&gt; warrants with a previous exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zB4Cdrckei1h" title="Exercise price"&gt;7.10&lt;/span&gt; and &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_904_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zGIhzk4KHX5l" title="Number of warrants repriced"&gt;50,000&lt;/span&gt; warrants with a previous exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313_ztdMSGu7CCBf" title="Exercise price"&gt;8.10&lt;/span&gt;
held by C.V. Starr to a new exercise price of $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zYKfrX5dCT29" title="Exercise price"&gt;5.895&lt;/span&gt;. The term of the warrants was unchanged.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F04_zDR8Xy7PCx4h" style="font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1E_zWd9mgsl4eQl" style="font-size: 10pt"&gt;On January 24, 2025, the
Company agreed to reduce the exercise price of the Dragasac warrants and the January 2024 PIPE warrants from $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zDOZqY4vlhF5" title="Exercise price"&gt;2.49&lt;/span&gt; per share to $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zfw8z5NDCiqh" title="Exercise price"&gt;2.07&lt;/span&gt;
per share. As a result of the price reduction, the holder agreed to immediately exercise the warrants in full and to purchase an aggregate
&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zs0kpvh31E5b" title="Aggregate shares"&gt;1,188,255&lt;/span&gt; shares of the Company&#x2019;s Class A common stock for gross proceeds to the Company of approximately $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250124__20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJKjoIgtMeje" title="Proceeds from the exercise of warrants"&gt;2.5&lt;/span&gt; million&lt;i&gt;.&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_DragasacWarrantMember"
      decimals="INF"
      id="Fact002497"
      unitRef="Shares">652981</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_DragasacWarrantMember"
      decimals="INF"
      id="Fact002499"
      unitRef="USDPShares">2.4898</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_DragasacWarrantMember"
      id="Fact002501">2025-03-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact002503"
      unitRef="Shares">1437447</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact002505"
      unitRef="USDPShares">115.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_PublicWarrantsMember"
      id="Fact002507">2026-07-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_SponsorWarrantsMember"
      decimals="INF"
      id="Fact002509"
      unitRef="Shares">849999</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SponsorWarrantsMember"
      decimals="INF"
      id="Fact002511"
      unitRef="USDPShares">115.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_SponsorWarrantsMember"
      id="Fact002513">2026-07-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002515"
      unitRef="Shares">405405</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002517"
      unitRef="USDPShares">3.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyTwoPrivateInvestmentInPublicEquityWarrantsMember"
      id="Fact002519">2028-10-10</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002521"
      unitRef="Shares">208485</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002523"
      unitRef="USDPShares">30.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      id="Fact002525">2028-03-27</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember"
      decimals="INF"
      id="Fact002527"
      unitRef="Shares">729698</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember"
      decimals="INF"
      id="Fact002529"
      unitRef="USDPShares">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsModifiedMember"
      id="Fact002531">2028-03-27</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember"
      decimals="INF"
      id="Fact002533"
      unitRef="Shares">75000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember"
      decimals="INF"
      id="Fact002535"
      unitRef="USDPShares">5.8950</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember"
      id="Fact002537">2028-03-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember"
      decimals="INF"
      id="Fact002539"
      unitRef="Shares">435625</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember"
      decimals="INF"
      id="Fact002541"
      unitRef="USDPShares">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsMember"
      id="Fact002543">2028-10-10</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember"
      decimals="INF"
      id="Fact002545"
      unitRef="Shares">487451</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember"
      decimals="INF"
      id="Fact002547"
      unitRef="USDPShares">3.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_AprilTwoThousandTwentyThreeRegisteredDirectWarrantsModifiedMember"
      id="Fact002549">2028-10-10</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002551"
      unitRef="Shares">581394</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      decimals="INF"
      id="Fact002553"
      unitRef="USDPShares">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_MayTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember"
      id="Fact002555">2028-05-17</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact002557"
      unitRef="Shares">50000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeWarrantsMember"
      decimals="INF"
      id="Fact002559"
      unitRef="USDPShares">5.8950</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeWarrantsMember"
      id="Fact002561">2028-06-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember"
      decimals="INF"
      id="Fact002563"
      unitRef="Shares">300000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember"
      decimals="INF"
      id="Fact002565"
      unitRef="USDPShares">8.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_JuneTwoThousandTwentyThreeLoanWarrantsMember"
      id="Fact002567">2028-06-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember"
      decimals="INF"
      id="Fact002569"
      unitRef="Shares">857142</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember"
      decimals="INF"
      id="Fact002571"
      unitRef="USDPShares">3.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_JulyTwoThousandTwentyThreeRegisteredDirectWarrantsMember"
      id="Fact002573">2029-01-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="INF"
      id="Fact002575"
      unitRef="Shares">535274</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      decimals="INF"
      id="Fact002577"
      unitRef="USDPShares">2.4898</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourPipeWarrantsMember"
      id="Fact002579">2029-01-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember"
      decimals="INF"
      id="Fact002581"
      unitRef="Shares">1650000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember"
      decimals="INF"
      id="Fact002583"
      unitRef="USDPShares">2.4898</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheOneWarrantsMember"
      id="Fact002585">2029-01-16</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember"
      decimals="INF"
      id="Fact002587"
      unitRef="Shares">1350000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember"
      decimals="INF"
      id="Fact002589"
      unitRef="USDPShares">2.9880</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_JanuaryTwoThousandTwentyFourBridgeLoanTrancheTwoWarrantsMember"
      id="Fact002591">2029-07-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember"
      decimals="INF"
      id="Fact002593"
      unitRef="Shares">300000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember"
      decimals="INF"
      id="Fact002595"
      unitRef="USDPShares">5.8958</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_MarchTwoThousandTwentyFourRwiForbearanceWarrantsMember"
      id="Fact002597">2028-06-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember"
      decimals="INF"
      id="Fact002599"
      unitRef="Shares">263156</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember"
      decimals="INF"
      id="Fact002601"
      unitRef="USDPShares">2.85</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_srt_MinimumMember"
      id="Fact002603">2029-11-25</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPurchaseWarrantsMember_srt_MaximumMember"
      id="Fact002605">2029-12-03</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember15565437"
      decimals="INF"
      id="Fact002607"
      unitRef="Shares">52500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember15565437"
      decimals="INF"
      id="Fact002609"
      unitRef="USDPShares">3.56</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_srt_MinimumMember"
      id="Fact002611">2029-11-25</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2024-12-31_custom_NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_srt_MaximumMember"
      id="Fact002613">2029-12-03</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact002615"
      unitRef="Shares">11221557</us-gaap:ClassOfWarrantOrRightOutstanding>
    <CELU:NumberOfWarrantsRepriced
      contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember"
      decimals="INF"
      id="Fact002618"
      unitRef="Shares">652981</CELU:NumberOfWarrantsRepriced>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_us-gaap_CommonClassAMember_custom_DragasacWarrantMember"
      decimals="INF"
      id="Fact002620"
      unitRef="USDPShares">67.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-01-12_custom_TwoThousandTwentyFourWarrantRepricingMember"
      decimals="INF"
      id="Fact002622"
      unitRef="USDPShares">2.4898</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:WarrantsOutstanding
      contextRef="AsOf2024-12-31_custom_PublicWarrantsMember"
      decimals="INF"
      id="Fact002625"
      unitRef="Shares">14374478</CELU:WarrantsOutstanding>
    <CELU:WarrantsOutstanding
      contextRef="AsOf2024-12-31_custom_SponsorWarrantsMember"
      decimals="INF"
      id="Fact002627"
      unitRef="Shares">8499999</CELU:WarrantsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-12-31_custom_SponsorWarrantsMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002629"
      unitRef="USDPShares">115.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:NumberOfWarrantsRepriced
      contextRef="AsOf2024-03-13_custom_StarrForbearanceAgreementMember"
      decimals="INF"
      id="Fact002632"
      unitRef="Shares">75000</CELU:NumberOfWarrantsRepriced>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-13_custom_StarrForbearanceAgreementMember"
      decimals="INF"
      id="Fact002634"
      unitRef="USDPShares">7.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <CELU:NumberOfWarrantsRepriced
      contextRef="AsOf2024-03-13_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002636"
      unitRef="Shares">50000</CELU:NumberOfWarrantsRepriced>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-13"
      decimals="INF"
      id="Fact002638"
      unitRef="USDPShares">8.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-03-13_custom_CVStarrCoIncMember"
      decimals="INF"
      id="Fact002640"
      unitRef="USDPShares">5.895</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-24_custom_JanuaryTwoThousandTwentyFourPIPEWarrantMember_us-gaap_SubsequentEventMember_srt_MinimumMember"
      decimals="INF"
      id="Fact002643"
      unitRef="USDPShares">2.49</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-01-24_custom_JanuaryTwoThousandTwentyFourPIPEWarrantMember_us-gaap_SubsequentEventMember_srt_MaximumMember"
      decimals="INF"
      id="Fact002645"
      unitRef="USDPShares">2.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002647"
      unitRef="Shares">1188255</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2025-01-242025-01-24_custom_TwoThousandTwentyFourWarrantRepricingMember_us-gaap_SubsequentEventMember_us-gaap_CommonClassAMember"
      decimals="-5"
      id="Fact002649"
      unitRef="USD">2500000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002651">&lt;p id="xdx_807_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z0NGXDvd3URc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;14. &lt;span id="xdx_822_zWTRJlARrpBc"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2021 Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In July 2021, the Company&#x2019;s
board of directors adopted, and the Company&#x2019;s stockholders approved the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;).
The 2021 Plan provides for the grant of incentive stock options (&#x201c;ISOs&#x201d;) to employees and for the grant of nonstatutory stock
options (&#x201c;NSOs&#x201d;), stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and
other forms of stock awards to employees, directors and consultants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The number of shares of Class
A Common Stock initially reserved for issuance under the 2021 Plan is &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20210731__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zQtlAGgt2VK4"&gt;2,091,528&lt;/span&gt;.
As of December 31, 2024, &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zc3pCPWh7Mqh"&gt;330,391
&lt;/span&gt;shares were reserved for issuance and those shares remain available for future grant under the 2021 Plan. The number of shares
reserved for issuance will automatically increase on January 1 of each year, for a period of &lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zmA2bGuNGDeb"&gt;10
&lt;/span&gt;years, from January 1, 2022 through January 1, 2031, by &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_pid_dp_uPure_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember_zjF5fDVKnRdf"&gt;4.0&lt;/span&gt;%
of the total number of shares of Celularity common stock outstanding on December 31 of the preceding calendar year, or a lesser number
of shares as may be determined by the Company&#x2019;s board of directors. On January 1, 2025, the number of shares reserved for issuance
increased to &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250101__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneEquityIncentivePlanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zyZH2dar6LRj" title="Number of shares reserved for issuance"&gt;1,229,890&lt;/span&gt; and those shares remain available for future grant under the 2021 Plan. The shares added to the 2021 Plan on
January 1, 2025, remain subject to an effective registration statement on Form S-8. Shares subject to stock awards granted under the
2021 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce
the number of shares available for issuance under the 2021 Plan. Additionally, shares issued pursuant to stock awards under the 2021
Plan that are repurchased or forfeited, as well as shares that are reacquired as consideration for the exercise or purchase price of
a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2021
Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The 2021 Plan is administered
by the Company&#x2019;s board of directors. The Company&#x2019;s board of directors, or a duly authorized committee thereof, may delegate
to one or more officers the authority to (i) designate employees other than officers to receive specified stock awards and (ii) determine
the number of shares to be subject to such stock awards. Subject to the terms of the 2021 Plan, the plan administrator has the authority
to determine the terms of awards, including recipients, the exercise price or strike price of stock awards, if any, the number of shares
subject to each stock award, the fair market value of a share, the vesting schedule applicable to the awards, together with any vesting
acceleration, the form of consideration, if any, payable upon exercise or settlement of the stock award and the terms and conditions of
the award agreements for use under the 2021 Plan. The plan administrator has the power to modify outstanding awards under the 2021 Plan.
Subject to the terms of the 2021 Plan and in connection with a corporate transaction or capitalization adjustment, the plan administrator
may not reprice or cancel and regrant any award at a lower exercise price, strike price or purchase price or cancel any award with an
exercise price, strike price or purchase price in exchange for cash, property or other awards without first obtaining the approval of
the Company&#x2019;s stockholders.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2017 Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The 2017 Equity Incentive Plan
(the &#x201c;2017 Plan&#x201d;) adopted by Legacy Celularity&#x2019;s board of directors and approved by Legacy Celularity&#x2019;s stockholders
provided for Legacy Celularity to grant stock options to employees, directors and consultants of Legacy Celularity. In connection with
the closing of the merger and effectiveness of the 2021 Plan, no further grants were made under the 2017 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The total number of stock options
that could have been issued under the 2017 Plan was &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember_ziF5CSSxU6q4" title="Number of shares remaining available for future grant"&gt;3,234,204&lt;/span&gt;. Shares that expired, forfeited, canceled or otherwise terminated without
having been fully exercised were available for future grant under the 2017 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The 2017 Plan is
administered by the Company&#x2019;s board of directors or, at the discretion of the Company&#x2019;s board of directors, by a
committee of the board of directors. The exercise prices, vesting and other restrictions were determined at the discretion of Legacy
Celularity&#x2019;s board of directors, or its committee if so delegated, except that the exercise price per share of stock options
could not be less than &lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember_z5Eb2iTmkd29" title="Percentage of fair market value"&gt;100&lt;/span&gt;%
of the fair market value of the share of common stock on the date of grant and the term of stock option could not be greater than &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20240101__20240930__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zbP0wfLWFZGl" title="Stock option, expiration period"&gt;ten
years&lt;/span&gt;. Stock options granted to employees, officers, members of the board of directors and consultants typically vested over
a three&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_zKNd1ARCEp5b" style="display: none"&gt;3&lt;/span&gt; or four&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndSeventeenEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zbhMpSrZRHX2" style="display: none" title="Options vesting period"&gt;4&lt;/span&gt;
year period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock Option Valuation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Awards with Service Conditions&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The fair value of each option
is estimated on the date of grant using a Black-Scholes option pricing model that takes into account inputs such as the exercise price,
the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest
rate, and dividend yield. The fair value of each grant of stock options was determined by the Company using the methods and assumptions
discussed below. Certain of these inputs are subjective and generally require judgment to determine.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.4in"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The expected term of employee stock options with service-based vesting is determined using the &#x201c;simplified&#x201d; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#x2019;s lack of sufficient historical data. The expected term of non-employee options is equal to the contractual term or its estimated term based on the underlying agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The expected stock price
volatility is based on historical volatilities of comparable public entities within the Company&#x2019;s industry.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-size: 10pt"&gt;&lt;/span&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The risk-free interest rate
is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with
the respective expected term or contractual term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The expected dividend yield
is &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dpxL_uPure_c20240101__20241231_zw9j1ThKW2Z1" title="Expected dividend yield::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2668"&gt;0&lt;/span&gt;&lt;/span&gt;% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common
stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zHSi7VNtimMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table presents,
on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of
stock options granted during the years ended December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zYZqiUnPXdY6" style="display: none"&gt;Schedule
of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_z2potn9roIG5" title="Risk-free interest rate"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zHl1CZ2pHpVh" title="Risk-free interest rate"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zkwd3rGxq8T2" title="Expected term (in years)"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_z9cm5bOa8hn7" title="Expected term (in years)"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_z4S89HLms7e6" title="Expected volatility"&gt;104.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zAbmS7zcuBj2" title="Expected volatility"&gt;86.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zplEkoymBS58" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2684"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zbEOdeV1aY8b" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2686"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zadLJXErc7ic" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The weighted average grant-date
fair value per share of stock options granted during the years ended December 31, 2024 and 2023 was $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20241231_zWZaSb40nqD" title="Weighted average grant-date fair value of stock options granted"&gt;2.66&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_z8rsPSk2yGY8" title="Weighted average grant-date fair value of stock options granted"&gt;5.35&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zbJRYdYPlJFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table summarizes
option activity with service conditions under the 2021 Plan and the 2017 Plan:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zG2i2ti5NyG7" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Contract Term&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36%"&gt;Outstanding at January 1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zF3IYl6nrHu7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options beginning balance"&gt;2,820,187&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zoyox20ifwRb" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, beginning balance"&gt;40.16&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zXdRJbXwnUFh" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Contract Term"&gt;5.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zCES6e24mm3i" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl2700"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zHBRRWhxZNU8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Granted"&gt;1,503,394&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z9wP3RaRS9J7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;3.26&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zM79G07533W7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Exercised"&gt;(20,744&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zJMc6pjrZmz2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;2.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt"&gt;Forfeited/Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zEN22apL8W43" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options  Forfeited/Expired"&gt;(341,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zGwGKKQKXEGa" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited/Expired"&gt;29.51&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____ziiElOR6ieD1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options ending balance"&gt;3,961,525&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zCXYjC5bYQ96" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, ending balance"&gt;27.27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zzU2IuFCZSPi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Contract Term"&gt;6.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____z2g25bNo2c86" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value"&gt;16&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vested and expected to vest at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z4DWpWCjrpp6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Vested and expected to vest"&gt;3,961,525&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z6uGximBcL7e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Vested and expected to vest"&gt;27.27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zG1uF8gKqDjb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Contract Term, Vested and expected to vest"&gt;6.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zwzPVArM19v2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Vested and expected to vest"&gt;16&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zueTC5c1bAi9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Exercisable"&gt;2,586,561&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zI8ItzR1OnB8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;37.49&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zku2lDcJSgTg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Contract Term Exercisable"&gt;4.9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zUGFYOScdgS" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2736"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0F_zB4AoTlKrtr2" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td id="xdx_F1D_zLXerFXny1Wc" style="text-align: justify"&gt;Options outstanding at December 31, 2024 under the 2021 Plan and 2017 Plan were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zJXOtNTlcnPg" title="Options outstanding"&gt;2,569,029&lt;/span&gt; and
                                                                             &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zBXUGuFGvff8" title="Options outstanding"&gt;1,437,496&lt;/span&gt;, respectively. Options outstanding at December 31, 2024 under the 2021 Plan include &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_z1vLdctHuub8" title="Options outstanding including awards"&gt;45,000&lt;/span&gt; awards with performance
                                                                             conditions (see below).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8A9_zbWkmUhL99Bl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The aggregate intrinsic value
of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company&#x2019;s Class
A common stock for those options that had exercise prices lower than the fair value of Class A common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company recorded stock-based
compensation expense relating to option awards with service conditions of $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zVoTZaTbQlz9" title="Stock-based compensation expense"&gt;8,336&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAidfgl5l4R3" title="Stock-based compensation expense"&gt;9,293&lt;/span&gt; for the years ended December 31, 2024 and
2023, respectively. During the years ended December 31, 2024 and 2023, the aggregate intrinsic value was $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20240101__20241231_z2qlZRNPNFm8" title="Aggregate intrinsic value, stock option exercised"&gt;8&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_pn3n3_c20230101__20231231_ziIVqEioo094" title="Aggregate intrinsic value, stock option exercised"&gt;0&lt;/span&gt;, respectively, for
the stock options exercised. As of December 31, 2024, unrecognized compensation cost for options issued with service conditions was $&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zr5a2gDZWsub" title="Unrecognized compensation cost for options issued"&gt;7,129&lt;/span&gt;
and will be recognized over an estimated weighted-average amortization period of &lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmasEAcJvBre" title="Estimated weighted-average amortization period"&gt;2.09&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Awards with Performance Conditions&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In connection with the advisory
agreement signed with Robin L. Smith, MD (see Note 20), the Company awarded options under the 2021 Plan to acquire a total of &lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zDU1UinCtXA9" title="Vested options to acquire shares"&gt;105,000
&lt;/span&gt;shares with an exercise price of $&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_ztfIXeIU6hld" title="Vested options to acquire per share"&gt;29.90
&lt;/span&gt;to Dr. Smith, a former member of the Company&#x2019;s board of directors. The initial tranche of &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember__us-gaap--VestingAxis__custom--InitialTrancheMember_zXZvvIfxBOu1" title="Vested options to acquire shares"&gt;25,000
&lt;/span&gt;stock options vested upon execution of the advisory agreement on August 16, 2022. The remaining &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_pid_c20220816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zPEeCOAp7SR2" title="Stock option vesting"&gt;80,000
&lt;/span&gt;stock options are subject to vesting upon achievement of certain predefined milestones in relation to the expansion of the degenerative
disease business. On November 1, 2022, the second tranche of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20221101__20221101__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember__us-gaap--VestingAxis__custom--SecondTrancheMember_zHNDKY5vzIG7" title="Vested options to acquire shares"&gt;20,000
&lt;/span&gt;stock options vested upon achievement of the first milestone. The fair value of the award was determined based on a Black-Scholes
option-pricing model. The Company&#x2019;s grant date fair value assumptions were &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20221101__20221101__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zfDLt0ldrHIc" title="Expected volatility"&gt;79.9&lt;/span&gt;%
expected volatility, &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_z4qecaMATcBh" title="Risk-free interest rate"&gt;2.95&lt;/span&gt;%
risk-free interest rate, five&lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zstFfh2JjH52" style="display: none" title="Expected term (in years)"&gt;5&lt;/span&gt;-year
expected term, and &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zJNQsvrJPNX7" title="Expected dividend yield"&gt;0&lt;/span&gt;%
expected dividend yield. The remaining &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20230816__20230816__us-gaap--AwardTypeAxis__custom--AwardsWithPerformanceConditionsMember_zVJoatRXjjz4" title="Remaining stock options forfeited upon termination of the advisory agreement"&gt;60,000
&lt;/span&gt;stock options were forfeited on August 16, 2023 upon termination of the advisory agreement. There were no milestones achieved
or probable of being achieved and accordingly there was &lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_do_c20230101__20231231_zcCv8Tx1Slq6" title="Stock based compensation"&gt;no&lt;/span&gt; stock-based compensation expense recorded during the year ended December 31,
2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 23.75pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company issues restricted
stock units (&#x201c;RSUs&#x201d;) to employees that generally vest over a four&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDcQ3FA3Ugv4" style="display: none"&gt;4&lt;/span&gt;-year
period, with &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheOneMember_zXzUpGs5YaOf" title="Vesting percentage"&gt;25&lt;/span&gt;%
vesting on the anniversary of the grant date, and the remainder vesting in equal annual installments thereafter so that the RSUs are
vested in full on the four-year anniversary of the grant date. At times, the board of directors may approve exceptions to the standard
RSU vesting terms. Any unvested shares will be forfeited upon termination of services. The fair value of an RSU is equal to the fair
market value price of the Company&#x2019;s common stock on the date of grant. RSU expense is amortized straight-line over the vesting
period. There are no RSUs outstanding under the 2017 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zqTyDgwas09a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table summarizes
activity related to RSU stock-based payment awards under the 2021 Plan:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BC_zSXrC3ysNlUj" style="display: none"&gt;Schedule
of Activity Related to RSU Stock-Based Payment Awards&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;Number of&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Outstanding at January 1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNALfbpj75qb" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of Shares, Outstanding beginning balance"&gt;823,332&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zytdOBicjFqk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value,Outstanding beginning balance"&gt;13.77&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPpuztLsUrMk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted"&gt;337,080&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqSxsnwAFd6a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;2.23&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Released&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb9ccMxJtKmc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Released"&gt;(400,996&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaMY8zj0UKFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Released"&gt;11.58&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXrulQsvRS1b" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited"&gt;(99,977&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z09oFjThdPM6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;13.24&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTMssxfDjrkd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Outstanding ending balance"&gt;659,439&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfIVN9J5UJud" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding ending balance"&gt;9.29&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zkivrNzpp2f4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company recorded stock-based
compensation expense of $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGMsTsOX3Re6" title="Stock-based compensation expense"&gt;3,022&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgxjToMJNQFi" title="Stock-based compensation expense"&gt;5,724&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively, related to RSUs. As of December
31, 2024, the total unrecognized expense related to all RSUs was $&lt;span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2Jw3T2Wx3s7" title="Stock-based compensation expense"&gt;4,136&lt;/span&gt;, which the Company expects to recognize over a weighted-average
period of &lt;span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zO7nJ4XsE9y8" title="Estimated weighted-average amortization period"&gt;1.44&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock Units with Market Condition Vesting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;In July 2023, the Company granted
&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zGQAA9vfK7gg" title="Number of shares granted"&gt;174,500
&lt;/span&gt;market condition stock unit awards (&#x201c;MCUs&#x201d;) under the 2021 Plan to certain members of management. The awards are scheduled
to vest over a period of one&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember__srt--RangeAxis__srt--MinimumMember_zcNthJVudLQf" style="display: none"&gt;1&lt;/span&gt;
to three&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230701__20230731__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember__srt--RangeAxis__srt--MaximumMember_zdiw7pywvJMd" style="display: none"&gt;3&lt;/span&gt;
years from the grant date based on continuous employment and specified market conditions based on the Company&#x2019;s stock price
at the time of vest. As of December 31, 2024, &lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn3n3_c20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zXY3Uc9m9Gs5"&gt;145,833
&lt;/span&gt;of the MCUs were forfeited as a result of the participant&#x2019;s termination of continuous service. Stock-based compensation
expense for the remaining &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_zGZS0NtUWivf"&gt;28,667
&lt;/span&gt;MCUs is being recognized over the requisite service period based on the award&#x2019;s fair value on the grant date, which was
determined based on the Company&#x2019;s closing stock price on the date of grant of $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_z1eHeYU75zlh" title="Grant date fair value of units granted"&gt;5.00&lt;/span&gt;,
further discounted to reflect the effects of the market condition of the award. The Company recorded stock-based compensation expense
relating to MCUs of $&lt;span id="xdx_90D_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20240101__20241231__us-gaap--AwardTypeAxis__custom--MarketConditionStockUnitMember_z5dzjiq4qnAk" title="Stock based compensation expense"&gt;211
&lt;/span&gt;for the year ended December 31, 2024. Stock-based compensation expense relating to MCUs for the year ended December 31, 2023 was
de minimis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zFenUch6J8Pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company recorded stock-based
compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B8_zGrfAobJxpB1" style="display: none"&gt;Schedule
of Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zpCCS3OARQOk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zlS3CHNW0iY7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zBJyVCyCdy3a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Cost of revenues&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;450&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;580&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4xEVC9YXIW4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,287&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,832&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zdpAFtrQkOKi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,832&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,605&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z5JTi4sY6kU1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
    compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,569&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zNA8pyrQr0Sb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-07-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002652"
      unitRef="Shares">2091528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact002653"
      unitRef="Shares">330391</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <CELU:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember"
      id="Fact002654">P10Y</CELU:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedForFutureIssuanceAutomaticIncreasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002655"
      unitRef="Pure">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-01-01_custom_TwoThousandAndTwentyOneEquityIncentivePlanMember_us-gaap_CommonClassAMember_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="Fact002657"
      unitRef="Shares">1229890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002659"
      unitRef="Shares">3234204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002661"
      unitRef="Pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2024-01-012024-09-30_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MaximumMember"
      id="Fact002663">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MinimumMember"
      id="Fact002664">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndSeventeenEquityIncentivePlanMember_srt_MaximumMember"
      id="Fact002666">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002670">&lt;p id="xdx_894_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zHSi7VNtimMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table presents,
on a weighted average basis, the assumptions used in the Black-Scholes option-pricing model to determine the grant-date fair value of
stock options granted during the years ended December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BE_zYZqiUnPXdY6" style="display: none"&gt;Schedule
of Weighted Average Grant Fair Value of Stock Options using Black-Scholes Option-pricing Model&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20240101__20241231_z2potn9roIG5" title="Risk-free interest rate"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231_zHl1CZ2pHpVh" title="Risk-free interest rate"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20241231_zkwd3rGxq8T2" title="Expected term (in years)"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_z9cm5bOa8hn7" title="Expected term (in years)"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20240101__20241231_z4S89HLms7e6" title="Expected volatility"&gt;104.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231_zAbmS7zcuBj2" title="Expected volatility"&gt;86.5&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20241231_zplEkoymBS58" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2684"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231_zbEOdeV1aY8b" title="Expected dividend yield"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2686"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002672"
      unitRef="Pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002674"
      unitRef="Pure">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-01-01to2024-12-31" id="Fact002676">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-01-012023-12-31" id="Fact002678">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002680"
      unitRef="Pure">1.049</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002682"
      unitRef="Pure">0.865</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002688"
      unitRef="USDPShares">2.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002690"
      unitRef="USDPShares">5.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002692">&lt;p id="xdx_89B_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zbJRYdYPlJFb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table summarizes
option activity with service conditions under the 2021 Plan and the 2017 Plan:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zG2i2ti5NyG7" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Contract Term&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36%"&gt;Outstanding at January 1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zF3IYl6nrHu7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Options beginning balance"&gt;2,820,187&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zoyox20ifwRb" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price, beginning balance"&gt;40.16&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zXdRJbXwnUFh" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Contract Term"&gt;5.6&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zCES6e24mm3i" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Aggregate Intrinsic Value"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl2700"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zHBRRWhxZNU8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Granted"&gt;1,503,394&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z9wP3RaRS9J7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Granted"&gt;3.26&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zM79G07533W7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Exercised"&gt;(20,744&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zJMc6pjrZmz2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;2.80&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt"&gt;Forfeited/Expired&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zEN22apL8W43" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options  Forfeited/Expired"&gt;(341,312&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zGwGKKQKXEGa" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Exercise Price, Forfeited/Expired"&gt;29.51&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024*&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____ziiElOR6ieD1" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options ending balance"&gt;3,961,525&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zCXYjC5bYQ96" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Exercise Price, ending balance"&gt;27.27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____zzU2IuFCZSPi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Contract Term"&gt;6.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_fKg_____z2g25bNo2c86" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value"&gt;16&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Vested and expected to vest at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z4DWpWCjrpp6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Vested and expected to vest"&gt;3,961,525&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_z6uGximBcL7e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Vested and expected to vest"&gt;27.27&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zG1uF8gKqDjb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Contract Term, Vested and expected to vest"&gt;6.4&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zwzPVArM19v2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Vested and expected to vest"&gt;16&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zueTC5c1bAi9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Options Exercisable"&gt;2,586,561&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zI8ItzR1OnB8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;37.49&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pid_dtY_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zku2lDcJSgTg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Contract Term Exercisable"&gt;4.9&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_pn3n3_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember_zUGFYOScdgS" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Aggregate Intrinsic Value Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2736"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td id="xdx_F0F_zB4AoTlKrtr2" style="width: 15pt; text-align: right"&gt;*&lt;/td&gt;&lt;td id="xdx_F1D_zLXerFXny1Wc" style="text-align: justify"&gt;Options outstanding at December 31, 2024 under the 2021 Plan and 2017 Plan were &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zJXOtNTlcnPg" title="Options outstanding"&gt;2,569,029&lt;/span&gt; and
                                                                             &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zBXUGuFGvff8" title="Options outstanding"&gt;1,437,496&lt;/span&gt;, respectively. Options outstanding at December 31, 2024 under the 2021 Plan include &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_z1vLdctHuub8" title="Options outstanding including awards"&gt;45,000&lt;/span&gt; awards with performance
                                                                             conditions (see below).&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002694"
      unitRef="Shares">2820187</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002696"
      unitRef="USDPShares">40.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      id="Fact002698">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002702"
      unitRef="Shares">1503394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002704"
      unitRef="USDPShares">3.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002706"
      unitRef="Shares">20744</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002708"
      unitRef="USDPShares">2.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002710"
      unitRef="Shares">341312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002712"
      unitRef="USDPShares">29.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002714"
      unitRef="Shares">3961525</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002716"
      unitRef="USDPShares">27.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      id="Fact002718">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="-3"
      id="Fact002720"
      unitRef="USD">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002722"
      unitRef="Shares">3961525</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002724"
      unitRef="USDPShares">27.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      id="Fact002726">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="-3"
      id="Fact002728"
      unitRef="USD">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002730"
      unitRef="Shares">2586561</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      decimals="INF"
      id="Fact002732"
      unitRef="USDPShares">37.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-01-012024-12-31_custom_TwoThousandAndTwentyOneAndTwoThousandAndSeventeenEquityIncentivePlanMember"
      id="Fact002734">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-12-31_custom_TwoThousandTwentyOnePlanMember"
      decimals="INF"
      id="Fact002739"
      unitRef="Shares">2569029</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2024-12-31_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      id="Fact002741"
      unitRef="Shares">1437496</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-01-012024-12-31_custom_TwoThousandTwentyOnePlanMember"
      decimals="INF"
      id="Fact002743"
      unitRef="Shares">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember15566546"
      decimals="-3"
      id="Fact002745"
      unitRef="USD">8336000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_EmployeeStockOptionMember15566546"
      decimals="-3"
      id="Fact002747"
      unitRef="USD">9293000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact002749"
      unitRef="USD">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002751"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact002753"
      unitRef="USD">7129000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_us-gaap_EmployeeStockOptionMember15566546"
      id="Fact002755">P2Y1M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-08-162022-08-16_custom_AwardsWithPerformanceConditionsMember"
      decimals="INF"
      id="Fact002757"
      unitRef="Shares">105000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="From2022-08-162022-08-16_custom_AwardsWithPerformanceConditionsMember"
      decimals="INF"
      id="Fact002759"
      unitRef="USDPShares">29.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-08-162022-08-16_custom_AwardsWithPerformanceConditionsMember_custom_InitialTrancheMember"
      decimals="INF"
      id="Fact002761"
      unitRef="Shares">25000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-08-16_custom_AwardsWithPerformanceConditionsMember"
      decimals="INF"
      id="Fact002763"
      unitRef="Shares">80000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-11-012022-11-01_custom_AwardsWithPerformanceConditionsMember_custom_SecondTrancheMember"
      decimals="INF"
      id="Fact002765"
      unitRef="Shares">20000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-11-012022-11-01_custom_AwardsWithPerformanceConditionsMember"
      decimals="INF"
      id="Fact002767"
      unitRef="Pure">0.799</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-01-012024-12-31_custom_AwardsWithPerformanceConditionsMember"
      decimals="INF"
      id="Fact002769"
      unitRef="Pure">0.0295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2024-01-012024-12-31_custom_AwardsWithPerformanceConditionsMember"
      id="Fact002771">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-01-012024-12-31_custom_AwardsWithPerformanceConditionsMember"
      decimals="INF"
      id="Fact002773"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-08-162023-08-16_custom_AwardsWithPerformanceConditionsMember"
      decimals="INF"
      id="Fact002775"
      unitRef="Shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-12-31"
      decimals="0"
      id="Fact002777"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843"
      id="Fact002778">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="Fact002780"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002782">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zqTyDgwas09a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table summarizes
activity related to RSU stock-based payment awards under the 2021 Plan:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BC_zSXrC3ysNlUj" style="display: none"&gt;Schedule
of Activity Related to RSU Stock-Based Payment Awards&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;Number of&lt;/p&gt;
                                                                                &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;b&gt;Grant Date Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Outstanding at January 1, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zNALfbpj75qb" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Number of Shares, Outstanding beginning balance"&gt;823,332&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zytdOBicjFqk" style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right" title="Weighted Average Grant Date Fair Value,Outstanding beginning balance"&gt;13.77&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPpuztLsUrMk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted"&gt;337,080&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zqSxsnwAFd6a" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Granted"&gt;2.23&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;Released&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zb9ccMxJtKmc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Released"&gt;(400,996&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zaMY8zj0UKFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Grant Date Fair Value, Released"&gt;11.58&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1pt"&gt;Forfeited&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_iN_pid_di_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXrulQsvRS1b" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited"&gt;(99,977&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z09oFjThdPM6" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted Average Grant Date Fair Value, Forfeited"&gt;13.24&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zTMssxfDjrkd" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Outstanding ending balance"&gt;659,439&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zfIVN9J5UJud" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted Average Grant Date Fair Value, Outstanding ending balance"&gt;9.29&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002784"
      unitRef="Shares">823332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002786"
      unitRef="USDPShares">13.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843"
      decimals="INF"
      id="Fact002788"
      unitRef="Shares">337080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843"
      decimals="INF"
      id="Fact002790"
      unitRef="USDPShares">2.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843"
      decimals="INF"
      id="Fact002792"
      unitRef="Shares">400996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843"
      decimals="INF"
      id="Fact002794"
      unitRef="USDPShares">11.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843"
      decimals="INF"
      id="Fact002796"
      unitRef="Shares">99977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843"
      decimals="INF"
      id="Fact002798"
      unitRef="USDPShares">13.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002800"
      unitRef="Shares">659439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact002802"
      unitRef="USDPShares">9.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843"
      decimals="-3"
      id="Fact002804"
      unitRef="USD">3022000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_RestrictedStockUnitsRSUMember15566875"
      decimals="-3"
      id="Fact002806"
      unitRef="USD">5724000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-12-31_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact002808"
      unitRef="USD">4136000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-01-012024-12-31_us-gaap_RestrictedStockUnitsRSUMember15566843"
      id="Fact002810">P1Y5M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember"
      decimals="INF"
      id="Fact002812"
      unitRef="Shares">174500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember_srt_MinimumMember"
      id="Fact002813">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2023-07-012023-07-31_custom_MarketConditionStockUnitMember_srt_MaximumMember"
      id="Fact002814">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2024-12-31_custom_MarketConditionStockUnitMember"
      decimals="-3"
      id="Fact002815"
      unitRef="USD">145833000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_MarketConditionStockUnitMember"
      decimals="-3"
      id="Fact002816"
      unitRef="USD">28667000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-01-012024-12-31_custom_MarketConditionStockUnitMember"
      decimals="INF"
      id="Fact002818"
      unitRef="USDPShares">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-01-012024-12-31_custom_MarketConditionStockUnitMember"
      decimals="-3"
      id="Fact002820"
      unitRef="USD">211000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002822">&lt;p id="xdx_896_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zFenUch6J8Pg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company recorded stock-based
compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B8_zGrfAobJxpB1" style="display: none"&gt;Schedule
of Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231_zpCCS3OARQOk" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zlS3CHNW0iY7" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--CostOfSalesMember_zBJyVCyCdy3a" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Cost of revenues&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;450&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;580&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_z4xEVC9YXIW4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,287&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,832&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--SellingGeneralAndAdministrativeExpensesMember_zdpAFtrQkOKi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Selling, general and administrative&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;9,832&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,605&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z5JTi4sY6kU1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
    compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11,569&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,017&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="Fact002824"
      unitRef="USD">450000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_CostOfSalesMember"
      decimals="-3"
      id="Fact002825"
      unitRef="USD">580000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact002827"
      unitRef="USD">1287000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact002828"
      unitRef="USD">1832000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-012024-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact002830"
      unitRef="USD">9832000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact002831"
      unitRef="USD">12605000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact002833"
      unitRef="USD">11569000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002834"
      unitRef="USD">15017000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002836">&lt;p id="xdx_800_eus-gaap--RevenueFromContractWithCustomerTextBlock_z9mChV1hdOsd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;15. &lt;span id="xdx_82D_zCp4DW6FVf7b"&gt;Revenue Recognition&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_zROoRw6VM9Xh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table provides information
about disaggregated revenue by product and services:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BF_zt6RnZ0QmU8g" style="display: none"&gt;Schedule
of Disaggregated Revenue by Product and Services&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231_zdrQC8CKc5xl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zLt4mVa3r0qe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zEW9OaK2KmO9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Product sales, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;35,336&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;13,149&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zCj0kf6Hgt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Services&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,140&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,441&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_zH04zl1TXRIh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;License, royalty and other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,744&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,181&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zPX4N7a5iaJl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total revenues&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;54,220&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,771&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zHlJ8wyJqCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Net revenues include: (i) sales
of biomaterial products, including Biovance, Biovance 3L, Rebound, Interfyl, and CentaFlex, of which our direct sales are included in
Product Sales while sales through our network of distribution partners are included in License, royalty and other; and (ii) the collection,
processing and storage of umbilical cord and placental blood and tissue after full-term pregnancies, collectively, Services.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zxrUfkApAj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table provides changes
in deferred revenue from contract liabilities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&lt;span id="xdx_8B0_z6sEHbgyCuyb" style="display: none"&gt;Schedule of Changes in Deferred Revenue from Contract Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_zgcH59FHu7Hf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_z0aJk7FE0jFl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zpdE3pR8daW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Balance at January 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;6,020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;4,492&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zKWnLp2hTeXe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Beginning Balance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,492&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_pn3n3_z9cqP8P7KSz8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Deferral of revenue &lt;span id="xdx_F44_zlYoFHsrAbjb"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,731&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,266&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn3n3_zIryK7iBJilg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Recognition of unearned revenue &lt;span id="xdx_F49_z9a1Na1pz1L"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5,496&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,738&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zchUp2VJK0P9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance at December 31&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,255&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zRUhVhWBte6d" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Ending Balance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,255&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F06_zR7xVvRdZReb" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F14_zvoy2DxJ072b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferral
    of revenue includes $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DeferredRevenue_iI_pn3n3_c20241231_zbtl13DKTSt6"&gt;5,061&lt;/span&gt; in 2024 resulting from payments received in advance of performance under the biobanking services storage
    contracts that are recognized as revenue under the contract as performance is completed.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F00_z2KygN5bQh7d" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zil4UEkHihvf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognition
    of unearned revenue includes $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_ecustom--UnearnedRevenue_iI_pn3n3_c20241231_zQdD2DbYPnl6"&gt;2,561&lt;/span&gt; that was included in the beginning deferred revenue balance at January 1, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_zBrwprJACCh5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002838">&lt;p id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_zROoRw6VM9Xh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table provides information
about disaggregated revenue by product and services:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BF_zt6RnZ0QmU8g" style="display: none"&gt;Schedule
of Disaggregated Revenue by Product and Services&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231_zdrQC8CKc5xl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230101__20231231_zLt4mVa3r0qe" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ProductMember_zEW9OaK2KmO9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"&gt;Product sales, net&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;35,336&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;13,149&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__us-gaap--ServiceMember_zCj0kf6Hgt7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Services&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,140&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,441&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--LicenseRoyaltyAndOtherMember_zH04zl1TXRIh" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;License, royalty and other&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,744&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,181&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zPX4N7a5iaJl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total revenues&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;54,220&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;22,771&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_ProductMember"
      decimals="-3"
      id="Fact002840"
      unitRef="USD">35336000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_ProductMember"
      decimals="-3"
      id="Fact002841"
      unitRef="USD">13149000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_us-gaap_ServiceMember"
      decimals="-3"
      id="Fact002843"
      unitRef="USD">5140000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_us-gaap_ServiceMember"
      decimals="-3"
      id="Fact002844"
      unitRef="USD">5441000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_LicenseRoyaltyAndOtherMember"
      decimals="-3"
      id="Fact002846"
      unitRef="USD">13744000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_LicenseRoyaltyAndOtherMember"
      decimals="-3"
      id="Fact002847"
      unitRef="USD">4181000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact002849"
      unitRef="USD">54220000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002850"
      unitRef="USD">22771000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenueByArrangementDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002852">&lt;p id="xdx_891_eus-gaap--DeferredRevenueByArrangementDisclosureTextBlock_zxrUfkApAj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The following table provides changes
in deferred revenue from contract liabilities:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&lt;span id="xdx_8B0_z6sEHbgyCuyb" style="display: none"&gt;Schedule of Changes in Deferred Revenue from Contract Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: bold 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20241231_zgcH59FHu7Hf" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_z0aJk7FE0jFl" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zpdE3pR8daW9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 60%"&gt;Balance at January 1&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;6,020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"&gt;4,492&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iS_pn3n3_zKWnLp2hTeXe" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Beginning Balance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;4,492&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue_pn3n3_z9cqP8P7KSz8" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Deferral of revenue &lt;span id="xdx_F44_zlYoFHsrAbjb"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,731&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,266&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized_pn3n3_zIryK7iBJilg" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"&gt;Recognition of unearned revenue &lt;span id="xdx_F49_z9a1Na1pz1L"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(5,496&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(4,738&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zchUp2VJK0P9" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Balance at December 31&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,255&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ContractWithCustomerLiability_iE_pn3n3_zRUhVhWBte6d" style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;Ending Balance&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,255&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;6,020&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span id="xdx_F06_zR7xVvRdZReb" style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F14_zvoy2DxJ072b" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferral
    of revenue includes $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_908_eus-gaap--DeferredRevenue_iI_pn3n3_c20241231_zbtl13DKTSt6"&gt;5,061&lt;/span&gt; in 2024 resulting from payments received in advance of performance under the biobanking services storage
    contracts that are recognized as revenue under the contract as performance is completed.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_F00_z2KygN5bQh7d" style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span id="xdx_F1B_zil4UEkHihvf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognition
    of unearned revenue includes $&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_907_ecustom--UnearnedRevenue_iI_pn3n3_c20241231_zQdD2DbYPnl6"&gt;2,561&lt;/span&gt; that was included in the beginning deferred revenue balance at January 1, 2024.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:DeferredRevenueByArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002854"
      unitRef="USD">6020000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact002855"
      unitRef="USD">4492000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002857"
      unitRef="USD">6020000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact002858"
      unitRef="USD">4492000</us-gaap:ContractWithCustomerLiability>
    <CELU:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact002860"
      unitRef="USD">5731000</CELU:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue>
    <CELU:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002861"
      unitRef="USD">6266000</CELU:ContractWithCustomerLiabilityIncreaseDecreaseForContractFromBusinessCombinationAndDeferredRevenue>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact002863"
      unitRef="USD">-5496000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002864"
      unitRef="USD">-4738000</us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002866"
      unitRef="USD">6255000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002867"
      unitRef="USD">6020000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002869"
      unitRef="USD">6255000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002870"
      unitRef="USD">6020000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002872"
      unitRef="USD">5061000</us-gaap:DeferredRevenue>
    <CELU:UnearnedRevenue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002874"
      unitRef="USD">2561000</CELU:UnearnedRevenue>
    <CELU:LicenseAndDistributionAgreementsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002876">&lt;p id="xdx_806_ecustom--LicenseAndDistributionAgreementsTextBlock_zdTgqvdlL5Mk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;16. &lt;span id="xdx_827_z0FFb1lSaFL6"&gt;License and Distribution Agreements&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sequence LifeScience, Inc. Independent Distribution
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 27.15pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On August 23, 2024, the Company
entered into an Independent Distributor Agreement (the &#x201c;Distribution Agreement&#x201d;) with Sequence LifeScience, Inc. (&#x201c;Sequence&#x201d;),
which provided the Company exclusive rights to market, sell and distribute Rebound&lt;sup&gt;TM&lt;/sup&gt;, a full thickness placental-derived allograft
matrix product, in the U.S. for a period of ninety (90) days. Under the terms of the Distribution Agreement, Sequence made Rebound available
for purchase to the Company at a fixed price consistent with market terms. The Distribution Agreement was intended to be a bridge to allow
the parties to cooperatively market the product prior to consummating an asset purchase agreement. The Company acquired Rebound on October
9, 2024, through an asset purchase agreement with Sequence. See Note 3 for more information about the Rebound asset purchase.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Regeneron Research Collaboration Services Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On August 25, 2023, the Company
entered into a multi-year research collaboration services agreement with Regeneron Pharmaceuticals, Inc. (&#x201c;Regeneron&#x201d;), pursuant
to which the Company will support the research effort of Regeneron&#x2019;s allogeneic cell therapy candidates (the &#x201c;Regeneron Services
Agreement&#x201d;). The Regeneron Services Agreement&#x2019;s initial focus is the research on a targeted allogeneic gamma delta chimeric
antigen receptor (CAR) T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. Payments
to the Company under the Regeneron Services Agreement included a non-refundable up-front payment of $&lt;span id="xdx_900_ecustom--NonrefundableUpfrontPayment_pn3n3_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_zrVgzXoUiyc6" title="Nonrefundable up-front payment"&gt;750&lt;/span&gt; and payments based upon the achievement
of defined milestones according to written statements of work. The Regeneron Services Agreement will expire &lt;span id="xdx_904_ecustom--ServiceAgreementTerm_dc_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_z3OGOBmFS3J9" title="Service agreement term"&gt;five years&lt;/span&gt; from the effective
date and may be terminated immediately by either party for the uncured material breach, bankruptcy, or insolvency of the other party.
Regeneron may also terminate for convenience upon &lt;span id="xdx_901_ecustom--LicenseAgreementNoticePeriod_dtD_c20230825__20230825__us-gaap--TypeOfArrangementAxis__custom--RegeneronResearchCollaborationServicesAgreementMember_zTGlJd6Q5vib" title="License agreement notice period"&gt;30&lt;/span&gt; days&#x2019; written notice.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Regeneron Services Agreement
grants Regeneron a royalty-free, fully-paid up, worldwide, non-exclusive license, with the right to grant sublicenses, to the Company&#x2019;s
intellectual property (&#x201c;IP&#x201d;) to the extent that any such license is necessary for Regeneron to fully use the Company&#x2019;s
research services. The Company determined that the (1) research licenses and (2) the research activities performed by the Company represent
a single combined performance obligation under the Regeneron Services Agreement. The Company determined that Regeneron cannot benefit
from the licenses separately from the research activities because these services are specialized and rely on the Company&#x2019;s expertise
such that these activities are highly interrelated and therefore not distinct. Accordingly, the promised goods and services represent
one combined performance obligation and the entire transaction price was allocated to that single combined performance obligation. The
performance obligation will be satisfied over the research term as the Company performs the research activities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;As of December 31, 2024, the Company
received payments totaling $&lt;span id="xdx_905_eus-gaap--DeferredRevenueRevenueRecognized1_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--RegeneronServicesAgreementMember_zCERV8PWfpuf" title="Received payments"&gt;1,325&lt;/span&gt; under the Regeneron Services Agreement, of which $&lt;span id="xdx_90A_eus-gaap--Revenues_pn3n3_c20241001__20241231__us-gaap--TypeOfArrangementAxis__custom--RegeneronServicesAgreementMember_z1gJR610XnPa" title="Revenues"&gt;688&lt;/span&gt; was recognized in revenue during the fourth quarter
of 2024 based on achievement of defined milestones. As of December 31, 2024, the remaining $&lt;span id="xdx_90E_eus-gaap--DeferredRevenue_iI_pn3n3_c20241231__us-gaap--TypeOfArrangementAxis__custom--RegeneronServicesAgreementMember_zghB0gSjHUHe" title="Deferred Revenue"&gt;637&lt;/span&gt; was recorded as deferred revenue to be
recognized based on satisfaction of future performance obligations. The Company recognizes revenue using the cost-to-cost method, which
it believes best depicts the transfer of control to the customer over time. Under the cost-to-cost method, the extent of progress towards
completion is measured based on the ratio of actual costs incurred to the total estimated costs expected upon satisfying the identified
performance obligation. Under this method, revenue is recorded as a percentage of the estimated transaction price based on the extent
of progress towards completion.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Sorrento Therapeutics, Inc. License and Transfer
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The Company and Sorrento Therapeutics,
Inc. (&#x201c;Sorrento&#x201d;), a related party through September 30, 2023, are party to a License and Transfer Agreement for the exclusive
worldwide license to CD19 CAR-T constructs for use in placenta-derived cells and/or cord blood-derived cells for the treatment of any
disease or disorder (the &#x201c;2020 Sorrento License Agreement&#x201d;). The Company retains the right to sublicense the rights granted
under the agreement with Sorrento&#x2019;s prior written consent. As consideration for the license, the Company is obligated to pay Sorrento
a royalty equal to low single-digit percentage of net sales (as defined within the agreement) and a royalty equal to low double-digit
percentage of all sublicensing revenues (as defined within the agreement). The 2020 Sorrento License Agreement will remain in effect until
terminated by either the Company or Sorrento for uncured material breach upon 90 days written notice or, after the first anniversary of
the effective date of the 2020 Sorrento License Agreement, by the Company for convenience upon six months&#x2019; written notice to Sorrento.
On October 19, 2023, Sorrento filed a Plan of Reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court
for the Southern District of Texas which plan contemplates a liquidation of the debtor. If the Plan is confirmed by the Bankruptcy Court,
the Company believes that Sorrento will not be able to perform under the license and that any rights the Company might have under the
license would be unenforceable. After assessing the status of the IND to determine an optional path forward for the program, the Company
elected to terminate development of CYCART-19 for B-cell malignancies during the third quarter of 2023. The Company may continue pre-clinical
development of other T-cell candidates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"&gt;&lt;b&gt;&lt;i&gt;Genting Innovation PTE LTD Distribution Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On May 4, 2018, concurrently with
Dragasac&#x2019;s equity investment in Legacy Celularity, Legacy Celularity entered into a distribution agreement with Genting Innovation
PTE LTD (&#x201c;Genting Innovation&#x201d;) pursuant to which Genting Innovation was granted supply and distribution rights to certain
Company products in select Asia markets (the &#x201c;Genting Agreement&#x201d;). The Genting Agreement granted Genting Innovation limited
distribution rights to the Company&#x2019;s then-current portfolio of degenerative disease products and provides for the automatic rights
to future products developed by or on behalf of the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;The term of the Genting Agreement
was renewed on January 31, 2023, and automatically renews for successive 12 month terms unless: Genting provides written notice of its
intention not to renew at least three months prior to a renewal term or the Genting Agreement is otherwise terminated by either party
for cause.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;Genting Innovation and Dragasac
are both direct subsidiaries of Genting Berhad, a public limited liability company incorporated and domiciled in Malaysia.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On June 14, 2023, the Genting
Agreement was amended and restated to include manufacturing rights in the territories covered under the agreement, expansion to two new
countries, and a commitment by the Company to provide technology transfer pursuant to the plan established by a Joint Steering Committee.
On January 17, 2024, the Company further amended the Genting Agreement to include distribution and manufacturing rights to certain of
the Company&#x2019;s cell therapy products, including PSC-100, PDA-001, PDA-002, pEXO-001, APPL-001 and CYNK-001. As of December 31, 2024,
the Company has not recognized any revenue under the Genting Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Celgene
Corporation License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is party to a license agreement with Celgene (the &#x201c;Celgene Agreement&#x201d;) pursuant to which the Company granted Celgene
two separate licenses to certain intellectual property. The Celgene Agreement grants Celgene a royalty-free, fully-paid up, worldwide,
non-exclusive license to the certain intellectual property (&#x201c;IP&#x201d;) for pre-clinical research purposes in all fields and a
royalty-free, fully-paid up, worldwide license, with the right to grant sublicenses, for the development, manufacture, commercialization
and exploitation of products in the field of the construction of any CAR, the modification of any T-lymphocyte or NK cell to express
such a CAR, and/or the use of such CARs or T-lymphocytes or NK cells for any purpose, including prophylactic, diagnostic, and/or therapeutic
uses thereof. The Celgene Agreement will remain in effect until its termination by either party for cause&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Pulthera,
LLC Binding Term Sheet&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Concurrent
with the entry into the securities purchase agreement for the March 2023 private placement described in Note 13 above, the Company executed
a binding term sheet to negotiate and enter into a sublicense agreement of certain assets from an affiliate of Pulthera, LLC (the &#x201c;sublicensor&#x201d;).
Pursuant to the binding term sheet, the Company paid the sublicensor a $&lt;span id="xdx_901_ecustom--PaymentOfOptionFeeInCash_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember_zp0MPzqwCgZc" title="Payment of option fee in cash"&gt;3,000&lt;/span&gt; option fee in cash and issued $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzcLYNEd0blj" title="Issuance of common stock"&gt;1,000&lt;/span&gt; of shares of its Class
A common stock (&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230317__20230317__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcvKqHcxYuJ4" title="Purchase and sale of shares"&gt;169,492&lt;/span&gt; shares based on the closing price on March 17, 2023) as consideration for stem-cells inventory to be used in
research and development. The option fee paid by the Company will be applied towards an initial license fee as outlined in the sublicense
agreement. The Company is required to use diligent and reasonable efforts to develop and obtain regulatory approval to market at least
one licensed product contingent upon a firm written commitment to provide further financing to the Company. The $&lt;span id="xdx_905_ecustom--OptionFeeExpense_pn3n3_c20230317__20230317__us-gaap--TypeOfArrangementAxis__custom--PultheraLLCBindingTermSheetMember__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zPNvr80kRnhj" title="Option fee expense"&gt;3,000&lt;/span&gt; option fee was
recorded as acquired IPR&amp;amp;D expense included in research and development expense on the consolidated statements of operations and
comprehensive loss for the year ended December 31, 2023, as the acquired IPR&amp;amp;D had no alternative future use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;License
Agreement with BioCellgraft, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 11, 2023, the Company and BioCellgraft, Inc. (&#x201c;BioCellgraft&#x201d;) entered into a license agreement whereby the
Company granted an exclusive license to BioCellgraft, with the right to sublicense, to develop and commercialize certain licensed
products to the dental market in the United States over an initial four&lt;span id="xdx_90F_ecustom--CommercialLicenseToDentalProductsAgreementPeriod_dtY_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zVuYnNlGRql8" style="display: none" title="Commercial license"&gt;4&lt;/span&gt;
year term and it will automatically renew for an additional &lt;span id="xdx_905_ecustom--CommercialLicenseToDentalProductsAgreementRenewalTerm_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_z5dDGyQAJHN" title="Commercial license to dental products agreement renewal term"&gt;two
years&lt;/span&gt; unless either party provides written notice of termination. BioCellgraft will pay to the Company total license fees of
$&lt;span id="xdx_901_ecustom--LicenseFeeExpense_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zDf81aDSIRik" title="License fee expense"&gt;5,000&lt;/span&gt;
over a &lt;span id="xdx_909_ecustom--LicenseFeesPaymentPeriod_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_z9jRDWxxAdMk" title="License fees payment period"&gt;two
year&lt;/span&gt; period, as defined. Upon execution of the agreement, the Company received a $&lt;span id="xdx_902_ecustom--LicenseFeePayment_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zI7buGLLxO5f" title="License fee payment"&gt;300&lt;/span&gt;
payment towards the first year payment. To date, the Company has not received any additional consideration beyond the $&lt;span id="xdx_904_ecustom--AdditionalLicenseFee_pn3n3_c20231211__20231211__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementWithBiocellgraftIncMember_zavzXl2EEc2b" title="Additional license fee"&gt;300&lt;/span&gt; license payment under the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</CELU:LicenseAndDistributionAgreementsTextBlock>
    <CELU:NonrefundableUpfrontPayment
      contextRef="From2023-08-252023-08-25_custom_RegeneronResearchCollaborationServicesAgreementMember"
      decimals="-3"
      id="Fact002878"
      unitRef="USD">750000</CELU:NonrefundableUpfrontPayment>
    <CELU:ServiceAgreementTerm
      contextRef="From2023-08-252023-08-25_custom_RegeneronResearchCollaborationServicesAgreementMember"
      id="Fact002880">P5Y</CELU:ServiceAgreementTerm>
    <CELU:LicenseAgreementNoticePeriod
      contextRef="From2023-08-252023-08-25_custom_RegeneronResearchCollaborationServicesAgreementMember"
      id="Fact002882">P30D</CELU:LicenseAgreementNoticePeriod>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="From2024-01-012024-12-31_custom_RegeneronServicesAgreementMember"
      decimals="-3"
      id="Fact002884"
      unitRef="USD">1325000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:Revenues
      contextRef="From2024-10-012024-12-31_custom_RegeneronServicesAgreementMember"
      decimals="-3"
      id="Fact002886"
      unitRef="USD">688000</us-gaap:Revenues>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2024-12-31_custom_RegeneronServicesAgreementMember"
      decimals="-3"
      id="Fact002888"
      unitRef="USD">637000</us-gaap:DeferredRevenue>
    <CELU:PaymentOfOptionFeeInCash
      contextRef="From2023-01-012023-12-31_custom_PultheraLLCBindingTermSheetMember"
      decimals="-3"
      id="Fact002890"
      unitRef="USD">3000000</CELU:PaymentOfOptionFeeInCash>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_custom_PultheraLLCBindingTermSheetMember_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact002892"
      unitRef="USD">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-03-172023-03-17_custom_PultheraLLCBindingTermSheetMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact002894"
      unitRef="Shares">169492</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <CELU:OptionFeeExpense
      contextRef="From2023-03-172023-03-17_custom_PultheraLLCBindingTermSheetMember_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact002896"
      unitRef="USD">3000000</CELU:OptionFeeExpense>
    <CELU:CommercialLicenseToDentalProductsAgreementPeriod
      contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember"
      id="Fact002898">P4Y</CELU:CommercialLicenseToDentalProductsAgreementPeriod>
    <CELU:CommercialLicenseToDentalProductsAgreementRenewalTerm
      contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember"
      id="Fact002900">P2Y</CELU:CommercialLicenseToDentalProductsAgreementRenewalTerm>
    <CELU:LicenseFeeExpense
      contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember"
      decimals="-3"
      id="Fact002902"
      unitRef="USD">5000000</CELU:LicenseFeeExpense>
    <CELU:LicenseFeesPaymentPeriod
      contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember"
      id="Fact002904">P2Y</CELU:LicenseFeesPaymentPeriod>
    <CELU:LicenseFeePayment
      contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember"
      decimals="-3"
      id="Fact002906"
      unitRef="USD">300000</CELU:LicenseFeePayment>
    <CELU:AdditionalLicenseFee
      contextRef="From2023-12-112023-12-11_custom_LicenseAgreementWithBiocellgraftIncMember"
      decimals="-3"
      id="Fact002908"
      unitRef="USD">300000</CELU:AdditionalLicenseFee>
    <us-gaap:DefinedBenefitPlanTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002910">&lt;p id="xdx_80A_eus-gaap--DefinedBenefitPlanTextBlock_zXS3pxKshPif" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;17.
&lt;span id="xdx_827_zNftIQHdsuC7"&gt;Benefit Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. This plan covers all
employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a
pre-tax basis. Matching contributions to the plan may be made at the discretion of the Company&#x2019;s board of directors. During
the years ended December 31, 2024 and 2023, the Company made contributions of &lt;span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20240101__20241231_zdfqdFxpxFPc" title="Contributions made to the plan"&gt;$139&lt;/span&gt;
and $&lt;span id="xdx_906_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_pn3n3_c20230101__20231231_zAkawPEAlzq4" title="Contributions made to the plan"&gt;198&lt;/span&gt;,
respectively. During the year ended December 31, 2022, the Company accrued $1,159 but
has not made the matching contribution to the plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DefinedBenefitPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact002912"
      unitRef="USD">139000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002914"
      unitRef="USD">198000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002916">&lt;p id="xdx_808_eus-gaap--IncomeTaxDisclosureTextBlock_zDQcziwyEVpe" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;18.
&lt;span id="xdx_821_zblnKLZ3FlZ7"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z3M0NuN8Cwh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s current and deferred tax provision is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BC_zsHdMHqJd9v2" style="display: none"&gt;Schedule
of Current and Deferred Tax Provision&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_z0e9IhQQ7L64" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zhtwx24pxe87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current income tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzRNM_zI2maAw2fDNb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2920"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2921"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzRNM_zK6Vep8cO504" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; width: 62%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 15%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2923"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 15%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzRNM_maITEBzV7j_zQ0IhocEGkLb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2926"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred income tax expense
    (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDFSALzhM1_zmBbGExPym8b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDFSALzhM1_zvr8Jt4Pjd1e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_pn3n3_mtDFSALzhM1_maITEBzV7j_zjJeOyoGOYj3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2935"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2936"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzV7j_z7w27h2KP5Cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2938"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zfLXsvzyS3R5" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUgOlIqXjr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BD_zsLPthYADiCf" style="display: none"&gt;Schedule
of Reconciliation of the U.S &#160;federal statutory income tax&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231_zIdyspTUrI7e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zPxflrFiO1yk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zOJd785Svxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Federal statutory income tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zy0opPxbvWu3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;State income taxes, net of federal benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_pid_dp_uPure_maABC_zkQCKuYaPwfl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Interest accretion expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zyWyox63eEFh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_pid_dp_uPure_maABC_zmnevfawRT1f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Mark to market warrant&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2955"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueUp_pid_dp_uPure_maABC_z2aTJcj9tgo9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_maABC_zY4hNHLT3E3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt"&gt;Impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2961"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maABC_zfCjhXbNEKsd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other permanent items&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_zeWtlL2hemk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2967"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2968"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zlAHjbUu4jy" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zi4QXOddxo86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
deferred income tax liabilities as of December 31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BB_zds472WMQSuh" style="display: none"&gt;Schedule
of Deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_z9xT3qbgUaR" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_zHCNmkSzn9u7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzt0C_zhpy46YqYn3d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; width: 62%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;121,804&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;109,544&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_iI_pn3n3_maDTAGzt0C_zk5UBaetBOUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzt0C_zm4MVrbOMqyc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxAssetsStartupCosts_iI_pn3n3_maDTAGzt0C_z0NT2rqjyJ6e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Startup costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzt0C_z1UrxDPPExS1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_maDTAGzt0C_z91X2XbqNxc6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxAssetsUnicap_iI_pn3n3_maDTAGzt0C_zLqVzXBNyxwk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt"&gt;Unicap&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DeferredTaxAssetsImputedInterestOnContingentPayments_iI_pn3n3_maDTAGzt0C_zVlS9nBr0tni" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Imputed interest on contingent payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_iI_pn3n3_maDTAGzt0C_ztssh3ZI7SO9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Legal fee capitalization and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopment_iI_pn3n3_maDTAGzt0C_zFYvavF3XMna" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsIrcSectionInterest_iI_pn3n3_maDTAGzt0C_ztuSB1QKAfYf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;IRC Section 163j interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1,471&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3003"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzt0C_zT1EZe8s2U0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,755&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,751&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzt0C_msDTLz2tA_zsDbjdal1e1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 20pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLz2tA_zyXNPfWiCFPf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(181,416&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(169,797&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_mtDTLz2tA_z7zamQdTwQEf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_z5fwHJ1DgCy5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zPIXQ5CkpcV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span id="xdx_8B5_z1hwNIxNUSgd" style="display: none"&gt;Schedule
of Unrecognized Tax&#160;Benefits&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unrecognized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Tax Benefits&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 81%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20230101__20231231_zBSXdntP5td8" style="width: 15%; text-align: right" title="Balance beginning"&gt;1,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt"&gt;Decrease related to current year tax provision&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_iN_pn3n3_di_c20230101__20231231_zmnL1nNWgZej" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3021"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20240101__20241231_zXIYdJT8wvY1" style="text-align: right" title="Balance beginning"&gt;1,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt"&gt;Decrease related to current year tax provision&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_pn3n3_c20240101__20241231_zonEQghkWPml" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3025"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20240101__20241231_zDdvDxShsZVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"&gt;1,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_ziaga27DDco7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company had U.S. federal and state net operating loss carryforwards of $&lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_ziDmdJeQCBY2" title="Net operating loss carryforwards"&gt;121,804&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--OperatingLossCarryforwards_iI_pn3n3_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zVXgNipR6lu1" title="Net operating loss carryforwards"&gt;109,544&lt;/span&gt;, respectively,
which may be available to offset future taxable income and begin to expire in &lt;span id="xdx_906_ecustom--OperatingLossCarryforwardsExpirationYear_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zUSFUR0TXuD6" title="Operating loss carryforwards expiration year"&gt;2040&lt;/span&gt;. As of December 31, 2024 and 2023, the Company also
had U.S. federal and state research and development tax credit carryforwards of $&lt;span id="xdx_90D_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_c20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zIgos4UtZTj5" title="Tax credit carryforwards"&gt;&lt;span id="xdx_90E_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3n3_c20231231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zz64ZTRvZZc3" title="Tax credit carryforwards"&gt;5,674&lt;/span&gt;&lt;/span&gt;, which may be available to offset future tax liabilities
and begin to expire in &lt;span id="xdx_901_ecustom--TaxCreditCarryforwardsExpirationYear_c20240101__20241231__us-gaap--IncomeTaxAuthorityAxis__custom--UnitedStatesFederalAndStateMember_zpFztl0uagQc" title="Tax credit carryforwards expiration year"&gt;2032&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Utilization
of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to
an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due
to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of
carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change, as defined
by Section 382, results from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than
50% over a three-year period. A corporation that experiences an ownership change is subject to an annual limitation under Section 382,
which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable
long-term tax-exempt rate subject to additional adjustments, as required. The Company experienced an ownership change on August 15, 2017.
The annual limitation from the ownership change is not expected to result in the expiration of net operating losses or research and development
credits before utilization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
realization of deferred tax assets is dependent upon the Company&#x2019;s ability to generate taxable income in future years. ASC 740-10,
&lt;i&gt;Income Taxes,&lt;/i&gt; requires a valuation allowance to be applied against deferred tax assets when it is considered &#x201c;more likely
than not&#x201d; that some or all of the gross deferred tax assets will not be realized. The Company considers all available positive
and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies,
and recent financial performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
December 31, 2024, based upon the weight of available evidence, the Company concluded that it is not more likely than not that the
benefits of the federal and state deferred tax assets will be realized. Accordingly, the Company has recorded a valuation allowance
against its federal and state gross deferred tax assets. The valuation allowance increased by $&lt;span id="xdx_909_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20240101__20241231_zfhL2wkih1p2" title="Valuation allowance increased amount"&gt;11,619&lt;/span&gt;
and $&lt;span id="xdx_901_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn3n3_c20230101__20231231_zXaeuFAfY6E" title="Valuation allowance increased amount"&gt;39,272&lt;/span&gt; during the years ended December 31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
impact of an uncertain income tax position is recognized at the largest amount that is &#x201c;more likely than not&#x201d; to be sustained
upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of
being sustained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2024 and 2023, the Company had gross unrecognized tax benefits of $&lt;span id="xdx_908_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_c20241231_zfS5TTMtMjm" title="Unrecognized tax benefits"&gt;&lt;span id="xdx_90D_eus-gaap--UnrecognizedTaxBenefits_iI_pn3n3_c20231231_zJ4oHnG87CG6" title="Unrecognized tax benefits"&gt;1,028&lt;/span&gt;&lt;/span&gt;. The Company does not expect that there will
be a significant change in the unrecognized tax benefits over the next 12 months. The Company&#x2019;s policy is to record interest and
penalties related to income taxes as part of its income tax provision. As of December 31, 2024 and 2023, the Company had &lt;span id="xdx_90E_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20241231_zprHYbbMtRI3" title="Interest accrued"&gt;&lt;span id="xdx_904_eus-gaap--UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_iI_do_c20231231_zbdimWnO0gbl" title="Interest accrued"&gt;no&lt;/span&gt;&lt;/span&gt; accrued interest
or penalties related to uncertain tax positions and no amounts had been recognized in the Company&#x2019;s consolidated statements of
operations and comprehensive loss. The Company files income tax returns in the U.S. and numerous states, as prescribed by the tax laws
of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state
jurisdictions, where applicable. There are currently no pending tax examinations. The Company is open to future tax examination under
statute from 2019 to the present; however, carryforward attributes that were acquired may still be adjusted upon examination by federal,
state or local tax authorities if they either have been or will be used in a future period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002918">&lt;p id="xdx_89B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z3M0NuN8Cwh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of the Company&#x2019;s current and deferred tax provision is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BC_zsHdMHqJd9v2" style="display: none"&gt;Schedule
of Current and Deferred Tax Provision&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20240101__20241231_z0e9IhQQ7L64" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230101__20231231_zhtwx24pxe87" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Current income tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzRNM_zI2maAw2fDNb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2920"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2921"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzRNM_zK6Vep8cO504" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; width: 62%; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 15%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2923"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 15%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzRNM_maITEBzV7j_zQ0IhocEGkLb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    current income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2926"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred income tax expense
    (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDFSALzhM1_zmBbGExPym8b" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDFSALzhM1_zvr8Jt4Pjd1e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefit_iT_pn3n3_mtDFSALzhM1_maITEBzV7j_zjJeOyoGOYj3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    deferred tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2935"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2936"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzV7j_z7w27h2KP5Cb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2938"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002924"
      unitRef="USD">10000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002927"
      unitRef="USD">10000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact002929"
      unitRef="USD">1000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002930"
      unitRef="USD">1000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact002932"
      unitRef="USD">-1000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002933"
      unitRef="USD">-1000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact002939"
      unitRef="USD">10000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002941">&lt;p id="xdx_898_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zUgOlIqXjr8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BD_zsLPthYADiCf" style="display: none"&gt;Schedule
of Reconciliation of the U.S &#160;federal statutory income tax&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20240101__20241231_zIdyspTUrI7e" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_zPxflrFiO1yk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maABC_zOJd785Svxuf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 62%; text-align: left"&gt;Federal statutory income tax rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maABC_zy0opPxbvWu3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;State income taxes, net of federal benefits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1.3&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationInterestAccretionExpense_pid_dp_uPure_maABC_zkQCKuYaPwfl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Interest accretion expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11.0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maABC_zyWyox63eEFh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Change in valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant_pid_dp_uPure_maABC_zmnevfawRT1f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Mark to market warrant&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2955"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--EffectiveIncomeTaxRateReconciliationDeferredTrueUp_pid_dp_uPure_maABC_z2aTJcj9tgo9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Deferred true-up&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2.4&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_pid_dp_uPure_maABC_zY4hNHLT3E3a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt"&gt;Impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2961"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(12.0&lt;/td&gt;&lt;td style="text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_pid_dp_uPure_maABC_zfCjhXbNEKsd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt"&gt;Other permanent items&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.4&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;0.5&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtABC_zeWtlL2hemk7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2967"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2968"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002943"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002944"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002946"
      unitRef="Pure">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002947"
      unitRef="Pure">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <CELU:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002949"
      unitRef="Pure">0.001</CELU:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense>
    <CELU:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002950"
      unitRef="Pure">0.110</CELU:EffectiveIncomeTaxRateReconciliationInterestAccretionExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002952"
      unitRef="Pure">-0.201</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002953"
      unitRef="Pure">-0.200</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <CELU:EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002956"
      unitRef="Pure">0.005</CELU:EffectiveIncomeTaxRateReconciliationMarkToMarketWarrant>
    <CELU:EffectiveIncomeTaxRateReconciliationDeferredTrueUp
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002958"
      unitRef="Pure">-0.001</CELU:EffectiveIncomeTaxRateReconciliationDeferredTrueUp>
    <CELU:EffectiveIncomeTaxRateReconciliationDeferredTrueUp
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002959"
      unitRef="Pure">-0.024</CELU:EffectiveIncomeTaxRateReconciliationDeferredTrueUp>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002962"
      unitRef="Pure">-0.120</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact002964"
      unitRef="Pure">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2023-01-012023-12-31"
      decimals="INF"
      id="Fact002965"
      unitRef="Pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact002970">&lt;p id="xdx_896_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zi4QXOddxo86" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net
deferred income tax liabilities as of December 31, 2024 and 2023 consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8BB_zds472WMQSuh" style="display: none"&gt;Schedule
of Deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20241231_z9xT3qbgUaR" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231_zHCNmkSzn9u7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzt0C_zhpy46YqYn3d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; width: 62%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;121,804&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 15%; text-align: right"&gt;109,544&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_iI_pn3n3_maDTAGzt0C_zk5UBaetBOUl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,674&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pn3n3_maDTAGzt0C_zm4MVrbOMqyc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Stock-based compensation expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxAssetsStartupCosts_iI_pn3n3_maDTAGzt0C_z0NT2rqjyJ6e" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Startup costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;498&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzt0C_z1UrxDPPExS1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,442&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsDeferredIncome_iI_pn3n3_maDTAGzt0C_z91X2XbqNxc6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,441&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxAssetsUnicap_iI_pn3n3_maDTAGzt0C_zLqVzXBNyxwk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt"&gt;Unicap&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--DeferredTaxAssetsImputedInterestOnContingentPayments_iI_pn3n3_maDTAGzt0C_zVlS9nBr0tni" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Imputed interest on contingent payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DeferredTaxAssetsLegalFeeCapitalizationAndAmortization_iI_pn3n3_maDTAGzt0C_ztssh3ZI7SO9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Legal fee capitalization and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,053&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopment_iI_pn3n3_maDTAGzt0C_zFYvavF3XMna" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;Capitalized research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,903&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;26,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--DeferredTaxAssetsIrcSectionInterest_iI_pn3n3_maDTAGzt0C_ztuSB1QKAfYf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left"&gt;IRC Section 163j interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1,471&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3003"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzt0C_zT1EZe8s2U0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 10pt; padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;5,755&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,751&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzt0C_msDTLz2tA_zsDbjdal1e1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 20pt; text-align: left"&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181,407&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;169,788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_maDTLz2tA_zyXNPfWiCFPf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 20pt; text-align: left; padding-bottom: 1pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(181,416&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(169,797&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxLiabilities_iNTI_pn3n3_di_mtDTLz2tA_z7zamQdTwQEf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 20pt; text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002972"
      unitRef="USD">121804000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002973"
      unitRef="USD">109544000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <CELU:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002975"
      unitRef="USD">5674000</CELU:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <CELU:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002976"
      unitRef="USD">5674000</CELU:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002978"
      unitRef="USD">17717000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002979"
      unitRef="USD">16539000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <CELU:DeferredTaxAssetsStartupCosts
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002981"
      unitRef="USD">431000</CELU:DeferredTaxAssetsStartupCosts>
    <CELU:DeferredTaxAssetsStartupCosts
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002982"
      unitRef="USD">498000</CELU:DeferredTaxAssetsStartupCosts>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002984"
      unitRef="USD">3028000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002985"
      unitRef="USD">3442000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002987"
      unitRef="USD">1469000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002988"
      unitRef="USD">1441000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <CELU:DeferredTaxAssetsUnicap
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002990"
      unitRef="USD">5000</CELU:DeferredTaxAssetsUnicap>
    <CELU:DeferredTaxAssetsUnicap
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002991"
      unitRef="USD">5000</CELU:DeferredTaxAssetsUnicap>
    <CELU:DeferredTaxAssetsImputedInterestOnContingentPayments
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002993"
      unitRef="USD">97000</CELU:DeferredTaxAssetsImputedInterestOnContingentPayments>
    <CELU:DeferredTaxAssetsImputedInterestOnContingentPayments
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002994"
      unitRef="USD">110000</CELU:DeferredTaxAssetsImputedInterestOnContingentPayments>
    <CELU:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002996"
      unitRef="USD">1053000</CELU:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization>
    <CELU:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact002997"
      unitRef="USD">1171000</CELU:DeferredTaxAssetsLegalFeeCapitalizationAndAmortization>
    <CELU:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact002999"
      unitRef="USD">22903000</CELU:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <CELU:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact003000"
      unitRef="USD">26613000</CELU:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <CELU:DeferredTaxAssetsIrcSectionInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact003002"
      unitRef="USD">1471000</CELU:DeferredTaxAssetsIrcSectionInterest>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact003005"
      unitRef="USD">5755000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact003006"
      unitRef="USD">4751000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact003008"
      unitRef="USD">181407000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact003009"
      unitRef="USD">169788000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact003011"
      unitRef="USD">181416000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact003012"
      unitRef="USD">169797000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact003014"
      unitRef="USD">9000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact003015"
      unitRef="USD">9000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact003017">&lt;p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_zPIXQ5CkpcV5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the beginning and ending amounts of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&lt;span id="xdx_8B5_z1hwNIxNUSgd" style="display: none"&gt;Schedule
of Unrecognized Tax&#160;Benefits&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Unrecognized&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Tax Benefits&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 81%"&gt;Balance at January 1, 2023&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20230101__20231231_zBSXdntP5td8" style="width: 15%; text-align: right" title="Balance beginning"&gt;1,028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt"&gt;Decrease related to current year tax provision&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_iN_pn3n3_di_c20230101__20231231_zmnL1nNWgZej" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3021"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at December 31, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--UnrecognizedTaxBenefits_iS_pn3n3_c20240101__20241231_zXIYdJT8wvY1" style="text-align: right" title="Balance beginning"&gt;1,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-indent: 10pt; text-align: left; padding-bottom: 1pt"&gt;Decrease related to current year tax provision&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_pn3n3_c20240101__20241231_zonEQghkWPml" style="border-bottom: Black 1pt solid; text-align: right" title="Decrease related to current year tax provisions"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3025"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--UnrecognizedTaxBenefits_iE_pn3n3_c20240101__20241231_zDdvDxShsZVe" style="border-bottom: Black 2.5pt double; text-align: right" title="Balance ending"&gt;1,028&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2022-12-31"
      decimals="-3"
      id="Fact003019"
      unitRef="USD">1028000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact003023"
      unitRef="USD">1028000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact003027"
      unitRef="USD">1028000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-12-31_custom_UnitedStatesFederalAndStateMember"
      decimals="-3"
      id="Fact003029"
      unitRef="USD">121804000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2023-12-31_custom_UnitedStatesFederalAndStateMember"
      decimals="-3"
      id="Fact003031"
      unitRef="USD">109544000</us-gaap:OperatingLossCarryforwards>
    <CELU:OperatingLossCarryforwardsExpirationYear
      contextRef="From2024-01-012024-12-31_custom_UnitedStatesFederalAndStateMember"
      id="Fact003033">2040</CELU:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2024-12-31_custom_UnitedStatesFederalAndStateMember"
      decimals="-3"
      id="Fact003035"
      unitRef="USD">5674000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2023-12-31_custom_UnitedStatesFederalAndStateMember"
      decimals="-3"
      id="Fact003037"
      unitRef="USD">5674000</us-gaap:TaxCreditCarryforwardAmount>
    <CELU:TaxCreditCarryforwardsExpirationYear
      contextRef="From2024-01-012024-12-31_custom_UnitedStatesFederalAndStateMember"
      id="Fact003039">2032</CELU:TaxCreditCarryforwardsExpirationYear>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003041"
      unitRef="USD">11619000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003043"
      unitRef="USD">39272000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact003045"
      unitRef="USD">1028000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact003047"
      unitRef="USD">1028000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="AsOf2024-12-31"
      decimals="0"
      id="Fact003049"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact003051"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact003053">&lt;p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_zmQtIdTxCWbe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;19.
&lt;span id="xdx_821_zo88cKvPnDl2"&gt;Segment Information&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company regularly reviews its segments and the approach used by management to evaluate performance and allocate resources. The
Company manages its operations through an evaluation of &lt;span id="xdx_904_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20240101__20241231_zlCMeSBJwb6i" title="Number of operating segments"&gt;three&lt;/span&gt;
distinct operating segments: Cell Therapy, Degenerative Disease, and BioBanking. The chief operating decision maker, who is the
Company&#x2019;s chief executive officer, uses the actual segment contribution results compared to budgets, among other factors, for
performance evaluation and resource allocation among these segments. The segment contribution is calculated as net revenues less the cost of
revenues (excluding amortization of acquired intangible assets) and direct expenses. Direct expenses in the Cell Therapy operating segment
consist of research and development costs, and direct expenses in the Degenerative Disease and Biobanking operating segments consist
mainly of selling, general, and administrative costs. The CODM assesses actual results against budgets and forecasts, and uses this information
to make decisions about strategic investment into the Company&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
reportable segments, which are the same as the operating segments, were determined based on the distinct nature of the activities performed by each segment. Cell Therapy broadly refers
to therapies the Company is researching and developing. Therapies being researched are unproven and in various phases of development.
Degenerative Disease produces, sells and licenses products used in surgical and wound care markets. BioBanking collects stem cells from
umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company manages its assets on a total company basis, not by operating segment. Therefore, the chief operating decision maker does not
regularly review any asset information or related income statement effects by operating segment and, accordingly, asset information is
not reported by reportable segment. Refer to the Consolidated Balance Sheet for information about total assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7MsvFz8HyC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
information by segment is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_z4dnuEopRayj" style="display: none"&gt;Schedule
of Financial Information by Segment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zaJeG6QuIika" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cell&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Therapy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zRdiwc27IrG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioBanking&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zmWAsGw2FLTl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Degenerative Disease&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zdNVWlpmDQZ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cell&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Therapy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioBanking&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Degenerative Disease&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zFlxIwfO1ZLa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;48,392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;54,220&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_z6oD0O66Pp32" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cost of revenues (excluding amortization of acquired intangible assets)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3064"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,817&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zsn5f4L3Lfq1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Direct expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,807&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,673&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20,846&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38,326&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zKp3SXBNZjTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Segment contribution&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(15,119&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,295&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,729&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;905&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zvokvZw8jKPh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;37,703&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_z9YmKl0Zm4y9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Indirect expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,560&lt;/td&gt;&lt;td style="text-align: left"&gt;(a)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_zy9Ir4UQXRgj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;(38,358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NonoperatingIncomeExpense_pn3n3_zM86SXyYRgT5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(19,534&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zbYRBRQML3ub" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(57,892&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;(a) Components of indirect expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_pn3n3_zU5qMoswLhw6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of contingent consideration liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(193&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GoodwillImpairmentLoss_pn3n3_zaPW4LNidUte" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_zvsVRcpDXuek" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;-&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_zuBp989h8Zcl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;1,753&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zHvY1GYh1Vg2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Total other&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1,560&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zkkFar7V0Ty" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cell&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Therapy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zK8GvaIWaIsa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioBanking&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zFKHznCBYLIk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Degenerative Disease&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zzI6AJoePq4b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cell&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Therapy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioBanking&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Degenerative Disease&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zflaTG577tNd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3129"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;17,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;22,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_zPC8oVzarJK3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cost of revenues (excluding amortization of acquired intangible assets)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3134"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,016&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zG4Cj5FVOJdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Direct expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;28,694&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,720&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zHkcP6fon5J8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Segment contribution&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,694&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,039&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(6,756&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(33,411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zp1Kw2Vt6bXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;40,876&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zTB24HnD9AM5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Indirect expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;118,001&lt;/td&gt;&lt;td style="text-align: left"&gt;(a)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z5dCtCMTfXre" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(192,287&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_pn3n3_zMhWuZqxowS3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(3,998&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zWhYAfDaejy8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(196,285&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;(a) Components of indirect expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_pn3n3_zsoqlzgUqxrh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of contingent consideration liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(104,339&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GoodwillImpairmentLoss_pn3n3_zH1R7OOaPDg3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;112,347&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_zjf98iY3BuJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;IPR&amp;amp;D impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;107,800&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_zX4hqGkHilGh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;2,193&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zCmpparvduik" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Total other&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;118,001&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_z18RdlWjc1W3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="From2024-01-01to2024-12-31"
      decimals="INF"
      id="Fact003055"
      unitRef="Segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact003057">&lt;p id="xdx_897_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_z7MsvFz8HyC5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
information by segment is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B5_z4dnuEopRayj" style="display: none"&gt;Schedule
of Financial Information by Segment&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zaJeG6QuIika" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cell&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Therapy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zRdiwc27IrG6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioBanking&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20240101__20241231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zmWAsGw2FLTl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Degenerative Disease&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240101__20241231_zdNVWlpmDQZ7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cell&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Therapy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioBanking&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Degenerative Disease&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zFlxIwfO1ZLa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;688&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;48,392&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;54,220&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_z6oD0O66Pp32" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cost of revenues (excluding amortization of acquired intangible assets)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3064"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,172&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,817&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,989&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zsn5f4L3Lfq1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Direct expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;15,807&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,673&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;20,846&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38,326&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zKp3SXBNZjTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Segment contribution&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(15,119&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,295&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,729&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;905&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zvokvZw8jKPh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;37,703&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_z9YmKl0Zm4y9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Indirect expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,560&lt;/td&gt;&lt;td style="text-align: left"&gt;(a)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_zy9Ir4UQXRgj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;(38,358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NonoperatingIncomeExpense_pn3n3_zM86SXyYRgT5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(19,534&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zbYRBRQML3ub" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(57,892&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;(a) Components of indirect expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_pn3n3_zU5qMoswLhw6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of contingent consideration liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(193&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--GoodwillImpairmentLoss_pn3n3_zaPW4LNidUte" style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_zvsVRcpDXuek" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;-&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_zuBp989h8Zcl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;1,753&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zHvY1GYh1Vg2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Total other&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; vertical-align: bottom; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;1,560&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CellTherapyMember_zkkFar7V0Ty" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cell&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Therapy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--BiobankingMember_zK8GvaIWaIsa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioBanking&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--DegenerativeDiseaseMember_zFKHznCBYLIk" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Degenerative Disease&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20230101__20231231_zzI6AJoePq4b" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Cell&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Therapy&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;BioBanking&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Degenerative Disease&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zflaTG577tNd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3129"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;5,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;17,330&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;22,771&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CostOfRevenue_pn3n3_zPC8oVzarJK3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Cost of revenues (excluding amortization of acquired intangible assets)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl3134"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,650&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,016&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DirectOperatingCosts_pn3n3_zG4Cj5FVOJdk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Direct expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;28,694&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,720&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;40,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--SegmentContribution_pn3n3_zHkcP6fon5J8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Segment contribution&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(28,694&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,039&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(6,756&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(33,411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherGeneralAndAdministrativeExpense_pn3n3_zp1Kw2Vt6bXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other general and administrative expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;40,876&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--IndirectExpenses_pn3n3_zTB24HnD9AM5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Indirect expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;118,001&lt;/td&gt;&lt;td style="text-align: left"&gt;(a)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_pn3n3_z5dCtCMTfXre" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Loss from operations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(192,287&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_pn3n3_zMhWuZqxowS3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;Other expenses&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(3,998&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zWhYAfDaejy8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Loss before income taxes&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(196,285&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-style: italic; text-align: left"&gt;(a) Components of indirect expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_pn3n3_zsoqlzgUqxrh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in fair value of contingent consideration liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;(104,339&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--GoodwillImpairmentLoss_pn3n3_zH1R7OOaPDg3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Goodwill impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;112,347&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--InProcessResearchAndDevelopmentImpairment_pn3n3_zjf98iY3BuJe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;IPR&amp;amp;D impairment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;107,800&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_zX4hqGkHilGh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;2,193&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_pn3n3_zCmpparvduik" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Total other&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;118,001&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_CellTherapyMember"
      decimals="-3"
      id="Fact003059"
      unitRef="USD">688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_BiobankingMember"
      decimals="-3"
      id="Fact003060"
      unitRef="USD">5140000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-12-31_custom_DegenerativeDiseaseMember"
      decimals="-3"
      id="Fact003061"
      unitRef="USD">48392000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003062"
      unitRef="USD">54220000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_BiobankingMember"
      decimals="-3"
      id="Fact003065"
      unitRef="USD">1172000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-12-31_custom_DegenerativeDiseaseMember"
      decimals="-3"
      id="Fact003066"
      unitRef="USD">13817000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003067"
      unitRef="USD">14989000</us-gaap:CostOfRevenue>
    <us-gaap:DirectOperatingCosts
      contextRef="From2024-01-012024-12-31_custom_CellTherapyMember"
      decimals="-3"
      id="Fact003069"
      unitRef="USD">15807000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="From2024-01-012024-12-31_custom_BiobankingMember"
      decimals="-3"
      id="Fact003070"
      unitRef="USD">1673000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="From2024-01-012024-12-31_custom_DegenerativeDiseaseMember"
      decimals="-3"
      id="Fact003071"
      unitRef="USD">20846000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003072"
      unitRef="USD">38326000</us-gaap:DirectOperatingCosts>
    <CELU:SegmentContribution
      contextRef="From2024-01-012024-12-31_custom_CellTherapyMember"
      decimals="-3"
      id="Fact003074"
      unitRef="USD">-15119000</CELU:SegmentContribution>
    <CELU:SegmentContribution
      contextRef="From2024-01-012024-12-31_custom_BiobankingMember"
      decimals="-3"
      id="Fact003075"
      unitRef="USD">2295000</CELU:SegmentContribution>
    <CELU:SegmentContribution
      contextRef="From2024-01-012024-12-31_custom_DegenerativeDiseaseMember"
      decimals="-3"
      id="Fact003076"
      unitRef="USD">13729000</CELU:SegmentContribution>
    <CELU:SegmentContribution
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003077"
      unitRef="USD">905000</CELU:SegmentContribution>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003082"
      unitRef="USD">37703000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <CELU:IndirectExpenses
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003087"
      unitRef="USD">1560000</CELU:IndirectExpenses>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003092"
      unitRef="USD">-38358000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003097"
      unitRef="USD">-19534000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003102"
      unitRef="USD">-57892000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003107"
      unitRef="USD">-193000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003122"
      unitRef="USD">1753000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-01-01to2024-12-31"
      decimals="-3"
      id="Fact003127"
      unitRef="USD">1560000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_BiobankingMember"
      decimals="-3"
      id="Fact003130"
      unitRef="USD">5441000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_DegenerativeDiseaseMember"
      decimals="-3"
      id="Fact003131"
      unitRef="USD">17330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003132"
      unitRef="USD">22771000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_custom_BiobankingMember"
      decimals="-3"
      id="Fact003135"
      unitRef="USD">1650000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31_custom_DegenerativeDiseaseMember"
      decimals="-3"
      id="Fact003136"
      unitRef="USD">14366000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003137"
      unitRef="USD">16016000</us-gaap:CostOfRevenue>
    <us-gaap:DirectOperatingCosts
      contextRef="From2023-01-012023-12-31_custom_CellTherapyMember"
      decimals="-3"
      id="Fact003139"
      unitRef="USD">28694000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="From2023-01-012023-12-31_custom_BiobankingMember"
      decimals="-3"
      id="Fact003140"
      unitRef="USD">1752000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="From2023-01-012023-12-31_custom_DegenerativeDiseaseMember"
      decimals="-3"
      id="Fact003141"
      unitRef="USD">9720000</us-gaap:DirectOperatingCosts>
    <us-gaap:DirectOperatingCosts
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003142"
      unitRef="USD">40166000</us-gaap:DirectOperatingCosts>
    <CELU:SegmentContribution
      contextRef="From2023-01-012023-12-31_custom_CellTherapyMember"
      decimals="-3"
      id="Fact003144"
      unitRef="USD">-28694000</CELU:SegmentContribution>
    <CELU:SegmentContribution
      contextRef="From2023-01-012023-12-31_custom_BiobankingMember"
      decimals="-3"
      id="Fact003145"
      unitRef="USD">2039000</CELU:SegmentContribution>
    <CELU:SegmentContribution
      contextRef="From2023-01-012023-12-31_custom_DegenerativeDiseaseMember"
      decimals="-3"
      id="Fact003146"
      unitRef="USD">-6756000</CELU:SegmentContribution>
    <CELU:SegmentContribution
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003147"
      unitRef="USD">-33411000</CELU:SegmentContribution>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003152"
      unitRef="USD">40876000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <CELU:IndirectExpenses
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003157"
      unitRef="USD">118001000</CELU:IndirectExpenses>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003162"
      unitRef="USD">-192287000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003167"
      unitRef="USD">-3998000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003172"
      unitRef="USD">-196285000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003177"
      unitRef="USD">-104339000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003182"
      unitRef="USD">112347000</us-gaap:GoodwillImpairmentLoss>
    <CELU:InProcessResearchAndDevelopmentImpairment
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003187"
      unitRef="USD">107800000</CELU:InProcessResearchAndDevelopmentImpairment>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003192"
      unitRef="USD">2193000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-12-31"
      decimals="-3"
      id="Fact003197"
      unitRef="USD">118001000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact003199">&lt;p id="xdx_809_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zumD8rrpiVr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&lt;b&gt;20. &lt;span id="xdx_827_z8jnspUMxdpf"&gt;Related
Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Amended and Restated Employment Agreement with
Dr. Robert Hariri&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 25, 2023, in order to address the Company&#x2019;s current working capital requirements, Robert Hariri, M.D., Ph.D., the Company&#x2019;s
Chairman and Chief Executive Officer, agreed to temporarily reduce payment of his salary pursuant to his employment agreement to minimum
wage level with the remaining salary deferred until December 31, 2023. As of December 31, 2024, $&lt;span id="xdx_90C_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iI_c20241231__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember_zCQej8C0bARi" title="Accrued expenses"&gt;1,274&lt;/span&gt; was recorded to accrued expenses
on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
order to comply with the Securities Purchase Agreement dated &lt;span id="xdx_90E_ecustom--SecuritiesPurchaseAgreementDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember_zQHu6YsW1vS5" title="Securities purchase agreement date"&gt;January 12, 2024&lt;/span&gt; with Dragasac Limited, Dr. Hariri is not to be paid the
$&lt;span id="xdx_901_ecustom--UnpaidBaseSalary_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zWuovfOGLzji" title="Unpaid base salary"&gt;1,088&lt;/span&gt; in base salary that was otherwise due to him for the 2023 calendar year unless the Company raises additional cash through offerings
of equity securities with aggregate net proceeds equal or greater to $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zAbPi7EMMWD7" title="Net proceeds from offerings of equity securities"&gt;21,000&lt;/span&gt; at a valuation at least equal to the valuation, cost per
security or exercise/conversion price, as applicable, of the Class A common stock and January 2024 PIPE Warrant purchased by Dragasac
Limited in January 2024. In compliance with the requirements of Internal Revenue Code Section 409A, the compensation committee of the
Company&#x2019;s board of directors approved a cash bonus program, or bonus program, effective &lt;span id="xdx_90A_ecustom--BonusProgramEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--AmendedAndRestatedEmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrRobertHaririMember_zuyD7XAVMZyd" title="Bonus program effective date"&gt;February 16, 2024&lt;/span&gt;, pursuant to which Dr.
Hariri will be paid &lt;span id="xdx_90B_ecustom--PercentageOfUnpaidBaseSalary_pid_dp_uPure_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zdptatZHHLX6" title="Percentage of unpaid base salary"&gt;125&lt;/span&gt;% of his unpaid base salary upon the satisfaction of the foregoing performance conditions. Accordingly, the Company
entered into a second amendment to Dr. Hariri&#x2019;s employment agreement implementing the &lt;span id="xdx_903_ecustom--PercentageOfBaseSalary_pid_dp_uPure_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYwaxCPxxmpb" title="Percentage of base salary"&gt;85&lt;/span&gt;% base salary reduction effective as of
&lt;span id="xdx_90F_ecustom--BonusProgramEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zcPSW2mToMK2" title="Bonus program effective date"&gt;February 16, 2024&lt;/span&gt; and documenting the bonus program. As a result of the reduction, Dr. Hariri&#x2019;s annual rate of base salary for
the 2024 year will be $&lt;span id="xdx_90C_ecustom--AnnualRateOfBaseSalary_pn3n3_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_z44GM73MMXJ5" title="Annual rate of base salary"&gt;180&lt;/span&gt;. Payment of Dr. Hariri&#x2019;s base salary at the rate in effect prior to the reduction will resume on &lt;span id="xdx_90D_ecustom--BaseSalaryEffectiveDate_dd_c20230125__20230125__us-gaap--RelatedPartyTransactionAxis__custom--DrRobertHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zm7D7HqGLhyh" title="Bonus program effective date"&gt;January
1, 2025&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;March
2023 PIPE&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 20, 2023, the Company entered into a securities purchase agreement with two accredited investors, including its Chairman and Chief
Executive Officer, Dr. Robert Hariri, for an aggregate purchase price of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--DrRobertHaririMember_zsZ8mMXEu9fl" title="Proceeds from PIPE financings"&gt;9,000&lt;/span&gt; (of which Dr. Hariri subscribed for $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn3n3_c20230320__20230320__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember__srt--TitleOfIndividualAxis__custom--DrHaririMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_ztjRMGwjsXva" title="Proceeds from PIPE financings"&gt;2,000&lt;/span&gt;). See Note
13 under March 2023 PIPE caption for further details.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Loan
Agreement with Dr. Robert Hariri&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 21, 2023, the Company entered into a $&lt;span id="xdx_908_ecustom--DebtInstrumentContributionAmount_iI_pn3n3_c20030821__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zvRQjfj7J3dd" title="Debt instrument contribution amount"&gt;1,000&lt;/span&gt; loan agreement with Dr. Robert Hariri, M.D., Ph.D., the Company&#x2019;s Chairman and
Chief Executive Officer, which bears interest at a rate of &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20030821__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_z59R2Q8O24w1" title="Loan interest rate"&gt;15.0&lt;/span&gt;% per year, with the first year of interest being paid in kind on the
last day of each month and was scheduled to mature on August 21, 2024. The loan maturity date was subsequently extended to December 31,
2024. On September 30, 2024, Dr. Hariri assumed the loans of two unaffiliated lenders who were parties to an August 21, 2023 loan agreement.
On January 29, 2025, Dr. Hariri extended the maturity date of the loan to December 31, 2025. See Note 10, Short-Term Debt - Other and
CEO Promissory Note, for more information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 12, 2023, in order to further address the Company&#x2019;s immediate working capital requirements, Dr. Hariri and the Company
signed a promissory note (&#x201c;CEO Promissory Note&#x201d;) for $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20231012__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zNn7sVaR62Rg" title="Principal amont"&gt;285&lt;/span&gt; which bears interest at a rate of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20231012__20231012__us-gaap--ShortTermDebtTypeAxis__custom--CeoPromissoryNoteMember__srt--TitleOfIndividualAxis__custom--ChairmanAndChiefExecutiveOfficerMember_zAs2q4x8Ryjf" title="Interest rate"&gt;15.0&lt;/span&gt;% per year (Note 10).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Consulting
&amp;amp; Advisory Agreements with Dr. Andrew Pecora&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--RelatedPartyTransactionTermsAndMannerOfSettlement_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zpms6Azy9Lsf" title="Related party description"&gt;On
August 31, 2022, Dr. Pecora resigned as the Company&#x2019;s President, and subsequently entered into a consulting agreement with the
Company dated September 21, 2022, to receive a $&lt;span id="xdx_905_ecustom--ReceiveForMonth_pn3n3_c20220901__20220921__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_z5Q1XgESzH3" title="Receive for month"&gt;10&lt;/span&gt; monthly fee for an initial six-month term and which would be automatically renewed
for one additional six- month term if either party did not provide notice of non-renewal.&lt;/span&gt; Simultaneously, the Company entered into a
scientific and clinical advisor agreement (the &#x201c;SAB Agreement&#x201d;), effective as of September 1, 2022, whereby Dr. Pecora agreed
to serve as co-chair of the Company&#x2019;s scientific and clinical advisory board for a $&lt;span id="xdx_908_ecustom--ReceiveForMonth_pn3n3_c20220901__20220901__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zVCJNmEtNcPe" title="Receive for month"&gt;10&lt;/span&gt; monthly fee and a one-time grant of RSUs
having a value of $&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pn3n3_c20220901__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zn9M3ZvmbV4g" title="RSUs one-time grant value"&gt;125&lt;/span&gt; on the grant date and which vest equally over &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20220901__20220901__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--TypeOfArrangementAxis__custom--ScientificAndClinicalAdvisorAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DrAndrewPecoraMember_zvNByTqAupFk" title="Options vesting period"&gt;four years&lt;/span&gt;. The SAB Agreement had a one-year term and may be renewed
for successive one-year terms upon mutual agreement of both parties. The consulting agreement was early terminated effective January
14, 2023. As of August 8, 2024, Dr. Pecora no longer serves on the Company&#x2019;s scientific and clinical advisory board.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Advisory
Agreement with Robin L. Smith MD&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 16, 2022, the Company entered into an advisory agreement with Robin L. Smith, MD, a then member of the Company&#x2019;s board of
directors, to receive $&lt;span id="xdx_90D_ecustom--ReceiveForMonth_pn3n3_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zhFvxGFY3Aoe" title="Receive for month"&gt;20&lt;/span&gt; per month for advisory fees, an equity grant for a total amount of &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_ze9FhPN6M83" title="Vested options to acquire shares"&gt;105,000&lt;/span&gt; stock options with the initial tranche
of &lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--VestingAxis__custom--InitialTrancheMember_z7Z6vWabPqwj" title="Vested options to acquire shares"&gt;25,000&lt;/span&gt; stock options vesting upon execution of the advisory agreement and the remaining shares subject to vesting upon achievement
of certain predefined milestones. On November 1, 2022, the second tranche of &lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20220901__20220901__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember__us-gaap--VestingAxis__us-gaap--ShareBasedCompensationAwardTrancheTwoMember_zSAdhf9MvmF" title="Vested options to acquire shares"&gt;20,000&lt;/span&gt; stock options vested upon achievement of the milestone.
The agreement also provided for a one-time cash bonus of $&lt;span id="xdx_901_ecustom--RelatedPartyCashBonus_pn3n3_c20220816__20220816__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_zgWDh8JLzM67" title="One-time cash bonus"&gt;1,500&lt;/span&gt; upon the successful achievement of the trigger event, as defined in the
agreement. The Company paid advisory fees of $&lt;span id="xdx_904_ecustom--PaymentsToRelatedParty_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_z5AMetMKU4Jh" title="Amount paid"&gt;0&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--PaymentsToRelatedParty_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--RobinLSmithMdMember__us-gaap--TypeOfArrangementAxis__custom--AdvisoryAgreementMember_z48DEbWUbSGc" title="Amount paid"&gt;20&lt;/span&gt; for the years ended December 31, 2024 and 2023, respectively. The advisory agreement
expired pursuant to the terms of the agreement on August 16, 2023 and was not renewed for an additional term. Dr. Smith resigned from
the Company&#x2019;s board effective December 24, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;COTA,
Inc&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2020, Legacy Celularity and COTA, Inc. (&#x201c;COTA&#x201d;) entered into an Order Schedule (the &#x201c;Order Schedule No. 2&#x201d;),
to the Master Data License Agreement between Legacy Celularity and COTA, dated October 29, 2018, pursuant to which COTA will provide
the licensed data in connection with AML patients. The COTA Order Schedule No. 2 will terminate on the one-year anniversary following
the final licensed data deliverable described therein. Andrew Pecora, M.D., Celularity&#x2019;s former President, is the Founder and Chairman
of the Board of COTA and Dr. Robin L. Smith, a former member of the Company&#x2019;s board of directors, is an investor in COTA. The Company
did &lt;span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_do_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--COTAIncMember_zACmZrmRqpnj" title="Contribution made"&gt;&lt;span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_do_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--COTAIncMember_zQED0LyNLbhf" title="Contribution made"&gt;no&lt;/span&gt;&lt;/span&gt;t make any payments to COTA during either of the years ended December 31, 2024 and 2023. As of August 8, 2024, Dr. Pecora no longer
serves on the Company&#x2019;s scientific and clinical advisory board and therefore, COTA is no longer a related party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Cryoport
Systems, Inc&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the years ended December 31, 2024 and 2023, the Company made payments totaling $&lt;span id="xdx_90A_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20240101__20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CryoportSystemsIncMember_zXvS4XjsfdRi" title="Contribution made"&gt;2&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_pn3n3_c20230101__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CryoportSystemsIncMember_z5BLWuaBKlF2" title="Contribution made"&gt;33&lt;/span&gt;, respectively, to Cryoport Systems, Inc (&#x201c;Cryoport&#x201d;)
for transportation of cryopreserved materials. The Company&#x2019;s Chief Executive Officer and director, Dr. Robert Hariri, M.D, Ph.D.,
has served on Cryoport&#x2019;s board of directors since September 2015.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;C.V.
Starr Loan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 17, 2023 the Company entered into a $&lt;span id="xdx_909_ecustom--LoanAgreement_iI_pn3n3_c20230317__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember_zLVcKK4AVDqi"&gt;5,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;loan agreement with C.V. Starr. C.V. Starr is
an investor in the Company, beneficially owning &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandTwentyThreeLoanWarrantsMember_zeD0gMf4MF1l"&gt;125,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants to purchase Class A common stock and
&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CVStarLoanMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zzAMWNQfcDa3"&gt;1,528,138
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Class A common stock as of December
31, 2024. See Note 10, Short-Term Debt &#x2013; Related Parties &#x2013; C.V. Starr and RWI for more information.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Resorts World Inc Pte
Ltd&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;On May 16, 2023, the Company entered
into a $&lt;span id="xdx_90F_ecustom--LoanAgreement_iI_pn3n3_c20230316__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember_z5LOP61EL9pc" title="Loan agreement"&gt;12,000&lt;/span&gt; loan agreement, as amended on June 21, 2023, with RWI. On January 12, 2024, the Company entered into a $&lt;span id="xdx_90C_ecustom--SecondLoanAgreement_iI_pn3n3_c20240112__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember_zVKlXukmp0v8" title="Second loan agreement"&gt;15,000&lt;/span&gt; second loan
agreement with RWI. RWI is affiliated with Lim Kok Thay, a significant stockholder and former member of the Company's board of directors,
beneficially owning &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230316__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zKJfDRqxF7ml" title="Warrants"&gt;3,600,000&lt;/span&gt; warrants to purchase Class A common stock and &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ResortsWorldIncPteLtdMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zYRUYP8oMIKa" title="Warrants"&gt;6,338,161&lt;/span&gt; shares of Class A common stock as of December 31,
2024. See Note 10, Short-Term Debt &#x2013; Related Parties &#x2013; C.V. Starr and RWI for more information.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Employment
of an Immediate Family Member &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Alexandra
Hariri, the daughter of Robert J. Hariri, M.D., Ph.D., Celularity&#x2019;s Chairman and Chief Executive Officer, is employed by the Company
as an Executive Director, Corporate Strategy &amp;amp; Business Development. Ms. Hariri&#x2019;s annual base salary for 2024 and 2023 was
$&lt;span id="xdx_90C_ecustom--RelatedPartyBaseSalary_pn3n3_c20240101__20241231__srt--CounterpartyNameAxis__custom--MsHaririMember__us-gaap--RelatedPartyTransactionAxis__custom--EmploymentOfImmediateFamilyMemberMember_z5svl5zpKhH1" title="Base salary"&gt;&lt;span id="xdx_90D_ecustom--RelatedPartyBaseSalary_pn3n3_c20230101__20231231__srt--CounterpartyNameAxis__custom--MsHaririMember__us-gaap--RelatedPartyTransactionAxis__custom--EmploymentOfImmediateFamilyMemberMember_zZXcnQgQ0fC3" title="Base salary"&gt;265&lt;/span&gt;&lt;/span&gt;. Ms. Hariri has received and continues to be eligible to receive a bonus, equity awards and benefits on the same general terms and
conditions as applicable to unrelated employees in similar positions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Fountain
Life Management LLC &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 46.25pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 7, 2024, the Company entered into a Technology Services Agreement with Fountain Life Management LLC (&#x201c;Fountain Life&#x201d;),
under which the Company agreed to process and store mononuclear cells isolated from blood samples collected by Fountain Life or its authorized
representatives in accordance with the Company&#x2019;s adult banking enrollment processes. In consideration of the services, Fountain
Life will pay the Company a one-time fee of two thousand five hundred dollars per sample collected and stored. The initial term of the
agreement is one year and the term automatically extends for one-year periods unless earlier terminated by either party. The Company&#x2019;s
Chairman and Chief Executive Officer, Dr. Robert Hariri, M.D, Ph.D., and director, Peter Diamandis, M.D., are founding partners of Fountain
Life.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="AsOf2024-12-31_custom_DrRobertHaririMember"
      decimals="0"
      id="Fact003201"
      unitRef="USD">1274</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <CELU:SecuritiesPurchaseAgreementDate
      contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember"
      id="Fact003203">2024-01-12</CELU:SecuritiesPurchaseAgreementDate>
    <CELU:UnpaidBaseSalary
      contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-3"
      id="Fact003205"
      unitRef="USD">1088000</CELU:UnpaidBaseSalary>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-3"
      id="Fact003207"
      unitRef="USD">21000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <CELU:BonusProgramEffectiveDate
      contextRef="From2023-01-252023-01-25_custom_AmendedAndRestatedEmploymentAgreementMember_custom_DrRobertHaririMember"
      id="Fact003209">2024-02-16</CELU:BonusProgramEffectiveDate>
    <CELU:PercentageOfUnpaidBaseSalary
      contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact003211"
      unitRef="Pure">1.25</CELU:PercentageOfUnpaidBaseSalary>
    <CELU:PercentageOfBaseSalary
      contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      id="Fact003213"
      unitRef="Pure">0.85</CELU:PercentageOfBaseSalary>
    <CELU:BonusProgramEffectiveDate
      contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember"
      id="Fact003215">2024-02-16</CELU:BonusProgramEffectiveDate>
    <CELU:AnnualRateOfBaseSalary
      contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-3"
      id="Fact003217"
      unitRef="USD">180000</CELU:AnnualRateOfBaseSalary>
    <CELU:BaseSalaryEffectiveDate
      contextRef="From2023-01-252023-01-25_custom_DrRobertHaririMember_custom_SecuritiesPurchaseAgreementMember"
      id="Fact003219">2025-01-01</CELU:BaseSalaryEffectiveDate>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_SecuritiesPurchaseAgreementMember_custom_DrRobertHaririMember"
      decimals="-3"
      id="Fact003221"
      unitRef="USD">9000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2023-03-202023-03-20_custom_MarchTwoThousandTwentyThreePrivateInvestmentInPublicEquityWarrantsMember_custom_DrHaririMember_custom_SecuritiesPurchaseAgreementMember"
      decimals="-3"
      id="Fact003223"
      unitRef="USD">2000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <CELU:DebtInstrumentContributionAmount
      contextRef="AsOf2003-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fact003225"
      unitRef="USD">1000000</CELU:DebtInstrumentContributionAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2003-08-21_custom_LoanAgreementMember_custom_ChairmanAndChiefExecutiveOfficerMember"
      decimals="INF"
      id="Fact003227"
      unitRef="Pure">0.150</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember"
      decimals="-3"
      id="Fact003229"
      unitRef="USD">285000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-10-122023-10-12_custom_ChairmanAndChiefExecutiveOfficerMember_custom_CEOPromissoryNoteMember"
      decimals="INF"
      id="Fact003231"
      unitRef="Pure">0.150</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement
      contextRef="From2023-01-012023-12-31_custom_ConsultingAgreementMember_custom_DrAndrewPecoraMember"
      id="Fact003233">On
August 31, 2022, Dr. Pecora resigned as the Company&#x2019;s President, and subsequently entered into a consulting agreement with the
Company dated September 21, 2022, to receive a $10 monthly fee for an initial six-month term and which would be automatically renewed
for one additional six- month term if either party did not provide notice of non-renewal.</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <CELU:ReceiveForMonth
      contextRef="From2022-09-012022-09-21_custom_ConsultingAgreementMember_custom_DrAndrewPecoraMember"
      decimals="-3"
      id="Fact003235"
      unitRef="USD">10000</CELU:ReceiveForMonth>
    <CELU:ReceiveForMonth
      contextRef="From2022-09-012022-09-01_custom_ScientificAndClinicalAdvisorAgreementMember_custom_DrAndrewPecoraMember"
      decimals="-3"
      id="Fact003237"
      unitRef="USD">10000</CELU:ReceiveForMonth>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2022-09-01_custom_ScientificAndClinicalAdvisorAgreementMember_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact003239"
      unitRef="USD">125000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="From2022-09-012022-09-01_us-gaap_RestrictedStockUnitsRSUMember_custom_ScientificAndClinicalAdvisorAgreementMember_custom_DrAndrewPecoraMember"
      id="Fact003241">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <CELU:ReceiveForMonth
      contextRef="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember"
      decimals="-3"
      id="Fact003243"
      unitRef="USD">20000</CELU:ReceiveForMonth>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember"
      decimals="INF"
      id="Fact003245"
      unitRef="Shares">105000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember_custom_InitialTrancheMember"
      decimals="INF"
      id="Fact003247"
      unitRef="Shares">25000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-09-012022-09-01_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember"
      decimals="INF"
      id="Fact003249"
      unitRef="Shares">20000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <CELU:RelatedPartyCashBonus
      contextRef="From2022-08-162022-08-16_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember"
      decimals="-3"
      id="Fact003251"
      unitRef="USD">1500000</CELU:RelatedPartyCashBonus>
    <CELU:PaymentsToRelatedParty
      contextRef="From2024-01-012024-12-31_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember"
      decimals="-3"
      id="Fact003253"
      unitRef="USD">0</CELU:PaymentsToRelatedParty>
    <CELU:PaymentsToRelatedParty
      contextRef="From2023-01-012023-12-31_custom_RobinLSmithMdMember_custom_AdvisoryAgreementMember"
      decimals="-3"
      id="Fact003255"
      unitRef="USD">20000</CELU:PaymentsToRelatedParty>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_COTAIncMember"
      decimals="-3"
      id="Fact003257"
      unitRef="USD">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-012023-12-31_custom_COTAIncMember"
      decimals="-3"
      id="Fact003259"
      unitRef="USD">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2024-01-012024-12-31_custom_CryoportSystemsIncMember"
      decimals="-3"
      id="Fact003261"
      unitRef="USD">2000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-012023-12-31_custom_CryoportSystemsIncMember"
      decimals="-3"
      id="Fact003263"
      unitRef="USD">33000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <CELU:LoanAgreement
      contextRef="AsOf2023-03-17_custom_CVStarLoanMember"
      decimals="-3"
      id="Fact003264"
      unitRef="USD">5000000</CELU:LoanAgreement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_CVStarLoanMember_us-gaap_CommonClassAMember_custom_MarchTwoThousandTwentyThreeLoanWarrantsMember"
      decimals="INF"
      id="Fact003265"
      unitRef="Shares">125000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_CVStarLoanMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact003266"
      unitRef="Shares">1528138</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CELU:LoanAgreement
      contextRef="AsOf2023-03-16_custom_ResortsWorldIncPteLtdMember"
      decimals="-3"
      id="Fact003268"
      unitRef="USD">12000000</CELU:LoanAgreement>
    <CELU:SecondLoanAgreement
      contextRef="AsOf2024-01-12_custom_ResortsWorldIncPteLtdMember"
      decimals="-3"
      id="Fact003270"
      unitRef="USD">15000000</CELU:SecondLoanAgreement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-03-16_custom_ResortsWorldIncPteLtdMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact003272"
      unitRef="Shares">3600000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2024-12-31_custom_ResortsWorldIncPteLtdMember_us-gaap_CommonClassAMember"
      decimals="INF"
      id="Fact003274"
      unitRef="Shares">6338161</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <CELU:RelatedPartyBaseSalary
      contextRef="From2024-01-012024-12-31_custom_MsHaririMember_custom_EmploymentOfImmediateFamilyMemberMember"
      decimals="-3"
      id="Fact003276"
      unitRef="USD">265000</CELU:RelatedPartyBaseSalary>
    <CELU:RelatedPartyBaseSalary
      contextRef="From2023-01-012023-12-31_custom_MsHaririMember_custom_EmploymentOfImmediateFamilyMemberMember"
      decimals="-3"
      id="Fact003278"
      unitRef="USD">265000</CELU:RelatedPartyBaseSalary>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2024-01-01to2024-12-31" id="Fact003280">&lt;p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zB8PstfAYygj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;21.
&lt;span id="xdx_825_z0MZfQGUNV3i"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;On May 1, 2025, the
Company executed a cash advance agreement to sell $&lt;span id="xdx_908_eus-gaap--AccountsReceivableNet_iI_pn3n3_c20250501__dei--LegalEntityAxis__custom--GenesisEquityGroupFundingLlcMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zAbA5qMzLSU4" title="Accounts receivable"&gt;990&lt;/span&gt;
of accounts receivable to Genesis Equity Group Funding LLC (&#x201c;GEG&#x201d;) to provide incremental funding to address immediate
cash needs. Net funds, after applicable fees, were $&lt;span id="xdx_90C_ecustom--ApplicableFees_iI_pn3n3_c20250501__dei--LegalEntityAxis__custom--GenesisEquityGroupFundingLlcMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpGhJPCAcdx6" title="Applicable fees"&gt;594&lt;/span&gt;.
The amount GEG will collect from the Company towards the receivables purchased amount is capped at $&lt;span id="xdx_900_eus-gaap--InterestIncomePurchasedReceivables_pn3n3_c20250501__20250501__dei--LegalEntityAxis__custom--GenesisEquityGroupFundingLlcMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zWUZPooueIql" title="Receivables purchased"&gt;47&lt;/span&gt;
for twenty-one (21) weeks.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact003282"
      unitRef="USD">990000</us-gaap:AccountsReceivableNet>
    <CELU:ApplicableFees
      contextRef="AsOf2025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact003284"
      unitRef="USD">594000</CELU:ApplicableFees>
    <us-gaap:InterestIncomePurchasedReceivables
      contextRef="From2025-05-012025-05-01_custom_GenesisEquityGroupFundingLlcMember_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="Fact003286"
      unitRef="USD">47000</us-gaap:InterestIncomePurchasedReceivables>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact003287">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2024-10-012024-12-31" id="Fact003288">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact003289">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2024-10-012024-12-31" id="Fact003290">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact001309"
          xlink:label="Fact001309"
          xlink:type="locator"/>
        <link:footnote id="Footnote001358" xlink:label="Footnote001358" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As discussed
in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001309"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001311"
          xlink:label="Fact001311"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001311"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001313"
          xlink:label="Fact001313"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001313"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001315"
          xlink:label="Fact001315"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001315"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001319"
          xlink:label="Fact001319"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001319"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001321"
          xlink:label="Fact001321"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001321"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001323"
          xlink:label="Fact001323"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001323"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001325"
          xlink:label="Fact001325"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001325"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001329"
          xlink:label="Fact001329"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001329"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001331"
          xlink:label="Fact001331"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001331"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001335"
          xlink:label="Fact001335"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001335"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001337"
          xlink:label="Fact001337"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001337"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001339"
          xlink:label="Fact001339"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001339"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001341"
          xlink:label="Fact001341"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001341"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001345"
          xlink:label="Fact001345"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001345"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001347"
          xlink:label="Fact001347"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001347"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001349"
          xlink:label="Fact001349"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001349"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001351"
          xlink:label="Fact001351"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001351"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001355"
          xlink:label="Fact001355"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001355"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001357"
          xlink:label="Fact001357"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001357"
          xlink:to="Footnote001358"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001436"
          xlink:label="Fact001436"
          xlink:type="locator"/>
        <link:footnote id="Footnote001453" xlink:label="Footnote001453" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As discussed
further in Note 10, the warrants were not exercisable and the exercise price was not set until certain conditions were met. As of July
15, 2024, the warrants became exercisable and no longer contain adjustment provisions to the exercise price that are not indexed to the
Company&#x2019;s own stock. As such, the warrants were adjusted to fair value as of the initial exercise date and then reclassified from
liability classified to equity classified.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001436"
          xlink:to="Footnote001453"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001459"
          xlink:label="Fact001459"
          xlink:type="locator"/>
        <link:footnote id="Footnote001514" xlink:label="Footnote001514" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As discussed in Note 10, the securities purchase agreement dated November 25, 2024 provided for multiple closings.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001459"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001461"
          xlink:label="Fact001461"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001461"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001463"
          xlink:label="Fact001463"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001463"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001465"
          xlink:label="Fact001465"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001465"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001467"
          xlink:label="Fact001467"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001467"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001469"
          xlink:label="Fact001469"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001469"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001471"
          xlink:label="Fact001471"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001471"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001473"
          xlink:label="Fact001473"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001473"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001475"
          xlink:label="Fact001475"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001475"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001485"
          xlink:label="Fact001485"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001485"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001487"
          xlink:label="Fact001487"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001487"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001491"
          xlink:label="Fact001491"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001491"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001493"
          xlink:label="Fact001493"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001493"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001495"
          xlink:label="Fact001495"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001495"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001497"
          xlink:label="Fact001497"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001497"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001501"
          xlink:label="Fact001501"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001501"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001503"
          xlink:label="Fact001503"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001503"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001505"
          xlink:label="Fact001505"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001505"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001507"
          xlink:label="Fact001507"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001507"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001511"
          xlink:label="Fact001511"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001511"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact001513"
          xlink:label="Fact001513"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact001513"
          xlink:to="Footnote001514"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1477"
          xlink:label="xdx2ixbrl1477"
          xlink:type="locator"/>
        <link:footnote id="Footnote001515" xlink:label="Footnote001515" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The exercise price of the November 2024 Purchaser Warrants is based on the lesser of (i) $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zqWPryMPDFY"
  title="Exercise price"><xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zay0CNo8kkFc"
      title="Exercise price">2.85</xhtml:span></xhtml:span> or (ii) the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_906_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zHA1eE5Olt08"
  title="Floor price"><xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_90B_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPurchaserWarrantsMember_zJ5hleIJxI8l"
      title="Floor price">1.00</xhtml:span></xhtml:span>. </link:footnote>
        <link:footnote id="Footnote001524" xlink:label="Footnote001524" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The exercise price of the November 2024 Placement Agent Warrants is based on the lesser of (i) $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zO2jaDs7pQ78"
  title="Exercise price"><xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zCedlLw6AzQh"
      title="Exercise price">3.56</xhtml:span></xhtml:span> or (ii) <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_900_ecustom--OfferingPricePercentage_iI_pid_dp_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z7jn9S0Q2kz4"
  title="Offering price"><xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_90F_ecustom--OfferingPricePercentage_iI_pid_dp_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6z2KSFYOoUa"
      title="Offering price">125</xhtml:span></xhtml:span>% of the offering price of a Subsequent Financing (see Note 10), subject to a floor price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
  id="xdx_909_ecustom--FloorPrice_iI_pid_c20241231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_z6RlELFC2O76"
  title="Floor price"><xhtml:span
      class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIE5vdmVtYmVyIDIwMjQgUHVyY2hhc2VyIGFuZCBQbGFjZW1lbnQgQWdlbnQgV2FycmFudHMgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_"
      id="xdx_909_ecustom--FloorPrice_iI_pid_c20241125__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyFourPlacementAgentWarrantsMember_zXObzrFkExgd"
      title="Floor price">1.00</xhtml:span></xhtml:span>.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1477"
          xlink:to="Footnote001515"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1477"
          xlink:to="Footnote001524"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1479"
          xlink:label="xdx2ixbrl1479"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1479"
          xlink:to="Footnote001515"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1479"
          xlink:to="Footnote001524"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl1481"
          xlink:label="xdx2ixbrl1481"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1481"
          xlink:to="Footnote001515"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl1481"
          xlink:to="Footnote001524"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002497"
          xlink:label="Fact002497"
          xlink:type="locator"/>
        <link:footnote id="Footnote002616" xlink:label="Footnote002616" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In connection with the execution of the January 2024 PIPE described above, the Company agreed to reprice <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_909_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_z0CxQy6hgMJh"
  title="Number of warrants repriced">652,981</xhtml:span> legacy warrants held by Dragasac with a previous exercise price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--StatementEquityComponentsAxis__custom--DragasacWarrantMember_zJ7gS6haRbBc"
  title="Exercise price per share or per unit of warrants or rights outstanding">67.70</xhtml:span> to a new exercise price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240112__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember_zYVzxB4PfIah"
  title="Exercise price">2.4898</xhtml:span>. The term of the warrants was unchanged.</link:footnote>
        <link:footnote id="Footnote002641" xlink:label="Footnote002641" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">On January 24, 2025, the
Company agreed to reduce the exercise price of the Dragasac warrants and the January 2024 PIPE warrants from $<xhtml:span
  id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MinimumMember_zDOZqY4vlhF5"
  title="Exercise price">2.49</xhtml:span> per share to $<xhtml:span
  id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--JanuaryTwoThousandTwentyFourPIPEWarrantMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--RangeAxis__srt--MaximumMember_zfw8z5NDCiqh"
  title="Exercise price">2.07</xhtml:span>
per share. As a result of the price reduction, the holder agreed to immediately exercise the warrants in full and to purchase an aggregate
<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zs0kpvh31E5b"
  title="Aggregate shares">1,188,255</xhtml:span> shares of the Company&#x2019;s Class A common stock for gross proceeds to the Company of approximately $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90A_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20250124__20250124__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyFourWarrantRepricingMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zJKjoIgtMeje"
  title="Proceeds from the exercise of warrants">2.5</xhtml:span> million<xhtml:i>.</xhtml:i></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002497"
          xlink:to="Footnote002616"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002497"
          xlink:to="Footnote002641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002499"
          xlink:label="Fact002499"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002499"
          xlink:to="Footnote002616"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002499"
          xlink:to="Footnote002641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002501"
          xlink:label="Fact002501"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002501"
          xlink:to="Footnote002616"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002501"
          xlink:to="Footnote002641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002503"
          xlink:label="Fact002503"
          xlink:type="locator"/>
        <link:footnote id="Footnote002623" xlink:label="Footnote002623" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The number of Public Warrants
and Sponsor Warrants outstanding was not adjusted for the reverse stock split. There are <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_903_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--PublicWarrantsMember_zHSrw9l6fBM"
  title="Warrants outstanding">14,374,478</xhtml:span> Public Warrants and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90B_ecustom--WarrantsOutstanding_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember_zhb8lpf7vX1c"
  title="Warrants outstanding">8,499,999</xhtml:span> Sponsor
Warrants outstanding. After the reverse stock split, the number of warrants outstanding remains the same. However, each outstanding warrant
is now exercisable for one-tenth of a share of Class A common stock, and the exercise price per share was adjusted to $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20241231__us-gaap--StatementEquityComponentsAxis__custom--SponsorWarrantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember_zfdpdBsJpoed"
  title="Exercise per share price (in Dollars per share)">115.00</xhtml:span> as a result
of the split.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002503"
          xlink:to="Footnote002623"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002505"
          xlink:label="Fact002505"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002505"
          xlink:to="Footnote002623"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002507"
          xlink:label="Fact002507"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002507"
          xlink:to="Footnote002623"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002509"
          xlink:label="Fact002509"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002509"
          xlink:to="Footnote002623"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002511"
          xlink:label="Fact002511"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002511"
          xlink:to="Footnote002623"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002513"
          xlink:label="Fact002513"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002513"
          xlink:to="Footnote002623"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002533"
          xlink:label="Fact002533"
          xlink:type="locator"/>
        <link:footnote id="Footnote002630" xlink:label="Footnote002630" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In connection with the execution
of the Starr Forbearance Agreement on March 13, 2024, described above under Warrant Modification and further in Note 10, the Company
agreed to reprice <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_903_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zNKnX4iQB39l"
  title="Number of warrants repriced">75,000</xhtml:span> warrants with a previous exercise price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--StarrForbearanceAgreementMember_zB4Cdrckei1h"
  title="Exercise price">7.10</xhtml:span> and <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_904_ecustom--NumberOfWarrantsRepriced_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zGIhzk4KHX5l"
  title="Number of warrants repriced">50,000</xhtml:span> warrants with a previous exercise price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313_ztdMSGu7CCBf"
  title="Exercise price">8.10</xhtml:span>
held by C.V. Starr to a new exercise price of $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFN1bW1hcnkgb2YgdGhlIFdhcnJhbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA"
  id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240313__us-gaap--LineOfCreditFacilityAxis__custom--CVStarrCoIncMember_zYKfrX5dCT29"
  title="Exercise price">5.895</xhtml:span>. The term of the warrants was unchanged.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002533"
          xlink:to="Footnote002630"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002535"
          xlink:label="Fact002535"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002535"
          xlink:to="Footnote002630"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002537"
          xlink:label="Fact002537"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002537"
          xlink:to="Footnote002630"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002557"
          xlink:label="Fact002557"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002557"
          xlink:to="Footnote002630"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002559"
          xlink:label="Fact002559"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002559"
          xlink:to="Footnote002630"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002575"
          xlink:label="Fact002575"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002575"
          xlink:to="Footnote002641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002577"
          xlink:label="Fact002577"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002577"
          xlink:to="Footnote002641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002579"
          xlink:label="Fact002579"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002579"
          xlink:to="Footnote002641"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002714"
          xlink:label="Fact002714"
          xlink:type="locator"/>
        <link:footnote id="Footnote002737" xlink:label="Footnote002737" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Options outstanding at December 31, 2024 under the 2021 Plan and 2017 Plan were <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_zJXOtNTlcnPg"
  title="Options outstanding">2,569,029</xhtml:span> and
                                                                             <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_c20241231__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zBXUGuFGvff8"
  title="Options outstanding">1,437,496</xhtml:span>, respectively. Options outstanding at December 31, 2024 under the 2021 Plan include <xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFN0b2NrIE9wdGlvbiBBY3Rpdml0eSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20240101__20241231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyOnePlanMember_z1vLdctHuub8"
  title="Options outstanding including awards">45,000</xhtml:span> awards with performance
                                                                             conditions (see below).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002714"
          xlink:to="Footnote002737"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002716"
          xlink:label="Fact002716"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002716"
          xlink:to="Footnote002737"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002718"
          xlink:label="Fact002718"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002718"
          xlink:to="Footnote002737"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002720"
          xlink:label="Fact002720"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002720"
          xlink:to="Footnote002737"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002860"
          xlink:label="Fact002860"
          xlink:type="locator"/>
        <link:footnote id="Footnote002871" xlink:label="Footnote002871" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Deferral
    of revenue includes $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_908_eus-gaap--DeferredRevenue_iI_pn3n3_c20241231_zbtl13DKTSt6">5,061</xhtml:span> in 2024 resulting from payments received in advance of performance under the biobanking services storage
    contracts that are recognized as revenue under the contract as performance is completed.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002860"
          xlink:to="Footnote002871"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002861"
          xlink:label="Fact002861"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002861"
          xlink:to="Footnote002871"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002863"
          xlink:label="Fact002863"
          xlink:type="locator"/>
        <link:footnote id="Footnote002873" xlink:label="Footnote002873" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Recognition
    of unearned revenue includes $<xhtml:span
  class="xdx_phnt_RGlzY2xvc3VyZSAtICBTY2hlZHVsZSBvZiBDaGFuZ2VzIGluIERlZmVycmVkIFJldmVudWUgZnJvbSBDb250cmFjdCBMaWFiaWxpdGllcyAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__"
  id="xdx_907_ecustom--UnearnedRevenue_iI_pn3n3_c20241231_zQdD2DbYPnl6">2,561</xhtml:span> that was included in the beginning deferred revenue balance at January 1, 2024.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002863"
          xlink:to="Footnote002873"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact002864"
          xlink:label="Fact002864"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact002864"
          xlink:to="Footnote002873"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
